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Background: Amyotrophic Lateral Sclerosis, in which cortical and spinal MN’s deg-
enerate, is a late onset neurodegenerative condition that accounts for ~1 in 400 UK 
deaths, typically within 3-5 years from the initial manifestations of disease. It forms 
part of a broad spectrum of clinically, genetically as well as pathologically hetergen-
eous disorders that include behavioural variant frontotemporal lobar degeneration 
(bvFTLD). A large intronic hexanucleotide G4C2 repeat expansion of >30 copies was 
recently identified, in 2011, in the previously uncharacterised chromosome 9 open 
reading frame 72 (C9ORF72) gene which is now thought to explain up to 43% of fam-
ilial ALS (~20-30% of familial FTLD) and around 7% of sporadic cases. Rationale & 
Hypothesis: The principle aim of the PhD was to perform gene expression profiling 
of peripheral tissues in ALS. In the first instance whole blood was trialled. However, 
this proved unreliable, owing to the sheer abundance of erythrocyte derived alpha 
and beta haemoglobin transcripts that are contained within the sample and the var-
iability in the efficiency of its removal using the Ambion® GLOBINClearTM or NuGEN 
Ovation® WB reduction strategies. Instead disease related changes in transcription/ 
alternative splicing were detected in a large bank (n=820) of patient and control ly-
mphoblastoid cell lines (LCL’s) with the main purpose of: 1) elucidating further the 
mechanism(s) of neurotoxicity associated with the C9ORF72 G4C2 repeat expansion 
and, 2) establishing within this specific genetic subtype, modifiers of a fast (<2yrs) 
versus slow (≥4yrs) disease progression in order to identify potential new areas of 
therapeutic research. Methodology: Biotinylated, sense-strand cDNA targets of ~40 
-70nt were hybridized onto Human Exon 1.0ST GeneChip® Arrays. A GC-RMA norm- 
alisation procedure was carried out in Partek® Genomics SuiteTM and differentially 
expressed or alternatively spliced transcripts were detected at the 5% significance 
level (p<0.05) with a fold-change threshold of ≥ ±1.20 applied. Findings: Overall a 
marginal increase in gene transcription was observed with respect to C9ORF72 (59. 
3%, n=650/1,096) and nonC9ORF72-related_SALS patients (63.9%, n=1,148/1,796) 
compared to neurologically healthy controls. DAVID enriched gene ontology terms 
included translation, which was specific to carriers of the G4C2 repeat, in addition to 
RNA processing, DNA metabolism, RNP complex biogenesis and the cell cycle which 
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reflect more common features of the broader ALS phenotype. A number of key vali-
dation targets, including several RNA binding partners of the G4C2 repeat (FUS, RPL 
22, NUDT2, PURA, EIF4H and HNRNPA0/F) were subsequently confirmed in a qRT-
PCR assay. Isoform A/B specific transcripts of the C9ORF72 gene, itself, were found 
not to be differentially expressed across the LCL’s in the ECACC discovery and repli-
cation cohorts. Conclusions: Whether pathogenicity of the G4C2 expanded allele ar-
ises as a consequence of haploinsufficiency or through an aberrant gain of function 
mechanism has yet to be determined; although emerging evidence favours a role of 
RNA toxicity. In light of this model, an up-regulation in the expression of C9ORF72 
binding partners and other, RNA processing & splicing related transcripts fits with 
the hypothesis that the cells are attempting to compensate for the sequestration of 
these proteins into toxic RNA foci in the cytoplasm which leads to disruption of their 
normal physiological function. Small sample sizes meant limited conclusions could 
be drawn from the analysis of C9ORF72 specific modifiers of survival in ALS. Clinical 
data points towards a possible effect of gender which is supported in the literature 
but other factors such as correlations with expansion length would need to be con-
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CHAPTER 1: INTRODUCTION 
 
1.1 Motor Neurone Disease Spectrum              
1.1.1 Background  
Motor Neurone Disease (MND), originally coined by Brain in 1933, is a term used to 
encompass a broad clinical spectrum of rapidly progressive (Hardiman et al 2011) 
and invariably fatal (Dion et al 2009), late onset neurodegenerative disorders which 
include: Amyotrophic Lateral Sclerosis (ALS) (~60%) (Section 1.2.1); ALS with con-
comitant frontotemporal lobar degeneration (ALS+FTLD) (~5-10%) or Parkinson’s 
disease (ALS+PD) (~5%) (Lomen-Hoerth et al 2003, Manno et al 2013); Progressive 
Bulbar Palsy (PBP) (~20%) (Section 1.2.2.1); Progressive Muscular Atrophy (PMA) 
(~10%) (Section 1.2.2.3) and Primary Lateral Sclerosis (PLS) (~2-5%) (Section 2.2. 
2.2).    
 
1.1.2 Epidemiology  
MND has a prevalence of 3.4 or 5.2 (range 4-8) per 100,000 of the North American 
and European Caucasian populations, respectively (Traynor et al 1999). Incidence 
rates vary, but are reported to occur within the region of 0.6 (Sicily) (De Domenico 
et al 1988, Rosati et al 1977) and 2.4 (Finland) (Murros & Fogelholm 1983) with an 
average of 1 or 2 individuals per 100,000/year (Chio et al 2013a, Logroscino et al 
2008, Werneck et al 2007). This confers a relative lifetime risk of ~1 in 400 by the 
age of 70 (Johnston et al 2006). In non-European countries the frequency has been 
estimated to be higher in the Chamorro tribe, of the Western Pacific island of Guam 
(22 per 100,000/year) (Plato et al 2002, Waring et al 2004), and in several regions 
of the Kii peninsula of the Japanese island, Honshu (9.5 per 100,000/year) (Kaji et 
al 2012, Okamoto et al 2009) where there have been reports of a ALS/Parkinsonism 
-dementia complex; but is, however, considerably lower across the Far East (1.3 per 
100,000/year) (Kihira et al 2005, Yoshida et al 1998), Africa (0.9 per 100,000/year) 
(Marin et al 2012, Radhakrishnan et al 1986) and Asia (0.3 per 100,000/year) (Fong 
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et al 1996). A slight trend towards a male preponderance is evident (Leblond et al 
2014) with male to female (M:F) ratios ranging between 1.2 and 1.5:1 (Logroscino 
et al 2010, McCombe & Henderson 2010). Prognostic factors that have been found 
to correlate negatively with survival include poor nutritional status, signs of bulbar 
or respiratory muscle involvement, early age at symptom onset, a short diagnostic 
delay and evidence of cognitive dysfunction (Logroscino & Bennett 2014, Scotton et 
al 2012).  
 
1.1.3 Diagnosis  
A single definitive diagnostic test for MND does not currently exist (Hardiman et al 
2011). Clinical evaluations, based upon a detailed history and physical examination 
of the patient, are supported by electrophysiological testing [e.g. electromyography 
(EMG) as well as sensory and motor nerve conduction velocities], neuropsychiatric 
evaluation, imaging [e.g. magnetic resonance imaging (MRI) of the brain and spinal 
cord (SC)], genetic consultation and neuropathological information (McDermott & 
Shaw 2008). Other laboratory investigations, such as muscle biopsy, cerebrospinal 
fluid (CSF) analysis, serum creatine kinase measurements, thyroid function tests, a 
full blood count, erythrocyte sedimentation rate and urine protein electrophoresis, 
may also aid in the exclusion of other neuromuscular disorders that can mimic MN 
degeneration (Hardiman et al 2011, Sathasivam 2010, Turner & Talbot 2013). The 
World Federation of Neurology introduced the El Escorial Rating Criteria (EEC) in 
1994, later amended in 1998, to ensure standardization in the diagnosis of MND, 
for the purposes of clinical research (Figure 1.1) (Brooks 1994, Brooks et al 2000). 
According to this system, patients are assigned to one of four diagnostic categories, 
namely definite, probable, possible or suspected ALS, as determined by the various 
levels of certainty with which clinical and laboratory assessments are made. Signs 
of upper MN (UMN) dysfunction include increased muscle tone, hyperreflexia and 
spasticity, whereas lower MN (LMN) dysfunction is characterised by severe muscle 
wasting & weakness, as well as hyporeflexia, fasciculations and cramping (Kinsley & 
Siddique 2001). Often, however, the initial manifestations of the disease are mild and 
relatively non-descript (McDermott & Shaw 2008). Its insidious nature means that a 




Figure 1.1 El Escorial Rating Criteria (EEC) for the Diagnosis of MND   
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, LMN - lower motor neurone, MND - Motor 
Neurone Disease and UMN - upper motor neurone.      
 
 
2014) before a patient is referred to a specialist neurologist and a diagnosis of MND 
can be confirmed (Nzwalo et al 2014). Hence, an urgent need exists for the identifi-
cation of specific biological markers or biomarkers that can facilitate an earlier dia-
gnosis and more accurate monitoring of disease progression, as well as offering the 
potential to better predict individual responses to novel therapeutic agents and/or 
treatment strategies (Frank & Hargreaves 2003, Lehnert et al 2014, Mendez & Satt-
ler 2014, Silani et al 2011, Su et al 2013).  
  
1.1.4 Clinical Management  
As yet there is no known cure for MND. Clinical management is based on guidelines 
which have been published by the American Academy of Neurology® (AAN) and the 
European Federation of Neurological Societies (EFNS). Over the years there have be-
en more than thirty phase II and phase III clinical trials of promising therapeutic ag-
ents identified from various in vitro and in vivo studies, including lithium carbonate 
(LiCALS), brain derived neurotrophic factor (BDNF), Novartis (Ozanezumab), ONO-
2506 (Arundic acid), minocycline and Copaxone® (glatiramer acetate) which relate 
to patient LCL samples in the National MNDA DNA Bank, held at the Health Protect-
ion Agency (Public Health England, UK), that were subsequently recruited into the 
ECACC discovery (Section 4.1.1) and replication (Section 4.1.2) cohorts [REVIEWED 
BRIEFLY IN APPENDIX TABLE B4]. Disappointingly, however, these have yielded li-
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ttle success, with the glutamate antagonist, Riluzole (Bensimon et al 1994) remain-
ing the only Food and Drug Administration (FDA) approved drug for the treatment 
of MND in the UK (Hardiman et al 2011). Individual responses vary with a modest in-
crease in survival of ~2-3 months (Miller et al 2007, Riviere et al 1998) reported in 
some sufferers, but not others. Current efforts, therefore, are largely focused on sy-
mptom management and alleviating pain and discomfort in order to maintain as go-
od a quality of life for as long as possible (McDermott & Shaw 2008).  
The provision of palliative care is heavily reliant upon a multidisciplinary approach 
that requires a specialist neurologist and a team of trained nursing staff supported 
by additional healthcare professionals including a psychiatrist, genetic counsellor, 
nutritionist, pulmonologist, social worker and speech/occupational therapist (Bede 
et al 2011, Kinsley & Siddique 2001). Muscle relaxants such as benzodiazepine and 
baclofen may be administered to relieve spasticity and cramping (Ashworth et al 20 
04). Oral secretions can be controlled with the use of a saline nebulizer in combinat-
ion with a beta (β)-receptor antagonist (e.g. metoprolol/propranolol), tricyclic anti-
depressant compounds, mucolytic agents and mechanical suctioning devices (And-
ersen et al 2007, Miller et al 2009b). Complications associated with increased meta-
bolic activities and difficulties in swallowing (dysphagia) (Miller et al 2009a) such as 
weight loss and malnutrition can be overcome by modifying the consistency of food 
and fluid intake initially, or in more advanced cases, through the insertion of a per-
cutaneous endoscopic gastrostomy (PEG) feeding tube. If tolerated, non-invasive p-
ositive pressure ventilation (NIPPV) assistance is highly recommended for patients 
with a forced vital capacity (FVC) lung function test <50% (Miller et al 1999). It has 
proven a particularly beneficial intervention in instances where it is used for a min-
imum of five hours daily and can be implemented before the onset of severe bulbar 
dysfunction, with reports of median survival times being extended by approximately 
7 months (Bourke et al 2006, Farrero et al 2005, Hannan et al 2014). Several studies 
have also evaluated the use of Vitamin C/E or multivitamin supplements, herbal pr-
eparations such as Gingko biloba and Ginseng, coenzyme Q10, antioxidant therapies 
and zinc but sample sizes have been small and the effects of these agents remain con-
troversial (Cameron & Rosenfeld 2002, Galbussera et al 2006, Kaufmann et al 2009, 
Orrell et al 2007).     
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1.2 Amyotrophic Lateral Sclerosis              
1.2.1 ALS  
Amyotrophic meaning atrophy of the muscles and Lateral Sclerosis referring to the 
hardened tissues and scarring of the lateral spinal cord (ALS) was first reported by 
French physician and neurologist, Jean-Martin Charcot over a century ago (Charcot 
& Joffroy 1869) (Leblond et al 2014). It represents by far the most common form of 
MND accounting for up to two-thirds (~60%) of cases (Ekbom 1992, Gomes Mda & 
Engelhardt 2013, Kumar et al 2011). In America it is more commonly referred to as 
Lou Gehrig’s disease in memory of the famous New York Yankees baseball player of 
the same name (Lewis & Gordon 2007), who died prematurely from the condition in 
1941, aged just 37 years. ALS is characterised by the rapid degeneration and progr-
essive loss of both UMN’s, consisting of giant Betz, as well as, other large pyramidal 
cells of the primary motor cortex and LMN’s which include the cranial motor nerve 
nuclei and anterior horn cells (AHC’s) of the brainstem and SC (Hardiman et al 2011, 
McDermott & Shaw 2008) (Section 1.2.3). Denervation results in muscle weakness, 
atrophy and spasticity that leads to a failure in initiating and controlling voluntary 
movements (Gordon et al 2003, Kinsley & Siddique 2001, Sathasivam 2010). Onset 
usually occurs focally and is asymmetric (Korner et al 2011) with symptoms initially 
restricted to the upper or lower extremities (~66%) (limb or spinal onset), bulbar 
region (~30%) or, more infrequently, the respiratory muscles, which account for ≤ 
5% of cases (Gautier et al 2010, Ravits et al 2007, Sekiguchi et al 2014). Contiguous 
advancement and eventual widespread paralysis culminates in respiratory failure, 
typically within 3-5yrs from the initial point of diagnosis (Cluskey & Ramsden 2001). 
Although some patients will progress more rapidly, dying inside a year, it is anticip-
ated that only around one in twenty cases will survive beyond a decade (Gordon 20 
11, McDermott & Shaw 2008, Preux et al 1996). Additionally, executive and memory 
deficits also afflict between 25 and 50% of cases (Goldstein & Abrahams 2013); with 
10 to 20% of these meeting the diagnostic criteria for frontotemporal lobar degene-
ration (FTLD) (Barson et al 2000, Massman et al 1996, Phukan et al 2012, Ringholz 
et al 2005, Strong et al 2009) by the time they have reached their terminal stages of 
disease progression and vice versa, ~15% of FTLD patients (Burrell et al 2011, Lom-
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en-Hoerth et al 2002, Strong et al 1999) have reportedly presented with some deg-
ree of motor dysfunction. After Alzheimer’s disease (ALZ), FTLD is recognised as the 
second most frequent cause of presenile dementia, accounting for between five and 
fifteen percent of cases occurring in individuals before the age of 65 (Cooper-Knock 
et al 2014a). It is characterised by a progressive phenotype in which severe frontal 
and temporal lobe atrophy leads to alterations in personality and behaviour as well 
as impaired cognitive functioning and language difficulties (Neumann 2013, Riedl et 
al 2014). According to the Neary defined consensus criteria of 1998, three clinically 
distinct subtypes are thought to exist: a) behavioural variant FTLD (bvFTLD) most 
commonly associated with ALS; b) progressive non-fluent aphasia (PNFA) including 
word retrieval problems and loss of speech and c) semantic dementia (SD) produc-
ing deficits in word comprehension and memory (Mignarri et al 2014, Morimoto et 
al 2012). Evidence of a family history of MND or dementia is usually apparent in ar-
ound 25 to 50% of cases, with mutations having been identified in the microtubule 
associated protein, tau (MAPT), progranulin (PGRN) and presenilin (PSEN) [Briefly 
reviewed in Section 1.2.5.3], in addition to a number of ALS causative genes, namely 
transactive response (TAR) DNA binding protein (TARDBP), fused in sarcoma (FUS), 
angiogenin (ANG), ataxin 2 (ATXN2), ubiquilin 2 (UBQLN2), profilin 1 (PFN1), sigma 
non-opioid intracellular receptor 1 (SIGMAR1), charged multivesicular body protein 
2b (CHMP2B), valosin-containing protein (VCP), heterogeneous nuclear ribonucleo-
protein A1 (HNRNPA1) (Section 1.2.5.1) (Ferrari et al 2012, Mackenzie et al 2014) 
and chromosome 9 open reading frame 72 (C9ORF72) (Section 1.2.5.4) which is the 
focus of this project. A long established clinical, neuropathological and genetic over-
lap between ALS and bvFTLD is suggestive of these two heterogeneous disorders of 
the brain and central nervous system (CNS) lying on a continuum rather than form-
ing distinct and entirely separate disease entities (Pliner et al 2014). In some insta-
nces, ~4% of ALS and around 20-30% of FTLD patients, Parkinsonian features may 
also be apparent including poor response to Levodopa (L-dopa), rigidity, bradykin-
esia without resting tremor and a vertical gaze palsy (Karageorgiou & Miller 2014, 
Park & Chung 2013, Seelaar et al 2008).        
The rarer and more benign brachial amyotrophic diplegia variant or Flail Arm (FA) 
syndrome was originally described by Alfred Vulpian in 1886 and accounts for ~11 
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% of cases. It is a condition of predominant LMN dysfunction, characterised by pro-
ximal wasting and progressive weakness of the upper limbs. Traditionally, it is tho-
ught of as having a higher predisposition in men versus women, with a M:F ratio of 
9:1 (Hu et al 1998). Age at symptom onset does not differ from that of “classical ALS” 
which has a peak in the mid-60’s and 70’s for sporadic (SALS) patients and a second 
in the early 40’s or 50’s for instances where there is known to be at least one other 
first or second degree relative who is affected (Calvo et al 2014b, Kinsley & Siddique 
2001). One distinguishing feature, however, is disease duration with 52% exceeding 
5 years survival and 17.4% extending beyond 10 years (Chio et al 2011a, Wijesekera 
et al 2009). Furthermore, FTLD which is typically diagnosed in 5 to 10% of “classical 
ALS” patients is found to be distinctly lacking in cases associated with the FA synd-
rome (~1.4%) (Wolf et al 2014)  
The rarer still pseudopolyneuritic variant or Flail Leg (FL) syndrome was first iden-
tified in 1918 by a student of Pierre Marie, namely Jean Patrikios (Patrikios 1918), 
and accounts for a further 6% of cases. It is a condition of predominant LMN dysfu-
nction characterised, in the absence of overt pyramidal signs, by distal wasting and 
progressive weakness of the lower limbs, abnormal tendon reflexes and extensive 
demyelination of the corticospinal tracts (CST). The median age of symptom onset is 
reported to be 55 (range 31-79yrs) with roughly equal numbers of male and female 
patients affected. Disease progression is typically slower than that of “classical ALS” 
with a mean duration of 71 versus 36 months, respectively (Wijesekera et al 2009).  
  
1.2.2  Other Rare Variants of MND 
1.2.2.1 PBP  
Progressive bulbar palsy (PBP) was originally described in 1860 by Guillaume Ben-
jamin Amand Duchenne as labioglossopharyngeal paralysis (Broussolle et al 2012), 
which was later renamed by Wachsmuth in 1864. It is a condition of both UMN and 
LMN involvement that primarily affects the muscles controlling speech and swallow-
ing (Hughes & Wiles 1998, Rocha et al 2005). Symptoms include weak palatal move-
ment, an excessive/uncontrollable production of saliva, reduced gag reflexes, tongue 
fasciculations and emotional lability (EL), in addition to, dysarthria (speech impair-
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ment) and dysphagia (Cerero Lapiedra et al 2002, Talacko & Reade 1990). PBP has 
a higher prevalence in women than men (Kuhnlein et al 2008a, McDermott & Shaw 
2008) and is associated with an especially poor prognosis in which the majority of 
patients will succumb to the onset of pulmonary pneumonia, 1-3yrs after the initial 
manifestations of disease. Although initially thought to be a distinct phenotypic en-
tity, accounting for up to a fifth of MND cases, recent evidence has emerged to sugg-
est that as many of 87% will progress to fulfil the diagnostic criteria of definite ALS 
(Figure 1.1) and in much of the current literature many of these cases have been re-
classified accordingly as having bulbar-onset ALS (Karam et al 2010).  
 
1.2.2.2 PLS  
Primary Lateral Sclerosis (PLS) is a relatively rare, atypical form of MND which acc-
ounts for between 2 and 5% of cases (Kuipers-Upmeijer et al 2001, Le Forestier et al 
2001, Pringle et al 1992, Singer et al 2005, Zhai et al 2003). It was initially described 
by Wilhelm Heinrich Erb in 1902 as a condition of pure UMN involvement that typ-
ically has a slower disease course of up to 17 years (Almeida et al 2013b, Hardiman 
et al 2011) and is almost exclusively idiopathic in nature (Tartaglia et al 2007). PLS 
presents clinically from CST degeneration, and in the absence of pronounced musc-
ular atrophy, as a triad of hyperreflexia, mild to moderate lower limb weakness and 
spasticity with patients often reporting stiffness, clumsiness/reduced coordination 
and occasional bladder symptoms (Gordon et al 2006, Singer et al 2007).  
 
1.2.2.3 PMA  
Progressive Muscular Atrophy (PMA) was originally described in 1850 by François-
Amilcar Aran as a condition of pure LMN involvement that accounts for around 10% 
of the total number of MND cases (Kim et al 2009, Riku et al 2014). It is virtually al-
ways sporadic, although a few incidences involving a prior family history have been 
recorded (Rowland 2010). Progressive degeneration of the AHC’s within the brain-
stem and SC are known to bring about fasciculations that ultimately lead to severe 
muscle weakness and atrophy (Cervenakova et al 2000, Jansen et al 1986). In com-
parison to those diagnosed with “classical ALS”, PMA patients exhibit a greater male 
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preponderance with a slightly older than anticipated age of symptom onset and a l-
onger disease duration [median survival 48 versus 36 months (Tsuchiya et al 2004, 
Visser et al 2008)]. 
  
1.2.3 ALS Pathology 
At autopsy, specimens derived from familial ALS (FALS) and SALS patients are larg-
ely indistinguishable. Both are characterised by: a) degeneration of the CST carrying 
axonal nerve fibres, which project from the primary motor cortex to the LMN’s and 
extensive loss of LMN’s within the brainstem and SC (Ghatak et al 1986, Hughes 19 
82); b) degeneration and loss of UMN’s including giant Betz and other, large pyram-
idal cells of the primary motor cortex (Hammer et al 1979, Maekawa et al 2004, Ud-
aka et al 1986) and c) widespread reactive gliosis which is a more generic feature of 
CNS injury and inflammation (Ekblom et al 1994, Kawamata et al 1992, Murayama 
et al 1991, Schiffer et al 1996). Residual, atrophied MN’s are classically hallmarked 
by the presence of ubiquitinated intracellular proteinaceous Lewy body (LB) (20-40 
%) or skein-like inclusions (90%) that are immunoreactive for TDP-43 or FUS (Arai 
et al 2006, Deng et al 2010, Ling et al 2010, Neumann et al 2006). Additional cresc-
ent shaped inclusions (SCI’s) (infrequent) may be seen in the upper cortical layers II 
to IV and dentate gyrus of MND patients with dementia (Al-Sarraj et al 2002). More-
over, there have also been reports of cystatin C containing Bunina bodies (70-80%) 
(Okamoto et al 1993, Sasaki & Maruyama 1994) and axonal spheroids (frequent) oc-
curring in MN’s of the SC (Corbo & Hays 1992, Millecamps et al 2006). Hyaline con-
glomerate inclusions (HCI’s) that are composed of hyperphosphorylated accumula-
tions of neurofilament subunits and peripherin are a much rarer occurrence and us-
ually restricted to cases involving mutant SOD1 (mtSOD1) (Ince et al 1998, Leblond 
et al 2014, Munoz et al 1988, Sobue et al 1990).    
In addition to the classic ubiquitinated, p62 and TDP-43 positive, neuronal and glial 
cytoplasmic inclusions described above in the motor cortex and AHC’s of the brain-
stem and SC (Cooper-Knock et al 2015a), C9ORF72+ ALS and ALS-FTLD related cases 
can also be characterised by the superimposition of extra-motor features which are 
observed in the hippocampus, frontal neocortex and cerebellum (Al-Sarraj et al 20 
11, Cooper-Knock et al 2012b, Murray et al 2011, Stewart et al 2012). These include 
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further ubiquitinated, p62 positive but TDP-43 negative, neuronal cytoplasmic (NCI) 
and intranuclear (NII) inclusion bodies which are immunoreactive for both sense as 
well as antisense dipeptide repeat proteins (DPR’s) (poly-GA, GR and GP) produced 
from non-ATG mediated or RAN translation of the aberrantly expanded G4C2 repeat 
(Section 1.2.5.4) (Gendron et al 2013a, Mann et al 2013, Mori et al 2013c).   
  
1.2.4 Mechanisms Underlying MN Degeneration in ALS 
Most of our current understanding of the mechanisms which underlie MN degener-
ation in ALS has come from the study of transgenic SOD1G93A mice (Ferraiuolo et al 
2007) with particular emphasis on the importance of glutamate excitotoxicity (Sect-
ion 1.2.4.2), mitochondrial dysfunction (Section 1.2.4.3) and oxidative stress (Secti-
on 1.2.4.1). Mutations, however, in the antioxidant gene copper/zinc superoxide di-
smutase 1 (SOD1) are responsible for only a minority, (~2%) of the total number of 
ALS cases (Rosen et al 1993) (Section 1.2.5.1.1). With the emergence of many new 
genetic subtypes (Table 1.1), most notably C9ORF72; accounting for up to 43% of F 
ALS and around 7% of SALS cases (Section 1.2.5.4) (Cooper-Knock et al 2012b), and 
the identification of TDP-43 as well as other mutated proteins as major constituents 
of NCI’s (Section 1.2.3) (Neumann et al 2006) a complex interplay between multiple 
disease causative mechanisms is now thought to exist which supports diverse roles 
such as axonal transport defects (Section 1.2.4.4), intracellular protein aggregation 
(Section 1.2.4.5), non-cell autonomous glia and inflammation (Section 1.2.4.6), aut-
ophagy (Section 1.2.4.7), apoptosis (Section 1.2.4.8) and, perhaps most significantly 
RNA processing (Section 1. 2.4.9) (Ferraiuolo et al 2011).   
 
1.2.4.1 Oxidative Stress 
Oxidative stress (OS) is a phenomenon which arises as a consequence of a cytosolic 
imbalance between the production of reactive oxygen species (ROS), a consequence 
of aerobic respiration, and their subsequent neutralisation, degradation or removal, 
to affect the prevailing reducing environment inside the cell (Barber & Shaw 2010); 
together with the system’s inability to overcome or repair ROS damage to structural 
constituents of lipids, proteins and nucleic acids. The leakage of electrons from the 
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mitochondrial respiratory electron transport chain, along with xanthine oxidase and 
cytochrome P450, contribute to incomplete oxidative phosphorylation of molecular 
oxygen (O2). This leads to the generation of superoxide anions (O2.-) and hydrogen 
peroxide (H2O2) which are themselves relatively unstable and may undergo further 
downstream reactions to produce even more potent oxidizing species e.g. hydroxyl 
free radicals (.HO) and peroxynitrite (ONOO-); molecules which subsequently cause 
protein carbonyls to form, nitrosylation of tyrosine residues, lipid peroxidation and 
oxidative damage to DNA and RNA (Turner et al 2013).   
 
1.2.4.2 Glutamate Excitotoxicity 
A state of excitotoxicity arises from an increased or prolonged stimulation of post-
synaptic, sodium-dependent inotropic AMPA (alpha-Amino-3-hydroxyl-5-methyl-4 
-isoxazolepropionic acid) or NMDA (N-methyl-D-aspartate) receptors by glutamate 
which triggers a large influx of calcium ions (Ca2+) (Corona et al 2007, Turner et al 
2013). Elevated levels of this excitatory neurotransmitter compound are detectable 
in patient CSF which is found to correlate with disease severity (Spreux-Varoquaux 
et al 2002). The permeability of AMPA receptors is determined in a large part by the 
GluR2 (glutamate receptor 2) subunit which is relatively lowly expressed in MN’s. 
This, in combination with the fact that these cells have a smaller calcium buffering 
capacity compared to other neuronal populations (e.g. oculomotor neurons which 
are generally spared in ALS), offers an insight as to the reasons why it is perhaps the 
MN’s which are most susceptible to excitotoxic injury & death in neurodegeneration 
(Robberecht & Philips 2013). A substantial rise in intracellular Ca2+ concentrations 
results in the production of ROS from the mitochondrion that establishes a negative 
feedback loop involving impaired EAAT2 (glial excitatory amino acid transporter 2) 
function and reduced re-uptake of glutamate from the synaptic cleft (Grosskreutz et 
al 2010, Kong et al 2014). Significant decreases in the level of EAAT2 protein expre-
ssion have been observed in around 80% of human autopsy derived brain and SC ti-
ssue (Rothstein et al 1995); whereas overexpressing endogenous forms in the tran-
sgenic SOD1G93A mouse has been shown to delay the onset of motor deficits (Guo et 
al 2003). The minor allele of SNP rs12608932 (Table 1.3) (Section 1.2.5.1.11) in the 
unc-13 homolog A (UNC13A) gene (Diekstra et al 2012, van Es et al 2009c), an imp-
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ortant regulator of synaptic glutamate release, is associated with an increased risk 
of developing ALS (OR 1.33, p<0.005) which correlates negatively with survival. Ul-
timately, activation of the calpain and/or cathepsin protease enzymes regulate the 
cleavage of apoptosis inducing factor (AIF) and its subsequent translocation into the 
nucleus where it elicits large scale DNA fragmentation and programmed cell death in 
a caspase independent manner (Cande et al 2002, Oh et al 2006, Shibata et al 2009).               
 
1.2.4.3 Mitochondrial Dysfunction  
Mitochondria are critical for the survival of eukaryotic cells, acting as a powerhouse 
which drives adenosine 5’-triphosphate (ATP) production. In addition to providing 
the cell with a source of energy, these organelles are also required for the regulation 
of apoptosis and calcium ion homeostasis (Kasahara & Scorrano 2014) (Section 1.2. 
4.2). Morphological, ultra-structural and biochemical abnormalities have been obs-
erved in both FALS and SALS cases in the form of enlarged, vacuolated mitochondria 
with inner membrane defects and aberrantly arranged cristae (Hirano et al 1984). 
There is also evidence to suggest that transportation of mitochondria along microt-
ubles in ALS may be impaired, which supports a “dying-back” axonopathy model of 
the disease (Shi et al 2010). Several mitochondrial modulators with neuroprotective 
properties in mammalian cell and animal systems are currently under investigation 
including the immunosuppressant cyclosporine (CsA) which prevents formation of 
the mitochondrial permeability transition pore complex (Karlsson et al 2004, Keep 
et al 2001) and the cholesterol-like compound, Olesoxime, that stabilizes the outer-
membrane, through its association with voltage-dependent anion-selective channel 
(VDAC) and benzodiazepine receptors (Bordet et al 2007, Martin 2010, Sunyach et 
al 2012).      
 
1.2.4.4 Axonal Transport  
MN’s are reliant upon mechanisms of anterograde and retrograde axonal transport 
to maintain cellular homeostasis and for communication between the cell body and 
distant nerve terminals (Chevalier-Larsen & Holzbaur 2006). Genetic alterations in 
a number of cytoskeletal components, adaptor molecules and motor proteins have 
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been associated with the disease including dynactin (DCTN1), neurofilament heavy 
chain (NEFH) (Section 1.2.5.1.10), profilin 1 (PFN1) (Section 1.2.5.2.9) and kinesin-
associated protein 3 (KIFAP3) (Section 1.2.5.1.11). Reduced messenger RNA (mRNA) 
transcript levels pertaining to neurofilament light chain (NEFL), a causative gene of 
Charcot Marie Tooth (CMT) disease, have also been observed in the AHC’s of SALS 
patients (Bergeron et al 1994). RNA processing proteins TDP-43 (Section 1.2.5.2.1) 
and FUS (Section 1.2.5.2.2) bind NFL (Lagier-Tourenne et al 2012, Polymenidou et 
al 2011, Strong et al 2007) to disrupt its normal physiological function by resulting 
in its aberrant sequestration into stress granules (SG’s) (Volkening et al 2009).     
 
1.2.4.5 Intracellular Protein Aggregation  
A major pathological feature of ALS, as discussed previously in Section 1.2.3, is the 
presence of p62 positive, ubiquitinated intracellular proteinaceous inclusion bodies 
which accumulate in the cytoplasm of residual, atrophied MN’s and glia of the CNS. 
Many have been shown to be immunoreactive for C9ORF72, TDP-43, FUS or SOD1; 
among several other translated products of ALS causative genes, depending on the 
underlying genetic cause of the disease. For example, whilst FUS and SOD1 mutation 
carriers contain aggregates of these proteins, they are found to be negative for TDP-
43, unlike TARDBP and most other ALS cases. The precise manner in which protein 
aggregation contributes to MN degeneration is unclear with experimental evidence 
pointing towards both loss of function and gain of function mechanisms (Blokhuis et 
al 2013).  
 
1.2.4.6 The Role of Non-Cell Autonomous Glia and Inflammation  
Evidence which suggests that the astrocytes and microglia surrounding MN’s in the 
CNS are determinants of disease onset and progression (Boillee et al 2006, Wang et 
al 2011, Wang et al 2009, Yamanaka et al 2008, Zhu et al 2014) implicates a role for 
non-cell autonomous neurodegeneration in the pathogenesis of ALS (Appel et al 20 
11, Ilieva et al 2009). The increasing activation and proliferation of these cells prod-
uces a neuroinflammatory response (Glass et al 2010, McGeer & McGeer 2002, Phi-
lips & Robberecht 2011) with elevated levels of proinflammatory cytokines and ot-
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her markers of inflammation including tumor necrosis factor alpha (TNFα) and Fas 
ligand (FasL); a potent inducer of apoptosis (Section 1.2.4.8) (Petri et al 2006, Kuhle 
et al 2009, Meissner et al 2010, Mitchell et al 2009, Sekizawa et al 1998). Treatment 
with anti-inflammatory compounds such as Celastrol, a triterpene which is extract-
ed from the roots of the traditional Chinese herb, Tripterygium wilfordii (Thunder 
god vine), or Thalidomide and its derivative REVLIMID® (lenalidomide) have prov-
ed beneficial in prolonging the lifespan of ALS rodents with reports of a significant 
dose-dependent increase in survival, reduced weight loss, improved rota-rod perfo-
rmance, higher neuronal cell counts and a delay in the onset of symptoms (Kiaei et 
al 2005, Kiaei et al 2006, Neymotin et al 2009).     
 
1.2.4.7 Autophagy  
In ALS aggregates of misfolded mutant (mt) or wild-type (WT) proteins (Section 1.2. 
4.5) accumulate in the cytosol which overwhelms the ubiquitin-proteasome system 
(UPS) and causes it to become impaired. The cells attempt to compensate, in order 
to maintain a homeostatic environment, by activating the autophagosome-lysosome 
clearance pathway (Li et al 2008b, Sasaki 2011). This along with several autophagy 
inducing compounds such as lithium, resveratrol and trehalose (Albani et al 2010, 
Fornai et al 2008, Gomes et al 2010) have proven beneficial in promoting survival of 
MN’s and delaying disease progression in the SOD1G93A mouse model (Ghavami et al 
2014).     
 
1.2.4.8 Apoptosis  
Activation of cell surface death receptors (e.g. Fas) by extrinsic factors such as TNFα 
and TNF-related apoptosis-inducing ligand (TRAIL), or endoplasmic reticulum (ER) 
stress and mitochondrial release of cytochrome c caused by intrinsic factors such as 
DNA damage and OS triggers a cascade of caspase (cysteine-aspartic acid protease) 
enzymes that initiate apoptosis or programmed cell death. Morphological features 
associated with this process include cell rounding, chromatin condensation, nuclear 
fragmentation, shrinking cell volume, cytoskeletal disassembly and blebbing of the 
plasma membrane prior to phagocytosis by macrophages, which have been seen in 
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ALS (Ghavami et al 2014).       
 
1.2.4.9 RNA Processing  
The identification of RNA binding proteins TDP-43 and FUS as constituents of NCI’s 
in up to 90% of non-SOD1 linked FALS and SALS cases (Arai et al 2006, Neumann et 
al 2006) and the segregation of a number of pathological changes with the disease in 
these as well as other related genes (Table 1.1), including C9ORF72 (Section 1.2.5.4) 
is strong evidence in support of a role of RNA toxicity in causing MN’s to degenerate 
in ALS (Baumer et al 2010, Polymenidou et al 2012).   
  
1.2.5 Genetic Factors 
MND and its clinical variants (Sections 1.1.1) represent a genetically heterogeneous 
group of neurological disorders with more than twenty different chromosomal loci 
(Table 1.1) having been identified through linkage analysis [ALS1-8, 10, 15, 17, 19 
and ALS-FTLD1-2], candidate gene association (CGA) studies [ALS9], homozygosity 
mapping [ALS12 and 16], targeted sequencing [ALS11], repeat association studies 
[ALS13] and next generation sequencing (NGS) approaches including exome/whole 
genome analyses [ALS14, 18 and 20-21] (Goodall et al 2012, Renton et al 2014). 
Between 5 and 10% of cases are reported to have a family history in which there is 
at least one other first or second degree relative who is known to be affected (Byrne 
et al 2011). Mutations in SOD1 (Section 1.2.5.1.1), TARDBP (Section 1.2.5.2.1), FUS 
(Section 1.2.5.2.2) and C9ORF72 (Section 1.2.5.4), among others listed in Table 1.1, 
are now thought to explain up to two-thirds of pedigrees (Ravits 2014, Renton et al 
2014). The mode of transmission follows a Mendelian pattern of inheritance that is 
largely autosomal dominant (AD); although autosomal recessive (AR) and X-linked 
forms have been described. In the majority of instances disease onset is expected to 
occur during mid-late adulthood, however, juvenile onset (<25yrs) and young onset 
ALS (<45yrs) are also known to account for ~1 or 10% of cases, respectively (Calvo 
et al 2014b, Leblond et al 2014, Logroscino et al 2010). 
In the following sections, ALS (Section 1.2.5.1), ALS-FTLD (Section 1.2.5.2 and 1.2.5.
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Locus  Chr. Gene  Function Mode Onset Mutation Diagnosis Ref.(s) 
ALS1 21q22.11 SOD1 oxidative stress AD/AR adult SNV ALS, PMA (Rosen et al 1993) 
ALS2 2q33.2 ALSIN guanine nucleotide exchange factor AR juvenile  SNV ALS, PLS, HSP (Hand et al 2003) 
ALS3 18q21 unknown unknown AD adult unknown ALS (Hand et al 2002) 
ALS4 9q34.13 SETX DNA/RNA helicase AD juvenile SNV ALS, AOA2 (Chen et al 2004) 
ALS5 15q21.1 SPG11 transmembrane protein  AR juvenile SNV ALS, HSP (Daoud et al 2012b) 
ALS6 16p11.2 FUS pre-mRNA splicing and export   AD adult SNV ALS, FTLD (Chio et al 2009a) 
ALS7 20p13 unknown unknown AD adult unknown ALS (Sapp et al 2003) 
ALS8 20q13.33 VAPB vesicular trafficking AD adult SNV ALS, SMA (Nishimura et al 2004) 
ALS9 14q11.1 ANG blood vessel formation   AD adult SNV ALS, FTLD, PD (Greenway et al 2006) 
ALS10 1p36.22 TARDBP regulator of transcription/splicing  AD adult SNV ALS, FTLD, PD (Sreedharan et al 2008) 
ALS11 6q21 FIG4 phosphoinositide phosphatase activity  AD adult SNV ALS, PLS, CMT (Chow et al 2009) 
ALS12 10p13 OPTN ocular tension, vesicular trafficking AD/AR adult SNV ALS, POAG (Maruyama et al 2010) 

















FTLD, CMT, HSP 
 
(Johnson et al 2010) 
ALS15 Xp11.2.1 UBQLN2 ubiquitination, protein degradation X-linked adult, juvenile SNV ALS-FTLD (Deng et al 2011) 
ALS16 9p13.3 SIGMAR1 endoplasmic reticulum chaperone AR juvenile SNV ALS-FTLD (Luty et al 2010) 
ALS17 3p12.1 CHMP2B vesicular trafficking AD adult SNV ALS, PMA, FTLD  (Parkinson et al 2006) 
ALS18 17p13.3 PFN1 cytoskeletal dynamics AD adult SNV ALS, FTLD (Wu et al 2012a) 
ALS19 2q33-q34 ERBB4 epidermal growth factor receptor  AD adult SNV ALS  (Takahashi et al 2013) 
ALS20 12q13.1 HNRNPA1 RNA metabolism  AD adult SNV IBMPFD/ALS   (Kim et al 2013) 
ALS21 5q31.2 MATR3 RNA metabolism  AD adult SNV ALS, VCPDM (Johnson et al 2014) 


















(DeJesus-Hernandez et al 
2011, Renton et al 2011) 
 




.4) and FTLD (Section 1.2.5.3) loci are discussed with a focus on those genes which 
have been designated an ALS number according to information attained from ALSoD, 
the Amyotrophic Lateral Sclerosis Online Genetics Database that is freely available 
at alsod.iop.kcl.ac.uk (Abel et al 2013). 
 
1.2.5.1 ALS Loci 
1.2.5.1.1 SOD1  
The free radical scavenging enzyme copper/zinc superoxide dismutase 1 (SOD1), 
situated at the chromosome 21q22.11 locus (Table 1.1), was discovered by Rosen 
et al (1993) more than twenty years ago as the first causative gene linked to the 
pathogenesis of AD and, across parts of Scandinavia, AR inherited forms of adult-
onset ALS (ALS1). Since then >170 missense mutations of variable penetrance have 
been identified, spanning the gene’s five coding exons (Al-Chalabi et al 2012, Su et 
al 2014). These account for between 12 and 23% of FALS cases and a further 2 to 
7% of SALS cases (Ajroud-Driss & Siddique 2014, Battistini et al 2005, Chio et al 
2008, Gros-Louis et al 2006, Ling et al 2013, Shaw et al 1998). Almost half of all 
carriers will become symptomatic by the time they have reached their fifth decade 
with around 90% becoming symptomatic before the age of 70 (Siddique et al 1991). 
Patients present with predominantly lower limb weakness and in the absence of 
impaired executive functioning (Millecamps et al 2010, Turner et al 2005). Median 
survival mirrors that of “classical ALS” (Section 1.2.1) which ranges between 2 and 
4 years from the initial manifestation of disease symptoms until the onset of 
respiratory failure; although considerable phenotypic variability has been observed 
with respect to SOD1-linked ALS (Renton et al 2014, Su et al 2014). For example a 
dominant p.A4V substitution that arose twice from a single common ancestor in 
Europe and North America, where it accounts for 50% of FALS cases, is associated 
with a particularly aggressive disease course of ~12 months (Cudkowicz et al 1997, 
Saeed et al 2009). Homozygous carriers of the p.D90A mutation, on the other hand, 
develop a much milder phenotype that is characterised by a long disease duration 
extending beyond 10 years (Al-Chalabi et al 1998, Andersen et al 1996). A distinct 
neuropathological profile apparent in FALS patients with a SOD1 mutation or the 
transgenic SOD1G93A mouse model has been described (Bruijn et al 2004, Mackenzie 
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et al 2007, Pickles & Vande Velde 2012) which is found to be absent in the majority 
of SALS cases (Brotherton et al 2012, Kerman et al 2010, Liu et al 2009). Aggregates 
of mutant or misfolded WT protein are observed in the cytoplasm of residual MN’s 
and glia of the brain and CNS (Banci et al 2008). These inclusions are found to be 
immunoreactive against antibodies for ubiquitin but stain negative for TDP-43 
(Section 1.2.5.3.1) and FUS (Section 1.2.5.3.2) (Ling et al 2013).  
SOD1 is a ubiquitously expressed metalloenzyme with antioxidant properties that 
normally functions to protect cells against elevated levels of ROS (Section 1.2.4.1). 
Specifically, it has been shown to act as a catalyst for the conversion of superoxide 
anions (O2-) into molecular oxygen (O2) and hydrogen peroxide (H2O2) (Therrien & 
Parker 2014). A correlation between reduced enzyme activity and disease severity 
is not evident (Borchelt et al 1994, Saccon et al 2013) pointing towards a toxic gain 
of function mechanism in which pathogenicity arises from both cell autonomous as 
well as non-cell autonomous processes (Ajroud-Driss & Siddique 2014, Ling et al 
2013).   
  
1.2.5.1.2 ALSIN  
Mutations (n=23) in the gene encoding alsin (ALSIN), situated at the chromosome 
2q33.2 locus (Table 1.1), are the cause of a rare spectrum of AR inherited disorders 
including a juvenile onset form of ALS (ALS2) (Hadano et al 2001, Yang et al 2001), 
PLS with oculomotor signs (Section 1.2.2.2) (Pringle et al 1992) and infantile-onset 
ascending spastic paraplegia (IAHSP) (Eymard-Pierre et al 2002, Eymard-Pierre et 
al 2006, Gros-Louis et al 2003, Wakil et al 2014). The latter are both conditions of 
primary UMN involvement with IAHSP characterised by progressive degeneration 
of the corticospinal and corticobulbar (CBT) tracts that usually begins in the distal 
extremities of the lower limbs and slowly advances to affect the upper limbs and 
bulbar muscles (Devon et al 2003, Herzfeld et al 2009, Racis et al 2014, Sztriha et 
al 2008, Verschuuren-Bemelmans et al 2008). Alsin is a ubiquitously expressed 
protein of undetermined function. Its structure contains three putative guanosine 
exchange factor (GEF) motifs including: a) the N-terminal Ran GTPase (guanosine 
triphosphatase) regulator of chromatin condensation 1 (RCC1) domain; b) the Rho 
GTPase diffuse B cell lymphoma/Pleckstrin homology (Db1/PH) domain and c) the 
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C-terminal Rab5-GTPase vacuolar protein sorting 9 (VPS9) domain. There are also 
seven membrane occupation and recognition nexus (MORN) repeats which span a 
region between the Db1/PH and VPS9 domains that have since been recognised as 
key modulators of Rab5-GTPase activity (Chandran et al 2007, Hadano et al 2007, 
Wakil et al 2014). So far most of the pathological changes that have been identified 
to date result in a frameshift/nonsense mutation. The introduction of a premature 
stop codon promoting early termination of translation leads to the production of a 
truncated protein that is inherently unstable (Yamanaka et al 2003). Of interest is 
the observation that genetic abnormalities of both long (6.5kb) and short (2.6kb) 
form ALSIN mRNA transcripts are apparent in cases of ALS2 whereas those which 
only affect the long form tend to be associated with UMN variants PLS and ISHAP 
(Panzeri et al 2006, Yang et al 2001). Chandran et al (2007) have since proposed a 
neuroprotective role for the short form product in LMNs as a possible explanation 
for the clinical diversity observed in the presence of these mutations. Furthermore, 
Alsin deficient MN’s are shown to have impaired AMPA receptor mediated trafficking 
which increases their susceptibility to glutamate excitotoxicity (Section 1.2.4.2) (Lai 
et al 2006). In addition, the WT protein has been found to interact with mtSOD1 to 
attenuate Nox2-dependent endosomal ROS damage (Section 1.2.5.1.1) (Kanekura et 
al 2004, Li et al 2011).               
 
1.2.5.1.3 SETX  
Senataxin (SETX), a DNA/RNA helicase situated at the chromosome 9q34.13 locus, 
(Table 1.1) is a rare cause of ataxia oculomotor apraxia type 2 (AOA2) (Asaka et al 
2006, Duquette et al 2005, Moreira et al 2004) and an AD inherited juvenile onset 
form of ALS (ALS4) (Avemaria et al 2011, Chance et al 1998, Chen et al 2004, Zhao 
et al 2009). The latter is a condition which is characterised by a distal hereditary 
motor neuropathy (dHMN) with progressive weakness and severe muscle wasting 
of all four limbs, a prolonged survival and extensive pyramidal features (Rabin et al 
1999). The precise function of senataxin is not known. However, its structure is 
predicted to contain a P-loop adenosine triphosphate and guanosine triphosphate 
(ATP-GTP) binding site which is highly conserved across yeast and mammalian 
systems and has been shown to play a critical role in nucleotide unwinding (Chen 
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et al 2004, Molnar et al 1997); a process that is required for gene transcription in 
addition to mechanisms of DNA replication, recombination & repair (Su et al 2014, 
Tanner & Linder 2001).                
 
1.2.5.1.4 SPG11  
Spatacsin (SPG11) which is situated at the chromosome 15q21.1 locus (Table 1.1) 
is the most common cause of hereditary spastic paraplegia (HSP) with occasional 
Parkinsonian features and pronounced thinning of the corpus callosum (Anheim et 
al 2009, Guidubaldi et al 2011, Liao et al 2008, Rajakulendran et al 2011, Stevanin 
et al 2008, Winner et al 2004, Zhao et al 2013). In recent years it has also been 
associated with a rare AR inherited juvenile onset form of ALS (ALS5) (Orlacchio et 
al 2010) characterised by a disease onset of less than 25yrs and a median survival 
spanning three and a half decades (Daoud et al 2012b). Clinical manifestations vary 
with the majority of patients experiencing distal muscle weakness, spasticity and 
atrophy accompanied by a bulbar phenotype, abnormal gait and signs of pyramidal 
involvement which occur in the absence of overt cognitive or sensory impairment 
(Su et al 2014). Truncating loss of function, nonsense or frameshift mutations have 
been identified as well as a small number of splice site alterations and insertions or 
deletions which promote early termination of translation through the introduction 
of a premature UAG/UAA/UGA stop codon (Iguchi et al 2013, Orlacchio et al 2010). 
Although spatacsin has not yet been fully characterised in the mammalian system, 
it is shown to be an essential requirement for neuromuscular junction connectivity 
and axonal outgrowth in the developing zebrafish (Martin et al 2012, Southgate et 
al 2010).                 
 
1.2.5.1.5 VAPB  
Two single base substitutions in the VAMP (vesicle-associated membrane protein) 
associated protein B (VAPB) gene, situated at the chromosome 20q13.33 locus, have 
been associated with <1% of familial cases of AD inherited adult-onset ALS (ALS8) 
(Table 1.1) (Chen et al 2010, Millecamps et al 2010). Phenotypic heterogeneity has 
been observed, with a wide variety of clinical presentations ranging from cases with 
“classical ALS” and a faster than anticipated disease course to delayed onset forms 
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of PMA (Section 1.2.2.3) or ALS with essential tremor (Nishimura et al 2004). The 
mtVAPB protein sequesters its WT counterpart into ubiquitin, p62 and TDP-43 
positive inclusion bodies within the cytoplasm of residual MNs and glia of the CNS 
(Teuling et al 2007). Aggregation in this manner has been shown to elicit the UPR 
which is expected to lead to an increase in vulnerability to ER stress (Gkogkas et al 
2008, Ling et al 2013, Su et al 2014, Suzuki et al 2009). Another implication of a 
loss of function of WT VAPB is the disruption of ephrin (Eph) receptor mediated 
signalling via a reduction in ligand availability from the cleavage and secretion of 
VAPB amino-terminal domains that would ordinarily serve to protect the cells 
against glutamate excitotoxicity (Section 1.2.4.2) (Tsuda et al 2008).                      
 
1.2.5.1.6 FIG4  
The FIG4 gene encoding the phosphoinositide 5-phosphatase enzyme, situated at 
the chromosome 6q21 locus (Table 1.1), is reported to account for around 2% of 
AD inherited adult onset ALS (ALS11) and PLS (Section 1.2.2.2) cases in addition to 
having been identified as a cause of the AR inherited juvenile onset CMT4J (Charcot 
Marie Tooth type 4J); a severe and rapidly progressive sensory & motor peripheral 
neuropathy (Chow et al 2009, Chow et al 2007, Verdiani et al 2013). Its function is 
to regulate the cellular abundance of the signalling lipid phosphatidylinositol 3, 5-
bisphosphate [PI(3,5)2] which has been implicated in aspects of autophagy as well 
as retrograde membrane transport through the trans-Golgi network (Ferguson et al 
2010, Iguchi et al 2013, Rutherford et al 2006, Zhang et al 2007).                       
 
1.2.5.1.7 OPTN  
The optineurin (OPTN) gene, situated at the chromosome 10p13 locus (Table 1.1), 
was originally identified as a major cause of primary open angle glaucoma (POAG) 
(Fuse et al 2004, Huang et al 2014, Rezaie et al 2002, Xiao et al 2009) and more 
recently Paget’s disease of bone (PDB) (Albagha et al 2010, Chung et al 2010). In 
2010, Maruyama and colleagues described a deleterious heterozygous c.1743A>G 
(p.E478G) missense substitution, c.1502C>T (p.Q398X) truncation and an exon five 
deletion in three Japanese consanguineous families which co-segregated with an 
AD/AR inherited form of adult-onset ALS (ALS12). Subsequent studies reported 
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mutations in OPTN to be a relatively rare occurrence in Caucasian populations of 
North European or Scandinavian descent (~0.2%) (Chio et al 2012b, Kenna et al 
2013, Tumer et al 2012, van Blitterswijk et al 2012c, Weishaupt et al 2013). The 
gene itself encodes the ubiquitously expressed 67kDa cytosolic optic neuropathy 
inducing protein that has been shown to play a key role in cellular morphogenesis, 
membrane trafficking and transcriptional activation in addition to vasoconstriction 
and host defence against viral pathogens (Kachaner et al 2012, Renton et al 2014). 
So far, two plausible mechanisms of action have been proposed in order to explain 
the neurotoxicity of mutant optineurin towards MN’s in ALS: 1) Loss of function of 
the WT protein lifts inhibition of activation of the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) transcriptional regulator complex to induce 
mitochondrial apoptotic signalling cascades and programmed cell death or 2) Gain 
of function mediated by an impaired autophagosome system and the subsequent 
accumulation of toxic intracellular protein aggregates (Akizuki et al 2013, Korac et 
al 2013).                            
 
1.2.5.1.8 ERBB4  
Recently, two single nucleotide variants (SNV’s) of reduced penetrance in the v-erb 
-b2 avian erythroblastic leukemia viral oncogene homolog 4 (ERBB4) gene, situated 
at the chromosome 2q33-q34 locus (Table 1.1), have been identified through whole 
genome sequencing (WGS) and linkage analysis as a rare cause of AD inherited 
adult onset ALS (ALS19) in three pedigrees of Japanese or Canadian descent. Signs 
of UMN and LMN involvement (Section 1.1.3) were prominent in all affected family 
members with a distinct lack of overt cognitive dysfunction (Takahashi et al 2013). 
The disease course was relatively slow, with a median survival of greater than five 
years. The c.2780G>A (p.R927Q) alteration occurring within the protein’s tyrosine 
kinase domain is associated with an older than anticipated age of symptom onset 
peaking in the mid-sixties or early seventies, whereas the less common c.3823C>T 
(p.R1275W) substitution at the highly conserved C-terminal region is associated 
with a younger onset ALS of around 45 years. ERBB4 is a member of the epidermal 
growth factor (EGF) receptor family and is one of four structurally related proteins 
which are modulated through autophosphorylation upon neuregulin-1 (NRG1) 
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binding (Takahashi et al 2013). ERBB4 knock-down in mice is demonstrated to be 
embryonically lethal (Gassmann et al 1995) and in the residual MN’s of autopsy 
derived human post-mortem SC tissue depleted levels of the cysteine-rich domain 
(CRD) containing isoforms of NRG1 have been detected (Song et al 2012), further 
implicating the NRG1-ERBB signalling pathway as another plausible mechanism of 
pathogenicity in ALS (Takahashi et al 2013).                             
 
1.2.5.1.9 MATR3  
NGS approaches have identified several missense substitutions (n=4) in the matrin 
3 (MATR3) gene, situated at the chromosome 5q32.2 locus (Table 1.1), as a cause of 
AD inherited adult onset ALS (ALS21) (Johnson et al 2014, Millecamps et al 2014) 
or vocal cord and pharyngeal weakness with distal myopathy (VCPDM) (Muller et 
al 2014, Senderek et al 2009, Yamashita et al 2014) in four large, multigenerational 
pedigrees of North European descent. Sequencing data obtained from an additional 
204 UK patients suggest that mutations occur at a frequency of 2.75% for FALS and 
<1% of SALS cases. Clinical manifestations include widespread UMN and LMN signs 
with evidence of a ‘split-hand’ pattern of weakness, brisk tendon reflexes, extensor 
plantar responses, increased jaw jerk with clonus, fasciculations, severe wasting of 
the tongue and respiratory dysfunction with normal cognition and a relatively slow 
disease course of up to 15 years. Neuropathological evaluations of human derived 
post-mortem SC tissue from patient carriers and non-carriers of a MATR3 mutation 
revealed universal matrin-3 proteinopathy in residual MN’s with intense nuclear 
staining and occasional, more diffuse cytoplasmic staining (Johnson et al 2014). The 
gene encodes an RNA and DNA binding domain containing nuclear matrix protein 
of 125kDa that has been shown to interact with TDP-43 (Section 1.2.5.2.1) (Salton 
et al 2011). Its importance in the neurodegenerative disease process is not yet well 
understood, although it is known to function in aspects of RNA processing including 
the nuclear retention of hyper-edited RNA’s and mRNA transport, DNA repair and 
gene silencing/chromatin remodelling (Hock et al 2007, Zhang & Carmichael 2001). 
 
1.2.5.1.10 Other Rare Genetic Causes of FALS 
Additional loci that have been implicated in the pathogenesis of AD inherited forms
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of the disease, for which a designated ALS number has not yet been assigned in the 
ALSoD (alsod.iop.kcl.ac.uk) (Abel et al 2013) either due to lack of evidence regarding 
transmission (i.e. low penetrance) or its rarity, are summarised in Table 1.2.  
 
Gene Name Locus Reference 
ARHGEF28 Rho guanine nucleotide exchange 
factor (GEF) 28  
5q13 (Droppelmann et al 
2013) 
CHCHD10 coiled-coil-helix-coiled-coil-helix 
domain containing 10 
22q11 (Bannwarth et al 2014) 
DAO D-amino-acid oxidase  12q24 (Mitchell et al 2010) 
DCTN1 dynactin 1 2p13 (Puls et al 2003) 
EWSR1 Ewing’s sarcoma breakpoint region 
1 
22q12.2 (Couthouis et al 2012) 
HNRNPA2B1 heterogeneous nuclear 
ribonucleoprotein A2/B1 
7p15 (Kim et al 2013) 
LMNB1 lamin B1 5q23 (Johnson et al 2014) 
NEFH neurofilament, heavy polypeptide 22q12-q13 (Figlewicz et al 1994) 
PRPH peripherin  12q12 (Gros-Louis et al 2004) 
SPAST spastin 2p24-p21 (Meyer et al 2005) 
SQSTM1 sequestosome 1 5q35 (Rubino et al 2012) 
TAF15 TAF15 RNA polymerase II, TATA box 
binding protein 
17q11.1-q11.2 (Couthouis et al 2011) 
 




1.2.5.1.11 Genetic Susceptibility Factors and Other Rare Causes of SALS   
It has been documented that the majority of patients diagnosed with ALS, between 
90 and 95%, will have developed an idiopathic form of the condition for which the 
cause(s) are still largely unknown (Byrne et al 2011). Estimates of heritability from 
studies conducted using twin data are predicted to lie between 0.38 and 0.78 (Al-Ch 
alabi et al 2010). A 17 and 9-fold increase, respectively in the relative lifetime risk of 
the siblings and progeny of sporadic index cases in a large Swedish population based 
study has also been reported (Fang et al 2009, Hanby et al 2011). This is indicative 
of SALS being multifactorial in origin with a combination of complex genetic effects 
and environmental risk factors such as heavy metal exposure (e.g. lead, manganese 
and mercury) (Wang et al 2014), cigarette smoking (Armon 2009), de Jong et al 20 
12, Gallo et al 2009), lifetime physical activity (Huisman et al 2013) and traumatic 
head injury (Pupillo et al 2012, Schmidt et al 2010) contributing to its aetiology (Wi-
ngo et al 2011).  
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Both clinically and pathologically, SALS patients are virtually indistinguishable from 
their FALS counterparts suggesting that they share common mechanisms which un-
derlie MN degeneration (Section 1.2.4) (Wijesekera & Leigh 2009). Indeed in a small 
proportion of cases, fewer than 10%, mutations have been identified within the co-
ding regions of causal candidate genes of FALS including C9ORF72 (Section 1.2.5.4), 
SOD1 (Section 1.2.5.1.1), TARDBP (Section 1.2.5.2.1) and FUS (Section 1.2.5.2.2) (An 
dersen & Al-Chalabi 2011, Rademakers & van Blitterswijk 2013, van Blitterswijk et 
al 2012a). In most instances, however, the genetic component has yet to be determ-
ined. Genome-wide association studies (GWAS) appeared, at least initially, to have 
highlighted a number of promising susceptibility loci, including 9p21 (Section 1.2.5. 
4) which led to the discovery of a large, intronic hexanucleotide repeat expansion in 
C9ORF72 (Renton et al 2011, DeJesus-Hernandez et al 2011) that is now thought to 
account for up to 43% of FALS and ~7% of apparently SALS cases (Cooper-Knock et 
al 2012b). Disappointingly, however, many GWAS findings are associated with risk 
alleles that have small odds ratios (OR’s) and have yet to be convincingly replicated 
(Chio et al 2009b, Cronin et al 2009, Daoud et al 2010, Fernandez-Santiago et al 20 
11, Fogh et al 2011, Iida et al 2011, Kwee et al 2012, Nicholl et al 1999, Schymick et 
al 2007, van Es et al 2009b). In a recent report, published by Koppers et al (2013), 
sequencing of exons of potential candidate genes from several of these studies, inc-
luding UNC13A and C9ORF72 (Table 1.3), failed to establish a significant enrichment 
of coding variants in a large (n=2,122) SALS case-control population (Leblond et al 
2014, Renton et al 2014) of Dutch descent. This provides evidence in support of the 
proposition of a rare variant hypothesis: Rather than the associated SNP or micros-
atellite marker representing a signpost that reflects the effects of a common proxim-
al causal site it is now anticipated that there are multiple, rare and distant variants 
of substantially higher impact which are responsible for producing so called synth-
etic associations. In this scenario, a significant number of potential hits are expected 
to go undetected, not as a consequence of many individuals sharing identical weak 
effect variants, but because minority groups of SALS patients are likely to each har-
bour a different high impact variant (Dickson et al 2010, Robinson 2010).  
The spontaneous occurrence of de novo mutations are also a possibility (Alexander 
et al 2002, Calvo et al 2014a, Chio et al 2011b, DeJesus-Hernandez et al 2010, Laffita- 
26 
 
Gene Name Locus Reference 
ALAD aminolevulinate dehydratase 9q33.1 (Kamel et al 2003) 
C9ORF72 chromosome 9 open reading frame 72 9p21.2 (Ahmeti et al 2013; Laaksovirta et al 
2010; Le Ber et al 2009; Morita et al 
2006; Shatunov et al 2010) 
CABIN1 calcineurin binding protein 1 22p11 (Deng et al 2013b) 
CAMK1G calcium/calmodulin-dependent protein kinase IG  1q32 (Deng et al 2013b) 
CENPV centromere protein V 17p11.2 (Ahmeti et al 2013) 
CRYM crystallin, mu 16p12 (Daoud et al 2011) 
CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6 22q13.1 (Siddons et al 1996) 
DPP6 dipeptidyl-peptidase 6 7q36.2 (Cronin et al 2008; van Es et al 2008) 
ELP3 elongator acetyltransferase complex subunit 3 8p21.1 (Simpson et al 2009) 
FGGY FGGY carbohydrate kinase domain containing  1p32 (Chio et al 2009b; van Es et al 2009b)  
ITPR2 inositol 1,4,5-triphosphate receptor type 2 12p12.1-p11.23 (van Es et al 2007) 
KIFAP3 kinesin-associated protein 3 1q24.2 (Landers et al 2009) 
LIF leukemia inhibitory factor 22q12.2 (Giess et al 2000; Meyer & Potter 1995) 
LUM lumican 12q21.3 (Daoud et al 2011) 
OGG1 8-oxoguanine DNA glycosylase 1 3p26 (Coppede et al 2007) 
PLCD1 phospholipase C, delta 1 3p22.2 (Staats et al 2013) 
SUSD2 sushi domain containing 2 22p11 (Deng et al 2013b) 
UNC13A unc-13 homolog A (C. elegans) 19p13.12 (Ahmeti et al 2013; van Es et al 2009c) 
 
Table 1.3 Genetic Susceptibility Loci Implicated in the Pathogenesis of SALS 
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Mesa et al 2013, Zou et al 2013a). Whole exome sequencing of 47 SALS trio pedigr-
ees [i.e. the proband and both unaffected parents] led to the identification of novel 
changes in SS18L1 (alternatively named calcium-responsive transactivator (CREST)) 
(Chesi et al 2013); a subunit of the neuronal chromatin remodelling (nBAF) complex 
that has since been independently verified in a French cohort comprising a further 
87 FALS patients (Teyssou et al 2014).                
 
1.2.5.2 ALS-FTLD Loci   
1.2.5.2.1 TARDBP  
Transactive response (TAR) DNA binding protein 43kDa (TARDBP), situated at the 
chromosome 1p36.23 locus (Table 1.1), is a cause of AD inherited adult onset ALS 
(ALS10), bvFTLD and the combined ALS-FTLD syndrome (Borroni et al 2009, Chio 
et al 2010, Kabashi et al 2008, Kovacs et al 2009, Sreedharan et al 2008, Yokoseki 
et al 2008). More than 40 mutations primarily occurring in the C-terminus of the 
gene (Abel et al 2013, Renton et al 2014), a region considered important for normal 
protein-protein interactions and ribonucleoprotein (RNP) binding, are now thought 
to account for 4-5% of FALS cases with fewer than 2% of SALS and bvFTLD patients 
affected (Al-Chalabi et al 2012, Gitcho et al 2008, Lattante et al 2013, Van Deerlin 
et al 2008). A trend towards a “classical ALS” phenotype is observed with a slightly 
earlier than anticipated age of symptom onset, moderately prolonged survival and 
predominant upper limb involvement (Corcia et al 2012). Originally identified as a 
protein that bound the TAR element of human immunodeficiency virus (HIV), TDP-
43 comprises nuclear export and import signals in addition to two RNA recognition 
motifs (RRMs) and a glycine rich, low sequence complexity PrLD (King et al 2012). 
Under normal physiological conditions it is ubiquitously expressed and is regarded 
to be essential for the regulation of gene transcription as well as multiple aspects of 
RNA metabolism including but not limited to microRNA (miRNA) biogenesis, stress 
granule (SG) formation, precursor messenger RNA (pre-mRNA) splicing, transport 
& stability, long non-coding RNA (lncRNA) processing and chromatin remodelling 
(Buratti & Baralle 2012, Lagier-Tourenne et al 2010, Polymenidou et al 2012). It is 
also known to bind a UG-rich sequence in intron 8 of the CFTR gene (cystic fibrosis 
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transmembrane conductance regulator) in order to promote pathological skipping 
of exon 9 in patients with cystic fibrosis (CF) (Buratti et al 2004, Buratti et al 2001, 
Lukavsky et al 2013). Moreover, it has also been demonstrated to act as a scaffold 
for nuclear bodies (NB’s) through its interaction with the SMN protein (Wang et al 
2002).     
The pathogenicity of mtTDP-43 towards MN’s in ALS is not fully understood and it 
remains uncertain as to whether toxicity arises from a loss of function mechanism, 
gain of function mechanism or indeed a combination of the two (Iguchi et al 2013, 
Ling et al 2013, Su et al 2014, Vanden Broeck et al 2014). At steady state, TDP-43 is 
concentrated in the nucleus where it carries out the majority of its activities (Ayala 
et al 2008, Winton et al 2008). Aberrant shuttling of TDP-43, however, results in its 
depletion from the nucleus and redistribution into the cytoplasm (Che et al 2011, 
Highley et al 2014, Polymenidou et al 2011, Tollervey et al 2011, Van Deerlin et al 
2008). Within the cytoplasm, the mislocalised protein forms aggregates which are a 
major constituent of neuronal and glial inclusion bodies which are immunoreactive 
for ubiquitin and p62 but negative for α-synuclein and the microtubule associated 
protein, tau (Arai et al 2006, Neumann et al 2006). These are present in more than 
ninety percent of non-SOD1 linked FALS and SALS cases as well as a subset of FTLD 
patients (~50%) who may or may not carry a mutation in the TARDBP gene (Ling et 
al 2013, Mackenzie et al 2007, Renton et al 2014, Tan et al 2007).                               
 
1.2.5.2.2 FUS  
Missense mutations (n=78) in the fused in sarcoma or translocated in liposarcoma 
(FUS/TLS) gene, situated at the chromosome 16p11.2 locus (Table 1.1), account for 
a further 4-5% of AD inherited adult onset ALS (ALS6) as well as rarer instances of 
the combined ALS-FTLD syndrome (<1%) (Abel et al 2013, Kwiatkowski et al 2009, 
Van Langenhove et al 2010, Vance et al 2009). Approximately equal proportions of 
male and female patients are affected (Kinsley & Siddique 2001). Penetrance of the 
disease varies widely between pedigrees with 50 to 70% of individuals developing 
symptoms by the time they have reached their fifth decade and more than ninety 
percent becoming symptomatic before the age of 71 (Blair et al 2010). Phenotypes 
associated with some of the most common pathological changes resemble those of 
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“classical ALS” (Section 1.2.1) that are characterised by predominant lower limb 
involvement, median onset of 45 years and an average disease duration of between 
30 and 48 months (Groen et al 2010, Iguchi et al 2013, Millecamps et al 2010, Yan 
et al 2010). The gene encodes a ubiquitously expressed DNA/RNA binding protein 
that shares considerable structural and functional homology with TDP-43 (Renton 
et al 2014, Su et al 2014). It contains a nuclear export and import signal, RRMs, two 
arginine rich regions and a glycine rich, low complexity PrLD (King et al 2012) and 
is involved in many of the same activities which relate to genomic maintenance, SG 
formation and RNA metabolism/processing (Lagier-Tourenne et al 2010, Ling et al 
2013). Both TDP-43 and FUS are found to associate with the survival motor neuron 
(SMN) complex that is important for the regulation of the spliceosome (Tsuiji et al 
2013, Yamazaki et al 2012). Additionally, FUS has also been implicated in the DNA 
damage response & repair pathways (Wang et al 2013). The precise mechanism by 
which mutant forms of the protein exert their neurotoxicity towards MNs in ALS is 
not known. However, in a similar manner as was described previously for TDP-43 
(Section 1.2.5.2.1), aberrant shuttling of mtFUS is expected to result in its depletion 
from the nucleus and the subsequent accumulation of misfolded aggregates within 
the cytoplasm which has led to both a loss of as well as gain of function mechanism 
having been proposed (Su et al 2014, Therrien & Parker 2014). It is of interest to 
note that mutation specific patterns of FUS pathology have been recorded which are 
found to correlate with disease severity. Round basophilic NCI’s, for example, are 
associated with a rapidly progressive, young onset variant of ALS which begins in 
the late teens or early twenties (Baumer et al 2010) whereas tangle-like inclusions 
in residual MN’s and glia of the CNS are a pathological feature of the more typical 
late onset ALS (Ling et al 2013, Mackenzie et al 2011).                                
 
1.2.5.2.3 ANG  
Mutations of low penetrance in the gene encoding angiogenin (ANG), situated at the 
chromosome 14q11.2 locus, have been identified in rare instances of AD inherited 
adult onset ALS (ALS9) (Table 1.1), ALS-FTLD or PD of predominantly Scottish or 
Irish ancestry (Greenway et al 2006, Kirby et al 2013, Rayaprolu et al 2012, van Es 
et al 2009a, van Es et al 2011, Zou et al 2012). Patient carriers are characterised in 
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approximately two-thirds of cases by a predominantly bulbar phenotype with a 
rapid decline in respiratory function that requires mechanical ventilation support, 
usually within the first 12 months of the initial manifestation of disease (Section 1. 
1.4) (Greenway et al 2006, Seilhean et al 2004). ANG is a secreted protein found in 
serum. It is a member of the pancreatic ribonuclease (RNase) A superfamily and is 
a potent inducer of neovascularisation which shares functional homology with the 
vascular endothelial growth factor (VEGF); a potential modifier of ALS progression 
(Lambrechts et al 2003, Seilhean et al 2009) . Under hypoxic conditions, angiogenin 
binds actin at the outer surface of the endothelial cells where it is internalised and 
transported into the nucleus. Here it is responsible for stimulating stress induced 
ribosomal RNA (rRNA) transcription, a rate limiting step which has implications for 
ribosome biogenesis, protein maturation and ultimately cellular growth & survival 
(Greenway et al 2006, Yamasaki et al 2009). Treatment with exogenous ANG even 
after the initial onset of symptoms improved motor function in SOD1G93A mice and 
increased life expectancy which has led to the postulation that the WT protein may 
play an important neuroprotective role within the mammalian system (Kieran et al 
2008, Sebastia et al 2009).                 
 
1.2.5.2.4 ATXN2  
Intermediate length polyglutamine (polyQ) tracts of 27 to 33 CAG repeats in exon 1 
of Ataxin 2 (ATXN2), situated at the chromosome 12q24.12 locus (Table 1.1), have 
recently been confirmed in a minority of cases with a rare AD inherited adult onset 
form of ALS (ALS13) (~1%) and bvFTLD with non-fluent aphasia (<5%) (Elden et 
al 2010, Lee et al 2011, Ross et al 2011). Expansions of more than 34 CAG repeats 
have also been associated with PD (Section 1.2.1) and spinocerebellar ataxia type 2 
(SCA2) (Gwinn-Hardy et al 2000, Imbert et al 1996, Nanetti et al 2009). Typically, 
patient carriers have a M:F ratio of 1.5:1 with signs of UMN and LMN dysfunction 
becoming apparent in the sixth or seventh decade and an average disease duration 
of approximately two to five years. Clinical manifestations include brisk deep tendon 
reflexes, pronounced fasciculations and weakness & spasticity of all four limbs (Van 
Langenhove et al 2012). Neuronal intranuclear inclusion bodies (NII’s) positive for 
polyQ and p62 (sequestosome) are primarily concentrated within the pontine nuclei 
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with more widespread TDP-43 proteinopathy apparent in the neocortex and SC. It 
has been shown to act in vitro and in vivo in an RNA dependent manner in order to 
influence TDP-43 toxicity, although the exact mechanism by which ATXN2 mutations 
cause MN degeneration in ALS is not fully understood (Baumer et al 2014, Elden et 
al 2010).       
                         
1.2.5.2.5 VCP  
Valosin-containing protein (VCP), situated at the chromosome 9p13.3 locus (Table 
1.1), is a rare genetic cause of AD inherited adult onset forms of HSP (de Bot et al 
2012), CMT (Gonzalez et al 2014), ALS (ALS14) (~1-2%) (Abramzon et al 2012), 
ALS-FTLD and IBMPFD/ALS (Bersano et al 2009, Gidaro et al 2008, Haubenberger 
et al 2005, Watts et al 2004, Weihl et al 2009); a multisystem disorder of variable 
penetrance which is characterised by FTLD with inclusion body myopathy (IBM) 
and PDB. Clinical manifestations of IBM and PDB which include atrophic, angulated 
muscle fibres and rimmed vacuoles with unremarked inflammation and an elevated 
rate of osteoclastic bone resorption may be apparent at the age of 40 (Daroszewska 
& Ralston 2006, Spina et al 2013) with evidence of impaired executive functioning 
and behavioural abnormalities or UMN and LMN signs not normally evident until 
the fifth or sixth decade (Gonzalez-Perez et al 2012, Jacquin et al 2013). Ubiquitin 
immunoreactive, TDP-43 positive NII’s and dystrophic neurites (DN’s) with some 
VCP staining and occasional NCI’s are a prominent feature upon neurohistochemical 
evaluation (Forman et al 2006, Guyant-Marechal et al 2006). The VCP protein is a 
molecular chaperone of the AAA superfamily [adenosine triphosphatase (ATPase) 
associated with diverse cellular activities] that has been implicated in a diverse 
array of cellular processes from transcriptional activation of the NF-κB signalling 
cascade to mechanisms of double-stranded DNA break (DSB) repair, membrane 
fusion and protein degradation (Ju et al 2009, Vandermoere et al 2006, Vij 2008, 
Wolf & Stolz 2012, Zhang et al 2000). An in vitro loss of function mutation affecting 
the cell division control (CDC48) domain of exon 5 in neuroblastoma SH-SY5Y cell 
lines resulted in mislocalization of TDP-43 to the cytosol, ER stress and impaired 
proteasome activity with a concomitant increase in the extent of caspase mediated 
apoptosis (Gitcho et al 2009).       
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1.2.5.2.6 UBQLN2  
Mutations of the ubiquilin 2 (UBQLN2) gene, situated at the chromosome Xp11.2.1 
locus (Table 1.1), are responsible for 2% of FALS and FTLD cases (Deng et al 2011, 
Gellera et al 2013, Synofzik et al 2012, Williams et al 2012) and a further 0.4% of 
SALS cases (Daoud et al 2012a). Originally found to co-segregate with the disease 
in a five generation kindred of 19 ALS (ALS15)/ALS-FTLD affected family members 
both adult and juvenile onset forms have now been reported. The genetic trait has 
a dominant mode of transmission that exhibits incomplete penetrance (Deng et al 
2011). Clinical manifestations include symptoms of dysarthria and dysphagia with 
spastic paralysis of the limbs and diminished fine motor dexterity which may occur 
in the presence or absence of behavioural and executive function deficits that are 
associated with FTLD (Fahed et al 2014). Age at diagnosis ranges between 16 and 
71 years with a mean of 33.9±14 or 47.3±11 years for male and female patients, 
respectively and average survival of approximately 3 to 4 years. At autopsy, brain 
atrophy, AHC loss, CST degeneration and astrogliosis of the SC are apparent (Deng 
et al 2011, Gellera et al 2013). Ubiquitinated, p62 positive skein-like or compact 
ubiquilin 2 immunoreactive inclusion bodies that co-localise with TDP-43 (Section 
1.2.5.3.1), FUS (Section 1.2.5.3.2) or OPTN (Section 1.2.5.1.7) but not SOD1 (Section 
1.2.5.1.1) or tau protein (Section 1.2.5.2.1) have been described (Fahed et al 2014, 
Nolle et al 2013, Williams et al 2012). Single base substitutions in the N-terminal 
proteasome binding domain (PBD) (Daoud et al 2012a) or the PXX tandem repeat 
of the collagen-like region that is important for protein-protein interactions (Deng 
et al 2011, Fahed et al 2014) impair the normal function of ubiquilin 2 which leads 
to disturbances in autophagy, the UPS (Zhang et al 2014) and ER-associated protein 
degradation (ERAD) pathway (Xia et al 2014).                                 
 
1.2.5.2.7 SIGMAR1  
The ER chaperone SIGMAR1 (sigma non-opioid intracellular receptor 1), situated 
at the chromosome 9p13.3 locus (Table 1.1), has been identified as a genetic cause 
of AD inherited ALS-FTLD and pure FTLD in three Caucasian pedigrees of Australian 
or Polish ancestry (Luty et al 2010). A nonpolymorphic c.672*51G>T substitution 
which affects the three prime (3’) untranslated region (UTR) was shown to disrupt 
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mRNA splicing and transcript stability. This led to an increase in expression and a 
higher abundance of the SIGMAR1 protein in human post-mortem brain tissue and 
patient derived lymphocytes. In vitro experimentation also found overexpression 
of SIGMAR1 to result in an aberrant 2.30 or 5.20-fold induction, respectively, in the 
nuclear-cytoplasmic shuttling of TDP-43 (Section 1.2.5.3.1) and FUS (Section 1.2.5. 
3.2) (Luty et al 2010). Soon thereafter, a deleterious c.304G>C (p.E102Q) missense 
mutation in an evolutionary conserved residue of the transmembrane domain that 
is important for ligand binding was also identified as a cause of a rare AR inherited   
form of juvenile onset ALS (ALS16) (Table 1.1). Symptoms of lower limb weakness 
and spasticity in the absence of bulbar or respiratory signs were accompanied by 
exaggerated tendon reflexes and a typically slower than anticipated disease course 
(Al-Saif et al 2011). TDP-43 and FUS immunoreactive inclusions were prominent in 
the pyramidal cells of the cerebral cortex and hippocampal neurones of the dentate 
gyrus (Luty et al 2010). SIGMAR1 is a ubiquitously expressed protein considered to 
have neuroprotective effects under normal physiological conditions (Hayashi & Su 
2004, Katnik et al 2006). It is important for maintaining aspects of learning and 
memory as well as having been implicated in the unfolded protein response (UPR), 
lipid raft formation and neurite outgrowth (Al-Saif et al 2011, Hayashi & Su 2003). 
Specifically, it has been shown to play a critical role in Ca2+ homeostasis, autophagy 
and mitochondrial cytochrome c mediated programmed cell death in response to 
ER stress and glutamate excitotoxicity (Section 1.2.4.2) (Prause et al 2013, Vollrath 
et al 2014).                                  
 
1.2.5.2.8 CHMP2B 
Heterozygous missense substitutions identified in the charged multivesicular body 
protein 2b (CHMP2B) gene (n=6), situated at the chromosome 3p12.1 locus (Table 
1.1), are a rare cause of AD inherited adult onset ALS (ALS17) and bvFTLD (<1%) 
which also account for ~10% of instances involving PMA (Section 1.2.2.3) (Cox et 
al 2010, Ghanim et al 2010, Isaacs et al 2011, Momeni et al 2006, Parkinson et al 
2006, Skibinski et al 2005). Towards the motor end of the spectrum the disease is 
characterised by a predominantly LMN phenotype. Clinical manifestations typically 
include a flaccid, atrophic tongue with severe fasciculations, dysarthria & dysphagia, 
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dyspnoea (a shortness of breath), respiratory muscle weakness, bilateral wasting of 
the intrinsic hand muscles and an abnormal flexor plantar response with brisk deep 
tendon reflexes. Age and site of onset varies considerably and along with survival, 
which has a range spanning 15 months to 5½ years, appears to be mutation specific. 
Pathologically, CHMP2B cases are hallmarked by the presence of ubiquitinated p62 
and TDP-43 immunoreactive inclusion bodies in surviving MN’s of the cortex and 
ventral horn of the SC which stain negatively for the microtubule associated protein, 
tau and α-synuclein. There is also a lack of overt extramotor signs with substantial 
microglial activation occurring in subcortical regions (Cox et al 2010, Parkinson et 
al 2006).                
The CHMP2B protein forms an essential component of the third endosomal sorting 
complex required for transport (ESCRT)-III; responsible for surrendering ubiquitin 
tagged cargo to multivesicular bodies (MVB’s) which ultimately deliver them to the 
lysosomal machinery for degradation (Henne et al 2011, Skibinski et al 2005). An 
exon 6 mutation of the gene’s acceptor splice site at the intron/exon boundary that 
produces a C-terminal truncated protein has been shown to disrupt this pathway 
(Han et al 2012, Urwin et al 2010, van der Zee et al 2008) leading to disturbances 
in intracellular Notch signalling and eye irregularities in the Drosophila invertebrate 
system (Cheruiyot et al 2014).                                           
 
1.2.5.2.9 PFN1 
Missense substitutions of incomplete penetrance (n=7) concentrated within or in 
close proximity to the actin binding domain of the profilin 1 (PFN1) gene, situated 
at the chromosome 17p13.2 locus (Table 1.1), are responsible for rare instances of 
AD inherited adult onset ALS (ALS18) (~1-2%) and bvFTLD (~0.5%) with a small 
number of SALS patients (~0.2%) also affected (Chen et al 2013, Ingre et al 2013, 
Tiloca et al 2013, van Blitterswijk et al 2013a, Wu et al 2012a, Yang et al 2013). In 
a meta-analysis of 5,118 cases and 13,089 neurologically healthy controls in the 
UK population an odds ratio (OR) of 2.44 (p<0.05) was produced for the dinucleotide 
variant c.350A>G (p.E117G) in exon 3 (Fratta et al 2014). The minor allele (T) of a 
synonymous c.334C>T (p.L112L) single nucleotide polymorphism (SNP) (rs13204) 
has also been reported to be a disease modifier of SALS in China with an OR of 0.73 
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(p<0.005) (Chen et al 2013). Phenotypic heterogeneity exists with bulbar or spinal 
onset occurring in the late twenties to early seventies and a median survival which 
spans a minimum of 36 months to almost three decades (Chen et al 2013, Ingre et 
al 2013, Wu et al 2012a). Upon neurohistochemical evaluation, TDP-43 pathology 
is observed with the presence of ubiquitinated, p62 positive inclusion bodies that 
are not immunoreactive for PFN1 (van Blitterswijk et al 2013a). Profilin 1 encodes 
a 140 amino acid peptide that is ubiquitously expressed and has been found to 
associate with SG’s; cytoplasmic RNP granules composed of repressed translation 
complexes (Figley et al 2014). It is a major growth regulator that is required for the 
conversion of monomeric or globular (G)-actin into filamentous (F)-actin which is 
essential for actin polymerization (Mockrin & Korn 1980). In primary MN’s which 
express mtPFN1, evidence of growth cone arrest and morphological deficits were 
apparent with a marked reduction in the ratio of (F) to (G)-actin (Wu et al 2012a). 
Homozygous knock-out (KO) mice were not viable, demonstrating embryonic 
lethality in an in vivo study conducted by Witke et al (2001) whilst heterozygous 
littermates exhibited a significantly shortened lifespan.                                            
 
1.2.5.2.10 HNRNPA1 
Exome sequencing and linkage analysis has recently highlighted the heterogeneous 
ribonucleoprotein A1 (HNRNPA1) gene, situated at the chromosome 12q13.1 locus 
(Table 1.1), as a rare cause of AD inherited adult onset ALS (ALS20) and IBMPFD/ 
ALS with FTLD (Section 1.2.5.2.5), otherwise known as multisystem proteinopathy 
(MSP), in a four generation kindred of American ancestry. Subsequent screening of 
a large FALS (n=212) and SALS (n=305) cohort identified two additional missense 
substitutions in the C-terminal, glycine-rich PrLD of isoform a and b at a frequency 
of 0.47 or 0.32%, respectively (Kim et al 2013). HNRNPA1 encodes an RNA binding 
protein that has been found to interact with TDP-43 (Section 1.2.5.2.1) (Buratti et 
al 2005). It has the propensity to form spontaneously into self-seeding fibrils which 
is exacerbated by the presence of a disease causing mutation. In a Drosophila model 
that recapitulates many of the human pathological hallmarks of ALS-FTLD including 
TDP-43 proteinopathy defective isoforms of hnRNPA1 accelerated the accumulation 
of the protein into SG’s and drove the formation of ubiquitinated, p62 and TDP-43 
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positive NCI’s (King et al 2013).           
 
1.2.5.3 FTLD Loci   
1.2.5.3.1 MAPT  
The microtubule associated protein tau (MAPT) gene, situated at the chromosome 
17q21.32 locus, is associated with as many as 50% of familial FTLD cases (Hutton 
et al 1998, Onyike & Diehl-Schmid 2013, Rademakers et al 2004, Riedl et al 2014, 
Sieben et al 2012). Since its discovery almost two decades ago more than 40 genetic 
alterations/splicing defects and a further two extended haplotypes, namely H1 and 
H2 have been described (Park & Chung 2013). Patient carriers typically have a M:F 
ratio of 1.25:1 (n=8) with a median age at symptom onset of less than 50 years and 
an average disease duration of 9.40±5.0 years (Karageorgiou & Miller 2014, Le Ber 
2013, Van Langenhove et al 2013). Symmetric frontal lobe atrophy, a characteristic 
feature upon neuroimaging of MAPT mutations in FLTD (Boeve & Hutton 2008), is 
linked to behavioural abnormalities, personality changes and dementia with rigid 
akinetic Parkinsonism & oculomotor dysfunction (Espay & Litvan 2011, Haugarvoll 
et al 2007, Park & Chung 2013, Slowinski et al 2007). At protein level, pathogenicity 
is conferred through a loss of function or haploinsufficiency mechanism whereby 
microtubule assembly and axonal transport is impaired, leading to an accumulation 
of hyperphosphorylated tau filaments which form aggregates within the cytoplasm 
of residual MNs and microglia of the CNS (Brandt et al 2005, Gasparini et al 2007, 
Goedert et al 2012, Iovino et al 2014, Robinson et al 2014).                                               
 
1.2.5.3.2 PGRN 
Mutations in the progranulin (PGRN) gene, situated at the chromosome 17q21.31 
locus that is in close proximity to MAPT (Section 1.2.5.3.1) (Karageorgiou & Miller 
2014), are thought to account for a further 5 to 25% of familial FTLD cases (Baker 
et al 2006, Pan & Chen 2013, Sieben et al 2012). So far at least sixty-seven different 
genetic alterations of pathological significance have been reported in the literature 
(Park & Chung 2013); giving rise to a heterogeneous clinical phenotype that varies 
greatly from bvFTLD or PNFA without apraxia of speech to semantic dementia and 
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corticobasal syndrome (CBS) (Beck et al 2008, Le Ber et al 2008, Puoti et al 2014, 
Snowden et al 2006). Patient carriers typically have a M:F ratio of 0.69:1 (n=27) 
with median age at symptom onset of 60 years and an average survival of 5.80±1.9 
years (Van Langenhove et al 2013). Initial manifestations may include behavioural 
abnormalities & personality changes as well as rigid akinetic Parkinsonism and 
language impairment (Boeve & Hutton 2008, Haugarvoll et al 2007). Evidence of 
asymmetric frontal lobe atrophy which extends to the temporal/inferior parietal 
lobes is present upon MRI (Rohrer et al 2010, Whitwell et al 2009). Reactive gliosis 
and white matter disease pathology have also been found to be prominent features 
of PGRN mutations (Kelley et al 2009, McMillan et al 2014). Moreover, tau negative 
and TDP-43 positive ubiquitinated neuronal cytoplasmic inclusion bodies (NCI’s) 
have been detected in the superficial layers of the cerebral neocortex as well as the 
hippocampal granule cells of the dentate gyrus (Josephs et al 2011, Mackenzie et al 
2010, Riedl et al 2014, Robinson et al 2014). Null mutations are thought to confer 
pathogenicity through a loss of function mechanism although the precise function 
of this particular growth factor in neuronal differentiation and survival has yet to 
be fully elucidated (Puoti et al 2014, Riedl et al 2014).                                                  
 
1.2.5.3.3 PSEN1 
A dominant negative heterozygous 3bp TCG insertion of an arginine residue at the 
position of the 352nd codon (insR352) in exon 10 of the presenilin 1 (PSEN1) gene, 
situated at the chromosome 14q24.3 locus, has been reported in a single kindred 
in which there are at least three instances of dementia (Amtul et al 2002). Although 
not associated with altered CSF or plasma β-amyloid (Aβ) levels as seen in cases of 
ALZ, the mutation is thought to affect cleavage of amyloid precursor protein (APP) 
through its inhibition of gamma (γ)-secretase activity (Golde & Younkin 2001). The 
proband presented at 56 years of age with features of Parkinsonism, asymmetric 
paraparesis, forgetfulness, visual hallucinations, increased appetite (hyperphagia), 
personality and behavioural disturbances, delusions, hypersexuality, incontinence, 
cognitive decline and social disinhibition (Section 1.2.1) (Tang-Wai et al 2002). At 
autopsy cortical atrophy, thinning of the corpus callosum and enlarged lateral 
ventricles were apparent with marked striatal degeneration, neurophil vacuolation 
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and gliosis. The presence of ubiquitinated NCI’s, NII’s and DN’s immunoreactive for 
TDP-43 which stained negative for FUS and the microtubule associated protein, tau 
were consistent with a diagnosis of FTLD-U (FTLD with ubiquitin and TDP-43 +ve 
inclusions). The pathogenicity of the insR352 mutation, however, was called into 
question upon discovery of an IVS1+1G>A substitution in exon 1 of the PGRN gene 
(Section 1.2.5.3.2) in the same pedigree which abolishes a 5’ splice site upstream of 
the ATG start codon encoded by a methionine residue and blocks protein synthesis 
(Boeve et al 2006).                
 
1.2.5.4 C9ORF72   
A long established association between the 9p21.2 locus of the human genome and 
a risk for developing ALS, bvFTLD or the combined ALS-FTLD syndrome can now be 
explained, at least partially, by the discovery in October 2011 of a pathogenic non-
coding hexanucleotide G4C2 repeat expansion that is situated in the first intron of 
exon 1a containing transcripts or proximal promoter region of exon 1b containing 
transcripts of the previously uncharacterised chromosome 9 open reading frame 72 
(C9ORF72) gene (DeJesus-Hernandez et al 2011, Renton et al 2011). Repeat-primed 
PCR and Southern blotting hybridization techniques have sort to size the expansion 
in post-mortem material isolated from human frontal cortex, cerebellum and brain-
stem in addition to patient derived skin fibroblasts, peripheral whole blood and EBV-
transformed, immortalised B-lymphocytes (LCL’s) (Beck et al 2013, Buchman et al 
2013, Dols-Icardo et al 2014, Harms et al 2013, Hubers et al 2013, van Blitterswijk 
et al 2013c). Somatic instability of the expanded G4C2 sequence may explain a large 
degree of the variability which arises between affected members of the same family 
and across different tissue types with average repeat lengths ranging in size between 
a few hundred and several thousand copies. Uncertainty, however, remains as to the 
precise number of repeats that are required in order to exert neurotoxicity towards 
MN’s in ALS. Although a threshold of more than 30 copies is widely accepted, some 
studies have suggested as few as 20 or 22 copies could be pathological (Byrne et al 
2013, Gomez-Tortosa et al 2013).  
The gene itself is comprised of 11 exons which span a 27.3Mb region of the short 
arm of chromosome 9p. Multiple alternatively spliced transcripts are described (n= 
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5) (ensembl.org) including three that are protein coding: two full length transcripts 
with alternated first exons [Variant I (NM_001256054) exons 1a, 2-11 and Variant 
III (NM_018325) exons 1b, 2-11] and a stable truncation [Variant II (NM_145005) 
exons 1a, 2-5]. Since the methionine residue encoding the translation initiation ATG 
start site is situated in exon 2, transcript variants I to III produce only two protein 
isoforms: isoform a of 481a.a (54.3kDa) and isoform b of 222a.a (24.8kDa) (Flicek et 
al 2014). C9ORF72 is predicted to be a putative member of the DENN superfamily of 
differentially expressed in normal and neoplastic domain containing proteins which 
are thought to function as GEF’s for small Rab GTPases (Levine et al 2013, Zhang et 
al 2012); thus, implicating them in a possible role in membrane trafficking and the 
autophagosome-lysosome clearance pathway (Farg et al 2014).  
By the autumn of 2013 several thousand incidences (n>3,300) (Woollacott & Mead 
2014) of the C9ORF72 G4C2 repeat expansion had been reported worldwide, making 
it the most common genetic cause of both conditions identified to date with as many 
as 43% of FALS (0.4-21% SALS) and approximately 25 to 30% of hereditary bvFTLD 
(2.0-23% sporadic bvFTLD) patients affected (Cooper-Knock et al 2012b, Cruts et 
al 2013, Devenney et al 2014, Gijselinck et al 2012, Majounie et al 2012, Smith et al 
2013). It has yet to be determined, however, whether pathogenicity arises from a loss 
of function (haploinsufficiency) or gain of function mechanism mediated by repeat 
associated non-ATG (RAN) translation of DPR (dipeptide repeat) proteins (Gendron 
et al 2013b) or the formation of toxic RNA foci (Donnelly et al 2013).  
 
1.3 Microarray Based Gene Expression Profiling              
1.3.1 Affymetrix® Platform 
The application of microarray based technology offers the end user a rapid, high-
throughput approach to global gene expression profiling that is both reproducible 
and unbiased (Tang et al 2005). Since the advent of the Human Genome Project, 
launched almost twenty-five years ago (Watson 1990), it has become increasingly 
possible to simultaneously measure the activity of transcripts pertaining to many 
thousands of genes or EST’s on a single GeneChip® or array (Sharp et al 2006b).  
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Briefly, total RNA isolated from the cellular model or tissue of interest is reverse 
transcribed into complementary DNA (cDNA) that is subsequently transformed in 
vitro to yield copy RNA (cRNA) which is fluorescently labelled with an covalently 
attached biotin molecule. The “target” sample is then fragmented and hybridized to 
oligonucleotide probes that are synthesised directly onto the glass slide by means 
of combinatorial chemistry and photolithography. On traditional 3’ IVT expression 
arrays each transcript is represented by 11 probe pairs. These comprise a probeset 
which contains equal numbers of perfect match (PM) and mismatch (MM), in order 
to control for hybridization specificity, 25-mer oligonucleotide sequences that are 
scattered at random across the chip (affymetrix.com). Signal intensity readouts from 
the GeneChip® scanner once the array has been washed, stained and processed can 
be considered proportional to the amount of cRNA for any given transcript which 
has bound to its complementary sequence(s) on the GeneChip® and, hence, provides 




Figure 1.2 Schematic Overview of the Affymetrix® Oligonucleotide Microarray Platform for 
Global GEP of Peripheral Tissues in ALS  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, cDNA - complementary DNA, cRNA - copy RNA 
and GEP - gene expression profiling.  
 
 
The microarray platform introduced by Affymetrix® has quickly become one of the 
most extensively used systems for generating gene expression profiling (GEP) data
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around the globe with a full range of different GeneChips® now supported including 
the Human Genome (HG) U133 Plus 2.0 GeneChip® [Chapter 3: ‘Whole Blood Study’] 
and Human Exon 1.0ST GeneChip® [Chapter 5: ‘C9ORF72 GEP Study’ and Chapter 6: 
‘C9ORF72 Survival Study’] Arrays which are discussed in detail in Sections 2.3.1.8.1 
and 2.3.2.4.1, respectively of Chapter 2: Materials and Methods (Auer et al 2009, Dal 
ma-Weiszhausz et al 2006, Okoniewski et al 2007).  
 
1.3.2 Limitations of Using Human Post-Mortem Tissue 
Whilst invaluable insights have been gained, specifically with regards to elucidating 
further the neuropathophysiological mechanisms which underlie MN degeneration 
in ALS and indeed other neurodegenerative, as well as neuropsychiatric conditions, 
there are several limitations associated with the use of human post-mortem derived 
tissue for generating GEP’s (Altar et al 2009, Bowser et al 2006, Cooper-Knock et al 
2012c, Heath et al 2013, Malaspina & de Belleroche 2004, Papapetropoulos et al 20 
07, Tanaka et al 2006), and the subsequent identification of biologically meaningful 
markers of potential diagnostic and/or prognostic relevance that could in the future 
be applied in a clinical setting. Although representative of the most vulnerable neu-
ronal cell populations, brain and spinal cord tissue can be difficult to obtain and is 
often in short supply; thus, restricting the sample sizes that can be used. This limits 
the statistical power of such studies which may ultimately compromise their reliab-
ility (Cooper-Knock et al 2012a). There have also been reports of significant levels 
of RNA degradation and protein modification that can occur ex vivo. Additional con-
siderations include inter- and intra-individual variability, the extent of neuroinflam-
mation at autopsy, PM delay and brain pH (Maes et al 2007). Decisions concerning 
whether to sample grey versus white matter, for example, or choosing to enrich for 
cortical MN’s over AHC’s will also have a profound impact. Moreover, transcription-
al profiling of PM material inevitability reflects only the very terminal stages of dise-
ase progression (i.e. the point at which the majority of MN’s will have degenerated 
and already been lost from the system) (Sharp et al 2006a). Hence, the difficulty in 
establishing whether the GE changes detected on the microarray have occurred in 
response to a pathogenic trigger, are a consequence of dying MN’s initiating apopt-
osis (Section 1.2.4.8) or due to survival signals emanating from the remaining non-
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neuronal cell populations. The latter may be particularly problematic when prepari-
ng whole tissue homogenates rather than deploying laser capture microdissection 
(LCM) techniques to isolate specific cell subtypes (Lederer et al 2007). In an attempt 
to overcome some of the aforementioned issues discussed above, a number of more 
readily accessible tissues have been investigated (Table 1.4); which include periph-
eral whole venous blood specimens and immortalised, EBV-transformed B-lympho 
cytes (LCL’s) that are reviewed briefly in Sections 1.4.1 and 1.4.2, respectively.    
    
Peripheral Tissue Advantages Limitations 
Whole Blood - readily accessible 
- longitudinal collection 
- large sample volumes 
- good standardisation of technical 
   procedures 
- no direct involvement in ALS 
- unrelated to MN’s 
- mixed cell population 
- high abundance of erythrocyte  
   alpha/beta haemoglobin 
PBMC - readily accessible 
- longitudinal collection 
- homogeneous cell population 
- no direct involvement in ALS 
- unrelated to MN’s 
- ex vivo handling 
LCL’s - non-invasive collection 
- good standardisation of technical 
   procedures  
- almost limitless resource 
- large Biobank available  
- homogeneous cell population  
- no direct involvement in ALS 
- unrelated to MN’s 
Muscle biopsy material - direct involvement in ALS - accessibility 
- invasive collection  
CSF - obtained from CNS - invasive collection 
Skin fibroblasts - readily accessible  
- model system with the genetic  
   background of the patient 
- can be reprogrammed into MN- 
   like cells 
- source for generation of iPSC’s  
- no direct involvement in ALS 
 
Table 1.4 Advantages and Limitations Associated with the Use of Peripheral Tissues for GEP 
Analysis in ALS 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, CNS - central nervous system, CSF - cerebrospinal 
fluid, GEP - gene expression profiling, iPSC - induced pluripotent stem cell, LCL - lymphoblastoid cell 
line, MN - motor neuron and PBMC - peripheral blood mononuclear cell.    
 
 
1.3.3 The Use of Peripheral Tissues 
Since the MN’s which degenerate in ALS cannot be harvested during life, there are 
great benefits to be had in sampling peripheral tissues that lend themselves to better 
standardization of technical procedures, are readily accessible and can be collected 
in large volumes without the need for re-sampling or longitudinally over the course 
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of the disease duration e.g. whole blood (Borovecki et al 2005, Grunblatt et al 2010, 
Maes et al 2007, Runne et al 2007, Saris et al 2009, Scherzer et al 2007, Tsuang et al 
2005) (Section 1.4.1) and, immortalised B-lymphocytes (Section 1.4.2) (Antonell et 
al 2010, Bittel et al 2007, Kakiuchi et al 2008, Nishimura et al 2007, Talebizadeh et 
al 2014). The advantages and limitations of each of these in addition to peripheral 
blood mononuclear cells (PBMC’s) (Bayatti et al 2014), skin fibroblasts (Raman et al 
2014), muscle biopsy material (Calvo et al 2012) and CSF (Jones 2011) are summ-
arised in Table 1.4. 
 
1.4 GEP Studies in Neurodegenerative Disease              
1.4.1  Examples Using Peripheral Whole Venous Blood  
1.4.1.1 ALS  
Currently in the literature there has only been a single published report by Saris et 
al (2009) which documents the use of peripheral whole blood for the generation of 
ALS related transcriptomics data. In this study, 79 spinal onset and 44 bulbar onset 
cases of an idiopathic nature that met the EEC of either ‘definite’ or ‘probable’ ALS 
(Section 1.1.3) were recruited from The Netherlands along with 123 unrelated, age 
as well as gender matched, neurologically normal healthy control subjects. These 
were further subdivided into a discovery cohort which comprised 30 SALS patients 
and controls (Dataset 1) plus two additional replication cohorts including one that 
contained a further 30 SALS patients and controls (Dataset 2) and a third containing 
the remaining 63 SALS patients and controls (Dataset 3).   
Application of the Illumina based microarray platform using Sentrix® HumanRef-8 
Expression BeadChip Arrays which represent >22,000 RefSeq curated gene targets 
identified 2,300 probes (9.4%) as being differentially expressed (DE) between the 
SALS and control groupings in the discovery cohort (student’s t-test p<0.05) (Saris 
et al 2009); although no validation by qRT-PCR (quantitative real-time polymerase 
chain reaction) was performed. Dysregulation of CHMP2B (Section 1.2.5.2.8) (⇩1.06 
-fold, p<0.001) and RAB5A (⇩1.12-fold, p<0.001) were of particular interest given 
their prior association with the disease. RAB5A is a member of the Ras superfamily 
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of monomeric G-proteins that are responsible for regulating intracellular trafficking 
and endosome formation, transportation, membrane docking & fusion (Gohre et al 
2012, Li et al 2013c, Lu et al 2014, Nayak et al 2013). They play a critical role in the 
autophagosome lysosome clearance pathway which is an important mechanism for 
cellular homeostasis and survival that has also been linked to the pathogenesis of 
ALS (Section 1.2.4.7) (Barmada et al 2014, Ferguson et al 2009, Hetz et al 2009, Li 
et al 2013b, Tarabal et al 2005). Moreover, the RAB5A guanine nucleotide exchange 
factor encoded by ALSIN (Section 1.2.5.1.2) is recognised as a causative gene of a 
rare AR inherited form of juvenile onset ALS (ALS2) (Table 1.1) (Yang et al 2001). 
 
Saris et al (2009) proceeded in performing Weighted Gene Co-expression Network 
Analysis (WGCNA) on ~8,000 probes (36.4%) which had a statistically significant 
Benjamini-Hochberg false discovery rate (FDR) corrected mean detection signal of 
p<0.05. Hierarchical clustering produced five colour coded modules ranging in size 
between 199 and 842 genes which demonstrated an association with ALS disease 
status but were found not to correlate with specific clinical phenotypes such as age 
of onset, presentation or survival. Bonferroni multiple comparison tests identified 
Blue [r1=0.48(⇧), p=3.60E-05] and Yellow [r1=0.61(⇩), p=6.20E-09] modules which 
were highly preserved across all three datasets and comprised predominantly up-
regulated or down-regulated clusters, respectively. Ingenuity Pathway Analysis of 
each of the top 500 ranking gene lists highlighted transcripts that are involved in 
the post-transcriptional or post-translational modification of mRNA’s and proteins 
as being significantly over-represented in the Blue module with neurodegeneration 
of the CNS, OS response (Section 1.2.4.1) & inflammation (Section 1.2.4.6) enriched 
in the Yellow module. Of particular interest is the dysregulation of ATXN2 (Section 
1.2.5.2.4) (⇧1.10-fold, p<0.001) since polyQ expansions in this gene are associated 
with a rare AD inherited form of adult onset ALS (ALS13), bvFTLD with non-fluent 
aphasia, PD and SCA2 (Table 1.2) (Elden et al 2010, Imbert et al 1996). In a further 
analysis of the top 100 most highly interconnected hub genes, Saris et al (2009) also 
identified transcripts relating to cellular stress, apoptosis and the UPR which were 
shared in common between modules with those involved in vesicular trafficking or 
mitochondrial function found to be specific for either the Blue or Yellow modules, 
respectively. Similar findings to the latter have been recapitulated in the spinal cord, 
peripheral whole blood and muscle biopsy tissue of the transgenic SOD1G93A mouse 
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model (Saris et al 2013). 
Altered mRNA transcript levels of several genes (n=16) have also been reported in 
the motor and sensory cortices of five additional SALS patients (Wang et al 2006). 
These included ATP/GTP binding protein 1 (AGTPBP1) (⇩1.09-fold, p<0.01) which 
is thought to contribute to Purkinje cell degeneration and loss in hereditary forms 
of cerebellar ataxia (Fernandez-Gonzalez et al 2002, Lim et al 2006) and has since 
been validated in a third independent study comparing GEP’s from 11 SALS patients 
and 9 neurologically healthy, control subjects (Lederer et al 2007). Other DE genes 
commonly dysregulated in peripheral whole blood and human post-mortem derived 
SC tissue include a number of those involved in DNA replication & repair as well as 
RNA processing, protein degradation, cellular response to stress, inflammation, Ca2+ 
homeostasis, cell cycle control, CNS vasculogenesis and glucose metabolism [ABL1, 
CAMLG, CD74, CYBA, ENG, GYS1, POLD2, RELA, S100A9, SF1, SPN, SRPK1, TXN, UBL5, 
USP11 and VIL2] (Dangond et al 2004, Ishigaki et al 2002, Jiang et al 2005, Kudo et 
al 2010, Malaspina et al 2001, Offen et al 2009).     
 
1.4.1.2 Other Neurodegenerative Disorders  
1.4.1.2.1 Huntington’s Disease  
Huntington’s disease (HD), which has a prevalence of 12.3 per 100,000 of the UK 
Caucasian population (Pringsheim et al 2012), is an adult onset movement disorder 
of monogenic inheritance that is caused by a polyQ expansion of 40 repeat lengths 
or greater in exon 1 of the HTT gene encoding the huntingtin protein (MacDonald 
et al 1993). The condition is characterised by the loss of gamma-Aminobutyric acid 
or GABAergic neurons and widespread reactive gliosis in the striatum and cerebral 
cortex (Runne et al 2007). Extrapyramidal signs include rigidity and bradykinesia, 
dystonia, reduced coordination, weight loss and chorea with cognitive decline and 
psychiatric disturbances (e.g. irritability, anxiety & depression) normally apparent 
before the onset of overt motor impairment (Ross & Tabrizi 2011).  
Transcriptional profiling comparing pre-symptomatic (n=5) or symptomatic (n=12) 
HD patients to fourteen unrelated, age and gender matched, neurologically normal 
healthy control subjects identified 322 of ~11,000 probes (2.9%) common to both 
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Affymetrix Human Genome U133A GeneChip® Arrays and Amersham BioSciences 
CodeLink Uniset Human I and II bioarrays with an average expression ratio of >1.8 
or <0.6 (student’s t-test p<0.0005) for up and down-regulated changes, respectively. 
The majority of transcripts were increased in peripheral blood of patients relative 
to controls and reflected diverse biological processes including transcription/RNA 
processing, ubiquitin-mediated proteasomal degradation, vesicular trafficking and 
signal transduction. The top 30 highest ranking genes, as determined by probability 
value and fold-change, were assessed by qRT-PCR and a subset of 12 demonstrating 
the most significant DE selected to form a biomarker panel which could be applied, 
using principal component analysis (PCA) mapping software, to distinguish not only 
between HD and controls, but also between different stages of disease progression 
with pre-symptomatic patients clustering distinctly between individuals which are 
symptomatic and those that are neurologically healthy in two independent cohorts 
comprising a) 16 late pre-symptomatic, 14 symptomatic and 25 controls or b) nine 
early pre-symptomatic and a further nine controls. The panel also proved effective 
in a Phase I clinical trial in monitoring individual patient responses to the histone 
deacetylase (HDAC) inhibitor sodium phenylbutyrate (Borovecki et al 2005) which 
has been shown to exhibit neuroprotective properties in a transgenic mouse model 
of the disease (Gardian et al 2005). Moreover, an up-regulation in the expression of 
7 of the 12 candidate genes (58.3%) was confirmed by qRT-PCR in human derived 
post-mortem tissue from the caudate nucleus of five additional HD brains and four 
controls (Borovecki et al 2005). In another study comparing HD (n=61), PD (n=20) 
and ischemic stroke (n=10) patients, the same approach was conducted by Lovrecic 
et al (2009) using a standard logistic regression based model which was successful 
in generating a positive predictive score of 78% with sensitivity 82% and specificity 
53%. This finding, however, could not be replicated in lymphocytes suggesting that 
this particular panel of biomarkers may be specific to blood (Runne et al 2007).    
                                               
1.4.1.2.2 Parkinson’s Disease 
PD affects approximately 1% of the population over the age of 65 (Wirdefeldt et al 
2011) and is characterised as a slowly progressive neurodegenerative disorder 
that is characterised by a resting tremor, rigidity, gait abnormalities, asymmetric 
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bradykinesia and postural instability. Pathologically the condition is hallmarked by 
the presence of α-synuclein containing LB’s as well as a substantial loss of 
dopaminergic neurons from within the substantia nigra pars compacta region of 
the brain (Ali & Morris 2014).  
Transcriptional profiling of 50 early stage PD patients with a mean Hoehn and Yahr 
score of 2.3 (range 1-4) and 55 unrelated controls including 33 disease mimics [ALZ, 
progressive supranuclear palsy (PSP), CBS or multiple systems atrophy (MSA)] and 
22 neurologically healthy control subjects which were age, gender and blood count 
matched identified 22 unique genes represented on the Affymetrix Human Genome 
U133A GeneChip® Arrays as being DE between PD patients and controls with SAM 
(significance analysis of microarrays) FDR p<0.03 and a fold-change (FC) threshold 
of ±1.25. Functional categories that were highlighted included the cell cycle, DNA/ 
RNA turnover, protein phosphorylation & transport, carbohydrate metabolism and 
apoptosis. Of particular interest is the down-regulation of the heat shock protein 70 
(HSP70) co-chaperone suppression of tumorigenicity 13, ST13 (⇩1.63-fold, p<0.01) 
which has been implicated in the aberrant folding of α-synuclein and its subsequent 
toxicity towards dopaminergic neurones in PD (Flower et al 2005, Klucken et al 
2004). This was later confirmed in two independent qRT-PCR assays using different 
housekeeping genes (Scherzer et al 2007). The authors also divided the cohort into 
a training set (62.9%) [31 PD, 18 mimics and 17 controls] and a test set (37.1%) 
[19 PD, 15 mimics and 5 controls] in order to determine an optimum biomarker 
panel of 8 candidate genes that correlated significantly with the risk of developing 
PD [OR of third tertile leave one out cross-validation 5.7 with 95% confidence 
interval (CI) between 1.6 and 21, p<0.01] (Scherzer et al 2007). In a re-analysis of 
the aforementioned dataset, Soreq et al (2008) were able to further improve the 
discriminative power of the study by deploying distribution plots and PCA mapping 
to allow for the effective removal of outliers that may have arisen from technical 
inconsistencies. In doing so they have highlighted previously unreported changes 
in the mRNA transcript levels of genes relating to neuro-immune signalling (Soreq 
et al 2008). It is also worth noting that an intron 8 SNP encoded within one of these 
markers, VDR (vitamin D receptor), is found to be disproportionately over-represen 
ted in Korean PD sufferers relative to the general population (Butler et al 2001, Kim
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et al 2005, Li et al 2014).  
In a more recently published report by Grunblatt et al (2010), 4 of 12 (33.3%) pre-
selected candidates based upon prior GEP analyses of human post-mortem derived 
brain tissue [ALDH1A1, HIST1H3, LAMB2 and PSMA2] (Grunblatt et al 2004, Hauser 
et al 2006, Lu et al 2005, Simunovic et al 2009, Zhang et al 2005) could successfully 
differentiate between sporadic PD cases [11 drug naïve and 116 mediated], disease 
mimics diagnosed with ALZ and neurologically healthy, elderly control subjects with 
a sensitivity and specificity of greater than 80% in qRT-PCR assays of RNA isolated 
from peripheral whole blood (Grunblatt et al 2010).        
 
1.4.1.2.3 Alzheimer’s Disease  
ALZ represents the most common form of age-related dementia that afflicts between 
3 and 7% of the global population older than 75 years (Abdulrahman & Jnr 2014, 
Takizawa et al 2014). Progressive memory loss and a decline in cognitive function is 
accompanied by reactive gliosis, atrophy of the basal forebrain and hippocampus, 
extracellular depositions of Aβ (senile plaques) and intracellular accumulations of 
hyperphosphorylated tau (neurofibrillary tangles) (Duyckaerts et al 2009, Sabuncu 
et al 2011).    
Transcriptional profiling of peripheral blood mononuclear cells (PBMC’s) from 14 
mildly symptomatic sporadic ALZ patients [Mini Mental State Examination (MMSE) 
scores of 23.4±3 out of a possible 30] and an equal number of neurologically healthy 
age and education matched elderly control subjects using the National Institute on 
Aging (NIA) Human Mammalian Gene Collection (MGC) cDNA Arrays identified 942 
of 6,424 probes as being DE including 849 (90.1%) down-regulated and 93 (9.9%) 
up-regulated transcripts with an average expression ratio of >1.2 or <0.9 and SAM 
2-way analysis of variance (ANOVA) FDR threshold of p<0.05. Gene Set Enrichment 
Analysis (GSEA) using the online open source database that is freely available from 
the Gene Expression Omnibus (GEO) repository highlighted genes associated with 
apoptosis, protein translation & inflammation that were significantly increased and 
genes associated with cytoskeletal maintenance, cellular trafficking, mitochondrial 
function, lipid metabolism, redox homeostasis, neurotransmission, transcription & 
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DNA repair or cellular response to stress which were significantly decreased in the 
PBMC’s of ALZ patients in relation to the controls (Maes et al 2007). Whilst a large 
proportion of these have been found to be gender specific, changes in 78% of those 
selected in males and 56% in females were confirmed in a qRT-PCR assay (albeit in 
the same cohort of samples used in the microarray experiments) and >160 probes 
exhibited similar expression changes in human derived post-mortem brain tissue 
(Blalock et al 2004, Colangelo et al 2002, Yao et al 2003) and/or transgenic animal 
models of the disease (Dickey et al 2003, Ho et al 2001, Reddy et al 2004).  
                                                  
1.4.1.2.4 Schizophrenia and Bipolar Disorder  
Schizophrenia (SCHIZ) and Bipolar disorder (BPD) are severely debilitating chronic 
remitting and relapsing neuropsychiatric illnesses that each occur in approximately 
1% of the population. The former is characterised by psychosis with symptoms of 
hallucinations & delusions, disorganised speech, catatonia and variable degrees of 
motor, cognitive and/or social dysfunction (Tandon et al 2013, Tandon et al 2009); 
whereas the latter, conversely, is a mood affective disorder that is characterised by 
episodes of mania and depression and is often associated with paranoia as well as 
sleep-wake disturbances (Fagiolini et al 2013, Oswald et al 2007).     
Transcriptional profiling of individuals of Han Chinese descent including SCHIZ (n= 
30) and BPD (n=16) patients diagnosed according to the IV criteria of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) and 28 unrelated, neurologically 
healthy control subjects identified 89 of 12,674 probes (~0.7%) on the Affymetrix 
U133A/plus2.0 GeneChip® Arrays as being DE between the two patient groupings 
and controls, applying a non-parametric ANOVA (Kruskal-Wallis) p<0.005 without 
performing a multiple comparisons correction. Two-dimensional (2D) hierarchical 
clustering using the Spearman’s correlation statistic demonstrated three genetically 
defined subgroups on the HeatMap which corresponded to SCHIZ, BPD and control 
cases in the original microarray experiment. Logistic regression and ROC (Receiver 
Operating Characteristic) curve analysis from pair-wise comparisons of SCHIZvctrl, 
BPDvctrl and SCHIZvBPD determined linear and non-linear combinations of eight 
of the highest ranking genes, which were confirmed by qRT-PCR, to be successful in 
discriminating not only between a healthy versus disease status but also between 
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SCHIZ and BPD with an overall efficiency of 95% (Tsuang et al 2005). Many of these 
putative markers were found to reside at chromosomal loci which have previously 
been linked to SCHIZ [1cen.q12 (ADSS), 1q21 (S100A9), 20q13 (DATF1) and 22q13 
(APOBEC3B)], BPD [4p16 (CTBP1) and 4q21 (CXCL1)] or alternatively both of these 
neuropsychiatric conditions [11q22 (ATM) and 19q13 (CLC)] (Badner & Gershon 
2002, Cassidy et al 2007, Cheng et al 2006, Francks et al 2010, Fullerton et al 2010, 
Lewis et al 2003). Furthermore, an increase in the expression levels of chemokine 
(C-X-C motif) ligand 1 melanoma growth stimulating activity, alpha (CXCL1) (⇧1.58 
-fold, p<0.001) has been independently verified in a second qRT-PCR cohort which 
was comprised of an additional 30 SCHIZ patients and 26 unrelated, neurologically 
healthy control subjects (Yao et al 2008).   
 
1.4.2 Examples Using Immortalised Lymphoblastoid Cell Lines 
1.4.2.1 ALS 
To date, no reports have been published on the use of peripheral EBV-transformed 
B-lymphocytes (LCL’s) to measure gene expression in ALS.         
 
1.4.2.2 Other Neurodegenerative Disorders    
1.4.2.2.1 Schizophrenia  
Transcriptional profiles of EBV-transformed B-lymphocytes from two pairs of MZ 
(monozygotic) twins that have a homogeneous background and are discordant for 
SCHIZ [(A) 54 year old males one of whom had diabetes mellitus with both positive 
and negative symptoms and (B) 24 year old females with one individual exhibiting 
purely negative symptoms and signs of auditory hallucinations] were generated on 
the Affymetrix® platform using Human Genome U133A Plus 2.0 GeneChip® Arrays 
containing >22,000 probes for the interrogation of upwards of 14,500 genes. From 
the analysis of five independent replicates, performed for each pair, several (n=5) 
transcripts were identified as being DE (p<0.05) between affected and unaffected 
twin members according to GeneSpring conducted parametric and non-parametric 
testing. These included adrenomedullin (ADM) and selenoprotein X1 (SEPX1) that 
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were significantly up-regulated and the B-lymphocyte and neuron specific CD200 
antigen (CD200) which was significantly down-regulated (Kakiuchi et al 2008). The 
former two alterations have been verified in LCLs (Huang et al 2004) and plasma 
(Yilmaz et al 2007, Zoroglu et al 2002) or peripheral whole blood (Glatt et al 2005) 
in least one other independent SCHIZ cohort as reported elsewhere in the literature. 
ADM encodes a potent vasodilator peptide which is abundantly synthesised in the 
thalamus, hypothalamus and pituitary gland where it is responsible for controlling 
the body’s neuroendocrine responses to stress (Taylor & Samson 2004). Although 
the precise molecular function of this member of the selenoprotein family has yet 
to be elucidated, Benton (2002) has suggested that in the presence of deficiency, 
preferential retention of selenium ions (Se2-) within the brain could be contributing 
to mood abnormalities. The remaining immunoglobulin related genes (n=2) were 
considered potential artefacts of the EBV transformation process and subsequently 
had been excluded from all further analysis (Kakiuchi et al 2008). 
                                                       
1.4.2.2.2 Bipolar Disorder  
Transcriptome profiling of immortalised, EBV-transformed B-lymphocytes (LCL’s) 
generated from two pairs of male MZ twins, aged 42 and 49 years, respectively that 
were discordant for BPD using Affymetrix Hu95A GeneChip® Arrays which contain 
probes for the interrogation of ~12,600 well characterised genes revealed overall 
down-regulation in the expression of 17 transcripts (~0.1%) (⇩1.60-fold or greater, 
p<0.05) which are associated with the ER stress response pathway (Kakiuchi et al 
2003). These included an ER chaperone, heat shock 70kDa protein 5 (HPSA5) 
which is known for its assistance in the refolding of aberrantly formed peptides 
(Ellgaard & Helenius 2003, Kleizen & Braakman 2004) as well as the HPSA5 
regulator, X-box binding protein 1 (XBP1) (Dunys et al 2014, Zhang & Kaufman 
2006). The former resides at the chromosome 22q12.3 locus which has previously 
been implicated in BPD (Marcheco-Teruel et al 2006, Mujaheed et al 2000, Potash 
et al 2008, Potash et al 2003). Moreover, a -116 C⇢G polymorphism identified 
within the upstream promoter region of the XBP1 gene, which disrupts its putative 
binding site by altering the consensus motif from an ACGT to AGGT, is reported to 
be a significant risk factor for BPD in a Japanese cohort comprising 140 bipolar I 
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and 57 bipolar II disorder cases and 451 unrelated neurologically healthy control 
subjects [OR 4.60 with 95% CI between 2.1 and 10.2] (Kakiuchi et al 2003). Upon 
induction of the ER stress response pathway by thapsigargin mediated Ca2+ 
ATPase inhibition the authors demonstrated substantially smaller elevations in the 
qRT-PCR mRNA levels of XBP1 and HPSA5A transcripts in cultured LCL’s from BPD 
patients versus controls in a direct comparison between the treated and untreated 
groups. Further in vitro experimentation introduced a 7 day pre-incubation period 
exposing the cells to therapeutic concentrations of the mood stabilizing compound, 
semisodium valproate, which led to enhanced activation of the transcription factor 
ATF6 (activating transcription factor 6) and an amelioration of this potentially toxic 
outcome (Shen & Prywes 2005, Yoshida et al 2001).   
The findings of Kakiuchi et al (2003), however, could not be replicated in a more 
recent case-control study of three additional pairs of Australian MZ twins including 
one male aged 23 years and two females aged 38 and 58 years, respectively which 
were profiled using the Affymetrix Human Genome U133 plus 2.0 GeneChip® Arrays 
(Section 1.3.2.2.2). In contrast, Matigian et al (2007) reported the DE of a number of 
transcripts involved in the WNT signalling cascade that influences cell migration & 
proliferation during embryonic development. It is also important for axon guidance 
in the CNS as well as being a key determinant of cell fate via its mediation of pro-
apoptotic pathways.                                                                   
 
1.5 Summary of Project Aims and Objectives              
The principle aim of the PhD was to perform GEP of peripheral tissues in ALS. In the 
first instance whole blood was trialled since it lends itself to good standardisation of 
technical procedures, it is readily accessible and it can be collected in large volumes, 
longitudinally. However, in evaluating NuGEN Technologies Inc., UK patented linear 
single primer isothermal amplification (SPIATM) method this proved no more reliab-
le than the previously unsuccessful Ambion® GLOBINClearTM protocol developed in 
house by Dr Rohini Raman (2011). Evidence is suggestive of the sheer abundance of 
erythrocyte derived alpha and beta haemoglobin transcripts (constituting up to 70% 
of the total RNA species isolated from peripheral whole blood) producing interfere-
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nce on the microarray which could mask the detection of other, less abundant tran-
scripts of equal biological importance that are also contained within the sample. For 
this reason, we proceeded instead to investigate the use of immortalised EBV-trans-
formed B-lymphocytes or lymphoblastoid cell lines (LCL’s) (representing a genetic-
ally homogenous cell population which can be cultured in vitro to support downstr-
eam functional assays) in order to address the following: 1) Upon discovery, in 2011, 
of a large, intronic hexanucleotide G4C2 repeat expansion (DeJesus-Hernandez et al; 
Renton et al) of >30 copies in the previously uncharacterised C9ORF72 gene, which 
is now recognised as the most frequent cause of ALS and bvFTLD, elucidate further 
the mechanism(s) of C9ORF72 neurotoxicity in ALS and 2) Within this specific gene-
tic subtype, establish whether there are modifiers of survival [i.e. a fast (<2yrs) ver-
sus slow (≥4yrs) disease progression] that can led us to identify potential new areas 
of future therapeutic research.      
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Clinical Characteristics              
2.1.1 NuGEN Ovation® Whole Blood Study 
Participants recruited into the NuGEN Ovation® Whole Blood Study were Caucasian 
and of North European descent. These were comprised of six Riluzole treated SALS 
[3-M, 3-F] patients and an equal number of age, as well as gender, matched neuro-
logically normal, healthy control [3-M, 3-F] subjects. Age at symptoms onset ranged 
between 38 and 71 years with a mean of 60.3±15yrs (Table 2.1). Survival from the 
time of diagnosis to the point at which the tissue samples were donated ranged from 
12 months to a minimum of 6 years with average disease duration of approximately 
3 years and 4 months.   
 
Sample ID Diagnosis Gender Age at Onset Survival 
BLDCON01 control M 48 n/a 
BLDCON02 control F 47 n/a 
BLDCON04 control M 54 n/a 
BLDCON07 control F 56 n/a 
BLDCON08 control M 40 n/a 
BLDCON10 control F 43 n/a 
BLDPAT21 SALS M 66 1yr 
BLDPAT23 SALS F 70 2yrs 
BLDPAT26 SALS F 38 ≥4yrs 
BLDPAT27 SALS M 71 ≥5yrs 
BLDPAT35 SALS M 71 2yrs 
BLDPAT38 SALS F 46 ≥6yrs 
    
Table 2.1 Clinical Characteristics of SALS Patient and Control Samples Re-
cruited to the NuGEN Ovation® Whole Blood Study Symptom onset could be 
defined as the age at which the patient first presented with significant weakness. 
Survival was approximated to the nearest year and in instances where an indiv-
idual was still reported to be alive, a minimum disease duration was calculated 
using the time of diagnosis to the point at which the tissue samples were donat-
ed [indicated by the greater than or equal to (≥) symbol].  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, BLDCON - blood control, BLD 
PAT - blood patient, F - female, M - male, n/a - not applicable and S - sporadic.        
 
 
2.1.2 ECACC LCL Study  
ECACC established lymphoblastoid cell lines (LCL’s) (n=820) [120-FALS, 500-SALS 
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and 200-CTRL] were obtained from patients and their spouses or unrelated carers 
attending clinics in the Birmingham (28.8%), London (29.6%) or Sheffield (41.6%) 
districts between November 2003 and June 2011 (Figure 2.1). The Birmingham hub 
included satellite centres from Belfast City Hospital (BBe) (n=11/236), Oxford (BOx) 
(n=3/236), Bristol’s Frenchay Hospital (BBr) (n=2/236) and Liverpool (BLi) (n=27/ 
236); The London hub included satellite centres from Plymouth Derriford Hospital 
(LPy) (n=2/243), Cambridge (LCa) (n=6/243), Southampton General Hospital (LSh) 
(n=9/243), Poole General Hospital (LPo) (n=17/243), London Royal Free Hospital 
(LRf) (n=2/243), Royal London Hospital (LRo) (n=3/243) and the London National 
Hospital (LNh) (n=14/243); The Sheffield hub included satellite centres from Prest-
on (SPr) (n=10/341), Manchester (SMa) (n=19/341), Newcastle (SNc) (n=48/341), 
Nottingham (SNt) (n=22/341) and Durham (SDu) (n=5/341) (Figure 2.1).   
 
Figure 2.1 ECACC LCL Breakdown of UK Biosample Collection Centres Three National Research 
Hubs are represented in Orange [B] (Birmingham), Green [L] (London) and Red [S] (Sheffield) with 
the surrounding satellite centres encoded by the prefixes: Li - Liverpool, Be - Belfast City Hospital, Ox 
- Oxford, Br - Bristol Frenchay Hospital, Po - Poole General Hospital, LNh - London National Hospital, 
Sh - Southampton General Hospital, Ca - Cambridge, LRo - Royal London Hospital, LPy - Plymouth’s 
Derriford Hospital, LRf - London Royal Free Hospital, Nc - Newcastle, Nt - Nottingham, Pr - Preston, 
Ma - Manchester and Du - Durham.  
 
Abbreviations: BC - Birmingham control, BP - Birmingham patient, ECACC - European Collection of 
Cell Cultures, LC - London control, LCL - lymphoblastoid cell line, LP - London patient, SC - Sheffield 
control and SP - Sheffield patient.        
 
All of the participants recruited to the study were Caucasian and of North European 
descent. Patients were diagnosed according to the World Federation of Neurology’s 
amended EEC of 1998 (Section 1.1.3) (Figure 1.1) with either definite (n=248/620) 
or probable (n=345/620) ALS in 95.7% of cases, which included four incidences of 
concomitant FTLD (Section 1.2.1) and two incidences of concomitant PD (Section 
1.2.1). In the remaining 4.3% of the cohort there were also several reported cases 
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of rare variants of MND including PBP (n=23/620) (Section 1.2.2.1), PLS (n=3/620) 
(Section 1.2.2.2) and PMA (n=1/620) (Section 1.2.2.3). Two hundred neurologically 
normal, healthy control subjects selected from the National MNDA (Motor Neurone 
Disease Association) DNA Bank were age and gender matched to the SALS (n=500) 
population with the average FALS patient developing symptoms approximately five 
years earlier. M:F ratios were comparable across SALS cases and controls but were 











  FALS SALS Control 
M:F 1.45:1 1.75:1 1.74:1 
Age  55.4±12yrs 60.2±11yrs 63.2±11yrs 
Total 120 500 200 
 
Figure 2.2 Age Frequency Distribution of Patient and Control LCL’s in the 
ECACC Microarray Study (n=820) [120-FALS, 500-SALS and 200-CTRL]  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, Ctrl - control, ECACC - Euro-
pean Collection of Cell Cultures, F - female, F - familial, LCL - lymphoblastoid cell 
line, M - male and S - sporadic.   
 
 
All of the FALS cases were assigned to the discovery cohort. Controls and SALS, on 
the other hand, were ranked, in ascending order according to age, and allocated the 
number one (discovery cohort) (Section 4.1.1) or two (replication cohort) (Section 
4.1.2) alternately down the list. A further detailed analysis of the two cohorts can be 
found at the beginning of Chapter 4: ‘Characterisation of LCL’s’.   
 




































This project was funded by EuroMOTOR (European Multidisciplinary ALS Network 
Identification to Cure Motor Neurone Degeneration) under the Seventh Framework 
Health Cooperation Programme (FP7/2007-2013) (euromotorproject.eu). The work 
was approved by the South Sheffield Research Ethics Committee [REC12/YH/0330; 
STH16573]. Prior to biosample collection informed written consent was obtained for 
all patient and control donors agreeing to participate in either of the two studies.                        
 
2.2.1 Biological Specimens   
2.2.1.1 Peripheral Whole Blood  
PAXgene® Blood RNA Collection Tubes (2.5mL) (PreAnalytiX, GmbH) and BD Vacu-
tainer® Venous Collection Tubes (6.0mL) (BD Diagnostics) were purchased from BD 
Biosciences, UK.                                  
 
2.2.1.2 Lymphoblastoid Cell Pellets    
Frozen EBV-transformed, immortalised lymphoblastoid cell (LCL) pellets, preserved 
in RNAlaterTM (Sigma-Aldrich®, UK), were obtained from the National MNDA DNA 
Bank held at the Health Protection Agency’s (HPA) European Collection of Cell Cult-
ures (ECACC) (Public Health England, UK) (Section 2.3.2.1).            
 
2.2.2 Solutions, General Chemicals and Laboratory Consumables 
Nuclease free (NF) double-distilled water (ddH20) was purchased from QIAGEN Ltd., 
UK. TE buffer [10mM tris-(hydroxymethyl)-aminomethane hydrogen chloride (Tris-
HCl) and 1mM ethylenediaminetetraacetic acid (EDTA), pH 7.5 at 250C] was supplied 
by EPICENTRE® Biotechnologies (Illumina Inc., UK). TAE buffer [0.4mM Tris-acetate 
EDTA and 0.01mM Sodium EDTA, pH 8.2 at 250C] was prepared using reagents sup-
plied by Sigma-Aldrich®, UK. Molecular grade agarose was purchased from Bioline, 
UK. The intercalating nucleic acid stain, GelRedTM was purchased from Biotium, UK. 
All other general chemicals were purchased from Thermo Fisher Scientific® Inc., UK 
including analytical grade isopropanol and absolute ethanol.       
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Stratagene qPCR Human Reference Total RNA [1μg/μL in 0.1mM EDTA/RNase-free 
H20] was purchased from Agilent Technologies Ltd., UK. Actin, beta (ACTB) primers, 
designed by Dr Marta Milo (Department of Biomedical Science (BMS), University of 
Sheffield), were supplied by InvitrogenTM (Life Technologies Ltd., UK). Haemoglobin 
alpha 2 (HBA2) primers, designed by Dr Paul Heath (SITraN), were purchased from 
Sigma-Aldrich®, UK and optimised, previously by Dr Rohini Raman (Department of 
Neuroscience, University of Sheffield). 18S ribosomal RNA (18SrRNA) forward and 
reverse sequences were designed and optimised by Dr J Robin Highley (SITraN). All 
other standard qRT-PCR primers were synthesised and shipped from Eurofins MWG 
Operon, Germany. Stratagene Brilliant II and FastStart Universal SYBR® Green PCR 
Master Mixes were purchased from Agilent Technologies Ltd., UK and Roche Diagn-
ostics (GmbH, Germany), respectively. The IDT PrimeTime® Mini qPCR Assays were 
supplied by Integrated DNA Technologies® Inc., USA. Brilliant III Ultra-Fast qRT-PCR 
Master Mix was purchased from Agilent Technologies Ltd., UK. Thin-walled 96-well 
plates and optical caps were manufactured by Geneflow Ltd., UK.  
For performing gel shift assays precast 15-well (15μL) 4-20% polyacrylamide mini-
PROTEAN® TBETM gels were purchased from Bio-Rad Laboratories Ltd., UK. Neutr 
AvidinTM biotin-binding protein and a 1X phosphate buffered saline (PBS) solution, 
supplied at pH of 7.2±0.05 (Invitrogen Gibco®), were purchased from Thermo Fisher 
Scientific® Inc., UK. A 1X Tris Borate EDTA (TBE) buffer solution [89mM Tris-borate 
and 2M EDTA, pH 8.3±0.1 at 250C] was prepared using reagent supplied by Sigma-
Aldrich®, UK. Ethidium bromide was also purchased from Sigma-Aldrich®, UK. DNA 
Loading Buffer Blue (5X) and the molecular weight markers HyperLadderTM IV (100 
-1000bp) and HyperLadderTM V (25-500bp) were purchased from Bioline Reagents 
Ltd., UK.  
Human Genome U133 (HG_U133) Plus 2.0 GeneChip® Arrays used in the analysis of 
Chapter 3: ‘Whole Blood Study’ and the Human Exon 1.0ST GeneChip® Arrays used 
in the analysis of Chapter 5: ‘C9ORF72 GEP Study’ and Chapter 6: ‘C9ORF72 Survival 
Study’, were purchased from Affymetrix® Ltd., UK. More traditional 3’ IVT Expression 
Arrays were selected for the whole blood study to maintain consistency between the 
JB and RR (Raman 2011) generated datasets and in order to draw direct comparis-
ons between the NuGEN Ovation® Whole Blood Solution (Section 3.5.1.2.1) and the 
59 
 
Ambion® GLOBINClearTM (Section 3.5.1.2.2) protocols. For the subsequent profiling 
of EBV-transformed, immortalised B-lymphocytes (LCL’s) (Section 2.1.2), for which 
a large bank of cases and controls was available, the more comprehensive Human 
Exon 1.0ST GeneChip® Arrays were chosen since they provide better coverage [>1. 
4M probesets with sequences designed to span the entire length of the gene, rather 
than being targeted at the far 3’ end of the transcript, which may be prone to small 
amounts of degradation during storage/handling (Section 2.3.2.4.1)] and in addition 
to differential expression, are also beneficial in detecting novel alternative splicing 
events.        
              
2.2.3 Reagents and Kits   
The PAXgene® Blood RNA Isolation Kits (PreAnalytiX, GmbH) and RNeasy® Mini Kits 
were purchased from QIAGEN Ltd., UK. DNase I (RNase-freeTM) (2,000 units/mL) and 
10X deoxyribonuclease (DNase) reaction buffer [25mM MgCl2 (magnesium chloride), 
5mM CaCl2 (calcium chloride) and 100mM Tris-HCl (Tris hydrochloride), pH 7.6 at 
250C] were purchased from New England BioLabs® Ltd., UK. Eukaryotic Total RNA 
6000 Nano LabChip® Kits were purchased from Agilent Technologies Ltd., UK. ABI 
High Capacity RNA to cDNA Synthesis Kits (Applied Biosystems®) were purchased 
from Life Technologies Ltd., UK.  
The NuGEN Ovation® Amplification System V2, Whole Blood Solution and EncoreTM 
Biotin Module were purchased from NuGEN Technologies Inc., The Netherlands. The 
MinElute® Reaction Clean-Up Kits were purchased from QIAGEN Ltd., UK. The Amb-
ion® TURBO DNA-freeTM DNase Treatment and Removal Kit (Applied Biosystems®) 
was purchased from Life Technologies Ltd., UK.  
Ambion® Kits required for the Whole Transcriptome (WT) Expression Assay were 
purchased from Life Technologies Ltd., UK. The GeneChip® Eukaryotic Poly-A RNA 
Control, Fragmentation & Terminal Labelling Kits were purchased from Affymetrix® 
Ltd., UK. The SAPE (Streptavidin Phycoerythrin) staining solution, stringency wash 





2.3.1 GEP from Peripheral Whole Blood  
2.3.1.1 Tissue Collection and Storage  
Patient donors and their spouses or unrelated carers were fasted overnight prior to 
phlebotomy which was performed between the hours of 8.00 and 11.00am. Whole 
venous blood was collected directly into sterile (2.5mL) evacuated PAXgene® Blood 
RNA Collection Tubes containing a proprietary reagent for the immediate stabilizat-
ion of intracellular RNA. Blood specimens were transported at RT (room temperat-
ure) and stored at -200C upon arrival, for no more than 3 years. 
 
2.3.1.2 PAXgene® Extraction of Total RNA from Whole Blood    
Blood specimens were defrosted overnight in the refrigerator, set at 40C, and equil-
ibrated to RT for a minimum of 2 hours, to ensure the complete lysis of blood cells, 
immediately prior to extraction using the PAXgene® Blood RNA Isolation Kit. Briefly, 
PAXgene® Blood RNA Collection Tubes (2.5mL) were centrifuged for 10 minutes at 
5,000g, the supernatant was discarded and the pellet re-dissolved in RNase-freeTM 
water. This step was repeated using 350μL re-suspension buffer and the samples in-
cubated in a 550C shaking water bath, set a 190rpm for 10 minutes, in the presence 
of 40μL proteinase K and 300μL binding buffer in order to bring about protein dige-
stion. An additional centrifugation step through the PAXgene® shredder column was 
required for 3 minutes at 13,000g to homogenise the cell lysate and to remove any 
residual debris. The supernatant was then transferred into a fresh microcentrifuge 
tube and the binding conditions adjusted with absolute ethanol. After a brief 1 to 2 
second centrifugation at 1,000g the lysate was pipetted directly onto the PAXgene® 
RNA spin column and centrifuged for a further minute at 13,000g, to permit select-
ive binding of the RNA onto the silica membrane. The membrane was then treated 
for 15 minutes at RT with 10μL DNase I and 70μL DNA digestion buffer to eradicate 
unwanted traces of bound DNA. A series of subsequent wash steps were performed 
in pre-optimised buffers in order to remove any remaining contaminants. The liquid 
flow-through was discarded and the spin columns transferred to fresh microcentrif-
61 
 
uge tubes. Two applications of elution buffer, each followed by a centrifugation step 
for 1 minute at 13,000g eluted the RNA. Samples (40μL) were heat-denatured for 5 
minutes at 650C and snap-cooled on ice.     
                 
2.3.1.3 RNA Yield and Quality Assessment    
Nucleic acid concentrations were determined using the NanoDropTM 1000 Spectro-
photometer (Thermo Fisher Scientific® Inc., UK). The ratio of sample absorbance (A) 
at 260/280 or 260/230nm wavelengths was used in order to measure the purity of 
the isolated material. RNA that is pure should have a value of approximately 2.0±0.2. 
Anything below 1.8 (A260/280) is indicative of DNA/protein contamination or may be 
due to some residual carryover (A260/230) of phenolic compounds and/or chaotropic 
salts from the extraction process. A small quantity of sample (1μL) was also removed 
to perform a Eukaryotic Total RNA 6000 Nano Assay on the Agilent 2100 Bioanalyzer 
(Agilent Technologies Ltd., UK). An algorithm applied by the software assesses the 
degree of separation between 18S and 28S ribosomal peaks on the electropherogram 
trace in order to compute an RNA integrity number (RIN) between 0 (undetectable, 
completely degraded) and 10 (high quality, intact RNA) (Schroeder et al 2006). In a 
study conducted by Copois et al (2007) the authors suggest that a threshold of 7.8 is 
sufficient for the generation of robust microarray gene expression data.                        
 
2.3.1.4 cDNA Synthesis    
2.3.1.4.1 cDNA Synthesis for qRT-PCR  
Total RNA isolated from peripheral whole blood was reverse transcribed into single-
stranded complementary DNA (ss-cDNA). cDNA synthesis was performed using the 
ABI High Capacity RNA to cDNA Synthesis Kit in accordance with the manufacturers 
guidelines. To 1μg of starting material, a 1X enzyme and reverse transcriptase (RT) 
buffer mix was added and the total reaction volume (20μL) made up in NF ddH20. A 
no-RT control to check for the presence of potentially contaminating genomic DNA 
was prepared as described without the addition of RNA-dependent DNA polymerase 
that is required for reverse transcription. Sample preparations were incubated in a 
G-storm GS2 Thermal Cycler (GRI Gene Technologies Ltd., UK) at 370C for 1 hour and 
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heat-denatured at 950C for 5 minutes. In each reaction it is assumed that there is an 
approximate 1:1 conversion of RNA to cDNA. The cDNA products were diluted in NF 
ddH20 and stored at 40C overnight or at -200C prior to use in either traditional SYBR® 
Green qRT-PCR or IDT PrimeTime® Mini qPCR Assays at an optimised concentration  
of 12.5ng/μL.                                                                          
 
2.3.1.4.2 cDNA Synthesis for Linear SPIATM Amplification  
The Ovation® RNA Amplification System V2 was used in order to generate reverse 
transcribed cDNA for the NuGEN Technologies Inc. patented SPIATM method of single 
primer isothermal amplification. Approximately 50ng total RNA dissolved in NF dd 
H20 was combined with the first-strand primer mix and incubated in a pre-warmed 
MJ Research PTC-100® Peltier Thermal Cycler (Bio-Rad Laboratories Inc., UK) at an 
annealing temperature of 650C for 5 minutes. The tubes were snap-cooled on ice for 
a minimum of 2 minutes prior to the addition a first-strand buffer and enzyme master 
mix. Incubation occurred at 480C for 60 minutes and the samples heat-denatured at 
700C for 15 minutes. Second-strand cDNA synthesis was performed at 370C for 30 
minutes followed by an additional incubation step at 750C for 15 minutes. The tubes 
were cooled to 40C and placed on ice before proceeding immediately with the SPIATM 
amplification protocol outlined in Section 2.3.1.5.1.                       
 
2.3.1.5 NuGEN Ovation® Whole Blood Solution    
2.3.1.5.1 NuGEN Linear SPIATM Amplification  
Linear SPIATM amplification was performed using the NuGEN Ovation® Whole Blood 
Solution in conjunction with the NuGEN Ovation® RNA Amplification System V2. The 
procedure was carried out under sterilised conditions in the Clean View UV Cabinet 
(Cleaver Scientific Ltd., UK). Briefly, products of the cDNA synthesis reaction (Secti-
on 2.3.1.4.2) were combined with an SPIATM Master Mix containing a unique DNA/ 
RNA chimeric primer, DNA polymerase and RNase H. The reaction was incubated in 
a pre-warmed MJ Research PTC-100® Peltier Thermal Cycler for 1 hour at 370C. Aft-
er the first 30 minutes the programme was paused to permit the separate addition 
of the Ovation® Whole Blood Reagent and, following a second 30 minute incubation 
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the tubes were heat-denatured to 950C, for 5 minutes and snap-cooled on ice for at 
least 2 minutes before being stored at -200C, prior to purification (Section 2.3.1.5.2).    
 
2.3.1.5.2 QIAGEN MinElute® Purification of NuGEN Amplified Material   
Amplified SPIATM cDNA was purified using the QIAGEN MinElute® Reaction Clean-Up 
Kit, according to the recommendations of NuGEN Technologies Inc., UK. Briefly, the 
samples were combined with binding buffer ERC and passed through a QIAGEN Min-
Elute® Spin Column at a centrifugation speed of 13,000g for 1 minute. Under a high 
chaotropic salt concentration the cDNA is adsorbed onto the silica membrane whilst 
unwanted traces of enzymes/detergents and unincorporated nucleotides are effec-
tively removed from the system. The membrane is washed with buffer PE and 80% 
freshly prepared ethanol solution. Following each addition the columns were centr-
ifuged at 13,000g, for 1 minute and the flow-through, containing contaminants was 
discarded. The purified products were eluted in 30μL NF ddH20 at RT and quantified 
using the NanoDropTM 1000 Spectrophotometer (Section 2.3.1.3), prior to being st-
ored at -200C.   
In addition, pre-amplified material from BLDPAT23 was treated with the Ambion® 
TURBO DNA-freeTM DNase Treatment and Removal Kit. Briefly, 10μg of sample was 
combined with a 1X TURBO DNase buffer and 2 units of TURBO DNase enzyme in a 
50μL reaction volume. Following 30 minutes incubation at 370C, 0.1 volumes of re-
suspended DNase inactivation reagent was added and the sample maintained at RT 
for 5 minutes. A short centrifugation step was performed at 10,000g for 90 seconds 
and the supernatant containing purified cDNA carefully transferred to a fresh 0.5mL 
Eppendorf tube.                                                                                 
 
2.3.1.5.3 EncoreTM Biotin-Labelling of Fragmented cDNA Targets   
The NuGEN EncoreTM Biotin Module was used to generate fragmented, biotinylated 
ss-cDNA targets suitable for hybridization onto Affymetrix® Human Genome U133 
Plus 2.0 GeneChip® Arrays. A fragmentation buffer/enzyme master mix was applied 
to 4.4μg purified SPIATM cDNA dissolved in NF H20 to create a final reaction volume 
of 32μL. The samples were incubated in a pre-warmed MJ Research PTC-100® Peltier
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Thermal Cycler at 370C for 30 minutes before reaching a denaturation temperature  
of 950C for 2 minutes and snap-cooled on ice. A second incubation in the presence of 
a proprietary labelling buffer, reagent and enzyme mater mix was then performed at 
370C for 60 minutes, followed by 700C for 10 minutes. This resulted in attachment of 
a single biotin molecule to the 3-hydroxyl terminal nucleotide of each SPIATM cDNA 
fragment; with typical fragments ranging in length between 50 and 100bp. Products 
were analysed on the Agilent Bioanalyser (Section 2.3.1.3) and stored at -200C. 
A detailed description of the Ambion® GLOBINClearTM procedure, carried out by Dr 
Rohini Raman (Raman 2011), can be found on page 67 of her doctoral dissertation 
titled: “Gene Expression Profiling to Identify Biomarkers of Motor Neuron Disease”.                        
 
2.3.1.6 Quantitative Real-Time PCR    
Quantitative RT-PCR (qRT-PCR) was performed in duplicate 10μL reaction volumes 
(Table 2.2) containing 12.5ng of cDNA template, optimum concentrations of forward 
(F’) and reverse (R’) primer sequences, a 1X Stratagene Brilliant II SYBR® Green/2X 
FastStart Universal SYBR® Green PCR Master Mix and RNase-freeTM water. Each run 
also included a negative no-RT and no template control (NTC). Haemoglobin, alpha 
2 (HBA2) transcript levels were measured pre- and post-SPIATM amplification using 
the standard housekeeping gene actin, beta (ACTB) which served as a positive end-
ogenous control. ACTB was selected over other commonly chosen normalisers, such 
as 18S ribosomal RNA (18SrRNA) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) since it was found to exhibit the most stable level of expression, across all 
of the samples in the experiment, using MAS 5.0 pivot data displayed by GeneChip® 
Operating Software (GCOS), Affymetrix® Ltd., UK.  
A “Normal 2 Step” profile for qRT-PCR products of less than 150bp was set up with 
FAM as the reporter dye and ROX the internal reference control, using a Stratagene 
Mx3000PTM Real Time PCR Thermal Cycler from Agilent Technologies Ltd., UK. An 
initial temperature step at 950C for 10 minutes was required in order to activate the 
SureStart Taq DNA polymerase. This was followed by 40 cycles of heat denaturation 
at 950C for 30 seconds and primer annealing/extension at 600C for 60 seconds. The 
programme ended with three final temperature steps; one at 950C for 60 seconds, a 
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 Gene Transcript Region Primer Sequence (5’ ---> 3’)  Tm GC% Amplicon Optimum conc. 



















Table 2.2 qRT-PCR Primers and Optimum Concentrations for Validation of the NuGEN Ovation® Whole Blood Study 
 
Abbreviations: 3’ - three prime, 5’ - five prime, ACTB - actin, beta, F’ - forward primer sequence, HBA2 - haemoglobin, alpha 2, qRT-PCR - quantitative real-time 
PCR, R’ - reverse primer sequence and Tm - melting temperature.         
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second at 600C for 30 seconds and a third at 950C for 30 seconds.  
This technology utilises fluorescence based detection chemistry, which enables the 
investigator to accurately detect and quantify the abundance of a particular nucleic 
acid transcript during each amplification cycle of the PCR reaction. It is reliant upon 
an intercalating dye, in this case SYBR® Green I, that binds indiscriminately and with 
high affinity to the minor groove of newly synthesised double-stranded DNA/cDNA. 
SYBR® Green I absorbs light at a maximum wavelength of 497nm and, in its excited 
state, it has an emission peak of around 520nm. During the exponential phase, the 
quantity of fluorescently labelled product accumulates, in a linear manner, as more 
and more amplicons are created. This leads to a quantifiable increase in the signal 
intensity readout; which is a measure directly relating to the length of the amplified 
target, as well as, the number of copies produced. Version 4.10, build 389 of Strata-
gene MxProTM QPCR Software (Agilent Technologies Ltd., UK) records the Ct or cycle 
threshold value which is defined as the minimum number of cycles required before 
the signal can be detected above background levels of the NTC. Relative mean conc-
entrations were determined by calculating the differences in Ct values between the 
gene of interest and the endogenous housekeeping control.                               
 
2.3.1.7 Agarose Gel Electrophoresis 
In order to ascertain whether pre- and post-SPIATM amplified PCR products were of 
an anticipated size for measurements of ACTB and HBA2 transcript levels in periph-
eral whole blood three SALS patient and control samples were selected at random to 
perform agarose gel electrophoresis. PCR products (7μL) and a 25-500bp molecular 
weight marker (5μL) (HyperLadderTM V) were run at 120V for approximately 30 to 
40 minutes on a 3.0% agarose gel made up in a 1X TAE buffer solution [0.4Mm Tris-
acetate and 0.01mM Sodium EDTA, pH 8.2 at 250C] and 3X concentration of the int-
ercalating nucleic acid stain GelRedTM (a non-toxic alternative to Ethidium Bromide) 
[APPENDIX FIGURE A3]. The bands which formed were visualised under a UV light 
source using the Syngene GENi Gel Documentation System.  
 
2.3.1.8 Affymetrix® HG_U133 Plus 2.0 GeneChip® Arrays 
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2.3.1.8.1 HG_U133 Plus 2.0 GeneChip® Arrays  
Affymetrix® HG_U133 Plus 2.0 GeneChip® Arrays are high-density oligonucleotide 
arrays with 1.3M distinct features, comprising ~54,000 probesets [11 pairs of PM 
and MM probes of 25-mer synthesised in situ directly onto the glass slide by photo-
lithography. The latter deviates from its complementary target by a single base at the 
13th position where an adenine (A) is substituted for thymine (T) and guanine (G) is 
substituted for cytosine (C), or vice versa] for the detection of >47,000 unique tran-
scripts and variants including more than 38,500 well characterised genes which are 
represented in the National Centre for Biotechnology Information (NCBI) (ncbi.nlm 
.nih.gov) GenBank®, dbEST or RefSeq database (Benson et al 2014, Boguski et al 19 
93, Pruitt et al 2014). Compared to previous generations, Plus 2.0 GeneChip® Arrays 
provide coverage of an additional 6,500 genes (Boguski & Schuler 1995, Schuler 19 
97, Schuler et al 1996) with sequence clusters generated from the UniGene build 133 
(April 2001) and 159 (January 2003) of the human genome.     
 
2.3.1.8.2 Hybridization     
SPIATM ss-cDNA targets, post-fragmentation and labelling, were hybridized onto the  
Affymetrix® HG_U133 Plus 2.0 GeneChip® Arrays following recommendations made 
by NuGEN Technologies Inc., UK and in accordance with the instructions contained 
in the GeneChip® Expression Analysis Technical Manual (Affymetrix® Ltd., UK) for 
use with the Affymetrix® GeneChip® 3’ IVT Expression Kit.   
GeneChips® were equilibrated to RT immediately prior to their use. Reagents were 
thawed on ice and the 20X Eukaryotic hybridization control stock heated to 650C for 
5 minutes or until the cRNA was completely re-suspended. A hybridization cocktail 
was prepared in 1.5mL Eppendorf tubes by combining 50μL of sample with the 20X 
Eukaryotic hybridization control stock (11μL) [bacterial genes bioB, bioC and bioD 
of the E. coli biotin synthesis pathway and the recombinase protein cre from the P1 
bacteriophage at respective concentrations of 1.5 (represents the limit of detection), 
5, 25 and 100pM (American Type Culture Collection)], 2X hybridization buffer (100 
μL) [100mM 2-(N-morpholino)ethanesulfonic acid (MES), 0.01% Tween-20 (pH 6.6 
at 250C), 1M [Na+] and 20mM EDTA], 10% dimethyl sulfoxide (DMSO) (22μL), 2nM 
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concentrations of control oligonucleotide B2 (3.7μL) and sufficient amounts of RNa 
se-freeTM water to bring the total reaction volume up to 220μL.  
Control oligonucleotide B2 hybridizes to the checkerboard pattern in each corner of 
the array as well as predefined features along its outer edge. These distinct patterns 
are important in aiding Microarray Suite version 5.0 (MAS5.0) (Affymetrix® Ltd., UK) 
in correctly aligning each array to a grid during the initial stages of image handling. 
Signal intensities generated from the serial concentrations of bioB, bioC, bioD and cre 
are used to provide the software with additional information on the efficiency of the 
hybridization, washing and staining procedures.   
After the preparation of the hybridization cocktail, the tubes were flicked to mix and 
their contents collected by centrifugation. The reaction mixture was heated to 990C 
for 2 minutes, then cooled to 450C for 5 minutes and centrifuged at maximum speed 
for 1 minute. The microarrays were primed with 200μL of pre-hybridization mix be-
fore being loaded into the GeneChip® Hybridization Oven 640 (Affymetrix® Ltd., UK) 
with rotation set at 60rpm. Following an incubation step at 450C for 10 minutes, the 
pre-hybridization mix was discarded and replaced with an identical volume, 200μL 
of the hybridization cocktail before being returned to the oven for 18±2 hours over-
night.                                                                                      
 
2.3.1.8.3 Washing, Staining and Scanning      
Post-hybridization washing and staining was performed on the GeneChip® Fluidics 
Station 450 applying fluidics protocol FS450_0004 and the standard 49 format Euk-
GEWS2v4_450 script, which are outlined in the GeneChip® Expression Wash, Stain 
and Scan User Manual for Cartridge Arrays (Affymetrix® Ltd., UK). Briefly, the hybr-
idization cocktail was removed and stored at 40C. Cartridges were loaded with 200 
μL non-stringent Wash Buffer A [6X SSPE containing 0.02M EDTA, 3M NaCl (sodium 
chloride), 0.2M NaH2PO4 (monosodium phosphate) and 0.01% Tween-20] and equ-
ilibrated to RT. Fresh solutions of staining reagents were then prepared. The SAPE 
mix for the first and third stain contained 2X stain buffer (300μL) [100nM MES, 1M 
[Na+] and 0.05% Tween-20], 1mg/mL (6μL) SAPE, 50mg/mL (24μL) Bovine Serum 
Albumin (BSA) and 270μL molecular biology grade water for a final reaction volume  
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of 600μL per sample. The antibody (Ab) mix for the second stain contained the same 
2X stain buffer (300μL), 10mg/mL (6μL) Goat IgG (immunoglobulin G) stock, 0.5mg 
/mL (3.6μL) biotinylated Ab, 50mg/mL (24μL) BSA and 266.4μL molecular biology 
grade water, again to achieve a final volume of 600μL per sample.   
Two post-hybridization washes, one with non-stringent Wash Buffer A at 250C, for 
10 cycles with 2 mixes per cycle and another, with stringent Wash Buffer B [100mM 
MES, 0.1M [Na+] and 0.01% Tween-20] at 500C, for 4 cycles with 15 mixes per cycle 
was followed by the first stain in SAPE solution at 250C for 10 minutes. A post-stain 
wash with non-stringent Wash Buffer A at 250C for 10 cycles with 4 mixes per cycle 
is then followed by a second and third stain at 250C for 10 minutes in the Ab solution 
and 10 minutes in the SAPE solution. A final wash step is then performed with non-
stringent Wash Buffer A at 300C for 15 cycles with 4 mixes per cycle. The cartridges 
are filled with 250μL of Array Holding Buffer prior to scanning.                                
 
2.3.1.9 Bioinformatics Analysis 
2.3.1.9.1 Affymetrix® GeneChip® Operating Software   
Images processed by the Affymetrix® GeneChip® Scanner 3000 were extracted using 
the GeneChip® Operating Software (GCOS) version 1.2 (Affymetrix® Ltd., UK).                                                                                  
 
2.3.1.9.2 GeneSpring GX v11.5.1   
CEL files containing information regarding probeset signal intensities as well as the 
percentages of present (P) or absent (A) calls for patients and controls recruited to 
the NuGEN Ovation® Whole Blood Study were imported into GeneSpring GX software 
version 11.5.1 (Agilent Technologies Genomics Ltd., UK) (Chu et al 2001, Dresen et 
al 2003, Xu et al 2004). Raw expression values were log2 transformed and a PLIER 
(Probe Logarithmic Intensity Error) 16 normalisation procedure applied without the 
need for performing a baseline conversion to the median of all the samples (Gyorffy 
et al 2009). DE transcripts were detected at the 5% significance level by means of an 
unpaired student’s t-test with an FDR corrected p<0.05 and FC threshold of greater 
than or equal to (≥) to plus or minus (±) 1.50.                                                                                         
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2.3.1.9.3 Gene Ontology Enrichment Analysis   
Affymetrix® ID’s were uploaded into the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) bioinformatics resource version 6.7 from the National 
Institute for Allergy and Infectious Diseases (NIAID) which is freely available online 
at david.abcc.ncifcrf.gov (Huang da et al 2009a, Huang da et al 2009b). Applying an 
Homo sapiens background, functional annotation clustering analysis was performed 
on GOTERM_BP_FAT and GOTERM_MF_FAT gene ontology (GO) terms with ‘Medium’ 
classification stringency [Kappa: similarity term overlap 3, similarity threshold 0.50; 
Classification: Initial group membership 3, final group membership 3 and multiple 
linkage threshold 0.50]. Those categories identified as being significantly enriched 
within the patient populations were defined as having a minimum EASE score above 
1.30 and Benjamini-Hochberg FDR corrected p<0.05. Kyoto Encyclopaedia of Genes 
and Genomes (KEGG) pathways were also interrogated using a Fishers Exact t-test 
conducted at the 5% significance threshold.           
An overview of the workflow and analysis pipeline for the 3’ IVT Expression Arrays 
used in the assessment of the JB NuGEN Ovation® WB Solution versus RR Ambion® 
GLOBINClearTM protocol, for performing GEP from peripheral whole blood in ALS, is 
provided in Figure 2.3. CEL files generated by Dr Rohini Raman (Raman 2011) were 
re-analysed in GeneSpring GX v11.5.1 using the same methods as described above in 
Section 2.3.1.8.2.                                   
 
2.3.2 GEP from Lymphoblastoid Cell Lines 
2.3.2.1 Tissue Collection and Storage  
Peripheral whole blood (6.0mL) was collected directly into sterile BD Vacutainer® 
Venous Collection Tubes containing anticoagulants, in order to prevent clotting, and 
1.0mL acid citrate dextrose solution B (ACD-B) [14.7g/L dextrose, 13.2g/L trisodium 
citrate and 4.8g/L citric acid]. The samples were transported at RT to the HPA ECACC 
where isolated peripheral blood lymphocytes were transformed in vitro, by Epstein-
Barr viral (EBV) infection, into stabilised immortal polyclonal B-cell lines. Suspension 






























Figure 2.3 Flowchart Schematic of 3’ IVT Expression Array Analysis Pipeline Established for 
Peripheral Whole Blood in ALS. 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, cRNA - copy RNA, DE - differential expression, 
GCOS - GeneChip® Operating Software, HG - Human Genome, IVT - in vitro transcription, KEGG -
Kyoto Encyclopaedia of Genes and Genomes,  mRNA - messenger RNA, PCA - principal component 
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analysis, SPIATM - single primer isothermal amplification and ss-cDNA - single-stranded complemen-
tary DNA.    
 
 
40mL Roswell Park Memorial Institute (RPMI) 1640 medium [370C incubator with 
5% carbon dioxide (C02) levels]; supplemented with 20% Foetal Bovine Serum (FBS) 
and 2mM concentrations of the essential amino acid, glutamate. Frozen cell pellets 
(LCL’s), containing approximately 2x107 cells per sample, were preserved in 300μL 
RNAlaterTM. These were shipped on dry ice and stored at -800C upon arrival.                              
 
2.3.2.2 QIAGEN Extraction of Total RNA from Frozen LCL’s     
Frozen lymphoblastoid cell pellets, preserved in RNAlaterTM, were thawed on ice for 
a minimum of 1 hour prior to extraction using the RNeasy® Mini Kit. The tubes were 
flicked gently until the pellet was dislodged and vortexed at a low speed in order to 
re-suspend the cells. A 75μL suspension, containing approximately 5x106 cells, was 
transferred to a sterile 1.5mL microcentrifuge tube. The samples were centrifuged at 
13,000g for 1 minute and the supernatant containing the RNAlaterTM stabilization 
reagent discarded. Cell lysis was immediately brought about by the addition of 600μL 
buffer RLT. The denaturant within this buffer, guanidine thiocyanate, also functions 
to preserve RNA integrity through its inhibition of RNase activity. The samples were 
then vortexed at maximum speed for 1 minute to ensure complete homogenisation 
of the cell lysate. Appropriate binding conditions were achieved with the addition of 
1 volume of freshly prepared 70% ethanol solution. The lysate was pipetted up and 
down three times to mix and 700μL transferred to an RNeasy® spin column, placed 
inside a 2mL collection tube, which was centrifuged at 10,000g for 15 seconds. The 
liquid flow-through was discarded and the procedure repeated with the remaining 
500μL of sample in order to permit selective binding of up to 100μg total RNA, of > 
200bp in length, to the silica membrane. A series of subsequent wash steps flushes 
the membrane of any remaining contaminants. Following each separate addition of 
700μL buffer RW1 and 500μL buffer RPE the spin columns were centrifuged for 15 
seconds at 10,000g and the liquid flow-through discarded. A second application of 
500μL buffer RPE with a centrifugation step at 10,000g for 2 minutes removed any 
residual ethanol which would otherwise have had the potential to interfere with a 
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number of downstream reactions. A dry spin at 13,000g for 1 minute was perform-
ed using a fresh 2mL collection tube in order to reduce the carryover of buffer RPE. 
The spin columns were transferred to sterile 1.5mL microcentrifuge tubes and the 
total RNA eluted in 40μL RNase-freeTM water, requiring a further centrifugation step 
at 13,000g for 1 minute. Nucleic acid concentrations could then be determined using 
the NanoDropTM 1000 Spectrophotometer. RNA products were subsequently stored 
at -800C. The quality of the extracted material was later assessed on the Agilent 21 
00 Bioanalyser (Section 2.3.1.3). 
RNA products of particularly poor quality (RIN score below 5.0) underwent DNase 
treatment to purify the isolated material and to remove potentially contaminating 
genomic DNA. Briefly, 10μg total RNA was incubated in a pre-warmed MJ Research 
PTC-100® Peltier Thermal Cycler at 370C for 10 minutes in the presence of 2 units 
of DNase I (1μL) and a 1X DNase reaction buffer [10mM Tris-HCl, 2.5mM MgCl2 and 
0.5mM CaCl2, pH 7.6 at 250C]. The program was paused and, following the separate 
addition of 5mM EDTA, the samples were heated to an inactivation temperature of 
700C for 10 minutes. Tubes were snap-cooled on ice for a minimum of 2 minutes and 
their contents collected by centrifugation. In instances where there was no visible 
improvement in the electropherogram trace of the Agilent 2100 Bioanalyser repeat 
RNA extractions were performed.    
                           
2.3.2.3 Affymetrix® WT Sense-Target Labelling Assay        
2.3.2.3.1 Linear Amplification   
Total RNA isolated from peripheral LCL’s was prepared for exon level microarray 
analysis using the Ambion® Whole Transcriptome (WT) Expression Kit. The protocol 
utilises a proprietary reverse transcription priming method, designed to specifically 
prime non-ribosomal RNA including both polyadenylated and non-polyadenylated 
mRNA. Briefly, on Day 1, total RNA is reverse transcribed into cDNA, which is then 
converted into anti-sense copy RNA (as-cRNA) by in vitro transcription (IVT) using 
a T7 RNA polymerase. Purification of the amplified as-cRNA was carried out on Day 
2, the product of which then became the template for the synthesis of ss-cDNA. 
Day 1 On ice, an initial 3μL reaction volume was prepared containing ~300ng total
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RNA made up in NF ddH20. Serial dilutions of positive premixed exogenous controls 
for the Bacillus subtilis genes lys (1:100,000), phe (1:50,000), thr (1:25,000) and dap 
(1:6,667) was performed according to instructions contained within the Affymetrix 
GeneChip® Eukaryotic Pol-A RNA Control Kit. In the first dilution, 2μL Poly-A control 
stock is added to 38μL of the supplied dilution buffer (1:20). After thorough mixing 
and a short spin in the microcentrifuge, 2μL of the first dilution is added to a further 
98μL of dilution buffer (1:50) to prepare the second dilution. The same volume of the 
second dilution (2μL) is again added to 98μL of dilution buffer (1:50) to prepare the 
third dilution. The fourth and final dilution was prepared by mixing 7μL of the third 
dilution with 21μL of dilution buffer (1:4).  
Pre-prepared total RNA was then combined with 2μL of the fourth dilution of Pol-A 
spike in controls prior to the introduction of the first-strand cDNA buffer (4μL) and 
enzyme (1μL) master mix. Gentle vortexing and a brief 5 second centrifugation step 
ensured thorough mixing and that the contents of the reaction were collected at the 
bottom of the tube before proceeding immediately with a 2 hour incubation in a pre-
warmed MJ Research PTC-100® Peltier Thermal Cycler. The samples were heated to 
250C for 60 minutes, followed by 420C for a further 60 minutes and then cooled to 
40C for a minimum of 2 minutes. The temperature of the lid was maintained at 500C 
throughout the cycle. At the end of the programme the tubes were centrifuged for 5 
seconds and placed on ice. A second-strand cDNA buffer (12.5μL) and enzyme (5μL) 
master mix was then added and the reaction volume made up to 60μL with NF ddH20. 
The tubes were vortexed, spun-down in a microcentrifuge and incubated, this time 
with the heated lid disabled, at 160C for 60 minutes followed by 650C for 10 minutes 
and then 40C for at least of 2 minutes. At the end of the programme the tubes were 
again centrifuged for 5 seconds and placed on ice. An IVT buffer (24μL) and enzyme 
(6μL) master mix was prepared at RT and 30μL transferred to each 60μL second-
strand cDNA sample. The tubes were vortexed, spun-down in a microcentrifuge and 
incubated at 400C for 16 hours with the heat lid set at 500C, and then maintained at 
40C overnight.  
Day 2 Purification of the newly synthesised as-cRNA was reliant on a magnetic bead-
based assay developed by Ambion® which removes unincorporated nucleotides and 
traces of unwanted salts, enzymes as well as inorganic phosphates. At RT the nucleic 
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acid binding beads (10μL) are combined with a concentrated buffer (50μL) and 60μL 
applied to the sample. After pipetting up and down three times to mix, the reaction 
was transferred to the well of a U-bottom plate, 60μL analytical grade isopropanol 
was added and the mixture pipetted up and down a further three times. The samples 
were gently shaken (setting G) on a Grant Bio PMS-1000 microplate shaker (Grant 
Instruments Ltd., UK) for 5 minutes in order to facilitate the binding of as-cRNA to 
the nucleic acid binding beads. The U-bottom plate was removed and placed on the 
Magnetic Stand-96 (Life Technologies Ltd., UK) for 10 minutes until the solution was 
completely transparent and the beads had formed a tight pellet against the magnets. 
The supernatant was then carefully aspirated and discarded ensuring not to disturb 
the pellet. Working quickly to prevent the beads from drying out, 100μL nucleic acid 
wash solution was added, the samples were shaken at a moderate speed (setting M) 
for 2½ minutes, the beads captured on the magnetic stand for 10 minutes and the 
supernatant discarded. This step was repeated and the samples shaken vigorously 
(setting V) for 1 minute to evaporate any residual ethanol. To each of the wells, 40μL 
of pre-heated (550C) elution solution was applied and the magnetic beads pipetted 
up and down several times until fully dispersed. Following a 2 minute incubation at 
RT, the samples were shaken vigorously for 3 minutes, the beads then captured on 
the magnetic stand for 60 seconds and purified as-cRNA transferred to sterile 0.2mL 
Eppendorf tubes on ice. As-cRNA concentrations were measured on the NanoDropTM 
1000 Spectrophotometer as previously described (Section 2.3.1.3).  
To perform the sense-strand cDNA synthesis, 2μL of random primers were initially 
combined with 10μg as-cRNA in a total reaction volume of 24μL which is equivalent 
to an as-cRNA concentration of 455ng/μL made up in NF ddH20. The samples were 
incubated, with the heated lid set at 750C, to a denaturation temperature of 700C for 
5 minutes, followed by 250C for another 5 minutes and then cooled to 40C for at least 
2 minutes. At the end of the programme tubes were centrifuged for 5 seconds and 
placed on ice. A second cycle sense-strand cDNA synthesis buffer (8μL) and enzyme 
(8μL) master mix was prepared and 16μL transferred to the reaction mixture. The 
tubes were vortexed, spun-down in a microcentrifuge and incubated, with the heated 
lid set at 750C, to an annealing temperature of 250C for 10 minutes, then 420C for 1 
hour 30 minutes followed by a heat denaturation step at 700C for 10 minutes before
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being cooled to 40C for a minimum of 2 minutes. At the end of the programme, the 
tubes were centrifuged for 5 seconds and placed on ice. The as-cRNA template was 
then degraded by the addition of 2μL RNase H. Pipetting up and down three times 
ensured the complete transfer of the enzyme from the pipette tip to the sample. The 
tubes were vortexed, spun-down in a microcentrifuge and incubated at 370C for 45 
minutes, with the heated lid set at 750C, followed by 950C for 5 minutes before being 
cooled to 40C for at least 2 minutes. At the end of the programme, tubes containing 
the newly synthesised ss-cDNA were centrifuged for 5 seconds and placed on ice.  
Purification of the ss-cDNA was achieved applying the same basic principles of the 
magnetic bead-based assay described above, with a few minor adjustments made to 
the protocol. Briefly, introducing 18μL of NF ddH20 water brought the final reaction 
volume up to 60μL. At RT nucleic acid binding beads (10μL) were combined with a 
concentrated buffer (50μL) and 60μL applied to the sample. After pipetting up and 
down 3 times to mix the reaction was transferred to the well of a U-bottom plate, 
120μL of absolute ethanol added and the mixture pipetted up and down a further 3 
times. Samples were gently shaken (setting G) for 5 minutes, the beads captured on 
a magnetic stand for 10 minutes and the supernatant discarded. Two applications of 
nucleic acid wash solution (100μL) were each followed by a moderate shake (setting 
M) for 2½ minutes and a capture time of 10 minutes before carefully aspirating and 
discarding the supernatant. Residual ethanol was evaporated by vigorously shaking 
the plate (setting V) for 1 minute. Purified ss-cDNA was then eluted by adding 30μL 
elution solution preheated to 550C and pipetting up and down until the beads were 
fully dispersed. Following a 2 minute incubation step at RT the samples were shaken 
vigorously for a further 3 minutes, the beads captured on the magnetic stand for 60 
seconds and the ss-cDNA transferred on ice to sterile 0.2mL Eppendorf tubes. Again 
concentrations were measured using the NanoDropTM 1000 Spectrophotometer as 
previously described (Section 2.3.1.3). The products were stored at -200C.                                                                                             
 
2.3.2.3.2 Fragmentation    
The ss-cDNA targets were fragmented into lengths of approximately forty to seventy 
nucleotides (~40-70nt) applying the Affymetrix® GeneChip® WT Fragmentation and 
Terminal Labelling Kit. To 5.5μg of starting material, NF ddH20 water was added to 
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bring the total reaction volume up to 31.2μL. A fragmentation master mix containing 
a 10X cDNA fragmentation buffer, 1,000 units Apurinic/Apyrimidinic Endonuclease 
1 (APE 1), 10 units Uracil-DNA Glycosylase (UDG) and RNase-freeTM water (10μL) 
was prepared on ice and 16.8μL transferred to each cDNA sample. The tubes were 
flicked to mix and the contents collected by centrifugation immediately prior to an 
incubation step at 370C for 60 minutes in a pre-warmed MJ Research PTC-100® Pel-
tier Thermal Cycler with the heated lid set at 1000C. The enzymes were heated to an 
inactivation temperature of 950C for 2 minutes and the tubes snap-cooled on ice. A 
1μL aliquot was retained for size distribution analysis on the Agilent 2100 Bioanal-
yser (Section 2.3.1.3).                                                                                                  
 
2.3.2.3.3 Labelling   
To a 45μL fragmentation reaction, 15μL labelling master mix was applied containing 
terminal deoxynucleotidyl transferase (TdT) (2μL), 5X TdT buffer (12μL) and 5mM 
concentrations of DNA labelling reagent (1μL). The tubes were flicked to mix and the 
samples centrifuged for 5 seconds immediately prior to an incubation step at 370C 
for 60 minutes in a pre-warmed MJ Research PTC-100® Peltier Thermal Cycler with 
the heated lid maintained at 1000C. At the end of the programme the samples were 
heated to a denaturation temperature of 700C for 10 minutes, before being cooled 
to 40C for a minimum of 2 minutes and placed on ice. The products were stored at -
200C.                                                                                                       
 
2.3.2.3.4 Electrophoretic Mobility Gel-Shift Assay   
The biotinylation efficiency of a proportion of the samples selected at random from 
each fragmentation and labelling batch was assessed in an Electrophoretic Mobility 
Shift Assay (EMSA) using the NeutrAvidinTM biotin-binding protein (Holden & Tacon 
2011, Ludwig et al 1995) in accordance with the recommendations of Affymetrix® 
Ltd., UK. Precast 15-well (15μL) 4 to 20% polyacrylamide gels were loaded into the 
Mini-PROTEAN® Tetra Cell (Bio-Rad Laboratories Inc., UK) and the system filled with 
a 1X TBE buffer solution containing 89mM Tris-borate and 2mM EDTA, pH 8.3±0.1 
at 250C. Two 1μL aliquots for each sample were transferred to separate Eppendorf 
tubes and heated to 700C for 2 minutes. A 2mg/mL concentration of NeutrAvidinTM 
78 
 
biotin-binding protein was prepared in a 1X PBS solution, pH 7.2±0.05 at 250C and 
5μL added to the first aliquot with the volume of the second aliquot being made up 
with PBS. The tubes were vortexed, spun-down in a microcentrifuge and incubated 
at RT for 5 minutes. Molecular weight markers HyperLadderTM IV (100-1000bp) and 
V (25-500bp) were loaded into the first and final lane of each gel. The samples were 
then combined with 5X DNA loading buffer (5μL), the mixture pipetted up and down 
3 times to mix and 10μL loaded onto the gel which was run at 150 volts for 1 hour. 
After electrophoresis the gel was stained in a 0.001% ethidium bromide solution in 
1X TBE buffer for 20 to 30 minutes and visualised under a UV light source using the 
Syngene GENi Gel Documentation System.                                      
 
2.3.2.4 Affymetrix® Human Exon 1.0ST Arrays        
2.3.2.4.1 GeneChip® HuEx-1_0-st-v2   
The Affymetrix® high-density Human Exon 1.0ST GeneChip® Arrays (HuEx-1_0-st-v 
2) contain more than 5.5M distinct features spotted directly onto a 5μm square glass 
slide by means of photolithography. In total there are in excess of 1.4M probesets [4 
PM probes assigned to each individual exon] for the interrogation of upwards of one 
million exon clusters, within probe selection regions of empirically supported trans-
cribed sequences, including putative full length mRNA transcripts: from the RefSeq 
(ncbi.nlm.nih.gov/refseq) (Pruitt et al 2014), GenBank® (ncbi.nlm.nih.gov/genbank) 
(Benson et al 2014) (n=289,961), Ensembl (ensembl.org) (n=306,583) (Fernandez-
Suarez & Schuster 2010, Flicek et al 2014) or dbEST (ncbi.nlm.nih.gov/genbank/d 
best) (n=665,175) (Boguski et al 1993) databases; synteny mapped mouse/rat gen-
omes (genome.ucsc.edu) (n=220,262) (Kuhn et al 2013), in addition to, those which 
have been predicted computationally in Ensembl, TWINSCAN (mblab.wustl.edu/ns 
can) (Brent 2008, Gross & Brent 2006), Exoniphy (cgwb.nci.nih.gov) (Blanchette et 
al 2004, Kent et al 2003), MITOMAP (mitomap.org) (Brandon et al 2005, Kogelnik et 
al 1996, Ruiz-Pesini et al 2007), VEGA (Vertebrate Genome Annotation) (sanger.ac. 
uk/resources/databases/vega) (Wilming et al 2008), GENSCAN (genes.mit.edu/gen 
scan) (Burge & Karlin 1997, Burge & Karlin 1998), or using structural RNA predict-
ion software (genome.ucsc.edu) (Karolchik et al 2014), GeneID (genome.crg.es/soft 
ware.geneid) (Guigo 1998, Parra et al 2000) and the microRNA (miRNA) registry (s 
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anger.ac.uk/software/Rfam/mirna) (Griffith-Jones 2004) for the discovery of novel 
expression changes and/or alternative splicing events that have not previously been 
reported (n=883,105).  
Each 25-mer oligonucleotide probe is designed to target the sense-strand of the July 
2003 NCBI build 34 of the human genome. On average, a typical gene composed of 
10 exons will be represented by approximately 30 to 40 probes distributed across 
the entire length of the protein coding transcript and not just the far 3’ end which is 
associated with the more traditional IVT expression arrays. Another distinguishing 
feature of the Human Exon 1.0ST GeneChip® Arrays is the strategy that Affymetrix® 
has adopted for subtracting background noise. Rather than possessing a paired MM 
probe for each PM probe, they have utilised a surrogate approach that incorporates 
measurements of background signal intensities from a smaller number of around a 
thousand, pooled probes with identical GC contents; referred to as an ‘antigenomic’ 
background probeset.  
                                                                                                         
2.3.2.4.2 Hybridization    
Sense-strand cDNA targets, post-fragmentation and labelling, were hybridized onto 
Human Exon 1.0ST GeneChip® Arrays according to the manufacturer’s instructions 
provided in the GeneChip® Hybridization, Wash and Stain Module (Affymetrix® Ltd., 
UK). GeneChips® were equilibrated to RT immediately prior to use. Reagents were 
thawed on ice and the 20X Eukaryotic hybridization control stock heated to 650C for 
5 minutes or until the cRNA had been completely re-suspended. The hybridization 
cocktail was prepared in 1.5mL Eppendorf tubes by combining the remainder of the 
sample [58 to 60μL depending on whether a 2μL aliquot had been removed in order 
to perform an EMSA (Section 2.3.2.3.4)] with 3nM control oligonucleotide B2 (3.7μL), 
20X Eukaryotic hybridization controls (11μL) [bioB, bioC, bioD and cre at respective 
concentrations of 1.5 (represents the limit of detection), 5, 25 and 100pM (American 
Type Culture Collection)], 2X hybridization mix (110μL), 7% DMSO (15.4μL) and a 
sufficient quantity of RNase-freeTM water in order to bring the total reaction volume 
up to 220μL. The tubes were flicked to mix and their contents collected by centrifu-
gation. The hybridization cocktail was heated to 990C for 5 minutes, cooled to 450C 
for 5 minutes and centrifuged at maximum speed for 1 minute. Arrays were loaded 
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with 200μL of sample and incubated at 450C in the GeneChip® Hybridization Oven 
640 (Affymetrix® Ltd., UK) for 16±0.5 hours overnight with rotation set at 60rpm.                                                                                                              
 
2.3.2.4.3 Washing, Staining and Scanning    
Post-hybridization, washing and staining was performed on the GeneChip® Fluidics 
Station 450 (Affymetrix® Ltd., UK) according to instructions contained in the Whole 
Transcript Sense Target Labelling Assay Manual for fluidics protocol FS450_0001 
that has been specifically developed for the Human Exon 1.0ST GeneChip® Arrays. 
Briefly, the hybridization cocktail was removed and stored at 40C. Cartridges were 
loaded with 200μL non-stringent Wash Buffer A [6X SSPE (3M NaCl, 0.2M NaH2PO4, 
0.02M EDTA) and 0.01% Tween-20] and equilibrated to RT. Fresh solutions of the 
staining reagents were prepared. SAPE mix for the first and third stain contained 2X 
stain buffer (300μL) [100mM MES, 1M [Na+] and 0.05% Tween-20], 50mg/mL BSA 
(24μL), 1mg/mL SAPE (6μL) and 270μL of molecular biology grade water for a final 
volume of 600μL per sample. The Ab mix for the second stain contained the same 2X 
stain buffer (300μL), 10mg/mL Goat IgG stock (6μL), 0.5mg/mL biotinylated Ab (3.6 
μL), 50mg/mL BSA (24μL) and 266.4μL of molecular grade water, again to achieve 
a final volume of 600μL per sample.  
Two post-hybridization washes, one with non-stringent Wash Buffer A at 300C for 
10 cycles with 2 mixes per cycle and another with stringent Wash Buffer B [100mM 
MES, 0.1M [Na+] and 0.01% Tween-20] at 500C for 6 cycles with 15 mixes per cycle, 
was followed by the first stain in SAPE solution at 350C for 5 minutes. A post-stain 
wash with non-stringent Wash Buffer A at 300C for 10 cycles with 4 mixes per cycle 
was followed by a second and third stain at 350C for 5 minutes in the Ab solution and 
5 minutes in the SAPE solution. A final wash step was performed with non-stringent 
Wash Buffer A at 350C for 15 cycles with 4 mixes per cycle and the cartridges filled 
with 800μL Array Holding Buffer prior to being scanned on the GeneChip® Scanner 
3000 (Affymetrix® Ltd., UK).     
It is important to note that in the design of this study several steps were taken so as 
to avoid any potential confounding effects of merging datasets from different batches 
of microarrays: 1) Kits and reagents were ordered in bulk from the same supplier so 
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consistent LOT numbers could be maintained; 2) The time that had elapsed between 
processing each of the batches was kept to a minimum; 3) The same stopping points, 
storage conditions & number of freeze thaw cycles were strictly adhered to for each 
run; 4) Groupings were assigned randomly and re-assigned at each level from RNA 
extractions right the way through to the point at which the cartridges were scanned 
and 5) Each of the groups contained roughly equal proportions of female and male 
samples with a mixture of controls, FALS and SALS cases of variable age, onset and 
disease duration.                                          
 
2.3.2.5 Bioinformatics Analysis        
2.3.2.5.1 Affymetrix® GeneChip® Operating Software    
Images processed by the Affymetrix® GeneChip® Scanner 3000 were extracted using 
GCOS version 1.2 (Affymetrix® Ltd., UK). Reports were generated at gene (transcript 
clusters) and exon (probesets) level which plotted signal distributions and other QC 
metrics used to evaluate the efficiency of individual hybridizations.                                                                                                                  
 
2.3.2.5.2 Partek® Genomics SuiteTM    
CEL files which had passed the QC metrics assessed by Expression ConsoleTM softw-
are version 1.3.0.187 (Affymetrix® Ltd., UK) (Section 2.3.2.5.2) were imported into 
Partek® Genomics SuiteTM software version 6.60 copyright © 2013 (Partek® Inc. St 
Louis, MO, USA) (Downey 2006, Fan et al 2011). Raw expression values were log2 
transformed, a pre-background adjustment for GC content was applied and a quant- 
ile normalisation procedure performed using the Robust Multi-array Average (RMA) 
median polish probeset summarization algorithm (Irizarry et al 2003, Qu et al 2010) 
which excludes outlying values falling below 1 or greater than 3 standard deviations 
away from the mean (Wu et al 2004). Only core meta-probesets were considered (n 
=287,329). At transcript level these include ~22,000 unique clusters which relate to 
full-length protein coding mRNA sequences in the RefSeq and GenBank® databases.    
DE transcripts were determined at the 5% significance threshold (Partek® unadjusted 
p<0.05) by means of a 2-way ANalysis of COVAriance (ANCOVA) statistical test which 
controls for the effects of age and gender. Lists were subsequently filtered to remove
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unannotated transcripts (n=4,377/22,011) and a FC threshold of ≥ ±1.20 applied.   
Aberrant splicing events were predicted at the same level of statistical significance 
using the Partek® alternative splicing index (ALT-SPLICE ANOVA) in which exon to 
exon comparisons were drawn between disease and control groupings for each gene 
in relation to the transcript’s overall DE [Partek® unadjusted p-value (fold-change) 
≥0.05 and p-value (alt. splicing) <0.05]. To reduce the probability of predicting false 
outcomes attributed to a type I error: a) Probesets with a maximum value for log2 
transformed signal intensities below 3 across all the GeneChips® in the experiment 
were removed except for instances where a significant difference in the expression 
of a single exon exists between the two groupings; b) Exons residing in genes whose 
expression at the level of the whole transcript was found to be significantly altered 
were excluded and c) Filtered transcript clusters with no observable differences in 
the expression levels of individual exons [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
(Gillett et al 2009, Rabin et al 2010, Tian et al 2011). Additional transcripts (n=2,077 
/17,273) with fewer than four or more than forty probesets were also removed since 
the presence of a such small/large number of markers makes it prohibitively more 
difficult to interpret the alternative splicing events predicted to occur within these 
genes (Whistler et al 2010). Graphical outputs were obtained using easyExon 1.0.4 
Java-based platform copyright © 2008 which is freely available online at microarray. 
ym.edu.tw/easyExon (National Yang-Ming University, Taiwan) (Chang et al 2008).                                                                                                                  
 
2.3.2.5.3 Qlucore Omics Explorer    
Partek® GC-RMA normalised pivot data could also be interpreted visually in Qlucore 
Omics Explorer software version 2.3 (Lund, Sweden). F-test statistical outputs for 
the ANOVA were filtered at the 5% significance level (p<0.05) in order to generate 
lists of variables or genes (transcripts) which are best able to separate patient and 
control groupings on a PCA plot or hierarchically clustered HeatMap. Any potentially 
confounding effects due to ‘Age’ (continuous) or ‘Gender’ (nominal) were eliminated 
as factors and the lists filtered to remove unannotated transcripts (n=3,356/22,011) 
using the NetAffxTM Analysis Centre, which is freely available online at affymetrix.co 
m/analysis/index/affx (Affymetrix® Ltd., UK) (Liu et al 2003), before applying a FC 
threshold of ≥ ±1.20.                                                                                                   
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2.3.2.5.4 Gene Ontology Enrichment Analysis   
Affymetrix® transcript cluster ID’s (gene level) or probeset identification numbers 
(exon level) were uploaded into DAVID bioinformatics resource version 6.7 (Section 
2.3.1.8.3). With a Homo sapiens background applied, function annotation clustering 
analysis was performed on GOTERM_BP_FAT and GOTERM_MF_FAT gene ontology 
(GO) terms using ‘Medium’ classification stringency [Kappa: similarity term overlap 
3, similarity threshold 0.50; Classification: Initial group membership 3, final group 
membership 3 and multiple linkage threshold 0.50]. Those categories identified as 
being significantly enriched within the patient populations were defined as having a 
minimum EASE score above 1.30 and Benjamini-Hochberg FDR corrected p<0.05.    
An overview of the workflow and analysis pipeline for the Human Exon 1.0ST Gene 
Chip® Arrays used for the transcriptional profiling of peripheral EBV-transformed B-
lymphocytes (LCL’s) in C9ORF72-related ALS [Chapter 5: ‘C9ORF72 GEP Study’ and 
Chapter 6: ‘C9ORF72 Survival Study’] is provided in Figure 2.4. 
 
2.3.2.6 Quantitative Real-Time PCR        
2.3.2.6.1 Primer Design    
Gene level expression changes observed on the Human Exon 1.0ST GeneChip® Arrays 
were validated by qRT-PCR. Standard primers ordered from Eurofins MWG Operon, 
Germany were designed using the NCBI Primer-BLAST tool which is freely available 
online at ncbi.nlm.nih.gov/tools/primer-blast. The reference sequence (RefSeq) of 
the full protein-coding transcript was obtained in FASTA format from ensembl.org 
and primers were designed to the region exhibiting the largest and most significant 
FC between the patient and control groupings. This was determined by plotting the 
mean probeset signal intensities from Partek® GC-RMA normalised pivot data along 
the y-axis against the Affymetrix® probeset identification numbers along the x-axis 
using Microsoft Excel 2010 (Microsoft Corporation, UK). Standard error of the mean 
(SEM) was calculated by dividing the standard deviation (stdev) by the square root 
of n which represents the number of samples in each group. Oligonucleotide probes 
were mapped to the genome and their specificity for the gene of interest confirmed 























Figure 2.4 Flowchart Schematic of the Human Exon 1.0ST GeneChip® Array Analysis Pipeline 
Established for Peripheral EBV-Transformed B-Lymphocytes (LCL’s) in ALS. 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C - cytosine, EBV - Epstein Barr virus, G - guan-
ine, GCOS - GeneChip®  Operating Software, GO - gene  ontology, LCL - lymphoblastoid cell line, RMA 
- Robust Multi-array Average, ss-cDNA - single-stranded complementary DNA and ST - sense target.    
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al.es/xgate/principal.php (Bioinformatics and Functional Genomics Research Group 
at the Salamanca Cancer Research Centre, Spain). Predicted dissociation curves for 
RT-PCR products could be visualised using uMELTTM software version 2.0.2 which is 
freely available online at dna.utah.edu/umelt/um.php (Wittwer lab for DNA Analysis 
University of Utah, USA).  
For optimal qRT-PCR efficiency, amplicon sizes were restricted to ~100±5bp. The 
oligonucleotides were around 15 to 25bp in length to ensure adequate specificity to 
their targeted sequence on the cDNA template but also that they remain sufficiently 
short to bind with ease under the appropriate annealing conditions. In order to limit 
the level of background genomic DNA amplification, primer pairs were designed to 
span an exon-exon junction wherever possible. GC content ranged between 35 and 
60% with no more than three guanine (G) or cytosine (C) residues occurring within 
the last five at the 3’ end of the sequence. This was important since the formation of 
a third hydrogen bond between these two residues means they have the propensity 
to bind to one another with a much higher affinity than the alternate pair of adenine 
(A) and thymine (T) residues. Although the presence of a small number of G’s and C’s 
at the 3’ end can improve the degree of association between the primer and cDNA 
template, having more than three results in too strong an association which causes 
a rise in melting temperature (Tm) and prevents the GC clamp from denaturing at 
the correct temperature. Tm is defined as the temperature at which 50% of the DNA 
duplex will separate to become single-stranded molecules and is usually optimal in  
the region of 58 to 600C.          
                                                                                           
2.3.2.6.2 Primer Optimisation and Standard Curve Analysis   
Primer optimisation was performed in triplicate 10μL reaction volumes using reverse 
transcribed Stratagene qPCR Human Reference Total RNA at an initial concentration 
of 12.5ng/μL. Oligonucleotide sequences were assayed at differing combinations of 
forward (F’) and reverse (R’) concentrations ranging between 150 and 600nmol. A 
NTC control was also included in each run [F’ - 300nmol, R’ - 300nmol] (Table 2.3). 
The standard deviation of the mean was calculated as a measure of the consistency 
between replicates of any given concentration and was used in order to determine 
the optimum combination of F’ and R’ primers for each gene which was selected as  
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  Reverse (R’) primer 





































BLANK 600/300 600/600 
           
Table 2.3 qRT-PCR Primer Optimization Oligonucleotides purchased 
from Eurofins MWG Operon, Germany were optimized for use in SYBR® 
Green qRT-PCR Assays using differing combinations of forward (F’) and 
reverse (R’) primer concentrations.  
 
Abbreviations: qRT-PCR - quantitative real-time PCR. 
 
 
a target for qRT-PCR validation. Specificity could be confirmed by the presence of a 
single peak on the dissociation melting curve.  
A standard curve was also produced by performing a two-fold serial dilution of the 
starting material using NF ddH20. Cycle threshold (Ct) values (y-axis) were plotted 
against the log of each known concentration of universal cDNA (copy number) along 
the x-axis. Efficiency and the coefficient of correlation (R2) were computed from the 
gradient of the incline. For reactions that were 100% efficient (slope - 3.32, R2 > 
0.99) the amount of PCR product should be seen to double with every amplification 
cycle.                                                                                                     
 
2.3.2.6.3 RNA Pooling   
RNA was pooled from 75 C9ORF72+ cases (i.e. all 39 from the microarray experiment 
plus an additional 36 G4C2 repeat carriers from the ECACC discovery and replication 
cohorts combined) and 35 neurologically normal, healthy control subjects matched 
for age and gender to incorporate measurements from a greater number of samples 
in each run. This approach was used in order to maximise the statistical power of the 
qRT-PCR assay whilst avoiding potential complications associated with running the 
experiments on multiple 96-well plates at differing time points and with different 
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batches of reagents. Each pool combined 200ng of good quality RNA (RIN score ≥ 
7.0), from five randomly selected patient or control derived LCL samples to achieve 









































































































































































































































































































   
 
Table 2.4 ECACC LCL Pooled RNA Samples for qRT-PCR Validation RNA of good quality 
[RIN score ≥7.0 on the Agilent 2100 Bioanalyser] was pooled from 75 C9ORF72+ cases and 35 
neurologically normal, healthy control subjects which had been matched for age and gender.    
Patient (P) and control (C) groupings were assigned at random with each pool incorporating 
material from five samples (200ng total RNA per sample).  
 
Abbreviations: (+) - positive, BC - Birmingham control, Be - Belfast City Hospital, BP - 
Birmingham patient, Br - Bristol Frenchay Hospital, C9ORF72 - chromosome 9 open reading 
frame 72, Ca - Cambridge, Du - Durham, ECACC - European Collection of Cell Cultures, F - 
female, LC - London control, LCL - lymphoblastoid cell line, Li - Liverpool, LNh - London 
National Hospital, LP - London patient, M - male, Ma - Manchester, Nc - Newcastle, Nt -
Nottingham, Pr - Preston, Po - Poole General Hospital, Py - Plymouth Derriford Hospital, qRT-
PCR - quantitative real-time PCR, RIN - RNA integrity number, SC - Sheffield control, Sh - 
Southampton Hospital and SP - Sheffield patient.        
 
 
2.3.2.6.4 cDNA Synthesis   
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Stratagene qPCR Human Reference Total RNA and pooled mRNA samples derived 
from patient or control LCL’s were reverse transcribed into ss-cDNA using the ABI 
High Capacity RNA to cDNA Synthesis Kit as previously described in Section 2.3.1.4. 
1. Products were diluted in NF ddH20 to a concentration of 12.5ng/μL and stored at 
-200C prior to use in either traditional SYBR® Green or IDT PrimeTime® Mini qPCR 
Assays.                                                                                                              
 
2.3.2.6.5 SYBR® Green Assays   
Traditional qRT-PCR was performed in duplicate 10μL reaction volumes containing 
12.5ng of cDNA template, optimum concentrations of F’ and R’ primers (Table 2.5), 
a 1X Stratagene Brilliant II SYBR® Green PCR Master Mix and RNase-freeTM water as 
previously described in Section 2.3.1.6. Negative no-RT and NTC’s were included in 
each run. Relative concentrations were normalised against the housekeeping gene 
18SrRNA and visualised using GraphPad Prism® software version 5.04 copyright © 
1992-2014 (GraphPad Software Inc., USA). Significance values were calculated in 
Microsoft Excel 2010 (Microsoft Corporation, UK) using a one-tailed student’s t-test. 
Gene expression changes were confirmed if the direction of change was the same as 
the microarray with p<0.05.    
 
2.3.2.6.6 PrimeTime® Mini qPCR Assays   
PrimeTime® Mini qPCR Assays from Integrated DNA Technologies INC., USA were 
also performed in duplicate 10μL reaction volumes with a negative no-RT and NTC. 
Each well contained 12.5ng of cDNA template, 500nM F’/R’ primer and 250nM probe 
re-suspended in TE buffer [10mM Tris-HCl and 1mM EDTA, pH 7.5 at 250C], RNase-
freeTM water and 2X Brilliant III Ultra-Fast qPCR Master Mix (Table 2.6). The samples 
were run applying a “Normal 2 Step” profile on the Stratagene Mx3000PTM Real Time 
PCR Thermal Cycler as outlined previously in Section 2.3.1.6. Relative concentrations 
were normalised against the standard housekeeping gene 18SrRNA and visualised in 
GraphPad Prism® software version 5.04 copyright © 1992-2014 (GraphPad® Soft-
ware Inc., CA USA). Significance values were calculated using Microsoft Excel 2010 
(Microsoft Corporation, UK) using a one-tailed student’s t-test. Expression changes 
were confirmed if the direction of change was identical to the microarray with a p<
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Gene Transcript Region Primer Sequence (5’ ---> 3’)  Tm GC% Amplicon Optimum conc. Efficiency 







98bp 150/150nmol 99.8% 







104bp 150/150nmol 101.1% 







74bp 150/300nmol 102.4% 







147bp 300/150nmol 115.3% 







104bp 300/600nmol 96.0% 







96bp 150/300nmol 102.3% 







120bp 150/150nmol 110.8% 







74bp 150/150nmol 111.8% 







83bp 150/150nmol 97.4% 







84bp 150/150nmol 107.5% 







109bp 300/150nmol 95.3% 







139bp 150/300nmol 103.0% 
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137bp 300/300nmol 99.4% 







106bp 150/150nmol 108.7% 







76bp 300/150nmol 100.4% 







90bp 600/300nmol 100.4% 







76bp 300/150nmol 98.3% 







100bp 150/150nmol 102.9% 







75bp 300/150nmol 102.8% 
Housekeeping Gene 
 







131bp 300/600nmol 115.5% 
 
Table 2.5 ECACC Eurofins MWG Operon qRT-PCR Primer Sequences and Optimum Concentrations   
 
Abbreviations: bp - base pairs, C9ORF72 - chromosome 9 open reading frame 72, DENR - density-regulated protein, F’ - forward primer sequence, FGFR1 - fibroblast 
growth factor receptor 1, HNRNPA0 - heterogeneous nuclear ribonucleoprotein A0, HNRNPF - heterogeneous nuclear ribonucleoprotein F, ITGAE - integrin, alpha E, KARS 
- lysyl-tRNA synthetase, MRPL41 - mitochondrial ribosomal protein L41, NUDT21 - nudix (nucleoside diphosphate linked moiety X)-type motif 21, PHAX - phosphorylated 
adaptor for RNA export, PRPF19 - PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae), PURA - purine-rich element binding protein A, R’ - reverse primer 
sequence, RBM3 - RNA binding motif (RNP1, RRM) protein 3, RPL22 - ribosomal protein L22, TAF13 - TAF13 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 18kDa, Tm - melting temperature, UTP15 - UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. cerevisiae), UTR - untranslated region, ZCRB1 - 
zinc finger CCHC-type and RNA binding motif 1 and 18SrRNA - 18S ribosomal RNA. 
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Gene PrimeTime®  RefSeq  Region Primer Sequence (5’ ---> 3’)  Probe Sequence (5’ ---> 3’) Amplicon 












FUS Hs.PT.58.40679981 NM_001170634 Exon 6-9 
F’ CCTTGCACAAAGATGGTGTTG 
















































Table 2.6 ECACC PrimeTime® Mini qPCR Primer and Probe Sequences   
 
Abbreviations: bp - base pairs, CLNS1A - chloride channel, nucleotide-sensitive, 1A, EIF4H - eukaryotic translation initiation factor 4H, F’ - forward primer sequence, FUS - fused 
in sarcoma, GEMIN6 - gem (nuclear organelle) associated protein 6, HNRNPH2 - heterogeneous nuclear ribonucleoprotein H2 (H’), KARS - lysyl-tRNA synthetase, NCBP2 - nuclear 
cap binding protein subunit 2, 20kDa, POLR2G - polymerase (RNA) II (DNA directed) polypeptide G, R’ - reverse primer sequence, UNRIP (STRAP) - UNR-interacting protein 




For improved specificity IDT utilises 5’ nuclease chemistry in which a non-extendable 
DNA hydrolysis probe is fluorescently labelled with a reporter dye and either one or 
two quenchers. When the probe is intact, the two molecules are maintained in close 
proximity to one another allowing energy emitted by the reporter to be absorbed by 
quencher(s). During the extension phase of the amplification reaction the hydrolysis 
probe is cleaved by the 5’ to 3’ exonuclease activity of SureStart Taq DNA polymerase 
causing the two molecules to dissociate from the target. A consequence of the spatial 
separation of the reporter dye and quencher(s) is a sharp increase in fluorescence 
which is then detected and recorded by the instrument.                                       
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CHAPTER 3: WHOLE BLOOD STUDY   
 
3.1 Clinical Characteristics of the NuGEN Cohort 
An overview of the clinical characteristics of participants recruited into the NuGEN 
Ovation® Whole Blood Study is provided in Table 2.1 (Section 2.1.1). Briefly, these 
comprised 6 Riluzole treated SALS patients of North European, Caucasian descent 
and an equal number of neurologically normal, healthy control subjects that were 
as far as possible age and gender matched. Age at symptom onset ranged between 
38 and 71 years with a mean of 60.3±15yrs and an average disease duration of ~3 
years and 4 months.                                      
 
3.2 PAXgene® Blood RNA Extraction 
PAXgene® isolated material extracted from whole venous peripheral blood derived 
from each of the 12 individuals in the final NuGEN microarray cohort (Section 3.1) 
yielded between 2.82 and 9.32μg total RNA for downstream applications including 
linear SPIATM amplification (Section 3.3.1) and cDNA synthesis prior to performing 
qRT-PCR (Section 3.4). Measurements of concentration and purity (Section 2.3.1.3) 
obtained using the NanoDropTM 1000 Spectrophotometer were found to be reason-
ably consistent across patient and control groupings with respective means of 65.00 
±25ng/μL and 69.37±28ng/μL and A260/280 ratios close to 2.20. Distinct separation 
of the 18S and 28S ribosomal peaks could also be observed on the electropherogram 
traces displayed by the Agilent 2100 Bioanalyser with rRNA ratios of 1.70±0.2 and 
RNA integrity values of 7.5 or above (Table 3.1) [Mean RIN 8.1±0.5 for SALS patients 
and 8.2±0.5 for controls] (Figure 3.1). 
 
3.3 Human Genome U133 Plus 2.0 GeneChip® Arrays              
3.3.1 NuGEN Ovation® Whole Blood Solution 
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Control ID RNA Concentration RNA Yield A260/280 RIN 
BLDCON01 48.66  ng/μL 3.89 μg 2.23 8.4 
BLDCON02 77.91  ng/μL 6.23 μg 2.21 7.7 
BLDCON04 35.29  ng/μL 2.82 μg 2.46 8.8 
BLDCON07 46.36  ng/μL 3.71 μg 2.16 7.7 
BLDCON08 101.26  ng/μL 8.10 μg 2.23 8.8 
BLDCON10 80.53  ng/μL 6.44 μg 2.12 7.9 
Mean Values 69.37 ng/μL 5.55 μg 2.24 8.2 
     
Patient ID RNA Concentration RNA Yield A260/280 RIN 
BLDPAT21 47.08  ng/μL 3.77 μg 2.28 8.4 
BLDPAT23 116.48  ng/μL 9.32 μg 2.15 7.5 
BLDPAT26 77.65  ng/μL 6.21 μg 2.12 8.0 
BLDPAT27 80.54  ng/μL 6.44 μg 2.14 8.1 
BLDPAT35 45.55  ng/μL 3.64 μg 2.25 8.8 
BLDPAT38 48.91  ng/μL 3.91 μg 2.14 7.7 
Mean Values 65.00 ng/μL 5.20 μg 2.18 8.1 
 
Table 3.1 PAXgene® Blood RNA Isolation Kit Extractions: An Assessment of Quality 
and Yield from Samples in the NuGEN Ovation® Whole Blood Study Measurements of 
concentration (ng/μL) and purity (A260/280), as determined by the ratio of absorbance (A) 
at 260/280nm, were assessed using NanoDropTM 1000 Spectrophotometer (Section 2.3. 
1.3) (Thermo Fisher Scientific® Inc., UK). Total RNA yields were calculated in micrograms 
(μg) and RNA integrity numbers (RIN’s) computed on a scale of zero (undetectable, com-
pletely degraded) to ten (high quality, intact RNA) using Agilent 2100 Bioanalyzer (Agilent 
Technologies Ltd, UK). Mean values recorded across the blood control (top) [BLDCON] or 












Figure 3.1 Agilent 2100 Bioanalyzer Assessment of PAXgene® Blood RNA Integrity 
Agilent RNA 6000 Nano Ladder with a 25 nucleotide [nt] molecular weight marker and 
peaks corresponding to the 18S and 28S ribosomal RNA’s (rRNA’s) have been labelled 
accordingly. Fragment lengths were plotted along the x-axis with RNA concentrations 
defined by arbitrary units of fluorescence [FU] plotted along the y-axis. In this example 
blood control [BLDCON] 01 was selected as a representative electropherogram trace for 
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3.3.1.1 NuGEN Ovation® RNA Amplification System V2 
Total RNA using a 50ng input of starting material was reverse transcribed into ss-c 
DNA following the NuGEN Technologies Inc., UK patented SPIATM method outlined 
in the previous Materials & Methods Chapter (Section 2.3.1.4.2 and 2.3.1.5.1). Yields 
of between 4.83 and 6.51μg were achieved, as determined by the NanoDropTM 1000 
Spectrophotometer (Section 2.3.1.3). Mean concentrations were largely comparable 
across the blood patient [BLDPAT] (179.23±21ng/μL) and blood control [BLDCON] 
(199.39±10ng/μL) groupings with A260/280 ratios consistently above the previously 
accepted threshold of 1.8. Pre-amplified material extracted from BLDPAT23, which 
produced the lowest RNA integrity value [RIN score 7.5 (Table 3.1)] also underwent 
DNase treatment (Section 2.3.1.5.2) in order to remove any potentially contaminat-
ing genomic DNA that may have been present in this sample. Nucleic acid products 
were purified using the QIAGEN MinElute® Reaction Clean-Up Kit before being run 
on the Agilent 2100 Bioanalyser (Section 2.3.1.3). An illustrated electropherogram 
trace (right) and corresponding gel image (left) typically generated by the instrum-












Figure 3.2 Agilent 2100 Bioanalyzer Assessment of Purified SPIATM ss-cDNA 
Integrity Electropherogram trace (right) and corresponding gel image (left) for 
blood patient [BLDPAT] 21 and the external RNA 6000 Nano Ladder with a 25nt 
molecular weight marker and 0.2, 0.5, 1.0, 2.0, 4.0 and 6.0kb fragments which are 
loaded at a total concentration of 150ng/μL. Fragment lengths [nt] are indicated 
along the x-axis with RNA concentrations defined by arbitrary units of fluoresc-
ence [FU] along the y-axis.   
 
Abbreviations: cDNA - complementary DNA, SPIATM - single primer isothermal 
amplification and ss - single-stranded.    
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  Purified SPIATM ss-cDNA                       Biotin-Labelled ss-cDNA 
Control ID  DNase Concentration Yield A260/280 RIN Concentration  Yield RIN 
BLDCON01  N 205.10  ng/μL 6.15 μg 2.38 2.2 96.00  ng/μL 4.80 μg 2.6 
BLDCON02  N 206.25  ng/μL 6.19 μg 1.89 2.2 110.00  ng/μL 5.50 μg 2.6 
BLDCON04  N 193.35  ng/μL 5.80 μg 2.38 2.0 93.00  ng/μL 4.65 μg 2.5 
BLDCON07  N 205.17  ng/μL 6.16 μg 2.18 2.2 114.00  ng/μL 5.70 μg 2.5 
BLDCON08  N 182.32  ng/μL 5.47 μg 1.88 2.3 105.00  ng/μL 5.25 μg 2.5 
BLDCON10  N 204.16  ng/μL 6.12 μg 1.83 1.9 111.00  ng/μL 5.55 μg 2.5 
Mean Values   199.39  ng/μL 5.98 μg 2.09 2.1 104.83  ng/μL 5.24 μg  2.5 
 
  
       
  Purified SPIATM ss-cDNA                                       Biotin-Labelled ss-cDNA 
Patient ID  DNase Concentration Yield A260/280 RIN Concentration  Yield RIN 
BLDPAT21  N 217.05  ng/μL 6.51 μg 1.86 2.4 96.00  ng/μL 4.80 μg 2.6 
BLDPAT23  Y 167.51  ng/μL 5.03 μg 1.92 2.0 92.00  ng/μL 4.60 μg 2.5 
BLDPAT26  N 191.50  ng/μL 5.75 μg 1.89 2.1 108.00  ng/μL 5.40 μg 2.5 
BLDPAT27  N 168.34  ng/μL 5.05 μg 1.87 2.0 110.00  ng/μL 5.50 μg 2.5 
BLDPAT35  N 170.16  ng/μL 5.11 μg 2.41 2.2 102.00  ng/μL 5.10 μg 2.5 
BLDPAT38  N 160.82  ng/μL 4.83 μg 2.40 2.0 96.00 ng/μL 4.80 μg 2.5 
Mean Values   179.23  ng/μL 5.38 μg 2.06 2.1   100.67  ng/μL 5.03 μg 2.5 
 
Table 3.2 Purified SPIATM ss-cDNA: An Assessment of Quality and Yield Pre- (Left)/Post- (Right) Fragmentation & Labelling Measure-
ments of concentration (ng/μL) and purity (A260/280), as determined by the ratio of absorbance (A) at 260/280nm wavelengths, assessed using 
the NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific® Inc., UK) (Section 2.3.1.3). Yields were calculated in micrograms (μg) and 
RNA integrity numbers (RIN scores) computed on a scale of zero (undetectable, completely degraded) to ten (high quality, intact RNA) using 
the Agilent 2100 Bioanalyzer (Agilent Technologies Ltd., UK). Mean values recorded across the blood control [BLDCON] (top) or blood patient 
[BLDPAT] (bottom) groupings are represented in bold.    
 
Abbreviations: cDNA - complementary DNA, DNase - deoxyribonuclease, N - untreated, ss - single-stranded, SPIATM - single primer isothermal 
amplification and Y - treated.    
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3.3.1.2 NuGEN EncoreTM Biotin Module 
The NuGEN EncoreTM Biotin Module (Section 2.3.1.5.3) generated between 4.60 and 
5.70μg biotinylated ss-cDNA fragments [Mean concentration of 100.67±7ng/μL for 
the SALS patients and 104.83±9ng/μL for the controls] of ~50 to 2,000 nucleotides 
in length (Table 3.2). These included >80% of targets with fewer than two hundred 
bases which were suitable for hybridization onto Affymetrix® Human Genome U133 










Figure 3.3 Agilent 2100 Bioanalyzer Assessment of Fragmented SPIATM ss-
cDNA Integrity Fragment lengths in nucleotides [nt] are indicated along the x-
axis with RNA concentrations, defined by arbitrary units of fluorescence [FU], 
along the y-axis. In this instance the representative electropherogram trace was 
selected from blood control [BLDCON] 02.    
 
Abbreviations: cDNA - complementary DNA, SPIATM - single primer isothermal 
amplification and ss - single-stranded. 
 
 
3.3.2 Affymetrix® Expression ConsoleTM QC Metrics 
3.3.2.1 Eukaryotic Hybridization Controls 
Signals produced by the bacterial spike in controls BioB, BioC, BioD (three E. coli 
derived genes of the biotin synthesis pathway) and CreX (a recombinase gene from 
the P1 bacteriophage) (Section 2.3.1.7.2) were called absent for BLDCON02, 08 and 
10 and BLDPAT21, 27 and 35. For this reason these 6 SALS cases and controls were 
not represented on the plots displayed in Figure 3.4. Given that all the samples had 
     Ladder 
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been processed together and in the same batch, it can be speculated, therefore, that 
these failings have most likely arisen due to a technical error in which the hybridi-
zation controls were not spiked in at correct concentrations sufficient for detection 
on Affymetrix® Human Genome Plus 2.0 GeneChip® Arrays. Subsequent assessment 
of the remaining 6 SALS cases and controls identified BLDCON07, highlighted in red, 
as a potential outlier (Figure 3.4) which requires careful consideration before deter-
mining whether or not this sample should be included in any further downstream 





Figure 3.4 Eukaryotic Hybridization Controls for Samples in the NuGEN Ovation® Whole Blood 
Study Three bacterial derived genes of the E. coli biotin synthesis pathway [BioB, BioC and BioD] and 
the recombinase gene CreX from the P1 bacteriophage were spiked in at increasing concentrations 
(left-hand panel) [1.5pM (representing the limit of detection), 5pM, 25pM and 100pM, respectively] 
immediately prior to labelling, in order to monitor the efficiency of the hybridization reaction. In the 
right-hand panel mean signal intensities (y-axis) for probesets spotted onto the Affymetrix® Human 
Genome U133 Plus 2.0 GeneChip® Arrays, which correspond to each of the aforementioned genes (x-
axis) are also provided. Assessment of Affymetrix® QC metrics was performed using the Expression 
ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK) (Section 2.3.1.7.2). Intensity plots were 
generated in Microsoft Excel 2010 (Microsoft Corporation UK). Potential outliers are highlighted in 
red.  
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient and QC - quality control. 
 
 
3.3.2.2 GeneChip® Normalisation  
3.3.2.2.1 Noise (Raw Q)  
Noise (Raw Q) measures the extent of pixel to pixel variation between the individual 
spots, otherwise referred to as ‘features’, on the Affymetrix® Human Genome U133 
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Plus 2.0 GeneChip® Arrays. Its value can be computed from data that is contained
within the .DAT files, using the Microarray Suite 5.0 (MAS 5.0) statistical algorithm, 
applied in Expression ConsoleTM software version 1.3.0.187. Noise is calculated as a 
function of the amount of inherent electrical noise that is associated with the operat-
ion of each individual scanner as well as the quality of the samples being hybridized 
(Figure 3.5).    
 












Figure 3.5 Noise (Raw Q) Calculation Microarray Suite (MAS) 
5.0 statistical algorithm for measuring the extent of pixel to pixel 
variation between individual spots or so called ‘features’ on the 
Affymetrix® Human Genome U133 Plus 2.0 GeneChip® Arrays in 
the NuGEN Ovation® Whole Blood Study. Noise (Raw Q) values 
computed in Expression ConsoleTM software version 1.3.0.187 
(Affymetrix® Ltd., UK). Equation adapted from the Report File 
Glossary pdf available at Affymetrix.com.      
 
 
Values for noise (Raw Q) were found to be consistent across multiple batches [Batch 
1 run on the 14th June 2011 0.657±0.02 and Batch 2 run on the 23rd June 2011 0.623 
±0.03; two-tailed student’s t-test not significant] with a slight difference having been 
observed between alternate sample types [Blood control (BLDCON) 0.620±0.02 and 
Blood patient (BLDPAT) 0.659±0.03; two-tailed student’s t-test producing a p-value 
below the 5% significance threshold (p<0.05*)] (Figure 3.6).   
  
3.3.2.2.2 Scaling Factor
One key assumption, fundamental to most normalisation procedures that have been 
described for high throughput arrays to date, including Affymetrix® Human Genome 
U133 Plus 2.0 GeneChip® Arrays is that the majority of transcripts should remain un-
 
𝑅𝑎𝑤 𝑄 = (1 𝑁⁄ ) ∗ (∑
𝑠𝑡𝑑𝑒𝑣𝑛
√𝑝𝑖𝑥𝑒𝑙𝑛
⁄ ) ∗ 𝑆𝐹 ∗ 𝑁𝐹 
 
   N = number of background features on the array 
   stdev = standard deviation 
   pixel = total number of pixels   
   n = nth background feature  
   SF = scaling factor 













Figure 3.6 Noise (Raw Q) Measurements for Samples in the NuGEN Ovation® 
Whole Blood Study A Microarray Suite (MAS) 5.0 statistical algorithm was applied 
in Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK) in order 
to measure the extent of pixel to pixel variation between individual spots or so call-
ed ‘features’ on the Affymetrix® Human Genome U133 Plus 2.0 GeneChip® Arrays. 
GraphPad Prism® software version 5.04 © 1992-2014 (GraphPad Software Inc., CA 
USA) was used to plot the data and two-tailed student’s t-tests performed to draw 
comparisons between the different experimental batches (left panel) [p-value was 
not significant] and sample types (right panel) [Average noise: 0.659 for SALS pat-
ients versus 0.620 in controls (p<0.05*)]. 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, BLDCON - blood control, BLD 
PAT - blood patient and S - sporadic.       
 
 
altered regardless of which experimental conditions are under manipulation; for ex-
ample, healthy versus disease status in the NuGEN Ovation® Whole Blood Study. In 
other words, if this statement holds true then the proportion of transcripts that are 
classified as either up (⇧)- or down (⇩)-regulated, for a given threshold of statistical 
significance, should not influence the overall fluorescence intensity of each GeneCh-
ip® which should remain comparable across the study.  
A MAS 5.0 statistical algorithm deployed by Expression ConsoleTM software version 
1.3.0.187 is used to apply a scaling factor (SF) which standardises the mean probe-
set signal intensities, in order to control for brightness. In this scenario, a measure-
ment close to 1.000 indicates that the average array intensity is approximately equal 
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to its target intensity. According to the manufacturer’s website SF values are expect-
ed to vary considerably across species, and between different tissue/sample types, 
explaining why currently no set guidelines have been published. Nevertheless, Affy 
metrix. com does advocate that there should be no more than a 3-fold difference in 
the minimum and maximum SF values recorded for a particular experiment. Exclu-
ding BLDCON07 (19.673), this was found to be broadly the case for samples in the 
NuGEN Ovation® Whole Blood Study [Mean SF values: BLDCON’s 4.581±2.7 versus 
BLDPAT’s 2.725±2.9 and Batch 1 run on the 14th June 2011 1.662±0.6 versus Batch 
2 run on the 23rd June 2011 5.158±3.1 with respective fold changes of 1.70 or 3.10]. 
 
3.3.2.3 RNA Quality 
Affymetrix® have selected the standard housekeeping genes ACTB and GAPDH with 
which to assess the quality of input RNA; owing to their long transcript lengths and 
ubiquitous expression. The probesets for these genes are designed to span their five 
prime (5’), mid (M) and three prime (3’) regions. Similar signal intensities across all 
three regions is indicative of the presence of good quality RNA that is intact and has 
been labelled reliably along the full length of its sequence. For samples in the NuGEN 
Ovation® Whole Blood Study, 3’/M ratios [ACTB 2.04±0.44-fold and GAPDH 1.80±0. 
51-fold] were found to be reasonably consistent, with slightly higher and more var-
iable changes recorded for the 3’/5’ ratios [ACTB 5.68±1.6-fold and GAPDH 2.43±0. 
71-fold]; suggesting that a small amount of RNA degradation may have occurred at 
the far 5’ end of the transcript. However, given that these are 3’ IVT expression arr-
ays this is not expected to cause further downstream complications (Figure 3.7).        
 
3.3.2.4 Overall Signal Quality 
3.3.2.4.1 Average Background  
The average background signal intensity values ranged from 25.575 (BLDCON07) to 
27.534 (BLDPAT23) for the 12 SALS patient and control samples in the final NuGEN 
Ovation® Whole Blood Study. Consistency was observed between multiple batches 
[Batch 1 run on the 14th June 2011 27.100±0.75 versus Batch 2 run on the 23rd June 




Figure 3.7 RNA Quality Control Check for Samples in the NuGEN Ovation® 
Whole Blood Study Microarray Suite (MAS) 5.0 signal intensity ratios between 
3’ and 5’ ends (█) or 3’ end and M (middle region) (█) of the standard house-
keeping genes beta, actin (ACTB) [left-hand panel] and glyceraldehyde-3-phos 
phate dehydrogenase (GAPDH) [right-hand panel] plotted along the y-axis. Box 
and whisker plots were generated, applying a Tukey multiple comparisons test, 
using GraphPad Prism® software version 5.04 © 1992-2014 (GraphPad Softw-
are, Inc. CA USA). Assessment of Affymetrix® QC metrics was performed using 
Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK).  
 
Abbreviations: 3’ - three prime, 5’ - five prime and QC - quality control.   
 
 
nate sample types [BLDCON’s 26.520±0.80 and BLDPAT’s 27.182±0.44; two-tailed 
student’s t-test not significant] (Table 3.8).    
 
3.3.2.4.2 Average Percentage Presence Calls  
In total, 54,675 probesets are represented on the Affymetrix® Human Genome U133 
Plus 2.0 GeneChip® Arrays. Each one is comprised of 11 probe pairs which contain a 
mix of PM, as well as, MM 25-mer oligonucleotide sequences pertaining to a similar 
number of gene transcripts or EST’s (Section 2.3.1.7.1). On average, 44.5% of genes 
were called as present (P) for controls (n=24,330), compared to 51.2% of genes for 
SALS patients (n=27,994) in the NuGEN Ovation® Whole Blood Study. A scatter dot 
plot displaying the mean and standard error of the mean (SEM) flagged BLDCON07, 
highlighted in red, as a potential outlier which had a significantly lower %P then the 
remainder of the cohort (p<0.01**) (Figure 3.8).  
 















Figure 3.8 Average Percentage Presence Calls for Samples in the 
NuGEN Ovation® Whole Blood Study Scatter dot plot was generated 
using GraphPad Prism® software version 5.04 © 1992 to 2014 (Graph 
Pad Software, Inc. CA USA) displaying the mean and standard error of 
the mean (SEM) number of probesets as a percentage (%) of the 54,67 
5 total which were called present (P) on Affymetrix® Human Genome 
U133 Plus 2.0 GeneChip® Arrays for SALS patient (∎) and control (•) 
samples in the NuGEN Ovation® Whole Blood Study. The range of %P 
calls which was considered acceptable is represented by the YELLOW 
shaded region between the two dashed lines at the 40 and 60% thres-
hold. Any potential outliers were highlighted in red. Assessment of QC 
metrics was performed using Expression ConsoleTM software version 
1.3.0.187 (Affymetrix® Ltd., UK). 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, BLDCON - blood 
control, BLDPAT - blood patient, QC - quality control and S - sporadic. 
 
 
The mean absolute relative log expression (RLE) can be used as a measure of how 
the signal intensities on each individual GeneChip® compare with those across the 
rest of the experiment. A cohort which exhibits relative homogeneity should have a 
score close to zero with a small spread of values around the mean. This was found 
to be largely the case for samples in the NuGEN Ovation® Whole Blood Study with 
the exception of BLDCON07 which is highlighted in red (Figure 3.9). 
 
3.3.2.6 Pearson’s Correlation Coefficient  
For each pair of GeneChips® in a microarray experiment the Expression ConsoleTM 
software version 1.3.0.187 determines a Pearson’s product-moment correlation co-
efficient (r), from the covariance divided by the product of the standard deviations. 
This is computed on a scale of -1 to 1 where zero equals no correlation (i.e. the data 
points are randomly distributed) and a value approaching plus (positive) or minus
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Figure 3.9 Mean Absolute Relative Log Expression (RLE) Boxplots for Samples 
in the NuGEN Ovation® Whole Blood Study RLE means and standard deviations 
for blood patient [BLDPAT] and control [BLDCON] samples in the NuGEN Ovation® 
Whole Blood Study. Whiskers represent minimum (lower) and maximum (upper) 
average probeset signal intensity values for each Affymetrix® Human Genome U133 
Plus 2.0 GeneChip® Array in the experiment. Assessment of QC metrics was perfor-
med using Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK). 
Potential outliers are highlighted in red.  
 
Abbreviations: QC - quality control. 
 
 
(negative) one is indicative of their being a strong linear relationship between the X 
and Y variables (Figure 3.10). This data can be illustrated qualitatively on a coloured 
matrix as depicted in Figure 3.11. Of the samples in the NuGEN Ovation® Whole Blo-
od Study BLDCON07, highlighted in red, produced by far the weakest correlation (r) 










Figure 3.10 Pearson’s Product-Moment Correlation Co-
efficient (r) Calculation Equation adapted from Hartman 
et al 2015, which is freely available online at gcat.davidson. 
edu/DGPB/clust/background (Davidson College, NC USA © 
2015).  
 
𝑟𝑃𝑒𝑎𝑟𝑠𝑜𝑛𝑠  =  
∑ 𝑋𝑌 − 
∑ 𝑋 ∑ 𝑌
𝑁
√(∑ 𝑋2 −  
(∑ 𝑋)2
𝑁 ) (




     
      X - Signal intensity values (Sample X) 
      Y - Signal intensity values (Sample Y) 































Figure 3.11 Pearson’s Correlation Coefficient (r) for Samples in 
the NuGEN Ovation® Whole Blood Study For each pair-wise comp-
arison in the coloured matrix a value for r is assigned on a scale of 0. 
322 (Blue) to 1.000 (Red) where the higher the score is indicative of 
a stronger linear relationship between the X and Y variables. Potent-
ial outliers are highlighted in red. Assessment of the Affymetrix® QC 
metrics were performed in Expression ConsoleTM software version 1. 
3.0.187 (Affymetrix® Ltd., UK). 
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient and 
QC - quality control.   
 
 
3.4 Pre- and Post-SPIATM qRT-PCR Measurements 
In order to monitor the efficiency of the NuGEN Ovation® Whole Blood Solution (Se-
ction 2.3.1.4.2 and 2.3.1.5.1) a qRT-PCR experiment was performed using tradition-
al SYBR® Green technology as outlined in Section 2.3.1.6. Relative Haemoglobin, al-
pha 2 (HBA2) mRNA transcript levels were measured against the standard housek-
eeping control, actin, beta (ACTB) (Figure 3.12) immediately prior to and following 
NuGEN Technologies Inc., UK patented SPIATM method of linear single primer isoth-
ermal amplification. ACTB was selected as the most suitable internal reference gene 
since it was found to have exhibited from MAS 5.0 pivot data (not shown) the most 
stable level of expression, of all the transcripts which are routinely assessed. Mean 
cycle threshold (Ct) values for post-SPIATM amplified material were significantly lo-
wered for ACTB [pre-SPIATM 19.278 (n=12) and post-SPIATM measurements 10.801 






















  Pre-SPIATM  Post-SPIATM  
  N mean Ct SEM  N mean Ct SEM p-value 
 BLDPAT’S 6 19.417 0.243  4 12.498 1.001 0.012 
ACTB BLDCON’S 6 19.138 0.150  4 9.105 0.357 2.56E-05 
 ALL 12 19.278 0.142  8 10.801 0.808 2.23E-05 
 BLDPAT’S 6 11.713 0.457  4 10.258 0.170 0.031 
HBA2 BLDCON’S 6 11.955 4.881  3 8.870 1.610 0.147 
 ALL 12 11.834 0.271  7 9.663 0.676 0.030 
 
Figure 3.12 Pre- and Post-SPIATM qRT-PCR Measurements of HBA2 mRNA Transcript 
Levels Relative to ACTB Using the NuGEN Ovation® Whole Blood Solution Mean and 
SEM cycle threshold (Ct) values (y-axis) for haemoglobin, alpha 2 (HBA2) (█) and the int-
ernal reference control gene actin, beta (ACTB) (█) are provided for each treatment group 
(x-axis). The bar chart in the uppermost panel was created in GraphPad Prism® software 
version 5.04 © 1992-2014 (GraphPad Software, Inc. CA USA). Probability values were de-
termined at the 5% significance threshold (p<0.05) with a paired student’s t-test applied 
in Microsoft Excel 2010 (Microsoft Corporation UK).  
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient, mRNA - messenger RNA, 
N - number, qRT-PCR - quantitative real-time polymerase chain reaction, SEM - standard 
error of the mean and SPIATM - single primer isothermal amplification 
 
 
SPIATM 11.833 (n=12) and post-SPIATM measurements 9.663 (N=7); ⇩1.20-fold (p< 
0.05*)]; an observation that also held true when the different sample types were in-
terpreted individually [Blood control (BLDCON): ACTB ⇩2.10-fold (p<0.001***) and 
HBA2 ⇩1.40-fold (p-value not significant) and Blood patient (BLDPAT): ACTB ⇩1.60- 
fold (p<0.05*) and HBA2 ⇩1.10-fold (p<0.05*) (Figure 3.12)]. These findings suggest 
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that the NuGEN Ovation® Whole Blood Solution, which utilises a unique DNA/RNA 
chimeric primer and proprietary whole blood reagent, has been successful in limit-
ing the amplification of globin mRNA relative to other transcripts, in this case ACTB, 
that are also contained within the sample in order to reduce interference on the mi-
croarray (Wright et al 2008).                                      
 
3.5 Peripheral Whole Blood Gene Expression Data 
Direct comparisons were drawn between the JB NuGEN Ovation® and RR Ambion® 
GLOBINClearTM (Raman 2011) strategies for performing GEP from peripheral whole 
blood using identical, age and as far as possible, gender matched patient (BLDPAT) 
and control (BLDCON) samples which were collected at the same time in PAXgene® 
Blood RNA Collection Tubes and stored at -200C for up to three years prior to being 
processed (Table 2.1) (Section 2.3.1.1).    
    
3.5.1 GeneSpring GX v11.5.1  
3.5.1.1 Normalisation  
Affymetrix® CEL files with the exclusion of BLDCON07, which was reported to have 
failed a number of the QC parameters (Section 3.3.2.1 and 3.3.2.6) assessed by Exp-
ression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd, UK), were uploaded 
into GeneSpring GX v11.5.1 analysis suite (Agilent Technologies Genomics Ltd., UK).  
Raw expression values were log2 transformed and a PLIER16 estimation algorithm 
applied (Section 2.3.1.9.2) without the need for performing a baseline conversion to 
the median of all the samples (Figure 3.13). Normalised signal intensities (Figure 3. 
14) were visualised on a profile plot in which each of the 54,675 probesets that are 
present on Human Genome U133 Plus 2.0 GeneChip® Arrays, is represented under 
different experimental conditions (i.e. healthy versus disease status) by a single co-
loured line where red, yellow and blue indicates whether the corresponding trans-


















Figure 3.13 PLIER 16 Normalised Distribution of Relative Log2 
Transformed Signal Intensity Values for Samples in the NuGEN 
Ovation® Whole Blood Study Box and Whisker plot generated usi-
ng GeneSpring GX v11.5.1 (Agilent Technologies Genomics Ltd., UK). 
BLDCON07 was omitted on the basis that it had failed several of the 
QC parameters assessed in Expression ConsoleTM software version 
1.3.0.187. 
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient, 





















































































































































































































































































Figure 3.14 Profile Plot of PLIER 16 Normalised Signal Intensity 
Values for Samples in the NuGEN Ovation® Whole Blood Study 
Mean absolute expression values which are displayed along the y-axis 
are represented under different experimental conditions (x-axis) [i.e. 
healthy (left panel) versus disease (right panel) status] for each of the 
54,675 probesets on the Affymetrix® Human Genome U133 Plus 2.0 
GeneChip® Arrays. Red, yellow and blue lines signify high, intermediate 
and low expressing transcripts, respectively. The plot was generated 
using GeneSpring GX software version 11.5.1 (Agilent Technologies 
Genomics Ltd., UK) with BLDCON07 having already been excluded on 
the basis that it failed several QC parameters assessed by Expression 
ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK).  
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient, 
PLIER - Probe Logarithmic Intensity Error and QC - quality control.  
 
 
3.5.1.2 Detection of Differentially Expressed Transcripts  
DE transcripts were detected at the 5% significance level in GeneSpring GX v11.5.1 
using an unpaired student’s t-test with an FDR corrected p<0.05 and FC threshold of 
≥ ±1.50 (Section 2.3.1.9.2).        
 
3.5.1.2.1 JB NuGEN Ovation® Dataset  
Analysis of the JB NuGEN Ovation® dataset identified 706 DE transcripts [unpaired 
student’s t-test FDR p<0.05, FC ≥ ±1.50]; considerably fewer than would ordinarily 
be expected by chance (n=2,733) (Figure 3.15). These included 239 genes (33.9%) 
that were significantly up-regulated (⇧) and a further 467 genes (66.1%) which we-
re significantly down-regulated (⇩) [APPENDIX TABLE A1].    
 
3.5.1.2.2 RR Ambion® GLOBINClearTM Dataset   
In contrast, analysis of the RR Ambion® GLOBINClearTM dataset (Dr Rohini Raman) 
identified a substantially greater proportion of transcripts (n=4,520) (Figure 3.15) 
as being DE [unpaired student’s t-test FDR p<0.05, FC ≥ ±1.50]. These included 3,4 
40 genes (76.1%) that were significantly up-regulated (⇧) and a further 1,080 genes 
which were significantly down-regulated (⇩) [APPENDIX TABLE A2].  
 










 ALL p<0.05 p<0.02 p<0.01 p<0.005 p<0.001 
ALL 54,675 3,785 1,449 728 371 81 
FC>1.1 22,242 3,426 1,325 685 351 78 
FC>1.5 1,643 706 296 161 82 22 
FC>2.0 74 50 27 16 11 5 
FC>3.0 6 3 3 3 3 2 








 ALL p<0.05 p<0.02 p<0.01 p<0.005 p<0.001 
ALL 54,675 11,103 7,064 4,983 3,473 1,389 
FC>1.1 33,707 11,072 7,055 4,982 3,473 1,389 
FC>1.5 5,560 4,520 3,611 2,869 2,246 1,074 
FC>2.0 1,264 1,213 1,126 986 833 492 
FC>3.0 198 192 180 176 172 132 
Expected by Chance  2,733 1,093 546 273 54 
 
Figure 3.15 Volcano Plots of the 706 and 4,520 Gene Lists Detected in GeneSpring GX 
v11.5.1 Between JB NuGEN Ovation® and RR GLOBINClearTM Datasets 
   
Abbreviations: FC - fold change, JB - Joanna Bury generated CEL files and RR - Dr Rohini 
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A GeneVenn diagram depicted in Figure 3.16, of the formerly discussed JB NuGEN 
Ovation® and RR Ambion® GLOBINClearTM (Section 3.5.1.2.1 and 3.5.1.2.2) datasets 
revealed substantial differences between the 706 and 4,520 lists. Only a handful of 
transcripts (n=82) (Table 3.3) representing just 11.6 or 1.8% of genes, respectively 
were shared in common with the majority of these disease related changes found to 













Figure 3.16 GeneVenn of JB NuGEN Ovation® and RR GLOBINClearTM 
Datasets DE transcripts were detected at the 5% significance level using 
an unpaired student’s test (p<0.05) and applying a FC threshold of ≥ ±1.50 
in GeneSpring GX software version 11.5.1 (Agilent Technologies Genomics 
Ltd., UK). The Venn diagram was created using the GeneVenn application 
that is freely available online at genevenn.sourceforge.net (University of 
Southern Mississippi, USA) (Pirooznia et al 2007).     
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, DE - differentially 
expressed, FC - fold-change, JB - Joanna Bury generated CEL files, RR - Dr 




Clustering analysis conducted at the 5% significance threshold in GeneSpring GX v1 
1.5.1 applying the 706 (Section 3.5.1.2.1) and 4,520 (Section 3.5.1.2.2) filtered gene 
lists [unpaired student’s t-test FDR p<0.05, FC ≥ ±1.50] demonstrated more distinct 
patient (BLDPAT) (blue) and control (BLDCON) (red) groupings on the PCA plot and 
hierarchically clustered HeatMap for the RR Ambion® GLOBINClearTM (Figure 3.17) 




   JB NuGEN Ovation® RR GLOBINClearTM 
Transcript Symbol Gene Name  FC p-value FC p-value 
206697_s_at HP  haptoglobin  ⇧ 2.40-fold 0.021 ⇧ 2.69-fold 2.48E-03 
211781_x_at --- --- ⇧ 2.34-fold 0.033 ⇧ 1.97-fold 0.020 
219359_at ATHL1 ATH1, acid trehalase-like 1 (yeast) ⇧ 2.09-fold 4.06E-03 ⇧ 1.75-fold 0.021 
208470_s_at HP  haptoglobin  ⇧ 2.05-fold 0.031 ⇧ 1.98-fold 0.046 
238591_at HEXDC hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing ⇧ 1.83-fold 0.028 ⇧ 1.59-fold 0.030 
1559128_at HSDL2 hydroxysteroid dehydrogenase like 2 ⇧ 1.71-fold 9.18E-03 ⇧ 1.86-fold 8.87E-04 
226322_at TMTC1 transmembrane and tetratricopeptide repeat containing 1 ⇧ 1.69-fold 0.026 ⇧ 4.47-fold 4.55E-03 
203326_x_at COL5A1 collagen, type V, alpha 1 ⇧ 1.58-fold 0.014 ⇧ 1.97-fold 4.61E-04 
221996_s_at CLTB clathrin, light chain (Lcb) ⇧ 1.57-fold 8.79E-03 ⇧ 1.91-fold 5.91E-04 
213457_at MFHAS1 malignant fibrous histiocytoma amplified sequence 1 ⇧ 1.56-fold 8.95E-03 ⇧ 1.66-fold 0.048 
229392_s_at PIK3R2 phosphoinositide-3-kinase, regulatory subunit 2 (beta) ⇧ 1.54-fold 6.70E-03 ⇧ 2.04-fold 8.85E-04 
1558739_at DUSP16 dual specificity phosphatase 16 ⇧ 1.53-fold 0.042 ⇧ 1.80-fold 3.07E-03 
206237_s_at NRG1 neuregulin 1 ⇧ 1.51-fold 0.041 ⇧ 1.59-fold 0.046 
218978_s_at SLC25A37 solute carrier family 25, member 37 ⇧ 1.51-fold 0.046 ⇧ 1.95-fold 0.047 
205215_at RNF2 ring finger protein 2 ⇩ 1.50-fold 0.027 ⇧ 1.93-fold 6.58E-03 
206544_x_at SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 
⇩ 1.50-fold 0.025 ⇩ 3.06-fold 5.37E-04 
241242_at FAM120A family with sequence similarity 120A ⇩ 1.51-fold 3.96E-03 ⇧ 1.94-fold 5.62E-03 
226109_at C21ORF91 chromosome 21 open reading frame 91 ⇩ 1.52-fold 0.048 ⇧ 1.52-fold 0.032 
222313_at CNOT2 CCR4-NOT transcription complex, subunit 2 ⇩ 1.52-fold 0.038 ⇧ 2.04-fold 0.014 
1555199_at GOSR1 golgi SNAP receptor complex member 1 ⇩ 1.53-fold 0.011 ⇧ 1.62-fold 1.72E-03 
200806_s_at HSPD1 heat shock 60kDa protein 1 (chaperonin) ⇩ 1.53-fold 0.015 ⇩ 2.87-fold 5.53E-04 
223254_s_at G2E3 G2/M-phase specific E3 ubiquitin ligase ⇩ 1.55-fold 0.026 ⇧ 1.89-fold 0.041 
242760_x_at PIGB phosphatidylinositol glycan anchor biosynthesis, class B ⇩ 1.55-fold 0.026 ⇧ 1.70-fold 0.018 
1555977_at LOC727918 hypothetical LOC727918 ⇩ 1.55-fold 0.043 ⇧ 2.00-fold 1.98E-03 
216072_at --- --- ⇩ 1.55-fold 0.039 ⇧ 1.56-fold 4.89E-04 
240248_at C10ORF46 chromosome 10 open reading frame 46 ⇩ 1.57-fold 0.045 ⇧ 2.35-fold 0.036 
201409_s_at PPP1CB protein phosphatase 1, catalytic subunit, beta isoform ⇩ 1.57-fold 0.048 ⇧ 1.73-fold 0.027 
229966_at EWSR1 Ewing sarcoma breakpoint region 1 ⇩ 1.57-fold 0.048 ⇧ 2.13-fold 2.88E-03 
202412_s_at USP1 ubiquitin specific peptidase 1 ⇩ 1.57-fold 2.42E-03 ⇧ 2.50-fold 4.91E-03 
217608_at SFRS12IP1 SFRS12-interacting protein 1 ⇩ 1.58-fold 0.015 ⇧ 1.73-fold 0.018 
200889_s_at SSR1 signal sequence receptor, alpha ⇩ 1.58-fold 5.27E-04 ⇩ 1.92-fold 2.71E-03 




1560017_at TMTC3 transmembrane and tetratricopeptide repeat containing 3 ⇩ 1.60-fold 0.049 ⇧ 1.58-fold 5.54E-04 
1555439_at GTF3C3 general transcription factor IIIC, polypeptide 3, 102kDa ⇩ 1.61-fold 0.043 ⇧ 1.67-fold 5.84E-03 
241294_at AP1G1 adaptor-related protein complex 1, gamma 1 subunit  ⇩ 1.62-fold 0.023 ⇧ 1.78-fold 0.011 
225980_at C14ORF43 chromosome 14 open reading frame 43 ⇩ 1.62-fold 0.027 ⇩ 1.72-fold 7.84E-03 
202068_s_at LDLR low density lipoprotein receptor ⇩ 1.63-fold 0.045 ⇩ 1.83-fold 5.36E-03 
222850_s_at DNAJB14 DnaJ (Hsp40) homolog, subfamily B, member 14 ⇩ 1.63-fold 0.047 ⇧ 2.84-fold 4.39E-03 
241610_x_at PACS1 phosphofurin acidic cluster sorting protein 1 ⇩ 1.64-fold 3.51E-03 ⇧ 4.94-fold 1.01E-04 
1569302_at KIAA1731 KIAA1731 ⇩ 1.64-fold 0.033 ⇧ 1.84-fold 0.017 
229353_s_at NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 ⇩ 1.65-fold 0.027 ⇧ 3.10-fold 2.90E-03 
236752_at PKP4 plakophilin 4 ⇩ 1.66-fold 1.12E-03 ⇧ 1.97-fold 0.011 
232311_at B2M Beta-2-microglobulin ⇩ 1.67-fold 0.019 ⇧ 3.33-fold 3.07E-04 
212479_s_at RMND5A required for meiotic nuclear division 5 homolog A (S. cerevisiae) ⇩ 1.67-fold 0.023 ⇧ 1.87-fold 1.23E-03 
213518_at PRKCI protein kinase C, iota ⇩ 1.67-fold 0.047 ⇧ 2.36-fold 6.86E-04 
1561015_at KLF3 Kruppel-like factor 3 (basic) ⇩ 1.68-fold 0.014 ⇧ 1.67-fold 0.011 
235060_at LOC100190986 hypothetical LOC100190986 ⇩ 1.68-fold 0.029 ⇧ 1.67-fold 0.016 
202006_at PTPN12 protein tyrosine phosphatase, non-receptor type 12 ⇩ 1.69-fold 0.020 ⇩ 1.77-fold 0.038 
222111_at FAM63B family with sequence similarity 63, member B ⇩ 1.71-fold 0.013 ⇧ 1.57-fold 0.016 
243233_at RNU6-1 RNA, U6 small nuclear 1 ⇩ 1.72-fold 0.021 ⇧ 2.41-fold 6.03E-03 
1554241_at COCH coagulation factor C homolog, cochlin (Limulus polyphemus) ⇩ 1.72-fold 0.048 ⇧ 3.13-fold 4.26E-05 
242576_x_at N4BP2L2 NEDD4 binding protein 2-like 2 ⇩ 1.72-fold 5.97E-03 ⇧ 2.89-fold 2.11E-03 
220369_at SMEK1 SMEK homolog 1, suppressor of mek1 (Dictyostelium) ⇩ 1.72-fold 0.024 ⇧ 1.75-fold 0.016 
244679_at STK38 serine/threonine kinase 38 ⇩ 1.72-fold 0.025 ⇧ 2.23-fold 0.017 
211352_s_at NCOA3 nuclear receptor coactivator 3 ⇩ 1.73-fold 0.032 ⇧ 1.80-fold 0.033 
218294_s_at NUP50 nucleoporin 50kDa ⇩ 1.73-fold 0.016 ⇧ 2.10-fold 0.013 
200751_s_at HNRNPC heterogeneous nuclear ribonucleoprotein C (C1/C2) ⇩ 1.73-fold 5.38E-03 ⇩ 1.90-fold 1.32E-03 
201299_s_at MOBKL1B MOB1, Mps One Binder kinase activator-like 1B (yeast) ⇩ 1.75-fold 0.037 ⇧ 1.50-fold 0.016 
238317_x_at RBMS1 RNA binding motif, single stranded interacting protein 1 ⇩ 1.75-fold 0.027 ⇧ 2.62-fold 1.03E-03 
227259_at CD47 CD47 molecule ⇩ 1.76-fold 6.15E-03 ⇧ 1.85-fold 7.84E-03 
1563975_at RNF130 ring finger protein 130 ⇩ 1.76-fold 5.12E-04 ⇧ 1.56-fold 0.016 
242844_at PGGT1B protein geranylgeranyltransferase type I, beta subunit ⇩ 1.77-fold 2.46E-03 ⇧ 1.82-fold 0.022 
237461_at NLRP7 NLR family, pyrin domain containing 7 ⇩ 1.85-fold 0.020 ⇩ 1.79-fold 0.019 
214352_s_at KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ⇩ 1.85-fold 8.23E-03 ⇧ 2.45-fold 2.60E-03 
201407_s_at PPP1CB protein phosphatase 1, catalytic subunit, beta isoform ⇩ 1.86-fold 0.044 ⇧ 2.01-fold 1.11E-03 
227364_at CAPZA1 capping protein (actin filament) muscle Z-line, alpha 1 ⇩ 1.86-fold 0.039 ⇧ 2.16-fold 6.57E-03 




233898_s_at FGFR1OP2 FGFR1 oncogene partner 2 ⇩ 1.89-fold 0.036 ⇧ 1.79-fold 0.037 
212418_at ELF1 E74-like factor 1 (ets domain transcription factor) ⇩ 1.94-fold 0.025 ⇩ 1.75-fold 5.43E-03 
224778_s_at TAOK1 TAO kinase 1 ⇩ 1.98-fold 0.041 ⇧ 2.01-fold 2.71E-03 
222409_at CORO1C coronin, actin binding protein, 1C ⇩ 1.98-fold 7.03E-03 ⇧ 1.94-fold 0.025 
230180_at DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 ⇩ 1.99-fold 0.017 ⇧ 1.71-fold 0.047 
215635_at PDE8A phosphodiesterase 8A ⇩ 1.99-fold 0.037 ⇧ 2.05-fold 0.021 
228471_at ANKRD44 ankyrin repeat domain 44 ⇩ 2.06-fold 0.033 ⇧ 3.12-fold 1.62E-05 
239957_at SETD5 SET domain containing 5 ⇩ 2.14-fold 0.026 ⇧ 2.03-fold 8.30E-03 
1552480_s_at PTPRC protein tyrosine phosphatase, receptor type, C ⇩ 2.19-fold 0.035 ⇧ 1.99-fold 0.026 
219978_s_at NUSAP1 nucleolar and spindle associated protein 1 ⇩ 2.23-fold 3.82E-03 ⇧ 2.01-fold 0.014 
228222_at PPP1CB protein phosphatase 1, catalytic subunit, beta isoform ⇩ 2.25-fold 0.030 ⇧ 3.34-fold 1.34E-03 
1552552_s_at CLEC4C C-type lectin domain family 4, member C ⇩ 2.28-fold 2.31E-03 ⇩ 2.27-fold 0.018 
201237_at CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 ⇩ 2.36-fold 0.031 ⇧ 2.53-fold 0.019 
1555687_a_at CLEC4C C-type lectin domain family 4, member C ⇩ 2.73-fold 0.015 ⇩ 2.15-fold 0.018 
231484_at ATP8A1 ATPase, aminophospholipid transporter (APLT) class I, type 8A, member 1 ⇩ 2.84-fold 0.046 ⇧ 3.82-fold 0.028 
 
Table 3.3 JB NuGEN Ovation® and RR GLOBINClearTM GeneSpring Common List (n=82) [unpaired student’s t-test p<0.05, FC ≥ ±1.50] Affymetrix® transcript 
IDs are ranked in order of fold-change (FC) for whole blood samples in the JB NuGEN Ovation® dataset and corresponding values for the same BLDCON and BLDPAT 
cases are provided in the adjacent columns for the RR GLOBINClearTM dataset. Unannotated transcripts as determined using the NetAffxTM Analysis Centre, which is 
freely available at affymetrix.com/analysis/index.affx (Affymetrix® Ltd, UK) (Liu et al 2003), were represented by three dashed lines under the ‘Symbol’ and ‘Gene 
Name’ headings. Arrows were used to indicate the direction of change [up-regulation (red) and down-regulation (green)]. Transcripts with the same direction of 
change for both datasets are highlighted in grey.  
 
Abbreviations: ATH1 - acid trehalase 1, ATP - adenosine triphosphate, BLDCON - blood control, BLDPAT - blood patient, CCR4 - chemokine (C-C motif) receptor 4, 
FGFR - fibroblast growth factor receptor, JB - Joanna Bury generated CEL files, NEDD - neural precursor cell expressed, developmentally down-regulated, NLR - 
NOD-like receptor, RR - Dr Rohini Raman generated CEL files, SNAP - snRNA activating protein, snRNA - small nuclear RNA and TAO - Thousand and One Amino Acid 
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Figure 3.17 Clustering Analysis of the JB NuGEN Ovation® Dataset Apply-
ing the 706 Gene List in GeneSpring GX v11.5.1 [unpaired student’s t-test 
FDR p<0.05, FC ≥ ± 1.50]  
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient, FC - fold 
change, JB - Joanna Bury generated CEL files and PCA - principal components 


























































































































































Figure 3.18 Clustering Analysis of the RR GLOBINClearTM Dataset 
Applying the 4,520 Gene List in GeneSpring GX v11.5.1 [unpaired 
student’s t-test FDR p<0.05, FC ≥ ± 1.50]  
 
Abbreviations: BLDCON - blood control, BLDPAT - blood patient, FC - 
fold change, PCA - principal components analysis and RR - Dr Rohini 
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3.5.1.4 DAVID Functional Annotation Enrichment Analysis  
The GeneSpring GX v11.5.1 generated 706 and 4,520 gene lists [unpaired student’s 
t-test FDR p<0.05, FC ≥ ±1.50] pertaining to JB NuGEN Ovation® (Section 3.5.1.2.1) 
and RR Ambion® GLOBINClearTM (Section 3.5.1.2.2) datasets could also be imported 
into DAVID bioinformatics resource version 6.7 (Huang da et al 2009a, Huang et al 
2009b). Functional annotation clustering analysis was subsequently performed on 
GOTERM_BP_FAT and GOTERM_MF_FAT gene ontology (GO) terms applying a Homo 
sapiens background and filtering using ‘Medium’ classification stringency (Section 2. 
3.1.8.3). Note that for the analysis of the RR Ambion® GLOBINClearTM dataset the 4, 
520 list was necessarily trimmed to include only the top ranking 3,000 probeset IDs 
as determined by probability value since this represents the upper limit which the 
software is capable of handling in each run. Categories with a minimum EASE score 
above 1.30 and Benjamini-Hochberg FDR corrected p<0.05 were considered statist-
ically significant. In total, DAVID mapped 686 (97.2%) of 706 [230 genes ⇧ and 456 
genes ⇩] and 2,692 (89.7%) of 3,000 (4,520) [2,130 genes ⇧ and 562 genes ⇩] Affy-
metrix® probeset IDs identified from each comparison.       
 
3.5.1.4.1 JB NuGEN Ovation® Dataset  
The 706 list of DE transcripts in GeneSpring GX v11.5.1 [unpaired student’s t-test 
FDR p<0.05, FC ≥ ±1.50] from the JB NuGEN Ovation® dataset was enriched for GO 
categories associated with protein serine/threonine kinase activity, enzyme binding, 
intracellular transport as well as the regulation of gene transcription from the RNA 
polymerase II promoter (Table 3.4).  
 
# GO term Functional Category EASE Count Benjamini 
1 GO:0004674 protein serine/threonine kinase activity 4.40 39 8.30E-05 
2 GO:0019899 enzyme binding 3.66 38 5.60E-03 
3 GO:0046907 intracellular transport 2.48 44 0.030 
4 GO:0006357 regulation of transcription from RNA 
polymerase II promoter 
2.47 47 0.028 
5 GO:0003702 RNA polymerase II transcription factor 
activity 
1.33 21 0.019 
  
Table 3.4 JB NuGEN Ovation® DAVID Functional Annotation Clustering Analysis  
 
Abbreviations: # - rank, DAVID - Database of Annotation, Visualisation and Integrated Discovery, 





3.5.1.4.2 RR Ambion® GLOBINClearTM Dataset 
Conversely, the 3,000 highest ranking genes in the GeneSpring GX v11.5.1 4,520 list 
of DE transcripts from the RR Ambion® GLOBINClearTM dataset [unpaired student’s 
t-test FDR p<0.05, FC ≥ ±1.50] were found to be enriched for GO categories that are 
associated with chromosome organisation, nucleotide binding, mRNA metabolism, 
protein transport and negative regulation of gene transcription (Table 3.5).      
 
# GO term Functional Category EASE Count Benjamini 
1 GO:0051276 chromosome organization 5.60 95 4.80E-04 
2 GO:0016071 mRNA metabolic process 4.17 70 0.014 
3 GO:0015031 protein transport 4.05 126 0.016 
4 GO:0045892 negative regulation of transcription, DNA 
-templated 
3.22 80 0.029 
5 GO:0000166 nucleotide binding 3.17 321 1.90E-03 
6 GO:0009057 macromolecular catabolic process 2.80 121 0.049 
7 GO:0051173 negative regulation of nitrogen 
compound metabolic process 
2.50 103 0.049 
8 GO:0006351 transcription, DNA-templated 2.28 291 0.031 
9 GO:0051169 nuclear transport 2.05 35 0.038 
 
Table 3.5 RR GLOBINClearTM DAVD Functional Annotation Clustering Analysis  
 
Abbreviations: # - rank, DAVID - Database for Annotation, Visualisation and Integrated Discovery, 
EASE - enrichment score, GO - gene ontology, mRNA - messenger RNA and RR - Dr Rohini Raman 
generated CEL files.           
 
 
3.5.1.4.3 JB NuGEN Ovation® and RR Ambion® GLOBINClearTM Comparison   
The DAVID comparative analyses of functionally enriched GO categories which are 
summarised in Table 3.4 and 3.5 highlighted very few commonalities, with perhaps 
the exception of gene transcription, between the JB NuGEN Ovation® (Section 3.5.1. 
4.1) and RR Ambion® GLOBINClearTM (Section 3.5.1.4.2) datasets. EASE scores of 5. 
6 or below coupled with relatively low gene counts suggest that both methodologies 
assessed here for GEP from peripheral whole blood in ALS are highly variable.      
 
3.5.1.5 KEGG Pathway Analysis  
KEGG pathway analysis also conducted in DAVID (Huang da et al 2009a, Huang et al 
2009b) identified six shared pathways common to both the JB NuGEN Ovation® and 




[Rank 1 (13), count 20 (46), 3.2% (2.0%) uncorrected p<0.001*** (Table 3.6 and 3. 
7)], Non-small cell lung cancer, T cell receptor signalling, chronic myeloid leukemia 
and gonadotropin releasing hormone (GnRH) signalling. In the following two secti-
ons, JB NuGEN Ovation® related gene expression changes which are associated with 
the top two most significant KEGG pathways, namely the MAPK (Section 3.5.1.5.1) 
and neurotrophin (Section 3.5.1.5.2) signalling cascades, are discussed further.  
 
# KEGG Pathway Count % p-value Benjamini 
1 MAPK signalling pathway 20 3.2 1.60E-03 0.210 
2 Oocyte meiosis 11 1.8 4.00E-03 0.250 
3 Long-term potentiation 8 1.3 7.90E-03 0.320 
4 Neurotrophin signalling pathway 11 1.8 9.20E-03 0.280 
5 Non-small cell lung cancer 7 1.1 9.50E-03 0.240 
6 T cell receptor signalling pathway 10 1.6 0.011 0.230 
7 RNA degradation 7 1.1 0.012 0.230 
8 Chronic myeloid leukemia 8 1.3 0.013 0.210 
9 NOD-like receptor signalling pathway 7 1.1 0.018 0.250 
10 Endometrial cancer 6 1.0 0.031 0.360 
11 GnRH signalling 8 1.3 0.048 0.480 
 
Table 3.6 JB NuGEN Ovation® KEGG Pathway Analysis Highlighted in yellow JB NuGEN Ovation® 
and RR Ambion® GLOBINClearTM common pathways.  
 
Abbreviations: # - rank, GnRH - gonadotropin releasing hormone, JB - Joanna Bury generated CEL 
files, KEGG - Kyoto Encyclopaedia of Genes and Genomes, MAPK - mitogen activated protein kinase, 
NOD - nucleotide binding oligomerization domain and RR - Dr Rohini Raman generated CEL files. 
 
 
3.5.1.5.1 MAPK Signalling Cascade  
The mitogen-activated protein kinases (MAPK’s) (otherwise known as extracellular 
signal-regulated kinases (ERK’s)) are a family of serine/threonine/tyrosine specific 
kinases which are responsible for the phosphorylation of cytoplasmic components 
and nuclear transcription factors (NTF’s) that regulate gene expression in response 
to a diverse array of extracellular stimuli including growth factors [classical MAPK 
cascade], pro-inflammatory cytokines, osmotic stress, heat shock and UV radiation 
[c-Jun N-terminal kinase (JNK)/p38 MAPK cascade] (Murai et al 2010, Strniskova et 
al 2002). 
Upon ligand binding to the receptor tyrosine kinases of the classical MAPK cascade 
autophosphorylation is triggered in order to attract protein complexes containing 




# KEGG Pathway Count % p-value Benjamini 
1 Fc gamma R-mediated phagocytosis 23 1.0 8.50E-04 0.140 
2 Glioma 17 0.8 1.50E-03 0.130 
3 Endocytosis 36 1.6 1.50E-03 0.090 
4 Chronic myeloid leukemia 19 0.8 1.60E-03 0.071 
5 B cell receptor signalling pathway  19 0.8 1.60E-03 0.071 
6 Insulin signalling pathway 28 1.2 2.50E-03 0.087 
7 Adipocytokine signalling pathway 17 0.8 3.00E-03 0.089 
8 Ubiquitin mediated proteolysis 28 1.2 3.10E-03 0.078 
9 Neurotrophin signalling pathway 26 1.2 3.10E-03 0.070 
10 Phosphatidylinositol signalling system  18 0.8 3.50E-03 0.069 
11 Spliceosome 26 1.2 3.90E-03 0.070 
12 VEGF signalling pathway 18 0.8 4.00E-03 0.066 
13 MAPK signalling pathway 46 2.0 4.40E-03 0.066 
14 Renal cell carcinoma 17 0.8 4.80E-03 0.066 
15 ErbB signalling pathway 19 0.8 8.60E-03 0.110 
16 RNA degradation  14 0.6 0.011 0.120 
17 Adherens junction 17 0.8 0.012 0.130 
18 Pathways in cancer 52 2.3 0.013 0.130 
19 GnRH signalling pathway 20 0.9 0.014 0.140 
20 Pancreatic cancer 16 0.7 0.015 0.140 
21 T cell receptor signalling pathway 21 0.9 0.020 0.170 
22 Leukocyte transendothelial migration 22 1.0 0.026 0.200 
23 Natural killer cell mediated cytotoxicity 24 1.1 0.028 0.210 
24 Jak-STAT signalling pathway 27 1.2 0.028 0.210 
25 Acute myeloid leukemia 13 0.6 0.029 0.200 
26 Fc epsilon R1 signalling pathway 16 0.7 0.029 0.200 
27 mTOR signalling pathway 12 0.5 0.031 0.200 
28 Progesterone-mediated oocyte maturation 17 0.8 0.033 0.210 
29 Inositol phosphate metabolism 12 0.5 0.040 0.230 
30 Non-small cell lung cancer 12 0.5 0.040 0.230 
31 Regulation of actin cytoskeleton 34 1.5 0.047 0.260 
 
Table 3.7 RR Ambion® GLOBINClearTM KEGG Pathway Analysis Highlighted in yellow JB NuGEN 
Ovation® and RR Ambion® GLOBINClearTM common pathways.  
 
Abbreviations: # - rank, ErbB - epidermal growth factor receptor, GnRH - gonadotropin releasing 
hormone, JAK - Janus kinase, JB - Joanna Bury generated CEL files, KEGG - Kyoto Encyclopaedia of 
Genes and Genomes, MAPK - mitogen activated protein kinase, mTOR - mammalian target of 
rapamycin, RR - Dr Rohini Raman generated CEL files, STAT - signal transducers and activators of 
transcription and VEGF - vascular endothelial growth factor.   
 
 
the GRB2 [GAPT (growth factor receptor-bound protein 2 (GRB2) binding adaptor 
protein, transmembrane) ⇩1.60-fold SALS, p<0.05] adaptor molecule to the plasma 
membrane which, in turn, leads to the activation of Ras [KRAS (Kirsten rat sarcoma 
viral oncogene homolog) ⇩1.85-fold SALS, p<0.01 accompanied by the inhibitory re-
gulator RASA1 (RAS p21 protein activator GTPase activating protein 1) ⇩1.51-fold S 
ALS, p<0.05].  
In the presence of the guanine nucleotide exchange factor, RasGRP [RASGRP2 (Ras 




directly, or indirectly via protein kinase C, activates Raf1, B-Raf and the oncogene 
homolog Mos which leads to the sequential phosphorylation of MAP2K1 (⇩1.56-fold 
SALS, p<0.05), MAPK1, RPS6K [RPS6KA2/A5 (ribosomal protein S6 kinase, 90 kDa) 
⇧1.96-fold SALS, p<0.001 and ⇩1.86-fold SALS, p<0.05 for the second and fifth poly-
peptide respectively] and cyclic adenosine monophosphate (cAMP) response elem-
ent binding transcription factor CREB (Di Giacomo et al 2009, Lu et al 2010) in ord-
er to promote cell differentiation and survival (Figure 3.19). Furthermore, MAPK1 
that is negatively regulated by DUSP16 [DUSP16 (dual specific phosphatase 16) ⇧1. 
53-fold SALS, p<0.05] is known to phosphorylate the calcium independent phosph-
olipase PLA2G [PLA2G4C (phospholipase A2, group IVC (cytosolic, calcium-indepen 
dent) ⇧1.81-fold SALS, p<0.01 and PLA2G6 (phospholipase A2, group VI (cytosolic, 
calcium-independent) ⇧1.76-fold SALS, p<0.05]; a molecule considered essential for 
normal lipid metabolism (Murakami et al 2011) which may also play an important 
role in FasL mediated apoptosis (Figure 3.19) (Section 1.2.4.8) (Atsumi et al 1998). 
An overall down-regulation in Ras GTPase activity observed on the 3’ IVT expression 
arrays in the peripheral whole blood of SALS patients recruited to the NuGEN Ovat-
ion® Whole Blood Study is expected to lead to a reduction in the levels of mitochon-
drial membrane associated B-cell CLL/lymphoma 2 protein (Bcl2) [BCLAF1 (BCL2-
associated transcription factor 1) ⇩1.77-fold SALS, p<0.01; BCL2L13 (BCL2-like 13 
(apoptosis facilitator)) ⇩1.59-fold SALS, p<0.01], which under normal physiological 
conditions, is known to suppress cell death signals by binding to apoptotic peptida-
se activating factor 1 (APAF1) and blocking cytochrome c release (Brunet et al 2001, 
Hockenbery et al 1990, Liu et al 1996, Ruvolo et al 2001). A significant depletion in 
the abundance of Bcl2 lifts its inhibition of apoptosis-related cysteine peptidase act-
ivation [CASP5 (caspase 5) ⇧2.03-fold SALS, p<0.05] thereby inducing programmed 
cell death (Kuranaga 2012, Momeni et al 2013).      
Several components of the JNK/p38 MAPK cascades, responsible for mediating cell 
cycle arrest and inducing potent pro-apoptotic signals upon detecting DNA damage 
(Ghosh et al 2009, Kim et al 2011, Ryazantseva et al 2008, Tamagno et al 2003, Van 
Laethem et al 2006), were also found to be dysregulated in the peripheral whole ve-
nous blood of SALS patients compared to controls. These include protein LAK1 [NLK 




amino acid protein kinase) ⇩1.98-fold SALS, p<0.05], TGFR-2 [TGFBR2 (transforming 
growth factor, beta receptor II (70/80kDa)) ⇩1.82-fold SALS, p<0.05], p58 [PAK2 p 
21 protein Cdc42/Rac associated kinase 2) ⇩1.60-fold SALS, p<0.05], MEKK1 [MAP 
3K1 ⇩1.70-fold SALS, p<0.05], MEKK7 [MAP3K7 ⇩ 1.61-fold SALS, p<0.05] and MAP 
3K7 interacting protein 1 (TAB1) [MAP3K7IP1 (TGF-beta activated kinase 1) ⇧1.59-
fold SALS, p<0.05].         
 
3.5.1.5.2 Neurotrophin Signalling Cascade  
The neurotrophic factors NT-3 (neurotrophin-3), NT-4/5 (neurotrophin-4/5), NGF 
(nerve growth factor) and BDNF represent a family of small secreted proteins which 
are responsible for promoting cell survival and cell death signals in the developing 
sensory/MN’s and microglial cells of the mammalian CNS (Ernsberger 2009). Their 
engagement of tropomyosin-related tyrosine kinase receptors, namely TrkA, TrkB 
and TrkC, induces receptor dimerization and autophosphorylation which attracts a 
whole plethora of signal transducing molecules to the plasma membrane (Chao et al 
2006, Skaper 2008). Of particular relevance were the SHC (Src homology 2 domain, 
containing) and SH2-B (SH2 domain containing signalling mediator) adaptor proteins 
which are involved in the recruitment of GRB2 (⇩1.60-fold SALS, p<0.05) and SOS2 
(⇧1.71-fold SALS, p<0.05) complexes that leads to the activation of Ras (⇩1.85-fold 
SALS, p<0.01); a small GTPase important for a diverse array of processes including 
cellular differentiation, retrograde axonal transport, neurite outgrowth and synaptic 
plasticity (Figure 3.19) (Bhattacharyya et al 1997, Feig 2011, Stornetta & Zhu 2011, 
Tartaglia & Gelb 2010). The Ras proteins K, N and H function as molecular switches 
which exert their effects via several intracellular signalling cascades including MAP 
K (Section 3.5.1.5.1) and the PI3K-AKT pathways [PIK3R2 (phosphoinositide-3-kin-
ase (PI3K) regulatory subunit 2, beta) ⇧1.54-fold SALS, p<0.01 which enhances AKT 
(alternative name protein kinase B (PKB)) inhibition of forkhead box O3a (FBXO3) ⇩  
1.54-fold, p<0.05 and glycogen synthase kinase 3, beta (GSK3B) proteins (Leger et al 
2006)]. Increases in PI3K-mediated phosphorylation of the serine/threonine specif-
ic kinase, AKT (Brunet et al 1999), is expected to block the translocation of FOXO3a 
into the nucleus; thereby preventing the subsequent activation of FasL gene transc-





Figure 3.19 KEGG Pathway Schematic of Neurotrophin Signalling Cascade    
 
Abbreviations: +P - phosphorylation, (⇧) - up-regulated, (⇩) - down-regulated, AKT - v-akt murine 
thymoma viral oncogene homolog, ARMS - ankyrin repeat rich membrane spanning, ASK - 
associated X protein, Bcl2 - B-cell CLL/lymphoma 2, BDNF - brain derived neurotrophic factor, B-
Raf - v-raf murine sarcoma viral oncogene homolog B, C3G - guanine nucleotide releasing protein, 
Cdc42 - cell division control protein 42 homolog, CREB - cyclic adenosine monophosphate (cAMP) 
responsive element binding protein, Crk - v-crk avian sarcoma virus CT10 oncogene homolog, Fas - 
first apoptosis signal, FasL - Fas ligand, FBXO3 - forkhead box O3, Gab - GRB2 associated binding 
protein, GRB2 - growth factor receptor bound protein 2, GSK3β - glycogen synthase kinase 3, beta, 
JNK - c-Jun N-terminal kinase, KEGG - Kyoto Encyclopaedia of Genes and Genomes, MAPK - mitogen 
activated protein kinase, NADE - p75NTR associated cell death executor, NGF - nerve growth factor, 
NRAGE - neurotrophin receptor interacting melanoma antigen gene (MAGE) homolog, NTR - 
neurotrophin receptor, PI3K - phosphoinositide 3 kinase, PTPN11 - tyrosine protein phosphatase 
non-receptor type 11, Rap1A - Ras related protein, RPS6K - ribosomal protein S6 kinase, SC1 - 
Schwann cell factor 1, SH2B - SH2 domain containing signalling mediator, Shc - Src homology 2 
domain containing, SOS - son of sevenless, TRAF6 - TNF receptor associated factor 6, E3 ubiquitin 
protein ligase, TNF - tumour necrosis factor, Trk - tyrosine kinase receptor and YWHAH - tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein, eta. 
 
 
Additionally, Ras is also known to interact with the Raf family of serine/threonine 
specific kinases that are known to mediate MAP2K1 (⇩1.56-fold SALS, p<0.05) and 
RPS6K activity (⇧1.96-fold SALS, p<0.001 and ⇩1.86-fold SALS, p<0.05 for the seco-
nd and fifth polypeptides, respectively (Gysin et al 2011)). Rap1A, a member of the 




 GDS/AF-6) domain family member 5) ⇩1.59-fold SALS, p<0.01] exert a similar fun-
ction which is initiated by the establishment of long lived complexes several additi-
onal adaptor molecules including C3G (guanine nucleotide releasing protein), SHP-
2 (protein tyrosine phosphatase, non-receptor type 11 (PTPN11)), GAP2 (glycosyl-
ation-associated protein 2) and the v-crk avian sarcoma virus CT10 oncogene hom-
olog (Gotoh et al 1995) [CRK ⇩1.59-fold SALS, p<0.05].   
NGF bound to the type I transmembrane protein sortilin (SORT1) is also a common 
ligand of the p75 neurotrophin receptor (p75NTR); a member of the TNF-receptor 
superfamily which activates several intracellular signalling cascades including the 
MAP3K1/JNK/p53/Bax [MAP3K1 (mitogen-activated protein kinase kinase kinase 
1, E3 ubiquitin protein ligase) ⇩1.70-fold SALS, p<0.01 (Figure 3.19)], NADE/YWH 
AH [YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, eta) ⇩1.69-fold SALS, p<0.001] and NRAGE [neurotrophin receptor-intera-
cting MAGE (melanoma antigen gene) homolog] pathways that can induce cell cycle 
arrest and programmed cell death. An overall down-regulation in the expression of 
a number of these transcripts detected in the peripheral whole venous blood of SALS 
patients compared to controls would be expected to further promote signals which 
enhance cell survival (Arnett et al 2007, Chen et al 2008, Feng et al 2010, Fortress 
et al 2011, Nykjaer et al 2004, Teng et al 2005).          
 
3.6 DISCUSSION 
In ALS the tissue which is primarily affected remains inaccessible during life. There 
are also a number of limitations (Section 1.3.2) (Cooper-Knock et al 2012a, Sharp et 
al 2006a, Sutherland at al 2011) associated with the use of human post-mortem SC 
and brain specimens; not least of all that the GEP’s generated from such material is 
only representative of the terminal stages of disease progression at which point the 
majority of vulnerable neuronal cell populations will have already been lost from the 
system. In more recent years a wide range of peripheral tissues (Section 1.3.1 and 1. 
3.2) including whole venous blood [Chapter 3: ‘Whole Blood Study’] and immortal-
ised EBV-transformed B-lymphocytes (LCL’s) [Chapter 5: ‘C9ORF72 GEP Study’ and 




the pathogenesis of a number of neurodegenerative and neuropsychiatric conditions 
including ALS (Saris et al 2009) (Section 1.4.1.1), SCHIZ and BPD (Tsuang et al 2005) 
(Section 1.4.1.2.4 and 1.4.2.2.1-2), ALZ (Maes et al 2007) (Section 1.4.1.2.3), HD (Bo-
rovecki et al 2005) (Section 1.4.1.2.1) and PD (Scherzer et al 2007) (Section 1.4.1.2. 
2) that have been reviewed briefly in Chapter 1: ‘Introduction’ and elsewhere in the 
literature by Borovecki & Habek (2010), Cooper-Knock et al (2012c), Mohr & Liew 
(2007), Sharp et al (2006b) and Woelk et al (2011).  
Blood offers a particularly attractive source of material for microarray applications 
owing to good standardization of technical procedures, non-invasive collection and 
longitudinal sampling in large volumes (Table 1.4) (Burczynski & Dorner 2006). At 
least 80% of the genes which are routinely expressed in the CNS are also detectable 
in the transcriptome profile of circulating blood (Liew et al 2006). Additionally, the 
majority of disease causative genes in ALS have been reported to be ubiquitously ex-
pressed (Cooper-Knock et al 2012c). Quantifiably changes in the mRNA levels of th-
ese transcripts in response to perturbations in the micro- or macroenvironment, th-
erefore, is suggestive of blood constituting a rich biosensor pool which has the pot-
ential to act as a sentinel of the neurodegenerative disease process (Kennedy et al 
2008, Pahl 2005, Staratschek-Jox et al 2009). It has become apparent, however, that 
the sheer abundance (Raghavachari et al 2009, Winn et al 2010) of erythrocyte de-
rived alpha (α) and beta (β) haemoglobin transcripts, comprising up to 70% of total 
RNA species isolated from peripheral whole blood preparations, could be producing 
interference on the microarray that is masking the detection of other, less abundant 
transcripts of equal biological importance within the sample (Section 1.3.3) (Feezor 
et al 2004, Kam et al 2012, Wright et al 2008). In order to overcome this challenge, 
and to improve the overall reliability and sensitivity of such studies, several globin 
reduction strategies have been developed (Vartanian et al 2009) including Ambion® 
GLOBINClearTM (Raman 2011) which utilises selective hybridization and a magnetic 
bead based separation method of depletion (Field et al 2007) and NuGEN Technolo-
gies Inc., UK patented SPIATM system that uses a proprietary reagent in the Ovation® 
Whole Blood Solution for generating ss-cDNA targets, from as little as 5ng starting 
material (Dafforn et al 2004); which have proven less prone to non-specific hybrid-




al 2005, Debey et al 2006, Eklund et al 2006, Parrish et al 2010, Tian et al 2009) int-
eractions. Previously obtained results using the Ambion GLOBINClearTM protocol in 
combination with the PAXgene® Blood RNA collection tubes (Dumeaux et al 2008, Li 
et al 2008a, Liu et al 2006) demonstrated high interindividual variability, low sam-
ple integrity and poor reproducibility (Raman 2011); with inconsistencies between 
microarray findings and subsequent qRT-PCR validation experiments.  
The initial aim of the PhD was to evaluate the NuGEN Ovation® Whole Blood Soluti-
on as a suitable alternative for the generation of robust gene expression data from 
peripheral whole blood. For direct comparability, patient and control samples were 
recruited to the study from the Raman (2011) cohort with specimens collected at the 
same time in different PAXgene® Blood RNA Collection Tubes (Section 2.3.1.1) and 
stored at -200C for a maximum of 3 years prior to being processed. Although stora-
ge times differed considerably between the RR Ambion® GLOBINClearTM and the JB 
NuGEN Ovation® datasets, PreAnalytiX does advocate that intracellular RNA should 
remain stable for up to 8 years without a significant degree of degradation occurring 
ex vivo (preanalytix.com). The achievement of comparable RNA concentrations and 
yields that produced similar ratios of absorbencies at 260/280nm wavelengths and 
high RNA integrity values [RIN’s 7.5 or above (Section 2.3.1.3)] on the Agilent 2100 
Bioanalyzer is supportive of this statement. The electropherogram traces are illust-
rative of good quality, intact RNA having been extracted using the PAXgene® Blood 
RNA Isolation Kits (Section 2.3.1.2) (Figure 3.1) and post-hybridization QC measures 
assessed using Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., 
UK) were also relatively consistent between the two (Table 3.8) with reduced noise 
(Raw Q), lower background (bgrd) signal intensities and higher %P calls associated 
with the JB NuGEN Ovation®  dataset.  
Circulating blood is classified as a fluid connective tissue that is in a permanent state 
of renewal and is known to play a pivotal role in physiological homeostasis, cellular 
immunity and inflammation. It is composed of a mixed cell population that contains 
plasma (55%), erythrocytes (43%), leukocytes (<1%) [neutrophils, lymphocytes (T-
cells, B-cells and natural killer or NK cells), monocytes, basophils and eosinophils] 
and platelets (1.5%) which continuously permeates and interacts with every other 




a) JB NuGEN Ovation® dataset  
 RNA Yield  A260/280 RIN Bgrd Raw(Q) SF %P 
GAPDH 
3’-5’ ratio 
BLDCON01 3.89 μg 2.23 8.4 27.3 0.643 2.3 51 1.70 
BLDCON02 6.23 μg 2.21 7.7 25.6 0.598 8.3 42 3.09 
BLDCON04 2.82 μg 2.46 8.8 27.4 0.637 2.2 52 1.72 
BLDCON07 3.71 μg 2.16 7.7 25.6 0.643 19.7 31 1.94 
BLDCON08 8.10 μg 2.23 8.8 26.4 0.605 3.6 48 3.54 
BLDCON10 6.44 μg 2.12 7.9 26.8 0.596 6.6 43 2.61 
BLDPAT21 3.77 μg 2.28 8.4 26.6 0.613 8.6 40 3.27 
BLDPAT23 9.32 μg 2.15 7.5 27.5 0.670 1.5 54 1.64 
BLDPAT26 6.21 μg 2.12 8.0 27.5 0.654 1.3 53 1.97 
BLDPAT27 6.44 μg 2.14 8.1 26.7 0.665 1.9 53 3.19 
BLDPAT35 3.64 μg 2.25 8.8 27.5 0.660 2.1 51 1.82 
BLDPAT38 3.91 μg 2.14 7.7 27.3 0.692 1.1 56 2.68 
Mean 5.37 μg  2.21 8.2 26.9 0.640 3.6 49 2.43 
         
b) RR Ambion GLOBINClearTM dataset 
 RNA Yield  A260/280 RIN Bgrd Raw(Q) SF %P 
GAPDH 
3’-5’ ratio 
BLDCON01 1.44 μg 2.11 8.5 51.6 1.800 0.5 45 3.57 
BLDCON02 1.91 μg 2.20 8.1 38.9 1.100 0.9 49 3.60 
BLDCON04 1.47 μg 2.05 8.4 61.9 2.100 0.6 43 2.70 
BLDCON07 2.10 μg 2.20 8.8 39.6 1.200 0.9 45 3.04 
BLDCON08 4.18 μg 2.18 8.9 38.7 1.100 1.0 44 3.68 
BLDCON10 1.89 μg 2.17 8.8 45.4 1.400 0.8 43 2.30 
BLDPAT21 1.89 μg 2.09 8.4 65.3 2.200 0.6 44 2.30 
BLDPAT23 4.35 μg 2.13 8.8 84.5 2.800 0.5 44 1.99 
BLDPAT26 1.72 μg 2.13 8.9 74.5 2.400 0.4 46 2.02 
BLDPAT27 1.70 μg 2.14 8.7 73.6 2.400 0.4 47 4.30 
BLDPAT35 1.68 μg 2.08 8.8 55.8 1.800 0.6 47 3.09 
BLDPAT38 1.90 μg 1.99 8.8 58.2 1.900 0.5 47 2.94 
Mean 2.19 μg 2.12 8.7 57.3 1.850 0.6 42 2.96 
 
Table 3.8 Summary of JB NuGEN Ovation® and RR Ambion® GLOBINClearTM QC Parameters 
RNA purity, as determined by absorbance ratios at 260/280nm (A260/280) wavelengths, and yield 
were measured using the NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific® Inc., 
UK). RNA integrity numbers (RIN’s) were computed on a scale of zero (undetectable, completely 
degraded) to ten (high quality, intact RNA) using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies Ltd., UK). Mean values recorded across the JB NuGEN Ovation® (top) or RR Ambion® GLOBIN 
ClearTM (bottom) datasets are represented in bold. Affymetrix® QC parameters including noise 
(Raw Q), average background (bgrd) signal intensities, scaling factor (SF), percentage presence 
(%P) calls and GAPDH 3’-5’ ratio were assessed in Expression ConsoleTM software version 1.3. 
0.187 (Affymetrix® Ltd., UK). Significant outliers removed from subsequent downstream analyses 
are highlighted in red. 
 
Abbreviations: 3’ - three prime, 5’ - five prime, BLDCON - blood control, BLDPAT - blood patient, 
GAPDH - glyceraldehyde 3-phosphate dehydrogenase, JB - Joanna Bury generated CEL files, QC - 
quality control and RR - Dr Rohini Raman generated CEL files.      
 
 
Consequentially, a distinct possibility exists that there are a number of potentially 
confounding environmental covariates which may also influence the transcriptome 




for the variability introduced by such factors: a) Individuals were matched as far as 
possible for their age, gender and ethnicity; b) BLDPAT donors were all on a stable 
dose of Riluzole (50mg twice daily); c) BLDCON donors were recruited from patient 
partners or unrelated carers; d) Samples were collected by venepuncture between 
the hours of 8.00am and 11.00am and e) The subjects were fasted overnight prior to 
phlebotomy. One limitation of the study, however, still remained. Since a full blood 
count was not performed at the time the tissue was donated (Raman 2011) it is not 
possible to determine the extent to which differences in the relative abundance of 
different cell populations is having on the resultant GEP’s (Bennett et al 2003, Jiang 
et al 2005, Whitney et al 2003).   
The efficiency of the NuGEN Technologies Inc., UK patented linear SPIATM system in 
limiting the amount of amplified globin cDNA relative to other, less abundant trans-
cripts also contained within the sample, which are of equal biological importance (in 
this case the standard housekeeping control, beta actin) was assessed in a qRT-PCR 
assay with the size of the amplified products having been confirmed by agarose gel 
electrophoresis (Section 3.4) [APPENDIX FIGURE A3]. Across the cohort mean cycle 
threshold (Ct) values were shown to be significantly lowered for ACTB [pre-SPIATM 
19.278 (n=12) versus post-SPIATM 10.801 (n=8) measurements; ⇩1.80-fold (p<0.00 
1***)] but had remained reasonably consistent for HBA2 [pre-SPIATM 11.833 (n=12) 
versus post-SPIATM 9.663 (n=7) measurements; ⇩1.20-fold (p<0.05*) (Figure 3.12)]; 
suggesting, initially, that the NuGEN Ovation® Whole Blood Solution had been suc-
cussful in reducing the levels of globin. However, despite multiple attempts Ct val-
ues could not be recorded for more than 40% of the post-SPIATM samples analysed, 
as demonstrated by a sizeable reduction in N (Figure 3.12). The reason for this is un-
clear, although it is plausible, given the uncharacteristic nature of the amplification 
plots which were generated using Stratagene Brilliant II [APPENDIX FIGURE A1] or 
Roche FastStart Universal [APPENDIX FIGURE A2] Master Mix, that NuGEN’s prop-
rietary reagent may not be compatible with the SYBR® Green fluorescence based de- 
tection method deployed in this study and alternatives, such as TaqMan probes, wo-
uld need to be trialled. There is also evidence in the literature that ACTB may not be 
the most suitable candidate for use as an endogenous control when analysing whole 




would also need to be considered alongside the more traditional choices (Pachot et 
al 2004). In Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK) 
MAS 5.0 normalised pivot data for Affymetrix® Human Genome U133 Plus 2.0 Gene 
Chip® Arrays found mean probeset signal intensities for HBA2 and ACTB to be com-





Figure 3.20 MAS 5.0 Signal Intensities for HBA1/2 Transcripts and 
the Housekeeping Genes ACTB, GAPDH and 18SrRNA Mean probeset 
signal intensity values for the JB NuGEN Ovation® Human Genome U133 
Plus 2.0 GeneChip® Arrays normalised in Expression ConsoleTM software 
version 1.3.0.187 (Affymetrix® Ltd., UK) using Microarray Suite 5.0 (MAS 
5.0) and plotted in GraphPad Prism® software version 5.04 © 1992-2014 
(GraphPad Software Inc., CA USA). Error bars represent SEM (standard 
error of the mean). 
 
Abbreviations: ACTB - actin beta, GAPDH - glyceraldehyde 3-phosphate 
dehydrogenase, HBA1/2 - haemoglobin alpha 1/2, JB - Joanna Bury ge-
nerated CEL files and rRNA - ribosomal RNA.   
 
 
An overall down-regulation in the level of gene transcription was apparent in the JB 
NuGEN Ovation® dataset (Figure 3.15) (Section 3.5.1.2.1) with 467 (66.1%) of the 
706 DE transcripts in GeneSpring GX v11.5.1 [unpaired student’s t-test FDR p<0.05, 
FC ≥ ±1.50] exhibiting a significant decrease in expression in the peripheral whole 
venous blood of SALS patients (n=6) compared to equal numbers of neurologically 




skin fibroblasts derived from a second cohort of SALS patients and controls (n=12) 
in which a total of twenty-eight commonly dysregulated transcripts were identified 
including zinc finger DNA binding protein 652 (ZNF652) [JB NuGEN Ovation® ⇩2.30 
-fold SALS, p<0.01; RR Fibroblast ⇩2.04, p<0.05] and protein tyrosine phosphatase, 
receptor type, C (PTPRC) [JB NuGEN Ovation® ⇩2.20-fold, p<0.05; RR Fibroblast ⇩ 
1.12-fold, p<0.05] (Raman et al 2014). ZNF652 interacts with the putative breast 
tumor suppressor core-binding factor runt domain alpha subunit 2; translocated to 
3 (CBFA2T3) to inhibit transcription of the HeLa E-box binding protein (HEB) which 
has important implications for myogenesis and haematopoiesis (Kumar et al 2008). 
PTPRC may be associated with apoptosis (Yi et al 2011) and has been shown to play 
a pivotal role in maintaining intracellular Ca2+ homeostasis (Duplay et al 1996, Lane 
et al 1991, Qin & Chock 2002) which could link it to the induction of excitotoxicity; a 
major mechanism contributing to the degeneration and loss of MN’s in ALS (Section 
1.2.4.2) (Grosskreutz et al 2010). Aberrations in the PTPRC gene have also conferred 
increased susceptibility for developing certain autoimmune diseases including MS 
(Do et al 2006, Schwinzer et al 2003) and rheumatoid arthritis (Miterski et al 2004, 
Plant et al 2012). Moreover, loss of CD45 function in a mouse model of ALZ induces 
widespread microglial activation and the formation of Aβ plaques (Zhu et al 2011); 
a pathological hallmark of this disease (Section 1.4.1.2.3).  
In contrast, an overall up-regulation in the level of gene transcription was apparent 
in the RR Ambion GLOBINClearTM dataset (Figure 3.15) with 3,440 (76.1%) of 4,520 
DE transcripts in GeneSpring GX v11.5.1 [unpaired student’s t-test FDR p<0.05, FC ≥ 
±1.50] exhibiting a significant increase in expression in the peripheral whole venous 
blood of SALS patients compared to controls (Section 3.5.1.2.2). This percentage was 
even higher (86.9%) in an analysis of the top 1,215 hits, ranked by probability value, 
with an FC ≥ ±2.0. It is also of interest to note that despite the use of identical age, 
gender & ethnicity matched donor samples there was more than a 6-fold difference 
in the number of DE transcripts in GeneSpring GX v11.5.1 [unpaired student’s t-test 
FDR p<0.05, FC ≥ ±1.50] between the JB NuGEN Ovation® (n=706) and RR Ambion 
GLOBINClearTM (n=4,520) datasets with 2,733 expected to occur by chance (Figure 
3.14). It can be speculated, therefore, that the latter may provide a more sensitive 




false positive outcomes which is supported by a lack of qRT-PCR validation of gene 
targets identified in the RR Ambion GLOBINClearTM dataset (Raman 2011).  
Very few of the aforementioned transcriptional changes detected in the peripheral 
blood of SALS patients compared to controls were shared in common between the 
JB NuGEN Ovation® and RR Ambion GLOBINClearTM datasets (Figure 3.15) with only 
a third (34.2%) of these 82 transcripts (encoding 78 unique genes) reported to occur 
in the same direction of change (Table 3.3). These included: haptoglobin (HP), a risk 
factor for idiopathic PD (Alberio et al 2013, Costa-Mallen et al 2008) which confers 
protection against elevated levels of OS (Section 1.2.4.1) and has been shown to play 
an important role in iron (Fe2+) homeostasis (Arguelles et al 2010); the ER adaptor 
molecule transmembrane tetratricopeptide repeat containing 1 (TMTC1) (Sunryd et 
al 2014); neuregulin 1 (NRG1), a possible candidate gene of SCHIZ and BPD (Deng 
et al 2013a, Walker et al 2010) that promotes skeletal muscle fibre development 
and maintains synaptic plasticity in the hippocampus during learning and memory 
(Liu et al 2011, Mei & Xiong 2008, Neddens et al 2009) and DUSP16, a key regulator 
of T helper (Th) cell differentiation (Musikacharoen et al 2011) that has been shown 
to interact with the MAPK signalling cascade (Section 3.5.1.5.1) which were up-
regulated in addition to the type II transmembrane glycoprotein C-type lectin 
domain family, 4 member C (CLEC4C) implicated in the innate immune response 
and inflammation (Riboldi et al 2011); protein tyrosine phosphatase, non-receptor 
type 12 (PTPN12), a potent tumor suppressor critical for cell adhesion and migration 
(Luo et al 2014); signal sequence receptor, alpha (SSR1) responsible for protein 
translocation across the ER membrane (Mesbah et al 2006); molecular chaperone 
heat shock 60kDa protein 1 (HSPD1), a rare cause of hereditary spastic paraplegia 
(SPG13) (Hansen et al 2002, Hewamadduma et al 2008) which is essential for the 
correct folding and assembly of newly imported proteins into the mitochondria 
(Magnoni et al 2014) as well as the RNA processing gene heterogeneous nuclear 
ribonucleoprotein C (HNRNPC) (Romano & Buratti 2013) which were shown to be 
consistently down-regulated. 
 
KEGG pathway analysis produced better enrichment using the DAVID bioinformatics 
resource version 6.7 than functional annotation clustering performed on GO terms 




did not reach the 5% significance threshold. Commonly dysregulated pathways (n= 
7) included the MAPK (Section 3.5.1.5.1) [Rank #1 (13), count 20 (46), percentage 
3.2 (2.0), p=1.60E-03 (4.40E-03)] and Neurotrophin (Section 3.5.1.5.2) [Rank #4 (9) 
count 11 (26), percentage 1.8 (1.2), p=9.20E-03 (3.10E-03)] signalling cascades with 
oocyte meiosis, NOD-like receptor signalling, endometrial cancer and LTP (long term 
potentiation) specific to the JB NuGEN Ovation® dataset (Table 3.6) and endocytosis, 
ubiquitin-mediated proteolysis, phosphatidylinositol signalling, spliceosome, ErbB 
signalling, VEGF signalling and regulation of the actin cytoskeleton specific to the RR 
Ambion GLOBINClearTM dataset (Table 3.7). PIK3R2, which is associated with four 
of these pathways, was identified as the only DE transcript [JB NuGEN Ovation® ⇧ 
1.54-fold, p<0.01; RR Ambion GLOBINClearTM ⇧2.04-fold, p<0.001] with a direction 
of change that correlated between the two methodologies (Table 3.3). This enzyme 
was found to be significantly up-regulated in the blood of SALS patients compared 
to controls and is considered to be important in regulating DNA replication and cell 
survival (Marques et al 2009). However, it remains unclear as to the reasons why so 
many other transcripts including PTPRC [JB NuGEN Ovation® ⇩2.19-fold, p<0.05; RR 
Ambion GLOBINClearTM ⇧1.99-fold, p<0.05] and the v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog (KRAS) [JB NuGEN Ovation® ⇩1.85-fold, p<0.05; RR Ambion 
GLOBINClearTM ⇧2.45-fold, p<0.05] appear to exert apposing regulatory effects in 
blood specimens derived from identical patient and control samples. Dysregulation 
of the MAPK signalling cascade is, nevertheless, an interesting finding that warrants 
further investigation (Limviphuvadh et al 2007). Previously elevated levels of p38 
MAPK have been observed in the ventral horn MN’s and microglia of the SOD1G93A 
transgenic mouse model of the disease which is linked to the induction of apoptosis 
(Veglianese et al 2006) and genes of the same pathway have also been shown to be 
significantly altered in ALS patients carrying a CHMP2B mutation (Section 1.2.5.2.8) 
(Cox et al 2010).   
In conclusion, a lack of consistency between the JB NuGEN Ovation® and RR Ambion 
GLOBINClearTM datasets analysed in this chapter suggests that the abundance of α 
and β globin transcripts still remains a contentious issue which will require further 
clarification. Given the problems outlined above (i.e. blood is composed of a mixed 




is influenced by environmental covariates) there is good rationale in the alternative 
use of immortalised EBV-transformed B-lymphocytes (LCL’s) (Section 1.3.2) which 
eliminate the need for re-sampling, are a genetically homogeneous cell population 
and can be cultured in vitro to support downstream functional assays (Gladkevich 
et al 2004, Hu et al 2011, Min et al 2010, Shtilbans et al 2011).  
 







CHAPTER 4: CHARACTERISATION OF LCL’S 
 
The focus of this methodological chapter was to characterise the large bank of LCL’s 
in the ECACC discovery and replication cohorts, which were being screened as part 
of a wider project (N0 259867) funded by EuroMOTOR (FP7/2007-2013), under the 
Seventh Framework Health Cooperation Programme. Due to time constraints, it was 
not possible to include all cases and controls in the scope of the PhD. Instead specific 
subsets of LCL’s were selected, according to strict criteria (e.g. matched for age and 
gender), in order to perform the subsequent downstream comparative analyses out-
lined in ‘Chapter 5: C9ORF72 GEP Study’ and ‘Chapter 6: C9ORF72 Survival Study’. A 
detailed summary of the clinical and genetic information of each cohort is provided 
(Section 4.1.1 and 4.1.2), along with measures of RNA yield (Section 4.2) and micro-
array QC parameters, as assessed by the Affymetrix® Expression ConsoleTM (Section 
4.3).                                                
 
4.1 ECACC EBV-Transformed B-Lymphocytes  
4.1.1 ECACC Discovery Cohort   
4.1.1.1 Clinical Characteristics  
4.1.1.1.1 Control Cases  
Neurologically normal, healthy control LCL’s (n=100) [63-M, 37-F] were largely re-
cruited to the ECACC discovery cohort (Section 2.1.2) from patient partners or their 
unrelated carers in the National MNDA DNA Bank. These were comprised of 27 Bir-
mingham (27.0%) cases including one from Belfast City Hospital [C020-(BBe0006)],   
one from Oxford [C090-(BOx0073)] and eight from Liverpool [C02-(BLi0245), C039 
-(BLi0169), C065-(BLi0123), C083-(BLi 0269), C086-(BLi0217), C093-(BLI0196), C 
096-(BLi0029) and C097-(BLi0083)]; 26 London (26.0%) cases including two from 
Cambridge [C019-(LCa0022) and C021-(LCa0076)], three from Poole General Hos-




ampton General Hospital [C012-(LSh0025), C015-(LSh0032), C038-(LSh0022) and 
C046-(LSh0023)] and 47 Sheffield (47.0%) cases including three from Nottingham 
[C048-(SNt0005), C052-(SNt0073) and C024-(SNt0035)], four from Manchester [C0 
1-(SMa0033), C033-(SMa0183), C036-(SMa0156) and C077-(SMa0047)], one from 
Durham [C013-(SDu0012)], five from Preston [C08-(SPr0050), C010-(SPr0014), C0  
22-(SPr0086), C072-(SPr0048) and C074-(SPr0068)] and eleven from Newcastle [C 
04-(SNc0091), C07-(SNc0038), C09-(SNc0103), C011-(SNc0045), C019-(SNc0096), 
C025-(SNc0218), C029-(SNc0023), C044-(SNc0041), C047-(SNc0149), C076-(SNc0 
106106) and C085-(SNc0035)]. Age at consultation ranged between 33 and 84 yea-
rs with a mean of 63.2±11yrs. The M:F ratio was 1.70:1 (Figure 4.1) [APPENDIX TAB 
LE B1].  















Figure 4.1 Age Frequency Distribution of Patient and Control LCL’s 
in the ECACC Discovery Cohort (n=470)   
 
  Abbreviations: ALS - Amyotrophic Lateral Sclerosis, Ctrl - control, 
ECACC - European Collection of Cell Cultures, F - familial, F - female, LCL 
- lympho-blastoid cell line, M - male and S - sporadic.         
 
 
4.1.1.1.2 Familial Cases   
FALS patient derived LCL’s (n=120) [71-M, 49-F] recruited to the ECACC discovery 




























23-28            35-40           47-52           59-64           71-76           83-88 
Age (years) 
 
 FALS SALS Control 
M:F 1.45:1 1.43:1 1.70:1 
Age  55.4±12yrs 60.6±12yrs 63.2±11yrs 









 ----------- Replication Cohort ----------- --------------------------------------- Discovery Cohort --------------------------------------- 
 SALS CTRL SALS FALS ALL CTRL 
M:F 2.17:1 1.78:1 1.43:1 1.45:1 1.43:1 1.70:1 
Age       
        range 31-87yrs 35-83yrs 22-86yrs 23-82yrs 22-86yrs 33-84yrs 
        mean 60yrs 63yrs 61yrs 55yrs 59yrs 63yrs 
Onset       
        Limb 161  (64.4%) n/a 146  (58.4%)     57  (47.5%) 203  (54.9%) n/a 
        Bulbar         60   (24.0%) n/a         76  (30.4%)     38  (31.7%) 114  (30.8%) n/a 
        Mixed         20       (8.0%) n/a         23     (9.2%)     17  (14.1%)         40   (10.8%) n/a 
        Respiratory            4     (1.6%) n/a            5     (2.0%)             2     (1.7%)           7     (1.9%) n/a 
        unknown           5     (2.0%) n/a            0     (0.0%)              6      (5.0%)           6     (1.6%) n/a 
Diagnosis        
        ALS 242  (96.8%) n/a 234  (93.6%)   111  (92.6%)  345  (93.2%) n/a 
        ALS+FTLD           0     (0.0%) n/a            3     (1.2%)             1     (0.8%)           4     (1.1%) n/a 
        ALS+PD           1     (0.4%) n/a            0     (0.0%)             1     (0.8%)           1     (0.3%) n/a 
        PBP           5     (2.0%) n/a         12     (4.8%)             6     (5.0%)         18     (4.8%) n/a 
        PLS           2     (0.8%) n/a           0     (0.0%)                1     (0.8%)            1     (0.3%) n/a 
        PMA           0     (0.0%) n/a           1     (0.4%)               0     (0.0%)            1     (0.3%) n/a 
ALSFRS-R       
        range 0-48 n/a 0-48 0-48 0-48 n/a 
        mean 34 n/a 33 32 33 n/a 
Survival       
        range 0.4-10.3yrs n/a 0.3-7.7yrs 0.5-18.7yrs 0.3-18.7yrs n/a 
         mean 3.7yrs n/a 2.8yrs 2.9yrs 2.8yrs n/a 
Total 250 (249) 100 (100) 250 (244) 120 (118) 370 (362) 100 (97) 
 
Table 4.1 Clinical Summary of Patient and Control LCL’s in the ECACC Discovery (n=470) and Replication (n=350) Cohort Highlighted in red 
are the final sample numbers obtained following assessment of QC metrics in Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., 
UK).    
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, CTRL - control, ECACC - European Collection of Cell Cultures, F - familial, F - female, FRS-R - 
Revised Functional Rating Scale, FTLD - frontotemporal lobar degeneration, LCL - lymphoblastoid cell line, M - male, n/a - not available, PBP - 





[F078-(BOx0029)], one from Bristol Frenchay Hospital [F48-(BBr0015)] and seven 
from Liverpool [F020-(BLi0236), F038-(BLi0249), F045-(BLi0254), F072-(BLi025 
1), F074-(BLi0272), F094-(BLi0246) and F103-(BLi0265)]; 48 London (40.0%) ca-
ses including one from Southampton General Hospital [F102-(LSh0038)], one from 
Plymouth Derriford Hospital [F029-(LPy0018)], one from Poole General Hospital [F 
058-(LP0036)] and two from Cambridge [F014-(LCa0111) and F052-(LCa0026)] a-
nd 44 Sheffield (34.2%) cases including three from Preston [F010-(SPr0085), F025 
-(SPr0059) and F101-(SPr0026)], five from Newcastle [F027-(SNc0204), F064-(SN 
c0063), F071-(SNc0031), F109-(SNc0202) and F118-(SNc0189)] and five from Ma-
nchester [F028-(SMa0020), F081-(SMa0006), F095-(SMa0008), F108-(SMa0078) 
and F117-(SMa0166)]. The M:F ratio was 1.45:1 (Figure 4.1) [APPENDIX TABLE B2].  
The majority of FALS patients, 94.2% (n=113/120) were diagnosed according to the 
World Federation of Neurology’s amended EEC of 1998 (Section 1.1.3) (Figure 1.1) 
with either definite (n=57/113) or probable ALS (n=56/113) (Table 4.1) including 
one incidence of concomitant FTLD [F115-(SP3118)] and another of concomitant PD 
[F114-(SP3560)] (Section 1.2.1). Of the remaining 5.8% (n=7/120) of patients, one 
was diagnosed with PLS [F087-(SP3216)] (Section 1.2.2.2) and six were diagnosed 
with PBP [F029-(LPy0018), F041-(LP0440), F052-(LCa0026), F058-(LPo0036), F1 
00-(SP3070) and F118-(SNc0189)] (Section 1.2.2.1). Age at symptom onset ranged 
between 23 and 82 years with a mean of 55.4±12yrs. Survival ranged from 6 months 
to 18 years and 8 months in 81.7% of cases (n=98/120) with a mean of 2.92±2.3yrs. 
For 14.2% of FALS (n=17/120) this information was not available and in the remai-
ning 4.1% of cases (n=5/120) the individual was still reported to be alive as of June 
2013 with a minimum disease duration of either 4 [F047-(BP6502)], 6 [F013-(BP6 
494)], 9 [F054-(SP3048) and F119-(SP3218)] or 11 years [F015-(LP0460)], respe-
ctively. Limb or spinal onset at 47.5% (n=57/120) [56-FALS, 1-PLS (familial)] was 
more prominent than the onset of bulbar weakness 31.7% (n=38/120) [32-FALS a-
nd 6-PBP (familial)], a mixed presentation 14.2% (n= 17/120) [17-FALS] or the on-
set of respiratory muscle dysfunction 1.7% (n=2/120) [2-FALS]. Information regar-
ding presentation was unavailable for the remaining 4. 9% (n=6/120) [6-FALS] of 
the cohort. Revised ALS Functional Rating Scale (ALSFRS-R) scores ranged between 




aum et al 1999, Gordon & Cheung 2006, Kollewe et al 2008) with an average of 31. 












Figure 4.2 ALSFRS-R Frequency Distribution of FALS (n=120) Recruited to 
the ECACC Discovery Cohort. Revised ALS Functional Rating Scale scores on a 
scale of 0 to 48 where zero represents severe disability and a score of forty-eight 
signifies that normal function is preserved. Mean ALSFRS-R plotted along the x-
axis is computed based on measurements that are incorporated from a series of 
twelve questions relating to the patient’s ability to perform common daily tasks 
including but not limited to: speech, salivation, swallowing, dressing & hygiene, 
walking, climbing stairs, handwriting and shortness of breath (SOB) (Cedarbaum 
et al 1999). Relative counts or frequencies along the y-axis were calculated as a 
percentage of the total number of FALS (n=119/120) in the ECACC discovery 
cohort for which this information was available. 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, ECACC - European Collection 
of Cell Cultures, F - familial and FRS-R - Functional Rating Scale Revised.   
 
 
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these, 7.3% (n=3/41) [2-FALS and 1-PLS (familial)] were pro-
ne to EL, a further 2.4% (n=1/41) [1-FALS] suffered from excessive salivation or hy-
persialorrhea and approximately a fifth (n=8/41) [8-FALS] reported dyspnoea with 
37.5% of these latter cases requiring NIPPV support (n=3/8) [3-FALS] (Section 1.1. 
4). Dysarthria and dysphagia was also apparent in 29.3% (n=12/41) [10-FALS, 1-F 
ALS+PD and 1-PBP (familial)] of the cohort with PEG feeding becoming a necessary 
intervention in four of these latter cases [3-FALS and 1-FALS+PD]. One in ten (n=4/ 
41) [3-FALS and 1-FALS+PD] patients were non-ambulant and a further 17.1% (n= 
7/41) [7-FALS] were unable to walk without assistance. Current smokers comprised 




smoked a cigarette in the last 18 years 2.4% (n=1/41) [1-FALS] and non-smokers a 
further 46.3% (n=19/41) [18-FALS and 1-FALS+PD]. For the remaining 43.9% (n= 
18/41) [13-FALS and 5-PBP (familial)] of cases this information was not disclosed. 
A strong family history of dementia was associated with up to 4.9% of the Sheffield 
pedigrees (n=2/41) [F089-(SP3331) and F115-(SP3118)]. There were also reports 
of at least one other neurological condition occurring in a first degree relative of an 
additional 12.2% of kindreds (n=5/41). These included one incidence of ALZ [F089- 
(SP3331)] (Section 1.3.1.3.1) and another of hereditary PD (Section 1.2.1) [F114-(S 
P3560)].             
 
4.1.1.1.3 Sporadic Cases   
SALS patient derived LCL’s (n=250) [147-M, 103-F] recruited to the ECACC discovery 
cohort were comprised of 40 Birmingham (16.0%) cases including three from Liver-
pool [S074-(BLi0048), S098-(BLi0037) and S181-(BLi0039)] and eight from Belfast 
City Hospital [S05-(BBe0007), S09-(BBe0018), S052-(BBe0016), S058-(BBe0001), 
S087-(BBe0009), S122-(BBe0014), S196-(BBe0013) and S248-(BBe0003)]; 45 Lon- 
don (18.0%) cases including one from Poole General Hospital [S035-(LPo0010)] and 
165 Sheffield (66.0%) cases including twenty-one from Newcastle [S012-(SNc0022), 
S046-(SNc0001), S077-(SNc0042), S088-(SNc0086), S089-(SNc0053), S105-(SNc00 
18), S106-(SNc0077), S130-(SNc0010), S134a-(SNc0016), S141-(SNc0071), S152-( 
SNc0090), S155-(SNc0055), S156-(SNc0029), S182-(SNc0008), S193-(SNc0024), S 
203-(SNc0059), S209-(SNc0012), S212-(SNc0002), S223-(SNc0095), S225-(SNc009 
2) andS232-(SNc0051) and twelve from Nottingham [S036-(SNt0031), S067-(SNt0 
038), S075-(SNt0034), S096-(SNt0001), S115-(SNt0004), S129-(SNt0024), S138b-( 
SNt0017), S140-(SNt0020), S158-(SNt0006), S198-(SNt0016), S219-(SNt0036) and 
S240-(SNt0030)]. The M:F ratio was 1.43:1 (Figure 4.1) [APPENDIX TABLE B3]. 
The majority of SALS patients, 94.8% (n=237/250) were diagnosed with either def-
inite (n=110/237) or probable ALS (n=127/237) (Section 1.1.3) (Figure 1.1) (Table 
4.1) including three incidences of concomitant FTLD [S093-(SP3049), S178-(SP314 
5) and S191-(SP3042)] (Section 1.2.1). Of the remaining 5.2% of the cohort (n=13 




twelve were diagnosed with PBP [S040-(SP3271), S044-(SP3329), S045-(SP3289), 
S105-(SNc0018), S106-(SNc0077), S129-(SNt0024) and S232-(SNc0051)] (Section 
1.2.2.1). Age at symptom onset ranged between 22 and 86 years with a mean of 60. 
6±12yrs (Table 4.1). Survival ranged from 4 months to 7 years and 8 months with a 
mean of 2.75±1.3yrs. Limb onset 58.4% (n=146/250) [145-SALS, 1-PMA (sporadic)] 
was more prominent than the onset of bulbar weakness 30.4% (n=76/250) [64-SA 
LS and 12-PBP (sporadic)], a mixed presentation 9.2% (n=23/250) [23-SALS] or on-
set in the respiratory muscles 2.0% (n=5/250) [5-SALS] combined. ALSFRS-R scores    
ranged between 0 (severe disability) and 48 (normal function) (Figure 4.3) with an 






Figure 4.3 ALSFRS-R Frequency Distribution of SALS (n=250) Recruited to 
the ECACC Discovery Cohort. Revised ALS Functional Rating Scale scores on a 
scale of 0 to 48 where zero represents severe disability and a score of forty-eight 
signifies that normal function is preserved. Mean ALSFRS-R plotted along the x-
axis is computed based on measurements that are incorporated from a series of 
twelve questions relating to the patient’s ability to perform common daily tasks 
including but not limited to: speech, salivation, swallowing, dressing & hygiene, 
walking, climbing stairs, handwriting and shortness of breath (SOB) (Cedarbaum 
et al 1999). Relative counts or frequencies along the y-axis were calculated as a 
percentage of the total number of SALS (n=210/250) in the ECACC discovery 
cohort for which this information was available. 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, ECACC - European Collection 
of Cell Cultures, F - familial and FRS-R - Functional Rating Scale Revised.   
 
 
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these 12.7% (n=21/165) [19-SALS and 2-PBP (sporadic)] were 




almost a quarter (n=39/165) [36-SALS and 3-PBP (sporadic)] displayed symptoms 
of dyspnoea, with 33.3% of these latter cases (n=13/39) [13-SALS] requiring NIPPV 
support (Section 1.1.4). Dysarthria and dysphagia was also apparent in 31.5% (n=5 
2/165) [49-SALS an d3-PBP (sporadic)] of the cohort with PEG feeding becoming a 
necessary intervention in eighteen of these latter cases [17-SALS and 1-PBP (spora-
dic)]. Four individuals presented with the rare FA variant of the disease (Section 1. 
1.5.1) [S015-(SP3299), S042-(SP3122), S060-(SP3338) and S223-(SNc0095)] and t-
wo additional cases presented with a clinical history of depression [S113-(SP3347) 
and S116-(SP3351)]. One in twenty-five patients were non-ambulant (n=7/165) [7-
SALS] with a further 18.2% (n=30/165) unable to walk without assistance. Current 
smokers comprised 3.6% of the cohort (n=6/165) [6-SALS], ex-smokers who had n-
ot smoked a cigarette for a minimum of 12 months (mean 21.4±9yrs) (n=17/165) [ 
16-SALS and 1-PMA (sporadic)] a further 10.3% and non-smokers 55.8% (n=92/16 
5) [87-SALS and 5-PBP (sporadic)]. For the remaining 30.3% (n=50/165) [43-SALS 
and 7-PBP (sporadic)] of cases this information was not disclosed.  
There were reports of at least one other neurological condition occurring in a first 
degree relative of 7.3% (n=12/165) of apparently sporadic, Sheffield ALS kindreds 
including ALZ (Section 1.3.1.3.1) [S010-(SP3275), S054-(SP3179), S060-(SP3338), 
S069-(SP3230), S112-(SP3363), S121-(SP3420), S162-(SP3326) and S247-(SP335 
3)], PD (Section 1.2.1) [S146-(SP3132), S148-(SP3368), S167-(SP3327) and S227-
(SP3043)] and Multiple Sclerosis (MS) (Etemadifar et al 2012, Ismail et al 2013) [S 
148-(SP3368), S153-(SP3423) and S236-(SP3286)]. A family history of dementia [S 
08-(SP3111), S042-(SP3122), S078-(SP3140), S116-(SP3351), S172-(SP3067), S19 
1-(SP3042) and S227-(SP3043)] was also associated with up to 4.2% (n=7/165) of 
cases. In addition, cancer affected a further 11.5% (n=19/165) [12-colon, 2-throat, 
4-stomach and 1-other], cerebrovascular disease (CVA) 1.2% (n=2/165), inflamma-
tory bowel disease (IBD) 0.6% (n=1/165) and depression/strokes 1.2% (n=2/165) 
of Sheffield pedigrees.  
 
4.1.1.2 Therapeutics Used to Treat the Cohort  




Riluzole, administered at a dose of 50mg twice daily, was being used to treat 76.7% 
of FALS (n=92/120) [89-FALS, 1-FALS+PD and 2-PBP] with two additional patients 
waiting to commence treatment at the time of biosample collection. Vitamin C/E or 
multivitamin supplements were collectively being taken by 15.8% (n=19/120) [19-
FALS] of the cohort. As well as the Riluzole therapy, several patients (n=3/120) [3-
FALS] were also participants of the BDNF [F091-(SP3534)], minocycline [F073-(BP 
6165)] or lithium carbonate (LiCALS) [F053-(SP3610)] drug trials [APPENDIX TAB 
LE B4]. In contrast, 14.2% (n=17/120) [14-FALS, 2-PBP (familial) and 1-PLS (famil-
ial)] chose not to receive any kind of disease modifying therapy and for the remain-
ing 7.5% of FALS (n=9/120) [7-FALS and 2-PBP (familial)] this information was not 
available.  
 
4.1.1.2.2 Sporadic Cases   
Riluzole was also used to treat 88.0% of SALS patients (n=220/250) [205-SALS, 3-
SALS+FTLD, 11-PBP and 1-PMA (sporadic)]. In a small number of cases, approxima-
tely 1.8% (n=4/220) [3-SALS and 1-PBP (sporadic)] the individual experience adv-
erse side effects and the medication was withdrawn. Vitamin C/E and multivitamin 
supplements were collectively being taken by 40.8% (n=102/250) [93-SALS, 1-SAL 
S+FTLD, 6-PBP and 1-PMA (sporadic)] of the cohort. As well as the Riluzole therapy 
several patients (n=12/250) [12-SALS] were also participants of the glatiramer ac-
etate (Copaxone®) [S176-(SP3385)], ONO-2506 (Arundic acid) [S118-(SP3030), S1 
32-(SP3413), S149-(SP3391), S168-(LP0001), S203-(SNc0059) and S237-(BP6008 
)] or minocycline [S050-(SP3023), S121-(SP3420), S157-(LP0015), S164-(LP0053) 
and S212-(SNc0002)] drug trials [APPENDIX TABLE B4]. In contrast, 11.6% (n=29/  
250) [28-SALS and 1-PBP (sporadic)] chose not to receive any kind of disease mod-
ifying therapy and for the remaining 0.4% (n=1/250) [1-SALS] of SALS this inform-
ation was not available.  
 
4.1.1.3 Genetic Status of the Cohort  
At the beginning of the project the genetic status of the majority of LCL’s was unkn-




C2 hexanucleotide repeat expansion (Renton et al 2011, DeJesus-Hernandez et al 20 
11) in intron 1 of the previously uncharacterised C9ORF72 gene (Section 1.2.5.4), a 
further 40.8% of FALS (n=49/120) [42-FALS, 1-FALS+PD and 6-PBP] and 10.0% of 
SALS (n=25/250) [24-SALS and 1-PBP (sporadic)] cases have now been genetically 
assigned.   
  
4.1.1.3.1 Familial Cases   
All familial index cases in the ECACC discovery cohort for which DNA was available 
in the local Sheffield or National MNDA DNA Bank were screened for genetic defects 
in SOD1, TARDBP and FUS prior to the commencement of this study. SOD1 mutations 
occurred at a frequency of 4.4% (n=5/115) (Section 1.2.5.1.1). These were primarily 
clustered in exon 4 and included the single base substitutions c.305A>G (p.D102G) 
[F120-(SP3218)], c.335G>A (p.C111Y) [F103-(BLi0265)] and c.341T>C (p.I114T) [F 
031-(SP3526) and F053-(SP3610)]. For London individual [F068-(LP0075)] the am-
ino acid change was not known. Rarer pathological changes were also described in 
exon 6 of TARDBP including c.1043G>T (p.G348V) [F092-(SP3154)] and c.1009A>G 
(p.M337V) [F015-(LP0460), F040-(SP3068) and F067-(SP3086)] and in exon 15 of 
FUS including c.1555C>G (p.Q519E) [F086-(LP0051)] and c.1562G>A (p.R521H) [F 
036-(LP0193) and F03-(LP0048)]; accounting for ~3.8% (n=4/106) (Section 1.2.5. 
2.1) or 2.9% (n=3/103) (Section 1.2.5.2.2) of FALS cases, respectively. In a more re-
cent screening of the C9ORF72 gene (Cooper-Knock et al 2012b), repeat-primed PCR 
detected >30 copies of the G4C2 repeat in 48.4% (n=15/31) of Birmingham, 39.6% 
(19/48) of London and 36.6% (n=15/41) of Sheffield FALS cases. There was also o-
ne example of oligogenic inheritance: Patient sample [F056-(SP3462)], in addition 
to carrying the expansion in C9ORF72, was also known to harbour a heterozygous c. 
964G>A (p.E322K) missense substitution in exon 10 of the OPTN gene (Section 5.3. 
2.1) (Bury et al 2015) (Table 4.2). 
 
4.1.1.3.2 Sporadic Cases   
Of the sporadic cases, patient samples [S166-(SP3082) and S146-(SP3132)] carry a 
SNP in the first [c.85A>G (p.I29V)] or third [c.618A>C (p.Q206H)] exon of CHMP2B, 






Table 4.2 Summary of Genetic Variants Reported in the ECACC Discovery Cohort 
 
Abbreviations: ANG - angiogenin, C9ORF72 - chromosome 9 open reading frame 72, CHMP2B - 
charged multivesicular protein 2B, ECACC - European Collection of Cell Cultures, FUS - fused in 
sarcoma, OPTN - optineurin, SNP - single nucleotide polymorphism, SOD1 - copper/zinc superoxide 
dismutase 1 and TARDBP - transactive response (TAR) DNA binding protein. 
 
 
was heterozygous for a c.232A>G (p.K54E) missense substitution in exon 2 of ANG 
(Section 1.2.5.2.3) (Kirby et al 2013). An additional 5.0% (n=2/40) of Birmingham, 
4.4% (n=2/45) of London and 12.7% (n=21/165) of Sheffield SALS cases were also 
known to harbour the G4C2 repeat expansion in C9ORF72 (Table 4.2).        
  
4.1.2 ECACC Replication Cohort  
4.1.2.1 Clinical Characteristics  
4.1.2.1.1 Control Cases  
Neurologically normal, healthy control LCL’s (n=100) [64-M, 36-F] were largely re-
cruited to the ECACC replication cohort from patient partners and their unrelated 
carers in the National MNDA DNA Bank (Section 2.1.2). These were comprised of 31  
   Birmingham London Sheffield ALL 
Familial       
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C9ORF72 non-coding G4C2 repeat 15 19 15 40.8% 
C9ORF72+OPTN exon 10 p.E322K 0 0 1 0.8% 
Total   16 24 21 50.8% 
       
Sporadic       
ANG exon 2 p.K54E 0 0 1 0.4% 
C9ORF72  non-coding G4C2 repeat 2 2 21 10.0% 
















Birmingham (31.0%) cases including nine from Liverpool [C117-(BLi0224), C130-( 
BLi0105), C148-(BLi0259), C160-(BLi0032), C162-(BLi0198), C175-(BLi0021), C18 
5-(BLi0240), C188-(BLi0074) and C195-(BLi0204)], one from Oxford [C110-(BOx0 
008)], one from Belfast City Hospital [C153-(BBe0002)] and one from Bristol Fren-
chay Hospital [C150-(BBr0020)]; 28 London (28.0%) cases including two from Po-
ole General Hospital [C119-(LPo0059) and C122-(LPo0087)], two from Cambridge 
[C189-(LCa0093) and C190-(LCa0134)] and one from Plymouth Derriford Hospital 
[C125-(LPy0011)] and 41 Sheffield (41.1%) cases including six from Newcastle [C1 
02-(SNc0201), C109-(SNc0158), C135-(SNc0125), C144-(SNc0078), C146-(SNc016 
7) and C157-(SNc0015)], ten from Manchester [C111-(SMa0096), C124-(SMa0227), 
C133-(SMa0009), C139-(SMa0188), C151-(SMa0050), C163-(SMa0054), C167-(SM 
a0203), C170-(SMa0232), C171-(SMa0133) and C194-(SMa0013)], one from Prest-
on [C104-(SPr0016)], one from Nottingham [C177-(SNt0075)] and two from Durh-
am [C197-(SDu0009) and C120-(SDu0007)]. Age at consultation ranged between 35 
and 83 years with a mean of 63.4±10yrs. The M:F ratio was 1.78:1 (Figure 4.4) [APP 









 SALS Control 
M:F 2.17:1 1.78:1 
Age  59.7±11yrs 63.4±10yrs 
Total 250 100 
 
Figure 4.4 Age Frequency Distribution of Patient and Control LCL’s 
in the ECACC Replication Cohort (n=350)   
 
 Abbreviations: ALS - Amyotrophic Lateral Sclerosis, Ctrl - control, ECACC 
- European Collection of Cell Cultures, F - female, LCL - lymphoblastoid 





































4.1.2.1.2 Sporadic Cases   
SALS patient derived LCL’s (n=250) [171-M, 79-F] recruited to the ECACC replicati-
on cohort were comprised of 107 Birmingham (42.8%) cases including one from Be-
lfast City Hospital [S432-(BBe0015)]; 96 London (38.4%) cases including four from 
Southampton General Hospital [S322-(LSh0002), S326-(LSh0016), S405-(LSh0028 
) and S473-(LSh0004)] and nine from Poole General Hospital [S289-(LPo0003), S29 
8-(LPo0001), S349-(LPo0016), S362-(LPo0019), S383-(LPo0018), S394-(LPo0009), 
S429-(LPo0039), S485-(LPo0005) and S489-(LPo0017)] and 47 Sheffield (18.8%) 
cases including two from Preston [S446-(SPr0005) and S456-(SPr0001)], two from 
Durham [S327-(SDu0001) and S476-(SDu0005)], seven from Nottingham [S274-(S 
Nt0008), S359-(SNt0012), S407-(SNt0042), S427-(SNt0021), S463-(SNt0013), S46 
4-(SNt0040) and S492-(SNt0019)] and five from Newcastle [S299-(SNc0028), S305 
-(SNc0043), S380-(SNc0049), S420-(SNc0057) and S466-(SNc0020)]. The M:F ratio 
was 2.17:1 (Figure 4.4) [APPENDIX TABLE B6]. 
The majority of SALS patients, 97.2% (n=243/250) were diagnosed (Section 1.1.3) 
(Figure 1.1) with either definite (n=81/243) or probable ALS (n=162/243) includ-
ing one incidence of concomitant PD (Section 1.2.1) [S455-(BP6152)] (Table 4.1). 
Of the remaining 2.8% (n=7/250) of the cohort, two patients were diagnosed with 
PLS (Section 1.2.2.2) [S301-(SP3402) and S497-(SP3234)] and five were diagnosed 
with PBP (Section 1.2.2.1) [S272-(SP3253, S299-(SNc0028), S308-(BP6328), S349-
(BP6100) and S359-(SNt0012)]. Age at symptom onset ranged between 31 and 87 
years with a mean of 59.7±11yrs. Survival ranged from 5 months to 10 years and 3 
months in 80.0% (n=200/250) of cases with a mean of 3.72±2.0yrs. For 14.8% (n= 
37/250) of SALS this information was not available and in the remaining 5.2% (n=1 
3/250) of cases the individual was still reported to be alive as of June 2013 with mi-
nimum disease duration of either 7 [S281-(LP0482) and S304-(LP0400)], 8 [S298-
(LPo0001), S326-(LSh0016), S351-(LP0451), S452-(LP0195), S453-(LP0380) and 
S454-(LP0364)], 9 [S311-(LP0086), S334-(LP0442) and S395-(LP0109)], 10 [S321 
-(LP0003)] or 12 years [S300-(LNh0020)], respectively. Onset occurred focally in at 
least 90.0% (n=225/250) of cases. Of these, 71.5% (n=161/225) [150-SALS and 2-
PLS (sporadic)] presented with asymmetric weakness in the upper and/or lower li-




toms and a further 1.8% (n=4/225) [4-SALS] had impaired respiratory function. The 
remaining 10.0% (n=25/250) of the cohort comprised 20 SALS cases of mixed pres-
entation and five incidences where the site of onset was not known. ALSFRS-R scores 
ranged between 0 (severe disability) and 48 (normal function) with an average of 3 







Figure 4.5 ALSFRS-R Frequency Distribution of SALS (n=250) Recruited to 
the ECACC Replication Cohort Revised ALS Functional Rating Scale scores on a 
scale of 0 to 48 where zero represents severe disability and a score of forty-eight 
signifies that normal function is preserved. Mean ALSFRS-R plotted along the x-
axis is computed based on measurements that are incorporated from a series of 
twelve questions relating to the patient’s ability to perform common daily tasks 
including but not limited to: speech, salivation, swallowing, dressing and hygiene, 
walking, climbing stairs, handwriting and shortness of breath (SOB) (Cedarbaum 
et al 1999). Relative counts or frequencies along the y-axis were calculated as a 
percentage of the total number of SALS (n=139/250) in the ECACC replication 
cohort for which this information was available.   
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, ECACC - European Collection 
of Cell Cultures, FRS-R - Revised Functional Rating Scale and S - sporadic. 
 
 
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these 4.3% (n=2/47) [2-SALS] were prone to EL, 10.6% (n=5 
/47) [5-SALS] suffered pronounced dyspnoea with a fifth in need of NIPPV support 
(Section 1.1.4) and one individual presented with the rarer FA variant (Section 1.1. 
5.1) [S467-(SP3198)]. Dysarthria and dysphagia were also apparent in 23.4% (n=11 
/47) [10-SALS and 1-PBP (sporadic)] of the cohort with PEG feeding becoming a ne-
cessary intervention in the case the PBP patient. Three individuals were non-ambu-




rrent smokers comprised 10.6% (n=5/47) [5-SALS] of the cohort, ex-smokers who 
had not smoked a cigarette in the last 8 years a further 4.3% (n=2/47) [2-SALS] and 
non-smokers 42.6% (n=20/47) [19-SALS and 1-PBP (sporadic)]. For the remaining 
42.5% (n=20/47) [13-SALS, 1-SALS+PD, 4-PBP (sporadic) and 2-PLS (sporadic)] of 
cases this information was not disclosed.  
There were reports of at least one other neurological condition occurring in a first 
degree relative of 8.5% (n=4/47) of Sheffield pedigrees which received a diagnosis 
of SALS in the ECACC replication cohort including PD (Section 1.2.1) [S306-(SP343 
9) and S482-(SP3367)], HD (Section 1.4.1.2.1) [S284-(SP3069)], tremor [S461-(SP3 
107)] and ALZ (Section 1.3.1.3.1) [S272-(SP3253)]. Incidences of cancer affecting 6 
.4% (n=3/47) [1-bowel, 1-breast and 1-other], strokes 2.1% (n=1/47) or post-viral 
motor/immune disorder 2.1% (n=1/47) were also reported.  
 
4.1.2.2 Therapeutics Used to Treat the Cohort  
Riluzole, administered at a dose of 50mg twice daily, was being used to treat 88.4% 
of SALS cases (n=221/250) [213-SALS, 1-SALS+PD, 4-PBP and 2-PLS (sporadic)]. In 
a small number of instances, approximately 3.6% (n=8/221) [8-SALS] the individual 
experienced adverse side effects and the medication was withdrawn. Vitamin C/E or 
multivitamin supplements were collectively being taken by 26.4% (n=66/250) [63-
SALS, 2-PBP and 1-PLS (sporadic)] of the cohort. As well as the Riluzole therapy, se-
veral patients (n=4/250) [4-SALS] were also participants of the Novartis [S450-(LP 
0014)], ONO-2506 (Arundic acid) [S413-(LP0019)], minocycline [S253-(BP6180)] 
or glatiramer acetate (Copaxone®) [S333-(LP0432)] drug trials [APPENDIX TABLE 
B4]. In contrast, 14.0% (n=35/250) [34-SALS and 1-PBP (sporadic)] chose not to re- 
ceive any kind of disease modifying therapy and for the remaining 0.8% (n=2/250) 
[2-SALS] of the cohort this information was not available.  
 
4.1.2.3 Genetic Status of the Cohort  
TARDBP mutations were reported in the ECACC replication cohort at a frequency of 
1.2% (n=3/250). They included a c.269C>T (p.A90V) SNP in exon 3 [S412-(SP3147)] 




c.962C>T (p.A321V) [S352-(SP3484)] in exon 6. In addition, 5.6% (n=6/107) of Bir-
mingham, 9.4% (n=9/104) of London and 2.1% (n=1/48) of Sheffield SALS carried 
a minimum of thirty copies of the G4C2 repeat expansion in C9ORF72. There was also 
one example of oligogenic inheritance (Section 5.3.2.2) involving patient sample [S3 
52-(SP3484)] which was C9ORF72+ and also found to harbour a heterozygous mis-
sense c.962C>T (p.A321V) mutation in exon 6 of TARDBP (Kirby et al 2010) (Table 
4.3).  
 
   Birmingham London Sheffield ALL 












C9ORF72 non-coding G4C2 repeat 6 9 1 6.4% 
C9ORF72+TARDBP exon 6 p.A321V 0 0 1 0.4% 
Total   6 9 3 7.2% 
 
Table 4.3 Summary of Genetic Variants Reported in the ECACC Replication Cohort  
 
Abbreviations: C9ORF72 - chromosome 9 open reading frame 72, ECACC - European Collection of 
Cell Cultures, SNP - single nucleotide polymorphism and TARDBP - transactive response (TAR) DNA 
binding protein.   
 
 
4.2 QIAGEN Extraction of Total RNA  
Having assigned LCL samples from the National MNDA DNA Bank to each of the two 
cohorts described above in Section 4.1.1 and 4.1.2, aliquots of frozen stocks, preser-
ved in RNAlaterTM, were requested from ECACC (Section 2.2.1.2). One Sheffield con- 
trol [C200-(SC3479)] and three SALS patients including two from Birmingham [S49 
8-(BP6326) and S499-(BP6272)] and one from Belfast City Hospital [S248-(BBe000 
3)] were no longer available. These samples failed the EBV-transformation process 
and, following two unsuccessful attempts, were removed from our study design.  
Using QIAGEN’s RNeasy® Mini Kit (Section 2.3.2.2), total RNA was isolated from 469 
(99.8%) of 470 LCL samples [120-FALS, 249-SALS and 100-CTRL] in the ECACC dis-
covery cohort and 347 (99.1%) of 350 LCL samples [248-SALS and 99-CTRL] in the 
ECACC replication cohort. Collectively, 617 patients [120-FALS and 497-SALS] and 
199 age and, as far as possible, gender matched neurologically normal, healthy con-




3.1.3) on the NanoDropTM 1000 Spectrophotometer were reasonably consistent ac-
ross cohorts, with respective means and standard deviations of 171.37±64.9ng/μL 
(Section 4.1.1) and 140.51±46.3ng/μL (Section 4.1.2). Consistency was also observ-
ed across the different sample types [Discovery: 145.84±48.2ng/μL CTRL, 172.67± 
64.4ng/μL FALS and 181.72±68.4ng/μL SALS versus Replication: 130.39±42.5ng/μ 
L CTRL and 144.56±47.3ng/μL SALS (Figure 4.6)], extraction batches (Table 4.4 and 
Figure 4.8) and kits (Figure 4.7). Absorbance ratios at 260/280nm wavelengths ra-
nged 1.8 and 2.2 in 99.3% (n=810/816) of cases [APPENDIX TABLE B7].  
RNA integrity was assessed on the Agilent 2100 Bioanalyzer. Distinct separation of 
the 18S and 28S ribosomal peaks was observed on the electropherogram trace with 
rRNA ratios [28S/18S] of around 2.2 (Figure 4.9). Average RIN scores were 8.3 for 
samples in the ECACC discovery cohort and 7.4 for samples in the ECACC replication 
cohort (Figure 4.6). These remained reasonably consistent across the different sam-
ple types within each cohort [Discovery: 8.1 CTRL, 8.3 FALS and 8.3 SALS versus Re-
plication: 7.0 CTRL and 7.6 SALS] but steadily declined over time when examined by 
extraction batch (Table 4.4 and Figure 4.8) or kit (Figure 4.7). Despite the reduction, 
mean values did not fall below the previously accepted threshold of 7.0 (Raman et al 
2009, Strand et al 2007, Thompson et al 2007) that is considered to be of sufficient 
quality, in order to, reliably proceed with microarray profiling and downstream GE 
analyses.   
Samples of poor quality (RIN scores below 5.0) were DNase treated to remove any 
potentially contaminating genomic DNA. This additional processing step had failed 
to improve the purity of the isolated material (Figure 4.10) and what’s more, in the 
majority of instances, performing repeat extractions from frozen LCL pellets using 
a fresh QIAGEN RNeasy® Mini Kit also had little impact on the RNA quality and yield 
that was achieved (Table 4.5).                                                   
 
4.3 Human Exon 1.0ST GeneChip® Array Profiling 






















Figure 4.6 ECACC RNA Extraction Boxplots Grouped by Sample Type Summary plots 
produced using GraphPad Prism® software version 5.04. Whiskers represent minimum 
and maximum RNA concentrations measured on the NanoDropTM 1000 Spectrophoto-
meter (left panels)  or RNA integrity values (RIN) as determined by the Agilent 2100 Bio-
analyzer (right panels) that were achieved for control, familial ALS (FALS) and sporadic 
ALS (SALS) samples in the ECACC Discovery (a) or Replication (b) cohort.      
 
Figure 4.7 ECACC RNA Extraction Boxplots Grouped by QIAGEN RNeasy® Mini Kit Summary 
plots produced using GraphPad Prism® software version 5.04. Whiskers represent minimum and 
maximum RNA concentrations measured on the NanoDropTM 1000 Spectrophotometer (left panel) 
or RNA integrity values (RIN’s) as determined on a scale of 0 (undetectable, completely degraded) 
to 10 (high quality, intact RNA) by the Agilent 2100 Bioanalyser (right panel).  
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Figure 4.8 ECACC RNA Extraction Boxplots Grouped by Batch Summary plots produced 
using GraphPad Prism® software version 5.04. Whiskers represent minimum and maximum 
RNA concentrations measured on the NanoDropTM 1000 Spectrophotometer (upper) or RNA 
integrity values (RIN’s) as determined by the Agilent 2100 Bioanalyzer (lower) which were 
achieved for each batch of lymphoblastoid cell lines in the ECACC Discovery (left) [I-V] and 
Replication (right) [VI-X] cohorts. 
   
 ECACC Batch number (#) 
 I II III IV V 
FALS F1-24 F25-48 F49-72 F73-96 F97-120 
SALS S1-50 S51-100 S101-149 S150-199 S200-248 
Control C1-20 C21-40 C41-60 C61-80 C81-100 
 
ECACC Batch number (#) 
 VI VII VIII IX X 
SALS S249-299 S300-349 S350-399 S400-449 S450-499 
Control C101-120 C121-140 C141-160 C161-180 C181-200 
 
Table 4.4 ECACC LCL Batches Cell pellets were preserved in RNAlaterTM and shipped on dry ice. 
Dispatch dates and freezer code a) Discovery Cohort I 15/11/2011 [D-ORANGE], II 22/11/2011 
[D-GREEN], III 29/11/2011 [D-BLUE], IV 6/12/2011 [D-YELLOW], V 13/12/2011 [D-PINK] and 
b) Replication Cohort VI 20/12/2011 [R-ORANGE], VII 11/01/2012 [R-GREEN], VIII 24/01/ 
2012 [R-BLUE], IX 31/01/2012 [R-YELLOW], X 7/02/2012 [R-PINK]. For the purposes of this 
study each sample was assigned a unique reference number with the prefixes: C - control, F - 
familial patient or S - sporadic patient. 
        Discovery                                          Replication 
































Figure 4.9 Agilent 2100 Bioanalyzer Assessment of LCL RNA Integrity External standard a) 
RNA 6000 Nano Ladder with a 25nt molecular weight marker and 0.2kb, 0.5kb, 1kb, 2kb, 4kb and 
6kb fragments at a total concentration of 150ng/μL. Representative electropherogram traces and 
corresponding electrophoresis gel images for b) control samples c) familial patient samples and 
d) sporadic patient samples in the ECACC Discovery and Replication cohort  
 
Abbreviations: BC - Birmingham control, BP - Birmingham patient, [FU] - fluorescent units, [nt] - 













Figure 4.10 Agilent 2100 Bioanalyzer Assessment of DNase Treated Samples of Low Quality 
Representative electropherogram traces and corresponding electrophoresis gel images for poor 
quality RNA isolated from pelleted lymphoblastoid cell lines derived from sporadic sample S227 
(SP3043) in the ECACC Discovery cohort a) pre DNase treatment and b) post DNase treatment.   
Abbreviations: [FU] - fluorescent units, [nt] - nucleotide, S - sedimentation coefficient and SP - 
Sheffield patient.   
S S 
     a)                                   Ladder 
L C 
    b)                         BC6323 
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 First Extraction Second Extraction 
 260/280 260/230 RNA Yield RIN 260/280 260/230 RNA Yield RIN 
C084 1.99 2.07 3.68 - 2.02 1.65 4.44 6.6 
C087 2.02 1.23 4.31 2.6 2.05 2.23 4.86 2.5 
C091 2.09 2.12 4.99 - 2.06 0.82 3.21 - 
F094 2.06 1.50 8.57 5.2 2.07 2.09 7.33 3.3 
F096 1.96 0.60 3.40 - 2.06 1.73 7.19 7.7 
F100 2.04 2.25 12.52 2.9 2.06 1.23 9.25 4.8 
S153 2.05 2.16 12.52 3.0 2.08 1.67 13.86 - 
S154 2.06 2.13 13.36 2.8 2.09 2.24 7.52 - 
S220 2.06 1.59 3.95 - 2.06 1.77 6.77 - 
S227 2.09 2.02 8.77 - 2.09 2.19 12.09 2.4 
S244 2.02 2.06 6.73 1.9 2.06 2.25 5.69 2.6 
 
Table 4.5 QIAGEN RNeasy® Mini Kit Repeat RNA Extractions from Frozen LCL Pellets Concent-
rations and absorbance (A) ratios at 260/280nm and 260/230nm wavelengths were recorded on 
the NanoDropTM 1000 Spectrophotometer. Total yield was calculated in micrograms (μg) and the 
RNA integrity number (RIN) computed on a scale of zero (undetectable, completely degraded) to ten 
(intact, high quality RNA) by the Agilent 2100 Bioanalyzer. Green shading indicates improved yield 
and/or quality of the isolated material when the extraction procedure was repeated. Conversely, red 
represents samples that produced equally poor or even lower quality RNA following the second ext-
raction.  
  
Abbreviations: C - control, F - familial, LCL - lymphoblastoid cell line, RIN - RNA integrity number 
and S - sporadic.   
 
 
4.3.1 Affymetrix® WT Sense-Target Labelling Assay   
4.3.1.1 Linearly Amplified Material   
4.3.1.1.1 Anti-Sense cRNA  
The isolated material was in vitro transcribed (Section 2.3.2.3.1), following the first 
step of linear amplification, into as-cRNA using the Ambion® Whole Transcriptome 
(WT) Expression Kit [APPENDIX TABLE B7]. Concentrations of between 395.64ng/ 
μL and 3,498.70ng/μL were achieved from an input of 312.7±36.5ng total RNA with 
minimum and maximum yield of 16μg and 140μg, respectively. Samples comprised 
all of the LCL’s that were received in the ECACC discovery cohort (n=469/470) [100 
-CTRL, 120-FALS and 249-SALS], plus an additional seven C9ORF72+ SALS patients 
in the ECACC replication cohort which met the criteria for inclusion into the long (≥ 
4yrs) versus short (<2yrs) survival study [S268-(BP6107), S319-(LP0203), S368-(L 
P0454), S373-(LP0359), S352-(SP3484), S440-(BP6297) and S438-(LP0411)]. Me-
asurements on the NanoDropTM 1000 Spectrophotometer were found to be consist-




40±739.33ng/μL, 1,832.27±674.18ng/μL and 1,933.25±608.71ng/μL for CTRL, FA 
LS and SALS, respectively. Absorbance ratios at 260/280nm wavelengths ranged be- 
tween 1.97 and 2.32 (Figure 4.11). 
  
 







Figure 4.11 ECACC as-cRNA Amplification Boxplot Grouped by Sample 
Type Summary plots produced using GraphPad Prism® software version 
5.04 copyright © 1992-2014 (GraphPad Prism® Inc., USA). Whiskers rep-
resent minimum and maximum anti-sense copy RNA (as-cRNA) concentra-
tions achieved on the NanoDropTM 1000 Spectrophotometer for linearly 
amplified material derived from control (CTRL), familial ALS (FALS) and 
sporadic ALS (SALS) samples in the final ECACC LCL microarray cohort 
(n=476/470) [100-CTRL, 120-FALS and 256-SALS].  
 
 
4.3.1.1.2 Single-Stranded cDNA  
Following the second step of linear amplification using the Ambion® WT Expression 
Kit (Section 2.3.2.3.1) an input of 10μg purified as-cRNA yielded between 5.79μg and 
12.98μg of newly synthesised ss-cDNA. Measurements on the NanoDropTM 1000 Sp-
ectrophotometer were consistent across the different sample types with means and 
standard deviations of 269.80±35.14ng/μL, 268.25±30.30ng/μL and 270.84±26.25 
ng/μL for CTRL, FALS and SALS, respectively. Absorbance ratios at 260/280nm wa-
velengths ranged between 1.95 and 2.10 (Figure 4.12) [APPENDIX TABLE B7].    
 
4.3.1.2 Fragmented ss-cDNA  
Sense-strand cDNA targets were generated from 451 (94.8%) of 476 LCL samples [ 
96-CTRL, 116-FALS and 239-SALS] comprising the final microarray cohort, with the 










Figure 4.12 ECACC ss-cDNA Amplification Boxplot Grouped by Sample 
Type Summary plots produced using GraphPad Prism® software version 
5.04 copyright © 1992 to 2014 (GraphPad® Software Inc., CA USA). Whisk-
ers represent the minimum and maximum single-stranded complementary 
DNA (ss-cDNA) concentrations on the NanoDropTM 1000 Spectrophotome-
ter that were achieved for linearly amplified material derived from control 
(CTRL), familial ALS (FALS) or sporadic ALS (SALS) samples in the final 




plication of the Affymetrix GeneChip® WT Fragmentation and Terminal Labelling Kit 
produced fragments of ~40 to 70nt in length. Size distribution analysis of a random-
ly selected subset of pre- and post-fragmented nucleic acid products was performed 
on the Agilent 2100 Bioanalyzer. Representative traces and their corresponding gel 







Figure 4.13 Agilent 2100 Bioanalyzer Size Distribution Analysis of Fragmented ss-cDNA Mic-
roarray Targets Representative electropherogram traces and corresponding gel images for a) pre-
fragmented and b) post-fragmented single-stranded complementary DNA (ss-cDNA) amplified from 
sporadic sample [S440-(BP6297)] in the ECACC replication cohort using the Affymetrix GeneChip® 
Whole Transcriptome (WT) Fragmentation and Terminal Labelling Kit. 
 
Abbreviations: BP - Birmingham patient, ECACC - European Collection of Cell Cultures, [FU] - fluore-
scent units, [nt] - nucleotides, [s] - seconds, S - sedimentation coefficient  




4.3.1.3 Biotinylation of Sense-Strand Targets  
The biotinylation efficiency (Section 2.3.2.3.4) of the labelling process was assessed 
on randomly selected ECACC control, FALS and SALS LCL samples from each of the 
amplification batches by performing an electrophoretic mobility shift assay (EMSA) 
as depicted in Figure 4.14. Fragmented sense-strand cDNA targets were incubated 
in the presence or absence of the biotin-binding protein, NeutrAvidinTM before being 
loaded onto 4 to 20% gradient polyacrylamide gels and electrophoresed at 150v for 
approximately 1 hour. Negative controls containing unbound biotin-tagged cDNA in 
lanes 3, 5, 7, 9 and 11 ran close to the dye front. In the NeutrAvidinTM positive sam-
ples in lanes 2, 4, 6, 8, 10 and 12 nucleic acid-protein complexes (~60kDa) formed 
of a substantially larger molecular weight which migrate through the non-denatur-
ing gel matrix at a slower rate; resulting in the detection of a shifted band at around 
300 to 400bp (red arrow). Staining with a 0.001% ethidium bromide solution for 30 
to 40 minutes permits this change in banding pattern between NeutrAvidinTM posi-
tive (+) and NeutrAvidinTM negative (-) lanes (Figure 4.14) to be visualised under a 
UV light source using the  Syngene GENi Gel Documentation System.   








Figure 4.14 Electrophoretic Mobility Shift Assay (EMSA) Representative electrophoresis 
gel image assessing labelling efficiency of fragmented sense-strand cDNA targets generated 
from LCL’s in the final microarray cohort (n=451/476) [96-CTRL, 116-FALS and 239-SALS]. 
Samples incubated in the presence (+) or absence (-) of biotin-binding protein NeutrAvidinTM 
were run with DNA markers of 25bp molecular weight (HyperLadderTM V) in lane 1 and 
100bp (HyperLadderTM IV) molecular weight in lane 13 on 4 to 20% gradient polyacrylamide 
gels at 150v for approximately 1 hour, stained in a 0.001% Ethidium Bromide solution for 20 
to 30 minutes and visualised under a ultraviolet (UV) light source using the Syngene GENi Gel 





Abbreviations: ALS - Amyotrophic Lateral Sclerosis, CTRL - control, bp - base pairs, cDNA - 
complementary DNA, EMSA - electrophoretic mobility shift assay, F - familial, LCL - lympho-
blastoid cell line and S - sporadic.       
 
 
4.3.2 Affymetrix® Expression ConsoleTM QC Metrics  
4.3.2.1 Eukaryotic Hybridization Controls  
Three genes of the E. coli biotin synthesis pathway (BioB, BioC and BioD) in addition 
to the recombinase gene from the P1 bacteriophage (CreX) (Section 2.3.2.4.2) were 
spiked in at increasing concentrations [1.5pM, 5pM, 25pM and 100pM, respectively] 
of the hybridization reaction. Since it is anticipated that these targets will not cross-
hybridize with samples of a non-bacterial or non-viral origin, the intensity pattern 
for these controls should be seen to mimic the increase in target concentration [i.e. 
BioB<BioC<BioD<CreX] described above. For the ECACC LCL’s this proved to be the  
case in all but one instance (Figure 4.15) involving familial sample [F042-(SP3303)] 
which is represented by the red line in plot b) of Figure 4.16.  
BioB, at a concentration of 1.5pM, represents the absolute limit of detection. In the 
Affymetrix® Expression ConsoleTM software version 1.3.0.187 at least one probeset 
pertaining to this endogenous control was flagged as present for each array which 
is a strong indicator of having achieved good overall sensitivity.       
 
  
Figure 4.15 Eukaryotic Hybridization Controls Bacterial spike in controls [E. coli derived genes 
of the biotin synthesis pathway BioB (blue), BioC (red), BioD (pink) and the recombinase gene CreX 
(green) from the P1 bacteriophage] at staggered concentrations of 1.5pM (representing the limit of 
detection), 5pM, 25pM and 100pM, respectively. Assessment of Affymetrix® quality control metrics 











Figure 4.16 Bacterial Spike in Controls Mean signal intensities of BioB, BioC, BioD and CreX prob-
esets on the Affymetrix Human Exon 1.0ST GeneChip® Arrays for a) control (CTRL), b) familial (FAL 
S) and c) sporadic (SALS) samples in the final microarray cohort [95-CTRL (C73 failed to scan), 116-
FALS and 239-SALS]. Each line represents a single array with outliers highlighted in red [F042-(SP 
3303)]. Assessment of Affymetrix® QC metrics performed using the Expression ConsoleTM software 
version 1.3.0.187.    
 
 
4.3.2.2 Overall Signal Quality 
4.3.2.2.1 Average Background  
Average background signal intensities ranged between 80.566 and 367.741 for the 
450 GeneChips® [95-CTRL, 116-FALS and 239-SALS] in the final microarray cohort 
which excluded one Birmingham control [C073-(BC6091)] that failed to scan. Values 
were comparable across the different sample types with means and standard devia-
tions of 191.448±45.92, 204.245±45.03 and 204.609±45.88 for controls, FALS and 
SALS, respectively (Figure 4.17). 
Tukey defined outliers with significantly higher (n=5/450) [1-CTRL, 2-FALS and 2-
SALS] or lower (n=3/450) [3-SALS] average background signal intensities included 
one female control [C031-(SC3709)], five FALS patients (3-M, 2-F) [F01-(LP0137), 
F08-(BP6074), F076-(SP3670), F079-(SP3508) and F099-(LP0073)] and two SALS 
patients (2-F) [S033-(SP3045) and S203-(SNc0059)]. 
 
4.3.2.2.2 Average Percentage Presence Calls  
On average, 63.1% (n=181,305) of the 287,329 ‘core’ metaprobesets annotated by 
RefSeq which are incorporated onto the Affymetrix® Human Exon 1.0ST GeneChip® 
Arrays were flagged as present (P) (Figure 4.18). This percentage proved reasonably 
consistent across the different sample types with means and standard deviations of

















Figure 4.17 Mean Background Signal Intensities Across LCL Sample Types 
Summary box and whisker plots were generated in GraphPad® Prism software 
version 5.04 copyright © 1992-2014 (GraphPad® Software Inc., CA USA) applying 
a Tukey multiple comparison test. Samples of significantly higher or lower mean 
background (bgrd) signal intensities (outliers) were highlighted in red (n=8/450) 
[1-CTRL, 5-FALS and 2-SALS]. Assessment of Affymetrix® QC metrics performed 
using Expression ConsoleTM software version 1.3.0.187. 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, CTRL - control, F - familial, 
LCL - lymphoblastoid cell line, QC - quality control and S - sporadic.   
   











Figure 4.18 Average Percentage Presence (%P) Calls Across LCL Sample Types 
Summary box and whisker plots produced in GraphPad Prism® software version 5.04 
copyright © 1992-2014 (GraphPad® Software Inc., CA USA) applying a Tukey multiple 
comparisons test. Outliers of insufficient quality with fewer than 143,665 ‘core’ meta-
probesets called as present (P) on Affymetrix® Human Exon 1.0ST GeneChip® Arrays 
are highlighted in red (n=9/450) [1-CTRL, 2-FALS and 6-SALS]. The green data points 
represent Tukey identified outliers that have a percentage presence call above the 
user defined threshold of 50.0%. Assessment of Affymetrix® QC metrics performed 













Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C - control, CTRL - control, F - 
familial, LCL - lymphoblastoid cell line, QC - quality control, S - sporadic and ST - 
sense target.      
 
 
64.0±3.6% (n=183, 891±10,344), 62.9±4.7% (n=180,730±13,505) and 62.8±4.5% 
(n=180, 443±12,930) for controls, FALS and SALS, respectively.  
Outliers were determined by performing a Tukey multiple comparisons test (Figure 
4.18). Samples with %P calls below the applied threshold of 50.0% were considered 
to be of poorer quality. These included one female control [C076-(SNc0106)], two F 
ALS patients (1-M, 1-F) [F042-(SP3303) and F095-(SMa0008)] and 6 SALS patients 
(2-M, 4-F) [S044-(SP3329), S090-(SP3304), S112-(SP3363), S123-(BP6021), S130- 
(SNc0010) and S180-(BP6025)].                    
 
4.3.2.2.3 Area Under the Receiver Operating Characteristic Curve   
The Receiver Operating Characteristic (ROC) curve plots the detection rate of true 
positive (+ve) controls, a measurement of sensitivity, against the false detection rate 
of negative (-ve) controls; which is a function of specificity. AUC values for the area 
under the curve lied between 0.8 and 0.9 for 432 (96.0%) of 450 GeneChips® in the 
final microarray cohort. Consistency was observed across sample types with means 
and standard deviations of 0.845±0.02, 0.849±0.02 and 0.854±0.03 for controls, FA 
LS and SALS, respectively. Samples falling outside this range included four controls 
(3-M, 1-F) [C038-(LSh0022), C076-(SNc0106), C087-(BC6166) and C091-(SC3741)], 
four FALS patients (2-M, 2-F) [F042-(SP3303), F080-(SP3508), F085-(LP0013) and 
F095-(SMa0008)] and ten SALS patients (6-M, 4-F) [S108-(SP3384), S119-(SP3073), 
S123-(BP6021), S130-(SNc0010), S145-(SP3065), S162-(SP3326), S215-(SP3187), 
S220-(SP3105), S244-(BP6052) and S352-(SP3484)].                
 
4.3.2.3 Signal Comparability 
4.3.2.3.1 All Probeset Mean Signal Intensities  




(n=22,011) (Figure 4.19a) were found to be marginally lower than those observed 
at the level of the individual exon (n=287,329) (Figure 4.19b). Means and standard 
deviations were comparable between different sample types [GENE LEVEL 6.94±0. 
12, 6.95±0.10 and 6.98±0.11 for controls, FALS and SALS versus EXON LEVEL 7.05± 









   
 
 
Figure 4.19 Mean Probeset Signal Intensities Across LCL Sample Types Summary box and 
whisker plots at a) whole transcript or b) individual exon level were produced using GraphPad 
Prism® software version 5.04 copyright © 1992 to 2014 (GraphPad® Software Inc., CA USA) 
with a Tukey multiple comparison test applied. Outliers are represented in red. Assessment of 
Affymetrix® QC metrics were performed in Expression ConsoleTM software version 1.3.0.187.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, CTRL - control, F - familial, LCL - lympho-
blastoid cell lines, QC - quality control and S - sporadic.   
 
 
Tukey defined outliers which were detected at both levels of analyses included four 
controls (2-M, 2-F) [C079-(SC3279), C087-(BC6166), C090-(BOx0073) and C091-(S 
C3741)], for FALS patients (2-M, 2-F) [F014-(LCa0111), F042-(SP3303), F085-(LP0 
013) and F095-(SMa0008)] and six SALS patients (3-M, 3-F) [S06-(SP3062), S162-( 
SP3326), S186-(SP3090), S215-(SP3187), S220-(SP3105) and S352-(SP3484)]. 
 
4.3.2.3.2 Signal Histogram   
Density histograms pertaining to log2 transformed average GC-RMA normalised si-
gnal intensity values were plotted at a) whole transcript and b) individual exon level 
in Expression ConsoleTM software version 1.3.0.187. In general distributions appear 
highly correlated across all 450 arrays (Figure 4.20) in the final ECACC LCL micro-
a) Whole Transcript                                                                                  b) Individual Exon  


































Figure 4.20 Signal Histogram Plots Each series of coloured bars represents the distribution 
of log2 transformed, average GC-RMA normalised signal intensity values for a single array at 
a) whole transcript and b) individual exon level. Assessment of QC metrics was performed in 
Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., UK).  
 
Abbreviations: QC - quality control and RMA - Robust Multi-array Average.       
 
 
array cohort with a good degree of concordance between the two different levels of 
analyses.  
 
4.3.2.3.3 Relative Log Expression Signal         
Mean absolute relative log expression (RLE) is used as a measure of how the signal 
intensities on each individual chip compare with those across the rest of the exper-
iment. A cohort which exhibits relative homogeneity should have scores close to ze-
ro with a small spread of values around the mean. Samples in the ECACC microarray 
study that deviated significantly from this scenario (Section 3.3.2.6), with means or 













standard deviations above the 0.500 threshold, included six controls (3-M, 3-F) [C0 
38-(LSh0002), C076-(SNc0106), C079-(SC3279), C087-(BC6166), C090-(BOx0073) 
and C091-(SC3741)], three FALS (1-M, 2-F) [F042-(SP3303), F080-(SP3508) and F0 
95-(SMa0008)] and eleven SALS (8-M, 3-F) [S108-(SP3384), S112-(SP3363), S119-
(SP3073), S123-(BP6021), S130-(SNc0010), S145-(SP3065), S162-(SP3326), S189-
(SP3090), S215-(SP3187), S220-(SP3105) and S352-(SP3484)] patients (Figure 4.2 
1).       
 
4.3.2.4 Pearson’s Correlation Coefficient 
For each pair of arrays, Expression ConsoleTM software version 1.3.0.187 determines 
the Pearson’s product-moment correlation coefficient (r) (Section 3.3.2.6) from the 
covariance divided by the product of the standard deviations. This is computed on a 
scale of -1 to 1 where zero equals no correlation (i.e. the data points are randomly 
distributed) and a value to close to plus (positive) or minus (negative) one indicates 
that there is a strong linear relationship between the X and Y variables (Figure 3.10). 
The data can be illustrated qualitatively on a coloured matrix as depicted in Figure 
4.22. In the ECACC microarray experiment r exceed 0.725 for all pair-wise compar-
isons made across the three sample types with those hybridizations producing the 
weakest relationships represented in blue (r<0.800) or white (0.800<r<0.850). Th-
ese included one male control [C091-(SC3741)], two FALS patients (1-M, 1-F) [F04-
2-(SP3303) and F095-(SMa0008)] and three SALS patients (2-M, 1-F) [S189-(SP30 
90), S215-(SP3187) and S352-(SP3484)] (Figure 4.22). 
 
4.3.2.5 Affymetrix® Expression ConsoleTM Summary 
In total, 7.8% (n=35/450) LCL’s in the final ECACC microarray cohort [7/95-CTRL, 
10/116-FALS and 18/239-SALS (Table 4.6)] failed one or more post-hybridization 
QC parameters assessed in Expression ConsoleTM software version 1.3.0.187. Signal 
intensity files (CEL files) generated for three controls (2-M, 1-F) [C076-(SNc0106), 
C087-(BC6166) and C091-(SC3741)], two FALS patients (1-M, 1-F) [F042-(SP3303) 
and F095-(SMa000 8)] and seven SALS patients (4-M, 3-F) [S123-(BP6021), S130-




























Figure 4.21 Mean Absolute RLE Boxplots Absolute Relative Log Expression (RLE) means and sta-
ndard deviations for a) control (CTRL) samples, C1-100, b) familial (FALS) samples, F1-120, c) spo-
radic (SALS) samples, S1-132 and d) sporadic (SALS) samples, S133-440 in the ECACC microarray 
experiment. Whiskers represent minimum and maximum average probeset signal intensities at the 
level of the whole transcript. Assessment of Affymetrix® quality control (QC) metrics was performed 
using Expression ConsoleTM software version 1.3.0.187.  
 









































Figure 4.22 Pearson’s Correlation Coefficient Each pair-wise comparison in the coloured 
matrix is assigned a value for r on a scale of 0.726 (blue) to 1.000 (red) where the higher the 
score is indicative of a stronger linear relationship between the X and Y variables. Assessment of 
Affymetrix® QC metrics performed in Expression ConsoleTM software version 1.3.0.187. 
 
Abbreviations: C - control, F - familial, QC - quality control and S - sporadic.  
 
 
 Control FALS SALS 
National DNA Bank 100 120 257 
ECACC -0 -0 -1 
RNA -0 -0 -0 
ss-cDNA -4 -4 -17 
Hybridization  -1 -0 -0 
Final Total 95 116 239 
 
Table 4.6 Summary of Control, FALS and SALS LCL Samples in Final ECACC 
Microarray Cohort The initial cohort was comprised of 100 controls, 120 FALS 
and 257 SALS to include all of the LCLs in the ECACC discovery cohort plus an 
additional seven C9ORF72+ cases from the ECACC replication cohort which met 
the criteria for the long (>4yrs) versus short (<2yrs) survival study. A break-
down of the number of samples passing each of the handling and processing 
steps is provided with the final totals highlighted in bold.        
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 
open reading frame 72, ECACC - European Collection of Cell Cultures, F - familial, 




52-(SP3484)] were of particularly poor quality having failed three or more of the QC 
metrics summarised in Table 4.7. 
 
   Affymetrix® Expression ConsoleTM QC Metric 
 bac_spike bgrd_mean %P AUC all_probeset_mean RLE PPMCC 
C076        
C087        
C091        
F042        
F095        
S123        
S130        
S162        
S189        
S215        
S220        
S352        
 
Table 4.7 Affymetrix® Expression ConsoleTM Summary of Failed LCL Samples in the ECACC 
Discovery and Replication Cohorts 
 
Key:   █ Passed    █ Failed    
 
Abbreviations: AUC - area under receiver operating curve (ROC), bac-spike - bacterial spike in 
control, bgrd - background, C - control, F - familial, LCL - lymphoblastoid cell line, P - present 
calls, PPMCC - Pearson’s product moment correlation coefficient, QC - quality control, RLE - 




Participants (n=820) [120-FALS, 500-SALS and 200-CTRL] attending clinics (Section 
2.1.2) in the Birmingham, London or Sheffield districts (Figure 2.1) between Novem-
ber 2003 and June 2011, who were subsequently recruited to the ECACC microarray 
cohort, were Caucasian and of North European descent. Patient partners or their un-
related carers were selected as neurologically normal, healthy control subjects. Th-
ese were matched for age and gender across the SALS group, with a slightly higher 
than previously reported M:F ratio of approximately 1.75:1. Typically, ratios range 
between 1.20 and 1.50:1 (Section 1.1.2); which is comparable to the FALS group at 
1.45:1 (McCombe & Henderson 2010). All patients were diagnosed according to the 
World Federation of Neurology’s amended EEC of 1998 (Figure 1.1) (Section 1.1.3) 
with the majority having either definite 39.4% (n=244/620) or probable ALS 55.3% 




1.5.5) [1-FALS and 3-SALS] and two further incidences of ALS with concomitant PD 
(Section 1.2.1) [1-FALS and 1-SALS]. In the remaining 4.4% (n=27/620) of cases it 
is likely that a revision has been made to the original diagnosis of ALS after the sam-
ples were accepted into the National MNDA DNA Bank. These comprised several ra-
rer variants of MND including: PBP (Section 1.2.2.1) (n=23/27) [6-FALS and 17-SA 
LS] in which the bulbar muscles are primarily affected (Gregoriou et al 1969, Karam 
et al 2010, Talacko & Reade 1990); PLS (Section 1.2.2.2) (n=3/27) [1-FALS and 2-SA 
LS] of pure UMN involvement (Gotkine & Argov 2007, Praline et al 2010, Pringle et 
al 1992, Tartaglia et al 2007) and PMA (Section 1.2.2.3) (n=1/27) [1-SALS] of pure 
LMN involvement (de Carvalho et al 2007, Visser et al 2008, Visser et al 2007).   
FALS cases exhibited a moderately younger mean age of symptom onset (defined as 
the point at which the patient first presented with significant weakness) than SALS 
cases that peaked in the mid-fifties compared to early sixties [FALS 55±11.9 (range 
23-82) years and SALS 60±11.4 (range 22-87) years (student’s t-test p<0.001***)]. 
This was consistent with the reports of Calvo et al (2014b) and Kinsley & Siddique 
(2001). The proportion of patients with limb onset (50%), bulbar onset (~30%), a 
mixed presentation (10-15%) or onset in the respiratory muscles (~2%) were also 
comparable to the figures published in the literature (Gautier et al 2010, Korner et 
al 2011, Ravits et al 2007, Sekiguchi et al 2014). In addition, survival was observed 
to be similar between FALS and SALS groups [FALS 2.9±2.28 (range 0.5-18.7) years 
and SALS 3.2±1.74 (range 0.39-10.3) years]; although differences were reported to 
occur between SALS of the ECACC discovery (Section 4.1.1) and replication (Section 
4.1.2) cohorts with respective means and standard deviations of 2.8±1.34 years or 
4.0±2.30 years and a student’s t-test derived probability value of 7.26E-12 (Cluskey 
& Ramsden 2001, McDermott & Shaw 2007). One possible explanation for this skew 
in survival data stems from the fact that samples with complete clinical information 
immediately available to hand were prioritised to the discovery cohort at the start of 
the project, to prevent delays in commencing the study. Another unintentional con-
sequence of how the LCL’s were consigned to a cohort (ranking of SALS and controls 
in ascending order of age and arbitrarily assigning them number one or two altern-
ately down the list) was the considerably higher M:F ratio for SALS in the replication 




This can be rectified, however, using the Partek® Genomics SuiteTM analysis pipeline 
outlined in Section 2.3.2.5.2 which includes age and gender as covariates (Figure 2. 
4) in order to control for any potential bias that may be introduced by such factors. 
Mutations were detected in the FALS patients at a frequency of 40.8% for C9ORF72 
(n=49/120) (Section 1.2.5.4), 4.4% for SOD1 (n=5/115) (Section 1.2.5.1.1), 3.8% for 
FUS (n=4/106) (Section 1.2.5.2.2) and 2.9% for TARDBP (n=3/103) (Section 1.2.5.2. 
1) (Table 4.2) and in the SALS patients at a frequency of 8.0% for C9ORF72 (n=40/ 
500), 0.6% for TARDBP (n=3/500), 0.4% for CHMP2B (n=2/500) (Section 1.2.5.2.8) 
and 0.2% for ANG (n=1/500) (Section 1.2.5. 2.3) (Table 4.3). With the exception of 
familial SOD1 (Rosen et al 1993) and TARDBP (Sreedharan et al 2008), which were 
recorded at a lower than anticipated frequency, the majority were found to be con-
sistent with the previously published reports of Cooper-Knock et al (2012b), DeJes-
us-Hernandez et al (2011), Greenway et al (2006), Kwiatkowski et al (2009), Park-
inson et al (2006), Renton et al (2011) and Vance et al (2009). Among the C9ORF72 
cases were two examples of oligogenic inheritance, including one FALS patient [F05 
6-(SP3462)] with an OPTN mutation (Bury et al 2015) (Section 5.3.2.1) and a second 
SALS patients [S352-(SP3484)] with a TARDBP mutation (Kirby et al 2010) (Section 
5.3.2.2). In this latter instance, although the patient was entered into the database as 
a sporadic case, it is likely, especially in light of the above, that the individual does in 
fact represent a familial case which has arisen as a consequence of incomplete pen-
etrance or may have been misclassified due to a lack of information regarding fam-
ily history. Since ALS is typically an adult onset disorder of relatively short life exp-
ectancy there is a chance that affected relatives of some seemingly SALS cases have 
died (Al-Chalabi & Lewis 2011, Conforti et al 2011) either before clinical manifesta-
tions of disease or prior to a formal diagnosis of MND having been made.  
Across the ECACC discovery (Section 4.1.1) and replication (Section 4.1.2) cohorts  
four LCL samples [3-SALS and 1-CTRL] failed the EBV-transformation process and, 
following two unsuccessful attempts, were rejected from the final study design. On 
the NanoDropTM 1000 Spectrophotometer (Section 2.3.1.3) high yields [APPENDIX 
TABLE B7] and purity (A260/280 2.0±0.2, 99.3%) was achieved for the remaining 816 
[120-FALS, 497-SALS and 199-CTRL] samples with little or no evidence of protein/ 




the frozen cell pellets (Figure 4.6-8). The quality of the isolated material, as assess-
ed using the Agilent 2100 Bioanalyzer, was found to be consistent across different 
sample types, within in each of the cohorts [Mean RIN: discovery cohort 8.3 versus 
replication cohort 7.4 (student’s t-test p<0.001***)], but had steadily declined over 
time. All of the QIAGEN RNeasy® Mini Kits were purchased in a single batch and lot 
# at the beginning of the project. To test whether the storage of the kits was having 
an impact, some repeat extractions (Table 4.5) were performed using a new kit and 
freshly prepared 70% ethanol solution. This, however, proved ineffective and in so-
me instances the RNA quality and yield had actually deteriorated rather than show-
ing an improvement; suggesting freeze thawing of the LCL’s may have caused some 
degradation to occur ex vivo (Caliskan et al 2014). Also, in simply taking a fixed vol-
ume of the suspension, different densities of cells could have been present in each 
round of the extractions. Another factor worth considering is the quality of the ori-
ginal sample used for EBV-transformation, since the extractions were performed in 
the order in which they were received from ECACC and it is a likely proposition that 
the LCL’s proving most difficult to process would have been dispatched in the later 
batches.   
For the ECACC microarray study in the subsequent two results chapters (Chapter 5: 
‘C9ORF72 GEP Study’ and Chapter 6: ‘C9ORF72 Survival Study’) the Ambion® Whole 
Transcriptome (WT) Expression Kit was used to generate linearly amplified mater-
ial for all samples received in the discovery cohort (Section 4.1.1), plus an addition-
al seven C9ORF72+ cases in the replication cohort (Section 4.1.2) [120-FALS, 256-S 
ALS and 100-CTRL] which met the criteria for inclusion into the analysis of Long (≥ 
4yrs) versus Short (<2yrs) survival. Sufficient quantities of ss-cDNA were achieved 
in 94.7% of cases (n=451/476) [116-FALS, 239-SALS and 96-CTRL] [APPENDIX TA 
BLE B7]. Post-fragmentation and labelling, targets of ~40-70nt were hybridized on 
to Affymetrix® Human Exon 1.0ST GeneChip® Arrays. For one control, namely [C07 
3-(BC6091)], the GeneChip® failed to scan and a signal intensity or (CEL) file could 
not be created. The remaining samples were processed using Expression ConsoleTM 
software version 1.3.0.187 (Section 2.3.2.5.1) [116-FALS, 239-SALS and 95-CTRL]. 
Following assessment of a series of quality control (QC) parameters summarized in    




failed at least three of these measures and were removed from any subsequent do-
wnstream comparative analyses. Later it was established that 10 of the 12 LCL’s (8 
3.3%) had a RIN score of below 5.0 which suggests that the original samples were of 
poor quality. Therefore, given the size of the cohort, it did not warrant the expense 
of repeating these individual amplifications.    
 
  





CHAPTER 5: C9ORF72 GEP STUDY 
 
The discovery by Renton et al and DeJesus-Hernandez et al, in 2011, of a pathogenic 
G4C2 repeat expansion in the previously uncharacterised C9ORF72 gene represented 
a unique opportunity in which to study a specific genetic subtype that accounts for 
a greater proportion of cases than SOD1 (Section 1.2.5.1.1), TARDBP (Section 1.2.5.2. 
1) or FUS (Section 1.2.5.2.2) mutations combined. In this chapter global GEP’s from 
patient derived, EBV-transformed B-lymphocytes carrying the C9ORF72 expansion, 
were compared on Affymetrix® Human Exon 1.0ST GeneChip® Arrays to a subset of 
ECACC SALS patients and controls. Subsequent, downstream functional annotation 
clustering analysis conducted in DAVID bioinformatics resource version 6.7 enabled 
us to elucidate further the mechanisms of C9ORF72 toxicity. In addition, it was also 
anticipated that this approach would aid in distinguishing between the mechanisms 
linked, specifically, to C9ORF72-related disease from those which contribute to MN 
degeneration more widely in ALS.                   
 
5.1 C9ORF72 and nonC9ORF72-Related_SALS Cohort  
5.1.1 ECACC EBV-Transformed B-Lymphocytes  
5.1.1.1 Clinical Characteristics  
5.1.1.1.1 Control Cases  
Neurologically normal, healthy control LCL’s (n=27/100) [15-M, 12-F] selected from 
the ECACC discovery cohort were largely recruited from patient partners or their un-
related carers (Section 4.1.1). These were comprised of 8 Birmingham (29.6%) cases 
including two from Liverpool [C039-(BLi0169) and C097-(BLi0083)] and one from 
Belfast City Hospital [C020-(BBe0006)]; 4 London (14.8%) cases including one from 
Cambridge [C021-LCa0076)] and one from Poole General Hospital [C05-(LPo0033)] 
and 15 Sheffield (55.6%) cases including three from Newcastle [C04-(SNc0091), C07 




Manchester [C036-(SMa0156)]. Age at consultation ranged between 36 and 84 years 








 C9ORF72+ SALS Control 
M:F 0.91:1 1.42:1 1.25:1 
Age  55.7±11yrs 61.3±12yrs 60.7±13yrs 
Total 40 58 27 
 
Figure 5.1 Age Frequency Distribution of Patient and Control LCL’s in 
the ECACC C9ORF72 and NonC9ORF72-Related_SALS Study   
 
 Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 
9 open reading frame 72, Ctrl - control, ECACC - European Collection of Cell 
Cultures, F - female, LCL - lymphoblastoid cell lines, M - male and S - sporadic.         
 
 
5.1.1.1.2 C9ORF72+ Cases   
Patient derived LCL’s carrying the G4C2 repeat expansion in C9ORF72 (n=40/620) 
[19-M, 21-F] consisted of 18 FALS and 22 SALS selected from the ECACC discovery 
(Section 4.1.1) and replication (Section 4.1.2) cohorts. These were comprised of 7 
Birmingham (17.5%) cases including one from Oxford [F078-(BOx0029)]; 9 London 
(22.5%) cases and 24 Sheffield (60.0%) cases including one from Newcastle [S203-
(SNc0059)] and two from Manchester [F081-(SMa0006) and F117-(SMa0166)]. The 
combined M:F ratio was 0.91:1. However, differences were observed between the 
two sample types [C9ORF72+ FALS 0.80:1 and C9ORF72+ SALS 1.00:1] (Figure 5.1).  
The majority of C9ORF72+ cases, 95.0% (n=38/40) were diagnosed according to the 
World Federation of Neurology’s amended EEC of 1998 (Figure 1.1) (Section 1.1.3) 






































familial, 8-sporadic] ALS including one incidence of concomitant FTLD [F115-(SP31 
18)] and another of concomitant PD (Section 1.2.1) [F114-(SP3560)]. The remaining 
5.0% (n=2/40) of the cohort were diagnosed with PBP (Section 1.2.2.1) [F100-(SP3 
070) and S165-(SP3222)]. Age at symptom onset (i.e. when the patient first experi-
enced significant weakness) ranged between 28 and 70 years with a mean of 55.7± 
11yrs for C9ORF72+ FALS or 36 and 71 years with a mean of 55.6±11yrs for C9ORF 
72+ SALS. Disease duration ranged from 7 to 107 months or 11 to 73 months with a 
mean of 2.93±2.3yrs for C9ORF72+ FALS and 2.54±1.4yrs for C9ORF72+ SALS, resp-
ectively (Table 5.1). Limb onset accounted for 50.0% of cases (n=20/40) [6-FALS, 1- 
FASL+PD and 13-SALS], bulbar onset and a further 32.5% (n=13/40) [6-FALS, 1-FA 
LS+FTLD, 6-SALS and 1-PBP (sporadic)] and a mixed presentation 15.0% (n=6/40) 
[3-FALS, 2-SALS and 1-PBP (sporadic)]. Information regarding site of onset was not 
available for the remaining 2.5% of the cohort (n=1/40) [1-FALS]. ALSFRS-R scores 
ranged between 0 (severe disability) and 46 (near normal function) with an average 
of 30.1±12 for 100% of C9ORF72+ FALS and 30.2±14 for 86.4% of C9ORF72+ SALS 
(n=19/22).  
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Approximately a fifth, 20.8% (n=5/24) [1-FALS and 4-SALS] were 
prone to EL, another 20.8% (n=5/24) [1-FALS, 1-FALS+FTLD and 3-SALS] displayed 
symptoms of dyspnoea and 8.3% (n=2/24) [1-FALS and 1-SALS] had suffered from 
hypersialorrhea. Dysarthria and dysphagia were apparent in 45.8% (n=11/24) [2-
FALS, 1-FALS+PD, 1-FALS+FTLD, 5-SALS and 2-PBP (1-familial, 1-sporadic)] of the 
cohort with PEG feeding (Section 1.1.4) becoming a necessary intervention in 36.4% 
(n=4/11) [1-FALS, 1-FALS+PD and 2-SALS] of these latter cases. There was also one 
sporadic individual who presented with the rare and more benign FA variant of the 
disease [S042-(SP3122)] (Section 1.2.1). Three patients, 12.5% [1-FALS, 1-FALS+PD 
and 1-SALS] were non-ambulant with a further 8.3% (n=2/24) [1-FALS and 1-SALS] 
unable to walk without needing assistance. Current smokers comprised 4.2% of the 
cohort (n=1/24) [1-PBP (familial)], ex-smokers a further 8.3% (n=2/24) [2-SALS] 
and non-smokers 66.7% (n=16/24) [5-FALS, 1-FALS+PD, 9-SALS and 1-PBP (spora-
dic)]. For the remaining 20.8% of the cohort (n=5/24) [2-FALS and 3-SALS] this in-




 C9ORF72neg ------------------------------------ C9ORF72pos  ------------------------------------ -------- Control -------- 
 SALS SALS FALS ALL CTRL 
M:F 1.42:1 1.00:1 0.80:1 0.91:1 1.25:1 
Age      
        range 22-82yrs 36-71yrs 28-70yrs 28-71yrs 36-84yrs 
        mean 61yrs 56yrs 56yrs 56yrs 61yrs 
Onset      
        Limb 28 (48.2%) 13 (59.1%)    7 (38.9%) 20 (50.0%) n/a 
        Bulbar 24 (41.4%)              7 (31.8%)              6 (33.3%) 13 (32.5%) n/a 
        Mixed              4    (6.9%)              2    (9.1%)              4 (22.2%)              6 (15.0%) n/a 
        Respiratory              2    (3.5%)              0    (0.0%)              0    (0.0%)              0    (0.0%) n/a 
        unknown              0    (0.0%)              0    (0.0%)              1    (5.6%)              1    (2.5%) n/a 
Diagnosis       
        ALS 51 (87.9%) 21 (95.5%) 15 (83.3%) 36 (90.0%) n/a 
        ALS+FTLD              2    (3.5%)              0    (0.0%)              1    (5.6%)              1    (2.5%) n/a 
        ALS+PD              0    (0.0%)              0    (0.0%)              1    (5.6%)              1    (2.5%) n/a 
        PBP              5    (8.6%)              1    (4.5%)              1    (5.6%)              2    (5.0%) n/a 
        PLS              0    (0.0%)              0    (0.0%)              0    (0.0%)              0    (0.0%) n/a 
        PMA              0    (0.0%)              0    (0.0%)              0    (0.0%)              0    (0.0%) n/a 
ALSFRS-R      
        range 0-46 0-45 0-46 0-46 n/a 
        mean 31 30 30 30 n/a 
Survival      
        range 0.4-7.7yrs 0.9-6.1yrs 0.5-9.0yrs 0.5-9.0yrs n/a 
         mean 2.8yrs 2.5yrs 2.9yrs 2.7yrs n/a 
Total 58 (56) 22 (20) 18 (18) 40 (38) 27 (26) 
 
Table 5.1 Clinical Summary of Patient and Control LCL’s in the ECACC C9ORF72 and NonC9ORF72-Related_SALS Study Highlighted in red 
are the final sample numbers obtained following assessment of QC metrics using Expression ConsoleTM software version 1.3.0.187 (Affymetrix® Ltd., 
UK).    
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 72, CTRL - control, ECACC - European 
Collection of Cell Cultures, F - familial, F - female, FRS-R - Functional Rating Scale Revised, FTLD - frontotemporal lobar degeneration, LCL - 
lymphoblastoid cell lines, M - male, PD - Parkinson’s disease, PBP - Progressive Bulbar Palsy, PLS - Primary Lateral Sclerosis, PMA - Progressive 




A strong family history of ALZ [F089-(SP3331) and S121-(SP3420)], PD [F144-(SP 
3560)] or dementia [F115-(SP3118) and S042-(SP3122)] was associated with up to 
16.7% of C9ORF72+ FALS (n=3/18) and 9.1% of C9ORF72+ SALS (n=2/22). In the 
case of sporadic sample [S186-(SP3431)] at least one incidence of colon cancer in a 
first degree relative had also been reported.            
 
5.1.1.1.3 NonC9ORF72-Related_SALS Cases   
The non-expansion carrying LCL’s consisted of 58 SALS [34-M, 24-F] selected from 
the ECACC discovery cohort (Section 4.1.1). These were comprised of 7 Birmingham 
(12.1%) cases including two from Belfast City Hospital [S05-(BBe0007) and S052-
(BBe0016)]; 7 London (12.1%) cases including one from Poole General Hospital [S0 
35-(LPo0010)] and 44 Sheffield (75.8%) cases including two from Newcastle [S012-
(SNc0022) and S089-(SNc0053)] and four from Nottingham [S036-(SNt0031), S129 
-(SNt0024), S198-(SNt0016) and S219-(SNt0036)]. The M:F ratio was 1.42:1 (Figure 
5.1).   
The majority of nonC9ORF72-related_SALS cases, 91.4% (n=53/58) were diagnosed 
with either definite (n=34/53) or probable (n=19/53) ALS including two incidences 
of concomitant FTLD [S093-(SP3049) and S178-(SP3145)]. The remaining 8.6% of 
the cohort (n=5/58) were diagnosed with PBP [S040-(SP3271), S044-(SP3329), S1 
29-(SNt0024), S198-(SNt 0016) and S230-(SP3159)]. Age at symptom onset ranged 
between 22 and 82 years with a mean of 61.3±12yrs. Disease duration ranged from 
4½ to 92 months with a mean of 2.76±1.5yrs (Table 5.1). Limb onset accounted for 
48.3% of cases (n=28/58) [28-SALS], bulbar onset a further 41.4% (n=24/58) [17-
SALS, 2-SALS+FTLD and 5-PBP (sporadic)], mixed presentation 6.9% (n=4/58) [4-
SALS] and onset in the respiratory muscles the remaining 3.4% (n=2/58) [2-SALS]. 
ALSFRS-R scores ranged between 0 (severe disability) and 46 (near normal funct-
ion) with an average of 30.8±10 for 87.9% of nonC9ORF72-related_SALS (n=51/58) 
[44-SALS, 2-SALS+FTLD and 5-PBP (sporadic)].   
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these, 20.5% (n=9/44) [7-SALS and 2-PBP (sporadic)] were 




depression and approximately one third, 34.1% (n=15/44) [12-SALS, 1-SALS+FTLD 
and 2-PBP (sporadic)] displayed symptoms of dyspnoea with six patients [6-SALS] 
requiring NIPPV support (Section 1.1.4). Dysarthria and dysphagia were apparent in 
50.0% of the cohort (n=22/44) [18-SALS, 2-SALS+FTLD and 2-PBP (sporadic)] with 
PEG feeding becoming a necessary intervention in seven of these latter cases [6-SALS 
and 1-PBP (sporadic)]. Two patients, 4.6% [2-SALS] were non-ambulant with 22.7% 
(n=10/44) [10-SALS] unable to walk without needing assistance. Current smokers 
comprised 2.3% of the cohort (n=1/44) [1-SALS], ex-smokers who had not smoked 
a cigarette for a minimum of 20 years (mean 21.7±2.9yrs) a further 6.8% (n=3/44) 
[2-SALS and 1-SALS+FTLD] and non-smokers 63.6% (n=28/44) [24-SALS, 1-SALS+ 
FTLD and 3-PBP (sporadic)]. For the remaining 27.3% of the cohort (n=12/44) [10-
SALS and 2-PBP (sporadic)] this information was not disclosed.   
A strong family history of dementia was associated with up to 6.9% of nonC9ORF72-
related_SALS (n=4/58) [S08-(SP3111), S078-(SP3140), S116-(SP3351) and S172-SP 
3067)]. An additional sporadic individual [S236-(SP3286)] was also known to have 
a maternal cousin who was diagnosed with MS and in a further 8.6% of cases (n=5/ 
58) at least one incidence of colon [S044-(SP3329)], bowel/stomach [S032-(SP339 
7), S062-(SP3301) and S078-(SP3140)] or throat [S076-(SP3396)] cancer had been 
reported in a first degree relative.                     
 
5.1.1.2 Therapeutics Used to Treat the Cohort  
5.1.1.2.1 C9ORF72+ Cases  
Riluzole, administered at a dose of 50mg twice daily, was being used to treat 77.8% 
of C9ORF72+ FALS (n=14/18) [13-FALS, 1-FALS+FTLD and 1-FALS+PD] and 95.5% 
of C9ORF72+ SALS (n=21/22) [20-SALS and 1-PBP (sporadic)]. One Sheffield patient, 
sporadic case [S440-(BP6297)], experienced adverse side effects and the medication 
was withdrawn. Vitamin C and/or E (n=12/40) [3-FALS and 9-SALS] or multivitamin 
supplements (n=3/40) [1-FALS and 2-SALS] were collectively being taken by 37.5% 
(n=15/40) of the cohort (Section 1.1.4). In addition to Riluzole, several individuals 
were also participants of the BDNF [F091-(SP3534)], minocycline [F073-(BP6165) 




59)] drug trials [APPENDIX TABLE B4]. Conversely, 16.7% of C9ORF72+ FALS (n=3 
/18) [2-FALS and 1-PBP (familial)] and 4.5% of C9ORF72+ SALS (n=1/22) [1-SALS] 
chose not to receive any disease modifying therapy and for the remaining 2.5% of 
the cohort (n= 1/40) [1-FALS] this information was not available.               
 
5.1.1.2.2 NonC9ORF72-Related_SALS Cases   
Riluzole was also being used to treat 96.6% of the nonC9ORF72-related_SALS cases 
(n=56/58) [49-SALS, 2-SALS+FTLD and 5-PBP (sporadic)]. One Birmingham patient, 
sporadic case [S210-(BP6041)], experienced adverse side effects and the medication 
was withdrawn. Vitamin C and/or E (n=28/58) [23-SALS, 1-SALS+FTLD and 4-PBP 
(sporadic)] or multivitamin supplements (n=1/58) [1-SALS] were collectively being 
taken by 51.8% (n=29/58) of the cohort. In addition to Riluzole, several individuals 
were also participants of the Copaxone® (glatiramer acetate) [S176-(SP3385)], ONO-
2506 (Arundic acid) [S149-(SP3391)] or minocycline [S050-(SP3023) and S157-(LP 
0015)] drug trials. Conversely, the remaining 3.4% of the cohort (n=2/58) [2-SALS] 
chose not receive any kind of disease modifying therapy.                                    
 
5.1.1.3 Genetic Status of the Cohort  
5.1.1.3.1 C9ORF72+ Cases  
All C9ORF72+ FALS (n=18) [8-M, 10-F] and SALS (n=22) [11-M, 11-F] patients carry 
more than 30 copies of the non-coding G4C2 hexanucleotide repeat expansion that 
has recently been identified in intron 1 of the previously uncharacterised C9ORF72 
gene (Cooper-Knock et al 2012b) (Section 1.2.5.4). There was also one example of 
oligogenic inheritance involving an apparently sporadic Sheffield sample [S352-(SP 
3484)] with a deleterious heterozygous c.962C>T (p.A321V) missense mutation in 
exon 6 of the TARDBP gene (Section 4.1.2.3) (Kirby et al 2010).                    
 
5.1.1.3.2 NonC9ORF72-Related_SALS Cases   
One nonC9ORF72-related_SALS patient was reported to carry a non-synonymous 




gene (Kirby et al 2013) (Section 4.1.1.2.2). Besides the aforementioned change no 
further mutations which affect this cohort have been described.       
 
5.1.2 Affymetrix® Expression ConsoleTM QC Metrics 
In vitro transcribed biotinylated ss-cDNA targets of ~40-70nt were hybridized onto 
Human Exon 1.0ST GeneChip® Arrays (Section 2.3.2.3 and 2.3.2.4). Affymetrix® QC 
metrics were assessed in Expression ConsoleTM software version 1.3.0.187 (Section 
4.3.2). One male control (n=1/27) [C08-(SPr0050)] and a further four SALS patients 
including two female cases from the C9ORF72+ group (n=2/40) [S123-(BP6021) and 
S352-(SP3484)] and one male [S044-(SP3329)] and a third female [S114-(SP3356)] 
from the nonC9ORF72-related_SALS group (n=2/58) scored poorly against three or 
more of the parameters summarised in Table 5.2. These samples were removed from 
the final ECACC LCL microarray cohort and were consequently not included in any 
of the subsequent downstream comparative analyses (Figure 5.2, 5.3 and 5.4).  
 
 
Table 5.2 Affymetrix® Expression ConsoleTM Summary of Failed LCL Samples in the 
C9ORF72 and NonC9ORF72-Related_SALS Study 
 
Key:   █ Passed    █ Failed    
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, AUC - area under receiver operating 
curve (ROC), bac-spike - bacterial spike in control, bgrd - background, C - control, C9ORF72 
- chromosome 9 open reading frame 72, LCL - lymphoblastoid cell line, PPMCC - Pearson’s 
product moment correlation coefficient, P - present calls, RLE - relative log expression, QC 
- quality control  and S - sporadic.                         
 
 
5.2 Human Exon 1.0ST GeneChip® Array Profiling               
5.2.1 Differential Gene Expression Analysis  
5.2.1.1 Partek® Genomics SuiteTM  
 Affymetrix® Expression ConsoleTM QC Metrics 
 bac_spike bgrd_mean %P AUC all_probeset_mean RLE PPMCC 
C008        
S044        
S114        
S123        

























Figure 5.2 Eukaryotic Hybridization Controls for LCL Samples in the ECACC C9ORF72 and Non 
C9ORF72-Related_SALS Study Bacterial derived genes of the E. coli biotin synthesis pathway [BioB 
(blue), BioC (red) and BioD (pink)] and the recombinase gene CreX (green) from the P1 bacterioph-
age were spiked in at increasing concentrations (top panel) [1.5pM (limit of detection), 5pM, 25pM 
and 100pM respectively] immediately prior to labelling to monitor the efficiency of the hybridization 
reaction. In the bottom panel mean signal intensities for each of the probesets spotted onto the Affy-
metrix® Human Exon 1.0ST GeneChip® Arrays are provided for a) controls (n=27), b) C9ORF72+ FA 
-LS and SALS (n=40) and c) nonC9ORF72-related_SALS (n=58) patients. Assessment of Affymetrix® 
QC metrics was performed using Expression ConsoleTM software version 1.3.0.187.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 
72, ECACC - European Collection of Cell Cultures, F - familial, LCL - lymphoblastoid cell lines, QC - 
quality control and S - sporadic.   


































Figure 5.3 Mean Absolute RLE Boxplots for LCL Samples in the ECACC C9ORF72 and NonC9ORF 
72-Related_SALS Study Relative log expression (RLE) means and standard deviations for a) control 
(n=27), b) C9ORF72+ FALS (n=18) and c) expansion/non-expansion carrying SALS (n=80). Whiskers 
represent minimum and maximum average probeset signal intensities for each array at the level of 
the whole transcript. Asterisks (red) highlight significant outliers. Assessment of the Affymetrix® QC 
metrics was performed using Expression ConsoleTM software version 1.3.0.187.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 
72, C - control, ECACC - European Collection of Cell Cultures, F - familial, LCL - lymphoblastoid cell 
lines, QC - quality control and S - sporadic.   
a) Control                                                              b) C9orf72                                                            c) SALS 
 |--------- Control ----------| |------- FALS ------| |--------------------------------------------- SALS -------------------------------------------|  





   























Figure 5.4 Expression ConsoleTM Summary of Quality Control (QC) Metrics Assessed for LCL 
Samples in the C9ORF72 and NonC9ORF72-Related_SALS Study. In the top four panels box and 
whisker plots were generated for the controls (checkerboard), C9ORF72+ (unfilled) or nonC9ORF72-
related_SALS (filled) using GraphPad Prism® software version 5.04 and applying a Tukey multiple 
comparison test: a) average background (bgrd) signal, b) percentage presence (%P) calls, c) mean 
probeset signal intensities at transcript level and d) mean probeset signal intensities at individual 
exon level. Samples flagged as outliers are highlighted in red. Note that for %P statistically outlying 
cases with at least fifty percent of probesets called as present were still included in the downstream 
comparative analyses; these are represented in green. The coloured matrix in the bottom left hand 
panel e) represents the Pearson’s product moment correlation coefficient (r) in which each pair-wise 
comparison is assigned a value on a scale of 0.820 (blue) to 1.000 (red) with a high score indicative 
of a strong linear relationship between the X and Y variables. Signal histogram plots are provided at 
f) transcript and g) individual exon level in the bottom right hand panel. Each series of coloured bars 
represents the distribution of log2 transformed, average GC-RMA normalised signal intensities for a 
single array in the experiment. Assessment of Affymetrix® QC metrics was performed in Expression 
ConsoleTM software version 1.3.0.187.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 














































Affymetrix® CEL files (n=120/125) [C9ORF72+ (n=38), SALS (n=56) and Ctrl (n=26)] 
were imported into Partek® Genomics SuiteTM software version 6.6. Raw expression 
values were log2 transformed and a GC-RMA background normalisation procedure 
applied using core metaprobesets (n=287,329) (Section 2.3.2.5.2) that relate to over 
twenty-two thousand unique clusters pertaining to full length protein coding mRNA 
sequences in the RefSeq or GenBank® database. DE transcripts identified between 
ECACC C9ORF72+ or nonC9ORF72-related_SALS LCL cases and neurologically normal 
healthy controls were detected at the 5% significance level (unadjusted p<0.05) by 
performing a 2-way ANCOVA statistical test controlling for the effects of gender and 
age. Lists were filtered to remove unannotated transcripts (n=4,377/22,011) and a 
FC threshold of ≥ ±1.20 applied. In instances where there were multiple Affymetrix® 
transcript cluster ID’s for a single gene the identification number producing the most 
significant outcome with the greatest level of coverage (i.e. highest number of probe-
sets and/or exon clusters) was retained (Section 2.3.2.5.2). However, if the direction 
of change was opposing then both transcripts were removed.   
 
5.2.1.1.1 C9ORF72vCtrl    
An analysis of C9ORF72+ FALS and SALS (n=40) patients in comparison to controls 
(n=26) identified 1,096 DE transcripts [Partek® unadjusted p<0.05, FC ≥ ±1.20] that 
included 650 genes (59.3%) which were significantly up-regulated (⇧) and a further 
446 genes (40.7%) which were significantly down-regulated (⇩).                       
 
5.2.1.1.2 NonC9ORF72-Related_SALSvCtrl    
A similar analysis of non-expansion carrying SALS (n=56) patients in comparison to 
identical controls identified 1,796 DE transcripts [Partek® unadjusted p<0.05, FC ≥ 
±1.20] that included 1,148 genes (63.9%) which were significantly up-regulated (⇧) 
and a further 648 genes (36.1%) which were significantly down-regulated (⇩).                          
 
5.2.1.1.3 C9ORF72vCtrl and NonC9ORF72-Related_SALSvCtrl Comparison    
A GeneVenn diagram of the two analyses described above in Sections 5.2.1.1.1 and 5. 




207 genes ⇩] as being specifically dysregulated in C9ORF72+ FALS and SALS patients 
(i.e. absent from nonC9ORF72-related_SALS patients and controls) and an additional 
1,201 (66.9%) of 1,796 DE transcripts (Green) [792 genes ⇧ and 409 genes ⇩] which 
were specifically dysregulated in nonC9ORF72-related_SALS patients. The remaining 
54.3% (n=595/1,096) or 33.1% (n=595/1,796) of DE transcripts [356 genes ⇧ and 
239 genes ⇩] represented by the intersection of the GeneVenn diagram depicted in 
Figure 5.5 [Partek® unadjusted p<0.05, FC ≥ ±1.20] are shared in common between 
the C9ORF72vctrl and nonC9ORF72-related_SALSvctrl analyses. It is likely, therefore 
that these reflect disease relevant changes associated with the broader ALS pheno-
type rather than being specific to individual genetic subtypes [APPENDIX TABLE B8, 












Figure 5.5 GeneVenn C9ORF72vCtrl and NonC9ORF72-Related_SALSvctrl 
[Partek® unadjusted p<0.05, FC≥ ±1.20] Lists of DE transcripts generated 
in Partek® Genomics SuiteTM software version 6.6 copyright © 2013 (Partek® 
Inc., St Louis, MO, USA). The GeneVenn application was freely available online 
at genevenn.sourceforge.net (Pirooznia et al 2007) (University of Southern 
Mississippi, USA).     
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 
9 open reading frame 72, ctrl - control, DE - differentially expressed, FC - fold-
change and S - sporadic.               
 
 
5.2.1.2 DAVID Functional Enrichment Analysis 
Partek® generated lists of Affymetrix® transcript cluster ID’s [Partek® unadjusted
1,096                              1,796 
Control C9ORF72+ SALS 





p<0.05, FC ≥ ±1.20] were imported into DAVID bioinformatics resource version 6.7.
Functional annotation clustering analysis was performed on GOTERM_BP_FAT and 
GOTERM_MF_FAT gene ontology (GO) terms applying a Homo sapiens background 
and filtering using ‘Medium’ classification stringency (Section 2.3.2.5.4). Categories 
with an EASE score above 1.30 and Benjamini-Hochberg FDR corrected p<0.05 were 
considered as statistically significant. Transcripts identified as being significantly up 
(⇧) or down (⇩)-regulated under different experimental conditions were analysed 
independently. The software mapped 1,088 (99.3%) of 1,096 [644 genes ⇧ and 444 
genes ⇩] and 1,778 (99.0%) of 1,796 [1,137 genes ⇧ and 641 genes ⇩] DE transcripts 
identified in the analysis of C9ORF72vctrl (Section 5.2.1.1.1) or nonC9ORF72-related 
_SALSvctrl (Section 5.2.1.1.2), respectively. DAVID ID’s could not be returned for the 
remaining 26 transcript clusters which were subsequently removed.       
 
5.2.1.2.1 C9ORF72vCtrl    
In C9ORF72+ patient derived LCL’s the single most significant biologically enriched
GO term associated with the G4C2 hexanucleotide repeat expansion from the Partek® 
generated list of up-regulated gene expression changes (n=644/650) was related to 
RNA processing [Partek® unadjusted p<0.05, FC ≥ ±1.20]. RNP complex biogenesis 
and endoribonuclease activity, producing 5’-phosphomonoesters were also ranked 
highly. Other categories included translation and translation factor activity, nucleic 
acid binding, in addition to, several processes involved in DNA metabolism, the cell 
cycle and respiratory electron transport chain (Table 5.3a). From the list of down-
regulated gene expression changes (n=444/446) ion binding and transport were 
among those most significantly featured along with cell adhesion, lipid biosynthesis 
and sterol metabolism [Partek® unadjusted p<0.05, FC ≥ ±1.20]. Other categories 
included the regulation of cell migration, glycoprotein binding & metabolism as well 
as ATPase activity, coupled to the transmembrane movement of substances (Table 
5.3b).       
 
5.2.1.2.2 NonC9ORF72-Related_SALSvCtrl 
Conversely, some of the most significant biologically enriched GO terms associated 




a) C9ORF72vctrl ⇧reg [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0006396 RNA processing 8.62 55 1.30E-08 
2 GO:0006412 translation 7.52 41 9.30E-09 
3 GO:0006259 DNA metabolic process 5.45 43 6.20E-05 
4 GO:0022613 ribonucleoprotein complex biogenesis 3.92 23 8.90E-05 
5 GO:0016891 
endoribonuclease activity, producing 5’-
phosphomonoesters  
3.24 8 5.40E-03 
6 GO:0007049 cell cycle 3.18 61 2.60E-06 
7 GO:0044265 cellular macromolecule catabolism 3.10 50 1.50E-03 
8 GO:0043933 macromolecular complex organisation  2.74 50 1.00E-03 
9 GO:0022904 respiratory electron transport chain 2.72 11 6.40E-03 
10 GO:0008135 translation factor activity, nucleic acid binding 2.61 13 0.020 
11 GO:0051340 regulation of ligase activity 2.61 13 3.10E-03 
12 GO:0051656 establishment of organelle localisation 2.19 10 0.034 
13 GO:0000166 nucleotide binding 1.46 105 0.036 
 
b) C9ORF72vctrl ⇩reg [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0006811 ion transport 5.83 48 6.60E-06 
2 GO:0007155 cell adhesion 4.56 39 8.20E-04 
3 GO:0016125 sterol metabolic process 3.89 14 3.40E-04 
4 GO:0043167 ion binding 3.68 137 5.40E-04 
5 GO:0008610 lipid biosynthetic process 3.29 33 3.90E-08 
6 GO:0031418 L-ascorbic acid binding 3.11 7 5.30E-04 
7 GO:0030334 regulation of cell migration 3.10 14 0.028 
8 GO:0042626 
ATPase activity, coupled to transmembrane 
movement of substances  
3.05 14 5.20E-04 
9 GO:0016717 oxidoreductase activity, acting on paired 
donors, with oxidation of a pair of donors 
resulting in the reduction of molecular oxygen 
to two molecules of water  
2.86 5 4.70E-04 
10 GO:0009100 glycoprotein metabolic process 2.70 19 6.00E-04 
11 GO:0015295 solute:hydrogen symporter activity 2.48 6 9.60E-03 
12 GO:0001666 response to hypoxia 2.42 12 0.039 
13 GO:0015294 solute:cation symporter activity 2.30 12 8.10E-04 
14 GO:0000041 transition metal ion transport 2.24 10 6.80E-03 
15 GO:0001948 glycoprotein binding 1.94 6 0.043 
16 GO:0030246 carbohydrate binding 1.41 20 0.023 
 
Table 5.3 DAVID Partek® C9ORF72vCtrl Functional Annotation Clustering Analysis  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9ORF72 - chromosome 9 open 
reading frame 72, ctrl - control, EASE - enrichment score, FC - fold-change, DAVID - Database for 
Annotation, Visualisation and Integrated Discovery and GO - gene ontology.                   
 
 
up-regulated gene expression changes (n=1,137/1,148) were relating to aspects of 
the cell cycle including cell cycle checkpoint control, chromosome localisation, DNA 
packaging, spindle organisation, regulation of the cell cycle, mitotic sister chromatid 
segregation and interphase of the mitotic cell cycle [Partek® unadjusted p<0.05, FC 




repair pathways also featured prominently. Other categories included several which 
are important for RNA processing and RNP biogenesis as well as DNA metabolism & 
protein degradation (Table 5.4a). From the list of down-regulated gene expression 
changes (n=641/648) ion transport & homeostasis [Partek® unadjusted p<0.05, FC 
≥ ±1.20] were among those most significantly enriched along with regulation of cell 
migration, carbohydrate binding, phospholipid biosynthesis and signal transduction 
(Table 5.4b). Other categories included solute: hydrogen symporter activity, positive 
regulation of transferase activity and response to wounding. 
              
5.2.1.2.3 C9ORF72vctrl and NonC9ORF72-Related_SALSvctrl Comparison             
The results of a direct comparison between DAVID C9ORF72vctrl (Section 5.2.1.2.1) 
and nonC9ORF72-related_SALSvctrl (Section 5.2.1.2.2) analyses could be displayed 
in the form of a stacked column graph that is represented in Figure 5.6. Biologically 
significant GO terms which were found to be specific to the C9ORF72+ FALS and SALS 
patient derived LCL’s were highlighted in yellow. In descending order of enrichment 
these included: translation as well as translation factor activity, nucleic acid binding 
relating to protein synthesis; endoribonuclease activity, producing 5’-phosphomono 
-esters and the respiratory electron transport chain (Figure 5.6a) from the list of up- 
regulated gene expression changes, in addition to, cell adhesion, sterol metabolism, 
ion binding, lipid biosynthesis and ATPase activity, coupled to the transmembrane 
movement of substances (Figure 5.6b) [Partek® unadjusted p<0.05, FC ≥ ±1.20] from 
the list of down-regulated gene expression changes. In contrast, GO terms specific to 
non-expansion carrying SALS patient derived LCL’s were highlighted in green. These 
included multiple categories involved in regulating the cell cycle, as well as, protein 
degradation, DNA replication/recombination and mechanisms relating to the DNA 
damage response & repair pathways (Figure 5.6a) from the list of up-regulated gene 
expression changes, in addition to, signal transduction, phospholipid metabolism and 
homeostasis (Figure 5.6b) [Partek® unadjusted p<0.05, FC ≥ ±1.20] from the list of 
down-regulated gene expression changes. Shared categories (ALS common) which 
were significantly up-regulated included RNP complex biogenesis, RNA processing 
and DNA metabolism (Figure 5.6a) whereas those reported to be significantly down-




a) nonC9ORF72-related_SALSvctrl ⇧reg [Partek® unadjusted p<0.05, FC ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0007049 cell cycle  34.27 169 2.10E-44 
2 GO:0006259 DNA metabolic process 23.00 110 5.00E-28 
3 GO:0022613 ribonucleoprotein complex biogenesis 7.98 42 1.10E-10 
4 GO:0051276 chromosome organisation 7.81 89 3.30E-17 
5 GO:0000070 mitotic sister chromatid segregation 7.68 18 1.80E-09 
6 GO:0051329 interphase of mitotic cell cycle 7.33 27 1.10E-07 
7 GO:0051726 regulation of cell cycle 7.21 57 2.70E-09 
8 GO:0006323 DNA packaging  7.09 32 9.90E-10 
9 GO:0000166 nucleotide binding 6.82 200 3.00E-06 
10 GO:0043933 macromolecular complex organisation  6.53 91 3.30E-08 
11 GO:0006310 DNA recombination 6.52 25 3.10E-06 
12 GO:0006302 double-strand break repair 6.25 22 1.30E-08 
13 GO:0006396 RNA processing 6.23 77 1.30E-08 
14 GO:0007051 spindle organisation 5.50 17 7.20E-07 
15 GO:0000072 cell cycle checkpoint 4.49 27 6.50E-09 
16 GO:0031396 regulation of protein ubiquitination 4.31 23 2.00E-05 
17 GO:0009314 response to radiation 3.47 31 5.10E-04 
18 GO:0006297 nucleotide-excision repair, DNA gap filling 3.37 9 2.00E-04 
19 GO:0050000 chromosome localization 2.85 7 6.40E-03 
20 GO:0051186 cofactor metabolic process 2.82 29 1.90E-03 
21 GO:0044265 cellular macromolecular catabolism 2.53 71 0.012 
22 GO:0051052 regulation of DNA metabolic process 2.43 19 0.010 
23 GO:0009451 RNA modification 2.37 11 0.020 
24 GO:0010605 negative regulation of macromolecule 
metabolic process 
2.25 80 1.90E-04 
25 GO:0003677 DNA binding 2.16 200 3.10E-05 
26 GO:0051259 protein oligomerization 2.07 23 0.042 
27 GO:0032259 methylation  1.61 15 9.10E-03 
28 GO:0006282 regulation of DNA repair 1.31 7 0.047 
 
b) nonC9ORF72-related_SALSvctrl ⇩reg [Partek® unadjusted p<0.05, FC ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0006811 ion transport 4.73 52 3.80E-03 
2 GO:0015295 solute:hydrogen symporter activity 3.75 10 2.70E-05 
3 GO:0042592 homeostatic process 3.57 51 1.50E-03 
4 GO:0030334 regulation of cell migration 3.33 18 4.90E-03 
5 GO:0009967 positive regulation of signal transduction 2.66 28 2.20E-03 
6 GO:0008654 phospholipid biosynthetic process 2.51 15 1.60E-03 
7 GO:0000041 transition metal ion transport 2.46 13 1.10E-03 
8 GO:0006826 iron ion transport 2.45 8 4.00E-03 
9 GO:0006643 membrane lipid metabolic process 2.32 12 6.00E-03 
10 GO:0009611 response to wounding  2.25 33 0.043 
11 GO:0051347 positive regulation of transferase activity 1.99 22 5.10E-03 
12 GO:0030246 carbohydrate binding 1.99 27 0.010 
13 GO:0031418 L-ascorbic acid binding 1.68 6 0.042 
14 GO:0050850 positive regulation of calcium-mediated 
signalling 
1.52 6 0.013 
 
Table 5.4 DAVID Partek® NonC9ORF72-Related_SALSvCtrl Functional Annotation Clustering 
Analysis  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9ORF72 - chromosome 9 open 
reading frame 72, ctrl - control, ALS - Amyotrophic Lateral Sclerosis, EASE - enrichment score, GO - 
gene ontology, DAVID - Database for Annotation, Visualisation and Integrated Discovery, FC - fold-




























































Figure 5.6 DAVID Comparison GO Terms C9ORF72vCtrl and NonC9ORF72-Related_SALSvCtrl  
 
Abbreviations: ⇧reg - up-regulated, ⇩reg - down-regulated, ALS - Amyotrophic Lateral Sclerosis, ctrl - 
control, C9ORF72 - chromosome 9 open reading frame 72, GO - gene ontology, DAVID - Database for 
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In order to elucidate further the molecular signatures underpinning mechanisms of 
neurotoxicity associated with the hexanucleotide G4C2 repeat expansion in C9ORF72 
the top two most highly enriched GO terms [GO: 0006396 RNA processing (Section 
5.2.1.3) and GO: 0006412 translation (Section 5.2.1.4) (Table 5.3)] were selected for 
a more in depth comparative analysis and the subsequent identification of potential 
candidate genes that could be taken forward for qRT-PCR validation.                 
 
5.2.1.3 RNA Processing  
Over the past few years aberrant RNA metabolism has emerged as one of the major 
players in the pathogenesis of a number of neurodegenerative diseases that include 
ALS and FTLD (Section 1.2.4.9) (Baumer et al 2010, Droppelmann et al 2014, Lee et 
al 2013b, Ling et al 2013, Polymenidou et al 2012, van Blitterswijk & Landers 2010). 
It encompasses a diverse array of biological processes, from the regulation of RNA 
transcription (Section 5.2.1.3.1) and small nuclear RNP (snRNP) biogenesis (Figure 
5.7) (Section 5.2.1.3.2) to pre-mRNA splicing & editing (Section 5.2.1.3.3) in addition 
to stabilization, transportation and post-translational degradation of mature mRNA 
species (Al-Chalabi et al 2013). Table 5.5 lists the DAVID output of RNA processing 
related genes identified in the C9ORF72vctrl analysis [Partek® unadjusted p<0.05, 
FC ≥ ±1.20]. DE transcripts specific to the G4C2 repeat expansion are denoted by the 
three asterisks inserted immediately after the gene symbol in the first column. Key 
validation targets selected for qRT-PCR are shaded in grey.             
 
5.2.1.3.1 Regulation of RNA Transcription 
A GeneVenn diagram comparing DAVID outputs of RNA processing related genes for 
the Partek® generated lists of up-regulated gene expression changes in the analysis 
of C9ORF72vctrl (n=56/644) (Section 5.2.1.2.1) and nonC9ORF72-related_SALSvctrl 
(n=77/1,137) (Section 5.2.1.2.2) identified DNA-directed RNA polymerase activity 
as a GO term which was specific to LCL cases carrying the G4C2 repeat (Figure 5.8). 
The category contained three transcripts encoding the 4th, 6th and 7th subunit of the 
large 550kDa complex that constitutes RNA polymerase II (Pol II). Collectively, they 




Figure 5.7 SnRNP Biogenesis Schematic DE transcripts [Partek® unadjusted 
p<0.05, FC ≥ ±1.20] identified on the Affymetrix® Human Exon 1.0ST GeneChip® 
Arrays as being specifically dysregulated in relation to C9ORF72 (⋆) or shared in 
common between C9ORF72 and nonC9ORF72-related_SALS (⋆) (i.e. changes that 
are associated with a broader ALS phenotype) are denoted by different coloured 
stars.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 
open reading frame 72, CBC/(CBP) - nuclear cap binding complex/protein, CB - 
cajal bodies, DE - differentially expressed, GDP/(GTP) - guanosine diphosphate/ 
triphosphate, FC - fold-change, m7G - seven methyl guanosine, mRNA - messen-
ger RNA, IGC - interchromatin granule cluster, NPC - nuclear pore complex, Oct-
1 - Octamer binding protein 1, p20/80 - CBP20/80 subunit, PF - perichromatin 
fibril, PHAX - phosphorylated adaptor for RNA export, plCLn - chloride channel 
nucleotide-sensitive 1A, Pol II - RNA polymerase II, PRMT5 - protein arginine 
methyltransferase, PSE - proximal sequence element, RAN - RAN, member RAS 
oncogene family, SMN - survival motor neurone, SNAPc - snRNA activating com-
plex, snRNP - small nuclear ribonucleoprotein, S - sporadic, TAF - TATA-binding 
protein (TBP) associated factor, TF - transcription initiation factor, TGS1 - trim-
ethylguanosine synthase 1, unrip - Unr-interacting protein, YY1 - Yin Yang-1 and 




Symbol RefSeq Transcript Gene   Fold p-value 
ARFGAP3*** NM_014570 3962587 ADP-ribosylation factor GTPase activating protein 3 ⇧ 1.24 1.28E-03 
ARL6IP4*** NM_001002252 3435681 ADP-ribosylation-like factor 6 interacting protein 4 ⇧ 1.26 8.01E-05 
CD2BP2 NM_006110 3687698 CD2 (cytoplasmic tail) binding protein 2 ⇧ 1.21 0.015 
CDKN2A NM_001195132 3201437 cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) ⇧ 1.24 5.29E-03 
CLNS1A*** NM_001293 3382948 chloride channel, nucleotide-sensitive, 1° ⇧ 1.20 7.29E-03 
ELAC1*** NM_018696 3788270 elaC homolog 1 (E. coli) ⇧ 1.24 1.30E-03 
EXOSC4*** NM_019037 3120008 exosome component 4 ⇧ 1.27 2.04E-04 
FTSJ2 NM_013393 3035682 FtsJ homolog 2 (E. coli)  ⇧ 1.30 1.86E-04 
FUS NM_004960 3656904 fused in sarcoma ⇧ 1.23 7.50E-04 
GAR1*** NM_018983 2739242 GAR1 ribonucleoprotein homolog (yeast) ⇧ 1.31 6.95E-05 
GEMIN6*** NM_024775 2477980 gem (nuclear organelle) associated protein 6 ⇧ 1.29 1.16E-04 
GEMIN8P4*** NR_002830 2422227 gem (nuclear organelle) associated protein 8 pseudogene 4 ⇧ 1.25 0.014 
HNRNPA0 NM_006805 2877141 heterogeneous nuclear ribonucleoprotein A0 ⇧ 1.23 2.35E-07 
HNRNPF*** NM_004966 3286286 heterogeneous nuclear ribonucleoprotein F ⇧ 1.22 6.15E-04 
HNRNPH2 NM_019597 3984779 heterogeneous nuclear ribonucleoprotein H2 (H’) ⇧ 1.28 0.024 
HNRNPM NM_005968 3819543 heterogeneous nuclear ribonucleoprotein M ⇧ 1.21 8.06E-03 
LAP7*** NM_016648 2740005 La ribonucleoprotein domain family, member 7 ⇧ 1.20 0.022 
LSM4 NM_012321 3854892 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) ⇧ 1.24 7.86E-03 
NCBP2*** NM_007362 2713074 nuclear cap binding protein subunit 2, 20kDa ⇧ 1.20 0.010 
NOP10 NM_018648 3617403 NOP10 ribonucleoprotein homolog (yeast) ⇧ 1.32 0.013 
NUDT21*** NM_007006 3692895 nudix (nucleoside diphosphate linked moiety X)-type motif 21 ⇧ 1.20 6.68E-05 
PHAX NM_032177 2827156 phosphorylated adaptor for RNA export ⇧ 1.27 1.79E-04 
PHF5A*** NM_0327528 3961955 PHD finger protein 5A ⇧ 1.21 0.020 
POLR2D*** NM_004805 2575134 polymerase (RNA) II (DNA directed) polypeptide D ⇧ 1.22 0.010 
POLR2F*** NM_021974 3945133 polymerase (RNA) II (DNA directed) polypeptide F ⇧ 1.22 0.020 
POLR2G*** NM_002696 3333622 polymerase (RNA) II (DNA directed) polypeptide G ⇧ 1.24 3.80E-04 
POP4*** NM_006627 3828032 processing of precursor 4, ribonuclease P/MRP subunit (S. cerevisiae) ⇧ 1.20 0.022 
POP7 NM_005837 3015769 processing of precursor 7, ribonuclease P/MRP subunit (S. cerevisiae) ⇧ 1.23 9.28E-03 
PPIL1*** NM_016059 2952065 peptidylprolyl isomerase (cyclophilin)-like 1 ⇧ 1.22 0.017 
PRPF19*** NM_014502 3375049 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) ⇧ 1.21 2.24E-04 
PRPF4 NM_004697 3185558 PRP4 pre-mRNA processing factor 4 homolog (yeast) ⇧ 1.24 7.62E-05 
RBM3*** NM_017495 3976519 RNA binding motif (RNP1, RRM) protein 3 ⇧ 1.22 9.22E-05 
RPL11*** NM_170739 2325192 ribosomal protein L11 ⇧ 1.25 0.035 




RPP21*** NM_024839 2901552 ribonuclease P/MRP 21kDa subunit ⇧ 1.23 5.12E-03 
RPP38*** NM_183005 3236538 ribonuclease P/MRP 38kDa subunit  ⇧ 1.34 0.011 
RRAGC*** NM_022157 2407729 Ras-related GTP binding C ⇧ 1.25 6.98E-04 
SF3B14*** NM_016047 2544179 splicing factor 3B, 14kDa subunit ⇧ 1.21 1.84E-03 
SF3B4*** NM_005850 2434159 splicing factor 3B, subunit 4, 49kDa ⇧ 1.20 0.019 
SNRNP40 NM_004814 2404377 small nuclear ribonucleoprotein 40kDa (U5) ⇧ 1.30 0.027 
SNRPB2 NM_003092 3877776 small nuclear ribonucleoprotein polypeptide B ⇧ 1.24 0.040 
SNRPD2*** NM_177542 3865568 small nuclear ribonucleoprotein D2 polypeptide 16.5kDa ⇧ 1.23 0.012 
SNRPF NM_003095 3427014 small nuclear ribonucleoprotein polypeptide F ⇧ 1.27 7.15E-03 
SRSF3 NR_036610 2905118 serine/arginine-rich splicing factor 3 ⇧ 1.20 0.015 
SSU72*** NM_014188 2391647 SSU72 RNA polymerase II CTD phosphatase homolog (S. cerevisiae) ⇧ 1.25 0.034 
STRAP*** NM_007178 3406421 serine/threonine kinase receptor associated protein  ⇧ 1.20 1.27E-03 
TAF13*** NM_005645 4054117 TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 18kDa ⇧ 1.37 3.39E-04 
TRMT6 NM_015939 3896524 tRNA methyltransferase 6 homolog (S. cerevisiae) ⇧ 1.27 1.11E-05 
TRUB2 NM_015679 3226493 TruB pseudouridine (psi) synthase homolog 2 (E. coli) ⇧ 1.21 2.04E-03 
TSEN15 NR_023349 2371474 tRNA splicing endonuclease 15 homolog (S. cerevisiae) ⇧ 1.28 6.40E-03 
TYW3*** NR_027962 2342391 tRNA-yW synthesizing protein 3 homolog (S. cerevisiae) ⇧ 1.24 9.91E-03 
UTP15 NM_032175 2815455 UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. cerevisiae) ⇧ 1.28 5.25E-04 
UTP23 NM_032334 3112543 UTP23, small subunit (SSU) processome component, homolog (yeast) ⇧ 1.25 1.38E-03 
WBP4*** NM_007187 3486807 WW domain binding protein 4 (formin binding protein 21) ⇧ 1.20 2.28E-03 
ZCRB1*** NM_033114 3451318 zinc finger CCHC-type and RNA binding motif 1 ⇧ 1.26 7.15E-05 
ZMAT5*** NM_019103 3956984 zinc finger, matrin-type 5 ⇧ 1.26 2.98E-04 
 
Table 5.5 DAVID C9ORF72vCtrl List of RNA Processing Related Genes (n=56) [Partek® unadjusted p<0.05, FC ≥ ±1.20]  
 
Abbreviations: C9ORF72 - chromosome 9 open reading frame 72, ctrl - control, DAVID - Database for Annotation, Visualisation and Integrated Discovery and FC - fold-













a) C9ORF72+ specific 
 
# GO term Functional category EASE Count Benjamini 
1 GO:0008380 RNA splicing 15.42 21 5.40E-24 
2 GO:0034470 ncRNA processing  6.24 10 1.10E-08 
3 GO:0022613 ribonucleoprotein complex biogenesis 4.34 10 9.00E-09 
4 GO:0003899 DNA-directed RNA polymerase activity 1.32 3 0.022 
 
      b) ALS common 
 
 # GO term Functional category EASE Count Benjamini 
1 GO:0006397 mRNA processing 11.65 13 2.70E-13 
2 GO:0034470 ncRNA processing 6.74 9 4.10E-09 
 
      c) nonC9ORF72-related_SALS specific  
 
# GO term Functional category EASE Count Benjamini 
1 GO:0022613 ribonucleoprotein complex biogenesis 27.44 29 1.40E-36 
2 GO:0006397 mRNA processing 16.44 27 2.30E-26 
3 GO:0008033 tRNA processing 5.57 8 4.00E-07 
4 GO:0009451 RNA modification 4.00 7 6.40E-07 
5 GO:0010608 posttranscriptional regulation of gene 
expression 
2.53 8 2.90E-04 
6 GO:0004540 ribonuclease activity 2.49 4 0.033 
 
Figure 5.8 GeneVenn of DAVID C9ORF72vCtrl and NonC9ORF72-Related_SALSvCtrl RNA 
Processing Related Genes Lists of DE transcripts generated using Partek® Genomics SuiteTM 
software version 6.6 copyright © 2013 (Partek® Inc., St Louis, MO, USA). GeneVenn application 
freely available online at genevenn.sourceforge.net (University of Southern Mississippi, USA) 
(Pirooznia et al 2007). Functional annotation clustering analysis of up (⇧)/down (⇩) regulated 
Affymetrix® transcript cluster ID’s was performed independently using DAVID bioinformatics 
resource version 6.7 (david.abccc.ncifcrf.gov) (Huang da et al 2009a, Huang da et al 2009b).  
 
Abbreviations: # - rank, ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open 
reading frame 72, ctrl - control, DAVID - Database for Annotation, Visualisation and Integrated 
Discovery, DE - differentially expressed, EASE - enrichment score, GO - gene ontology, mRNA 
- messenger RNA, ncRNA - non-coding RNA, S - sporadic and tRNA - transfer RNA.  
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POLR2D (subunit 4) [POLR2D (polymerase (RNA) II (DNA directed) polypeptide D) 
⇧1.22-fold, p=0.01], with POLR2G (subunit 7) [POLR2G (polymerase (RNA) II (DNA 
directed) polypeptide G) ⇧1.24-fold, p<0.001] and POLR2F (subunit 6) (Figure 5.8) 
[POLR2F (polymerase (RNA) II (DNA directed) polypeptide F ⇧1.22-fold, p<0.05]. 
An IDT PrimeTime® Mini qPCR assay, conducted using a larger validation cohort of 
pooled RNA samples from the microarray plus additional C9ORF72+ case (n=75) and 
control (n=35) LCL’s from the ECACC discovery and replication cohorts (Section 2.3. 
2.6.3), confirmed a disease related increase in the expression of POLR2G (subunit 7) 








Figure 5.9 Regulation of RNA Transcription qRT-PCR Validation Relative concentrations 
measured against the standard housekeeping gene 18SrRNA. Means and SEM were plotted in 
GraphPad® Prism software version 5.04. Probability values calculated in Microsoft Excel 2010 
(Microsoft Corporation UK) using a one tailed student’s t-test. Gene expression changes were 
confirmed if the direction of change (arrow) was the same as the microarray with p<0.05*  
 
Abbreviations: 18SrRNA - 18S ribosomal RNA, C9ORF72 - chromosome 9 open reading frame 
72, POLR2G - polymerase (RNA) II (DNA directed) polypeptide G, qRT-PCR - quantitative real-
time PCR, SEM - standard error of the mean and TAF13 - RNA polymerase II, TATA box binding 
protein (TBP)-associated protein, 18kDa.                         
 
 
RNA polymerase II is found in all eukaryotic cells. It functions as an enzyme which is 
essential for the synthesis of mRNA precursors during transcription and to a lesser 
extent the synthesis of spliceosomal small nuclear RNA’s (snRNA’s) (Egloff & Murphy 
2008) including: U1, U2, U4 (U4atac) and U5 [SNRNP40 (small nuclear ribonucleo- 
protein, 40kDa (U5)) ⇧1.30-fold, p<0.05 C9ORF72vctrl and ⇧1.50-fold, p<0.001 non- 
C9ORF72-related_SALSvctrl], which are all components of the major spliceosome, in 
addition to, the U7 and U11/12 [SNRNP25 (small nuclear ribonucleoprotein, 25kDa 









minor spliceosome. SnRNA’s produce transcripts which are intronless and typically 
shorter (~150nt), than those derived from protein-coding mRNA’s, and rather than 
being under the direction of a poly(A) signal their 3’-end formation is controlled by 
a unique cis-acting 3’ box element (Cuello et al 1999, Zaborowska et al 2012).  
The five subunit snRNA activating complex (SNAPc) [SNAPC5 (small nuclear RNA 
activating complex, polypeptide 5, 19kDa) ⇧1.27-fold, p<0.05 C9ORF72vctrl; ⇧1.44-
fold, p<0.0001 nonC9ORF72-related_SALSvctrl] is triggered by the Yin Yang-1 (YY1) 
transcription factor and Octamer-binding protein 1 (Oct-1) in order to initiate Pol II 
mediated transcription (Emran et al 2006). SNAPc recognises the proximal sequence 
element (PSE) contained within the upstream promoter region which promotes the 
subsequent assembly of the pre-initiation complex (PIC) at this site (Figure 5.8). The 
PIC comprises Pol II and a set of general transcription factors (GTF’s) (Hanzlowsky 
et al 2006, Kim et al 2010) which include TFIIA/B (GTF2A1-2/B), TFIID (GTF2D), 
TFIIEαβ (GTF2E1-2) [GTF2E2 (general transcription factor IIE, polypeptide 2, beta 
34kDa) ⇧1.23-fold, p<0.01 C9ORF72vctrl], TFIIFαβ (GTF2F1-2) and TFIIH (GTF2H3) 
[GTF2H3 (general transcription factor IIH, polypeptide 3, 34kDa) ⇧1.20-fold, p<0.01 
C9ORF72vctrl]. TFIID (GTF2D) is itself a multiprotein complex containing the TATA-
binding protein (TBP) and various TBP associated factors (TAF’s), including TAF9B 
(TFIID subunit 9-like) [TAF9B (TAF9B RNA polymerase II, TBP associated factor, 31 
kDa) ⇧1.34-fold, p<0.05 C9ORF72vctrl and ⇧1.42-fold, p<0.01 nonC9ORF72-related_ 
SALSvctrl (Zaborowska et al 2012)], TAF12 (TFIID subunit 12) [TAF12 (TAF12 RNA 
polymerase II, TBP associated factor, 20kDa) ⇧1.30-fold, p<0.001 C9ORF72vctrl and  
⇧1.27-fold, p<0.001 nonC9ORF72-related_SALSvctrl] and TAF13 (TFIID subunit 13) 
[TAF13 (TAF13 RNA polymerase II, TBP associated factor, 18kDa) ⇧1.38-fold, p<0.01 
C9ORF72vctrl and ⇧1.27-fold, p<0.01 nonC9ORF72-related_SALSvctrl]. The increase 
in TAF13 expression in C9ORF72+ cases compared to controls was later confirmed in 
a SYBR® Green qRT-PCR Assay (p<0.05*) (Figure 5.9).              
 
5.2.1.3.2 SnRNP Biogenesis  
Precursor snRNA’s are bound by the nuclear cap binding (CBC)-complex composed 
of CBP20/80 subunits [NCBP2 (nuclear cap binding protein subunit 2, 2kDa) ⇧1.20-




adaptor for RNA export) ⇧1.27-fold, p<0.001 C9ORF72vctrl and ⇧1.22-fold, p<0.001 
nonC9ORF72-related_SALSvctrl] transported into the cytoplasm under the direction 
of exportin 1 (Xpo1) and Ran-GTPase (RAN) (Massenet et al 2002, Pabis et al 2013) 
(Figure 5.7). 
Within the cytoplasm, snRNP’s are assembled by the survival motor neurone (SMN) 
complex comprising SMN protein (Battle et al 2006); reduced levels of which are a 
cause of AR inherited juvenile-onset Spinal Muscular Atrophy (SMA) (Lefebvre et al 
1995, Rodrigues et al 1995), gemins 2 through to 8 (Carissimi et al 2006a, Carissimi 
et al 2006b) [GEMIN6 (gem (nuclear organelle) associated protein 6) ⇧1.29-fold, p< 
0.001 C9ORF72vctrl; GEMIN8 (gem (nuclear organelle) associated protein 8) ⇧1.25-
fold, p<0.05 C9ORF72vctrl] and the Unr interacting protein, unrip (alternative name 
STRAP) (Carissimi et al 2005) [STRAP (serine/threonine kinase receptor associated 
protein) ⇧1.20-fold, p<0.01 C9ORF72vctrl]. The SMN complex associates with seven 
members of the Sm protein family that include B/B” (snRNP-B/B”) [SNRPB2 (small 
nuclear ribonucleoprotein polypeptide B) ⇧1.24-fold, p<0.05 C9ORF72vctrl and ⇧1. 
38-fold, p<0.01 nonC9ORF72-related_SALSvctrl], D1, D2 (snRNP-D2) [SNRPD2 (small 
nuclear ribonucleoprotein polypeptide D2) ⇧1.23-fold, p<0.05 C9ORF72vctrl], D3, E, 
F (snRNP-F) [SNRPF (small nuclear ribonucleoprotein polypeptide F) ⇧1.27-fold, p 
<0.01 C9ORF72vctrl and ⇧1.27-fold, p<0.01 nonC9ORF72-related_SALSvctrl] and G. 
The affinity for SMN binding is further regulated in a subset of these, namely snRNP 
-B/B’’, D1 and D3, by plCLn [CLNS1A (chloride channel, nucleotide-sensitive, 1a) ⇧1. 
20-fold, p<0.01 C9ORF72vctrl] (Figure 5.7) and PRMT5 (protein methyltransferase 
5), which serves as a catalyst for the symmetrical dimethylation of specific arginine 
residues. The subsequent interaction between the SMN complex, bound Sm proteins 
and precursor snRNA’s (Matera et al 2007, Meister et al 2001, Pesiridis et al 2009) 
drives the ATP-dependent formation of an evolutionarily conserved heptameric ring 
structure that constitutes the Sm core of the mature snRNP. Following hypermethyl-
ation, by TGS1 (trimethylguanosine synthase 1), of the 5’ cap, and truncation of the 
3’ end, snRNP specific nuclear import receptor, Snurportin 1, binds and the importin 
sub-complex, containing alpha and beta subunits (alternative name karyopherins) 
[KPNA4 (karyopherin alpha 4 (importin alpha 3)) ⇧1.27-fold, p<0.001 C9ORF72vctrl 




localisation signal (NLS) (Massenet et al 2002), which facilitates snRNP import into 
the nucleus. Transportation occurs through nuclear pore complexes (NPC’s) [NUP43 
(nucleoporin 43kDa) ⇧1.21-fold, p<0.0001 C9ORF72vctrl] which are embedded in 
the nuclear envelope (Figure 5.7).  
The SMN complex may also function in ribosome biogenesis and multiple aspects of 
pre-ribosomal RNA (pre-rRNA) processing through its association with Cajal bodies 
(CB’s) and small nucleolar RNP’s (snoRNP’s) including FBL (fibrillarin), GAR1 [GAR1 
(GAR1 ribonucleoprotein homolog (yeast)) ⇧1.31-fold, p<0.0001 C9ORF72vctrl] and 
UTP15 [UTP15 (U3 small nucleolar ribonucleoprotein homolog (S. cerevisiae)) ⇧1.28-
fold, p<0.001 C9ORF72vctrl and ⇧1.20-fold, p<0.01 nonC9ORF72-related_SALSvctrl] 
(Pellizzoni et al 2001, Sato et al 2013, Whitehead et al 2002).  
From the snRNP biogenesis pathway six genes were selected as candidates for qRT-
PCR. Of the six, only two (33.3%) validated: CLNS1A which was confirmed in an IDT 
PrimeTime® Mini qPCR Assay (p<0.05*) and UTP15 which was confirmed using the 
traditional SYBR® Green technology (p<0.001***) (Figure 5.10). GEMIN6, NCBP2 and 
PHAX were not significant and for STRAP (unrip) a small trend (⇧1.14-fold, p=0.068) 
in the same direction as the microarray was observed (Table 5.5). 
              
5.2.1.3.3 Regulation of the Spliceosome   
With an enrichment score of 15.42 (count 21, 61.8%) RNA splicing was identified as 
the highest ranking RNA processing related GO term in DAVID (Figure 5.8) which is 
specific to the C9ORF72 expansion. Transcripts of interest included: those encoding 
nudix (nucleoside diphosphate linked moiety X)-type motif 21 (NUDT21) [NUDT21 
⇧1.20-fold, p<0.0001 C9ORF72vctrl], a component of the cleavage factor Im (CFIm)-
complex that is strongly associated with nuclear paraspeckles and has been shown 
to be responsible for regulating alternative polyadenylation as well as 3’ end poly(A) 
site cleavage of nascent lncRNA’s (Naganuma et al 2012); serine/arginine-rich (SR) 
splicing factor 3 (SRp20) [SRSF3 ⇧1.20-fold, p<0.05 C9ORF72vctrl and ⇧1.33-fold, p< 
0.0001 nonC9ORF72-related_SALSvctrl]; pre-mRNA processing factors 4 (hRprp4p) 
[PRPF4 ⇧1.24-fold, p<0.0001 C9ORF72vctrl and ⇧1.24-fold, p<0.0001 nonC9ORF72-






















Figure 5.10 SnRNP Biogenesis qRT-PCR Validation Relative concentrations measured 
against the standard housekeeping gene 18SrRNA. Means and SEM were plotted using 
GraphPad® Prism software version 5.04. Probability values calculated in Microsoft Excel 
2010 (Microsoft Corporation UK) using a one tailed student’s t-test. Gene expression 
changes were confirmed if the direction of change was the same as the microarray with 
p<0.05* (arrow).  
 
Abbreviations: 18SrRNA - 18S ribosomal RNA, C9ORF72 - chromosome 9 open reading 
frame 72, CLNS1A - chloride channel, nucleotide-sensitive, 1A, GEMIN6 - gem (nuclear 
organelle) associated protein 6, NS - not significant, NCBP2 - nuclear cap binding protein 
subunit 2, 20kDa, PHAX - phosphorylated adaptor for RNA export, qRT-PCR - quantitative 
real-time PCR, RNP - ribonucleoprotein, SEM - standard error of the mean, snRNP - small 
nuclear RNP, STRAP - serine/threonine kinase receptor associated protein and UTP15 - 


















developmentally controlled, cold inducible apoptotic regulator; RNA binding motif 
(RNP1, RRM) protein 3 (RBM3) [RBM3 ⇧ 1.22-fold, p<0.0001 C9ORF72vctrl] that is 
of fundamental importance in miRNA biogenesis and has been shown, under both 
normal physiological conditions, as well as, mild hypoxia to be capable of enhancing 
the basal rate of protein synthesis, particularly in the dendritic branches of cortical 
and hippocampal MN’s (Dresios et al 2005, Pilotte et al 2011, Smart et al 2007) and 
the minor U11/12 spliceosomal component, zinc finger CCHC-type and RNA binding 
motif 1 (ZCRB1) [ZCRB1 ⇧1.26-fold, p<0.0001 C9ORF72vctrl] (Figure 5.11). Several 
members of the ubiquitously expressed heterogeneous nuclear RNP (hnRNP) class of 
RNA binding proteins that regulate aspects of the spliceosomal machinery, essential 
for pre-mRNA splicing & editing [HNRNPA0 ⇧1.23-fold, p<0.0001 C9ORF72vctrl and 
⇧1.23-fold, p<0.0001 nonC9ORF72-related_SALSvctrl; HNRNPH2 ⇧1.28-fold, p<0.05 
and ⇧1.32-fold, p<0.01 nonC9ORF72-related_SALSvctrl and HNRNPF ⇧1.22-fold, p< 
0.001 C9ORF72vctrl] and their associated partners including the ALS causative gene 
FUS [FUS ⇧1.23-fold, p<0.001 C9ORF72vctrl and ⇧1.33-fold, p<0.0001 nonC9ORF72- 
related_SALSvctrl (Section 1.2.5.2.2)] had also exhibited altered levels of expression 
between hexanucleotide G4C2 repeat, expansion carrying and control LCL’s (Baralle 
et al 2013, Baumer et al 2010, Bekenstein & Soreq 2013, Romano & Buratti 2013). 
Eight of the aforementioned genes were taken forward as candidates for qRT-PCR 
including five (62.5%) which validated: HNRNPA0 (p<0.01**), HNRNPF (p<0.01**), 
NUDT21 (p<0.01**) and ZCRB1 (p<0.05*) were confirmed using traditional SYBR® 
Green technology whilst FUS (p<0.01**) was confirmed in an IDT PrimeTime® Mini 
qPCR Assay. HNRNPH2 was not significant (Figure 5.13) and for PRPF19 (⇧1.14-fold, 
p=0.071) and RBM3 (⇧1.14-fold, p=0.069) a small trend in the same direction as the 
microarray was observed (Figure 5.12).    
                           
5.2.1.4 Translation  
Translation and translation factor activity, nucleic acid binding with EASE scores of 
7.52 or 2.61, respectively (Table 5.3a) were ranked as the 2nd (count 41, 6.4%) and 
10th (count 13, 2.0%) most highly enriched GO terms (Section 5.2.1.2.1) in a DAVID 




Figure 5.11 DAVID 2D Heat-Map Visualisation of C9ORF72vCtrl (n=56) 
RNA Processing Genes-to-Term Relationships Analysis performed using 
DAVID bioinformatics resource version 6.7 which is freely available online at 
david.abcc.ncifcrf.gov (Huang da et al 2009a, Huang da et al 2009b). Green 
(█)/black (█) squares represent a positive or negative association between 
the gene of interest (right) and the GO term displayed along the bottom; these 
were listed from left to right in increasing order of enrichment. 
  
Abbreviations: C9ORF72 - chromosome 9 open reading frame 72, ctrl - control, 
DAVID - Database for Annotation, Visualisation and Integrated Discovery, GO 






















Figure 5.12 Regulation of the Spliceosome qRT-PCR Validation I Relative concentrations 
measured against the standard housekeeping gene 18SrRNA. Means and SEM were plotted in 
GraphPad® Prism software version 5.04. Probability values calculated in Microsoft Excel 2010 
(Microsoft Corporation UK) using a one tailed student’s t-test. Gene expression changes were 
confirmed if the direction of change (arrow) was the same as the microarray with p<0.05* 
(p<0.01**). 
 
Abbreviations: 18SrRNA - 18S ribosomal RNA, C9ORF72 - chromosome 9 open reading frame 
72, FUS - fused in sarcoma, HNRNPA0 - heterogeneous nuclear ribonucleoprotein A0, NUDT21 
- nudix (nucleoside diphosphate linked moiety X)-type motif 21, pre-mRNA - precursor 
mRNA, PRPF19 - PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae), qRT-
PCR - quantitative real-time PCR, RBM3 - RNA binding motif (RNP1, RRM) protein 3, SEM - 




























Figure 5.13 Regulation of the Spliceosome qRT-PCR Validation II Relative concentrations 
measured against the standard housekeeping gene 18SrRNA. Means and SEM were plotted in 
GraphPad® Prism software version 5.04. Probability values calculated in Microsoft Excel 2010 
(Microsoft Corporation UK) using a one tailed student’s t-test. Gene expression changes were 
confirmed if the direction of change (arrow) was the same as the microarray with p<0.01**   
 
Abbreviations: 18SrRNA - 18S ribosomal RNA, C9ORF72 - chromosome 9 open reading frame 
72, HNRNPF - heterogeneous nuclear ribonucleoprotein F, HNRNPH2 - heterogeneous nuclear 
ribonucleo protein H2, NS - not significant, qRT-PCR - quantitative real-time PCR and SEM - 
standard error of the mean.                          
 
 
unadjusted p<0.05, FC ≥ ±1.20] up-regulated gene expression changes. A list of the 
DAVID output of genes relating to translation is provided in Table 5.6. DE transcripts 
specific to the G4C2 repeat are denoted by three asterisks inserted immediately after 
the gene symbol in the first column. Key validation targets which were selected for 
qRT-PCR are shaded in grey. 
Translation describes the processes by which mRNA targets that are transcribed in 
the nucleus are decoded by the ribosomal machinery in the cytoplasm. In eukaryotes 
protein synthesis is an ongoing, cyclical event that is defined by an initiation phase 
(Section 5.2.1.4.1) followed by an elongation (Section 5.2.1.4.2), termination (Section 
5.2.1.4.3) and ribosome recycling step (Section 5.2.1.4.4).                 
 
5.2.1.4.1 Translation Initiation    
Translation initiation begins with the assembly of the 43S PIC (Figure 5.14) (Jackson 
et al 2010, Mayer et al 2001, RajBhandary 1994) comprising components of the 40S 
ribosomal subunit [RPS15A (ribosomal protein S15a) ⇧1.27-fold, p<0.05 C9ORF72v 
ctrl; RPS2 (ribosomal protein S2) ⇧1.49-fold, p<0.01 C9ORF72vctrl], a ternary sub- 










Symbol RefSeq Transcript Gene   Fold p-value 
DENR NM_003677 3435490 density-regulated protein  ⇧ 1.30 1.64E-03 
EIF3J NM_003758 3591963 eukaryotic translation initiation factor 3, subunit J ⇧ 1.23 0.012 
EIF3K*** NM_013234 3832616 eukaryotic translation initiation factor 3, subunit K ⇧ 1.33 1.68E-04 
EIF4B*** NM_001417 3455946 eukaryotic translation initiation factor 4B ⇧ 1.45 0.011 
EIF4E2*** NM_004846 2532422 eukaryotic translation initiation factor 4E, family member 2 ⇧ 1.23 0.011 
EIF4H NM_022170 3008144 eukaryotic translation initiation factor 4H ⇧ 1.31 5.01E-03 
EIF5*** NM_183004 3553607 eukaryotic translation initiation factor 5 ⇧ 1.20 1.12E-03 
ETF1 NM_004730 2877465 eukaryotic translation termination factor 1 ⇧ 1.27 6.75E-05 
GARS*** NM_002047 2995420 glycyl-tRNA synthetase  ⇧ 1.24 3.85E-03 
HARS NM_002109 2878474 histidyl-tRNA synthetase ⇧ 1.20 4.98E-03 
ICT NM_001545 3734575 immature colon carcinoma transcript 1 ⇧ 1.22 4.71E-03 
KARS NM_001130089 3699757 lysyl-tRNA synthetase ⇧ 1.20 2.32E-04 
MRPL10*** NM_145255 3760945 mitochondrial ribosomal protein L10 ⇧ 1.21 0.037 
MRPL15*** NM_014175 3098454 mitochondrial ribosomal protein L15 ⇧ 1.27 1.83E-04 
MRPL16*** NM_017840 3374856 mitochondrial ribosomal protein L16 ⇧ 1.21 0.022 
MRPL18 NM_014161 2934167 mitochondrial ribosomal protein L18 ⇧ 1.22 5.06E-03 
MRPL19*** NM_014763 2489806 mitochondrial ribosomal protein L19 ⇧ 1.22 0.012 
MRPL21*** NM_181515 3379708 mitochondrial ribosomal protein L21 ⇧ 1.32 3.21E-03 
MRPL22 NM_014180 2836886 mitochondrial ribosomal protein L22 ⇧ 1.22 0.014 
MRPL30*** NM_145212 2495806 mitochondrial ribosomal protein L30 ⇧ 1.20 0.014 
MRPL34*** NM_023937 3824197 mitochondrial ribosomal protein L34 ⇧ 1.33 6.39E-05 
MRPL4*** NM_146388 3820414 mitochondrial ribosomal protein L4 ⇧ 1.21 1.82E-03 
MRPL41 NM_032477 3195344 mitochondrial ribosomal protein L41 ⇧ 1.43 5.85E-04 
MRPL47 NM_020409 2706985 mitochondrial ribosomal protein L47 ⇧ 1.34 2.52E-03 
MRPL51 NM_016497 3441955 mitochondrial ribosomal protein L51 ⇧ 1.22 1.80E-05 
MRPL9*** NM_031420 2435195 mitochondrial ribosomal protein L9 ⇧ 1.21 6.78E-03 
MRPS11*** NM_022839 3607183 mitochondrial ribosomal protein S11 ⇧ 1.33 1.60E-05 
MRPS12*** NM_021107 3832777 mitochondrial ribosomal protein S12 ⇧ 1.29 1.89E-05 
MRPS16*** NM_016065 3294348 mitochondrial ribosomal protein S16 ⇧ 1.21 1.83E-04 
MRPS2*** NM_016034 3193900 mitochondrial ribosomal protein S2 ⇧ 1.26 1.35E-03 
MTFMT*** NM_139242 3629378 mitochondrial methionyl-tRNA formyltransferase ⇧ 1.24 7.48E-03 




RPL11*** NM_170739 2325192 ribosomal protein L11 ⇧ 1.25 0.035 
RPL22*** NM_000983 2394558 ribosomal protein L22 ⇧ 1.40 1.06E-04 
RPL36A NM_019597 3984779 ribosomal protein L36a ⇧ 1.28 0.024 
RPL39L*** NM_052969 2709606 ribosomal protein L39L ⇧ 1.35 7.08E-03 
RPL5*** NM_014570 3962587 ribosomal protein L5 ⇧ 1.24 1.28E-03 
RPL9*** NM_001024921 2766419 ribosomal protein L9 ⇧ 1.24 0.014 
RPS15A*** NM_001019 3683018 ribosomal protein S15a ⇧ 1.27 0.039 
RPS2*** NM_002952 3676300 ribosomal protein S2 ⇧ 1.49 2.73E-03 
TRMT6*** NM_015939 3896524 tRNA methyltransferase 6 homolog (S. cerevisiae) ⇧ 1.27 1.11E-05 
 
Table 5.6 DAVID C9ORF72vCtrl List of Translation Related Genes (n=41) [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
 
Abbreviations: C9ORF72 - chromosome 9 open reading frame 72, ctrl - control, DAVID - Database of Annotation, Visualisation and Integrated Discovery, FC - fold-



































Figure 5.14 Eukaryotic Translation Initiation, Elongation, Termination and Ribosome Recycling Schematic 
 
Abbreviations: DHX29 - DExH box protein DEAH (Asp-Glu-Ala-His) box polypeptide 29, eEF - eukaryotic translation elongation 
factor, eIF - eukaryotic translation initiation factor, eRF - eukaryotic translation release factor, fMet - N-formylmethionine, GTP - 




transferase 6 homolog (S. cerevisiae)) encoding the substrate binding motif, TRM6 ⇧ 
1.27-fold, p<0.0001 C9ORF72vctrl and ⇧1.26-fold, p<0.0001 nonC9ORF72-related_ 
SALSvctrl] in association with guanosine triphosphate (GTP) bound eIF2 (eukaryotic 
translation initiation factor 2) and eukaryotic translation initiation factors eIF1/1A 
and eIF3 (Figure 5.14) [EIF3J (eukaryotic translation initiation factor 3, subunit J) ⇧ 
1.23-fold, p<0.05 C9ORF72vctrl and ⇧1.24-fold, p<0.05 nonC9ORF72-related_SALSv 
ctrl; EIF3K (eukaryotic translation initiation factor 3, subunit K) ⇧1.33-fold, p<0.001 
C9ORF72vctrl]. Attachment of the 43S PIC to the seven methylguanosine (m7G) cap 
structure at the 5’ end of the mRNA target is mediated by eIF4B [EIF4B (eukaryotic 
translation initiation factor 4B) ⇧1.44-fold, p<0.05 C9ORF72vctrl] and 4F; the latter 
of which is itself composed of three subunits containing a scaffolding protein eIF4G, 
an ATP-dependent RNA helicase eIF4A, that is under the direction of eIF4H [EIF4H 
(eukaryotic translation initiation factor 4H) ⇧1.31-fold, p<0.01 C9ORF72vctrl and ⇧ 
1.38-fold, p<0.001 nonC9ORF72-related_SALSvctrl], and cap binding complex eIF4E 
[EIF4E2 (eukaryotic translation initiation factor 4E, family member 2) ⇧1.23-fold, p< 
0.05 C9ORF72vctrl]. Scanning is then prompted by the DExH-box protein DEAH (Asp 
-Glu-Ala-His) box polypeptide 29 (DHX29) (Hashem et al 2013) (Figure 5.14). The 
increase in EIF4H expression in C9ORF72+ cases compared to controls (p<0.001***) 
(Figure 5.15) was later confirmed in an IDT PrimeTime® Mini qPCR Assay.         
Upon recognition of the translation initiation start codon, hydrolysis of bound GTP 
into guanosine diphosphate (GDP) and, release of inorganic phosphate (Pi), triggers 
eIF2 dissociation from the ternary sub-complex. Established base pairing between 
the tRNAimet and the AUG trinucleotide sequence now located within the P site of the 
ribosomal 40S subunit results in the formation of the 48S initiation complex (Figure 
5.14). The recruitment of eIF5 [EIF5 (eukaryotic translation initiation factor 5) ⇧1.20 
-fold, p<0.01 C9ORF72vctrl] and 5B are required for docking of the large ribosomal 
60S subunit [RPL5 (ribosomal protein L5) ⇧1.24-fold, p<0.01 C9ORF72vctrl; RPL9 
(ribosomal protein L9) ⇧1.24-fold, p<0.05 C9ORF72vctrl; RPL11 (ribosomal protein 
L11) ⇧1.25-fold, p<0.05 C9ORF72vctrl; RPL22 (ribosomal protein L22) ⇧1.40-fold, 
p<0.01 C9ORF72vctrl; RPL36A (ribosomal protein L36a) ⇧1.28-fold p<0.05 C9ORF72 
vctrl and ⇧1.32-fold, p<0.01 nonC9ORF72-related_SALSvctrl and RPL39L (ribosomal 
















Figure 5.15 Eukaryotic Translation qRT-PCR Validation Relative concentrations were 
measured against the standard housekeeping gene 18SrRNA. Means and SEM plotted in 
GraphPad® Prism software version 5.04. Probability values calculated in Microsoft Excel 
2010 (Microsoft Corporation UK) with a one tailed student’s t-test applied. Gene expression 
changes were confirmed if the direction of change (arrow) was the same as the microarray 
with p<0.05* (p<0.01**, p<0.001***). 
 
Abbreviations: C9ORF72 - chromosome 9 open reading frame 72, DENR - density-regulated 
protein, EIF4H - eukaryotic translation initiation factor 4H, KARS - lysyl-tRNA synthase, 
qRT-PCR - quantitative real-time PCR, 18SrRNA - 18S ribosomal RNA, RPL22 - ribosomal 
protein L22, SEM - standard error of the mean and tRNA - transfer RNA.                          
 
 
al 2011)] in order to establish an 80S ribosome that is primed for elongation (Figure 
5.14) (Lomakin & Steitz 2013). An increase in RPL22 expression in C9ORF72+ cases 
compared to controls (p<0.01**) (Figure 5.15) was later confirmed in a traditional 
SYBR® Green qRT-PCR Assay.  
It is interesting to note that whilst an overall up-regulation in the gene expression of 
transcripts associated with protein synthesis was observed in C9ORF72vctrl (Table 
5.3a) [Partek® unadjusted p<0.05, FC ≥ ±1.20] the abundance of mRNA encoding the 













binding protein 2) ⇧1.32-fold, p<0.0001 nonC9ORF72-related_SALSvctrl (Ayuso et al 
2013, Banko et al 2005, Paku et al 2012)] was found to be significantly elevated in the 
SALS patient derived LCL’s which do not carry the G4C2 repeat. In these cases there 
was also a concomitant decrease in the expression of eEF1a1 [EEF1A1 (eukaryotic 
translation elongation factor 1, alpha 1) ⇩1.29-fold, p<0.0001 nonC9ORF72-related 
_SALSvctrl] in addition to a marked reduction in the levels of multiple components of 
the 60S ribosomal subunit [RPL5 ⇩1.28-fold, p<0.0001; RPL10 (ribosomal subunit 
L10) ⇩1.37-fold, p<0.001; RPL13 (ribosomal subunit L13) ⇩1.29-fold, p<0.05; RPL17 
(ribosomal subunit L17) ⇩1.28-fold, p<0.01 nonC9ORF72-related_SALSvctrl].                        
 
5.2.1.4.2 Translation Elongation   
Elongation of the nascent polypeptide chain is driven by the eukaryotic translation 
elongation factor 1 (eEF-1) complex composed of five subunits that include: eEF1A-
1 (alpha 1), eEF1A-2 (alpha 2), eEF1B-2 (beta 2), eEF1D (delta) and eEF1E (epsilon) 
responsible for delivering amino-acetylated tRNA molecules to the ribosomal A site 
which normally occurs at a rate of approximately two amino acids per second. EEF-
2 (eukaryotic translation elongation factor 2) is then required, following sequential 
formation of each peptide bond (Figure 5.14), in order to shift the mRNA template 
along one codon at a time in relation to the positioning of the 80S ribosome (Skabkin 
et al 2013).    
The charging of the tRNA molecules with their cognate amino acids is performed by 
the class I and class II aminoacyl-tRNA synthetase enzymes; several of which were 
found to be DE in expansion carrying LCL’s (Guo et al 2010, Hausmann & Ibba 2008, 
Ibba & Soll 2000) [GARS (glycyl-tRNA synthetase) ⇧1.24-fold, p<0.01 C9ORF72vctrl; 
HARS (histidyl-tRNA synthetase) ⇧1.20-fold, p<0.01 C9ORF72vctrl and KARS (lysyl-
tRNA synthetase) ⇧1.20-fold, p<0.001 C9ORF72vctrl and ⇧1.23-fold, p<0.0001 non  
C9ORF72-related_SALSvctrl (Table 5.6)]. An increase in KARS expression (p<0.01**) 
(Figure 5.15) was later confirmed in a traditional SYBR® Green qRT-PCR Assay.                        
 
5.2.1.4.3 Translation Termination    




by occupation of the ribosomal A site by one of three stop codons, namely UAG, UAA 
or UGA which are decoded by the eukaryotic release factor eRF1 [ETF1 (eukaryotic 
translation termination factor 1) ⇧1.27-fold, p<0.0001 C9ORF72vctrl and ⇧1.21-fold, 
p<0.001 nonC9ORF72-related_SALSvctrl (Alkalaeva et al 2006)]. Recognition of any 
one of these specific trinucleotide sequences at this site triggers GTPase mediated 
inactivation of a second eukaryotic release factor (eRF3a/b) (Beznoskova et al 2013). 
The subsequent dissociation of GDP-bound eRF3a/b liberates eRF1 and facilitates its 
mobilisation of the ribosomal peptidyl transferase centre responsible for the hydro-
lytic breakdown of the covalently linked amide bond between the P-site deacylated 
tRNA and the carboxyl-terminus of the newly synthesised protein; thus, releasing it 
from the translational machinery (Figure 5.14) (Dever & Green 2012).                        
 
5.2.1.4.4 Ribosome Recycling    
The dissolution of the eukaryotic translation post-termination (post-TC) complex is 
understood to be under the control of the ABCE1 protein (alternative name RNase L 
(2’, 5’-oligoisodenylate synthetase dependent inhibitor (Rli1)) [ABCE1 (ATP-binding 
cassette, sub-family E (OABP), member 1) ⇧1.29-fold, p<0.01 C9ORF72vctrl (Pisarev 
et al 2010, Shoemaker & Green 2011) (Figure 5.14)]. A molecular switch that results 
in the hydrolysis of bound ATP into adenosine diphosphate (ADP) and the release of 
Pi produces a conformational change which leads to the dissociation of the ribosomal 
60S subunit (Barthelme et al 2011, Becker et al 2012, Dever & Green 2012). EIF1/1A 
and eIF3J complete the cycle; either acting alone or in concert with the solute carrier 
family 16 (monocarboxylate transporter), member 1 (MCT-1) and density regulated 
protein (DRP1) complex [DENR ⇧1.30-fold, p<0.01 C9ORF72vctrl and ⇧1.31-fold, p< 
0.001 nonC9ORF72-related_SALSvctrl] to release the mRNA template and deacylated 
tRNA from the 40S ribosomal subunit (Figure 5.14) (Dever & Green 2012, Dmitriev 
et al 2010, Pisarev et al 2007, Skabkin et al 2010). An increase in DENR expression 
was later confirmed in a traditional SYBR® Green qRT-PCR Assay (p<0.05*) (Figure 
5.15).          
                           




The Partek® generated GC-RMA normalised pivot tables of log2 transformed signal 
intensities relating to Affymetrix® core meta-probesets (n=287,329) on the Human 
Exon 1.0ST GeneChip® Arrays for samples in the final ECACC microarray experiment 
(n=120/125) [C9ORF72+ (n=38), SALS (n=56) and Ctrl (n=26) (Section 5.2.1.1)] were 
also interrogated visually using Qlucore Omics Explorer software version 2.3. F-test 
statistical outputs for the ANOVA were applied at the 5% significance level (p<0.05) 
in order to generate lists of variables or genes (transcripts) (Section 2.3.2.5.3) which 
are best able to separate patient and control groupings [i.e. C9ORF72vctrl (Section 
5.2.1.5.1) and nonC9ORF72-related_SALSvctrl (Section 5.2.1.5.2)] on the PCA plot or 
hierarchically clustered HeatMap. Any potentially confounding effects due to age or 
gender were eliminated and the lists filtered to removed unannotated clusters using 
the NetAffxTM Analysis Centre (n=3,356/22,011) which is freely available online at 
affymetrix.com/analysis/index.affx (Affymetrix® Ltd, UK) (Liu et al 2003). Finally, a 
FC threshold of ≥ ±1.20 was applied and functional annotation clustering analysis 
performed using DAVID bioinformatics resource version 6.7 (Section 2.3.2.5.4). GO 
categories with an EASE score above 1.30 and Benjamini-Hochberg FDR corrected 
p<0.05 were considered statistically significant. Transcripts identified as being up 
(⇧)/down(⇩)-regulated under different experimental conditions were analysed in-
dependently.    
 
5.2.1.5.1 C9ORF72vCtrl     
Qlucore Omics Explorer identified 1,173 of 18,655 variables or genes (transcripts) 
as being differentially regulated between LCL’s carrying the G4C2 repeat expansion 
in C9ORF72 and neurologically normal, healthy controls. These included 755 (64.4%) 
variables that were significantly up-regulated (⇧) and a further 418 (35.6%) variab-
les which were significantly down-regulated (⇩). Overall there was a good degree of 
concordance between the Qlucore (n=1,173/18,655) [ANOVA F-test p<0.05, FC ≥ ± 
1.20] and Partek® (n=1,097/17,635) [Partek® unadjusted p<0.05, FC ≥ ±1.20 (Sect-
ion 5.2.1.1.1)] generated lists with a respective 84.5% (n=991/1,173) or 90.3% (n= 
991/17,635) [597 genes ⇧ and 394 genes ⇩] of DE transcripts (Figure 5.16) shared 
in common between to two analyses platforms. 












Figure 5.16 GeneVenn C9ORF72vctrl [ANOVA F-test p<0.05, FC ≥ ±1.20; 
Partek® unadjusted p<0.05, FC ≥ ±1.20] Lists of DE variables/genes were 
generated using Qlucore Omics Explorer software version 2.3 (Lund, Sweden) 
or Partek® Genomics SuiteTM software version 6.6 copyright © 2013 (Partek® 
Inc., St Louis, MO, USA). The GeneVenn application was freely available online 
from genevenn.sourceforge.net (Pirooznia et al 2007) (University of Southern 
Mississippi, USA).     
 
Abbreviations: ANOVA - analysis of variance, C9ORF72 - chromosome 9 open 
reading frame 72, ctrl - control, DE - differentially expressed and FC - fold-
change.   
 
 
91.6% of the 1,173 DE variables [644 genes ⇧ and 410 genes ⇩]. GO terms highlighted 
in Table 5.7 were almost identical (Yellow) to those identified in the original Partek® 
C9ORF72vctrl analysis (Table 5.3). Once again RNA processing (Section 5.2.1.3) and 
translation (Section 5.2.1.4) featured prominently and were, by far, the most highly 
enriched categories, with respective EASE scores of 8.56 (count 57, FDR p<0.0001) 
and 13.10 (count 56, FDR p<0.0001) (Table 5.7).     
The same list of 1,173 DE variables [ANOVA F-test p<0.05, FC ≥ ±1.20] could also be 
applied in Qlucore Omics Explorer in order to determine whether, following a PCA, 
clearly defined genetic sub-groups were evident within the C9ORF72+ LCL samples. 
This, however, proved not to be the case when comparing the software generated 
PCA plot [C9ORF72+ (Yellow) and Ctrl (Blue)] and hierarchically clustered HeatMap 
[Up (⇧)-regulated (Red) and down (⇩)-regulated (Green)]. Although the separation 
was not entirely distinct, yellow spheres representing the G4C2 repeat carriers were 
predominantly concentrated within the upper (Figure 5.17a) or right (Figure 5.17b)
C9ORF72+ 
   1,173                              1,097 
Control C9ORF72+ 
   182                                        107                                        
   991                                        




a) C9ORF72vctrl ⇧reg [ANOVA F-test p<0.05, FC ≥ ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0006412 translation 13.10 56 1.80E-18 
2 GO:0006396 RNA processing 8.56 57 1.80E-09 
3 GO:0006974 response to DNA damage stimulus 5.08 35 1.10E-04 
4 GO:0007049 cell cycle 4.14 65 3.50E-07 
5 GO:0022613 ribonucleoprotein complex biogenesis 3.96 26 2.70E-06 
6 GO:0051340 regulation of ligase activity 3.93 16 3.10E-05 
7 GO:0044265 cellular macromolecule catabolic process 3.75 53 2.30E-04 
8 GO:0043933 macromolecular complex subunit 
organisation 
3.50 52 2.50E-04 
9 GO:0008135 translation factor activity, nucleic acid 
binding 
3.44 17 6.10E-05 
10 GO:0006368 RNA elongation from RNA polymerase II 
promoter 
2.88 10 2.70E-03 
11 GO:0034622 cellular macromolecular complex assembly 2.43 27 5.20E-03 
12 GO:0006297 nucleotide-excision repair, DNA gap filling 2.15 6 0.012 
13 GO:0022904 respiratory electron transport chain 2.04 10 0.020 
14 GO:0000166 nucleotide binding 1.53 109 0.029 
 
b) C9ORF72vctrl ⇩reg [ANOVA F-test p<0.05, FC ≥ ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0007155 cell adhesion 5.06 39 2.60E-04 
2 GO:0016125 sterol metabolic process 4.59 14 2.50E-04 
3 GO:0006811 ion transport 4.47 43 8.20E-05 
4 GO:0008610 lipid biosynthetic process 3.32 31 1.30E-07 
5 GO:0005506 iron ion binding 3.12 20 4.50E-03 
6 GO:0015294 solute:cation symporter activity 3.11 11 3.80E-03 
7 GO:0051270 regulation of cellular component movement 2.78 14 0.050 
8 GO:0009100 glycoprotein metabolic process 2.56 17 2.80E-03 
9 GO:0043167 ion binding 2.33 117 0.017 
10 GO:0042626 ATPase activity, coupled to transmembrane 
movement of substances 
2.29 12 0.011 
11 GO:0016717 oxidoreductase activity, acting on paired 
donors, with oxidation of a pair of donors 
resulting in the reduction of molecular 
oxygen to two molecules of water 
1.97 4 0.010 
12 GO:0030246 carbohydrate binding  1.67 20 9.60E-03 
13 GO:0030169 low-density lipoprotein binding 1.51 5 0.030 
 
Table 5.7 DAVID Qlucore C9ORF72vCtrl Functional Annotation Clustering Analysis  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, ANOVA - analysis of variance, 
C9ORF72 - chromosome 9 open reading frame 72, ctrl - control, EASE - enrichment score, FC - 
fold-change and GO - gene ontology.          
 
 
segment whilst blue spheres which represent the control cases were predominantly 
concentrated within the lower (Figure 5.17a) or left (Figure 5.17b) segment of each 
graph, respectively.                   
 

























Figure 5.17 C9ORF72vctrl Clustering Analysis Applying the 1,173 List of Variables in Qlucore 
Omics Explorer [ANOVA F-test p<0.05, FC ≥ ±1.20] 
 
Abbreviations: ANOVA - analysis of variance, C9ORF72 - chromosome 9 open reading frame 72, ctrl 








































Qlucore Omics Explorer also identified 1,960 of 18,655 variables or genes as being 
differentially regulated between non-expansion carrying SALS patient and control 
LCL’s including 1,299 (66.3%) variables which were significantly up-regulated (⇧) 
and a further 661 (33.7%) variables that were significantly down-regulated (⇩). As 
seen before (Section 5.2.1.5.1), there was a good degree of concordance between the 
Qlucore (n=1,960/18,655) [ANOVA F-test p<0.05, FC ≥ ±1.20] and Partek® (n=1,802/ 
17,635) [Partek® unadjusted p<0.05, FC ≥ ±1.20 (Section 5.2.1.1.2)] generated lists 
with a respective 83.3% (n=1,730/1,173) or 96.0% (n=1,730/17,635) [1,113 genes 
⇧ and 617 genes ⇩] of DE transcripts shared in common between the two analyses 









Figure 5.18 GeneVenn NonC9ORF72-Related_SALSvCtrl [ANOVA F-test p< 
0.05, FC ≥ ±1.20; Partek® unadjusted p<0.05, FC ≥ ±1.20] Lists of DE genes 
/variables generated using Qlucore Omics Explorer software version 2.3 (Lund, 
Sweden) or Partek® Genomics SuiteTM software version 6.6 copyright © 2013 
(Partek® Inc., St Louis, MO, USA). The GeneVenn application is freely available 
online at genevenn.sourceforge.net (University of Southern Mississippi, USA) 
(Pirooznia et al 2007). 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, ANOVA - analysis of 
variance, C9ORF72 - chromosome 9 open reading frame 72, ctrl - control, DE - 
differentially expressed, FC - fold-change and S - sporadic.   
 
 
In the functional annotation clustering analysis 1,768 DAVID ID’s were returned for 
90.2% of the 1,960 DE variables [1,299 genes ⇧ and 661 genes ⇩]. The GO categories 
highlighted in Table 5.8 were almost identical (yellow) to those identified from the 
original Partek® nonC9ORF72-related_SALSvctrl analysis (Table 5.4) and once again 
SALS 
   1,960                              1,802 
Control SALS 
   72                                        230                                        
   1,730                                        




a) nonC9ORF72-related_SALSvctrl ⇧reg [ANOVA F-test p<0.05, FC ≥ ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0007049 cell cycle 36.02 174 2.00E-46 
2 GO:0006259 DNA metabolic process 21.34 109 1.30E-26 
3 GO:0007059 chromosome segregation  9.00 33 2.30E-15 
4 GO:0006396 RNA processing 8.99 86 8.90E-12 
5 GO:0051276 chromosome organisation 8.35 90 4.20E-17 
6 GO:0022613 ribonucleoprotein complex biogenesis 8.10 43 4.70E-11 
7 GO:0051329 interphase of mitotic cell cycle 7.64 28 3.40E-08 
8 GO:0006323 DNA packaging 7.06 32 1.60E-09 
9 GO:0043933 macromolecular complex subunit 
organisation 
6.66 93 2.10E-08 
10 GO:0006310 DNA recombination 6.36 25 4.20E-06 
11 GO:0000166 nucleotide binding 6.31 204 1.10E-06 
12 GO:0006302 double-strand break repair 6.14 22 2.00E-08 
13 GO:0007051 spindle organisation 5.33 17 9.60E-07 
14 GO:0031396 regulation of protein ubiquitination 4.71 24 6.30E-06 
15 GO:0000072 cell cycle checkpoint 3.48 27 1.10E-08 
16 GO:0009314 response to radiation 3.34 31 6.60E-04 
17 GO:0006297 nucleotide-excision repair, DNA gap filling 3.32 9 2.00E-04 
18 GO:0006511 ubiquitin-dependent protein catabolism 2.81 33 3.80E-03 
19 GO:0051186 cofactor metabolic process 2.72 29 2.50E-03 
20 GO:0010605 regulation of macromolecule metabolism  2.50 84 3.70E-05 
21 GO:0003677 DNA binding 2.47 202 4.20E-05 
22 GO:0008134 transcription factor binding 2.46 52 0.028 
23 GO:0051052 regulation of DNA metabolic process 2.37 19 0.012 
24 GO:0009451 RNA modification 2.32 11 0.023 
25 GO:0051259 protein oligomerization  2.17 24 0.025 
26 GO:0016579 protein deubiquitination  2.04 8 0.026 
27 GO:0050000 chromosome localisation 2.03 6 0.045 
28 GO:0032259 methylation 1.57 15 0.011 
 
b) nonC9ORF72-related_SALSvctrl ⇩reg [ANOVA F-test p<0.05, FC ≥ ±1.20] 
# GO term Functional category EASE Count Benjamini 
1 GO:0006811 ion transport 4.00 49 4.50E-03 
2 GO:0030334 regulation of cell migration 3.83 18 5.80E-03 
3 GO:0015295 solute:hydrogen symporter activity 3.80 10 2.20E-05 
4 GO:0042592 homeostatic process 3.36 50 4.30E-03 
5 GO:0008219 cell death 2.83 42 0.019 
6 GO:0010647 positive regulation of cell communication 2.81 29 3.30E-03 
7 GO:0008654 phospholipid biosynthetic process 2.44 14 6.00E-03 
8 GO:0000041 transition metal ion transport 2.44 12 5.90E-03 
9 GO:0006643 membrane lipid metabolic process 2.42 11 0.020 
10 GO:0006826 iron ion transport 2.26 7 0.018 
11 GO:0010038 response to metal ion 2.18 14 0.019 
12 GO:0051347 positive regulation of transferase activity 1.95 22 5.50E-03 
13 GO:0051249 regulation of lymphocyte activation 1.91 15 0.020 
14 GO:0031418 L-ascorbic acid binding 1.67 6 0.037 
15 GO:0050850 regulation of calcium-mediated signalling 1.49 6 0.013 
16 GO:0006826 iron ion transport 1.34 7 0.018 
 
Table 5.8 DAVID Qlucore NonC9ORF72-Related_SALSvCtrl Functional Annotation Clustering 
Analysis  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, ALS - Amyotrophic Lateral 
Sclerosis, ANOVA - analysis of variance, C9ORF72 - chromosome 9 open reading frame 72, ctrl - 




cell cycle and DNA metabolism featured prominently with respective EASE scores of 
36.02 (count 174, FDR p<0.0001) and 21.34 (count 109, FDR p<0.0001). 
 
Applying the same list of 1,960 DE variables [ANOVA F-test p<0.05, FC ≥ ±1.20] in 
Qlucore Omics Explorer was unsuccessful in producing distinct clusters on the PCA 
plot [SALS (Pink) and Ctrl (Blue)] or hierarchically clustered HeatMap (Figure 5.19); 
thus, highlighting the heterogeneity that is present within the ECACC nonC9ORF72-
related_SALS patient and control LCL populations.                
 
5.2.2 Alternative Splicing Analysis 
Alternatively spliced transcripts (Section 2.3.2.5.2) were predicted at the level of the 
whole gene by performing an ALT-SPLICE ANOVA using Partek® Genomics SuiteTM 
software version 6.6. In order to reduce the probability of predicting a false positive 
outcome, attributable to a type I error: a) probesets with a maximum value for log2 
transformed signal intensities below three across all of the GeneChips® in the ECACC 
C9ORF72vctrl and nonC9ORF72-related_SALSvctrl experiment were removed except 
for instances where there was a significant difference in the expression of a single 
exon between two groups; b) exons residing in genes whose expression at the whole 
transcript level was found to be significantly altered [Partek® unadjusted p<0.05, FC 
≥ ±1.20] were excluded and c) transcript clusters were filtered which had no obser-
vable difference in the expression of individual exons (Gillett et al 2009, Rabin et al 
2010, Tian et al 2011). In addition, transcripts with fewer than four or greater than 
forty probesets were removed (n=2,077/17,273) since the presence of such a small 
or large number of markers makes it prohibitively more difficult to interpret the alt-
ernative splicing events occurring within these genes (Whistler et al 2010).  
At the 5% significance threshold [Partek® unadjusted p-value (fold-change) ≥0.05 
and p-value (alt. splicing) <0.05] this approach identified 2,511 (14.5%) of 17,273 
transcripts predicted to be alternatively spliced in the analysis of C9ORF72vctrl and 
a further 3,163 (18.3%) of 17,273 transcripts predicted to be alternatively spliced in 
the analysis of nonC9ORF72-related_SALSvctrl. These included: a) 1,765 (70.3%) of 
2,511 transcripts that were specifically altered in relation to the G4C2 repeat; b) 746 
































Figure 5.19 NonC9ORF72-Related_SALSvCtrl Clustering Analysis Applying the 1,960 List 
of Variables in Qlucore Omics Explorer [ANOVA F-test p<0.05, FC ≥ ±1.20] 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, ANOVA - analysis of variance, C9ORF72 - 
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transcripts, respectively which are commonly shared and more broadly reflect those 
changes associated with the wider ALS disease process and c) 2,417 (76.4%) of 3,1 
63 transcripts that are specifically altered in relation to the non-expansion carrying 
SALS patient derived LCL’s (Figure 5.20) [APPENDIX TABLE B11 and B12].         













a) C9ORF72+ specific 
# GO term Functional category EASE Count p-value 
1 GO:0030528 transcription regulator activity 2.98 190 1.30E-05 
2 GO:0006357 regulation of transcription from RNA 
polymerase II promoter  
2.94 99 3.40E-04 
3 GO:0001882 nucleoside binding 2.35 187 1.30E-03 
4 GO:0043167 ion binding 2.21 450 7.40E-04 
5 GO:0005524 ATP binding 1.90 168 5.10E-03 
6 GO:0016570 histone modification  1.81 22 6.10E-03 
7 GO:0000278 mitotic cell cycle  1.66 52 5.60E-03 
8 GO:0010629 negative regulation of gene expression 1.47 68 4.00E-03 
 
b) ALS common  
 # GO term Functional category EASE Count p-value 
1 GO:0006915 apoptosis 2.95 49 7.70E-06 
2 GO:0048871 multicellular organismal homeostasis 2.31 12 6.80E-04 
3 GO:0019941 modification-dependent protein 
catabolic process 
1.74 37 7.50E-03 
4 GO:0000166 nucleotide binding  1.72 118 3.40E-03 
5 GO:0030695 GTPase regulator activity 1.68 31 1.40E-03 
6 GO:0008134 transcription factor binding 1.60 34 7.80E-03 
7 GO:0043167 ion binding 1.40 200 0.014 
8 GO:0048870 cell motility 1.40 21 0.028 
 
c) nonC9ORF72-related_SALS specific  
# GO term Functional category EASE Count p-value 




2 GO:0030182 neuron differentiation 2.17 81 2.70E-04 
3 GO:0043169 cation binding 1.86 579 3.70E-03 
4 GO:0010828 positive regulation of glucose transport 1.57 8 0.015 
5 GO:0043010 camera-type eye development  1.48 24 6.10E-03 
6 GO:0009991 response to extracellular stimulus 1.46 41 9.20E-03 
7 GO:0035295 tube development 1.46 41 9.20E-03 
8 GO:0032559 adenyl ribonucleotide binding 1.46 221 8.20E-03 
 
Figure 5.20 ALT-SPLICE GeneVenn C9ORF72vCtrl and NonC9ORF72-Related_SALSvCtrl 
[Partek® unadjusted p-value (fold-change) ≥0.05 and p-value (alt. splicing) <0.05] The 
Affymetrix® transcript cluster ID’s predicted to be alternatively spliced between disease and 
control LCL’s in the ECACC microarray cohort were detected using Partek® Genomics SuiteTM 
software version 6.6 copyright © 2013 (Partek® Inc., St Louis, MO, USA). GeneVenn application 
freely available online at genevenn.sourceforge.net (University of Southern Mississippi, USA) 
(Pirooznia et al 2007). Functional Annotation Clustering performed in DAVID bioinformatics 
resource version 6.7 (david.abccc.ncifcrf.gov) (Huang da et al 2009a, Huang da et al 2009b).  
 
Abbreviations: # - rank, ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open 
reading frame 72, ctrl - control, DAVID - Database for Annotation, Visualisation and Integrated 
Discovery, EASE - enrichment score, ECACC - European Collection of Cell Cultures, GO - gene 
ontology, LCL - lymphoblastoid cell line and S - sporadic. 
 
 
In DAVID a fixed upper limit of 3,000 represents the maximum number of transcript 
cluster ID’s that the software is capable of handling in each run. In view of this, it was 
not possible, therefore, to conduct down-stream comparative analyses in exactly the 
same manner as described previously for Partek® generated gene level expression 
data (Section 5.2.1.2). Since the nonC9ORF72-related_SALSvctrl alt. splicing list (n= 
3,163) could not be interrogated in its entirety, functional annotation clustering was 
performed instead by exploring the C9ORF72+ (99.4% of 1,765 ID’s mapped), ALS 
common (99.7% of 746 ID’s mapped) or SALS specific (99.0% of 2,417 ID’s mapped) 
lists independently (Figure 5.20). Initially, applying a Homo sapiens background and 
filtering on GOTERM_BP_FAT and GOTERM_MF_FAT gene ontology (GO) terms using 
‘Medium’ classification stringency (Section 2.3.2.5.4), very few biologically enriched 
categories were returned; only two in fact across all three comparisons (highlighted 
in red). When the stringency was lowered to remove the Benjamini-Hochberg FDR 
correction, but maintaining a 5% significance threshold (p<0.05) (EASE score ≥1.30), 
this number was markedly increased (Figure 5.20). Upon re-analysis of the gene lists 
GO terms associated with the regulation of transcription, ATP binding and histone 
modification were identified in relation to the G4C2 repeat carrying LCL’s in contrast 
to phosphorylation, neuron differentiation/tube development and glucose transport 
which were described in relation to non-expansion carrying SALS cases. Universally 




activity, in addition to protein degradation in the form of proteolysis and apoptosis 
(programmed cell death) (Figure 5.20). 
Graphical outputs from the easyExon 1.0.4 Java-based platform copyright © 2006 to 
2014 (National Yang-Ming University, Taiwan) (Chang et al 2008) for the top 5 most 
highly ranked C9ORF72vctrl aberrant splicing events are represented in Figure 5.21. 
These include transcripts which encode: a) tight junction protein 2 (TJP2) [AS-ANO 
VA p=4.08E-18]; b) peptidylprolyl isomerase F (PPIF) [AS-ANOVA p=3.77E-16]; c) 
nuclear factor of activated T-cells 5 (NFAT5) [AS-ANOVA p=1.58E-15]; d) epidermal 
growth factor receptor (EGFR) [AS-ANOVA p=1.67E-14] and e) RNA binding motif 
protein 5 (RBM5) [AS-ANOVA p=4.76E-14] (Figure 5.21). Despite probability values 
exceeding orders of magnitude below 10-14, bars representing SEM were substantial. 
Moreover, changes in mean probeset signal intensities associated with the different 
sample types [C9ORF72+ (Red) versus Ctrl (Blue)] appeared modest. Consequently, 
it was decided not to pursue selected targets for qRT-PCR validation.                   
 
5.2.3 C9ORF72 
Following publication of C9ORF72 haploinsufficiency (Section 1.2.5.4) as a potential 
mechanism of action in ALS (DeJesus-Hernandez et al 2011) an initial subset of the 
LCL’s (n=14) [C9ORF72+ (n=7) and Ctrl (n=7)] were assayed against the endogenous 
standard actin, beta (ACTB) in a traditional SYBR® Green based qRT-PCR (Section 2.3. 
2.6.5) that used isoform A specific primers [Variant I (NM_001256054) and Variant 
II (NM_145005) (Figure 5.22)] designed to target the 3’UTR (Figure 5.23a) of the full 
length protein coding mRNA. A subsequent 1.64-fold reduction in the abundance of 
isoform A was confirmed in carriers of the G4C2 repeat relative to controls (p<0.05*) 
(Figure 5.24) (Cooper-Knock et al 2013b).  
A similar strategy was extended to include both isoform A (full length) and isoform 
B (truncated) [Variant III (NM_018325) (Figure 5.22)] specific transcripts with 18S 
ribosomal RNA (18SrRNA) now selected as the new internal reference control gene 
(Figure 5.23b). The size of the validation cohort was also increased to accommodate 
all C9ORF72+ FALS and apparently SALS cases in the ECACC discovery (Section 4.1.1) 





Figure 5.21 Graphical Representations of the C9ORF72vCtrl Top 5 Most Significant Aberrant 
Splicing Events [Partek® unadjusted p-value (fold-change) ≥0.05 and p-value (alt. splicing) 
<0.05] Lists of AS transcripts predicted in Partek® Genomics SuiteTM software version 6.6 copyright 
© 2013 (Partek® Inc., St Louis, MO, USA). Mean probeset signal intensities and SEM plotted using the 
easyExon 1.0.4 Java-based platform copyright © 2006 to 2014 (microarray.ym.edu.tw/easyExon) 
(National Yang-Ming University, Taiwan) (Chang et al 2008).      
 




















Figure 5.22 Schematic of C9ORF72 Transcript Variants and Protein Isoforms The C9ORF72 gene 
consists of 11 exons which span a 27.3Mb region of the human 9p21.2 locus. There are multiple alt. 
spliced transcripts in the Ensembl database (ensembl.org) (Flicek et al 2014); three of which were 
protein coding. These include two full length variants with alternate first exons [Variant I (NM_0012 
56054) exon 1a, 2-11 and Variant III (NM_018325) exon 1b, 2-11] in addition to a stable truncation 
[Variant II (NM_145005) exon 1a, 2-5]. The translational start site (ATG/methionine codon) resides 
in exon 2. As a consequence only two protein isoforms are produced from the three different mRNA 
sequences [Isoform A (54.3kDa) 481a.a. and Isoform B (24.8kDa) 222a.a]. The hexanucleotide G4C2 
repeat expansion identified in ALS and FTLD patients (DeJesus-Hernandez et al 2011, Renton et al 
2011) is located between exons 1a and 1b in the first intronic region and is situated upstream of the 
translational start site (illustrated by the red lightning bolt). Pathogenicity is thought to arise when 
the expanded allele contains 30 or more copies of the 6bp repeat (Cooper-Knock et al 2012b). Figure  
adapted from Donnelly et al (2013) and Fernandes et al (2013).  
 
Key: Grey – non-coding exons [5’ UTR upstream of ATG start codon and 3’ UTR downstream of TAA 
stop codon] and White – coding exons.  
 
Abbreviations: 3’ - three prime, 5’ - five prime, ALS - Amyotrophic Lateral Sclerosis, alt. - alternative, 
C9ORF72 - chromosome 9 open reading frame 72, FTLD - frontotemporal lobar degeneration, mRNA 










































                                                                
Figure 5.23 Exon Level GC-RMA Normalised Signal Intensities for the Differentially Spliced 
C9ORF72 Transcript Variants I/III (Isoform A) and II (Isoform B) Affymetrix® Human Exon 
1.0ST GeneChip® Array probeset ID’s for a) C9ORF72 full length transcript variant I (NM_001256 
054) and III (NM_018325) and b) C9ORF72 truncated transcript variant II (NM_145005) plotted 
(x-axis) against GC-RMA normalised signal intensities (y-axis) for control (n=26) [checkerboard 
pattern] and C9ORF72+ (n=38) [white] LCL’s in the final ECACC microarray cohort (Table 5.1). Box 
and Whisker plots generated using GraphPad Prism® software version 5.04 copyright © 1992 to 
2014 (GraphPad® Software Inc., CA, USA). Whiskers represent the minimum and maximum raw 
expression values. Significance was determined in Partek® Genomics SuiteTM software version 6.6 
© copyright 2013 (Partek® Inc., St Louis, MO, USA) [p<0.05* and p<0.001***]. Fold-changes (FC) 
and probability (p)-values provided in panels c) full length isoform A and d) truncated isoform B. 
Primer sequences for qRT-PCR and their binding sites on the cDNA template are represented in 
Green.  
 
Abbreviations: 3’ - three prime, 5’ - five prime, C9ORF72 - chromosome 9 open reading frame 72, 
cDNA - complementary DNA, ECACC - European Collection of Cell Cultures, F’ - forward primer 
sequence, LCL - lymphoblastoid cell line, qRT-PCR - quantitative real-time PCR, R’ - reverse primer 
sequence, RMA - Robust Multi-array Average, ST - sense target and UTR - untranslated region. 
   
 
Probeset ID Region FC p-value 
3202431 exon 8 -1.33 0.012 
3202427 exon 10 -1.45 0.022 
    
Probeset ID Region FC p-value 
3202436 3’ UTR -1.31 0.014 





a) C9ORF72 full length  
b) C9ORF72 truncated 
c) Variant I (NM_001256054) and III (NM_018325) 




















C006 LC0455 21.98 13.81 8.17       
C021 LCa0076 22.44 14.57 7.87       
C026 BC6295 22.52 13.05 9.47       
C031 SC3709 21.97 13.76 8.21       
C036 SMa0156 22.48 13.30 9.18       
C037 BC6448 22.76 13.41 9.35       
C099 SC3282 22.20 14.28 7.92       
 Mean 22.34 13.74 8.60 0.00 1.00 1.63 0.61   










F046 LP0008 22.49 13.69 8.80       
F106 BP6029 22.65 13.71 8.94       
S059 SP3041 23.20 12.73 10.47       
S110 SP3298 23.12 13.77 9.35       
S121 SP3420 23.16 13.85 9.31       
S132 SP3413 22.94 13.61 9.33       
S186 SP3431 22.84 13.87 8.97       
 Mean 22.91 13.60 9.31 0.71 0.61 0.90 0.41 1.64 0.029 
 SD  0.56       
 
Figure 5.24 Reduced C9ORF72 Transcript Variant I/III (Isoform A) Levels Detected by qRT-
PCR in a Subpopulation of ECACC LCL’s in the Discovery Cohort Relative concentrations were 
measured against the standard housekeeping gene ACTB. Means and SEM plotted using GraphPad® 
Prism software version 5.04 copyright © 1992 to 2014 (GraphPad Software Inc., USA). Probability 
values calculated in Microsoft Excel 2010 (Microsoft Corporation, UK) with a one tailed student’s t-
test applied. Gene expression changes were confirmed if the direction of change was the same as the 
microarray with p<0.05*.  
 
Abbreviations: ACTB - actin, beta, BC - Birmingham control, BP - Birmingham patient, Ca - Cambridge, 
C - control, C9ORF72 - chromosome 9 open reading frame 72, cT - cycle threshold, Δ - delta, ECACC - 
European Collection of Cell Cultures, F - familial, LC - London control, LCL - lymphoblastoid cell line, 
LP - London patient, Ma - Manchester, qRT-PCR - quantitative real-time PCR, SC - Sheffield control, S 
- sporadic, SD - standard deviation, SEM - standard error of the mean and SP - Sheffield patient.        
 
 
and an additional 28 controls (total n=35). In order to achieve maximum statistical 
power cDNA synthesis reactions were performed on pooled RNA samples with 5X 





on a single 96-well plate (Section 2.3.2.6.3).       
Contrary to those previously discussed, these latest findings suggest overall there is 
no discernable difference in the abundance of isoform A or B (Figure 5.25) specific 
transcripts between LCL’s carrying the G4C2 repeat and controls. It was of interest to 
note, however, the presence of two distinct groupings on the qRT-PCR scatter plot 
for isoform A (Figure 5.25a) with the first cluster, highlighted in yellow, appearing 
to have a significantly higher level of expression than controls [⇧1.20-fold, (p<0.01 
**) (█)] and a second cluster, highlighted in green, appearing to have a significantly 
lower level of expression than the controls [⇩1.23-fold, (p<0.01**) (█)]. Further qRT 
-PCR analyses on a small number of individually selected targets was performed in 
order to ascertain whether or not the differences observed in C9ORF72 expression 
could be correlated with a fast (survival <2yrs) versus slow (survival ≥4yrs) disease 













Figure 5.25 qRT-PCR of Pooled RNA C9ORF72 Full Length Variants I/III (Isoform A) and 
Truncated Variant II (Isoform B) Specific Transcripts Relative concentrations measured 
against the standard housekeeping gene 18SrRNA. The box (left) and scatter plots (right) were 
generated using GraphPad® Prism software version 5.04 copyright © 1992-2014 (GraphPad 
Software Inc., USA). The probability values were calculated in Microsoft Excel 2010 (Microsoft 
Corporation, UK) applying a one tailed student’s t-test.  












Abbreviations: 18SrRNA - 18S ribosomal RNA, C9ORF72 - chromosome 9 open reading frame 
72 and qRT-PCR - quantitative real-time PCR.     
 
 
5.2.4 qRT-PCR Validation of C9ORF72 RNA Binding Partners  
An RNA pull-down assay was developed in house by Dr Matthew Walsh (SITraN) and 
colleagues from the Department of Molecular Biology & Biotechnology and Chemical 
Engineering at the Life Science Interface (ChELSI) institute, University of Sheffield as 
a detection method for the identification of key candidate binding partners (Cooper-
Knock et al 2014b) of the hexanucleotide expansion recently discovered in C9ORF72 
(DeJesus-Hernandez et al 2011, Renton et al 2011) (Section 1.2.5.4). Briefly, in vitro 
transcribed 3’ biotinylated molecules of RNA containing 5X repeats of the GGGGCC 
sequence (AAAAUU for the control experiments) were pre-incubated with protein 
extracts derived from post-mortem cerebellar granule neurones or human neuronal 
SH-SY5Y cell lines (Cooper-Knock et al 2014b); including, both cellular lysates, and 
nuclear separated fractions prior to irradiation with UV light. The RNA-protein com-
plexes which form are captured with streptavidin Sepharose® and eluted by RNase 
digestion. Peptide products are then analysed using mass spectrometry. Across the 
three different extracts (i.e. total, nuclear and cerebellum), this approach identified 
103 unique protein species including forty which are encoded by genes found to be 
dysregulated in the ECACC C9ORF72vctrl analysis of the LCL’s [Partek® unadjusted 
p<0.05, FC ≥ ±1.20] (Table 5.9). Nine candidates (EIF4H, PURA, HNRNPA0, HNRNPF, 
HNRNPH2, NUDT21, FUS, RBM3 and RPL22) were selected for qRT-PCR using either 
traditional SYBR® Green technology (Section 2.3.1.6) or IDT PrimeTime® Mini qPCR 
Assays (Section 2.3.2.6.6). Of these nine, 77.8% (n=7/9) validated including purine-
rich element binding protein A (PURA) (p<0.01**) (Figure 5.26), HNRNPA0 (p<0.01 
**), FUS (p<0.01**), NUDT21 (p<0.01**) (Figure 5.12), HNRNPF (p<0.01**) (Figure 
5.13) (Section 5.2.1.3.3), EIF4H (p<0.001***) and RPL22 (p<0.01**) (Section 5.2.1.4. 
1) (Figure 5.15). HNRNPH2 was not significant (Section 5.2.1.3.3) (Figure 5.13) and 
for RBM3 a small trend in the same direction as the microarray was observed (Figure 
5.12) (Section 5.2.1.3.3). 




Symbol Gene Name Direction Fold p-value Nuclear Cerebellum Total Reference 
ATP5B*** ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta polypeptide 
⇧ 1.11 0.013   X 
 
CALM1 calmodulin 1 (phosphorylase kinase, delta) ⇧ 1.24 3.01E-03  X   
CPSF6*** cleavage and polyadenylation specific factor 6, 68kDa ⇩ 1.12 8.08E-04   X  
DNAJC9 DnaJ (Hsp40) homolog, subfamily C, member 9 ⇧ 1.22 0.012   X  
EIF4H eukaryotic translation initiation factor 4H ⇧ 1.31 5.01E-03   X  
FUS fused in sarcoma ⇧ 1.23 7.50E-04 X X X (Mori et al 2013b)  
HDGFRP3 hepatoma-derived growth factor, related protein 3 ⇧ 1.49 1.56E-03  X   
HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 ⇧ 1.23 2.35E-07 X    
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 ⇧ 1.09 0.038 X  X (Mori et al 2013b) 
HNRNPAB heterogeneous nuclear ribonucleoprotein A/B ⇧ 1.26 6.49E-05 X    
HNRNPD heterogeneous nuclear ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 37kDa) 
⇧ 1.19 2.65E-04 X 
   
HNRNPF heterogeneous nuclear ribonucleoprotein F ⇧ 1.22 6.15E-04 X  X  
HNRNPH2 heterogeneous nuclear ribonucleoprotein H2 (H’) ⇧ 1.28 0.024 X  X (Lee et al 2013b)  
HNRNPR heterogeneous nuclear ribonucleoprotein R ⇧ 1.19 7.78E-04 X X  (Mori et al 2013b) 
HNRNPUL1 heterogeneous nuclear ribonucleoprotein U-like 1 ⇧ 1.12 3.20E-03   X  
HMGA1*** high mobility group AT-hook 1 ⇧ 1.16 0.011 X    
ILF2 interleukin enhancer binding factor 2, 45kDa ⇧ 1.19 1.52E-03 X X  (Mori et al 2013b) 
MYH9*** myosin, heavy chain 9, non-muscle ⇩ 1.08 0.040   X  
MYL6*** myosin, light chain 6, alkali, smooth muscle and non-
muscle 




NACA*** nascent polypeptide-associated complex alpha subunit ⇧ 1.18 0.017   X  
NCL nucleolin ⇧ 1.13 0.015 X X X  
NPM1*** nucleophosmin (nucleolar phosphoprotein B23, numatrin) ⇧ 1.06 0.034   X  
NUDT21 nudix (nucleoside diphosphate linked moiety X)-type motif 
21 












(Sareen et al 2013, 
Xu et al 2013)  
PURB*** purine-rich element binding protein B ⇧ 1.14 0.020  X X  
RBM3 RNA binding protein motif (RNP1, RRM) protein 3 ⇧ 1.22 9.22E-05 X  X  
RPL22*** ribosomal protein L22 ⇧ 1.40 1.06E-04   X  
SEPT2 septin 2 ⇧ 1.10 7.82E-03   X  
SERBP1 SERPINE1 mRNA binding protein 1 ⇧ 1.11 0.027   X  
SFPQ splicing factor proline/glutamine-rich ⇧ 1.14 0.028 X   (Mori et al 2013b)  
SFRS3 serine/arginine-rich splicing factor 3 ⇧ 1.20 0.015  X   
SRP14*** signal recognition particle 14kDa (homologous Alu RNA 
binding protein) 




TAF15 TAF RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 60kDa 




THOC4 THO complex 4 ⇧ 1.17 0.027   X  
TRMT112*** tRNA methyltransferase 11-2 homolog (S. cerevisiae) ⇧ 1.14 0.017   X  
U2AF2 U2 small nuclear RNA auxiliary factor 2 ⇧ 1.19 1.76E-03 X  X  
XRCC6 X-ray repair complementing defective repair in Chinese 
hamster cells 6 
⇩ 1.16 0.011 X  X 
 
YWHAG tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide 




YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide 




Total     15 12 27  
 
Table 5.9 RNA Pull-Down List of MW Predicted GGGGCC(5) Binding Partners (n=40/103) which are Differentially Expressed in C9ORF72+ LCL’s from the 
ECACC Microarray Study [Partek® unadjusted p<0.05, FC ≥ ±1.20] C9ORF72 specific gene expression changes not detectable in nonC9ORF72-related_SALS cases 
or neurologically normal, healthy control subjects are denoted by three asterisks inserted immediately after the gene symbol in column 1. Candidates taken forward 
for qRT-PCR validation are shaded in grey.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 72, ECACC - European Collection of Cell Cultures, FC - fold-change, 












Figure 5.26 PURA qRT-PCR Validation Relative concentrations were 
measured against the standard housekeeping gene 18SrRNA. Means 
and SEM plotted in GraphPad® Prism software version 5.04 copyright 
© 1992-2014 (GraphPad Software Inc., USA). Probability values were 
calculated in Microsoft Excel 2010 (Microsoft Corporation, UK) with a 
one tailed student’s t-test applied. Gene expression changes confirmed 
if the direction of change (arrow) was the same as the microarray with 
p<0.05* (p<0.01**). 
 
Abbreviations: 18SrRNA - 18S ribosomal RNA, C9ORF72 - chromosome 
9 open reading frame 72, PURA - purine-rich element binding protein 
A, qRT-PCR - quantitative real-time PCR and SEM - standard error of 
the mean.   
 
  
RNA binding partners were also predicted to be aberrantly spliced in the ECACC LCL 
analysis of C9ORF72vctrl (Table 5.10) [Partek® unadjusted p-value (fold-change) ≥ 
0.05 and p-value (alt. splicing) <0.05]. These were comprised of: calmodulin 1 (CAL 
M1), a murine biomarker of ALS in the SOD1G93A transgenic animal model (Calvo et al 
2012) [AS-ANOVA p<0.0001]; heterogeneous nuclear ribonucleoprotein H1 (HNRNP 
H1) [AS-ANOVA p<0.01] and H3 (2H9) (HNRNPH3) [AS-ANOVA p<0.05]; chromatin 
architectural factor high mobility group AT-hook 1 (HMGA1) (Malini et al 2011, Sga-
rra et al 2010) [AS-ANOVA p<0.05]; cell-cycle regulated SFRS protein kinase 2 (SRP 
K2) [AS-ANOVA p<0.05]; splicing factors, arginine/serine-rich 1 (SF2) (SFRS1) [AS-
ANOVA p<0.01], 2 (SC35) (SFRS2) [AS-ANOVA p<0.0001], 5 (Srp40) (SFRS5) [AS-AN 
OVA p<0.0001] and 7, 35kDa (9G8) (SFRS7) [AS-ANOVA p<0.0001]; actin filament 
binding protein tropomyosin 2, beta (TPM2) [AS-ANOVA p<0.001] and transcription-
al co-activator PC4 and SFRS1 interacting protein 1 (PSIP1) [AS-ANOVA p<0.0001], 
that stimulates homologous recombination, as well as mechanisms of DSB repair, to 








Symbol Gene p-value (alt.splicing) Nuclear Cerebellum Total Reference 
CALM1*** calmodulin 1 (phosphorylase kinase, delta) 9.71E-09  X   
HMGA1*** high mobility group AT-hook 1 0.049 X    
HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 (H) 4.18E-03 X X X  
HNRNPH3 heterogeneous nuclear ribonucleoprotein H3 (2H9) 1.56E-03 X  X  
PSIP1 PC4 and SFRS1 interacting protein 1 2.04E-07  X   
SFRS1 splicing factor, arginine/serine-rich 1 (splicing factor 2, 
alternate splicing factor) 
9.94E-03 X X X (Reddy et al 2013)  
SFRS2 splicing factor, arginine/serine-rich 2 6.22E-05 X X X (Lee et al 2013b)  
SFRS5*** splicing factor, arginine/serine-rich 5 8.59E-14   X  
SFRS7 splicing factor, arginine/serine-rich 7, 35kDa 6.17E-06  X   
SRPK2 SFRS protein kinase 2 0.047  X   
TPM2 tropomyosin 2 (beta) 1.97E-04   X  
Total   5 7 6  
 
Table 5.10 RNA Pull-Down List of MW Predicted GGGGCC(5) Binding Partners (n=11/103) which are Aberrantly Spliced in the C9ORF72+ LCL’s from the 
ECACC Microarray Study [Partek® unadjusted p-value (fold-change) ≥0.05 and p-value (alt. splicing) <0.05] C9ORF72 specific alternative splicing events not 
detectable in nonC9ORF72-related_SALS cases or neurologically normal, healthy control subjects are denoted by three asterisks inserted immediately after the gene 
symbol in column 1.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 72, ECACC - European Collection of Cell Cultures, LCL - lympho-







Graphical representations from the easyExon 1.0.4 Java-based platform copyright © 
2006 to 2014 (National Yang-Ming University, Taiwan) (Chang et al 2008) of CALM1, 
SRPK2, SFRS5, SFRS7 and HNRNPH1 are illustrated in Figure 5.27. Again, changes in 
mean probeset signal intensities between different sample types [C9ORF72+ (Red) 
and Ctrl (Blue)] appeared modest and with large values for the SEM, it was decided 
not to pursue selected targets for qRT-PCR validation (Section 5.2.2).                 
 
5.3 DISCUSSION               
5.3.1 Frequency of the G4C2 Repeat in a Large Caucasian Cohort  
Patient derived LCL’s [120-FALS and 500-SALS] selected from the National MNDA 
DNA Bank, which were later recruited to the ECACC discovery (n=370) (Section 4. 
1.1) and replication (n=250) (Section 4.1.2) cohorts were screened for the C9ORF72 
expansion, using the repeat-primed PCR method described by Renton et al (2011); 
with a minor adjustment made to the ratio of forward, reverse and anchor primers 
(Cooper-Knock et al 2012b). G4C2 repeat lengths of more than 30 copies were de-
tected at an overall frequency of 14.4% (n=89/620), incorporating 40.8% of FALS 
(n=49/120) [42-FALS, 1-FALS+PD and 6-PBP (familial)] and a further 8.2% of SALS 
(n=41/500) [40-SALS and 1-PBP (sporadic)]. These figures were consistent with a 
number of previously published statistics for other Caucasian populations from the 
Northern States of America and Canada (DeJesus-Hernandez et al 2011) or Western 
Europe including: Italy (Xi et al 2012); Belgium (Debray et al 2013, Gijselinck et al 
2012, Renton et al 2011, van Rheenen et al 2012); Germany (Majounie et al 2012); 
Spain (Garcia-Redondo et al 2013) and the UK (Beck et al 2013, Cooper-Knock et al 
2012b). Global incidence rates vary but have generally been considered to be high-
est in Scandinavia [Finland 46.4% of FALS (n=52/112) and 21.1% of SALS (n=61/ 
289); Sweden 57.1% of FALS (n=8/14) and 12.2% of SALS (n=9/74) (Majounie et al 
2012, van der Zee et al 2013)] and lowest across Asia and the Far East [China 6.7% 
of FALS (n=1/15) and 0.9% of SALS (n=1/113); Japan 3.4% of FALS (n=2/58) and 
0.4% of SALS (n=2/552) and Taiwan 18.2% of FALS (n=4/22) and 2.0% of SALS (n 
































Figure 5.27 Graphical Representations of C9ORF72+ GGGGCC(5) RNA Binding Partners Top 5 
Most Significant Aberrant Splicing Events [Partek® unadjusted p-value (fold-change) ≥0.05 
and p-value (alt. splicing) <0.05] Lists of AS transcripts predicted in Partek® Genomics SuiteTM 
software version 6.6 copyright © 2013 (Partek® Inc., St Louis, MO, USA). The mean probeset signal 
intensities and SEM were plotted using the easyExon 1.0.4 Java-based platform copyright © 2006 to 
2014 (microarray.ym.edu.tw/easyExon) (National Yang-Ming University, Taiwan) (Chang et al 2008).  
 




al 2012, Zou et al 2013b)]. 
The minor allele (A) of surrogate marker rs3849942 and a 42- or 82-SNP haplotype 
commonly shared by G4C2 repeat carriers of all ethnicities has led to the hypothesis 
that the expansion has descended from a single common ancestor originating from 
Finland around 500 A.D. (i.e. ~100 to 250 generations ago which roughly coincides 
with the fall of the Roman empire and the start of the Viking’s invasion of Europe), 
rather than recurrent de novo mutations having occurred throughout history (Mok 
et al 2012, Pliner et al 2014, Smith et al 2013).                    
 
5.3.2 C9ORF72 and Mutations in Other ALS-FTLD Causative Genes
The frequent observation of incomplete penetrance in ALS-FTLD pedigrees with an 
apparent AD mode of transmission provides evidence which supports an oligogenic 
model of the disease (van Blitterswijk et al 2012a). There have been several reports 
in the literature of patients carrying more than one mutation in multiple ALS-FTLD 
causative genes. C9ORF72 for example has been found in combination with TARDBP 
in <2.0% of cases (Chio et al 2012c), FUS or SOD1 in <0.9% of cases (van Blitterswijk 
et al 2012a) and OPTN in ~0.4% of cases (Cooper-Knock et al 2012b, Millecamps et 
al 2012); among others listed in Table 5.11, relating to ALS, and in combination with 
TARDBP in 1.3% of cases (Kaivorinne et al 2014), PSEN2 in 1.9% of cases (Ferrari et 
al 2012), PGRN in 1.4% of cases (Lashley et al 2014, Mignarri et al 2014) and MAPT 
in 0.5% of cases (King et al 2013, van Blitterswijk et al 2013b) relating to FTLD. 
Across the ECACC discovery (Section 4.1.1) and replication (Section 4.1.2) cohorts of 
LCL’s there were two examples of oligogenic inheritance including: One involving a 
single C9ORF72+ FALS patient with an OPTN mutation which occurs at a higher than 
previously reported frequency of 0.8% (Section 5.3.2.1) (Cooper-Knock et al 2012b) 
and a second involving an C9ORF72+ SALS patient with an TARDBP mutation which 
occurs at a lower than previously reported frequency of 0.2% (Section 5.3.2.2) (Chio 
et al 2012c). Concurrence of the G4C2 repeat with a second genetic variant of patho-
logical significance in ALS and/or FTLD is predicted to have arisen at a much greater 
incidence than what would ordinarily be expected by chance (p=1.6x10-7) (van Blit-




 Frequency Reference(s)  Comments 
ALS Loci    
Common Co-occurrences 
TARDBP ~1.5-1.8% (Chio et al 2012c) (Section 1.2.5.2.1) 
VAPB 0.9%  (van Blitterswijk et al 2012b) (Section 1.2.5.1.5) 
FUS <0.9% (van Blitterswijk et al 2012a)  (Section 1.2.5.2.2) 
SOD1 <0.9% (van Blitterswijk et al 2012a)  (Section 1.2.5.1.1) 
Rarer Co-occurrences 
ANG ~0.2-1.1% (Williams et al 2013)  (Section 1.2.5.2.3) 
OPTN 0.4% (Cooper-Knock et al 2012b, 
Millecamps et al 2012)  
(Section 1.2.5.1.7) 
UBQLN2 0.4%  (Kenna et al 2013) (Section 1.2.5.2.6) 
CHMP2B 0.2% (Kenna et al 2013)  (Section 1.2.5.2.8) 
    
FTLD Loci    
PSEN2 1.9%  (Ferrari et al 2012) (Section 1.2.5.3.3) 
PGRN 1.4% (Lashley et al 2014, Mignarri 
et al 2014)  
(Section 1.2.5.3.2) 
TARDBP 1.3% (Kaivorinne et al 2014)  (Section 1.2.5.2.1) 
MAPT 0.5% (King et al 2013, van 
Blitterswijk et al 2013b)  
(Section 1.2.5.3.1) 
 
Table 5.11 Oligogenic Frequencies of the C9ORF72 G4C2 Repeat Expansion in 
ALS and FTLD 
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, ANG - angiogenin, C9ORF72 - 
chromosome 9 open reading frame 72, CHMP2B - charged multivesicular protein 
2B, FTLD - frontotemporal lobar degeneration, FUS - fused in sarcoma, MAPT - 
microtubule associated protein tau, OPTN - optineurin, PGRN2 - progranulin 2, 
PSEN2 - presenilin 2, SOD1 - copper/zinc superoxide dismutase 1, TARDBP - trans-
active response (TAR) DNA binding protein, UBQLN2 - ubiquilin 2 and VAPB - 
vesicle associated membrane protein (VAMP) associated protein B.  
 
 
many previously published studies (Blasco et al 2013, Hewitt et al 2010, Kuhnlein et 
al 2008b) have routinely excluded cases where there is a known mutational change 
from any further genetic screening (Sreedharan et al 2008).                
                           
5.3.2.1 C9ORF72 and OPTN  
Sheffield patient [F056-(SP3462)] is one of the familial ALS cases known to carry the 
expansion in C9ORF72 which was also identified as having a heterozygous c.964G>A 
(p.E322K) missense mutation in exon 10 of the OPTN gene. The single base substit-
ution is localised to a highly conserved coiled-coil region of the mature peptide seq-
uence (Bury et al 2015). In silico analysis predicts that a switch at the position of the 




and basic residue, lysine would serve to decrease overall stability and is likely to be 
pathogenic. Although initially reported as a non-synonymous SNP, the minor allele 
(A) of rs523747 (Sugihara et al 2011) has only been found very infrequently across 
Sub-Saharan Africa: 0.028 Yoruba in Ibadan, Nigeria (YRI) (n=5/176); 0.062 Luhya 
in Webuye, Kenya (LWK) (n=12/194). The change could not be detected in 375 age 
and gender matched neurologically normal, healthy control subjects screened from 
the North of England (Bury et al 2015) or 180 (Utah) residents (CEU reference pop-
ulation) with ancestry from Northern and Western Europe. It was also absent from 
Han Chinese, Beijing (CHB) and Japanese, Tokyo (JPT) populations attained as part 
of the International HapMap or 1000Genomes Project.  
The female index case had a strong family history of MND and dementia. Her father, 
aged 74yrs, and a male paternal cousin aged 34yrs, were both known to be affected. 
The proband [F056-(SP3462)] was a non-smoker. She presented at fifty with a pre-
dominantly bulbar phenotype and symptoms of EL. Signs of dysarthria & dysphagia 
also developed, 6 months prior to the individual having received a formal diagnosis 
of ALS (Section 1.1.3). Despite treatment with Riluzole, contiguous advancement led 
to severe muscle wasting and paralysis which eventually culminated in respiratory 
failure and death approximately 2½ years after the initial onset of disease.     
The neuropathology of this case closely resembled that of “classical ALS” (Section 1. 
1.5.1) with the presence of ubiquitinated, p62 and TDP-43 positive inclusion bodies 
within residual MN’s of the primary motor cortex, brainstem and AH of the SC (Bury 
et al 2015). In less abundance, there were also a number of OPTN immunoreactive, 
p62 positive, but TDP-43 negative skein-like or compact inclusions, described else-
where by Maruyama et al (2010) and Hortobagyi et al (2011); concentrated within 
the frontal neocortex, hippocampus and cerebellum. These were found to colocalise 
with approximately 5% of aggregated poly-GA DPR proteins, produced by the RAN 
mediated translation of sense and antisense C9ORF72 transcripts (Bury et al 2015) 
(Ash et al 2013, Mackenzie et al 2014, Mori et al 2013c, Proudfoot et al 2014). OPTN 
labelling was also apparent in 10 of 12 G4C2 repeat carriers without a mutation and 
in two FALS cases including: One individual with a heterozygous c.338T>C (p.I133T) 
missense substitution in exon 4 of SOD1 (Ince et al 1996) (Section 1.2.5.1.1) and a 




of FUS (Hewitt et al 2010) (Section 1.2.5.2.2). Therefore, OPTN immunostaining is 
not necessarily specific for OPTN mutation carriers.   
The c.964G>A (p.E322K) mutation has also been identified in two Caucasian siblings 
from a German ALS and glaucoma pedigree who were reported to carry, on the same 
allele, a second non-synonymous variant in OPTN [rs11258194 c.293T>A (p.M98K) 
found at a frequency of 6.7% (n=6/90) in the North of England; situated in the Rab8 
binding site of the coiled coil I domain (Bury et al 2015)], in addition to, a previously 
established heterozygous c.1055A>G (p.N352S) missense substitution in exon 5 of 
TARDBP (Weishaupt et al 2013) (Section 1.2.5.2.1). The female index case initially 
presented with elevated intraocular pressure (IOP); though this later turned out to 
be normal. At the age of 39 she developed progressive descending tetraparesis that 
began in the right upper limb with symptoms of mild bulbar involvement, abnormal 
deep tendon reflexes, fasciculations and severe muscular atrophy, in the absence of 
overt cognitive impairment. Respiratory function deficits were also prominent with 
NIPPV support (Section 1.1.4) being required for a minimum of 18 hours daily after 
the first 7 years. The patient and her brother, who so far has remained healthy, are 
still reported to be alive at the age of 52 and 57yrs, respectively. Consequently, there 
was no autopsy material available for conducting neuropathological investigations 
(Weishaupt et al 2013).  
 
5.3.2.2 C9ORF72 and TARDBP  
A second Sheffield patient [S352-(SP3484)] with an apparently sporadic form of the 
disease was also known to carry the C9ORF72 expansion (Section 4.1.2.3) in addition 
to a novel heterozygous c.962C>T (p.A321V) missense substitution in exon 6 of the 
TARDBP gene (Kirby et al 2010). The alanine to valine change at the position of the 
321st amino acid was predicted to be pathological from in silico analysis and is also 
known to occur within a highly conserved C-terminal glycine rich domain that binds 
several of the hnRNP proteins, namely A0 (⇧1.23-fold, p<0.001), A2B1 (⇧1.09-fold,  
p<0.05) and R (⇧1.19-fold, p<0.001) (Table 5.10); reported to be up-regulated in the 
microarray (Section 5.2.4) and qRT-PCR (Figure 5.12) analyses of C9ORF72-related 




et al 2014, He et al 2014, Yu et al 2012). Functional studies were conducted in vitro 
using p.G287S, A321V and M337V affected patient (n=3) and control (n=6) derived 
fibroblast cell cultures to measure the abundance of CDK6 (cyclin-dependent kinase 
6) specific mRNA transcripts in response to WT or mtTDP-43 protein. A significant 
increase in the level of CDK6 (p<0.05) was observed in patient fibroblasts compared 
to controls suggesting normal repression of CDK6 transcription had been impaired 
(Kirby et al 2010).  
The female index case reported no prior family history of MND or dementia. Both of 
her parents died of malignancy and her two remaining siblings, aged 37 and 41yrs, 
respectively were healthy at the time of the initial study; although the youngest has 
since received a diagnosis of ALS. The proband [S352-(SP3484)] was a non-smoker. 
She presented at thirty-seven with progressive weakness and loss of dexterity in the 
left-hand. EMG recordings established more widespread denervation consistent with 
a diagnosis of MND. Towards the advanced stages of the disease the individual also 
developed signs of dyspnoea. Riluzole was being administered, in combination with 
Vitamin E supplements, for 4 years 9 months before the onset of respiratory failure 
which culminated in her death at the age of forty-two. Clinically overt symptoms of 
cognitive or behavioural dysfunction were distinctly lacking in this case which is un-
common in instances involving a hexanucleotide G4C2 repeat expansion in C9ORF72. 
Since the individual in question was screened from cases in the local Sheffield Blood 
Bank it meant post-mortem material was unavailable for neuropathological invest-
igation (Kirby et al 2010). 
One interesting remark that was also observed by Chio et al (2012c) is with respect 
to an emerging theme in which individuals who have acquired an oligogenic form of 
inheritance are more likely to become symptomatic at an earlier age. In the ECACC 
LCL’s, patient carriers of two or more mutations in ALS-FTLD causative genes were 
on average 17½ years younger [43½ versus 61yrs (two-tailed student’s t-test p=0. 
041)] than the mean of the nonC9ORF72-related_SALS cases and ~12½ years young-
er than the mean of the C9ORF72 FALS and SALS cases combined. Although [F056-
(SP3462)] and [S352-(SP3484)] represent only a small sample size of (n=2) it does, 




etic burden can act as a modifier of disease severity/progression (Chio et al 2012c, 
van Blitterswijk et al 2013b).         
 
5.3.3 Clinical Features Relating to the C9ORF72 Phenotype 
Expression ConsoleTM assessment of post-hybridization QC parameters (Table 5.2) 
(Section 5.1.2) of C9ORF72+ LCL’s recruited to the ECACC discovery cohort, as well 
as, selected samples from the ECACC replication cohort [i.e. meeting the criteria for 
inclusion into Chapter 6: ‘C9ORF72 Survival Study’] resulted in 38 individuals being 
included in the final microarray analysis, along with an additional 56 nonC9ORF72-
related_SALS cases and 26 neurologically normal, age and gender matched, healthy 
controls (Table 5.1). A discussion of technical tissues relating to the storage, handl-
ing and processing of peripheral EBV-transformed B-lymphocytes (LCL’s) for GEP is 
provided at the end of Chapter 4 (Section 4.4).          
Core presentations associated with the expansion, generally speaking, mimic those 
of “classical ALS” (Cooper-Knock et al 2012b, Gijselinck et al 2012, Murray et al 201 
1), bvFTLD or the combined ALS-FTLD syndrome (Section 1.2.1) (Cooper-Knock et 
al 2014a). Instances involving PLS (~0.5%) (Section 1.2.2.2) and PMA (<2%) (Sect-
ion 1.2.2.3) have been reported elsewhere in the literature but are exceedingly rare 
and were absent from the ECACC LCL’s (van Rheenen et al 2012). Approximately 50. 
0% of patient carriers are diagnosed with spinal onset ALS which is comparable to 
the proportion of sporadic cases and consistent with our findings (Table 5.1) (Woo 
llacott & Mead 2014). Several groups have observed a greater than expected incide-
nce of bulbar predominant involvement (Chio et al 2012a, Cooper-Knock et al 2014a, 
Debray et al 2013, Ratti et al 2012, Snowden et al 2013, Stewart et al 2012). Howe-
ver, this has not always been the case and could not be replicated in the ECACC LCL’s 
(Table 5.1) (Byrne et al 2012). A high prevalence of cognitive and behavioural impa-
irment, with or without a family history of dementia, is anticipated in C9ORF72-relat 
ed versus nonC9ORF72-related ALS (Boeve et al 2012, Byrne et al 2012, Cooper-Kno 
ck et al 2012b, Garcia-Redondo et al 2013, Gijselinck et al 2012, Millecamps et al 20 
12, Sabatelli et al 2012). Although this was not necessarily true of the LCL’s our con-




London cases (Section 5.1.1.1); which collectively comprised one third of the cohort. 
There are also reports of a higher than expected chance of other motor and extram-
otor phenotypes associating the with the C9ORF72 expanded repeat including ALZ 
(<1%) (Section 1.4.1.2.3) (Kohli et al 2013) and PD (~4%) (Section 1.2.1) (Cooper-
Knock et al 2013a). Normally a slight male preponderance is apparent is cases invo-
lving “classical ALS” with M:F ratios ranging between 1.2 and 1.5:1 (Section 1.1.2) ( 
Leblond et al 2014). Conversely, in C9ORF72+ familial and apparently sporadic ALS 
patients this has been shown to be closer to 1.00:1 (Woollacott & Mead 2014) with 
marginally more females than males having been identified in the familial LCL’s of 
the ECACC microarray cohort (Table 5.1).          
In comparison to nonC9ORF72-related_SALS, LCL carriers of >30 copies of the G4C2 
repeat were symptomatic at an earlier age [Average 56±10.9yrs versus 61±11.9yrs 
(student’s t-test p<0.05*)] which supports the previously published findings of By-
rne et al (2012), Cooper-Knock et al (2012b), Garcia-Redondo et al (2013) and Xi 
et al (2012). In the ECACC microarray cohort the largest effect size was observed for 
the female patients [Average 52±12.1yrs versus 64±12.3yrs (student’s t-test p<0.01 
**)] with no significant difference reported for the male patients [Average 60±7.7yrs 
versus 59±11.3yrs (student’s t-test p>0.05)]. A gender bias has also been described 
in a study conducted by Williams et al (2013); albeit in the reverse direction with an 
earlier age at symptom onset recorded for male C9ORF72-related versus nonC9ORF 
72-related ALS cases. In addition there have been several reports in the literature of 
the G4C2 repeat being associated with a shorter survival (Byrne et al 2012, Cooper-
Knock et al 2012b, Debray et al 2013, Garcia-Redondo et al 2013, Irwin et al 2013, 
Millecamps et al 2012, Ratti et al 2012, Stewart et al 2012). In the ECACC LCL’s, this 
was the case across all of the C9ORF72+ (n=89) and nonC9ORF72-related_SALS (n= 
531) patients in the discovery and replication cohorts combined [Hazard ratio 0.85 
(95% CI 0.68-1.08) with Median survival of 29 months for C9ORF72+ FALS and SALS 
and 34 months for nonC9ORF72-related_SALS (Wilcoxon t-test p=0.009)] [APPEND 
IX FIGURE B1] but was not the case for selected samples in the C9ORF72 (n=38) and 
nonC9ORF72-related_SALS (n=56) study [Hazard ratio 0.89 (95% CI 0.59-1.33) with 
Median survival of 24 months for C9ORF72+ FALS and SALS and 27 months for non 














Figure 5.28 Kaplan-Meier Survival Curve for LCL’s in the ECACC C9ORF72 
(Red) and NonC9ORF72-Related_SALS (Blue) Study  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 
open reading frame 72, ECACC - European Collection of Cell Cultures, LCL - 
lymphoblastoid cell line and S - sporadic.  
  
 
5.3.4 Microarray Profiles Associated with the G4C2 Repeat 
On the Affymetrix Human Exon 1.0ST GeneChip® Arrays an overall up-regulation in 
the level of gene transcription was apparent with 650 (59.3%) of 1,096 [unadjusted 
p<0.05, FC ≥ ±1.20] or 755 (64.4%) of 1,173 [ANOVA F-test p<0.05, FC ≥ ±1.20] DE 
transcripts detected using Partek® Genomics SuiteTM (Section 5.2.1.1.1) and Qlucore 
Omics Explorer (Section 5.2.1.5.1) exhibiting an significant increase in expression in 
the immortalised EBV-transformed B-lymphocytes (LCL’s) of C9ORF72+ FALS (n=18) 
and SALS (n=20) patients compared to a subset of 26, age as well as gender, matched 
neurologically normal, healthy control subjects selected from the ECACC discovery 
cohort. These gene lists were almost identical with a 90% overlap portrayed by the 
GeneVenn diagram depicted in Figure 5.16 (Section 5.2.1.5.1). Such a high degree of 
concordance increases our confidence that the algorithms deployed by each of these 
computational analyses programs produces consistent and reliable readouts which 
reflect biologically meaningful alterations in gene expression and not just artifactual 
findings associated with the different sample types. In DAVID, functional annotation 




Translation (GO: 006412) (Section 5.2.1.4) as the top two most highly enriched gene 
ontology categories with EASE scores of 7.5 or above and FDR corrected probability 
values below 10-08 [Partek® Genomics SuiteTM (Table 5.3); Qlucore Omics Explorer 
(Table 5.7)]. 
Among the transcripts highlighted were a significant proportion of those encoding 
RRM containing proteins predicted to bind the G4C2 repeat [n=40/103 identified in 
an RNA pull-down assay performed by Dr Matthew Walsh and colleagues from the 
University of Sheffield (Table 5.10) (Section 5.2.4)]. These comprised several of the 
hnRNP proteins (n=8/40) [HNRNPA0 (⇧reg) (p<0.01**) and HNRNPF (⇧reg) (p<0.01 
**) confirmed in the ECACC LCL’s by qRT-PCR between pooled C9ORF72+ cases and 
control samples (Figure 5.12)] in addition to the ALS causative gene FUS (Section 1. 
1.8.2.2) (⇧reg) which was also confirmed in the ECACC LCL’s by qRT-PCR (p<0.01**) 
and further validated by western blot analysis in a similar assay conducted by Mori 
et al (2013b) using nuclear extracts derived from human embryonic kidney (HEK-
293) cell lines. The authors also corroborated four more candidate binding partners 
of C9ORF72 including: HNRNPA2B1 (⇧1.09-fold, p<0.05) and R (⇧1.19-fold, p<0.001) 
with genetic alterations in the former, PrLD, having recently been implicated in the 
pathogenesis of ALS and MSP (Table 1.2) (Section 1.2.5.2.10); interleukin enhancer 
binding factor 2, 45kDa (ILF-2) [ILF2 ⇧1.19-fold (p<0.01) C9ORF72vctrl; ⇧1.13-fold 
(p<0.01) nonC9ORF72-related_SALSvctrl] which forms the minor constituent of the 
nuclear factor of activated T-cells (NFAT) complex (Karmakar et al 2010, Kiesler et 
al 2010) [a heterodimeric association between the ILF-2 (NF45) and ILF-3 (NF90) 
transcription factors found, through its association with the DNA-dependent protein 
kinase (DNA-PK), to be important in modulating non-homologous end joining (NHEJ) 
during the repair of DSB (Shamanna et al 2011)] and a second DNA damage response 
protein, polypyrimidine tract binding (PTB)-associated splicing factor (PSF) [SFPQ 
(splicing factor proline/glutamine rich) ⇧1.14-fold (p<0.05) C9ORF72vctrl; ⇧1.24-
fold (p<0.001) nonC9ORF72-related_SALS vctrl] (Ha et al 2011, Krietsch et al 2012, 
Rajesh et al 2011, Salton et al 2010) which has been demonstrated in vivo using the 
zebrafish ortholog (whitesnake) (Lowery et al 2007) to be essential for cell survival 
and brain organogenesis throughout normal embryonic development.  




vctrl; not significant in a PrimeTime Mini qPCR Assay (Figure 5.12)] and F [HNRNPF 
⇧1.22-fold (p<0.001) C9ORF72vctrl; up-regulation confirmed in a traditional SYBR 
Green qRT-PCR Assay (Figure 5.12)] were demonstrated by RNA fluorescence in situ 
hybridization (FISH) and immunohistochemistry (IHC) to co-localise with up to 30% 
(Cooper-Knock et al 2014b) or 70% (Lee et al 2013b), respectively of the G4C2 repeat 
containing intranuclear RNA foci detected in human post-mortem cerebellum tissue 
derived from a minimum of three C9ORF72+ ALS and/or FTLD patients in each study. 
In the former instance, Cooper-Knock et al (2014b) also showed co-localisation of hn 
RNPH1/F with ~20% of G4C2 repeat containing RNA foci identified in the residual 
MN’s of the ventral horn of the SC [i.e. the most vulnerable neuronal cell population 
susceptible to degeneration in ALS (Morrison et al 1996)].  
Lee et al (2013b) proceeded to transfect neuroblastoma SH-SY5Y cell lines with enh-
anced green fluorescent protein (EGFP) tagged expression vectors containing either 
8X (control), 38X or 72X constructs of the C9ORF72 intronic G4C2 repeat in which a 
positive correlation was observed between the size of the expansion and the amount 
of RNA foci that had formed. RNase/DNase treatment proved ineffective in ablating 
these toxic accumulations; consistent with an earlier finding that the hexanucleotide 
repeat can form stable stem-loop structures in the DNA sequence which are capable 
of generating uni- or multi-molecular RNA G-quadruplexes in vitro (Fratta et al 2012, 
Reddy et al 2013). In a time course experiment the authors witnessed a substantial 
reduction in the number of neuronal SH-SY5Y cells that contained RNA foci over a 
24 and 72hr period. Of the remaining cells which still expressed EGFP, analysis con- 
ducted using fluorescence-activated cell sorting (FACS), highlighted a three- (38X) 
and five- (72X) fold increase in the abundance of the apoptotic marker (annexin V) 
compared to the 8X control lines. Moreover, immunocytochemistry (ICC) also found 
activation of caspase 3 (CASP3) to be significantly enhanced in the presence of RNA 
foci induced by the expansion in neuronal SH-SY5Y cell lines. Accordingly, evidence 
of PARP cleavage was detected in cells transfected with the 38X or 72X constructs 
but not the 8X control lines. Interestingly, in the LCL’s both CASP3 [CASP3 (caspase-
3, apoptosis-related cysteine peptidase) ⇧1.42-fold (p<0.0001) C9ORF72vctrl and ⇧ 
1.30-fold (p<0.001) nonC9ORF72-related_SALSvctrl] and PARP9 [PARP9 (poly(ADP 




-fold (p<0.05) nonC9ORF72-related_SALSvctrl] were increased more in the C9ORF72 
-related cases than the nonC9ORF72-related_SALS cases, compared to controls. The 
findings of Lee et al (2013b) were further substantiated in vivo when the same EGFP 
tagged expression vectors were introduced into the zebrafish. Embryos injected with 
the 38X or 72X constructs were found to contain a considerably greater proportion 
of apoptotic cells than controls that were CASP3 active and which stained positively 
for the universal marker of DNA fragmentation, TUNEL (terminal deoxynucleotidyl 
transferase dUTP nick end labelling).  
Another binding partner identified by Dr Mathew Walsh, PURA [⇧1.20-fold, (p<0.01) 
C9ORF72vctrl; up-regulation confirmed in a traditional SYBR Green qRT-PCR Assay 
(Figure 5.26)] has also been recapitulated by Xu et al (2013), using in vitro and in vi-
vo model systems, to interact with the G4C2 repeat in a manner that is both dose-de 
pendent and sequence specific. In this study the authors transfected 3X (control) or 
30X (disease) constructs and EGFP-alone tagged expression vectors into the comm-
on fruit fly (Drosophila melanogaster) and mouse neuroblastoma (Neuro-2a) cell li-
ne. Thirty copies of the aberrantly expanded sequence in C9ORF72 proved sufficient 
to cause neurotoxicity and death, which is conserved between mammals and invert-
ebrates. Targeting 30X constructs to the retina in Drosophila severely affected eye 
morphology and locomotor activity, with ommatidia irregularities and loss of pigm-
entation. In addition, ubiquitinated p62 and TDP-43 positive inclusions immunore-
active for PURA were also shown to be present, as seen in human post-mortem der-
ived cerebellum tissue from patient carriers expressing the C9ORF72 expansion with 
FTLD-U pathology. Furthermore, overexpression of PURA in the fruit fly and Neuro-
2a model mitigated neurodegeneration associated with the G4C2 repeat and rescued 
cell viability. PURA is a transcriptional activator that is highly abundant in the brain 
and is known to play a prominent role in regulating the cell cycle and differentiation 
(White et al 2009). Recently, WES has revealed de novo mutations in PURA to be a 
genetic cause of neurodevelopmental delay and learning disabilities in children (n= 
4/1,133) screened as part of the Deciphering Developmental Disorders (DDD) UK 
study group (Hunt et al 2014), with other complications including: neonatal hypo-
tonia; seizures/seizure-like movements and difficulties in feeding.  




ed RNA editing regulator, adenosine deaminase, RNA-specific, B2 (ADARB2) [ADAR 
B2 ⇩1.36-fold, (p<0.05) C9ORF72vctrl; ⇩1.34-fold, (p<0.05) nonC9ORF72-related_S 
ALSvctrl] as one of 19 ORF’s on a custom proteome array, which exhibited a consist-
ly high affinity for the G4C2 expanded repeat (6.5X) in C9ORF72+ ALS patient derived 
skin fibroblast induced pluripotent stem cell (iPSC) differentiated MN’s in compari-
son to GC scrambled control lines. Sequestration of ADARB2 into toxic intranuclear 
RNA foci formed by the G4C2 repeat is expected to lead to a reduction in the rate of 
GluR2 AMPA receptor adenosine (A) to inosine (I) editing of the glutamine/argin-
ine (Q/R) site (Donnelly et al 2013); thereby conferring an increased susceptibility 
to excitotoxic stress (Hideyama et al 2012) (Section 1.2.4.2). 
 
5.3.5 Reduced C9ORF72 Expression Confirmed in a Subset of LCL’s 
A significant reduction in the abundance of isoform a (full length) [Variant I (NM_00 
1256054) and III (NM_018325) (Figure 5.22)] specific mRNA transcripts pertaining 
to the C9ORF72 gene was confirmed [⇩1.62-fold, (p<0.01) C9ORF72vctrl (Figure 5. 
24)] in a traditional SYBR® Green qRT-PCR Assay using an initial subset of the LCL’s 
(n=14) selected from the ECACC discovery cohort (Section 5.2.3) (Cooper-Knock et 
al 2013b). Other groups have also reported similar findings in human post-mortem 
derived frontal cortex and cerebellum tissue (Belzil et al 2013, Ciura et al 2013, DeJ-
esus-Hernandez et al 2010, Donnelly et al 2013, Gijselinck et al 2012, Waite et al 20 
14); which is supportive of a loss of function/haploinsufficiency mechanism of neu-
rotoxicity.  
In zebrafish and C. elegans models, antisense oligonucleotide mediated knockdown 
of the C9ORF72 ortholog in vivo has been shown to cause axonal degeneration of the 
MN’s leading to age-dependent motility deficits & hypersensitivity to environmental 
stress (Ciura et al 2013, Therrien et al 2013). Overexpression of human WT protein 
in the zebrafish was subsequently found to have ameliorated these effects (Ciura et 
al 2013). Several epigenetic events involving the trimethylation of specific lysine re- 
sidues in histone molecules H3 and H4 for example (Belzil et al 2013) or the hyper-
methylation of a cysteine-phosphate-guanine (CpG) island (Xi et al 2014, Xi et al 20 




rolling the negative regulation of C9ORF72 gene expression (Belzil et al 2014).  
Contrary to these findings, however, no observable difference in the overall levels of 
isoform a (full length) or isoform b (truncated) [Variant II (NM_145005) (Figure 5. 
22)] specific transcripts was apparent in an extended qRT-PCR assay using pooled 
RNA samples from the entire population of C9ORF72+ LCL’s with a RIN score of 7.5 
or above in the combined ECACC discovery and replication cohorts (n=75) (Figure 
5.25). Another study conducted by Sareen et al (2013) using C9ORF72+ ALS and ALS 
-FTLD patient and control (n=4) derived skin biopsy material to generate fibroblast 
cell lines and MN cultures differentiated from iPSC’s also failed to detect a significa-
nt change in the overall abundance of C9ORF72 mRNA transcripts (RNA-seq and qR 
T-PCR) [qRT-PCR primers designed in exon 2 to target all three transcript variants]    
or protein expression (western blot analysis). The use of an informative SNP, which 
was found to occur naturally within the population at a frequency of 17% (rs10757 
668), enabled the authors to distinguish between those sequences originating from 
the WT allele and those emanating from the expansion carrying allele in two of their 
C9ORF72 cases (Sareen et al 2013). Five prime rapid amplification of cDNA ends (5’-
RACE) identified predominantly exon 1b containing transcripts [Variant III (NM_01 
8325) (Figure 5.22)] in WT and control, versus, increased transcriptional start site 
variability and a greater proportion of exon 1a containing transcripts [Variant I (NM 
_001256054) and II (NM_145005) (Figure 5.22)] in the mutants. This paradoxical 
shift towards the transcription of variants containing the six base pair repeat is sup-  
portive of the notion that C9ORF72 mediated neurodegeneration may also arise thr-
ough a toxic gain of function as well as a loss of function mechanism. RNA FISH det-
ected aberrantly formed aggregates of >30 copies of the expanded G4C2 sequence in 
discrete & punctate nuclear RNA foci in approximately a fifth of C9ORF72+ ALS and 
and ALS+FTLD iPSC differentiated MN cultures which exhibited co-localisation with 
two previously discussed proteins of interest: Namely, hnRNPA1 a well-established 
binding partner of TDP-43 (Buratti et al 2005) that has recently been identified thr-
ough exome sequencing and linkage analysis (Kim et al 2013) to be a rare cause of 
AD inherited adult-onset ALS (ALS20) (Table 1.2) and MSP (Section 1.2.5.2.10) and 
PURA (Table 5.10) [⇧1.20-fold, (p<0.001) C9ORF72vctrl] which was confirmed by q 




Others have subsequently recognised RAN translation as an unconventional mode 
of protein synthesis that generates aggregate prone poly-GA (glycine-alanine), poly- 
GP (glycine-proline) or poly-GR (glycine-arginine) peptides which have been shown 
to colocalise with p62 positive, TDP-43 negative NCI’s in human post-mortem CNS 
tissue; a characteristic molecular hallmark of C9ORF72 pathology (Section 1.2.5.4) 
(Almeida et al 2013a, Ash et al 2013, Gendron et al 2013b). Furthermore, emerging 
evidence suggests that bidirectional transcription of the six base pair repeat occurs 
which would be responsible for producing bosh sense as well as antisense transcri-
pts and DPR’s (Gendron et al 2013a, Mori et al 2013a, Zu et al 2013).  
RNA foci and RAN translated products have also been linked to the pathogenesis of 
several other neurodegenerative conditions that are associated with a microsatellite 
repeat expansion including: Myotonic dystrophy type 1 (DM1) (Jiang et al 2004, Zu 
et al 2011); fragile X tremor/ataxia syndrome (FXTAS) (Tassone et al 2004, Todd et 
al 2013); Huntinton-disease like 2 (HDL2) (Rudnicki et al 2007) and spinocerebell-
ar ataxia type 8 (SCA8) (Chen et al 2009, Daughters et al 2009, Moseley et al 2006) 
(Wojciechowska & Kryzosiak 2011). In DM1 patients, for example, nuclear RNA foci 
containing CTG expanded dystrophia myotonica-protein kinase (DMPK) sequester a 
number of RNA binding proteins, including muscleblind-like regulator 1 (MBNL1) in 
order to disrupt their normal physiological function (Childs-Disney et al 2013, Myk-
owska et al 2011, Osborne et al 2009); leading to alterations in gene expression and 
a dysregulation of splicing.   
In summary, RNA processing appears to be a major pathway that has been shown to 
be disrupted in relation to the newly discovered intronic hexanucleotide G4C2 repeat 
expansion identified in C9ORF72. Transcriptional profiling of the ECACC LCL’s using 
Human Exon 1.0ST GeneChip® Arrays highlighted a significant increase in the overall 
expression of many of these genes in comparison to nonC9ORF72-related_SALS cases 
and controls. The up-regulation observed on the microarray could possibly reflect a 
compensatory mechanism in which the cells are trying to overcome sequestration of 
the C9ORF72 protein and RNA binding partners in toxic RNA foci that are known to 




CHAPTER 6: C9ORF72 SURVIVAL STUDY 
 
The principal aim of this chapter was to identify genetic factors which are associated 
with a fast (<2yrs survival) versus slow (≥4yrs survival) disease progression in the 
peripheral LCL’s of patients carrying a large, pathogenic hexanucleotide G4C2 repeat 
expansion in the newly identified C9ORF72 gene. As more microarrays were being 
run and as further clinical information from the MNDA became available throughout 
the course of the project additional cases from the ECACC discovery and replication 
cohorts, meeting the selection criteria outlined above, were included. Given recently 
emerging evidence from the SOD1G93A mouse (Alves et al 2011, Cervetto et al 2013, 
Gunther et al 2014, Heiman-Patterson et al 2005, Naumenko et al 2011) it was also 
of interest to determine whether there were any gender specific effects of survival 
on the global GEP’s of patients carrying the C9ORF72 expansion.                  
 
6.1 C9ORF72 Long versus Short Survival Cohort  
6.1.1 ECACC EBV-Transformed B-Lymphocytes  
6.1.1.1 Clinical Characteristics  
6.1.1.1.1 Control Cases  
Neurologically normal, age and gender matched, healthy control LCL’s (n=33/100) 
[19-M, 14-F] selected from the ECACC discovery cohort were largely recruited from 
patient partners or their unrelated carers (Section 4.1.1). These were comprised of 
10 Birmingham (30.3%) cases including one from Liverpool [C02-(BLi0245)], one 
from Oxford [C090-(BOx0073)] and one from Belfast City Hospital [C020-(BBe000 
6)]; 8 London (24.2%) cases including two from Cambridge [C019-(LCa0022) and 
C021-(LCa0076)], one from Poole General Hospital [C017-(LPo0027)] and one from 
Southampton General Hospital [C015-(LSh0032)] and 15 Sheffield (45.5%) cases 
including one from Manchester [C01-(SMa0033)], two from Preston [C010-(SPr00 




45), C029-(SNc0023), C076-(SNc0106) and C085-(SNc0035)]. Age at consultation 
ranged between 36 and 71 years with a mean of 58.1±10yrs. The M:F ratio was 1.36: 
1 (Figure 6.1).                    
 
  





 C9-Long C9-Short Control 
M:F 0.67:1 2.00:1 1.36:1 
Age  53.7±12yrs 58.4±11yrs 58.1±10yrs 
Total 15 27 33 
 
Figure 6.1 Age Frequency Distribution of Patient and Control 
LCL’s in the C9ORF72 Long (≥4yrs) versus Short (<2yrs) Survival 
Study 
 
Abbreviations: C9ORF72 (C9) - chromosome 9 open reading frame 72, 
Ctrl - control, F - female, LCL - lymphoblastoid cell line and M - male. 
 
 
6.1.1.1.2 C9ORF72+ Short Survival Cases   
Patient derived, expansion carrying LCL’s (n=27/88) [18-M, 9-F] with a survival of 
less than two years (i.e. defined as having a fast disease progression) comprised 16 
FALS and 11 SALS selected from the ECACC discovery (Section 4.1.1) and replication 
(Section 4.1.2) cohorts. These consisted of 6 Birmingham (22.2%) cases including 
one from Liverpool [F072-(BLi0251)], one from Oxford [F078-(BOx0029)] and one 
from Bristol Frenchay Hospital [F048-(BBr0015)]; 10 London (37.0%) cases and 11 
Sheffield (40.8%) cases including one from Preston [F025-(SPr0059)]. The M:F ratio 
was 2.00:1 (Figure 6.1). 
 
MALES The majority of male C9ORF72+ short (<2yrs) survival cases, 94.4% (n=17/ 



























of 1998 with either definite (n=8/17) [3-familial, 5-sporadic] or probable (n=9/17) 
[5-familial, 4-sporadic] ALS (Figure 1.1) including one incidence of concomitant PD 
[F114-(SP3560)] (Section 1.2.1). The remaining 5.6% (n=1/18) of the cohort were 
diagnosed with PBP [F100-(SP3070)] (Section 1.2.2.1). Age at symptom onset ranged 
between 45 and 71 years with a mean of 58.4±11yrs. Disease duration ranged from 
6½ to 22 months with a mean of 1.35±0.3yrs (Table 6.1). Limb onset accounted for 
61.1% of cases (n=11/18) [2-FALS, 1-FALS+PD and 8-SALS], bulbar onset a further 
22.2% (n=4/18) [3-FALS and 1-SALS] and a mixed presentation 11.1% (n=2/18) [1-
FALS and 1-PBP (familial)]. Information regarding site of onset was not available for 
the remaining 5.6% of the cohort (n=1/18) [1-FALS]. The ALSFRS-R scores ranged 
between 0 (severe disability) and 46 (near normal function) with an average of 27.6 
±15 for 88.9% of male C9ORF72+ short (<2yrs) survival cases (n=16/18) [7-FALS, 1-
FALS+PD, 7-SALS and 1-PBP (familial)].    
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these, 14.3% (n=1/7) [1-SALS] were prone to EL and a further 
14.3% (n=1/7) [1-SALS] displayed symptoms of dyspnoea without requiring NIPPV 
support. One individual presenting with a family history of dementia was diagnosed 
with the rare FA variant of the disease [S042-(SP3122)] (Section 1.2.1). Dysarthria 
and dysphagia were also apparent in 42.9% of the cohort (n=3/7) [1-FALS, 1-FALS 
+PD and 1-SALS] with PEG feeding becoming a necessary intervention in 33.3% of 
these latter cases (n=1/3) [1-FALS+PD] (Section 1.1.4). Two patients (28.6%) were 
non-ambulant with a further 14.3% unable to walk without assistance (n=1/7) [1-
SALS]. Current smokers comprised 14.3% of the cohort (n=1/7) [1-PBP (familial)], 
non-smokers 57.1% (n=4/7) [1-FALS+PD and 3-SALS] and for the remaining 28.6% 
(n=2/7) [2-SALS] this information was not disclosed.  
 
FEMALES Similarly, the majority of female C9ORF72+ short (<2yrs) survival cases, 
88.9% (n=8/9) were also diagnosed (Section 1.1.3) (Figure 1.1) with either definite 
(n=4/8) [4-familial] or probable (n=4/8) [2-familial, 2-sporadic] ALS including one 
incidence of concomitant FTLD [F115-(SP3118)]. The remaining 11.1% (n=1/9) of 
the cohort was diagnosed with PBP [F041-(LP0440)]. Age at symptom onset ranged 
between 28 and 71 years with a mean of 55.1±15yrs. Disease duration ranged from 




 -------------------------- Survival (<2yrs) ------------------------- -------------------------- Survival (≥4yrs) ------------------------- 
 MALE FEMALE ALL CONTROL MALE FEMALE ALL CONTROL 
M:F n/a n/a 2.00:1 2.25:1 n/a n/a 0.67:1 0.67:1 
Age          
        range 45-71yrs 28-71yrs 28-71yrs 36-71yrs 43-65yrs 35-71yrs 35-71yrs 36-71yrs 
        mean 58yrs 55yrs 58yrs 59yrs 57yrs 52yrs 54yrs 54yrs 
Onset         
        Limb 11  (61.1%) 1  (11.1%) 12  (44.5%) n/a 6  (100.0%) 7  (77.8%) 13  (86.6%) n/a 
        Bulbar       4   (22.2%)      5  (55.6%)       9    (33.3%) n/a    0           (0.0%)     2   (22.2%)       2    (13.4%) n/a 
        Mixed       2  (11.1%)      3  (33.3%)       5   (18.5%) n/a    0            (0.0%)     0      (0.0%)       0      (0.0%) n/a 
        Respiratory       0     (0.0%)      0    (0.0%)       0     (0.0%) n/a    0         (0.0%)     0     (0.0%)            0     (0.0%) n/a 
        unknown       1     (5.6%)     0     (0.0%)       1     (3.7%) n/a    0         (0.0%)     0      (0.0%)            0     (0.0%) n/a 
Diagnosis         
        ALS 16  (88.8%) 7   (77.8%) 23  (85.2%) n/a 5    (83.3%) 8   (88.9%) 13  (86.6%) n/a 
        ALS+FTLD       0     (0.0%)     1    (11.1%)       1     (3.7%) n/a     1    (16.7%)     0       (0.0%)       1     (6.7%) n/a 
        ALS+PD       1     (5.6%)     0      (0.0%)       1     (3.7%) n/a     0       (0.0%)     0      (0.0%)       0     (0.0%) n/a 
        PBP       1     (5.6%)     1    (11.1%)       2     (7.4%) n/a     0       (0.0%)     1    (11.1%)       1     (6.7%) n/a 
        PLS       0     (0.0%)     0      (0.0%)       0     (0.0%) n/a     0       (0.0%)     0      (0.0%)       0     (0.0%) n/a 
        PMA       0     (0.0%)     0      (0.0%)       0     (0.0%) n/a     0       (0.0%)     0      (0.0%)       0     (0.0%) n/a 
ALSFRS-R         
        range 0-46 18-38 0-46 n/a 33-45 30-45 30-45 n/a 
        mean 28 27 27 n/a 40 38 39 n/a 
Survival         
        range 0.5-1.8yrs 1.2-1.9yrs 0.5-1.7yrs n/a 4.1-8.9yrs 4.1-6.9yrs 4.1-8.9yrs n/a 
        mean 1.4yrs 1.6yrs 1.5yrs n/a 6.2yrs 5.1yrs 5.4yrs n/a 
Total 18 (18) 9 (8) 27 (26) 26 (24) 6 (6) 9 (8) 15 (14) 15 (15) 
 
Table 6.1 Clinical Summary of Male and Female C9ORF72+ LCL’s in the ECACC Long (≥4yrs) versus Short (<2yrs) Survival Study with Age and Gender Mat-
ched Controls The National MNDA DNA Bank didn’t have a suitable match for familial sample F24 (SP3148) of 28yrs explaining the small discrepancy in age range 
and M:F ratio between patients and controls of the short survivors group. In total 33 individuals were selected as neurologically normal, healthy controls with a 
different subset of this pool used for each of the downstream comparative analyses. Affymetrix® post-QC numbers are provided in brackets and highlighted in red.     
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 72, ECACC - European Collection of Cell Cultures, F - familial, F - 
female, FRS-R - Revised Functional Rating Scale, FTLD - frontotemporal lobar degeneration, LCL - lymphoblastoid cell line, M - male, MNDA - Motor Neurone Disease 
Association, n/a - not applicable, PD - Parkinson’s disease, PBP - Progressive Bulbar Palsy, PLS - Primary Lateral Sclerosis, PMA - Progressive Muscular Atrophy, QC 




11.1% (n=1/9) [1-SALS], bulbar onset a further 55.6% (n=5/9) [1-FALS+FTLD, 3-
FALS and 1-PBP (familial)] and a mixed presentation the remaining 33.3% of cases 
(n=3/9) [2-FALS and 1-SALS]. The ALSFRS-R scores ranged between 18 (moderate 
disability) and 38 (mild disability) with an average of 27.0±7 for 77.8% of female 
C9ORF72+ short (<2yrs) survival cases (n=7/9) [4-FALS, 1-FALS+FTLD, 1-SALS and 
1-PBP (familial)]. 
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these, 50.0% (n=2/4) [1-FALS and 1-SALS] were prone to EL, 
with one familial patient also suffering from hypersialorrhea and a further 50.0% 
(n=2/4) [1-FALS and 1-FALS+FTLD] displaying symptoms of dyspnoea that did not 
require NIPPV support. Dysarthria and dysphagia were apparent in 75.0% (n=3/4) 
[1-FALS, 1-FALS+FTLD and 1-SALS] of the cohort without PEG feeding becoming a 
necessary intervention. All patients were ambulant with the majority, 75.0% able to 
walk unaided and only one sporadic individual requiring assistance. Current or ex-
smokers were absent in this instance with non-smokers comprising three-quarters 
(n=3/4) [1-FALS, 1-FALS+FTLD and 1-SALS] of cases and for the remaining 25.0% 
(n=1/4) [1-FALS] this information was not disclosed.                     
 
6.1.1.1.3 C9ORF72+ Long Survival Cases   
Patient derived, expansion carrying LCL’s (n=15/88) [6-M, 9-F] with a survival of at 
least four years following the initial onset of symptoms (i.e. defined as having a slow 
disease progression) were comprised of 9 FALS and 6 SALS selected from the ECACC 
discovery (Section 4.1.1) and replication (Section 4.1.2) cohorts. These consisted of 
4 Birmingham (26.7%) cases; 4 London (26.7%) including one from Southampton 
General Hospital [F102-(LSh0038)] and one from Plymouth Derriford Hospital [F0 
29-(LPy0018)] and 7 Sheffield (46.6%) cases including one from Newcastle [S203-
(SNc0059)] and one from Manchester [F081-(SMa0006)]. The M:F ratio was 0.67:1 
(Figure 6.1).  
 
MALES All of the male C9ORF72+ long (≥4yrs) survival cases (n=6/6) [4-familial, 2-
sporadic] were diagnosed with probable ALS including one incidence of concomitant 




and 65 years with a mean of 56.7±8yrs (Table 6.1). Disease duration ranged from 49 
to 107 months with a mean of 6.18±2.3yrs for 66.7% of the cohort (n=4/6) [2-FALS, 
1-SALS and 1-SALS+FTLD]. For the remaining 33.3% of cases (n=2/6) [2-FALS] the 
individuals were still reported to be alive as of June 2013 with a minimum disease 
duration of 4 [F047-(BP6502)] or 6 [F013-(BP6494)] years, respectively. All of the 
patients presented focally with asymmetric upper and/or lower limb weakness. The 
ALSFRS-R scores ranged between 33 (mild disability) and 45 (near normal function) 
with an average of 39.8±5 for 100.0% of male C9ORF72+ long (≥4yrs) survival cases 
(n=6/6) [4-FALS, 1-SALS and 1-SALS+FTLD]. 
For the three Sheffield cases some additional clinical information regarding smoking 
status could be extracted from the local database. Two thirds of patients (n=2/3) [1-
SALS and 1-SALS+FTLD] were non-smokers and for the remaining 33.3% of cases 
(n=1/3) [1-FALS] this information was not disclosed.   
 
FEMALES The vast majority of female C9ORF72+ long (≥4yrs) survival cases, 88.9% 
(n=8/9) were also diagnosed with either definite (n=4/8) [2-familial, 2-sporadic] or 
probable (n=4/8) [2-familial, 2-sporadic] ALS. One additional familial patient [F029-
(LPy0018)] comprising the remaining 11.1% of the cohort was diagnosed with PBP. 
Age at symptom onset ranged between 35 and 71 years with a mean of 51.7±14yrs. 
Disease duration ranged from 49 to 83 months with a mean of 5.09±0.9yrs (Table 6. 
1). Limb onset accounted for 77.8% (n=7/9) [4-FALS and 3-SALS] and bulbar onset 
the remaining 22.2% of cases (n=2/9) [1-SALS and 1-PBP (familial)]. The ALSFRS-R 
scores ranged between 30 (mild disability) and 45 (near normal function) with an 
average of 38.1±6 for 100.0% of female C9ORF72+ long (≥4yrs) survival cases (n=9/ 
9) [4-FALS, 4-SALS and 1-PBP (familial)].  
For the Sheffield cases some additional clinical information could be extracted from 
the local database. Of these, 25.0% (n=1/4) [1-SALS] suffered from dyspnoea that did 
not require NIPPV support. Dysarthria and dysphagia was also apparent in a further 
25.0% (n=1/4) [1-SALS] of the cohort with PEG feeding (Section 1.1.4) becoming a 
necessary intervention in this latter instance. The majority of patients, 75.0% were 
ambulant with only one familial case unable to walk without assistance. Current or 




and 2-SALS] and for the remainder of the cohort (n=1/4) [1-SALS] this information 
was not disclosed.                   
 
6.1.1.2 Therapeutics Used to Treat the Cohort  
6.1.1.2.1 C9ORF72+ Short Survival Cases 
Riluzole, administered at a dose of 50mg twice daily, was being used to treat 83.3% 
of male (n=15/18) [5-FALS, 1-FALS+PD and 10-SALS] and 66.7% of female (n=6/9) 
[3-FALS, 1-FALS+FTLD and 2-SALS] C9ORF72+ short (<2yrs) survival cases. A small 
proportion of individuals, 4.8% (n=1/21) [1-SALS] experienced adverse side effects 
and the medication was withdrawn. Vitamin C and/or E (n=5/27) [1-FALS and 4-
SALS] or multivitamin supplements (n=1/27) [1-SALS] were collectively being taken 
by 22.2% (n=6/27) of the cohort. Conversely, 14.8% of patients (n=2/27) [3-FALS 
and 1-PBP (familial)] chose not to receive any kind of disease modifying therapy and 
for the remaining 7.4% (n=2/27) [1-FALS and 1-PBP (familial)] this information was 
not available.                       
 
6.1.1.2.2 C9ORF72+ Long Survival Cases   
The glutamate antagonist, Riluzole was also being used to treat 83.3% of male (n=5/ 
6) [3-FALS, 1-SALS and 1-SALS+FTLD] and 88.9% of female (n=8/9) [4-FALS, 1-PBP 
(familial) and 3-SALS] C9ORF72+ long (≥4yrs) survival cases. Vitamin C and/or E (n= 
5/15) [4-SALS and 1-SALS+FTLD] or multivitamin supplements (n=2/15) [2-FALS] 
were collectively being taken by 46.7% (n=7/15) of the cohort. As well as Riluzole, 
several patients were also participants of the minocycline [F073-(BP6165)], BDNF 
[F091-(SP3534)] or ONO-2506 (Arundic acid) [S203-(SNc0059)] drug trials [APP-
ENDIX TABLE B4]. Conversely, the remaining 13.3% (n=2/15) [1-FALS and 1-SALS] 
of the cohort chose not to receive any kind of disease modifying therapy.                    
 
6.1.1.3 Genetic Status of the Cohort  
All of the FALS and SALS patients (n=42/88) [24-M, 18-F] in the ECACC microarray 




1.1.1.3) versus short (<2yrs) (Section 6.1.1.1.2) survival study were identified from 
a repeat-primed PCR screen as carriers of more than 30 copies of the expanded G4C2 
sequence in intron 1 of the C9ORF72 gene (Cooper-Knock et al 2012b) (Section 1.1. 
8.4). Additionally, in the slow progressing female cases there was also one example 
of oligogenic inheritance involving an apparently sporadic Sheffield sample [S352-
(SP3484)] with a deleterious c.962C>T (p.A321V) missense mutation in exon 6 of the 
TARDBP gene (Kirby et al 2010) (Section 5.3.2.2).        
 
6.1.2 Affymetrix® Expression ConsoleTM QC Metrics
In vitro transcribed biotinylated ss-cDNA targets of ~40-70nt were hybridised onto 
Human Exon 1.0ST GeneChip® Arrays (Section 2.3.2.3 and 2.3.2.4). Affymetrix® QC 
metrics were assessed in Expression ConsoleTM software version 1.3.0.187 (Section 
4.3.2). Two female controls (n=2/33) [C076-(SNc0106) and C079-(SC3279)] and a 
further two SALS patients, including one from the C9ORF72+ short (<2yrs) survival 
group (n=1/27) [S123-(BP6021)] and a second (n=1/15) [S352-(SP3484)] from the 
C9ORF72+ long (≥4yrs) survival group, scored poorly against three or more of the 
parameters summarised in Table 6.2 (Figure 6.2, 6.3 and 6.4). The aforementioned 
cases (n=4/75), therefore, which represent 5.3% of the initial cohort, were removed 
from any subsequent downstream comparative analyses (Table 6.1). This generated 
a final cohort comprised of 40 FALS and SALS patients with a fast (n=26) [18-M, 8-F] 
versus slow (n=14) [6-M, 8-F] disease progression and 31, age and gender matched, 
neurologically healthy control subjects.    
    
 Affymetrix® Expression ConsoleTM QC Metrics 
 bac_spike bgrd_mean %P AUC all_probeset_mean RLE PPMCC 
C056        
C076        
C079        
C090        
S123        
S352        
 
Table 6.2 Affymetrix® Expression ConsoleTM Summary of Failed LCL Samples in the 
C9ORF72+ Long (≥4yrs) versus Short (<2yrs) Survival Study 
 
Key:        Passed        Failed    
 
Abbreviations: AUC - area under the receiver operating curve (ROC), bac_spike - bacterial 
spike in controls, bgrd - background, C9ORF72 - chromosome 9 open reading frame 72, C - 




coefficient, P - present calls, QC - quality control, RLE - relative log expression and S - 
sporadic.                
 
Figure 6.2 Eukaryotic Hybridization Controls for LCL Samples in the C9ORF72+ Long (≥4yrs) 
versus Short (<2yrs) Survival Study Bacterial derived genes of the E. coli biotin synthesis pathway 
[BioB (blue), BioC (red) and BioD (pink)] and the recombinase gene CreX (green) from the P1 
bacteriophage were spiked in at increasing concentrations (top panel) [1.5pM (limit of detection), 
5pM, 25pM and 100pM] immediately prior to labelling to monitor the efficiency of the hybridization 
reaction. In the bottom panel mean signal intensities for each of the probesets spotted onto the 
Affymetrix® Human Exon 1.0ST GeneChip® Arrays are provided for a) controls (n=33), b) C9ORF72+ 
long (≥4yrs) survival cases (n=27) and c) C9ORF72+ short (<2yrs) survival cases (n=15). Assessment 














Figure 6.3 Mean Absolute RLE Boxplots for LCL Samples in the C9ORF72+ Long (≥4yrs) versus 
Short (<2yrs) Survival Study Relative log expression means and standard deviations for age and 
gender matched M (male) and F (female) control subjects (blue) and C9ORF72+ FALS and SALS 
patients with either a fast (<2yrs) (pink) or slow (≥4yrs) (yellow) disease progression. Whiskers 
represent the minimum and maximum average probeset signal intensities for each array at the 
level of the whole transcript. Asterisks (red) highlight significant outliers. Assessment of Affymetrix® 
QC metrics was performed using Expression ConsoleTM software version 1.3.0.187.  
 
Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 
72, C - control, F - familial, LCL - lymphoblastoid cell line, QC - quality control, RLE - relative log 
expression, S - sporadic and ST - sense-target. 
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Figure 6.4 Expression ConsoleTM Summary of the QC Metrics Assessed for LCL Samples in the 
C9ORF72+ Long (≥4yrs) versus Short (<2yrs) Survival Study In the top four panels box and 
whisker plots were generated for male (M) [█] and female (F) [█] control cases (checkerboard) or 
C9ORF72+ FALS and SALS with a long (L) (≥4yrs) (unfilled) versus short (S) (<2yrs) (diagonally 
stripped) survival using GraphPad Prism® software version 5.04 and applying a Tukey multiple 
comparison test: a) average background (bgrd) signal, b) %P calls, c) mean probeset signal intensities 
at transcript level and d) mean probeset signal intensities at individual exon level. Samples flagged 
as outliers are highlighted in red. Note that for %P calls statistically outlying cases with at least fifty 
percent of probesets called as present were still included in downstream comparative analyses; 
these are represented in green. The coloured matrix in e) represents Pearson’s product Moment 
correlation coefficient (r) in which each pair-wise comparison is assigned a value on a scale of 
0.8333 (blue) to 1.000 (red) with a high score indicative of a strong linear relationship between the 
X and Y variables. Signal histogram plots are provided at f) transcript and g) individual exon level in 
the bottom right-hand panels. Each series of coloured bars represents the distribution of log2 
transformed, average GC-RMA normalised signal intensities for a single array in the experiment. 
Assessment of Affymetrix® QC metrics was performed using Expression ConsoleTM software version 
1.3.0.187. 
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Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 open reading frame 
72, C - control, F - familial, LCL - lymphoblastoid cell line, P - present calls, QC - quality control, RMA 
- Robust Multi-array Average and S - sporadic.                   
 
6.2 Human Exon 1.0ST GeneChip® Array Profiling  
Affymetrix® CEL files, 94.7% (n=71/75) [C9-Long (n=14), C9-Short (n=26) and Ctrl 
(n=31)] were imported into Partek® Genomics SuiteTM software version 6.6 (Section 
2.3.2.5.2). Raw expression values were log2 transformed and a GC-RMA background 
normalisation procedure applied using core metaprobesets (n=287,329). At whole 
transcript level these relate to over twenty-two thousand unique clusters pertaining 
to full length protein coding mRNA sequences in the RefSeq or GenBank® database. 
Post-normalised pivot tables were exported as text files which were reconfigured in 
Microsoft® Excel 2010 and the data visualised using Qlucore Omics Explorer software 
version 2.3. ANOVA F-tests were filtered on ‘Sample Type’ [Multi-group comparisons 
between C9-Long v C9-Short v Ctrl and Two-group comparisons between C9-Long v 
Ctrl, C9-Short v Ctrl and C9-Long v C9-Short] in order to generate lists of variables 
or gene transcripts that best separate the groupings on a PCA plot or hierarchically 
clustered HeatMap. Bias attributed to the effects of any potential confounders such 
as ‘Age’ (continuous) and ‘Gender’ (nominal) were removed by eliminating these as 
factors. 
DE transcripts identified between the ECACC C9ORF72+ LCL cases with a fast versus 
slow disease progression and a subset of neurologically healthy controls, that were 
matched for age and gender, were detected at the 5% significance level (unadjusted 
p<0.05) by performing a 2-way ANCOVA statistical test in Partek® Genomics SuiteTM 
software version 6.6. Lists were filtered to remove unannotated transcripts (n=4,3 
77/22,011) and a FC threshold ≥ ±1.20 applied (Section 2.3.2.5.2). Where multiple 
Affymetrix® transcript cluster ID’s were present for a single gene the identification 
number producing the most significant outcome with the greatest level of coverage 
(i.e. highest number of probesets and/or exon clusters) was retained. However, if 
the direction of change was opposing then both transcripts were removed.   




could also be imported into DAVID bioinformatics resource version 6.7. Functional 
annotation clustering analysis was performed on GOTERM_BP_FAT and GOTERM_ 
MF_FAT gene ontology (GO) terms applying a Homo sapiens background and filtering 
using ‘Medium’ classification stringency (Section 2.3.2.5.4). Categories with an EASE 
score above 1.30 and Benjamini-Hochberg FDR uncorrected p<0.05 were considered 
statistically significant. Transcripts identified as being significantly up (⇧)/down (⇩) 
regulated under different experimental conditions were analysed independently.         
 
6.2.1 ALL Samples Combined  
6.2.1.1 Clustering Analysis  
A multi-group comparative analysis conducted at the 5% significance level [ANOVA 
F-test p<0.05, FC ≥ ±1.20] using Qlucore Omics Explorer software version 2.3 of all 
LCL cases (n=40) and controls (n=31) (Blue) in the ECACC C9ORF72+ long (≥4yrs) 
(Yellow) versus short (<2yrs) (Pink) survival study (Figure 6.5a) identified 2,792 of 
22,011 variables that explain up to 21% of the variance in GEP’s generated between 
patient and control samples along the y-axis of the first principal component (PC1) 
and 12% (PC2) or 8% (PC3), respectively of the variance between a fast versus slow 
disease progression which is represented by the x and z-axes of the second and third 
principal components. 
Two-group comparative analyses performed at the same 5% significance threshold 
[ANOVA F-test p<0.05, FC ≥ ±1.20] identified corresponding lists of 1,162 (C9-Long 
v C9-Short), 2,805 (C9-Long v Ctrl) or 2,374 (C9-Short v Ctrl) variables, respectively 
which may explain up to 27% of the variance in GEP’s generated between C9ORF72+ 
LCL’s with a long (≥4yrs) (Yellow) versus short (<2yrs) (Pink) survival (Figure 6.5b) 
or controls (Blue) (Figure 6.5c) and a further 23% of the variance that is generated 
between C9ORF72+ short (<2yrs) survival cases and controls (Figure 6.5d). 
Clustering analysis was also conducted in Qlucore Omics Explorer software version 
2.3 at a higher stringency of applying a 1% significance threshold [ANOVA F-test p< 
0.01, FC ≥ ±1.20] (Figure 6.6a-d). However, given that the lists of variables which are 


























# ANOVA Comparison Eliminated Factors p-value Fold Variables 
a) Multi-Group  ‘Age’ and ‘Gender’  <0.05 ±1.20 2,792/22,011 
b) Two-Group  ‘Age’ and ‘Gender’  <0.05 ±1.20 1,162/22,011 
c) Two-Group  ‘Age’ and ‘Gender’  <0.05 ±1.20 2,805/22,011 
d) Two-Group  ‘Age’ and ‘Gender’  <0.05 ±1.20 2,374/22,011 
 
Figure 6.5 Qlucore Omics Explorer Clustering Analysis [ANOVA F-test p<0.05, FC ≥ ±1.20] of 
ALL Samples Combined in the C9ORF72+ Long (≥4yrs) versus Short (<2yrs) Survival Study    
 
Abbreviations: ANOVA - analysis of variance, C9ORF72 - chromosome 9 open reading frame 72 and 
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# ANOVA Comparison Eliminated Factors p-value Fold Variables 
a) Multi-Group  ‘Age’ and ‘Gender’  <0.01 ±1.20 968/22,011 
b) Two-Group  ‘Age’ and ‘Gender’  <0.01 ±1.20 227/22,011 
c) Two-Group  ‘Age’ and ‘Gender’  <0.01 ±1.20 1,069/22,011 
d) Two-Group  ‘Age’ and ‘Gender’  <0.01 ±1.20 812/22,011 
 
Figure 6.6 Qlucore Omics Explorer Clustering Analysis [ANOVA F-test p<0.01, FC ≥ ±1.20] of 
ALL Samples Combined in the C9ORF72+ Long (≥4yrs) versus Short (<2yrs) Survival Study     
 
Abbreviations: ANOVA - analysis of variance, C9ORF72 - chromosome 9 open reading frame 72 and 













































PCA plots proved no more distinct than those which have already been discussed, a 
decision was made to adhere to the original 5% threshold used also in Chapter 5 for 
the analysis of the C9ORF72 and nonC9ORF72-related_SALS study (Section 5.2.1.5).                   
 
6.2.1.2 DAVID Enrichment of Partek® Generated Gene Lists  
6.2.1.2.1 C9ORF72+ LongvShort Survival  
A direct comparison between C9ORF72+ long (≥4yrs) versus short (<2yrs) survival 
of all samples combined at the 5% significance level [Partek® unadjusted p<0.05, FC 
≥ ±1.20] identified 628 DE transcripts in Partek® Genomics SuiteTM software version 
6.6. These included 301 genes (47.9%) that were significantly up-regulated (⇧) and 
a further 327 genes (52.1%) which were significantly down-regulated (⇩). In DAVID 
these corresponded to 624 mapped ID’s [299 genes ⇧ and 325 genes ⇩] which were 
found to be enriched for GO categories that are associated with gene transcription, 
negative regulation of apoptosis and vesicle-mediated transport (Table 6.3a) as well 
as the cell cycle, DNA damage response mechanisms and Golgi-mediated trafficking 
(Table 6.3b) [APPENDIX TABLE B13].  
 
a) ALL Samples C9-Long v C9-Short ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0006355 regulation of transcription, DNA-templated 2.32 50 2.50E-05 
2 GO:0045892 negative regulation of transcription, DNA-
templated 
2.22 18 7.40E-04 
3 GO:0043066 negative regulation of apoptotic process 2.00 14 3.30E-03 
4 GO:0016192 vesicle-mediated transport 1.71 20 1.40E-03 
 
b) ALL Samples C9-Long v C9-Short ⇩reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0007067 mitotic nuclear division 2.84 14 2.40E-04 
2 GO:0045841 negative regulation of mitotic metaphase/ 
anaphase transition 
1.70 4 9.30E-04 
3 GO:0006974 cellular response to DNA damage stimulus 1.51 15 9.90E-03 
4 GO:0048193 Golgi vesicle transport 1.30 8  0.011 
 
Table 6.3 DAVID Enrichment of ALL Samples Combined in the ECACC C9ORF72+ Long (≥4yrs) 
versus Short (<2yrs) Survival Study  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9ORF72 - chromosome 9 open 
reading frame 72, DAVID - Database for Annotation, Visualisation and Integrated Discovery, EASE - 
enrichment score, ECACC - European Collection of Cell Cultures, FC - fold-change and GO - gene 





6.2.1.2.2 C9ORF72+ LongvCtrl and ShortvCtrl Survival  
The GeneVenn diagram which is depicted in Figure 6.7 [Partek® unadjusted p<0.05, 
FC ≥ ±1.20] highlights 1,218 DE transcripts between C9ORF72+ long (≥4yrs) survival 
cases and controls including 742 genes (60.9%) that were significantly up-regulated 
and 476 genes (39.1%) which were significantly down-regulated. Additionally, 751 
DE transcripts were highlighted between the C9ORF72+ short (<2yrs) survival cases 
and controls including 436 genes (58.1%) that were significantly up-regulated and 
315 genes (41.9%) which were significantly down-regulated. Among the transcripts 
highlighted were 1,007 genes found to be specifically dysregulated in the C9ORF72+ 
long (≥4yrs) survival cases [604 genes ⇧ and 403 genes ⇩] and a further 540 genes 
which were found to be specifically dysregulated in C9ORF72+ short (<2yrs) survival 
cases [297 genes ⇧ and 243 genes ⇩]. Of the 211 commonly shared transcripts that 
represent 17.3% or 28.1% of the aforementioned gene lists, respectively (Figure 6.7) 
only one, heat shock 70kDa protein 1A (HSPA1A) [C9-Longvctrl ⇩1.44-fold, p<0.05; 
C9-Shortvctrl ⇧1.33-fold, p<0.05], exhibited opposing directions of change. 
 




   
 
 
                                                  
Figure 6.7 GeneVenn of ALL Samples Combined in the ECACC C9ORF72+ 
Long (≥4yrs) versus Short (<2yrs) Survival Study Lists of DE transcripts 
generated using Partek® Genomics SuiteTM software version 6.6 copyright © 
2013 (Partek® Inc., St Louis, MO, USA). GeneVenn application freely available 
online at genevenn.sourceforge.net (University of Southern Mississippi, USA) 
(Pirooznia et al 2007). 
 
Abbreviations: C9ORF72 (C9) - chromosome 9 open reading frame 72, DE - 
differentially expressed and ECACC - European Collection of Cell Cultures. 
211 1,007 540 
Control C9-Long C9-Short 




Importation of the C9ORF72+ long (≥4yrs) specific gene list (n=1,007) into DAVID 
returned 998 mapped ID’s [598 genes ⇧ and 400 genes ⇩] which were found to be 
enriched for GO categories associated with translation & ribosome biogenesis, gene 
transcription, RNA processing, response to ROS and regulation of apoptosis (Table 
6.4a) in addition to metabolism, solute: cation symporter activity and organisation 
of the lysosome (Table 6.4b) [APPENDIX TABLE B14].  
 
a) ALL Samples C9-Long Specific ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0006412 translation 5.52 38 4.30E-11 
2 GO:0003743 translation initiation factor activity 4.74 12 3.90E-06 
3 GO:0034062 RNA polymerase activity 2.28 7 2.60E-03 
4 GO:0044265 cellular macromolecule catabolic process 2.07 39 2.40E-03 
5 GO:0004721 phosphoprotein phosphatase activity 2.01 15 1.10E-03 
6 GO:0006351 transcription 1.92 103 1.00E-05 
7 GO:0043933 macromolecular complex subunit organisation 1.88 40 8.60E-04 
8 GO:0006396 RNA processing 1.79 38 1.90E-05 
9 GO:0000302 response to reactive oxygen species 1.76 9 2.90E-03 
10 GO:0006351 transcription, DNA-dependent  1.75 20 3.10E-03 
11 GO:0006119 oxidative phosphorylation 1.62 11 1.30E-03 
12 GO:0042254 ribosome biogenesis  1.61 13 5.90E-04 
13 GO:0042981 regulation of apoptotic process 1.53 42 2.60E-03 
14 GO:0051262 protein tetramerisation 1.38 7 1.50E-03 
 
b) ALL Samples C9-Long Specific ⇩reg [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0015923 mannosidase activity  4.30 6 8.80E-06 
2 GO:0009311 oligosaccharide metabolic process 3.19 8 3.30E-06 
3 GO:0016125 sterol metabolic process 2.87 11 6.00E-05 
4 GO:0015293 symporter activity 2.26 10 2.00E-03 
5 GO:0009100 glycoprotein metabolic process 2.09 15 1.20E-04 
6 GO:0046942 carboxylic acid transport 1.89 10 4.40E-03 
7 GO:0006643 membrane lipid metabolic process 1.84 8 1.70E-03 
8 GO:0015294 solute:cation symporter activity 1.53 8 3.30E-03 
9 GO:0009267 cellular response to starvation 1.42 5 4.60E-03 
10 GO:0007040 lysosome organisation 1.32 5 1.80E-03 
11 GO:0016052 carbohydrate catabolic process 1.31 7 0.032 
 
Table 6.4 DAVID Enrichment of ALL Samples Combined C9-Long Specific Gene Lists    
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9 - chromosome 9 open reading 
frame 72, DAVID - Database for the Annotation, Visualisation and Integrated Discovery, EASE - 
enrichment score, FC - fold-change and GO - gene ontology.      
 
 
Conversely, importation of the C9ORF72+ short (<2yrs) specific gene list (n=540) 
returned 535 mapped ID’s [294 genes ⇧ and 241 genes ⇩] enriched for GO categories 




of cellular response to stress (Table 6.5a) as well as cell motility, modulation of the 
immune response, protein kinase activity, nucleotide binding and organisation of the 
cytoskeleton (Table 6.5b) [APPENDIX TABLE B15].     
 
a) ALL Samples C9-Short Specific ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0006259 DNA metabolic process 3.24 22 3.80E-05 
2 GO:0006261 DNA-dependent DNA replication 1.65 6 2.00E-03 
3 GO:00fv07049 cell cycle 1.53 23 4.30E-03 
4 GO:0080135 regulation of cellular response to stress 1.41 7 5.20E-03 
 
b) ALL Samples C9-Short Specific ⇩reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0051270 regulation of cell motion 2.66 12 2.70E-05 
2 GO:0051249 regulation of lymphocyte activation 2.00 9 5.00E-04 
3 GO:0002706 regulation of lymphocyte mediated immunity 1.96 5 4.40E-03 
4 GO:0031589 cell-substrate adhesion 1.82 7 1.30E-03 
5 GO:0032147 activation of protein kinase activity 1.71 8 5.20E-04 
6 GO:0030247 polysaccharide binding 1.38 7 0.013 
7 GO:0001883 purine nucleoside binding 1.36 30 0.028 
8 GO:0007010 cytoskeleton organisation  1.34 12 0.019 
9 GO:0002683 negative regulation of immune system process 1.31 7 5.60E-04 
 
Table 6.5 DAVID Enrichment of ALL Samples Combined C9-Short Specific Gene Lists    
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9 - chromosome 9 open reading 
frame 72, DAVID - Database for the Annotation, Visualisation and Integrated Discovery, EASE - 
enrichment score, FC - fold-change and GO - gene ontology.    
 
 
6.2.2 FEMALE Samples  
6.2.2.1 Clustering Analysis  
A Qlucore Omics Explorer multi-group comparative analysis [ANOVA F-test p<0.05, 
FC ≥ ±1.20] of female only LCL cases (n=16) and controls (n=12) (Blue) in the ECACC 
C9ORF72+ long (≥4yrs) (Yellow) versus short (<2yrs) (Pink) survival study (Figure 
6.8a) identified 1,216 of 22,011 variables that explain up to 34% of the variance in 
GEP’s generated between patient and control samples along the y-axis of PC1 and 9% 
or 8%, respectively, of the variance between a fast versus slow disease progression 
along the x and z-axes of PC2 and PC3.  
Two-group comparative analyses, which were also conducted at the 5% significance 






















# ANOVA Comparison Eliminated Factor p-value Fold Variables 
a) Multi-Group  ‘Age’ <0.05 ±1.20 1,216/22,011 
b) Two-Group  ‘Age’ <0.05 ±1.20 1,038/22,011 
c) Two-Group  ‘Age’ <0.05 ±1.20 2,028/22,011 
d) Two-Group  ‘Age’ <0.05 ±1.20 402/22,011 
 
Figure 6.8 Qlucore Omics Explorer Clustering Analysis [ANOVA F-test p<0.05, FC ≥ ±1.20] of 
FEMALE ONLY Samples in the C9ORF72+ Long (≥4yrs) versus Short (<2yrs) Survival Study     
 
Abbreviations: ANOVA - analysis of variance, C9ORF72 - chromosome 9 open reading frame 72 and 
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groups that form distinct clusters on the PCA plots depicted in Figure 6.8b-d. These 
generated corresponding lists of 1,038 (C9-Long v C9-Short), 2,028 (C9-Long v Ctrl) 
and 402 (C9-Short v Ctrl) variables, respectively which may explain up to 43% of the 
variance in GEP’s generated between C9ORF72+ LCL’s with a long (≥4yrs) (Yellow) 
versus short (<2yrs) (Pink) survival (Figure 6.8b) in addition to 41% of the variance 
between C9ORF72+ long (≥4yrs) survival cases versus controls (Blue) (Figure 6.8c) 
and a further 34% of the variance between C9ORF72+ short (<2yrs) survival cases 
versus controls (Figure 6.8d).                     
 
6.2.2.2 DAVID Enrichment of Partek® Generated Gene Lists  
6.2.2.2.1 C9ORF72+ LongvShort Survival  
A Partek® Genomics SuiteTM analysis [unadjusted p<0.05, FC ≥ ±1.20] of female only 
samples conducted at the 5% significance threshold identified 550 DE transcripts in 
a direct comparison between C9ORF72+ LCL cases with a long (≥4yrs) versus short 
(<2yrs) survival including 292 genes (53.1%) which were significantly up-regulated 
(⇧) and a further 258 genes (46.9%) that were significantly down-regulated (⇩). In 
DAVID these corresponded to 548 mapped ID’s [291 genes ⇧ and 257 genes ⇧] which 
were found to be enriched for GO categories associated with gene transcription and 
the induction of apoptosis (Table 6.6a) as well as regulation of the cell cycle, phospholipid 
biosynthesis and protein N-linked glycosylation (Table 6.6b) [APPENDIX TABLE B16].     
 
a) FEMALE Samples C9-Long v C9-Short ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0006355 regulation of transcription, DNA-templated 2.22 62 5.30E-04 
2 GO:0006915 induction of apoptosis 2.21 15 5.50E-04 
 
b) FEMALE Samples C9-Long v C9-Short ⇩reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0022402 cell cycle process 2.08 18 2.00E-03 
2 GO:0008654 phospholipid biosynthesis process 1.75 7 2.80E-03 
3 GO:0006487 protein N-linked glycosylation 1.65 5 3.10E-03 
4 GO:0010564 regulation of cell cycle process 1.48 7 4.90E-03 
 
Table 6.6 DAVID Enrichment of FEMALE ONLY Samples in the ECACC C9ORF72+ Long (≥4yrs) 
versus Short (<2yrs) Survival Study  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9ORF72 - chromosome 9 open 




enrichment score, ECACC - European Collection of Cell Cultures, FC - fold-change and GO - gene 
ontology.               
 
 
6.2.2.2.2 C9ORF72+ LongvCtrl and ShortvCtrl Survival 
The GeneVenn diagram which is depicted in Figure 6.9 [Partek® unadjusted p<0.05,
FC ≥ ±1.20] highlights 1,325 DE transcripts between C9ORF72+ long (≥4yrs) survival 
cases and controls including 849 genes (64.1%) that were significantly up-regulated 
and 476 genes (35.9%) which were significantly down-regulated. Additionally, 212 
DE transcripts were highlighted between the C9ORF72+ short (<2yrs) survival cases 
and controls including 151 genes (71.2%) that were significantly up-regulated and 
61 genes (28.8%) which were significantly down-regulated. Among the transcripts 
highlighted were 1,250 genes found to be specifically dysregulated in the C9ORF72+ 
long (≥4yrs) survival cases [787 genes ⇧ and 463 genes ⇩] and a further 137 genes 
which were found to be specifically dysregulated in C9ORF72+ short (<2yrs) survival 
cases [90 genes ⇧ and 47 genes ⇩]. Commonly shared transcripts (n=75) represent 
5.7% or 35.4% of the aforementioned gene lists, respectively and included the stress 
granule and nucleolar protein, SGNP (alternative name DNAPTP6) [DNAPTP6 (DNA 
polymerase-transactivated protein 6) C9-Longvctrl ⇧1.45-fold, p<0.05; C9-Shortvctrl 
⇩1.62-fold, p<0.01] which was the only transcript to exhibit opposing directions of 
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Figure 6.9 GeneVenn of FEMALE ONLY Samples in the ECACC C9ORF72+ 
Long (≥4yrs) versus Short (<2yrs) Survival Study Lists of DE transcripts 
generated using Partek® Genomics SuiteTM software version 6.6 copyright © 
2013 (Partek® Inc., St Louis, MO, USA). GeneVenn application freely available 
online at genevenn.sourceforge.net (University of Southern Mississippi, USA) 
(Pirooznia et al 2007). 
 
Abbreviations: C9ORF72 (C9) - chromosome 9 open reading frame 72, DE - 
differentially expressed and ECACC - European Collection of Cell Cultures.   
 
 
Importation of the female C9ORF72+ long (≥4yrs) specific gene list (n=1,250) into 
DAVID returned 1,242 mapped ID’s [784 genes ⇧ and 458 genes ⇩] that were found 
to be enriched for GO categories associated with the initiation of translation, protein 
transport/degradation, energy metabolism, ribonucleoprotein complex biogenesis, 
regulation of the cell cycle, gene transcription and induction of apoptosis (Table 6. 
7a) as well as transmembrane transporter activity, protein N-linked glycosylation 
and homeostasis (Table 6.7b) [APPENDIX TABLE B17].     
 
a) FEMALE Samples C9-Long Specific ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0044265 cellular macromolecule catabolic process 4.31 60 3.10E-06 
2 GO:0003743 translation initiation factor activity 3.59 13 9.40E-06 
3 GO:0019001 guanyl nucleotide binding 3.09 32 5.70E-04 
4 GO:0015031 protein transport 2.45 60 1.40E-05 
5 GO:0006511 ubiquitin-dependent protein catabolic process 2.14 26 6.40E-05 
6 GO:0022613 ribonucleoprotein complex biogenesis 2.09 18 2.40E-03 
7 GO:0006351 transcription, DNA-templated 2.06 123 5.20E-04 
8 GO:0032268 regulation of cellular protein metabolic process 1.83 34 6.10E-03 
9 GO:0006091 generation of precursor metabolites and energy 1.81 28 6.50E-04 
10 GO:0019787 small conjugating protein ligase activity 1.77 16 5.50E-03 
11 GO:0000278 mitotic cell cycle 1.70 35 3.90E-05 
12 GO:0006915 induction of apoptosis 1.57 27 1.90E-03 
13 GO:0065003 macromolecular complex assembly 1.40 43 0.011 
14 GO:0003899 DNA-directed RNA polymerase activity 1.30 6 0.037 
 
b) FEMALE Samples C9-Long Specific ⇩reg [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0006487 protein N-linked glycosylation 3.33 9 1.10E-05 
2 GO:0015175 neutral amino acid transmembrane transporter 
activity 
2.85 6 9.90E-05 
3 GO:0008610 lipid biosynthetic process 2.64 25 2.00E-06 
4 GO:0008203 cholesterol metabolic process 1.79 10 4.80E-04 
5 GO:0015297 antiporter activity 1.74 7 4.90E-03 
6 GO:0009267 cellular response to starvation 1.50 5 7.90E-03 
7 GO:0019842 vitamin binding 1.46 11 9.10E-04 
8 GO:0042592 homeostatic process 1.44 32 4.10E-03 




  activity    
 
Table 6.7 DAVID Enrichment of FEMALE ONLY C9-Long Specific Gene Lists    
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9 - chromosome 9 open reading 
frame 72, DAVID - Database for the Annotation, Visualisation and Integrated Discovery, EASE - 
enrichment score, FC - fold-change and GO - gene ontology.               
 
 
Conversely, importation of the female C9ORF72+ short (<2yrs) specific gene list (n= 
137) returned 136 mapped ID’s [89 genes ⇧ and 47 genes ⇩] which were found not 
to contain any GO categories that could be considered statistically significant [EASE 
score ≥1.30, Benjamini-Hochberg FDR uncorrected p<0.05 (Section 2.3.2.5.4)] with 
‘Medium’ classification stringency defined in the DAVID online functional annotation 
enrichment analysis described in Section 6.2 [APPENDIX TABLE B18].            
 
6.2.3 MALE Samples  
6.2.3.1 Clustering Analysis  
A Qlucore Omics Explorer multi-group comparative analysis [ANOVA F-test p<0.05, 
FC ≥ ±1.20] of male only LCL cases (n=24) and controls (n=21) (Blue) in the ECACC 
C9ORF72+ long (≥4yrs) (Yellow) versus short (<2yrs) (Pink) survival study (Figure 
6.10a) identified 2,410 of 22,011 variables that explain up to 19% of the variance in 
GEP’s generated between patient and control samples along the y-axis of PC1 and a 
further 17% or 8%, respectively of the variance between a fast versus slow disease 
progression along the x and z-axes of PC2 and PC3.  
Two-group comparative analyses, which were also conducted at the 5% significance 
threshold [ANOVA F-test p<0.05, FC ≥ ±1.20], identified corresponding lists of 1,376 
(C9-Long v C9-Short), 2,131 (C9-Long v Ctrl) and 2,470 (C9-Short v Ctrl) variables, 
respectively that explain up to 35% of the variance in GEP’s generated between the 
C9ORF72+ LCL’s with a long (≥4yrs) (Yellow) versus short (<2yrs) (Pink) survival 
(Figure 6.10b) in addition to 38% of the variance between C9ORF72+ long (≥4yrs) 
survival cases versus control (Blue) (Figure 6.10c) and a further 26% of the variance 
between C9ORF72+ short (<2yrs) survival cases versus controls (Figure 6.10d).                     
 






















# ANOVA Comparison Eliminated Factor p-value Fold Variables 
a) Multi-Group  ‘Age’ <0.05 ±1.20 2,410/22,011 
b) Two-Group  ‘Age’ <0.05 ±1.20 1,376/22,011 
c) Two-Group  ‘Age’ <0.05 ±1.20 2,131/22,011 
d) Two-Group  ‘Age’ <0.05 ±1.20 2,470/22,011 
 
Figure 6.10 Qlucore Omics Explorer Clustering Analysis [ANOVA F-test p<0.05, FC ≥ ±1.20] of 
MALE ONLY Samples in the C9ORF72+ Long (≥4yrs) versus Short (<2yrs) Survival Study     
 
Abbreviations: ANOVA - analysis of variance, C9ORF72 - chromosome 9 open reading frame 72 and 





















6.2.3.2.1 C9ORF72+ LongvShort Survival  
A Partek® Genomics SuiteTM analysis conducted at the 5% significance threshold of 
male only samples identified 1,024 DE transcripts [unadjusted p<0.05, FC ≥ ±1.20] 
in a direct comparison between the C9ORF72+ LCL cases with a long (≥4yrs) versus 
short (<2yrs) survival. These included 551 genes (53.8%) which were significantly 
up-regulated (⇧) and 473 genes (46.2%) that were significantly down-regulated (⇩). 
In DAVID, 1,015 mapped ID’s [546 genes ⇧ and 469 genes ⇩] were returned which 
were found to be enriched for GO categories associated with DNA helicase activity, 
negative regulation of gene transcription, hormone receptor binding and ubiquitin-
mediated proteolysis (Table 6.8a) as well as aspects of RNA processing/metabolism, 
Golgi vesicle transport, initiation of translation, response to cellular stress and the 
modulation of immunity (Table 6.8b) [APPENDIX TABLE B19].        
 
a) MALE Samples C9-Long v C9-Short ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0006355 regulation of transcription, DNA-templated 4.27 122 3.30E-09 
2 GO:0010629 negative regulation of gene expression 2.47 29 5.30E-04 
3 GO:0019941 modification-dependent protein catabolic 
process 
2.01 29 3.70E-03 
4 GO:0008026 ATP-dependent helicase activity 1.91 10 2.50E-03 
5 GO:0051427 hormone receptor binding 1.50 8 0.016 
6 GO:0043933 macromolecular complex subunit organisation 1.49 22 1.30E-03 
 
b) MALE Samples C9-Long v C9-Short ⇩reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0043933 macromolecular complex subunit organisation 2.60 35 4.90E-04 
2 GO:0006396 RNA processing 2.39 33 1.80E-05 
3 GO:0034660 ncRNA metabolic process 2.20 17 3.70E-04 
4 GO:0048193 Golgi vesicle transport 2.01 11 2.30E-03 
5 GO:0017076 purine nucleotide binding 1.94 71 9.10E-04 
6 GO:0008104 protein localisation  1.68 44 5.70E-05 
7 GO:0015780 nucleotide-sugar transport 1.38 3 9.60E-03 
8 GO:0050662 coenzyme binding 1.37 11 0.017 
9 GO:0016876 ligase activity, forming aminoacyl-tRNA and 
related compounds 
1.36 5 0.031 
10 GO:0051028 mRNA transport 1.36 7 0.026 
11 GO:033554 cellular response to stress 1.35 25 0.014 
12 GO:006446 regulation of translation initiation 1.33 5 0.022 
13 GO:0032395 MHC class II receptor activity 1.32 4 0.012 
 
Table 6.8 DAVID Enrichment of MALE ONLY Samples in the ECACC C9ORF72+ Long (≥4yrs) ver-
sus Short (<2yrs) Survival Study  
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, ATP - adenosine triphosphate, 
C9ORF72 - chromosome 9 open reading frame 72, DAVID - Database for Annotation, Visualisation 




FC - fold-change, GO - gene ontology, MHC - major histocompatibility complex, mRNA  - messenger 
RNA, ncRNA - non-coding RNA and tRNA - transfer RNA.                  
 
 
6.2.3.2.2 C9ORF72+ LongvCtrl and ShortvCtrl Survival 
The GeneVenn diagram which is depicted in Figure 6.11 [Partek® unadjusted p<0.05, 
FC ≥ ±1.20] highlights 1,045 DE transcripts between C9ORF72+ long (≥4yrs) survival 
cases and controls including 705 genes (78.9%) that were significantly up-regulated 
and 340 genes (21.1%) which were significantly down-regulated. Additionally, 1,067 
DE transcripts were highlighted between the C9ORF72+ short (<2yrs) survival cases 
and controls including 639 genes (59.9%) that were significantly up-regulated and 
428 genes (40.1%) which were significantly down-regulated. Among the transcripts 
highlighted were 894 genes found to be specifically dysregulated in the C9ORF72+ 
long (≥4yrs) survival cases [609 genes ⇧ and 285 genes ⇩] and a further 916 genes 
that were found to be specifically dysregulated in C9ORF72+ short (<2yrs) survival 
cases [544 genes ⇧ and 372 genes ⇩]. Commonly shared transcripts (n=151), which 
represent 14.5% or 14.2% of the aforementioned gene lists, respectively included 
calcium binding protein 1 (CABP1) [C9-Longvctrl ⇧1.36-fold, p<0.05; C9-Shortvctrl 
⇩1.34-fold, p<0.01] which was the only transcript to exhibit opposing directions of 











Figure 6.11 GeneVenn of MALE ONLY Samples in the ECACC C9ORF72+ 
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Long (≥4yrs) versus Short (<2yrs) Survival Study Lists of DE transcripts 
were generated using Partek® Genomics SuiteTM software version 6.6 
copyright © 2013 (Partek® Inc., St Louis, MO, USA). GeneVenn application 
freely available online at genevenn.sourceforge.net (University of Southern 
Mississippi, USA) (Pirooznia et al 2007). 
 
Abbreviations: C9ORF72 (C9) - chromosome 9 open reading frame 72, DE - 
differentially expressed and ECACC - European Collection of Cell Cultures.    
 
 
Importation of the male C9ORF72+ long (≥4yrs) specific gene list (n=894) into DAVID 
returned 879 mapped ID’s [598 genes ⇧ and 281 genes ⇩] which were found to be 
enriched for GO categories associated with structural constituents of the ribosome, 
GTPase activity, ubiquitin-mediated proteolysis, gene transcription, DNA helicase 
activity and ncRNA processing (Table 6.9a) as well as Golgi vesicle transport and the 
modulation of immunity (Table 6.9b) [APPENDIX TABLE B20].            
 
a) MALE Samples C9-Long Specific ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0003735 structural constituent of ribosome 4.26 19 3.70E-06 
2 GO:0003924 GTPase activity 2.68 19 8.20E-05 
3 GO:0030163 protein catabolic process 2.46 35 8.30E-04 
4 GO:0003714 transcription corepressor activity 2.41 15 1.40E-04 
5 GO:0070035 purine NTP-dependent helicase activity 1.71 9 0.010 
6 GO:0034470 ncRNA processing 1.57 13 0.013 
7 GO:0034622 cellular macromolecular complex assembly 1.40 20 4.50E-03 
 
b) MALE Samples C9-Long Specific ⇩reg [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0048193 Golgi vesicle transport 1.42 7 0.017 
2 GO:0032395 MHC class II receptor activity 1.31 3 0.032 
 
Table 6.9 DAVID Enrichment of MALE ONLY C9-Long Specific Gene Lists    
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9 - chromosome 9 open reading 
frame 72, DAVID - Database for the Annotation, Visualisation and Integrated Discovery, EASE - 
enrichment score, FC - fold-change, GTPase - guanosine triphosphatase, ncRNA - non-coding RNA 
and NTP - nucleotide triphosphate.   
 
 
Conversely, importation of the male C9ORF72+ short (<2yrs) specific gene list (n=9 
16) returned 906 mapped ID’s [536 genes ⇧ and 370 genes ⇩] which were enriched 
for GO categories associated with ncRNA metabolism, structural constituents of the 
ribosome, DNA damage response, cellular respiration, unfolded protein binding and 




the cytoskeleton, cell adhesion, cell junction assembly, GTPase mediated signalling, 
regulation of cellular component movement and skeletal system development (Table 
6.10b) [APPENDIX TABLE B21].               
 
a) MALE Samples C9-Short Specific ⇧reg [Partek® unadjusted p<0.05, FC≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0034660 ncRNA metabolic process 4.31 21 6.60E-06 
2 GO:0003735 structural constituent of ribosome 3.14 17 1.10E-05 
3 GO:0006974 cellular response to DNA damage stimulus 3.12 24 3.10E-04 
4 GO:0045333 cellular respiration 1.99 10 1.50E-03 
5 GO:0004526 ribonuclease P activity 1.94 4 2.00E-03 
6 GO:0051289 protein homotetramerization  1.67 5 5.40E-03 
7 GO:0016879 ligase activity, forming carbon-nitrogen bonds 1.53 15 3.80E-03 
8 GO:0001836 release of cytochrome c from mitochondria 1.46 4 0.020 
9 GO:0010212 response to ionizing radiation 1.38 7 6.30E-03 
10 GO:0006396 RNA processing 1.37 34 2.40E-05 
11 GO:0007264 small GTPase mediated signal transduction 1.36 16 0.024 
12 GO:0051082 unfolded protein binding 1.30 8 0.035 
 
b) MALE Samples C9-Short Specific ⇩reg [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
# GO term Functional Category EASE Count p-value 
1 GO:0007010 cytoskeleton organisation 5.27 27 5.60E-07 
2 GO:0007155 cell adhesion 3.77 32 2.30E-05 
3 GO:0051270 regulation of cellular component movement 3.69 17 1.50E-06 
4 GO:0031267 small GTPase binding 2.43 9 9.00E-04 
5 GO:0030695 GTPase regulator activity 2.17 23 1.90E-05 
6 GO:0032147 activation of protein kinase activity 2.05 12 1.60E-05 
7 GO:0046983 protein dimerization activity 1.92 21 5.80E-03 
8 GO:0031418 L-ascorbic acid binding 1.84 4 7.90E-03 
9 GO:0019838 growth factor binding 1.82 9 1.20E-03 
10 GO:0009101 glycoprotein biosynthetic process 1.73 10 4.20E-03 
11 GO:0016702 oxidoreductase activity, acting on single donors 
with incorporation of molecular oxygen, 
incorporation of two atoms of oxygen 
1.59 6 9.90E-03 
12 GO:0009611 response to wounding 1.56 20 9.20E-03 
13 GO:0034329 cell junction assembly  1.55 5 8.60E-03 
14 GO:0048567 ectodermal digestive tract morphogenesis 1.47 3 0.016 
15 GO:0001883 purine nucleoside binding 1.42 47 6.10E-03 
16 GO:0001501 skeletal system development 1.40 15 4.60E-03 
17 GO:0031349 positive regulation of defence response 1.36 6 0.015 
 
Table 6.10 DAVID Enrichment of MALE ONLY C9-Short Specific Gene Lists    
 
Abbreviations: # - rank, ⇧reg - up-regulated, ⇩reg - down-regulated, C9 - chromosome 9 open reading 
frame 72, DAVID - Database for the Annotation, Visualisation and Integrated Discovery, EASE - 
enrichment score, FC - fold-change, GTPase - guanosine triphosphatase and ncRNA - non-coding 
RNA.                       
 
 





In the C9ORF72+ long (≥4yrs) versus short (<2yrs) survival study there was a slight 
trend towards a younger age of symptom onset predicting a slower disease course 
(Table 6.1) [C9ORF72+ long (≥4yrs) 53.7±12yrs (n=14) and C9ORF72+ short (<2yrs) 
58.4±11yrs (n=26) for all samples combined; unpaired student’s t-test p>0.05 (not 
significant)] which supports the previously published findings of Lee et al (2013a), 
Magnus et al (2002), Mandrioli et al (2006), Williams et al (2013) and Yoshida et al 
(1986). A significantly higher percentage of spinal onset cases were apparent in the 
C9ORF72+ long (≥4yrs) survival cohort; consistent with the reports of Louwerse et 
al (1997), Pupillo et al (2014), Tysnes et al (1994) and Zoccolella et al (2008). Across 
the C9ORF72+ short (<2yrs) survival cohort males had a similar proportion of spinal 
(55.6%) and bulbar (22.2%) onset cases in comparison to the wider ALS population 
(Korner et al 2011) (Section 1.2.1). In contrast, female patients had a considerably 
greater incidence of bulbar (44.4%) or mixed (33.3%) presentation, which has also 
been observed elsewhere in the literature (Beghi et al 2007, Chancellor et al 1993, 
del Aguila et al 2003, Kristensen & Melgaard 1977, Salemi et al 1989, Scotton et al 
2012). Other prognostic factors that correlate negatively with survival include EEC 
(i.e. definite versus probable/suspected ALS), low ALSFRS-R scores [C9ORF72+ long 
(≥4yrs) 38.5±5 (n=14) and C9ORF72+ short (<2yrs) 27.4±13 (n=26) for all samples 
combined; unpaired student’s t-test (p<0.01**)] and a short diagnostic delay (Table 
6.1) (Hardiman et al 2011, Kaufmann et al 2005, Lo Coco et al 2007, Louwerse et al 
1997, Pupillo et al 2014, Zoccolella et al 2008).    
Another interesting observation is that more patients in the C9ORF72+ long (≥4yrs) 
survival cohort had received Riluzole therapy (86.7%) and were taking Vitamin C/E 
or multivitamin supplements (46.7%) at the time of biosample collection compared 
to patients in the C9ORF72+ short (<2yrs) survival cohort which had percentages of 
77.8% and 22.2%, respectively (Section 1.1.4).  
Initially, in an analysis of all samples combined [Partek® unadjusted p<0.05, FC ≥ ± 
1.20], a direct comparison was drawn between ECACC LCL’s carrying the C9ORF72 
expanded allele which have a fast (Section 6.1.1.1.2) versus slow (Section 6.1.1.1.3) 
disease progression, to identify genetic modifiers of survival that may or may not be 
influenced by the underlying pathogenesis of ALS (Section 6.2.1.2.1) (de Magalhaes 




transcripts which were found to be enriched for DAVID returned GO categories that 
are associated with gene transcription, negative regulation of apoptosis and vesicle-
mediated transport from the list of up-regulated changes (Table 6.3a) as well as the 
cell cycle, DNA damage response pathways and Golgi-mediated transport from the 
list of down-regulated changes (Table 6.3b). Dysregulation of vesicular trafficking in 
relation to the C9ORF72+ long (≥4yrs) survival cases has also been observed in post-
mortem brain tissue from 30 participants recruited to a human ageing study (Lu et 
al 2004). A diminished response to DNA damage and the possibility of cell cycle 
arrest are also interesting findings, especially given prior links between genomic 
instability and cellular senescence in premature ageing disorders such as Werner’s 
syndrome and Hutchinson-Gilford progeria syndrome (Kudlow et al 2007, Lei et al 
2012, Scaffidi et al 2005, Serio 2011). 
 
In a subsequent analysis of C9ORF72+ long (≥4yrs) and short (<2yrs) survival cases 
versus neurologically normal, age and gender matched, healthy controls (n=31) a 
GeneVenn diagram depicted in Figure 6.7 highlighted many more genetic modifiers 
of a fast or slow disease progression which were specific to ALS (Section 6.2.1.2.2). 
These included DE transcripts enriched for GO categories that are associated with 
RNA processing (Section 5.2.1.3) (also seen to have increased with age in skin cells 
derived from a large number of female MZ and dizygotic (DZ) twins (n=856) (Glass 
et al 2013)) and translation or ribosome biogenesis identified previously from the 
analysis of Chapter 5 (Section 5.2.1.4) in addition to RNA polymerase activity, gene 
transcription, oxidative phosphorylation, response to ROS (Section 1.2.4.1) and the 
regulation of apoptosis from the list of up-regulated changes and cellular response 
to starvation, solute: cation symporter activity, carboxylic acid transport, multiple 
metabolic pathways as well as organisation of the lysosome from the list of down-
regulated changes (Table 6.4). Evidence of an elevated response to ROS specifically 
occurring in relation to the C9ORF72+ long (≥4yrs) survival cases was a significant 
finding given the importance of oxidative stress in the neurodegenerative disease 
process; particularly in instances of SOD1-linked ALS (Section 1.2.5.1.1) (Barber et 
al 2006, Cluskey & Ramsden 2001) and in view of the well-established free radical 
theory of ageing (Beckman & Ames 1998, Harman 1956, Hekimi & Guarente 2003, 
Hughes & Reynolds 2005). Contrastingly, for the C9ORF72+ short (<2yrs) survival 




cellular response to stress and the cell cycle from the list of up-regulated changes 
(Table 6.5a) as well as cell-substrate adhesion, cell motion, protein kinase activity, 
polysaccharide binding, regulation of the immune response [a noteworthy feature 
given the potential role for non-cell autonomous mediated toxicity in ALS (Section 
1.2.4.6) (Appel et al 2011, Ilieva et al 2009)] and cytoskeletal organisation from the 
list of down-regulated changes (Table 6.5b). The fact that C9ORF72+ short (<2yrs) 
survival cases appear to be going into the cell cycle is interesting since it is also a 
phenomenon that has been discussed in transcriptional profiling of MN’s, a disease 
relevant tissue, isolated from the transgenic SOD1G93A mouse model (Ferraiuolo et al 
2007). 
In the literature a number of key genetic determinants of survival in ALS have been 
recorded including vascular endothelial growth factor A (VEGFA) (Anand et al 2012, 
Gupta et al 2011, Vijayalakshmi et al 2014, Wang et al 2007), unc-13 homolog A (C. 
elegans) (UNC13A) (Section 1.2.5.1.11) (Chio et al 2013b), zinc finger protein 512B 
(ZNF512B) (Tetsuka et al 2013), activating transcription factor 3 (ATF3) (Seijffers et 
al 2014), kinesin-associated protein 3 (KIFAP3) (Landers et al 2009), EPH receptor 
A4 (EPHA4) (Van Hoecke et al 2012) and glutamate receptor, metabotropic 1 (GRM1) 
(Milanese et al 2014). With the exception of VEGFA [⇩1.28-fold, p<0.05 C9-LongvCtrl 
and ⇩1.27-fold, p<0.05 C9-LongvShort], a potent angiogenic factor which has been 
demonstrated through its activation of the anti-apoptotic PI3K-Akt pathway to delay 
disease onset and to slow down the rate of progression in the transgenic SOD1G93A 
mouse, none of the other genes mentioned above were found to be dysregulated in 
the ECACC LCL’s possibly owing, at least in part, to the fact that some or all of these 
genes may not be expressed in B-lymphocytes (Azzouz et al 2004, Storkebaum et al 
2005).   
A notable gender imbalance between the C9ORF72+ long (≥4yrs) and short (<2yrs) 
[M:F ratio 0.67:1 and 2.00:1, respectively (Figure 6.1)] survival cases prompted an 
independent analysis [Partek® unadjusted p<0.05, FC ≥ ±1.20] of male (Section 6.2. 
3) and female (Section 6.2.2) only samples. In a former, direct comparison between 
male G4C2 repeat carriers which have a fast versus slow disease progression DAVID 
identified GO categories associated with gene transcription (common to all samples 




up-regulated changes (Table 6.8a) in addition to RNA processing, a major pathway 
implicated in the pathogenesis of a number of neurodegenerative diseases (Section 
1.2.4.9) (Anthony & Gallo 2010), ncRNA metabolism, Golgi vesicle transport, mRNA 
transport/translation, protein localisation and cellular response to stress from the 
list of down-regulated changes (Table 6.8b). In an identical analysis of female G4C2 
repeat carriers, DAVID identified GO categories associated with gene transcription 
and the induction of apoptosis from the list of up-regulated changes (Table 6.6a) as 
well as the cell cycle (common to all samples combined), phospholipid biosynthesis 
and protein N-linked glycosylation from the list of down-regulated changes (Table 
6.6b). Dysregulation of the cell cycle has also been seen in a meta-analysis of more 
than 20 ageing studies combining datasets from humans and animal (mouse and rat) 
models (de Magalhaes et al 2009).  
Of the C9ORF72+ long (≥4yrs) specific categories ribosome biogenesis (common to 
all samples combined), GTPase activity and ncRNA metabolism (opposing direction 
to above C9-LongvShort analysis) were found to be significantly up-regulated (Table 
6.9a) whereas Golgi vesicle transport and major histocompatibility complex (MHC) 
class II receptor activity were significantly down-regulated in male cases relative to 
controls (Table 6.9b). In contrast, female C9ORF72+ long (≥4yrs) specific categories 
included gene transcription/translation (common to all samples combined), protein 
transport, ubiquitin-mediated proteolysis, RNP complex biogenesis, the regulation 
of apoptosis, energy metabolism and the cell cycle (opposing direction to above C9-
LongvShort analysis) which were significantly up-regulated (Table 6.7a) as well as 
cholesterol metabolism, protein N-linked glycosylation, vitamin binding and cellular 
response to starvation (common to all samples combined) (Table 6.7b) which were 
significantly down-regulated in relation to controls. Perturbations in the latter were 
interesting findings in respect to the fact that a higher proportion of C9ORF72+ long 
(≥4yrs) survival cases were taking vitamin C/E or multivitamin supplements (Section 
6.1.1.2) and given the connection between poor nutritional status and shortened life 
expectancy in those patients who develop more severe symptoms of dysarthria and 
dysphagia during the clinical course of the disease (Scotton et al 2012).  
Of the C9ORF72+ short (<2yrs) specific categories none were found to be enriched 




to controls, DE transcripts associated with ncRNA metabolism, structural constituent 
of the ribosome and small GTPase mediated signal transduction (i.e. similar to those 
in the C9ORF72+ long (≥4yrs) specific list) along with cellular respiration, response 
to DNA damage stimulus, RNA processing and mitochondrial release of cytochrome 
c (Section 1.2.4.8) were identified as being significantly up-regulated (Table 6.10a) 
whereas the organisation of the cytoskeleton, cell adhesion and activation of protein 
kinase activity (similar to all samples combined) were found to be significantly down 
-regulated (Table 6.10b).  
 
The C9ORF72+ ALS common lists, represented by the intersection of the GeneVenn 
diagram depicted in Figures 6.7, 6.9 and 6.11, were also interrogated to determine 
whether any transcripts of interest occur in opposing directions of change between 
cases with a fast versus slow disease progression. These included: chaperonin, heat 
shock 70kDa protein 1A (HSPA1A) [⇩1.44-fold, p<0.05 C9-LongvCtrl and ⇧1.33-fold, 
p<0.05 C9-ShortvCtrl] from an analysis of all samples combined which is interesting 
given a potential therapeutic role for Arimoclomol in an ongoing phase II clinical trial 
(Kalmar et al 2014); neuron specific calcium binding protein 1 (CABP1) [⇧1.36-fold, 
p<0.05 C9-LongvCtrl and ⇩1.34-fold, p<0.01 C9-ShortvCtrl] in the male only group, 
which modulates the activity of inositol 1,4,5-triphosphate receptors (Li et al 2009, 
Li et al 2013a) and has been shown to be highly expressed in human brain tissue 
and the retina (Wingard et al 2005) as well as stress granule and nucleolar protein, 
SGNP [DNAPTP6 (DNA polymerase transactivated protein 6) ⇧1.45-fold, p<0.05 C9-
Long vCtrl and ⇩1.62-fold, p<0.01 C9-ShortvCtrl] from the female only group which 
is considered important for the regulation of ribosomal biogenesis and translational 
control in response to OS (Section 1.2.4.1) (Zhu et al 2008).    
 
Overall, similar proportions of up and down-regulated genes (Partek®) [unadjusted 
p<0.05, FC ≥ ±1.20] or variables (Qlucore) [ANOVA F-test p<0.05, FC ≥ ±1.20] were 
identified in all three comparisons with the molecular signatures from GEP analyses 
most likely reflecting a combination of the underlying neurodegenerative processes 
and transcriptional changes that occur in response to ageing. These may be difficult 
to dissect apart fully especially since ALS is a late onset disorder in which patients do 
not typically manifest symptoms of the disease before their sixth or seventh decade 





Despite the female only samples demonstrating a clearer degree of separation on the 
PCA plot (Figure 6.8 in comparison to Figures 6.5, 6.6 and 6.10) (i.e. fewer variables 
having a larger effect size and explaining more of the variance in GEP’s along the y-
axis of the first principal component) lists of Partek® generated DE transcripts were 
notably smaller and underpowered to detect biologically enriched GO categories in 
the DAVID functional annotation clustering analysis tool (lower EASE scores, poor 
gene counts and weaker p-values with the exception of the C9ORF72+ short (<2yrs) 
specific changes which failed to return a significant result altogether); possibly due 
to the limited sample numbers in this group. Not only that, in some instances it has 
also been difficult to obtain accurate survival data with the dates of onset provided 
in the local or national databases normally accurate to within 3 to 6 months which 
partially stems from the insidious nature of the disease (Nzwalo et al 2014, Paganoni 
et al 2014). In future studies these issues could be addressed by recruiting a larger 
patient cohort and widening the gap between the thresholds for defining a fast (<12 
months) versus slow (>5yrs) progression which was not possible in the scope of this 

















CHAPTER 7: CONCLUDING REMARKS  
 
Since the advent of the Human Genome Project (Watson 1990), launched almost 25 
years ago, microarray analysis has become an invaluable tool (Bombard et al 2014, 
Lohmann et al 2013, Moroi & Heckenlively 2008, Waldman & Terzic 2008) which is 
paving the way towards a more personalised health care system in the UK and else-
where. Its technology offers the end user a rapid, high-throughput approach to glo-
bal GEP (Agostini et al 2012, Wu et al 2012b) that is accurate, reproducible and un-
biased. Using a single GeneChip® or array, it has become possible to take a snap shot 
of the level of gene expression pertaining to a vast number of mRNA targets and/or 
splice variants within a particular tissue or cell of interest at any given point in time 
(Sharp et al 2006b). Though the generation of patient specific molecular profiles or 
gene signatures it is anticipated that clinicians will soon be able to sub-classify com-
plex aetiologies into genetically defined sub-groups which correlate with certain as-
pects of the phenotypic information available to them; thus providing more inform-
ative ways of stratifying diverse patient populations. This aims to improve diagnos-
tic and prognostic decision making, as well as, being able to more reliably predict an 
individual’s response to novel therapeutic or treatment strategies as already demo-
nstrated in respect to paediatric septic shock (Wong et al 2010, Wong et al 2014), I 
BD (van Lierop et al 2013) and Acute Myeloid Leukemia (Haferlach et al 2010, Tsut-
sumi et al 2004); a heterogeneous disorder of neoplasms which has led to the inve-
ntion of the world’s first diagnostic DNA chip, the AML-profilerTM (Skyline Diagnost-
ics, The Netherlands).   
The MN’s which degenerate in ALS remain inaccessible during life. There are also a 
number of limitations associated with the use of post-mortem material; not least of 
all that the GEP’s generated will inevitability only reflect the very terminal stages of 
disease progression (i.e. the point at which the majority of vulnerable neuronal cell 
populations will have already been lost from the system which makes it difficult to 
establish cause or effect) (Cooper-Knock et al 2012a, Sharp et al 2006a, Sutherland 
et al 2011). Therefore, great benefits are to be had in sampling surrogate peripheral 
tissues that lend themselves to better standardisation of technical procedures. Whole 




longitudinal sampling method it supports and the overall ease with which it can be 
collected (Burczynski & Dorner 2006). The fact that it interacts with and permeates 
every other tissue & organ of the mammalian body is suggestive of circulating blood 
constituting a rich biosensor pool which has the potential to act as a sentinel of the 
neurodegenerative disease process (Kennedy et al 2008, Pahl 2005). It has become 
apparent, however, that the sheer abundance of erythrocyte derived alpha and beta 
haemoglobin transcripts (~70% total RNA) (Winn et al 2010) produces interference 
on the microarray which masks the detection of other, less abundant transcripts of 
equal biological importance within the sample (Feezor et al 2004, Wright et al 2008). 
The initial aim of this project in evaluating, following PAXgene® RNA extraction, the 
use of two globin reduction strategies, concluded that the Ambion® GLOBINClearTM 
protocol (Dr Rohini Raman) and NuGEN Ovation® Whole Blood Solution were both 
highly variable and inefficient, with inconsistent findings reported across identical 
SALS patient and control samples collected at the same time in separate PAXgene® 
Blood RNA Collection Tubes. Given these challenges it was hypothesised, therefore, 
that immortalised EBV-transformed B-lymphocytes (LCL’s) which represent a more 
homogeneous cell population would be advantageous in the detection of robust GE 
changes that can reliably aid in the sub-classification of disease using a large bank of 
frozen LCL pellets obtained from the ECACC held at the HPA (Public Health England, 
UK). In light of a pathogenic non-coding G4C2 hexanucleotide repeat expansion, of > 
30 copies, having recently been identified in C9ORF72 (Renton et al 2011, DeJesus-
Hernandez et al 2011), which is now thought to account for up to 43% of FALS and 
around 7% of SALS cases (Cooper-Knock et al 2012b) (Section 1.2.5.4), it was also of 
interest to: 1) elucidate further mechanism(s) of neurotoxicity associated with the 
expansion and 2) determine genetic modifiers of a fast (<2yrs survival) versus slow       
(≥4yrs survival) disease progression in C9ORF72-related cases of ALS.  
Due to time constraints, and various delays in obtaining samples from the National 
MNDA DNA Bank, along with the relevant and most up-to-date clinical information 
(e.g. gender, age and site of onset, EEC, ALSFRS-R, Riluzole status and time to death) 
and mutational screening data, particularly of the C9ORF72 gene, it meant not all of 
the LCL samples recruited to the original ECACC discovery (Section 4.1.1) and repl-




be analysed in the scope of this study. Across the LCL’s that were processed and had 
subsequently passed the Affymetrix® QC metrics assessed in Expression ConsoleTM 
software version 1.3.0.187, there was an overall increase in the level of gene trans-
cription which was observed in respect to C9ORF72 (59.3%, n=650/1,096) and no-
nC9ORF72-related_SALS (63.9%, n=1,148/1,796) [Partek® unadjusted p<0.05, FC ≥ 
±1.20] cases compared to a subset of neurologically healthy, age and gender match-
ed, controls. In DAVID, functionally enriched gene ontology (GO) categories included 
translation which was specific to the C9ORF72 expansion, as well as RNA processing, 
DNA metabolism, RNP complex biogenesis and regulation of the cell cycle that were 
found to be a more common feature of the broader ALS phenotype. The differential 
expression of a number of key validation targets including several C9ORF72 binding 
partners (NUDT21, RPL22, EIF4H, PURA, HNRNPA0/F and FUS) (Section 5.2.4) of the 
G4C2 repeat were subsequently confirmed by qRT-PCR (traditional SYBR® Green or 
IDT Prime Time® Mini qPCR Assays) using pooled RNA samples with a RIN score of 
7.5 or above, from the microarray plus additional C9ORF72+ cases (n=75) and con-
trols (n=35) from the ECACC discovery and replication cohorts. 
The C9ORF72 gene itself was down-regulated in a subset of the LCL’s (Section 5.2.3) 
(Cooper-Knock et al 2013b); however this could not be replicated across the rest of 
the cohort. This could, at least partially, be due to the presence of alternative splice 
variants encoding different protein isoforms (a/b) which exert contradictory effects 
depending upon the location of the expanded G4C2 repeat sequence with respect to 
exons 1a [Variant I (NM_001256054) full length 481a.a. and Variant II (NM_145005) 
truncated 222a.a.] and 1b [Variant III (NM_018325) full length 481a.a. (Figure 5.22) 
]. From the literature it can be speculated that in exon 1b containing transcripts the 
expansion is situated within the core promotor region which is expected to lead to a 
significant reduction in its expression whereas, in exon 1a containing transcripts the 
expansion is known to reside in intron 1 which results in aberrant transcription of 
the hexanucleotide G4C2 repeat (Renton et al 2011, DeJesus-Hernandez et al 2011). 
On the Human Exon 1.0ST GeneChip® Arrays and by qRT-PCR it was not possible to 
distinguish between full length transcript Variants I and III (isoform a); thus provid-
ing some explanation as to why no overall effect was observed in the LCL’s or iPSC 




Whether pathogenicity of the expansion arises from a loss of function (haploinsuff-
iciency) or gain of function mechanism mediated by the formation of toxic RNA foci 
(Donnelly et al 2013) or RAN translated DPR proteins (Gendron et al 2013b) is not 
fully understood. However, an up-regulation in the expression of C9ORF72 binding 
partners of the G4C2 repeat and other RNA processing related genes supports a role 
for RNA toxicity whereby the cells are attempting to compensate for the sequestrat-
ion of these proteins by aberrantly formed foci in the cytoplasm (Cooper-Knock et al 
2014b).     
One limitation of the PhD was the technology and software constraints in analysing 
alternative splicing events that are estimated to affect more than 90% of the human 
genome (Pan et al 2008, Wang et al 2008). On Human Exon 1.0ST GeneChip® Arrays 
probeset (exon level) signal intensities are normalised to the mean intensity value 
for the gene as a whole rather than the overall mRNA levels for all the transcripts on 
the microarray which is used as an index of the extent to which a particular exon is 
included or excluded in relation to the global expression of the relevant gene that it 
represents a constituent part of. This means whilst detailed information regarding 
the total number of splice variants and the proportion of these variants that contain 
each of the individual exons is available, the precise manner in which the inclusion 
or exclusion of one probeset relates to another is lacking (Highley et al 2014). The 
recent launch of the Transcriptome Analysis Console 2.0 software (Affymetrix® Ltd., 
UK) is expected to simplify the interpretation of future experiments, along with the 
release of the Human Transcriptome GeneChip® Array 2.0 which will provide even 
greater coverage with over six million probes [~150 probes/gene, 10 probes/exon 
and 4 probes/exon-exon splice junction].    
In the ECACC analysis of a fast (<2yrs survival) versus slow (≥4yrs survival) disease 
progression sample sizes were too small to be able to draw meaningful conclusions. 
Clinical data pointed towards a possible effect of gender which is supported in the 
literature from manipulation of the murine SOD1G93A mouse model (Alves et al 2011, 
Cervetto et al 2013, Gunther et al 2014, Heiman-Patterson et al 2005, Naumenko et 
al 2011, Pan et al 2012); although other factors, such as correlations with expansion 




FUTURE WORK   
 Due to time constraints it was not feasible to wait for all of the arrays in the 
ECACC discovery and replication cohorts to be processed before commencing 
the downstream comparative analyses described in Chapter 5: ‘C9ORF72 GEP 
Study’ and Chapter 6: ‘C9ORF72 Long (≥4yrs) versus Short (<2yrs) Survival 
Study’. However, now that more CEL files have become available it would be of 
interest to re-run the bioinformatics pipelines using an independent validation 
cohort in order to confirm the reproducibility of our findings. Further 
corroboration of the microarray data could come from western blotting, to 
verify protein level changes, and functional in vitro studies using live LCL 
cultures; although the later would require additional ethical approval to be put 
in place. Checking to see whether DE or alternatively spliced transcripts 
detected in the ECACC EBV-transformed B-lymphocytes correlate with those 
identified from laser capture micro-dissected MN’s (i.e. representing the most 
vulnerable cell population affected by the neurodegenerative disease process) 
would be an important next step in confirming the utility of peripheral tissues in 
performing GEP in ALS.  
 
 Re-analyse the exon level data using the Transcriptome Analysis Console (TAC), 
recently launched by Affymetrix® Ltd., UK which aims to simplify the analysis of 
functional gene networks/pathways and alternative splicing events. Packages 
are now also available within R [e.g. work carried out by Cooper-Knock et al 
(2015b) using FIRMA (‘finding isoforms using robust multichip analysis’) 
concluded that there was no significant difference in the overall number of 
alternative splicing events pertaining to the same bank of ECACC LCL’s between 
C9ORF72 and nonC9ORF72-related ALS, however, splicing associated with the 
G4C2 hexanucleotide repeat was found to be less consistent and more prone to 
errors which correlated with disease severity].    
 
 Where possible, obtain more accurate survival data for the C9ORF72+ LCL’s in 




patients who were still reported to be alive in June 2013 have now passed the 
threshold for inclusion into the C9ORF72+ Long (≥4yrs) versus Short (<2yrs) 
Survival Study. Also investigate whether any additional cell lines, which met the 
necessary selection criteria, have been recruited to the National MNDA DNA 
Bank since commencing the PhD. If the cohort used in the analysis of Chapter 6 
could be expanded in some way then the statistical power of the study could be 
greatly improved. Numbers depending, we could also consider widening the 
thresholds to examine, for example, cases with less than twelve months survival 
versus those with greater than five years survival. Failing that, an alternative 
approach may be to compare GEP’s generated from biosamples collected at the 
point of symptom onset to those taken later on in the disease course (e.g. after 
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Figure A1: Representative Pre- and Post-SPIATM qRT-PCR Profile 
Plots for HBA2 and ACTB Measurements Using the Stratagene 
Brilliant II SYBR® Green Master Mix 
 
 
a) Pre-SPIATM Amplification Plots 
 
 
b) Post-SPIATM Amplification Plots 
 
Abbreviations: ACTB - actin, beta, HBA2 - haemoglobin alpha 2, qRT-PCR - quantitative real-time 





Figure A2: Representative Post-SPIATM qRT-PCR Profile Plots for 
HBA2 and ACTB Measurements Using the Roche FastStart 
Universal SYBR® Green Master Mix 
 
  
Abbreviations: ACTB - actin, beta, HBA2 - haemoglobin alpha 2, qRT-PCR - quantitative real-time 
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Probeset ID Symbol Fold p-value  Probeset ID Symbol Fold p-value  Probeset ID Symbol Fold p-value 
1556970_at --- ⇧ 5.97 2.96E-06  209081_s_at COL18A1 ⇧ 2.14 7.70E-03  223763_at DTNBP1 ⇧ 1.95 1.07E-03 
1570357_at STX8 ⇧ 3.26 5.54E-05  222399_s_at TM9SF3 ⇩ 2.13 0.012  212418_at ELF1 ⇩ 1.94 0.025 
201151_s_at MBNL1 ⇩ 3.16 3.68E-03  229067_at ODF3B ⇧ 2.12 0.036  238706_at PAPD4 ⇩ 1.93 0.042 
231484_at --- ⇩ 2.84 0.046  238327_at SRGAP2P1 ⇩ 2.12 1.84E-03  222467_s_at IRF7 ⇧ 1.93 0.039 
216951_at FCGR1A ⇧ 2.74 0.040  219845_at BARX1 ⇧ 2.12 1.79E-04  208436_s_at SAPS3 ⇩ 1.93 0.025 
212671_s_at HLA-DQA1/2 ⇧ 2.74 0.017  219359_at ATHL1 ⇧ 2.09 4.06E-03  218040_at --- ⇩ 1.92 0.043 
1555687_a_at CLEC4C ⇩ 2.73 0.015  210371_s_at RBBP4 ⇩ 2.08 0.043  227428_at TAZ ⇧ 1.92 0.028 
202118_s_at CPNE3 ⇩ 2.54 0.040  220000_at SIGLEC5 ⇧ 2.07 0.040  1560047_s_at GABPA ⇩ 1.92 0.022 
231982_at LOC284422 ⇧ 2.53 0.030  228471_at --- ⇩ 2.06 0.033  203977_at PRPF38B ⇩ 1.92 0.018 
206196_s_at RUNDC3A ⇧ 2.47 0.035  226792_s_at HP  ⇧ 2.05 0.031  220404_at --- ⇧ 1.91 0.037 
206697_s_at HP  ⇧ 2.40 0.021  208470_s_at KIFC2 ⇧ 2.05 0.016  213439_x_at RUNDC3A ⇧ 1.91 0.029 
224797_at ARRDC3 ⇩ 2.37 9.47E-03  207117_at AASDHPPT ⇩ 2.04 0.014  211065_x_at GPR97 ⇧ 1.91 0.027 
210756_s_at NOTCH2 ⇩ 2.37 2.94E-03  222633_at ZNF117 ⇩ 2.04 0.010  1565777_at PFKL ⇧ 1.91 7.95E-03 
201237_at CAPZA2 ⇩ 2.36 0.031  202169_s_at TBL1XR1 ⇩ 2.04 1.22E-04  204285_s_at FOXH1 ⇧ 1.90 0.019 
200605_s_at PRKAR1A ⇩ 2.34 0.043  207500_at CASP5 ⇧ 2.03 0.021  200785_s_at LRP1 ⇧ 1.90 8.08E-03 
211781_x_at --- ⇧ 2.34 0.033  239012_at RNF144B ⇩ 2.02 0.046  231407_s_at PMAIP1 ⇩ 1.90 8.20E-04 
231828_at LOC253039 ⇧ 2.34 0.017  229198_at METRNL ⇧ 2.02 0.030  212530_at --- ⇧ 1.89 0.044 
243495_s_at --- ⇩ 2.31 6.01E-03  225955_at USP35 ⇧ 2.02 3.62E-04  213805_at FGFR1OP2 ⇩ 1.89 0.036 
212720_at PAPOLA ⇩ 2.29 0.019  32502_at GDPD5 ⇧ 2.01 0.045  233898_s_at CUL4A ⇧ 1.89 0.027 
1552552_s_at CLEC4C ⇩ 2.28 2.31E-03  222839_s_at PAPOLG ⇩ 2.00 9.16E-03  225290_at ETNK1 ⇩ 1.89 0.020 
223578_x_at MALAT1 ⇩ 2.26 0.012  215635_at --- ⇩ 1.99 0.037  244889_at NEK7 ⇩ 1.89 0.016 
228222_at --- ⇩ 2.25 0.030  230180_at FCHO2 ⇩ 1.99 0.019  229373_at ABHD5 ⇩ 1.89 0.013 
212368_at C16orf7 ⇧ 2.23 0.038  202859_x_at --- ⇩ 1.99 0.017  227757_at LOC388210 ⇧ 1.89 9.07E-03 
219978_s_at ZNF292 ⇩ 2.23 0.015  228220_at IL8 ⇩ 1.99 5.14E-03  1558747_at --- ⇩ 1.88 0.038 
205781_at NUSAP1 ⇩ 2.23 3.82E-03  222409_at --- ⇩ 1.98 0.041  207172_s_at SMCHD1 ⇩ 1.88 0.036 
222562_s_at TNKS2 ⇩ 2.22 0.024  224778_s_at DNPEP ⇧ 1.98 9.65E-03  212943_at MYO1G ⇧ 1.88 0.016 
235645_at PTPRC ⇩ 2.19 0.035  241403_at CORO1C ⇩ 1.98 7.03E-03  227953_at CDH11 ⇩ 1.88 7.89E-03 
1552480_s_at ESCO1 ⇩ 2.19 9.17E-03  215135_at CLK4 ⇩ 1.98 4.19E-03  227799_at KIAA0528 ⇩ 1.88 7.55E-03 
229327_s_at --- ⇩ 2.16 0.017  242312_x_at --- ⇩ 1.97 0.043  225178_at DAPK1 ⇩ 1.87 0.033 
207605_x_at ZNF117 ⇩ 2.16 9.16E-03  223940_x_at MALAT1 ⇩ 1.96 0.022  210116_at PREPL ⇩ 1.87 0.030 
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212215_at PHF10 ⇩ 1.87 0.026  208944_at --- ⇩ 1.82 0.026  216555_at STAT6 ⇧ 1.77 0.050 
225048_at TTC14 ⇩ 1.87 0.011  202478_at TGFBR2 ⇩ 1.82 9.24E-03  201408_at PPP1CB ⇩ 1.77 0.021 
212887_at PPP1CB ⇩ 1.86 0.044  223964_x_at RGS18 ⇩ 1.81 0.045  214499_s_at C22orf30 ⇩ 1.77 0.017 
218733_at --- ⇩ 1.86 0.039  213875_x_at --- ⇩ 1.81 0.031  242844_at MTG1 ⇧ 1.77 0.016 
210057_at ANO9 ⇧ 1.86 0.036  223809_at CDV3 ⇩ 1.81 0.026  204088_at P2RX4 ⇧ 1.77 0.011 
227364_at RPS6KA5 ⇩ 1.86 0.032  228746_s_at SFRS4 ⇩ 1.81 0.021  201332_s_at BCLAF1 ⇩ 1.77 8.57E-03 
201407_s_at SEC23A ⇩ 1.86 0.022  239512_at C6orf62 ⇩ 1.81 0.020  238333_s_at PGGT1B ⇩ 1.77 2.46E-03 
204633_s_at MSL2 ⇩ 1.86 0.015  218738_s_at RNF138 ⇩ 1.81 0.018  220832_at SFRS12 ⇩ 1.76 0.037 
227393_at REC8 ⇧ 1.86 8.29E-03  209785_s_at ESPN ⇧ 1.81 0.016  1563975_at NSUN5C ⇧ 1.76 0.034 
218599_at SMG1 ⇩ 1.86 4.96E-03  223549_s_at PLA2G4C ⇧ 1.81 9.30E-03  227259_at NUDT14 ⇧ 1.76 0.029 
226010_at SLC25A23 ⇧ 1.86 8.19E-05  211575_s_at --- ⇧ 1.80 0.042  212721_at TLR8 ⇩ 1.76 0.018 
219132_at LAG3 ⇧ 1.85 0.040  239339_at C4orf48 ⇧ 1.80 0.028  228631_s_at PLA2G6 ⇧ 1.76 0.017 
214352_s_at NSUN5C ⇧ 1.85 0.031  238506_at UBE3A ⇩ 1.80 5.44E-03  213460_x_at ZNF688 ⇧ 1.76 9.61E-03 
212515_s_at NFIX ⇧ 1.85 0.025  229607_at LRRC58 ⇩ 1.80 5.36E-03  204691_x_at CD47 ⇩ 1.76 6.15E-03 
237461_at DDX3X ⇩ 1.85 0.022  229860_x_at --- ⇩ 1.80 1.32E-03  231914_at RNF130 ⇩ 1.76 5.12E-04 
243435_at NLRP7 ⇩ 1.85 0.020  222453_at RAB14 ⇩ 1.79 0.041  225362_at NUPL1 ⇩ 1.75 0.045 
227400_at KRAS ⇩ 1.85 8.23E-03  223263_s_at DOM3Z ⇧ 1.79 0.026  238317_x_at MOBKL1B ⇩ 1.75 0.037 
213842_x_at PELI2 ⇩ 1.85 6.58E-03  210281_s_at SIRT1 ⇩ 1.79 0.011  201299_s_at --- ⇩ 1.75 0.027 
206486_at KCNQ1OT1 ⇩ 1.85 5.93E-04  218878_s_at FGFR1OP2 ⇩ 1.79 8.69E-03  223984_s_at TRIOBP ⇩ 1.75 0.012 
222040_at CENPT ⇧ 1.84 0.038  200927_s_at CYBRD1 ⇩ 1.79 6.05E-03  1552334_at FLYWCH1 ⇧ 1.75 8.50E-03 
216241_s_at TCEA1 ⇩ 1.84 0.029  204522_at ZMYM2 ⇩ 1.79 3.41E-03  223950_s_at FAM122B ⇩ 1.75 1.99E-03 
206543_at HNRNPA1 ⇩ 1.84 9.92E-03  225243_s_at SLC11A1 ⇧ 1.78 0.045  226251_at ASXL2 ⇩ 1.74 0.045 
235461_at SMARCA2 ⇩ 1.84 8.12E-03  226464_at GLCCI1 ⇩ 1.78 0.037  229951_x_at --- ⇩ 1.74 7.81E-03 
218148_at TET2 ⇩ 1.84 4.83E-03  227525_at ZNF518A ⇩ 1.78 0.034  216899_s_at AGPAT3 ⇧ 1.74 1.98E-03 
218528_s_at RNF38 ⇩ 1.83 0.044  216511_s_at TCF7L2 ⇩ 1.78 0.031  223182_s_at SKAP2 ⇩ 1.74 1.02E-03 
223138_s_at MVP ⇧ 1.83 0.038  204291_at TAZ ⇧ 1.78 0.028  200751_s_at HNRNPA1 ⇩ 1.73 0.044 
210313_at LILRA4 ⇩ 1.83 0.032  212408_at C3orf58 ⇩ 1.78 0.023  218294_s_at HMGB1 ⇩ 1.73 0.043 
200728_at --- ⇧ 1.83 0.028  235721_at GSTT1 ⇧ 1.78 0.019  200731_s_at CARD8 ⇩ 1.73 0.043 
228730_s_at DHX36 ⇩ 1.83 0.026  210423_s_at SLMAP ⇩ 1.78 0.013  230775_s_at SLC30A7 ⇩ 1.73 0.039 
238591_at SCRN2 ⇧ 1.83 0.010  37278_at DTX3 ⇧ 1.78 8.17E-03  221919_at LRRC1 ⇩ 1.73 0.037 
202180_s_at ACTR2 ⇩ 1.83 5.50E-03  236430_at TOR1AIP1 ⇩ 1.78 5.70E-03  201493_s_at NCOA3 ⇩ 1.73 0.032 
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201133_s_at BCL6 ⇧ 1.73 0.028  223047_at ZNF24 ⇩ 1.70 0.046  212140_at LRCH4 ⇧ 1.68 0.022 
211352_s_at PJA2 ⇩ 1.73 0.025  214786_at --- ⇩ 1.70 0.043  209586_s_at PDS5A ⇩ 1.68 0.019 
224734_at DOM3Z ⇧ 1.73 0.024  221760_at LOC650392 ⇧ 1.70 0.029  229350_x_at C6orf62 ⇩ 1.68 0.018 
218816_at PTP4A1 ⇩ 1.73 0.023  226441_at CNOT8 ⇩ 1.70 0.026  37796_at PRUNE ⇩ 1.68 0.015 
226601_at NUP50 ⇩ 1.73 0.016  241245_at MAP3K2 ⇩ 1.70 0.021  1555874_x_at PPP2R5E ⇩ 1.68 0.014 
1554479_a_at --- ⇧ 1.73 0.015  202164_s_at SFRS4 ⇩ 1.70 0.020  237340_at --- ⇩ 1.68 0.014 
222235_s_at RP11 ⇩ 1.73 0.014  203247_s_at PCMTD1 ⇩ 1.70 0.018  204954_s_at DNAJC10 ⇩ 1.68 9.18E-03 
228758_at PELI1 ⇩ 1.73 0.013  206875_s_at HEXDC ⇧ 1.70 9.56E-03  203240_at DYRK1B ⇧ 1.68 9.10E-03 
38157_at CSGALNACT2 ⇩ 1.73 6.88E-03  235385_at SLK ⇩ 1.70 8.45E-03  226201_at MGC21881 ⇧ 1.68 5.37E-03 
238717_at HNRNPC ⇩ 1.73 5.38E-03  1569872_a_at MAP3K1 ⇩ 1.70 3.03E-03  213518_at PRKCI ⇩ 1.67 0.047 
244679_at COCH ⇩ 1.72 0.048  1555866_a_at SNX30 ⇩ 1.70 2.79E-03  202890_at GP1BB/SEPT5 ⇧ 1.67 0.047 
220369_at KLHL15 ⇩ 1.72 0.038  203397_s_at --- ⇧ 1.69 0.048  221918_at SMAD4 ⇩ 1.67 0.045 
242576_x_at --- ⇩ 1.72 0.025  216037_x_at C11orf58 ⇩ 1.69 0.040  216035_x_at HMGCR ⇩ 1.67 0.045 
244103_at SMEK1 ⇩ 1.72 0.024  201020_at GALNT3 ⇩ 1.69 0.029  202527_s_at PCTK2 ⇩ 1.67 0.044 
1554241_at --- ⇩ 1.72 0.021  213494_s_at DENND1C ⇧ 1.69 0.028  233329_s_at BMP2K ⇩ 1.67 0.038 
226370_at C1orf55 ⇩ 1.72 0.017  200084_at TMTC1 ⇧ 1.69 0.026  238619_at --- ⇧ 1.67 0.038 
243233_at LOC692247 ⇧ 1.72 9.80E-03  202006_at TMEM41B ⇩ 1.69 0.025  202540_s_at MAP7 ⇩ 1.67 0.034 
224041_at N4BP2L2 ⇩ 1.72 5.97E-03  212623_at LOC440731 ⇧ 1.69 0.025  226853_at --- ⇩ 1.67 0.030 
1569453_a_at TTTY6 ⇧ 1.72 2.07E-03  212306_at CLASP2 ⇩ 1.69 0.021  212479_s_at TCF7L2 ⇩ 1.67 0.028 
222111_at VARS2 ⇧ 1.71 0.050  221080_s_at PTPN12 ⇩ 1.69 0.020  219303_at KRCC1 ⇩ 1.67 0.028 
225997_at GPAA1 ⇧ 1.71 0.049  226322_at YY1 ⇩ 1.69 0.019  232311_at RASA4/4B  ⇧ 1.67 0.024 
201901_s_at --- ⇧ 1.71 0.034  202452_at TCF7L2 ⇩ 1.69 0.014  231647_s_at RMND5A ⇩ 1.67 0.023 
220515_at YY1 ⇩ 1.71 0.033  238973_s_at ZER1 ⇧ 1.69 0.013  212707_s_at RNF219 ⇩ 1.67 0.021 
203253_s_at C8orf73 ⇧ 1.71 0.032  201770_at SNRPA ⇧ 1.69 4.43E-03  239944_at B2M ⇩ 1.67 0.019 
1559957_a_at HISPPD1 ⇩ 1.71 0.019  238376_at YWHAH ⇩ 1.69 8.71E-04  206655_s_at FCRL5 ⇩ 1.67 3.10E-03 
226200_at DUSP21 ⇩ 1.71 0.016  203338_at WDR43 ⇩ 1.68 0.042  201599_at RSBN1 ⇩ 1.66 0.050 
201618_x_at --- ⇩ 1.71 0.013  213872_at SLC26A8 ⇧ 1.68 0.040  224046_s_at NSUN5 ⇧ 1.66 0.050 
227672_at HSDL2 ⇧ 1.71 9.18E-03  235060_at PARP10 ⇧ 1.68 0.037  225565_at C16orf35 ⇧ 1.66 0.048 
1559128_at MOBKL1A ⇩ 1.71 3.77E-03  1561015_at RBM25 ⇩ 1.68 0.034  208783_s_at MED28 ⇩ 1.66 0.037 
233369_at LOC642852 ⇧ 1.71 1.54E-03  225174_at LOC100190986 ⇩ 1.68 0.029  220038_at OAT ⇩ 1.66 0.034 
226249_at CMTM6 ⇩ 1.70 0.046  214662_at DOT1L ⇧ 1.68 0.029  223336_s_at FUK ⇧ 1.66 0.029 
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240592_at LCORL ⇩ 1.66 0.024  211671_s_at SLC38A2 ⇩ 1.64 0.045  208810_at SAMD9 ⇩ 1.63 0.031 
222789_at CPSF3L ⇧ 1.66 0.021  223925_s_at RBM7 ⇩ 1.64 0.045  225032_at CEP170 ⇩ 1.63 0.027 
217544_at SGK3 ⇩ 1.66 0.019  225133_at BACH1 ⇩ 1.64 0.045  204057_at FBXL4 ⇩ 1.63 0.025 
206015_s_at CD46 ⇩ 1.66 0.018  1555948_s_at STK16 ⇧ 1.64 0.045  213090_s_at LMF1 ⇧ 1.63 0.025 
209170_s_at RAB18 ⇩ 1.66 0.017  202694_at KDM4C ⇩ 1.64 0.042  221423_s_at YIPF5 ⇩ 1.63 0.017 
236752_at GPM6B ⇩ 1.66 0.015  202228_s_at LOC100130332 ⇩ 1.64 0.040  232225_at FNDC3B ⇩ 1.63 0.012 
224416_s_at LOC729806 ⇩ 1.66 0.012  241610_x_at CHKB/CPT1B ⇧ 1.64 0.038  46142_at SMARCA5 ⇩ 1.63 0.011 
226072_at FOXJ3 ⇩ 1.66 6.73E-03  227368_at KIAA1731 ⇩ 1.64 0.033  1553993_s_at --- ⇧ 1.63 0.011 
217994_x_at CREB1 ⇩ 1.66 3.45E-03  220924_s_at STK17A ⇩ 1.64 0.032  33736_at MIER1 ⇩ 1.63 8.33E-03 
205614_x_at MST1 ⇧ 1.66 2.49E-03  218379_at FAM120A ⇩ 1.64 0.030  225980_at LEMD3 ⇩ 1.62 0.050 
203802_x_at PDE7A ⇩ 1.66 1.82E-03  210233_at --- ⇩ 1.64 0.028  204742_s_at PRKD3 ⇩ 1.62 0.050 
210672_s_at --- ⇩ 1.66 1.12E-03  208859_s_at KLF3 ⇩ 1.64 0.019  218604_at TMEM63C ⇧ 1.62 0.050 
213016_at SPAG9 ⇩ 1.65 0.043  209984_at ZMIZ2 ⇧ 1.64 0.017  218191_s_at PKN2 ⇩ 1.62 0.041 
1555762_s_at PUM1 ⇩ 1.65 0.043  218318_s_at NLK ⇩ 1.64 0.016  241294_at SBNO2 ⇧ 1.62 0.040 
224866_at DGKZ ⇧ 1.65 0.042  204194_at IL1RAP ⇩ 1.64 0.015  222656_at MED21 ⇩ 1.62 0.039 
217843_s_at BBX ⇩ 1.65 0.041  210070_s_at NPTN ⇩ 1.64 0.013  225697_at TRPT1 ⇧ 1.62 0.039 
212468_at FAR1 ⇩ 1.65 0.038  221924_at ATRX ⇩ 1.64 0.011  209362_at EML3 ⇧ 1.62 0.036 
229322_at PPP2R5E ⇩ 1.65 0.037  238572_at --- ⇩ 1.64 3.51E-03  1562836_at CPSF3L ⇧ 1.62 0.029 
203491_s_at USP15 ⇩ 1.65 0.035  214532_x_at POU5F1B ⇧ 1.64 3.28E-03  218236_s_at --- ⇧ 1.62 0.028 
223888_s_at --- ⇩ 1.65 0.035  240666_at --- ⇧ 1.64 1.82E-03  225904_at C14orf43 ⇩ 1.62 0.027 
222473_s_at IQGAP2 ⇩ 1.65 0.029  1558720_at STOML1 ⇧ 1.63 0.050  212628_at GPN2 ⇧ 1.62 0.026 
209475_at PNN ⇩ 1.65 0.029  201152_s_at MBNL1 ⇩ 1.63 0.049  218552_at --- ⇩ 1.62 0.023 
203011_at NUCKS1 ⇩ 1.65 0.027  202769_at DNAJB14 ⇩ 1.63 0.047  204166_at ZNF444 ⇧ 1.62 0.022 
201165_s_at PLA2G6 ⇧ 1.65 0.025  235450_at MED25 ⇧ 1.63 0.047  218799_at --- ⇩ 1.62 0.021 
238100_at RBM15 ⇩ 1.65 0.020  222850_s_at LDLR ⇩ 1.63 0.045  227733_at UBE2W ⇩ 1.62 0.019 
203474_at IMPA1 ⇩ 1.65 0.017  202303_x_at IRF8 ⇩ 1.63 0.043  229066_at C1orf96 ⇩ 1.62 0.017 
229353_s_at LARS ⇩ 1.65 0.012  219691_at --- ⇩ 1.63 0.041  50376_at PDS5B ⇩ 1.62 0.012 
231035_s_at MED4 ⇩ 1.65 0.012  202068_s_at DNAJB6 ⇩ 1.63 0.040  223436_s_at CRKRS ⇩ 1.62 0.010 
212037_at ERBB2IP ⇩ 1.65 8.84E-03  225475_at --- ⇩ 1.63 0.039  224312_x_at ECHDC2 ⇧ 1.62 9.48E-03 
210647_x_at AAK1 ⇩ 1.65 7.54E-03  212746_s_at RP6 ⇩ 1.63 0.038  212969_x_at LOC338799 ⇧ 1.62 2.48E-03 
207556_s_at CEP57 ⇩ 1.65 6.12E-03  229212_at TAF4 ⇩ 1.63 0.036  226369_at LMBRD1 ⇩ 1.62 1.06E-03 
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242628_at UNKL ⇩ 1.61 0.047  1552386_at SPTBN5 ⇧ 1.60 0.020  211174_s_at RASSF5 ⇩ 1.59 2.57E-03 
209034_at GTF3C3 ⇩ 1.61 0.043  202014_at ACAP3 ⇧ 1.60 0.019  220178_at ZC3H15 ⇩ 1.59 2.30E-03 
221064_s_at MAP3K7 ⇩ 1.61 0.042  37462_i_at PIAS1 ⇩ 1.60 0.017  203901_at CCKAR ⇧ 1.59 1.76E-03 
201951_at PLCD1 ⇧ 1.61 0.042  226470_at BOD1L ⇩ 1.60 0.014  221049_s_at C19orf28 ⇧ 1.59 2.22E-04 
237001_at ARHGAP4 ⇧ 1.61 0.033  1556839_s_at --- ⇩ 1.60 0.013  206989_s_at LNX1 ⇩ 1.58 0.048 
236368_at RFNG ⇧ 1.61 0.033  206402_s_at GAPT ⇩ 1.60 0.012  225885_at AP1G2 ⇧ 1.58 0.048 
206853_s_at --- ⇩ 1.61 0.032  204375_at HBP1 ⇩ 1.60 0.011  223611_s_at ERAP2 ⇩ 1.58 0.046 
1555439_at ALCAM ⇩ 1.61 0.030  236541_at TMEM167B ⇩ 1.60 6.99E-03  200889_s_at MED24 ⇧ 1.58 0.046 
205819_at WDTC1 ⇧ 1.61 0.027  233625_x_at ZEB1 ⇩ 1.60 6.88E-03  227462_at IREB2 ⇩ 1.58 0.045 
216036_x_at --- ⇩ 1.61 0.025  235383_at PAK2 ⇩ 1.60 6.43E-03  225892_at HEMK1 ⇧ 1.58 0.042 
204425_at KIAA0368 ⇩ 1.61 0.021  228198_s_at ACTR2 ⇩ 1.60 2.68E-03  203689_s_at CR1 ⇩ 1.58 0.041 
205125_at MARCO ⇧ 1.61 0.015  225529_at G2E3 ⇩ 1.60 1.07E-03  206244_at POLRMT ⇧ 1.58 0.039 
212968_at PNRC1 ⇩ 1.61 4.23E-03  208276_at IGFBP3 ⇧ 1.59 0.049  204286_s_at SMOX ⇧ 1.58 0.035 
210966_x_at LARP1 ⇧ 1.61 8.77E-05  243280_at SPOPL ⇩ 1.59 0.046  217608_at EEA1 ⇩ 1.58 0.027 
218196_at TMTC3 ⇩ 1.60 0.049  201593_s_at CXXC1 ⇧ 1.59 0.044  235216_at PMAIP1 ⇩ 1.58 0.027 
236645_at PPP1CC ⇩ 1.60 0.047  225658_at MAP3K7IP1 ⇧ 1.59 0.037  218128_at TMEM63A ⇧ 1.58 0.024 
217862_at SOAT1 ⇩ 1.60 0.046  223650_s_at RAB21 ⇩ 1.59 0.034  210357_s_at GPR162 ⇧ 1.58 0.023 
208876_s_at --- ⇩ 1.60 0.040  228153_at SF3A2 ⇧ 1.59 0.031  203782_s_at FMR1 ⇩ 1.58 0.019 
222495_at MYO7B ⇧ 1.60 0.038  209701_at CRK ⇩ 1.59 0.030  213043_s_at ESCO1 ⇩ 1.58 0.017 
1560017_at SF3A2 ⇧ 1.60 0.034  202226_s_at RRAGD ⇩ 1.59 0.029  218620_s_at SFRS12IP1 ⇩ 1.58 0.015 
222980_at CPSF3L ⇧ 1.60 0.030  203885_at CACNB3 ⇧ 1.59 0.027  203326_x_at --- ⇧ 1.58 0.014 
200726_at NPFF ⇧ 1.60 0.029  1558093_s_at POLL ⇧ 1.59 0.023  201613_s_at SCYE1 ⇧ 1.58 0.012 
225039_at --- ⇩ 1.60 0.028  1554834_a_at ERAP1 ⇩ 1.59 0.022  235594_at SFRS2IP ⇩ 1.58 8.48E-03 
227293_at ARSA ⇧ 1.60 0.027  217955_at OGFOD2 ⇧ 1.59 0.022  229559_at FLJ40125 ⇧ 1.58 7.76E-03 
223255_at TMEM33 ⇩ 1.60 0.024  221523_s_at --- ⇩ 1.59 0.019  224821_at ABHD14B ⇧ 1.58 5.11E-03 
242388_x_at GGT7 ⇧ 1.60 0.024  209344_at RNF144B ⇩ 1.59 0.019  205056_s_at NFYB ⇩ 1.58 8.36E-04 
212758_s_at RPE ⇩ 1.60 0.023  48580_at MATR3 ⇩ 1.59 0.017  202700_s_at SSR1 ⇩ 1.58 5.27E-04 
235009_at RAB10 ⇩ 1.60 0.022  210095_s_at GPSN2 ⇧ 1.59 0.015  241866_at HDAC2 ⇩ 1.57 0.049 
238831_at PPP1R15A ⇧ 1.60 0.022  34726_at --- ⇩ 1.59 0.014  202539_s_at EWSR1 ⇩ 1.57 0.048 
212867_at LOC729234 ⇧ 1.60 0.022  208336_s_at TPM4 ⇩ 1.59 0.013  212461_at PPP1CB ⇩ 1.57 0.048 
1558015_s_at OSTM1 ⇩ 1.60 0.021  209381_x_at BCL2L13 ⇩ 1.59 6.95E-03  201833_at ZAP70 ⇧ 1.57 0.047 
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200641_s_at LRCH4 ⇧ 1.57 0.044  244177_at SGK1 ⇩ 1.56 0.034  205227_at CCNG2 ⇩ 1.55 0.036 
217845_x_at RNF207 ⇧ 1.57 0.041  212709_at LPGAT1 ⇩ 1.56 0.033  225509_at SMAD5 ⇩ 1.55 0.035 
204156_at FBXL3 ⇩ 1.57 0.030  214753_at IFRD1 ⇩ 1.56 0.032  202304_at MDM4 ⇩ 1.55 0.033 
223943_s_at ZNF862 ⇧ 1.57 0.030  202832_at MGC42157 ⇩ 1.56 0.030  209525_at MBD3 ⇧ 1.55 0.032 
218313_s_at LOC731424 ⇧ 1.57 0.028  226505_x_at GCC2 ⇩ 1.56 0.028  224863_at ARSD ⇧ 1.55 0.031 
225132_at DNHD1 ⇧ 1.57 0.027  231090_s_at C16orf58 ⇧ 1.56 0.028  238490_at ADD3 ⇩ 1.55 0.029 
229966_at HIGD1A ⇩ 1.57 0.025  202670_at HMGN4 ⇩ 1.56 0.027  216072_at STRN3 ⇩ 1.55 0.028 
236207_at FBXL18 ⇧ 1.57 0.024  202651_at ARID2 ⇩ 1.56 0.027  216915_s_at SAP30L ⇩ 1.55 0.028 
240099_at FHIT ⇧ 1.57 0.024  235072_s_at SNRPD1 ⇩ 1.56 0.021  1555977_at PIGB ⇩ 1.55 0.026 
240789_at GALNT7 ⇩ 1.57 0.022  201739_at --- ⇩ 1.56 0.020  212441_at G2E3 ⇩ 1.55 0.026 
201409_s_at HMGCR ⇩ 1.57 0.018  202147_s_at --- ⇩ 1.56 0.018  218929_at RASGRP2 ⇧ 1.55 0.022 
240248_at --- ⇩ 1.57 0.018  204872_at LMF1 ⇧ 1.56 0.018  201916_s_at BZW1 ⇩ 1.55 0.021 
230500_at GMCL1 ⇩ 1.57 0.018  203552_at --- ⇩ 1.56 0.017  202770_s_at KPNA4 ⇩ 1.55 0.021 
218458_at KIAA0999 ⇩ 1.57 0.015  225716_at CLCN7 ⇧ 1.56 0.014  242760_x_at FNDC3A ⇩ 1.55 0.020 
37586_at YWHAZ ⇩ 1.57 0.012  205905_s_at N4BP2L2 ⇩ 1.56 0.013  214578_s_at WDR74 ⇧ 1.55 0.020 
244759_x_at ZNF142 ⇧ 1.57 0.010  38069_at PPP3CA ⇩ 1.56 9.88E-03  225267_at PPP4R2 ⇩ 1.55 0.019 
213444_at CLTB ⇧ 1.57 8.79E-03  219135_s_at MFHAS1 ⇧ 1.56 8.95E-03  235765_at GNAQ ⇩ 1.55 0.019 
229631_at PDE7A ⇩ 1.57 7.60E-03  213457_at LOC285147 ⇩ 1.56 8.78E-03  226683_at CENPB ⇧ 1.55 0.018 
205104_at SNPH ⇧ 1.57 7.14E-03  222190_s_at TLE4 ⇩ 1.56 8.68E-03  223254_s_at --- ⇩ 1.55 0.016 
1569095_at SSFA2 ⇩ 1.57 3.59E-03  205655_at RFFL ⇩ 1.55 0.049  226558_at SNX18 ⇩ 1.55 0.016 
1556645_s_at --- ⇧ 1.57 3.28E-03  225219_at LOC389834 ⇩ 1.55 0.048  202463_s_at HDGFRP3 ⇩ 1.55 0.014 
221996_s_at USP1 ⇩ 1.57 2.42E-03  237919_at C1orf103 ⇩ 1.55 0.047  212390_at TMC4 ⇧ 1.55 0.014 
204692_at --- ⇩ 1.57 2.28E-03  235493_at IL1RAP ⇩ 1.55 0.047  214368_at MST1 ⇧ 1.55 0.013 
227500_at GNG2 ⇩ 1.57 2.10E-03  201753_s_at PDE4DIP ⇧ 1.55 0.047  212437_at SEC63 ⇩ 1.55 8.71E-03 
206492_at SLC16A7 ⇩ 1.57 1.50E-03  205842_s_at SH3GLB1 ⇩ 1.55 0.043  226403_at KIAA0232 ⇩ 1.55 7.96E-03 
214032_at AZIN1 ⇩ 1.57 1.19E-03  200777_s_at --- ⇩ 1.55 0.043  216320_x_at PHF3 ⇩ 1.55 5.98E-03 
202691_at MAP4K5 ⇩ 1.56 0.046  225519_at TLE4 ⇩ 1.55 0.042  218301_at PTPN12 ⇩ 1.55 3.29E-03 
236166_at CASP8AP2 ⇩ 1.56 0.045  1565544_at RNPEPL1 ⇧ 1.55 0.042  220616_at KIAA2026 ⇩ 1.55 1.51E-03 
222201_s_at USP32 ⇩ 1.56 0.043  220235_s_at --- ⇩ 1.55 0.039  225280_x_at ZNF384 ⇧ 1.55 5.36E-04 
202579_x_at NUP160 ⇩ 1.56 0.039  204496_at CDKN2AIP ⇩ 1.55 0.039  221712_s_at RNF141 ⇩ 1.55 2.69E-05 
202457_s_at MICA/B ⇧ 1.56 0.035  217951_s_at ROCK1 ⇩ 1.55 0.039  219289_at FBXO3 ⇩ 1.54 0.045 
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227013_at ZAP70 ⇧ 1.54 0.038  1555199_at API5 ⇩ 1.53 0.034  201775_s_at ARPC5 ⇩ 1.52 0.033 
222145_at AP3D1 ⇧ 1.54 0.037  214959_s_at FMR1 ⇩ 1.53 0.031  226109_at MED20 ⇩ 1.52 0.033 
212686_at CPSF3L ⇧ 1.54 0.037  215245_x_at MMP24 ⇧ 1.53 0.028  218559_s_at --- ⇩ 1.52 0.032 
218637_at TIGIT ⇧ 1.54 0.037  236723_at HHEX ⇩ 1.53 0.026  200679_x_at CCDC137 ⇧ 1.52 0.032 
208737_at --- ⇩ 1.54 0.034  220789_s_at LOC728903  ⇧ 1.53 0.024  217970_s_at RAP2C ⇩ 1.52 0.030 
239923_at HEATR3 ⇩ 1.54 0.033  211323_s_at TBRG4 ⇧ 1.53 0.023  217776_at CLTB ⇧ 1.52 0.029 
233308_at IMPACT ⇩ 1.54 0.024  203233_at --- ⇩ 1.53 0.021  218669_at ZNF107 ⇩ 1.52 0.028 
218432_at --- ⇩ 1.54 0.022  208534_s_at IL4R ⇧ 1.53 0.021  211749_s_at --- ⇧ 1.52 0.022 
218614_at MAF1 ⇧ 1.54 0.021  1560957_at DPM1 ⇩ 1.53 0.017  218127_at HIP1R ⇧ 1.52 0.021 
229392_s_at MBD3 ⇧ 1.54 0.020  1555872_a_at HSPD1 ⇩ 1.53 0.015  47069_at FREM3 ⇧ 1.52 0.018 
222998_at C7orf38 ⇧ 1.54 0.016  213171_s_at --- ⇩ 1.53 0.012  238893_at ST3GAL6 ⇩ 1.52 0.015 
238965_at LATS2 ⇩ 1.54 0.013  1558836_at UHRF1BP1L ⇩ 1.53 0.011  203839_s_at MPI ⇧ 1.52 0.014 
210974_s_at PABPC1L ⇧ 1.54 0.013  211849_s_at GOSR1 ⇩ 1.53 0.011  227464_at CCPG1 ⇩ 1.52 0.012 
1555613_a_at C12orf35 ⇩ 1.54 7.71E-03  1558739_at RNGTT ⇧ 1.53 0.011  243337_at HMGB1 ⇩ 1.52 0.010 
233563_s_at C21orf2 ⇧ 1.54 7.13E-03  1554085_at RASA4 ⇧ 1.53 1.11E-03  210106_at --- ⇩ 1.52 9.63E-03 
41160_at PIK3R2 ⇧ 1.54 6.70E-03  213549_at --- ⇩ 1.52 0.049  1556308_at ANKRD12 ⇩ 1.52 9.16E-03 
240070_at ATP6V1G1 ⇩ 1.54 5.46E-03  211963_s_at NFYB ⇩ 1.52 0.049  209558_s_at ITPA ⇧ 1.52 9.12E-03 
229762_at SBF1 ⇧ 1.54 3.93E-03  225222_at SLC2A9 ⇧ 1.52 0.049  240223_at KIAA0494 ⇩ 1.52 9.03E-03 
226670_s_at PPM1H ⇩ 1.54 3.82E-03  224823_at C21orf91 ⇩ 1.52 0.048  202472_at LOC338758 ⇧ 1.52 6.34E-03 
212393_at GTF2F2 ⇩ 1.54 2.21E-03  202777_at MAFB ⇩ 1.52 0.045  225933_at VAMP3 ⇩ 1.52 5.53E-03 
200806_s_at CHMP2B ⇩ 1.53 0.046  1560854_s_at ARSD ⇧ 1.52 0.044  218985_at RDH5 ⇧ 1.52 3.84E-03 
202536_at RBM15 ⇩ 1.53 0.045  212099_at MYLK ⇩ 1.52 0.044  244429_at CA5BP ⇩ 1.52 2.05E-03 
219286_s_at COPS8 ⇩ 1.53 0.043  222313_at PRR5 ⇧ 1.52 0.044  223695_s_at PRRT3 ⇧ 1.52 1.32E-03 
244662_at ERAP2 ⇩ 1.53 0.042  242471_at ACSF3 ⇧ 1.52 0.043  230026_at HIAT1 ⇩ 1.52 1.14E-03 
1554915_a_at --- ⇧ 1.53 0.042  242273_at RHOB ⇩ 1.52 0.040  209171_at --- ⇩ 1.52 5.99E-04 
202142_at PDE12 ⇩ 1.53 0.041  213355_at CNOT6 ⇩ 1.52 0.040  205172_x_at SLC2A8 ⇧ 1.52 3.50E-04 
235104_at KIAA0240 ⇩ 1.53 0.041  223079_s_at SHOC2 ⇩ 1.52 0.039  208883_at PTPN23 ⇧ 1.51 0.048 
213118_at ITPR1 ⇧ 1.53 0.040  212872_s_at MRPL43 ⇧ 1.52 0.039  238687_x_at FAM20B ⇩ 1.51 0.047 
213208_at --- ⇧ 1.53 0.039  212289_at --- ⇩ 1.52 0.038  241242_at SLC25A37 ⇧ 1.51 0.046 
226543_at --- ⇧ 1.53 0.038  238435_at TNK2 ⇧ 1.52 0.036  231747_at NRG1 ⇧ 1.51 0.041 
204689_at DDX51 ⇧ 1.53 0.036  222156_x_at RDH11 ⇩ 1.52 0.035  225350_s_at MSRB3 ⇩ 1.51 0.040 
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225693_s_at CCHCR1 ⇧ 1.51 0.040  238568_s_at MARK4 ⇧ 1.51 5.65E-03  205215_at SMARCA2 ⇩ 1.50 0.042 
202915_s_at UBTD2 ⇩ 1.51 0.039  206237_s_at LIMS1 ⇩ 1.51 5.48E-03  1559369_at CES2 ⇧ 1.50 0.042 
210621_s_at TM2D1 ⇩ 1.51 0.035  243757_at --- ⇧ 1.51 4.49E-03  200767_s_at FAM159A ⇧ 1.50 0.040 
232964_at KCTD9 ⇩ 1.51 0.035  218978_s_at --- ⇩ 1.51 3.96E-03  225976_at FCHO2 ⇩ 1.50 0.032 
224827_at ZNF770 ⇩ 1.51 0.032  212193_s_at SPDYE1 ⇩ 1.51 1.77E-03  206542_s_at FAM120A ⇩ 1.50 0.030 
221579_s_at ZYG11B ⇩ 1.51 0.027  223150_s_at UBR5 ⇩ 1.51 1.72E-03  222688_at TRADD ⇧ 1.50 0.029 
213882_at RASA1 ⇩ 1.51 0.025  230095_at HMGXB4 ⇧ 1.51 4.65E-04  1555153_s_at RNF2 ⇩ 1.50 0.027 
207198_s_at CAMTA1 ⇩ 1.51 0.021  209698_at LARP1 ⇧ 1.51 1.52E-05  231927_at ATF6 ⇩ 1.50 0.027 
226810_at OGFRL1 ⇩ 1.51 0.017  241642_x_at C5orf44 ⇩ 1.50 0.048  222206_s_at NCLN ⇧ 1.50 0.026 
218823_s_at COASY ⇧ 1.51 0.017  226128_at TLK1 ⇩ 1.50 0.043  1729_at SMARCA2 ⇩ 1.50 0.025 
55065_at CYSLTR1 ⇩ 1.51 0.016  202056_at ACER3 ⇩ 1.50 0.043  209667_at --- ⇩ 1.50 0.013 
201913_s_at NUDT3 ⇩ 1.51 0.013  206544_x_at BTF3L4 ⇩ 1.50 0.042  237033_at KPNA1 ⇩ 1.50 5.32E-03 
212596_s_at --- ⇧ 1.51 0.012             
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Probeset ID Symbol Fold p-value  Probeset ID Symbol Fold p-value  Probeset ID Symbol Fold p-value 
224559_at MALAT1 ⇧ 13.2 8.30E-07  215599_at LOC653188 ⇧ 4.25 4.90E-04  242431_at --- ⇧ 3.86 3.20E-06 
228582_x_at MALAT1 ⇧ 12.2 4.60E-05  239014_at CCAR1 ⇩ 4.24 2.10E-04  230206_at DOCK5 ⇧ 3.85 1.60E-05 
217414_x_at HBA1/2 ⇩ 9.12 0.030  213757_at --- ⇧ 4.23 2.40E-03  1555745_a_at LYZ ⇩ 3.84 0.020 
221491_x_at HLA-DRB1/3-5  ⇩ 9.11 0.025  228251_at LOC100130930 ⇧ 4.21 4.50E-04  1559142_at MYST3 ⇧ 3.83 1.40E-05 
228697_at HINT3 ⇧ 8.34 1.80E-05  222179_at CDC5L ⇩ 4.19 2.20E-04  231484_at --- ⇧ 3.82 0.028 
1559500_at VPS8 ⇧ 7.45 1.40E-04  1569706_at MYSM1 ⇧ 4.17 4.40E-05  226762_at PURB ⇧ 3.81 6.50E-04 
241879_at LPP ⇧ 7.17 2.20E-06  1565743_at --- ⇧ 4.16 1.70E-05  235999_at --- ⇧ 3.81 2.10E-04 
232535_at --- ⇧ 6.68 9.60E-07  232958_at --- ⇧ 4.14 1.10E-03  241702_at --- ⇧ 3.79 8.10E-04 
211699_x_at HBA1/2 ⇩ 6.46 0.046  233706_at --- ⇧ 4.12 2.10E-04  237590_at --- ⇧ 3.79 4.30E-05 
235008_at --- ⇩ 6.17 5.50E-06  1560662_s_at WHAMML1/2 ⇧ 4.11 7.10E-05  1562467_at --- ⇧ 3.75 4.70E-05 
204270_at SKI ⇩ 5.95 7.10E-05  243559_at --- ⇧ 4.10 1.80E-03  239453_at --- ⇧ 3.75 1.50E-05 
213998_s_at DDX17 ⇩ 5.93 8.10E-05  208442_s_at ATM ⇧ 4.10 4.20E-04  242975_s_at --- ⇧ 3.71 9.90E-05 
236201_at --- ⇧ 5.83 6.20E-03  238185_at --- ⇧ 4.08 9.90E-06  228248_at RICTOR ⇧ 3.69 8.50E-05 
1570361_a_at --- ⇧ 5.75 6.00E-05  222787_s_at TMEM106B ⇧ 4.07 1.30E-04  239393_at --- ⇧ 3.66 2.90E-05 
229982_at QSER1 ⇧ 5.32 1.20E-04  243089_at --- ⇧ 4.04 4.00E-04  218400_at OAS3 ⇩ 3.65 0.016 
215175_at PCNX ⇧ 5.26 2.40E-03  1556277_a_at PAPD4 ⇧ 4.02 1.90E-04  236930_at NUMB ⇧ 3.64 2.50E-04 
204018_x_at HBA1/2 ⇩ 5.23 0.045  236808_at FGFR1OP2 ⇧ 3.99 7.20E-04  235613_at --- ⇧ 3.62 7.10E-04 
226931_at TMTC1 ⇧ 5.15 3.60E-04  241041_at --- ⇧ 3.99 4.40E-04  236000_s_at --- ⇧ 3.61 1.10E-03 
241610_x_at --- ⇧ 4.94 1.00E-04  240652_at --- ⇧ 3.97 1.60E-04  211310_at EZH1 ⇧ 3.61 1.00E-04 
207604_s_at SLC4A7 ⇧ 4.88 1.20E-06  1567045_at --- ⇧ 3.97 2.70E-05  221745_at WDR68 ⇧ 3.60 2.00E-04 
242974_at CD47 ⇧ 4.78 3.50E-06  1562283_at --- ⇧ 3.96 1.10E-03  1565788_at --- ⇧ 3.60 1.30E-04 
205654_at C4BPA ⇧ 4.75 0.029  224829_at CPEB4 ⇧ 3.96 2.20E-04  208523_x_at HIST1H2BI ⇩ 3.60 4.30E-06 
239751_at LOC100506860 ⇧ 4.74 4.60E-06  208930_s_at ILF3 ⇧ 3.94 2.30E-04  201340_s_at ENC1 ⇧ 3.58 5.20E-06 
242029_at FNDC3B ⇧ 4.67 5.10E-05  208268_at ADAM28 ⇧ 3.90 2.40E-03  234044_at --- ⇧ 3.57 2.30E-03 
220900_at --- ⇧ 4.48 7.50E-06  235643_at SAMD9L ⇧ 3.89 1.60E-03  214690_at TAF1B ⇧ 3.57 2.00E-04 
226322_at TMTC1 ⇧ 4.47 4.50E-03  242903_at IFNGR1 ⇧ 3.89 8.00E-05  231173_at PYROXD1 ⇧ 3.56 2.80E-03 
232365_at SIAH1 ⇧ 4.40 4.60E-04  1560776_at --- ⇧ 3.89 3.70E-05  241860_at --- ⇧ 3.55 1.90E-03 
212182_at NUDT4 ⇧ 4.39 5.60E-05  233724_at ARNT ⇧ 3.89 5.10E-07  1557244_a_at --- ⇩ 3.55 1.60E-04 
242659_at --- ⇧ 4.36 3.40E-06  232386_at VPS13C ⇧ 3.88 3.30E-05  1566002_at --- ⇧ 3.55 1.50E-04 
1565868_at CD44 ⇧ 4.30 3.40E-05  231097_at --- ⇧ 3.87 4.20E-04  208579_x_at H2BFS ⇩ 3.54 6.80E-05 
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211734_s_at FCER1A ⇩ 3.53 0.020  238787_at DENND1B ⇧ 3.34 5.00E-03  241843_at SNORA28 ⇧ 3.16 1.20E-03 
234210_x_at ACTR2 ⇧ 3.52 4.50E-04  228222_at PPP1CB ⇧ 3.34 1.30E-03  238761_at ELK4 ⇧ 3.16 2.50E-04 
226999_at RNPC3 ⇧ 3.52 2.30E-05  242693_at --- ⇧ 3.34 7.90E-04  234059_at --- ⇧ 3.16 4.60E-06 
1569408_at EIF2C4 ⇧ 3.51 2.60E-04  203496_s_at MED1 ⇧ 3.34 1.10E-04  243458_at --- ⇧ 3.15 1.50E-03 
217160_at TSPY1 ⇧ 3.51 1.40E-04  239167_at --- ⇧ 3.34 8.10E-05  237963_x_at --- ⇧ 3.15 5.10E-04 
236435_at --- ⇧ 3.49 7.10E-04  203290_at HLA-DQA1 ⇩ 3.33 0.023  222319_at --- ⇧ 3.15 1.90E-04 
212172_at AK2 ⇧ 3.49 1.10E-04  232311_at B2M ⇧ 3.33 3.10E-04  1557811_a_at --- ⇧ 3.14 3.10E-04 
1560926_at --- ⇧ 3.48 6.30E-04  211745_x_at HBA1/2 ⇩ 3.31 0.027  1555194_at --- ⇧ 3.14 1.50E-04 
225720_at SYNPO2 ⇩ 3.47 6.50E-03  228498_at B4GALT1 ⇧ 3.30 2.00E-03  209398_at HIST1H1C ⇩ 3.13 3.50E-03 
215483_at AKAP9 ⇧ 3.47 1.90E-03  1559201_a_at OSTF1 ⇧ 3.30 6.10E-04  243876_at --- ⇧ 3.13 6.90E-05 
210867_at CNOT4 ⇧ 3.47 2.70E-04  240103_at --- ⇧ 3.30 4.90E-04  236794_at --- ⇧ 3.13 5.10E-05 
1557036_at ZBTB1 ⇧ 3.46 5.40E-03  242622_x_at PTEN ⇧ 3.29 2.00E-03  1554241_at COCH ⇧ 3.13 4.30E-05 
1556462_a_at --- ⇧ 3.46 5.30E-04  1558080_s_at DNAJC3 ⇧ 3.29 1.60E-03  228471_at ANKRD44 ⇧ 3.12 1.60E-05 
1556158_at FAM154B ⇧ 3.45 0.012  241824_at --- ⇧ 3.28 9.80E-04  222728_s_at TAF1D ⇧ 3.11 4.00E-04 
233964_at --- ⇧ 3.45 2.00E-04  224230_at IL1F8 ⇧ 3.28 1.20E-05  229353_s_at NUCKS1 ⇧ 3.10 2.90E-03 
206088_at LRRC37A2/3 ⇧ 3.44 1.30E-03  240593_x_at --- ⇧ 3.27 3.20E-04  236354_at --- ⇧ 3.09 1.20E-03 
236043_at LOC100130175 ⇧ 3.43 7.40E-05  203749_s_at RARA ⇧ 3.26 3.50E-03  228638_at FAM76A ⇧ 3.09 3.50E-04 
209458_x_at HBA1/2 ⇩ 3.42 0.024  1554676_at SRGN ⇧ 3.26 2.80E-03  230270_at PRPF38B ⇧ 3.09 2.50E-04 
238611_at --- ⇧ 3.42 3.80E-05  214405_at --- ⇧ 3.26 1.70E-03  222826_at PLDN ⇧ 3.09 4.30E-05 
1565620_at AGAP4 ⇧ 3.41 7.30E-04  1557707_at --- ⇧ 3.26 8.20E-04  1558315_s_at HOOK3 ⇧ 3.09 2.00E-05 
243490_at --- ⇧ 3.40 1.00E-03  235879_at MBNL1 ⇧ 3.26 9.70E-05  215659_at GSDMB ⇧ 3.07 2.70E-04 
236432_at --- ⇧ 3.38 4.20E-03  1558710_at --- ⇧ 3.26 6.10E-06  1555423_at SSH2 ⇧ 3.06 7.20E-04 
242467_at --- ⇧ 3.38 4.80E-05  1565915_at --- ⇧ 3.26 1.20E-06  206544_x_at SMARCA2 ⇩ 3.06 5.40E-04 
205118_at FPR1 ⇧ 3.37 2.50E-03  222341_x_at --- ⇧ 3.23 0.019  212081_x_at BAT2 ⇧ 3.05 0.018 
234326_at --- ⇧ 3.36 2.90E-03  1554306_at ITPKB ⇧ 3.23 1.90E-04  242859_at --- ⇧ 3.05 9.30E-04 
1556461_at --- ⇧ 3.36 7.70E-04  216300_x_at RARA ⇧ 3.21 2.60E-03  242299_at --- ⇧ 3.05 5.00E-04 
1564164_at DENND1B ⇧ 3.36 1.10E-04  231829_at MAVS ⇧ 3.19 7.30E-04  239861_at --- ⇧ 3.04 6.30E-04 
240544_at --- ⇧ 3.36 1.30E-06  1570021_at --- ⇧ 3.19 3.20E-04  219186_at ZBTB7A ⇧ 3.04 1.00E-04 
220338_at RALGPS2 ⇧ 3.35 2.40E-03  243496_at RAB18 ⇧ 3.19 3.20E-04  1555167_s_at NAMPT ⇩ 3.03 0.037 
215986_at --- ⇧ 3.35 1.70E-04  1558842_at --- ⇧ 3.18 3.00E-03  1565811_at --- ⇧ 3.03 3.30E-03 
216765_at MAP2K5 ⇧ 3.35 9.60E-05  238931_at METT10D ⇧ 3.18 6.70E-04  220494_s_at --- ⇧ 3.03 7.40E-04 
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238769_at --- ⇧ 3.01 3.90E-03  232179_at LOC158863 ⇧ 2.93 4.10E-04  242261_at IREB2 ⇧ 2.84 1.10E-03 
234112_at --- ⇧ 3.01 2.10E-03  229422_at NRD1 ⇧ 2.92 2.40E-04  233314_at PTEN ⇩ 2.84 6.70E-04 
237067_at --- ⇧ 3.00 2.10E-03  238193_at --- ⇧ 2.92 7.70E-05  1568866_at --- ⇧ 2.84 5.90E-04 
1555920_at CBX3 ⇧ 3.00 9.30E-04  1558802_at --- ⇧ 2.91 9.30E-04  243964_at --- ⇧ 2.84 3.30E-04 
236254_at VPS13B ⇧ 3.00 5.30E-04  1561340_at --- ⇧ 2.91 5.40E-06  217534_at FAM49B ⇧ 2.84 5.80E-05 
1565913_at --- ⇧ 3.00 1.80E-04  226736_at CHURC1 ⇧ 2.90 0.035  230621_at IAH1 ⇧ 2.83 3.80E-05 
236237_at --- ⇧ 2.99 7.20E-03  236975_at --- ⇧ 2.90 0.018  235172_at --- ⇧ 2.82 5.60E-03 
243134_at --- ⇧ 2.99 4.60E-04  236659_x_at --- ⇧ 2.90 1.80E-03  211644_x_at IGK ⇩ 2.82 3.30E-04 
208629_s_at HADHA ⇧ 2.99 4.10E-04  224563_at WASF2 ⇩ 2.89 6.00E-03  231252_at C2orf67 ⇧ 2.82 2.00E-04 
1561654_at --- ⇧ 2.99 7.50E-05  1569262_x_at UBE2CBP ⇧ 2.89 5.10E-03  220655_at TNIP3 ⇧ 2.82 2.50E-05 
1560058_at LOC399900 ⇧ 2.98 6.90E-03  237322_at MIAT ⇧ 2.89 2.90E-03  204192_at CD37 ⇩ 2.81 0.018 
208764_s_at ATP5G2 ⇩ 2.98 3.50E-04  242576_x_at N4BP2L2 ⇧ 2.89 2.10E-03  235851_s_at GNAS ⇧ 2.81 6.10E-03 
237387_at --- ⇧ 2.98 6.20E-05  232418_at LZTFL1 ⇧ 2.89 9.40E-04  243182_at --- ⇧ 2.81 5.80E-03 
204863_s_at IL6ST ⇧ 2.97 9.50E-03  238902_at PCMTD1 ⇧ 2.89 8.70E-04  236533_at ASAP1 ⇧ 2.81 1.90E-04 
223487_x_at GNB4 ⇧ 2.97 3.10E-03  1559039_at DHX36 ⇧ 2.89 1.60E-05  1560048_at --- ⇧ 2.81 1.30E-04 
212417_at SCAMP1 ⇧ 2.97 1.10E-03  217811_at SELT ⇩ 2.88 9.30E-03  227897_at --- ⇧ 2.81 1.90E-05 
237197_at --- ⇩ 2.97 9.30E-04  1567044_s_at --- ⇧ 2.88 2.40E-03  222067_x_at HIST1H2BD ⇩ 2.81 1.50E-05 
243149_at --- ⇧ 2.97 7.00E-04  222929_at FAM160B2 ⇧ 2.88 5.70E-05  1563226_at SLC38A10 ⇧ 2.80 6.60E-03 
1555392_at LOC100128868 ⇧ 2.97 6.20E-04  233995_at --- ⇧ 2.87 4.20E-03  1554084_a_at NOL9 ⇧ 2.80 3.00E-04 
219980_at C4orf29 ⇧ 2.97 1.70E-04  200806_s_at HSPD1 ⇩ 2.87 5.50E-04  243454_at --- ⇧ 2.80 8.30E-05 
1564767_at --- ⇧ 2.97 4.10E-05  206454_s_at RHO ⇩ 2.86 0.014  208546_x_at HIST1H2BH ⇩ 2.80 2.40E-05 
230392_at --- ⇧ 2.96 4.00E-03  226663_at ANKRD10 ⇧ 2.86 1.60E-03  1562255_at SYTL3 ⇧ 2.79 0.011 
217363_x_at --- ⇩ 2.96 2.40E-03  205310_at FBXO46 ⇧ 2.86 2.70E-04  1555116_s_at SLC11A1 ⇧ 2.79 1.70E-03 
1565810_at --- ⇧ 2.96 1.40E-03  238672_at --- ⇧ 2.86 7.70E-05  215874_at --- ⇧ 2.79 1.10E-03 
203533_s_at CUL5 ⇧ 2.96 3.50E-04  210666_at IDS ⇧ 2.86 5.70E-05  1552302_at TMEM106A ⇧ 2.79 4.40E-05 
238363_at --- ⇧ 2.95 8.30E-05  207631_at NBR2 ⇧ 2.86 3.70E-05  241497_at --- ⇧ 2.78 0.013 
1556323_at CUGBP2 ⇧ 2.94 5.40E-04  244508_at SEPT7 ⇧ 2.85 8.10E-03  1566608_at --- ⇧ 2.78 2.00E-03 
238610_s_at --- ⇧ 2.94 2.70E-05  1560349_at --- ⇧ 2.85 2.80E-04  235220_at YIPF4 ⇧ 2.78 1.30E-03 
213954_at FAM169A ⇧ 2.93 7.80E-03  1559347_at --- ⇧ 2.85 1.50E-04  233872_x_at ARHGAP5 ⇧ 2.78 9.90E-04 
244473_at --- ⇧ 2.93 7.20E-03  1564776_at --- ⇧ 2.84 5.40E-03  233239_at --- ⇧ 2.78 2.20E-04 
221688_s_at IMP3 ⇩ 2.93 4.00E-03  222850_s_at DNAJB14 ⇧ 2.84 4.40E-03  237459_at --- ⇧ 2.78 9.40E-05 
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215392_at --- ⇧ 2.77 1.50E-03  231507_at --- ⇧ 2.70 2.80E-03  206965_at KLF12 ⇧ 2.66 3.10E-03 
233400_at --- ⇧ 2.77 1.50E-03  238013_at PLEKHA2 ⇧ 2.70 1.40E-03  240105_at --- ⇧ 2.66 2.70E-03 
232392_at SFRS3 ⇧ 2.76 2.10E-03  224697_at WDR22 ⇩ 2.70 6.00E-04  227062_at NCRNA00084 ⇧ 2.65 9.60E-03 
233204_at LOC728153 ⇧ 2.76 9.30E-04  230407_at SBNO1 ⇧ 2.70 4.40E-04  1559747_at SPG11 ⇧ 2.65 1.40E-03 
232412_at FBXL20 ⇧ 2.76 7.00E-04  236985_at --- ⇧ 2.70 3.90E-04  230128_at IGL ⇧ 2.65 0.017 
209060_x_at NCOA3 ⇧ 2.76 4.40E-04  244539_at --- ⇧ 2.70 2.80E-04  203415_at PDCD6 ⇩ 2.65 0.017 
243031_at --- ⇧ 2.75 8.30E-03  221829_s_at TNPO1 ⇧ 2.70 3.20E-05  242712_x_at RGPD1-8 ⇧ 2.64 1.60E-03 
215434_x_at NBPF1/10 ⇧ 2.75 7.30E-03  216735_x_at --- ⇧ 2.70 8.90E-06  AFFX-r2-Bs-
lys-5_at 
--- ⇩ 2.63 0.022 
232622_at --- ⇧ 2.75 1.20E-03  1557543_at --- ⇧ 2.69 2.60E-03  1558569_at UNQ6228 ⇧ 2.63 0.017 
235926_at ANAPC5 ⇧ 2.75 8.00E-04  206697_s_at HP  ⇧ 2.69 2.50E-03  219158_s_at NARG1 ⇧ 2.63 4.80E-03 
239405_at --- ⇧ 2.75 6.10E-04  208490_x_at HIST1H2BF ⇩ 2.69 1.60E-03  1558922_at --- ⇧ 2.63 3.00E-03 
1566003_x_at --- ⇧ 2.75 4.00E-04  228545_at ZNF148 ⇧ 2.69 1.20E-03  238271_x_at --- ⇧ 2.63 7.10E-04 
1558515_at FTX ⇧ 2.75 2.60E-04  243178_at --- ⇧ 2.69 5.30E-04  1559391_s_at --- ⇧ 2.63 5.90E-04 
216198_at ATF7IP ⇧ 2.75 1.50E-04  227145_at LOXL4 ⇧ 2.69 2.20E-04  203482_at FAM178A ⇧ 2.63 5.60E-04 
231005_at --- ⇧ 2.75 1.10E-04  214777_at IGKV4-1 ⇩ 2.68 3.80E-03  230543_at --- ⇧ 2.63 2.60E-04 
232637_at SEPT2 ⇧ 2.75 6.80E-06  228834_at TOB1 ⇧ 2.68 2.60E-03  216767_at --- ⇧ 2.63 9.10E-05 
243469_at --- ⇧ 2.74 2.20E-03  201868_s_at TBL1X ⇧ 2.68 1.80E-03  241259_at GAB3 ⇧ 2.63 2.30E-05 
1557797_a_at --- ⇧ 2.74 9.90E-04  233009_at --- ⇧ 2.68 1.60E-03  211424_x_at METTL7A ⇧ 2.63 2.30E-05 
234009_at --- ⇧ 2.74 7.90E-04  235957_at GRIP1 ⇧ 2.68 8.80E-04  207067_s_at HDC ⇩ 2.62 0.031 
242117_at --- ⇧ 2.74 5.50E-04  1566426_at --- ⇧ 2.68 8.10E-04  209750_at NR1D2 ⇧ 2.62 0.011 
214693_x_at NBPF10 ⇧ 2.73 4.30E-03  230629_s_at EP400 ⇧ 2.68 4.90E-04  238851_at ANKRD13A ⇧ 2.62 2.20E-03 
238982_at DENR ⇧ 2.73 3.30E-03  240482_at --- ⇧ 2.68 9.90E-07  239661_at --- ⇧ 2.62 1.40E-03 
233824_at --- ⇧ 2.73 1.20E-03  1555091_at PPM1F ⇧ 2.67 4.80E-03  238317_x_at --- ⇧ 2.62 1.00E-03 
207492_at NGLY1 ⇧ 2.72 5.40E-04  1557305_at TACC1 ⇧ 2.67 8.30E-04  239364_at --- ⇧ 2.62 3.30E-04 
203007_x_at LYPLA1 ⇧ 2.72 1.70E-04  238430_x_at SLFN5 ⇧ 2.67 4.10E-04  231281_at --- ⇧ 2.62 2.80E-05 
220572_at --- ⇧ 2.72 1.20E-04  208527_x_at HIST1H2BE ⇩ 2.67 1.10E-04  AFFX-LysX-
5_at 
--- ⇩ 2.62 0.013 
215524_x_at TRAC ⇩ 2.72 1.00E-05  230461_s_at --- ⇧ 2.67 6.50E-05  1566113_at --- ⇧ 2.61 4.40E-03 
217753_s_at RPS26 ⇧ 2.71 4.30E-03  230466_s_at RASSF3 ⇧ 2.67 5.40E-05  1558747_at SMCHD1 ⇧ 2.61 3.40E-03 
238563_at --- ⇧ 2.71 5.80E-04  1558698_at ZNF264 ⇧ 2.66 0.019  236907_at --- ⇧ 2.61 2.10E-03 
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205594_at ZNF652 ⇧ 2.61 1.50E-04  219125_s_at RAG1AP1 ⇧ 2.56 2.90E-06  224346_at --- ⇩ 2.51 2.20E-04 
241692_at --- ⇧ 2.61 3.00E-05  234288_at --- ⇧ 2.55 0.027  241050_at --- ⇩ 2.50 0.020 
232537_x_at MARK3 ⇧ 2.60 8.00E-03  209127_s_at SART3 ⇧ 2.55 0.010  202412_s_at USP1 ⇧ 2.50 4.90E-03 
210384_at PRMT2 ⇧ 2.60 5.10E-03  242384_at --- ⇧ 2.55 7.90E-03  208151_x_at DDX17 ⇧ 2.50 4.00E-03 
220710_at C15orf28 ⇧ 2.60 1.20E-03  215464_s_at TAX1BP3 ⇩ 2.55 4.10E-03  231848_x_at ZNF207 ⇧ 2.50 3.90E-03 
243667_at --- ⇧ 2.60 7.50E-04  1565566_a_at --- ⇧ 2.55 1.30E-03  211395_x_at FCGR2C ⇩ 2.50 2.10E-03 
1555945_s_at FAM120A ⇧ 2.60 3.30E-04  236841_at --- ⇧ 2.55 6.50E-04  1556318_s_at CAND1 ⇧ 2.50 7.90E-04 
236327_at --- ⇧ 2.60 2.60E-04  210484_s_at TNFRSF10C ⇩ 2.55 4.70E-04  214257_s_at --- ⇧ 2.50 5.40E-04 
240036_at SEC14L1 ⇧ 2.59 9.20E-03  215385_at --- ⇧ 2.55 2.90E-04  230494_at SLC20A1 ⇧ 2.50 4.90E-04 
235567_at RORA ⇧ 2.59 6.80E-03  217368_at ATP5G2 ⇩ 2.55 4.60E-05  214768_x_at FAM20B ⇩ 2.50 2.90E-04 
234474_x_at IL6ST ⇧ 2.59 6.60E-03  216373_at TAPT1 ⇧ 2.55 1.50E-05  211411_at --- ⇧ 2.50 3.70E-05 
208200_at IL1A ⇧ 2.59 1.40E-03  201237_at CAPZA2 ⇧ 2.53 0.019  1564794_at --- ⇧ 2.50 3.30E-05 
239629_at CFLAR ⇧ 2.59 6.10E-04  236223_s_at RIT1 ⇧ 2.53 4.80E-03  229606_at --- ⇧ 2.50 1.70E-05 
229398_at RAB18 ⇧ 2.59 5.00E-04  216401_x_at LOC652493 ⇩ 2.53 3.90E-03  242280_x_at CPEB4 ⇧ 2.49 0.024 
1564021_at --- ⇧ 2.59 3.80E-04  229858_at --- ⇧ 2.53 3.70E-03  213328_at NEK1 ⇧ 2.49 0.019 
225304_s_at NDUFA11 ⇩ 2.59 1.70E-04  1555814_a_at RHOA ⇩ 2.53 3.30E-03  212027_at RBM25 ⇧ 2.49 0.016 
224726_at MIB1 ⇧ 2.59 1.10E-04  205727_at TEP1 ⇧ 2.53 2.70E-03  201670_s_at MARCKS ⇧ 2.49 0.011 
210517_s_at AKAP12 ⇩ 2.58 0.041  1560486_at STXBP3 ⇧ 2.53 4.40E-04  1558732_at MAP4K4 ⇧ 2.49 5.20E-03 
229187_at LOC283788 ⇧ 2.58 5.70E-03  236356_at NDUFS1 ⇧ 2.53 3.40E-04  239778_x_at --- ⇧ 2.49 3.20E-03 
232978_at --- ⇧ 2.58 3.90E-03  243498_at --- ⇧ 2.53 3.10E-04  230375_at SFRS18 ⇧ 2.49 2.80E-03 
1558028_x_at LOC647979 ⇧ 2.58 2.90E-03  214815_at TRIM33 ⇧ 2.52 0.021  237216_at --- ⇧ 2.49 1.70E-03 
242343_x_at --- ⇧ 2.58 1.90E-03  235811_at --- ⇧ 2.52 0.015  213517_at PCBP2 ⇧ 2.49 1.50E-03 
227851_s_at --- ⇧ 2.58 1.10E-04  211459_at --- ⇧ 2.52 5.10E-03  219382_at SERTAD3 ⇧ 2.49 3.90E-04 
229010_at CBL ⇧ 2.57 0.019  215029_at --- ⇧ 2.52 5.00E-03  63825_at ABHD2 ⇧ 2.48 0.024 
201369_s_at ZFP36L2 ⇧ 2.57 0.012  224766_at RPL37 ⇧ 2.52 2.20E-03  233261_at EBF1 ⇧ 2.48 0.013 
1557238_s_at --- ⇧ 2.57 3.70E-03  239605_x_at --- ⇧ 2.52 1.50E-03  236429_at ZNF83 ⇧ 2.48 5.40E-03 
239978_at --- ⇧ 2.57 1.20E-03  243910_x_at CAND1 ⇧ 2.52 1.60E-04  1564378_a_at --- ⇧ 2.48 2.30E-03 
242480_at --- ⇧ 2.57 9.30E-04  1558699_a_at HERPUD2 ⇧ 2.52 8.20E-05  211941_s_at PEBP1 ⇩ 2.48 2.20E-03 
235660_at --- ⇧ 2.57 4.50E-05  226548_at SBK1 ⇧ 2.51 4.90E-03  1557810_at --- ⇧ 2.48 1.80E-03 
235271_s_at ZNF397 ⇧ 2.57 4.30E-05  229193_at LUC7L3 ⇧ 2.51 4.80E-03  1552664_at FLCN ⇧ 2.48 1.30E-03 
206408_at LRRTM2 ⇧ 2.57 1.20E-05  240498_at --- ⇧ 2.51 1.70E-03  239392_s_at POGK ⇧ 2.48 8.40E-04 
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240706_at --- ⇧ 2.48 3.80E-05  210992_x_at FCGR2C ⇩ 2.44 3.90E-03  235009_at BOD1L ⇧ 2.41 2.80E-03 
216252_x_at FAS ⇩ 2.47 0.025  1555425_x_at SSH2 ⇧ 2.44 1.30E-03  1553727_at B4GALNT3 ⇧ 2.41 2.20E-03 
222330_at --- ⇧ 2.47 4.00E-03  1555303_at --- ⇧ 2.44 1.00E-03  217378_x_at --- ⇩ 2.41 1.90E-03 
242646_at --- ⇧ 2.47 3.60E-03  1557737_s_at NKTR ⇧ 2.44 9.20E-04  1558173_a_at LUZP1 ⇧ 2.41 1.80E-03 
216380_x_at RPS28P6 ⇩ 2.47 3.60E-03  1556060_a_at ZNF451 ⇧ 2.44 8.70E-04  1556007_s_at CSNK1A1 ⇧ 2.41 1.10E-03 
215176_x_at --- ⇩ 2.47 2.90E-03  1563473_at --- ⇧ 2.44 6.30E-04  1554178_a_at FAM126B ⇧ 2.40 0.012 
212384_at BAT1 ⇧ 2.47 2.50E-03  232312_at SAPS3 ⇧ 2.44 1.30E-04  213742_at SFRS11 ⇧ 2.40 1.70E-03 
216813_at --- ⇧ 2.47 1.40E-03  209225_x_at TNPO1 ⇧ 2.44 3.50E-05  232775_at --- ⇧ 2.40 9.50E-05 
215252_at --- ⇧ 2.47 1.00E-03  218866_s_at POLR3K ⇩ 2.44 3.10E-06  234149_at --- ⇧ 2.40 4.10E-06 
205462_s_at HPCAL1 ⇩ 2.47 7.10E-04  221205_at --- ⇧ 2.43 7.90E-03  221563_at DUSP10 ⇧ 2.40 2.40E-06 
230000_at RNF213 ⇧ 2.47 4.80E-04  240478_at --- ⇧ 2.43 1.30E-03  206371_at FOLR3 ⇩ 2.39 0.027 
234488_s_at GMCL1  ⇧ 2.47 4.60E-04  223380_s_at LATS2 ⇧ 2.43 1.30E-03  230014_at --- ⇧ 2.39 0.015 
232188_at AKAP13 ⇧ 2.46 5.10E-03  211643_x_at IGK ⇩ 2.43 9.90E-04  239274_at --- ⇧ 2.39 9.60E-03 
233819_s_at RNF160 ⇧ 2.46 5.10E-03  214305_s_at SF3B1 ⇧ 2.43 7.30E-04  243789_at --- ⇧ 2.39 7.00E-03 
242024_at --- ⇧ 2.46 3.10E-03  242248_at PHKB ⇧ 2.43 4.70E-04  233309_at --- ⇧ 2.39 3.40E-03 
236224_at RIT1 ⇧ 2.46 1.90E-03  1562611_at --- ⇧ 2.43 4.10E-04  236266_at RORA ⇧ 2.39 1.10E-03 
237588_at --- ⇧ 2.46 7.20E-04  230892_at --- ⇧ 2.43 2.60E-04  241413_at --- ⇧ 2.39 9.60E-04 
208819_at RAB8A ⇧ 2.46 3.70E-04  217591_at SKIL ⇧ 2.43 1.80E-04  222529_at SLC25A37 ⇧ 2.39 9.60E-04 
1566848_x_at --- ⇧ 2.46 3.40E-04  208132_x_at BAT2 ⇧ 2.42 0.029  243981_at STK4 ⇧ 2.39 7.20E-04 
233816_at --- ⇧ 2.46 2.90E-04  204174_at ALOX5AP ⇩ 2.42 0.025  243908_at --- ⇧ 2.39 4.60E-04 
215719_x_at FAS ⇩ 2.45 0.033  234000_s_at PTPLAD1 ⇧ 2.42 9.20E-03  227039_at AKAP13 ⇧ 2.39 3.80E-04 
236862_at GOPC ⇧ 2.45 8.70E-03  1559479_at PI4K2B ⇧ 2.42 4.70E-03  229257_at TNRC18 ⇧ 2.39 1.20E-04 
214352_s_at KRAS ⇧ 2.45 2.60E-03  227931_at INO80D ⇧ 2.42 1.30E-03  240044_x_at TNRC6B ⇧ 2.39 1.50E-05 
230970_at --- ⇧ 2.45 2.00E-03  1555339_at RAP1A ⇩ 2.42 1.10E-03  240772_at --- ⇧ 2.38 0.011 
229293_at --- ⇧ 2.45 5.60E-04  208627_s_at YBX1 ⇩ 2.42 3.50E-04  239742_at TULP4 ⇧ 2.38 3.70E-03 
232885_at --- ⇧ 2.45 1.60E-04  205221_at HGD ⇩ 2.42 3.30E-04  242498_x_at --- ⇧ 2.38 3.40E-03 
215956_at --- ⇧ 2.45 1.40E-04  1558830_at --- ⇧ 2.42 1.70E-04  230833_at ACRBP ⇩ 2.38 2.90E-03 
227697_at SOCS3 ⇧ 2.45 1.10E-04  240080_at --- ⇧ 2.42 1.70E-04  1556821_x_at DLEU2 ⇧ 2.38 2.20E-03 
227419_x_at PLAC9 ⇧ 2.45 9.20E-06  221483_s_at ARPP19 ⇧ 2.42 1.60E-06  215398_at --- ⇧ 2.38 2.10E-03 
239486_at --- ⇧ 2.44 0.017  240016_at --- ⇧ 2.41 0.012  235526_at SOX6 ⇩ 2.38 1.30E-03 
239487_at FAM98A ⇧ 2.44 0.013  234151_at --- ⇧ 2.41 9.40E-03  212641_at HIVEP2 ⇩ 2.38 9.60E-04 
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215620_at RREB1 ⇧ 2.38 4.10E-04  239948_at NUP153 ⇧ 2.35 1.70E-03  204180_s_at ZBTB43 ⇧ 2.31 1.90E-03 
1562849_at --- ⇧ 2.38 1.80E-04  217653_x_at --- ⇧ 2.35 6.20E-04  242144_at --- ⇧ 2.31 1.80E-03 
227639_at PIGK ⇧ 2.38 4.50E-05  217445_s_at GART ⇧ 2.35 3.00E-04  1561963_at MIR4296 ⇧ 2.31 1.70E-03 
215894_at PTGDR ⇧ 2.37 0.026  1553047_at PIP4K2B ⇧ 2.35 1.80E-04  244753_at --- ⇧ 2.31 1.10E-03 
1563621_at --- ⇧ 2.37 0.024  214246_x_at MINK1 ⇧ 2.35 6.70E-05  207038_at SLC16A6 ⇧ 2.31 1.10E-03 
1569142_at TRIM13 ⇧ 2.37 0.016  1568867_x_at --- ⇧ 2.34 1.50E-03  238536_at --- ⇧ 2.31 7.20E-04 
243561_at --- ⇧ 2.37 5.30E-03  235668_at PRDM1 ⇧ 2.34 6.30E-04  233099_at --- ⇧ 2.31 4.10E-04 
1559044_at EXOSC1 ⇧ 2.37 3.20E-03  216844_at ZC3H7B ⇧ 2.34 4.20E-05  206681_x_at GP2 ⇧ 2.31 3.00E-04 
240254_at --- ⇧ 2.37 2.70E-03  221211_s_at C21orf7 ⇩ 2.33 0.021  243997_x_at --- ⇧ 2.30 0.011 
240146_at --- ⇧ 2.37 1.80E-03  201294_s_at WSB1 ⇧ 2.33 0.011  1555058_a_at LPGAT1 ⇧ 2.30 0.010 
239545_at --- ⇧ 2.37 1.80E-03  1558924_s_at CLIP1 ⇧ 2.33 9.60E-03  243005_at --- ⇧ 2.30 9.90E-03 
222582_at PRKAG2 ⇧ 2.37 1.60E-03  238303_at STT3B ⇧ 2.33 6.10E-03  237018_at --- ⇧ 2.30 7.70E-03 
216983_s_at ZNF224 ⇧ 2.37 6.70E-04  1559895_x_at --- ⇧ 2.33 4.50E-03  242558_at --- ⇧ 2.30 6.60E-03 
224974_at SUDS3 ⇧ 2.37 5.70E-04  1570248_at --- ⇧ 2.33 3.10E-03  242877_at --- ⇧ 2.30 6.20E-03 
230779_at TNRC6B ⇧ 2.37 5.40E-04  241631_at --- ⇧ 2.33 3.00E-03  233007_at --- ⇧ 2.30 5.90E-03 
240554_at AKAP8L ⇧ 2.37 4.20E-04  238722_x_at NAPEPLD ⇧ 2.33 2.90E-03  1556820_a_at DLEU2 ⇧ 2.30 3.40E-03 
244818_at LOC390933 ⇧ 2.37 2.10E-04  237586_at --- ⇧ 2.33 2.30E-04  241508_at --- ⇧ 2.30 2.20E-03 
236419_at --- ⇧ 2.36 0.037  240691_at --- ⇧ 2.33 6.10E-05  1569368_at LOC283693 ⇩ 2.30 1.90E-03 
236495_at --- ⇧ 2.36 0.011  213120_at UHRF1BP1L ⇧ 2.33 1.40E-05  242755_at --- ⇧ 2.30 1.70E-03 
1559331_x_at --- ⇧ 2.36 6.10E-03  206565_x_at SMA4 ⇧ 2.32 0.012  241501_at --- ⇧ 2.30 1.60E-03 
238040_at --- ⇧ 2.36 6.00E-03  204713_s_at F5 ⇧ 2.32 0.011  232931_at SNRNP200 ⇧ 2.30 1.30E-03 
216947_at DES ⇩ 2.36 3.40E-03  231793_s_at CAMK2D ⇧ 2.32 5.20E-03  232858_at --- ⇧ 2.30 8.70E-04 
241838_at --- ⇧ 2.36 2.90E-03  201918_at SLC25A36 ⇧ 2.32 4.90E-03  238534_at LRRFIP1 ⇧ 2.30 8.70E-04 
235469_at FAM133B  ⇧ 2.36 1.40E-03  228030_at --- ⇧ 2.32 4.70E-03  226085_at CBX5 ⇧ 2.30 6.80E-04 
231878_at C16orf53 ⇧ 2.36 7.80E-04  221905_at CYLD ⇧ 2.32 2.70E-03  240210_at ATAD3C ⇧ 2.30 3.50E-04 
213518_at PRKCI ⇧ 2.36 6.90E-04  225265_at RBMS1 ⇧ 2.32 1.00E-03  214488_at RAP2B ⇧ 2.30 3.40E-04 
223217_s_at NFKBIZ ⇧ 2.36 2.60E-04  214871_x_at --- ⇧ 2.32 7.10E-04  215070_x_at RABGAP1 ⇧ 2.30 2.90E-04 
242146_at SNRPA1 ⇧ 2.36 9.70E-05  221540_x_at GTF2H2B-D ⇧ 2.32 2.40E-04  242691_at --- ⇧ 2.30 2.70E-04 
240248_at --- ⇧ 2.35 0.036  204119_s_at ADK ⇩ 2.32 1.50E-04  1553625_at FAM98B ⇧ 2.30 1.20E-04 
214918_at HNRNPM ⇧ 2.35 0.025  243512_x_at --- ⇧ 2.31 0.012  1559964_at FLJ38717 ⇧ 2.29 0.033 
238970_at --- ⇧ 2.35 0.019  216022_at --- ⇧ 2.31 4.70E-03  203939_at NT5E ⇩ 2.29 0.019 
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225414_at RNF149 ⇧ 2.29 8.40E-03  218008_at C7orf42 ⇧ 2.27 6.40E-04  228496_s_at CRIM1 ⇧ 2.25 1.50E-03 
236941_at C22orf30 ⇧ 2.29 6.80E-03  211902_x_at TRA ⇩ 2.27 6.00E-04  1552536_at VTI1A ⇧ 2.25 8.30E-04 
230703_at --- ⇧ 2.29 5.70E-03  234395_at --- ⇧ 2.27 5.10E-05  205069_s_at ARHGAP26 ⇧ 2.25 7.60E-04 
242110_at --- ⇧ 2.29 5.40E-03  222196_at LOC286434 ⇧ 2.26 0.048  232216_at YME1L1 ⇧ 2.25 7.40E-04 
235409_at MGA ⇧ 2.29 3.60E-03  241620_at SMCHD1 ⇧ 2.26 0.040  215587_x_at --- ⇧ 2.25 1.80E-04 
223934_at SP140L ⇧ 2.29 3.40E-03  211430_s_at IGH ⇩ 2.26 0.037  231235_at NKTR ⇧ 2.24 0.036 
207470_at --- ⇧ 2.29 1.70E-03  242163_at THRAP3 ⇧ 2.26 0.019  215314_at --- ⇧ 2.24 0.017 
215058_at DENND5B ⇧ 2.29 7.00E-04  1566809_a_at --- ⇧ 2.26 0.018  1569512_at --- ⇧ 2.24 0.017 
216112_at --- ⇧ 2.29 2.20E-04  231495_at --- ⇧ 2.26 8.70E-03  207057_at SLC16A7 ⇧ 2.24 0.017 
1562071_at --- ⇧ 2.29 1.30E-04  228603_at ACTR3 ⇧ 2.26 5.60E-03  232584_at --- ⇧ 2.24 0.014 
213553_x_at APOC1 ⇧ 2.29 4.70E-05  1552486_s_at LACTB ⇩ 2.26 4.60E-03  211645_x_at --- ⇩ 2.24 7.50E-03 
206354_at SLCO1B3 ⇩ 2.28 0.033  1559949_at --- ⇧ 2.26 4.40E-03  215996_at --- ⇧ 2.24 7.20E-03 
1559496_at PPA2 ⇧ 2.28 0.013  213650_at GOLGA8A/B ⇧ 2.26 3.80E-03  241940_at --- ⇧ 2.24 6.40E-03 
211192_s_at CD84 ⇩ 2.28 0.012  217610_at SPDYE2 ⇧ 2.26 3.40E-03  1553973_a_at SPINK6 ⇩ 2.24 3.90E-03 
216147_at --- ⇧ 2.28 8.40E-04  201883_s_at B4GALT1 ⇩ 2.26 2.60E-03  238595_at --- ⇧ 2.24 2.90E-03 
1569380_a_at HERPUD1 ⇧ 2.28 7.80E-04  200914_x_at KTN1 ⇧ 2.26 2.10E-03  242279_at --- ⇧ 2.24 2.50E-03 
200796_s_at MCL1 ⇩ 2.28 3.70E-04  235028_at --- ⇧ 2.26 2.00E-03  1570571_at CCDC91 ⇧ 2.24 2.30E-03 
209024_s_at SYNCRIP ⇧ 2.27 0.035  239905_at YTHDC1 ⇧ 2.26 1.80E-03  1553515_at MYEOV2 ⇩ 2.24 5.50E-04 
1558154_at --- ⇧ 2.27 0.020  1559600_at --- ⇧ 2.26 1.60E-03  204318_s_at GTSE1 ⇧ 2.24 1.50E-04 
1552552_s_at CLEC4C ⇩ 2.27 0.018  214522_x_at HIST1H3D ⇩ 2.26 1.40E-03  241346_at ARHGAP30 ⇧ 2.23 0.018 
233302_at --- ⇧ 2.27 0.014  226533_at HINT3 ⇧ 2.26 9.50E-04  244679_at --- ⇧ 2.23 0.017 
241837_at --- ⇧ 2.27 0.013  230179_at LOC285812 ⇧ 2.26 5.40E-04  202323_s_at ACBD3 ⇧ 2.23 0.014 
1561276_at DOCK5 ⇧ 2.27 0.013  244614_at TFG ⇧ 2.26 4.20E-04  237456_at --- ⇧ 2.23 0.013 
1562307_at --- ⇧ 2.27 0.012  1566043_at --- ⇧ 2.26 1.20E-04  243263_at C17orf55 ⇧ 2.23 9.00E-03 
226880_at NUCKS1 ⇧ 2.27 0.012  235713_at ALKBH8 ⇧ 2.26 1.10E-06  221496_s_at TOB2 ⇧ 2.23 6.40E-03 
236552_at --- ⇧ 2.27 0.011  236140_at GCLM ⇧ 2.25 6.40E-03  216351_x_at DAZ1-4 ⇧ 2.23 2.90E-03 
236966_at ARMC8 ⇧ 2.27 6.20E-03  1562443_at RLBP1L2 ⇩ 2.25 6.10E-03  229091_s_at CCNJ ⇧ 2.23 2.10E-03 
236484_at --- ⇧ 2.27 4.90E-03  231152_at INO80D ⇧ 2.25 5.60E-03  205127_at PTGS1 ⇩ 2.23 1.10E-03 
1559612_at --- ⇧ 2.27 3.20E-03  228147_at SEPT7P2 ⇧ 2.25 4.90E-03  232951_at --- ⇧ 2.23 8.70E-04 
230808_at FNTA ⇧ 2.27 3.00E-03  244447_at --- ⇧ 2.25 3.70E-03  1569004_at --- ⇧ 2.23 7.70E-04 
224275_at GPR98 ⇧ 2.27 1.60E-03  232441_at KRR1 ⇧ 2.25 2.70E-03  239296_at --- ⇧ 2.23 5.90E-04 
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200892_s_at TRA2B ⇩ 2.23 5.70E-04  236310_at ZNF37BP ⇧ 2.21 1.00E-05  242983_at --- ⇧ 2.18 2.20E-03 
235380_at --- ⇧ 2.23 4.00E-04  1566040_at --- ⇧ 2.20 0.031  205209_at ACVR1B ⇧ 2.18 4.70E-04 
243013_at --- ⇧ 2.23 3.10E-04  212634_at KIAA0776 ⇧ 2.20 0.022  237878_at --- ⇧ 2.18 4.60E-04 
207238_s_at PTPRC ⇩ 2.22 0.044  228907_at --- ⇧ 2.20 0.011  1566598_at --- ⇧ 2.18 1.80E-04 
223134_at BBX ⇧ 2.22 0.010  232094_at C15orf29 ⇧ 2.20 8.50E-03  244187_at --- ⇧ 2.18 7.20E-05 
238159_at --- ⇧ 2.22 7.90E-03  215567_at FCF1 ⇧ 2.20 5.10E-03  200947_s_at GLUD1 ⇧ 2.18 9.60E-06 
1566191_at SUZ12 ⇧ 2.22 7.70E-03  210792_x_at SIVA1 ⇩ 2.20 5.10E-03  244349_at --- ⇧ 2.17 0.048 
224185_at WRAP53 ⇧ 2.22 6.40E-03  243229_at --- ⇧ 2.20 4.60E-03  222895_s_at BCL11B ⇧ 2.17 0.012 
234148_at --- ⇧ 2.22 3.90E-03  216576_x_at IGKC ⇩ 2.20 4.40E-03  232521_at PCSK7 ⇧ 2.17 0.010 
244270_at --- ⇧ 2.22 2.10E-03  238530_at NNT ⇧ 2.20 2.10E-03  205798_at IL7R ⇧ 2.17 8.30E-03 
225191_at CIRBP ⇧ 2.22 2.00E-03  233915_at C5orf36 ⇧ 2.20 5.20E-04  232356_at --- ⇧ 2.17 5.50E-03 
220477_s_at C20orf30 ⇩ 2.22 3.50E-04  209947_at UBAP2L ⇧ 2.20 2.60E-05  217602_at PPIA ⇧ 2.17 4.80E-03 
229355_at UBE2D3 ⇧ 2.22 8.40E-05  201120_s_at PGRMC1 ⇩ 2.19 0.039  1555759_a_at CCL5 ⇩ 2.17 4.20E-03 
1558882_at LOC401233 ⇧ 2.21 0.047  1569346_a_at --- ⇧ 2.19 0.024  207130_at ZMYND8 ⇧ 2.17 3.00E-03 
244035_at --- ⇧ 2.21 0.038  241913_at --- ⇧ 2.19 0.020  207445_s_at CCR9 ⇩ 2.17 2.40E-03 
236558_at --- ⇧ 2.21 0.017  213281_at JUN ⇧ 2.19 0.018  241203_at --- ⇧ 2.17 2.00E-03 
224943_at BTBD7 ⇧ 2.21 0.014  1565627_a_at --- ⇧ 2.19 0.015  241717_at LOC285281 ⇩ 2.17 1.60E-03 
222266_at C19orf2 ⇧ 2.21 0.014  215338_s_at NKTR ⇧ 2.19 0.011  213015_at BBX ⇧ 2.17 9.30E-04 
1562317_at FAM186A ⇩ 2.21 0.013  220072_at CSPP1 ⇧ 2.19 8.00E-03  232629_at PROK2 ⇧ 2.17 6.70E-04 
212890_at SLC38A10 ⇩ 2.21 6.70E-03  213922_at TTBK2 ⇧ 2.19 2.60E-03  1559355_at NXPH2 ⇧ 2.17 1.60E-04 
244105_at WHAMML1 ⇧ 2.21 5.80E-03  1566607_at --- ⇧ 2.19 1.80E-04  212926_at SMC5 ⇧ 2.17 1.70E-05 
226167_at SYT7 ⇧ 2.21 5.30E-03  224535_s_at MRP63 ⇩ 2.19 1.30E-04  202971_s_at DYRK2 ⇧ 2.16 0.023 
239601_at --- ⇧ 2.21 3.70E-03  216166_at --- ⇧ 2.19 6.50E-05  209911_x_at HIST1H2BD ⇩ 2.16 0.012 
239421_at FLJ35776 ⇧ 2.21 3.30E-03  203094_at MAD2L1BP ⇩ 2.19 2.70E-05  202166_s_at PPP1R2 ⇩ 2.16 0.012 
217565_at GRIA3 ⇧ 2.21 2.20E-03  1555780_a_at RHEB ⇩ 2.18 0.041  238146_at --- ⇧ 2.16 8.40E-03 
1566209_at --- ⇩ 2.21 1.70E-03  240971_x_at --- ⇧ 2.18 0.012  226404_at RBM39 ⇧ 2.16 7.90E-03 
1558831_x_at --- ⇧ 2.21 6.10E-04  243395_at --- ⇧ 2.18 0.012  227364_at --- ⇧ 2.16 6.60E-03 
229733_s_at --- ⇧ 2.21 5.30E-04  243739_at --- ⇧ 2.18 0.011  240238_at --- ⇧ 2.16 3.60E-03 
213026_at ATG12 ⇧ 2.21 5.10E-04  202124_s_at TRAK2 ⇧ 2.18 8.60E-03  232952_at --- ⇧ 2.16 2.50E-03 
217649_at ZFAND5 ⇧ 2.21 4.60E-04  230580_at --- ⇧ 2.18 7.40E-03  237333_at RBBP4 ⇧ 2.16 2.20E-03 
210972_x_at TRAC ⇩ 2.21 3.00E-04  216207_x_at IGKC  ⇩ 2.18 3.90E-03  1559038_at SEPT2 ⇧ 2.16 1.60E-03 
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225647_s_at CTSC ⇩ 2.16 1.70E-04  1570249_x_at --- ⇧ 2.14 2.50E-04  233599_at hCG_2003663 ⇧ 2.12 8.30E-05 
1565862_a_at --- ⇩ 2.15 0.026  224651_at CCNY ⇧ 2.14 1.70E-04  1554281_at --- ⇩ 2.11 0.036 
1555687_a_at CLEC4C ⇩ 2.15 0.018  242617_at TMED8 ⇧ 2.14 4.80E-05  221830_at RAP2A ⇧ 2.11 0.030 
224480_s_at AGPAT9 ⇧ 2.15 0.012  204774_at EVI2A ⇧ 2.13 0.047  240265_at TRAF3IP3 ⇧ 2.11 0.025 
1557895_at FLJ35934 ⇧ 2.15 0.011  244267_at SATB1 ⇧ 2.13 0.039  220674_at CD22 ⇧ 2.11 0.019 
222024_s_at AKAP13 ⇧ 2.15 8.60E-03  230324_at --- ⇧ 2.13 0.018  233700_at --- ⇧ 2.11 0.017 
214678_x_at ZFX ⇧ 2.15 7.40E-03  240601_at --- ⇧ 2.13 0.015  241627_x_at FLJ10357 ⇧ 2.11 0.012 
218859_s_at ESF1 ⇧ 2.15 7.10E-03  1552622_s_at POLR2J2/4 ⇧ 2.13 7.40E-03  218280_x_at HIST2H2AA3 ⇩ 2.11 0.012 
227741_at PTPLB ⇧ 2.15 6.60E-03  235429_at EIF3E ⇧ 2.13 5.80E-03  242260_at MATR3 ⇧ 2.11 9.40E-03 
228315_at ZMAT3 ⇧ 2.15 6.50E-03  229905_at RAP1GDS1 ⇧ 2.13 5.60E-03  224140_at NPCDR1 ⇧ 2.11 7.90E-03 
232410_at --- ⇧ 2.15 5.60E-03  218050_at UFM1 ⇧ 2.13 5.40E-03  242347_at --- ⇧ 2.11 7.30E-03 
203934_at KDR ⇧ 2.15 5.30E-03  225294_s_at TRAPPC1 ⇩ 2.13 5.20E-03  1557360_at LRPPRC ⇧ 2.11 7.10E-03 
243341_at --- ⇧ 2.15 1.90E-03  216984_x_at IGLV2-11  ⇩ 2.13 5.10E-03  232890_at --- ⇧ 2.11 6.00E-03 
209671_x_at TRAC ⇩ 2.15 1.00E-03  243660_at CHD9 ⇧ 2.13 4.80E-03  226267_at JDP2 ⇧ 2.11 3.50E-03 
242672_at --- ⇧ 2.15 9.80E-04  229966_at EWSR1 ⇧ 2.13 2.90E-03  221222_s_at C1orf56 ⇧ 2.11 2.90E-03 
1559249_at ATXN1 ⇧ 2.15 6.20E-04  243868_at RFX3 ⇧ 2.13 1.40E-03  241904_at --- ⇧ 2.11 2.00E-03 
218848_at THOC6 ⇧ 2.15 3.70E-04  240813_at --- ⇧ 2.13 1.10E-03  217157_x_at IGK ⇩ 2.11 1.90E-03 
223432_at OSBP2 ⇧ 2.14 0.032  1560445_x_at ARHGEF1 ⇧ 2.13 8.20E-04  232724_at MS4A6A ⇧ 2.11 1.80E-03 
225954_s_at MIDN ⇧ 2.14 0.020  234890_at LOC100288175 ⇧ 2.13 7.50E-05  239021_at TLR6 ⇧ 2.11 8.60E-04 
233248_at --- ⇧ 2.14 0.013  204506_at PPP3R1 ⇧ 2.13 2.80E-05  217643_x_at --- ⇧ 2.11 8.40E-04 
243748_at --- ⇧ 2.14 7.30E-03  229943_at TRIM13 ⇧ 2.12 0.031  1560827_at --- ⇧ 2.11 6.00E-04 
232338_at --- ⇧ 2.14 5.30E-03  222731_at ZDHHC2 ⇧ 2.12 0.018  214656_x_at MYO1C ⇧ 2.11 3.20E-04 
230999_at FLJ39051 ⇧ 2.14 4.60E-03  243807_at NCOA7 ⇧ 2.12 7.20E-03  238277_at --- ⇧ 2.11 3.00E-04 
1563130_a_at --- ⇧ 2.14 3.80E-03  240282_at WDR1 ⇧ 2.12 6.00E-03  233014_at --- ⇧ 2.11 2.20E-04 
225507_at SFRS18 ⇧ 2.14 2.70E-03  229694_at BRWD2 ⇧ 2.12 2.30E-03  225210_s_at FAM103A1 ⇧ 2.11 1.80E-04 
207643_s_at TNFRSF1A ⇧ 2.14 2.70E-03  210693_at SPPL2B ⇧ 2.12 1.30E-03  235540_at GNRH1 ⇧ 2.11 1.60E-04 
1560741_at SNRPN ⇧ 2.14 2.60E-03  219617_at C2orf34 ⇧ 2.12 6.40E-04  237152_at hCG_17324 ⇧ 2.11 1.60E-04 
213812_s_at CAMKK2 ⇧ 2.14 2.10E-03  216274_s_at SEC11A ⇩ 2.12 3.70E-04  1561855_x_at --- ⇧ 2.11 6.20E-05 
219606_at PHF20L1 ⇧ 2.14 1.10E-03  210334_x_at BIRC5 ⇧ 2.12 2.70E-04  1566966_at --- ⇧ 2.11 4.10E-05 
210501_x_at EIF3K ⇩ 2.14 1.00E-03  216769_x_at --- ⇧ 2.12 1.50E-04  205234_at SLC16A4 ⇧ 2.11 2.40E-05 
1560119_at LOC389634 ⇧ 2.14 7.10E-04  241688_at --- ⇧ 2.12 8.80E-05  222154_s_at LOC26010 ⇩ 2.10 0.046 
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218294_s_at NUP50 ⇧ 2.10 0.013  235374_at MDH1 ⇧ 2.09 5.10E-03  228726_at SERPINB1 ⇧ 2.08 6.70E-06 
234430_at ANTXR1 ⇧ 2.10 0.012  232556_at --- ⇧ 2.09 4.60E-03  206176_at BMP6 ⇩ 2.07 0.025 
1557953_at ZKSCAN1 ⇧ 2.10 0.012  224851_at CDK6 ⇧ 2.09 4.50E-03  235376_at --- ⇧ 2.07 0.020 
236524_at --- ⇧ 2.10 0.011  203028_s_at CYBA ⇩ 2.09 4.00E-03  236088_at NTNG1 ⇩ 2.07 0.018 
241619_at CALM1 ⇧ 2.10 6.10E-03  243904_at STXBP5 ⇧ 2.09 3.40E-03  54970_at ZMIZ2 ⇧ 2.07 0.016 
1552621_at POLR2J2 ⇧ 2.10 5.30E-03  234594_at C14orf85 ⇧ 2.09 2.90E-03  216585_at --- ⇩ 2.07 0.013 
225046_at LOC100132181 ⇩ 2.10 4.50E-03  233061_at FITM2 ⇧ 2.09 2.70E-03  204982_at GIT2 ⇧ 2.07 9.00E-03 
208662_s_at TTC3 ⇧ 2.10 3.80E-03  1569841_x_at --- ⇧ 2.09 1.60E-03  219024_at PLEKHA1 ⇧ 2.07 8.80E-03 
215429_s_at ZNF428 ⇧ 2.10 2.50E-03  214843_s_at USP33 ⇧ 2.09 4.60E-04  1562338_at MARCH1 ⇧ 2.07 8.70E-03 
1557100_s_at HECTD1 ⇧ 2.10 1.90E-03  242430_at CCDC69 ⇧ 2.09 3.20E-04  225034_at ST3GAL1 ⇧ 2.07 8.10E-03 
200745_s_at GNB1 ⇧ 2.10 1.50E-03  237267_at LOC100506675 ⇧ 2.09 1.50E-04  220943_s_at C2orf56 ⇧ 2.07 4.80E-03 
212220_at PSME4 ⇧ 2.10 9.20E-04  231453_at LOC284067 ⇧ 2.09 8.10E-05  242403_at --- ⇧ 2.07 4.40E-03 
1568858_at --- ⇧ 2.10 5.30E-04  204331_s_at MRPS12 ⇩ 2.09 2.50E-05  219831_at CDKL3 ⇧ 2.07 4.10E-03 
1564242_at --- ⇩ 2.10 5.10E-04  216580_at RPL7  ⇩ 2.08 0.037  227480_at SUSD2 ⇧ 2.07 2.40E-03 
207185_at SLC10A1 ⇧ 2.10 3.70E-04  1557252_at --- ⇧ 2.08 0.032  236107_at UBE2Z ⇧ 2.07 1.60E-03 
226052_at BRD4 ⇧ 2.10 4.60E-05  214850_at LOC100170939 ⇧ 2.08 0.031  243895_x_at --- ⇧ 2.07 1.30E-03 
215652_at SDHD ⇧ 2.09 0.045  240307_at --- ⇧ 2.08 0.025  229704_at PDS5B ⇧ 2.07 9.90E-04 
217022_s_at IGH ⇩ 2.09 0.042  207674_at FCAR ⇩ 2.08 0.018  229334_at RUFY3 ⇧ 2.07 6.90E-04 
236610_at --- ⇧ 2.09 0.025  230980_x_at --- ⇧ 2.08 0.016  1553265_at SLC23A3 ⇧ 2.07 1.60E-04 
208694_at PRKDC ⇧ 2.09 0.024  239557_at --- ⇧ 2.08 0.013  216216_at SLIT3 ⇧ 2.07 1.40E-04 
203387_s_at TBC1D4 ⇩ 2.09 0.014  232030_at KIAA1632 ⇧ 2.08 0.012  237650_at --- ⇧ 2.07 8.70E-05 
233867_at --- ⇧ 2.09 0.013  222620_s_at DNAJC1 ⇧ 2.08 8.00E-03  233622_x_at --- ⇧ 2.07 4.20E-05 
243646_at --- ⇧ 2.09 0.011  217671_at DSERG1 ⇧ 2.08 7.80E-03  203756_at ARHGEF17 ⇧ 2.07 9.90E-06 
232879_at CRTC3 ⇧ 2.09 0.010  221761_at ADSS ⇩ 2.08 6.50E-03  214128_at DAGLA ⇧ 2.07 8.80E-06 
243356_at FAM7A3 ⇧ 2.09 0.010  1565821_at --- ⇧ 2.08 4.30E-03  211000_s_at IL6ST ⇧ 2.06 0.028 
203628_at IGF1R ⇧ 2.09 9.60E-03  219622_at RAB20 ⇩ 2.08 2.70E-03  237009_at --- ⇧ 2.06 0.022 
1557581_x_at --- ⇧ 2.09 7.80E-03  241520_x_at --- ⇧ 2.08 8.80E-04  240339_at --- ⇧ 2.06 0.014 
202905_x_at NBN ⇧ 2.09 7.40E-03  243578_at --- ⇧ 2.08 6.10E-04  229765_at ZNF207 ⇧ 2.06 0.014 
1569601_at --- ⇧ 2.09 6.80E-03  237104_at --- ⇧ 2.08 3.10E-04  200612_s_at AP2B1 ⇧ 2.06 0.012 
244226_s_at --- ⇧ 2.09 5.70E-03  238395_at --- ⇧ 2.08 1.60E-04  200951_s_at CCND2 ⇩ 2.06 0.011 
239464_at --- ⇧ 2.09 5.60E-03  214798_at ATP2C2 ⇧ 2.08 1.20E-04  1558766_at --- ⇧ 2.06 7.90E-03 
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242572_at --- ⇧ 2.06 6.40E-03  1562454_at --- ⇧ 2.05 1.60E-03  208077_at C9orf38 ⇧ 2.04 1.60E-04 
209579_s_at MBD4 ⇧ 2.06 4.60E-03  1557169_x_at HCG11 ⇧ 2.05 8.90E-04  239115_at --- ⇧ 2.04 2.40E-05 
222320_at --- ⇧ 2.06 4.10E-03  229593_at H2AFY ⇧ 2.05 4.70E-04  209703_x_at METTL7A ⇧ 2.04 1.10E-05 
216922_x_at DAZ1-4 ⇧ 2.06 2.70E-03  204094_s_at TSC22D2 ⇧ 2.05 3.90E-04  1566541_at --- ⇧ 2.04 2.90E-06 
207735_at RNF125 ⇧ 2.06 2.20E-03  242780_at VAPA ⇧ 2.05 3.20E-04  1566446_at --- ⇧ 2.03 0.030 
240737_at --- ⇧ 2.06 2.00E-03  1552628_a_at HERPUD2 ⇧ 2.05 1.40E-04  224531_at GPR61 ⇩ 2.03 0.027 
244607_at --- ⇧ 2.06 1.80E-03  220252_x_at CXorf21 ⇧ 2.05 6.60E-05  208661_s_at TTC3 ⇧ 2.03 0.025 
204000_at GNB5 ⇧ 2.06 1.80E-03  AFFX-HUMRGE 
/M10098_5_at 
--- ⇩ 2.04 0.012  
227223_at RBM39 ⇧ 2.03 0.022 
243587_x_at --- ⇧ 2.06 1.20E-03  243528_at --- ⇧ 2.04 0.025  214911_s_at BRD2 ⇧ 2.03 0.020 
243870_at --- ⇧ 2.06 7.80E-04  243109_at MCTP2 ⇧ 2.04 0.024  227962_at ACOX1 ⇧ 2.03 0.012 
241722_x_at --- ⇧ 2.06 7.50E-04  231866_at LNPEP ⇧ 2.04 0.019  243683_at MORF4L2 ⇧ 2.03 0.011 
241716_at HSPD1 ⇧ 2.06 7.10E-04  242068_at --- ⇧ 2.04 0.015  1552867_at --- ⇧ 2.03 0.010 
222443_s_at RBM8A ⇩ 2.06 1.40E-04  222313_at --- ⇧ 2.04 0.014  239957_at --- ⇧ 2.03 8.30E-03 
243771_at --- ⇧ 2.06 9.20E-06  1557145_at STK38 ⇧ 2.04 0.014  220216_at C8orf44 ⇧ 2.03 7.60E-03 
1554690_a_at TACC1 ⇧ 2.05 0.032  203299_s_at AP1S2 ⇧ 2.04 0.013  238651_at --- ⇧ 2.03 6.40E-03 
237113_at --- ⇩ 2.05 0.025  222404_x_at PTPLAD1 ⇧ 2.04 0.010  240141_at --- ⇧ 2.03 6.30E-03 
215635_at --- ⇧ 2.05 0.021  228594_at C5orf33 ⇧ 2.04 8.60E-03  211048_s_at PDIA4 ⇧ 2.03 6.10E-03 
228483_s_at TAF9B ⇧ 2.05 0.020  215474_at --- ⇧ 2.04 6.90E-03  214291_at RPL17  ⇧ 2.03 4.80E-03 
227747_at MPZL3 ⇧ 2.05 0.018  242803_at --- ⇧ 2.04 6.70E-03  222667_s_at ASH1L ⇧ 2.03 4.20E-03 
1557580_at --- ⇧ 2.05 0.016  238660_at WDFY3 ⇧ 2.04 6.60E-03  237798_at --- ⇧ 2.03 3.60E-03 
214469_at HIST1H2AE ⇩ 2.05 0.015  217087_at C1orf68 ⇧ 2.04 4.60E-03  208987_s_at KDM2A ⇧ 2.03 3.50E-03 
237803_x_at --- ⇧ 2.05 0.012  222027_at NUCKS1 ⇧ 2.04 3.90E-03  226266_at PGS1 ⇧ 2.03 3.50E-03 
236346_at --- ⇧ 2.05 0.012  233815_at NAALAD2 ⇧ 2.04 1.80E-03  243381_at --- ⇧ 2.03 2.60E-03 
229897_at ZNF641 ⇧ 2.05 0.012  1556209_at CLEC2B ⇧ 2.04 1.50E-03  212917_x_at RECQL ⇧ 2.03 2.10E-03 
208601_s_at TUBB1 ⇩ 2.05 0.011  213574_s_at --- ⇧ 2.04 1.10E-03  240957_at --- ⇧ 2.03 1.80E-03 
238869_at --- ⇧ 2.05 7.10E-03  229392_s_at PIK3R2 ⇧ 2.04 8.80E-04  216645_at --- ⇧ 2.03 1.50E-03 
217304_at SHMT1 ⇧ 2.05 6.90E-03  237954_x_at --- ⇧ 2.04 6.80E-04  222395_s_at UBE2Z ⇧ 2.03 1.40E-03 
220845_at ACOXL ⇧ 2.05 5.20E-03  1563482_at --- ⇧ 2.04 5.50E-04  1557589_a_at --- ⇧ 2.03 9.60E-04 
242040_at GCNT7 ⇧ 2.05 5.10E-03  233693_at C1orf201 ⇧ 2.04 3.20E-04  230027_s_at MRPL43 ⇩ 2.03 7.90E-04 
243037_at --- ⇧ 2.05 3.60E-03  233109_at COL12A1 ⇧ 2.04 2.70E-04  1568801_at C15orf44 ⇧ 2.03 3.30E-04 
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213818_x_at TMEM223 ⇧ 2.03 2.80E-04  239504_at --- ⇧ 2.01 0.018  226035_at USP31 ⇧ 2.01 1.40E-04 
215656_at LMAN2 ⇩ 2.03 1.50E-04  229272_at FNBP4 ⇧ 2.01 0.017  214802_at EXOC7 ⇧ 2.00 0.024 
201296_s_at WSB1 ⇧ 2.03 5.90E-05  238949_at RNF145 ⇩ 2.01 0.015  1569159_at LZTS1 ⇩ 2.00 0.023 
AFFX-M27830 
_5_at 
--- ⇩ 2.03 0.013  219978_s_at NUSAP1 ⇧ 2.01 0.014  242916_at CEP110 ⇧ 2.00 0.019 
204750_s_at DSC2 ⇧ 2.02 0.045  244341_at --- ⇧ 2.01 0.011  209138_x_at IGL ⇩ 2.00 0.019 
205961_s_at PSIP1 ⇩ 2.02 0.021  222357_at ZBTB20 ⇧ 2.01 9.70E-03  201996_s_at SPEN ⇧ 2.00 0.018 
211467_s_at NFIB ⇩ 2.02 0.019  1557236_at APOL6 ⇧ 2.01 9.50E-03  239171_at --- ⇧ 2.00 0.013 
1560443_at --- ⇧ 2.02 8.00E-03  235970_at LCORL ⇧ 2.01 8.90E-03  230733_at --- ⇧ 2.00 0.013 
241930_x_at LOC442113 ⇧ 2.02 6.30E-03  1555273_at GALNTL6 ⇧ 2.01 8.50E-03  1554638_at ZFYVE16 ⇧ 2.00 0.013 
230379_x_at C2orf56 ⇧ 2.02 5.20E-03  204643_s_at ENOX2 ⇩ 2.01 8.20E-03  1556493_a_at KDM4C ⇧ 2.00 0.011 
242728_at --- ⇧ 2.02 5.10E-03  213803_at --- ⇧ 2.01 7.70E-03  1570200_at HELB ⇧ 2.00 8.60E-03 
207474_at SNRK ⇧ 2.02 4.00E-03  1559663_at --- ⇧ 2.01 7.20E-03  239724_at --- ⇧ 2.00 6.60E-03 
216783_at --- ⇧ 2.02 3.90E-03  235954_at --- ⇧ 2.01 7.00E-03  208549_x_at PTMAP7 ⇧ 2.00 6.40E-03 
236149_at --- ⇧ 2.02 3.10E-03  236613_at RBM25 ⇧ 2.01 6.10E-03  215231_at PRKAG2 ⇧ 2.00 6.20E-03 
207648_at DRP2 ⇧ 2.02 3.10E-03  243514_at --- ⇧ 2.01 4.80E-03  237943_at --- ⇧ 2.00 5.70E-03 
228088_at SESTD1 ⇧ 2.02 2.50E-03  240221_at CSNK1A1 ⇧ 2.01 2.90E-03  233274_at --- ⇧ 2.00 5.00E-03 
215648_at --- ⇧ 2.02 1.90E-03  224778_s_at TAOK1 ⇧ 2.01 2.70E-03  236953_s_at NHLRC3 ⇧ 2.00 5.00E-03 
1569450_at CAPZA2 ⇧ 2.02 1.90E-03  201070_x_at SF3B1 ⇧ 2.01 2.60E-03  1565762_at --- ⇧ 2.00 4.70E-03 
237062_at --- ⇧ 2.02 1.70E-03  227396_at PTPRJ ⇧ 2.01 2.40E-03  222023_at AKAP13 ⇧ 2.00 4.20E-03 
215468_at LOC647070 ⇧ 2.02 1.70E-03  243509_at --- ⇧ 2.01 2.30E-03  237118_at --- ⇧ 2.00 3.90E-03 
209499_x_at TNFSF13 ⇩ 2.02 1.20E-03  232141_at U2AF1 ⇧ 2.01 2.20E-03  208180_s_at HIST1H4B ⇩ 2.00 3.40E-03 
243992_at --- ⇧ 2.02 1.00E-03  216621_at --- ⇧ 2.01 2.10E-03  234737_at NT5DC3 ⇧ 2.00 3.20E-03 
217704_x_at SUZ12P ⇧ 2.02 7.20E-04  239937_at ZNF207 ⇧ 2.01 1.90E-03  200622_x_at CALM3 ⇩ 2.00 3.10E-03 
236715_x_at UACA ⇧ 2.02 5.20E-04  243724_at --- ⇧ 2.01 1.40E-03  237555_at CARS2 ⇧ 2.00 3.10E-03 
220374_at KLHL28 ⇧ 2.02 1.80E-04  1556655_s_at --- ⇧ 2.01 1.30E-03  220612_at --- ⇧ 2.00 2.70E-03 
237232_at --- ⇧ 2.02 1.60E-04  243709_at SLC38A9 ⇧ 2.01 1.20E-03  1555977_at MYL12A ⇧ 2.00 2.00E-03 
AFFX-r2-Bs-
dap-5_at 
--- ⇧ 2.02 0.032  218314_s_at C11orf57 ⇧ 2.01 1.10E-03  226874_at KLHL8 ⇧ 2.00 1.90E-03 
209583_s_at CD200 ⇩ 2.01 0.031  201407_s_at PPP1CB ⇧ 2.01 1.10E-03  226400_at CDC42 ⇧ 2.00 1.60E-03 
204908_s_at BCL3 ⇧ 2.01 0.024  230868_at --- ⇧ 2.01 7.70E-04  230123_at NECAP2 ⇧ 2.00 1.60E-03 
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1560204_at NT5DC4 ⇧ 2.00 1.20E-03  224438_at --- ⇧ 1.99 4.70E-04  236752_at --- ⇧ 1.97 0.011 
230681_at TBRG1 ⇧ 2.00 4.50E-04  220113_x_at POLR1B ⇧ 1.99 4.30E-04  208811_s_at DNAJB6 ⇩ 1.97 0.011 
220864_s_at NDUFA13 ⇩ 2.00 3.80E-04  214594_x_at ATP8B1 ⇧ 1.99 4.10E-04  209686_at S100B ⇩ 1.97 0.011 
220791_x_at SCN11A ⇧ 2.00 3.70E-04  208470_s_at HP  ⇧ 1.98 0.046  223193_x_at FAM162A ⇩ 1.97 9.90E-03 
234479_at PCDHB18 ⇧ 2.00 2.40E-04  219529_at CLIC3 ⇩ 1.98 0.031  239571_at --- ⇧ 1.97 9.30E-03 
218000_s_at PHLDA1 ⇧ 2.00 2.40E-04  202131_s_at RIOK3 ⇧ 1.98 0.029  233105_at --- ⇧ 1.97 9.30E-03 
215604_x_at --- ⇧ 2.00 2.20E-04  227668_at C17orf56 ⇩ 1.98 0.028  229713_at PIP4K2A ⇧ 1.97 7.40E-03 
239967_at --- ⇧ 2.00 5.20E-05  223802_s_at RBBP6 ⇩ 1.98 0.025  242819_at --- ⇧ 1.97 7.10E-03 
235894_at --- ⇧ 2.00 3.70E-05  243450_at --- ⇧ 1.98 0.020  220942_x_at FAM162A ⇩ 1.97 6.90E-03 
215548_s_at SCFD1 ⇩ 1.99 0.037  201666_at TIMP1 ⇩ 1.98 0.018  215946_x_at IGLL3 ⇩ 1.97 6.60E-03 
231370_at --- ⇧ 1.99 0.028  1561644_x_at --- ⇧ 1.98 5.00E-03  244801_at PSMB7 ⇧ 1.97 5.40E-03 
1552480_s_at PTPRC ⇧ 1.99 0.026  217966_s_at FAM129A ⇧ 1.98 2.70E-03  238449_at LOC595101 ⇧ 1.97 4.70E-03 
202955_s_at ARFGEF1 ⇩ 1.99 0.020  209796_s_at CNPY2 ⇩ 1.98 2.60E-03  225640_at LOC401504 ⇧ 1.97 3.90E-03 
239651_at ANAPC5 ⇧ 1.99 0.015  203392_s_at CTBP1 ⇧ 1.98 2.40E-03  220901_at GPR157 ⇧ 1.97 3.60E-03 
217814_at CCDC47 ⇩ 1.99 9.00E-03  243296_at NAMPT ⇧ 1.98 2.40E-03  220342_x_at EDEM3 ⇧ 1.97 3.40E-03 
223080_at GLS ⇧ 1.99 8.30E-03  36711_at MAFF ⇧ 1.98 2.30E-03  221939_at YIPF2 ⇧ 1.97 3.30E-03 
1554543_at SPAG9 ⇧ 1.99 7.50E-03  215012_at ZNF451 ⇧ 1.98 2.30E-03  242121_at --- ⇧ 1.97 2.40E-03 
238295_at C17orf42 ⇧ 1.99 6.20E-03  226080_at SSH2 ⇧ 1.98 2.10E-03  233585_at SDK2 ⇩ 1.97 1.80E-03 
243072_at --- ⇧ 1.99 5.70E-03  1567251_at OR10A3 ⇧ 1.98 1.40E-03  239614_x_at --- ⇧ 1.97 1.50E-03 
224345_x_at FAM162A ⇩ 1.99 5.50E-03  1570134_at --- ⇧ 1.98 1.30E-03  208900_s_at TOP1 ⇧ 1.97 1.50E-03 
1559060_a_at FNIP1 ⇧ 1.99 5.50E-03  1559597_at --- ⇧ 1.98 6.30E-04  229467_at PCBP2 ⇧ 1.97 1.40E-03 
213718_at RBM4 ⇧ 1.99 5.50E-03  227948_at FGD4 ⇧ 1.98 5.60E-04  218924_s_at CTBS ⇧ 1.97 1.30E-03 
237310_at --- ⇧ 1.99 5.40E-03  1566778_at --- ⇧ 1.98 5.10E-04  201726_at ELAVL1 ⇧ 1.97 1.20E-03 
223209_s_at SELS ⇩ 1.99 4.80E-03  217481_x_at --- ⇩ 1.98 3.00E-04  1563488_at TMEM132B ⇧ 1.97 9.20E-04 
1557270_at --- ⇧ 1.99 3.70E-03  1559616_x_at ZNF626 ⇧ 1.98 2.50E-04  1560540_x_at --- ⇧ 1.97 5.30E-04 
225551_at C1orf71 ⇧ 1.99 3.50E-03  1558740_s_at --- ⇧ 1.98 2.10E-04  203326_x_at --- ⇧ 1.97 4.60E-04 
232363_at --- ⇧ 1.99 2.90E-03  1562645_at LOC401176 ⇩ 1.97 0.047  221176_x_at WBSCR23 ⇧ 1.97 2.80E-04 
242423_x_at --- ⇧ 1.99 1.90E-03  236934_at --- ⇧ 1.97 0.046  238863_x_at COG8 ⇧ 1.97 2.20E-04 
215908_at --- ⇧ 1.99 1.30E-03  209287_s_at CDC42EP3 ⇩ 1.97 0.032  239029_at LOC100129701 ⇧ 1.97 7.10E-05 
243852_at LUC7L2 ⇧ 1.99 1.30E-03  226686_at CISD2 ⇧ 1.97 0.026  215086_at IBTK ⇧ 1.97 1.80E-05 
1553020_at SMCR5 ⇧ 1.99 1.20E-03  242214_at RPS27A ⇧ 1.97 0.023  219533_at CDKN1C ⇧ 1.97 1.60E-05 
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238150_at --- ⇩ 1.96 0.044  216679_at TIGD1L ⇧ 1.96 1.20E-04  214805_at EIF4A1 ⇧ 1.95 1.20E-03 
243350_at --- ⇧ 1.96 0.031  239335_at ZNF710 ⇧ 1.96 1.10E-04  223519_at ZAK ⇧ 1.95 1.20E-03 
242695_at --- ⇧ 1.96 0.031  1559821_at --- ⇧ 1.96 9.80E-05  205642_at CEP110 ⇩ 1.95 1.00E-03 
1558011_at --- ⇧ 1.96 0.024  209463_s_at TAF12 ⇩ 1.96 7.80E-05  222439_s_at THRAP3 ⇧ 1.95 4.30E-04 
232980_at LMBRD1 ⇧ 1.96 0.024  1558890_at --- ⇩ 1.96 3.60E-06  1564148_at --- ⇧ 1.95 3.20E-04 
226184_at FMNL2 ⇩ 1.96 0.018  218978_s_at SLC25A37 ⇧ 1.95 0.047  1559530_at --- ⇧ 1.95 2.10E-04 
242482_at PRKAR1A ⇧ 1.96 0.017  209581_at PLA2G16 ⇩ 1.95 0.038  203210_s_at RFC5 ⇩ 1.95 1.70E-04 
228195_at C2orf88 ⇩ 1.96 0.013  244659_at LOC100131015 ⇩ 1.95 0.030  1556831_at DYNC1H1 ⇧ 1.95 1.50E-04 
215206_at --- ⇧ 1.96 0.011  240326_at --- ⇧ 1.95 0.024  1559971_at BSDC1 ⇧ 1.95 1.40E-04 
235956_at KIAA1377 ⇧ 1.96 0.011  223955_at EFCAB4B ⇩ 1.95 0.015  233075_at HERC2P7 ⇩ 1.95 1.30E-04 
239954_at ZNF160 ⇧ 1.96 0.011  237239_at --- ⇧ 1.95 0.014  228068_at GOLGA7B ⇧ 1.95 4.90E-05 
213879_at --- ⇧ 1.96 8.70E-03  240271_at --- ⇧ 1.95 0.014  243827_at --- ⇧ 1.94 0.046 
210802_s_at DIMT1L ⇩ 1.96 7.90E-03  212386_at TCF4 ⇧ 1.95 0.014  237452_at --- ⇧ 1.94 0.045 
1569041_at --- ⇧ 1.96 7.10E-03  230425_at EPHB1 ⇩ 1.95 0.011  233869_x_at --- ⇧ 1.94 0.042 
210285_x_at WTAP ⇩ 1.96 6.30E-03  241106_at --- ⇧ 1.95 8.50E-03  223952_x_at DHRS9 ⇩ 1.94 0.042 
202065_s_at PPFIA1 ⇧ 1.96 5.00E-03  244023_at SYK ⇧ 1.95 7.00E-03  218521_s_at UBE2W ⇧ 1.94 0.040 
221986_s_at KLHL24 ⇧ 1.96 4.30E-03  240148_at MSH6 ⇧ 1.95 6.70E-03  240442_at --- ⇧ 1.94 0.035 
219675_s_at UXS1 ⇩ 1.96 3.50E-03  215457_at --- ⇧ 1.95 6.20E-03  215379_x_at IGL ⇩ 1.94 0.027 
243201_at HNRNPH2 ⇧ 1.96 3.20E-03  231042_s_at --- ⇧ 1.95 5.80E-03  222409_at CORO1C ⇧ 1.94 0.025 
222286_at SNAPC3 ⇧ 1.96 3.20E-03  232575_at PCA3 ⇧ 1.95 4.50E-03  215342_s_at RABGAP1L ⇧ 1.94 0.024 
225814_at XRN1 ⇧ 1.96 3.00E-03  212040_at TGOLN2 ⇧ 1.95 4.30E-03  243768_at --- ⇧ 1.94 0.023 
219031_s_at NIP7 ⇧ 1.96 2.60E-03  236666_s_at LOC390205 ⇧ 1.95 3.50E-03  208496_x_at HIST1H3G ⇩ 1.94 0.020 
222387_s_at VPS35 ⇧ 1.96 2.50E-03  1558418_at --- ⇧ 1.95 3.40E-03  207507_s_at ATP5G3 ⇩ 1.94 0.018 
236235_at ITCH ⇧ 1.96 2.40E-03  1553704_x_at ZNF791 ⇧ 1.95 2.80E-03  231316_at --- ⇧ 1.94 0.013 
226667_x_at EPN1 ⇧ 1.96 1.90E-03  215375_x_at LRRFIP1 ⇧ 1.95 2.70E-03  212451_at SECISBP2L ⇧ 1.94 0.013 
237825_x_at --- ⇧ 1.96 1.70E-03  1559270_at ZFHX4 ⇩ 1.95 2.40E-03  241036_at --- ⇧ 1.94 0.012 
1557302_at ZNF585B ⇧ 1.96 1.20E-03  214754_at TET3 ⇩ 1.95 2.20E-03  1560474_at --- ⇧ 1.94 0.011 
205683_x_at TPSAB1 ⇧ 1.96 7.40E-04  222214_at --- ⇧ 1.95 2.00E-03  222507_s_at TMEM9B ⇩ 1.94 7.30E-03 
222033_s_at FLT1 ⇧ 1.96 2.90E-04  203590_at DYNC1LI2 ⇧ 1.95 1.70E-03  1558678_s_at MALAT1 ⇧ 1.94 6.80E-03 
1570020_at AACSL ⇧ 1.96 1.90E-04  1563321_s_at MLLT10 ⇧ 1.95 1.70E-03  241242_at --- ⇧ 1.94 5.60E-03 
1566597_at --- ⇧ 1.96 1.70E-04  219267_at GLTP ⇧ 1.95 1.30E-03  243630_at NDUFB1 ⇧ 1.94 5.30E-03 
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212852_s_at TROVE2 ⇧ 1.94 4.10E-03  205215_at RNF2 ⇧ 1.93 6.60E-03  242167_at --- ⇧ 1.92 0.018 
201212_at LGMN ⇩ 1.94 3.90E-03  212536_at ATP11B ⇧ 1.93 6.40E-03  207322_at ITSN1 ⇩ 1.92 0.016 
1565604_at PWP2 ⇧ 1.94 2.80E-03  244010_at --- ⇧ 1.93 4.80E-03  236944_at --- ⇧ 1.92 0.013 
207728_at ATF7IP ⇧ 1.94 2.40E-03  1563502_at ZDHHC2 ⇧ 1.93 4.50E-03  244412_at --- ⇧ 1.92 9.80E-03 
1554641_a_at TET3 ⇧ 1.94 1.70E-03  204616_at UCHL3 ⇩ 1.93 3.70E-03  200952_s_at CCND2 ⇧ 1.92 9.70E-03 
234084_x_at --- ⇧ 1.94 1.60E-03  235551_at WDR4 ⇧ 1.93 3.50E-03  234459_at PPHLN1 ⇧ 1.92 9.60E-03 
241882_at CAMTA1 ⇧ 1.94 1.50E-03  240521_at --- ⇧ 1.93 3.10E-03  212420_at ELF1 ⇧ 1.92 8.60E-03 
1556894_at NT5DC2 ⇧ 1.94 1.50E-03  216290_x_at --- ⇧ 1.93 2.90E-03  206756_at CHST7 ⇩ 1.92 8.40E-03 
1560209_at --- ⇧ 1.94 1.40E-03  203489_at SIVA1 ⇩ 1.93 2.50E-03  231366_at FDPSL2A ⇧ 1.92 8.40E-03 
233263_at --- ⇧ 1.94 1.20E-03  235240_at ATXN3 ⇧ 1.93 2.10E-03  242958_x_at --- ⇧ 1.92 6.90E-03 
207133_x_at ALPK1 ⇧ 1.94 8.30E-04  232096_x_at FOXP1-IT1 ⇧ 1.93 2.10E-03  218775_s_at WWC2 ⇧ 1.92 6.60E-03 
217793_at RAB11B ⇧ 1.94 6.10E-04  1553252_a_at BRWD3 ⇧ 1.93 1.90E-03  1559979_at SYF2 ⇧ 1.92 6.10E-03 
232636_at SLITRK4 ⇩ 1.94 4.80E-04  1560422_at --- ⇧ 1.93 1.30E-03  236251_at --- ⇧ 1.92 5.10E-03 
231597_x_at --- ⇧ 1.94 4.60E-04  208759_at NCSTN ⇧ 1.93 7.70E-04  204786_s_at IFNAR2 ⇧ 1.92 3.40E-03 
220352_x_at FLJ42627 ⇧ 1.94 2.50E-04  241223_x_at --- ⇧ 1.93 6.70E-04  224074_at VSX1 ⇩ 1.92 2.80E-03 
225668_at FAM173B ⇧ 1.94 2.40E-04  234656_x_at --- ⇧ 1.93 5.60E-04  226975_at RNPC3 ⇧ 1.92 2.70E-03 
232894_at --- ⇧ 1.94 2.10E-04  1558142_at TNRC6B ⇧ 1.93 5.50E-04  200889_s_at SSR1 ⇩ 1.92 2.70E-03 
216151_at --- ⇧ 1.94 2.00E-04  242578_x_at SLC22A3 ⇧ 1.93 4.20E-04  214130_s_at PDE4DIP ⇩ 1.92 2.40E-03 
214308_s_at HGD ⇩ 1.94 1.50E-04  242182_x_at --- ⇧ 1.93 4.10E-04  221276_s_at SYNC ⇧ 1.92 2.00E-03 
242277_at --- ⇧ 1.94 2.10E-05  233321_x_at LOC90834 ⇧ 1.93 3.90E-04  239692_at --- ⇧ 1.92 1.60E-03 
1564236_at --- ⇧ 1.93 0.039  218525_s_at HIF1AN ⇧ 1.93 2.20E-04  1565603_at PWP2 ⇧ 1.92 1.40E-03 
223210_at CHURC1 ⇧ 1.93 0.039  1561471_at LOC441009 ⇧ 1.93 2.00E-04  238083_at PARP10 ⇧ 1.92 1.30E-03 
1560259_at --- ⇧ 1.93 0.038  233757_x_at --- ⇧ 1.93 1.70E-04  225234_at CBL ⇧ 1.92 1.20E-03 
226189_at ITGB8 ⇩ 1.93 0.031  209619_at CD74 ⇩ 1.92 0.047  1552274_at PXK ⇧ 1.92 1.00E-03 
242911_at MED13L ⇧ 1.93 0.029  244026_at --- ⇧ 1.92 0.045  220875_at --- ⇧ 1.92 6.50E-04 
212249_at PIK3R1 ⇧ 1.93 0.027  207291_at PRRG4 ⇧ 1.92 0.035  222363_at --- ⇧ 1.92 4.40E-04 
1569647_at LOC643623 ⇧ 1.93 0.023  239833_at --- ⇧ 1.92 0.022  225197_at LOC100505487 ⇧ 1.92 3.80E-04 
1570566_at --- ⇧ 1.93 0.019  238468_at TNRC6B ⇧ 1.92 0.022  1553531_at PCSK6 ⇧ 1.92 3.60E-04 
243316_x_at VPS26A ⇧ 1.93 0.012  222875_at DHX33 ⇧ 1.92 0.021  218155_x_at TSR1 ⇧ 1.92 1.70E-04 
243640_x_at --- ⇧ 1.93 0.011  205767_at EREG ⇧ 1.92 0.021  204373_s_at CEP350 ⇧ 1.92 1.50E-04 
1567997_x_at --- ⇧ 1.93 9.20E-03  232627_at HGS ⇧ 1.92 0.020  235709_at GAS2L3 ⇧ 1.92 1.30E-04 
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215555_at --- ⇧ 1.91 0.043  217385_at --- ⇧ 1.91 1.30E-03  230058_at SDCCAG3 ⇧ 1.90 8.40E-03 
227958_s_at GSN ⇩ 1.91 0.043  1555317_at POLK ⇧ 1.91 1.30E-03  235698_at ZFP90 ⇧ 1.90 7.10E-03 
214814_at YTHDC1 ⇧ 1.91 0.041  215439_x_at --- ⇧ 1.91 1.10E-03  203189_s_at NDUFS8 ⇩ 1.90 6.80E-03 
1555730_a_at CFL1 ⇩ 1.91 0.037  1553600_at TMIE ⇧ 1.91 1.10E-03  209187_at DR1 ⇧ 1.90 5.60E-03 
209255_at KLHDC10 ⇩ 1.91 0.036  203090_at SDF2 ⇩ 1.91 7.80E-04  209321_s_at ADCY3 ⇩ 1.90 4.80E-03 
239023_at --- ⇧ 1.91 0.024  221996_s_at CLTB ⇧ 1.91 5.90E-04  1566111_at PIEZO1 ⇧ 1.90 4.30E-03 
241776_at --- ⇧ 1.91 0.023  233090_at --- ⇧ 1.91 4.90E-04  233216_at ZDHHC21 ⇧ 1.90 4.10E-03 
218026_at CCDC56 ⇩ 1.91 0.022  210417_s_at PI4KB ⇧ 1.91 4.50E-04  210240_s_at CDKN2D ⇩ 1.90 3.20E-03 
217148_x_at IGL ⇩ 1.91 0.020  216229_x_at HCG2P7 ⇧ 1.91 4.40E-04  208514_at KCNE1 ⇩ 1.90 2.90E-03 
237383_at --- ⇧ 1.91 0.015  217554_at --- ⇧ 1.91 4.30E-04  203542_s_at KLF9 ⇧ 1.90 2.80E-03 
232912_at GPR180 ⇧ 1.91 0.015  232644_x_at OCIAD1 ⇧ 1.91 2.60E-04  232929_at --- ⇧ 1.90 2.20E-03 
240948_at --- ⇧ 1.91 0.014  1569417_at --- ⇧ 1.91 1.80E-04  239251_at --- ⇧ 1.90 2.10E-03 
236685_at --- ⇧ 1.91 0.010  233495_at EXOSC3  ⇧ 1.91 1.80E-04  1559725_at --- ⇧ 1.90 1.90E-03 
240383_at UBE2D3 ⇧ 1.91 0.010  234724_x_at PCDHB18 ⇧ 1.91 1.10E-04  203398_s_at GALNT3 ⇧ 1.90 1.90E-03 
228337_at PWWP2A ⇧ 1.91 9.70E-03  1563012_x_at --- ⇧ 1.91 1.00E-04  244716_x_at TMIGD2 ⇧ 1.90 1.70E-03 
236846_at LOC284757 ⇧ 1.91 9.50E-03  202464_s_at PFKFB3 ⇧ 1.91 9.30E-05  242438_at ASXL1 ⇧ 1.90 1.60E-03 
232145_at C2orf68 ⇩ 1.91 7.60E-03  1552975_x_at --- ⇧ 1.91 6.00E-05  234346_x_at --- ⇧ 1.90 1.30E-03 
210943_s_at LYST ⇧ 1.91 7.40E-03  242740_at --- ⇧ 1.91 2.70E-05  200751_s_at HNRNPC ⇩ 1.90 1.30E-03 
200081_s_at RPS6 ⇩ 1.91 7.10E-03  1559025_at SEPT9 ⇧ 1.90 0.044  232915_at DDX49 ⇧ 1.90 1.10E-03 
234949_at LOC283788 ⇧ 1.91 6.50E-03  218136_s_at SLC25A37 ⇩ 1.90 0.023  235654_at TMEM218 ⇧ 1.90 1.10E-03 
236590_at --- ⇧ 1.91 6.20E-03  240866_at --- ⇧ 1.90 0.022  232169_x_at NDUFS8 ⇧ 1.90 1.00E-03 
202697_at NUDT21 ⇩ 1.91 6.10E-03  231578_at GBP1 ⇧ 1.90 0.021  203276_at LMNB1 ⇧ 1.90 9.00E-04 
210895_s_at CD86 ⇩ 1.91 5.90E-03  242563_at --- ⇧ 1.90 0.018  239830_at --- ⇧ 1.90 8.60E-04 
202233_s_at UQCRH ⇩ 1.91 5.50E-03  227529_s_at AKAP12 ⇩ 1.90 0.017  210368_at PCDHGA8 ⇧ 1.90 6.70E-04 
233730_at FAM135A ⇧ 1.91 3.00E-03  209421_at MSH2 ⇩ 1.90 0.016  232266_x_at CDC2L5 ⇧ 1.90 5.50E-04 
215863_at TFR2 ⇧ 1.91 2.90E-03  215069_at NMT2 ⇧ 1.90 0.014  241617_x_at --- ⇩ 1.90 3.80E-04 
233473_x_at --- ⇧ 1.91 2.10E-03  225156_at ELOF1 ⇧ 1.90 0.012  242171_at --- ⇧ 1.90 2.60E-04 
214103_s_at RAP2A ⇧ 1.91 2.00E-03  208615_s_at PTP4A2 ⇧ 1.90 0.012  203735_x_at PPFIBP1 ⇩ 1.90 2.40E-04 
1558652_at KIAA1310 ⇧ 1.91 1.90E-03  212007_at UBXN4 ⇧ 1.90 0.012  241743_at --- ⇧ 1.90 1.90E-04 
233056_x_at DLGAP4 ⇧ 1.91 1.80E-03  215440_s_at BEX4 ⇩ 1.90 0.011  224548_at HES7 ⇩ 1.90 1.40E-04 
1556359_at C6orf89 ⇧ 1.91 1.70E-03  1555086_at STAT5B ⇧ 1.90 0.011  1556003_a_at --- ⇧ 1.90 1.10E-04 
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220068_at VPREB3 ⇩ 1.89 0.048  bioB-3_at      241594_at LOC643449 ⇧ 1.88 2.40E-04 
231038_s_at --- ⇧ 1.89 0.044  224009_x_at DHRS9 ⇩ 1.88 0.046  207657_x_at TNPO1 ⇧ 1.88 2.40E-04 
223254_s_at G2E3 ⇧ 1.89 0.041  1558220_at MUC20 ⇧ 1.88 0.037  233605_x_at HNRNPM ⇧ 1.88 1.80E-04 
235049_at ADCY1 ⇧ 1.89 0.032  1560271_at --- ⇧ 1.88 0.036  207756_at --- ⇧ 1.88 1.70E-04 
237181_at --- ⇧ 1.89 0.029  214677_x_at IGL ⇩ 1.88 0.036  232719_at BRUNOL4 ⇩ 1.88 3.30E-05 
205861_at SPIB ⇩ 1.89 0.023  232796_at --- ⇧ 1.88 0.033  229841_at --- ⇧ 1.87 0.050 
213361_at TDRD7 ⇩ 1.89 0.022  1569180_at --- ⇧ 1.88 0.026  235369_at C14orf28 ⇧ 1.87 0.048 
39313_at WNK1 ⇧ 1.89 0.021  1562280_at --- ⇧ 1.88 0.021  202708_s_at HIST2H2BE ⇩ 1.87 0.047 
235222_x_at XIAP ⇧ 1.89 0.018  230698_at CALN1 ⇧ 1.88 0.018  232614_at --- ⇧ 1.87 0.046 
215221_at --- ⇧ 1.89 0.016  226386_at C7orf30 ⇩ 1.88 0.017  214201_x_at BAT2 ⇧ 1.87 0.044 
240673_at --- ⇧ 1.89 0.014  211868_x_at IGH ⇩ 1.88 0.016  243473_at --- ⇧ 1.87 0.028 
238199_x_at LOC440552 ⇧ 1.89 0.012  242853_at --- ⇧ 1.88 0.015  213741_s_at KPNA1 ⇧ 1.87 0.025 
232315_at LOC400713 ⇩ 1.89 7.90E-03  219293_s_at OLA1 ⇧ 1.88 0.012  222600_s_at UBA6 ⇧ 1.87 0.022 
1569080_at RNF165 ⇧ 1.89 7.50E-03  240723_at --- ⇧ 1.88 9.00E-03  210100_s_at ABCA2 ⇧ 1.87 0.020 
1569331_at --- ⇧ 1.89 7.20E-03  242878_at --- ⇧ 1.88 8.90E-03  239474_at --- ⇧ 1.87 0.019 
220586_at CHD9 ⇧ 1.89 7.10E-03  222906_at FLVCR1 ⇧ 1.88 7.70E-03  230341_x_at ADAMTS10 ⇧ 1.87 0.019 
212517_at ATRN ⇩ 1.89 6.30E-03  232264_at --- ⇧ 1.88 7.60E-03  1558877_at --- ⇧ 1.87 0.018 
211930_at HNRNPA3 ⇧ 1.89 5.90E-03  215224_at SNORA21 ⇧ 1.88 6.70E-03  219279_at DOCK10 ⇩ 1.87 0.018 
208872_s_at REEP5 ⇩ 1.89 5.80E-03  242609_x_at --- ⇧ 1.88 5.90E-03  239237_at LOC100506776 ⇧ 1.87 0.015 
215866_at --- ⇧ 1.89 4.90E-03  242946_at CD53 ⇧ 1.88 5.80E-03  231886_at --- ⇧ 1.87 0.011 
204347_at AK3L1 ⇧ 1.89 4.20E-03  224281_s_at NGRN ⇩ 1.88 5.80E-03  1559232_a_at --- ⇧ 1.87 0.011 
1557131_at LOC254100 ⇧ 1.89 3.80E-03  224853_at SLAIN2 ⇩ 1.88 5.40E-03  224241_s_at LOC100132388 ⇩ 1.87 0.011 
1560042_at FAM82A1 ⇧ 1.89 3.10E-03  200983_x_at CD59 ⇩ 1.88 2.90E-03  1560112_at WDFY2 ⇧ 1.87 0.011 
222796_at PTCD1 ⇧ 1.89 2.40E-03  241616_at --- ⇧ 1.88 2.60E-03  235061_at PPM1K ⇧ 1.87 0.010 
1559119_at --- ⇧ 1.89 2.00E-03  201106_at GPX4 ⇩ 1.88 1.70E-03  215036_at IGLC1 ⇧ 1.87 8.20E-03 
204618_s_at GABPB1 ⇧ 1.89 1.70E-03  238279_x_at --- ⇧ 1.88 1.60E-03  220010_at KCNE1L ⇧ 1.87 7.80E-03 
242531_at RRAGC ⇧ 1.89 5.70E-04  1562352_at --- ⇧ 1.88 8.00E-04  218609_s_at NUDT2 ⇩ 1.87 7.70E-03 
238050_at ANTXR2 ⇧ 1.89 4.80E-04  1558826_at ZNF831 ⇩ 1.88 6.50E-04  213168_at SP3 ⇧ 1.87 6.10E-03 
1570198_x_at --- ⇧ 1.89 3.10E-04  215846_at --- ⇧ 1.88 6.40E-04  214807_at --- ⇧ 1.87 5.70E-03 
1565769_at --- ⇧ 1.89 2.20E-04  222649_at XPO4 ⇧ 1.88 5.30E-04  233653_at --- ⇧ 1.87 4.60E-03 
205153_s_at CD40 ⇩ 1.89 1.90E-04  238980_x_at C17orf56 ⇧ 1.88 5.00E-04  1558816_at ZNF664 ⇧ 1.87 3.70E-03 
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212525_s_at H2AFX ⇧ 1.87 3.10E-03  219874_at SLC12A8 ⇩ 1.86 0.011  205442_at MFAP3L ⇩ 1.85 0.021 
1552788_a_at HELB ⇧ 1.87 2.50E-03  242714_at --- ⇧ 1.86 9.40E-03  220467_at --- ⇧ 1.85 0.015 
203954_x_at CLDN3 ⇧ 1.87 2.00E-03  1567458_s_at RAC1 ⇧ 1.86 9.10E-03  221531_at WDR61 ⇩ 1.85 0.014 
211605_s_at RARA ⇧ 1.87 2.00E-03  1570108_at --- ⇧ 1.86 8.80E-03  222378_at --- ⇧ 1.85 0.012 
1559882_at SAMHD1 ⇧ 1.87 1.50E-03  242661_x_at ALS2CR12 ⇧ 1.86 7.90E-03  1570259_at LIMS1 ⇧ 1.85 0.012 
242126_at --- ⇧ 1.87 1.30E-03  228106_at C4orf30 ⇧ 1.86 7.20E-03  233228_at --- ⇧ 1.85 0.011 
239188_at PPP2R3C ⇧ 1.87 1.20E-03  221449_s_at ITFG1 ⇩ 1.86 6.80E-03  1556432_at --- ⇧ 1.85 0.011 
212479_s_at RMND5A ⇧ 1.87 1.20E-03  1555832_s_at KLF6 ⇧ 1.86 4.80E-03  232896_at ERBB2IP ⇧ 1.85 0.010 
220510_at RHBG ⇧ 1.87 1.10E-03  212208_at MED13L ⇧ 1.86 4.40E-03  217973_at DCXR ⇩ 1.85 8.90E-03 
200973_s_at TSPAN3 ⇩ 1.87 8.10E-04  235940_at C9orf64 ⇧ 1.86 3.60E-03  1563453_at --- ⇧ 1.85 8.50E-03 
1570205_at --- ⇧ 1.87 6.30E-04  243993_at --- ⇧ 1.86 2.80E-03  227259_at CD47 ⇧ 1.85 7.80E-03 
224105_x_at --- ⇧ 1.87 4.80E-04  216933_x_at APC ⇧ 1.86 2.80E-03  215018_at KIAA1731 ⇧ 1.85 7.70E-03 
241163_at --- ⇧ 1.87 3.40E-04  232445_at SYT9 ⇧ 1.86 1.70E-03  230064_at --- ⇧ 1.85 7.20E-03 
208224_at HOXB1 ⇧ 1.87 2.50E-04  237026_at --- ⇧ 1.86 1.30E-03  208614_s_at FLNB ⇩ 1.85 6.70E-03 
1566152_a_at CLP1 ⇧ 1.87 1.20E-04  211798_x_at IGLJ3 ⇩ 1.86 1.30E-03  203321_s_at ADNP2 ⇧ 1.85 6.30E-03 
201028_s_at CD99 ⇩ 1.87 9.50E-05  242633_x_at --- ⇧ 1.86 1.20E-03  228284_at TLE1 ⇩ 1.85 4.70E-03 
244869_at --- ⇧ 1.86 0.041  243067_at --- ⇧ 1.86 1.10E-03  236809_at --- ⇧ 1.85 4.60E-03 
227817_at PRKCB ⇧ 1.86 0.038  1559128_at HSDL2 ⇧ 1.86 8.90E-04  1561451_a_at ADAM29 ⇧ 1.85 4.30E-03 
211794_at FYB ⇧ 1.86 0.037  232516_x_at DAP3 ⇧ 1.86 7.00E-04  202113_s_at SNX2 ⇩ 1.85 4.20E-03 
205849_s_at UQCRB ⇩ 1.86 0.037  226062_x_at FAM63A ⇧ 1.86 6.50E-04  203798_s_at VSNL1 ⇩ 1.85 3.70E-03 
208685_x_at BRD2 ⇧ 1.86 0.032  222925_at DCDC2 ⇩ 1.86 6.30E-04  221269_s_at SH3BGRL3 ⇩ 1.85 3.60E-03 
237377_at --- ⇧ 1.86 0.028  210760_x_at TRIP11 ⇧ 1.86 5.40E-04  209865_at SLC35A3 ⇧ 1.85 3.10E-03 
208910_s_at C1QBP ⇩ 1.86 0.027  1552752_a_at CADM2 ⇧ 1.86 3.30E-04  241798_at --- ⇧ 1.85 3.00E-03 
210948_s_at LEF1 ⇧ 1.86 0.024  207436_x_at KIAA0894 ⇧ 1.86 2.30E-04  215213_at NUP54 ⇧ 1.85 2.50E-03 
1557632_at IKZF1 ⇧ 1.86 0.023  220796_x_at SLC35E1 ⇧ 1.86 2.30E-04  201225_s_at SRRM1 ⇧ 1.85 2.50E-03 
240397_x_at --- ⇧ 1.86 0.021  1555048_a_at C21orf29 ⇧ 1.86 9.60E-06  1562031_at JAK2 ⇧ 1.85 1.90E-03 
240139_at --- ⇧ 1.86 0.019  220940_at ANKRD36B ⇧ 1.85 0.047  1568618_a_at GALNT1 ⇧ 1.85 1.70E-03 
201757_at RPL10 ⇩ 1.86 0.018  239755_at --- ⇧ 1.85 0.043  208823_s_at PCTK1 ⇧ 1.85 1.20E-03 
239131_at --- ⇧ 1.86 0.017  231577_s_at GBP1 ⇧ 1.85 0.039  220448_at KCNK12 ⇧ 1.85 9.00E-04 
214058_at MYCL1 ⇩ 1.86 0.017  201360_at CST3 ⇩ 1.85 0.036  237230_at GPHA2 ⇩ 1.85 6.10E-04 
1562442_a_at SSBP1 ⇧ 1.86 0.016  200007_at SRP14 ⇩ 1.85 0.033  209696_at FBP1 ⇩ 1.85 3.90E-04 







   Table A2: RR Ambion® GLOBINClearTM Gene List (n=4,520) [GeneSpring unpaired student’s t-test p<0.05, FC ≥ ±1.50] 
 372 
 
221499_s_at STX16 ⇧ 1.85 3.10E-04  203114_at SSSCA1 ⇩ 1.84 3.40E-03  201490_s_at PPIF ⇩ 1.83 0.020 
200046_at DAD1 ⇩ 1.85 2.60E-04  239268_at NDUFS1 ⇧ 1.84 3.20E-03  238723_at ATXN3 ⇧ 1.83 0.018 
202493_x_at CSH1 ⇧ 1.85 2.30E-04  1560026_at --- ⇧ 1.84 2.90E-03  222316_at --- ⇧ 1.83 0.017 
233783_at --- ⇧ 1.85 1.20E-04  207037_at TNFRSF11A ⇧ 1.84 2.90E-03  234255_at --- ⇧ 1.83 0.016 
38892_at KIAA0240 ⇧ 1.85 1.00E-04  223350_x_at LIN7C ⇧ 1.84 2.70E-03  243127_x_at DNASE1 ⇧ 1.83 0.013 
1561918_at --- ⇧ 1.85 3.50E-05  232342_at MTMR14 ⇧ 1.84 2.50E-03  215513_at HYMAI ⇧ 1.83 0.012 
221844_x_at SPCS3 ⇧ 1.85 1.50E-05  215893_x_at --- ⇧ 1.84 2.20E-03  215287_at STRN ⇧ 1.83 0.010 
228304_at RBM43 ⇧ 1.84 0.044  236122_at --- ⇧ 1.84 2.00E-03  209281_s_at ATP2B1 ⇧ 1.83 9.50E-03 
239893_at --- ⇧ 1.84 0.041  218119_at TIMM23  ⇩ 1.84 1.70E-03  201606_s_at PWP1 ⇧ 1.83 9.20E-03 
243751_at CHD2 ⇧ 1.84 0.041  240791_at --- ⇧ 1.84 1.30E-03  212501_at CEBPB ⇧ 1.83 7.50E-03 
241885_at --- ⇧ 1.84 0.037  226377_at NFIC ⇧ 1.84 1.30E-03  1564438_at --- ⇧ 1.83 7.40E-03 
201794_s_at SMG7 ⇧ 1.84 0.036  232957_x_at --- ⇧ 1.84 1.20E-03  202874_s_at ATP6V1C1 ⇩ 1.83 7.10E-03 
222420_s_at UBE2H ⇧ 1.84 0.035  241799_x_at --- ⇧ 1.84 1.10E-03  1557562_at GRIPAP1 ⇧ 1.83 6.70E-03 
233510_s_at PARVG ⇩ 1.84 0.030  234098_at SOBP ⇧ 1.84 1.10E-03  240205_x_at --- ⇧ 1.83 5.90E-03 
227232_at EVL ⇧ 1.84 0.029  1554899_s_at FCER1G ⇩ 1.84 8.20E-04  228067_at C2orf55 ⇩ 1.83 5.60E-03 
1569181_x_at --- ⇧ 1.84 0.026  233939_at REXO1 ⇧ 1.84 8.00E-04  202068_s_at LDLR ⇩ 1.83 5.40E-03 
1565703_at SMAD4 ⇧ 1.84 0.021  217253_at SH3BP2 ⇧ 1.84 5.10E-04  1566507_a_at FBXO9 ⇧ 1.83 5.30E-03 
239655_at --- ⇧ 1.84 0.019  231781_s_at LRRC2 ⇧ 1.84 3.00E-04  244220_at --- ⇧ 1.83 3.70E-03 
222544_s_at WHSC1L1 ⇧ 1.84 0.019  238102_s_at LOC149478 ⇩ 1.84 1.20E-04  232767_at CADM1 ⇧ 1.83 3.60E-03 
207089_at NRAP 
⇩ 
1.84 0.018  AFFX-DapX-
5_at 
--- ⇧ 1.84 0.027  207352_s_at GABRB2 ⇩ 1.83 3.00E-03 
1569302_at KIAA1731 ⇧ 1.84 0.017  1566854_at --- ⇧ 1.83 0.041  231902_at ZNF827 ⇧ 1.83 2.70E-03 
219417_s_at C17orf59 ⇩ 1.84 0.016  213642_at --- ⇧ 1.83 0.039  1556778_at --- ⇧ 1.83 2.10E-03 
208054_at HERC4 ⇧ 1.84 0.016  226283_at WDR51B ⇧ 1.83 0.036  212487_at GPATCH8 ⇧ 1.83 2.10E-03 
1553271_at DIP2B ⇧ 1.84 0.014  222306_at --- ⇧ 1.83 0.033  243860_at --- ⇧ 1.83 2.00E-03 
237753_at IL21R ⇧ 1.84 0.011  206765_at KCNJ2 ⇧ 1.83 0.032  1558792_x_at AP2A1 ⇧ 1.83 2.00E-03 
1570587_at --- ⇧ 1.84 9.70E-03  213939_s_at RUFY3 ⇧ 1.83 0.032  238713_at --- ⇧ 1.83 1.50E-03 
243664_at TXNL1 ⇧ 1.84 8.70E-03  224605_at C4orf3 ⇧ 1.83 0.027  203191_at ABCB6 ⇩ 1.83 9.50E-04 
235761_at --- ⇧ 1.84 8.60E-03  209241_x_at MINK1 ⇧ 1.83 0.027  244024_at ZNF182 ⇧ 1.83 9.10E-04 
220221_at VPS13D ⇧ 1.84 6.30E-03  217594_at ZCCHC11 ⇧ 1.83 0.026  236395_at --- ⇧ 1.83 8.60E-04 
214509_at HIST1H3I ⇩ 1.84 4.40E-03  204513_s_at ELMO1 ⇧ 1.83 0.021  1557409_at --- ⇧ 1.83 8.30E-04 
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211775_x_at MGC13053 ⇧ 1.83 6.40E-04  200039_s_at PSMB2 ⇩ 1.82 1.40E-03  242645_at --- ⇧ 1.81 0.010 
215532_x_at ZNF492 ⇧ 1.83 5.40E-04  234020_x_at --- ⇧ 1.82 1.30E-03  203408_s_at SATB1 ⇧ 1.81 9.30E-03 
222356_at --- ⇧ 1.83 2.60E-04  230685_at FLJ33630 ⇧ 1.82 1.10E-03  237208_at WDR61 ⇧ 1.81 9.30E-03 
244135_at --- ⇧ 1.83 2.10E-04  200824_at GSTP1 ⇩ 1.82 1.10E-03  223181_at C18orf55 ⇩ 1.81 9.20E-03 
202190_at CSTF1 ⇩ 1.83 2.00E-04  1566150_at CALML4 ⇩ 1.82 9.40E-04  240659_x_at --- ⇧ 1.81 8.70E-03 
218381_s_at U2AF2 ⇧ 1.83 9.90E-05  232064_at FER ⇧ 1.82 9.10E-04  230669_at RASA2 ⇧ 1.81 8.70E-03 
237072_at --- ⇧ 1.83 1.50E-05  1552870_s_at C1orf125 ⇩ 1.82 9.00E-04  207431_s_at DEGS1 ⇧ 1.81 7.60E-03 
AFFX-BioB-
3_at 
--- ⇩ 1.82 2.59E-04  202057_at KPNA1 ⇧ 1.82 8.70E-04  204048_s_at PHACTR2 ⇧ 1.81 7.30E-03 
242879_x_at AKT3 ⇧ 1.82 0.035  215909_x_at MINK1 ⇧ 1.82 8.50E-04  239331_at --- ⇧ 1.81 5.60E-03 
240513_at EIF3M ⇧ 1.82 0.025  210679_x_at --- ⇧ 1.82 6.40E-04  242190_at SDAD1 ⇧ 1.81 5.10E-03 
227819_at LGR6 ⇧ 1.82 0.025  208137_x_at ZNF611 ⇧ 1.82 6.30E-04  1558783_at --- ⇧ 1.81 5.00E-03 
242844_at PGGT1B ⇧ 1.82 0.022  1560543_at GRK4 ⇧ 1.82 6.10E-04  221286_s_at MGC29506 ⇩ 1.81 4.40E-03 
233593_at --- ⇧ 1.82 0.019  236181_at LOC100132181 ⇧ 1.82 5.90E-04  221568_s_at LIN7C ⇧ 1.81 4.10E-03 
215630_at --- ⇧ 1.82 0.018  215588_x_at RIOK3 ⇧ 1.82 4.90E-04  209254_at KLHDC10 ⇧ 1.81 3.70E-03 
225850_at SFT2D1 ⇩ 1.82 8.80E-03  222223_s_at IL1F5 ⇧ 1.82 3.20E-04  202475_at TMEM147 ⇩ 1.81 2.80E-03 
238064_at --- ⇧ 1.82 8.20E-03  232455_x_at LOC340085 ⇧ 1.82 1.70E-04  212361_s_at ATP2A2 ⇩ 1.81 2.50E-03 
1563460_at --- ⇧ 1.82 7.50E-03  208817_at COMT ⇩ 1.82 9.20E-05  224806_at TRIM25 ⇧ 1.81 2.20E-03 
1561545_at EPN2-AS1 ⇧ 1.82 5.60E-03  243878_at --- ⇧ 1.81 0.045  215445_x_at --- ⇧ 1.81 1.80E-03 
219625_s_at COL4A3BP ⇧ 1.82 5.50E-03  206311_s_at PLA2G1B ⇧ 1.81 0.037  243221_at FAM20A ⇩ 1.81 1.80E-03 
222888_at CCNJ ⇧ 1.82 4.70E-03  232426_at SV2B ⇩ 1.81 0.037  215359_x_at ZNF44 ⇧ 1.81 1.70E-03 
1563166_at --- ⇧ 1.82 4.00E-03  204369_at PIK3CA ⇩ 1.81 0.036  222104_x_at GTF2H3 ⇧ 1.81 1.50E-03 
202298_at NDUFA1 ⇩ 1.82 3.90E-03  239227_at --- ⇧ 1.81 0.033  229749_at ANO4 ⇧ 1.81 1.20E-03 
220659_s_at C7orf43 ⇧ 1.82 3.80E-03  236621_at RPS27  ⇧ 1.81 0.027  220720_x_at FAM128B ⇧ 1.81 1.20E-03 
213158_at --- ⇧ 1.82 3.60E-03  1555913_at GON4L ⇧ 1.81 0.025  234224_at --- ⇧ 1.81 8.70E-04 
235730_at --- ⇧ 1.82 3.30E-03  204069_at MEIS1 ⇩ 1.81 0.020  214715_x_at ZNF160 ⇧ 1.81 7.70E-04 
233017_x_at --- ⇧ 1.82 2.70E-03  225451_at GRIPAP1 ⇧ 1.81 0.018  1557197_a_at LGALS3 ⇧ 1.81 6.40E-04 
234820_at MAS1L ⇩ 1.82 2.50E-03  239049_at --- ⇧ 1.81 0.016  238366_at C1orf228 ⇧ 1.81 6.30E-04 
215639_at SH2D3C ⇧ 1.82 2.40E-03  228853_at STYX ⇧ 1.81 0.015  232814_x_at KLC1 ⇧ 1.81 5.20E-04 
203433_at MTHFS ⇩ 1.82 1.70E-03  222809_x_at CCDC85C ⇩ 1.81 0.014  233381_at RUFY1 ⇧ 1.81 4.70E-04 
234245_at --- ⇧ 1.82 1.40E-03  209023_s_at STAG2 ⇧ 1.81 0.012  207730_x_at --- ⇧ 1.81 4.00E-04 
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208547_at HIST1H2BB ⇩ 1.81 9.40E-05  212814_at AHCYL2 ⇧ 1.80 6.00E-03  210869_s_at MCAM ⇧ 1.80 1.20E-04 
243655_x_at --- ⇧ 1.81 7.30E-05  217603_at ATP6V0A2 ⇧ 1.80 6.00E-03  208967_s_at AK2 ⇩ 1.80 1.80E-06 
210637_at TACR1 ⇧ 1.81 6.60E-05  1553747_at MGC16025 ⇧ 1.80 5.90E-03  201998_at ST6GAL1 ⇩ 1.79 0.045 
AFFX-r2-Ec-
bioC-5_at 
--- ⇩ 1.80 1.08E-05  1553972_a_at CBS ⇧ 1.80 5.60E-03  1565638_at --- ⇧ 1.79 0.042 
206267_s_at MATK ⇧ 1.80 0.041  240839_at --- ⇧ 1.80 5.20E-03  1565889_at --- ⇧ 1.79 0.037 
223243_s_at EDEM3 ⇧ 1.80 0.039  1570441_at NAPB ⇧ 1.80 5.10E-03  233898_s_at FGFR1OP2 ⇧ 1.79 0.037 
212509_s_at MXRA7 ⇧ 1.80 0.038  1557521_a_at --- ⇧ 1.80 4.10E-03  1556914_at --- ⇧ 1.79 0.032 
211352_s_at NCOA3 ⇧ 1.80 0.033  240510_at NBN ⇧ 1.80 3.90E-03  232486_at LRFN1 ⇧ 1.79 0.030 
234196_at --- ⇧ 1.80 0.027  205169_at RBBP5 ⇧ 1.80 3.90E-03  236839_at --- ⇧ 1.79 0.028 
213789_at --- ⇧ 1.80 0.026  1558739_at --- ⇧ 1.80 3.10E-03  232020_at SMURF2 ⇧ 1.79 0.026 
214388_at --- ⇧ 1.80 0.024  237725_x_at SMC5 ⇧ 1.80 2.90E-03  225957_at C5orf41 ⇧ 1.79 0.024 
209259_s_at SMC3 ⇩ 1.80 0.023  222708_s_at STX17 ⇧ 1.80 2.70E-03  208768_x_at RPL22 ⇩ 1.79 0.024 
226159_at C5orf51 ⇧ 1.80 0.022  202662_s_at ITPR2 ⇩ 1.80 2.20E-03  243916_x_at UBLCP1 ⇧ 1.79 0.023 
221775_x_at RPL22 ⇩ 1.80 0.022  243934_at ODF3B ⇧ 1.80 2.20E-03  212779_at KIAA1109 ⇩ 1.79 0.019 
207700_s_at NCOA3 ⇧ 1.80 0.019  213350_at RPS11 ⇧ 1.80 1.80E-03  237461_at NLRP7 ⇩ 1.79 0.019 
242233_at --- ⇧ 1.80 0.018  216612_x_at --- ⇧ 1.80 1.60E-03  213593_s_at TRA2A ⇧ 1.79 0.019 
224637_at LOC100128731 ⇩ 1.80 0.016  205469_s_at IRF5 ⇩ 1.80 1.10E-03  243846_x_at --- ⇧ 1.79 0.018 
1564029_at USP49 ⇧ 1.80 0.016  241046_at LOC100505903 ⇧ 1.80 1.00E-03  218495_at UXT ⇩ 1.79 0.017 
206295_at IL18 ⇧ 1.80 0.014  225712_at GEMIN5 ⇩ 1.80 8.90E-04  204861_s_at NAIP ⇧ 1.79 0.015 
203166_at CFDP1 ⇩ 1.80 0.013  1557512_at --- ⇧ 1.80 7.60E-04  1569201_a_at --- ⇧ 1.79 0.014 
212000_at SFRS14 ⇧ 1.80 0.013  240046_at --- ⇧ 1.80 6.60E-04  221494_x_at EIF3K ⇩ 1.79 0.012 
242970_at DIP2B ⇧ 1.80 0.012  224134_at MGC10814 ⇧ 1.80 6.60E-04  242059_at --- ⇧ 1.79 0.011 
234164_at --- ⇧ 1.80 0.011  241303_x_at --- ⇧ 1.80 5.70E-04  1557564_at --- ⇩ 1.79 0.010 
209408_at KIF2C ⇩ 1.80 0.011  231856_at KIAA1244 ⇧ 1.80 5.60E-04  228019_s_at MRPS18C ⇩ 1.79 0.010 
202784_s_at NNT ⇩ 1.80 0.010  1554476_x_at ZNF808 ⇧ 1.80 5.30E-04  1556339_a_at --- ⇧ 1.79 7.30E-03 
208301_at --- ⇧ 1.80 8.20E-03  213936_x_at SFTPB ⇧ 1.80 5.10E-04  237178_at --- ⇧ 1.79 5.30E-03 
1561036_at --- ⇩ 1.80 8.10E-03  241928_at --- ⇧ 1.80 4.50E-04  1553726_s_at C6orf170 ⇧ 1.79 4.90E-03 
224970_at NFIA ⇧ 1.80 7.10E-03  205988_at CD84 ⇧ 1.80 3.70E-04  210470_x_at NONO ⇧ 1.79 4.30E-03 
235780_at PRKACB ⇧ 1.80 6.60E-03  218291_at ROBLD3 ⇩ 1.80 3.70E-04  220855_at CLTC-IT1 ⇧ 1.79 3.70E-03 
36004_at IKBKG ⇩ 1.80 6.20E-03  1556352_at --- ⇧ 1.80 1.60E-04  230659_at --- ⇧ 1.79 2.90E-03 







   Table A2: RR Ambion® GLOBINClearTM Gene List (n=4,520) [GeneSpring unpaired student’s t-test p<0.05, FC ≥ ±1.50] 
 375 
 
222668_at KCTD15 ⇧ 1.79 2.70E-03  239166_at --- ⇧ 1.78 0.015  216459_x_at TIGD1L ⇧ 1.78 1.20E-03 
231818_x_at --- ⇧ 1.79 2.50E-03  211921_x_at PTMA ⇧ 1.78 0.015  1560031_at FRMD4A ⇧ 1.78 1.10E-03 
243866_x_at --- ⇧ 1.79 2.40E-03  237336_at ADD2 ⇧ 1.78 0.014  207109_at POU2F3 ⇧ 1.78 1.00E-03 
243482_at --- ⇧ 1.79 2.20E-03  33148_at ZFR ⇧ 1.78 0.014  230630_at AK3L1 ⇧ 1.78 5.90E-04 
239333_x_at --- ⇧ 1.79 1.90E-03  1564640_at MGA ⇧ 1.78 0.013  1557117_at --- ⇩ 1.78 3.00E-04 
1565754_x_at FGD2 ⇧ 1.79 1.70E-03  202996_at POLD4 ⇩ 1.78 0.012  212236_x_at KRT17 ⇧ 1.78 8.20E-05 
201577_at NME1 ⇩ 1.79 1.40E-03  241294_at --- ⇧ 1.78 0.011  208003_s_at NFAT5 ⇧ 1.77 0.049 
233273_at --- ⇧ 1.79 1.30E-03  235308_at ZBTB20 ⇧ 1.78 0.010  219521_at B3GAT1 ⇧ 1.77 0.046 
1569128_at C3orf38 ⇧ 1.79 1.30E-03  229835_s_at SLMO2 ⇧ 1.78 9.80E-03  236027_at C10orf78 ⇧ 1.77 0.045 
240906_at --- ⇧ 1.79 1.20E-03  232688_at BMP2K ⇧ 1.78 8.70E-03  235456_at --- ⇩ 1.77 0.044 
211006_s_at KCNB1 ⇧ 1.79 1.20E-03  1560500_at --- ⇧ 1.78 8.60E-03  207286_at CEP135 ⇧ 1.77 0.041 
211374_x_at --- ⇧ 1.79 9.00E-04  242562_at DNAJC24 ⇧ 1.78 7.70E-03  202006_at PTPN12 ⇩ 1.77 0.038 
216135_at IQCK ⇧ 1.79 8.30E-04  242197_x_at CD36 ⇧ 1.78 7.50E-03  1564154_at --- ⇧ 1.77 0.037 
206773_at LY6H ⇧ 1.79 7.20E-04  217446_x_at --- ⇧ 1.78 6.50E-03  213069_at HEG1 ⇩ 1.77 0.036 
244426_at --- ⇧ 1.79 6.90E-04  233431_x_at --- ⇧ 1.78 6.10E-03  230987_at --- ⇧ 1.77 0.034 
216051_x_at PRINS ⇧ 1.79 5.00E-04  238741_at FAM83A ⇩ 1.78 5.60E-03  237438_at --- ⇧ 1.77 0.033 
241099_at --- ⇧ 1.79 3.70E-04  242383_at --- ⇧ 1.78 4.50E-03  224227_s_at BDP1 ⇧ 1.77 0.028 
233796_at --- ⇧ 1.79 3.00E-04  232570_s_at ADAM33 ⇧ 1.78 3.70E-03  206204_at GRB14 ⇩ 1.77 0.027 
223928_s_at GUCA1C ⇧ 1.79 1.30E-04  32099_at SAFB2 ⇧ 1.78 3.50E-03  234576_at ANPEP ⇩ 1.77 0.025 
230340_s_at WASL ⇧ 1.79 5.60E-05  244021_at --- ⇧ 1.78 3.20E-03  202125_s_at TRAK2 ⇧ 1.77 0.024 
244164_at --- ⇧ 1.78 0.041  218084_x_at FXYD5 ⇩ 1.78 3.10E-03  91816_f_at MEX3D ⇧ 1.77 0.022 
1559413_at TCP11L2 ⇧ 1.78 0.038  1564004_at --- ⇧ 1.78 3.00E-03  239788_at --- ⇧ 1.77 0.019 
243236_at --- ⇧ 1.78 0.027  203665_at HMOX1 ⇩ 1.78 3.00E-03  1558111_at MBNL1 ⇧ 1.77 0.019 
239056_at SEC22C ⇩ 1.78 0.025  227991_x_at ZBTB43 ⇧ 1.78 2.90E-03  240758_at --- ⇧ 1.77 0.017 
242616_at --- ⇧ 1.78 0.023  223018_at NOB1 ⇩ 1.78 2.80E-03  210092_at MAGOH ⇩ 1.77 0.015 
205516_x_at CIZ1 ⇩ 1.78 0.021  232303_at ZNF608 ⇧ 1.78 2.60E-03  1559154_at --- ⇧ 1.77 0.014 
232581_x_at HIVEP3 ⇩ 1.78 0.021  221195_at RNFT1 ⇧ 1.78 2.50E-03  211764_s_at UBE2D1 ⇧ 1.77 0.014 
211612_s_at IL13RA1 ⇩ 1.78 0.021  234650_at --- ⇧ 1.78 2.20E-03  237448_at --- ⇧ 1.77 0.013 
239757_at ZFAND6 ⇧ 1.78 0.020  205063_at SIP1 ⇧ 1.78 2.00E-03  244546_at CYCS ⇧ 1.77 0.012 
204302_s_at KIAA0427 ⇧ 1.78 0.017  221367_at MOS ⇩ 1.78 1.30E-03  221928_at ACACB ⇧ 1.77 0.011 
1569311_at LOC554203 ⇧ 1.78 0.017  231775_at TNFRSF10A ⇧ 1.78 1.30E-03  235542_at TET3 ⇩ 1.77 0.011 
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212058_at SR140 ⇩ 1.77 9.60E-03  217656_at --- ⇧ 1.76 0.048  225748_at LTV1 ⇩ 1.76 8.00E-03 
217618_x_at HUS1 ⇧ 1.77 9.30E-03  243423_at TNIP1 ⇧ 1.76 0.047  213649_at SFRS7 ⇧ 1.76 7.90E-03 
200978_at MDH1 ⇩ 1.77 8.60E-03  222833_at LPCAT2 ⇧ 1.76 0.041  1558504_at --- ⇧ 1.76 7.30E-03 
228173_at GNAS ⇧ 1.77 8.50E-03  236955_at --- ⇧ 1.76 0.031  1553920_at C9orf84 ⇧ 1.76 6.60E-03 
230426_at DLD ⇧ 1.77 7.80E-03  226347_at FUT11 ⇧ 1.76 0.030  1566609_at --- ⇩ 1.76 6.40E-03 
224254_x_at --- ⇧ 1.77 6.80E-03  242549_at PRKD3 ⇧ 1.76 0.030  225684_at FAM33A ⇧ 1.76 6.10E-03 
201140_s_at RAB5C ⇧ 1.77 6.70E-03  232333_at --- ⇧ 1.76 0.027  224847_at CDK6 ⇩ 1.76 5.90E-03 
219775_s_at CPLX3 ⇧ 1.77 6.00E-03  229115_at DYNC1H1 ⇧ 1.76 0.025  233709_at --- ⇧ 1.76 4.20E-03 
1569551_at --- ⇧ 1.77 5.70E-03  1557527_at --- ⇧ 1.76 0.024  224322_at ARID4B ⇧ 1.76 4.00E-03 
1569538_at --- ⇧ 1.77 5.10E-03  244145_at --- ⇧ 1.76 0.023  235729_at ZNF514 ⇧ 1.76 3.70E-03 
1557522_x_at --- ⇧ 1.77 4.70E-03  218920_at FLJ10404 ⇧ 1.76 0.023  209376_x_at SFRS2IP ⇧ 1.76 3.20E-03 
216197_at ATF7IP ⇧ 1.77 3.00E-03  214101_s_at --- ⇧ 1.76 0.021  234822_at --- ⇩ 1.76 2.40E-03 
201280_s_at DAB2 ⇧ 1.77 2.90E-03  227369_at SERBP1 ⇧ 1.76 0.021  1559011_at FLJ13773 ⇧ 1.76 2.30E-03 
239627_at TMED9 ⇧ 1.77 2.50E-03  1565895_at --- ⇧ 1.76 0.018  241086_at --- ⇧ 1.76 2.20E-03 
227311_at SNX25 ⇧ 1.77 2.00E-03  1564568_at CRLF1 ⇧ 1.76 0.017  221120_at --- ⇧ 1.76 2.10E-03 
1553686_at C18orf25 ⇩ 1.77 1.90E-03  208581_x_at MT1X ⇩ 1.76 0.017  202499_s_at SLC2A3 ⇧ 1.76 1.80E-03 
208803_s_at SRP72 ⇩ 1.77 1.50E-03  1562945_at --- ⇩ 1.76 0.016  241065_x_at CMAS ⇧ 1.76 1.20E-03 
215582_x_at MCM3AP ⇧ 1.77 1.40E-03  1554177_a_at ATP5S ⇧ 1.76 0.016  1552745_at SLCO6A1 ⇧ 1.76 1.10E-03 
216466_at NAV3 ⇧ 1.77 1.40E-03  208206_s_at RASGRP2 ⇧ 1.76 0.016  203898_at CRCP ⇧ 1.76 9.40E-04 
233840_at --- ⇧ 1.77 1.20E-03  212794_s_at KIAA1033 ⇧ 1.76 0.014  207732_s_at DLG3 ⇧ 1.76 6.90E-04 
208247_at C3orf51 ⇧ 1.77 7.30E-04  223190_s_at MLL5 ⇧ 1.76 0.014  1562905_at --- ⇧ 1.76 6.40E-04 
209807_s_at NFIX ⇩ 1.77 6.60E-04  209074_s_at FAM107A ⇩ 1.76 0.013  240616_at LOC100131110 ⇧ 1.76 5.70E-04 
236812_at STMN4 ⇧ 1.77 5.10E-04  219757_s_at C14orf101 ⇧ 1.76 0.012  227514_at ITPRIPL2 ⇧ 1.76 5.00E-04 
208286_x_at POU5F1 ⇧ 1.77 4.60E-04  242837_at SFRS4 ⇧ 1.76 0.012  212466_at SPRED2 ⇧ 1.76 4.60E-04 
222337_at --- ⇧ 1.77 4.20E-04  207536_s_at TNFRSF9 ⇧ 1.76 0.012  242537_at --- ⇧ 1.76 2.20E-04 
219975_x_at OLAH ⇧ 1.77 3.20E-04  217701_x_at --- ⇧ 1.76 0.011  225700_at GLCCI1 ⇩ 1.76 2.20E-04 
217396_at --- ⇧ 1.77 2.80E-04  238170_at --- ⇧ 1.76 0.010  204468_s_at TIE1 ⇧ 1.76 2.20E-04 
1555014_x_at --- ⇧ 1.77 2.50E-04  213002_at MARCKS ⇧ 1.76 0.010  1553575_at ND6 ⇧ 1.76 1.30E-04 
1568915_at --- ⇧ 1.77 2.30E-04  1556434_at --- ⇧ 1.76 9.90E-03  204666_s_at RP5-1000E10.4 ⇧ 1.76 1.10E-04 
212258_s_at SMARCA2 ⇧ 1.77 1.90E-04  223178_s_at NT5DC1 ⇧ 1.76 9.90E-03  220696_at --- ⇧ 1.76 4.50E-05 
1559820_at --- ⇧ 1.77 1.70E-04  212965_at HIC2 ⇧ 1.76 8.70E-03  237748_at SCGBL ⇩ 1.76 2.50E-05 
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229168_at COL23A1 ⇧ 1.75 0.046  215490_at C1orf69 ⇧ 1.75 8.30E-03  209443_at SERPINA5 ⇧ 1.75 4.20E-04 
201904_s_at CTDSPL ⇩ 1.75 0.046  227546_x_at AURKAIP1 ⇧ 1.75 8.10E-03  241680_at --- ⇧ 1.75 3.10E-04 
235757_at --- ⇧ 1.75 0.045  1560558_at C9orf80 ⇧ 1.75 7.90E-03  1569100_a_at --- ⇧ 1.75 3.00E-04 
229497_at ANKDD1A ⇧ 1.75 0.042  224939_at NUFIP2 ⇧ 1.75 7.90E-03  219113_x_at HSD17B14 ⇧ 1.75 2.90E-04 
217802_s_at NUCKS1 ⇧ 1.75 0.042  226024_at COMMD1 ⇩ 1.75 6.70E-03  228511_s_at ZNF219 ⇧ 1.75 1.90E-04 
238890_at PSMG1 ⇧ 1.75 0.040  212418_at ELF1 ⇩ 1.75 5.40E-03  242991_at TJP2 ⇧ 1.75 1.10E-04 
232204_at EBF1 ⇧ 1.75 0.039  223882_at FAM172A ⇧ 1.75 5.20E-03  233038_at --- ⇧ 1.75 1.00E-04 
243648_at --- ⇧ 1.75 0.037  242175_at --- ⇧ 1.75 4.90E-03  218438_s_at MED28 ⇩ 1.74 0.049 
240358_at --- ⇧ 1.75 0.036  242560_at FANCD2 ⇧ 1.75 4.30E-03  210807_s_at SLC16A7 ⇧ 1.74 0.039 
241779_at MTX3 ⇧ 1.75 0.032  227703_s_at SYTL4 ⇩ 1.75 4.20E-03  228558_at C14orf80 ⇩ 1.74 0.038 
239709_at --- ⇧ 1.75 0.031  206247_at MICB ⇧ 1.75 3.50E-03  238513_at PRRG4 ⇧ 1.74 0.038 
241769_at --- ⇧ 1.75 0.029  240160_x_at --- ⇧ 1.75 3.30E-03  223270_at CTDSPL2 ⇧ 1.74 0.034 
1561763_at --- ⇧ 1.75 0.028  211864_s_at MYOF ⇩ 1.75 3.00E-03  203259_s_at HDDC2 ⇩ 1.74 0.033 
238558_at --- ⇧ 1.75 0.025  242357_x_at --- ⇧ 1.75 2.90E-03  220370_s_at USP36 ⇧ 1.74 0.033 
227082_at --- ⇧ 1.75 0.024  215250_at TMEM111 ⇧ 1.75 2.80E-03  235071_at WDR92 ⇧ 1.74 0.033 
206116_s_at TPM1 ⇩ 1.75 0.024  200655_s_at CALM1 ⇧ 1.75 2.60E-03  229987_at --- ⇧ 1.74 0.032 
214502_at HIST1H2BJ ⇩ 1.75 0.023  210873_x_at APOBEC3A ⇧ 1.75 2.50E-03  218360_at RAB22A ⇩ 1.74 0.031 
236386_at SUZ12P ⇧ 1.75 0.022  217016_x_at FLJ23172 ⇧ 1.75 2.30E-03  211922_s_at CAT ⇩ 1.74 0.029 
219359_at ATHL1 ⇧ 1.75 0.021  215853_at --- ⇧ 1.75 2.00E-03  232055_at SFXN1 ⇧ 1.74 0.029 
240594_at --- ⇧ 1.75 0.020  1552961_at --- ⇧ 1.75 1.90E-03  214182_at LOC100132430 ⇧ 1.74 0.024 
222035_s_at PAPOLA ⇩ 1.75 0.018  242256_x_at --- ⇧ 1.75 1.90E-03  1557452_at --- ⇧ 1.74 0.021 
220369_at SMEK1 ⇧ 1.75 0.016  1559731_x_at MACROD1 ⇧ 1.75 1.90E-03  1556931_at --- ⇧ 1.74 0.021 
202436_s_at CYP1B1 ⇧ 1.75 0.015  233074_at --- ⇩ 1.75 1.80E-03  1554089_s_at SBDS  ⇩ 1.74 0.021 
64371_at SFRS14 ⇧ 1.75 0.015  1570054_at --- ⇧ 1.75 1.70E-03  236554_x_at TMC8 ⇧ 1.74 0.019 
239597_at --- ⇧ 1.75 0.014  237133_at --- ⇧ 1.75 1.60E-03  1560456_at LSDP5 ⇧ 1.74 0.018 
237618_at --- ⇧ 1.75 0.014  216499_at --- ⇧ 1.75 1.20E-03  236696_at SR140 ⇧ 1.74 0.018 
213109_at TNIK ⇧ 1.75 0.013  204238_s_at C6orf108 ⇩ 1.75 1.20E-03  229262_at LRRC68 ⇧ 1.74 0.017 
220823_at --- ⇧ 1.75 0.012  215978_x_at LOC152719 ⇧ 1.75 1.20E-03  204064_at THOC1 ⇧ 1.74 0.016 
241786_at --- ⇧ 1.75 0.010  209193_at PIM1 ⇧ 1.75 1.10E-03  233658_at --- ⇧ 1.74 0.015 
1561181_at --- ⇧ 1.75 0.010  243793_at AHDC1 ⇧ 1.75 8.40E-04  233152_x_at --- ⇧ 1.74 0.014 
233271_at --- ⇧ 1.75 0.010  211387_x_at RNGTT ⇧ 1.75 4.80E-04  1557167_at HCG11 ⇧ 1.74 0.014 
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1562364_at GVINP1 ⇧ 1.74 0.013  221387_at NPFFR1 ⇧ 1.74 7.50E-04  223010_s_at OCIAD1 ⇩ 1.73 0.015 
223462_at TMEM175 ⇧ 1.74 0.013  1554697_at ADAMTS9 ⇧ 1.74 7.10E-04  225739_at RAB11FIP4 ⇩ 1.73 0.014 
240128_at --- ⇧ 1.74 0.011  210213_s_at EIF6 ⇩ 1.74 5.20E-04  217832_at SYNCRIP ⇩ 1.73 0.014 
219802_at PYROXD1 ⇧ 1.74 0.011  216460_at FLJ00049 ⇧ 1.74 5.00E-04  202191_s_at GAS7 ⇧ 1.73 0.012 
215824_at NUDT7 ⇧ 1.74 9.00E-03  215674_at KIAA1659 ⇧ 1.74 3.70E-04  203778_at MANBA ⇩ 1.73 0.011 
227278_at TAF13 ⇧ 1.74 8.30E-03  218634_at PHLDA3 ⇧ 1.74 3.70E-04  1558445_at --- ⇧ 1.73 0.010 
242109_at SYTL3 ⇧ 1.74 7.80E-03  233902_at GUCA1C ⇧ 1.74 3.20E-04  228916_at CWF19L2 ⇩ 1.73 9.90E-03 
1554251_at HP1BP3 ⇧ 1.74 7.20E-03  242687_at FAM160A1 ⇧ 1.74 2.10E-04  1559420_x_at CACNB2 ⇧ 1.73 9.60E-03 
234235_at --- ⇧ 1.74 7.10E-03  209650_s_at TBC1D22A ⇧ 1.74 1.30E-04  231863_at ING3 ⇧ 1.73 9.60E-03 
241062_at --- ⇧ 1.74 6.30E-03  1566670_at PDXK ⇧ 1.74 7.50E-05  56919_at WDR48 ⇧ 1.73 8.60E-03 
239060_at --- ⇧ 1.74 6.00E-03  223774_at SNHG12 ⇩ 1.74 3.50E-05  231242_at BHLHE41 ⇧ 1.73 5.70E-03 
1558075_at LOC339047 ⇧ 1.74 5.40E-03  223463_at RAB23 ⇧ 1.73 0.045  218906_x_at KLC2 ⇧ 1.73 5.70E-03 
1552303_a_at TMEM106A ⇧ 1.74 5.40E-03  217100_s_at UBXN7 ⇧ 1.73 0.045  229735_s_at NIPAL3 ⇧ 1.73 5.30E-03 
244279_at SOBP ⇧ 1.74 5.30E-03  212492_s_at KDM4B ⇧ 1.73 0.043  242912_at P704P ⇧ 1.73 5.30E-03 
208624_s_at EIF4G1 ⇧ 1.74 5.00E-03  232371_at MARCH7 ⇧ 1.73 0.039  1559771_at --- ⇧ 1.73 5.00E-03 
201011_at RPN1 ⇧ 1.74 4.50E-03  209389_x_at DBI ⇩ 1.73 0.038  243103_at --- ⇧ 1.73 4.90E-03 
233645_s_at C1RL ⇧ 1.74 4.20E-03  1570135_at ZNF230 ⇧ 1.73 0.037  237316_at ANKDD1A ⇧ 1.73 4.80E-03 
1553365_at DEPDC4 ⇧ 1.74 3.90E-03  1561092_at --- ⇧ 1.73 0.035  215763_at --- ⇧ 1.73 4.60E-03 
1555843_at HNRNPM ⇩ 1.74 3.60E-03  240743_at --- ⇧ 1.73 0.030  1564204_at FAM91A2 ⇧ 1.73 4.50E-03 
244872_at RBBP4 ⇧ 1.74 3.10E-03  201409_s_at PPP1CB ⇧ 1.73 0.027  212862_at CDS2 ⇧ 1.73 4.30E-03 
228254_at STAM2 ⇧ 1.74 3.00E-03  209691_s_at DOK4 ⇧ 1.73 0.024  217679_x_at --- ⇧ 1.73 4.20E-03 
219470_x_at CCNJ ⇧ 1.74 2.90E-03  1560145_at MKLN1 ⇩ 1.73 0.022  200761_s_at ARL6IP5 ⇧ 1.73 3.60E-03 
1562428_at LOC654780 ⇧ 1.74 2.60E-03  228412_at LOC643072 ⇩ 1.73 0.021  241993_x_at --- ⇧ 1.73 3.50E-03 
232107_at --- ⇧ 1.74 2.30E-03  227472_at DDA1 ⇧ 1.73 0.019  218113_at TMEM2 ⇧ 1.73 3.50E-03 
208195_at TTN ⇩ 1.74 2.20E-03  227934_at KPNA5 ⇧ 1.73 0.019  1568986_x_at PIGT ⇧ 1.73 3.30E-03 
1553037_a_at SYN2 ⇧ 1.74 2.10E-03  216748_at PYHIN1 ⇧ 1.73 0.019  211919_s_at CXCR4 ⇩ 1.73 3.10E-03 
203816_at DGUOK ⇩ 1.74 2.00E-03  1554565_x_at UNQ1887 ⇧ 1.73 0.019  1557224_at --- ⇧ 1.73 2.60E-03 
241757_x_at DYNC2LI1 ⇧ 1.74 2.00E-03  217608_at SFRS12IP1 ⇧ 1.73 0.018  37170_at BMP2K ⇧ 1.73 2.60E-03 
227507_at ZNF592 ⇧ 1.74 1.90E-03  218923_at CTBS ⇧ 1.73 0.017  227860_at CPXM1 ⇧ 1.73 2.30E-03 
210389_x_at TUBD1 ⇧ 1.74 1.70E-03  1564155_x_at --- ⇧ 1.73 0.016  214085_x_at GLIPR1 ⇧ 1.73 1.80E-03 
200908_s_at RPLP2 ⇩ 1.74 1.60E-03  237492_at --- ⇧ 1.73 0.015  240867_at --- ⇧ 1.73 1.70E-03 
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226888_at CSNK1G1 ⇧ 1.73 1.20E-03  238041_at TCF12 ⇧ 1.72 0.018  206556_at CLUL1 ⇧ 1.72 3.60E-04 
204175_at ZNF593 ⇩ 1.73 1.20E-03  226018_at C7orf41 ⇧ 1.72 0.016  1561614_at SLC8A1 ⇧ 1.72 3.30E-04 
237123_x_at KLHL9 ⇧ 1.73 1.00E-03  224400_s_at CHST9 ⇩ 1.72 0.016  208598_s_at HUWE1 ⇩ 1.72 2.70E-04 
1557501_a_at --- ⇧ 1.73 9.20E-04  1556416_s_at --- ⇧ 1.72 0.015  200881_s_at DNAJA1 ⇩ 1.72 2.50E-04 
222329_x_at --- ⇩ 1.73 9.00E-04  218043_s_at AZI2 ⇧ 1.72 0.014  1562669_at --- ⇧ 1.72 1.50E-04 
235797_x_at HMCN2 ⇩ 1.73 7.90E-04  243826_at --- ⇧ 1.72 0.013  239980_at C22orf28 ⇧ 1.72 1.30E-04 
206056_x_at SPN ⇧ 1.73 7.10E-04  216323_x_at TUBA3D ⇩ 1.72 0.013  1556383_at --- ⇩ 1.72 1.20E-04 
214902_x_at --- ⇧ 1.73 5.70E-04  226965_at FAM116A ⇧ 1.72 0.012  242520_s_at C1orf228 ⇩ 1.72 5.30E-05 
1557068_at KRT37 ⇧ 1.73 5.00E-04  208583_x_at HIST1H2AJ ⇩ 1.72 0.011  1562036_at --- ⇧ 1.72 6.40E-06 
205998_x_at CYP3A4 ⇧ 1.73 4.20E-04  212651_at RHOBTB1 ⇩ 1.72 0.011  AFFX-BioB-
M_at 
--- ⇩ 1.72 2.97E-04 
216343_at PCDHGA3 ⇧ 1.73 3.20E-04  206293_at SULT2A1 ⇧ 1.72 0.011  203828_s_at IL32 ⇩ 1.71 0.048 
233399_x_at ZNF252 ⇧ 1.73 2.70E-04  225980_at C14orf43 ⇩ 1.72 7.80E-03  230180_at DDX17 ⇧ 1.71 0.047 
214294_at KIAA0485 ⇧ 1.73 2.60E-04  223309_x_at PNPLA8 ⇧ 1.72 7.40E-03  1557300_s_at --- ⇧ 1.71 0.044 
203171_s_at RRP8 ⇩ 1.73 1.60E-04  217052_x_at --- ⇧ 1.72 4.90E-03  239175_at --- ⇧ 1.71 0.039 
1562142_at SKIV2L2 ⇧ 1.73 1.20E-04  223012_at UBXN6 ⇧ 1.72 4.60E-03  238892_at --- ⇧ 1.71 0.039 
211881_x_at IGLJ3 ⇩ 1.73 8.80E-05  216442_x_at FN1 ⇩ 1.72 4.00E-03  202335_s_at UBE2B ⇧ 1.71 0.035 
200599_s_at HSP90B1 ⇩ 1.72 0.046  1557842_at --- ⇧ 1.72 3.00E-03  240314_at --- ⇧ 1.71 0.031 
207310_s_at NOS1 ⇩ 1.72 0.045  212119_at RHOQ ⇧ 1.72 2.60E-03  226587_at SNRPN ⇧ 1.71 0.030 
211358_s_at CIZ1 ⇩ 1.72 0.043  216310_at TAOK1 ⇧ 1.72 2.30E-03  244826_at --- ⇧ 1.71 0.024 
243552_at MBTD1 ⇧ 1.72 0.043  1558560_s_at BLZF1 ⇧ 1.72 1.80E-03  241849_at --- ⇧ 1.71 0.024 
41657_at STK11 ⇧ 1.72 0.042  214951_at SLC26A10 ⇧ 1.72 1.80E-03  1561829_at --- ⇧ 1.71 0.023 
1561973_at SMARCC2 ⇧ 1.72 0.038  223718_at ACRBP ⇩ 1.72 1.60E-03  233078_at API5 ⇧ 1.71 0.023 
233114_at --- ⇧ 1.72 0.032  240251_at IFT80 ⇧ 1.72 1.60E-03  234260_at --- ⇧ 1.71 0.021 
1565598_at --- ⇧ 1.72 0.031  235907_at TMEM33 ⇧ 1.72 1.50E-03  225797_at MRPL54 ⇩ 1.71 0.019 
214544_s_at SNAP23 ⇩ 1.72 0.031  214707_x_at ALMS1 ⇧ 1.72 1.20E-03  238070_at CHD1L ⇧ 1.71 0.017 
215284_at --- ⇧ 1.72 0.024  207339_s_at LTB ⇩ 1.72 9.00E-04  218708_at NXT1 ⇩ 1.71 0.017 
216682_s_at FAM48A ⇧ 1.72 0.023  201871_s_at UBXN1 ⇩ 1.72 8.70E-04  206995_x_at SCARF1 ⇧ 1.71 0.017 
233229_at SCFD1 ⇧ 1.72 0.023  210169_at SEC14L5 ⇩ 1.72 7.20E-04  235760_at NSD1 ⇧ 1.71 0.014 
242274_x_at SLC25A42 ⇧ 1.72 0.021  236060_at --- ⇧ 1.72 5.30E-04  244061_at --- ⇧ 1.71 0.013 
203252_at CDK2AP2 ⇩ 1.72 0.018  1565269_s_at ATF1 ⇩ 1.72 4.40E-04  215913_s_at GULP1 ⇧ 1.71 0.012 
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227601_at METTL14 ⇧ 1.71 0.011  234120_at --- ⇧ 1.71 9.80E-04  227847_at EPM2AIP1 ⇧ 1.71 1.70E-03 
217550_at ATF6 ⇧ 1.71 8.40E-03  242896_at C2orf21 ⇧ 1.71 5.90E-04  201532_at PSMA3 ⇩ 1.70 0.023 
214295_at KIAA0485 ⇧ 1.71 7.80E-03  216187_x_at --- ⇧ 1.71 4.80E-04  240515_at --- ⇧ 1.70 0.018 
229128_s_at ANP32E ⇧ 1.71 7.50E-03  242025_at --- ⇧ 1.71 2.90E-04  208310_s_at C7orf28A/B ⇩ 1.70 0.018 
216491_x_at IGHM ⇩ 1.71 7.50E-03  207804_s_at FCN2 ⇩ 1.71 2.70E-04  242760_x_at PIGB ⇧ 1.70 0.018 
207126_x_at UGT1A1 ⇩ 1.71 7.40E-03  235792_x_at PIK3C2A ⇧ 1.71 2.20E-04  1570194_x_at --- ⇧ 1.70 0.017 
235601_at --- ⇧ 1.71 7.20E-03  203079_s_at CUL2 ⇧ 1.71 1.90E-04  239187_at C4orf30 ⇩ 1.70 0.017 
203893_at TAF9 ⇩ 1.71 6.60E-03  240568_at --- ⇧ 1.71 1.40E-04  1555653_at HNRNPA3 ⇧ 1.70 0.017 
208866_at CSNK1A1 ⇧ 1.71 6.50E-03  219965_s_at MAGIX ⇩ 1.71 1.20E-04  208057_s_at GLI2 ⇩ 1.70 0.016 
232350_x_at GPR161 ⇧ 1.71 6.20E-03  229277_at ADRB1 ⇧ 1.71 1.10E-04  221085_at TNFSF15 ⇧ 1.70 0.015 
1554196_at IZUMO1 ⇩ 1.71 6.00E-03  AFFX-r2-Ec-
bioB-5_at 
--- ⇩ 1.71 2.34E-04  244651_at --- ⇧ 1.70 0.013 
222368_at --- ⇧ 1.71 5.50E-03  241938_at QKI ⇧ 1.70 0.045  213462_at NPAS2 ⇩ 1.70 0.013 
243471_at --- ⇧ 1.71 5.50E-03  232156_at MUDENG ⇧ 1.70 0.044  242254_at --- ⇧ 1.70 0.012 
230966_at IL4I1 ⇩ 1.71 5.50E-03  201164_s_at PUM1 ⇩ 1.70 0.041  242797_x_at --- ⇧ 1.70 0.012 
225204_at PPTC7 ⇧ 1.71 5.30E-03  236974_at --- ⇧ 1.70 0.039  215579_at APOBEC3G ⇧ 1.70 0.012 
240870_at --- ⇧ 1.71 5.10E-03  202555_s_at MYLK ⇩ 1.70 0.037  1554316_at PGLS ⇧ 1.70 0.012 
222481_at FXC1 ⇧ 1.71 4.90E-03  224820_at FAM36A ⇧ 1.70 0.036  1557571_at VPS13D ⇧ 1.70 0.012 
205219_s_at GALK2 ⇩ 1.71 4.90E-03  238446_at SMA4 ⇧ 1.70 0.036  230795_at --- ⇧ 1.70 0.011 
236130_at SNORA37 ⇧ 1.71 3.90E-03  232174_at --- ⇧ 1.70 0.035  203643_at ERF ⇧ 1.70 0.011 
225444_at UBN2 ⇧ 1.71 3.80E-03  237218_at --- ⇧ 1.70 0.034  239213_at SERPINB1 ⇧ 1.70 0.011 
202736_s_at LSM4 ⇩ 1.71 3.60E-03  233359_at --- ⇧ 1.70 0.033  244077_at C10orf113 ⇧ 1.70 0.010 
214669_x_at IGKC ⇩ 1.71 3.30E-03  241434_at --- ⇧ 1.70 0.033  1565873_at --- ⇧ 1.70 8.80E-03 
203100_s_at CDYL ⇩ 1.71 3.10E-03  216384_x_at LOC643287 ⇧ 1.70 0.032  215208_x_at RPL35A ⇧ 1.70 8.80E-03 
209055_s_at CDC5L ⇩ 1.71 3.00E-03  214042_s_at RPL22 ⇩ 1.70 0.030  210829_s_at SSBP2 ⇩ 1.70 7.20E-03 
1553909_x_at FAM178A ⇧ 1.71 3.00E-03  201281_at ADRM1 ⇩ 1.70 0.029  234596_at --- ⇧ 1.70 6.50E-03 
1562353_x_at --- ⇧ 1.71 2.80E-03  217677_at PLEKHA2 ⇧ 1.70 0.028  201478_s_at DKC1 ⇩ 1.70 6.20E-03 
232002_at --- ⇧ 1.71 2.40E-03  201921_at GNG10 ⇧ 1.70 0.026  234306_s_at SLAMF7 ⇩ 1.70 5.70E-03 
240800_x_at --- ⇧ 1.71 2.30E-03  206098_at ZBTB6 ⇩ 1.70 0.025  211997_x_at H3F3B ⇩ 1.70 5.20E-03 
226716_at PRR12 ⇧ 1.71 2.30E-03  208808_s_at HMGB2 ⇧ 1.70 0.024  1556951_at --- ⇧ 1.70 4.40E-03 
217625_x_at LOC100506190 ⇧ 1.71 2.20E-03  237077_at --- ⇧ 1.70 0.023  219929_s_at ZFYVE21 ⇩ 1.70 4.40E-03 
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241777_x_at --- ⇧ 1.70 2.80E-03  233415_at --- ⇧ 1.69 0.035  216040_x_at --- ⇧ 1.69 6.30E-03 
241637_at --- ⇧ 1.70 2.60E-03  243282_at CCDC93 ⇧ 1.69 0.032  1554608_at TGOLN2 ⇧ 1.69 6.00E-03 
224597_at LOC647979 ⇧ 1.70 2.50E-03  201534_s_at UBL3 ⇧ 1.69 0.032  1565162_s_at MGST1 ⇩ 1.69 5.40E-03 
1569129_s_at C3orf38 ⇧ 1.70 2.30E-03  201326_at CCT6A ⇩ 1.69 0.031  235058_at --- ⇧ 1.69 5.00E-03 
1560779_a_at ZNF568 ⇧ 1.70 1.80E-03  226217_at SLC30A7 ⇧ 1.69 0.031  229265_at SKI ⇧ 1.69 4.80E-03 
243442_x_at --- ⇧ 1.70 1.60E-03  236472_at --- ⇧ 1.69 0.028  232962_x_at --- ⇧ 1.69 4.30E-03 
238489_at PRKAA2 ⇧ 1.70 1.30E-03  222887_s_at TMEM127 ⇩ 1.69 0.028  1558672_at --- ⇧ 1.69 4.30E-03 
201510_at ELF3 ⇧ 1.70 1.20E-03  207460_at GZMM ⇧ 1.69 0.024  204181_s_at ZBTB43 ⇧ 1.69 3.70E-03 
1564444_at LOC100130264 ⇧ 1.70 1.20E-03  1560156_at --- ⇧ 1.69 0.020  1565752_at FGD2 ⇧ 1.69 3.40E-03 
244489_at --- ⇧ 1.70 1.00E-03  239549_at --- ⇧ 1.69 0.017  1570329_at --- ⇧ 1.69 3.30E-03 
222364_at SLC44A1 ⇧ 1.70 9.60E-04  220694_at DDEF1IT1 ⇧ 1.69 0.015  223043_at TMEM85 ⇩ 1.69 3.30E-03 
231695_at --- ⇧ 1.70 9.50E-04  214153_at ELOVL5 ⇧ 1.69 0.015  202156_s_at CUGBP2 ⇧ 1.69 3.10E-03 
232215_x_at PRR11 ⇧ 1.70 9.50E-04  243985_at GTF2A2 ⇧ 1.69 0.015  230490_x_at RSU1 ⇧ 1.69 2.90E-03 
217348_x_at ARHGEF15 ⇧ 1.70 9.20E-04  1568857_a_at NBR1 ⇧ 1.69 0.015  1564317_at --- ⇧ 1.69 2.80E-03 
236880_at RAD52 ⇧ 1.70 9.10E-04  205946_at VIPR2 ⇩ 1.69 0.015  1569999_at --- ⇧ 1.69 2.80E-03 
238474_at NUP43 ⇧ 1.70 8.50E-04  1557504_at --- ⇧ 1.69 0.014  1556336_at RBMX ⇧ 1.69 2.10E-03 
1554039_at C14orf159 ⇧ 1.70 7.00E-04  214808_at --- ⇧ 1.69 0.013  204768_s_at FEN1 ⇩ 1.69 2.00E-03 
1556072_at C22orf37 ⇧ 1.70 6.60E-04  201846_s_at RYBP ⇧ 1.69 0.013  1566887_x_at --- ⇧ 1.69 1.90E-03 
211625_s_at DRD3 ⇧ 1.70 3.00E-04  239212_at LTV1 ⇧ 1.69 0.012  233428_at --- ⇧ 1.69 1.50E-03 
239934_x_at --- ⇧ 1.70 2.40E-04  206674_at FLT3 ⇩ 1.69 0.011  230784_at PRAC ⇧ 1.69 1.50E-03 
1553282_at C21orf128 ⇩ 1.70 2.10E-04  224252_s_at FXYD5 ⇩ 1.69 0.011  232685_at --- ⇧ 1.69 1.30E-03 
213624_at SMPDL3A ⇧ 1.70 7.50E-05  234884_x_at IGL ⇩ 1.69 0.011  215179_x_at PGF ⇧ 1.69 1.20E-03 
212051_at WIPF2 ⇩ 1.70 7.30E-05  209244_s_at KIF1C ⇧ 1.69 0.011  231212_x_at --- ⇧ 1.69 9.70E-04 
201616_s_at CALD1 ⇧ 1.70 6.90E-05  236470_at --- ⇧ 1.69 0.010  216811_at --- ⇧ 1.69 8.00E-04 
240621_at --- ⇧ 1.70 3.10E-05  218061_at MEA1 ⇩ 1.69 0.010  215850_s_at NDUFA5 ⇧ 1.69 6.70E-04 
1561101_at LOC153469 ⇩ 1.70 2.60E-05  201844_s_at RYBP ⇧ 1.69 0.010  236519_at C9orf135 ⇧ 1.69 6.60E-04 
240155_x_at ZNF273 ⇧ 1.69 0.048  237414_at F7 ⇧ 1.69 9.90E-03  222015_at CSNK1E ⇧ 1.69 5.50E-04 
243546_at --- ⇧ 1.69 0.047  1555088_x_at STAT5B ⇧ 1.69 9.20E-03  230125_at GUSB ⇧ 1.69 4.30E-04 
219364_at DHX58 ⇩ 1.69 0.045  242554_at TPCN2 ⇧ 1.69 8.50E-03  243120_at --- ⇧ 1.69 2.70E-04 
239432_at FLJ31306 ⇧ 1.69 0.045  224580_at SLC38A1 ⇧ 1.69 7.30E-03  1570229_at --- ⇧ 1.69 2.60E-04 
215992_s_at RAPGEF2 ⇧ 1.69 0.043  235626_at CAMK1D ⇧ 1.69 6.90E-03  203630_s_at COG5 ⇧ 1.69 2.50E-04 
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240909_at --- ⇧ 1.69 1.70E-04  212667_at SPARC ⇩ 1.68 0.015  1563310_a_at --- ⇧ 1.68 9.30E-04 
231965_at FAM113A ⇧ 1.69 4.60E-05  1557341_x_at --- ⇧ 1.68 0.013  1554657_a_at C20orf26 ⇧ 1.68 7.20E-04 
209689_at CCDC93 ⇩ 1.68 0.046  1562300_at --- ⇧ 1.68 0.013  1568813_at LOC100506392 ⇧ 1.68 6.70E-04 
224412_s_at TRPM6 ⇩ 1.68 0.044  239070_at --- ⇧ 1.68 0.013  244714_at --- ⇧ 1.68 5.00E-04 
232582_at --- ⇧ 1.68 0.043  233904_at --- ⇧ 1.68 0.013  241066_at ZNF449 ⇧ 1.68 3.30E-04 
1570038_at ZNF595 ⇩ 1.68 0.043  1555241_at C8orf59 ⇧ 1.68 0.013  244533_at PTPN14 ⇧ 1.68 1.90E-04 
209177_at NDUFAF3 ⇩ 1.68 0.040  206398_s_at CD19 ⇩ 1.68 0.012  1560033_at MCCC2 ⇧ 1.68 7.30E-05 
240829_at --- ⇧ 1.68 0.034  201694_s_at EGR1 ⇩ 1.68 0.010  208115_x_at C10orf137 ⇩ 1.68 4.50E-05 
217185_s_at ZNF259  ⇩ 1.68 0.034  217620_s_at PIK3CB ⇧ 1.68 0.010  241905_at PIK3C2A ⇧ 1.67 0.048 
213528_at C1orf156 ⇩ 1.68 0.029  1556817_a_at --- ⇩ 1.68 7.20E-03  1566166_at --- ⇧ 1.67 0.046 
202112_at VWF ⇩ 1.68 0.029  203582_s_at RAB4A ⇩ 1.68 7.00E-03  227854_at --- ⇧ 1.67 0.044 
223717_s_at ACRBP ⇩ 1.68 0.028  218618_s_at FNDC3B ⇩ 1.68 6.20E-03  1558586_at ZNF33B ⇧ 1.67 0.044 
225961_at KLHDC5 ⇧ 1.68 0.026  201627_s_at INSIG1 ⇩ 1.68 6.10E-03  208782_at FSTL1 ⇩ 1.67 0.043 
209207_s_at SEC22B ⇧ 1.68 0.025  217480_x_at --- ⇩ 1.68 5.70E-03  1552318_at GIMAP1 ⇧ 1.67 0.042 
211992_at WNK1 ⇧ 1.68 0.025  243379_at --- ⇧ 1.68 5.10E-03  203168_at ATF6B ⇧ 1.67 0.041 
224102_at P2RY12 ⇩ 1.68 0.023  1563643_at --- ⇧ 1.68 4.10E-03  205921_s_at SLC6A6 ⇧ 1.67 0.037 
230958_s_at --- ⇧ 1.68 0.022  1562579_at --- ⇧ 1.68 4.00E-03  204028_s_at RABGAP1 ⇧ 1.67 0.035 
1570111_at C14orf48 ⇧ 1.68 0.022  210601_at CDH6 ⇧ 1.68 3.50E-03  232705_at LRRFIP2 ⇧ 1.67 0.034 
230689_at --- ⇧ 1.68 0.021  232498_at HEATR7A ⇧ 1.68 3.00E-03  233866_at KLHL5 ⇧ 1.67 0.033 
232500_at C20orf74 ⇧ 1.68 0.021  1566207_at TCEA1 ⇧ 1.68 2.60E-03  207794_at CCR2 ⇩ 1.67 0.032 
215109_at RC3H1 ⇧ 1.68 0.020  237561_x_at --- ⇧ 1.68 2.30E-03  231920_s_at CSNK1G1 ⇧ 1.67 0.032 
223173_at SPNS1 ⇧ 1.68 0.020  214395_x_at EEF1D ⇩ 1.68 2.30E-03  220960_x_at RPL22 ⇩ 1.67 0.030 
206661_at DBF4B ⇧ 1.68 0.019  227130_s_at TLE1 ⇩ 1.68 2.20E-03  230337_at SOS1 ⇧ 1.67 0.030 
206416_at ZNF205 ⇧ 1.68 0.019  224029_x_at SCN11A ⇧ 1.68 2.10E-03  223490_s_at EXOSC3 ⇩ 1.67 0.028 
201163_s_at IGFBP7 ⇧ 1.68 0.018  201278_at DAB2 ⇩ 1.68 2.00E-03  1553906_s_at FGD2 ⇧ 1.67 0.028 
212044_s_at RPL27A ⇧ 1.68 0.018  234565_x_at --- ⇧ 1.68 1.80E-03  244047_at --- ⇧ 1.67 0.026 
238356_at DOCK11 ⇧ 1.68 0.017  244822_at GART ⇧ 1.68 1.70E-03  236505_at NUP62 ⇧ 1.67 0.022 
212843_at NCAM1 ⇧ 1.68 0.016  217434_at MC2R ⇧ 1.68 1.70E-03  232344_at --- ⇧ 1.67 0.021 
236557_at ZBTB38 ⇧ 1.68 0.016  241695_s_at --- ⇧ 1.68 1.50E-03  216657_at ATXN3 ⇧ 1.67 0.021 
241697_at --- ⇩ 1.68 0.015  204403_x_at FAM115A ⇧ 1.68 1.30E-03  210222_s_at RTN1 ⇩ 1.67 0.021 
212107_s_at DHX9 ⇧ 1.68 0.015  1553472_at FLJ32955 ⇩ 1.68 1.10E-03  239723_at --- ⇧ 1.67 0.020 
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205628_at PRIM2 ⇧ 1.67 0.018  243153_at CDK5RAP2 ⇧ 1.67 3.70E-03  215650_at --- ⇧ 1.66 2.10E-03 
209484_s_at NSL1 ⇧ 1.67 0.017  240168_at XPO7 ⇧ 1.67 3.60E-03  213457_at MFHAS1 ⇧ 1.66 0.048 
204929_s_at VAMP5 ⇩ 1.67 0.017  233128_at --- ⇧ 1.67 3.50E-03  228655_at --- ⇧ 1.66 0.046 
235060_at LOC100190986 ⇧ 1.67 0.016  210663_s_at KYNU ⇩ 1.67 3.30E-03  238462_at UBASH3B ⇩ 1.66 0.040 
224919_at MRPS6 ⇩ 1.67 0.016  206355_at GNAL ⇧ 1.67 3.00E-03  202947_s_at GYPC ⇧ 1.66 0.039 
231357_at CLEC12B ⇧ 1.67 0.015  243760_at LOC650794 ⇧ 1.67 2.90E-03  1555363_s_at LOC284440 ⇧ 1.66 0.039 
226122_at PLEKHG1 ⇩ 1.67 0.015  206330_s_at SHC3 ⇩ 1.67 2.80E-03  241489_at --- ⇧ 1.66 0.038 
218354_at TRAPPC2L ⇩ 1.67 0.015  228443_s_at SETD8 ⇧ 1.67 2.70E-03  203280_at SAFB2 ⇧ 1.66 0.038 
240302_at --- ⇧ 1.67 0.014  242889_x_at LOC645431 ⇧ 1.67 2.60E-03  242140_at ERVK3-1 ⇧ 1.66 0.036 
1564165_at PRKRIP1 ⇧ 1.67 0.013  222195_s_at C9orf156 ⇩ 1.67 2.40E-03  234764_x_at IGL ⇩ 1.66 0.036 
1554539_a_at RHOF ⇩ 1.67 0.013  227398_s_at MIDN ⇩ 1.67 2.40E-03  201416_at SOX4 ⇩ 1.66 0.033 
213956_at CEP350 ⇧ 1.67 0.012  1566278_at --- ⇧ 1.67 2.10E-03  242216_at --- ⇧ 1.66 0.032 
1563471_at KIAA1632 ⇧ 1.67 0.012  205971_s_at CTRB1/B2 ⇧ 1.67 2.10E-03  57739_at DND1 ⇧ 1.66 0.031 
1561015_at --- ⇧ 1.67 0.011  204232_at FCER1G ⇩ 1.67 1.80E-03  244031_at --- ⇧ 1.66 0.029 
1555460_a_at SLC39A6 ⇩ 1.67 0.011  225940_at EIF4E3 ⇧ 1.67 1.70E-03  203401_at PRPS2 ⇧ 1.66 0.027 
226934_at CPSF6 ⇧ 1.67 0.010  208548_at IFNA6 ⇧ 1.67 1.70E-03  230292_at --- ⇧ 1.66 0.026 
212188_at KCTD12 ⇧ 1.67 9.80E-03  215968_at --- ⇧ 1.67 1.60E-03  201211_s_at DDX3X ⇩ 1.66 0.025 
210553_x_at PCSK6 ⇧ 1.67 9.60E-03  210618_at RAP1GAP ⇧ 1.67 1.30E-03  234789_at --- ⇧ 1.66 0.022 
212880_at WDR7 ⇩ 1.67 9.60E-03  224321_at TMEFF2 ⇩ 1.67 1.30E-03  239780_at --- ⇧ 1.66 0.022 
214633_at SOX3 ⇧ 1.67 9.10E-03  242949_x_at CCDC157 ⇧ 1.67 1.10E-03  201353_s_at BAZ2A ⇧ 1.66 0.022 
237999_at --- ⇧ 1.67 8.60E-03  215063_x_at LRRC40 ⇧ 1.67 8.30E-04  225526_at MKLN1 ⇩ 1.66 0.021 
215162_at GARNL1 ⇧ 1.67 7.80E-03  238690_at --- ⇩ 1.67 7.20E-04  202753_at PSMD6 ⇩ 1.66 0.021 
202050_s_at ZMYM4 ⇩ 1.67 7.60E-03  224137_at CACNG7 ⇧ 1.67 6.80E-04  221671_x_at IGK ⇩ 1.66 0.018 
224582_s_at NUCKS1 ⇧ 1.67 7.40E-03  219206_x_at TMBIM4 ⇧ 1.67 6.00E-04  201986_at MED13 ⇧ 1.66 0.018 
244154_at DDHD1 ⇧ 1.67 6.90E-03  207419_s_at RAC2 ⇩ 1.67 5.40E-04  1557759_at ATP5SL ⇧ 1.66 0.017 
1563263_at PLCG2 ⇧ 1.67 6.20E-03  231162_at CLDND2 ⇧ 1.67 3.40E-04  213897_s_at MRPL23 ⇩ 1.66 0.017 
1555439_at GTF3C3 ⇧ 1.67 5.80E-03  1569409_x_at --- ⇧ 1.67 2.50E-04  224760_at SP1 ⇧ 1.66 0.017 
216751_at --- ⇧ 1.67 5.00E-03  233515_at --- ⇧ 1.67 2.40E-04  1554670_at GGA1 ⇧ 1.66 0.014 
228225_at PXMP3 ⇧ 1.67 4.60E-03  230216_at C12orf51 ⇧ 1.67 5.00E-05  227025_at PPHLN1 ⇧ 1.66 0.013 
204817_at ESPL1 ⇧ 1.67 4.30E-03  231349_at GPR150 ⇧ 1.66 0.011  204240_s_at SMC2 ⇩ 1.66 0.013 
1570032_at AP3B2 ⇧ 1.67 4.00E-03  203380_x_at SFRS5 ⇧ 1.66 5.51E-04  221166_at FGF23 ⇩ 1.66 0.012 
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212762_s_at TCF7L2 ⇧ 1.66 0.012  219341_at CLN8 ⇧ 1.66 2.80E-03  208962_s_at FADS1 ⇩ 1.65 0.045 
208899_x_at ATP6V1D ⇩ 1.66 0.011  215609_at --- ⇧ 1.66 2.60E-03  208949_s_at LGALS3 ⇧ 1.65 0.043 
205322_s_at MTF1 ⇧ 1.66 0.011  216463_at --- ⇧ 1.66 2.60E-03  242521_at LOC100505812 ⇧ 1.65 0.042 
240347_at --- ⇧ 1.66 0.010  234283_at C22orf28 ⇧ 1.66 2.30E-03  225644_at CCDC117 ⇧ 1.65 0.041 
1557621_at KCP ⇧ 1.66 9.70E-03  233182_x_at ATXN3 ⇧ 1.66 1.90E-03  218402_s_at HPS4 ⇩ 1.65 0.034 
221553_at MAGT1 ⇧ 1.66 9.70E-03  231992_x_at LOC493754 ⇧ 1.66 1.70E-03  224332_s_at MRPL43 ⇩ 1.65 0.034 
240875_at C17orf68 ⇧ 1.66 9.60E-03  206048_at OVOL2 ⇧ 1.66 1.50E-03  1558105_a_at SLC9A7 ⇩ 1.65 0.033 
1560199_x_at LOC728153 ⇧ 1.66 9.60E-03  214605_x_at GPR1 ⇧ 1.66 1.30E-03  242080_at --- ⇧ 1.65 0.032 
1557905_s_at CD44 ⇩ 1.66 8.30E-03  232942_at PYROXD2 ⇧ 1.66 1.30E-03  209006_s_at C1orf63 ⇧ 1.65 0.032 
209329_x_at HIGD2A ⇩ 1.66 7.80E-03  208246_x_at --- ⇧ 1.66 1.20E-03  210527_x_at TUBA3C ⇩ 1.65 0.032 
1555994_at DIAPH3-AS1 ⇧ 1.66 7.60E-03  240548_at --- ⇧ 1.66 1.10E-03  239804_at --- ⇧ 1.65 0.031 
225331_at CCDC50 ⇩ 1.66 7.10E-03  232420_x_at LOC286260 ⇧ 1.66 1.00E-03  243431_at --- ⇧ 1.65 0.031 
220905_at --- ⇧ 1.66 6.70E-03  204590_x_at VPS33A ⇧ 1.66 9.10E-04  1560303_at FKBP4 ⇩ 1.65 0.030 
227921_at --- ⇩ 1.66 6.60E-03  1552432_at MFSD6L ⇧ 1.66 8.50E-04  235093_at PEX13 ⇧ 1.65 0.030 
206429_at F2RL1 ⇩ 1.66 6.30E-03  1564635_a_at FHAD1 ⇩ 1.66 8.10E-04  208074_s_at AP2S1 ⇩ 1.65 0.029 
1566646_at LOC149086 ⇧ 1.66 6.20E-03  1559807_at --- ⇧ 1.66 7.80E-04  201444_s_at ATP6AP2 ⇩ 1.65 0.027 
202105_at IGBP1 ⇩ 1.66 5.90E-03  232921_at KIAA1549 ⇧ 1.66 6.30E-04  215013_s_at USP34 ⇧ 1.65 0.027 
1564424_at --- ⇧ 1.66 5.80E-03  220838_at EXD3 ⇧ 1.66 6.00E-04  1557339_at --- ⇧ 1.65 0.022 
208278_s_at --- ⇧ 1.66 5.60E-03  215404_x_at FGFR1 ⇧ 1.66 4.50E-04  223466_x_at COL4A3BP ⇧ 1.65 0.021 
218336_at PFDN2 ⇩ 1.66 4.80E-03  206334_at LIPF ⇧ 1.66 4.40E-04  244144_at SYNE1 ⇧ 1.65 0.021 
213794_s_at NGDN ⇩ 1.66 4.70E-03  217120_s_at MED14 ⇧ 1.66 4.10E-04  216614_at --- ⇧ 1.65 0.020 
209645_s_at ALDH1B1 ⇩ 1.66 4.50E-03  220955_x_at RAB23 ⇧ 1.66 3.20E-04  238700_at PIAS2 ⇧ 1.65 0.020 
231884_at CNTROB ⇧ 1.66 4.50E-03  1555717_at --- ⇧ 1.66 2.50E-04  203760_s_at SLA ⇧ 1.65 0.020 
224606_at KLF6 ⇧ 1.66 4.00E-03  233013_x_at LOC220906 ⇧ 1.66 2.50E-04  203745_at HCCS ⇧ 1.65 0.019 
208793_x_at SMARCA4 ⇩ 1.66 4.00E-03  221250_s_at MXD3 ⇧ 1.66 1.50E-04  1553123_at WDR62 ⇧ 1.65 0.019 
201688_s_at TPD52 ⇩ 1.66 3.70E-03  232083_at KIF16B ⇧ 1.66 1.40E-04  234723_x_at --- ⇧ 1.65 0.018 
211962_s_at ZFP36L1 ⇧ 1.66 3.70E-03  236410_x_at --- ⇧ 1.66 1.30E-04  236367_at SMG7 ⇧ 1.65 0.017 
211318_s_at RAE1 ⇩ 1.66 3.60E-03  1569983_at --- ⇧ 1.66 1.10E-04  1560334_at MEGF11 ⇧ 1.65 0.016 
214535_s_at ADAMTS2 ⇧ 1.66 3.50E-03  204977_at DDX10 ⇩ 1.66 1.10E-04  216278_at --- ⇧ 1.65 0.015 
238884_at --- ⇧ 1.66 3.30E-03  215072_x_at C10orf137 ⇩ 1.66 5.70E-05  205690_s_at BUD31 ⇩ 1.65 0.015 
216509_x_at MLLT10 ⇧ 1.66 3.10E-03  223189_x_at MLL5 ⇧ 1.65 0.048  227678_at XRCC6BP1 ⇩ 1.65 0.015 
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208698_s_at NONO ⇧ 1.65 0.012  227651_at NACC1 ⇧ 1.65 1.00E-03  224707_at C5orf32 ⇧ 1.64 0.029 
236703_at NT5C2 ⇧ 1.65 0.012  208082_x_at MKRN1 ⇧ 1.65 9.00E-04  243918_at --- ⇩ 1.64 0.028 
49306_at RASSF4 ⇧ 1.65 0.012  229988_at --- ⇧ 1.65 8.70E-04  216890_at --- ⇩ 1.64 0.026 
218833_at ZAK ⇧ 1.65 0.011  1570632_at --- ⇧ 1.65 8.00E-04  200757_s_at CALU ⇧ 1.64 0.025 
236732_at --- ⇧ 1.65 9.20E-03  208476_s_at FRMD4A ⇧ 1.65 7.90E-04  1556553_at --- ⇧ 1.64 0.024 
202334_s_at UBE2B ⇧ 1.65 8.80E-03  216875_x_at HAB1 ⇧ 1.65 6.00E-04  205789_at CD1D ⇩ 1.64 0.023 
1557505_a_at --- ⇧ 1.65 8.30E-03  243474_at --- ⇧ 1.65 5.90E-04  208909_at UQCRFS1 ⇩ 1.64 0.022 
1552607_at CXorf52 ⇧ 1.65 6.30E-03  207822_at FGFR1 ⇧ 1.65 5.50E-04  239151_at --- ⇧ 1.64 0.021 
223439_at NKAP ⇩ 1.65 5.90E-03  211703_s_at TM2D1 ⇩ 1.65 5.50E-04  223739_at PADI1 ⇩ 1.64 0.021 
244611_at MED13 ⇧ 1.65 4.80E-03  236850_at CAPRIN1 ⇧ 1.65 3.70E-04  232284_at PSMD6 ⇧ 1.64 0.020 
235317_at LOC284454 ⇧ 1.65 4.40E-03  215048_at ZNF280B ⇩ 1.65 3.70E-04  224365_s_at TIGD7 ⇩ 1.64 0.020 
1552400_a_at C15orf27 ⇩ 1.65 4.30E-03  236772_s_at --- ⇧ 1.65 3.50E-04  1569500_at --- ⇧ 1.64 0.019 
244197_x_at --- ⇧ 1.65 4.20E-03  1566882_at --- ⇧ 1.65 2.30E-04  204050_s_at CLTA ⇩ 1.64 0.019 
216110_x_at --- ⇧ 1.65 4.10E-03  227095_at LEPROT ⇧ 1.65 2.30E-04  227992_s_at NCRNA00085 ⇧ 1.64 0.019 
210156_s_at PCMT1 ⇩ 1.65 3.80E-03  209927_s_at C1orf77 ⇩ 1.65 2.20E-04  223743_s_at MRPL4 ⇩ 1.64 0.017 
232877_at --- ⇧ 1.65 3.50E-03  1553887_at FLJ40235 ⇧ 1.65 2.00E-04  223638_at NBPF3 ⇩ 1.64 0.015 
204221_x_at GLIPR1 ⇧ 1.65 3.10E-03  211600_at PTPRO ⇧ 1.65 1.50E-04  209328_x_at HIGD2A ⇩ 1.64 0.014 
233868_x_at ADAM33 ⇧ 1.65 3.00E-03  212106_at FAF2 ⇧ 1.65 1.10E-04  232150_at --- ⇧ 1.64 0.013 
226520_at LCOR ⇧ 1.65 3.00E-03  210667_s_at C21orf33 ⇩ 1.65 1.80E-05  242490_at LOC100653004 ⇧ 1.64 0.013 
210830_s_at PON2 ⇩ 1.65 3.00E-03  216814_at --- ⇩ 1.65 8.80E-06  200750_s_at RAN ⇩ 1.64 0.013 
233721_x_at --- ⇧ 1.65 2.80E-03  AFFX-r2-Ec-
bioC-3_at 
--- ⇩ 1.64 1.59E-04  1564729_at --- ⇧ 1.64 0.012 
210920_x_at --- ⇧ 1.65 2.40E-03  213154_s_at BICD2 ⇩ 1.64 0.048  238130_at NFATC2IP ⇧ 1.64 0.011 
216733_s_at GATM ⇩ 1.65 2.40E-03  240939_x_at --- ⇧ 1.64 0.045  243909_x_at GUSBL2 ⇩ 1.64 0.010 
1560499_at C14orf64 ⇧ 1.65 2.30E-03  244443_at CHD2 ⇧ 1.64 0.042  234140_s_at STIM2 ⇩ 1.64 0.010 
215038_s_at SETD2 ⇩ 1.65 2.20E-03  223705_s_at GPBP1 ⇩ 1.64 0.039  204203_at CEBPG ⇩ 1.64 9.90E-03 
212266_s_at SFRS5 ⇧ 1.65 1.90E-03  236908_at --- ⇧ 1.64 0.035  215529_x_at DIP2A ⇧ 1.64 9.60E-03 
215067_x_at PRDX2 ⇧ 1.65 1.70E-03  239035_at MTHFR ⇧ 1.64 0.035  224495_at TMEM107 ⇧ 1.64 7.20E-03 
1563565_at INPP5B ⇧ 1.65 1.60E-03  227208_at CCDC84 ⇧ 1.64 0.033  238943_at FIBCD1 ⇧ 1.64 7.00E-03 
206967_at CCNT1 ⇧ 1.65 1.50E-03  201055_s_at HNRNPA0 ⇧ 1.64 0.033  221547_at PRPF18 ⇩ 1.64 6.90E-03 
233087_at FBXL17 ⇧ 1.65 1.10E-03  223565_at MGC29506 ⇩ 1.64 0.032  243170_at --- ⇧ 1.64 6.30E-03 
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221434_s_at C14orf156 ⇩ 1.64 6.00E-03  205832_at CPA4 ⇧ 1.64 5.40E-05  218081_at C20orf27 ⇧ 1.63 0.018 
212533_at WEE1 ⇧ 1.64 6.00E-03  1565558_at --- ⇧ 1.64 4.80E-05  242369_x_at --- ⇧ 1.63 0.017 
206500_s_at C14orf106 ⇧ 1.64 5.90E-03  1554960_at C1orf110 ⇧ 1.64 2.30E-05  1562497_at --- ⇧ 1.63 0.017 
234938_at BACH1 ⇧ 1.64 5.30E-03  1566606_a_at TEX9 ⇧ 1.64 2.10E-05  231727_s_at MIF4GD ⇩ 1.63 0.017 
209105_at NCOA1 ⇩ 1.64 4.70E-03  212141_at MCM4 ⇩ 1.64 1.80E-05  237264_at --- ⇧ 1.63 0.016 
1554441_a_at WAPAL ⇩ 1.64 4.40E-03  224297_s_at SPTBN4 ⇧ 1.64 4.40E-07  1569540_at --- ⇧ 1.63 0.014 
244837_at --- ⇧ 1.64 4.20E-03  203594_at RTCD1 ⇩ 1.63 0.046  1553843_at C10orf67 ⇧ 1.63 0.014 
234408_at IL17F ⇩ 1.64 4.00E-03  241755_at UQCRC2 ⇧ 1.63 0.046  214965_at SPATA2L ⇧ 1.63 0.014 
1555157_at --- ⇧ 1.64 3.30E-03  222326_at --- ⇧ 1.63 0.044  212302_at RTF1 ⇧ 1.63 0.013 
205829_at HSD17B1 ⇧ 1.64 3.30E-03  1566342_at SOD2 ⇩ 1.63 0.043  223461_at TBC1D7 ⇩ 1.63 0.013 
224494_x_at HSD17B14 ⇧ 1.64 3.30E-03  242202_at --- ⇧ 1.63 0.041  1570192_at --- ⇧ 1.63 0.012 
210253_at HTATIP2 ⇧ 1.64 2.60E-03  1556035_s_at ZNF207 ⇧ 1.63 0.041  1563513_at SYTL4 ⇧ 1.63 0.012 
202417_at KEAP1 ⇧ 1.64 2.40E-03  1556338_at --- ⇧ 1.63 0.040  244835_at C16orf52 ⇧ 1.63 0.010 
231945_at FILIP1 ⇧ 1.64 2.30E-03  216557_x_at IGH ⇩ 1.63 0.039  240363_at ANK1 ⇧ 1.63 9.90E-03 
241301_at --- ⇧ 1.64 1.80E-03  230751_at WNT4 ⇩ 1.63 0.037  209153_s_at TCF3 ⇧ 1.63 9.30E-03 
236707_at DAPP1 ⇧ 1.64 1.80E-03  200638_s_at YWHAZ ⇧ 1.63 0.037  206181_at SLAMF1 ⇩ 1.63 8.60E-03 
1569668_at --- ⇧ 1.64 1.70E-03  219474_at C3orf52 ⇧ 1.63 0.035  200862_at DHCR24 ⇩ 1.63 8.40E-03 
202613_at CTPS ⇩ 1.64 1.40E-03  220529_at FLJ11710 ⇧ 1.63 0.033  232754_at --- ⇧ 1.63 7.20E-03 
233958_at --- ⇧ 1.64 1.30E-03  232963_at --- ⇧ 1.63 0.032  242355_at CRAMP1L ⇧ 1.63 6.90E-03 
243180_at --- ⇧ 1.64 1.20E-03  1557910_at HSP90AB1 ⇩ 1.63 0.032  244814_at UGGT1 ⇩ 1.63 6.80E-03 
224177_s_at CXorf26 ⇩ 1.64 1.10E-03  208887_at EIF3G ⇩ 1.63 0.031  201728_s_at KIAA0100 ⇩ 1.63 5.40E-03 
243525_at --- ⇧ 1.64 9.40E-04  229119_s_at ZSWIM7 ⇩ 1.63 0.031  242377_x_at THUMPD3 ⇧ 1.63 4.90E-03 
243801_x_at MRPL30 ⇧ 1.64 7.00E-04  244599_at --- ⇧ 1.63 0.030  1566480_x_at FLJ35848 ⇧ 1.63 4.00E-03 
217713_x_at --- ⇧ 1.64 6.90E-04  208670_s_at EID1 ⇧ 1.63 0.030  238502_at --- ⇧ 1.63 3.90E-03 
242311_x_at --- ⇧ 1.64 6.70E-04  223737_x_at CHST9 ⇩ 1.63 0.027  241851_x_at LOC100130429 ⇧ 1.63 3.80E-03 
1569921_at --- ⇧ 1.64 5.20E-04  216068_at --- ⇧ 1.63 0.025  239815_at --- ⇧ 1.63 3.70E-03 
209639_s_at RGS12 ⇧ 1.64 4.20E-04  1554816_at ASTN2 ⇧ 1.63 0.025  244722_at --- ⇧ 1.63 3.70E-03 
241302_at --- ⇩ 1.64 3.50E-04  239876_at --- ⇧ 1.63 0.023  212863_x_at CTBP1 ⇧ 1.63 3.70E-03 
1556345_s_at --- ⇧ 1.64 3.20E-04  223175_s_at FEM1A ⇧ 1.63 0.022  216768_x_at TTC38 ⇧ 1.63 3.30E-03 
1562415_a_at SPOCD1 ⇧ 1.64 3.20E-04  225177_at RAB11FIP1 ⇩ 1.63 0.021  243147_x_at --- ⇧ 1.63 3.10E-03 
228541_x_at --- ⇧ 1.64 1.90E-04  231017_at STK11 ⇧ 1.63 0.020  216883_x_at PDE6D ⇩ 1.63 2.90E-03 
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237960_at --- ⇩ 1.63 2.50E-03  222113_s_at EPS15L1 ⇧ 1.62 0.041  210565_at GCGR ⇩ 1.62 9.00E-03 
226027_at C9orf119 ⇩ 1.63 2.30E-03  219049_at CSGALNACT1 ⇩ 1.62 0.040  216527_at --- ⇧ 1.62 8.90E-03 
217957_at C16orf80 ⇩ 1.63 1.90E-03  218566_s_at CHORDC1 ⇧ 1.62 0.037  217179_x_at --- ⇩ 1.62 8.60E-03 
223104_at JAGN1 ⇩ 1.63 1.60E-03  222061_at CD58 ⇩ 1.62 0.035  244326_at --- ⇩ 1.62 8.10E-03 
1553755_at NXNL1 ⇧ 1.63 1.60E-03  236301_at IKZF3 ⇩ 1.62 0.035  205272_s_at PRH1/2 ⇧ 1.62 7.40E-03 
1563120_at LOC100129029 ⇧ 1.63 1.50E-03  238888_at --- ⇧ 1.62 0.030  1561966_at --- ⇧ 1.62 7.00E-03 
213329_at SRGAP2 ⇩ 1.63 1.50E-03  211086_x_at NEK1 ⇧ 1.62 0.030  1557553_at PPP1R12B ⇧ 1.62 6.70E-03 
228551_at DENND5B ⇩ 1.63 1.40E-03  203844_at VHL ⇧ 1.62 0.030  234886_at TRBV24-1 ⇩ 1.62 6.40E-03 
211776_s_at EPB41L3 ⇩ 1.63 1.00E-03  204097_s_at RBMX2 ⇧ 1.62 0.029  230528_s_at MGC2752 ⇧ 1.62 6.10E-03 
242398_x_at --- ⇧ 1.63 9.90E-04  203403_s_at RNF6 ⇩ 1.62 0.029  224467_s_at PDCD2L ⇩ 1.62 6.00E-03 
241137_at DPCR1 ⇧ 1.63 8.70E-04  236921_at --- ⇧ 1.62 0.028  209182_s_at C10orf10 ⇧ 1.62 5.50E-03 
207953_at RP5-886K2.1 ⇧ 1.63 8.10E-04  219236_at PAQR6 ⇧ 1.62 0.028  228055_at NAPSB ⇩ 1.62 5.30E-03 
226823_at PHACTR4 ⇩ 1.63 5.20E-04  201810_s_at SH3BP5 ⇧ 1.62 0.028  1559780_at --- ⇧ 1.62 4.00E-03 
201564_s_at FSCN1 ⇧ 1.63 4.50E-04  1560426_at C12orf55 ⇧ 1.62 0.025  1561653_at --- ⇧ 1.62 3.60E-03 
244626_at --- ⇧ 1.63 3.30E-04  1570339_x_at --- ⇧ 1.62 0.022  237475_x_at CCDC152 ⇧ 1.62 3.50E-03 
215383_x_at SPG21 ⇧ 1.63 3.30E-04  242876_at AKT3 ⇧ 1.62 0.021  214200_s_at COL6A1 ⇧ 1.62 3.50E-03 
220411_x_at PODNL1 ⇧ 1.63 2.70E-04  213920_at CUX2 ⇩ 1.62 0.021  233004_x_at --- ⇧ 1.62 3.30E-03 
228375_at IGSF11 ⇩ 1.63 1.80E-04  1560358_at PHKA2 ⇧ 1.62 0.021  1553551_s_at ND2 ⇧ 1.62 3.00E-03 
233148_at PODN ⇩ 1.63 1.40E-04  200749_at RAN ⇧ 1.62 0.021  229680_at CCDC44 ⇧ 1.62 2.80E-03 
220089_at L2HGDH ⇧ 1.63 1.20E-04  205427_at ZNF354A ⇩ 1.62 0.020  242229_at NAPEPLD ⇧ 1.62 2.70E-03 
242730_at MYRIP ⇧ 1.63 1.20E-04  203747_at AQP3 ⇩ 1.62 0.018  220539_at C10orf92 ⇩ 1.62 2.60E-03 
205010_at GNL3L ⇧ 1.63 9.10E-05  220925_at MAK10 ⇧ 1.62 0.016  231770_x_at C2orf86 ⇧ 1.62 2.60E-03 
222087_at PVT1 ⇧ 1.63 7.50E-05  221212_x_at PBRM1 ⇧ 1.62 0.016  213899_at METAP2 ⇧ 1.62 2.60E-03 
212711_at CAMSAP1 ⇩ 1.63 1.30E-05  222816_s_at ZCCHC2 ⇧ 1.62 0.016  215861_at --- ⇧ 1.62 2.30E-03 
217210_at --- ⇩ 1.63 6.90E-06  227154_at IGSF21 ⇩ 1.62 0.015  232665_x_at --- ⇧ 1.62 2.30E-03 
222934_s_at CLEC4E ⇩ 1.62 0.049  1558527_at --- ⇧ 1.62 0.014  220797_at METT10D ⇩ 1.62 2.30E-03 
200067_x_at SNX3 ⇧ 1.62 0.049  207914_x_at EVX1 ⇧ 1.62 0.014  1553927_at C7orf33 ⇩ 1.62 2.20E-03 
202760_s_at --- ⇧ 1.62 0.048  1569857_s_at TPP2 ⇧ 1.62 0.013  215864_at --- ⇧ 1.62 2.10E-03 
231735_s_at MALAT1 ⇧ 1.62 0.048  1566897_at --- ⇧ 1.62 0.012  1562947_x_at --- ⇧ 1.62 2.10E-03 
202941_at NDUFV2 ⇩ 1.62 0.046  231111_at --- ⇧ 1.62 0.012  216136_at --- ⇧ 1.62 2.10E-03 
237875_at --- ⇧ 1.62 0.043  200087_s_at TMED2 ⇧ 1.62 0.011  201551_s_at LAMP1 ⇩ 1.62 1.90E-03 
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1555199_at GOSR1 ⇧ 1.62 1.70E-03  228818_at --- ⇧ 1.61 0.032  235152_at --- ⇧ 1.61 0.014 
228576_s_at MXRA8 ⇧ 1.62 1.60E-03  1562511_at LYST ⇧ 1.61 0.031  217655_at --- ⇧ 1.61 0.014 
219105_x_at ORC6L ⇧ 1.62 1.60E-03  1553768_a_at DCBLD1 ⇧ 1.61 0.029  1561086_at --- ⇩ 1.61 0.013 
1557342_a_at LOC400931 ⇧ 1.62 1.40E-03  225579_at PQLC3 ⇩ 1.61 0.029  237502_at CRLS1 ⇧ 1.61 0.013 
1568847_at --- ⇧ 1.62 1.10E-03  211637_x_at IGH ⇩ 1.61 0.028  220575_at FAM106A ⇧ 1.61 0.012 
1555811_at ARHGDIB ⇩ 1.62 1.10E-03  210958_s_at MAST4 ⇩ 1.61 0.028  243677_at GORASP1 ⇩ 1.61 0.012 
211277_x_at APP ⇧ 1.62 1.00E-03  218526_s_at RANGRF ⇩ 1.61 0.027  220140_s_at SNX11 ⇩ 1.61 0.012 
201119_s_at COX8A ⇩ 1.62 8.80E-04  222790_s_at RSBN1 ⇧ 1.61 0.027  212312_at BCL2L1 ⇧ 1.61 0.011 
201199_s_at PSMD1 ⇩ 1.62 7.50E-04  214806_at BICD1 ⇧ 1.61 0.025  235623_at ELP2 ⇧ 1.61 0.011 
1564970_at SETDB2 ⇧ 1.62 7.10E-04  202487_s_at H2AFV ⇩ 1.61 0.025  214836_x_at IGKC ⇩ 1.61 0.011 
206466_at ACSBG1 ⇧ 1.62 6.30E-04  1564897_at TNR ⇧ 1.61 0.025  239640_at LOC401320 ⇧ 1.61 0.011 
222012_at C19orf72 ⇩ 1.62 6.00E-04  239577_at --- ⇧ 1.61 0.024  232097_at TOX4 ⇧ 1.61 0.011 
203091_at FUBP1 ⇧ 1.62 5.60E-04  221071_at --- ⇧ 1.61 0.024  207134_x_at TPSB2 ⇧ 1.61 0.011 
226053_at MAP2K7 ⇧ 1.62 1.90E-04  228993_s_at NCRNA00081 ⇧ 1.61 0.023  234849_at TRA ⇩ 1.61 0.011 
215455_at TIMELESS ⇧ 1.62 1.70E-04  232180_at UGP2 ⇧ 1.61 0.023  230599_at --- ⇧ 1.61 0.010 
212924_s_at LSM4 ⇧ 1.62 1.50E-04  219062_s_at ZCCHC2 ⇩ 1.61 0.023  233615_at CGA ⇧ 1.61 0.010 
234050_at TAGAP ⇧ 1.62 8.40E-05  216096_s_at NRXN1 ⇧ 1.61 0.022  217868_s_at METTL9 ⇧ 1.61 0.010 
233226_at PTPN9 ⇧ 1.62 3.60E-05  201108_s_at THBS1 ⇩ 1.61 0.022  211367_s_at CASP1 ⇩ 1.61 9.00E-03 
AFFX-r2-Ec-
bioB-M_at 
--- ⇩ 1.61 7.88E-04  234627_at FLJ21408 ⇩ 1.61 0.020  1552291_at PIGX ⇧ 1.61 8.50E-03 
243054_at --- ⇧ 1.61 0.048  201748_s_at SAFB ⇧ 1.61 0.020  217586_x_at --- ⇧ 1.61 7.60E-03 
213688_at CALM1 ⇧ 1.61 0.047  244834_at C1orf134 ⇧ 1.61 0.019  238826_x_at --- ⇧ 1.61 7.50E-03 
208979_at NCOA6 ⇩ 1.61 0.047  201252_at PSMC4 ⇩ 1.61 0.019  208404_x_at KCNJ5 ⇧ 1.61 6.70E-03 
205560_at PCSK5 ⇩ 1.61 0.047  205835_s_at YTHDC2 ⇩ 1.61 0.019  236248_x_at TADA2B ⇧ 1.61 6.30E-03 
209959_at NR4A3 ⇧ 1.61 0.046  213813_x_at --- ⇩ 1.61 0.018  234765_at --- ⇧ 1.61 5.90E-03 
214794_at PA2G4 ⇩ 1.61 0.043  234442_at --- ⇩ 1.61 0.017  216101_at --- ⇧ 1.61 4.90E-03 
239695_at JAK1 ⇧ 1.61 0.041  239991_at --- ⇧ 1.61 0.016  208576_s_at HIST1H3B ⇩ 1.61 4.30E-03 
233284_at --- ⇧ 1.61 0.036  207820_at ADH1A ⇩ 1.61 0.016  215810_x_at DST ⇧ 1.61 4.20E-03 
204490_s_at CD44 ⇩ 1.61 0.036  212786_at CLEC16A ⇩ 1.61 0.016  206551_x_at KLHL24 ⇧ 1.61 3.90E-03 
243249_at --- ⇧ 1.61 0.035  208281_x_at DAZ1-4 ⇧ 1.61 0.016  237246_at --- ⇧ 1.61 3.60E-03 
212582_at OSBPL8 ⇧ 1.61 0.035  242829_x_at FBXL3 ⇧ 1.61 0.016  209226_s_at TNPO1 ⇧ 1.61 3.60E-03 
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1554950_at ACAN ⇧ 1.61 3.30E-03  231116_at --- ⇧ 1.60 0.033  226293_at MED19 ⇧ 1.60 6.40E-03 
207365_x_at USP34 ⇧ 1.61 3.20E-03  236895_at --- ⇧ 1.60 0.033  241947_at LOC100233209 ⇧ 1.60 6.10E-03 
237865_x_at --- ⇧ 1.61 3.10E-03  209524_at HDGFRP3 ⇧ 1.60 0.033  211495_x_at TNFSF13 ⇩ 1.60 6.10E-03 
217579_x_at --- ⇧ 1.61 2.90E-03  234377_at TRBV7-8 ⇩ 1.60 0.031  215191_at --- ⇧ 1.60 4.90E-03 
215200_x_at --- ⇧ 1.61 2.80E-03  1569345_at --- ⇧ 1.60 0.029  227087_at INPP4A ⇧ 1.60 4.20E-03 
208066_s_at GTF2B ⇩ 1.61 2.80E-03  200723_s_at CAPRIN1 ⇩ 1.60 0.029  201545_s_at PABPN1 ⇧ 1.60 3.90E-03 
223281_s_at COX15 ⇧ 1.61 2.50E-03  222734_at WARS2 ⇩ 1.60 0.029  232065_x_at CENPL ⇧ 1.60 3.80E-03 
1552782_at SLC44A5 ⇧ 1.61 2.40E-03  237800_at --- ⇧ 1.60 0.021  210495_x_at FN1 ⇩ 1.60 3.80E-03 
234613_at --- ⇧ 1.61 1.80E-03  1554388_at VPS29 ⇧ 1.60 0.021  216064_s_at AGA ⇩ 1.60 3.70E-03 
205820_s_at APOC3 ⇧ 1.61 1.70E-03  215882_at CEP152 ⇩ 1.60 0.018  209136_s_at USP10 ⇧ 1.60 3.70E-03 
234773_x_at --- ⇩ 1.61 1.50E-03  209883_at GLT25D2 ⇧ 1.60 0.017  223871_x_at ING5 ⇧ 1.60 3.30E-03 
207965_at NEUROG3 ⇩ 1.61 1.50E-03  200734_s_at ARF3 ⇧ 1.60 0.015  229038_at CWF19L1 ⇩ 1.60 3.00E-03 
1566096_x_at --- ⇧ 1.61 1.30E-03  238809_at C5orf51 ⇩ 1.60 0.015  202738_s_at PHKB ⇩ 1.60 3.00E-03 
211672_s_at ARPC4 ⇩ 1.61 8.10E-04  203076_s_at SMAD2 ⇩ 1.60 0.015  215373_x_at --- ⇧ 1.60 2.90E-03 
229701_at DNAJC9 ⇧ 1.61 7.90E-04  239341_at --- ⇩ 1.60 0.014  234788_x_at --- ⇧ 1.60 2.80E-03 
214399_s_at KRT4 ⇧ 1.61 7.90E-04  241790_at --- ⇧ 1.60 0.014  216786_at LOC159110 ⇧ 1.60 2.50E-03 
243069_at --- ⇧ 1.61 7.50E-04  208529_at BTF3L1 ⇩ 1.60 0.014  1570210_x_at SAPS2 ⇧ 1.60 2.50E-03 
241857_at --- ⇧ 1.61 7.50E-04  216705_s_at ADA ⇩ 1.60 0.013  237959_at --- ⇧ 1.60 2.40E-03 
220593_s_at CCDC40 ⇧ 1.61 5.60E-04  224447_s_at C17orf37 ⇩ 1.60 0.013  222824_at NUDT5 ⇧ 1.60 2.40E-03 
221678_at ABHD6 ⇩ 1.61 3.20E-04  228625_at CITED4 ⇩ 1.60 0.013  217810_x_at LARS ⇧ 1.60 2.30E-03 
215403_at --- ⇧ 1.61 1.90E-04  212647_at RRAS ⇩ 1.60 0.012  223912_s_at CLN8 ⇧ 1.60 1.80E-03 
1561512_at --- ⇧ 1.61 6.80E-05  207917_at --- ⇧ 1.60 0.011  221470_s_at IL1F7 ⇩ 1.60 1.80E-03 
1552311_a_at RAX2 ⇧ 1.61 1.50E-05  203720_s_at ERCC1 ⇩ 1.60 0.011  229650_s_at C19orf42 ⇩ 1.60 1.70E-03 
201546_at TRIP12 ⇩ 1.60 0.048  214995_s_at APOBEC3F/G ⇩ 1.60 0.010  244541_x_at --- ⇧ 1.60 1.60E-03 
202308_at SREBF1 ⇩ 1.60 0.047  243662_at --- ⇧ 1.60 8.60E-03  208453_s_at XPNPEP1 ⇩ 1.60 1.50E-03 
1560013_at PDXDC1 ⇧ 1.60 0.044  232163_at WDR19 ⇧ 1.60 8.50E-03  1561905_at --- ⇩ 1.60 1.40E-03 
202929_s_at DDT ⇩ 1.60 0.043  1560104_at --- ⇧ 1.60 8.40E-03  236903_at --- ⇩ 1.60 1.30E-03 
227606_s_at STAMBPL1 ⇩ 1.60 0.043  232323_s_at TTC17 ⇧ 1.60 8.20E-03  211827_s_at KCND3 ⇧ 1.60 1.30E-03 
1555659_a_at TREML1 ⇩ 1.60 0.043  238738_at PSMD7 ⇧ 1.60 8.00E-03  231625_at SLC22A9 ⇧ 1.60 6.70E-04 
209921_at SLC7A11 ⇩ 1.60 0.042  219180_s_at PEX26 ⇧ 1.60 7.30E-03  228038_at SOX2 ⇩ 1.60 6.00E-04 
218912_at GCC1 ⇩ 1.60 0.040  225634_at ZC3HAV1 ⇩ 1.60 6.70E-03  206420_at IGSF6 ⇧ 1.60 5.50E-04 
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234201_x_at --- ⇧ 1.60 4.90E-04  209461_x_at WDR18 ⇩ 1.59 0.021  1560457_x_at LSDP5 ⇧ 1.59 6.00E-03 
219393_s_at AKT3 ⇧ 1.60 4.30E-04  218011_at UBL5 ⇧ 1.59 0.020  225083_at GTF3C6 ⇧ 1.59 5.80E-03 
241064_at hCG_1776047 ⇧ 1.60 4.20E-04  241351_at --- ⇧ 1.59 0.019  234266_at --- ⇧ 1.59 5.70E-03 
231659_at ST3GAL3 ⇩ 1.60 3.40E-04  219366_at AVEN ⇩ 1.59 0.019  219512_at DSN1 ⇩ 1.59 5.30E-03 
238017_at SDR16C5 ⇩ 1.60 3.20E-04  239851_at --- ⇧ 1.59 0.016  207476_at LOC100507630 ⇧ 1.59 5.30E-03 
207515_s_at POLR1C ⇩ 1.60 1.70E-04  225269_s_at RBMS1 ⇧ 1.59 0.016  1553224_at LUZP1 ⇧ 1.59 5.20E-03 
1558832_at FLJ32224 ⇧ 1.60 1.50E-04  1555883_s_at SPIN3 ⇧ 1.59 0.016  231736_x_at MGST1 ⇩ 1.59 5.20E-03 
1555278_a_at CKAP5 ⇩ 1.60 4.30E-05  232731_x_at LOC100190938 ⇧ 1.59 0.015  1556327_a_at --- ⇧ 1.59 5.10E-03 
AFFX-BioC-
5_at 
--- ⇩ 1.59 5.46E-05  227574_at OBSL1 ⇩ 1.59 0.015  204380_s_at FGFR3 ⇧ 1.59 5.00E-03 
1568815_a_at DDX50 ⇧ 1.59 0.050  234731_at --- ⇧ 1.59 0.014  206529_x_at SLC26A4 ⇧ 1.59 4.50E-03 
206237_s_at NRG1 ⇧ 1.59 0.046  200074_s_at RPL14  ⇩ 1.59 0.014  1554798_at SNED1 ⇩ 1.59 4.50E-03 
201896_s_at PSRC1 ⇩ 1.59 0.045  218851_s_at WDR33 ⇩ 1.59 0.014  1558561_at HM13 ⇧ 1.59 4.10E-03 
202483_s_at RANBP1 ⇩ 1.59 0.045  201307_at SEPT11 ⇩ 1.59 0.013  1564679_at ASB15 ⇧ 1.59 4.00E-03 
242433_at ZBTB11 ⇧ 1.59 0.045  1560491_at --- ⇧ 1.59 0.012  217394_at --- ⇩ 1.59 3.70E-03 
242836_at --- ⇧ 1.59 0.042  227435_at KIAA2018 ⇧ 1.59 0.011  233024_at --- ⇧ 1.59 3.70E-03 
224790_at ASAP1 ⇩ 1.59 0.042  206238_s_at YAF2 ⇩ 1.59 0.011  225756_at CSNK1E ⇧ 1.59 3.50E-03 
218439_s_at COMMD10 ⇩ 1.59 0.042  223137_at ZDHHC4 ⇧ 1.59 0.010  211008_s_at UBE2I ⇧ 1.59 3.50E-03 
216427_at --- ⇧ 1.59 0.036  210988_s_at PRUNE ⇩ 1.59 9.50E-03  243545_at --- ⇧ 1.59 3.40E-03 
243256_at MKNK1 ⇧ 1.59 0.035  204387_x_at MRP63 ⇧ 1.59 9.20E-03  214074_s_at CTTN ⇩ 1.59 3.30E-03 
212587_s_at PTPRC ⇧ 1.59 0.035  200848_at AHCYL1 ⇧ 1.59 8.60E-03  207263_x_at VEZT ⇧ 1.59 3.20E-03 
1560116_a_at NEDD1 ⇧ 1.59 0.034  233290_at --- ⇧ 1.59 8.30E-03  222252_x_at UBQLN4 ⇧ 1.59 3.10E-03 
234131_at --- ⇧ 1.59 0.031  240529_at --- ⇧ 1.59 8.10E-03  229542_at C20orf85 ⇩ 1.59 2.90E-03 
238591_at HEXDC ⇧ 1.59 0.030  202059_s_at KPNA1 ⇧ 1.59 7.70E-03  242675_x_at --- ⇧ 1.59 2.80E-03 
212770_at TLE3 ⇧ 1.59 0.030  221596_s_at C7orf64 ⇧ 1.59 7.20E-03  1557403_s_at --- ⇧ 1.59 2.60E-03 
242512_at MYO9A ⇧ 1.59 0.027  1556346_at COTL1 ⇧ 1.59 6.90E-03  213767_at KSR1 ⇩ 1.59 2.60E-03 
208680_at PRDX1 ⇩ 1.59 0.027  1569940_at SLC6A16 ⇩ 1.59 6.90E-03  202288_at FRAP1 ⇩ 1.59 2.30E-03 
1557520_a_at --- ⇧ 1.59 0.026  203694_s_at DHX16 ⇩ 1.59 6.60E-03  231459_at --- ⇧ 1.59 2.20E-03 
49878_at PEX16 ⇧ 1.59 0.025  219959_at MOCOS ⇩ 1.59 6.50E-03  229442_at C18orf54 ⇧ 1.59 2.20E-03 
231255_at MPRIP ⇧ 1.59 0.023  244780_at SGPP2 ⇧ 1.59 6.50E-03  236109_at RPUSD4 ⇧ 1.59 2.00E-03 
210876_at ANXA2P1 ⇩ 1.59 0.022  223060_at C14orf119 ⇩ 1.59 6.10E-03  224620_at MAPK1 ⇧ 1.59 1.60E-03 
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201716_at SNX1 ⇩ 1.59 1.10E-03  1552662_a_at PCDHGB7 ⇩ 1.58 0.032  243295_at RBM27 ⇧ 1.58 0.012 
207743_at --- ⇧ 1.59 1.00E-03  234072_at SEMA4A ⇧ 1.58 0.030  1569503_at HEATR5B ⇧ 1.58 0.011 
213238_at ATP10D ⇩ 1.59 1.00E-03  208816_x_at ANXA2P2 ⇩ 1.58 0.029  209080_x_at GLRX3 ⇩ 1.58 0.010 
240049_at --- ⇧ 1.59 8.20E-04  240024_at SEC14L2 ⇩ 1.58 0.028  201031_s_at HNRNPH1 ⇧ 1.58 0.010 
219392_x_at PRR11 ⇧ 1.59 8.00E-04  206386_at SERPINA7 ⇧ 1.58 0.027  213199_at C2CD3 ⇩ 1.58 9.90E-03 
208157_at SIM2 ⇧ 1.59 7.80E-04  1565886_at --- ⇧ 1.58 0.026  222373_at --- ⇧ 1.58 9.80E-03 
222907_x_at TMEM50B ⇧ 1.59 7.50E-04  224151_s_at AK3 ⇧ 1.58 0.026  223287_s_at FOXP1 ⇧ 1.58 9.60E-03 
211127_x_at EDA ⇧ 1.59 6.20E-04  205504_at BTK ⇩ 1.58 0.026  1566178_x_at --- ⇧ 1.58 9.50E-03 
214189_s_at GGA2 ⇧ 1.59 6.10E-04  239768_x_at GPATCH2 ⇧ 1.58 0.026  225772_s_at C12orf62 ⇩ 1.58 9.40E-03 
216778_s_at CYLC1 ⇩ 1.59 6.00E-04  238899_at --- ⇩ 1.58 0.025  235984_at --- ⇧ 1.58 9.30E-03 
218112_at MRPS34 ⇩ 1.59 5.20E-04  200956_s_at SSRP1 ⇩ 1.58 0.025  217672_x_at EIF1 ⇧ 1.58 8.70E-03 
206978_at CCR2 ⇩ 1.59 4.20E-04  211948_x_at BAT2D1 ⇩ 1.58 0.024  236737_at C17orf56 ⇧ 1.58 8.60E-03 
1562764_at LOC100507351 ⇩ 1.59 4.10E-04  211752_s_at NDUFS7 ⇩ 1.58 0.024  221315_s_at FGF22 ⇧ 1.58 8.30E-03 
220311_at N6AMT1 ⇧ 1.59 1.40E-04  1562161_at --- ⇧ 1.58 0.022  219163_at ZNF562 ⇧ 1.58 8.10E-03 
1563043_at LOC285375 ⇧ 1.59 9.90E-05  1563076_x_at --- ⇧ 1.58 0.022  1569091_at --- ⇧ 1.58 7.90E-03 
231328_s_at RASGRP4 ⇩ 1.59 9.60E-05  223318_s_at ALKBH7 ⇩ 1.58 0.022  1553567_s_at --- ⇧ 1.58 7.00E-03 
1554466_a_at C16orf13 ⇩ 1.59 3.50E-05  230296_at C16orf52 ⇧ 1.58 0.022  210355_at PTHLH ⇧ 1.58 7.00E-03 
1563075_s_at --- ⇧ 1.58 0.049  238353_at RASL11A ⇧ 1.58 0.022  233509_at HERC4 ⇧ 1.58 6.80E-03 
239931_at --- ⇩ 1.58 0.048  240527_at --- ⇧ 1.58 0.021  1554329_x_at STXBP4 ⇧ 1.58 6.60E-03 
210350_x_at ING1 ⇩ 1.58 0.047  232409_x_at FBXL16 ⇩ 1.58 0.019  211647_x_at IGHA1 ⇩ 1.58 6.30E-03 
1554492_at THADA ⇧ 1.58 0.047  1558557_at C16orf62 ⇧ 1.58 0.018  219397_at COQ10B ⇧ 1.58 4.70E-03 
224963_at SLC26A2 ⇧ 1.58 0.045  223059_s_at FAM107B ⇧ 1.58 0.018  207972_at GLRA1 ⇧ 1.58 4.00E-03 
209164_s_at CYB561 ⇧ 1.58 0.043  204621_s_at NR4A2 ⇧ 1.58 0.018  215615_x_at --- ⇧ 1.58 3.30E-03 
1555334_s_at SLC30A5 ⇩ 1.58 0.043  215387_x_at --- ⇧ 1.58 0.017  1564552_at --- ⇧ 1.58 2.70E-03 
238875_at --- ⇧ 1.58 0.042  204868_at ICT1 ⇩ 1.58 0.016  236169_at --- ⇧ 1.58 2.40E-03 
218029_at FAM65A ⇩ 1.58 0.040  212616_at CHD9 ⇧ 1.58 0.014  230619_at ARNT ⇧ 1.58 2.40E-03 
235381_at RSF1 ⇧ 1.58 0.039  213492_at COL2A1 ⇧ 1.58 0.013  1556651_at --- ⇧ 1.58 1.90E-03 
223273_at C14orf142 ⇩ 1.58 0.038  200043_at ERH ⇧ 1.58 0.013  239025_at --- ⇧ 1.58 1.60E-03 
211047_x_at AP2S1 ⇩ 1.58 0.033  215749_s_at GORASP1 ⇩ 1.58 0.013  243673_at --- ⇧ 1.58 1.50E-03 
58994_at CC2D1A ⇧ 1.58 0.033  225452_at MED1 ⇧ 1.58 0.013  206718_at LMO1 ⇧ 1.58 1.40E-03 
227809_at ZC3H6 ⇧ 1.58 0.033  202616_s_at MECP2 ⇧ 1.58 0.012  1556484_at LRRC52 ⇧ 1.58 1.40E-03 
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217136_at PPIAL4A  ⇩ 1.58 9.90E-04  217356_s_at PGK1 ⇩ 1.57 0.035  229436_x_at BRCC3 ⇧ 1.57 0.011 
207613_s_at CAMK2A ⇧ 1.58 9.30E-04  202316_x_at UBE4B ⇩ 1.57 0.034  212181_s_at NUDT4 ⇧ 1.57 0.011 
242309_at --- ⇧ 1.58 9.00E-04  226562_at ZSCAN29 ⇧ 1.57 0.033  214813_at ZNF75D ⇩ 1.57 0.010 
216966_at ITGA2B ⇧ 1.58 8.90E-04  225016_at APCDD1 ⇩ 1.57 0.032  1554480_a_at ARMC10 ⇧ 1.57 9.90E-03 
214667_s_at TP53I11 ⇧ 1.58 7.70E-04  223525_at DLL4 ⇩ 1.57 0.032  230147_at F2RL2 ⇧ 1.57 9.80E-03 
233221_at DEFB118 ⇧ 1.58 6.80E-04  235520_at ZNF280C ⇧ 1.57 0.032  1560176_s_at PPP4R1L ⇩ 1.57 9.20E-03 
1560017_at TMTC3 ⇧ 1.58 5.50E-04  1561139_at --- ⇧ 1.57 0.029  219226_at CRKRS ⇧ 1.57 9.10E-03 
1560181_at LOC100288122 ⇧ 1.58 4.70E-04  225878_at KIF1B ⇧ 1.57 0.029  1569277_at ZNF91 ⇧ 1.57 8.10E-03 
221354_s_at MCHR1 ⇩ 1.58 4.10E-04  241425_at NUPL1 ⇧ 1.57 0.029  1559936_at --- ⇧ 1.57 7.80E-03 
1556929_at PAPOLG ⇧ 1.58 3.90E-04  225095_at SPTLC2 ⇩ 1.57 0.029  221368_at NEU2 ⇧ 1.57 7.70E-03 
230054_at LOC100130536 ⇧ 1.58 2.50E-04  206555_s_at THUMPD1 ⇧ 1.57 0.028  235759_at --- ⇧ 1.57 7.60E-03 
235952_at --- ⇧ 1.58 2.30E-04  225737_s_at FBXO22 ⇩ 1.57 0.027  1563208_s_at C3orf65 ⇧ 1.57 7.60E-03 
241749_at MURC ⇧ 1.58 2.20E-04  205867_at PTPN11 ⇧ 1.57 0.027  229961_x_at YJEFN3 ⇧ 1.57 6.70E-03 
243065_at --- ⇧ 1.58 2.00E-04  204675_at SRD5A1 ⇧ 1.57 0.027  230862_at --- ⇧ 1.57 6.10E-03 
208846_s_at VDAC3 ⇩ 1.58 1.60E-04  226318_at TBRG1 ⇧ 1.57 0.027  201104_x_at NBPF10 ⇩ 1.57 6.00E-03 
211130_x_at EDA ⇧ 1.58 1.10E-04  234041_at --- ⇧ 1.57 0.026  222713_s_at FANCF ⇩ 1.57 5.80E-03 
1561612_at --- ⇧ 1.58 8.00E-05  212269_s_at MCM3AP ⇩ 1.57 0.025  227090_at PHF21A ⇧ 1.57 5.40E-03 
207488_at --- ⇧ 1.58 4.70E-05  202396_at TCERG1 ⇧ 1.57 0.022  220253_s_at LRP12 ⇧ 1.57 5.30E-03 
217458_at --- ⇧ 1.58 6.70E-06  207958_at UGT2A1/2 ⇩ 1.57 0.020  214031_s_at KRT7 ⇧ 1.57 4.90E-03 
AFFX-BioB-
5_at 
--- ⇩ 1.58 6.65E-04  219081_at ANKHD1 ⇩ 1.57 0.019  234133_s_at LOC728543 ⇧ 1.57 4.70E-03 
214188_at --- ⇧ 1.57 0.048  212983_at HRAS ⇩ 1.57 0.018  1565888_at --- ⇧ 1.57 4.20E-03 
212073_at CSNK2A1 ⇧ 1.57 0.048  239585_at KAT2B ⇧ 1.57 0.018  223619_x_at PECR ⇧ 1.57 4.10E-03 
1568713_a_at TBC1D1 ⇩ 1.57 0.047  243745_at --- ⇧ 1.57 0.016  234013_at TRD ⇩ 1.57 4.10E-03 
215212_at --- ⇧ 1.57 0.046  222111_at FAM63B ⇧ 1.57 0.016  233769_at --- ⇧ 1.57 4.00E-03 
233931_at --- ⇧ 1.57 0.045  45749_at FAM65A ⇩ 1.57 0.016  243531_at ORAOV1 ⇩ 1.57 4.00E-03 
1560609_at CRYZL1 ⇧ 1.57 0.045  223538_at SERF1A ⇧ 1.57 0.016  213219_at ADCY2 ⇧ 1.57 3.80E-03 
215669_at HLA-DRB4 ⇧ 1.57 0.041  207490_at TUBA4B ⇩ 1.57 0.014  1566098_at --- ⇧ 1.57 3.70E-03 
205133_s_at HSPE1 ⇩ 1.57 0.041  1563303_at --- ⇧ 1.57 0.012  33778_at TBC1D22A ⇧ 1.57 3.40E-03 
232262_at PIGL ⇧ 1.57 0.041  220690_s_at DHRS7B ⇩ 1.57 0.012  204209_at PCYT1A ⇩ 1.57 2.90E-03 
231718_at SLU7 ⇧ 1.57 0.040  241923_x_at NANS ⇧ 1.57 0.012  223647_x_at HSCB ⇧ 1.57 2.80E-03 
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1570411_at --- ⇧ 1.57 2.70E-03  244168_s_at ULK4 ⇧ 1.56 0.045  1558076_at ANKRD32 ⇧ 1.56 0.015 
207645_s_at CHD1L ⇧ 1.57 2.40E-03  238822_at --- ⇩ 1.56 0.044  1562650_at FRYL ⇧ 1.56 0.015 
232768_at CCNB2 ⇧ 1.57 2.20E-03  1555243_x_at C8orf59 ⇧ 1.56 0.043  213197_at ASTN1 ⇧ 1.56 0.014 
231557_at --- ⇩ 1.57 2.00E-03  218930_s_at TMEM106B ⇧ 1.56 0.043  218443_s_at DAZAP1 ⇧ 1.56 0.014 
1563315_s_at ERICH1 ⇩ 1.57 2.00E-03  242051_at --- ⇧ 1.56 0.040  226320_at THOC4 ⇧ 1.56 0.014 
201216_at ERP29 ⇩ 1.57 2.00E-03  207223_s_at ROD1 ⇩ 1.56 0.040  233270_x_at --- ⇧ 1.56 0.013 
233041_x_at --- ⇧ 1.57 1.90E-03  200832_s_at SCD ⇩ 1.56 0.038  212243_at GCOM1  ⇧ 1.56 0.013 
241724_x_at --- ⇧ 1.57 1.80E-03  201922_at TINP1 ⇩ 1.56 0.038  205498_at GHR ⇩ 1.56 0.013 
221552_at ABHD6 ⇩ 1.57 1.80E-03  208891_at DUSP6 ⇩ 1.56 0.037  216755_at OSBPL10 ⇧ 1.56 0.013 
1555944_at FAM120A ⇧ 1.57 1.70E-03  235440_at SPTY2D1 ⇧ 1.56 0.037  1562295_at LOC730057 ⇧ 1.56 0.012 
1553243_at ITIH5 ⇧ 1.57 1.70E-03  202155_s_at NUP214 ⇩ 1.56 0.034  226816_s_at KIAA1143 ⇧ 1.56 0.011 
234382_x_at --- ⇧ 1.57 1.50E-03  217235_x_at IGL ⇩ 1.56 0.031  222169_x_at SH2D3A ⇧ 1.56 0.011 
241596_at NUDT10 ⇧ 1.57 1.30E-03  236375_at --- ⇧ 1.56 0.030  215193_x_at HLA-DRB1/3/4 ⇩ 1.56 0.010 
1564658_at C7orf52 ⇧ 1.57 1.00E-03  212798_s_at ANKMY2 ⇩ 1.56 0.027  231601_at LOC100507224 ⇧ 1.56 0.010 
232190_x_at LOC115110 ⇧ 1.57 1.00E-03  202093_s_at PAF1 ⇩ 1.56 0.027  206340_at NR1H4 ⇩ 1.56 0.010 
213604_at TCEB3 ⇩ 1.57 1.00E-03  1558742_at --- ⇧ 1.56 0.026  200053_at SPAG7 ⇩ 1.56 0.010 
216184_s_at RIMS1 ⇧ 1.57 9.00E-04  201506_at TGFBI ⇩ 1.56 0.026  216057_at RAB3GAP2 ⇧ 1.56 8.40E-03 
224712_x_at C19orf42 ⇧ 1.57 8.60E-04  230998_at --- ⇧ 1.56 0.025  203829_at ELP4 ⇩ 1.56 8.30E-03 
222187_x_at G3BP1 ⇧ 1.57 7.80E-04  1566991_at ARID1B ⇩ 1.56 0.023  222339_x_at --- ⇧ 1.56 8.10E-03 
233456_at --- ⇩ 1.57 6.90E-04  242293_at ING3 ⇧ 1.56 0.023  205547_s_at TAGLN ⇧ 1.56 7.80E-03 
1563841_at --- ⇧ 1.57 5.90E-04  240733_at --- ⇧ 1.56 0.020  202706_s_at UMPS ⇩ 1.56 7.20E-03 
207986_x_at CYB561 ⇧ 1.57 2.60E-04  221290_s_at MUM1 ⇧ 1.56 0.020  204573_at CROT ⇧ 1.56 7.10E-03 
231413_at --- ⇧ 1.57 2.40E-04  202205_at VASP ⇧ 1.56 0.019  1555575_a_at KDELR1 ⇧ 1.56 6.80E-03 
237813_at PCBP2  ⇧ 1.57 1.90E-04  213889_at PIGL ⇩ 1.56 0.018  1560424_at --- ⇧ 1.56 6.40E-03 
1567286_at OR5L2 ⇩ 1.57 9.20E-05  232140_at --- ⇩ 1.56 0.017  210878_s_at KDM3B ⇧ 1.56 6.00E-03 
1554396_at UEVLD ⇩ 1.57 3.60E-05  225941_at EIF4E3 ⇧ 1.56 0.017  214801_at TOR1AIP2 ⇧ 1.56 6.00E-03 
214233_at GGA2 ⇩ 1.57 3.40E-05  239062_at LOC100131096 ⇩ 1.56 0.017  240777_at SYNE2 ⇧ 1.56 5.00E-03 
215626_at --- ⇧ 1.56 0.049  234166_at UBE3A ⇩ 1.56 0.017  217005_at LDLR ⇧ 1.56 4.90E-03 
230213_at C19orf43 ⇧ 1.56 0.048  240154_at --- ⇧ 1.56 0.016  225152_at ZNF622 ⇩ 1.56 4.80E-03 
238431_at --- ⇧ 1.56 0.047  211779_x_at AP2A2 ⇩ 1.56 0.016  1569916_at --- ⇧ 1.56 4.70E-03 
210685_s_at UBE4B ⇩ 1.56 0.047  238804_at LOC100131701 ⇧ 1.56 0.016  223697_x_at C9orf64 ⇧ 1.56 4.70E-03 
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234897_s_at LY6G6F ⇩ 1.56 4.60E-03  221681_s_at DSPP ⇧ 1.56 4.80E-04  236259_at STK4 ⇧ 1.55 0.012 
1562063_x_at NBPF1 ⇧ 1.56 4.60E-03  1552609_s_at IL28A/B ⇧ 1.56 3.30E-04  1558120_at DDX3X ⇧ 1.55 0.012 
1564049_at LOC339593 ⇧ 1.56 4.50E-03  233016_at --- ⇧ 1.56 2.70E-04  212204_at TMEM87A ⇩ 1.55 0.032 
212247_at NUP205 ⇩ 1.56 4.00E-03  237606_at CD53 ⇩ 1.56 2.60E-04  239377_at EIF1AD ⇧ 1.55 0.010 
1558714_at --- ⇧ 1.56 3.70E-03  217919_s_at MRPL42 ⇩ 1.56 2.40E-04  1560340_s_at RP9P ⇧ 1.55 0.013 
217374_x_at TARP  ⇩ 1.56 3.40E-03  215553_x_at --- ⇧ 1.56 2.30E-04  1564227_at --- ⇧ 1.55 0.011 
1555078_at ZNF843 ⇧ 1.56 3.30E-03  1564446_at LOC284930 ⇧ 1.56 2.30E-04  1558784_at --- ⇧ 1.55 0.013 
1561205_at --- ⇧ 1.56 3.10E-03  208871_at ATN1 ⇧ 1.56 2.10E-04  205917_at ZNF264 ⇧ 1.55 5.23E-03 
215533_s_at UBE4B ⇩ 1.56 3.00E-03  230456_at --- ⇧ 1.56 1.80E-04  205895_s_at NOLC1 ⇩ 1.55 9.13E-04 
212920_at REST ⇧ 1.56 2.70E-03  226519_s_at AGXT2L2 ⇧ 1.56 1.50E-04  1569078_at RNF213 ⇧ 1.55 0.024 
207598_x_at XRCC2 ⇧ 1.56 2.70E-03  1554985_at ZNF396 ⇧ 1.56 9.60E-05  230579_at LOC728705 ⇧ 1.55 0.010 
230641_at LOC100505938 ⇩ 1.56 2.60E-03  238517_at KLF7 ⇧ 1.56 3.40E-05  214606_at TSPAN2 ⇧ 1.55 0.024 
222913_at KLF3 ⇧ 1.56 2.50E-03  202115_s_at NOC2L ⇧ 1.55 1.31E-03  210838_s_at ACVRL1 ⇩ 1.55 3.31E-03 
1563472_at --- ⇧ 1.56 2.30E-03  201756_at RPA2 ⇩ 1.55 0.024  210251_s_at RUFY3 ⇧ 1.55 0.042 
208252_s_at CHST3 ⇩ 1.56 2.30E-03  227292_at C11orf84 ⇧ 1.55 0.035  243643_x_at SLC30A6 ⇧ 1.55 0.022 
1561300_at --- ⇧ 1.56 2.20E-03  202783_at NNT ⇩ 1.55 0.016  241686_x_at --- ⇧ 1.55 7.84E-04 
217042_at RDH11 ⇧ 1.56 2.00E-03  212069_s_at BAT2L ⇩ 1.55 0.042  229060_at YPEL2 ⇧ 1.55 2.46E-03 
209449_at LSM2 ⇩ 1.56 1.80E-03  223200_s_at LSG1 ⇧ 1.55 0.012  203729_at EMP3 ⇩ 1.55 0.048 
1553761_at C22orf30 ⇧ 1.56 1.60E-03  238036_at SHE ⇧ 1.55 4.57E-03  240047_at --- ⇧ 1.55 0.016 
216204_at COMT ⇧ 1.56 1.60E-03  209939_x_at CFLAR ⇧ 1.55 0.042  203142_s_at AP3B1 ⇩ 1.55 1.04E-03 
229839_at SCARA5 ⇩ 1.56 1.50E-03  1563241_at --- ⇧ 1.55 4.51E-03  230018_at DPP9 ⇧ 1.55 0.011 
207300_s_at F7 ⇧ 1.56 1.30E-03  232612_s_at ATG16L1 ⇧ 1.55 2.58E-03  1570366_x_at ZNF709 ⇧ 1.55 1.55E-04 
234293_x_at --- ⇧ 1.56 1.20E-03  216745_x_at --- ⇧ 1.55 3.21E-03  202569_s_at MARK3 ⇧ 1.55 8.77E-04 
243712_at XIST ⇩ 1.56 1.10E-03  228087_at CCDC126 ⇧ 1.55 0.024  1569527_at --- ⇧ 1.55 0.020 
214516_at HIST1H4B ⇧ 1.56 1.00E-03  218021_at DHRS4  ⇩ 1.55 1.03E-03  236594_at LLGL1 ⇧ 1.55 0.010 
239748_x_at OCIAD1 ⇧ 1.56 9.70E-04  61297_at CASKIN2 ⇩ 1.55 2.51E-03  242968_at --- ⇧ 1.55 0.027 
214943_s_at RBM34 ⇩ 1.56 8.80E-04  224073_at FLJ20464 ⇩ 1.55 9.85E-03  204698_at ISG20 ⇩ 1.55 0.022 
216123_x_at --- ⇧ 1.56 7.00E-04  207520_at TROVE2 ⇧ 1.55 0.039  1559987_at --- ⇧ 1.55 0.010 
1563571_at LOC285463 ⇧ 1.56 6.90E-04  243216_x_at --- ⇧ 1.55 8.38E-03  234628_at --- ⇧ 1.55 9.90E-03 
225616_at SPRYD4 ⇩ 1.56 6.90E-04  1561578_s_at MCART6 ⇧ 1.55 0.041  221625_at --- ⇧ 1.55 2.50E-03 
215595_x_at --- ⇧ 1.56 6.20E-04  211609_x_at PSMD4 ⇩ 1.55 1.18E-03  231801_at NFATC2 ⇧ 1.55 1.60E-04 
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219717_at C4orf30 ⇧ 1.55 0.015  243792_x_at PTPN13 ⇧ 1.55 4.94E-03  211166_at FAM153A ⇧ 1.54 4.73E-04 
1569202_x_at --- ⇧ 1.55 0.033  218242_s_at SUV420H1 ⇧ 1.55 0.029  224639_at UNQ1887 ⇧ 1.54 8.65E-03 
242131_at LOC440552 ⇧ 1.55 0.038  201167_x_at ARHGDIA ⇩ 1.55 3.92E-03  221620_s_at APOO ⇩ 1.54 0.044 
236494_x_at --- ⇧ 1.55 0.011  212544_at ZNHIT3 ⇩ 1.55 0.018  1561073_at --- ⇧ 1.54 5.81E-04 
213394_at MAPKBP1 ⇧ 1.55 0.011  214322_at CAMK2G ⇩ 1.55 0.027  222914_s_at TMEM121 ⇩ 1.54 2.12E-03 
242456_at MRE11A ⇧ 1.55 0.034  1565823_at --- ⇧ 1.55 6.67E-03  232376_at PCCA ⇧ 1.54 0.044 
243971_x_at LOC731789 ⇧ 1.55 2.57E-03  210161_at --- ⇧ 1.55 3.57E-04  214531_s_at SNX1 ⇩ 1.54 3.06E-03 
236599_at --- ⇧ 1.55 6.51E-03  222272_x_at SCIN ⇧ 1.55 0.016  236971_at --- ⇧ 1.54 9.27E-03 
220636_at DNAI2 ⇧ 1.55 5.39E-03  226598_s_at GTPBP5 ⇧ 1.55 0.048  211639_x_at IGHA1-2 ⇩ 1.54 0.047 
1568821_at TTC23 ⇧ 1.55 1.58E-05  227658_s_at PLEKHA3 ⇧ 1.55 0.048  227513_s_at LRRFIP1 ⇧ 1.54 4.65E-03 
222547_at MAP4K4 ⇩ 1.55 3.27E-03  1564121_at --- ⇧ 1.55 7.18E-03  225674_at BCAP29 ⇧ 1.54 0.019 
1557025_a_at --- ⇧ 1.55 0.039  208739_x_at SUMO2 ⇩ 1.55 6.15E-03  216161_at SBNO1 ⇧ 1.54 6.00E-03 
202296_s_at RER1 ⇩ 1.55 0.034  1554576_a_at ETV4 ⇧ 1.55 6.85E-04  231567_s_at CCDC62 ⇧ 1.54 1.90E-03 
244454_at --- ⇧ 1.55 0.045  1555595_at SCRN3 ⇧ 1.55 3.82E-04  238840_at LRRFIP1 ⇧ 1.54 0.036 
219924_s_at ZMYM6 ⇩ 1.55 4.36E-04  218156_s_at TSR1 ⇩ 1.54 3.18E-03  1562468_at --- ⇧ 1.54 0.040 
219275_at PDCD5 ⇩ 1.55 0.024  228515_at LOC90784 ⇩ 1.54 0.022  228544_s_at CSRP2BP ⇩ 1.54 0.027 
91826_at EPS8L1 ⇩ 1.55 1.12E-03  209620_s_at ABCB7 ⇩ 1.54 5.76E-03  1553386_at MFSD2 ⇧ 1.54 0.017 
227825_at NAIF1 ⇩ 1.55 8.45E-03  243242_at --- ⇧ 1.54 0.024  234096_at --- ⇧ 1.54 6.21E-03 
204558_at RAD54L ⇧ 1.55 3.28E-04  1566798_at SLC35E1 ⇧ 1.54 1.90E-03  1569573_at --- ⇧ 1.54 3.01E-03 
232569_at --- ⇧ 1.55 0.014  1558385_at --- ⇧ 1.54 0.013  227120_at FOXP4 ⇧ 1.54 4.34E-03 
229434_at --- ⇧ 1.55 0.028  1553036_at GPR111 ⇧ 1.54 8.35E-03  244048_x_at --- ⇧ 1.54 5.50E-03 
244464_at --- ⇧ 1.55 4.48E-03  223218_s_at NFKBIZ ⇧ 1.54 0.023  215636_at UBR4 ⇧ 1.54 8.37E-03 
219013_at GALNT11 ⇧ 1.55 0.031  1555259_at ZAK ⇧ 1.54 8.00E-04  220071_x_at HAUS2 ⇧ 1.54 4.56E-03 
237410_x_at --- ⇧ 1.55 0.014  206262_at ADH1C ⇩ 1.54 1.39E-03  1566673_at --- ⇧ 1.54 0.012 
242875_at --- ⇧ 1.55 0.014  233900_at --- ⇧ 1.54 2.92E-05  40016_g_at MAST4 ⇩ 1.54 0.015 
228151_at --- ⇧ 1.55 7.41E-03  1560137_at --- ⇧ 1.54 4.41E-03  216524_x_at --- ⇧ 1.54 1.58E-03 
209625_at PIGH ⇩ 1.55 0.048  208907_s_at MRPS18B ⇩ 1.54 3.27E-03  1559668_s_at --- ⇧ 1.54 5.58E-03 
208728_s_at CDC42 ⇧ 1.55 0.013  212559_at PRKAR1B ⇩ 1.54 0.011  1562970_at --- ⇧ 1.54 1.36E-03 
214957_at ACTL8 ⇧ 1.55 4.80E-03  202120_x_at AP2S1 ⇩ 1.54 0.032  226926_at DMKN ⇧ 1.54 9.53E-04 
214773_x_at TIPRL ⇧ 1.55 0.036  1565874_at --- ⇧ 1.54 1.51E-04  1559490_at LRCH3 ⇧ 1.54 1.90E-03 
200909_s_at RPLP2 ⇩ 1.55 0.045  1565692_at --- ⇧ 1.54 3.83E-03  203199_s_at MTRR ⇩ 1.54 0.011 
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239981_x_at LOC728902 ⇧ 1.54 1.87E-03  233642_s_at HEATR5B ⇩ 1.54 0.032  231715_s_at PYCR2 ⇩ 1.54 4.16E-03 
243943_x_at C6orf52 ⇧ 1.54 0.027  219846_at GON4L ⇧ 1.54 7.18E-03  200772_x_at PTMA ⇧ 1.53 0.034 
205770_at GSR ⇩ 1.54 0.012  210149_s_at ATP5H ⇩ 1.54 0.027  244813_at --- ⇧ 1.53 0.023 
224918_x_at MGST1 ⇩ 1.54 0.017  226023_at MAP2K7 ⇧ 1.54 5.84E-03  241376_at LOC100130097 ⇧ 1.53 4.04E-03 
241770_x_at --- ⇧ 1.54 7.65E-03  230628_at EP400 ⇧ 1.54 1.04E-03  200665_s_at SPARC ⇩ 1.53 0.043 
215494_at --- ⇩ 1.54 0.027  233163_at LOC731157 ⇩ 1.54 8.84E-03  216771_at --- ⇧ 1.53 0.016 
1555718_x_at --- ⇧ 1.54 1.28E-04  222763_s_at WDR33 ⇩ 1.54 2.38E-03  222098_s_at --- ⇩ 1.53 5.56E-03 
AFFX-BioC-
3_at 
--- ⇩ 1.54 2.97E-04  201417_at SOX4 ⇩ 1.54 8.97E-03  235021_at KIAA2026 ⇧ 1.53 0.022 
237560_at MRPS5 ⇧ 1.54 0.041  214617_at PRF1 ⇧ 1.54 0.049  210577_at CASR ⇩ 1.53 4.41E-03 
243641_at --- ⇧ 1.54 0.020  242474_s_at VMA21 ⇧ 1.54 3.16E-03  216045_at CCDC144A ⇧ 1.53 0.029 
231972_at --- ⇩ 1.54 0.033  226758_at LUC7L2 ⇩ 1.54 0.017  222299_x_at --- ⇧ 1.53 3.16E-04 
1563529_at HYDIN2 ⇧ 1.54 0.016  1560762_at LOC285972 ⇩ 1.54 0.031  1570022_at --- ⇧ 1.53 0.029 
230309_at --- ⇩ 1.54 4.12E-03  217376_at --- ⇧ 1.54 5.17E-03  225623_at KIAA1737 ⇩ 1.53 0.041 
244787_at --- ⇧ 1.54 0.030  203945_at ARG2 ⇩ 1.54 0.035  222593_s_at SPATS2 ⇧ 1.53 0.033 
237225_at --- ⇧ 1.54 0.033  223369_at METTL11A ⇩ 1.54 5.73E-04  242711_x_at FANCM ⇧ 1.53 0.034 
1556682_s_at --- ⇧ 1.54 0.024  228277_at FBXL19 ⇧ 1.54 2.80E-03  217188_s_at C14orf1 ⇩ 1.53 2.30E-03 
218323_at RHOT1 ⇧ 1.54 0.022  222280_at --- ⇧ 1.54 6.35E-03  227687_at HYLS1 ⇩ 1.53 0.012 
213175_s_at SNRPB ⇧ 1.54 0.041  AFFX-BioDn-
5_at 
--- ⇩ 1.54 7.42E-03  1570272_at --- ⇧ 1.53 1.50E-04 
243414_at PPIL2 ⇧ 1.54 0.034  206680_at CD5L ⇩ 1.54 2.17E-03  1563679_at LOC150577 ⇧ 1.53 5.91E-03 
207925_at CST5 ⇩ 1.54 0.017  221040_at CAPN10 ⇩ 1.54 5.98E-03  224904_at PDPR ⇩ 1.53 0.026 
213121_at SNRNP70 ⇧ 1.54 1.21E-05  205981_s_at ING2 ⇩ 1.54 0.014  209518_at SMARCD1 ⇧ 1.53 7.99E-04 
227670_at ZNF75A ⇩ 1.54 0.045  1556543_at --- ⇧ 1.54 0.034  229420_at --- ⇩ 1.53 4.76E-03 
217894_at KCTD3 ⇩ 1.54 0.048  232168_x_at MACF1 ⇧ 1.54 7.82E-03  209638_x_at RGS12 ⇧ 1.53 5.46E-04 
222843_at FIGNL1 ⇩ 1.54 0.041  218459_at TOR3A ⇩ 1.54 0.033  213684_s_at PDLIM5 ⇧ 1.53 0.035 
215597_x_at --- ⇧ 1.54 0.015  226368_at CHST11 ⇧ 1.54 0.025  241018_at TMEM59 ⇧ 1.53 0.045 
221997_s_at MRPL52 ⇧ 1.54 6.76E-04  232804_at --- ⇧ 1.54 0.015  205496_at KIAA0408 ⇧ 1.53 1.36E-04 
1561305_at --- ⇧ 1.54 0.011  219670_at BEND5 ⇩ 1.54 0.030  224316_at LOC100131728 ⇧ 1.53 0.016 
218942_at PIP4K2C ⇧ 1.54 2.76E-03  238149_at ZNF818P ⇩ 1.54 7.37E-03  206127_at ELK3 ⇧ 1.53 9.18E-04 
201576_s_at GLB1 ⇩ 1.54 2.51E-03  217281_x_at IGHA1-2 ⇩ 1.54 4.50E-03  216957_at USP22 ⇧ 1.53 0.013 
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233427_x_at --- ⇧ 1.53 3.43E-03  234981_x_at CMBL ⇧ 1.53 3.71E-04  237759_at CD48 ⇧ 1.53 0.016 
230316_at SEC14L2 ⇩ 1.53 0.040  217548_at LOC100129502 ⇧ 1.53 2.97E-03  1569353_at CP110 ⇧ 1.53 0.012 
212159_x_at AP2A2 ⇩ 1.53 0.015  226713_at CCDC50 ⇩ 1.53 4.46E-03  201583_s_at SEC23B ⇩ 1.53 6.29E-03 
234294_x_at GATAD2A ⇧ 1.53 3.16E-03  1569772_x_at --- ⇩ 1.53 0.030  208322_s_at ST3GAL1 ⇩ 1.53 0.021 
233457_at --- ⇧ 1.53 2.63E-03  223064_at RNF181 ⇩ 1.53 0.015  243378_at --- ⇧ 1.53 0.022 
203258_at DRAP1 ⇩ 1.53 0.019  217772_s_at MTCH2 ⇩ 1.53 3.32E-03  217165_x_at MT1F ⇩ 1.53 0.015 
1557172_x_at NEK8 ⇧ 1.53 7.80E-03  1554171_at ZMYM3 ⇧ 1.53 0.041  205451_at FOXO4 ⇧ 1.53 0.014 
244452_at C2orf30 ⇧ 1.53 4.89E-03  208238_x_at --- ⇧ 1.53 5.22E-03  238382_x_at --- ⇧ 1.53 0.038 
243594_x_at SPIRE2 ⇧ 1.53 1.85E-03  228568_at GCOM1 ⇩ 1.53 0.036  242995_at --- ⇧ 1.53 5.92E-03 
204526_s_at TBC1D8 ⇩ 1.53 9.76E-04  215840_at DNAH2 ⇧ 1.53 0.047  212109_at HN1L ⇧ 1.53 6.28E-03 
1553227_s_at BRWD1 ⇩ 1.53 0.026  215852_x_at C20orf117 ⇧ 1.53 7.20E-04  209271_at BPTF ⇩ 1.53 9.35E-03 
238778_at MPP7 ⇧ 1.53 0.046  209233_at EMG1 ⇩ 1.53 0.032  1562010_x_at --- ⇧ 1.53 1.88E-03 
218700_s_at RAB7L1 ⇧ 1.53 0.021  1570414_x_at FLJ13197 ⇧ 1.53 3.08E-03  227186_s_at MRPL41 ⇩ 1.53 8.85E-03 
1566535_at --- ⇧ 1.53 0.014  206877_at MXD1 ⇩ 1.53 0.031  200841_s_at EPRS ⇧ 1.53 0.029 
211354_s_at LEPR ⇩ 1.53 3.80E-03  201386_s_at DHX15 ⇩ 1.53 0.043  200853_at H2AFZ ⇩ 1.53 0.014 
224002_s_at FKBP7 ⇧ 1.53 8.24E-04  241329_s_at --- ⇧ 1.53 2.21E-03  1555467_a_at CUGBP1 ⇩ 1.53 0.042 
242036_x_at ATP2B3 ⇧ 1.53 2.27E-03  218835_at SFTPA2/B ⇩ 1.53 0.017  214403_x_at SPDEF ⇧ 1.53 9.76E-04 
213040_s_at NPTXR ⇧ 1.53 0.034  225317_at ACBD6 ⇩ 1.53 1.95E-03  213768_s_at ASCL1 ⇧ 1.53 2.44E-04 
233976_at --- ⇧ 1.53 0.035  214538_x_at RGS6 ⇩ 1.53 0.021  221578_at RASSF4 ⇩ 1.53 1.23E-03 
216853_x_at IGLV3-19 ⇩ 1.53 1.03E-03  207499_x_at UNC45A ⇧ 1.53 4.76E-03  1554627_a_at ASCC1 ⇩ 1.53 2.02E-04 
221861_at --- ⇩ 1.53 5.00E-03  207343_at LYZL6 ⇩ 1.53 5.06E-03  228420_at PDCD2 ⇧ 1.53 0.011 
214385_s_at MUC5AC ⇧ 1.53 7.59E-04  242936_at --- ⇧ 1.53 0.012  239536_at --- ⇧ 1.53 0.014 
1556672_a_at RBM6 ⇧ 1.53 0.029  242235_x_at --- ⇧ 1.53 4.24E-03  230212_at LOC729345 ⇩ 1.53 7.46E-03 
236387_at LOC100129961 ⇧ 1.53 1.70E-03  1554867_a_at PRR16 ⇩ 1.53 0.011  1556742_at LOC728411 ⇧ 1.53 5.93E-04 
234531_at --- ⇧ 1.53 7.62E-04  230790_x_at --- ⇧ 1.53 8.89E-03  244093_at --- ⇧ 1.52 3.64E-03 
204683_at ICAM2 ⇩ 1.53 0.033  240123_at --- ⇧ 1.53 0.012  229609_at LOC728190 ⇩ 1.52 0.010 
1554339_a_at COG3 ⇧ 1.53 0.031  207740_s_at NUP62 ⇩ 1.53 6.51E-03  235248_at BTBD9 ⇧ 1.52 1.67E-03 
236702_at C20orf43 ⇩ 1.53 0.036  233330_s_at --- ⇩ 1.53 5.93E-03  241531_at --- ⇧ 1.52 2.07E-03 
204638_at ACP5 ⇧ 1.53 0.037  208572_at HIST3H3 ⇧ 1.53 2.79E-03  208096_s_at COL21A1 ⇩ 1.52 1.00E-04 
210032_s_at SPAG6 ⇩ 1.53 2.43E-04  239807_at LOC728842 ⇧ 1.53 7.25E-03  228623_at --- ⇧ 1.52 0.026 
241286_at --- ⇩ 1.53 0.037  224121_x_at PLEKHB2 ⇧ 1.53 7.02E-03  240232_at --- ⇧ 1.52 0.039 
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225849_s_at SFT2D1 ⇧ 1.52 5.20E-03  236072_at --- ⇧ 1.52 0.013  224370_s_at CAPS2 ⇧ 1.52 0.017 
210801_at DIMT1L ⇧ 1.52 3.53E-03  236571_at --- ⇧ 1.52 3.20E-03  229165_at MRPL12 ⇩ 1.52 0.047 
225783_at UBE2F ⇧ 1.52 0.019  221503_s_at KPNA3 ⇧ 1.52 4.86E-03  202246_s_at CDK4 ⇩ 1.52 5.66E-03 
218678_at NES ⇩ 1.52 0.011  1561919_at --- ⇧ 1.52 2.07E-05  230742_at RBM6 ⇧ 1.52 0.043 
215246_at LARP7 ⇧ 1.52 2.72E-03  1557203_at PABPC1L2B ⇩ 1.52 0.021  235958_at PLA2G4F ⇧ 1.52 5.65E-03 
1566787_at --- ⇧ 1.52 5.00E-03  227384_s_at LOC727820 ⇧ 1.52 0.047  238486_at FRS2 ⇧ 1.52 5.38E-05 
214651_s_at HOXA9 ⇩ 1.52 0.019  238119_at --- ⇧ 1.52 0.022  1553901_x_at ZNF486 ⇧ 1.52 5.69E-04 
244875_at NCRNA00105 ⇩ 1.52 7.61E-03  201734_at CLCN3 ⇩ 1.52 0.035  1568619_s_at ITPRIPL2 ⇧ 1.52 4.79E-03 
1562981_at HBB ⇧ 1.52 5.91E-04  1554494_at MTHFSD ⇩ 1.52 0.040  223513_at CENPJ ⇩ 1.52 0.017 
211960_s_at RAB7A ⇧ 1.52 3.69E-03  235810_at ZNF182 ⇧ 1.52 0.032  31861_at IGHMBP2 ⇩ 1.52 7.76E-04 
1559434_at --- ⇧ 1.52 8.11E-04  229078_s_at KIAA1704 ⇧ 1.52 0.028  234330_at --- ⇧ 1.52 7.79E-03 
1554154_at GDAP2 ⇧ 1.52 0.024  236961_at --- ⇧ 1.52 5.45E-03  1561019_at --- ⇧ 1.52 2.46E-05 
207194_s_at ICAM4 ⇧ 1.52 0.038  206316_s_at KNTC1 ⇩ 1.52 0.012  220753_s_at CRYL1 ⇩ 1.52 0.027 
215507_x_at --- ⇧ 1.52 2.95E-03  221781_s_at DNAJC10 ⇩ 1.52 0.010  214962_s_at NUP160 ⇩ 1.52 2.29E-03 
212471_at AVL9 ⇩ 1.52 0.031  236797_at --- ⇧ 1.52 3.88E-06  231129_at LOC728012 ⇩ 1.52 1.07E-03 
228108_at --- ⇩ 1.52 0.029  224413_s_at TM2D2 ⇩ 1.52 1.85E-03  215052_at FRMPD4 ⇧ 1.52 7.37E-04 
1562281_at --- ⇧ 1.52 6.66E-04  1554668_a_at FAM151A ⇩ 1.52 3.62E-04  237112_at --- ⇧ 1.52 0.049 
242371_x_at --- ⇧ 1.52 9.94E-03  209358_at TAF11 ⇧ 1.52 0.044  1566208_at TCEA1 ⇩ 1.52 0.010 
216206_x_at MAP2K7 ⇧ 1.52 0.021  208644_at PARP1 ⇩ 1.52 7.97E-03  242194_at CUL4A ⇧ 1.52 0.010 
201643_x_at KDM3B ⇧ 1.52 6.12E-03  224533_s_at C6orf142 ⇩ 1.52 3.01E-03  240350_at --- ⇧ 1.52 7.69E-04 
1561389_at --- ⇩ 1.52 0.032  216231_s_at B2M ⇩ 1.52 0.019  231009_at PLA2G12B ⇩ 1.52 0.029 
240606_at --- ⇧ 1.52 1.75E-03  242472_x_at FNBP4 ⇧ 1.52 0.020  222070_at DND1 ⇧ 1.52 0.034 
216115_at NF1 ⇧ 1.52 2.31E-03  231734_at RBP2 ⇩ 1.52 0.018  1558124_at NUDCD2 ⇧ 1.52 0.024 
221192_x_at MFSD11 ⇧ 1.52 4.33E-03  209174_s_at QRICH1 ⇧ 1.52 0.022  223057_s_at XPO5 ⇩ 1.52 2.93E-04 
203883_s_at RAB11FIP2 ⇧ 1.52 0.032  232716_at --- ⇧ 1.52 0.016  213747_at LOC100134128 ⇧ 1.52 0.018 
243125_x_at --- ⇧ 1.52 5.13E-03  1563026_at --- ⇧ 1.52 0.018  201774_s_at NCAPD2 ⇩ 1.52 0.016 
206106_at MAPK12 ⇩ 1.52 4.19E-04  202486_at AFG3L2 ⇩ 1.52 5.70E-03  226109_at C21orf91 ⇧ 1.52 0.032 
216709_at --- ⇧ 1.52 0.016  219290_x_at DAPP1 ⇧ 1.52 3.55E-03  221903_s_at CYLD ⇩ 1.52 7.58E-03 
210934_at BLK ⇧ 1.52 3.30E-03  1563426_a_at LOC644613 ⇧ 1.52 4.60E-03  203789_s_at SEMA3C ⇩ 1.52 0.050 
1556595_at --- ⇧ 1.52 0.034  1565602_at --- ⇧ 1.52 0.015  232615_at --- ⇧ 1.52 0.039 
230559_x_at FGD4 ⇧ 1.52 0.047  211371_at MAP2K5 ⇩ 1.52 4.88E-04  239076_at SEPT13 ⇧ 1.52 9.74E-03 
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210134_x_at SHOX2 ⇩ 1.52 9.50E-03  228377_at KLHL14 ⇩ 1.51 0.035  212815_at ASCC3 ⇩ 1.51 0.014 
229700_at ZNF738 ⇧ 1.52 0.020  226986_at WIPI2 ⇧ 1.51 0.018  216503_s_at MLLT10 ⇩ 1.51 0.028 
201589_at SMC1A ⇩ 1.52 0.017  205692_s_at CD38 ⇩ 1.51 1.88E-03  217750_s_at UBE2Z ⇧ 1.51 7.57E-04 
1557588_at LOC100128946 ⇧ 1.52 2.76E-03  210933_s_at FSCN1 ⇧ 1.51 0.034  203304_at BAMBI ⇩ 1.51 5.63E-03 
218695_at EXOSC4 ⇩ 1.52 2.14E-03  1562608_at --- ⇧ 1.51 8.06E-03  1562946_at --- ⇧ 1.51 0.011 
1569905_at HSD11B1L ⇧ 1.52 5.91E-04  1564067_x_at TMEM151B ⇧ 1.51 0.039  204804_at TRIM21 ⇩ 1.51 0.023 
228902_at NUP214 ⇩ 1.52 8.65E-04  221385_s_at FFAR3 ⇩ 1.51 8.09E-04  220367_s_at SAP130 ⇩ 1.51 2.32E-04 
244522_at SYVN1 ⇧ 1.51 0.011  202928_s_at PHF1 ⇩ 1.51 0.013  238158_at MEIG1 ⇧ 1.51 0.021 
226914_at ARPC5L ⇧ 1.51 0.048  1562273_at CNGA4 ⇧ 1.51 1.37E-03  1553099_at TIGD1 ⇩ 1.51 6.65E-03 
225367_at PGM2 ⇧ 1.51 0.020  231961_at RBPMS ⇧ 1.51 0.037  242641_at --- ⇧ 1.51 9.19E-03 
236291_at RDH5 ⇧ 1.51 6.49E-03  1562270_at ARHGEF7 ⇧ 1.51 0.021  207819_s_at ABCB4 ⇩ 1.51 0.028 
1553218_a_at ZNF512 ⇩ 1.51 3.38E-03  1553349_at ARID2 ⇧ 1.51 0.046  229881_at KLF12 ⇧ 1.51 0.028 
227939_s_at TRA2A ⇧ 1.51 0.019  214542_x_at HIST1H2AI ⇩ 1.51 0.023  1561419_at --- ⇧ 1.51 5.98E-03 
223294_at CXorf26 ⇩ 1.51 0.021  215607_x_at --- ⇧ 1.51 0.031  214719_at SLC46A3 ⇧ 1.51 0.038 
239885_at --- ⇧ 1.51 1.54E-03  207190_at ZZEF1 ⇩ 1.51 0.011  1565829_at KIAA1731 ⇧ 1.51 1.20E-04 
220152_at C10orf95 ⇧ 1.51 0.040  237236_x_at LOC731789 ⇧ 1.51 1.84E-04  238058_at LOC150381 ⇧ 1.51 0.041 
231809_x_at PDCD7 ⇧ 1.51 0.040  59999_at HIF1AN ⇧ 1.51 9.40E-04  232250_at KIAA1257 ⇧ 1.51 0.010 
202053_s_at ALDH3A2 ⇩ 1.51 8.95E-03  207232_s_at DZIP3 ⇩ 1.51 4.67E-05  207433_at IL10 ⇧ 1.51 1.18E-03 
211713_x_at KIAA0101 ⇧ 1.51 9.13E-03  229370_at --- ⇩ 1.51 5.10E-03  231552_at --- ⇧ 1.51 0.034 
238684_at --- ⇧ 1.51 0.011  1554020_at BICD1 ⇩ 1.51 0.016  1570393_at EML5 ⇧ 1.51 4.70E-03 
212655_at ZCCHC14 ⇩ 1.51 0.023  228457_at --- ⇩ 1.51 2.12E-03  218583_s_at DCUN1D1 ⇧ 1.51 0.047 
230203_at FLJ46875 ⇧ 1.51 2.81E-03  209902_at ATR ⇩ 1.51 0.036  211649_x_at IGHA1-2 ⇩ 1.51 4.60E-03 
239252_at --- ⇧ 1.51 5.98E-03  241195_at --- ⇧ 1.51 5.33E-04  216924_s_at DRD2 ⇧ 1.51 2.00E-04 
228009_x_at ZNRD1 ⇩ 1.51 0.044  236935_at --- ⇧ 1.51 0.022  216002_at --- ⇧ 1.51 0.043 
218264_at BCCIP ⇩ 1.51 0.015  1562034_at NCRNA00163 ⇩ 1.51 8.39E-03  206770_s_at SLC35A3 ⇧ 1.51 0.048 
240887_at --- ⇧ 1.51 9.77E-03  227046_at SLC39A11 ⇩ 1.51 1.15E-03  223674_s_at CDC42SE1 ⇩ 1.51 0.010 
216640_s_at PDIA6 ⇩ 1.51 0.011  47083_at C7orf26 ⇩ 1.51 0.040  210460_s_at PSMD4 ⇩ 1.51 6.45E-03 
1554176_a_at C3orf33 ⇧ 1.51 0.020  1569577_x_at --- ⇧ 1.51 0.041  1561942_x_at --- ⇧ 1.51 0.034 
219575_s_at COG8 ⇩ 1.51 7.61E-03  242342_at --- ⇩ 1.51 1.23E-03  1565861_at --- ⇧ 1.51 1.05E-03 
206528_at TRPC6 ⇧ 1.51 1.69E-04  240240_at --- ⇧ 1.51 0.048  239959_x_at --- ⇩ 1.51 2.98E-03 
213124_at ZNF473 ⇩ 1.51 0.011  225149_at PCID2 ⇩ 1.51 7.64E-03  1560745_at --- ⇩ 1.51 4.24E-03 
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201969_at NASP ⇩ 1.50 2.35E-03  238257_at MLLT10 ⇧ 1.50 0.033  210433_at POFUT1 ⇧ 1.50 0.023 
211190_x_at CD84 ⇩ 1.50 9.25E-03  219038_at MORC4 ⇩ 1.50 0.049  203426_s_at IGFBP5 ⇩ 1.50 0.032 
239324_at --- ⇩ 1.50 0.037  228662_at SOCS7 ⇧ 1.50 0.034  1552927_at MAP3K7IP3 ⇧ 1.50 0.041 
1555189_a_at TAT ⇧ 1.50 3.33E-03  212079_s_at MLL ⇧ 1.50 0.035  228536_at LOC90826 ⇩ 1.50 0.012 
227177_at CORO2A ⇩ 1.50 7.54E-03  242555_at C16orf87 ⇧ 1.50 0.028  203447_at PSMD5 ⇧ 1.50 0.014 
1566716_at --- ⇧ 1.50 0.019  243675_at --- ⇧ 1.50 0.032  224667_x_at C10orf104 ⇧ 1.50 3.64E-03 
223781_x_at ADH4 ⇧ 1.50 8.92E-03  207966_s_at GLG1 ⇧ 1.50 0.048  223643_at CRYGS ⇧ 1.50 0.011 
1565628_at --- ⇩ 1.50 0.014  226993_at --- ⇧ 1.50 0.034  201299_s_at MOBKL1B ⇧ 1.50 0.016 
210185_at CACNB1 ⇧ 1.50 4.90E-03  209448_at HTATIP2 ⇧ 1.50 0.027  220242_x_at ZNF701 ⇧ 1.50 3.63E-03 
234135_x_at --- ⇧ 1.50 7.60E-04  217703_x_at --- ⇧ 1.50 1.27E-03  200878_at EPAS1 ⇩ 1.50 0.029 
209646_x_at ALDH1B1 ⇩ 1.50 0.017  230090_at GDNF ⇩ 1.50 1.98E-03  208346_at PPBPL2 ⇧ 1.50 0.024 
1564972_x_at SETDB2 ⇧ 1.50 1.58E-03  233873_x_at MTPAP ⇧ 1.50 2.52E-03  212192_at KCTD12 ⇧ 1.50 0.026 
204214_s_at RAB32 ⇩ 1.50 0.015  239992_at --- ⇧ 1.50 0.028  219217_at NARS2 ⇩ 1.50 4.25E-03 
228652_at ZNF776 ⇧ 1.50 0.018  1558444_at --- ⇩ 1.50 0.013  217492_s_at PTEN  ⇩ 1.50 0.047 
208216_at DLX4 ⇧ 1.50 6.36E-03  210521_s_at FETUB ⇧ 1.50 0.048  224989_at --- ⇧ 1.50 0.031 
220778_x_at SEMA6B ⇧ 1.50 0.013  210193_at MOBP ⇩ 1.50 2.68E-04  204413_at TRAF2 ⇩ 1.50 6.21E-03 
234562_x_at LOC728678 ⇧ 1.50 0.021  233930_at DMRT3 ⇩ 1.50 0.022  1564773_x_at --- ⇧ 1.50 0.024 
227175_at LOC100131311 ⇩ 1.50 0.043  216170_at --- ⇧ 1.50 0.038  244011_at PPM1K ⇧ 1.50 0.021 
241085_at --- ⇩ 1.50 0.018  224795_x_at IGKC ⇩ 1.50 0.035  243746_at IGHMBP2 ⇩ 1.50 0.037 
209123_at QDPR ⇩ 1.50 8.95E-03  214637_at OSM ⇧ 1.50 3.05E-03  234088_at --- ⇧ 1.50 0.046 
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Figure B1: Kaplan-Meier Survival Curve for LCL’s in the ECACC 
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Abbreviations: ALS - Amyotrophic Lateral Sclerosis, C9ORF72 - chromosome 9 
open reading frame 72, ECACC - European Collection of Cell Cultures, LCL - 
lymphoblastoid cell line and S - sporadic.  







 Table B1: Clinical Information Relating to Control LCL’s in the ECACC Discovery Cohort 
 404 
 
ID ECACC Sex Age  ID ECACC Sex Age  ID ECACC Sex Age  ID ECACC Sex Age  ID ECACC Sex Age 
C001 SMa0033 M 65  C021 LCa0076 M 69  C041 BC6397 M 52  C061 SC3150 M 36  C081 SC3738 M 49 
C002 BLi0245 M 61  C022 SPr0086 F 69  C042 SC3247 F 56  C062 LC0101 M 75  C082 BC6477 F 52 
C003 BC6548 M 69  C023 SC3672 M 71  C043 BC6231 M 62  C063 SC3293 F 76  C083 BLi0269 M 65 
C004 SNc0091 M 43  C024 SNt0035 M 51  C044 SNc0041 F 67  C064 SC3692 M 78  C084 LC0669 F 66 
C005 LPo0033 M 50  C025 SNc0218 M 61  C045 SC3406 M 47  C065 BLi0123 M 57  C085 SNc0035 M 68 
C006 LC0455 F 52  C026 BC6295 F 65  C046 LSh0023 M 70  C066 LC0262 M 48  C086 BLi0217 F 69 
C007 SNc0038 M 72  C027 LC0216 M 64  C047 SNc0149 M 73  C067 SC3504 F 48  C087 BC6166 M 39 
C008 SPr0050 M 75  C028 SC3452 F 39  C048 SNt0005 F 74  C068 LRo0007 M 67  C088 BC6323 M 61 
C009 SNc0103 F 79  C029 SNc0023 M 59  C049 SC3052 M 64  C069 BC6253 F 68  C089 SC3594 M 72 
C010 SPr0014 M 58  C030 LC0675 M 77  C050 LC0194 M 33  C070 SC3312 M 69  C090 BOx0073 F 57 
C011 SNc0045 F 63  C031 SC3709 F 84  C051 BC6300 M 57  C071 LC0583 M 72  C091 SC3741 M 57 
C012 LSh0025 M 55  C032 LC0573 M 46  C052 SNt0073 F 59  C072 SPr0048 M 52  C092 SC3690 M 75 
C013 SDu0012 F 66  C033 SMa0183 F 53  C053 LPo0062 M 69  C073 BC6091 F 63  C093 BLi0196 F 77 
C014 LC0433 M 70  C034 SC3151 M 66  C054 LNh0075 F 70  C074 SPr0068 M 64  C094 SC3699 M 78 
C015 LSh0032 M 63  C035 SC3021 F 67  C055 LC0367 M 72  C075 LC0311 M 71  C095 BLi0029 M 70 
C016 SC3489 F 69  C036 SMa0156 M 56  C056 LC0249 M 60  C076 SNc0106 F 71  C096 LC0692 M 71 
C017 LPo0027 M 71  C037 BC6448 F 59  C057 BC6335 F 65  C077 SMa0047 M 60  C097 BLi0083 F 72 
C018 SNc0096 F 73  C038 LSh0022 M 70  C058 SC3278 F 41  C078 BC6374 M 63  C098 BC6234 M 54 
C019 LCa0022 F 58  C039 BLi0169 M 73  C059 SC3246 M 78  C079 SC3279 F 56  C099 SC3282 F 63 







 Table B2: Clinical Information Relating to Familial LCL’s in the ECACC Discovery Cohort 
 405 
 
ID ECACC Sex Age EEC Diagnosis Genotype Survival Presentation ALSFRS-R Riluzole Meds Other Supplements Smoking 
F001 LP0137 M 61 Definite ALS Unknown 32 Limb 34 Y None None ? 
F002 LNh0101 M 67 Probable ALS C9ORF72 16 Bulbar 19 Y None None ? 
F003 LP0048 M 27 Definite ALS FUS 13 Mixed 0 Y None None ? 
F004 LP0614 M 38 Probable ALS Unknown 20 Mixed 42 N None None ? 
F005 LP0225 F 40 Probable ALS Unknown 19 Limb 46 N None Vitamin E ? 
F006 BP6206 M 45 Probable ALS Unknown 10 Bulbar 15 Y None None ? 
F007 LP0388 F 48 Definite ALS Unknown 17 Bulbar 45 N None None ? 
F008 BP6074 M 46 Definite ALS Unknown 33 Bulbar 31 Y None None ? 
F009 BP6061 F 50 Probable ALS Unknown 38 Unknown 34 Unknown None None ? 
F010 SPr0085 M 70 Probable ALS Unknown Unknown Mixed 24 Y None None ? 
F011 LP0637 F 68 Probable ALS C9ORF72 63 Limb 41 Y None None ? 
F012 SP3474 F 74 Probable ALS Unknown Unknown Limb 40 Y None None N 
F013 BP6494 M 58 Probable ALS C9ORF72 Alive Limb 33 N None None ? 
F014 LCa0111 F 63 Definite ALS Unknown 35 Bulbar 0 Y None None ? 
F015 LP0460 M 46 Definite ALS TARDBP Alive Unknown 33 Unknown None None ? 
F016 LP0328 M 53 Definite ALS Unknown 20 Bulbar 45 Y None None ? 
F017 BP6072 F 56 Probable ALS C9ORF72 33 Bulbar 30 Y None None ? 
F018 LP0631 M 63 Probable ALS Unknown 30 Limb 40 Y None None ? 
F019 BP6391 M 60 Probable ALS C9ORF72 28 Limb 41 Y None None ? 
F020 BLi0236 F 71 Probable ALS C9ORF72 33 Mixed 35 N None None ? 
F021 LP0125 M 57 Probable ALS C9ORF72 25 Limb 0 Y None None ? 
F022 LP0294 M 56 Probable ALS Unknown 75 Limb 47 Y None None ? 
F023 BP6054 F 61 Definite ALS Unknown 35 Limb 31 Y None None ? 
F024 SP3148 F 28 Definite ALS+EL C9ORF72 14 Bulbar 18 Y None Vitamin C/E N 
F025 SPr0059 F 69 Probable ALS C9ORF72 18 Bulbar 24 Y None None ? 
F026 LP0657 M 70 Definite ALS C9ORF72 18 Mixed 45 N None None ? 
F027 SNc0204 F 48 Definite ALS C9ORF72 41 Unknown 40 Unknown None None ? 
F028 SMa0020 M 49 Definite ALS Unknown 29 Mixed 39 Y None None ? 
F029 LPy0018 F 52 PBP PBP C9ORF72 58 Bulbar 45 Y None None ? 
F030 LP0475 M 59 Probable ALS C9ORF72 30 Limb 42 Y None None ? 
F031 SP3526 M 60 Definite ALS+EL SOD1 24 Respiratory 36 N None None N 
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F033 SP3006 M 62 Definite ALS C9ORF72 32 Limb 32 Y None Vitamin C/E N 
F034 BP6508 F 64 Probable ALS Unknown 49 Limb 40 Y None Vitamin C ? 
F035 SP3590 M 63 Definite ALS Unknown 39 Limb 37 Y None None ? 
F036 LP0193 F 31 Probable ALS FUS Unknown Limb 43 Unknown None None ? 
F037 LP0529 M 33 Definite ALS Unknown 22 Limb 45 Y None Vitamin C/E ? 
F038 BLi0249 M 40 Definite ALS Unknown 10 Mixed 40 Y None None ? 
F039 BP6447 M 56 Probable ALS Unknown 26 Bulbar 41 Y None Multivitamin ? 
F040 SP3068 M 57 Probable ALS TARDBP Unknown Bulbar 46 Y None None N 
F041 LP0440 F 58 PBP PBP C9ORF72 22 Bulbar 38 Unknown None None ? 
F042 SP3303 F 78 Definite ALS Unknown 11 Bulbar 36 Y None None N 
F043 LNh0046 M 43 Definite ALS Unknown 32 Respiratory 29 Y None None ? 
F044 LP0456 F 45 Definite ALS Unknown 18 Bulbar 27 Y None None ? 
F045 BLi0254 M 49 Definite ALS C9ORF72 Unknown Limb 41 Y None None ? 
F046 LP0008 M 69 Definite ALS C9ORF72 19 Limb 29 Y None None ? 
F047 BP6502 M 53 Probable ALS C9ORF72 Alive Limb 44 Y None Multivitamin ? 
F048 BBr0015 F 71 Definite ALS C9ORF72 19 Mixed Unknown N None None ? 
F049 LP0497 M 53 Probable ALS C9ORF72 13 Bulbar 43 Y None None ? 
F050 BP6308 F 55 Definite ALS C9ORF72 47 Limb 29 Y None None ? 
F051 LP0305 M 57 Probable ALS C9ORF72 21 Limb 27 Y None None ? 
F052 LCa0026 F 65 PBP PBP C9ORF72 Unknown Bulbar 35 N None None ? 
F053 SP3610 M 59 Probable ALS SOD1 24 Limb 26 Y Lithium None ? 
F054 SP3048 M 47 Definite ALS Unknown Alive Mixed 48 Y None None N 
F055 LP0682 M 49 Probable ALS Unknown Unknown Bulbar 41 Y None None ? 
F056 SP3462 F 50 Probable ALS C9ORF72-OPTN 28 Bulbar 31 Y None None N 
F057 LP0717 M 71 Definite ALS C9ORF72 32 Limb 36 N None None ? 
F058 LPo0036 M 62 PBP PBP C9ORF72 27 Bulbar 38 Y None None ? 
F059 BP6124 F 32 Definite ALS Unknown Unknown Limb 29 Y None None ? 
F060 SP3528 M 33 Probable ALS Unknown 16 Limb 35 Y None None N 
F061 LP0296 M 57 Probable ALS Unknown 33 Limb 36 Y None None ? 
F062 LP0148 M 67 Definite ALS Unknown 17 Bulbar 0 N None None ? 
F063 LP0405 F 72 Probable ALS Unknown 21 Mixed 34 Y None None ? 
F064 SNc0063 M 56 Definite ALS Unknown 69 Mixed 24 Y None Vitamin C/E ? 
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F066 SP3659 M 39 Definite ALS Unknown 44 Limb 44 Y None None ? 
F067 SP3086 F 40 Definite ALS TARDBP 224 Limb 15 N None None Y 
F068 LP0075 M 44 Definite ALS SOD1 33 Mixed 0 Y None None ? 
F069 LP0157 F 44 Probable ALS Unknown 78 Unknown 43 Unknown None None ? 
F070 BP6531 F 78 Probable ALS Unknown 33 Limb 28 Y None None ? 
F071 SNc0031 M 63 Definite ALS Unknown 67 Limb 39 Y None Vitamin C/E ? 
F072 BLi0251 F 70 Definite ALS C9ORF72 23 Bulbar 20 Y None None ? 
F073 BP6165 F 35 Definite ALS C9ORF72 53 Limb 31 Y Minocycline Vitamin E ? 
F074 BLi0272 M 36 Definite ALS Unknown Unknown Limb 46 Y None None ? 
F075 BP6551 M 41 Probable ALS Unknown Unknown Limb 45 Y None Vitamin C/E ? 
F076 SP3670 F 82 Probable ALS Unknown 35 Limb 38 Y None None ? 
F077 LP0437 M 54 Definite ALS C9ORF72 6 Bulbar 26 Y None None ? 
F078 BOx0029 F 57 Probable ALS C9ORF72 20 Mixed 29 N None None ? 
F079 LNh0050 M 43 Probable ALS Unknown 19 Limb 42 Y None None ? 
F080 SP3508 F 47 Probable ALS Unknown 40 Limb 40 Y None None N 
F081 SMa0006 M 62 Probable ALS C9ORF72 107 Limb 45 Y None None ? 
F082 LP0584 F 70 Definite ALS Unknown Unknown Bulbar 28 Y None None ? 
F083 LP0665 F 69 Definite ALS C9ORF72 28 Mixed 34 N None None ? 
F084 BP6063 M 71 Definite ALS C9ORF72 23 Bulbar 0 Y None None ? 
F085 LP0013 M 48 Definite ALS Unknown 35 Limb 41 Y None None ? 
F086 LP0051 M 49 Probable ALS FUS 79 Limb 48 Y None None ? 
F087 SP3216 F 50 PLS PLS+EL Unknown 48 Limb 0 N None None N 
F088 LP0091 M 62 Definite ALS C9ORF72 25 Bulbar 21 N None None ? 
F089 SP3331 F 61 Definite ALS C9ORF72 24 Bulbar 14 Y None Vitamin C/E N 
F090 SP3063 M 61 Probable ALS Unknown 6 Limb 0 Y None Vitamin C/E N 
F091 SP3534 F 63 Probable ALS C9ORF72 83 Limb 35 Y BDNF-trial None N 
F092 SP3154 M 57 Probable ALS TARDBP 36 Limb 40 Y None Vitamin C/E Ex-smoker 
F093 SP3033 M 59 Definite ALS Unknown 23 Bulbar 34 Y None None ? 
F094 BLi0246 F 60 Probable ALS C9ORF72 Unknown Limb 28 Y None None ? 
F095 SMa0008 M 62 Probable ALS Unknown 78 Mixed 10 Y None None ? 
F096 LP0480 M 59 Probable ALS C9ORF72 16 Unknown 46 Unknown None None ? 
F097 SP3277 M 43 Probable ALS Unknown 21 Limb 23 Y None None Y 
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F099 LP0073 F 61 Definite ALS C9ORF72 45 Mixed 35 Y None None ? 
F100 SP3070 M 63 PBP PBP C9ORF72 19 Bulbar 36 N None None Y 
F101 SPr0026 F 64 Definite ALS C9ORF72 32 Bulbar 12 Y None None ? 
F102 LSh0038 M 65 Probable ALS C9ORF72 87 Limb 38 Y None None ? 
F103 BLi0265 M 23 Definite ALS SOD1 Unknown Limb 46 Y None None ? 
F104 BP6535 M 37 Probable ALS Unknown Unknown Limb 47 Y None None ? 
F105 BP6504 F 39 Definite ALS Unknown 35 Limb 39 Y None Vitamin C ? 
F106 BP6029 F 55 Definite ALS C9ORF72 53 Limb 42 Y None None ? 
F107 BP6334 M 56 Probable ALS C9ORF72 31 Limb 36 Y None Vitamin C/E ? 
F108 SMa0078 M 59 Definite ALS Unknown 22 Limb 36 Y None None ? 
F109 SNc0202 M 71 Definite ALS Unknown Unknown Unknown 40 Unknown None None ? 
F110 LP0088 M 55 Probable ALS Unknown 58 Limb 45 Y None None ? 
F111 LP0582 F 73 Definite ALS Unknown Unknown Bulbar 20 Y None None ? 
F112 LP0198 M 67 Probable ALS Unknown 9 Bulbar 0 N None None ? 
F113 LP0393 F 69 Definite ALS Unknown 32 Bulbar 38 Y None None ? 
F114 SP3560 M 47 Probable ALS+PD C9ORF72 17 Limb 0 Y None None N 
F115 SP3118 F 50 Definite ALS+FTD C9ORF72 16 Bulbar 28 Y None None N 
F116 BP6077 M 51 Probable ALS Unknown Unknown Limb 44 N None None ? 
F117 SMa0166 M 60 Definite ALS C9ORF72 31 Mixed 24 Y None Multivitamin ? 
F118 SNc0189 M 59 PBP PBP C9ORF72 33 Bulbar 12 Unknown None None ? 
F119 SP3089 F 60 Definite ALS Unknown Alive Bulbar 43 Y None Vitamin C/E N 
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ID ECACC Sex Age EEC Diagnosis Genotype Survival Presentation ALSFRS-R Riluzole Meds Other Supplements Smoking 
S001 LP0061 F 22 Probable ALS Unknown 35 Limb 34 Y None Vitamin E ? 
S002 SP3003 F 82 Definite ALS Unknown 16 Mixed 22 Y None None ? 
S003 LP0021 F 64 Probable ALS Unknown 33 Bulbar 43 Y None Multivitamin ? 
S004 SP3486 M 62 Probable ALS Unknown 35 Limb 30 Y None Vitamin C/E  N 
S005 BBe0007 M 30 Probable ALS Unknown 46 Limb Unknown Y None Vitamin E ? 
S006 SP3062 F 38 Definite ALS+EL Unknown 58 Bulbar 42 Y None None Y 
S007 SP3185 M 44 Probable ALS Unknown 11 Mixed 41 Y None Vitamin C/E N 
S008 SP3111 F 50 Definite ALS Unknown 27 Limb 26 Y None None N 
S009 BBe0018 M 47 Probable ALS Unknown 18 Limb Unknown Y None None ? 
S010 SP3275 M 48 Probable ALS Unknown 21 Limb 25 Y None None N 
S011 BP6059 M 50 Probable ALS C9ORF72 36 Limb Unknown Y None None ? 
S012 SNc0022 F 54 Definite ALS Unknown 27 Mixed 14 Y None Vitamin C/E ? 
S013 LP0129 F 53 Probable ALS Unknown 21 Bulbar 40 Y None None ? 
S014 SP3064 M 53 Probable ALS Unknown 49 Limb 33 Y None None N 
S015 SP3299 M 54 Probable ALS-FA Unknown 70 Limb 32 Y None None Ex-Smoker 
S016 SP3162 M 71 Probable ALS Unknown 19 Limb 34 Y None Vitamin E N 
S017 LP0201 M 72 Probable ALS Unknown 71 Limb 43 Y None None ? 
S018 SP3197 F 75 Probable ALS Unknown 25 Limb 0 Y None Vitamin C/E N 
S019 SP3172 M 72 Definite ALS+EL Unknown 24 Respiratory 33 Y None Vitamin C/E N 
S020 SP3059 M 76 Definite ALS Unknown 10 Limb 19 Y None None ? 
S021 SP3249 F 76 Probable ALS Unknown 13 Bulbar 27 Y None None N 
S022 BP6013 M 83 Probable ALS Unknown 17 Limb Unknown Y None None ? 
S023 SP3057 M 59 Definite ALS C9ORF72 17 Bulbar 0 Y None None ? 
S024 LP0080 M 61 Probable ALS Unknown 30 Limb 43 Y None None ? 
S025 BP6066 F 63 Probable ALS Unknown 51 Limb Unknown N None None ? 
S026 SP3022 F 65 Definite ALS Unknown 13 Limb 0 Y None None ? 
S027 LP0172 M 54 Definite ALS Unknown 19 Mixed 45 N None None ? 
S028 SP3036 M 54 Definite ALS Unknown 21 Limb 20 Y None None ? 
S029 BP6037 F 57 Probable ALS Unknown 26 Limb Unknown Y None None ? 
S030 SP3050 F 59 Probable ALS Unknown 34 Limb 34 Y None Vitamin C/E ? 
S031 SP3106 M 66 Probable ALS Unknown 29 Bulbar 28 Y None None ? 
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S033 SP3045 F 70 Probable ALS Unknown 25 Limb 39 Y None None N 
S034 SP3378 F 70 Definite ALS Unknown 42 Limb 29 N None None N 
S035 LPo0010 M 62 Probable ALS Unknown 26 Limb 29 Y None None ? 
S036 SNt0031 M 61 Definite ALS Unknown 13 Limb 39 Y None None ? 
S037 BP6012 M 61 Definite ALS Unknown 24 Limb Unknown Y None None ? 
S038 BP6044 F 66 Probable ALS Unknown 48 Bulbar Unknown Y None None ? 
S039 SP3001 F 68 Definite ALS Unknown 37 Bulbar 26 Y None Vitamin C/E N 
S040 SP3271 M 70 PBP PBP Unknown 26 Bulbar 43 Y None Vitamin C/E N 
S041 LP0094 M 67 Definite ALS Unknown 44 Bulbar 23 Y None None ? 
S042 SP3122 M 68 Probable ALS-FA C9ORF72 16 Limb 38 Y None None N 
S043 SP3181 F 71 Probable ALS Unknown 19 Limb 25 Y None None N 
S044 SP3329 F 73 PBP PBP+EL Unknown 16 Bulbar 31 Y None None N 
S045 SP3289 M 56 PBP PBP Unknown 35 Bulbar 39 Y None Vitamin C/E N 
S046 SNc0001 M 57 Definite ALS Unknown 22 Limb 37 Y None Vitamin C/E ? 
S047 SP3269 F 61 Probable ALS+EL Unknown 44 Bulbar 38 Y None None N 
S048 SP3066 F 62 Definite ALS Unknown 44 Limb 35 N None Vitamin C ? 
S049 LP0163 M 38 Definite ALS Unknown 50 Limb 27 Y None None ? 
S050 SP3023 M 45 Probable ALS Unknown 39 Limb 35 N Minocycline Vitamin C/E ? 
S051 SP3437 M 65 Probable ALS Unknown 35 Limb 42 Y None Vitamin E N 
S052 BBe0016 M 65 Probable ALS Unknown 92 Limb Unknown Y None None ? 
S053 SP3371 M 66 Probable ALS Unknown 28 Limb 28 Y None Vitamin C/E N 
S054 SP3179 F 67 Probable ALS Unknown 29 Limb 42 Y None Vitamin C/E N 
S055 SP3300 F 68 Probable ALS Unknown 47 Bulbar 32 Y None None N 
S056 LP0085 F 70 Probable ALS Unknown 23 Mixed 40 Y None None ? 
S057 SP3361 M 70 Probable ALS Unknown 27 Bulbar 34 Y None None Ex-Smoker 
S058 BBe0001 M 71 Probable ALS Unknown 42 Limb Unknown N None None ? 
S059 SP3041 F 71 Definite ALS C9ORF72 57 Limb 32 Y None Vitamin C/E N 
S060 SP3338 M 71 Probable ALS-FA Unknown 53 Limb 40 Y None Vitamin C/E N 
S061 LP0052 M 50 Probable ALS Unknown 27 Limb 36 Y None None ? 
S062 SP3301 M 49 Probable ALS ANG 4 Limb 36 Y None Vitamin C/E N 
S063 LP0161 F 53 Probable ALS Unknown 35 Limb 42 N None None ? 
S064 LP0317 M 51 Probable ALS Unknown 15 Bulbar 12 Y None None ? 
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S066 LP0234 M 59 Definite ALS Unknown 41 Limb 41 Y None Multivitamin ? 
S067 SNt0038 F 63 Probable ALS Unknown 27 Limb 40 Y None None ? 
S068 SP3032 M 60 Definite ALS Unknown 38 Limb 34 Y None None ? 
S069 SP3230 M 60 PMA PMA Unknown 53 Limb 41 Y None Vitamin C/E Ex-Smoker 
S070 SP3239 F 62 Probable ALS Unknown 28 Limb 39 Y None None N 
S071 LP0039 F 65 Definite ALS Unknown 35 Bulbar 46 Y None None ? 
S072 BP6058 M 32 Definite ALS Unknown 72 Limb Unknown Y None Vitamin E ? 
S073 BP6051 F 35 Definite ALS Unknown 23 Limb Unknown Y None Vitamin C ? 
S074 BLi0048 M 35 Probable ALS Unknown 82 Limb Unknown Unknown None None ? 
S075 SNt0034 F 42 Probable ALS Unknown 42 Limb 45 Y None None ? 
S076 SP3396 M 55 Definite ALS+EL Unknown 38 Bulbar 25 Y None None Ex-Smoker 
S077 SNc0042 M 57 Definite ALS Unknown 36 Mixed 40 Y None Vitamin C/E ? 
S078 SP3140 F 59 Probable ALS+EL Unknown 18 Limb 28 Y None Vitamin C/E N 
S079 LP0155 F 62 Definite ALS Unknown 8 Bulbar 36 N None None ? 
S080 SP3292 M 75 Probable ALS Unknown 55 Limb 30 N None None N 
S081 SP3355 F 77 Definite ALS+EL Unknown 25 Bulbar 11 Y None Vitamin C/E N 
S082 SP3346 F 84 Definite ALS+EL Unknown 36 Bulbar 31 N None None N 
S083 SP3357 M 85 Definite ALS Unknown 15 Bulbar 28 Y None Vitamin C/E N 
S084 SP3469 M 43 Probable ALS C9ORF72 52 Limb 42 Y None Vitamin C/E N 
S085 BP6032 M 44 Probable ALS Unknown 25 Limb Unknown Y None None ? 
S086 BP6017 F 51 Definite ALS Unknown 32 Limb Unknown Y None None ? 
S087 BBe0009 M 60 Definite ALS Unknown 41 Mixed Unknown discontd None None ? 
S088 SNc0086 M 61 Definite ALS C9ORF72 29 Limb 40 Y None Vitamin C/E ? 
S089 SNc0053 M 62 Definite ALS Unknown 39 Respiratory 21 Y None Vitamin C/E ? 
S090 SP3304 F 65 Probable ALS Unknown 23 Limb 31 Y None None N 
S091 SP3143 F 67 Probable ALS+EL Unknown 23 Bulbar 31 Y None Vitamin C/E N 
S092 SP3310 M 52 Probable ALS Unknown 63 Limb 37 Y None None N 
S093 SP3049 M 53 Definite ALS+FTD Unknown 37 Bulbar 31 Y None None N 
S094 BP6038 F 55 Definite ALS Unknown 17 Bulbar Unknown Y None None ? 
S095 SP3095 M 55 Definite ALS Unknown 26 Limb 27 Y None Vitamin C/E ? 
S096 SNt0001 F 58 Definite ALS Unknown 72 Limb 45 Y None None ? 
S097 SP3306 M 67 Probable ALS Unknown 21 Limb 39 Y None Vitamin C/E N 
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S099 BP6034 M 71 Definite ALS Unknown 29 Limb Unknown Y None Vitamin C/E ? 
S100 LP0097 F 71 Definite ALS Unknown 49 Mixed 20 Y None None ? 
S101 SP3046 M 50 Definite ALS Unknown 32 Limb 13 Y None None ? 
S102 SP3266 M 52 Definite ALS+EL Unknown 37 Limb 44 Y None Vitamin C/E N 
S103 SP3156 F 57 Probable ALS Unknown 38 Limb 39 Y None Vitamin C/E Ex-Smoker 
S104 SP3101 F 57 Probable ALS Unknown 34 Bulbar 30 Y None Vitamin E N 
S105 SNc0018 M 59 PBP PBP Unknown 42 Bulbar 40 Y None Vitamin C/E ? 
S106 SNc0077 M 59 PBP PBP Unknown 24 Bulbar 46 Y None Vitamin C/E ? 
S107 SP3341 F 63 Probable ALS+EL C9ORF72 28 Bulbar 37 Y None None N 
S108 SP3384 M 46 Definite ALS Unknown 22 Mixed 40 Y None Vitamin E N 
S109 SP3414 M 48 Probable ALS Unknown 39 Limb 39 Y None Vitamin C/E N 
S110 SP3298 F 52 Definite ALS C9ORF72 24 Limb 33 Y None None N 
S111 BP6001 F 52 Definite ALS Unknown 40 Limb Unknown Y None None ? 
S112 SP3363 M 70 Definite ALS Unknown 13 Respiratory 25 Y None Vitamin C/E Ex-Smoker 
S113 SP3347 F 71 Probable ALS+D Unknown 49 Limb 42 Y None Vitamin C N 
S114 SP3356 M 72 Definite ALS Unknown 31 Limb 37 Y None Vitamin C/E Ex-Smoker 
S115 SNt0004 M 73 Probable ALS Unknown 32 Limb 37 Y None None ? 
S116 SP3351 M 59 Definite ALS+D Unknown 19 Bulbar 33 Y None Vitamin C/E N 
S117 SP3087 M 60 Probable ALS C9ORF72 31 Limb 45 Y None Vitamin C/E N 
S118 SP3030 M 62 Probable ALS Unknown 64 Limb 38 Y ONO-trial Vitamin C/E N 
S119 SP3073 M 63 Definite ALS+EL Unknown 29 Limb 43 Y None Vitamin C/E N 
S120 SP3409 F 66 Probable ALS Unknown 32 Limb 39 Y None Vitamin C/E N 
S121 SP3420 F 66 Definite ALS+EL C9ORF72 32 Bulbar 39 Y Minocycline None Ex-Smoker 
S122 BBe0014 M 36 Probable ALS Unknown 32 Bulbar Unknown Y None None ? 
S123 BP6021 F 36 Definite ALS C9ORF72 23 Limb Unknown Y None Vitamin C/E ? 
S124 LP0030 M 53 Definite ALS Unknown 24 Limb 45 Y None Vitamin C/E ? 
S125 SP3335 M 53 Probable ALS Unknown 52 Limb 34 Y None Vitamin  C/E N 
S126 SP3079 M 54 Probable ALS Unknown 27 Limb 31 Y None Vitamin C/E Y 
S127 LP0215 F 61 Definite ALS Unknown 23 Bulbar 25 Y None None ? 
S128 LP0222 F 58 Probable ALS Unknown 37 Bulbar 45 Y None None ? 
S129 SNt0024 M 68 PBP PBP Unknown 38 Bulbar 43 Y None Vitamin C/E ? 
S130 SNc0010 M 69 Definite ALS Unknown 36 Limb 33 Y None Vitamin C/E ? 
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S132 SP3413 M 56 Definite ALS C9ORF72 24 Limb 32 Y ONO-trial Vitamin C/E Ex-Smoker 
S133 SP3465 M 58 Definite ALS Unknown 24 Limb 46 Y None Vitamin C/E N 
S134 LP0316 F 62 Definite ALS Unknown 44 Bulbar 23 Y None None ? 
S135 SP3219 F 63 Probable ALS Unknown 19 Limb 0 N None None N 
S136 SP3417 M 39 Probable ALS Unknown 23 Limb 46 Y None None Y 
S137 LP0223 M 44 Definite ALS Unknown 25 Limb 30 Y None None ? 
S138a SNc0016 F 45 Definite ALS Unknown 41 Limb 36 N None None ? 
S138b SNt0017 M 74 Probable ALS Unknown 27 Bulbar 36 Y None None ? 
S139 SP3098 F 74 Probable ALS Unknown 28 Limb 33 Y None Vitamin C/E N 
S140 SNt0020 F 75 Definite ALS Unknown 18 Limb 45 Y None None ? 
S141 SNc0071 F 77 Definite ALS Unknown 29 Limb 22 Y None Vitamin C/E ? 
S142 SP3016 M 79 Probable ALS Unknown 15 Limb 37 Y None None ? 
S143 LP0265 M 83 Probable ALS Unknown 34 Limb 25 N None None ? 
S144 LP0286 F 83 Definite ALS Unknown 25 Bulbar 41 Y None None ? 
S145 SP3065 M 65 Probable ALS Unknown 13 Limb 40 N None None ? 
S146 SP3132 M 66 Probable ALS Unknown 10 Limb 36 Y None None N 
S147 SP3447 M 65 Probable ALS Unknown 43 Bulbar 37 Y None Vitamin E N 
S148 SP3368 F 67 Probable ALS Unknown 36 Limb 39 Y None Vitamin C/E N 
S149 SP3391 F 69 Definite ALS Unknown 29 Limb 36 Y ONO-trial None N 
S150 SP3237 M 24 Definite ALS Unknown 45 Limb 18 Y None None N 
S151 SP3475 M 38 Definite ALS Unknown 32 Mixed 31 Y None None N 
S152 SNc0090 F 39 Definite ALS Unknown 25 Limb 40 Y None Vitamin C/E ? 
S153 SP3423 F 75 Probable ALS+EL Unknown 20 Bulbar 46 Y None None Ex-Smoker 
S154 SP3370 F 81 Probable ALS Unknown 25 Bulbar 44 Y None None N 
S155 SNc0055 M 82 Definite ALS Unknown 80 Limb 36 N None Vitamin C ? 
S156 SNc0029 M 75 Definite ALS Unknown 44 Limb 28 N None None ? 
S157 LP0015 M 53 Definite ALS Unknown 26 Limb 18 Y Minocycline None ? 
S158 SNt0006 M 52 Definite ALS Unknown 47 Bulbar 42 Y None None ? 
S159 BP6042 M 54 Definite ALS Unknown 20 Bulbar Unknown Y None None ? 
S160 BP6039 M 55 Probable ALS Unknown 26 Limb Unknown Y None None ? 
S161 SP3174 F 57 Probable ALS Unknown 36 Limb 44 Y None None Ex-Smoker 
S162 SP3326 M 40 Probable ALS Unknown 51 Limb 45 Y None None N 
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S164 LP0053 M 47 Definite ALS Unknown 20 Mixed 41 Y Minocycline None ? 
S165 SP3222 F 48 PBP PBP C9ORF72 45 Bulbar 0 Y None None N 
S166 SP3082 M 64 Probable ALS Unknown 26 Limb 27 Y None Vitamin E N 
S167 SP3327 F 64 Probable ALS Unknown 31 Limb 40 N None Vitamin C/E N 
S168 LP0001 M 66 Probable ALS Unknown 37 Limb 30 Y ONO-trial Vitamin E ? 
S169 BP6006 F 66 Definite ALS Unknown 12 Limb Unknown Y None Vitamin C ? 
S170 SP3039 F 71 Definite ALS Unknown 26 Bulbar 27 Y None Vitamin C/E N 
S171 SP3058 M 71 Definite ALS C9ORF72 12 Limb 0 Y None Vitamin C/E ? 
S172 SP3067 M 72 Definite ALS Unknown 57 Bulbar 44 Y None None N 
S173 SP3103 F 75 Definite ALS Unknown 10 Limb 14 Y None None N 
S174 LP0005 M 49 Probable ALS Unknown 8 Limb 0 N None None ? 
S175 SP3309 M 49 Probable ALS Unknown 68 Limb 43 Y None Vitamin C/E N 
S176 SP3385 F 52 Definite ALS Unknown 23 Limb 22 Y Copaxone Vitamin C/E N 
S177 BP6045 F 54 Definite ALS Unknown 23 Bulbar Unknown Y None Vitamin C/E ? 
S178 SP3145 M 62 Definite ALS+FTD Unknown 16 Bulbar 36 Y None Vitamin C/E Ex-Smoker 
S179 SP3376 M 62 Probable ALS Unknown 43 Limb 21 Y None None Y 
S180 BP6025 F 64 PBP PBP Unknown 39 Bulbar Unknown Y None None ? 
S181 BLi0039 M 67 Definite ALS Unknown 61 Mixed Unknown Y None None ? 
S182 SNc0008 M 66 Definite ALS Unknown 19 Mixed 38 N None None ? 
S183 LP0069 F 67 Definite ALS Unknown 37 Respiratory 39 Y None None ? 
S184 LP0307 F 67 Probable ALS Unknown 49 Mixed 31 N None None ? 
S185 SP3383 F 69 Definite ALS+EL Unknown 17 Mixed 34 Y None Vitamin C/E N 
S186 SP3431 F 57 Definite ALS+EL C9ORF72 20 Mixed 32 Y None Vitamin C/E N 
S187 LP0104 M 55 Probable ALS Unknown 55 Limb 41 Y None None ? 
S188 LP0055 M 56 Definite ALS Unknown 49 Mixed 31 Y None None ? 
S189 SP3090 M 60 Probable ALS C9ORF72 27 Bulbar 39 Y None None N 
S190 SP3232 F 59 Probable ALS Unknown 47 Limb 37 Y None Vitamin C/E Ex-Smoker 
S191 SP3042 M 59 Probable ALS+FTD C9ORF72 49 Limb 37 Y None Vitamin C/E N 
S192 SP3478 M 59 Probable ALS Unknown 14 Limb 19 Y None None N 
S193 SNc0024 F 62 Definite ALS Unknown 29 Mixed 22 Y None Vitamin C/E ? 
S194 SP3281 M 61 Probable ALS Unknown 35 Limb 43 N None None N 
S195 LP0396 F 63 Probable ALS Unknown 16 Bulbar 41 N None None ? 
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S197 LP0232 M 69 Probable ALS Unknown 23 Limb 45 Y None Vitamin E ? 
S198 SNt0016 M 72 PBP PBP Unknown 82 Bulbar 40 Y None None ? 
S199 LP0176 M 79 Probable ALS Unknown 39 Bulbar 32 Y None None ? 
S200 LP0300 M 40 Probable ALS Unknown 37 Limb 30 Y None None ? 
S201 SP3453 M 44 Probable ALS Unknown 32 Limb 38 Y None None N 
S202 LP0064 M 46 Definite ALS C9ORF72 21 Limb 34 Y None None ? 
S203 SNc0059 F 47 Definite ALS C9ORF72 73 Limb 30 Y ONO-trial Vitamin C/E ? 
S204 LP0037 M 62 Definite ALS Unknown 23 Limb 42 Y None None ? 
S205 SP3433 M 63 Definite ALS+EL C9ORF72 11 Limb 29 Y None None N 
S206 SP3471 M 64 Probable ALS C9ORF72 27 Mixed 41 Y None None Ex-Smoker 
S207 SP3018 F 65 Probable ALS Unknown 33 Bulbar 44 Y None Vitamin C/E N 
S208 SP3078 F 66 Probable ALS Unknown 37 Limb 41 N None None Ex-Smoker 
S209 SNc0012 M 65 Definite ALS Unknown 37 Limb 33 Y None Vitamin C/E ? 
S210 BP6041 M 66 Definite ALS Unknown 32 Bulbar Unknown discontd None None ? 
S211 BP6056 F 69 Probable ALS Unknown 18 Bulbar Unknown Y None None ? 
S212 SNc0002 M 27 Definite ALS Unknown 43 Mixed 23 Y Minocycline Vitamin C/E ? 
S213 LP0207 F 37 Probable ALS C9ORF72 49 Bulbar 45 N None None ? 
S214 SP3037 M 37 Definite ALS Unknown 36 Bulbar 31 Y None Vitamin C/E ? 
S215 SP3187 M 56 Probable ALS Unknown 63 Limb 38 Y None Vitamin C/E Ex-Smoker 
S216 SP3288 M 57 Probable ALS C9ORF72 32 Bulbar 35 Y None Vitamin C/E N 
S217 BP6027 M 59 Definite ALS Unknown 25 Limb Unknown Y None None ? 
S218 SP3379 F 62 Probable ALS Unknown 80 Limb 39 Y None None N 
S219 SNt0036 M 71 Probable ALS Unknown 85 Limb 38 Y None None ? 
S220 SP3105 F 70 Probable ALS+EL Unknown 48 Limb 34 Y None None N 
S221 BP6047 F 71 Definite ALS Unknown 32 Bulbar Unknown Y None Vitamin C/E ? 
S222 SP3464 M 72 Probable ALS Unknown 37 Mixed 40 Y None None N 
S223 SNc0095 M 73 Probable ALS-FA Unknown 54 Limb 40 Y None Vitamin C/E ? 
S224 BP6010 F 74 Definite ALS Unknown 22 Bulbar Unknown Y None None ? 
S225 SNc0092 F 53 PBP PBP Unknown 21 Bulbar 24 discontd None None ? 
S226 LP0127 M 54 Probable ALS Unknown 43 Limb 45 Y None None ? 
S227 SP3043 M 54 Definite ALS Unknown 21 Bulbar 41 N None Vitamin C/E N 
S228 BP6030 M 57 Definite ALS Unknown 29 Limb Unknown Y None None ? 







 Table B3: Clinical Information Relating to Sporadic LCL’s in the ECACC Discovery Cohort 
 416 
 
S230 SP3159 F 75 PBP PBP+EL Unknown 27 Bulbar 44 Y None Vitamin C/E N 
S231 LP0397 M 81 Probable ALS Unknown 19 Bulbar 39 N None None ? 
S232 SNc0051 F 81 PBP PBP Unknown 47 Bulbar 19 N None None ? 
S233 LP0139 M 86 Definite ALS Unknown 12 Limb 0 N None None ? 
S234 SP3060 M 70 Definite ALS Unknown 15 Limb 19 Y None Vitamin E N 
S235 SP3243 M 69 Probable ALS Unknown 18 Respiratory 31 Y None None Ex-Smoker 
S236 SP3286 F 70 Definite ALS+EL Unknown 35 Limb 36 Y None Vitamin C/E N 
S237 BP6008 M 47 Definite ALS Unknown 31 Bulbar Unknown Y ONO-trial Vitamin E ? 
S238 LP0238 M 49 Probable ALS Unknown 30 Bulbar 41 Y None None ? 
S239 BP6049 F 54 Probable ALS Unknown 38 Mixed Unknown Y None Multivitamin ? 
S240 SNt0030 M 52 Probable ALS Unknown 55 Limb 38 discontd None None ? 
S241 BP6015 M 59 Definite ALS Unknown 27 Limb Unknown Y None None ? 
S242 SP3428 M 61 Definite ALS Unknown 27 Bulbar 30 Y None Vitamin C/E N 
S243 SP3010 F 61 Definite ALS C9ORF72 43 Bulbar 8 Y None None ? 
S244 BP6052 F 63 Probable ALS Unknown 25 Bulbar Unknown Y None None ? 
S245 LP0116 F 67 Probable ALS Unknown 13 Limb 35 Y None None ? 
S246 SP3393 M 65 Probable ALS Unknown 18 Limb 41 Y None None N 
S247 SP3353 F 58 Probable ALS Unknown 47 Limb 33 Y None Vitamin C/E Y 
S248 BBe0003 F 60 Definite ALS Unknown 47 Bulbar Unknown Y None None ? 
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 Table B4: Review of ALS Phase II/III Clinical Drug Trials (ClinicalTrials.gov) (U.S. National Library of Medicine, Bethesda)     
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Abbreviations: Ab - antibody, ALS - Amyotrophic Lateral Sclerosis, BDNF - brain derived neurotrophic factor, FRS-R - Functional Rating Scale Revised, FVC - forced vital capacity, GI - 
gastrointestinal, iNOS - inducible nitric oxide synthase, LiC - lithium carbonate, MN - motor neuron, MND - Motor Neurone Disease, MS - Multiple Sclerosis, N/A - not available, 
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ID ECACC Sex Age  ID ECACC Sex Age  ID ECACC Sex Age  ID ECACC Sex Age  ID ECACC Sex Age 
C101 LNh0053 M 51  C121 SC3734 F 40  C141 LC0414 M 35  C161 BC6084 F 57  C181 BC6162 F 77 
C102 SNc0201 F 52  C122 LPo0087 M 47  C142 LRo0025 M 38  C162 BLi0198 M 61  C182 SC3754 M 44 
C103 LC0162 M 59  C123 LRo0009 F 48  C143 SC3117 M 54  C163 SMa0054 F 48  C183 BC6416 M 51 
C104 SPr0016 M 73  C124 SMa0227 M 52  C144 SNc0078 F 56  C164 SC3571 M 50  C184 LC0290 M 56 
C105 LC0538 F 74  C125 LPy0011 F 55  C145 SC3425 M 57  C165 LC0095 F 71  C185 BLi0240 M 58 
C106 BC6048 M 77  C126 SC3386 M 57  C146 SNc0167 M 60  C166 SC3142 M 72  C186 LC0220 F 58 
C107 BC6434 F 80  C127 BM6403 F 59  C147 BC6043 F 61  C167 SMa0203 M 75  C187 SC3175 M 61 
C108 BC6428 M 62  C128 LC0441 M 60  C148 BLi0259 M 63  C168 BC6426 M 80  C188 BLi0074 M 64 
C109 SNc0158 F 63  C129 LC0521 M 62  C149 LC0045 M 65  C169 BC6274 F 63  C189 LCa0093 F 66 
C110 BOx0008 M 64  C130 BLi0105 F 65  C150 BBr0020 F 66  C170 SMa0232 M 63  C190 LCa0134 M 66 
C111 SMa0096 M 56  C131 SC3097 M 64  C151 SMa0050 F 67  C171 SMa0133 M 65  C191 LC0241 M 69 
C112 SC3170 F 58  C132 SC3141 M 67  C152 SC3533 M 69  C172 BC6511 F 66  C192 LC0394 M 70 
C113 LC0370 M 69  C133 SMa0009 F 67  C153 BBe0002 F 71  C173 LRf0012 M 68  C193 SC3178 M 71 
C114 SC3403 F 69  C134 LNh0073 M 69  C154 BC6067 M 71  C174 BC6525 M 70  C194 SMa0013 M 73 
C115 LC0459 M 70  C135 SNc0125 F 69  C155 LC0478 M 72  C175 BLi0021 M 71  C195 BLi0204 F 73 
C116 SC3305 M 71  C136 SC3780 M 70  C156 SC3248 M 75  C176 LC0329 F 52  C196 BC6196 M 76 
C117 BLi0224 F 36  C137 BC6238 M 72  C157 SNc0015 F 75  C177 SNt0075 M 57  C197 SDu0009 F 79 
C118 LC0466 M 46  C138 BC6170 M 74  C158 SC3040 M 78  C178 SC3283 M 41  C198 BC6200 F 69 
C119 LPo0059 M 66  C139 SMa0188 F 74  C159 LC0457 M 49  C179 LC0514 M 55  C199 SC3343 M 83 
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ID ECACC Sex Age EEC Diagnosis Genotype Survival Presentation ALSFRS-R Riluzole Meds Other Supplements Smoking 
S250 SP3375 M 46 Probable ALS Unknown Unknown Limb 46 Y None Vitamin C/E N 
S251 LP0077 M 47 Probable ALS Unknown 28 Limb 46 N None None ? 
S252 BP6185 M 49 Probable ALS Unknown Unknown Limb Unknown Y None Multivitamin ? 
S253 BP6180 F 50 Probable ALS Unknown 24 Limb Unknown Y Minocycline Vitamin E ? 
S254 LP0036 M 51 Definite ALS Unknown 32 Bulbar 38 Y None None ? 
S255 SP3388 F 51 Probable ALS Unknown Unknown Limb 34 Y None None N 
S256 LP0244 M 56 Definite ALS Unknown 34 Limb 42 Y None None ? 
S257 SP3394 M 56 Probable ALS Unknown 45 Mixed 32 Y None Vitamin C/E Y 
S258 BP6230 F 58 Definite ALS Unknown 21 Limb Unknown Y None Vitamin E ? 
S259 LNh0062 M 59 Probable ALS Unknown Unknown Bulbar 45 Y None None ? 
S260 SP3161 M 58 Probable ALS Unknown 32 Bulbar 27 discontd None Vitamin C/E ? 
S261 BP6163 F 60 Probable ALS Unknown 109 Limb Unknown Y None None ? 
S262 BP6273 M 61 Probable ALS Unknown 66 Limb Unknown Y None None ? 
S263 LP0407 F 73 Probable ALS Unknown 58 Limb 42 Y None None ? 
S264 LNh0049 M 75 Definite ALS Unknown 45 Limb 40 Y None None ? 
S265 BP6226 M 77 Definite ALS Unknown 74 Limb Unknown Y None None ? 
S266 BP6155 F 78 Probable ALS Unknown 40 Bulbar Unknown N None Vitamin C ? 
S267 SP3100 F 61 Probable ALS Unknown Unknown Limb 46 Y None None ? 
S268 BP6107 M 62 Probable ALS C9ORF72 21 Limb Unknown Y None Multivitamin ? 
S269 BP6262 M 61 Probable ALS Unknown 42 Limb Unknown Y None Vitamin E ? 
S270 SP3350 M 61 Probable ALS Unknown 95 Limb 32 N None None N 
S271 BP6345 F 64 Probable ALS Unknown 34 Bulbar Unknown Y None None ? 
S272 SP3253 M 52 PBP PBP Unknown Unknown Bulbar 37 Y None None N 
S273 LP0401 M 53 Probable ALS Unknown 66 Limb 0 Y None None ? 
S274 SNt0008 M 52 Definite ALS Unknown Unknown Limb 45 Y None None ? 
S275 LP0067 F 55 Definite ALS Unknown 24 Limb 43 Y None None ? 
S276 LP0066 F 56 Definite ALS Unknown 40 Limb 43 N None None ? 
S277 SP3267 M 55 Probable ALS Unknown 67 Limb 42 Y None None Y 
S278 BP6159 F 69 Probable ALS Unknown Unknown Limb Unknown Y None Vitamin C/E ? 
S279 BP6079 M 69 Definite ALS Unknown 25 Limb Unknown Y None None ? 
S280 BP6291 M 69 Probable ALS Unknown 13 Mixed Unknown Y None None ? 
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S282 LP0439 F 35 Probable ALS Unknown 76 Limb 38 Y None None ? 
S283 BP6096 M 35 Definite ALS Unknown 59 Limb Unknown Y None Vitamin C/E ? 
S284 SP3069 M 38 Probable ALS Unknown Unknown Limb 46 Y None Vitamin C/E N 
S285 LP0221 M 42 Definite ALS Unknown 72 Bulbar 41 Y None Vitamin C/E ? 
S286 SP3435 M 43 Definite ALS Unknown Unknown Limb 43 Y None None Y 
S287 BP6208 F 46 Definite ALS C9ORF72 36 Bulbar Unknown Y None None ? 
S288 LP0323 F 63 Probable ALS Unknown 57 Limb 45 N None Multivitamin ? 
S289 LPo0003 M 63 Definite ALS Unknown 41 Limb 19 N None None ? 
S290 LNh0040 M 65 Probable ALS C9ORF72 43 Limb 36 N None None ? 
S291 BP6098 M 66 Definite ALS C9ORF72 36 Limb Unknown Y None None ? 
S292 BP6361 M 66 Probable ALS Unknown 29 Limb Unknown Y None None ? 
S293 SP3302 M 67 Probable ALS Unknown 79 Limb 43 N None None N 
S294 BP6285 M 67 Definite ALS Unknown 38 Limb Unknown Y None Multivitamin ? 
S295 BP6357 M 75 Probable ALS Unknown 31 Limb Unknown Y None None ? 
S296 BP6369 F 67 Definite ALS Unknown 23 Bulbar Unknown discontd None None ? 
S297 LP0448 M 58 Definite ALS Unknown 22 Bulbar 29 Y None Vitamin E ? 
S298 LPo0001 M 72 Probable ALS Unknown Alive Limb 0 Y None None ? 
S299 SNc0028 F 73 PBP PBP Unknown 91 Bulbar 44 Y None Vitamin C/E ? 
S300 LNh0020 M 31 Probable ALS Unknown Alive Limb Unknown Y None Vitamin C ? 
S301 SP3402 F 32 PLS PLS Unknown Unknown Limb 15 Y None Vitamin E N 
S302 LP0260 M 39 Definite ALS Unknown 32 Limb 40 Y None None ? 
S303 BP6181 M 43 Definite ALS Unknown 94 Limb Unknown Y None Vitamin C/E ? 
S304 LP0400 M 42 Probable ALS Unknown Alive Limb 42 Y None None ? 
S305 SNc0043 F 45 Definite ALS Unknown 83 Limb 41 discontd None Vitamin C/E ? 
S306 SP3439 M 46 Definite ALS Unknown Unknown Limb 41 Y None None N 
S307 LNh0048 M 48 Definite ALS Unknown 28 Limb 16 Y None None ? 
S308 BP6328 M 50 PBP PBP Unknown Unknown Bulbar Unknown Y None None ? 
S309 BP6363 F 50 Probable ALS C9ORF72 45 Limb Unknown Y None Vitamin E ? 
S310 LNh0018 F 51 Definite ALS Unknown 20 Mixed Unknown Y None None ? 
S311 LP0086 M 52 Probable ALS Unknown Alive Limb 48 Y None Vitamin E ? 
S312 LP0199 M 52 Definite ALS Unknown 17 Limb 46 Y None None ? 
S313 BP6236 M 53 Definite ALS Unknown Unknown Bulbar Unknown Y None None ? 
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S315 LP0403 F 53 Probable ALS Unknown 56 Bulbar 42 Y None None ? 
S316 SP3332 M 53 Probable ALS Unknown 60 Limb 46 Y None Vitamin C/E N 
S317 LP0132 M 54 Probable ALS Unknown 28 Limb 27 Y None Vitamin E ? 
S318 LP0522 M 56 Probable ALS Unknown 28 Mixed 2 Y None None ? 
S319 LP0203 F 57 Definite ALS C9ORF72 24 Bulbar 44 Y None Multivitamin ? 
S320 BP6171 F 58 Probable ALS Unknown 46 Mixed Unknown Y None None ? 
S321 LP0003 M 59 Probable ALS Unknown Alive Limb 37 Y None Multivitamin ? 
S322 LSh0002 M 58 Probable ALS C9ORF72 30 Limb 39 Y None None ? 
S323 LP0308 M 59 Definite ALS Unknown 18 Bulbar 32 Y None None ? 
S324 SP3421 M 59 Probable ALS+EL Unknown Unknown Bulbar 45 Y None None Y 
S325 LP0248 F 61 Definite ALS C9ORF72 25 Bulbar 36 Y None None ? 
S326 LSh0016 F 60 Probable ALS Unknown Alive Bulbar 39 Y None None ? 
S327 SDu0001 M 62 Probable ALS Unknown 53 Limb 39 Y None Vitamin C ? 
S328 BP6070 M 63 Definite ALS Unknown 37 Bulbar Unknown Y None Vitamin E ? 
S329 BP6256 M 65 Probable ALS Unknown 44 Unknown Unknown Y None None ? 
S330 SP3311 F 63 Definite ALS Unknown Unknown Bulbar 45 Y None None N 
S331 BP6268 M 65 Definite ALS Unknown 19 Limb Unknown Y None None ? 
S332 BP6305 M 65 Probable ALS Unknown 110 Limb Unknown Y None None ? 
S333 LP0432 F 66 Probable ALS Unknown 29 Respiratory 45 Y Copaxone® Vitamin E ? 
S334 LP0442 M 65 Definite ALS Unknown Alive Limb 44 Y None None ? 
S335 SP3387 M 65 Definite ALS Unknown Unknown Limb 26 Y None Vitamin C/E N 
S336 BP6116 M 66 Probable ALS Unknown 57 Limb Unknown N None None ? 
S337 LP0012 M 67 Probable ALS Unknown 42 Limb 0 Y None None ? 
S338 LP0338 F 68 Probable ALS Unknown 39 Bulbar 48 discontd None None ? 
S339 BP6294 M 69 Definite ALS Unknown 18 Limb Unknown Y None None ? 
S340 LP0458 F 69 Probable ALS Unknown 24 Bulbar 43 Y None None ? 
S341 BP6175 M 70 Definite ALS Unknown 19 Bulbar Unknown Y None None ? 
S342 BP6275 M 71 Probable ALS Unknown Unknown Limb Unknown Y None Multivitamin ? 
S343 LP0330 F 71 Probable ALS Unknown 30 Mixed 22 Y None None ? 
S344 LNh0065 M 73 Definite ALS Unknown 55 Bulbar 37 Y None None ? 
S345 BP6320 M 75 Probable ALS Unknown 90 Limb Unknown Y None None ? 
S346 LPo0016 M 75 Definite ALS Unknown 45 Limb 32 Y None Multivitamin ? 
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S348 BP6177 F 82 Definite ALS Unknown 23 Bulbar Unknown N None None ? 
S349 BP6100 M 70 PBP PBP Unknown 82 Bulbar Unknown Y None None ? 
S350 LP0210 M 35 Probable ALS Unknown 33 Limb 41 Y None None ? 
S351 LP0451 M 37 Definite ALS Unknown Alive Limb 31 Y None None ? 
S352 SP3484 F 37 Probable ALS C9ORF72-TARDBP 57 Limb 42 Y None Vitamin E N 
S353 BP6075 M 43 Probable ALS Unknown 70 Limb Unknown Y None Vitamin C ? 
S354 BP6215 M 45 Probable ALS Unknown 51 Limb Unknown Y None Vitamin C/E ? 
S355 SP3031 F 47 Definite ALS Unknown Unknown Bulbar 38 Y None None N 
S356 LP0413 M 46 Probable ALS Unknown 54 Limb 44 N None Multivitamin ? 
S357 LP0331 M 48 Definite ALS Unknown 47 Bulbar 42 discontd None None ? 
S358 LP0321 M 50 Definite ALS Unknown 105 Mixed 26 Y None None ? 
S359 SNt0012 F 49 PBP PBP Unknown Unknown Bulbar 35 N None Multivitamin ? 
S360 BP6136 M 52 Probable ALS Unknown 27 Limb Unknown Y None Vitamin C/E ? 
S361 BP6266 M 52 Probable ALS Unknown 60 Limb Unknown Y None None ? 
S362 LPo0019 F 53 Probable ALS Unknown 27 Limb 36 discontd None None ? 
S363 BP6355 M 52 Definite ALS Unknown 34 Limb Unknown Y None None ? 
S364 LP0373 M 52 Definite ALS Unknown 37 Limb 40 N None None ? 
S365 BP6348 M 55 Probable ALS Unknown Unknown Limb Unknown N None None ? 
S366 LP0427 F 55 Probable ALS Unknown 54 Limb 44 N None None ? 
S367 BP6233 F 56 Probable ALS Unknown 62 Limb Unknown Y None None ? 
S368 LP0454 M 56 Probable ALS C9ORF72 28 Bulbar 43 Y None None ? 
S369 BP6197 F 58 Probable ALS Unknown 18 Bulbar Unknown Y None Vitamin C/E ? 
S370 LP0350 M 59 Definite ALS Unknown 26 Mixed 39 Y None None ? 
S371 BP6087 M 60 Probable ALS Unknown 44 Limb Unknown Y None None ? 
S372 LP0339 F 60 Probable ALS Unknown 43 Bulbar 43 Y None None ? 
S373 LP0359 M 61 Probable ALS C9ORF72 47 Mixed 35 Y None None ? 
S374 LP0395 M 62 Definite ALS Unknown 44 Limb 39 Y None Multivitamin ? 
S375 BP6120 F 64 Probable ALS Unknown 21 Limb Unknown N None None ? 
S376 BP6131 M 63 Probable ALS Unknown 67 Limb Unknown Y None Multivitamin ? 
S377 BP6289 M 64 Probable ALS Unknown 19 Limb Unknown Y None None ? 
S378 LP0280 M 64 Probable ALS Unknown 45 Limb 0 Y None None ? 
S379 SP3212 F 64 Definite ALS Unknown Unknown Limb 0 N None None N 
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S381 BP6240 M 87 Probable ALS Unknown 59 Limb Unknown Y None Vitamin C/E ? 
S382 LP0062 F 66 Probable ALS Unknown 38 Limb 42 Y None None ? 
S383 LPo0018 F 67 Definite ALS Unknown 39 Limb 37 Y None None ? 
S384 BP6343 M 68 Definite ALS Unknown 27 Bulbar Unknown Y None None ? 
S385 LP0063 M 68 Definite ALS Unknown 29 Respiratory 28 Y None None ? 
S386 LP0131 M 68 Probable ALS Unknown 30 Limb 31 N None Multivitamin ? 
S387 BP6224 M 69 Probable ALS Unknown 17 Mixed Unknown Y None None ? 
S388 BP6199 M 72 Probable ALS Unknown 31 Limb Unknown Unknown Unknown Unknown ? 
S389 BP6137 F 72 Definite ALS Unknown 24 Bulbar Unknown Y None None ? 
S390 LP0431 F 75 Probable ALS Unknown 49 Mixed 32 Y None None ? 
S391 BP6161 M 76 Probable ALS Unknown Unknown Limb Unknown Y None None ? 
S392 BP6324 M 81 Probable ALS Unknown Unknown Limb Unknown Y None None ? 
S393 BP6250 F 83 Probable ALS Unknown 28 Bulbar Unknown Y None None ? 
S394 LPo0009 M 57 Definite ALS Unknown 12 Limb 46 Y None None ? 
S395 LP0109 M 59 Probable ALS Unknown Alive Unknown 44 Y None None ? 
S396 BP6259 M 69 Probable ALS Unknown 37 Limb Unknown Y None None ? 
S397 LPo0047 F 68 Probable ALS Unknown 33 Bulbar 31 Y None None ? 
S398 BP6202 M 70 Probable ALS Unknown 52 Unknown Unknown Y None None ? 
S399 LP0040 M 76 Probable ALS Unknown 48 Limb 43 Y None None ? 
S400 BP6083 M 56 Probable ALS Unknown 78 Limb Unknown Y None None ? 
S401 BP6184 M 56 Probable ALS Unknown 36 Limb Unknown Y None Multivitamin ? 
S402 BP6307 F 58 Probable ALS Unknown 18 Bulbar Unknown N None None ? 
S403 BP6331 M 58 Probable ALS Unknown 32 Bulbar Unknown Y None None ? 
S404 LP0173 M 59 Definite ALS Unknown 71 Limb 45 Y None None ? 
S405 LSh0028 M 59 Probable ALS Unknown 45 Limb 41 Y None None ? 
S406 BP6153 F 62 Probable ALS Unknown 13 Mixed Unknown Y None None ? 
S407 SNt0042 M 35 Definite ALS Unknown 17 Limb 29 N None None ? 
S408 LP0082 M 40 Probable ALS Unknown 70 Limb 41 N None None ? 
S409 LP0227 F 44 Definite ALS Unknown 65 Limb 40 Y None None ? 
S410 BP6088 M 44 Probable ALS Unknown 29 Limb Unknown Y None Vitamin C/E ? 
S411 LP0281 M 44 Probable ALS Unknown 30 Limb 40 Y None None ? 
S412 SP3147 F 47 Probable ALS TARDBP 115 Limb 31 Y None None N 
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S414 LP0313 M 70 Definite ALS Unknown 61 Limb 40 Y None Multivitamin ? 
S415 BP6283 M 72 Definite ALS Unknown 69 Limb Unknown Y None None ? 
S416 LP0028 F 83 Definite ALS Unknown 32 Bulbar 33 N None None ? 
S417 BP6064 M 62 Probable ALS Unknown Unknown Limb Unknown Y None None ? 
S418 SP3194 M 64 Probable ALS+EL Unknown Unknown Limb 21 Y None None Ex-Smoker 
S419 LP0206 F 64 Definite ALS Unknown 5 Bulbar 44 Y None None ? 
S420 SNc0057 M 65 Definite ALS Unknown 123 Limb 41 Y None Vitamin C/E ? 
S421 BP6314 M 66 Definite ALS Unknown 24 Limb Unknown Y None None ? 
S422 LP0071 F 66 Probable ALS Unknown 29 Mixed 0 Y None None ? 
S423 LP0384 M 67 Probable ALS Unknown 50 Limb 36 Y None None ? 
S424 BP6174 F 69 Probable ALS Unknown Unknown Limb Unknown Y None None ? 
S425 BP6228 M 70 Probable ALS Unknown 22 Unknown Unknown Unknown Unknown Unknown ? 
S426 BP6279 M 51 Definite ALS Unknown 24 Limb Unknown Y None None ? 
S427 SNt0021 F 51 Probable ALS Unknown 17 Limb 40 Y None None ? 
S428 BP6299 F 54 Probable ALS Unknown 20 Limb Unknown Y None Vitamin E ? 
S429 LPo0039 M 53 Probable ALS Unknown 17 Mixed 34 Y None None ? 
S430 BP6270 M 54 Probable ALS Unknown Unknown Limb Unknown Y None Vitamin C/E ? 
S431 BP6190 M 55 Definite ALS Unknown 16 Bulbar Unknown Y None Vitamin C/E ? 
S432 BBe0015 M 45 Probable ALS Unknown Unknown Limb Unknown Y None None ? 
S433 BP6353 M 46 Probable ALS Unknown 70 Limb Unknown Y None Vitamin C ? 
S434 BP6306 M 51 Probable ALS Unknown Unknown Limb Unknown Y None None ? 
S435 BP6349 F 56 Probable ALS Unknown 25 Bulbar Unknown Y None None ? 
S436 BP6142 M 60 Probable ALS Unknown 28 Mixed Unknown Y None Multivitamin ? 
S437 LP0355 F 61 Definite ALS Unknown Unknown Limb 40 Y None None ? 
S438 LP0411 M 62 Probable ALS C9ORF72 12 Limb 34 Y None None ? 
S439 BP6090 M 64 Probable ALS Unknown 117 Unknown Unknown N None None ? 
S440 BP6297 M 65 Definite ALS C9ORF72 15 Limb Unknown discontd None None ? 
S441 LP0119 F 64 Definite ALS Unknown 29 Bulbar 30 N None None ? 
S442 SP3261 M 66 Probable ALS Unknown Unknown Limb 35 Y None None N 
S443 BP6239 F 67 Definite ALS Unknown 38 Limb Unknown Y None None ? 
S444 LP0349 M 68 Probable ALS Unknown 78 Limb 17 Y None Vitamin C/E ? 
S445 SP3407 M 69 Probable ALS Unknown 64 Limb 43 Y None None N 
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S447 BP6347 M 76 Probable ALS Unknown 19 Limb Unknown Y None None ? 
S448 LP0078 F 78 Probable ALS Unknown 31 Bulbar 38 N None None ? 
S449 BP6352 M 81 Probable ALS Unknown Unknown Respiratory Unknown N None None ? 
S450 LP0014 M 31 Probable ALS Unknown 40 Limb Unknown Y Novartis-trial None ? 
S451 BP6134 M 37 Definite ALS Unknown 55 Limb Unknown Y None Vitamin C/E ? 
S452 LP0195 M 41 Probable ALS Unknown Alive Limb 0 Y None None ? 
S453 LP0380 M 43 Probable ALS Unknown Alive Limb 43 Y None None ? 
S454 LP0364 M 44 Probable ALS Unknown Alive Limb 43 Y None None ? 
S455 BP6152 F 45 Definite ALS+PD Unknown 27 Mixed Unknown Y None None ? 
S456 SPr0001 M 49 Definite ALS Unknown 49 Bulbar 32 Y ONO-trial Vitamin E ? 
S457 LNh0016 M 50 Probable ALS Unknown 72 Limb Unknown Y None None ? 
S458 BP6085 F 50 Probable ALS Unknown 56 Limb Unknown Y None Vitamin C ? 
S459 BP6364 M 50 Probable ALS Unknown 53 Limb Unknown Y None None ? 
S460 BP6167 F 51 Probable ALS Unknown 27 Bulbar Unknown Y None None ? 
S461 SP3107 M 51 Probable ALS TARDBP 77 Limb 43 Y None Vitamin C/E Y 
S462 BP6094 F 54 Probable ALS C9ORF72 31 Limb Unknown Y None Vitamin C/E ? 
S463 SNt0013 F 54 Probable ALS Unknown 77 Bulbar 42 Y None Vitamin C/E ? 
S464 SNt0040 M 55 Definite ALS Unknown 38 Mixed 38 Y None None ? 
S465 SP3226 M 55 Probable ALS Unknown 33 Limb 0 N None None ? 
S466 SNc0020 M 55 Probable ALS Unknown 98 Bulbar 35 N None None ? 
S467 SP3198 M 56 Probable ALS-FA Unknown Unknown Limb 0 Y None None Ex-Smoker 
S468 BP6360 M 57 Probable ALS Unknown 31 Limb Unknown Y None None ? 
S469 BP6277 M 59 Definite ALS Unknown 35 Limb Unknown Y None Vitamin C/E ? 
S470 BP6122 M 60 Probable ALS Unknown 55 Bulbar Unknown Y None None ? 
S471 LP0382 M 59 Probable ALS Unknown 68 Limb 46 Y None None ? 
S472 BP6310 M 61 Probable ALS Unknown 81 Limb Unknown Y None None ? 
S473 LSh0004 M 61 Definite ALS Unknown 73 Bulbar 36 Y None None ? 
S474 LP0366 F 61 Definite ALS Unknown 53 Mixed 0 N None None ? 
S475 BP6264 F 63 Probable ALS Unknown 41 Limb Unknown Y None None ? 
S476 SDu0005 M 64 Probable ALS Unknown 18 Bulbar 36 Y None None ? 
S477 LP0208 F 65 Probable ALS Unknown 38 Limb 30 Y None None ? 
S478 LP0126 M 66 Definite ALS Unknown 17 Mixed 42 Y None None ? 
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S480 BP6278 M 67 Probable ALS Unknown 90 Limb Unknown Y None None ? 
S481 BP6292 M 66 Probable ALS Unknown 95 Limb Unknown Y None None ? 
S482 SP3367 M 67 Definite ALS Unknown Unknown Limb 37 N None None N 
S483 BP6252 M 68 Probable ALS Unknown 27 Respiratory Unknown Y None None ? 
S484 BP6269 F 67 Probable ALS Unknown 25 Mixed Unknown Y None None ? 
S485 LPo0005 M 68 Probable ALS C9ORF72 47 Bulbar 0 Y None None ? 
S486 SP3229 M 68 Probable ALS Unknown Unknown Limb 22 Y None None ? 
S487 LP0398 M 70 Probable ALS Unknown 20 Bulbar 41 N None None ? 
S488 BP6191 F 72 Probable ALS Unknown 23 Limb Unknown Y None Vitamin C ? 
S489 LPo0017 M 74 Probable ALS Unknown 17 Limb 34 Y None None ? 
S490 LP0312 F 75 Probable ALS Unknown 61 Limb 27 N None None ? 
S491 SP3344 M 75 Definite ALS Unknown 69 Limb 38 Y None None N 
S492 SNt0019 M 76 Definite ALS Unknown 106 Bulbar 30 Y None None ? 
S493 BP6321 M 82 Probable ALS Unknown 17 Bulbar Unknown Y None None ? 
S494 BP6172 F 59 Probable ALS Unknown 40 Bulbar Unknown Y None None ? 
S495 BP6316 M 66 Probable ALS Unknown 39 Limb Unknown N None Multivitamin ? 
S496 BP6350 F 68 Probable ALS Unknown 34 Limb Unknown Y None None ? 
S497 SP3234 F 79 PLS PLS Unknown 16 Limb 0 Y None None N 
S498 BP6326 M 53 Probable ALS Unknown 13 Bulbar Unknown Y None None ? 
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Sample Collection Extraction 260/280 260/230 RNA (ng/μl) RIN Amplification as-cRNA (ng/μl) ss-cDNA (ng/μl) Frag/Lab Scan Date GeneChip® 
C001 13/06/08 29/11/11 2.02 1.12 203.21 9.2 13/03/13 1049.94 278.81 03/04/13 23/04/13 LOT4188786 
C002 21/12/10 01/12/11 2.02 1.43 120.40 8.7 07/12/12 1710.48 331.49 08/04/13 30/04/13 LOT4187458 
C003 13/10/10 02/12/11 2.03 0.42 121.96 poor 26/03/13 2280.46 300.88 24/07/13 15/08/13 LOT4205079 
C004 25/04/07 02/12/11 2.08 0.74 150.47 9.9 26/10/12 896.68 211.87 ? 16/01/13 LOT4181223 
C005 22/05/07 05/12/11 2.02 1.74 103.67 9.4 15/11/12 1446.52 262.65 ? 29/01/13 LOT4181223 
C006 17/04/07 05/12/11 1.99 1.85 112.12 8.5 16/03/12 1007.90 237.31 25/04/12 02/05/12 LOT4156426 
C007 17/05/06 06/12/11 2.03 2.33 152.45 OK 24/10/12 724.60 218.01 ? 30/01/13 LOT4184161 
C008 28/01/09 06/12/11 2.00 2.33 150.16 poor 26/10/12 1249.30 245.70 ? 30/01/13 LOT4184161 
C009 04/04/08 06/12/11 1.91 2.00 48.85 6.5 20/03/13 1585.73 283.33 05/06/13 31/07/13 LOT4205079 
C010 28/05/08 07/12/11 2.01 1.07 117.04 7.7 25/04/13 2560.20 286.43 27/04/13 22/05/13 LOT4181871 
C011 15/06/06 07/12/11 2.05 2.00 91.10 9.3 07/12/12 2243.90 282.64 02/04/13 23/04/13 LOT4188786 
C012 02/04/08 07/12/11 1.84 0.60 30.76 7.0 22/03/13 1337.98 245.98 11/06/13 18/07/13 LOT4188786 
C013 06/02/09 08/12/11 2.01 1.86 141.51 7.0 19/03/13 1744.27 268.43 20/03/13 10/04/13 LOT4181871 
C014 06/03/07 08/12/11 2.06 0.56 160.91 9.1 07/05/13 2267.51 265.04 14/05/13 18/07/13 LOT4188786 
C015 10/06/09 08/12/11 1.98 0.83 67.52 8.3 30/04/13 1559.62 267.09 17/06/13 30/07/13 LOT4181223 
C016 06/03/08 08/12/11 2.02 1.96 195.38 7.5 15/11/12 1370.07 266.72 ? 29/01/13 LOT4181223 
C017 25/01/07 09/12/11 1.98 2.42 164.98 7.2 05/12/12 1411.07 255.17 02/04/13 24/04/13 LOT4187458 
C018 26/02/08 09/12/11 2.06 0.97 106.69 8.9 13/03/13 2198.64 274.72 03/04/13 24/04/13 LOT4187458 
C019 17/04/08 09/12/11 2.03 1.60 113.88 9.8 05/12/12 2343.48 275.36 26/03/13 12/04/13 LOT4181871 
C020 27/10/07 18/04/12 2.00 2.15 167.74 7.0 07/11/12 747.17 215.39 ? 06/02/13 LOT4181871 
C021 03/11/08 13/12/11 2.01 2.49 173.37 8.3 03/04/12 2156.61 311.82 26/04/12 03/05/12 LOT4156426 
C022 10/12/10 13/12/11 1.97 2.70 81.46 7.0 28/11/12 949.07 370.68 26/03/13 25/04/13 LOT4187458 
C023 17/07/10 14/12/11 1.97 1.60 148.86 7.8 22/03/13 2697.84 301.09 05/06/13 31/07/13 LOT4205079 
C024 14/07/05 14/12/11 2.06 2.09 158.63 9.7 14/03/13 2124.93 285.46 26/03/13 24/04/13 LOT4187458 
C025 17/02/11 15/12/11 2.02 2.56 149.47 9.3 20/03/13 2990.10 296.13 17/06/13 23/07/13 LOT4188786 
C026 23/05/07 15/12/11 2.03 1.79 223.37 9.4 03/04/12 2541.23 267.16 25/04/12 02/05/12 LOT4156426 
C027 28/10/05 16/12/11 1.95 1.76 183.78 9.5 28/11/12 2125.91 286.02 03/04/13 23/04/13 - 
C028 08/11/07 16/12/11 2.04 2.35 112.66 9.3 22/03/13 2290.58 277.15 17/06/13 02/07/13 LOT4181871 
C029 25/05/05 19/12/11 2.02 1.47 171.39 9.6 28/11/12 2238.83 277.64 26/03/13 23/04/13 LOT4188786 
C030 29/07/09 19/12/11 2.03 1.21 143.87 9.3 26/03/13 2463.98 288.94 29/07/13 15/08/13 LOT4205079 
C031 06/11/10 19/12/11 1.99 1.95 118.13 9.7 23/03/12 1142.49 221.59 26/04/12 01/05/12 LOT4153111 
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C033 21/01/11 20/12/11 2.00 0.71 64.94 5.2 22/03/13 1841.56 244.33 ------------------- FAILED ------------------- 
C034 26/08/05 20/12/11 2.01 3.15 62.10 9.4 16/04/13 1974.66 270.30 24/04/13 22/05/13 LOT4181871 
C035 22/01/04 20/12/11 2.01 1.18 151.19 8.9 26/10/12 1023.09 243.60 ? 05/02/13 LOT4184161 
C036 22/02/10 21/12/11 2.04 1.81 153.13 9.5 09/03/12 682.30 226.04 25/04/12 01/05/12 LOT4153111 
C037 19/02/09 21/12/11 2.05 0.95 138.30 9.6 12/04/12 868.78 249.42 25/04/12 09/05/12 LOT4158373 
C038 13/09/07 21/12/11 2.01 1.95 127.38 2.9 22/03/13 2937.83 272.05 12/06/13 16/07/13 LOT4181871 
C039 15/10/09 21/12/11 2.04 2.04 122.22 9.8 23/03/12 1125.91 217.39 26/04/12 02/05/12 LOT4156426 
C040 08/11/08 21/12/11 2.04 2.30 163.49 9.8 14/03/13 2429.54 281.56 08/04/13 01/05/13 LOT4187458 
C041 26/06/08 09/01/12 2.06 1.93 213.12 3.9 20/02/13 2606.84 269.00 25/03/13 11/04/13 LOT4188786 
C042 07/04/06 09/01/12 2.02 2.13 141.28 9.3 16/04/13 1602.42 257.86 24/04/13 22/05/13 LOT4181871 
C043 19/08/06 10/01/12 2.03 1.35 174.61 8.8 20/02/13 773.23 246.01 25/03/13 11/04/13 LOT4188786 
C044 15/06/06 10/01/12 2.09 1.85 206.00 8.8 30/08/12 611.13 214.29 ? 27/10/12 LOT4179034 
C045 05/07/07 11/01/12 2.05 1.59 244.71 9.5 02/03/12 477.79 203.49 25/04/12 09/05/12 LOT4158373 
C046 25/09/07 11/01/12 2.06 1.87 173.56 9.3 17/04/13 1664.34 263.85 17/06/13 24/07/13 LOT4181223 
C047 11/12/08 11/01/12 2.10 1.77 73.99 8.3 27/03/13 2603.59 293.78 31/07/13 06/08/13 LOT4205911 
C048 17/02/05 11/01/12 2.05 1.15 172.09 9.7 20/02/13 1877.06 263.63 02/04/13 25/04/13 LOT4187458 
C049 18/06/04 11/01/12 2.04 1.99 116.56 9.3 06/08/12 674.92 212.53 ? 26/10/12 LOT4174114 
C050 19/09/05 09/01/12 2.03 1.88 105.05 8.9 12/04/13 1464.91 284.22 20/03/13 10/04/13 LOT4181871 
C051 10/06/07 12/01/12 2.03 1.81 114.78 9.0 27/03/13 3498.70 298.36 24/07/13 13/08/13 LOT4205911 
C052 26/08/09 12/01/12 1.99 1.82 90.79 8.0 26/03/13 2800.67 432.64 29/07/13 15/08/13 LOT4205079 
C053 06/10/09 12/01/12 2.06 2.18 194.05 9.2 27/02/13 2194.73 282.66 02/04/13 23/04/13 LOT4188786 
C054 25/03/07 26/01/12 2.07 2.22 137.07 9.0 12/04/13 2515.20 292.41 ------------------- FAILED ------------------- 
C055 19/08/06 12/01/12 2.05 2.05 134.87 9.1 16/04/13 2397.82 271.77 24/04/13 18/07/13 - 
C056 13/01/06 12/01/12 2.07 1.12 185.85 10 12/04/13 2311.03 276.93 05/06/13 31/07/13 LOT4205079 
C057 25/10/07 12/01/12 2.05 1.66 134.50 9.2 27/03/13 2715.58 294.45 31/07/13 06/08/13 LOT4205911 
C058 02/06/06 13/01/12 2.09 2.14 192.79 10 04/09/12 1051.20 196.83 ? 25/10/12 LOT4174114 
C059 06/04/06 13/01/12 2.03 1.60 128.20 8.7 27/02/13 1895.96 262.85 26/03/13 30/04/13 LOT4187458 
C060 21/05/10 13/01/12 2.08 1.79 157.79 8.9 02/11/12 943.31 237.41 ? 30/01/13 LOT4184161 
C061 26/08/05 16/01/12 2.08 2.25 117.80 8.0 12/04/12 2666.64 252.83 25/04/12 03/05/12 LOT4156426 
C062 26/02/05 23/04/12 2.05 1.57 308.32 8.1 01/05/13 2283.50 289.81 17/06/13 24/07/13 LOT4181223 
C063 08/08/06 23/04/12 2.04 1.20 238.11 OK 25/04/13 1947.96 263.69 14/05/13 18/07/13 - 
C064 09/10/10 23/04/12 2.08 0.75 162.01 10 02/05/13 1709.54 285.75 15/05/13 30/07/13 LOT4181223 
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C066 13/01/06 17/01/12 2.05 0.98 182.55 10 18/04/13 3004.21 308.73 17/06/13 24/07/13 LOT4181223 
C067 11/04/08 17/01/12 2.03 1.51 146.34 poor 28/09/12 793.89 222.89 ? 29/01/13 LOT4181223 
C068 17/11/08 19/01/12 2.09 0.73 91.23 4.1 16/04/13 2920.08 283.83 03/06/13 09/07/13 - 
C069 13/10/06 19/01/12 1.97 1.77 117.27 8.9 17/04/13 2504.95 282.99 03/06/13 09/07/13 LOT4187458 
C070 24/11/06 19/01/12 2.07 1.40 133.21 9.1 08/05/13 1985.57 269.82 12/06/13 16/07/13 LOT4188786 
C071 29/04/08 19/01/12 2.04 1.03 142.94 9.3 19/04/13 2604.87 242.17 12/06/13 16/07/13 LOT4188786 
C072 26/01/09 19/01/12 2.05 2.20 181.69 9.5 02/05/13 3050.58 293.85 17/06/13 17/07/13 LOT4188786 
C073 12/05/05 20/01/12 2.08 1.90 283.45 3.0 02/11/12 2051.99 251.97 ------------------- FAILED ------------------- 
C074 25/02/10 20/01/12 2.03 1.07 63.81 9.6 18/04/13 2195.63 297.27 17/06/13 31/07/13 LOT4205079 
C075 21/04/06 20/01/12 2.05 2.22 151.01 9.7 28/09/12 578.21 221.99 ? 05/02/13 LOT4184161 
C076 24/04/08 20/01/12 2.05 0.97 121.32 3.3 18/04/13 2906.02 306.38 17/06/13 17/07/13 LOT4188786 
C077 25/07/08 20/01/12 2.05 1.64 105.89 OK 03/05/13 2536.71 347.58 11/06/13 31/07/13 LOT4205079 
C078 06/03/08 23/01/12 1.99 1.50 106.92 7.8 19/04/13 2130.91 299.15 12/06/13 24/07/13 LOT4188786 
C079 13/06/06 26/01/12 2.06 1.25 57.39 4.0 16/04/13 1838.20 280.91 24/04/13 02/07/13 LOT4181871 
C080 06/08/07 25/01/12 2.02 2.13 163.88 8.5 15/03/13 2449.40 279.63 08/04/13 25/04/13 LOT4187458 
C081 19/02/11 23/01/12 1.95 1.50 128.88 6.3 07/05/13 2045.19 293.28 12/06/13 31/07/13 LOT4205079 
C082 05/11/09 23/01/12 1.98 0.55 111.39 7.3 19/04/13 1526.32 279.38 05/06/13 31/07/13 LOT4205079 
C083 12/03/11 19/04/12 2.02 2.17 220.37 9.6 01/05/13 2537.44 294.92 11/06/13 30/07/13 LOT4181223 
C084 28/07/09 24/01/12 1.99 2.07 91.90 OK 14/02/13 866.27 262.10 02/04/13 30/04/13 LOT4187458 
C085 17/05/06 24/01/12 2.06 1.94 170.90 7.2 01/05/13 2342.98 294.67 12/06/13 31/07/13 LOT4205079 
C086 07/08/10 24/01/12 2.00 2.12 193.39 7.6 02/05/13 2016.99 284.69 ------------------- FAILED ------------------- 
C087 02/12/05 25/01/12 2.02 1.23 107.79 2.6 02/05/13 3140.04 286.58 17/06/13 17/07/13 LOT4188786 
C088 30/08/07 27/01/12 2.10 2.22 201.12 10 11/09/12 1082.94 224.58 ? 26/10/12 LOT4174114 
C089 02/05/09 26/01/12 2.05 2.04 220.86 8.8 03/05/13 2319.70 278.72 17/06/13 17/07/13 LOT4188786 
C090 03/02/11 31/01/12 2.00 2.06 145.08 7.4 01/05/13 2655.29 292.81 17/06/13 02/07/13 LOT4181871 
C091 25/02/11 26/01/12 2.09 2.12 124.77 poor 08/05/13 2714.89 281.39 11/06/13 09/07/13 LOT4188786 
C092 07/10/10 31/01/12 2.08 2.21 203.36 9.1 07/05/13 1105.14 247.41 ------------------- FAILED ------------------- 
C093 07/03/10 01/02/12 2.06 2.02 206.06 9.6 09/04/13 2050.72 265.54 17/06/13 16/07/13 LOT4188786 
C094 16/10/10 01/02/12 2.02 2.16 155.96 6.8 24/10/12 732.81 197.58 ? 16/01/13 LOT4181223 
C095 11/07/07 26/01/12 2.03 2.21 147.12 8.2 08/05/13 1675.19 275.87 12/06/13 17/07/13 LOT4188786 
C096 28/10/09 26/01/12 2.06 1.90 136.21 8.5 30/04/13 1696.15 275.01 29/07/13 15/08/13 LOT4205079 
C097 02/09/08 26/01/12 2.04 2.28 153.24 8.9 24/10/12 704.59 203.66 ? 16/01/13 LOT4181223 
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C099 08/06/06 27/01/12 2.04 2.19 182.49 9.6 03/04/12 2090.20 264.17 26/04/12 01/05/12 LOT4153111 
C100 07/03/08 13/03/12 2.04 1.86 101.83 8.3 09/04/13 3181.44 270.62 31/07/13 06/08/13 LOT4205911 
F001 21/05/05 29/11/11 2.03 1.46 267.27 9.9 15/11/12 1508.44 283.67 ? 16/01/13 LOT4181223 
F002 17/11/08 01/12/11 2.05 1.88 160.47 8.6 07/12/12 1995.32 271.67 20/03/13 10/04/13 LOT4181871 
F003 02/10/04 02/12/11 2.28 0.09 34.31 7.4 22/03/13 923.13 245.97 29/07/13 15/08/13 LOT4205079 
F004 22/08/08 02/12/11 2.01 0.60 145.30 8.2 05/12/12 1598.97 253.32 26/03/13 12/04/13 LOT4181871 
F005 12/11/05 02/12/11 2.10 0.18 77.32 7.7 07/11/12 528.08 205.64 ? 05/02/13 LOT4184161 
F006 01/06/06 05/12/11 2.04 1.86 207.82 8.4 22/03/13 2178.68 244.95 01/07/13 30/07/13 LOT4181223 
F007 23/10/06 05/12/11 2.01 1.83 305.28 9.4 15/11/12 1279.09 243.87 ? 05/02/13 LOT4184161 
F008 17/03/05 05/12/11 2.04 2.25 166.78 6.9 15/11/12 1494.11 272.62 ? 29/01/13 LOT4184161 
F009 10/02/05 05/12/11 2.06 2.04 131.10 9.8 07/12/12 2122.76 284.80 25/03/13 11/04/13 LOT4188786 
F010 10/12/10 06/12/11 2.01 1.45 161.47 7.0 13/03/13 1545.54 278.71 26/03/13 23/04/13 LOT4188786 
F011 04/02/09 06/12/11 1.99 0.97 60.08 8.8 18/09/12 632.75 237.18 ? 26/10/12 LOT4174114 
F012 30/01/08 06/12/11 2.06 1.13 107.63 9.1 05/12/12 2587.67 321.98 25/03/13 12/04/13 LOT4188786 
F013 19/03/10 07/12/11 2.05 0.96 74.57 5.4 13/03/13 1790.06 285.99 02/04/13 25/04/13 LOT4187458 
F014 05/03/09 07/12/11 2.04 1.24 55.96 4.8 20/03/13 1894.30 273.43 01/07/13 24/07/13 LOT4181223 
F015 13/03/07 07/12/11 1.99 1.96 143.40 8.8 07/05/13 2687.48 274.18 31/07/13 06/08/13 LOT4205911 
F016 19/06/06 07/12/11 1.97 1.88 106.93 7.7 07/11/12 1014.75 256.50 ? 29/01/13 LOT4184161 
F017 17/03/05 07/12/11 2.03 1.97 184.91 9.1 24/10/12 683.23 198.58 ? 05/02/13 LOT4184161 
F018 13/06/08 08/12/11 2.04 1.11 164.06 OK 07/11/12 1782.70 261.24 ? 16/01/13 LOT4181223 
F019 10/06/08 08/12/11 2.02 1.71 149.66 7.5 26/03/13 3089.85 287.98 29/07/13 13/08/13 LOT4205911 
F020 24/09/10 09/12/11 1.97 1.42 149.47 7.6 07/12/12 1463.05 275.11 26/03/13 23/04/13 LOT4188786 
F021 23/04/05 09/12/11 2.04 2.23 134.45 9.1 07/12/12 2143.96 289.11 26/03/13 30/04/13 LOT4187458 
F022 06/03/06 09/12/11 1.99 1.88 157.47 9.5 22/03/13 2188.56 272.61 30/07/13 06/08/13 LOT4205911 
F023 13/01/05 09/12/11 2.00 2.55 142.05 8.7 30/03/12 814.89 230.41 25/04/12 09/05/12 LOT4156426 
F024 26/08/05 25/01/12 2.02 0.60 104.02 7.5 16/03/12 652.66 217.10 26/04/12 03/05/12 LOT4156426 
F025 11/09/09 13/12/11 2.01 1.65 150.93 8.9 20/03/13 2008.51 285.02 20/03/13 10/04/13 LOT4181871 
F026 11/05/09 14/12/11 2.07 2.38 168.50 9.3 26/10/12 1479.01 242.38 ? 05/02/13 LOT4184161 
F027 07/10/10 14/12/11 2.03 2.01 216.52 9.3 14/03/13 1428.03 253.58 02/04/13 25/04/13 LOT4187458 
F028 23/05/08 14/12/11 1.99 1.09 79.51 8.8 27/03/13 2715.58 291.01 24/07/13 13/08/13 LOT4205911 
F029 16/07/08 14/12/11 2.00 2.07 145.99 7.6 28/11/12 1814.48 282.77 25/03/13 11/04/13 LOT4188786 
F030 22/04/07 15/12/11 2.03 2.33 208.65 9.3 20/03/13 1747.25 294.81 30/07/13 13/08/13 LOT4205911 
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F032 06/11/10 15/12/11 2.01 1.31 138.80 9.2 22/03/13 2354.91 252.12 31/07/13 06/08/13 LOT4205911 
F033 08/12/03 16/12/11 1.83 2.93 52.10 7.0 27/03/13 2159.92 293.47 30/07/13 06/08/13 LOT4205911 
F034 22/05/10 16/12/11 1.94 2.27 206.95 9.8 22/03/13 2170.01 282.25 30/07/13 02/05/12 - 
F035 17/04/09 16/12/11 1.94 2.47 157.19 9.3 12/04/13 2304.89 301.92 01/07/13 23/07/13 LOT4188786 
F036 19/09/05 14/02/12 2.07 2.33 188.19 9.4 13/03/13 2022.43 294.77 02/04/13 01/05/13 LOT4187458 
F037 06/10/07 16/12/11 2.07 2.31 222.14 4.8 26/03/13 3022.23 277.94 29/07/13 13/08/13 LOT4205911 
F038 08/01/11 16/12/11 2.04 2.55 128.63 10 20/03/13 3097.12 314.56 29/07/13 14/08/13 LOT4205079 
F039 19/02/09 19/12/11 2.03 2.48 164.71 8.9 14/03/13 1658.03 260.03 02/04/13 30/04/13 LOT4187458 
F040 04/11/04 19/12/11 2.01 1.20 208.45 7.7 18/04/13 2471.95 300.23 30/07/13 06/08/13 LOT4205911 
F041 07/08/07 19/12/11 2.01 1.36 131.62 8.8 12/04/13 2163.25 326.15 20/03/13 10/04/13 LOT4181871 
F042 02/09/06 19/12/11 2.03 1.68 206.17 9.7 02/03/12 521.92 278.34 25/04/12 09/05/12 LOT4158373 
F043 21/07/06 20/12/11 2.05 1.08 144.55 9.4 09/03/12 633.61 253.39 25/04/12 03/05/12 LOT4156426 
F044 04/04/07 20/12/11 2.01 0.95 98.79 8.1 12/04/12 1743.77 231.77 25/04/12 01/05/12 LOT4181223 
F045 08/01/11 20/12/11 1.98 2.42 180.17 7.8 12/04/13 2602.51 349.24 29/07/13 13/08/13 LOT4205911 
F046 22/03/04 20/12/11 2.03 2.54 141.95 8.8 30/03/12 1247.74 259.22 25/04/12 01/05/12 LOT4153111 
F047 14/05/10 21/12/11 2.04 0.30 86.67 4.6 28/11/12 1437.49 266.90 08/04/13 24/04/13 LOT4187458 
F048 10/06/08 21/12/11 2.02 1.32 161.27 9.7 28/11/12 2172.48 279.21 20/03/13 10/04/13 LOT4181871 
F049 01/08/07 09/01/12 2.02 2.05 138.63 9.5 17/04/13 2919.98 280.37 30/07/13 06/08/13 LOT4205911 
F050 22/06/07 09/01/12 2.03 2.06 129.59 8.8 18/04/13 2222.23 303.80 30/07/13 06/08/13 LOT4205911 
F051 13/04/06 10/01/12 2.07 1.13 129.05 8.7 27/02/13 2272.21 301.16 20/03/13 10/04/13 LOT4181871 
F052 27/05/08 10/01/12 2.03 1.81 136.23 6.6 20/02/13 1913.20 261.05 03/04/13 24/04/13 LOT4187458 
F053 29/08/09 10/01/12 2.06 2.00 174.91 7.7 24/10/12 480.70 192.97 ? 16/01/13 LOT4181223 
F054 10/06/04 11/01/12 2.06 2.15 171.37 9.4 09/03/12 467.77 254.34 25/04/12 02/05/12 LOT4156426 
F055 12/09/09 11/01/12 2.04 1.29 188.70 8.7 16/04/13 2225.63 275.43 24/04/13 22/05/13 LOT4181871 
F056 03/01/08 11/01/12 2.04 2.03 162.91 OK 26/03/13 2152.75 282.69 31/07/13 06/08/13 LOT4205911 
F057 16/03/10 11/01/12 2.00 1.80 136.45 9.4 17/04/13 2086.50 281.52 08/04/13 31/07/13 LOT4205079 
F058 20/03/07 11/01/12 2.03 0.79 119.32 8.6 16/04/13 2117.25 286.53 24/04/13 22/05/13 LOT4181871 
F059 07/10/05 09/01/12 2.09 1.36 152.87 10 27/02/13 2121.25 289.81 08/04/13 01/05/13 LOT4187458 
F060 27/06/08 09/01/12 2.07 0.77 78.96 9.8 20/02/13 1937.19 271.70 03/04/13 24/04/13 LOT4187458 
F061 16/03/06 12/01/12 2.00 2.06 147.64 9.0 19/04/13 2857.14 309.61 15/05/13 18/07/13 LOT4188786 
F062 25/05/05 12/01/12 2.08 2.14 142.68 8.8 18/04/13 2747.67 305.15 17/06/13 16/07/13 LOT4188786 
F063 18/01/07 12/01/12 2.02 2.11 126.81 9.0 07/05/13 2628.46 269.28 03/06/13 30/07/13 LOT4181223 
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F065 04/09/04 12/01/12 2.10 0.41 67.69 9.4 17/04/13 2387.06 275.53 12/06/13 02/07/13 LOT4181871 
F066 03/07/10 13/01/12 2.07 0.90 177.55 9.5 24/10/12 779.18 202.58 ? 06/02/13 LOT4181871 
F067 08/03/07 13/01/12 2.06 2.05 159.03 7.4 27/03/13 3243.61 313.24 29/07/13 14/08/13 LOT4205079 
F068 28/01/05 13/01/12 2.06 2.04 108.32 9.4 19/04/13 2133.06 284.08 17/06/13 17/07/13 LOT4188786 
F069 10/06/05 13/01/12 2.05 2.02 138.80 9.1 03/05/13 2369.75 287.66 12/06/13 02/07/13 LOT4181871 
F070 24/07/10 13/01/12 2.08 1.22 169.60 4.8 26/10/12 1159.85 234.36 ? 16/01/13 LOT4181223 
F071 29/03/06 13/01/12 2.03 1.12 81.92 8.8 12/04/12 854.84 241.28 25/04/12 03/05/12 LOT4156426 
F072 10/01/11 13/01/12 2.10 2.06 96.67 8.6 16/04/13 2068.14 297.22 24/04/13 22/05/13 LOT4181871 
F073 02/12/05 16/01/12 2.05 1.76 182.94 10 28/09/12 1425.80 245.62 ? 29/01/13 LOT4181223 
F074 19/03/11 16/01/12 2.06 1.87 260.55 7.1 25/04/13 2266.57 285.61 14/05/13 24/07/13 - 
F075 02/12/10 16/01/12 2.04 1.55 148.39 10 01/05/13 2059.86 277.72 11/06/13 09/07/13 LOT4188786 
F076 17/07/10 23/04/12 2.03 1.66 256.42 8.6 02/05/13 1897.40 295.05 05/06/13 30/07/13 LOT4181223 
F077 27/02/07 17/01/12 2.06 2.12 172.65 8.7 28/09/12 1831.61 240.46 ? 30/01/13 LOT4184161 
F078 21/05/08 17/01/12 2.03 1.03 153.59 3.8 11/09/12 967.66 220.53 ? 26/10/12 LOT4174114 
F079 11/08/06 17/01/12 2.07 2.11 269.73 8.3 02/05/13 2727.61 298.97 ------------------- FAILED ------------------- 
F080 18/04/08 17/01/12 2.06 1.91 97.14 3.3 01/05/13 3129.51 259.76 05/06/13 31/07/13 LOT4205079 
F081 18/04/08 19/01/12 2.07 1.32 172.56 8.7 06/08/12 787.05 223.70 ? 27/10/12 LOT4174114 
F082 29/04/08 19/01/12 2.05 1.61 251.17 9.1 03/05/13 2179.55 272.63 17/06/13 17/07/13 LOT4188786 
F083 31/05/09 19/01/12 2.08 1.60 146.00 8.9 19/04/13 2124.35 304.21 20/03/13 10/04/13 LOT4181871 
F084 10/02/05 19/01/12 2.05 2.15 215.08 9.1 19/03/13 1953.99 258.41 20/03/13 10/04/13 LOT4181871 
F085 17/05/04 19/01/12 2.01 2.12 159.24 4.2 03/05/13 2103.62 290.37 03/06/13 24/07/13 LOT4188786 
F086 02/10/04 19/01/12 2.05 2.21 231.04 9.3 08/05/13 1810.39 280.43 17/06/13 02/07/13 LOT4181871 
F087 07/02/06 19/01/12 2.09 2.02 162.87 2.9 01/05/13 2439.63 249.62 11/06/13 09/07/13 LOT4187458 
F088 15/02/05 20/01/12 2.03 2.22 205.31 10 07/05/13 2193.17 276.36 11/06/13 18/07/13 - 
F089 08/12/06 20/01/12 2.03 1.85 152.64 6.6 06/08/12 1735.60 236.44 ? 25/10/12 LOT4174114 
F090 27/08/04 20/01/12 2.05 1.83 194.74 9.3 01/05/13 2203.54 288.50 ------------------- FAILED ------------------- 
F091 01/08/08 20/01/12 2.05 1.50 212.08 9.0 30/08/12 1184.40 237.32 ? 27/10/12 LOT4174114 
F092 01/09/05 20/01/12 2.01 1.79 154.16 9.0 02/05/13 2501.73 291.59 17/06/13 16/07/13 LOT4188786 
F093 18/03/04 23/01/12 2.05 1.57 169.87 9.7 28/09/12 2155.02 245.04 ? 30/01/13 LOT4184161 
F094 21/12/10 23/01/12 2.06 1.50 214.23 5.2 25/04/13 2086.82 287.38 14/05/13 31/07/13 LOT4205079 
F095 18/04/08 23/01/12 2.06 2.13 245.41 2.9 08/05/13 2088.15 273.67 17/06/13 18/07/13 LOT4188786 
F096 28/03/07 12/04/12 2.06 1.73 179.77 7.7 19/09/12 770.48 230.45 ? 25/10/12 LOT4174114 
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F098 20/07/05 23/01/12 2.03 2.12 340.78 9.9 02/11/12 557.82 193.34 ? 06/02/13 LOT4181871 
F099 28/01/05 19/04/12 2.06 2.17 303.23 9.3 02/05/13 2085.13 295.28 05/06/13 31/07/13 LOT4205079 
F100 17/11/04 19/04/12 2.04 2.25 313.03 2.9 19/09/12 745.23 218.94 ? 26/10/12 LOT4174114 
F101 14/07/08 24/01/12 2.06 2.13 288.81 8.2 03/05/13 2289.08 284.83 17/06/13 16/07/13 LOT4188786 
F102 10/06/09 24/01/12 2.03 2.10 291.74 9.4 19/03/13 2076.06 276.29 20/03/13 10/04/13 LOT4181871 
F103 12/03/11 25/01/12 2.07 2.03 271.11 8.7 30/04/13 1880.94 272.62 12/06/13 24/07/13 LOT4188786 
F104 29/07/10 25/01/12 2.02 1.04 169.40 8.2 26/10/12 657.76 198.42 ? 30/01/13 LOT4184161 
F105 22/05/10 25/01/12 2.04 1.19 147.63 9.3 14/02/13 1433.23 259.47 03/04/13 30/04/13 LOT4187458 
F106 15/10/04 26/01/12 2.04 0.82 187.66 8.2 03/04/12 2054.21 264.95 25/04/12 02/05/12 LOT4156426 
F107 25/10/07 31/01/12 2.02 2.12 161.16 9.1 03/05/13 2030.45 289.93 15/05/13 09/07/13 LOT4181871 
F108 02/05/09 27/01/12 2.07 2.05 196.40 9.4 30/04/13 2366.21 316.79 12/06/13 17/07/13 LOT4188786 
F109 20/08/10 31/01/12 2.06 2.09 216.28 9.3 07/05/13 1977.93 285.68 17/06/13 16/07/13 LOT4188786 
F110 14/02/05 31/01/12 2.05 2.09 250.15 8.8 25/04/13 2006.88 278.70 14/05/13 18/07/13 LOT4188786 
F111 29/04/08 01/02/12 2.11 0.87 81.09 7.6 30/04/13 1548.27 276.66 ------------------- FAILED ------------------- 
F112 26/09/05 26/01/12 2.05 2.04 242.88 9.8 07/05/13 1705.33 273.91 11/06/13 02/07/13 LOT4181871 
F113 04/11/06 26/01/12 2.07 1.30 192.71 9.0 09/04/13 2009.71 279.91 12/06/13 17/07/13 LOT4188786 
F114 14/10/08 27/01/12 2.03 1.92 178.61 9.0 04/09/12 1005.40 206.38 ? 27/10/12 LOT4174114 
F115 27/05/05 27/01/12 2.04 2.23 219.45 8.4 03/04/12 2121.27 268.69 26/04/12 01/05/12 LOT4153111 
F116 30/03/05 26/01/12 2.05 2.01 363.00 9.6 09/04/13 1528.37 290.66 ------------------- FAILED ------------------- 
F117 03/07/10 27/01/12 2.05 2.18 349.83 9.6 02/11/12 619.00 201.64 ? 06/02/13 LOT4181871 
F118 03/02/10 25/01/12 2.03 1.88 247.45 9.5 14/02/13 1523.96 270.12 26/03/13 23/04/13 LOT4188786 
F119 03/02/05 27/01/12 2.04 1.67 245.51 9.0 03/04/12 2490.18 264.45 25/04/12 02/05/12 LOT4156426 
F120 01/02/07 27/01/12 2.04 2.10 148.19 9.3 09/04/13 2489.04 290.10 05/06/13 31/07/13 LOT4205079 
S001 15/12/04 29/11/11 1.99 1.58 154.16 OK 07/11/12 955.90 239.70 ? 05/02/13 LOT4184161 
S002 05/12/03 29/11/11 1.96 1.38 94.58 OK 12/04/12 1046.55 236.26 26/04/12 01/05/12 LOT4153111 
S003 23/07/04 01/12/11 2.01 1.68 135.97 9.0 15/11/12 1253.41 271.19 ? 05/02/13 LOT4184161 
S004 01/03/08 01/12/11 2.03 1.77 120.80 8.8 07/11/12 1961.13 273.53 ? 30/01/13 LOT4184161 
S005 15/08/07 02/12/11 2.09 0.90 158.61 10 15/11/12 1736.32 259.96 ? 29/01/13 LOT4181223 
S006 27/08/04 02/12/11 2.41 0.05 23.19 poor 22/03/13 738.71 238.59 17/06/13 17/07/13 LOT4188786 
S007 21/10/05 02/12/11 2.05 0.47 115.25 9.4 07/12/12 2134.28 293.89 26/03/13 12/04/13 LOT4188786 
S008 11/05/05 02/12/11 2.10 0.31 93.58 7.9 15/11/12 1488.19 257.40 ? 22/01/13 LOT4181223 
S009 17/02/08 02/12/11 2.11 0.31 100.42 9.9 07/12/12 1880.84 265.98 02/04/13 23/04/13 LOT4188786 
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S011 10/02/05 05/12/11 2.06 1.80 200.56 9.6 19/03/13 1951.71 279.59 ------------------- FAILED ------------------- 
S012 27/05/05 05/12/11 2.03 1.48 222.92 9.7 07/11/12 1316.08 259.14 ? 30/01/13 LOT4184161 
S013 06/05/05 05/12/11 2.02 2.06 154.82 9.2 05/12/12 2259.23 289.16 08/04/13 01/05/13 LOT4187458 
S014 27/08/04 05/12/11 2.07 1.97 188.06 8.4 28/09/12 1142.99 230.93 ? 30/01/13 LOT4184161 
S015 18/08/06 05/12/11 2.07 1.99 285.68 9.9 07/05/13 1946.25 277.64 05/06/13 18/07/13 - 
S016 23/09/05 06/12/11 2.01 2.20 95.04 8.8 07/05/13 2002.05 272.44 05/06/13 18/07/13 LOT4188786 
S017 30/09/05 06/12/11 2.05 2.24 228.11 9.5 05/12/12 2336.30 302.27 03/04/13 12/04/13 LOT4188786 
S018 10/11/05 06/12/11 2.03 1.76 83.69 9.6 07/12/12 1979.80 282.58 08/04/13 30/04/13 LOT4187458 
S019 06/10/05 06/12/11 2.02 1.98 188.43 8.4 30/03/12 566.15 229.86 26/04/12 02/05/12 LOT4156426 
S020 20/08/04 06/12/11 2.03 0.66 120.47 7.9 20/03/13 2073.13 295.82 12/06/13 09/07/13 LOT4181871 
S021 06/04/06 06/12/11 2.05 1.60 179.06 9.4 19/03/13 2107.41 287.73 03/04/13 12/04/13 LOT4188786 
S022 21/05/04 06/12/11 2.05 2.14 194.44 9.7 19/03/13 2142.93 276.76 03/04/13 12/04/13 LOT4188786 
S023 16/07/04 07/12/11 2.00 1.36 110.68 7.4 11/09/12 1003.06 237.00 ? 25/10/12 LOT4174114 
S024 05/02/05 07/12/11 2.07 1.88 264.48 9.7 19/03/13 1923.57 264.04 08/04/13 24/04/13 LOT4187458 
S025 03/03/05 07/12/11 2.03 1.34 141.68 8.9 05/12/12 2035.98 309.03 26/03/13 30/04/13 LOT4187458 
S026 30/01/04 07/12/11 2.07 0.79 106.37 9.0 12/04/12 938.51 285.72 25/04/12 01/05/12 LOT4156428 
S027 19/08/05 07/12/11 2.02 1.07 153.80 9.2 07/12/12 2516.20 285.86 26/03/13 24/04/13 LOT4187458 
S028 01/04/04 07/12/11 2.01 1.49 160.70 9.4 15/11/12 2422.41 266.67 ? 22/01/13 LOT4181223 
S029 26/11/04 07/12/11 2.00 0.79 92.56 8.7 07/05/13 1754.24 280.65 14/05/13 09/07/13 LOT4181871 
S030 18/06/04 07/12/11 1.98 1.44 165.49 8.9 05/12/12 1934.41 277.91 08/04/13 25/04/13 LOT4187458 
S031 05/05/05 08/12/11 2.07 1.54 191.96 9.9 24/10/12 794.36 202.31 ? 29/01/13 LOT4181223 
S032 17/05/07 08/12/11 2.06 1.85 230.34 9.8 03/04/12 2406.06 328.15 25/04/12 03/05/12 LOT4156426 
S033 07/05/04 08/12/11 2.12 1.98 200.71 9.7 07/12/12 2057.15 293.74 03/04/13 12/04/13 LOT4188786 
S034 23/03/07 08/12/11 1.76 0.69 174.57 9.0 22/03/13 2064.59 270.02 ------------------- FAILED ------------------- 
S035 27/04/06 08/12/11 2.03 2.28 213.90 9.5 15/11/12 1847.11 268.39 ? 22/01/13 LOT4181223 
S036 14/07/05 08/12/11 2.05 1.20 231.10 9.6 15/11/12 2246.07 278.74 ? 29/01/13 LOT4181223 
S037 21/05/04 08/12/11 2.03 1.98 215.97 9.4 05/12/12 2222.43 280.30 08/04/13 23/04/13 LOT4188786 
S038 10/12/04 08/12/11 2.00 1.16 159.89 9.7 07/11/12 1794.18 253.68 ? 29/01/13 LOT4181223 
S039 28/11/03 08/12/11 2.03 1.30 217.06 8.9 03/04/12 2245.35 217.31 25/04/12 03/05/12 LOT4156426 
S040 12/05/06 09/12/11 2.06 1.42 229.66 9.7 07/11/12 1330.06 269.86 ? 30/01/13 LOT4184161 
S041 16/02/05 09/12/11 2.07 1.77 202.29 9.3 05/12/12 2042.73 290.40 26/03/13 24/04/13 LOT4187458 
S042 08/07/05 09/12/11 2.07 1.45 183.35 9.1 06/08/12 1850.81 236.23 ? 26/10/12 LOT4174114 
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S044 18/11/06 09/12/11 2.08 0.91 306.79 4.8 15/11/12 1845.13 282.64 ? 22/01/13 LOT4181223 
S045 04/07/06 09/12/11 2.03 1.37 156.00 8.8 13/03/13 2185.36 302.11 08/04/13 25/04/13 LOT4187458 
S046 29/01/05 09/12/11 2.07 1.22 251.09 9.2 07/05/13 2036.52 290.69 05/06/13 18/07/13 - 
S047 12/05/06 09/12/11 2.03 1.99 221.87 8.6 22/03/13 1987.72 273.39 11/06/13 30/07/13 LOT4181223 
S048 27/10/04 09/12/11 2.03 1.87 190.44 9.3 24/10/12 807.40 206.84 ? 05/02/13 LOT4184161 
S049 02/07/05 25/01/12 2.04 1.36 135.14 9.3 07/11/12 1648.54 270.28 ? 22/01/13 LOT4181223 
S050 05/02/04 27/01/12 2.03 1.93 130.16 7.4 07/11/12 1812.26 284.12 ? 29/01/13 LOT4181223 
S051 08/09/07 13/12/11 2.00 1.20 147.55 8.9 22/03/13 2646.40 278.28 ? 14/08/13 LOT4205079 
S052 21/11/07 13/12/11 2.02 1.74 186.95 9.0 26/10/12 1999.49 266.59 ? 29/01/13 LOT4181223 
S053 08/03/07 13/12/11 2.03 1.15 132.87 9.5 22/03/13 2325.78 270.24 30/07/13 14/08/13 LOT4205079 
S054 13/10/05 13/12/11 2.02 1.41 242.85 9.3 14/03/13 1731.47 266.93 03/04/13 25/04/13 LOT4187458 
S055 18/08/06 13/12/11 2.05 1.38 188.31 9.9 28/09/12 2208.73 238.47 ? 22/01/13 LOT4181223 
S056 11/02/05 14/12/11 2.04 1.75 191.92 9.5 24/10/12 832.56 198.66 ? 29/01/13 LOT4181223 
S057 22/02/07 14/12/11 2.04 0.91 114.75 9.5 22/03/13 2614.14 292.49 30/07/13 06/08/13 LOT4205079 
S058 09/08/07 14/12/11 2.07 2.14 392.49 8.6 28/11/12 2276.57 280.57 02/04/13 23/04/13 LOT4188786 
S059 22/04/04 14/12/11 2.04 1.92 230.11 9.8 03/04/12 2624.19 258.43 25/04/12 02/05/12 LOT4156426 
S060 22/12/06 14/12/11 2.08 1.39 144.34 9.7 20/03/13 2088.02 273.54 30/07/13 14/08/13 LOT4205079 
S061 15/10/04 20/12/11 2.04 1.12 123.55 8.7 22/03/13 2607.22 293.65 29/07/13 13/08/13 LOT4205911 
S062 18/08/06 14/12/11 2.07 2.43 181.61 10 26/10/12 795.58 212.80 ? 06/02/13 LOT4181871 
S063 01/07/05 14/12/11 2.06 0.93 218.09 9.5 20/03/13 1914.06 279.29 30/07/13 14/08/13 LOT4205079 
S064 12/05/06 14/12/11 2.02 2.40 178.13 8.4 07/05/13 1898.51 272.46 29/07/13 13/08/13 LOT4205911 
S065 23/05/07 15/12/11 2.07 2.09 339.50 9.9 03/04/12 2147.53 253.31 25/04/12 03/05/12 LOT4156426 
S066 07/12/05 20/01/12 2.06 1.42 196.76 10 13/03/13 2435.44 293.76 25/03/13 11/04/13 LOT4188786 
S067 12/11/05 15/12/11 2.01 2.32 153.15 9.4 26/03/13 2866.31 301.02 30/07/13 14/08/13 LOT4205079 
S068 17/03/04 16/12/11 1.92 1.37 153.20 9.7 28/11/12 2655.00 265.67 26/03/13 23/04/13 LOT4188786 
S069 25/02/06 16/12/11 1.95 2.26 254.78 8.9 14/03/13 2014.04 279.78 25/03/13 12/04/13 LOT4188786 
S070 09/03/06 23/04/12 2.03 2.32 237.96 9.5 30/04/13 2329.43 277.95 29/07/13 15/08/13 LOT4205079 
S071 10/09/04 23/04/12 2.04 2.12 267.82 9.4 25/04/13 1918.56 280.55 24/07/13 14/08/13 LOT4205079 
S072 26/01/05 16/12/11 2.04 1.89 166.33 9.4 22/03/13 2092.88 268.55 31/07/13 15/08/13 LOT4205079 
S073 23/12/04 16/12/11 2.01 1.96 131.46 8.8 13/03/13 1824.37 278.21 03/04/13 24/04/13 LOT4187458 
S074 29/11/07 18/04/12 2.03 1.22 128.01 7.1 13/03/13 1712.30 308.64 08/04/13 30/04/13 LOT4187458 
S075 14/07/05 16/12/11 2.04 1.39 201.88 9.8 20/03/13 2564.60 298.30 01/07/13 09/07/13 LOT4181871 
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S077 15/06/06 19/12/11 2.05 1.51 136.13 10 22/03/13 2771.65 280.09 31/07/13 14/08/13 LOT4205079 
S078 11/08/05 19/12/11 2.04 1.12 185.14 10 26/10/12 1592.67 261.81 ? 06/02/13 LOT4181871 
S079 03/06/05 19/12/11 2.06 1.49 194.97 4.4 14/03/13 2135.62 270.73 03/04/13 25/04/13 LOT4187458 
S080 08/08/06 19/12/11 2.05 2.13 206.53 10 14/03/13 2258.33 277.57 26/03/13 01/05/13 LOT4187458 
S081 01/02/07 19/12/11 2.03 2.17 188.99 7.2 28/09/12 2116.58 228.77 ? 22/01/13 LOT4181223 
S082 18/01/07 23/04/12 2.03 2.04 281.54 9.5 30/04/13 1505.78 269.64 01/07/13 16/07/13 LOT4188786 
S083 15/02/07 23/04/12 2.04 2.19 267.04 10 25/04/13 1796.19 278.28 24/07/13 14/08/13 LOT4205079 
S084 17/01/08 20/12/11 2.04 0.71 117.14 8.7 14/03/13 1958.79 258.91 02/04/13 23/04/13 LOT4188786 
S085 11/11/04 20/12/11 2.05 1.25 190.15 1.9 28/09/12 2041.01 229.10 ? 06/02/13 LOT4181871 
S086 19/08/04 20/12/11 2.02 2.32 146.03 poor 13/03/13 2026.22 309.25 25/03/13 11/04/13 LOT4188786 
S087 23/09/07 20/12/11 2.03 0.87 177.77 5.9 22/03/13 2644.11 271.97 31/07/13 15/08/13 LOT4205079 
S088 09/11/06 20/12/11 2.08 2.31 266.16 6.5 27/03/13 3185.96 302.72 24/07/13 13/08/13 LOT4205911 
S089 15/06/06 20/12/11 2.05 0.31 93.92 9.5 12/04/12 1987.11 262.27 25/04/12 09/05/12 LOT4158373 
S090 13/09/06 20/12/11 2.04 0.79 157.12 9.8 07/05/13 2518.51 257.44 29/07/13 15/08/13 LOT4205079 
S091 11/08/05 20/12/11 2.06 1.02 111.87 9.3 28/11/12 2323.34 271.92 02/04/13 30/04/13 LOT4187458 
S092 22/09/06 21/12/11 2.03 0.95 140.15 8.6 26/03/13 3055.09 318.62 29/07/13 15/08/13 LOT4205079 
S093 18/06/04 21/12/11 2.07 2.31 134.90 9.5 09/03/12 885.18 284.29 25/04/12 09/05/12 LOT4156426 
S094 26/11/04 21/12/11 2.05 1.78 192.05 10 24/10/12 826.81 209.80 ? 30/01/13 LOT4184161 
S095 10/03/05 21/12/11 2.06 0.91 176.66 10 28/11/12 2052.47 329.36 08/04/13 25/04/13 LOT4187458 
S096 10/02/05 21/12/11 2.06 2.50 143.36 9.4 22/03/13 2459.44 272.07 17/06/13 09/07/13 LOT4181871 
S097 15/09/06 21/12/11 2.09 0.30 81.68 3.5 20/03/13 2568.65 290.34 12/06/13 09/07/13 LOT4181871 
S098 19/09/07 21/12/11 2.05 1.78 176.61 9.7 26/03/13 2640.22 289.40 30/07/13 15/08/13 LOT4205079 
S099 11/11/04 21/12/11 2.08 1.20 145.20 9.5 14/03/13 2200.19 312.91 03/04/13 24/04/13 LOT4187458 
S100 25/02/05 21/12/11 2.06 0.69 124.65 8.8 22/03/13 2109.23 272.90 12/06/13 16/07/13 LOT4188786 
S101 15/05/04 09/01/12 2.06 1.67 175.24 4.5 22/03/13 2659.45 267.66 ------------------- FAILED ------------------- 
S102 05/05/06 09/01/12 2.03 1.71 193.39 9.3 30/03/12 1432.11 240.09 25/04/12 02/05/12 LOT4156426 
S103 15/09/05 09/01/12 2.03 1.91 158.18 9.0 20/02/13 1942.87 262.85 02/04/13 25/04/13 LOT4187458 
S104 07/04/05 09/01/12 1.98 0.40 111.49 9.7 26/03/13 2425.84 284.51 31/07/13 13/08/13 LOT4205911 
S105 27/04/05 10/01/12 2.10 0.94 202.97 9.9 20/02/13 2783.43 290.68 03/04/13 24/04/13 LOT4187458 
S106 12/10/06 10/01/12 2.06 1.84 279.27 9.7 27/02/13 2202.53 320.92 03/04/13 24/04/13 LOT4187458 
S107 23/01/07 10/01/12 2.07 2.08 319.61 8.5 02/11/12 667.15 220.05 ? 30/01/13 LOT4184161 
S108 31/03/07 11/01/12 2.06 1.07 176.77 3.2 26/03/13 3053.39 271.60 24/07/13 13/08/13 LOT4205911 
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S110 02/09/06 11/01/12 2.03 1.35 201.66 9.1 12/04/12 1423.50 253.12 25/04/12 03/05/12 LOT4156426 
S111 06/11/03 11/01/12 2.06 2.17 268.01 9.7 27/03/13 1672.81 285.77 30/07/13 06/08/13 LOT4205911 
S112 22/02/07 11/01/12 2.08 1.56 162.68 3.4 27/03/13 2814.67 283.32 30/07/13 13/08/13 LOT4205911 
S113 30/01/07 11/01/12 2.08 1.06 153.85 9.3 22/03/13 2267.01 300.11 11/06/13 30/07/13 LOT4181223 
S114 09/02/07 11/01/12 2.06 0.34 98.14 9.2 12/04/12 1486.18 254.12 25/04/12 01/05/12 LOT4153111 
S115 17/02/05 11/01/12 2.07 2.10 232.75 9.5 12/04/13 2215.33 313.29 11/06/13 30/07/13 LOT4181223 
S116 01/02/07 11/01/12 2.09 1.41 120.47 8.8 23/03/12 528.06 195.56 26/04/12 03/05/12 LOT4156426 
S117 03/02/05 11/01/12 2.01 1.58 141.14 8.8 12/04/13 2421.62 290.92 12/06/13 17/07/13 LOT4188786 
S118 11/03/04 11/01/12 2.04 1.22 87.59 7.8 07/05/13 2522.19 267.79 ------------------- FAILED ------------------- 
S119 16/12/04 11/01/12 2.04 1.40 86.70 3.8 20/02/13 2697.62 259.26 03/04/13 24/04/13 LOT4187458 
S120 09/07/07 11/01/12 2.04 0.75 54.55 9.5 27/03/13 2575.59 295.13 15/05/13 23/07/13 LOT4188786 
S121 09/08/07 11/01/12 2.07 1.88 107.69 8.9 16/03/12 701.93 195.49 25/04/12 09/05/12 LOT4156426 
S122 27/10/07 09/01/12 2.06 2.05 138.25 9.3 16/04/13 1904.39 269.12 24/04/13 22/05/13 LOT4181871 
S123 23/09/04 09/01/12 2.07 1.03 185.14 2.7 19/09/12 854.39 231.38 ? 25/10/12 LOT4174114 
S124 20/08/04 12/01/12 2.04 2.04 193.46 9.6 26/03/13 2926.16 298.89 29/07/13 14/08/13 LOT4205079 
S125 22/12/06 26/01/12 2.02 1.69 114.92 8.4 07/05/13 2490.64 289.30 05/06/13 30/07/13 - 
S126 14/01/05 12/01/12 2.05 2.05 248.08 9.1 16/04/13 2082.28 290.35 24/04/13 22/05/13 LOT4181871 
S127 28/10/05 12/01/12 2.00 2.04 125.53 9.8 27/02/13 2039.99 261.80 25/03/13 10/04/13 LOT4181871 
S128 04/11/05 12/01/12 2.06 1.89 158.12 9.0 12/04/13 2292.95 304.59 ------------------- FAILED ------------------- 
S129 14/07/05 12/01/12 2.08 0.65 191.49 9.5 24/10/12 969.49 222.08 ? 29/01/13 LOT4181223 
S130 24/02/05 12/01/12 2.08 0.88 223.38 3.8 18/04/13 3107.25 294.05 11/06/13 30/07/13 LOT4181223 
S131 04/02/06 12/01/12 2.11 0.24 82.05 8.9 20/02/13 1965.53 265.74 08/04/13 30/04/13 LOT4187458 
S132 12/07/07 12/01/12 2.06 1.07 124.13 9.3 23/03/12 1845.94 222.69 26/04/12 09/05/12 LOT4156426 
S133 05/01/08 12/01/12 2.04 0.79 135.78 9.5 23/03/12 603.05 200.72 26/04/12 09/05/12 LOT4156426 
S134 12/05/06 12/01/12 2.08 0.51 86.28 9.4 16/04/13 1842.55 283.61 24/04/13 22/05/13 LOT4181871 
S135 13/02/06 12/01/12 2.02 1.72 101.98 8.9 18/04/13 2332.22 300.03 ------------------- FAILED ------------------- 
S136 06/08/07 13/01/12 2.07 2.18 113.51 9.0 12/04/13 2174.75 285.07 ------------------- FAILED ------------------- 
S137 12/11/05 25/01/12 2.05 1.84 101.44 6.0 27/02/13 1837.41 282.65 08/04/13 30/04/13 LOT4187458 
S138a 20/04/05 13/01/12 2.07 2.14 199.52 9.4 20/02/13 2653.52 272.39 02/04/13 01/05/13 LOT4187458 
S138b 08/04/05 13/01/12 2.01 2.03 107.22 7.1 18/04/13 2621.71 291.70 ------------------- FAILED ------------------- 
S139 24/03/05 13/01/12 2.02 1.91 134.31 9.0 27/02/13 2861.15 282.68 26/03/13 25/04/13 LOT4187458 
S140 29/04/05 13/01/12 2.01 2.01 126.86 9.0 27/03/13 2431.47 292.40 24/07/13 15/08/13 LOT4205079 
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S142 08/01/04 13/01/12 2.10 0.78 94.41 9.5 16/04/13 2594.63 300.89 24/04/13 22/05/13 LOT4181871 
S143 03/02/06 13/01/12 2.03 0.73 117.66 9.4 20/02/13 2610.71 284.17 26/03/13 12/04/13 LOT4181871 
S144 02/03/06 13/01/12 2.05 1.92 151.66 4.9 12/04/13 2539.75 285.07 11/06/13 24/07/13 LOT4188786 
S145 08/10/04 13/01/12 2.07 2.02 143.87 2.5 27/02/13 2127.97 288.90 03/04/13 24/04/13 LOT4187458 
S146 08/04/05 13/01/12 2.12 1.15 116.90 8.6 12/04/13 2201.52 297.89 03/06/13 09/07/13 LOT4181871 
S147 15/10/07 13/01/12 2.06 1.20 123.74 8.9 17/04/13 3023.54 288.38 05/06/13 24/07/13 LOT4181223 
S148 02/03/07 13/01/12 2.11 0.63 96.55 9.0 16/04/13 1700.73 261.42 24/04/13 22/05/13 LOT4181871 
S149 10/05/07 13/01/12 2.09 1.40 142.57 9.4 09/03/12 806.19 302.47 25/04/12 01/05/12 LOT4153111 
S150 09/03/06 16/01/12 2.07 1.43 164.69 2.3 17/04/13 2205.00 267.96 15/05/13 23/07/13 LOT4188786 
S151 30/01/08 16/01/12 2.07 1.77 245.61 9.5 03/04/12 2172.91 258.18 25/04/12 09/05/12 LOT4158373 
S152 25/04/07 16/01/12 2.05 1.56 157.81 9.6 16/04/13 2317.23 297.40 24/04/13 22/05/13 LOT4181871 
S153 09/08/07 23/04/12 2.05 2.16 313.11 3.0 30/04/13 1863.97 267.15 12/06/13 17/07/13 LOT4188786 
S154 15/03/07 23/04/12 2.06 2.13 333.95 2.8 01/05/13 1820.78 237.97 ------------------- FAILED ------------------- 
S155 15/06/06 23/04/12 2.11 2.20 493.02 9.4 25/04/13 2305.79 290.14 14/05/13 30/07/13 LOT4181223 
S156 23/03/06 23/04/12 2.04 1.59 399.34 7.6 25/04/13 1771.20 266.66 14/05/13 24/07/13 - 
S157 24/06/04 17/01/12 2.03 0.76 189.15 9.9 28/09/12 1144.85 242.92 ? 22/01/13 LOT4181223 
S158 25/02/05 17/01/12 2.04 2.02 130.49 9.7 18/04/13 2740.18 314.93 ------------------- FAILED ------------------- 
S159 10/12/04 17/01/12 2.05 2.06 145.24 9.9 19/04/13 2442.12 306.76 12/06/13 17/07/13 LOT4188786 
S160 02/12/04 17/01/12 2.03 0.98 145.92 4.4 17/04/13 2354.82 279.88 11/06/13 24/07/13 - 
S161 06/10/05 17/01/12 2.05 1.74 287.17 2.5 17/04/13 2904.61 266.12 11/06/13 09/07/13 LOT4188786 
S162 10/11/06 17/01/12 2.06 1.38 134.34 2.0 25/04/13 2673.10 268.44 14/05/13 23/07/13 LOT4188786 
S163 20/10/05 17/01/12 2.10 1.84 234.04 poor 30/08/12 1586.62 221.49 ? 26/10/12 LOT4174114 
S164 19/10/04 17/01/12 2.10 1.42 262.64 9.7 17/04/13 2035.26 298.06 03/06/13 23/07/13 LOT4188786 
S165 22/02/06 17/01/12 2.09 1.42 205.73 10 11/09/12 735.44 215.62 ? 27/10/12 LOT4174114 
S166 27/01/05 19/01/12 2.05 2.14 343.34 9.6 30/04/13 2165.92 296.69 17/06/13 17/07/13 LOT4188786 
S167 29/11/06 19/01/12 2.07 1.56 287.71 10 08/05/13 1516.29 275.07 05/06/13 31/07/13 LOT4205079 
S168 26/02/04 19/01/12 2.06 0.84 77.00 9.2 19/04/13 1826.81 299.64 11/06/13 24/07/13 - 
S169 18/05/04 19/01/12 2.07 0.97 169.04 9.2 18/04/13 1695.88 289.32 17/06/13 16/07/13 LOT4188786 
S170 20/04/04 19/01/12 2.06 2.11 204.14 9.2 30/03/12 994.31 227.59 26/04/12 02/05/12 LOT4156426 
S171 16/07/04 19/01/12 2.03 1.24 112.30 9.5 06/08/12 664.21 221.15 ? 26/10/12 LOT4174114 
S172 29/10/04 19/01/12 2.05 2.01 237.67 7.5 02/11/12 651.73 239.45 ? 06/02/13 - 
S173 19/04/05 19/01/12 2.06 1.37 182.51 9.8 12/04/12 1899.85 245.80 25/04/12 02/05/12 LOT4156426 
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S175 22/09/06 19/01/12 2.08 1.38 135.38 OK 30/04/13 2258.40 291.59 ------------------- FAILED ------------------- 
S176 19/04/07 19/01/12 2.07 1.38 104.88 9.7 28/03/12 395.64 194.04 26/04/12 03/05/12 LOT4156426 
S177 13/12/04 19/01/12 2.05 1.31 149.07 3.0 25/04/13 3209.71 299.71 14/05/13 18/07/13 - 
S178 18/08/05 20/01/12 2.08 1.31 233.92 4.4 02/11/12 1157.17 248.77 ? 05/02/13 LOT4184161 
S179 22/03/07 20/01/12 2.04 1.10 90.18 9.7 01/05/13 2326.04 281.85 31/07/13 13/08/13 LOT4205911 
S180 15/10/04 20/01/12 2.07 0.46 165.24 2.4 19/04/13 2277.57 289.00 30/07/13 13/08/13 LOT4205911 
S181 27/09/07 20/01/12 2.00 1.46 170.31 9.3 01/05/13 2260.42 292.53 29/07/13 14/08/13 LOT4205079 
S182 01/03/05 20/01/12 2.05 2.19 254.44 9.4 19/04/13 2682.08 305.71 31/07/13 14/08/13 LOT4205079 
S183 20/01/05 20/01/12 0.07 1.33 225.74 9.9 01/05/13 2067.72 294.80 01/07/13 09/07/13 LOT4181871 
S184 15/04/06 20/01/12 2.07 1.65 268.59 10 25/04/13 1906.88 290.59 24/07/13 14/08/13 LOT4205079 
S185 23/03/07 20/01/12 2.06 1.02 156.34 3.3 19/04/13 2631.04 293.84 29/07/13 13/08/13 LOT4205911 
S186 06/09/07 20/01/12 2.04 0.73 105.53 8.5 16/03/12 885.01 233.57 25/04/12 01/05/12 LOT4156428 
S187 04/03/05 20/01/12 2.03 2.06 174.87 9.5 02/05/13 2412.62 290.98 01/07/13 16/07/13 LOT4188786 
S188 29/10/04 20/01/12 2.01 0.71 140.66 8.9 03/05/13 2429.15 289.25 31/07/13 15/08/13 LOT4205079 
S189 25/02/05 20/01/12 1.98 0.72 73.19 9.3 19/04/13 2229.01 300.17 29/07/13 13/08/13 LOT4205911 
S190 02/03/06 20/01/12 2.03 0.73 173.85 9.5 02/05/13 2648.59 285.96 29/07/13 15/08/13 LOT4205079 
S191 27/04/04 23/01/12 2.07 1.26 266.01 10 06/03/13 2138.39 279.40 03/04/13 30/04/13 LOT4187458 
S192 31/01/08 23/01/12 2.04 1.32 166.25 9.1 02/05/13 1763.91 281.78 01/07/13 17/07/13 LOT4188786 
S193 26/08/05 23/01/12 2.06 1.74 228.80 9.4 03/05/13 1925.14 287.50 31/07/13 06/08/13 LOT4205079 
S194 08/06/06 23/01/12 2.07 0.43 133.64 9.6 03/05/13 1977.24 285.60 01/07/13 16/07/13 LOT4188786 
S195 10/11/06 25/01/12 2.01 0.78 84.63 OK 08/05/13 707.06 247.50 01/07/13 16/07/13 LOT4188786 
S196 25/10/07 25/01/12 2.06 2.24 205.85 OK 30/04/13 2158.75 267.13 31/07/13 06/08/13 LOT4181223 
S197 02/12/05 26/01/12 2.07 2.02 119.82 8.5 02/05/13 2675.95 287.44 05/06/13 30/07/13 LOT4181223 
S198 07/04/05 26/01/12 2.03 2.18 182.46 8.3 26/10/12 1738.62 230.31 ? 29/01/13 LOT4181223 
S199 09/09/05 01/02/12 2.01 2.13 99.87 7.2 02/11/12 1394.56 272.97 ? 30/01/13 LOT4184161 
S200 27/03/06 23/01/12 2.02 2.12 232.99 9.2 03/05/13 2146.87 291.39 11/06/13 18/07/13 LOT4188786 
S201 17/01/08 23/01/12 2.01 2.09 151.96 9.4 08/05/13 1544.26 274.67 15/05/13 23/07/13 LOT4188786 
S202 15/01/05 23/01/12 2.00 1.32 194.21 7.4 04/09/12 1063.12 250.14 ? 27/10/12 LOT4174114 
S203 15/06/06 23/01/12 2.05 2.17 241.16 9.5 30/08/12 947.31 225.87 ? 25/10/12 LOT4179034 
S204 10/09/04 19/04/12 2.05 2.13 261.02 9.3 30/04/13 1267.09 281.71 30/07/13 14/08/13 LOT4205911 
S205 06/09/07 19/04/12 2.04 2.06 280.13 9.5 11/09/12 1301.20 234.57 ? 27/10/12 LOT4179034 
S206 25/01/08 19/04/12 2.06 2.29 256.74 9.3 03/05/13 1994.19 266.68 11/06/13 18/07/13 LOT4188786 







Table B7: ECACC LCL QIAGEN Extraction and Ambion® RNA Amplification Data for Exon 1.0ST Expression Arrays     
 441 
 
S208 13/01/05 19/04/12 2.03 1.49 258.08 9.1 10/05/13 1652.51 250.13 ------------------- FAILED ------------------- 
S209 25/02/05 24/01/12 2.04 1.89 199.98 9.4 10/05/13 2102.08 277.92 05/06/13 24/07/13 - 
S210 04/12/04 24/01/12 2.06 1.13 188.41 9.4 28/09/12 1345.72 232.30 ? 06/02/13 LOT4181871 
S211 13/01/05 24/01/12 2.08 0.59 88.66 2.7 10/05/13 2123.93 274.16 ------------------- FAILED ------------------- 
S212 29/01/05 25/01/12 2.01 0.94 118.66 7.3 10/05/13 1951.42 296.12 05/06/13 18/07/13 LOT4188786 
S213 07/10/05 25/01/12 2.00 0.91 152.36 8.9 18/09/12 545.93 232.57 ? 26/10/12 LOT4174114 
S214 10/04/04 25/01/12 2.06 0.72 142.00 poor 15/03/13 2166.61 258.90 08/04/13 30/04/13 LOT4187458 
S215 03/11/05 31/01/12 2.00 2.09 140.19 3.9 10/05/13 2097.93 280.88 11/06/13 24/07/13 - 
S216 15/06/06 31/01/12 2.02 2.16 187.75 8.5 28/09/12 1866.10 258.48 ? 30/01/13 - 
S217 15/10/04 27/01/12 2.03 1.96 198.12 7.4 10/05/13 1307.94 279.91 03/06/13 31/07/13 LOT4205079 
S218 23/03/07 27/01/12 2.03 2.12 182.03 9.1 26/10/12 1906.36 266.75 ? 30/01/13 LOT4184161 
S219 22/09/05 26/01/12 2.08 1.50 185.32 9.9 26/10/12 1177.26 238.29 ? 06/02/13 LOT4181871 
S220 29/04/05 26/01/12 2.06 1.59 98.70 poor 09/04/13 2919.29 276.62 12/06/13 17/07/13 LOT4188786 
S221 14/12/04 26/01/12 2.02 1.91 157.71 8.6 10/05/13 1656.25 275.76 03/06/13 30/07/13 LOT4181223 
S222 03/01/08 26/01/12 2.05 2.10 246.65 9.3 09/04/13 2570.63 285.68 ------------------- FAILED ------------------- 
S223 26/02/08 31/01/12 2.06 2.02 216.87 8.4 09/04/13 2449.39 283.88 15/05/13 31/07/13 LOT4205079 
S224 15/05/04 31/01/12 2.05 2.01 283.46 9.2 02/11/12 1126.74 256.13 ? 29/01/13 LOT4181223 
S225 09/07/07 27/01/12 2.08 2.11 256.90 9.5 15/03/13 1966.03 270.31 08/04/13 01/05/13 LOT4187458 
S226 29/04/05 26/01/12 2.05 2.03 177.99 5.2 09/04/13 2024.22 251.87 05/06/13 18/07/13 LOT4188786 
S227 06/05/04 26/01/12 2.09 2.02 219.29 2.4 14/02/13 2211.91 281.03 08/04/13 30/04/13 LOT4187458 
S228 11/11/04 31/01/12 2.03 1.93 282.32 8.9 09/04/13 2299.09 278.55 15/05/13 09/07/13 LOT4181871 
S229 15/08/06 31/01/12 2.05 1.99 411.28 8.5 02/11/12 978.14 235.77 ? 05/02/13 LOT4184161 
S230 15/09/05 31/01/12 2.07 1.97 317.31 9.6 02/11/12 668.92 229.33 ? 30/01/13 LOT4184161 
S231 24/11/06 01/02/12 2.04 2.18 212.11 8.5 15/03/13 2046.53 268.01 26/03/13 01/05/13 LOT4187458 
S232 15/06/06 01/02/12 2.04 2.26 284.99 10 09/04/13 2258.55 276.43 ------------------- FAILED ------------------- 
S233 21/05/05 01/02/12 2.06 1.94 199.76 9.2 09/04/13 2149.72 276.43 15/05/13 02/07/13 LOT4181871 
S234 20/08/04 26/01/12 2.01 2.00 185.56 8.8 12/04/12 2049.73 306.49 25/04/12 02/05/12 LOT4156426 
S235 04/04/06 26/01/12 2.03 2.02 166.20 7.7 07/05/13 1828.61 282.75 ------------------- FAILED ------------------- 
S236 15/06/06 26/01/12 2.05 2.02 210.24 7.2 30/03/12 582.87 222.95 26/04/12 03/05/12 LOT4156426 
S237 15/05/04 27/01/12 2.02 2.10 263.97 7.6 14/02/13 1280.58 274.03 26/03/13 25/04/13 LOT4187458 
S238 12/12/05 27/01/12 2.02 2.03 199.26 9.5 10/05/13 1279.63 269.87 11/06/13 30/07/13 LOT4181223 
S239 30/12/04 26/01/12 2.09 2.13 296.96 8.1 15/03/13 1880.88 263.49 03/04/13 30/04/13 LOT4187458 
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S241 11/06/04 27/01/12 2.06 2.18 229.92 8.6 14/02/13 1640.17 272.77 03/04/13 25/04/13 LOT4187458 
S242 30/08/07 25/01/12 2.05 2.11 251.82 9.3 03/04/12 2374.99 279.17 25/04/12 01/05/12 LOT4158373 
S243 20/12/03 25/01/12 2.04 2.08 222.00 9.1 15/03/13 1803.93 260.74 25/03/13 10/04/13 LOT4181871 
S244 05/01/05 25/01/12 2.02 2.06 168.29 1.9 14/02/13 2391.92 259.21 02/04/13 23/04/13 LOT4188786 
S245 08/04/05 18/04/12 2.01 2.17 208.92 9.8 14/02/13 1778.67 293.96 25/03/13 10/04/13 LOT4181871 
S246 22/05/07 25/01/12 2.04 1.86 145.57 9.4 15/03/13 2420.68 278.54 08/04/13 01/05/13 LOT4187458 
S247 01/02/07 31/01/12 1.98 0.42 126.77 7.9 15/03/13 1721.38 261.67 02/04/13 23/04/13 LOT4188786 
S248 06/08/07 --------------------------------------------------------------- SAMPLE NOT RECEIVED FROM ECACC ----------------------------------------------------------------- 
S249 01/07/04 31/01/12 2.39 2.14 78.32 8.0 14/02/13 1751.73 268.03 08/04/13 24/04/13 LOT4187458 
S268 08/04/05 03/02/12 2.02 1.95 165.61 9.1 30/08/12 996.88 241.23 ? 26/10/12 LOT4174114 
S319 03/10/05 09/02/12 2.06 1.86 196.36 9.4 18/09/12 1232.66 257.00 ? 26/10/12 LOT4174114 
S352 28/02/08 14/02/12 2.02 0.12 47.96 4.8 11/09/12 1492.86 221.79 ? 25/10/12 LOT4179034 
S368 17/04/07 15/02/12 2.07 2.09 136.00 8.6 06/03/13 2160.88 271.99 20/03/13 10/04/13 LOT4181871 
S373 06/09/06 15/02/12 2.09 1.84 154.03 8.9 18/09/12 915.91 286.97 ? 26/10/12 LOT4174114 
S438 12/01/07 13/03/12 1.99 2.18 167.39 6.2 06/03/13 2255.68 298.73 20/03/13 10/04/13 LOT4181871 







 Table B8: C9ORF72 Specific Gene List (n=501) [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
 443 
 
RefSeq # Transcript Symbol Gene Name Fold p-value 
Apoptosis 
NM_012138 3719362 AATF apoptosis antagonizing transcription factor  ⇧ 1.21 3.19E-04 
NM_032306 3818395 ALKBH7 alkB, alkylation repair homolog 7 (E. coli) ⇧ 1.28 0.020 
NM_001188 2950753 BAK1 BCL2-antagonist/killer 1 ⇧ 1.28 0.001 
NM_003824 3338424 FADD Fas (TNFRSF6)-associated via death domain  ⇧ 1.20 0.012 
NM_005256 3323891 GAS2 growth arrest-specific 2 ⇩ 1.42 0.044 
NM_014320 2927722 HEBP2 heme binding protein 2 ⇧ 1.28 0.001 
NM_003897 2948630 IER3 immediate early response 3 ⇧ 1.31 0.010 
NM_018622 2708229 PARL presenilin associated, rhomboid-like  ⇧ 1.21 0.002 
NM_007350 3462816 PHLDA1 pleckstrin homology-like domain, family A, member 1 ⇩ 1.22 0.027 
NM_019006 3603884 ZFAND6 zinc finger, AN1-type domain 6 ⇧ 1.29 0.001 
Autophagy 
NM_003766 3758157 BECN1 beclin 1, autophagy related ⇧ 1.25 8.27E-04 
NM_017983 3768474 WIPI1 WD repeat domain, phosphoinositide interacting 1 ⇧ 1.20 0.034 
Cell Adhesion/Extracellular Matrix 
NM_058172 2774971 ANTXR2 anthrax toxin receptor 2 ⇩ 1.28 0.009 
NM_006614 2607568 CHL1 cell adhesion molecule with homology to L1CAM (close homolog of L1) ⇩ 1.80 0.016 
NM_004273 3251298 CHST3 carbohydrate (chondroitin 6) sulfotransferase 3 ⇩ 1.21 0.019 
NM_001858 2912649 COL19A1 collagen, type XIX, alpha 1 ⇩ 1.22 0.038 
NM_017549 2997907 EPDR1 ependymin related protein 1 (zebrafish) ⇩ 1.20 0.034 
NM_000885 2518272 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) ⇩ 1.25 0.007 
NM_002205 3456732 ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) ⇩ 1.34 0.032 
NM_002211 3284188 ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) ⇩ 1.24 0.019 
NM_021219 3916527 JAM2 junctional adhesion molecule 2 ⇩ 1.27 0.028 
NM_004994 3887210 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) ⇩ 1.31 0.038 
NM_001142864 3704376 PIEZO1 piezo-type mechanosensitive ion channel component 1 ⇩ 1.24 6.41E-04 
NM_000302 2320581 PLOD1 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 ⇩ 1.25 0.002 
NM_021111 3168309 RECK reversion-inducing-cysteine-rich protein with kazal motifs ⇩ 1.21 0.016 
NR_028076 3740432 SCARF1 scavenger receptor class F, member 1 ⇩ 1.23 0.020 
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NM_014000 3252071 VCL vinculin ⇩ 1.39 0.007 
Cellular Response to Stress 
NM_015696 2336439 GPX7 glutathione peroxidase 7 ⇧ 1.36 0.043 
NM_001540 3009399 HSPB1 heat shock 27kDa protein 1 ⇧ 1.24 0.046 
NM_016126 2413519 HSPB11 heat shock protein family B (small), member 11 ⇧ 1.21 0.020 
NM_000305 3061997 PON2 paraoxonase 2 ⇩ 1.39 0.038 
NM_003330 3429460 TXNRD1 thioredoxin reductase 1 ⇧ 1.21 5.48E-04 
Cytoskeleton 
NM_005720 3014714 ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa ⇧ 1.22 0.002 
NM_018462 2662581 BRK1 BRICK1, SCAR/WAVE actin-nucleating complex subunit ⇧ 1.51 0.026 
NM_020240 2828146 CDC42SE2 CDC42 small effector 2 ⇧ 1.25 6.72E-06 
NM_001011546 3878025 DSTN destrin (actin depolymerizing factor) ⇧ 1.20 0.038 
NM_000259 3624607 MYO5A myosin VA (heavy chain 12, myoxin) ⇩ 1.20 0.015 
NM_001142287 4051226 SEMA4D sema domain, immunoglobin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, 
(semaphoring) 4D 
⇩ 1.31 3.25E-05 
NM_020846 2726323 SLAIN2 SLAIN motif family, member 2 ⇧ 1.20 0.001 
NM_006088 4050485 TUBB2C tubulin, beta 2C ⇧ 1.20 0.001 
NM_006087 3847959 TUBB4 tubulin, beta 4 ⇧ 1.27 0.020 
Development 
NM_031443 3000167 CCM2 cerebral cavernous malformation 2 ⇧ 1.26 5.76E-04 
NM_130468 3589972 CHST14 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14 ⇩ 1.24 0.002 
NM_005618 2986350 DLL1 delta-like 1 (Drosophila) ⇩ 1.24 0.003 
NM_000138 3623031 FBN1 fibrillin 1 ⇩ 1.53 0.001 
NM_018972 3103607 GDAP1 ganglioside-induced differentiation-associated protein 1 ⇧ 1.21 0.013 
NM_001448 4022370 GPC4 glypican 4 ⇩ 1.86 0.001 
NM_019590 3238962 KIAA1217 KIAA1217 ⇩ 1.28 0.023 
NM_013349 2379068 NENF neuron derived neurotrophic factor  ⇧ 1.26 1.78E-04 
NM_017617 3230141 NOTCH1 notch 1 ⇩ 1.30 6.87E-05 
NM_002586 2949859 PBX2 B-cell leukemia homeobox 2 ⇩ 1.20 0.023 
NM_015068 3013255 PEG10 paternally expressed 10 ⇩ 1.31 0.017 
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NM_013441 2325479 RCAN3 RCAN family member 3 ⇧ 1.40 1.41E-04 
NM_001122752 2651165 SERPINI1 serpin peptidase inhibitor, clade I (neuroserpin), member 1 ⇩ 1.34 0.004 
NM_005841 2742224 SPRY1 sprout homolog 1, antagonist of FGF signalling (Drosophila) ⇩ 1.37 0.008 
DNA Damage & Repair 
NM_000465 2598099 BARD1 BRCA1 associated RING domain 1 ⇧ 1.21 0.001 
NM_152266 3829160 C19orf40 chromosome 19 open reading frame 40 ⇧ 1.26 1.47E-04 
NM_022774 2331959 DEM1 defects in morphology 1 homolog (S. cerevisiae) ⇧ 1.23 2.04E-04 
NM_023015 2359817 INTS3 integrator complex subunit 3 ⇩ 1.21 6.25E-06 
NM_001174084 3303870 POLL polymerase (DNA directed), lambda ⇩ 1.21 4.01E-04 
NM_006515 2608419 SETMAR SET domain and mariner transposase fusion gene ⇧ 1.28 0.001 
NM_003211 3429365 TDG thymine-DNA glycosylase ⇧ 1.21 0.004 
DNA Replication & the Cell Cycle 
NR_024400 2696379 ANAPC13 anaphase promoting complex subunit 13 ⇧ 1.25 0.011 
NM_173473 3251353 ANAPC16 anaphase promoting complex subunit 16 ⇧ 1.29 0.002 
NM_021178 3555300 CCNB1IP1 cyclin B1 interacting protein 1 ⇧ 1.25 0.018 
NM_032436 3503119 CHAMP1 chromosome alignment maintaining phosphoprotein 1 ⇧ 1.26 6.63E-04 
NM_001177611 3580319 CINP cyclin-dependent kinase 2 interacting protein ⇧ 1.20 0.019 
NM_052951 3887017 DNTTIP1 deoxynucleotidyltransferase, terminal, interacting protein 1 ⇧ 1.28 2.81E-04 
NM_022731 2452637 NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 ⇧ 1.20 8.75E-04 
NM_032346 3829751 PDCD2L programmed cell death 2-like  ⇧ 1.23 3.74E-04 
NM_001130475 3067644 THAP5 THAP domain containing 5 ⇧ 1.21 0.004 
NM_175866 2364155 UHMK1 U2AF homology motif (UHM) kinase 1 ⇧ 1.25 9.64E-05 
NM_016478 3072368 ZC3HC1 zinc finger, C3HC-type containing 1 ⇧ 1.23 8.56E-05 
Hormone Function 
NM_015893 2534324 PRLH prolactin releasing hormone  ⇧ 1.25 0.018 
Immune Response & Inflammation 
NM_001178098 3655109 CD19 CD19 molecule ⇩ 1.24 0.005 
NM_001782 3204648 CD72 CD72 molecule ⇩ 1.27 0.023 
NM_000651 2377332 CR1 complement component (3b/4b) receptor 1 (Knops blood group) ⇩ 1.56 0.007 
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NM_018284 2421843 GBP3 guanylate binding protein 3 ⇧ 1.24 0.020 
NM_130759 3031544 GIMAP1 GTPase, IMAP family member 1 ⇧ 1.32 0.016 
NM_012483 2491745 GNLY granulysin ⇧ 1.32 0.019 
NM_024503 2408681 HIVEP3 human immunodeficiency virus type I enhancer binding protein 3 ⇩ 1.23 0.007 
NM_002125 4048241 HLA-DRB5 major histocompatibility complex, class II, DR beta 5 ⇩ 3.61 0.027 
NM_024013 3164825 IFNA1 interferon, alpha 1 ⇩ 1.34 0.012 
NM_001551 3980455 IGBP1 immunoglobulin (CD79A) binding protein 1 ⇧ 1.31 0.011 
NM_002201 3607275 ISG20 interferon stimuluated exonuclease gene 20kDa ⇧ 1.21 0.012 
NM_000575 2571483 IL1A interleukin 1, alpha ⇧ 1.46 0.041 
NM_000880 3141589 IL7 interleukin 7 ⇩ 1.29 0.045 
NM_007360 3444086 KLRK1 killer cell lectin-like receptor subfamily K, member 1 ⇧ 1.41 0.008 
NM_005565 2886595 LCP2 lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa) ⇩ 1.27 0.045 
NM_001531 2370317 MR1 Mov10, Moloney leukemia virus 10, homolog (mouse) ⇩ 1.20 0.008 
NM_032322 3716993 RNF135 ring finger protein 135 ⇧ 1.22 0.001 
NM_022136 3925473 SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 ⇧ 1.24 0.046 
NM_003037 2440327 SLAMF1 signalling lymphocytic activation molecule family member 1 ⇩ 1.21 1.28E-04 
NM_001104587 3753500 SLFN11 schlafen family member 11 ⇩ 1.28 0.009 
NM_001030288 3655574 SPN sialophorin ⇩ 1.24 6.75E-05 
NM_001077238 3816424 SPPL2B signal peptide peptidase-like 2B ⇩ 1.24 3.22E-05 
Ion Binding 
NM_017623 2494749 CNNM3 cyclin M3 ⇩ 1.29 5.21E-05 
NM_005950 3692999 MT1G metallothionein 1G ⇧ 1.82 0.001 
NM_005951 3662201 MT1H metallothionein 1H ⇧ 1.54 0.007 
Membrane Trafficking 
NM_000443 3060117 ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 ⇩ 1.21 0.032 
NM_004996 3649890 ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 ⇩ 1.22 2.33E-04 
NM_005845 3521174 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ⇩ 1.25 0.005 
NM_005050 3571810 ABCD4 ATP-binding cassette, sub-family D (ALD), member 4 ⇩ 1.24 1.83E-07 
NM_002940 2746024 ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 ⇧ 1.29 0.003 
NM_020980 3595594 AQP9 aquaporin 9 ⇩ 1.39 0.016 
NM_022089 2398736 ATP13A2 ATPase type 13A2 ⇩ 1.23 0.005 
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NM_001001323 3464983 ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 ⇩ 1.20 0.002 
NM_014382 2642325 ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 ⇩ 1.24 5.19E-05 
NM_006095 2767378 ATP8A1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 ⇩ 1.20 0.002 
NM_001048210 2426791 CLCC1 chloride channel CLIC-like 1 ⇩ 1.24 7.24E-04 
NM_013943 2325593 CLIC4 chloride intracellular channel 4 ⇧ 1.24 0.012 
NM_001293 3382948 CLNS1A chloride channel, nucleotide-sensitive, 1A ⇧ 1.20 0.007 
NM_020897 2360818 HCN3 hyperpolarization activated cyclic nucleotide-gated potassium channel 3 ⇩ 1.20 0.003 
NM_012281 3021009 KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2 ⇩ 1.39 0.021 
NM_001160133 2913277 KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 ⇩ 1.21 3.74E-04 
NM_153259 2420642 MCOLN2 mucolipin 2 ⇩ 1.21 0.002 
NM_198887 2979056 NUP43 SAM domain, SH3 domain and nuclear localization signals 1 ⇧ 1.21 9.11E-05 
NM_032790 3434888 ORAI1 ORAI calcium release-activated calcium modulator 1 ⇩ 1.21 0.011 
NM_006598 2845699 SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 ⇩ 1.37 0.020 
NM_201566 3708245 SLC16A13 solute carrier family 16, member 13 (monocarboxylic acid transporter 13) ⇩ 1.27 0.004 
NM_004170 3160658 SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system xag), member 1 ⇩ 1.30 0.016 
NM_001040454 2673547 SLC26A6 solute carrier family 26, member 6 ⇩ 1.31 1.58E-05 
NM_001532 3378244 SLC29A2 solute carrier organic anion transporter family, member 2B1 ⇩ 1.22 0.004 
NM_021194 2454378 SLC30A1 solute carrier family 30 (zinc transporter), member 1 ⇩ 1.20 0.013 
NM_198277 3354443 SLC37A2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 ⇩ 1.29 0.035 
NM_003627 3373893 SLC43A1 solute carrier family 43, member 1 ⇩ 1.24 0.015 
NM_080669 3750685 SLC46A1 solute carrier family 46 (folate transporter), member 1 ⇩ 1.20 0.012 
NM_033262 3570373 SLC8A3 solute carrier family 8 (sodium/calcium exchanger), member 3 ⇩ 1.45 0.006 
NM_007256 3340449 SLCO2B1 solute carrier organic anion transporter family, member 2B1 ⇩ 1.24 0.010 
NM_152468 3736162 TMC8 transmembrane channel-like 8 ⇩ 1.24 2.90E-04 
Metabolism 
NM_006821 3543673 ACOT2 acyl-CoA thioesterase 2 ⇧ 1.22 0.030 
NM_025149 3726406 ACSF2 acyl-CoA synthetase family member 2 ⇩ 1.23 0.013 
NR_023318 3632298 ADPGK ADP-dependent glucokinase ⇩ 1.20 0.011 
NM_000687 3903361 AHCY adenosylhomocysteinase  ⇧ 1.30 0.002 
NM_006995 2899340 BTN2A2 butyrophilin, subfamily 2, member A2 ⇩ 1.22 0.002 
NM_006090 2351632 CEPT1 choline/ethanolamine phosphotransferase 1 ⇩ 1.20 0.008 







 Table B8: C9ORF72 Specific Gene List (n=501) [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
 448 
 
NM_024090 2781813 ELOVL6 ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast) ⇩ 1.26 0.020 
NM_005670 2977949 EPM2A epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) ⇧ 1.20 1.44E-04 
NM_018638 3408018 ETNK1 ethanolamine kinase 1 ⇩ 1.29 2.10E-06 
NM_207122 3328389 EXT2 exostosin 2 ⇩ 1.20 0.012 
NM_004265 3333247 FADS2 fatty acid desaturase 2 ⇩ 1.24 0.002 
NM_021727 3375582 FADS3 fatty acid desaturase 3 ⇩ 1.20 0.002 
NM_017423 2751936 GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7) ⇩ 1.26 0.010 
NM_000155 3167511 GALT galactose-1-phosphate uridylyltransferase ⇩ 1.20 6.30E-04 
NM_021996 3228523 GBGT1 globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 ⇩ 1.34 0.014 
NM_002061 2423625 GCLM glutamate-cysteine ligase, modifier subunit ⇧ 1.24 3.37E-06 
NM_001128227 3205108 GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase ⇧ 1.20 0.001 
NM_000190 3351841 HMBS hydroxymethylbilane synthase ⇧ 1.36 0.011 
NM_000859 2815965 HNGCR 3-hydroxy-3-methylglutaryl-CoA reductase ⇩ 1.24 3.55E-04 
NM_012262 2345196 HS2ST1 heparin sulfate 2-O-sulfotransferase 1 ⇩ 1.21 0.004 
NM_016142 3328069 HSD17B12 hydroxysteroid (17-beta) dehydrogenase 12 ⇩ 1.24 0.013 
NM_024552 3819401 LASS4 LAG1 homolog, ceramide synthase 4 ⇩ 1.24 1.32E-05 
NM_000527 3821015 LDLR low density lipoprotein receptor  ⇩ 1.23 7.82E-04 
NM_153613 3617412 LPCAT4 lysophosphatidylcholine acyltransferase 4 ⇩ 1.27 7.79E-05 
NM_145693 2469910 LPIN1 lipin 1 ⇧ 1.21 0.032 
NM_205834 3830246 LSR lipolysis stimulated lipoprotein receptor  ⇩ 1.25 4.87E-04 
NM_013283 2838688 MAT2B methionine adenosyltransferase II, beta ⇧ 1.27 6.51E-04 
NM_001080480 2944491 MBOAT1 membrane bound O-acyltransferase domain containing 1 ⇩ 1.22 4.72E-04 
NM_138799 2539607 MBOAT2 membrane bound O-acyltransferase domain containing 2 ⇩ 1.57 0.008 
NM_002413 2744734 MGST2 microsomal glutathione S-transferase 2 ⇩ 1.37 0.008 
NM_001018137 3726960 NME2 non-metastatic cells 2, protein (NM23B) expressed in ⇧ 1.20 0.003 
NM_005793 2673136 NME6 NME/NM23 nucleoside diphosphate kinase 6 ⇧ 1.25 0.001 
NM_002537 3629206 OAZ2 ornithine decarboxylase antizyme 2 ⇧ 1.21 0.003 
NM_018425 3259978 PI4K2A phosphatidylinositol 4-kinase type 2 alpha ⇧ 1.36 0.002 
NM_018323 2721777 PI4K2B phosphatidylinositol 4-kinase type 2 beta ⇧ 1.24 0.001 
NM_006556 2436920 PMVK phosphomevalonate kinase ⇧ 1.22 3.28E-06 
NM_001136113 3192171 POMT1 protein-O-mannosyltransferase 1 ⇩ 1.20 1.30E-05 
NM_017750 2562233 RETSAT retinol saturase (all-trans-retinol 13,14-reductase) ⇩ 1.21 0.010 
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NM_005505 3476665 SCARB1 scavenger receptor class F, member 1 ⇩ 1.29 3.77E-06 
NM_005063 3260586 SCD stearoyl-CoA desaturase (delta-9-desaturase) ⇩ 1.21 4.41E-04 
NM_001037582 2775735 SCD5 stearoyl-CoA desaturase 5 ⇩ 1.30 0.026 
NM_152386 2529421 SGPP2 sphingosine-1-phosphate phosphatase 2 ⇩ 1.25 3.68E-06 
NM_003101 2369557 SOAT1 sterol O-acyltransferase 1  ⇩ 1.21 0.016 
NM_006415 3214582 SPTLC1 serine palmitoyltransferase, long chain base subunit 1 ⇩ 1.22 0.005 
NM_000351 3967689 STS steroid sulfatase (microsomal), isozyme S ⇩ 1.24 0.043 
NM_003129 3114832 SQLE squalene epoxidase  ⇩ 1.27 8.78E-04 
NM_003358 3185063 UGCG UDP-glucose ceramide glucosyltransferase ⇩ 1.21 0.006 
NM_022167 3726325 XYLT2 xylosyltransferase II ⇩ 1.22 6.76E-04 
Mitochondrion & the Respiratory Electron Transport Chain 
NM_001190329 2588127 ATP5G3 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C3 (subunit 9) ⇧ 1.22 0.003 
NM_006012 3818376 CLPP ClpP caseinolytic peptidase, ATP-dependent, proteolytic subunit homolog (E. coli) ⇧ 1.21 2.95E-04 
NM_001040431 3758148 COA3 cytochrome c oxidase assembly factor 3 ⇧ 1.24 8.76E-04 
NR_029466 2961300 COX7A2 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) ⇧ 1.29 0.013 
NM_152783 2536800 D2HGDH D-2-hydroxyglutarate dehydrogenase ⇩ 1.21 0.014 
NM_001985 3868963 ETFB electron-transfer-flavoprotein, beta polypeptide ⇧ 1.31 9.96E-06 
NM_001085411 2853388 NADKD1 NAD kinase domain containing 1 ⇧ 1.20 6.68E-04 
NM_004541 3988987 NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa ⇧ 1.31 0.011 
NM_005000 3070658 NDUFA5 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13kDa ⇧ 1.31 0.038 
NM_004546 3027538 NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa ⇧ 1.20 0.021 
NM_003000 2398789 SDHB succinate dehydrogenase complex, subunit B, iron sulphur (Ip) ⇧ 1.27 0.001 
NM_001024465 2982319 SOD2 s⇧eroxide dismutase 2, mitochondrial ⇧ 1.26 0.001 
NM_013442 3204534 STOML2 stomatin (EPB72)-like 2 ⇧ 1.28 7.01E-05 
NM_003355 3381817 UCP2 unco⇧ling protein 2 (mitochondrial, proton carrier) ⇧ 1.24 2.19E-04 
NM_006830 3845352 UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI ⇧ 1.27 0.026 
Neurotransmission 
NM_001114 3659966 ADCY7 adenylate cyclase 7 ⇩ 1.25 1.05E-05 
NM_001009566 2395890 CLSTN1 calsyntenin 1 ⇩ 1.22 6.03E-04 
NM_014718 3403244 CLSTN3 calsyntenin 3 ⇩ 1.38 4.58E-05 
NM_003632 3721989 CNTNAP1 contactin associated protein 1 ⇩ 1.52 9.81E-04 
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NM_007278 3743486 GABARAP GABA(A) receptor-associated protein  ⇧ 1.21 4.72E-04 
NM_012428 3632492 NPTN neuroplastin ⇩ 1.24 0.001 
NM_004782 3937755 SNAP29 synaptosomal-associated protein, 29kDa ⇧ 1.48 1.45E-06 
Nucleosome 
NM_032482 3816264 DOT1L DOT1-like, histone H3 methyltransferase (S. cerevisiae) ⇩ 1.20 0.004 
NM_153757 2777447 NAP1L5 nucleosome assembly protein 1-like 5 ⇧ 1.24 2.03E-04 
NM_021062 2946225 HIST1H2BB histone cluster 1, H2bb ⇧ 1.57 0.024 
NM_003527 2900116 HIST1H2BO histone cluster 1, H2bo ⇧ 1.34 3.10E-04 
NM_003539 2946319 HIST1H4D histone cluster 1, H4d ⇧ 1.40 0.002 
NM_003540 2899243 HIST1H4F histone cluster 1, H4f ⇧ 1.23 0.010 
Protein Processing 
NM_024105 3965393 ALG12 asparagine-linked glycosylation 12, alpha-1,6-mannosyltransferase ⇩ 1.20 0.001 
NM_003917 3557614 AP1G2 adaptor-related protein complex 1, gamma 2 subunit ⇩ 1.20 0.001 
NM_001039569 2601287 APS3 adaptor-related protein complex 1, sigma 3 subunit ⇧ 1.21 0.010 
NM_014570 3962587 ARFGAP3 ADP-ribosylation factor GTPase activating protein ⇧ 1.24 0.001 
NM_024095 3453036 ASB8 ankyrin repeat and SOCS box-containing 8  ⇧ 1.36 0.020 
NM_001139457 4026669 BCAP31 B-cell receptor-associated protein 31 ⇩ 1.31 1.27E-05 
NM_024814 3018652 CBLL1 Cas-Br-M (murine) ecotropic retroviral transforming sequence-like 1 ⇧ 1.25 2.64E-06 
NM_005776 3565303 CNIH cornichon homolog (Drosophila) ⇩ 1.20 5.18E-04 
NM_007263 3855324 COPE coatomer protein complex, subunit epsilon ⇧ 1.24 0.002 
NM_024050 3824212 DDA1 DET1 and DDB1 associated 1 ⇧ 1.27 0.031 
NM_206831 2664607 DPH3 DPH3, KTI11 homolog (S. cerevisiae) ⇧ 1.25 0.016 
NM_013234 3832616 EIF3K eukaryotic translation initiation factor 3, subunit K ⇧ 1.33 1.68E-04 
NM_001417 3455946 EIF4B eukaryotic translation initiation factor 4B ⇧ 1.45 0.011 
NM_004846 2532422 EIF4E2 eukaryotic translation initiation factor 4E family member 2 ⇧ 1.23 0.011 
NM_183004 3553607 EIF5 eukaryotic translation initiation factor 5 ⇧ 1.20 0.001 
NM_033644 2886977 FBXW11 F-box and WD repeat domain containing 11 ⇧ 1.22 1.02E-04 
NM_000801 3894601 FKBP1A FK506 binding protein 1A, 12kDa ⇩ 1.23 0.006 
NM_015949 2986906 GET4 golgi to ER traffic protein 4 homolog (S. cerevisiae) ⇧ 1.24 0.002 
NM_022130 2852237 GOLPH3 golgi phosphoprotein 3 (coat-protein) ⇧ 1.20 0.002 
NM_014761 3667766 IST1 increased sodium tolerance 1 homolog (yeast) ⇧ 1.20 0.008 
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NR_033646 3675462 LMF1 lipase maturation factor 1 ⇩ 1.21 0.015 
NM_005358 3494137 LMO7 LIM domain 7 ⇩ 1.28 0.025 
NM_022149 2708610 MAGEF1 melanoma antigen family F, 1 ⇧ 1.20 0.007 
NM_032868 3817464 MPND MPN domain containing  ⇧ 1.22 1.86E-04 
NM_145255 3760945 MRPL10 mitochondrial ribosomal protein L10 ⇧ 1.21 0.037 
NM_014175 3098454 MRPL15 mitochondrial ribosomal protein L15 ⇧ 1.27 1.83E-04 
NM_017840 3374856 MRPL16 mitochondrial ribosomal protein L16 ⇧ 1.20 0.022 
NM_014763 2489806 MRPL19 mitochondrial ribosomal protein L19 ⇧ 1.22 0.012 
NM_181515 3379708 MRPL21 mitochondrial ribosomal protein L21 ⇧ 1.32 0.003 
NM_145212 2495806 MRPL30 mitochondrial ribosomal protein L30 ⇧ 1.20 0.014 
NM_023937 3824197 MRPL34 mitochondrial ribosomal protein L34 ⇧ 1.33 6.39E-05 
NM_146388 3820414 MRPL4 mitochondrial ribosomal protein L4 ⇧ 1.21 0.002 
NM_003776 3936887 MRPL40 mitochondrial ribosomal protein L40 ⇧ 1.22 0.023 
NM_053050 2560141 MRPL53 mitochondrial ribosomal protein L53 ⇧ 1.22 3.77E-04 
NM_031420 2435195 MRPL9 mitochondrial ribosomal protein L9 ⇧ 1.21 0.007 
NM_022839 3607183 MRPS11 mitochondrial ribosomal protein S11 ⇧ 1.33 1.60E-05 
NM_021107 3832777 MRPS12 mitochondrial ribosomal protein S12 ⇧ 1.29 1.89E-05 
NM_016065 3294348 MRPS16 mitochondrial ribosomal protein S16 ⇧ 1.21 1.83E-04 
NM_016034 3193900 MRPS2 mitochondrial ribosomal protein S2 ⇧ 1.26 0.001 
NM_016100 3878934 NAA20 N(alpha)-acetyltransferase 20, NatB catalytic subunit ⇧ 1.22 0.002 
NM_015678 3485292 NBEA neurobeachin ⇩ 1.27 0.014 
NM_006812 3418436 OS9 osteosarcoma amplified 9, endoplasmic reticulum lectin ⇩ 1.20 0.007 
NM_000287 2954280 PEX6 peroxisomal biogenesis factor 6 ⇩ 1.25 1.61E-04 
NM_012394 2440612 PFDN2 prefoldin subunit 2  ⇧ 1.20 0.003 
NM_176787 3811086 PIGN phosphatidylinositol glycan anchor biosynthesis, class N ⇩ 1.26 9.66E-04 
NM_032634 3204496 PIGO phosphatidylinositol glycan anchor biosynthesis, class O ⇩ 1.26 0.010 
NM_006221 3820177 PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 ⇧ 1.37 1.52E-05 
NM_012388 3592484 PLDN pallidin homolog (mouse) ⇧ 1.30 6.86E-04 
NM_017958 2505957 PLEKHB2 pleckstrin homology domain containing, family B (evectins) member 2 ⇧ 1.21 0.008 
NM_005817 3847005 PLIN3 perilipin 3 ⇧ 1.20 0.004 
NM_152329 3534785 PPIL5 peptidylprolyl isomerase (cyclophilin)-like 5 ⇧ 1.24 0.002 
NM_002792 3912861 PSMA7 proteasome (prosome, macropain) subunit, alpha type, 7 ⇧ 1.28 5.44E-05 
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NM_002814 4017519 PSMD10 proteasome (prosome, macropain) 26S subunit, non-ATPase, 10 ⇧ 1.22 7.62E-05 
NM_031296 2744674 RAB33B RAB33B, member RAS oncogene family ⇧ 1.27 0.004 
NM_014372 2335986 RNF11 ring finger protein 11 ⇧ 1.23 0.004 
NM_015528 3707352 RNF167 ring finger protein 167 ⇩ 1.23 2.12E-05 
NM_017763 3764399 RNF43 ringer finger protein 43 ⇩ 1.20 0.007 
NM_000975 2325192 RPL11 ribosomal protein L11 ⇧ 1.25 0.035 
NM_000983 2394558 RPL22 ribosomal protein L22 ⇧ 1.40 1.06E-04 
NM_052969 2709606 RPL39L ribosomal protein L39-like  ⇧ 1.35 0.007 
NM_021104 3717034 RPL41 ribosomal protein L41 ⇧ 1.32 0.003 
NM_001024921 2766419 RPL9 ribosomal protein L9 ⇧ 1.24 0.014 
NM_001019 3683018 RPS15A ribosomal protein S15a ⇧ 1.27 0.039 
NM_002952 3676300 RPS2 ribosomal protein S2 ⇧ 1.49 0.003 
NM_001042576 3899173 RRBP1 ribosome binding protein 1 homolog 180kDa (dog) ⇩ 1.26 0.009 
NM_005619 3865422 RTN2 reticulon 2 ⇩ 1.23 4.12E-05 
NM_013346 4011768 SNX12 sorting nexin 12 ⇧ 1.20 0.002 
NM_003134 3619165 SRP14 signal recognition particle 14kDa (homologous Alu RNA binding protein) ⇧ 1.34 0.002 
NM_152713 3354764 STT3A STT3, subunit of the oligosaccharyltransferase complex, homolog A (S. cerevisiae) ⇩ 1.21 0.009 
NM_004853 3744800 STX8 syntaxin 8 ⇧ 1.22 0.013 
NM_006936 3934669 SUMO3 SMT3 suppressor of mif two 3 homolog 3 (S. cerevisiae) ⇧ 1.32 5.38E-04 
NR_028383 3391234 TIMM8B translocase of inner mitochondrial membrane 8 homolog B (yeast) ⇧ 1.20 0.015 
NM_014506 3191147 TOR1B torsin family 1, member B (torsin B) ⇩ 1.20 0.006 
NM_003338 3247757 UBE2D1 ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast) ⇧ 1.21 0.001 
NM_015983 2999640 UBE2D4 ubiquitin-conjugating enzyme E2D 4 (putative) ⇧ 1.30 1.32E-04 
NM_003342 3742067 UBE2G1 ubiquitin-conjugating enzyme E2G 1 (UBC7 homolog, yeast) ⇧ 1.22 0.004 
NM_005339 2766532 UBE2K ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) ⇧ 1.38 0.009 
NM_015853 3376023 UBXN1 UBX domain protein 1 ⇧ 1.21 0.015 
NM_006634 2491676 VAMP5 vesicle-associated membrane protein 5 (myobrevin) ⇧ 1.24 0.040 
NM_006555 2999816 YKT6 YKT6 v-SNARE homolog (S. cerevisiae) ⇧ 1.28 5.00E-05 
RNA Processing 
NM_001002252 3435681 ARL6IP4 ADP-ribosylation-like factor 6 interacting protein 4 ⇧ 1.26 8.01E-05 
NM_018696 3788270 ELAC1 elaC homolog 1 (E. coli)  ⇧ 1.24 0.001 
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NM_032288 2659887 FYTTD1 forty-two-three domain containing 1 ⇧ 1.33 1.59E-04 
NM_203505 2773756 G3BP2 GTPase activating protein (SH3 domain) binding protein 2 ⇧ 1.24 4.20E-05 
NM_018983 2739242 GAR1 GAR1 ribonucleoprotein homolog (yeast) ⇧ 1.31 6.95E-05 
NM_002047 2995420 GARS glycyl-tRNA synthetase ⇧ 1.24 0.004 
NM_024775 2477980 GEMIN6 gem (nuclear organelle) associated protein 6 ⇧ 1.29 1.16E-04 
NM_004966 3286286 HNRNPF heterogeneous nuclear ribonucleoprotein F ⇧ 1.22 6.15E-04 
NM_015155 3273484 LARP4B La ribonucleoprotein domain family, member 4B ⇧ 1.20 0.025 
NM_016648 2740005 LARP7 La ribonucleoprotein domain family, member 7 ⇧ 1.20 0.022 
NM_139242 3629378 MTFMT mitochondrial methionyl-tRNA formyltransferase  ⇧ 1.24 0.007 
NM_007362 2713074 NCBP2 nuclear cap binding protein subunit 2, 20kDa ⇧ 1.20 0.010 
NM_007006 3692895 NUDT21 nudix (nucleoside diphosphate linked moiety X)-type motif 21 ⇧ 1.20 6.68E-05 
NM_005008 3962054 NHP2L1 NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) ⇧ 1.22 4.57E-04 
NM_001127460 3457696 PAN2 PAN2 poly(A) specific ribonuclease subunit homolog (S. cerevisiae) ⇩ 1.21 2.09E-05 
NM_020528 3924254 PCBP3 poly(rC) binding protein 3 ⇧ 1.23 0.025 
NM_032758 3961955 PHF5A PHD finger protein 5A ⇧ 1.21 0.020 
NM_004805 2575134 POLR2D polymerase (RNA) II (DNA directed) polypeptide D ⇧ 1.22 0.010 
NM_021974 3945133 POLR2F polymerase (RNA) II (DNA directed) polypeptide F ⇧ 1.22 0.020 
NM_002696 3333622 POLR2G polymerase (RNA) II (DNA directed) polypeptide G ⇧ 1.24 3.80E-04 
NM_006627 3828032 POP4 processing of precursor 4, ribonuclease P/MRP subunit (S. cerevisiae) ⇧ 1.20 0.022 
NM_016059 2952065 PPIL1 peptidylprolyl isomerase (cyclophilin)-like 1 ⇧ 1.22 0.017 
NM_006743 3976519 RBM3 RNA binding motif (RNP1, RRM) protein 3 ⇧ 1.22 9.22E-05 
NM_053043 3033397 RBM33 RNA binding motif protein 33 ⇩ 1.20 4.75E-04 
NM_001098783 2626141 RPP14 ribonuclease P/MRP 14kDa subunit ⇧ 1.37 0.001 
NM_014502 3375049 PRPF19 PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae) ⇧ 1.21 2.24E-04 
NM_024839 2901552 RPP21 ribonuclease P/MRP 21kDa subunit ⇧ 1.23 0.005 
NM_183005 3236538 RPP38 ribonuclease P/MRP 38kDa subunit ⇧ 1.34 0.011 
NM_016047 2544179 SF3B14 splicing factor 3B, 14kDa subunit  ⇧ 1.21 0.002 
NM_005850 2434159 SF3B4 splicing factor 3b, subunit 4, 49kDa ⇧ 1.20 0.019 
NM_019108 3864597 SMG9 Smg-9 homolog, nonsense mediated mRNA decay factor (C. elegans)  ⇩ 1.24 6.65E-05 
NM_177542 3865568 SNRPD2 small nuclear ribonucleoprotein D2 polypeptide 16.5kDa ⇧ 1.23 0.012 
NM_014188 2391647 SSU72 SSU72 RNA polymerase II CTD phosphatase homolog (S. cerevisiae) ⇧ 1.25 1.64E-04 
NM_007178 3406421 STRAP serine/threonine kinase receptor associated protein  ⇧ 1.20 0.001 
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NR_027962 2342391 TYW3 tRNA-yW synthesizing protein 3 homolog (S. cerevisiae) ⇧ 1.24 0.010 
NM_007187 3486807 WBP4 WW domain binding protein 4 (formin binding protein 21) ⇧ 1.20 0.002 
NM_033114 3451318 ZCRB1 zinc finger CCHC-type and RNA binding motif 1 ⇧ 1.26 7.15E-05 
Sensory Perception 
NM_001001963 2390253 OR2L8 olfactory receptor, family 2, subfamily L, member 8 ⇧ 1.34 0.032 
NM_001005278 2439508 OR6N2 olfactory receptor, family 6, subfamily N, member 2 ⇧ 1.34 0.032 
Signal Transduction 
NM_001040196 2320411 AGTRAP angiotensin II receptor-associated protein ⇩ 1.22 0.006 
NM_130847 3345222 AMOTL1 angiomotin like 1 ⇩ 1.20 0.036 
NM_018287 3283920 ARHGAP19 Rho GTPase activating protein 12 ⇩ 1.20 0.007 
NM_032900 3302177 ARHGAP19 Rho GTPase activating protein 19 ⇧ 1.22 0.042 
NM_012106 3662650 ARL2BP ADP-ribosylation factor-like 2 binding protein ⇧ 1.20 0.022 
NM_016289 2531522 CAB39 calcium binding protein 39 ⇧ 1.25 7.76E-04 
NM_030925 3513752 CAB39L calcium binding protein 39-like ⇧ 1.27 0.007 
NM_005795 2591367 CALCRL calcitonin receptor-like  ⇩ 1.33 0.037 
NM_006833 3015216 COPS6 COP9 constitutive photomorphogenic homolog subunit 6 (Arabidopsis) ⇧ 1.22 0.004 
NM_001130048 3522398 DOCK9 dedicator of cytokinesis 9 ⇩ 1.39 0.033 
NM_000118 3226097 ENG endoglin ⇩ 1.31 0.002 
NM_004447 3445908 EPS8 epidermal growth factor receptor pathway substrate 8 ⇧ 1.51 0.035 
NM_004101 2863363 F2RL2 coagulation factor II (thrombin) receptor-like 2 ⇩ 1.20 0.002 
NM_004112 3708644 FGF11 fibroblast growth factor 11 ⇩ 1.33 0.005 
NM_001174064 3132016 FGFR1 fibroblast growth factor receptor 1 ⇩ 1.73 6.68E-04 
NM_213647 2842911 FGFR4 fibroblast growth factor receptor 4 ⇩ 1.21 0.001 
NM_138445 2986999 GPR146 G protein-coupled receptor 146 ⇧ 1.55 0.003 
NM_014181 2485406 HSPC159 galectin-related protein ⇩ 1.34 0.011 
NM_002224 2903782 ITPR3 inositol 1,4,5-triphosphate receptor, type 3 ⇩ 1.22 7.81E-04 
NM_017907 3380980 LAMTOR1 late endosomal/lysosomal adaptor, MAPK and mTOR activator 1  ⇩ 1.29 6.93E-04 
NM_002309 3957160 LIF leukemia inhibitory factor (cholinergic differentiation factor) ⇧ 1.23 0.013 
NM_001040056 3687494 MAPK3 mitogen-activated protein kinase 3 ⇩ 1.32 0.001 
NM_001142633 3744680 PIK3R5 phosphoinositide-3-kinase, regulatory subunit 5 ⇧ 1.25 0.014 
NM_021959 2901352 PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit 11 ⇧ 1.21 0.002 
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NM_001033582 2316245 PRKCZ protein kinase C, zeta ⇩ 1.26 8.50E-04 
NM_000956 3535780 PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa ⇩ 1.23 6.53E-04 
NM_002838 2373842 PTPRC protein tyrosine phosphatase, receptor type, C ⇧ 1.24 0.011 
NM_014990 3561110 RALGAPA1 Ral GTPase activating protein, alpha subunit 1 (catalytic) ⇧ 1.20 0.023 
NM_001010935 2351872 RAP1A RAP1A, member of RAS oncogene family ⇩ 1.20 0.004 
NM_002886 2648378 RAP2B RAP2B, member of RAS oncogene family ⇧ 1.24 1.87E-04 
NM_024599 3771602 RHBDF2 rhomboid 5 homolog 2 (Drosophila) ⇧ 1.28 4.45E-05 
NM_022157 2407729 RRAGC Ras-related GTP binding C ⇧ 1.25 6.98E-04 
NM_021244 2964231 RRAGD Ras-related GTP binding D ⇧ 1.71 0.004 
NM_174919 3759824 SH3D20 SH3 domain containing 20 ⇩ 1.20 0.027 
NM_054114 2982076 TAGAP T-cell activation Rho GTPase activating protein ⇧ 1.22 0.007 
NM_014604 3741528 TAX1BP3 Tax1 (human T-cell leukemia virus type I) binding protein 3 ⇧ 1.24 0.036 
NM_003839 3791254 TNFRSF11A tumor necrosis factor receptor superfamily, member 11a, NFKB activator ⇩ 1.36 0.034 
NM_002546 3150455 TNFRSF11B tumor necrosis factor receptor superfamily 11b ⇩ 1.34 0.027 
NM_014452 2956052 TNFRSF21 tumor necrosis factor receptor superfamily, member 21 ⇩ 1.28 0.039 
NM_001243 2320683 TNFRSF8 tumor necrosis factor receptor superfamily, member 8 ⇩ 1.22 0.003 
NM_005981 3418492 TSPAN31 tetraspanin 31 ⇩ 1.25 0.005 
NM_003353 2545645 UCN urocortin ⇧ 1.20 0.003 
NM_003904 3392871 ZNF259 zinc finger protein 259 ⇧ 1.21 0.002 
Transcription 
NM_001129 2999755 AEBP1 AE binding protein 1 ⇩ 1.25 0.020 
NM_007021 3286776 C10orf10 chromosome 10 open reading frame 10 ⇩ 1.26 0.005 
NM_005760 2548459 CEBPZ CCAAT/enhancer binding protein (C/EBP), zeta ⇧ 1.20 0.015 
NM_001127192 2694644 CNBP CCHC-type zinc finger, nucleic acid binding protein ⇧ 1.21 0.008 
NM_014335 3593261 EID1 interacting inhibitor of differentiation 1 ⇧ 1.23 0.005 
NM_032377 3851055 ELOF1 elongation factor 1 homolog (S. cerevisiae) ⇧ 1.21 0.022 
NM_002095 3130113 GTF2E2 general transcription factor IIE, polypeptide 2, beta 34kDa ⇧ 1.23 0.002 
NM_001516 3435946 GTF2H3 general transcription factor IIH, polypeptide 3, 34kDa  ⇧ 1.20 0.003 
NM_012259 2924492 HEY2 hairy/enhancer-of-split related with YRPW motif 2 ⇧ 1.27 0.003 
NM_001080424 3709153 KDM6B lysine (K)-specific demethylase 6B ⇩ 1.20 0.004 
NM_199072 3019981 MDFIC MyoD family inhibitor domain containing  ⇧ 1.20 0.010 
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NM_018270 3892918 MRGBP MRG/MORF4L binding protein  ⇧ 1.21 0.010 
NM_030759 3248897 NRBF2 nuclear receptor binding factor 2 ⇧ 1.24 2.93E-05 
NM_013388 2545509 PREB prolactin regulatory element binding  ⇧ 1.21 7.15E-04 
NM_005859 2831567 PURA purine-rich element binding protein A ⇧ 1.20 1.39E-05 
NM_152501 2362351 PYHIN1 pyrin and HIN domain family, member 1 ⇧ 1.49 0.010 
NM_002904 2948713 RDBP RNA binding protein  ⇧ 1.21 0.002 
NM_134428 3196842 RFX3 regulatory factor X, 3 (influences HLA class II expression) ⇩ 1.20 0.006 
NM_001134338 3895795 RNF24 ring finger protein 24 ⇩ 1.21 0.002 
NM_001035235 2878347 SRA1 steroid receptor RNA activator 1 ⇧ 1.21 8.68E-04 
NM_004599 3947123 SREBF2 sterol regulatory element binding transcription factor 2 ⇩ 1.21 2.29E-06 
NM_003935 3954331 TOP3B topoisomerase (DNA) III beta ⇩ 1.24 3.93E-05 
NM_020368 2730531 UTP3 UTP3, small subunit (SSU) processome component, homolog (S. cerevisiae) ⇧ 1.24 0.002 
NM_153477 4007216 UXT ubiquitously-expressed transcript  ⇧ 1.25 0.035 
NM_016535 3842301 ZNF581 zinc finger protein 581 ⇧ 1.21 0.034 
NM_152457 3677612 ZNF597 zinc finger protein 597 ⇧ 1.27 2.12E-04 
NM_001082480 3119735 ZNF623 zinc finger protein 623 ⇧ 1.20 0.002 
NM_016331 2653902 ZNF639 zinc finger protein 639  ⇧ 1.32 2.20E-04 
NM_001159293 3856184 ZNF737 zinc finger protein 737 ⇧ 1.20 0.047 
NM_170783 2901333 ZNRD1 zinc ribbon domain containing 1 ⇧ 1.24 0.002 
NM_017580 3269373 ZRANB1 zinc finger, RAN-binding domain containing 1 ⇧ 1.29 0.039 
Miscellaneous 
NM_133174 2878368 APBB3 amyloid beta (A4) precursor protein-binding, family B, member 3 ⇩ 1.23 4.07E-04 
NM_001034850 2849992 FAM134B family with sequence similarity 134, member B ⇩ 1.33 0.043 
NM_014053 2379280 FLVCR1 feline leukemia virus subgroup C cellular receptor 1 ⇩ 1.22 0.012 
NM_173794 4006416 FUNDC1 FUN14 domain containing 1 ⇧ 1.27 0.004 
NM_198682 2787902 GYPE glycophorin E (MNS blood group) ⇧ 1.26 0.043 
NM_198527 3639007 HDDC3 HD domain containing 3 ⇧ 1.22 3.63E-04 
NM_001005405 3380769 KRTAP5-11 keratin associated protein 5-11 ⇧ 1.27 6.69E-04 
NM_018368 2960010 LMBRD1 LMBR1 domain containing 1 ⇩ 1.20 0.012 
NM_014623 2954324 MEA1 male-enhanced antigen 1 ⇧ 1.31 0.001 
NM_001161 3167383 NUDT2 nudix (nucleoside diphosphate linked moiety X)-type motif 2 ⇧ 1.29 0.005 
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NM_016104 2922756 RWDD1 RWD domain containing 1 ⇧ 1.26 2.93E-04 
NM_170601 3396003 SIAE sialic acid acetylesterase  ⇩ 1.32 0.005 
NM_145251 3535922 STYX serine/threonine/tyrosine interacting protein  ⇧ 1.20 0.004 
NM_022152 2599371 TMBIM1 transmembrane BAX inhibitor motif containing 1 ⇩ 1.20 0.004 
NM_199360 3893760 TPD52L2 tumor protein D52-like 2 ⇧ 1.20 0.007 
Unknown Function 
NM_019048 2519860 ASNSD1 asparagine synthetase domain containing 1 ⇧ 1.20 0.009 
NM_173694 4024160 ATP11C ATPase, class VI, type 11C ⇩ 1.24 0.001 
NM_003910 3014742 BUD31 BUD31 homolog (S. cerevisiae) ⇧ 1.21 0.005 
NM_024099 3375999 C11orf48 chromosome 11 open reading frame 48 ⇧ 1.27 0.049 
NM_014267 3322048 C11orf58 chromosome 11 open reading frame 58 ⇧ 1.20 7.36E-04 
NM_013300 3431553 C12orf24 chromosome 12 open reading frame 24 ⇩ 1.20 0.049 
NM_025113 3512948 C13orf18 chromosome 13 open reading frame 18 ⇧ 1.47 0.034 
NM_017799 3537264 C14orf101 chromosome 14 open reading frame 101 ⇩ 1.27 3.37E-06 
BC030270 3743734 C17orf61 chromosome 17 open reading frame 61 ⇧ 1.22 0.021 
NM_001162530 2330393 C1orf113 chromosome 1 open reading frame 113 ⇩ 1.21 0.006 
NM_020362 2325274 C1orf128 chromosome 1 open reading frame 128 ⇧ 1.26 7.02E-05 
NM_001136494 2460325 C1orf198 chromosome 1 open reading frame 198 ⇧ 1.22 0.001 
BC001508 2332767 C1orf50 chromosome 1 open reading frame 50  ⇧ 1.29 0.002 
NR_026761 2378710 C1orf97 chromosome 1 open reading frame 97 ⇧ 1.24 0.010 
NR_026562 388397 C20orf24 chromosome 20 open reading frame 24 ⇧ 1.23 0.004 
NM_015500 3933331 C2CD2 C2 calcium-dependent domain containing 2 ⇩ 1.27 4.14E-05 
NM_032319 2559494 C2orf7 chromosome 2 open reading frame 7 ⇧ 1.28 0.017 
NM_016474 2611981 C3orf19 chromosome 3 open reading frame 19 ⇧ 1.21 0.022 
NM_018356 2805176 C5orf22 chromosome 5 open reading frame 22 ⇧ 1.28 0.001 
NM_001048249 2858793 C5orf43 chromosome 5 open reading frame 43 ⇧ 1.27 5.44E-05 
NM_199184 2954489 C6orf108 chromosome 6 open reading frame 108 ⇧ 1.34 3.28E-04 
NM_001135674 3096271 C8orf40 chromosome 8 open reading frame 40 ⇧ 1.26 8.96E-04 
NM_033428 3198289 C9orf123 chromosome 9 open reading frame 123 ⇧ 1.24 0.003 
NM_032357 2575980 CCDC115 coiled-coil domain containing 115 ⇧ 1.21 0.012 
NM_015510 3714659 DHRS7B dehydrogenase/reductase (SDR family) member 7B ⇩ 1.20 0.007 
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NM_024693 3235255 ECHDC3 enoyl CoA hydratase domain containing 3 ⇧ 1.21 0.002 
NM_001015045 2777487 FAM13A family with sequence similarity 13, member A ⇩ 1.30 0.028 
NM_018999 3255402 FAM190B family with sequence similarity 190, member B ⇧ 1.20 0.019 
NM_030797 2541699 FAM49A family with sequence similarity 49, member A ⇧ 1.33 0.003 
NM_004699 3996430 FAM50A family with sequence similarity 50, member A ⇧ 1.22 8.57E-04 
AK127183 3110055 FLJ45248 FLJ45248 protein  ⇧ 1.23 0.001 
NR_002188 2437205 GBAP1 glucosidase, beta, acid pseudogene 1 ⇩ 1.34 0.014 
NR_002830 2422227 GEMIN8P4 gem (nuclear organelle) associated protein 8 pseudogene 4 ⇧ 1.25 0.014 
NM_022343 3168385 GLIPR2 GLI pathogenesis-related 2 ⇧ 1.21 0.018 
NM_001001413 3583541 GOLGA6L1 golgin A6 family-like 1 ⇧ 1.20 0.011 
NM_001036645 2341645 HHLA3 HERV-H LTR-associating 3 ⇧ 1.26 0.014 
BC034589 2399620 KIAA0090 KIAA0090 ⇩ 1.21 0.007 
NM_014734 3542145 KIAA0247 KIAA0247  ⇩ 1.20 0.004 
NM_033426 3545311 KIAA1737 KIAA1737 ⇧ 1.22 0.001 
NM_020803 2776998 KLHL8 kelch-like 8 (Drosophila) ⇧ 1.27 1.94E-06 
NM_006014 4027345 LAGE3 L antigen family, member 3 ⇧ 1.24 3.69E-07 
NR_036496 2555252 LOC339803 hypothetical LOC339803 ⇧ 1.26 0.011 
NR_015341 3717452 LRRC37BP1 leucine rich repeat containing 37B pseudogene 1 ⇩ 1.22 0.001 
NM_052940 2336913 LRRC42 leucine rich repeat containing 42 ⇧ 1.26 3.59E-05 
NM_001168465 4002081 MAP7D2 MAP7 domain containing 2 ⇩ 1.39 0.025 
NM_018349 3609592 MCTP2 multiple C2 domains, transmembrane 2 ⇩ 1.20 0.013 
NR_027345 3433466 NCRNA00173 non-protein coding RNA 173 ⇩ 1.35 0.031 
NM_004337 3106276 OSGIN2 oxidative stress induced growth inhibitor family member 2 ⇧ 1.22 0.035 
NM_207351 2662473 PRRT3 proline-rich transmembrane protein 3 ⇩ 1.25 0.002 
NM_017699 2636483 SIDT1 SID1 transmembrane family, member 1 ⇩ 1.26 2.04E-04 
NM_018225 3203382 SMU1 smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) ⇧ 1.32 0.011 
NM_139015 3474697 SPPL3 signal peptide peptidase 3 ⇩ 1.20 9.51E-04 
NM_003731 3195296 SSNA1 Sjogren syndrome nuclear autoantigen 1 ⇧ 1.25 0.015 
NM_001163436 2780734 TBCK TBC1 domain containing kinase ⇩ 1.23 8.60E-04 
NM_198563 2676471 TMEM110 transmembrane protein 110 ⇩ 1.20 0.011 
NM_032928 3194613 TMEM141 transmembrane protein 141 ⇧ 1.21 0.005 
NM_018342 2749380 TMEM144 transmembrane protein 144 ⇩ 1.28 0.039 
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NM_018004 2633691 TMEM45A transmembrane protein 45A ⇩ 1.30 0.019 
NM_014698 2458513 TMEM63A transmembrane protein 63A ⇩ 1.33 8.31E-07 
NM_032824 2500615 TMEM87B transmembrane protein 87B ⇩ 1.22 4.61E-04 
NM_001193451 3449068 TMTC1 transmembrane and tetratricopeptide repeat containing 1 ⇩ 1.49 0.034 
NM_01167942 3817602 TNFAIP8L1 tumor necrosis factor, alpha-induced protein 8-like 1 ⇧ 1.27 4.07E-05 
NM_182752 2317434 TPRG1L tumor protein p63 regulated 1-like ⇧ 1.21 0.015 
NM_181713 2472914 UBXN2A UBX domain protein 2A ⇧ 1.33 8.80E-05 
NM_020945 3245783 WDFY4 WDFY family member 4 ⇩ 1.22 1.44E-04 
NM_018268 2863535 WDR41 WD repeat domain 41 ⇧ 1.22 1.50E-04 
NM_018471 2519140 ZC3H15 zinc finger CCCH-type containing 15 ⇧ 1.20 3.26E-04 
NM_153251 3504691 ZDHHC20 zinc finger, DHHC-type containing 20 ⇩ 1.22 0.002 
NM_001011657 4016001 ZMAT1 zinc finger, amtrin-type 1 ⇩ 1.40 0.018 
NM_019103 3956984 ZMAT5 zinc finger, matrin-type 5 ⇧ 1.26 2.98E-04 
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RefSeq # Transcript Symbol Gene Name Fold p-value  Fold p-value 
    C9ORF72  SALS 
Apoptosis 
NM_006305 3630912 ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A ⇧ 1.26 1.91E-04  ⇧ 1.23 2.77E-04 
NM_000484 3927226 APP amyloid beta (A4) precursor protein  ⇩ 1.36 0.005  ⇩ 1.39 0.001 
NM_001114735 3635198 BCL2A1 BCL2-related protein A1 ⇧ 1.34 0.007  ⇧ 1.26 0.020 
NM_001168 3736290 BIRC5 baculoviral IAP repeat-containing 5 ⇧ 1.21 0.003  ⇧ 1.31 8.64E-06 
NM_145018 3342426 C11orf82 chromosome 11 open reading frame 82 ⇧ 1.25 0.024  ⇧ 1.64 2.72E-07 
NM_004346 2796484 CASP3 caspase 3 ⇧ 1.42 4.50E-05  ⇧ 1.30 8.42E-04 
NM_001226 2781693 CASP6 caspase 6 ⇧ 1.21 0.011  ⇧ 1.32 1.15E-04 
AF151902 3823613 FAM32A family with sequence similarity 32, member A ⇧ 1.25 0.004  ⇧ 1.34 6.12E-05 
NM_002342 3402444 LTBR lymphotoxin beta receptor (TNFR superfamily, member 3) ⇩ 1.21 0.037  ⇩ 1.20 0.030 
NM_003804 2892341 RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 ⇧ 1.27 0.003  ⇧ 1.21 0.008 
NM_024787 3130850 RNF122 ring finger protein 122 ⇩ 1.38 7.97E-04  ⇩ 1.23 0.016 
NM_053055 2435347 THEM4 thioesterase superfamily member 4 ⇧ 1.23 0.042  ⇧ 1.20 0.045 
NM_032027 2415728 TM2D1 TM2 domain containing 1 ⇩ 1.25 8.03E-04  ⇩ 1.28 8.08E-05 
NM_003842 3127703 TNFRSF10B tumor necrosis factor receptor superfamily, member 10b ⇩ 1.32 1.64E-04  ⇩ 1.25 0.001 
Autophagy 
NM_052936 3986672 ATG4A ATG4 autophagy related 4 homolog A (S. cerevisiae) ⇧ 1.24 3.02E-04  ⇧ 1.24 9.89E-05 
NM_001077198 2599955 ATG9A ATG9 autophagy related 9 homolog A (S. cerevisiae) ⇩ 1.28 6.35E-06  ⇩ 1.26 8.27E-06 
Cell Adhesion/Extracellular Matrix 
NM_001110 3626555 ADAM10 ADAM metallopeptidase domain 10 ⇩ 1.22 3.91E-04  ⇩ 1.23 6.52E-05 
NM_003183 2539821 ADAM17 ADAM metallopeptidase domain 17 ⇩ 1.26 0.001  ⇩ 1.32 2.72E-05 
NM_021723 3011492 ADAM22 ADAM metallopeptidase domain 22  ⇩ 1.47 1.39E-05  ⇩ 1.32 6.61E-04 
NM_007002 3892607 ADRM1 adhesion regulating molecule 1 ⇧ 1.24 2.48E-05  ⇧ 1.20 9.75E-05 
NM_022842 2671728 CDCP1 CUB domain containing protein 1 ⇩ 1.66 4.81E-04  ⇩ 1.53 0.001 
NM_001185072 3012019 CLDN12 claudin 12 ⇩ 1.22 0.039  ⇩ 1.40 1.75E-04 
NM_003798 3219621 CTNNAL1 catenin (cadherin-associated protein), alpha-like 1  ⇧ 1.30 0.004  ⇧ 1.41 4.76E-05 
NM_016938 3377933 EFEMP2 EGF-containing fibulin-like extracellular matrix protein 2 ⇩ 1.33 0.002  ⇩ 1.35 5.51E-04 
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NM_001099786 3766621 ICAM2 intracellular adhesion molecule 2 ⇩ 1.21 0.016  ⇩ 1.22 0.006 
NM_002210 2519229 ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) ⇩ 1.20 0.001  ⇩ 1.28 7.71E-06 
NM_004763 2539765 ITGB1BP1 integrin beta 1 binding protein 1 ⇧ 1.20 0.016  ⇧ 1.33 7.71E-06 
NM_000212 3724545 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ⇩ 1.52 0.005  ⇩ 1.53 0.003 
NM_002293 2371065 LAMC1 laminin, gamma 1 (formerly LAMB2) ⇩ 1.34 0.003  ⇩ 1.31 0.003 
NM_022356 2409004 LEPRE1 leucine proline-enriched proteoglycan (leprecan) 1 ⇩ 1.30 8.39E-05  ⇩ 1.29 4.00E-05 
NM_002428 3663074 MMP15 matrix metallopeptidase 15 (membrane-inserted) ⇩ 1.23 0.043  ⇧ 1.57 6.22E-06 
NM_002508 2462160 NID1 nidogen 1 ⇩ 1.45 0.009  ⇩ 1.34 0.027 
NM_000285 3859026 PEPD peptidase D ⇧ 1.20 0.008  ⇧ 1.29 8.90E-05 
NM_182943 2699564 PLOD2 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 2  ⇩ 1.69 0.006  ⇩ 1.57 0.010 
NM_001084 3064541 PLOD3 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 3 ⇩ 1.25 6.22E-05  ⇩ 1.32 1.62E-07 
NM_002855 3394488 PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C) ⇩ 1.23 0.004  ⇩ 1.21 0.004 
NM_001235 3340589 SERPINH1 serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 
(collagen binding protein 1) 
⇩ 1.40 2.90E-04  ⇩ 1.21 0.024 
NM_001099401 3061805 SGCE sarcoglycan, epsilon  ⇩ 1.48 1.15E-04  ⇩ 1.33 0.002 
Cellular Response to Stress 
NM_000637 3130161 GSR glutathione reductase ⇧ 1.36 2.29E-04  ⇧ 1.23 0.006 
NM_006948 3925439 HSPA13 heat shock protein 70kDa family, member 13 ⇩ 1.21 0.048  ⇩ 1.39 3.64E-04 
NM_020677 3678147 NMRAL1 NmrA-like family domain containing 1 ⇧ 1.23 0.007  ⇧ 1.21 0.006 
NM_007262 2318736 PARK7 Parkinson disease (autosomal recessive, early onset) 7 ⇧ 1.25 6.36E-05  ⇧ 1.20 3.54E-04 
NM_001012961 2333168 SZT2 seizure threshold 2 homolog (mouse) ⇩ 1.22 8.40E-04  ⇩ 1.20 9.92E-04 
NM_032731 3707990 TXNDC17 thioredoxin domain containing 7 ⇧ 1.22 0.019  ⇧ 1.29 0.001 
Cytoskeleton 
NM_002313 3307939 ABLIM1 acting binding LIM protein 1 ⇧ 1.32 3.10E-04  ⇧ 1.40 3.55E-06 
NM_001613 3299504 ACTA2 actin, alpha 2, smooth muscle, aorta ⇧ 1.26 0.027  ⇧ 1.27 0.016 
NM_013427 3999568 ARHGAP6 Rho GTPase activating protein 6 ⇩ 1.25 0.032  ⇩ 1.32 0.005 
NM_005717 2447454 ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa ⇧ 1.20 0.009  ⇧ 1.22 0.003 
NM_030978 3188993 ARPC5L actin related protein 2/3 complex, subunit 5-like ⇧ 1.31 3.22E-04  ⇧ 1.29 2.53E-04 
NM_004368 3815399 CNN2 calponin 2 ⇧ 1.34 0.002  ⇧ 1.50 6.63E-06 
NM_021149 3702547 COTL1 coactosin-like 1 (Dictylostelium) ⇧ 1.25 0.044  ⇧ 1.51 9.13E-05 
NM_144666 3318844 DNHD1 dynein heavy chain domain 1 ⇩ 1.25 3.31E-04  ⇩ 1.20 0.002 
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NM_080677 3728509 DYNLL2 dynein, light chain, LC8-type 2 ⇧ 1.29 8.27E-07  ⇧ 1.25 4.32E-06 
NM_006520 4004819 DYNLT3 dynein, light chain, Tctex-type 3 ⇧ 1.25 0.024  ⇧ 1.20 0.041 
NM_005103 3396593 FEZ1 fasciculation and elongation protein zeta 1 (zygin I) ⇧ 1.59 0.008  ⇧ 1.49 0.016 
NM_201274 3712363 MPRIP myosin phosphatase Rho interacting protein ⇩ 1.20 0.034  ⇩ 1.22 0.015 
NM_032242 2640579 PLXNA1 plexin A1 ⇩ 1.22 0.007  ⇩ 1.40 2.30E-06 
NM_203401 2402459 STMN1 stathmin 1 ⇧ 1.21 0.034  ⇧ 1.42 3.02E-05 
NM_001039141 3944922 TRIOBP TRIO and F-actin binding protein  ⇧ 1.20 0.003  ⇧ 1.21 0.001 
NM_001070 3721926 TUBG1 tubulin, gamma 1 ⇧ 1.29 0.005  ⇧ 1.37 2.68E-04 
Development 
NM_014913 3795501 ADNP2 ADNP homeobox 2 ⇧ 1.36 1.02E-04  ⇧ 1.26 0.001 
AY358167 2494579 ARID5A AT rich interactive domain 5A ⇩ 1.25 3.26E-04  ⇩ 1.22 5.55E-04 
NM_004078 2450865 CSRP1 cysteine and glycine-rich protein 1 ⇧ 1.22 0.008  ⇧ 1.31 1.20E-04 
NM_019074 3590239 DLL4 delta-like 4 (Drosophila) ⇩ 1.32 0.012  ⇩ 1.33 0.006 
NM_001197293 3091077 DPYSL2 dihydropyrimidinase-like 2 ⇧ 1.29 0.042  ⇧ 1.40 0.004 
NM_021783 4011096 EDA2R ectodysplasin A2 receptor  ⇩ 1.33 0.003  ⇩ 1.30 0.003 
NM_002146 3761313 HOXB3 homeobox B3 ⇩ 1.38 3.38E-06  ⇩ 1.23 0.001 
NM_024019 2782267 NEUROG2 neurogenin 2 ⇩ 1.40 0.009  ⇩ 1.52 5.26E-04 
NM_024408 2431112 NOTCH2 notch 2 ⇩ 1.28 0.044  ⇩ 1.42 0.002 
NM_020796 2872047 SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6A 
⇩ 1.52 8.13E-04  ⇩ 1.33 0.013 
NM_000346 3733590 SOX9 SRY (sex determining region Y)-box 9 ⇩ 1.30 0.008  ⇩ 1.27 0.009 
NM_181642 3590164 SPINT1 serine peptidase inhibitor, Kunitz type 1 ⇩ 1.37 0.001  ⇩ 1.26 0.008 
NM_001025366 2908179 VEGFA vascular endothelial growth factor A ⇩ 1.28 0.002  ⇩ 1.29 8.93E-04 
NM_025216 2528159 WNT10A wingless-type MMTV integration site family, member 10A ⇩ 1.30 0.008  ⇩ 1.22 0.027 
DNA Damage & Repair 
NM_015251 3670668 ATMIN ATM interactor  ⇧ 1.45 3.82E-07  ⇧ 1.24 0.001 
NM_020375 3401756 C12orf5 chromosome 12 open reading frame 5 ⇧ 1.47 0.004  ⇧ 1.51 0.001 
NM_022836 2352743 DCLRE1B DNA cross-link repair 1B ⇧ 1.22 6.15E-04  ⇧ 1.27 1.96E-05 
NM_024086 3687789 DCTPP1 dCTP pyrophosphatase 1 ⇧ 1.30 4.82E-04  ⇧ 1.27 7.24E-04 
NM_138287 2638962 DTX3L deltex 3-like (Drosophila) ⇧ 1.22 0.039  ⇧ 1.31 0.003 
NM_006482 3420854 DYRK2 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 ⇧ 1.33 0.003  ⇧ 1.22 0.022 
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complementation group 4 
NM_130398 2388219 EXO1 exonuclease 1 ⇧ 1.21 0.027  ⇧ 1.49 1.85E-06 
NM_004111 3333226 FEN1 flap structure-specific endonuclease 1 ⇧ 1.25 0.007  ⇧ 1.33 2.25E-04 
NM_021218 3221135 INIP INTS3 and NAPB interacting protein ⇧ 1.23 6.79E-04  ⇧ 1.28 2.71E-05 
NM_007349 3080843 PAXIP1 PAX interacting (with transcription-activation domain) protein 1 ⇧ 1.20 3.03E-04  ⇧ 1.24 3.99E-06 
NM_002592 3896200 PCNA proliferating cell nuclear antigen ⇧ 1.30 2.11E-04  ⇧ 1.46 3.91E-08 
NM_015584 3750625 POLDIP2 polymerase (DNA-directed), delta interacting protein 2 ⇧ 1.21 4.02E-04  ⇧ 1.22 4.91E-05 
NM_002692 3563395 POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit) ⇧ 1.20 0.024  ⇧ 1.44 2.03E-06 
NM_002875 3590086 RAD51 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) ⇧ 1.23 0.007  ⇧ 1.45 8.04E-07 
NM_002894 3781429 RBBP8 retinoblastoma binding protein 8 ⇧ 1.24 0.002  ⇧ 1.34 1.03E-05 
NM_018124 3699044 RFWD3 ring finger and WD repeat domain 3 ⇧ 1.25 1.22E-04  ⇧ 1.30 1.95E-06 
NM_152308 3648247 RMI2 RMI2, RecQ mediated genome instability 2, homolog (S. cerevisiae) ⇧ 1.30 0.003  ⇧ 1.39 7.20E-05 
NM_002946 2403301 RPA2 replication protein A2, 32kDa ⇧ 1.32 3.35E-04  ⇧ 1.26 0.001 
NM_001010984 2385258 SPRTN SprT-like N-terminal domain ⇧ 1.28 6.47E-04  ⇧ 1.23 0.002 
NM_016614 2945645 TDP2 tyrosyl-DNA phosphodiesterase 2 ⇧ 1.28 0.003  ⇧ 1.32 3.53E-04 
NM_017858 3630099 TIPIN TIMELESS interacting protein ⇧ 1.22 0.009  ⇧ 1.50 5.93E-08 
DNA Replication & the Cell Cycle 
NM_014042 3380996 ANAPC15 anaphase promoting complex subunit 15 ⇧ 1.32 0.006  ⇧ 1.38 6.01E-04 
NM_006401 3181417 ANP32B acidic (leucine-rich) nuclear phosphoprotein 32 family, member B  ⇧ 1.32 0.032  ⇧ 1.27 0.048 
NM_024037 2402416 AUNIP aurora kinase A and ninein interacting protein  ⇧ 1.20 1.20E-04  ⇧ 1.20 3.69E-05 
NM_001238 3828112 CCNE1 cyclin E1 ⇧ 1.30 0.003  ⇧ 1.40 4.06E-05 
NM_001789 2673085 CDC25A cell division cycle 25 homolog A (S. pombe) ⇧ 1.24 0.004  ⇧ 1.35 2.93E-05 
NM_080668 3377423 CDCA5 cell division cycle associated 5 ⇧ 1.20 0.035  ⇧ 1.47 2.85E-06 
NM_001786 3248289 CDK1 cyclin-dependent kinase 1 ⇧ 1.24 0.039  ⇧ 1.31 0.005 
NM_004642 3476097 CDK2AP1 cyclin-dependent kinase 2 associated protein 1 ⇧ 1.24 0.013  ⇧ 1.29 0.002 
NM_001195132 3201437 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) ⇧ 1.24 0.005  ⇧ 1.25 0.002 
NM_022909 2813442 CENPH centromere protein H ⇧ 1.35 4.95E-04  ⇧ 1.45 5.06E-06 
NM_001025248 3593147 DUT deoxyuridine triphosphatase ⇧ 1.30 0.031  ⇧ 1.51 3.35E-04 
NM_032231 3628923 FAM96A family with sequence similarity 96, member A ⇧ 1.30 0.003  ⇧ 1.24 0.009 
NM_023037 3484497 FRY furry homolog (Drosophila) ⇩ 1.33 0.048  ⇩ 1.44 0.008 
NM_021067 3880827 GINS1 GINS complex subunit 1 (Psf1 homolog) ⇧ 1.43 3.33E-04  ⇧ 1.57 1.66E-06 
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NM_001126129 3663228 GINS3 GINS complex subunit 3 (PSf3 homolog) ⇧ 1.28 6.47E-04  ⇧ 1.37 6.07E-06 
NM_015895 2898597 GMNN geminin, DNA replication inhibitor ⇧ 1.21 0.034  ⇧ 1.20 0.028 
NM_018097 3591044 HAUS2 HAUS augmin-like complex, subunit 2 ⇧ 1.25 3.35E-04  ⇧ 1.22 7.28E-04 
NM_016073 3636522 HDGFRP3 hepatoma-derived growth factor, related protein 3 ⇧ 1.49 0.002  ⇧ 2.19 3.58E-10 
NM_194282 2775858 LIN54 lin-54 homolog (C. elegans) ⇧ 1.23 2.74E-04  ⇧ 1.25 2.19E-05 
NM_001003690 2908144 MAD2L1BP MAD2L1 binding protein ⇧ 1.27 7.94E-05  ⇧ 1.25 8.38E-05 
NM_005914 3097152 MCM4 minichromosome maintenance complex component 4 ⇧ 1.21 0.019  ⇧ 1.39 3.71E-05 
NM_032485 3875195 MCM8 minichromosome maintenance complex component 8 ⇧ 1.29 1.93E-04  ⇧ 1.29 4.86E-05 
NM_024039 3707759 MIS12 MIS12, MIND kinetochore complex component, homolog (S. pombe) ⇧ 1.26 0.011  ⇧ 1.24 0.012 
NM_024629 2796510 MLF1IP MLF1 interacting protein  ⇧ 1.27 0.023  ⇧ 1.57 6.22E-06 
NM_002480 2334404 NASP nuclear autoantigenic sperm protein (histone-binding) ⇧ 1.20 0.023  ⇧ 1.33 2.57E-04 
NM_006600 2326799 NUDC nuclear distribution gene C homolog (A. nidulans) ⇧ 1.32 5.44E-04  ⇧ 1.39 1.49E-05 
NM_018492 3129149 PBK PDZ binding kinase  ⇧ 1.21 0.022  ⇧ 1.35 1.36E-04 
NM_002764 3986514 PRPS1 phosphoribosyl pyrophosphate synthetase 1 ⇧ 1.23 0.013  ⇧ 1.36 9.54E-05 
NM_001039091 3969047 PRPS2 phosphoribosyl pyrophosphate synthetase 2 ⇧ 1.26 9.64E-05  ⇧ 1.34 2.63E-07 
NM_002895 3904747 RBL1 retinoblastoma-like 1 (p107) ⇧ 1.20 0.008  ⇧ 1.26 4.76E-04 
NM_181471 3056414 RFC2 replication factor C (activator 1) 2, 40kDa ⇧ 1.28 8.26E-04  ⇧ 1.34 2.33E-05 
NM_002915 3485074 RFC3 replication factor C (activator 1) 3, 38kDa ⇧ 1.21 0.004  ⇧ 1.39 4.19E-07 
NM_001165931 2469252 RRM2 ribonucleotide reductase M2 ⇧ 1.23 0.043  ⇧ 1.55 6.07E-06 
NM_001039535 3788049 SKA1 spindle and kinetochore associated complex 1 ⇧ 1.24 0.029  ⇧ 1.33 0.002 
NM_182513 3850660 SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) ⇧ 1.31 0.011  ⇧ 1.53 2.98E-05 
NM_005862 2696802 STAG1 stromal antigen 1 ⇧ 1.20 0.019  ⇧ 1.28 7.71E-04 
Immune Response & Inflammation 
NM_001145009 2899372 BTN3A1 butyrophilin, subfamily 3, member A1 ⇩ 1.20 0.001  ⇩ 1.25 3.48E-05 
NM_001197247 2899298 BTN3A2 butyrophilin, subfamily 3, member A2 ⇩ 1.41 0.001  ⇩ 1.36 0.007 
NM_006994 2899413 BTN3A3 butyrophilin, subfamily 3, member A3 ⇩ 1.32 6.35E-06  ⇩ 1.28 1.37E-05 
NM_000064 3848039 C3 complement component 3 ⇩ 1.31 0.017  ⇩ 1.30 0.011 
NM_001771 3830353 CD22 CD22 molecule ⇩ 1.31 0.005  ⇩ 1.31 0.002 
NM_016382 2440385 CD244 CD244 molecule, natural killer cell receptor 2B4 ⇩ 2.05 8.73E-04  ⇩ 1.75 0.005 
NM_014143 3161082 CD274 CD274 molecule ⇩ 1.27 0.014  ⇩ 1.38 5.69E-04 
NM_007261 3734379 CD300A CD300a molecule ⇩ 1.29 2.28E-04  ⇩ 1.24 5.83E-04 
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NM_001250 3887302 CD40 CD40 molecule, TNF receptor superfamily member 5 ⇩ 1.32 0.001  ⇩ 1.37 6.66E-05 
NM_001114752 2377229 CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood 
group) 
⇩ 1.23 0.006  ⇩ 1.38 7.02E-06 
NM_203330 3368707 CD59 CD59 molecule, complement regulatory protein  ⇩ 1.20 0.004  ⇩ 1.27 8.89E-05 
NM_000626 3766533 CD79B CD79b molecule, immunoglobulin-associated beta ⇩ 1.29 0.007  ⇩ 1.20 0.032 
NM_002621 4007164 CFP complement factor properdin ⇩ 1.28 0.043  ⇩ 1.41 0.003 
NM_001276 2451593 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) ⇩ 1.79 0.008  ⇩ 1.89 0.002 
NM_005127 3443891 CLEC2B C-type lectin domain family 2, member B ⇩ 1.41 0.015  ⇩ 1.57 6.47E-04 
NM_001935 2584018 DPP4 dipeptidyl-peptidase 4 ⇩ 1.45 0.012  ⇩ 1.51 0.003 
NM_000605 3201319 IFNA2 interferon, alpha 2 ⇩ 1.48 0.013  ⇩ 1.60 0.001 
NM_001562 3391255 IL18 interleukin 18 (interferon-gamma-inducing factor) ⇧ 1.29 0.017  ⇧ 1.34 0.003 
NM_002286 3402757 LAG3 LTV1 homolog (S. cerevisiae) ⇩ 1.41 0.002  ⇩ 1.29 0.014 
NM_005356 2328841 LCK lymphocyte-specific protein tyrosine tyrosine kinase ⇧ 1.25 0.008  ⇧ 1.46 3.48E-06 
NM_052925 3841474 LENG8 leukocyte receptor cluster (LRC) member 8 ⇩ 1.23 0.002  ⇩ 1.24 4.77E-04 
NM_138441 2960872 MB21D1 Mab-21 domain containing 1 ⇧ 1.26 0.002  ⇧ 1.20 0.008 
NM_001172567 2617563 MYD88 myeloid differentiation primary response gene (88) ⇧ 1.22 0.004  ⇧ 1.25 5.04E-04 
NM_00136022 3529908 NFATC4 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 ⇩ 1.27 0.002  ⇩ 1.24 0.003 
NM_022162 3660175 NOD2 nucleotide-binding oligomerization domain containing 2 ⇩ 1.21 0.001  ⇩ 1.20 9.69E-04 
BC008975 3526425 PCID2 PCI domain containing 2 ⇩ 1.38 7.87E-04  ⇩ 1.62 1.25E-07 
NM_001184714 2440258 SLAMF6 SLAM family member 6 ⇩ 1.25 0.002  ⇩ 1.28 2.22E-04 
NM_030956 2766192 TLR10 toll-like receptor 10 ⇩ 1.37 7.79E-05  ⇩ 1.34 7.28E-05 
NM_012452 3747522 TNFRSF13B tumor necrosis factor receptor superfamily, member 13B ⇩ 1.36 0.002  ⇩ 1.33 0.002 
AK303468 2392584 TNFRSF14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry 
mediator) 
⇩ 1.23 0.011  ⇩ 1.36 4.53E-05 
Ion Binding 
NM_017649 3261971 CNNM2 cyclin M2 ⇩ 1.20 0.003  ⇩ 1.22 5.18E-04 
NM_152516 2484752 COMMD1 copper metabolism (Murr1) domain containing 1 ⇧ 1.33 4.78E-05  ⇧ 1.20 0.003 
NM_024843 2515240 CYBRD1 cytochrome b reductase 1 ⇩ 1.22 0.048  ⇩ 1.34 0.002 
NM_002032 3375648 FTH1 ferritin, heavy polypeptide 1 ⇩ 1.29 0.026  ⇩ 1.41 0.002 
NM_005929 2713111 MFI2 antigen p97 (melanoma associated) identified by monoclonal antibodies 
133.2 and 96.5) 
⇩ 1.32 7.19E-04  ⇩ 1.29 9.32E-04 
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NM_152999 3011861 STEAP2 six transmembrane epithelial antigen of the prostate 2 ⇩ 1.40 0.025  ⇩ 1.79 5.72E-05 
Membrane Trafficking 
NM_007189 3079463 ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 ⇧ 1.20 0.014  ⇧ 1.26 9.48E-04 
NM_001677 2366422 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide ⇩ 1.66 7.06E-04  ⇩ 1.37 0.021 
NM_001001396 2375706 ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 ⇩ 1.39 0.020  ⇩ 1.47 0.004 
NM_000052 3982423 ATP7A ATPase, Cu++ transporting, alpha polypeptide ⇩ 1.28 0.011  ⇩ 1.41 1.58E-04 
NM_001286 2320472 CLCN6 chloride channel 6 ⇩ 1.32 4.73E-05  ⇩ 1.23 7.09E-04 
NM_016433 3470964 GLTP glyolipid transfer protein  ⇧ 1.23 0.004  ⇧ 1.21 0.004 
NM_003740 2952834 KCNK5 potassium channel, subfamily K, member 5 ⇩ 1.26 0.020  ⇩ 1.42 2.33E-04 
NM_153369 2921456 KIAA1919 KIAA1919 ⇩ 1.25 5.47E-04  ⇩ 1.27 1.01E-04 
NM_001146069 2758043 MFSD10 major facilitator superfamily domain containing 10 ⇩ 1.21 3.98E-04  ⇩ 1.21 1.57E-04 
NM_001126340 3016768 ORAI2 ORAI calcium release-activated calcium modulator 2 ⇧ 1.23 0.013  ⇧ 1.24 0.006 
NM_022068 3798829 PIEZO2 piezo-type mechanosensitive ion channel component 2 ⇩ 1.77 0.027  ⇩ 1.64 0.037 
NM_001174129 3454576 SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporters) 
member 2 
⇩ 1.24 0.004  ⇩ 1.43 1.25E-06 
NM_001046 2827525 SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters) member 2 ⇩ 1.26 0.008  ⇩ 1.20 0.023 
NM_021082 2638728 SLC15A2 solute carrier family 15 (H+/peptide transporter) member 2SLC12A2 ⇩ 1.36 0.010  ⇩ 1.27 0.031 
NM_001042422 3738629 SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4) ⇩ 1.41 2.93E-06  ⇩ 1.36 5.03E-06 
NM_012434 2960955 SLC17A5 solute carrier family 17 (anion/sugar transporter), member 5 ⇩ 1.21 0.010  ⇩ 1.28 2.94E-04 
NM_001039355 3579501 SLC25A29 solute carrier family 25, member 29 ⇩ 1.32 0.007  ⇩ 1.31 0.005 
NM_032315 2319340 SLC25A33 solute carrier family 25, member 33SLC17A5  ⇧ 1.57 3.19E-04  ⇧ 1.29 0.028 
NM_00104647 2645275 SLC25A36 solute carrier family 25, member 36 ⇩ 1.22 0.012  ⇩ 1.29 4.68E-04 
NM_016612 3090006 SLC25A37 solute carrier family 25, member 37 ⇩ 1.23 0.033  ⇩ 1.21 0.036 
NM_006516 2409104 SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 ⇩ 1.29 0.04  ⇩ 1.23 0.014 
NM_006931 3442854 SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 ⇩ 1.35 9.02E-04  ⇩ 1.33 6.90E-04 
NM_006416 2916345 SLC35A1 solute carrier family 35 (CMP-sialic acid transporter), member 1 ⇩ 1.36 1.07E-04  ⇩ 1.24 0.003 
NM_015139 2417095 SLC35D1 solute carrier family 35 (UDP-glucuronic acid/UDP-N-acetylgalactosamine 
dual transporter), member D1 
⇩ 1.21 0.036  ⇩ 1.21 0.024 
NM_012319 3804195 SLC39A6 solute carrier family 39 (zinc transporter), member 6 ⇩ 1.22 0.004  ⇩ 1.23 0.001 
NM_033102 2452615 SLC45A3 solute carrier family 45, member 3  ⇩ 1.22 0.002  ⇩ 1.20 0.002 
NM_001098484 2730746 SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 ⇩ 1.40 0.018  ⇩ 1.33 0.032 
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NM_006933 3919033 SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 ⇩ 1.28 3.54E-06  ⇩ 1.30 1.73E-07 
NM_016354 3892812 SLCO4A1 solute carrier organic anion transporter family member 4A1 ⇩ 1.32 0.002  ⇩ 1.20 0.028 
NM_030958 3139580 SLC5A1 solute carrier organic anion transporter family member 5A1 ⇩ 1.41 2.30E-04  ⇩ 1.33 0.001 
NM_003156 3317915 STIM1 stromal interaction molecule 1 ⇩ 1.43 1.32E-08  ⇩ 1.31 2.76E-06 
NM_001169118 2722377 STIM2 stromal interaction molecule 2 ⇩ 1.23 0.008  ⇩ 1.21 0.007 
NM_183240 2502842 TMEM37 transmembrane protein 37 ⇩ 1.32 0.026  ⇩ 1.29 0.027 
NM_001143819 3432678 TPCN1 two pore segment channel 1 ⇩ 1.26 1.54E-05  ⇩ 1.22 4.06E-05 
NM_016113 3712062 TRPV2 transient receptor potential cation channel, subfamily V, member 2 ⇩ 1.28 2.54E-04  ⇩ 1.25 3.46E-04 
Metabolism 
NM_016006 2619761 ABHD5 abhydrolase domain containing 5 ⇧ 1.34 7.33E-04  ⇧ 1.26 9.84E-04 
NM_032169 2695648 ACAD11 acyl-CoA dehydrogenase family, member 11 ⇩ 1.22 0.002  ⇩ 1.26 2.31E-04 
NM_032592 3328349 ACCS aminocyclopropane-1-carobxylate synthase homolog (Arabidopsis) (non-
functional) 
⇩ 1.42 2.23E-05  ⇩ 1.33 1.86E-04 
NM_00160094 2898562 ACOT13 acyl-CoA thioesterase 13 ⇧ 1.30 0.001  ⇧ 1.20 0.014 
NM_018269 2538600 ADI1 acireductone dioxygenase 1 ⇧ 1.32 0.006  ⇧ 1.34 0.002 
NM_020133 2983030 AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid 
acyltransferase, delta) 
⇩ 1.23 5.62E-04  ⇩ 1.22 3.93E-04 
NM_001628 3073981 AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) ⇧ 1.27 0.020  ⇧ 1.25 0.019 
NM_000692 3169331 ALDH1B1 aldehyde dehydrogenase 1 family, member B1 ⇧ 1.25 0.016  ⇧ 1.23 0.015 
NM_000712 2999544 BLVRA biliverdin reductase A ⇧ 1.24 0.009  ⇧ 1.24 0.005 
NM_078476 2899437 BTN2A1 butyrophilin, subfamily 2, member A1 ⇩ 1.29 3.78E-05  ⇩ 1.20 0.001 
NM_001757 3919785 CBR1 carbonyl reductase 1 ⇧ 1.21 0.028  ⇧ 1.31 0.001 
NM_022766 3964154 CERK ceramide kinase ⇧ 1.25 0.001  ⇧ 1.25 4.91E-04 
NM_203463 2514122 CERS6 ceramide synthase 6 ⇩ 1.23 0.011  ⇩ 1.21 0.012 
NM_004820 3138204 CYP7B1 cytochrome P450, family 7, subfamily B, polypeptide 1 ⇩ 1.39 0.026  ⇩ 1.34 0.036 
NM_001360 3380697 DHCR7 dehydrocholesterol reductase ⇩ 1.28 0.002  ⇩ 1.20 0.012 
NM_006209 3150579 ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 ⇩ 1.59 0.005  ⇩ 1.44 0.018 
NM_032020 2977510 FUCA2 fucosidase, alpha-L-2, plasma  ⇩ 1.22 0.030  ⇩ 1.20 0.030 
NM_000153 3575103 GALC galactosylceramidease  ⇩ 1.21 0.005  ⇩ 1.29 9.93E-05 
NM_001498 2957700 GCLC glutamate-cysteine ligase, catalytic subunit  ⇧ 1.23 0.001  ⇧ 1.22 9.11E-04 
NM_024051 3044129 GGCT gamma-glutamylcyclotransferase ⇧ 1.21 0.023  ⇧ 1.25 0.003 
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NM_000181 3053691 GUSB glucuronidase, beta  ⇩ 1.24 0.001  ⇩ 1.25 4.99E-04 
NM_004130 2647154 GYG1 Glycogenin 1 ⇧ 1.36 0.002  ⇧ 1.38 4.99E-04 
NM_152740 3043165 HIBADH 3-hydroxyisobutyrate dehydrogenase ⇧ 1.29 0.001  ⇧ 1.21 0.009 
NM_001127205 3646199 HMOX2 heme oxygenase (decycling) 2 ⇧ 1.23 0.003  ⇧ 1.27 2.41E-04 
NM_031207 2409368 HYI hydroxypyruvate isomerase (putative) ⇧ 1.21 0.043  ⇧ 1.24 0.012 
NM_016133 2502424 INSIG2 insulin induced gene 2 ⇩ 1.34 0.004  ⇩ 1.44 1.44E-04 
NM_006033 3787855 LIPG lipase, endothelial ⇩ 1.72 2.11E-04  ⇩ 1.56 9.85E-04 
NM_014873 2454485 LPGAT1 lysophosphatidylglycerol acyltransferase 1 ⇩ 1.30 0.025  ⇩ 1.30 0.016 
NM_004897 3256560 MINPP1 multiple inositol-polyphosphate phosphatase 1 ⇩ 1.32 6.65E-04  ⇩ 1.25 0.003 
NM_006441 3635125 MTHFS 5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate cyclo-
ligase) 
⇧ 1.28 0.009  ⇧ 1.32 0.002 
NM_002539 2540157 ODC1 ornithine decarboxylase 1 ⇧ 1.25 9.26E-04  ⇧ 1.38 3.83E-07 
NM_015900 2638077 PLA1A phospholipase A1 member A ⇩ 1.39 0.013  ⇩ 1.45 0.002 
NM_001031689 3202171 PLAA phospholipase A2-activating protein  ⇧ 1.21 0.003  ⇧ 1.28 4.89E-05 
NM_002662 2705445 PLD1 phospholipase D1, phosphatidylcholine-specific ⇩ 1.60 0.009  ⇩ 1.45 0.024 
NM_016026 3569401 RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) ⇩ 1.20 0.007  ⇩ 1.20 0.004 
NM_144563 2492938 RPIA ribose 5-phosphate isomerase A ⇧ 1.24 0.002  ⇧ 1.20 0.004 
NM_006745 2750594 SC4MOL sterol-C4-methyl oxidase-like ⇩ 1.20 0.016  ⇩ 1.21 0.005 
NM_006918 3352904 SC5DL sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. cerevisiae) ⇩ 1.21 0.008  ⇩ 1.20 0.008 
NM_004169 3748323 SHMT1 serine hydroxymethyltransferase 1 (soluble) ⇧ 1.28 0.011  ⇧ 1.36 7.94E-04 
NM_003132 2396461 SRM spermidine synthase ⇧ 1.37 7.38E-06  ⇧ 1.21 0.002 
NM_000367 2944025 TPMT thiopurine S-methyltransferase  ⇧ 1.64 8.09E-05  ⇧ 1.50 4.74E-04 
NR_033437 2639874 UMPS uridine monophosphate synthetase ⇧ 1.23 0.005  ⇧ 1.26 9.06E-04 
NR_036510 2334279 UROD uroporphyrinogen decarboxylase  ⇧ 1.31 2.28E-05  ⇧ 1.21 0.001 
Mitochondrion & the Respiratory Electron Transport Chain 
NM_003488 3728097 AKAP1 A kinase (PRKA) anchor protein 1 ⇩ 1.21 0.008  ⇩ 1.24 9.43E-04 
NM_001001937 3806253 ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, 
cardiac muscle 
⇧ 1.31 5.92E-04  ⇧ 1.28 6.44E-04 
NM_005175 3725456 ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 
(subunit 9) 
⇧ 1.21 5.14E-04  ⇧ 1.23 8.17E-05 
NM_025147 2521446 COQ10B coenzyme Q10 homolog B (S. cerevisiae) ⇧ 1.26 3.21E-04  ⇧ 1.23 3.99E-04 
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NM_004374 3146433 COX6C cytochrome c oxidase subunit Vic ⇧ 1.26 0.033  ⇧ 1.29 0.012 
NM_012062 3410695 DNM1L dynamin 1-like ⇧ 1.36 0.004  ⇧ 1.44 2.88E-04 
AY568085 2950798 MNF1 mitochondrial nucleoid factor 1 ⇧ 1.22 0.018  ⇧ 1.33 3.09E-04 
NM_001099286 2975655 MTFR2 mitochondrial fission regulator 2 ⇧ 1.27 0.007  ⇧ 1.26 0.005 
NR_027405 2489172 MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
⇧ 1.23 0.004  ⇧ 1.26 6.50E-04 
NM_014222 3224197 NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa ⇧ 1.34 7.20E-04  ⇧ 1.29 0.001 
NM_016013 3619991 NDUFAF1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 1 ⇧ 1.22 0.032  ⇧ 1.38 2.55E-04 
NM_004548 3644220 NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa ⇧ 1.25 0.006  ⇧ 1.22 0.008 
NM_002493 3203162 NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa ⇧ 1.28 0.013  ⇧ 1.32 0.003 
NM_004552 2331178 NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-coenzyme 
Q reductase) 
⇧ 1.31 0.003  ⇧ 1.23 0.015 
Neurotransmission 
NM_032810 3299255 ATAD1 ATPase family, AAA domain containing 1 ⇩ 1.30 1.61E-05  ⇩ 1.30 3.21E-06 
NM_033133 3721548 CNP 2’,3’-cyclic nucleotide 3’ phosphodiesterase ⇧ 1.24 0.005  ⇧ 1.22 0.005 
NM_031412 3404636 GABARAPL1 GABA(A) receptor-associated protein like 1 ⇧ 1.43 0.005  ⇧ 1.41 0.003 
NM_005467 3344142 NAALAD2 N-acetylated alpha-linked acidic dipeptidase 2 ⇩ 1.36 0.023  ⇩ 1.40 0.008 
NM_006228 3091699 PNOC prepronociceptin ⇧ 1.27 0.009  ⇧ 1.20 0.028 
NM_014849 2434139 SV2A synaptic vesicle glycoprotein 2A ⇩ 1.49 7.63E-04  ⇩ 1.39 0.003 
Nucleosome 
NM_018154 3852565 ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) ⇧ 1.31 0.002  ⇧ 1.38 6.13E-05 
NM_005441 3920003 CHAF1B chromatin assembly factor 1, subunit B (p60) ⇧ 1.24 0.004  ⇧ 1.43 5.36E-07 
NM_017444 3118451 CHRAC1 chromatin accessibility complex 1 ⇧ 1.26 0.005  ⇧ 1.25 0.003 
NM_005325 2946194 HIST1H1A histone cluster 1, H1a ⇧ 1.37 0.026  ⇧ 1.65 1.95E-04 
NM_080596 2899772 HIST1H2AH histone cluster 1, H2ah ⇧ 1.37 0.008  ⇧ 1.29 0.020 
NM_021018 2946364 HIST1H3F histone cluster 1, H3f ⇧ 1.34 0.021  ⇧ 1.33 0.017 
NM_003538 2899095 HIST1H4A histone cluster 1, H4a ⇧ 1.51 0.007  ⇧ 1.32 0.048 
NM_003544 2946208 HIST1H4B histone cluster 1, H4b ⇧ 1.35 0.019  ⇧ 1.38 0.007 
NM_175055 2384268 HIST3H2BB histone cluster 3, H2bb ⇧ 1.30 0.038  ⇧ 1.27 0.043 
Protein Processing 
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NM_001663 3535000 ARF6 ADP-ribosylation factor 6 ⇧ 1.31 5.27E-05  ⇧ 1.21 0.002 
NM_198150 2820865 ARSK arylsulfatase family, member K ⇩ 1.59 2.39E-05  ⇩ 1.54 2.52E-05 
NM_004317 3821847 ASNA1 arsA arsenite transporter, ATP-binding, homolog 1 (bacterial) ⇧ 1.22 6.46E-04  ⇧ 1.26 2.24E-05 
NM_004775 3803120 B4GALT6 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 ⇩ 1.29 7.99E-04  ⇩ 1.23 0.003 
NM_004282 2911372 BAG2 BCL2-associated athanogene 2 ⇧ 1.49 9.47E-04  ⇧ 1.56 1.02E-04 
NM_005868 3061651 BET1 blocked early in transport 1 homolog (S. cerevisiae) ⇧ 1.20 0.026  ⇧ 1.23 0.006 
NM_001487 3416909 BLOC1S1 biogenesis of lysosomal organelles complex-1, subunit 1 ⇧ 1.39 2.24E-04  ⇧ 1.24 0.008 
NM_025238 3636470 BTBD1 BTB (POZ) domain containing 1 ⇧ 1.20 1.17E-04  ⇧ 1.21 3.32E-05 
NM_001219 3023060 CALU calmodulin 1 (phosphorylase kinase, delta) ⇩ 1.21 0.033  ⇩ 1.26 0.007 
NM_001762 3003193 CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) ⇧ 1.24 0.020  ⇧ 1.21 0.023 
NM_014169 3557947 CHMP4A charged multivesicular body protein 4A ⇧ 1.42 2.94E-05  ⇧ 1.36 8.71E-05 
NM_018590 3243908 CSGALNACT2 chondroitin sulfate N-acetylgalactosaminyltransferase 2 ⇩ 1.26 0.002  ⇩ 1.27 5.81E-04 
NM_015397 3203855 DCAF12 DDB1 and CUL4 associated factor 12 ⇧ 1.24 2.14E-04  ⇧ 1.24 4.74E-05 
NM_003677 3435490 DENR density-regulated protein  ⇧ 1.30 0.002  ⇧ 1.31 5.76E-04 
NM_001539 3166718 DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 ⇧ 1.30 0.019  ⇧ 1.36 0.004 
NM_017629 2330002 EIF2C4 eukaryotic translation initiation factor 2C, 4 ⇧ 1.22 0.002  ⇧ 1.20 0.002 
NM_003758 3591963 EIF3J eukaryotic translation initiation factor, subunit J ⇧ 1.23 0.012  ⇧ 1.24 0.006 
NM_022170 3008144 EIF4H eukaryotic translation initiation factor 4H ⇧ 1.31 0.005  ⇧ 1.38 4.23E-04 
NM_006459 3303255 ERLIN1 ER lipid raft associated 1 ⇩ 1.28 0.003  ⇩ 1.22 0.009 
NM_004730 2877465 ETF1 eukaryotic translation termination factor 1 ⇧ 1.27 6.75E-05  ⇧ 1.21 7.48E-04 
NM_001439 2425400 EXTL2 exostoses (multiple)-like 2 ⇩ 1.53 3.40E-05  ⇩ 1.37 8.07E-04 
NM_024619 3739108 FN3KRP fructosamine 3 kinase related protein ⇧ 1.24 7.73E-04  ⇧ 1.33 4.58E-06 
NMN_004481 2384788 GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyl 
transferase 2 (GalNAc-T2) 
⇩ 1.23 5.30E-05  ⇩ 1.21 6.58E-05 
NM_198066 3564872 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 ⇧ 1.29 0.004  ⇧ 1.33 5.93E-04 
NM_016548 3212848 GOLM1 golgi membrane protein 1 ⇩ 1.51 0.008  ⇩ 1.45 0.010 
NM_016072 3407824 GOLT1B golgi transport 1B ⇩ 1.21 0.021  ⇩ 1.40 1.56E-05 
NM_004466 3496409 GPC5 glypican 5 ⇩ 1.46 0.004  ⇩ 1.34 0.014 
NM_001545 3734575 ICT1 immature colon carcinoma transcript 1 ⇧ 1.22 0.005  ⇧ 1.32 4.28E-05 
NM_006547 2992863 IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 ⇧ 1.35 1.85E-05  ⇧ 1.26 3.77E-04 
NM_018439 3782166 IMPACT impact homolog (mouse) ⇧ 1.27 0.022  ⇧ 1.32 0.005 
NM_030980 2438482 ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2 ⇧ 1.28 6.09E-05  ⇧ 1.34 6.43E-07 
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NM_001142292 2565484 LMAN2L lectin, mannose-binding 2-like  ⇩ 1.23 0.011  ⇩ 1.21 0.012 
NM_144703 3892452 LSM14B LSM14B, SCD6 homolog B (S. cerevisiae) ⇧ 1.35 0.010  ⇧ 1.28 0.025 
NM_006122 3608466 MAN2A2 mannosidase, alpha, class 2A, member 2 ⇩ 1.26 6.07E-05  ⇩ 1.26 1.76E-05 
NM_005908 2779897 MANBA mannosidase, beta A, lysosomal  ⇩ 1.31 3.15E-04  ⇩ 1.37 6.74E-06 
NM_014730 3434525 MLEC malectin ⇩ 1.20 2.99E-04  ⇩ 1.23 1.07E-05 
NM_006302 2560122 MOGS mannosyl-oligosaccharide glucosidase ⇩ 1.21 0.004  ⇩ 1.25 2.97E-04 
NM_014161 2934167 MRPL18 mitochondrial ribosomal protein L18 ⇧ 1.22 0.005  ⇧ 1.28 1.85E-04 
NM_014180 2836886 MRPL22 mitochondrial ribosomal protein L22 ⇧ 1.22 0.014  ⇧ 1.31 4.23E-04 
NM_032477 3195344 MRPL41 mitochondrial ribosomal protein L41 ⇧ 1.43 5.85E-04  ⇧ 1.27 0.014 
NM_020409 2706985 MRPL47 mitochondrial ribosomal protein L47 ⇧ 1.34 0.003  ⇧ 1.26 0.011 
NM_016497 3441955 MRPL51 mitochondrial ribosomal protein L51 ⇧ 1.22 1.80E-05  ⇧ 1.23 1.97E-06 
NM_016183 2323559 MRTO4 mRNA turnover 4 homolog (S. cerevisiae) ⇧ 1.36 9.11E-04  ⇧ 1.22 0.022 
NM_033049 2692883 MUC13 mucin 13, cell surface associated ⇩ 1.49 0.025  ⇩ 1.59 0.002 
NM_025146 2689208 NAA50 N(alpha)-acetyltransferase 50, NatE catalytic subunit ⇧ 1.23 0.002  ⇧ 1.28 1.12E-04 
NM_016101 3666686 NIP7 nuclear import 7 homolog (S. cerevisiae) ⇧ 1.34 6.11E-05  ⇧ 1.32 4.53E-05 
NM_006178 3724197 NSF ethylmaleimide-sensitive factor ⇧ 1.20 0.046  ⇧ 1.36 3.83E-04 
NM_002484 3647956 NUBP1 nucleotide binding protein 1 (MinD homolog, E. coli) ⇧ 1.21 0.003  ⇧ 1.28 4.28E-05 
NM_000917 3294159 P4HA1 prolyl 4-hydroxylase, alpha polypeptide I ⇩ 1.25 0.002  ⇩ 1.31 4.99E-05 
NM_004199 2875193 P4HA2 prolyl 4-hydroxylase, alpha polypeptide II ⇩ 1.26 0.033  ⇩ 1.38 0.002 
NM_000919 2822215 PAM peptidylglycine alpha-amidating monooxygenase  ⇩ 1.27 2.69E-05  ⇩ 1.26 1.73E-05 
NM_001146106 2692060 PARP9 poly (ADP-ribose) polymerase family, member 9 ⇧ 1.32 0.005  ⇧ 1.24 0.023 
NM_024989 2593407 PGAP1 post-GPI attachment to proteins 1 ⇩ 1.24 0.011  ⇩ 1.41 2.14E-05 
NM_173074 2551690 PIGF phosphatidylinositol glycan anchor biosynthesis, class F ⇩ 1.23 0.034  ⇩ 1.45 7.08E-05 
NM_080476 3903481 PIGU phosphatidylinositol glycan anchor biosynthesis, class U ⇩ 1.29 0.011  ⇩ 1.22 0.035 
NM_138717 2903075 PPT2 palmitoyl-protein thioesterase 2 ⇩ 1.22 4.74E-04  ⇩ 1.30 1.37E-06 
NM_018137 2349848 PRMT6 protein arginine methyltransferase 6 ⇧ 1.29 4.87E-04  ⇧ 1.26 5.39E-04 
NM_002790 2427074 PSMA5 proteasome (prosome, macropain) subunit, alpha type, 5 ⇧ 1.28 0.001  ⇧ 1.30 3.36E-04 
NM_002798 3707199 PSMB6 proteasome (prosome, macropain) subunit, beta type, 6 ⇧ 1.48 7.64E-05  ⇧ 1.26 0.010 
NM_002804 3372209 PSMC3 proteasome (prosome, macropain) 26S subunit, ATPase, 3  ⇧ 1.26 0.002  ⇧ 1.42 1.94E-06 
NM_002805 3730941 PSMC5 proteasome (prosome, macropain) 26S subunit, ATPase, 5 ⇧ 1.24 0.038  ⇧ 1.41 5.11E-04 
NM_176863 3722152 PSME3 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) ⇧ 1.21 0.004  ⇧ 1.25 3.77E-04 
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NM_020673 3890870 RAB22A RAB22A, member RAS oncogene family ⇧ 1.21 0.002  ⇧ 1.22 6.36E-04 
NM_004580 3625271 RAB27A RAB27A, member RAS oncogene family ⇧ 1.31 0.002  ⇧ 1.26 0.005 
NM_173647 2567583 RNF149 ringer finger protein 149 ⇩ 1.22 0.012  ⇩ 1.36 5.16E-05 
NM_015169 3101622 RRS1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) ⇧ 1.40 1.40E-04  ⇧ 1.26 0.004 
NR_027280 3837132 SAE1 SUMO1 activating enzyme subunit 1 ⇧ 1.20 0.004  ⇧ 1.35 6.92E-07 
NM_015490 3303478 SEC31B SEC31 homolog B (S. cerevisiae) ⇩ 1.25 5.76E-04  ⇩ 1.26 1.52E-04 
NM_013257 3101802 SGK3 serum/glucocorticoid regulated kinase family, member 3 ⇧ 1.20 0.003  ⇧ 1.20 0.002 
NM_007241 3761632 SNF8 SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae) ⇧ 1.33 9.36E-04  ⇧ 1.34 2.84E-04 
NM_014035 2826343 SNX24 sorting nexin 24 ⇧ 1.24 0.028  ⇧ 1.23 0.023 
NM_006100 2633256 ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 ⇩ 1.40 0.025  ⇩ 1.67 2.97E-04 
NM_003764 2929127 STX11 syntaxin 11 ⇧ 1.51 0.001  ⇧ 1.31 0.018 
NM_016360 3730784 TACO1 translational activator of mitochondrially encoded cytochrome c oxidase 1 ⇧ 1.20 0.004  ⇧ 1.34 1.12E-06 
NM_019022 3812206 TMX3 thioredoxin-related transmembrane protein 3 ⇩ 1.23 1.12E-04  ⇩ 1.20 3.51E-04 
NM_020243 3945376 TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) ⇧ 1.26 4.26E-04  ⇧ 1.23 6.15E-04 
NM_0022347 2446240 TOR1AIP2 torsin A interacting protein 2 ⇧ 1.43 0.007  ⇧ 1.42 0.004 
NM_003596 3005444 TPST1 tyrosylprotein sulfotransferase 1 ⇩ 1.31 0.018  ⇩ 1.38 0.003 
NM_015049 2594812 TRAK2 trafficking protein, kinesin binding 2 ⇧ 1.26 0.002  ⇧ 1.29 2.47E-04 
NM_015939 3896524 TRMT6 tRNA methyltransferase 6 homolog (S. cerevisiae) ⇧ 1.27 1.11E-05  ⇧ 1.26 5.41E-06 
NM_003314 2838042 TTC1 tetratricopeptide repeat domain 1 ⇧ 1.33 6.88E-04  ⇧ 1.33 2.48E-04 
NM_005783 2566740 TXNDC9 thioredoxin domain containing 9 ⇧ 1.21 0.001  ⇧ 1.29 8.42E-06 
NM_080678 2534564 UBE2F ubiquitin-conjugating enzyme E2F (putative) ⇧ 1.26 0.004  ⇧ 1.26 0.002 
NM_016021 2964200 UBE2J1 ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) ⇧ 1.20 0.008  ⇧ 1.22 0.003 
NM_005339 2724472 UBE2K ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast) ⇧ 1.23 6.65E-05  ⇧ 1.22 3.92E-05 
NM_145049 2837810 UBLCP1 ubiquitin-like domain containing CTD phosphatase 1 ⇧ 1.27 0.015  ⇧ 1.37 6.60E-04 
NM_152277 2887128 UBTD2 ubiquitin domain containing 2 ⇧ 1.45 6.18E-05  ⇧ 1.42 5.35E-05 
NM_001048201 3817698 UHRF1 ubiquitin-like with PHD and ring finger domains 1 ⇧ 1.31 0.041  ⇧ 1.80 5.01E-06 
NM_003368 2339414 USP1 ubiquitin specific peptidase 1 ⇧ 1.33 8.09E-04  ⇧ 1.32 4.48E-04 
NM_025076 2568968 UXS1 UDP-glucuronate decarboxylase 1 ⇩ 1.21 0.039  ⇩ 1.32 0.001 
NM_016079 2562821 VPS24 vacuolar protein sorting 24 homolog (S. cerevisiae) ⇧ 1.26 0.002  ⇧ 1.34 2.75E-05 
NM_022916 3475545 VPS33A vacuolar protein sorting 33 homolog A (S. cerevisiae) ⇧ 1.20 0.006  ⇧ 1.21 0.002 
NM_018639 3473727 WSB2 WD repeat and SOCS box-containing 2 ⇧ 1.25 0.001  ⇧ 1.27 2.90E-04 
NM_022494 3307120 ZDHHC6 zinc finger, DHHC-type containing 6 ⇩ 1.30 6.49E-06  ⇩ 1.23 1.05E-04 
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NM_024646 2336497 ZYG11B zyg-11 homolog B (C. elegans) ⇧ 1.31 1.05E-04  ⇧ 1.20 0.004 
RNA Processing 
NM_018702 3273667 ADARB2 adenosine deaminase, RNA-specific, B2 ⇩ 1.36 0.012  ⇩ 1.34 0.010 
NM_006110 3687698 CD2BP2 CD2 (cytoplasmic tail) binding protein 2 ⇧ 1.21 0.015  ⇧ 1.29 4.86E-04 
NM_014026 3355114 DCPS decapping enzyme, scavenger ⇧ 1.22 0.003  ⇧ 1.20 0.003 
NM_004728 3250055 DDX21 DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 ⇧ 1.21 0.004  ⇧ 1.22 0.001 
NM_001159936 2409220 EBNA1BP2 EBNA1 binding protein 2 ⇧ 1.29 0.003  ⇧ 1.48 1.04E-06 
NM_013393 3035682 FTSJ2 FtsJ homolog 2 (E. coli) ⇧ 1.30 1.86E-04  ⇧ 1.20 0.005 
NM_004960 3656904 FUS  fused in sarcoma  ⇧ 1.23 7.50E-04  ⇧ 1.33 6.02E-07 
NM_002109 2878474 HARS histidyl-tRNA synthetase  ⇧ 1.20 0.005  ⇧ 1.20 0.002 
NM_006805 2877141 HNRNPA0 heterogeneous nuclear ribonucleoprotein A0 ⇧ 1.23 2.35E-07  ⇧ 1.23 4.48E-08 
NM_031266 2843619 HNRNPAB heterogeneous nuclear ribonucleoprotein A/B ⇧ 1.26 6.49E-05  ⇧ 1.29 2.25E-06 
NM_019597 3984779 HNRNPH2 heterogeneous nuclear ribonucleoprotein H2 (H’) ⇧ 1.28 0.024  ⇧ 1.32 0.006 
NM_005968 3819543 HNRNPM heterogeneous nuclear ribonucleoprotein M ⇧ 1.21 0.008  ⇧ 1.35 2.01E-05 
NM_001130089 3699757 KARS lysyl-tRNA synthetase ⇧ 1.20 2.32E-04  ⇧ 1.23 1.03E-05 
NM_012321 3854892 LSM4 LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) ⇧ 1.24 0.008  ⇧ 1.21 0.012 
NM_018648 3617403 NOP10 NOP10 ribonucleoprotein homolog (yeast) ⇧ 1.32 0.013  ⇧ 1.25 0.031 
NM_032177 2827156 PHAX phosphorylated adaptor for RNA export ⇧ 1.27 1.79E-04  ⇧ 1.22 7.09E-04 
NM_005837 3015769 POP7 processing of precursor 7, ribonuclease P/MRP subunit (S. cerevisiae) ⇧ 1.23 0.009  ⇧ 1.28 0.001 
NM_021129 3293280 PPA1 pyrophosphatase (inorganic) 1 ⇧ 1.34 0.005  ⇧ 1.20 0.028 
NM_017922 3434201 PRPF39 PRP39 pre-mRNA processing factor 39 homolog (S. cerevisiae) ⇩ 1.24 4.00E-05  ⇩ 1.21 1.05E-04 
NM_004697 3185558 PRPF4 PRP4 pre-mRNA processing factor 4 homolog (yeast) ⇧ 1.24 7.62E-05  ⇧ 1.24 2.10E-05 
NM_006328 3336402 RBM14 RNA binding motif protein 14 ⇩ 1.30 0.002  ⇩ 1.22 0.012 
NM_016836 2583602 RBMS1 RNA binding motif, single stranded interacting protein 1 ⇧ 1.43 0.034  ⇧ 1.71 7.17E-04 
NM_033112 2907596 RRP36 ribosomal RNA processing 36 homolog (S. cerevisiae) ⇧ 1.31 0.004  ⇧ 1.34 0.001 
NM_015703 3962448 RRP7A ribosomal RNA processing 7 homolog A (S. cerevisiae) ⇧ 1.27 0.002  ⇧ 1.26 0.001 
NM_018130 2682568 SHQ1 SHQ1 homolog (S. cerevisiae) ⇧ 1.20 0.011  ⇧ 1.24 0.002 
NM_004818 2404377 SNRNP40 small nuclear ribonucleoprotein 40kDa (U5) ⇧ 1.30 0.027  ⇧ 1.50 2.21E-04 
NM_003090 3642162 SNRPA1 small nuclear ribonucleoprotein polypeptide A’ ⇩ 1.27 0.011  ⇩ 1.40 1.67E-04 
NM_003092 3877776 SNRPB2 small nuclear ribonucleoprotein polypeptide B ⇧ 1.24 0.040  ⇧ 1.38 0.001 
NM_0203095 3427014 SNRPF small nuclear ribonucleoprotein polypeptide F ⇧ 1.27 0.007  ⇧ 1.27 0.004 
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NM_015679 3226493 TRUB2 TruB pseudouridine (psi) synthase homolog 2 (E. coli) ⇧ 1.21 0.002  ⇧ 1.32 1.86E-06 
NR_023349 2371474 TSEN15 tRNA splicing endonuclease 15 homolog (S. cerevisiae) ⇧ 1.28 0.006  ⇧ 1.26 0.006 
NM_032175 2815455 UTP15 UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. cerevisiae) ⇧ 1.28 5.25E-04  ⇧ 1.20 0.005 
NM_032334 3112543 UTP23 UTP23, small subunit (SSU) processome component, homolog (yeast) ⇧ 1.25 0.001  ⇧ 1.28 2.38E-04 
Sensory Perception 
NM_176889 3444476 TAS2R20 taste receptor, type 2, member 20 ⇩ 1.34 0.030  ⇩ 1.69 4.07E-05 
Signal Transduction 
NM_015270 3453252 ADCY6 adenylate cyclase 6 ⇩ 1.35 1.98E-04  ⇩ 1.20 0.015 
NM_004309 3774283 ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha ⇧ 1.39 0.009  ⇧ 1.48 8.17E-04 
NM_014786 3339812 ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17 ⇩ 1.33 0.004  ⇩ 1.25 0.015 
NM_005737 2604390 ARL4C ADP-ribosylation factor-like 4C ⇧ 1.47 2.88E-04  ⇧ 1.41 5.04E-04 
NM_006888 3548346 CALM1 calmodulin 1 (phosphorylase kinase, delta) ⇧ 1.24 0.003  ⇧ 1.35 1.74E-05 
NM_001278 3303300 CHUK conserved helix-loop-helix ubiquitous kinase ⇧ 1.33 1.45E-04  ⇧ 1.37 9.87E-06 
NM_020248 2395965 CTNNBIP1 catenin, beta interacting protein 1 ⇧ 1.27 0.018  ⇧ 1.26 0.012 
NM_001008540 2578028 CXCR4 chemokine (C-X-C motif) receptor 4 ⇩ 1.70 6.76E-06  ⇩ 1.57 3.41E-05 
NM_020311 2533999 CXCR7 chemokine (C-X-C motif) receptor 7 ⇩ 1.61 0.009  ⇩ 1.51 0.015 
NM_144973 3449760 DENND5B DENN/MADD domain containing 5B ⇧ 1.27 0.042  ⇧ 1.31 0.012 
NM_005306 3830484 FFAR2 free fatty acid receptor 2 ⇩ 1.64 0.005  ⇩ 1.49 0.013 
NM_001042747 2403215 FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog ⇩ 1.23 0.009  ⇩ 1.24 0.003 
NM_002019 3507282 FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular 
permeability factor receptor) 
⇩ 1.61 0.006  ⇩ 1.47 0.017 
NM_002569 3608398 FURIN furin (paired basic amino acid cleaving enzyme) ⇩ 1.21 0.026  ⇩ 1.33 2.97E-04 
NM_007353 3035892 GNA12 guanine nucleotide binding protein (G protein) alpha 12 ⇧ 1.24 0.029  ⇧ 1.28 0.006 
NM_031498 3761714 GNGT2 guanine nucleotide binding protein (G protein), gamma transducing activity 
polypeptide 2 
⇧ 1.26 0.008  ⇧ 1.26 0.006 
NM_001039966 2987038 GPER G protein-coupled estrogen receptor 1 ⇩ 1.26 0.033  ⇩ 1.29 0.012 
NM_016472 3550328 GSKIP GSK3B interacting protein ⇧ 1.47 7.01E-04  ⇧ 1.43 7.93E-04 
NM_000876 2934308 IGF2R insulin-like growth factor 2 receptor  ⇩ 1.22 1.49E-04  ⇩ 1.22 4.83E-05 
NM_000208 3848243 INSR insulin receptor  ⇩ 1.48 2.59E-04  ⇩ 1.64 1.01E-06 
NM_018697 3002873 LANCL2 LanC lantibiotic synthetase component C-like 2 (bacterial) ⇧ 1.49 1.85E-04  ⇧ 1.55 1.43E-05 
NM_002758 3733065 MAP2K6 mitogen-activated protein kinase kinase 6 ⇧ 1.37 0.009  ⇧ 1.57 9.65E-05 
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NM_004759 2376922 MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 ⇧ 1.20 0.011  ⇧ 1.27 4.46E-04 
NM_019094 3426169 NUDT4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 ⇩ 1.20 0.027  ⇩ 1.25 0.003 
NM_014142 3277751 NUDT5 nudic (nucleoside diphosphate linked moiety X)-type motif 5 ⇧ 1.39 0.003  ⇧ 1.31 0.009 
NM_001165899 2858134 PDE4D phosphodiesterase 4D, cAMP-specific  ⇩ 1.28 0.044  ⇩ 1.37 0.006 
NM_001008709 3378790 PPP1CA protein phosphatase 1, catalytic subunit, alpha isozyme  ⇧ 1.24 0.001  ⇧ 1.32 1.49E-05 
NM_212461 3453556 PRKAG1 protein kinase, AMP-activated, gamma 1 non-catalytic subunit ⇧ 1.24 1.30E-04  ⇧ 1.24 4.66E-05 
NM_016203 3079803 PRKAG2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit ⇧ 1.29 3.28E-04  ⇧ 1.21 0.003 
NM_000960 3866094 PTGIR prostaglandin I2 (prostacyclin) receptor (IP) ⇩ 1.26 0.006  ⇩ 1.27 0.002 
NM_002834 3432333 PTPN11 protein tyrosine phosphatase, non-receptor type 11 ⇧ 1.24 0.007  ⇧ 1.34 8.68E-05 
NM_006504 3270270 PTPRE protein tyrosine phosphatase, receptor type, E ⇧ 1.20 0.025  ⇧ 1.28 0.001 
NM_002881 2503200 RALB v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding 
protein) 
⇧ 1.23 0.013  ⇧ 1.21 0.016 
NM_178169 3419898 RASSF3 Ras association (RalGDS/AF-6) domain family member 3 ⇧ 1.36 1.33E-04  ⇧ 1.25 0.002 
NM_012425 3279575 RSU1 Ras suppressor protein 1 ⇧ 1.28 0.001  ⇧ 1.30 2.17E-04 
NM_178006 3508898 STARD13 StAR-related lipid transfer (START) domain containing 13 ⇩ 1.27 0.036  ⇩ 1.27 0.023 
NM_012338 3069955 TSPAN12 tetraspanin 12 ⇩ 1.38 0.021  ⇩ 1.67 1.05E-04 
NM_001025237 3316375 TSPAN4 tetraspanin 4 ⇩ 1.32 0.008  ⇩ 1.33 0.002 
NM_003383 3160175 VLDLR very low density lipoprotein receptor  ⇩ 1.58 0.001  ⇩ 1.33 0.003 
NM_003405 3943207 YWHAH tyrosine 3-monooxygenase/tryptophoan 5-monooxygenase activation 
protein, eta polypeptide 
⇧ 1.27 0.002  ⇩ 1.66 1.26E-04 
NM_016653 2515933 ZAK sterile alpha motif and leucine zipper containing kinase AZK ⇧ 1.27 0.004  ⇧ 1.32 3.74E-04 
Transcription 
NM_013375 2899519 ABT1 activator of basal transcription 1 ⇧ 1.22 0.001  ⇧ 1.22 4.45E-04 
NM_178042 2654023 ACTL6A actin-like 6A ⇧ 1.22 0.016  ⇧ 1.34 2.03E-04 
NM_005171 3414695 ATF1 activating transcription factor 1 ⇧ 1.43 4.14E-04  ⇧ 1.31 0.004 
NM_003972 3257938 BTAF1 BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa 
(Mot 1 homolog, S. cerevisiae) 
⇩ 1.22 0.002  ⇩ 1.27 8.75E-05 
NM_001755 3665116 CBFB core-binding factor, beta subunit  ⇧ 1.23 4.95E-04  ⇧ 1.23 1.82E-04 
NM_001806 3829313 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma ⇧ 1.24 0.008  ⇧ 1.23 0.007 
NM_005225 3903146 E2F1 E2F transcription factor 1 ⇧ 1.25 2.01E-04  ⇧ 1.20 0.001 
NM_203394 3463112 E2F7 E2F transcription factor 7 ⇧ 1.21 0.019  ⇧ 1.41 7.39E-06 
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NM_005230 3427098 ELK3 ELK3, ETS-domain protein (SRF accessory protein 2) ⇧ 1.27 0.038  ⇧ 1.25 0.041 
NM_012081 2867873 ELL2 elongation factor, RNA polymerase II, 2 ⇧ 1.25 0.037  ⇧ 1.47 1.51E-04 
NM_002097 3482888 GTF3A general transcription factor IIIA ⇧ 1.35 0.001  ⇧ 1.31 0.001 
NM_138408 2921346 GTF3C6 general transcription factor IIIC, polypeptide 6, alpha 35kDa ⇧ 1.30 0.019  ⇧ 1.33 0.006 
NM_004133 3103818 HNF4G hepatocyte nuclear factor 4, gamma ⇩ 1.33 0.008  ⇩ 1.27 0.018 
NM_006060 3001479 IKZF1 IKAROS family zinc finger 1 (ikaros) ⇧ 1.32 0.005  ⇧ 1.35 0.001 
NM_021078 3757630 KAT2A K (lysine) acetyltransferase 2A ⇩ 1.26 4.50E-05  ⇩ 1.24 5.50E-05 
NM_006769 2345286 LMO4 LIM domain only 4 ⇧ 1.20 0.035  ⇧ 1.32 5.07E-04 
NM_145113 3568667 MAX MYC associated factor X ⇩ 1.23 0.005  ⇩ 1.33 4.46E-05 
NM_001001683 3707127 MED11 mediator complex subunit 11 ⇧ 1.31 0.004  ⇧ 1.35 7.07E-04 
NM_001127392 3333169 MYRF myelin regulatory factor  ⇩ 1.22 0.021  ⇩ 1.26 0.003 
NM_004688 2580955 NMI myc (and STAT) interactor  ⇧ 1.29 0.046  ⇧ 1.40 0.004 
NM_001080951 2977621 PLAGL1 pleiomorphic adenoma gene-like 1 ⇩ 1.26 0.018  ⇩ 1.27 0.009 
NM_007212 2371694 RNF2 ring finger protein 2 ⇧ 1.26 0.008  ⇧ 1.25 0.006 
NM_015138 3590422 RTF1 Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) ⇧ 1.25 5.80E-04  ⇧ 1.24 2.72E-04 
NM_001001890 3930360 RUNX1 runt-related transcription factor 1 ⇧ 1.25 0.005  ⇧ 1.25 0.003 
NM_003707 2694123 RUVBL1 RuvB-like 1 (E. coli) ⇧ 1.29 0.006  ⇧ 1.31 0.002 
NM_006049 3630156 SNAPC5 small nuclear RNA activating complex polypeptide 5, 19kDa ⇧ 1.27 0.015  ⇧ 1.44 8.83E-05 
NM_017635 3379390 SUV420H1 suppressor of variegation 4-20 homolog 1 (Drosophila) ⇧ 1.23 0.004  ⇧ 1.23 0.002 
NM_001135218 2403585 TAF12 TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
20kDa 
⇧ 1.30 1.98E-04  ⇧ 1.27 0.004 
NM_005645 4054117 TAF13 TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
18kDa 
⇧ 1.38 3.44E-04  ⇧ 1.27 0.004 
NM_015975 4013434 TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
31kDa 
⇧ 1.34 0.014  ⇧ 1.42 0.002 
NM_001139466 3967122 TBL1X transducing (beta)-like 1X-linked ⇧ 1.28 0.011  ⇧ 1.33 0.001 
NM_007109 2902178 TCF19 transcription factor 19 ⇧ 1.31 0.003  ⇧ 1.29 0.002 
NM_021045 3285552 ZNF248 zinc finger protein 248  ⇩ 1.31 0.002  ⇩ 1.35 2.23E-04 
NM_080764 3954525 ZNF280B zinc finger protein 280B ⇧ 1.35 6.65E-05  ⇧ 1.20 0.008 
NM_199441 3907934 ZNF334 zinc finger protein 334 ⇩ 1.25 0.024  ⇩ 1.33 0.002 
NM_152493 2329266 ZNF362 zinc finger protein 362 ⇧ 1.25 0.048  ⇧ 1.51 1.47E-04 
NM_153695 3216319 ZNF367 zinc finger protein 367 ⇧ 1.25 2.45E-05  ⇧ 1.25 5.71E-06 
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NM_152478 3842724 ZNF583 zinc finger protein 583 ⇧ 1.20 0.026  ⇧ 1.29 8.17E-04 
NM_015871 2326311 ZNF593 zinc finger protein 593 ⇧ 1.42 2.94E-04  ⇧ 1.23 0.020 
NM_017865 2466039 ZNF692 zinc finger protein 692 ⇩ 1.21 2.48E-04  ⇩ 1.20 2.61E-04 
Miscellaneous 
NM_004318 3137530 ASPH aspartate beta-hydroxylase ⇩ 1.38 3.70E-05  ⇩ 1.21 0.007 
NM_001707 3056108 BCL7B B-cell CLL/lymphoma 7B ⇧ 1.21 0.001  ⇧ 1.28 1.29E-05 
NM_001874 3461341 CPM carboxypeptidase M ⇩ 1.45 0.047  ⇩ 1.47 0.028 
NM_001165958 3755903 GSDMB gasdermin B ⇩ 1.28 0.027  ⇩ 1.62 8.97E-06 
NM_015987 3445123 HEBP1 heme binding protein 1 ⇧ 1.30 0.002  ⇧ 1.20 0.020 
NM_000271 3801411 NPC1 Niemann-Pick disease, type C1 ⇩ 1.33 2.35E-05  ⇩ 1.34 3.64E-06 
NM_012383 3175119 OSTF1 osteoclast stimulating factor 1 ⇧ 1.29 0.013  ⇧ 1.40 3.93E-04 
NM_178422 2402431 PAQR7 progestin and adipoQ receptor family member VII ⇩ 1.21 0.025  ⇩ 1.41 2.05E-05 
NM_015393 2731636 PARM1 prostate androgen-regulated mucin-like protein 1 ⇩ 1.67 0.002  ⇩ 1.41 0.024 
NM_002658 3252036 PLAU plasminogen activator, urokinase ⇩ 1.26 0.031  ⇩ 1.41 6.59E-04 
NM_018465 3197528 PLGRKT plasminogen receptor, C-terminal lysine transmembrane protein ⇧ 1.22 0.003  ⇧ 1.20 0.003 
NM_018663 3439178 PXMP2 peroxisomal membrane protein 2, 22kDA ⇧ 1.49 7.55E-04  ⇧ 1.29 0.020 
NM_018339 3210457 RFK riboflavin kinase ⇧ 1.28 1.16E-04  ⇧ 1.21 0.001 
NM_003116 3883441 SPAG4 sperm associated antigen 4 ⇩ 1.27 0.003  ⇩ 1.43 3.57E-06 
NM_001013694 3941010 SRRD SRR1 domain containing  ⇧ 1.31 0.002  ⇧ 1.22 0.013 
NM_003714 2887490 STC2 stanniocalcin 2 ⇩ 1.39 0.006  ⇩ 1.50 3.60E-04 
NM_001171137 3224591 STRBP spermatid perinuclear RNA binding protein ⇧ 1.22 0.001  ⇧ 1.25 1.57E-04 
NM_004237 2798915 TRIP13 thyroid hormone receptor interactor 13 ⇧ 1.31 0.003  ⇧ 1.52 1.36E-06 
NM_007275 2675192 TUSC2 tumor suppressor candidate 2 ⇧ 1.24 0.004  ⇧ 1.22 0.003 
Unknown Function 
NM_025092 3315607 ATHL1 ATH1, acid trehalase-like 1 (yeast) ⇩ 1.24 0.002  ⇩ 1.23 0.001 
NM_020453 2726072 ATP10D ATPase, class V, type 10D ⇩ 1.36 2.73E-04  ⇩ 1.21 0.012 
NM_001031746 3288518 C10orf72 chromosome 10 open reading frame 72 ⇩ 1.22 0.022  ⇩ 1.25 0.005 
NM_020374 3441215 C12orf4 chromosome 12 open reading frame 4 ⇧ 1.21 3.51E-04  ⇧ 1.28 2.33E-06 
BC014661 3474815 C12orf43 chromosome 12 open reading frame 43 ⇧ 1.20 0.021  ⇧ 1.36 4.12E-05 
AK298857 3473331 C12orf49 chromosome 12 open reading frame 49 ⇧ 1.23 0.003  ⇧ 1.20 0.004 
BC027935 3862564 C19orf47 chromosome 19 open reading frame 47 ⇧ 1.21 2.80E-05  ⇧ 1.20 1.27E-05 







 Table B9: C9ORF72 and NonC9ORF72-Related_SALS Common Gene List (n=595) [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
 478 
 
NM_032324 2385696 C1orf57 chromosome 1 open reading frame 57 ⇧ 1.30 0.012  ⇧ 1.25 0.022 
NM_016407 3890218 C20orf43 chromosome 20 open reading frame 43 ⇧ 1.26 0.003  ⇧ 1.37 2.80E-05 
NM_00110042 3926138 C21orf91 chromosome 21 open reading frame 91 ⇧ 1.38 1.77E-04  ⇧ 1.27 0.002 
NM_014807 3351895 C2CD2L C2CD2-like ⇩ 1.24 0.005  ⇩ 1.24 0.002 
NM_032359 2633460 C3orf26 chromosome 3 open reading frame 26 ⇧ 1.24 0.004  ⇧ 1.24 0.002 
NM_173552 2646327 C3orf58 chromosome 3 open reading frame 58 ⇩ 1.34 1.19E-04  ⇩ 1.20 0.007 
NM_020199 2875929 C5orf15 chromosome 5 open reading frame 15 ⇩ 1.30 2.68E-04  ⇩ 1.34 1.25E-05 
NM_022090 2884647 C5orf54 chromosome 5 open reading frame 54 ⇩ 1.29 0.003  ⇩ 1.29 0.001 
AK298490 2931683 C6orf211 chromosome 6 open reading frame 211 ⇧ 1.29 0.003  ⇧ 1.37 1.51E-04 
NM_032307 3212277 C9orf64 chromosome 9 open reading frame 64 ⇧ 1.24 0.003  ⇧ 1.28 3.14E-04 
NM_016520 3227121 C9orf78 chromosome 9 open reading frame 78 ⇧ 1.37 8.53E-05  ⇧ 1.27 0.001 
NM_144609 3759305 CCDC43 coiled-coil domain containing 43 ⇧ 1.20 8.32E-04  ⇧ 1.26 1.05E-05 
NM_015621 2881860 CCDC69 coiled-coil domain containing 69 ⇧ 1.27 0.003  ⇧ 1.29 6.09E-04 
NM_025140 3476330 CCDC92 coiled-coil domain containing 92 ⇧ 1.28 0.030  ⇧ 1.26 0.027 
NM_001008708 2482211 CHAC2 ChaC, cation transport regulator homolog 2 (E. coli) ⇧ 1.20 0.023  ⇧ 1.30 6.53E-04 
NM_016094 2700500 COMMD2 COMM domain containing 2 ⇧ 1.32 2.35E-04  ⇧ 1.20 0.010 
NM_017845 2768145 COMMD8 COMM domain containing 8 ⇧ 1.27 0.009  ⇧ 1.36 3.26E-04 
NM_014186 3369762 COMMD9 COMM domain containing 9 ⇧ 1.34 3.90E-04  ⇧ 1.33 2.23E-04 
NM_145858 3929821 CRYZL1 crystalline, zeta (quinone reductase)-like 1 ⇩ 1.26 4.61E-04  ⇩ 1.21 0.001 
NM_032299 3388914 DCUN1D5 DCN1, defective in cullin neddylation 1, domain containing 5 (S. cerevisiae) ⇧ 1.29 0.004  ⇧ 1.30 0.001 
NM_015291 2321849 DNAJC16 DnaJ (Hsp 40) homolog, subfamily C, member 16 ⇩ 1.21 0.003  ⇩ 1.25 2.79E-04 
NM_015190 3294280 DNAJC9 DnaJ (Hsp 40) homolog, subfamily C, member 9 ⇧ 1.22 0.012  ⇧ 1.27 0.001 
NM_173666 2872471 DTWD2 DTW domain containing 2 ⇧ 1.20 0.018  ⇧ 1.20 0.012 
NM_133455 3941848 EMID1 EMI domain containing 1 ⇩ 1.32 0.017  ⇩ 1.33 0.008 
NM_014936 2909020 ENPP4 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative) ⇩ 1.43 0.006  ⇩ 1.44 0.003 
NR_034165 3541937 EXD2 exonuclease 3’-5’ domain containing 2 ⇩ 1.29 0.008  ⇩ 1.22 0.026 
BC064407 3278813 FAM107B family with sequence similarity 107, member B ⇧ 1.55 1.05E-05  ⇧ 1.36 7.18E-04 
NM_024556 3355021 FAM118B family with sequence similarity 118, member B ⇧ 1.39 0.001  ⇧ 1.54 8.81E-06 
NM_001134456 2634058 FAM55C family with sequence similarity 55, member C ⇧ 1.22 0.043  ⇧ 1.30 0.005 
NM_018172 3339167 FAM86C family with sequence similarity 86, member C ⇧ 1.26 0.016  ⇧ 1.22 0.028 
NM_015475 2547716 FAM98A family with sequence similarity 98, member A ⇧ 1.22 0.004  ⇧ 1.22 0.003 
NM_031904 3335131 FRMD8 FERM domain containing 8 ⇧ 1.26 0.001  ⇧ 1.24 0.001 
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NR_027264 3698919 GLG1 golgi glycoprotein 1 ⇩ 1.26 9.38E-06  ⇩ 1.24 6.70E-06 
NM_001164372 3471224 GPN3 GPN-loop GTPase 3 ⇧ 1.20 0.045  ⇧ 1.33 8.96E-04 
NM_198827 3438061 GPR133 G protein-coupled receptor 133 ⇩ 1.38 0.027  ⇩ 1.66 2.31E-04 
NM_022036 3734355 GPRC5C G protein-coupled receptor, family C, group 5, member C ⇩ 1.44 0.001  ⇩ 1.40 0.001 
NM_006613 3748659 GRAP GRB2-related adaptor protein  ⇧ 1.25 0.005  ⇧ 1.21 0.010 
NM_016185 3770606 HN1 haematological and neurological expressed 1 ⇧ 1.27 6.16E-04  ⇧ 1.29 8.84E-05 
NR_003086 3243262 HSD17B7P2 hydroxysteroid (17-beta) dehydrogenase 7 pseudogene 2 ⇩ 1.45 0.003  ⇩ 1.38 0.006 
NR_028045 3444180 KLRAP1 killer cell lectin-like receptor subfamily A pseudogene 1 ⇩ 1.30 0.001  ⇩ 1.20 0.014 
NM_018113 3453774 LMBR1L limb region 1 homolog (mouse)-like ⇩ 1.24 4.69E-04  ⇩ 1.36 1.51E-07 
AY358681 3396179 LOC100130428 LOC100130428 ⇩ 1.25 0.015  ⇩ 1.25 0.009 
AY358688 2802681 LOC100133299 LOC100133299 ⇩ 1.40 0.009  ⇩ 1.52 5.71E-04 
NM_032860 2929036 LTV1 LTV1 homolog (S. cerevisiae) ⇧ 1.30 0.001  ⇧ 1.27 0.002 
NM_017816 2758686 LYAR Ly1 antibody reactive homolog (mouse) ⇧ 1.28 1.43E-04  ⇧ 1.28 4.81E-05 
NM_203462 2759303 MRFAP1L1 Morf4 family associated protein 1-like 1 ⇧ 1.27 0.003  ⇧ 1.45 1.31E-06 
NM_001020818 3841076 MYADM myeloid-associated differentiation marker ⇩ 1.25 0.026  ⇩ 1.23 0.030 
NR_024321 2390976 NCRNA00115 non-protein coding RNA 115 ⇩ 1.20 0.030  ⇩ 1.34 2.03E-04 
NM_016391 2888284 NOP16 NOP16 nucleolar protein homolog (yeast) ⇧ 1.27 0.008  ⇧ 1.22 0.018 
NM_024028 2835021 PCYOX1L prenylcysteine oxidase 1 like  ⇩ 1.24 0.002  ⇩ 1.21 0.003 
NM_024854 3407793 PYROXD1 pyridine nucleotide-disulphide oxidoreductase domain 1 ⇧ 1.34 0.003  ⇧ 1.25 0.015 
NM_178865 2328273 SERINC2 serine incorporator 2 ⇩ 1.48 0.007  ⇩ 1.83 1.18E-05 
NM_001040455 3350775 SIDT2 SID1 transmembrane family, member 1 ⇩ 1.28 2.17E-05  ⇩ 1.29 4.48E-06 
NM_016045 3911814 SLMO2 slowmo homolog 2 (Drosophila) ⇧ 1.36 5.88E-05  ⇧ 1.20 0.008 
NM_018373 3570475 SYNJ2BP synaptojanin 2 binding protein ⇧ 1.36 0.002  ⇧ 1.29 0.004 
NM_022484 3068476 TMEM168 transmembrane protein 168 ⇩ 1.20 0.003  ⇩ 1.26 6.53E-05 
NM_018247 2961317 TMEM30A transmembrane protein 30A ⇩ 1.21 0.004  ⇩ 1.27 1.16E-04 
NM_018266 2690850 TMEM39A transmembrane protein 39A ⇩ 1.26 0.003  ⇩ 1.33 1.19E-04 
NM_024334 2611779 TMEM43 transmembrane protein 43 ⇩ 1.23 0.001  ⇩ 1.27 5.39E-05 
NM_001136216 2321645 TMEM51 transmembrane protein 51 ⇩ 1.32 0.005  ⇩ 1.51 8.59E-06 
NM_152588 3424442 TMTC2 transmembrane and tetratricopeptide repeat containing 2 ⇩ 1.30 0.001  ⇩ 1.34 1.64E-04 
NM_030927 3254521 TSPAN14 tetraspanin 14 ⇩ 1.26 0.019  ⇩ 1.33 0.002 
NM_024331 3886512 TTPAL tocopherol (alpha) transfer protein-like ⇧ 1.29 0.004  ⇧ 1.27 0.003 
NM_005452 2950561 WDR46 WD repeat domain 46 ⇧ 1.25 0.001  ⇧ 1.24 9.39E-04 
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NM_016258 2327630 YTHDF2 YTH domain family, member 2 ⇧ 1.24 0.022  ⇧ 1.25 0.009 
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RefSeq #  Transcript Symbol Gene Name Fold p-value 
Apoptosis 
NM_020371 3617170 AVEN apoptosis, caspase activation inhibitor ⇧ 1.20 0.004 
NM_004323 3203482 BAG1 BCL2-associated athanogene 1 ⇧ 1.22 1.18E-04 
NM_001015049 3580791 BAG5 BCL2-associated athanogene 5 ⇧ 1.51 0.001 
NM_003921 2420808 BCL10 B-cell CLL/lymphoma 10 ⇧ 1.25 0.001 
NM_138578 3902489 BCL2L1 BCL2-like 1 ⇧ 1.24 0.003 
NM_004050 3529064 BCL2L2 BCL2-like 2 ⇩ 1.21 4.61E-05 
NM_033338 3264948 CASP7 caspase 7, apoptosis-related cysteine peptidase ⇧ 1.22 0.010 
NM_033657 2361036 DAP3 death associated protein 3 ⇧ 1.22 8.44E-04 
NM_00114196 2950668 DAXX death-domain associated protein ⇧ 1.20 2.22E-05 
NM_004944 2678298 DNASE1L3 deoxyribonuclease I-like 3 ⇩ 1.70 0.007 
NM_001375 3851826 DNASE2 deoxyribonuclease II, lysosomal ⇩ 1.29 1.36E-05 
NM_00103303 2644702 FAIM Fas apoptotic inhibitory molecule ⇧ 1.37 3.30E-04 
NM_001564 2753952 ING2 inhibitor of growth family, member 2 ⇧ 1.33 4.20E-06 
NM_020360 3743701 PLSCR3 phospholipid scramblase 3 ⇧ 1.21 8.41E-05 
NM_015316 3580876 PPP1R13B protein  phosphatase 1, regulatory (inhibitor) subunit 13B ⇧ 1.24 2.14E-04 
NM_013258 3688311 PYCARD PYD and CARD domain containing  ⇧ 1.31 7.39E-04 
NM_194271 3434823 RNF34 ring finger protein 34 ⇧ 1.29 6.18E-05 
NM_004760 2999485 STK17A serine/threonine kinase 17a ⇧ 1.23 7.77E-04 
NM_003844 3127775 TNFRSF10A tumor necrosis factor receptor superfamily, member 10a ⇩ 1.27 0.002 
NM_003840 3127745 TNFRSF10D tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain ⇩ 1.32 0.005 
NM_001066 2320727 TNFRSF1B tumor necrosis factor receptor superfamily, member 1B ⇩ 1.21 0.019 
NM_005802 3203135 TOPORS topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein ligase ⇧ 1.20 0.004 
NM_000546 3743906 TP53 tumor protein p53 ⇧ 1.35 1.34E-05 
Autophagy 
NM_020773 2717165 TBC1D14 TBC1 domain family, member 14 ⇧ 1.20 7.75E-04 
NM_006405 3557898 TM9SF1 transmembrane 9 superfamily member 1 ⇩ 1.21 0.013 
NM_004872 2413578 TMEM59 transmembrane protein 59 ⇩ 1.25 0.001 
Cell Adhesion/Extracellular Matrix 
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NM_001777 2687739 CD47 CD47 molecule  ⇩ 1.24 6.37E-04 
NM_022478 3557069 CDH24 cadherin 24, type 2 ⇩ 1.35 2.09E-06 
NM_016946 2440476 F11R F11 receptor  ⇩ 1.32 8.68E-06 
NM_000201 3820443 ICAM1 intercellular adhesion molecule 1 ⇩ 1.26 1.90E-04 
NM_004517 3318890 ILK integrin-linked kinase ⇧ 1.22 9.94E-06 
NM_181501 2809128 ITGA1 integrin, alpha 1 ⇩ 1.35 0.020 
NM_000425 4026798 L1CAM L1 cell adhesion molecule  ⇩ 1.20 0.005 
NM_005567 3772719 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein  ⇩ 1.42 0.014 
NM_001143995 3374402 LPXN leupaxin  ⇧ 1.21 3.05E-05 
NM_005926 3621692 MFAP1 microfibrillar-associated protein 1 ⇧ 1.28 4.53E-06 
NM_004385 2818517 VCAN versican ⇩ 1.43 0.025 
NM_003461 3029129 ZYX zyxin ⇧ 1.28 4.99E-05 
Cellular Response to Stress 
NM_012111 3545466 AHSA1 AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) ⇧ 1.37 1.26E-05 
NM_152392 2484552 AHSA2 AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) ⇩ 1.22 0.003 
NM_000067 3105600 CA2 carbonic anhydrase II ⇧ 1.37 0.004 
NM_001752 3326400 CAT catalase ⇧ 1.23 0.001 
NM_016230 2915490 CYB5R4 cytochrome b5 reductase 4 ⇧ 1.20 0.004 
NM_004417 2887309 DUSP1 dual specificity phosphatase 1 ⇩ 1.41 0.002 
NM_007207 2457261 DUSP10 dual specificity phosphatase 10 ⇧ 1.31 1.13E-04 
NM_014584 3564790 ERO1L ERO1-like (S. cerevisiae) ⇩ 1.21 0.013 
NM_019891 2462329 ERO1LB ERO1-like beta (S. cerevisiae) ⇩ 1.33 1.55E-04 
NM_000402 4027416 G6PD glucose-6-phosphate dehydrogenase  ⇧ 1.20 3.57E-04 
NM_032569 3678395 GLYR1 glyoxylate reductase 1 homolog (Arabidopsis) ⇧ 1.22 0.010 
NM_201397 2674229 GPX1 glutathione peroxidase 1 ⇩ 1.22 0.001 
NM_000178 3903670 GSS glutathione synthetase ⇧ 1.21 4.77E-04 
NM_001031720 2738314 GSTCD glutathione S-transferase, C-terminal domain containing  ⇧ 1.21 8.13E-04 
NM_013332 3022814 HILPDA hypoxia inducible lipid droplet-associated ⇩ 1.50 0.003 
NM_005348 3580179 HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 ⇧ 1.31 1.42E-05 
NM_002154 2828856 HSPA4 heat shock 70kDa protein 4 ⇧ 1.22 0.002 
NM_006644 3508330 HSPH1 heat shock 105kDa/110kDa protein 1 ⇧ 1.27 0.003 
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NM_000903 3696666 NQO1 NAD(P)H dehydrogenase, quinone 1 ⇧ 1.47 1.41E-05 
NM_016332 3676262 SEPX1 selenoprotein X, 1 ⇧ 1.34 0.009 
NM_000454 3917851 SOD1 superoxide dismutase 1 ⇧ 1.34 3.36E-04 
NM_006819 3334224 STIP1 stress-induced-phosphoprotein 1 ⇧ 1.23 0.001 
Cytoskeleton 
NM_001005386 2485784 ACTR2 ARP2 actin-related protein 2 homolog (yeast) ⇧ 1.35 0.001 
NM_016824 3263555 ADD3 adducing 3 (gamma) ⇧ 1.21 0.006 
NM_016293 3454841 BIN2 bridging integrator 2 ⇧ 1.32 0.013 
NM_006136 3020444 CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 ⇧ 1.40 6.34E-04 
NM_005507 3377886 CFL1 cofilin 1 (non-muscle) ⇧ 1.27 1.45E-07 
NM_018204 3490655 CKAP2 cytoskeleton associated protein 2 ⇧ 1.21 5.92E-04 
NM_014063 2999710 DBNL drebrin-like ⇧ 1.22 2.75E-04 
NM_00104251 3515965 DIAPH3 diaphanous homolog 3 (Drosophila) ⇧ 1.36 6.90E-05 
NM_144666 3318731 DNHD1 dynein heavy chain domain 1 ⇩ 1.28 0.003 
NM_007044 2978957 KATNA1 katanin p60 (ATPase-containing) subunit A1 ⇧ 1.23 9.33E-05 
NM_001014380 3507962 KATNAL1 katanin p60 subunit A-like 1 ⇧ 1.20 0.012 
NM_014846 3152220 KIAA0196 KIAA0196 ⇧ 1.20 0.001 
NM_015634 3250093 KIAA1279 KIAA1279 ⇧ 1.20 0.007 
NM_004523 3258168 KIF11 kinesin family member 11 ⇧ 1.30 4.47E-04 
NM_020242 2620256 KIF15 kinesin family member 15 ⇧ 1.41 7.49E-05 
NM_024704 3898796 KIF16B kinesin family member 16B ⇧ 1.25 5.63E-04 
NM_138555 3599811 KIF23 kinesin family member 23 ⇧ 1.25 2.93E-04 
NM_007054 2875419 KIF3A kinesin family member 3A ⇩ 1.32 0.006 
NM_004798 3881824 KIF3B kinesin family member 3B ⇧ 1.29 1.53E-04 
NM_012310 3980560 KIF4A kinesin family member 4A ⇧ 1.20 1.53E-04 
NM_006148 3719980 LASP1 LIM and SH3 protein 1 ⇧ 1.22 6.46E-05 
NM_001113546 3454331 LIMA1 LIM domain and actin binding 1 ⇧ 1.21 0.020 
NM_002314 3008108 LIMK1 LIM domain kinase 1 ⇧ 1.23 1.04E-04 
NM_005573 2827185 LMNB1 lamin B1 ⇧ 1.32 2.00E-04 
AK023285 2331505 MACF1 microtubule-actin crosslinking factor 1 ⇩ 1.27 0.040 
NM_012325 3882069 MAPRE1 microtubule-associated protein, RP/EB family, member 1 ⇧ 1.23 2.97E-05 
NM_001172303 3240012 MASTL microtubule-associated serine/threonine kinase-like ⇧ 1.21 2.16E-05 
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NM_006901 3631794 MYO9A myosin IXA ⇧ 1.20 4.58E-04 
NM_144573 2343231 NEXN nexilin (F actin binding protein) ⇧ 1.43 0.002 
NM_016418 3942062 NF2 neurofibromin 2 ⇧ 1.34 3.14E-07 
NM_020992 3301218 PDLIM1 PDZ and LIM domain 1 ⇧ 1.25 2.37E-05 
NM_005022 3742400 PFN1 profilin 1 ⇧ 1.24 0.015 
NM_016274 2358044 PLEKHO1 pleckstrin homology domain containing, family O member 1 ⇧ 1.27 5.01E-06 
NM_001080855 3474372 PXN paxillin ⇧ 1.35 1.84E-06 
NM_021021 3150844 SNTB1 syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1) ⇧ 1.42 5.75E-04 
NM_006750 3666601 SNTB2 syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic component 2) ⇧ 1.27 2.22E-05 
NM_001024858 3568485 SPTB spectrin, beta, erythrocytic  ⇩ 1.22 0.010 
NM_003128 2482505 SPTBN1 spectrin, beta, non-erythrocytic 1 ⇩ 1.22 9.67E-06 
NM_001130965 2986825 SUN1 Sad1 and UNC84 domain containing 1 ⇩ 1.34 9.33E-07 
NM_001079515 2386418 TBCE tubulin folding cofactor E ⇧ 1.34 2.66E-06 
NM_015602 2446244 TOR1AIP1 torsin A interacting protein 1 ⇩ 1.30 1.11E-04 
NM_012112 3881443 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) ⇧ 1.21 7.03E-04 
NR_027779 3962734 TTLL1 tubulin tyrosine ligase-like family, member 1 ⇧ 1.22 2.60E-04 
NR_003659 3612166 WASH3P WAS protein family homolog 3 pseudogene ⇩ 1.23 0.024 
NM_017491 2760371 WDR1 WD repeat domain 1 ⇧ 1.22 8.86E-05 
Development 
NM_152698 2505793 AMER3 APC membrane recruitment protein 3 ⇩ 1.21 8.55E-04 
NM_001002858 3627248 ANXA2 annexin A2 ⇧ 1.23 0.002 
NM_031301 3597521 APH1B anterior pharynx defective 1 homolog B (C. elegans) ⇩ 1.21 0.003 
NM_147147 2967249 BVES blood vessel epicardial substance ⇩ 1.33 0.001 
BC022092 3432641 C12orf52 chromosome 12 open reading frame 52 ⇧ 1.20 4.15E-04 
NM_006324 3699508 CFDP1 craniofacial development protein 1 ⇧ 1.20 0.003 
NM_145234 4018080 CHRDL1 chordin-like 1 ⇩ 1.31 1.05E-04 
NM_025212 2780388 CXXC4 CXXC finger protein 4 ⇧ 1.44 4.33E-04 
NM_016651 3538087 DACT1 dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) ⇧ 1.23 0.041 
NM_005227 2360633 EFNA4 ephrin-A4 ⇩ 1.21 0.038 
NM_000399 3291601 EGR2 early growth response 2 ⇧ 1.23 0.018 
NM_003633 2862696 ENC1 ectodermal-neural cortex 1 (with BTB-like domain) ⇧ 1.40 0.004 
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NM_022475 2745899 HHIP hedgehog interacting protein ⇩ 1.20 0.031 
NM_000597 2527253 IGFBP2 isulin-like growth factor binding protein 2, 36kDa ⇩ 1.28 4.47E-04 
NM_016269 2781138 LEF1 lymphoid enhancer-binding factor 1 ⇩ 1.46 0.026 
NM_022458 3081613 LMBR1 limb region 1 homolog (mouse) ⇩ 1.44 2.31E-05 
NM_014839 2348514 LPPR4 lipid phosphate phosphatase-related protein type 4 ⇩ 1.28 0.001 
NM_015884 3971329 MBTPS2 membrane-bound transcription factor peptidase, site 2 ⇩ 1.22 0.011 
NM_001012334 3329343 MDK midkine (neurite growth-promoting factor 2) ⇩ 1.20 0.042 
NM_014791 3168508 MELK maternal embryonic leucine zipper kinase ⇧ 1.38 3.11E-04 
NM_006154 3625539 NEDD4 neural precursor cell expressed, developmentally up-regulated 4, E3 ubiquitin protein ligase  ⇧ 1.21 0.011 
NM_015514 3529156 NGDN neuroguidin, EIF4E binding protein ⇧ 1.25 0.002 
NM_153026 3451375 PRICKLE1 prickle homolog 1 (Drosophila) ⇧ 1.28 0.005 
NM_006717 3178416 SPIN1 spindlin 1 ⇧ 1.21 0.003 
NM_153365 2761941 TAPT1 transmembrane anterior posterior transformation 1 ⇩ 1.31 8.09E-07 
NM_005149 2366184 TBX19 T-box 19 ⇩ 1.25 4.09E-04 
NM_001135243 2835440 TCOF1 Treacher Collins-Franceschetti syndrome 1 ⇧ 1.22 7.97E-06 
NM_015631 3301556 TCTN3 tectonic family member 3 ⇩ 1.23 0.002 
NM_020457 3665846 THAP11 THAP domain containing 11 ⇧ 1.27 1.47E-04 
NM_181783 3425134 TMTC3 transmembrane and tetratricopeptide repeat containing 3 ⇩ 1.21 8.40E-04 
NM_020648 3778372 TWSG1 twisted gastrulation homolog 1 (Drosophila) ⇩ 1.31 0.002 
NM_138959 2353283 VANGL1 vang-like 1 (van gogh, Drosophila) ⇧ 1.37 0.016 
NM_004626 3382523 WNT11 wingless-type MMTV integration site family, member 11 ⇩ 1.24 0.025 
DNA Damage & Repair 
NM_139178  3328214 ALKBH3 alkB, alkylation repair homolog 3 (E. coli) ⇧ 1.28 4.14E-05 
NM_138775 3389878 ALKBH8 alkB, alkylation repair homolog 8 (E. coli) ⇧ 1.21 7.09E-05 
NM_014481 3978620 APEX2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2 ⇧ 1.21 1.90E-04 
NM_024857 3716893 ATAD5 ATPase family, AAA domain containing 5 ⇧ 1.24 0.001 
NM_001033549 3824153 BABAM1 BRISC and BRCA1 A complex member 1 ⇧ 1.20 2.26E-04 
NM_032408 3056044 BAZ1B bromodomain adjacent to zinc finger domain, 1B ⇧ 1.20 7.07E-05 
NM_000057 3608298 BLM Bloom syndrome, RecQ helicase-like  ⇧ 1.43 7.44E-06 
NM_007300 3758317 BRCA1 breast cancer 1, early onset ⇧ 1.44 4.57E-06 
NM_000059 3484641 BRCA2 breast cancer 2, early onset ⇧ 1.26 9.43E-04 
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NM_032043 3765580 BRIP1 BRCA1 interacting protein C-terminal helicase 1 ⇧ 1.32 1.05E-05 
NM_001114122 3354799 CHEK1 CHK1 checkpoint homolog (S. pombe) ⇧ 1.29 1.49E-05 
NM_022111 2406420 CLSPN claspin ⇧ 1.39 1.14E-04 
NM_00103385 3278977 DCLRE1C DNA cross-link repair 1C ⇧ 1.21 0.005 
NM_016448 2378937 DTL denticleless homolog (Drosophila) ⇧ 1.25 6.88E-04 
NM_139076 2776088 FAM175A family with sequence similarity 175, member A ⇧ 1.22 0.004 
NM_00101811 4000370 FANCB Fanconi anemia, complementation group B ⇧ 1.25 2.29E-04 
NM_000136 3215701 FANCC Fanconi anemia, complementation group C ⇧ 1.35 1.24E-05 
NM_021922 2904663 FANCE Fanconi anemia, complementation group E ⇧ 1.20 4.56E-05 
NM_00111337 3607537 FANCI Fanconi anemia, complementation group I ⇧ 1.38 1.19E-05 
NM_202002 3440598 FOXM1 forkhead box M1 ⇧ 1.39 4.55E-06 
NM_015675 3816509 GADD45B growth arrest and DNA-damage-inducible, beta ⇩ 1.27 0.017 
NM_007266 2474681 GPN1 GPN-loop GTPase 1 ⇧ 1.21 0.002 
NM_016426 3949055 GTSE1 G-2 and S-phase expressed 1 ⇧ 1.27 2.48E-05 
NM_001130688 2793951 HMGB2 high-mobility group box 2 ⇧ 1.31 0.003 
NM_014736 3629103 KIAA0101 KIAA0101 ⇧ 1.47 1.12E-04 
NM_000251 2480992 MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) ⇧ 1.35 6.98E-05 
NM_000179 2481142 MSH6 mutS homolog 6 (E. coli)  ⇧ 1.25 1.05E-04 
NM_173685 3114878 NSMCE2 non-SMC element 2, MMS21 homolog (S. cerevisiae) ⇧ 1.29 2.18E-04 
NM_024675 3685329 PALB2 partner and localizer of BRCA2 ⇧ 1.26 6.30E-06 
NM_002690 3096171 POLB polymerase (DNA directed), beta ⇧ 1.22 9.80E-05 
NM_199420 2691575 POLQ polymerase (DNA directed), theta ⇧ 1.26 0.005 
NM_005053 3822074 RAD23A RAD23 homolog A (S. cerevisiae) ⇧ 1.20 2.71E-04 
NM_058216 3728776 RAD51C RAD51 homolog C (S. cerevisiae) ⇧ 1.44 4.01E-06 
NM_134424 3439836 RAD52 RAD52 homolog (S. cerevisiae) ⇩ 1.22 4.37E-05 
NM_003579 2334646 RAD54L RAD54-like (S. cerevisiae) ⇧ 1.20 0.002 
NM_002945 3706000 RPA1 replication protein A1, 70kDa ⇧ 1.21 3.50E-05 
NM_006666 3838118 RUVBL2 RuvB-like 2 (E. coli)  ⇧ 1.22 3.32E-04 
NM_001042550 3182781 SMC2 structural maintenance of chromosomes 2 ⇧ 1.32 6.79E-05 
NM_005496 2650199 SMC4 structural maintenance of chromosomes 4 ⇧ 1.21 0.002 
NM_003350 3097208 UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 ⇧ 1.22 0.017 
NM_003362 3430926 UNG uracil-DNA glycosylase ⇧ 1.30 5.61E-05 
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NM_022550 2818454 XRCC4 X-ray repair complementing defective repair in Chinese hamster cells 4 ⇧ 1.22 0.003 
NM_032143 2577700 ZRANB3 zinc finger, RAN-binding domain containing 3 ⇧ 1.25 0.002 
DNA Replication & the Cell Cycle 
NM_015120 2488785 ALMS1 Alstrom syndrome 1 ⇧ 1.26 0.009 
NM_198433 3910785 AURKA aurora kinase A ⇧ 1.27 0.002 
NM_058243 3853193 BRD4 bromodomain containing 4 ⇧ 1.26 0.001 
NM_001211 3589697 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B ⇧ 1.26 2.83E-04 
NM_001100619 3781531 CABLES Cdk5 and Abl enzyme substrate 1 ⇧ 1.22 2.71E-04 
NM_001743 2551924 CALM2 calmodulin 2 (phosphorylase kinase, delta) ⇧ 1.25 0.022 
NM_005184 3836841 CALM3 calmodulin 3 (phosphorylase kinase, delta) ⇧ 1.25 8.06E-07 
NM_001237 2784113 CCNA2 cyclin A2 ⇧ 1.32 9.36E-05 
NM_031966 2813414 CCNB1 cyclin B1 ⇧ 1.25 0.002 
NM_004701 3595979 CCNB2 cyclin B2 ⇧ 1.26 6.56E-04 
NM_057749 3145107 CCNE2 cyclin E2 ⇧ 1.52 3.82E-04 
NM_004748 3625326 CCPG1 cell cycle progression 1 ⇩ 1.25 0.004 
NM_006023 3235461 CDC123 cell division cycle 123 homolog (S. cerevisiae) ⇧ 1.32 3.04E-06 
NM_001255 2333136 CDC20 cell division cycle 20 homolog (S. cerevisiae) ⇧ 1.30 0.032 
NM_021873 3874439 CDC25B cell division cycle 25 homolog B (S. pombe)  ⇧ 1.22 1.06E-05 
NM_001178010 3936913 CDC45 cell division cycle 45 homolog (S. cerevisiae) ⇧ 1.37 1.33E-04 
NM_001254 3720896 CDC6 cell division cycle 6 homolog (S. cerevisiae) ⇧ 1.62 8.87E-05 
NM_152562 3090697 CDCA2 cell division cycle associated 2 ⇧ 1.26 0.002 
NM_031942 2516023 CDCA7 cell division cycle associated 7 ⇧ 1.27 0.002 
NM_001127370 3040897 CDCA7L cell division cycle associated 7-like  ⇧ 1.24 0.027 
NM_018101 2330773 CDCA8 cell division cycle associated 8 ⇧ 1.44 1.80E-04 
NM_000075 3458783 CDK4 cyclin-dependent kinase 4 ⇧ 1.20 0.003 
NM_001260 3482498 CDK8 cyclin-dependent kinase 8 ⇧ 1.21 0.003 
NM_004064 3405440 CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) ⇩ 1.20 0.018 
NM_005192 3536336 CDKN3 cyclin-dependent kinase inhibitor 3 ⇧ 1.31 6.29E-06 
NM_006733 3984655 CENPI centromere protein I ⇧ 1.30 6.71E-04 
NM_022145 2859667 CENPK centromere protein K ⇧ 1.25 0.004 
NM_024322 2473284 CENPO centromere protein O ⇧ 1.33 4.69E-04 
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NM_018132 2909723 CENPQ centromere protein Q ⇧ 1.24 0.003 
NM_018131 3258444 CEP55 centrosomal protein 55kDa ⇧ 1.36 1.21E-04 
NM_024899 3799542 CEP76 centrosomal protein 76kDa ⇧ 1.20 1.17E-04 
NM_004344 4026263 CETN2 centrin, EF-hand protein, 2 ⇧ 1.36 1.63E-05 
NM_005483 3817501 CHAF1A chromatin assembly factor 1, subunit A (p150) ⇧ 1.32 3.84E-08 
NM_001039690 369454 CHTF8 CTF8, chromosome transmission fidelity factor 8 homolog (S. cerevisiae) ⇧ 1.24 8.92E-05 
NM_001827 3178583 CKS2 CDC28 protein kinase regulatory subunit 2 ⇧ 1.27 0.014 
NM_014711 3651018 CP110 centriolar coiled coil protein 110kDa ⇧ 1.23 0.003 
NM_015986 3752002 CRLF3 cytokine receptor-like factor 3 ⇧ 1.22 7.69E-04 
NM_00114601 3565663 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 ⇧ 1.22 0.013 
NM_014689 2601648 DOCK10 dedicator of cytokinesis 10 ⇧ 1.25 0.001 
NM_024094 3150715 DSCC1 defective in sister chromatid cohesion 1 homolog (S. cerevisiae) ⇧ 1.31 3.26E-05 
NM_001943 3783529 DSG2 desmoglein 2 ⇩ 1.60 0.007 
NM_207042 2434490 ENSA endosulfine alpha ⇩ 1.32 2.09E-04 
NM_017669 4012142 ERCC6L excision repair cross-complementing rodent repair deficiency, complementation group 6-like ⇧ 1.21 2.73E-04 
NM_030919 3884892 FAM83D family with sequence similarity 83, member D ⇧ 1.25 0.003 
NM_012177 2980241 FBXO5 F-box protein 5 ⇧ 1.35 3.22E-05 
NM_033417 3854218 HAUS8 HAUS augmin-like complex, subunit 8 ⇧ 1.21 3.80E-05 
NM_033402 3105430 LRRCC1 leucine rich repeat and coiled-coil domain containing 1 ⇧ 1.48 7.34E-07 
NM_182751 3235789 MCM10 minichromosome maintenance complex component 10 ⇧ 1.52 5.02E-06 
NM_004526 2640855 MCM2 minichromosome maintenance complex component 2 ⇧ 1.29 3.41E-05 
NM_002388 2957126 MCM3 minichromosome maintenance complex component 3 ⇧ 1.30 8.17E-05 
NM_005915 2577896 MCM6 minichromosome maintenance complex component 6 ⇧ 1.23 8.93E-04 
NM_018944 3929038 MIS18A MIS18 kinetochore protein homolog A (S. pombe) ⇧ 1.24 2.25E-06 
NM_022045 3113456 MTBP Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) binding protein, 104kDa ⇧ 1.30 6.93E-05 
NM_002466 3886223 MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 ⇧ 1.41 3.70E-04 
NM_015261 3399545 NCAPD3 non-SMC condensin II complex, subunit D3 ⇧ 1.22 4.65E-04 
NM_022346 2720251 NCAPG non-SMC condensin I complex, subunit G ⇧ 1.24 0.003 
NM_017760 3082181 NCAPG2 non-SMC condensin II complex, subunit G2  ⇧ 1.30 2.46E-04 
NM_015341 2494484 NCAPH non-SMC condensin I complex, subunit H ⇧ 1.30 3.57E-04 
NM_006101 3776139 NDC80 NDC80 homolog, kinetochore complex component (S. cerevisiae) ⇧ 1.46 4.89E-06 
NM_004542 3841198 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa ⇧ 1.39 0.004 
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NM_003157 2676352 NEK4 NIMA (never in mitosis gene a)-related kinase 4 ⇧ 1.21 0.001 
NM_004741 3261492 NOLC1 nucleolar and coiled-body phosphoprotein 1 ⇧ 1.26 5.22E-04 
NM_001033714 3442024 NOP2 NOP2 nucleolar protein homolog (yeast) ⇧ 1.22 5.71E-04 
NM_001042549 2454838 NSL1 NSL1, MIND kinetochore complex component, homolog (S. cerevisiae) ⇧ 1.22 2.73E-05 
NM_016359 3590388 NUSAP1 nucleolar and spindle associated protein 1 ⇧ 1.20 7.16E-04 
NM_007280 3619945 OIP5 Opa interacting protein 5 ⇧ 1.38 7.77E-06 
NM_004153 2412799 ORC1 origin recognition complex, subunit 1 ⇧ 1.27 0.001 
NM_006191 3417309 PA2G4 proliferation-associated 2G4, 38kDa ⇧ 1.21 3.75E-05 
NM_017884 3124180 PINX1 PIN2/TERF1 interacting, telomerase inhibitor 1 ⇧ 1.24 1.74E-04 
NM_014264 2742985 PLK4 polo-like kinase 4 ⇧ 1.31 3.01E-04 
NM_016937 3972093 POLA1 polymerase (DNA directed), alpha 1, catalytic subunit ⇧ 1.31 8.12E-04 
NM_006591 3340269 POLD3 polymerase (DNA-directed), delta 3, accessory subunit ⇧ 1.37 2.86E-06 
NR_027261 3221646 POLE3 polymerase (DNA directed), epsilon 3 (p17 subunit) ⇧ 1.20 4.54E-04 
NM_005973 2361731 PRCC papillary renal cell carcinoma (translocation-associated) ⇧ 1.21 8.56E-05 
NM_000946 3458133 PRIM1 primase, DNA, polypeptide 1 (49kDa) ⇧ 1.26 2.43E-04 
NM_000321 3489020 RB1 retinoblastoma 1 ⇧ 1.23 0.004 
NR_030725 2327482 RCC1 regulator of chromosome condensation 1 ⇧ 1.20 3.80E-04 
NM_002916 2709486 RFC4 replication factor C (activator 1) 4, 37kDa ⇧ 1.23 0.012 
NM_181578 3433747 RFC5 replication factor C (activator 1) 5, 36.5kDa ⇧ 1.26 2.31E-04 
NM_024945 3176999 RMI1 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae) ⇧ 1.24 0.001 
NM_006397 3821908 RNASEH2A ribonuclease H2, subunit A ⇧ 1.22 3.03E-04 
NM_001033 3318009 RRM1 ribonucleotide reductase M1 ⇧ 1.31 1.00E-04 
NM_144710 2569908 SEPT10 septin 10 ⇧ 1.91 0.008 
NM_001012410 2665572 SGOL1 shugoshin-like 1 (S. pombe) ⇧ 1.24 0.005 
NM_152524 2522212 SGOL2 shugoshin-like 2 (S. pombe) ⇧ 1.22 0.004 
NM_182620 3764738 SKA2 spindle and kinetochore associated complex subunit 2 ⇧ 1.43 0.005 
NM_145061 3504617 SKA3 spindle and kinetochore associated complex subunit 3 ⇧ 1.36 1.01E-04 
NM_005983 2806517 SKP2 S-phase kinase-associated protein 2 (p45) ⇧ 1.25 4.01E-05 
NM_006306 4009238 SMC1A structural maintenance of chromosomes 1A ⇧ 1.27 7.12E-04 
NM_020675 2585933 SPC25 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) ⇧ 1.52 3.88E-05 
NM_017785 2840002 SPDL1 spindle apparatus coiled-coil protein 1 ⇧ 1.29 0.002 
NM_001048166 2411228 STIL SCL/TAL1 interrupting locus  ⇧ 1.23 0.008 
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NM_001193424 3236448 SUV39H2 suppressor of variegation 3-9 homolog 2 (Drosophila)  ⇧ 1.22 5.95E-04 
NM_006342 2714955 TACC3 transforming, acidic coiled-coil containing protein 3 ⇧ 1.34 9.79E-05 
NM_001071 3775842 TYMS thymidylate synthetase ⇧ 1.20 2.24E-04 
NM_015045 3298738 WAPAL wings apart-like homolog (Drosophila) ⇧ 1.21 3.64E-05 
NM_007086 3565571 WDHD1 WD repeat and HMG-box DNA binding protein 1 ⇧ 1.37 2.21E-06 
NM_004724 3391769 ZW10 ZW10, kinetochore associated, homolog (Drosophila) ⇧ 1.25 3.27E-05 
NR_003105 3598721 ZWILCH Zwilch, kinetochore associated, homolog (Drosophila) ⇧ 1.41 1.56E-05 
NM_032997 3290210 ZWINT ZW10 interactor  ⇧ 1.57 5.09E-05 
Hormone Function 
NM_001124 3320123 ADM adrenomedullin ⇩ 1.62 0.002 
NM_022640 3766480 CSH1 chorionic somatomammotropin hormone 1 (placental lactogen) ⇩ 1.42 0.008 
NM_000805 3721421 GAST gastrin ⇩ 1.21 0.029 
NM_000515 3766512 GH1 growth hormone 1 ⇩ 1.22 0.019 
NM_000233 2552368 LHCGR luteinizing hormone/choriogonadot ropin receptor  ⇩ 1.24 0.002 
NM_005575 2821413 LNPEP leucyl/cystinyl aminopeptidase  ⇩ 1.65 1.37E-05 
Immune Response & Inflammation 
NM_181780 2688717 BTLA B and T lymphocyte associated  ⇩ 1.25 0.001 
NM_007047 2899333 BTN3A2 butyrophilin, subfamily 3, member A2 ⇩ 1.24 0.046 
NM_148672 2855542 CCL28 chemokine (C-C motif) ligand 28 ⇩ 1.22 0.038 
NM_002984 3718930 CCL4 chemokine (C-C motif) ligand 4 ⇩ 1.21 0.049 
NM_002985 3753860 CCL5 chemokine (C-C motif) ligand 5 ⇩ 1.24 0.037 
NM_001838 3756319 CCR7 chemokine (C-C motif) receptor 7 ⇩ 1.21 2.28E-04 
NM_001004196 2636125 CD200 CD200 molecule ⇩ 1.53 2.50E-04 
NM_006139 2523801 CD28 CD28 molecule ⇩ 2.18 3.68E-04 
NM_002389 2377427 CD46 CD46 molecule, complement regulatory protein  ⇩ 1.29 7.80E-08 
NM_005191 2690900 CD80 CD80 molecule ⇩ 1.35 7.24E-06 
NM_001184879 2440295 CD84 CD84 molecule ⇩ 1.43 0.001 
NM_198390 3670772 CMIP c-Maf-inducing protein ⇧ 1.21 4.49E-04 
NM_001142343 3470193 CMKLR1 chemokine-like receptor 1 ⇩ 1.29 0.013 
NM_000757 2351063 CSF1 colony stimulating factor 1 (macrophage) ⇩ 1.24 0.018 
NM_014395 2737318 DAPP1 dual adaptor of phosphotyrosine and 3-phosphoinositides  ⇧ 1.32 1.83E-04 
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NM_001040458 2868131 ERAP1 endoplasmic reticulum aminopeptidase 1 ⇩ 1.23 0.002 
NM_001007253 3053380 ERV3 endogenous retroviral sequence 3 ⇧ 1.33 0.024 
NM_002001 2362537 FCER1A Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide ⇩ 1.22 0.023 
NM_031282 2438938 FCRL4 Fc receptor-like 4 ⇧ 1.46 0.008 
NM_002053 2421883 GBP1 guanylate binding protein 1, interferon-inducible, 67kDa ⇧ 1.38 0.003 
NM_004951 3522662 GPR183 G protein-coupled receptor 183 ⇩ 1.22 0.005 
NM_012206 2883317 HAVCR1 hepatitis A virus cellular receptor 1 ⇩ 1.24 2.08E-04 
NM_032782 2883349 HAVCR2 hepatitis A virus cellular receptor 2 ⇩ 1.44 0.017 
NM_005335 2691668 HCLS1 hematopoietic cell-specific Lyn substrate 1 ⇧ 1.21 0.001 
NM_002119 2950307 HLA-DOA major histocompatibility complex, class II, DO alpha ⇩ 1.27 0.002 
NM_005516 2901620 HLA-E major histocompatibility complex, class I, E ⇩ 1.20 3.51E-04 
NM_001098479 2900974 HLA-F major histocompatibility complex, class I, F ⇩ 1.37 6.11E-07 
NR_027822 2901463 HLA-L major histocompatibility complex, class I, L ⇩ 1.22 0.048 
NM_005533 3722338 IFI35 interferon-induced protein 35 ⇧ 1.22 0.027 
NM_002038 2403261 IFI6 interferon, alpha-inducible protein 6 ⇩ 1.22 0.009 
NM_001548 3257246 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 ⇧ 1.38 0.021 
NM_021068 3201188 IFNA4 interferon, alpha 4 ⇩ 1.33 0.033 
NM_000416 2976113 IFNGR1 interferon gamma receptor 1 ⇩ 1.33 0.005 
NM_016584 3417557 IL23A interleukin 23, alpha subunit p19 ⇩ 1.21 0.015 
NM_002184 2857416 IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) ⇩ 1.21 0.006 
NM_002339 3317071 LSP1 lymphocyte-specific protein 1 ⇧ 1.31 2.61E-05 
NM_002349 2583254 LY75 lymphocyte antigen 75 ⇩ 1.33 2.81E-05 
NM_002348 2363248 LY9 lymphocyte antigen 9 ⇩ 1.26 0.033 
NM_002432 2362333 MNDA myeloid cell nuclear differentiation antigen  ⇧ 1.36 0.035 
NM_012340 3909553 NFATC2 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 ⇧ 1.41 0.008 
NM_020393 2435961 PGLYRP4 peptidoglycan recognition protein 4 ⇩ 1.20 0.005 
BC035736 3442249 PIANP PILR alpha associated neural protein ⇩ 1.22 0.003 
NM_017831 3783723 RNF125 ring finger protein 125 ⇧ 1.49 0.005 
NM_015474 3904691 SAMHD1 SAM domain and HD domain 1 ⇧ 1.41 8.63E-04 
NM_021966 3578152 TCL1A T-cell leukemia/lymphoma 1A ⇧ 1.23 0.004 
NM_006068 2766262 TLR6 toll-like receptor 6 ⇩ 1.39 8.88E-04 
NM_001561 2395146 TNFRSF9 tumor necrosis factor receptor superfamily, member 9 ⇩ 1.28 0.036 
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NM_003141 3360142 TRIM21 tripartite motif-containing 21 ⇧ 1.21 0.021 
NM_015294 3764680 TRIM37 tripartite motif-containing 37 ⇧ 1.21 3.47E-05 
NM_198057 4017381 TSC22D3 TSC22 domain family, member 3 ⇩ 1.30 0.029 
Ion Binding 
NM_002197 3166477 ACO1 aconitase 1, soluble ⇧ 1.25 0.001 
NM_000146 3838094 FTL ferritin, light polypeptide ⇩ 1.53 0.001 
NM_003234 2712632 TFRC transferrin receptor (p90, CD71) ⇩ 1.23 4.19E-05 
Membrane Trafficking 
NM_001089 3676763 ABCA3 ATP-binding cassette, sub-family A (ABC1), member 3 ⇩ 1.23 7.28E-04 
NM_018672 3768969 ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 ⇩ 1.30 0.001 
NM_005689 2599993 ABCB6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 ⇩ 1.28 9.71E-07 
NM_00102509 2901687 ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 ⇧ 1.20 3.21E-05 
NM_173872 2751385 CLCN3 chloride channel 3 ⇩ 1.22 5.66E-05 
NM_004004 3504193 GJB2 gap junction protein, beta 2, 26kDa ⇧ 1.38 0.033 
NM_005497 3759335 GJC1 gap junction protein, gamma 1, 45kDa ⇩ 1.58 0.018 
NM_020401 3421177 N⇧107 nucleoporin 107kDa ⇧ 1.24 2.36E-04 
NM_024057 3468261 N⇧37 nucleoporin 37kDa ⇧ 1.20 0.001 
NM_018698 3986933 NXT2 nuclear transport factor 2-like export factor 2 ⇧ 1.21 0.009 
NM_002560 3434760 P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 ⇩ 1.26 0.001 
NM_002561 3741547 P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 ⇩ 1.45 0.025 
NM_001042496 3617312 SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 ⇩ 1.20 0.002 
NM_016582 3375091 SLC15A3 solute carrier family 15, member 3  ⇩ 1.22 0.025 
NM_145648 3477917 SLC15A4 solute carrier family 15, member 4 ⇩ 1.23 4.94E-05 
NM_018593 2921402 SLC16A10 solute carrier family 16, member 10 (aromatic amino acid transporter) ⇩ 1.43 0.004 
NM_005116 3896078 SLC23A2 solute carrier family 23 (nucleobase transporters), member 2 ⇩ 1.50 0.010 
NM_024103 3847873 SLC25A23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 ⇧ 1.31 4.07E-04 
AF495725 3090053 SLC25A37 solute carrier family 25, member 37  ⇩ 1.20 0.028 
NM_133496 2349043 SLC30A7 solute carrier family 30 (zinc transporter), member 7 ⇩ 1.20 7.71E-04 
NM_004733 2701927 SLC33A1 solute carrier family 33 (acetyl-CoA transporter), member 1 ⇩ 1.27 0.003 
NM_012243 2348702 SLC35A3 solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 ⇩ 1.23 0.003 
NM_017945 2636185 SLC35A5 solute carrier family 35, member A5 ⇩ 1.21 0.002 
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NM_024881 3854000 SLC35E1 solute carrier family 35, member E1 ⇩ 1.20 3.61E-05 
NM_025181 2571979 SLC35F5 solute carrier family 35, member F5 ⇩ 1.21 1.34E-04 
NM_014437 2436378 SLC39A1 solute carrier family 39 (zinc transporter), member 1 ⇩ 1.22 2.59E-05 
NM_001128431 3089360 SLC39A14 solute carrier family 39 (zinc transporter), member 14 ⇩ 1.23 0.032 
NM_006979 2903470 SLC39A7 solute carrier family 39 (zinc transporter), member 7 ⇩ 1.28 0.002 
NM_001012661 3333711 SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 ⇩ 1.27 8.12E-04 
NM_018112 3183364 TMEM38B transmembrane protein 38B ⇩ 1.39 8.37E-04 
NM_003304 2645951 TRPC1 transient receptor potential cation channel, subfamily C, member 1 ⇩ 1.46 2.82E-04 
NM_032646 3734236 TTYH2 tweety homolog 2 (Drosophila) ⇩ 1.38 0.004 
Metabolism 
NM_017436 3962578 A4GALT alpha 1,4-galactosyltransferase ⇧ 1.22 0.026 
NM_005763 3070183 AASS aminoadipate-semialdehyde synthase ⇩ 1.33 0.002 
NR_033426 2641341 ACAD9 acyl-CoA dehydrogenase family, member 9 ⇧ 1.21 0.012 
NM_005891 2934131 ACAT2 acetyl-CoA acetyltransferase 2 ⇧ 1.22 0.006 
NM_152331 3543714 ACOT4 acyl-CoA thioesterase 4 ⇧ 1.27 0.002 
NM_001099 2642720 ACPP acid phosphatase, prostate ⇩ 1.28 0.048 
NM_001995 2796553 ACSL1 acyl-CoA synthetase long-chain family member 1 ⇩ 1.21 0.001 
NM_001159280 3591365 ADAL adenosine deaminase-like ⇧ 1.21 0.002 
NM_006721 3252170 ADK adenosine kinase  ⇧ 1.20 0.002 
NM_000026 3946351 ADSL adenylosuccinate lyase ⇧ 1.24 1.04E-04 
NM_018361 3083936 AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon) ⇩ 1.24 1.44E-05 
NM_003659 2517408 AGPS alkylgylcerone phosphate synthase ⇧ 1.27 1.04E-05 
NM_000696 2442103 ALDH9A1 aldehyde dehydrogenase 9 family, member A1 ⇧ 1.27 2.66E-04 
NM_015957 3369249 APIP APAF1 interacting protein   ⇧ 1.44 0.040 
NM_177924 3126087 ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 ⇩ 1.27 4.39E-04 
NM_006085 2456805 BPNT1 3’(2’), 5’-bisphosphate nucleotidase 2 ⇧ 1.23 2.61E-04 
NM_000078 3662417 CETP cholesteryl ester transfer protein, plasma ⇩ 1.20 0.029 
NM_138809 2848265 CMBL carboxymethylenebute nolidase homolog (Pseudomonas) ⇧ 1.39 0.002 
NM_001905 2332144 CTPS CTP synthase ⇧ 1.30 0.001 
NM_000774 3833967 CYP2F1 cytochrome P450, family 2, subfamily F, polypeptide 1 ⇩ 1.28 0.038 
NM_015954 3406493 DERA deoxyribose-phosphate aldolase (putative) ⇧ 1.31 7.62E-04 
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NM_005700 3336238 DPP3 dipeptidyl-peptidase 3 ⇧ 1.23 0.014 
NM_138924 3845175 GAMT guanidinoacetate N-methyltransferase ⇧ 1.21 0.014 
NM_000161 3565524 GCH1 GTP cyclohydrolase 1 ⇧ 1.23 0.008 
NM_000169 4015763 GLA galactosidase, alpha  ⇩ 1.27 0.017 
NM_000405 2835792 GM2A GM2 ganglioside activator  ⇩ 1.23 0.003 
NM_002079 3302990 GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1) ⇧ 1.21 0.003 
NM_000521 2815791 HEXB hexosaminidase B ⇩ 1.21 8.27E-04 
NM_002035 3811459 KDSR ketodihydrosphingosine reductase  ⇩ 1.21 9.42E-05 
NM_000221 2474240 KHK ketohexokinase (fructokinase) ⇧ 1.46 0.007 
NM_001145437 3935243 LSS lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) ⇩ 1.26 0.003 
NM_002395 2962820 ME1 malic enzyme 1, NADP(+)-dependent, cytosolic  ⇧ 1.52 0.003 
NM_018396 3022841 METTL2B methyltransferase like 2B ⇩ 1.25 4.25E-04 
NM_004685 3506153 MTMR6 myotubularin related protein 6 ⇧ 1.30 6.90E-04 
NM_000434 2949471 NEU1 sialidase 1 (lysosomal sialidase) ⇩ 1.28 1.10E-04 
NM_198175 3726934 NME1 non-metastatic cells 1, protein (NM23A) expressed in ⇧ 1.37 2.41E-04 
NM_002513 3676113 NME3 non-metastatic cells 3, protein expressed in  ⇩ 1.29 6.63E-05 
NM_024829 3445544 PLBD1 phospholipase B domain containing 1 ⇧ 1.29 0.002 
NM_018129 3724969 PNPO pyridoxamine 5’-phosphate oxidase ⇧ 1.22 0.009 
NM_002778 3293762 PSAP prosaposin ⇩ 1.20 0.003 
NM_144660 3252534 SAMD8 sterile alpha motif domain containing 8 ⇩ 1.20 0.004 
NR_027783 3971806 SAT1 spermidine/spermine N1-acetyltransferase 1 ⇩ 1.21 0.014 
NM_030791 3568108 SGPP1 sphingosine-1-phosphate phosphatase 1 ⇩ 1.21 0.004 
NM_000199 3773340 SGSH N-sulfoglucosamine sulfohydrolase ⇩ 1.29 4.52E-06 
NM_021947 3706219 SRR serine racemase ⇧ 1.34 0.009 
NM_003896 2562529 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 ⇩ 1.31 0.002 
NM_006755 3316208 TALDO1 transaldolase 1 ⇧ 1.29 8.50E-05 
NR_027483 3402935 TPI1 triosephosphate isomerase 1 ⇩ 1.23 0.003 
NM_022445 3077766 TPK1 thiamin pyrophosphokinase 1 ⇧ 1.26 6.13E-05 
NM_000375 3311715 UROS uroporphyrinogen III synthase ⇧ 1.26 2.67E-04 
Mitochondrion & the Respiratory Electron Transport Chain  
NM_000690 3432090 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) ⇧ 1.36 0.006 
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NM_015697 2775965 COQ2 coenzyme Q2 homolog, prenyltransferase (yeast) ⇧ 1.32 0.011 
NM_016035 3190339 COQ4 coenzyme Q4 homolog (S. cerevisiae) ⇧ 1.23 5.94E-06 
NM_004077 3457614 CS citrate synthase ⇧ 1.27 6.36E-04 
NM_030579 3666732 CYB5B cytochrome b5 type B (outer mitochondrial membrane) ⇧ 1.22 5.14E-06 
NM_001359 3106310 DECR1 2,4-dienoyl CoA reductase 1, mitochondrial  ⇧ 1.22 0.002 
NM_001931 3348852 DLAT dihydrolipoamide S-acetyltransferase  ⇧ 1.23 7.26E-05 
NM_024417 3770457 FDXR ferredoxin reductase ⇧ 1.21 4.27E-04 
NM_001012515 3809621 FECH ferrochelatase  ⇧ 1.28 8.80E-05 
NM_017547 3355056 FOXRED1 FAD-dependent Oxidoreductase domain containing 1 ⇧ 1.30 0.001 
NM_000144 3173831 FXN frataxin ⇧ 1.22 0.002 
NM_025196 2759404 GRPEL1 GrpE-like 1, mitochondrial (E. coli) ⇧ 1.30 2.18E-06 
NM_005333 3968664 HCCS holocytochrome c synthase ⇧ 1.23 0.018 
NM_004493 4009288 HSD17B10 hydroxysteroid (17-beta) dehydrogenase 10 ⇧ 1.20 0.007 
NM_016098 2984616 MPC1 mitochondrial pyruvate carrier 1 ⇧ 1.29 3.26E-04 
NM_018116 2360989 MSTO1 misato homolog 1 (Drosophila) ⇩ 1.23 0.003 
NM_014342 3372368 MTCH2 mitochondrial carrier homolog 2 (C. elegans) ⇧ 1.21 6.69E-06 
ENST0000361681 4037708 ND6 NADH dehydrogenase, subunit 9 (complex I) ⇩ 1.34 0.020 
NM_17883 2780099 NHEDC2 Na+/H+ exchanger domain containing 2 ⇩ 1.24 0.011 
NM_001161778 3107342 PDP1 pyruvate dehydrogenase phosphatase catalytic subunit 1 ⇧ 1.23 7.41E-04 
NM_018292 2919873 QRSL1 glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 ⇧ 1.31 3.51E-04 
NM_003850 3513293 SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit ⇧ 1.33 1.05E-05 
AK295839 2663083 TAMM41 TAM41, mitochondrial translocation assembly and maintenance protein homolog (S. cerevisiae) ⇩ 1.29 0.005 
NM_003201 3247784 TFAM transcription factor A, mitochondrial ⇧ 1.20 0.002 
NM_012456 3373946 TIMM10 translocase of inner mitochondrial membrane 10 homolog (yeast) ⇧ 1.44 0.001 
NM_006335 2374956 TIMM17A translocase of inner mitochondrial membrane 17 homolog A (yeast) ⇧ 1.25 0.020 
Neurotransmission 
NM_004857 3540068 AKAP5 A kinase (PRKA) anchor protein 5 ⇧ 1.24 0.002 
NM_000721 2370433 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit  ⇩ 1.36 0.047 
NM_005183 4007919 CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit  ⇩ 1.20 0.003 
NM_001039771 3558270 CBLN3 cerebellin 3 precursor ⇩ 1.22 0.013 
NM_014848 3608638 SV2B synaptic vesicle glycoprotein 2B ⇩ 1.38 9.29E-04 
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NM_199245 3441941 VAMP1 vesicle-associated membrane protein 1 (synaptobrevin 1) ⇩ 1.32 0.001 
Nucleosome 
NM_014034 2923359 ASF1A ASF1 anti-silencing function 1 homolog A (S. cerevisiae) ⇧ 1.23 0.006 
NM_012412 3639479 H2AFV H2A histone family, member V ⇧ 1.22 9.15E-04 
NM_002105 3394183 H2AFX H2A histone family, member X ⇧ 1.24 9.11E-05 
NM_004893 2876479 H2AFY H2A histone family, member Y ⇧ 1.24 0.001 
NM_005324 3770944 H3F3B H3 histone, family 3B (H3.3B) ⇧ 1.26 0.024 
NM_003642 2515369 HAT1 histone acetlytransferase 1 ⇧ 1.35 1.62E-04 
NM_005322 2947073 HIST1H1B histone cluster 1, H1b ⇧ 1.39 0.003 
NM_021058 2946681 HIST1H2BJ histone cluster 1, H2bj ⇧ 1.29 0.014 
NM_080593 2946714 HIST1H2BK histone cluster 1, H2bk ⇧ 1.37 0.009 
NM_003529 2899090 HIST1H3A histone cluster 1, H3a ⇧ 1.22 0.041 
NM_003531 2899102 HIST1H3C histone cluster 1, H3c ⇧ 1.22 0.006 
NM_003535 2947095 HIST1H3J histone cluster 1, H3j ⇧ 1.47 0.002 
NM_003545 2899216 HIST1H4E histone cluster 1, H4e ⇧ 1.21 0.024 
NM_003543 2946383 HIST1H4H histone cluster 1, H4h ⇧ 1.25 0.011 
NM_004537 3462843 NAP1L1 nucleosome assembly protein 1-like 1 ⇧ 1.29 0.005 
Protein Processing 
NM_018672 3768969 AAGAB alpha- and gamma-adaptin binding protein  ⇧ 1.33 1.16E-06 
NM_001144 3692856 AMFR autocrine motility factor receptor  ⇩ 1.21 0.001 
NM_003916 4000704 AP1S2 adaptor-related protein complex 1, sigma 2 subunit  ⇧ 1.20 4.13E-04 
NM_007347 3593770 AP4E1 adaptor-related protein complex 4, epsilon 1 subunit  ⇧ 1.20 4.13E-04 
NM_006577 2484841 B3GNT2 UDP-GlcNAc:betaGalbeta-1,3-N-acetylglucosaminyltransferase 2 ⇩ 1.28 8.53E-05 
NM_033637 3261165 BTRC beta-transducin repeat containing E3 ubiquitin protein ligase ⇧ 1.24 7.21E-08 
NM_012073 2801526 CCT5 chaperonin containing TCP1, subunit 5 (epsilon) ⇧ 1.32 2.80E-04 
NM_001083314 3704896 CHMP1A charged multivesicular body protein 1A ⇧ 1.20 1.46E-05 
NM_152284 3105033 CHMP4C charged multivesicular body protein 4C ⇧ 1.21 0.006 
NM_006493 3494502 CLN5 ceroid-lipofuscinosis, neuronal 5 ⇩ 1.40 4.52E-07 
NM_153607 2841491 CREBRF CREB3 regulatory factor  ⇩ 1.36 0.002 
NM_004388 2420467 CTBS chitobiase, di-N-acetyl- ⇩ 1.22 0.022 
NM_147780 3124537 CTSB cathepsin B ⇩ 1.42 3.96E-05 
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NM_004079 2434575 CTSS cathepsin S ⇩ 1.21 2.48E-04 
NM_006145 3852783 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 ⇧ 1.28 0.001 
NM_058246 3034027 DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 ⇧ 1.27 0.004 
NM_012328 3018866 DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 ⇩ 1.28 0.044 
NM_018198 2394841 DNAJC11 DnaJ (Hsp40) homolog, subfamily C, member 11  ⇧ 1.25 2.59E-04 
NR_037148 3184940 DNAJC25 DnaJ (Hsp40) homolog, subfamily C, member 25 ⇩ 1.21 6.79E-04 
NM_003315 3757487 DNAJC7 DnaJ (Hsp40) homolog, subfamily C, member 7 ⇧ 1.23 3.66E-06 
NM_001402 2960903 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 ⇩ 1.29 5.02E-05 
NR_027062 3484436 EEF1DP3 eukaryotic translation elongation factor 1 delta pseudogene 3 ⇩ 1.30 7.07E-04 
NM_004280 2940920 EEF1E1 eukaryotic translation elongation factor 1 epsilon 1 ⇧ 1.27 0.008 
NM_032325 3378024 EIF1AD eukaryotic translation initiation factor 1A domain containing  ⇧ 1.20 2.52E-05 
NM_004681 4031136 EIF1AY eukaryotic translation initiation factor 1A, Y-linked ⇧ 1.67 0.016 
NM_004836 2563654 EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 ⇩ 1.24 0.003 
NM_020365 2409904 EIF2B3 eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa ⇧ 1.44 1.29E-04 
NM_004096 3250699 EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 ⇧ 1.32 6.27E-05 
NM_001418 3362719 EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 ⇧ 1.22 3.89E-06 
NM_015904 2495881 EIF5B eukaryotic translation initiation factor 5B ⇧ 1.21 3.32E-04 
NM_019053 3258260 EXOC6 exocyst complex component 6 ⇧ 1.26 0.011 
NM_052966 2447877 FAM129A family with sequence similarity 129, member A ⇧ 1.33 0.015 
NM_012166 3205506 FBXO10 F-box protein 10 ⇧ 1.23 7.68E-04 
NM_012176 2807886 FBXO4 F-box protein 4 ⇧ 1.20 0.003 
NM_017946 3043936 FKBP14 FK506 binding protein 14, 22kDa ⇩ 1.43 1.31E-04 
NM_002013 3562721 FKBP3 FK506 binding protein 3, 25kDa ⇧ 1.24 0.003 
NM_198335 3375951 GANAB glucosidase, alpha; neutral AB ⇩ 1.22 3.26E-04 
NM_001097634 3175494 GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 ⇧ 1.56 0.013 
NM_004751 3596147 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type ⇩ 1.25 0.041 
NM_005836 3145980 HRSP12 heat-responsive protein 12 ⇧ 1.26 0.004 
NM_018085 2374872 IPO9 importin 9 ⇧ 1.20 5.82E-04 
NM_002267 3513883 KPNA3 karyopherin alpha 3 (importin alpha 4) ⇧ 1.21 4.29E-05 
NM_022126 3269065 LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase ⇧ 1.21 2.99E-04 
NM_005570 3810472 LMAN1 lectin, mannose-binding, 1 ⇩ 1.32 6.32E-07 
NM_005907 2971801 MAN1A1 mannosidase, alpha, class 1A, member 1 ⇩ 1.28 0.003 
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NM_005885 2801608 MARCH6 membrane-associated ring finger (C3HC4) 6 ⇩ 1.24 1.66E-06 
NM_006838 3426917 METAP2 methionyl aminopeptidase 2 ⇧ 1.21 8.83E-04 
NM_020236 2732611 MRPL1 mitochondrial ribosomal protein L1 ⇧ 1.28 0.001 
NM_014078 3150797 MRPL13 mitochondrial ribosomal protein L13 ⇧ 1.21 0.004 
NM_022915 2529782 MRPL44 mitochondrial ribosomal protein L44 ⇧ 1.21 0.040 
NM_022163 3638048 MRPL46 mitochondrial ribosomal protein L46 ⇧ 1.29 0.001 
NM_019051 3218067 MRPL50 mitochondrial ribosomal protein L50 ⇧ 1.20 0.045 
NM_015969 3003143 MRPS17 mitochondrial ribosomal protein S17 ⇧ 1.46 0.014 
NM_018997 2358153 MRPS21 mitochondrial ribosomal protein S21 ⇩ 1.27 2.34E-05 
NM_016070 3764002 MRPS23 mitochondrial ribosomal protein S23 ⇧ 1.24 0.013 
NM_005830 3510925 MRPS31 mitochondrial ribosomal protein S31 ⇧ 1.24 0.002 
NM_023936 3676127 MRPS34 mitochondrial ribosomal protein S34 ⇧ 1.34 4.23E-07 
NM_021821 3409330 MRPS35 mitochondrial ribosomal protein S35 ⇧ 1.23 0.001 
NM_033281 2813465 MRPS36 mitochondrial ribosomal protein S36 ⇧ 1.21 5.15E-04 
NM_031902 2564599 MRPS5 mitochondrial ribosomal protein S5 ⇧ 1.20 0.003 
NM_003491 4026902 NAA10 N(alpha)-acetyltransferase 10, NatA catalytic subunit ⇧ 1.20 0.001 
NM_022080 3901191 NAPB N-ethylmaleimide-sensitive factor attachment protein, beta ⇩ 1.40 4.37E-06 
NM_005381 2603460 NCL nucleolin ⇧ 1.23 3.41E-05 
NM_173474 3681674 NTAN1 N-terminal asparagine amidase ⇧ 1.21 0.002 
NM_016118 3032017 NUB1 negative regulator of ubiquitin-like proteins  ⇧ 1.21 0.004 
NM_016297 2487696 PCYOX1 prenylcysteine oxidase 1 ⇩ 1.28 0.018 
NM_001185181 2903588 PFDN6 prefoldin subunit 6 ⇧ 1.21 3.48E-04 
NM_005482 2418929 PIGK phosphatidylinositol glycan anchor biosynthesis, class K  ⇩ 1.23 0.045 
NM_004278 3711986 PIGL phosphatidylinositol glycan anchor biosynthesis, class L ⇩ 1.33 1.75E-05 
NM_033198 3750740 PIGS phosphatidylinositol glycan anchor biosynthesis, class S ⇩ 1.20 0.002 
NM_178517 3719150 PIGW phosphatidylinositol glycan anchor biosynthesis, class W ⇧ 1.20 0.011 
NM_032906 2777412 PIGY phosphatidylinositol glycan anchor biosynthesis, class Y ⇧ 1.20 0.021 
NM_015227 3934867 POFUT2 protein O-fucosyltransferase 2 ⇩ 1.28 2.61E-06 
NM_014337 3938244 PPIL2 peptidylprolyl isomerase (cyclophilin)-like 2 ⇧ 1.21 3.70E-04 
NM_002795 3719962 PSMB3 proteasome (prosome, macropain) subunit, beta type, 3 ⇧ 1.33 0.002 
NM_002803 3017206 PSMC2 proteasome (prosome, macropain) 26S subunit, ATPase, 2 ⇧ 1.33 0.009 
NM_002807 2531712 PSMD1 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 ⇧ 1.30 2.24E-04 
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NM_014814 2679864 PSMD6 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 ⇧ 1.30 4.44E-06 
NM_002818 3557811 PSME2 proteasome (prosome, macropain) activator subunit 2 (PA28 beta) ⇧ 1.27 0.041 
NM_004578 2384562 RAB4A RAB4A. member RAS oncogene family  ⇧ 1.24 0.005 
NM_201434 3757664 RAB5C RAB5C, member RAS oncogene family  ⇧ 1.20 0.003 
NM_002869 3381607 RAB6A RAB6A, member RAS oncogene family ⇧ 1.35 0.009 
NM_005370 3823554 RAB8A RAB8A, member RAS oncogene family ⇧ 1.26 2.03E-04 
NM_002871 245149 RABIF RAB interacting factor  ⇧ 1.21 0.030 
NM_006013 3996306 RPL10 ribosomal protein L10 ⇩ 1.36 5.40E-04 
NM_033251 3674146 RPL13 ribosomal protein L13 ⇩ 1.29 0.016 
NM_000985 3807487 RPL17 ribosomal protein L17 ⇩ 1.28 0.004 
NR_002229 2482683 RPL23AP32 ribosomal protein L23a pseudogene 32 ⇩ 1.23 0.007 
NR_026982 3951136 RPL23AP82 ribosomal protein L23a pseudogene 82 ⇩ 1.21 0.002 
NM_000969 2346863 RPL5 ribosomal protein L5 ⇩ 1.28 8.73E-05 
NR_002775 3333086 RPLP0P2 ribosomal protein, large, P0 pseudogene 2 ⇩ 1.22 0.003 
NM_002950 2694397 RPN1 ribophorin I ⇩ 1.21 0.002 
NM_001008 4028512 RPS4Y1 ribosomal protein S4, Y-linked 1 ⇧ 1.61 0.041 
NM_018144 3235414 SEC61A2 Sec61 alpha 2 subunit (S. cerevisiae) ⇩ 1.27 2.89E-05 
NM_005065 3574207 SEL1L sel-1 suppressor of lin-12-like 1 (C. elegans) ⇩ 1.24 3.60E-05 
NM_015670 3708798 SENP3 SUMO1/sentrin/SMT3 specific peptidase 3 ⇧ 1.21 8.04E-05 
NM_001037633 2877639 SIL1 SIL1 homolog, endoplasmic reticulum chaperone (S. cerevisiae) ⇩ 1.35 0.001 
NM_153816 2963313 SNX14 sorting nexin 14 ⇩ 1.23 1.94E-04 
NM_002959 2427007 SORT1 sortilin 1 ⇧ 1.56 0.013 
NM_001002255 2930698 SUMO4 SMT3 suppressor of mif two 3 homolog 4 (S. cerevisiae) ⇩ 1.34 0.001 
NM_201631 3621080 TGM5 transglutaminase 5 ⇩ 1.40 0.010 
NM_007364 3603687 TMED3 transmembrane emp24 protein transport domain containing 3 ⇩ 1.24 1.81E-05 
NM_182547 3048778 TMED4 transmembrane emp24 protein transport domain containing 4 ⇩ 1.30 5.78E-06 
NM_015476 3804358 TPGS2 tubulin polyglutamylase complex subunit 2 ⇧ 1.29 5.57E-05 
NM_000391 3361041 TPP1 tripeptidyl peptidase I ⇩ 1.21 0.002 
NM_018955 3712041 UBB ubiquitin B ⇧ 1.25 0.003 
NM_003336 3988874 UBE2A ubiquitin-conjugating enzyme E2A (RAD6 homolog) ⇧ 1.20 0.006 
NM_003337 2829275 UBE2B ubiquitin-conjugating enzyme E2B (RAD6 homolog) ⇩ 1.20 0.020 
NM_020131 2437893 UBQLN4 ubiquilin 4 ⇧ 1.22 0.025 
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NM_004181 2725013 UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) ⇧ 1.53 0.024 
NM_015984 2448971 UCHL5 ubiquitin carboxyl-terminal hydrolase L5 ⇧ 1.20 6.48E-04 
NM_001040697 3365487 UEVLD UEV and lactate/malate dehydrogenase domains ⇧ 1.24 0.001 
NM_003940 2654091 USP13 ubiquitin specific peptidase 13 (isopeptidase T-3) ⇧ 1.20 0.004 
NM_020718 3685051 USP31 ubiquitin specific peptidase 31 ⇧ 1.21 2.48E-05 
NM_022832 2769063 USP46 ubiquitin specific peptidase 46 ⇧ 1.22 0.001 
NM_004505 3748400 USP6 ubiquitin specific peptidase 6 (Tre-2 oncogene) ⇩ 1.46 1.73E-04 
NM_004654 4030063 USP9Y ubiquitin specific peptidase 9, Y-linked ⇧ 1.43 0.015 
NM_024667 3475838 VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) ⇧ 1.21 0.022 
NM_006370 3569374 VTI1B vesicle transport through interaction with t-SNAREs homolog 1B (yeast) ⇧ 1.30 0.012 
NM_007014 3666897 WWP2 WW domain containing E3 ubiquitin protein ligase 2 ⇧ 1.25 2.19E-05 
NM_001102420 3209623 ZFAND5 zinc finger, AN1-type domain 5 ⇩ 1.30 4.01E-04 
NM_144588 3260018 ZFYVE27 zinc finger, FYVE domain containing 27 ⇩ 1.29 4.40E-07 
RNA Processing 
NR_036460 3699707 ADAT1 adenosine deaminase, tRNA-specific 1 ⇧ 1.28 7.55E-04 
NM_006303 2988882 AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 ⇧ 1.25 0.004 
NM_001042476 3679533 CARHSP1 calcium regulated heat stable protein 1, 24kDa ⇧ 1.21 6.62E-04 
NM_030937 2391532 CCNL2 cyclin L2 ⇩ 1.21 0.005 
NR_027856 2594497 CLK1 CDC-like kinase 1 ⇩ 1.36 8.73E-04 
NM_020666 2889698 CLK4 CDC-like kinase 4 ⇩ 1.32 5.00E-05 
NM_017437 3548788 CPSF2 cleavage and polyadenylation specific factor 2, 100kDa ⇧ 1.21 3.91E-04 
NM_016207 2468920 CPSF3 cleavage and polyadenylation specific factor 3, 73kDa ⇧ 1.26 1.40E-05 
NM_016652 3899954 CRNKL1 crooked neck pre-mRNA splicing factor-like 1 (Drosophila) ⇧ 1.21 9.28E-05 
NM_030877 3884324 CTNNBL1 catenin, beta like 1 ⇧ 1.23 2.00E-05 
NM_005869 2812120 CWC27 CWC27 spliceosome-associated protein homolog (S. cerevisiae) ⇧ 1.22 0.003 
NM_004939 2470654 DDX1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 ⇧ 1.26 1.53E-04 
NM_00112266 4030162 DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked ⇧ 1.64 0.028 
NM_014314 3203086 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 ⇧ 1.29 0.016 
NM_022720 3937183 DGCR8 DiGeorge syndrome critical region gene 8 ⇧ 1.25 3.30E-05 
NM_198963 2549007 DHX57 DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 ⇧ 1.24 0.001 
NR_033302 2370991 DHX9 DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 9 ⇧ 1.21 0.015 
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NM_001363 3996667 DKC1 dyskeratosis congenita 1, dyskerin ⇧ 1.26 3.63E-05 
NM_013235 2851965 DROSHA drosha, ribonuclease type III ⇧ 1.20 3.80E-04 
NM_014285 3191695 EXOSC2 exosome component 2 ⇧ 1.27 3.17E-06 
NM_015962 3544216 FCF1 FCF1 small subunit (SSU) prcessome component homolog (S. cerevisiae) ⇧ 1.22 0.001 
NM_017647 3766373 FTSJ3 FtsJ homolog 3 (E. coli) ⇧ 1.21 0.002 
NM_015721 3739812 GEMIN4 gem (nuclear organelle) associated protein 4 ⇧ 1.24 2.11E-04 
NM_031370 2775463 HNRNPD heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) ⇧ 1.21 1.03E-05 
NM_033416 2505501 IMP4 IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) ⇧ 1.22 2.50E-04 
NM_017813 3136413 IMPAD1 inositol monophosphatase domain containing 1 ⇩ 1.26 0.011 
NM_020701 2694617 ISY1 ISY1 splicing factor homolog (S. cerevisiae) ⇧ 1.31 3.26E-05 
NM_007080 2746269 LSM6 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) ⇧ 1.23 1.29E-04 
NM_016424 3726772 LUC7L3 LUC7-like 3 (S. cerevisiae) ⇩ 1.20 0.004 
NM_018388 4022106 MBNL3 muscleblind-like splicing regulator 3 ⇧ 1.25 0.006 
NM_002486 3181302 NCBP1 nuclear cap binding protein subunit 1, 80kDa ⇧ 1.21 0.002 
NM_001145408 3980887 NONO non-POU domain containing, octamer-binding  ⇧ 1.29 1.45E-04 
NM_003703 2758076 NOP14 NOP14 nucleolar protein homolog (yeast) ⇧ 1.23 4.09E-05 
NM_032141 2343170 NSRP1 nuclear speckle splicing regulatory protein 1 ⇩ 1.21 2.12E-04 
NM_005016 3416036 PCBP2 poly(rC) binding protein 2 ⇧ 1.23 0.011 
NM_031307 3396736 PUS3 pseudouridylate synthase 3 ⇧ 1.26 6.95E-04 
NM_016732 3882720 RALY RNA binding protein, autoantigenic (hnRNP-associated with lethal yellow (mouse)) ⇧ 1.22 6.04E-06 
NM_017793 3633236 RPP25 ribonuclease P/MRP 25kDa subunit  ⇧ 1.30 7.51E-05 
NM_015056 3923218 RRP1B ribosomal RNA processing 1 homolog B (S. cerevisiae) ⇧ 1.22 0.001 
NM_016625 2649532 RSRC1 arginine/serine-rich coiled-coil 1 ⇧ 1.39 4.09E-05 
NM_006802 2407439 SF3A3 splicing factor 3a, subunit 3, 60kDa ⇧ 1.20 1.18E-06 
NM_005066 2406064 SFPQ splicing factor proline/glutamine-rich  ⇧ 1.24 2.23E-04 
NM_006527 2757319 SLBP stem-loop binding protein  ⇧ 1.28 0.003 
NM_024571 3642572 SNRNP25 small nuclear ribonucleoprotein 25kDa (U11/U12) ⇧ 1.32 3.29E-05 
NM_003093 2904248 SNRPC small nuclear ribonucleoprotein polypeptide C ⇧ 1.24 7.91E-04 
NM_006938 3781082 SNRPD1 small nuclear ribonucleoprotein polypeptide 16kDa ⇧ 1.43 7.62E-05 
NM_005701 3633522 SNUPN snurportin 1 ⇧ 1.22 0.002 
NM_003142 2514566 SSB Sjogren syndrome antigen B (autoantigen La) ⇧ 1.21 7.59E-06 
NM_014393 3140640 STAU2 staufen, RNA binding protein, homolog 2 (Drosophila) ⇧ 1.22 7.68E-04 
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NM_152295 2805786 TARS threonyl-tRNA synthetase ⇧ 1.24 0.005 
NM_014290 3181193 TDRD7 tudor domain containing 7 ⇧ 1.22 4.97E-04 
NM_024831 3098935 TGS1 trimethylguanosine synthase 1 ⇧ 1.26 6.41E-05 
NM_017872 2837479 THG1L tRNA-histidine guanylyltransferase 1-like (S. cerevisiae) ⇧ 1.20 7.90E-04 
AB052759 3041550 TRA2A transformer 2 alpha homolog (Drosophila) ⇩ 1.31 0.013 
NM_004593 2709062 TRA2B transformer 2 beta homolog (Drosophila) ⇧ 1.23 1.82E-05 
NM_006701 3814734 TXNL4A thioredoxin-like 4A ⇧ 1.24 2.86E-04 
NM_016037 2330899 UTP11L UTP11-like, U3 small nucleolar ribonucleoprotein, (yeast) ⇧ 1.27 0.001 
NM_006649 3990566 UTP14A UTP14, U3 small nucleolar ribonucleoprotein, homolog A (yeast) ⇧ 1.40 3.24E-06 
NM_014503 3428447 UTP20 UTP20, small subunit (SSU) processome component, homolog (yeast) ⇧ 1.20 0.007 
NM_018428 3752437 UTP6 UTP6, small subunit (SSU) processome component, homolog (yeast) ⇧ 1.24 1.04E-04 
NM_018256 2595443 WDR12 WD repeat domain 12 ⇧ 1.23 0.001 
NM_024102 2427930 WDR77 WD repeat domain 77 ⇧ 1.41 6.98E-06 
NM_032345 3457315 WIBG within bgcn homolog (Drosophila) ⇧ 1.24 5.82E-06 
Sensory Perception 
NM_001004473 2362270 OR10K1 olfactory receptor, family 10, subfamily K, member 1 ⇩ 1.21 0.008 
NM_001004474 3395811 OR10S1 olfactory receptor, family 10, subfamily S, member 1 ⇩ 1.42 0.002 
NM_001004458 3331692 OR1S olfactory receptor, family 1, subfamily S, member 1 ⇩ 1.34 9.14E-05 
NM_001001659 3029521 OR2A14 olfactory receptor, family 2, subfamily A, member 14 ⇩ 1.23 0.002 
NM_001005180 3318495 OR56B1 olfactory receptor, family 56, subfamily B, member 1 ⇩ 1.32 0.045 
NM_001004738 3330786 OR5L1 olfactory receptor, family 5, subfamily L, member 1 ⇩ 1.20 0.031 
NM_001005283 3331686 OR9Q2 olfactory receptor, family 9, subfamily Q, member 2 ⇩ 1.22 2.09E-04 
NM_005388 3224341 PDCL phosducin-like  ⇧ 1.20 0.011 
NM_024065 2496280 PDCL3 phosducin-like 3 ⇧ 1.21 8.72E-05 
NM_016943 3027943 TAS2R3 taste receptor, type 2, member 3 ⇩ 1.23 0.010 
NM_176885 3444503 TAS2R31 taste receptor, type 2, member 31 ⇩ 1.33 0.036 
NM_016944 3027956 TAS2R4 taste receptor, type 2, member 4 ⇩ 1.37 0.017 
Signal Transduction 
NM_007313 3191724 ABL1 abl oncogene 1, non-receptor tyrosine kinase ⇧ 1.30 1.63E-04 
NM_006869 3034987 ADAP1 ArfGAP with dual PH domains 1 ⇧ 1.28 0.003 
NM_182901 3319685 AKIP1 A kinase (PRKA) interacting protein 1 ⇧ 1.27 0.002 
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NM_004308 3371673 ARHGAP1 Rho GTPase activating protein 1 ⇧ 1.26 5.13E-06 
NM_014783 3587457 ARHGAP11A Rho GTPase activating protein 11A ⇧ 1.28 1.43E-04 
NM_152432 3346147 ARHGAP42 Rho GTPase activating protein 42 ⇧ 1.20 0.008 
NM_015313 3352503 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 ⇧ 1.43 7.56E-04 
NM_178815 3237548 ARL5B ADP-ribosylation factor-like 5B ⇩ 1.20 0.003 
NM_018482 3153428 ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 ⇧ 1.24 0.003 
NM_005186 3334954 CAPN1 calpain 1, (mu/I) large subunit  ⇧ 1.23 1.13E-04 
NM_0017848 2382117 CAPN2 calpain 2, (mu/II) large subunit  ⇧ 1.43 0.008 
NM_004357 3316344 CD151 CD151 molecule (Raph blood group) ⇩ 1.36 0.005 
NM_001780 3457160 CD63 CD63 molecule ⇩ 1.23 3.10E-04 
NM_002231 3328520 CD82 CD82 molecule ⇩ 1.24 4.21E-05 
NM_078481 3822657 CD97 CD97 molecule ⇩ 1.23 1.33E-05 
NM_007236 3590341 CHP calcium binding protein P22 ⇧ 1.25 0.001 
NM_000740 2387606 CHRM3 cholinergic receptor, muscarinic 3 ⇩ 1.23 2.95E-04 
NM_001004419 3404436 CLEC2D C-type lectin domain family 2, member D ⇩ 1.29 5.79E-04 
NM_003653 3747717 COPS3 COP9 constitutive photomorphogenic homolog subunit 3 (Arabidopsis) ⇧ 1.23 2.03E-04 
NM_016129 2733928 COPS4 COP9 constitutive photomorphogenic homolog subunit 4 (Arabidopsis) ⇧ 1.33 2.09E-04 
NM_177559 3894228 CSNK2A1 casein kinase 2, alpha 1 polypeptide ⇧ 1.25 1.72E-05 
NM_004227 3037251 CYTH3 cytohesin 3 ⇩ 1.34 0.016 
NM_139179 3037344 DAGLB diacylglycerols lipase, beta ⇩ 1.23 1.83E-05 
NM_013993 2901970 DDR1 discoidin domain receptor tyrosine kinase 1 ⇩ 1.22 0.015 
NM_015213 3362263 DENND5A DENN/MADD domain containing 5A ⇧ 1.28 0.002 
NM_003647 3727962 DGKE diacylglycerol kinase, epsilon 64kDa ⇩ 1.23 0.006 
NM_004717 3074912 DGKI diacylglycerol kinase, iota ⇩ 1.21 0.025 
NM_004418 3565119 DUSP2 dual specificity phosphatase 2 ⇩ 1.21 0.006 
NM_005228 3002640 EGFR epidermal growth factor receptor  ⇩ 1.29 0.001 
NM_001098785 3335338 FAM89B family with sequence similarity 89, member B ⇧ 1.31 0.005 
NM_207123 2745547 GAB1 GRB2-associated binding protein 1 ⇩ 1.32 0.008 
NM_057169 3471005 GIT2 G protein-coupled receptor kinase interacting ArfGAP 2 ⇧ 1.29 3.93E-05 
NM_002069 3010439 GNAI1 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 ⇧ 1.23 0.022 
NM_021629 2706938 GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 ⇧ 1.24 2.62E-04 
NM_004126 3012978 GNG11 guanine nucleotide binding protein (G protein), gamma 11 ⇧ 1.32 9.52E-04 
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NM_003608 3547375 GPR65 G protein-coupled receptor 65 ⇩ 1.22 0.003 
NM_003979 3405587 GPRC5A G protein-coupled receptor, family C, group 5, member A ⇩ 1.35 3.07E-04 
NM_212492 3738490 GPS1 G protein pathway suppressor 1 ⇧ 1.21 1.54E-04 
NM_015666 3892509 GTPBP5 GTP binding protein 5 (putative) ⇧ 1.25 3.92E-06 
NM_000867 2603395 HTR2B 5-hydroxytryptamine (serotonin) receptor 2B ⇩ 1.20 0.038 
NM_001130699 2980449 IPCEF1 interaction protein for cytohesin exchange factors 1 ⇧ 1.43 8.27E-04 
NM_015541 2680591 LRIG1 leucine-rich repeats and immunoglobulin-like domains 1 ⇩ 1.35 0.003 
NM_004631 2413203 LRP8 low density lipoprotein receptor-related protein associated protein 8, apolipoprotein E receptor  ⇩ 1.25 1.39E-05 
NM_002337 2758298 LRPAP1 low density lipoprotein receptor-related protein associated protein 1 ⇩ 1.25 0.002 
NM_145109 3714729 MAP2K3 mitogen-activated protein kinase kinase 3 ⇧ 1.20 0.001 
NM_005204 3240987 MAP3K8 mitogen-activated protein kinase kinase kinase 8 ⇩ 1.20 0.006 
NM_004579 3377091 MAP4K2 mitogen-activated protein kinase kinase kinase kinase 2 ⇧ 1.25 1.86E-04 
NM_001006617 3225456 MAPKAP1 mitogen-activated protein kinase associated protein 1 ⇧ 1.21 1.81E-04 
NM_002436 4027585 MPP1 membrane protein, palmitoylated 1, 55kDa ⇧ 1.24 0.012 
NM_000906 2359780 NPR1 natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) ⇩ 1.24 0.009 
NM_201266 2524301 NRP2 neuropilin 2  ⇩ 1.37 2.32E-05 
NM_017906 2894663 PAK1IP1 PAK1 interacting protein 1 ⇧ 1.41 2.87E-05 
NM_002603 3138464 PDE7A phosphodiesterase 7A ⇧ 1.30 0.001 
NM_002609 2881239 PDGFRB platelet-derived growth factor receptor, beta polypeptide ⇩ 1.22 0.008 
NM_006207 3087703 PDGFRL platelet-derived growth factor receptor-like ⇩ 1.24 0.002 
NM_002567 3433796 PEBP1 phosphatidylethanolamine binding protein 1 ⇧ 1.35 0.020 
NM_002649 3018309 PIK3CG phosphoinositide-3-kinase, catalytic, gamma polypeptide  ⇧ 1.44 0.019 
NM_052880 3957790 PIK3IP1 phosphoinositide-3-kinase interacting protein 1 ⇩ 1.33 1.81E-04 
NM_003629 2410470 PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) ⇧ 1.28 0.006 
NM_005028 3281068 PIP4K2A phosphatidylinositol-5-phosphate 4-kinase, type II, alpha  ⇧ 1.20 1.80E-05 
NM_006224 3740304 PITPNA phosphatidylinositol transfer protein, alpha ⇧ 1.24 0.001 
NM_181671 3732230 PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 ⇩ 1.66 0.004 
NM_001195608 3268274 PLEKHA1 pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1 ⇩ 1.23 0.024 
NM_002481 2375212 PPP1R12B protein phosphatase 1, regulatory (inhibitor) subunit 12B ⇩ 1.39 3.92E-05 
NM_006241 2712147 PPP1R2 protein phosphatase 1, regulatory (inhibitor) subunit 2 ⇩ 1.49 1.04E-06 
NM_002712 2536183 PPP1R7 protein phosphatase 1, regulatory (inhibitor) subunit 7 ⇧ 1.21 2.24E-04 
NM_000944 2449638 PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme ⇧ 1.30 0.003 
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NM_006247 3836760 PPP5C protein phosphatase 5, catalytic subunit ⇧ 1.22 6.06E-04 
NM_014931 3871256 PPP6R1 protein phosphatase 6, regulatory subunit 1 ⇧ 1.20 1.16E-05 
NM_005399 2433209 PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit ⇩ 1.33 2.66E-05 
NM_002730 3852529 PRKACA protein kinase, cAMP-dependent, catalytic, alpha ⇧ 1.30 1.54E-06 
NM_182948 2344393 PRKACB protein kinase, cAMP-dependent, catalytic, beta ⇧ 1.36 0.013 
NM_016457 3866135 PRKD2 protein kinase D2 ⇧ 1.22 1.01E-04 
NM_080391 2404819 PTP4A2 protein tyrosine phosphatase type IVA, member 2 ⇧ 1.32 4.08E-05 
NM_014369 2505529 PTPN18 protein tyrosine phosphatase, non-receptor type 18 (brain-derived) ⇧ 1.20 7.76E-05 
NM_080549 3403092 PTPN6 protein tyrosine phosphatase, non-receptor type 6 ⇧ 1.21 3.11E-09 
NM_002833 3633460 PTPN9 protein tyrosine phosphatase, non-receptor type 9 ⇧ 1.23 0.002 
NM_002843 3329983 PTPRJ protein tyrosine phosphatase, receptor type, J ⇩ 1.54 0.004 
NM_006861 3474228 RAB35 RAB35, member RAS oncogene family ⇧ 1.22 5.63E-05 
NM_001100426 2736853 RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 ⇧ 1.29 0.007 
NM_005739 3618736 RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) ⇩ 1.36 0.017 
NM_002928 2447148 RGS16 regulator of G-protein signalling 16 ⇧ 1.23 0.034 
NM_001039467 3914307 RGS19 regulator of G-protein signalling 19 ⇧ 1.23 0.001 
NM_002923 2372858 RGS2 regulator of G-protein signalling 2, 24kDa ⇧ 1.74 0.002 
NM_021205 2384401 RHOU ras homolog gene family, member U ⇧ 1.42 0.001 
NM_033103 3858852 RHPN2 rhophilin, Rho GTPase binding protein 2 ⇧ 1.27 0.005 
NM_002966 2435383 S100A10 S100 calcium binding protein A10 ⇧ 1.43 0.003 
NM_017789 2565592 SEMA4C sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4C 
⇩ 1.32 5.97E-05 
NM_003612 3632907 SEMA7A semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group) ⇩ 1.22 8.72E-05 
NM_004844 2664209 SH3BP5 SH3-domain binding protein 5 (BTK-associated) ⇧ 1.36 0.030 
NM_003028 3205659 SHB Src homology 2 domain containing adaptor protein B ⇩ 1.22 0.024 
NM_024745 3689880 SHCBP1 SHC SH2-domain binding protein 1 ⇧ 1.44 2.40E-05 
NM_003930 3042610 SKAP2 src kinase associated phosphoprotein 2 ⇧ 1.22 5.55E-04 
NM_005900 2746119 SMAD1 SMAD family member 1 ⇧ 1.32 0.029 
NM_021069 2796995 SORBS2 sorbin and SH3 domain containing 2 ⇧ 1.25 0.003 
NM_181784 2556752 SPRED2 sprout-related, EVH1 domain containing 2 ⇧ 1.30 0.001 
NM_012108 2729667 STAP1 signal transducing adaptor family member 1 ⇧ 1.27 0.008 
NM_018201 3190737 TBC1D13 TBC1 domain family, member 13 ⇧ 1.21 3.24E-04 







 Table B10: NonC9ORF72-Related_SALS Specific Gene List (n=1,201) [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
 506 
 
NM_012339 3250373 TSPAN15 tetraspanin 15 ⇩ 1.48 0.001 
NM_213655 3400384 WNK1 WNK lysine deficient protein kinase 1 ⇩ 1.35 0.010 
NM_003404 3886639 YWHAB tyrosine 3-monooxygenase/tryptophoan 5-monooxygenase activation protein, beta polypeptide ⇧ 1.21 9.37E-04 
NR_024058 3740126 YWHAE tyrosine 3-monooxygenase/tryptophoan 5-monooxygenase activation protein, epsilon polypeptide ⇧ 1.24 4.48E-04 
Transcription 
NM_018011 3524618 ARGLU1 arginine and glutamate rich 1 ⇩ 1.26 2.52E-05 
NM_004674 3094447 ASH2L ash 2 (absent, small, or homeotic)-like (Drosophila) ⇧ 1.29 5.94E-07 
NM_014670 2522439 BZW1 basic leucine zipper and W2 domains 1 ⇧ 1.22 0.016 
NM_138414 3686587 CCDC101 coiled-coil domain containing 101 ⇧ 1.28 2.10E-05 
NM_015076 2969467 CDK19 cyclin-dependent kinase 19 ⇧ 1.24 1.79E-04 
NM_015442 2616018 CNOT10 CCR4-NOT transcription complex, subunit 10 ⇧ 1.20 1.21E-04 
NM_004779 2836856 CNOT8 CCR4-NOT transcription complex, subunit 8 ⇧ 1.20 6.46E-04 
NM_182898 2994558 CREB5 cAMP responsive element binding protein 5 ⇩ 1.27 0.023 
NM_001039618 3385003 CREBZF CREB/ATF bZIP transcription factor  ⇩ 1.26 3.82E-05 
NM_183013 3242353 CREM cAMP responsive element modulator  ⇧ 1.27 6.12E-05 
NM_005730 3458911 CTDSP2 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2 ⇧ 1.22 7.21E-04 
NM_014633 3320301 CTR9 Ctr9, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) ⇧ 1.22 5.02E-04 
NM_003472 2944068 DEK DEK oncogene ⇧ 1.30 7.87E-06 
NM_194249 2878461 DND1 dead end homolog 1 (zebrafish) ⇩ 1.21 0.034 
NM_001130823 3850069 DNMT1 DNA (cytosine-5-)-methyltransferase 1 ⇧ 1.32 9.61E-06 
NM_014597 2423597 DNTTIP2 deoxynucleotidyltransferase, terminal, interacting protein 2 ⇧ 1.30 7.72E-05 
NM_032574 2547386 DPY30 dpy-30 homolog (C. elegans) ⇧ 1.21 0.002 
NM_001950 3665288 E2F4 E2F transcription factor 4, p107/p130-binding ⇧ 1.30 2.80E-05 
NM_024757 3195400 EHMT1 euchromatic histone-lysine N-methyltransferase 1 ⇧ 1.23 2.49E-04 
NM_001421 4021433 ELF4 E74-like factor 4 (ets domain transcription factor) ⇧ 1.27 2.58E-05 
NR_036472 3111530 ENY2 enhancer of yellow 2 homolod (Drosophila) ⇧ 1.24 0.014 
NM_015630 2509832 EPC2 enhancer of polycomb homolog 2 (Drosophila) ⇧ 1.28 7.83E-05 
NM_002017 3355733 FLI1 Friend leukemia virus integration 1 ⇧ 1.22 0.004 
NM_004514 3775147 FOXK2 forkhead box K2 ⇩ 1.26 4.41E-04 
NM_003934 3191589 FUBP3 far upstream element (FUSE) binding protein 3 ⇧ 1.23 6.94E-04 
NM_005254 3623683 GABPB1 GA binding protein transcription factor, beta subunit 1 ⇧ 1.21 1.48E-04 







 Table B10: NonC9ORF72-Related_SALS Specific Gene List (n=1,201) [Partek® unadjusted p<0.05, FC ≥ ±1.20] 
 507 
 
NM_017660 3825713 GATAD2A GATA zinc finger domain containing 2A ⇧ 1.28 1.77E-05 
NM_006582 2327603 GMEB1 glucocorticoid modulatory element binding protein 1 ⇧ 1.23 7.98E-05 
NM_001514 2421753 GTF2B general transcription factor IIB ⇧ 1.27 0.001 
NM_005513 2638467 GTF2E1 general transcription factor IIE, polypeptide 1, alpha 56kDa ⇧ 1.26 0.003 
NM_207118 29335522 GTF2H5 general transcription factor IIH, polypeptide 5 ⇧ 1.39 0.020 
NR_033441 2970532 HDAC2 histone deacetylase 2 ⇧ 1.20 1.64E-05 
NM_030763 4013828 HMGN5 high-mobility group nucleosome binding domain 5 ⇧ 1.48 0.001 
NM_001163280 3992521 HTATSF1 HIV-1 Tat specific factor 1 ⇧ 1.28 3.48E-04 
NM_002166 2468622 ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein  ⇧ 1.30 0.014 
NM_003884 2613441 KAT2B K(lysine) acetyltransferase 2B ⇧ 1.23 0.002 
NM_003597 2469213 KLF11 Kruppel-like factor 11 ⇧ 1.23 0.046 
NM_031918 3845553 KLF16 Kruppel-like factor 16 ⇧ 1.26 7.89E-05 
NM_001730 3493543 KLF5 Kruppel-like factor 5 (intestinal) ⇧ 1.22 0.001 
NM_030973 3838947 MED25 mediator complex subunit 25 ⇧ 1.27 1.56E-08 
NM_006337 3453882 MCRS1 microspherule protein 1 ⇧ 1.20 6.87E-05 
NM_005098 3140213 MSC musculin ⇧ 1.28 7.16E-04 
NM_006800 3968833 MSL3 male-specific lethal 3 homolog (Drosophila) ⇩ 1.29 0.001 
NM_005966 2520225 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1)  ⇩ 1.29 0.006 
NM_052876 3822195 NACC1 nucleus accumbens associated 1, BEN and BTB (POZ) domain containing ⇧ 1.29 9.63E-07 
NM_147223 2473149 NCOA1 nuclear receptor coactivator 1 ⇧ 1.34 6.71E-07 
NM_020967 3907652 NCOA5 nuclear receptor coactivator 5 ⇧ 1.35 2.94E-05 
NM_003204 3725035 NFE2L1 nuclear factor (erythroid-derived 2)-like 1 ⇩ 1.25 9.84E-05 
NM_205843 3816919 NFIC nuclear factor I/C (CCAAT-binding transcription factor) ⇧ 1.20 8.77E-05 
NM_021005 3610110 NR2F2 nuclear receptor subfamily 2, group F, member 2 ⇧ 1.45 0.022 
NM_012345 3512449 NUFIP1 nuclear fragile X mental retardation protein interacting protein 1 ⇧ 1.24 7.46E-04 
NM_018165 2676219 PBRM1 polybromo 1 ⇧ 1.20 0.002 
NM_020524 2436938 PBXIP1 pre-B-cell leukemia homeobox interacting protein 1 ⇩ 1.31 4.48E-06 
NM_003662 4000560 PIR pirin (iron-binding nuclear protein) ⇧ 1.22 0.048 
NM_002657 3902682 PLAGL2 pleiomorphic adenoma gene-like 2 ⇧ 1.20 0.007 
NM_018082 3430129 POLR3B polymerase (RNA) III (DNA directed) polypeptide B ⇧ 1.26 0.001 
NM_032305 2432571 POLR3GL polymerase (RNA) III (DNA directed) polypeptide G (32kD)-like ⇧ 1.32 2.96E-09 
NM_007062 3430552 PWP1 PWP1 homolog (S. cerevisiae) ⇧ 1.27 2.45E-06 
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NM_024604 3452622 RPAP3 RNA polymerase II associated protein 3 ⇧ 1.32 5.74E-06 
NM_002957 3193339 RXRA retinoid X receptor, alpha ⇧ 1.26 4.73E-04 
NM_005870 3480657 SAP18 Sin3A-associated protein, 18kDa ⇧ 1.20 0.012 
NR_024084 2836665 SAP30L SAP30-like ⇧ 1.21 2.76E-04 
NM_012237 3861689 SIRT2 sirtuin 2 ⇧ 1.21 0.019 
NM_024755 3626704 SLTM SAFB-like, transcription modulator  ⇧ 1.29 8.81E-04 
NM_003079 3756344 SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily E, member 1 ⇧ 1.23 1.87E-05 
NM_020197 2379754 SMYD2 SET and MYND domain containing 2 ⇧ 1.35 3.53E-05 
NM_001167740 2464909 SMYD3 SET and MYND domain containing 3 ⇧ 1.21 3.01E-04 
NM_003113 2531377 SP100 SP100 nuclear antigen ⇧ 1.20 0.006 
NM_003121 3839346 SPIB Spi-B transcription factor (Spi-1/PU.1 related) ⇧ 1.32 0.002 
NM_145716 2413685 SSBP3 single stranded DNA binding protein 3 ⇧ 1.36 0.005 
NM_003146 3373724 SSRP1 structure specific recognition protein 1 ⇧ 1.29 2.72E-04 
NM_006713 2805581 SUB1 SUB1 homolog (S. cerevisiae) ⇧ 1.21 0.013 
NM_139215 3718791 TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa ⇧ 1.20 4.58E-05 
NM_005680 2469094 TAF1B TATA box binding protein (TBP)-associated factor, RNA polymerase I, B, 63kDa ⇧ 1.23 0.009 
NM_138572 2907018 TAF8 TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor 43kDa ⇧ 1.20 0.003 
NM_001006933 3985644 TCEAL3 transcription elongation factor A (SII)-like 3 ⇧ 1.20 0.005 
NM_007111 3502710 TFDP1 transcription factor Dp-1 ⇧ 1.32 3.18E-08 
NM_007005 3176209 TLE4 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) ⇧ 1.38 9.07E-05 
NM_033502 2954025 TRERF1 transcriptional regulating factor 1 ⇩ 1.21 0.038 
NM_001076683 3758967 UBTF ⇧stream binding transcription factor, RNA polymerase I ⇧ 1.26 5.49E-07 
NM_003796 3828162 URI1 URI1, prefoldin-like chaperone  ⇧ 1.22 1.95E-04 
NM_007146 3764066 VEZF1 vascular endothelial zinc finger 1 ⇧ 1.21 2.66E-04 
NM_025234 3634588 WDR61 WD repeat domain 61 ⇧ 1.20 7.41E-04 
NM_006530 3421523 YEATS4 YEATS domain containing 4 ⇧ 1.22 0.003 
NM_006977 3568310 ZBTB25 zinc finger and BTB domain containing 25 ⇩ 1.35 1.28E-04 
NM_014383 3830680 ZBTB32 zinc finger and BTB domain containing 32 ⇩ 1.26 0.011 
NM_015898 3846594 ZBTB7A zinc finger and BTB domain containing 7A ⇧ 1.21 1.22E-06 
NM_153688 3668898 ZFP1 zinc finger protein 1 homolog (mouse)  ⇧ 1.24 3.27E-04 
NM_001143823 3797015 ZFP161 zinc finger protein 161 homolog (mouse) ⇧ 1.24 8.88E-04 
NM_020828 3842794 ZFP28 zinc finger protein 28 homolog (mouse) ⇧ 1.30 0.005 
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NM_003411 4028568 ZFY zinc finger protein Y-linked  ⇧ 1.25 0.008 
NM_006624 3231389 ZMYND11 zinc finger, MYND domain containing 11 ⇧ 1.25 5.99E-04 
NM_033204 3825911 ZNF101 zinc finger protein 101 ⇧ 1.22 0.025 
NM_003431 2465551 ZNF124 zinc finger protein 124 ⇧ 1.25 0.003 
NM_003432 2808290 ZNF131 zinc finger protein 131 ⇧ 1.27 0.003 
NM_013256 3864921 ZNF180 zinc finger protein 180 ⇧ 1.23 0.002 
NR_024565 3784509 ZNF271 zinc finger protein 271 ⇧ 1.21 0.006 
NM_001172674 3870135 ZNF347 zinc finger protein 347 ⇧ 1.31 0.002 
NM_001007094 3243164 ZNF37A zinc finger protein 37A ⇧ 1.20 0.002 
NM_007130 4007086 ZNF41 zinc finger protein 41 ⇧ 1.20 2.26E-04 
NM_001001668 3842839 ZNF470 zinc finger protein 470 ⇧ 1.22 9.59E-04 
NM_144684 3840142 ZNF480 zinc finger protein 480 ⇧ 1.41 2.96E-04 
NM_020855 3826803 ZNF492 zinc finger protein 492 ⇧ 1.34 0.005 
NR_003699 3840944 ZNF525 zinc finger protein 525 ⇧ 1.22 0.007 
NM_020951 3860552 ZNF529 zinc finger protein 529 ⇩ 1.21 0.008 
NM_018181 3790361 ZNF532 zinc finger protein 532 ⇧ 1.25 0.017 
NR_033418 3842675 ZNF542 zinc finger protein 542 ⇧ 1.36 1.81E-04 
NM_014630 3605832 ZNF592 zinc finger protein 592 ⇧ 1.24 4.94E-04 
NM_025040 3869379 ZNF614 zinc finger protein 614 ⇧ 1.24 0.004 
NM_145295 3821301 ZNF627 zinc finger protein 627 ⇧ 1.21 0.021 
NM_152320 3453120 ZNF641 zinc finger protein 641 ⇧ 1.20 0.009 
NM_023070 3453120 ZNF643 zinc finger protein 643 ⇧ 1.27 6.36E-04 
NM-152373 2331974 ZNF684 zinc finger protein 684 ⇧ 1.20 2.84E-06 
NM_001042510 3147020 ZNF706 zinc finger protein 706 ⇩ 1.24 0.014 
NM_153028 3645816 ZNF75A zinc finger protein 75A ⇧ 1.30 0.004 
AK093979 3645836 ZNF75A zinc finger protein 75A ⇧ 1.33 0.005 
NM_001008401 3840857 ZNF761 zinc finger protein 761 ⇧ 1.22 0.032 
NR_027788 3078656 ZNF767 zinc finger protein 767 ⇩ 1.21 0.010 
NM_015694 3078597 ZNF777 zinc finger protein 777 ⇧ 1.21 3.42E-04 
NR_027049 3821701 ZNF788 zinc finger protein 788 ⇧ 1.26 1.91E-05 
NM_001145434 3840194 ZNF880 zinc finger protein 880 ⇩ 1.28 0.024 











NM_001143948 2941972 ADTRP androgen-dependent TFPI-regulatory protein  ⇩ 1.30 0.019 
NM_018046 2816563 AGGF1 angiogenic factor with G patch and FHA domains 1 ⇧ 1.23 1.66E-04 
NM_031917 3850020 ANGPTL6 angiopoietin-like 6 ⇩ 1.28 3.80E-04 
NM_145343 3944404 APOL1 apolipoprotein L, 1 ⇩ 1.31 0.025 
NR_027833 3959350 APOL3 apolipoprotein L, 3 ⇧ 1.22 0.008 
NM_001174150 2632453 ARL13B ADP-ribosylation factor-like 13B ⇧ 1.23 1.18E-04 
NM_001183 3996381 ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 1 ⇩ 1.27 6.13E-05 
NM_004047 2333658 ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b ⇩ 1.27 0.002 
NM_012105 3921933 BACE2 beta-site APP-cleaving enzyme 2 ⇩ 1.55 0.010 
NM_001042440 2821194 CAST calpastatin ⇧ 1.23 1.46E-05 
NM_007097 2888304 CLTB clathrin, light chain B ⇧ 1.21 3.75E-05 
NM_001304 3716411 CPD carboxypeptidase D ⇩ 1.24 0.014 
NM_182485 2719361 CPEB2 cytoplasmic polyadenylation element binding protein 2 ⇩ 1.20 0.022 
NM_001308 3303227 CPN1 carboxypeptidase N, polypeptide 1 ⇧ 1.20 0.033 
NM_006565 3665603 CTCF CCCTC-binding factor (zinc finger protein) ⇧ 1.20 1.36E-04 
NM_00112605 3859761 DMKN dermokine ⇩ 1.21 0.032 
NM_182314 4021633 ENOX2 ecto-NOX disulphide-thiol exchanger 2 ⇧ 1.32 2.37E-05 
NM_018145 3619595 FAM82A2 family with sequence similarity 82, member A2 ⇩ 1.23 6.37E-04 
NR_024042 3382698 GUCY2E guanylate cyclase 2E ⇩ 1.23 0.005 
NM_001142556 2838656 HMMR hyaluronan-mediated motility receptor (RHAMM) ⇧ 1.21 0.048 
NM_020153 3393834 IFT46 intraflagellar transport 46 homolog (Chlamydomonas) ⇧ 1.20 8.72E-04 
NM_016004 3886179 IFT52 intraflagellar transport 52 homolog (Chlamydomonas) ⇧ 1.26 4.00E-05 
NM_198690 3923857 KRTAP10-9 keratin associated protein 10-9 ⇩ 1.23 0.005 
NM_181605 3917582 KRTAP6-3 keratin associated protein 6-3  ⇩ 1.35 0.003 
NM_002294 4019849 LAMP2 lysosomal-associated membrane protein 2 ⇩ 1.23 0.003 
NM_178428 2359377 LCE2A late cornified envelope 2A ⇩ 1.30 8.90E-04 
NM_000427 2359646 LOR loricrin ⇧ 1.21 0.033 
NM_001136493 2331679 MFSD2A major facilitator superfamily domain containing 2A ⇩ 1.20 0.004 
NM_152649 3699080 MLKL mixed lineage kinase domain-like  ⇧ 1.20 0.031 
NM_032117 2748163 MND1 meiotic nuclear divisions 1 homolog (S. cerevisiae) ⇧ 1.47 6.57E-04 
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NM_000252 3994795 MTM1 myotubularin 1 ⇧ 1.41 6.29E-05 
NM_006432 3571904 NPC2 Niemann-Pick disease, type C2 ⇩ 1.21 2.35E-04 
NM_002616 3744150 PER1 period homolog 1 (Drosophila) ⇩ 1.21 0.016 
NM_003847 3638566 PEX11A peroxisomal biogenesis factor 11 alpha ⇩ 1.22 0.002 
NM_000941 3009229 POR P450 (cytochrome) oxidoreductase ⇩ 1.23 0.001 
NM_016488 3412008 PPHLN1 periphilin 1 ⇧ 1.22 1.23E-05 
NM_000311 3874751 PRNP prion protein  ⇩ 1.26 0.004 
NM_007238 3903169 PXMP4 peroxisomal membrane protein 4, 24kDa ⇩ 1.23 2.86E-04 
NM_004160 3758775 PYY peptide YY ⇩ 1.26 0.008 
NR_024210 3942805 RNF185 ring finger protein 185 ⇧ 1.22 0.013 
NM_001031709 3299408 RNLS renalase, FAD-dependent amine oxidase ⇧ 1.24 0.002 
NM_006461 3750785 SPAG5 sperm associated antigen 5 ⇧ 1.20 0.004 
NM_004890 3742415 SPAG7 sperm associated antigen 7 ⇧ 1.21 0.001 
NM_080608 3907507 SPATA25 spermatogenesis associated 25 ⇩ 1.34 5.99E-06 
NM_145207 2742134 SPATA5 spermatogenesis associated 5 ⇧ 1.26 8.44E-05 
NM_001100422 2522094 SPATS2L spermatogenesis associated, serine-rich 2-like ⇧ 1.39 8.44E-05 
NM_004099 3223928 STOM stomatin ⇩ 1.20 0.011 
NM_032300 3431318 TCHP trichoplein, keratin filament binding ⇧ 1.24 5.78E-05 
NM_018073 3360189 TRIM68 tripartite motif-containing 68 ⇧ 1.27 1.78E-05 
NM_004622 2503618 TSN translin ⇧ 1.21 9.99E-04 
NM_178562 3023318 TSPAN33 tetraspanin 33 ⇩ 1.22 0.002 
NM_003920 3457824 TIMELESS timeless homolog (Drosophila) ⇧ 1.22 0.003 
NM_014688 3277468 USP6NL USP6 N-terminal like ⇧ 1.35 8.93E-05 
NM_172005 3887004 WFDC13 WAP four-disulfide core domain 13 ⇩ 1.21 0.007 
NM_032312 2476176 YIPF4 Yip1 domain family, member 4 ⇩ 1.26 9.68E-04 
Unknown Function 
NM_020676 2626097 ABHD6 adhydrolase domain containing 6 ⇩ 1.51 1.06E-04 
NM_020186 3013952 ACN9 ACN9 homolog (S. cerevisiae) ⇧ 1.29 1.12E-06 
NM_139056 2800026 ADAMTS16 ADAM metallopeptidase with thromospondin type 1 motif, 16 ⇩ 1.26 3.31E-05 
NM_178563 3025678 AGBL3 ATP/GTP binding protein-like 3 ⇩ 1.20 0.048 
NR_026903 3767280 AMZ2P1 archaelysin family metallopeptidase 2 pseudogene 1 ⇩ 1.22 0.008 
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NR_003366 2564520 ANKRD20B ankyrin repeat domain 20B ⇩ 1.22 0.012 
NM_032139 3858659 ANKRD27 ankyrin repeat domain 27 (VPS9 domain) ⇧ 1.33 8.03E-04 
NM_052855 3762416 ANKRD40 ankyrin repeat domain 40 ⇧ 1.23 1.92E-04 
NM_030920 2434319 ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E ⇧ 1.34 1.91E-04 
NM_174890 3286975 ANUBL1 AN1, ubiquitin-like, homolog (Xenopus laevis) ⇧ 1.25 0.002 
NM_006407 2628682 ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 ⇩ 1.25 0.003 
NM_182482 3924929 BAGE2 B melanoma antigen family, member 2 ⇩ 1.30 0.019 
NM_004326 2356818 BCL9 B-cell CLL/lymphoma 9 ⇧ 1.29 3.38E-04 
NM_032320 3363645 BTBD10 BTB (POZ) domain containing 10 ⇧ 1.28 1.81E-04 
NM_022153 3293724 C10orf54 chromosome 10 open reading frame 54 ⇩ 1.34 1.51E-04 
NM_025125 3254337 C10orf57 chromosome 10 open reading frame 57 ⇩ 1.27 0.004 
NM_170746 3331603 C11orf31 chromosome 11 open reading frame 31 ⇩ 1.22 4.86E-04 
BC056402 3333999 C11orf84 chromosome 11 open reading frame 84 ⇧ 1.23 4.88E-06 
NM_018169 3410384 C12orf35 chromosome 12 open reading frame 35 ⇧ 1.21 0.033 
NM_138779 3523855 C13orf27 chromosome 13 open reading frame 27 ⇧ 1.39 8.70E-06 
NM_032490 3577256 C14orf142 chromosome 14 open reading frame 142 ⇧ 1.67 3.03E-04 
NM_152446 3573933 C14orf145 chromosome 14 open reading frame 145 ⇧ 1.41 3.89E-04 
NM_152446 3573994 C14orf145 chromosome 14 open reading frame 145 ⇧ 1.23 0.011 
NM_015492 3602116 C15orf39 chromosome 15 open reading frame 39 ⇧ 1.23 0.001 
NM_020314 3651057 C16orf62 chromosome 16 open reading frame 62 ⇧ 1.21 0.006 
NM_024109 3647368 C16orf68 chromosome 16 open reading frame 68 ⇩ 1.21 3.76E-04 
NM_030806 2371547 C1orf21 chromosome 1 open reading frame 21 ⇩ 1.39 0.029 
NM_020317 2402111 C1orf63 chromosome 1 open reading frame 63 ⇩ 1.21 0.003 
NM_012261 3876084 C20orf103 chromosome 20 open reading frame 103 ⇧ 1.82 0.006 
NM_017896 3893072 C20orf11 chromosome 20 open reading frame 11 ⇧ 1.22 0.001 
NM_016470 3906821 C20orf111 chromosome 20 open reading frame 111 ⇩ 1.20 0.042 
NM_022106 3891643 C20orf177 chromosome 20 open reading frame 177 ⇧ 1.22 2.46E-04 
AF391113 3923982 C21orf70 chromosome 21 open reading frame 70 ⇧ 1.38 8.61E-05 
NR_026997 3965102 C22orf34 chromosome 22 open reading frame 34 ⇩ 1.22 0.036 
NM_00100988 3963676 C22orf9 chromosome 22 open reading frame 9  ⇧ 1.22 0.005 
AF236158 2627080 C3orf14 chromosome 3 open reading frame 14 ⇧ 1.25 0.005 
NM_178339 2617148 C3orf35 chromosome 3 open reading frame 35 ⇩ 1.21 0.005 
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NM_017867 2793310 C4orf27 chromosome 4 open reading frame 27 ⇧ 1.31 0.001 
NM_198567 2842429 C5orf25 chromosome 5 open reading frame 25 ⇧ 1.26 1.94E-05 
NM_198566 2855614 C5orf34 chromosome 5 open reading frame 34 ⇧ 1.22 0.003 
NM_021243 2927967 C6orf115 chromosome 6 open reading frame 115 ⇧ 1.33 0.005 
NR_024185 3074101 C7orf49 chromosome 7 open reading frame 49 ⇧ 1.20 0.018 
NM_001001551 3176933 C9orf103 chromosome 9 open reading frame 103 ⇧ 1.21 0.002 
NM_016390 3226709 C9orf114 chromosome 9 open reading frame 114 ⇧ 1.20 0.003 
AY598327 3182199 C9orf30 chromosome 9 open reading frame 30 ⇧ 1.42 1.05E-05 
NR_024274 3164999 C9orf53 chromosome 9 open reading frame 53 ⇩ 1.38 1.81E-04 
NM_153045 3186207 C9orf91 chromosome 9 open reading frame 91 ⇩ 1.28 8.45E-04 
NM_005093 3882533 CBFA2T2 core-binding factor, runt domain, alpha subunit 2; translocated to, 2 ⇩ 1.22 8.53E-04 
NM_201453 3208355 CBWD3 COBW domain containing 3 ⇩ 1.41 0.008 
NM_138442 3824648 CCDC124 coiled-coil domain containing 124 ⇧ 1.29 1.22E-05 
NM_176816 2860614 CCDC125 coiled-coil domain containing 125 ⇧ 1.22 5.46E-04 
NM_024821 3947096 CCDC134 coiled-coil domain containing 134 ⇩ 1.20 0.026 
NR_036647 3748449 CCDC144B coiled-coil domain containing 144B ⇩ 1.43 0.046 
NM_025004 3354389 CCDC15 coiled-coil domain containing 15 ⇧ 1.27 1.66E-05 
NM_206886 2347023 CCDC18 coiled-coil domain containing 18 ⇧ 1.20 0.031 
NM_199342 2409069 CCDC23 coiled-coil domain containing 23 ⇧ 1.41 0.048 
NM_018246 3129121 CCDC25 coiled-coil domain containing 25 ⇧ 1.20 1.70E-04 
NM_030771 3367036 CCDC34 coiled-coil domain containing 34 ⇧ 1.32 5.57E-06 
NM_020198 3766334 CCDC47 coiled-coil domain containing 47 ⇩ 1.21 1.27E-04 
NM_024661 2673257 CCDC51 coiled-coil domain containing 51 ⇧ 1.20 0.003 
NM_005436 3290785 CCDC6 coiled-coil domain containing 6 ⇧ 1.22 1.82E-05 
NM_032358 3400190 CCDC77 coiled-coil domain containing 77 ⇧ 1.20 3.07E-04 
NM_024098 3332548 CCDC86 coiled-coil domain containing 86 ⇧ 1.22 0.002 
NM_018074 3817400 CCDC94 coiled-coil domain containing 94 ⇧ 1.20 9.83E-05 
NM_052848 3834149 CCDC97 coiled-coil domain containing 97 ⇧ 1.22 9.77E-05 
NM_176096 3724989 CDK5RAP3 CDK5 regulatory subunit associated protein 3 ⇩ 1.25 1.37E-04 
NM_207390 3822849 CLEC17A C-type lectin domain family 17, member A ⇩ 1.28 1.07E-04 
NM_024734 3577940 CLMN calmin (calponin-like, transmembrane) ⇩ 1.49 0.008 
NM_001294 3835935 CLPTM1 cleft lip and palate associated transmembrane protein 1 ⇩ 1.20 7.15E-04 
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NM_001031717 2610136 CRELD1 cysteine-rich with EGF-like domains 1 ⇩ 1.26 5.71E-05 
NM_033027 2669930 CSRNP1 cysteine-serine-rich nuclear protein 1 ⇩ 1.26 0.008 
NM_024040 3304355 CUEDC2 CUE domain containing 2 ⇧ 1.20 5.12E-06 
BC001220 3982242 CXorf26 chromosome X open reading frame 26 ⇧ 1.26 4.60E-04 
NM_138496 3158697 CYHR1 cysteine/histidine-rich 1 ⇩ 1.20 0.002 
NM_032576 4031068 CYorf15B chromosome Y open reading frame 15B ⇧ 1.44 0.032 
NM_018369 2858592 DEPDC1B DEP domain containing 1B ⇧ 1.34 1.05E-04 
NM_024308 3719210 DHRS11 dehydrogenase/reductase (SDR family) member 11 ⇧ 1.22 0.004 
NM_017613 3929775 DONSON upstream neighbour of SON ⇧ 1.23 8.53E-04 
NM_152726 3504791 EFHA1 EF-hand domain family, member A1 ⇧ 1.23 1.37E-04 
NM_015036 3345427 ENDOD1 endonuclease domain containing 1 ⇩ 1.21 0.005 
NM_014805 2669157 EPM2AIP1 EPM2A (laforin) interacting protein 1 ⇩ 1.22 5.93E-05 
NM_020728 3082248 ESYT2 extended synaptotagmin-like protein 2 ⇩ 1.21 2.90E-05 
NM_138348 2802739 FAM105B family with sequence similarity 105, member B ⇧ 1.22 0.002 
NM_198947 3331903 FAM111B family with sequence similarity 111, member B ⇧ 1.59 1.18E-06 
NM_00107952 2889241 FAM153B family with sequence similarity 153, member B ⇩ 1.23 0.008 
NM_199133 2848233 FAM173B family with sequence similarity 173, member B ⇧ 1.20 0.039 
NM_198507 2821981 FAM174A family with sequence similarity 174, member A ⇩ 1.32 0.003 
NM_207446 3639406 FAM174B family with sequence similarity 174, member B ⇩ 1.38 0.010 
NM_004816 3173974 FAM189A2 family with sequence similarity 189, member A2 ⇩ 1.27 0.001 
NM_198076 2464484 FAM36A family with sequence similarity 36, member A ⇩ 1.29 0.002 
NM_017709 2353988 FAM46C family with sequence similarity 46, member C ⇧ 1.50 0.033 
BC017297 3153328 FAM49B family with sequence similarity 49, member B ⇧ 1.29 5.39E-04 
NM_152450 3596109 FAM81A family with sequence similarity 81, member A ⇧ 1.20 0.004 
AK123321 2536996 FLJ41327 FLJ41327 protein ⇩ 1.44 0.002 
AK127732 3902372 FLJ45832 FLJ45832 protein ⇩ 1.20 0.009 
NM_207647 3183238 FSD1L fibronectin type III and SPRY domain containing 1-like ⇧ 1.27 0.013 
NM_015660 3031556 GIMAP2 GTPase, IMAP family member 2 ⇧ 1.32 0.004 
NM_024711 3079103 GIMAP6 GTPase, IMAP family member 6 ⇧ 1.33 0.011 
NM_016080 3739827 GLOD4 glyoxalase domain containing 4 ⇧ 1.26 3.62E-04 
NM_144669 3437500 GLT1D1 glycosyltransferase 1 domain containing 1 ⇧ 1.36 0.036 
NM_015698 4007815 GPKOW G patch domain and KOW motifs ⇧ 1.22 2.26E-04 
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NM_001136557 3191273 GPR107 G protein-coupled receptor 107 ⇩ 1.26 9.66E-07 
NM_001033045 2587790 GPR155 G protein-coupled receptor 155 ⇩ 1.21 0.025 
NM_014373 2651835 GPR160 G protein-coupled receptor 160 ⇧ 1.50 0.005 
NM_001146321 2827057 GRAMD3 GRAM domain containing 3 ⇧ 1.30 0.034 
NR_003081 3955070 GSTTP1 glutathione S-transferase theta pseudogene 1 ⇩ 1.29 0.027 
NM_014170 2636272 GTPBP8 GTP-binding protein 8 (putative) ⇧ 1.20 0.010 
NR_003660 2958861 GUSBP4 glucuronidase, beta pseudogene 4 ⇩ 1.32 0.004 
NM_014282 3180957 HABP4 hyaluronan binding protein 4 ⇧ 1.21 0.008 
AY358246 2948169 HCG8 HLA complex group 8 ⇩ 1.27 0.022 
NM_016063 2972759 HDDC2 HD domain containing 2 ⇧ 1.21 0.003 
NM_001001520 3817546 HDGFRP2 hepatoma-derived growth factor-related protein 2 ⇧ 1.21 1.21E-04 
NM_001135565 3998444 HDHD1 haloacid dehalogenase-like hydrolase domain containing 1 ⇧ 1.32 1.89E-04 
NM_024746 2457496 HHIPL2 HHIP-like 2 ⇩ 1.20 0.008 
NM_145014 3354879 HYLS1 hydrolethalus syndrome 1 ⇧ 1.20 0.006 
NM_001542 2429914 IGSF3 immunoglobulin superfamily, member 3 ⇩ 1.25 8.68E-04 
NM_006844 3853063 ILVBL ilvB (bacterial acetolactate synthase)-like   ⇩ 1.21 1.40E-05 
NM_004867 4013549 ITM2A integral membrane protein 2A ⇩ 1.22 0.016 
NM_017969 2574884 IWS1 IWS1 homolog (S. cerevisiae) ⇧ 1.27 5.65E-05 
NM_001039846 3816225 IZUMO4 IZUMO family member 4 ⇩ 1.37 6.75E-05 
NM_032505 2628260 KBTBD8 kelch repeat and BTB (POZ) domain containing 8 ⇧ 1.23 0.025 
NM_152387 2594435 KCTD18 potassium channel tetramerisation domain containing 18 ⇧ 1.21 0.007 
NM_018992 3645204 KCTD5 potassium channel tetramerisation domain containing 5  ⇧ 1.23 2.24E-04 
NM_153033 3005684 KCTD7 potassium channel tetramerisation domain containing 7 ⇩ 1.24 0.004 
NM_014949 2437753 KIAA0907 KIAA0907 ⇩ 1.20 6.35E-04 
NM_001080392 3076753 KIAA1147 KIAA1147 ⇩ 1.26 0.021 
NR_026716 3841525 KIR3DX1 killer cell immunoglobulin-like receptor, three domain, X1 ⇧ 1.23 0.049 
ENST00000392647 2514563 KLHL23 kelch-like 23 (Drosophila) ⇧ 1.22 0.028 
NM_017644 2655113 KLHL24 kelch-like 24 (Drosophila) ⇩ 1.28 0.007 
NM_016027 3139950 LACTB2 lactamase, beta 2 ⇧ 1.26 0.006 
NM_014713 2542737 LAPTM4A lysosomal protein transmembrane 4 alpha ⇩ 1.20 5.77E-04 
NM_144652 3094611 LETM2 lymphoid enhancer-binding factor 1 ⇩ 1.21 0.006 
NM_032338 3460584 LLPH LLP homolog, long-term synaptic facilitation (Aplysia) ⇧ 1.34 2.60E-04 
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NR_034127 2855443 LOC100132356 hypothetical LOC100132356 ⇩ 1.22 0.002 
XM_003119162 2464129 LOC100506975 hypothetical protein LOC100506975 ⇩ 1.20 0.020 
NR_024333 3850501 LOC147727 hypothetical LOC147727 ⇩ 1.30 0.001 
NM_030891 3923764 LRRC3 leucine rich repeat containing 3 ⇩ 1.21 0.002 
NM_001105659 2418339 LRRIQ3 leucine-rich repeats and IQ motif containing 3 ⇧ 1.27 0.005 
NM_001128301 3651588 LYRM1 LYR motif containing 1 ⇧ 1.23 5.32E-05 
NM_153374 3624273 LYSMD2 LysM, putative peptidoglycan-binding, domain containing 2 ⇧ 1.22 0.013 
NR_002776 3924518 MCM3AP-AS MCM3AP antisense RNA (non-protein coding) ⇩ 1.28 4.15E-04 
NR_027350 3496366 MIR17HG MIR17 host gene (non-protein coding) ⇩ 1.26 0.005 
NM_024761 3202316 MOBKL2B MOB1, Mps One Binder kinase activator-like 2B (yeast) ⇧ 1.45 6.11E-04 
AB014771 2775390 MOP-1 MOP-1 ⇩ 1.24 0.013 
NM_015529 2974413 MOXD1 monooxygenase, DBH-like 1 ⇧ 1.60 0.018 
NM_018229 3537557 MUDENG MU-2/AP1M2 domain containing, death-inducing ⇧ 1.24 1.01E-04 
NM_052818 3508644 N4BP2L1 NEDD4 binding protein 2-like 1 ⇩ 1.23 0.015 
NM_174928 3504392 N6AMT2 N-6 adenine-specific DNA methyltransferase 2 (putative) ⇧ 1.21 0.002 
AY168775 3996598 NCRNA00204 non-protein coding RNA 204 ⇩ 1.48 0.029 
NR_024277 2983138 NCRNA00241 non-protein coding RNA 241 ⇩ 1.21 0.016 
NM_018376 3182984 NIPSNAP3B nipsnap homolog 3B (C. elegans) ⇩ 1.44 4.48E-04 
NM_130464 3684100 NPIPL3 nuclear pore complex interacting protein-like 3 ⇩ 1.20 0.013 
NM_001128211 3148796 NUDCD1 NudC domain containing 1 ⇧ 1.21 0.005 
NM_018233 3662041 OGFOD1 2-oxoglutarate and iron-dependent oxygenase domain containing 1 ⇧ 1.24 3.38E-04 
NM_016018 3116535 PHF20L1 PHD finger protein 20-like 1 ⇧ 1.22 0.002 
NM_024297 3743464 PHF23 PHD finger protein 23 ⇧ 1.30 1.22E-04 
NM_016619 2775909 PLAC8 placenta-specific 8 ⇧ 1.23 0.033 
NM_020143 2486740 PNO1 partner of NOB1 homolog (S. cerevisiae) ⇧ 1.28 0.001 
NR_034180 2360939 POU5F1P4 POU class 5 homeobox 1 pseudogene 4 ⇩ 1.34 7.77E-06 
NM_001102559 3131881 PPAPDC1B phosphatidic acid phosphatase type 2 domain containing 1B ⇩ 1.31 4.35E-05 
NM_018304 3728964 PRR11 proline rich 11 ⇧ 1.22 0.011 
NM_004676 4031692 PRY PTPN13-like, Y-linked  ⇩ 1.49 0.005 
NM_030664 3236786 PTER phosphotriesterase related ⇧ 1.26 2.41E-05 
NM_017432 3839006 PTOV1 prostate tumor overexpressed 1 ⇧ 1.29 4.25E-04 
NM_019042 3066436 PUS7 pseudouridylate synthase 7 homolog (S. cerevisiae) ⇧ 1.20 0.006 
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NM_024805 3795466 RBFA ribosome binding factor A (putative) ⇧ 1.23 9.61E-05 
NM_016024 3990795 RBMX2 RNA binding motif protein, X-linked 2 ⇧ 1.34 1.54E-05 
NM_001268 3513549 RCBTB2 regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing 2 ⇧ 1.46 3.07E-04 
NM_002901 3325503 RCN1 reticulocalbin 1, EF-hand calcium binding domain ⇩ 1.41 0.010 
NM_002902 3602723 RCN2 reticulocalbin 2, EF-hand calcium binding domain ⇩ 1.28 0.003 
NM_172239 3143112 REXO1L1 REX1, RNA exonuclease 1 homolog (S. cerevisiae)-like 1 ⇩ 1.62 0.002 
NM_031480 2893721 RIOK1 RIO kinase 1 (yeast) ⇧ 1.23 0.001 
NM_032194 2921374 RPF2 ribosome production factor 2 homolog (S. cerevisiae) ⇧ 1.29 4.22E-04 
BC0171734 3383046 RPS20P27 ribosomal protein S20 pseudogene 27 ⇩ 1.30 0.005 
NM_152260 3589997 RPUSD2 RNA pseudouridylate synthase domain containing 2 ⇧ 1.21 8.54E-05 
NM_198467 3010030 RSBN1L round spermatid basic protein 1-like ⇧ 1.21 0.001 
NM_032167 3648412 RUNDC2A RUN domain containing 2A ⇩ 1.21 0.002 
NM_016940 3928040 RWDD2B RWD domain containing 2B ⇧ 1.24 0.005 
NM_152682 2796066 RWDD4 RWD domain containing 4 ⇧ 1.26 0.046 
NM_017654 3061438 SAMD9 sterile alpha motif domain containing 9 ⇧ 1.30 0.015 
NR_004859 3605780 SCAND2 SCAN domain containing 2, pseudogene ⇩ 1.21 2.04E-04 
NM_001143998 3735752 SEC14L1 SEC14-like 1 (S. cerevisiae) ⇧ 1.22 0.003 
NM_015187 2764192 SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) ⇩ 1.32 0.041 
NM_020755 2972310 SERINC1 serine incorporator 1 ⇩ 1.31 7.62E-07 
NM_001174072 2864449 SERINC5 serine incorporator 5 ⇩ 1.25 0.015 
NM_002640 3791996 SERPINB8 serpin peptidase inhibitor, clade B (ovalbumin), member 8 ⇧ 1.41 5.40E-04 
NM_006216 2601414 SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 ⇩ 1.22 0.040 
NM_032840 3455973 SPRYD3 SPRY domain containing 3 ⇧ 1.22 9.62E-04 
NM_018079 2551327 SRBD1 S1 RNA binding domain 1 ⇧ 1.36 2.15E-06 
NM_022906 3006133 STAG3L4 stromal antigen 3-like 4 ⇩ 1.28 0.005 
NM_020799 3257031 STAMBPL1 STAM binding protein-like 1 ⇧ 1.23 0.017 
NM_012453 3056131 TBL2 transducing (beta)-like 2 ⇩ 1.26 2.16E-05 
NM_198524 3594986 TEX9 testis expressed 9 ⇧ 1.48 0.008 
NM_024838 3239380 THNSL1 threonine synthase-like 1 (S. cerevisiae) ⇧ 1.36 8.25E-04 
NM_017736 3683783 THUMPD1 THUMP domain containing 1 ⇧ 1.21 2.88E-04 
NM_145715 2735598 TIGD2 tigger transposable element derived 2 ⇧ 1.29 2.35E-04 
NM_003258 3772158 TK1 thymidine kinase 1, soluble  ⇧ 1.46 1.69E-06 
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NM_020123 3301857 TM9SF3 transmembrane 9 superfamily member 3 ⇩ 1.20 0.004 
NM_014742 3881686 TM9SF4 transmembrane 9 superfamily protein member 4 ⇩ 1.22 6.56E-06 
NM_020698 3466206 TMCC3 transmembrane and coiled-coil domain family 3 ⇧ 1.25 0.007 
NM_018447 2662491 TMEM111 transmembrane protein 111 ⇩ 1.23 0.002 
NM_031925 3057520 TMEM120A transmembrane protein 120A ⇩ 1.26 0.030 
NM_018295 3025740 TMEM140 transmembrane protein 140 ⇩ 1.31 1.80E-04 
NM_024943 2766289 TMEM156 transmembrane protein 156 ⇧ 1.35 0.037 
NM_017814 3855506 TMEM161A transmembrane protein 161A ⇩ 1.20 4.54E-04 
NM_198536 3850832 TMEM205 transmembrane protein 205 ⇩ 1.20 0.004 
NM_018252 2454661 TMEM206 transmembrane protein 206 ⇩ 1.27 0.002 
NM_014187 3665357 TMEM208 transmembrane protein 208 ⇩ 1.40 8.90E-06 
NM_152417 3136015 TMEM68 transmembrane protein 68 ⇩ 1.26 0.010 
NM_015497 3620515 TMEM87A transmembrane protein 87A ⇩ 1.23 9.16E-05 
NM_016456 2450668 TMEM9 transmembrane protein 9 ⇩ 1.27 1.48E-04 
NM_001042595 3834176 TMEM91 transmembrane protein 91 ⇩ 1.26 0.037 
NM_003449 2948259 TRIM26 tripartite motif-containing 26 ⇧ 1.46 1.39E-06 
NM_017583 3326842 TRIM44 tripartite motif-containing 44 ⇧ 1.21 2.55E-04 
NM_032765 2845078 TRIM52 tripartite motif-containing 52 ⇩ 1.22 0.025 
NM_030912 3261820 TRIM8 tripartite motif-containing 8 ⇧ 1.21 0.003 
NM_018259 3327948 TTC17 tetratricopeptide repeat domain 17 ⇩ 1.20 5.83E-06 
NM_001135993 3781980 TTC39C tetratricopeptide repeat domain 39C ⇧ 1.56 2.54E-04 
NM_175852 2328713 TXLNA taxilin alpha ⇧ 1.23 4.43E-05 
NM_014044 2495555 UNC50 ubiquitin specific peptidase 9, Y-linked ⇩ 1.20 7.82E-04 
NM_007125 4035017 UTY ubiquitously transcribed tetratricopeptide repeat gene, Y-linked ⇧ 1.49 0.043 
NM_024029 3850576 YIPF2 Yip1 domain family, member 2 ⇩ 1.31 4.28E-04 
NM_017665 2875634 ZCCHC10 zinc finger, CCHC domain containing 10 ⇧ 1.20 0.002 
NM_016505 2328236 ZCCHC17 zinc finger, CCHC domain containing 17 ⇧ 1.20 9.05E-04 
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Transcript Symbol p-value  Transcript Symbol p-value  Transcript Symbol p-value  Transcript  Symbol p-value 
3173880 TJP2 4.08E-18  3346548 BIRC3 1.71E-08  3023350 SMO 3.80E-07  3604147 KIAA1199 2.20E-06 
3253880 PPIF 3.77E-16  3129731 DUSP4 1.78E-08  3459120 LRIG3 4.09E-07  3064361 ACHE 2.25E-06 
3666779 NFAT5 1.58E-15  2400322 HP1BP3 2.22E-08  2878726 HDAC3 4.12E-07  3303059 SLC25A28 2.29E-06 
3002640 EGFR 1.69E-14  2888648 RAB24 2.41E-08  3806525 PIAS2 4.37E-07  2775214 PRKG2 2.30E-06 
2622469 RBM5 4.76E-14  2456849 RAB3GAP2 2.43E-08  3064006 C7orf47 4.40E-07  3081862 PTPRN2 2.31E-06 
3542207 SRSF5 8.59E-14  3233431 FBXO18 2.68E-08  3087813 PCM1 4.47E-07  3363923 COPB1 2.42E-06 
3377044 SF1 6.88E-13  3847814 KHSRP 2.81E-08  3628650 HERC1 5.14E-07  2768273 NFXL1 2.48E-06 
2655688 EIF4G1 1.42E-12  3393200 PCSK7 2.82E-08  2891241 DUSP22 5.50E-07  2610336 VHL 2.73E-06 
3989721 STAG2 1.57E-12  3204744 TLN1 4.26E-08  2800026 ADAMTS16 5.70E-07  2546008 SUPT7L 2.73E-06 
2400793 HSPG2 1.72E-12  3475717 RSRC2 4.67E-08  3724591 C17orf57 5.75E-07  2878778 FCHSD1 2.74E-06 
3400034 WNK1 1.74E-12  3860208 ALKBH6 5.72E-08  3741528 TAX1BP3 7.24E-07  3835675 CEACAM19 2.88E-06 
3955815 HPS4 1.95E-12  3484497 FRY 6.03E-08  2892738 PRPF4B 7.68E-07  3416256 HOXC13 2.88E-06 
3708663 CHRNB1 1.82E-11  3553872 KLC1 6.90E-08  3643966 CRAMP1L 7.83E-07  2436401 JTB 2.91E-06 
2964350 MDN1 3.65E-11  3602116 C15orf39 6.92E-08  3966000 TYMP 7.94E-07  3425108 C12orf29 3.13E-06 
3518496 MYCBP2 1.09E-10  2639054 PARP14 9.40E-08  3536706 LGALS3 8.65E-07  3815493 HMHA1 3.14E-06 
3614087 UBE3A 1.21E-10  3824395 PGLS 9.45E-08  3729834 TBX2 9.69E-07  2409344 MED8 3.30E-06 
3417842 LRP1 1.24E-10  2664099 MRPS25 9.97E-08  4027176 FLNA 1.10E-06  2476219 BIRC6 3.47E-06 
2704894 PHC3 1.41E-10  2842951 NSD1 1.05E-07  2545653 MPV17 1.10E-06  3719161 GGNBP2 4.17E-06 
3413344 PFKM 2.78E-10  3704717 ANKRD11 1.12E-07  3430776 ISCU 1.11E-06  2548500 PRKD3 4.22E-06 
2560254 AUP1 6.16E-10  2329887 NCDN 1.78E-07  2589017 PDE11A 1.12E-06  3611744 LRRK1 4.36E-06 
3607447 ABHD2 1.40E-09  3880767 PYGB 1.83E-07  2881747 ANXA6 1.17E-06  3338060 MYEOV 4.46E-06 
3372459 FNBP4 1.77E-09  3199790 PSIP1 2.04E-07  2673345 COL7A1 1.21E-06  2419235 FUBP1 4.65E-06 
2838598 CCNG1 2.20E-09  3539724 SYNE2 2.12E-07  3631498 LARP6 1.22E-06  2647898 MED12L 4.79E-06 
3607275 ISG20 3.56E-09  3552847 DYNC1H1 2.28E-07  2373336 CFH 1.25E-06  2320727 TNFRSF1B 4.80E-06 
2508611 ARHGAP15 4.52E-09  3310479 NSMCE4A 2.32E-07  2698738 XRN1 1.26E-06  2986546 PDCD2 5.11E-06 
3820865 CARM1 6.50E-09  2852591 ADAMTS12 2.33E-07  2866704 ARRDC3 1.26E-06  2524653 ADAM23 5.19E-06 
3311269 FAM53B 8.21E-09  3923436 TRAPPC10 2.83E-07  2372781 RGS1 1.27E-06  3831831 HKR1 5.21E-06 
3110999 OXR1 8.39E-09  2532699 INPP5D 2.95E-07  3387033 MRE11A 1.55E-06  3654859 ATXN2L 5.26E-06 
2888485 HK3 9.27E-09  3339261 IL18BP 3.05E-07  2621122 NBEAL2 1.57E-06  2831719 ANKHD1 5.69E-06 
3548346 CALM1 9.71E-09  3082248 ESYT2 3.36E-07  2789957 FBXW7 1.64E-06  2548970 SRSF7 6.17E-06 
2809128 ITGA1 1.27E-08  3795680 THOC1 3.46E-07  3860003 PRODH2 1.88E-06  3498502 TM9SF2 6.66E-06 
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2560076 RTKN 7.21E-06  3841157 CACNG8 1.73E-05  3466206 TMCC3 2.87E-05  3063685 MCM7 4.21E-05 
3868183 NUP62 7.63E-06  2340845 MIER1 1.75E-05  4012511 NAP1L2 2.98E-05  2619344 NKTR 4.24E-05 
3190463 ODF2 7.71E-06  3335517 KAT5 1.75E-05  2949885 GPSM3 3.01E-05  3703799 KLHDC4 4.27E-05 
2522616 CFLAR 7.90E-06  2520429 MYO1B 1.79E-05  3391816 USP28 3.02E-05  3261544 GBF1 4.42E-05 
3655140 NFATC2IP 7.95E-06  3665550 FAM65A 1.89E-05  3418214 MBD6 3.05E-05  2609960 TTLL3 4.43E-05 
3771513 PRPSAP1 8.33E-06  3282463 MKX 1.92E-05  2927506 TNFAIP3 3.09E-05  2991233 AHR 4.68E-05 
3744229 TMEM107 8.81E-06  3192693 CEL 1.93E-05  3551935 WDR25 3.12E-05  3457101 ITGA7 4.71E-05 
3354879 HYLS1 8.99E-06  2414505 C8B 1.98E-05  3976299 ARAF 3.20E-05  3850859 RGL3 4.76E-05 
3529601 FITM1 9.42E-06  3952360 PRODH 2.00E-05  2363248 LY9 3.23E-05  3690388 ABCC12 4.79E-05 
2714132 PDE6B 9.63E-06  2446198 TOR1AIP2 2.01E-05  3744263 AURKB 3.25E-05  3042421 HNRNPA2B1 4.86E-05 
3693183 CIAPIN1 9.76E-06  3000984 ABCA13 2.07E-05  3568310 ZBTB25 3.31E-05  3908963 B4GALT5 4.94E-05 
2920962 FIG4 9.98E-06  3986647 VSIG1 2.12E-05  3670772 CMIP 3.40E-05  3704299 MVD 4.95E-05 
2546795 CAPN13 1.00E-05  2321238 PRDM2 2.13E-05  3383081 INTS4 3.41E-05  4002081 MAP7D2 4.99E-05 
3741585 ITGAE 1.05E-05  2322103 SPEN 2.22E-05  3703164 COX4NB 3.49E-05  3417249 ERBB3 5.05E-05 
3120887 ZNF517 1.07E-05  3739679 VPS53 2.32E-05  2674229 GPX1 3.57E-05  3182409 ZNF189 5.07E-05 
3057550 STYXL1 1.09E-05  3381377 FCHSD2 2.32E-05  3740479 PRPF8 3.57E-05  3257559 RPP30 5.24E-05 
3354174 TBRG1 1.14E-05  2673937 QARS 2.34E-05  3914072 ARFRP1 3.63E-05  2788511 SLC10A7 5.26E-05 
2692573 CCDC14 1.27E-05  3933999 U2AF1 2.37E-05  2732844 ANXA3 3.78E-05  3284596 PARD3 5.29E-05 
3762198 COL1A1 1.28E-05  2992197 SP4 2.48E-05  3194635 C9orf86 3.87E-05  3119945 GRINA 5.32E-05 
2800906 MTRR 1.33E-05  2491615 MAT2A 2.50E-05  3750740 PIGS 3.88E-05  2406677 STK40 5.41E-05 
3721956 TUBG2 1.35E-05  2877028 KLHL3 2.50E-05  4011464 PJA1 3.90E-05  2539125 CMPK2 5.42E-05 
4015602 TRMT2B 1.37E-05  2623922 STAB1 2.59E-05  2655387 EIF2B5 3.95E-05  3190394 URM1 5.60E-05 
2318086 KCNAB2 1.40E-05  2889382 PROP1 2.63E-05  2934801 MAP3K4 3.96E-05  3011861 STEAP2 5.68E-05 
3335600 SNX32 1.42E-05  3795312 CTDP1 2.64E-05  2673312 PFKFB4 3.96E-05  3961955 PHF5A 5.73E-05 
4025339 IDS 1.42E-05  3556418 METTL3 2.66E-05  2806799 NIPBL 3.97E-05  2826159 SNCAIP 5.75E-05 
3634852 RASGRF1 1.45E-05  3706736 TMEM93 2.68E-05  3942648 TUG1 4.03E-05  3653317 RBBP6 5.76E-05 
3770944 H3F3B 1.46E-05  2827709 ISOC1 2.76E-05  3620380 PLA2G4D 4.05E-05  2362892 ATP1A2 6.01E-05 
3225003 PSMB7 1.50E-05  3273601 IDI1 2.77E-05  3147321 UBR5 4.09E-05  2442800 ADCY10 6.05E-05 
3656829 BCKDK 1.54E-05  3449368 CAPRIN2 2.79E-05  3933550 TFF2 4.11E-05  2590452 CERKL 6.05E-05 
3441941 VAMP1 1.56E-05  2551327 SRBD1 2.81E-05  3962997 EFCAB6 4.11E-05  3772581 USP36 6.14E-05 
3535125 ATP5S 1.65E-05  2402536 TRIM63 2.82E-05  2758978 EVC2 4.12E-05  3023318 TSPAN33 6.17E-05 
3445643 HIST4H4 1.66E-05  2623180 RAD54L2 2.82E-05  3168415 CLTA 4.13E-05  3334954 CAPN1 6.17E-05 
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3141857 TPD52 6.33E-05  3620880 UBR1 9.78E-05  3029129 ZYX 1.29E-04  2326912 WDTC1 1.68E-04 
3743611 NEURL4 6.35E-05  3490504 ALG11 9.92E-05  3260895 SEMA4G 1.30E-04  2389247 KIF26B 1.69E-04 
3911177 ZBP1 6.45E-05  3261723 TMEM180 1.00E-04  2798952 NKD2 1.31E-04  2730257 C4orf40 1.70E-04 
2346074 ZNF326 6.62E-05  2823820 WDR36 1.01E-04  2638988 PARP15 1.31E-04  3757690 KCNH4 1.71E-04 
3068519 C7orf60 6.73E-05  3708764 TNFSF12-13 1.02E-04  3442427 LPCAT3 1.31E-04  2442493 GPA33 1.75E-04 
2957499 ICK 6.98E-05  3859761 DMKN 1.03E-04  2475042 PLB1 1.33E-04  3655708 C16orf53 1.77E-04 
3164181 RRAGA 7.04E-05  3942179 MTMR3 1.03E-04  3960061 RAC2 1.34E-04  2886130 PANK3 1.80E-04 
2905664 ZFAND3 7.36E-05  3923257 PDXK 1.04E-04  2775994 HPSE 1.35E-04  3647504 PMM2 1.80E-04 
2621333 PTPN23 7.37E-05  3228007 SETX 1.04E-04  3625052 WDR72 1.39E-04  3484768 PDS5B 1.81E-04 
2425118 SASS6 7.38E-05  2592268 STAT1 1.07E-04  2903034 CYP21A2 1.40E-04  3685610 ARHGAP17 1.86E-04 
2491386 TCF7L1 7.42E-05  3360941 ARFIP2 1.09E-04  3290210 ZWINT 1.45E-04  3454006 FMNL3 1.86E-04 
2462329 ERO1LB 7.51E-05  2560625 FAM176A 1.10E-04  2443335 SLC19A2 1.48E-04  2659676 LOC152217 1.89E-04 
3903836 EIF6 7.54E-05  3118818 PTP4A3 1.11E-04  3279698 CUBN 1.48E-04  3229741 LHX3 1.90E-04 
3514639 DHRS12 7.54E-05  3692280 IRX3 1.11E-04  3771037 WBP2 1.51E-04  3837081 NPAS1 1.90E-04 
3034987 ADAP1 7.61E-05  2847264 MED10 1.13E-04  3398482 SNX19 1.52E-04  3010503 CD36 1.92E-04 
2450568 CACNA1S 7.75E-05  3349660 HTR3B 1.15E-04  3634588 WDR61 1.54E-04  2991395 HDAC9 1.93E-04 
3645549 CLDN9 7.94E-05  3701433 C16orf46 1.16E-04  2686646 SENP7 1.54E-04  2332999 WDR65 1.94E-04 
3663055 C16orf57 7.99E-05  3976766 WAS 1.16E-04  3848745 FBN3 1.56E-04  3040073 SNX13 1.94E-04 
3773174 CBX4 8.01E-05  3108901 VPS13B 1.16E-04  3962678 PACSIN2 1.56E-04  3398754 C11orf39 1.95E-04 
3846403 MATK 8.03E-05  4018080 CHRDL1 1.16E-04  2390489 ZNF672 1.57E-04  3204721 TPM2 1.97E-04 
2903574 B3GALT4 8.19E-05  3380365 SHANK2 1.19E-04  3304301 PSD 1.58E-04  3222534 ASTN2 2.09E-04 
3452865 COL2A1 8.20E-05  2440625 DEDD 1.19E-04  3268669 BUB3 1.59E-04  3597603 USP3 2.09E-04 
3633890 SCAPER 8.24E-05  3259087 C10orf129 1.20E-04  3475679 ZCCHC8 1.59E-04  2878987 PCDH12 2.09E-04 
3387771 CCDC82 8.43E-05  3977651 MAGED1 1.20E-04  2369110 RASAL2 1.61E-04  3336238 DPP3 2.10E-04 
3686080 NSMCE1 8.63E-05  3335952 PACS1 1.21E-04  2942432 C6orf114 1.61E-04  2755897 MGC39584 2.13E-04 
2756673 GAK 8.71E-05  4000704 AP1S2 1.22E-04  3866135 PRKD2 1.61E-04  2904788 C6orf81 2.14E-04 
2550790 LRPPRC 8.82E-05  3804000 INO80C 1.22E-04  3886889 PIGT 1.62E-04  3276337 ITIH5 2.15E-04 
3036985 RNF216 8.94E-05  3994964 GPR50 1.25E-04  3679812 GRIN2A 1.62E-04  3894545 SDCBP2 2.18E-04 
3822849 CLEC17A 9.41E-05  3741800 ATP2A3 1.26E-04  3085874 MTMR9 1.63E-04  3761395 HOXB6 2.19E-04 
3301556 TCTN3 9.50E-05  3768015 HELZ 1.27E-04  3867796 TEAD2 1.63E-04  2426385 VAV3 2.20E-04 
3846238 C19orf28 9.56E-05  2789266 LRBA 1.27E-04  2459793 C1orf96 1.64E-04  2342176 FPGT 2.22E-04 
2881370 CD74 9.62E-05  2876011 SKP1 1.27E-04  3028011 MGAM 1.65E-04  3281068 PIP4K2A 2.22E-04 
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2616596 ARPP21 2.24E-04  3035892 GNA12 2.99E-04  2835792 GM2A 3.75E-04  2319225 H6PD 4.71E-04 
3754469 ACACA 2.28E-04  2673594 CELSR3 2.99E-04  3592214 DUOX1 3.84E-04  3662876 CCDC135 4.73E-04 
3639031 PRC1 2.30E-04  3241316 ZEB1 3.03E-04  3741715 CAMKK1 3.88E-04  3750767 ALDOC 4.74E-04 
3846363 APBA3 2.31E-04  2626097 ABHD6 3.05E-04  3240340 WAC 3.89E-04  3619595 FAM82A2 4.79E-04 
2870828 STARD4 2.33E-04  3939498 SLC2A11 3.07E-04  2407496 POU3F1 3.98E-04  2742224 SPRY1 4.79E-04 
2769810 KDR 2.36E-04  2962525 IBTK 3.09E-04  2580304 ORC4 3.99E-04  2420790 C1orf52 4.80E-04 
2694817 PLXND1 2.39E-04  3922369 UMODL1 3.09E-04  2326954 TMEM222 4.09E-04  3075550 ZC3HAV1L 4.83E-04 
3326183 CAPRIN1 2.42E-04  3803194 TRAPPC8 3.10E-04  2389834 LOC149134 4.10E-04  3838757 SCAF1 4.89E-04 
3035464 MAD1L1 2.45E-04  3708399 SLC2A4 3.14E-04  3529064 BCL2L2 4.13E-04  3907335 SPINLW1 4.90E-04 
3304718 PCGF6 2.47E-04  3699335 LDHD 3.14E-04  3470734 FOXN4 4.15E-04  3204833 GBA2 4.92E-04 
2697490 CEP70 2.51E-04  2978989 LATS1 3.15E-04  3119017 BAI1 4.18E-04  3947604 BIK 4.94E-04 
3391029 PPP2R1B 2.54E-04  2832115 PCDHA12 3.20E-04  3758606 SOST 4.18E-04  3735107 SAP30BP 4.94E-04 
2767710 KCTD8 2.58E-04  3716411 CPD 3.20E-04  2909404 CD2AP 4.25E-04  2399908 TMCO4 4.95E-04 
3743906 TP53 2.58E-04  3147508 KLF10 3.21E-04  2960399 C6orf155 4.26E-04  2935475 QKI 4.99E-04 
2608801 EDEM1 2.60E-04  2766588 PDS5A 3.21E-04  2798586 AHRR 4.27E-04  2395245 RERE 5.01E-04 
3870449 VSTM1 2.65E-04  2655845 EPHB3 3.25E-04  3731228 CCDC45 4.27E-04  3862452 CNTD2 5.02E-04 
2418000 ZRANB2 2.66E-04  3951719 CECR6 3.26E-04  3672455 COX4I1 4.27E-04  2620538 LARS2 5.08E-04 
3446919 ABCC9 2.69E-04  2881165 TIGD6 3.32E-04  2570616 BUB1 4.29E-04  2731257 AFM 5.09E-04 
2904563 DEF6 2.72E-04  3815834 DAZAP1 3.36E-04  2544238 ITSN2 4.29E-04  3557504 MYH7 5.12E-04 
3875642 PLCB1 2.73E-04  3038065 ICA1 3.38E-04  3457201 SARNP 4.37E-04  3696016 PSMB10 5.14E-04 
3178611 SECISBP2 2.80E-04  2800503 PAPD7 3.40E-04  3814033 MBP 4.50E-04  3368054 PAX6 5.26E-04 
2321813 CELA2A 2.81E-04  2510713 FMNL2 3.46E-04  2817291 JMY 4.50E-04  3893033 DPH3P1 5.28E-04 
3453513 WNT10B 2.84E-04  3308619 PDZD8 3.46E-04  3742627 C17orf87 4.51E-04  3647632 C16orf72 5.30E-04 
2337147 ACOT11 2.88E-04  3907652 NCOA5 3.47E-04  3927949 LTN1 4.54E-04  3897505 JAG1 5.31E-04 
3305313 ITPRIP 2.88E-04  3458837 METTL1 3.47E-04  3461341 CPM 4.58E-04  3989180 MCTS1 5.43E-04 
3709244 CHD3 2.89E-04  3761291 HOXB2 3.48E-04  3924674 DIP2A 4.59E-04  3707990 TXNDC17 5.47E-04 
3104489 STMN2 2.89E-04  2634965 BBX 3.50E-04  3436117 DNAH10 4.60E-04  3844512 THEG 5.49E-04 
3746040 ELAC2 2.90E-04  4011096 EDA2R 3.51E-04  3660213 CYLD 4.60E-04  3494629 SCEL 5.50E-04 
3995975 SSR4 2.92E-04  2438657 ARHGEF11 3.53E-04  3458337 STAT6 4.62E-04  3548929 RIN3 5.52E-04 
2882897 GEMIN5 2.92E-04  3620421 PLA2G4F 3.54E-04  2525533 MAP2 4.66E-04  3779817 CEP192 5.53E-04 
2403261 IFI6 2.96E-04  3226804 SH3GLB2 3.59E-04  3764471 MTMR4 4.67E-04  3405032 ETV6 5.63E-04 
3373795 PRG3 2.97E-04  3380142 FGF4 3.62E-04  3621029 EPB42 4.69E-04  3017547 MLL5 5.74E-04 
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2475911 EHD3 5.78E-04  3021158 C7orf58 6.81E-04  3551407 HHIPL1 8.24E-04  3023103 CCDC136 9.39E-04 
3716113 TP53I13 5.83E-04  3934439 DNMT3L 6.87E-04  3016692 PRKRIP1 8.28E-04  3076076 SLC37A3 9.42E-04 
2706297 TBL1XR1 5.85E-04  3020496 ST7 6.92E-04  3750369 NOS2 8.29E-04  2543066 C2orf43 9.52E-04 
3709010 DNAH2 5.93E-04  3219788 EPB41L4B 7.02E-04  2360186 AQP10 8.34E-04  3056838 WBSCR16 9.59E-04 
2392528 PANK4 5.94E-04  2927604 KIAA1244 7.04E-04  3119289 GML 8.37E-04  3954545 ZNF280A 9.60E-04 
3274361 KLF6 5.94E-04  2606026 HDAC4 7.10E-04  3329206 CREB3L1 8.38E-04  3272761 PRAP1 9.77E-04 
3249788 CCAR1 5.99E-04  3846076 TLE2 7.12E-04  4041300 FAM195B 8.46E-04  4015763 GLA 9.88E-04 
3735447 FAM100B 6.02E-04  3619773 INO80 7.18E-04  3723378 FMNL1 8.48E-04  2809885 SKIV2L2 9.91E-04 
2404766 SPOCD1 6.03E-04  3278977 DCLRE1C 7.22E-04  3474935 ANAPC5 8.49E-04  2954771 GTPBP2 9.94E-04 
3393796 --- 6.08E-04  3451246 GXYLT1 7.25E-04  2968144 OSTM1 8.51E-04  3872542 ZNF418 9.95E-04 
3591909 CTDSPL2 6.09E-04  2360310 TDRD10 7.30E-04  3893796 DNAJC5 8.51E-04  3434681 HNF1A 1.01E-03 
2331822 ZMPSTE24 6.13E-04  2359780 NPR1 7.44E-04  3666897 WWP2 8.51E-04  2363679 --- 1.03E-03 
2636786 TIGIT 6.16E-04  3836317 VASP 7.47E-04  2947889 GABBR1 8.56E-04  2327283 C1orf38 1.03E-03 
3416577 NCKAP1L 6.17E-04  3335751 TSGA10IP 7.47E-04  3454680 TFCP2 8.59E-04  3051907 PHKG1 1.04E-03 
2955282 SUPT3H 6.24E-04  3488253 COG3 7.52E-04  2902463 BAT2 8.77E-04  2316953 PRDM16 1.04E-03 
3036476 RADIL 6.24E-04  3186137 ORM2 7.52E-04  2565119 DUSP2 8.84E-04  3088048 NSAP11 1.04E-03 
2408477 SLFNL1 6.26E-04  4051619 EXD3 7.53E-04  2566021 ACTR1B 8.85E-04  2542795 SDC1 1.04E-03 
3456260 ATF7 6.30E-04  3181417 ANP32B 7.54E-04  3455388 KRT75 8.85E-04  2890326 TBC1D9B 1.05E-03 
4029079 TBL1Y 6.31E-04  3394412 THY1 7.56E-04  3886765 PI3 8.88E-04  3154700 ZFAT 1.05E-03 
3791341 ZCCHC2 6.33E-04  3978819 RRAGB 7.57E-04  2869124 SLCO6A1 8.91E-04  3687752 SEPT1 1.06E-03 
3881443 TPX2 6.37E-04  2434746 FAM63A 7.60E-04  3229837 CARD9 8.92E-04  3853814 EPS15L1 1.07E-03 
2776305 NKX6-1 6.37E-04  3701297 CDYL2 7.67E-04  2375916 SOX13 8.93E-04  3155937 TRAPPC9 1.07E-03 
3012213 FZD1 6.37E-04  4002173 RPS6KA3 7.69E-04  3790704 PMAIP1 8.96E-04  3629811 DENND4A 1.07E-03 
3825260 KLHL26 6.39E-04  3414390 SMARCD1 7.73E-04  3132940 ANK1 8.97E-04  3352070 CBL 1.08E-03 
3474885 CAMKK2 6.41E-04  2832963 KIAA0141 7.77E-04  3146103 STK3 9.00E-04  2967249 BVES 1.09E-03 
2899216 HIST1H4E 6.50E-04  3576812 TRIP11 7.80E-04  2369843 CEP350 9.03E-04  3766651 ERN1 1.09E-03 
2524301 NRP2 6.53E-04  2489228 WDR54 7.84E-04  3431553 C12orf24 9.16E-04  3439603 KDM5A 1.09E-03 
3617230 C15orf24 6.54E-04  2428313 ST7L 7.93E-04  3902609 PDRG1 9.18E-04  3976930 PQBP1 1.10E-03 
3720739 CASC3 6.58E-04  3976716 WDR13 7.93E-04  3655806 TMEM219 9.21E-04  3045338 AAA1 1.10E-03 
3396249 HEPACAM 6.63E-04  2413943 USP24 7.98E-04  3029030 CASP2 9.21E-04  2327630 YTHDF2 1.10E-03 
3815165 PTBP1 6.70E-04  3862661 BLVRB 7.99E-04  3892409 LSM14B 9.26E-04  3819016 STXBP2 1.11E-03 
3413875 TROAP 6.74E-04  3859946 HSPB6 8.02E-04  2725332 TMEM33 9.32E-04  3897280 PAK7 1.11E-03 
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3768969 ABCA5 1.12E-03  3883207 PROCR 1.31E-03  2612401 BTD 1.48E-03  3190939 PPP2R4 1.69E-03 
2453881 IRF6 1.13E-03  2651671 MYNN 1.34E-03  2646818 ZIC1 1.50E-03  3569441 ZFYVE26 1.71E-03 
2453370 PLXNA2 1.13E-03  2703750 SI 1.34E-03  2391255 UBE2J2 1.51E-03  3188780 GPR144 1.71E-03 
3685051 USP31 1.13E-03  3000010 ZMIZ2 1.34E-03  3944129 HMOX1 1.53E-03  4007919 CACNA1F 1.71E-03 
2328465 KHDRBS1 1.13E-03  2316905 ACTRT2 1.34E-03  3394315 C1QTNF5 1.54E-03  3437801 PIWIL1 1.72E-03 
3726569 SPATA20 1.13E-03  3188299 RABGAP1 1.34E-03  3422231 TMEM19 1.55E-03  2609560 THUMPD3 1.73E-03 
3542847 SIPA1L1 1.14E-03  2662698 ATP2B2 1.35E-03  3188111 PTGS1 1.55E-03  3165825 TEK 1.73E-03 
3202421 C9orf72 1.16E-03  3773244 TBC1D16 1.35E-03  3444820 LRP6 1.56E-03  3336277 BBS1 1.74E-03 
3035281 INTS1 1.19E-03  3217167 CORO2A 1.35E-03  2448232 TPR 1.56E-03  3712675 RAI1 1.75E-03 
3663287 NDRG4 1.19E-03  3995885 PLXNB3 1.36E-03  3733275 KCNJ2 1.56E-03  3030799 KRBA1 1.76E-03 
3707141 ZMYND15 1.20E-03  2825514 DMXL1 1.37E-03  3249738 HNRNPH3 1.56E-03  3166844 CHMP5 1.76E-03 
3572278 NEK9 1.20E-03  2555277 USP34 1.38E-03  3665230 HSF4 1.57E-03  2453006 PIGR 1.80E-03 
2416522 JAK1 1.20E-03  2948630 IER3 1.39E-03  3507465 SLC46A3 1.57E-03  2759654 ABLIM2 1.81E-03 
3189545 LMX1B 1.21E-03  3523881 KDELC1 1.39E-03  2414958 TACSTD2 1.58E-03  3167553 IL11RA 1.81E-03 
3991992 ZNF449 1.21E-03  2943434 ATXN1 1.39E-03  2774365 CCNI 1.59E-03  2726483 OCIAD1 1.81E-03 
3646542 ALG1 1.22E-03  3484641 BRCA2 1.40E-03  2950384 COL11A2 1.60E-03  3995633 BGN 1.82E-03 
3881874 ASXL1 1.22E-03  2845879 CLPTM1L 1.40E-03  2550542 THADA 1.60E-03  3103062 KCNB2 1.83E-03 
2759158 JAKMIP1 1.22E-03  3381241 ARAP1 1.40E-03  2553282 PSME4 1.60E-03  3758615 DUSP3 1.83E-03 
2845043 TRIM41 1.24E-03  3852743 GIPC1 1.42E-03  3515009 VPS36 1.61E-03  2622607 SLC38A3 1.83E-03 
3627363 NARG2 1.24E-03  3833443 PLD3 1.42E-03  2437577 YY1AP1 1.61E-03  3919124 FAM165B 1.84E-03 
3231774 GTPBP4 1.24E-03  2897635 CDKAL1 1.44E-03  3403045 ATN1 1.61E-03  2441386 RGS5 1.85E-03 
3033209 INSIG1 1.25E-03  2415910 DOCK7 1.44E-03  2340695 SGIP1 1.61E-03  3288707 ERCC6 1.85E-03 
3188050 MRRF 1.25E-03  3371303 PEX16 1.44E-03  2673684 IP6K2 1.62E-03  2622638 GNAI2 1.86E-03 
3815210 AZU1 1.26E-03  2623568 PPM1M 1.44E-03  3449008 OVCH1 1.64E-03  3817116 TJP3 1.86E-03 
3387469 --- 1.27E-03  2334098 KIF2C 1.45E-03  2358136 C1orf51 1.65E-03  3374083 MED19 1.86E-03 
3017123 PMPCB 1.27E-03  3376914 NRXN2 1.45E-03  3603199 IDH3A 1.66E-03  3924929 BAGE2 1.87E-03 
2401448 E2F2 1.28E-03  2862380 ANKRA2 1.45E-03  3620590 ZFP106 1.66E-03  2953751 PGC 1.87E-03 
3405748 EMP1 1.29E-03  3427820 SLC25A3 1.46E-03  2705690 GHSR 1.68E-03  3842456 NLRP4 1.87E-03 
2478748 EML4 1.29E-03  2907754 CUL9 1.46E-03  4000370 FANCB 1.68E-03  3588125 C15orf55 1.88E-03 
2689378 DRD3 1.30E-03  3217395 ANKS6 1.46E-03  3601889 LMAN1L 1.68E-03  3715368 NLK 1.89E-03 
3847590 RFX2 1.30E-03  3866605 NAPA 1.47E-03  3624410 BCL2L10 1.69E-03  3803882 ZSCAN30 1.89E-03 
2322957 ARHGEF10L 1.30E-03  2565246 TMEM127 1.48E-03  3908631 PREX1 1.69E-03  2333599 IPO13 1.89E-03 
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3958475 SYN3 1.90E-03  3406179 H2AFJ 2.14E-03  3466110 CCDC41 2.39E-03  2363444 USP21 2.65E-03 
2796995 SORBS2 1.91E-03  3678516 NAGPA 2.15E-03  2948713 RDBP 2.39E-03  3362263 DENND5A 2.66E-03 
2337392 BSND 1.92E-03  3308489 KIAA1598 2.20E-03  3345427 ENDOD1 2.40E-03  3843848 ZNF544 2.67E-03 
3208995 KLF9 1.94E-03  2889542 COL23A1 2.20E-03  2669488 PLCD1 2.41E-03  3329983 PTPRJ 2.68E-03 
3815757 MUM1 1.94E-03  4021433 ELF4 2.20E-03  3981164 ACRC 2.42E-03  2428699 PHTF1 2.69E-03 
3597125 TLN2 1.94E-03  2557759 CNRIP1 2.21E-03  3614305 ATP10A 2.42E-03  3463727 LIN7A 2.72E-03 
3972862 MAGEB1 1.95E-03  3013054 COL1A2 2.21E-03  3988874 UBE2A 2.43E-03  3793760 CNDP2 2.73E-03 
3833040 SUPT5H 1.95E-03  3774029 NPLOC4 2.21E-03  2525989 CPS1 2.44E-03  3182019 STX17 2.74E-03 
3817984 SAFB 1.96E-03  3656665 ORAI3 2.21E-03  3190151 SLC25A25 2.44E-03  3403140 EMG1 2.75E-03 
3942838 LIMK2 1.96E-03  3278198 PHYH 2.22E-03  2763805 DHX15 2.44E-03  3393311 DSCAML1 2.75E-03 
3178952 SYK 1.96E-03  3420442 IRAK3 2.23E-03  3681377 PARN 2.45E-03  2793221 NEK1 2.76E-03 
3990512 SASH3 1.97E-03  2440354 CD48 2.23E-03  3802254 KCTD1 2.45E-03  2699844 ZIC4 2.76E-03 
3082373 VIPR2 1.97E-03  3766269 LIMD2 2.24E-03  2843163 GRK6 2.48E-03  3428783 DRAM1 2.77E-03 
3303774 LBX1 1.99E-03  3549033 GOLGA5 2.27E-03  3498589 CLYBL 2.49E-03  3867032 CCDC114 2.77E-03 
3443464 PZP 1.99E-03  3187577 CEP110 2.28E-03  3416036 PCBP2 2.49E-03  2660648 CRBN 2.79E-03 
2723605 C4orf19 1.99E-03  3447798 CASC1 2.28E-03  3918098 C21orf119 2.49E-03  3913821 KCNQ2 2.80E-03 
2495555 UNC50 1.99E-03  2910364 TMEM14A 2.28E-03  2955638 CLIC5 2.53E-03  2507209 CCNT2 2.81E-03 
2913123 RIMS1 1.99E-03  2952102 MTCH1 2.29E-03  3849044 MYO1F 2.53E-03  3358262 DEAF1 2.82E-03 
3870054 ZNF160 2.00E-03  3293390 NODAL 2.30E-03  3778372 TWSG1 2.54E-03  2454532 INTS7 2.84E-03 
2742093 BBS12 2.00E-03  2732068 SHROOM3 2.30E-03  3822551 IL27RA 2.54E-03  2975385 AHI1 2.84E-03 
3850725 DOCK6 2.00E-03  2692883 MUC13 2.30E-03  2451463 ADIPOR1 2.55E-03  3456212 MAP3K12 2.87E-03 
2376548 MFSD4 2.01E-03  2858134 PDE4D 2.30E-03  2476411 TTC27 2.56E-03  3679564 USP7 2.88E-03 
3642060 CHSY1 2.01E-03  3541137 EIF2S1 2.30E-03  4006326 EFHC2 2.56E-03  3707596 --- 2.88E-03 
3521484 UGGT2 2.01E-03  3866117 DACT3 2.31E-03  3797015 ZFP161 2.56E-03  3470927 TRPV4 2.88E-03 
3758692 MPP2 2.04E-03  3847356 LONP1 2.31E-03  3431483 ATP2A2 2.56E-03  3403015 ENO2 2.89E-03 
3729123 DHX40 2.05E-03  3348891 C11orf57 2.34E-03  3677356 HCFC1R1 2.58E-03  2704441 MECOM 2.90E-03 
3557069 CDH24 2.05E-03  2437871 SSR2 2.36E-03  3278234 SEPHS1 2.58E-03  2876793 TRPC7 2.90E-03 
3044518 NEUROD6 2.06E-03  3358854 DUSP8 2.37E-03  2486520 ETAA1 2.58E-03  3736087 TNRC6C 2.91E-03 
3180880 LOC158435 2.06E-03  3041875 OSBPL3 2.37E-03  3940124 UPB1 2.60E-03  3087703 PDGFRL 2.92E-03 
3083936 AGPAT5 2.08E-03  3861738 SARS2 2.38E-03  3908786 STAU1 2.60E-03  2334986 CYP4X1 2.92E-03 
2467249 ALLC 2.10E-03  2343823 LPHN2 2.38E-03  2555490 XPO1 2.61E-03  3624448 GNB5 2.92E-03 
2598868 TNP1 2.12E-03  3489212 FNDC3A 2.38E-03  2976417 PBOV1 2.62E-03  2515707 PDK1 2.92E-03 
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2916502 SPACA1 2.95E-03  2951916 STK38 3.43E-03  3209623 ZFAND5 3.80E-03  2655438 DVL3 4.13E-03 
3063795 GAL3ST4 2.97E-03  2409507 SLC6A9 3.44E-03  2967151 HACE1 3.81E-03  2443476 SELE 4.15E-03 
3507798 UBL3 2.98E-03  3896034 RASSF2 3.46E-03  3820571 ATG4D 3.81E-03  3103494 TMEM70 4.16E-03 
2317512 DFFB 2.98E-03  3120917 ZNF7 3.47E-03  3853495 PGLYRP2 3.83E-03  3715489 TMEM97 4.16E-03 
2898971 HIST1H2BA 2.99E-03  3279108 NMT2 3.47E-03  2896177 JARID2 3.85E-03  2663130 TIMP4 4.16E-03 
3158190 --- 3.02E-03  3811339 BCL2 3.49E-03  3865344 PPP1R13L 3.86E-03  2890148 HNRNPH1 4.18E-03 
3652489 POLR3E 3.02E-03  3150715 DSCC1 3.51E-03  3048517 CAMK2B 3.86E-03  2618665 ZNF619 4.19E-03 
3861352 GGN 3.04E-03  2887164 SH3PXD2B 3.52E-03  2793054 CBR4 3.87E-03  3675285 WDR24 4.20E-03 
2334404 NASP 3.07E-03  3698422 C16orf47 3.54E-03  2737257 MTTP 3.87E-03  2467691 TTC15 4.20E-03 
3373962 UBE2L6 3.07E-03  3544905 C14orf118 3.55E-03  2842530 ARL10 3.90E-03  3816225 IZUMO4 4.21E-03 
4011008 VSIG4 3.08E-03  3450775 KIF21A 3.56E-03  3114111 FAM83A 3.95E-03  3686339 XPO6 4.21E-03 
2783207 PRSS12 3.09E-03  3419239 MON2 3.57E-03  3614774 OCA2 3.96E-03  3713627 SLC5A10 4.22E-03 
3077004 TRYX3 3.11E-03  2527747 SLC11A1 3.58E-03  2471978 RHOB 3.99E-03  3646156 VASN 4.22E-03 
2746693 ARHGAP10 3.14E-03  3401920 GALNT8 3.58E-03  3268274 PLEKHA1 3.99E-03  3853658 CYP4F11 4.22E-03 
3938175 UBE2L3 3.18E-03  3633236 RPP25 3.59E-03  2532399 CHRNG 3.99E-03  3545564 ADCK1 4.23E-03 
3232944 AKR1E2 3.19E-03  3436082 DNAH10 3.60E-03  3499453 TPP2 3.99E-03  2393654 KIAA0495 4.23E-03 
3893910 TCEA2 3.20E-03  2726828 DCUN1D4 3.60E-03  3903525 NCOA6 4.00E-03  2771342 EPHA5 4.25E-03 
3571059 DPF3 3.25E-03  2572909 EN1 3.61E-03  3289948 PCDH15 4.00E-03  2438792 ETV3 4.25E-03 
3716337 CCDC55 3.26E-03  2473735 HADHB 3.61E-03  3444195 MAGOHB 4.01E-03  3839880 --- 4.27E-03 
2816681 PDE8B 3.27E-03  3915936 NCAM2 3.61E-03  3649714 C16orf45 4.01E-03  3844656 POLRMT 4.27E-03 
3191695 EXOSC2 3.28E-03  3832256 SPINT2 3.62E-03  4019486 SEPT6 4.02E-03  3464912 POC1B 4.27E-03 
3871302 HSPBP1 3.28E-03  3532313 SRP54 3.62E-03  3458857 AVIL 4.02E-03  2762468 DCAF16 4.27E-03 
3686750 RABEP2 3.30E-03  3816645 ZNF554 3.64E-03  3699634 TMEM231 4.02E-03  4007617 PIM2 4.31E-03 
3818596 EMR1 3.30E-03  3305081 COL17A1 3.66E-03  3216356 CDC14B 4.04E-03  2372924 TROVE2 4.32E-03 
3854311 USHBP1 3.31E-03  3290649 FAM13C 3.67E-03  2360728 TRIM46 4.04E-03  3381150 PDE2A 4.32E-03 
2573232 TMEM185B 3.35E-03  3557791 FAM158A 3.69E-03  3531163 COCH 4.04E-03  3765299 APPBP2 4.32E-03 
3096368 HOOK3 3.37E-03  3626826 MYO1E 3.69E-03  3065638 DNAJC2 4.04E-03  3471538 FAM109A 4.33E-03 
2946146 SLC17A2 3.38E-03  3236448 SUV39H2 3.71E-03  3845175 GAMT 4.08E-03  3214668 IARS 4.34E-03 
3601741 CLK3 3.40E-03  3666033 NFATC3 3.71E-03  3656418 SRCAP 4.08E-03  3693083 FAM192A 4.36E-03 
3450899 SLC2A13 3.40E-03  2438531 HDGF 3.75E-03  3464967 GALNT4 4.08E-03  2378121 TRAF3IP3 4.37E-03 
2934089 WTAP 3.42E-03  2624565 IL17RB 3.76E-03  2557948 BMP10 4.09E-03  2408111 TRIT1 4.38E-03 
3451814 NELL2 3.42E-03  2362351 PYHIN1 3.76E-03  3197509 RLN1 4.10E-03  2669803 SCN11A 4.39E-03 
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2692319 ADCY5 4.43E-03  3713794 EPN2 4.88E-03  3855701 --- 5.42E-03  3620022 LTK 5.98E-03 
3174121 MAMDC2 4.45E-03  3715839 TRAF4 4.90E-03  2866543 CETN3 5.43E-03  2746645 TMEM184C 5.99E-03 
3414632 DIP2B 4.47E-03  3529113 CMTM5 4.91E-03  3948528 UPK3A 5.45E-03  3719474 TADA2A 6.04E-03 
3080033 MLL3 4.47E-03  3707041 SMTNL2 4.93E-03  2813414 CCNB1 5.46E-03  3087167 TUSC3 6.05E-03 
3158478 FBXL6 4.50E-03  3777991 KIAA0802 4.93E-03  3961023 CBX7 5.47E-03  3554104 KIF26A 6.06E-03 
3620741 CDAN1 4.52E-03  2427898 OVGP1 4.94E-03  3947011 C22orf46 5.48E-03  3522327 SLC15A1 6.06E-03 
3016791 LRWD1 4.52E-03  3597421 LACTB 4.97E-03  2479560 ABCG8 5.49E-03  3199431 ZDHHC21 6.07E-03 
3368304 WT1 4.55E-03  2555174 PUS10 4.99E-03  2544781 DTNB 5.49E-03  3223738 TRAF1 6.08E-03 
2635263 DZIP3 4.56E-03  2993206 MPP6 5.00E-03  3430228 RFX4 5.53E-03  2442424 ILDR2 6.10E-03 
3737677 --- 4.59E-03  2754673 ANKRD37 5.00E-03  3762339 MRPL27 5.57E-03  3650953 TMC5 6.10E-03 
3853108 NOTCH3 4.61E-03  3842379 EPN1 5.02E-03  2523689 ABI2 5.64E-03  3457824 TIMELESS 6.11E-03 
2497252 SLC9A2 4.65E-03  3975455 DUSP21 5.05E-03  3836841 CALM3 5.64E-03  2655338 HTR3E 6.12E-03 
3015682 PCOLCE 4.67E-03  3977083 CCDC22 5.06E-03  2611122 TSEN2 5.64E-03  3950726 PPP6R2 6.12E-03 
3619400 C15orf52 4.67E-03  3744377 SLC25A35 5.07E-03  2690776 B4GALT4 5.65E-03  2993727 SNX10 6.13E-03 
3880629 CST7 4.67E-03  3339423 INPPL1 5.08E-03  2585476 SCN7A 5.65E-03  3229994 INPP5E 6.13E-03 
3918447 IFNAR2 4.68E-03  3867865 PIH1D1 5.08E-03  3045739 HERPUD2 5.66E-03  3390067 NPAT 6.15E-03 
3233605 PFKFB3 4.68E-03  3824596 B3GNT3 5.08E-03  2342475 LHX8 5.69E-03  3728625 OR4D2 6.16E-03 
2767295 BEND4 4.69E-03  3882720 RALY 5.09E-03  2554018 EFEMP1 5.72E-03  2565410 KIAA1310 6.17E-03 
3351531 ARCN1 4.72E-03  3757154 KRT14 5.10E-03  3094286 PROSC 5.73E-03  3409006 MED21 6.20E-03 
3848039 C3 4.74E-03  3092808 NRG1 5.13E-03  3671607 LRRC50 5.75E-03  3914327 C20orf201 6.21E-03 
2608469 ITPR1 4.76E-03  3859915 U2AF1L4 5.13E-03  3571553 C14orf43 5.77E-03  3456049 ITGB7 6.24E-03 
3710515 DNAH9 4.76E-03  2462456 HEATR1 5.16E-03  3018535 BCAP29 5.79E-03  2813524 RAD17 6.27E-03 
3490741 SUGT1 4.77E-03  3894995 SNRPB 5.19E-03  2560178 LBX2 5.79E-03  2910868 TINAG 6.29E-03 
2501140 IL1F6 4.79E-03  3846011 SGTA 5.22E-03  3568108 SGPP1 5.79E-03  2790486 DCHS2 6.36E-03 
3599669 --- 4.79E-03  2683763 ROBO1 5.24E-03  2464909 SMYD3 5.81E-03  3179975 PHF2 6.36E-03 
3973556 CXorf59 4.80E-03  3066751 SYPL1 5.25E-03  3436329 FAM101A 5.87E-03  3383322 NARS2 6.38E-03 
2708457 CLCN2 4.80E-03  2441043 OLFML2B 5.27E-03  3662750 POLR2C 5.90E-03  3012633 GATAD1 6.39E-03 
3751541 GIT1 4.81E-03  3745781 ZNF18 5.31E-03  3474787 --- 5.91E-03  2841802 HMP19 6.39E-03 
3766415 SMARCD2 4.81E-03  2737220 C4orf17 5.33E-03  3992747 ZIC3 5.91E-03  2855963 HCN1 6.39E-03 
2734629 PTPN13 4.82E-03  3972657 IL1RAPL1 5.33E-03  3048373 POLM 5.91E-03  3194896 TRAF2 6.40E-03 
2849992 FAM134B 4.84E-03  3573051 C14orf148 5.36E-03  2998536 CDK13 5.93E-03  3280902 DNAJC1 6.41E-03 
3851720 HOOK2 4.85E-03  3834519 ARHGEF1 5.40E-03  3556386 RAB2B 5.98E-03  3113133 COLEC10 6.41E-03 
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3230490 EDF1 6.43E-03  3029900 CNTNAP2 6.88E-03  3933039 TMPRSS2 7.57E-03  2818035 CKMT2 8.10E-03 
3954596 RTDR1 6.44E-03  3680583 RSL1D1 6.89E-03  2657025 RTP4 7.59E-03  3377789 RELA 8.10E-03 
2673509 UQCRC1 6.45E-03  2775965 COQ2 6.89E-03  3356115 APLP2 7.65E-03  3329724 MADD 8.11E-03 
3444304 TAS2R8 6.45E-03  3667281 SF3B3 6.90E-03  2675998 TLR9 7.66E-03  3934642 KRTAP12-1 8.11E-03 
3911485 APCDD1L 6.48E-03  3770305 CD300C 6.94E-03  3976341 TIMP1 7.66E-03  3418249 KIF5A 8.12E-03 
3825383 UPF1 6.48E-03  2421883 GBP1 6.97E-03  3318383 OR52B6 7.67E-03  2540210 NOL10 8.13E-03 
2595042 ALS2 6.50E-03  3238466 COMMD3 7.00E-03  2808748 PARP8 7.70E-03  2391302 ACAP3 8.15E-03 
3951927 BID 6.52E-03  3766960 SMURF2 7.00E-03  2906934 PRICKLE4 7.70E-03  3856554 ZNF100 8.16E-03 
3381063 CLPB 6.53E-03  3490655 CKAP2 7.01E-03  3740462 RILP 7.70E-03  2396480 EXOSC10 8.17E-03 
3434594 ACADS 6.53E-03  3429754 KIAA1033 7.04E-03  3332276 MS4A2 7.70E-03  2369252 C1orf49 8.18E-03 
2816298 IQGAP2 6.53E-03  2607110 HDLBP 7.04E-03  3004768 ZNF273 7.71E-03  2599433 USP37 8.23E-03 
2388794 ZNF238 6.54E-03  2443537 SCYL3 7.08E-03  2733287 PRDM8 7.72E-03  2716246 FLJ35424 8.23E-03 
2662491 TMEM111 6.56E-03  3528605 OR4E2 7.17E-03  4036497 TTTY5 7.73E-03  3345157 PIWIL4 8.24E-03 
3558012 TINF2 6.57E-03  3064462 VGF 7.18E-03  3715109 WSB1 7.74E-03  2382043 C1orf65 8.28E-03 
3628104 C2CD4B 6.57E-03  2820893 RFESD 7.19E-03  3560711 BAZ1A 7.75E-03  2641769 RHO 8.30E-03 
2899808 PRSS16 6.59E-03  2436576 C1orf43 7.23E-03  3727033 FLJ42842 7.77E-03  3581442 JAG2 8.31E-03 
2532314 ALPI 6.60E-03  3707095 ARRB2 7.23E-03  3074912 DGKI 7.79E-03  3509910 FAM48A 8.31E-03 
3695107 TK2 6.60E-03  3766512 GH1 7.24E-03  2973995 EPB41L2 7.79E-03  3674840 POLR3K 8.32E-03 
3956781 AP1B1 6.62E-03  3971923 ZFX 7.24E-03  2317317 TP73 7.79E-03  2805786 TARS 8.32E-03 
3820758 DNM2 6.64E-03  2756497 ATP5I 7.25E-03  3371339 PHF21A 7.80E-03  2350952 GSTM2 8.34E-03 
3826504 ZNF431 6.66E-03  2857112 CCNO 7.28E-03  3302572 CRTAC1 7.85E-03  3816509 GADD45B 8.36E-03 
2895945 --- 6.69E-03  3253683 ZMIZ1 7.29E-03  3438061 GPR133 7.86E-03  3759137 ITGA2B 8.41E-03 
3065740 RELN 6.71E-03  4013460 CYSLTR1 7.31E-03  3152220 KIAA0196 7.87E-03  2932219 OPRM1 8.41E-03 
3428190 SLC17A8 6.73E-03  3375894 EML3 7.33E-03  2721087 GBA3 7.96E-03  3228279 C9orf98 8.42E-03 
3071700 IMPDH1 6.73E-03  2358949 CGN 7.35E-03  3757433 ACLY 7.96E-03  3943101 DEPDC5 8.51E-03 
3149161 CSMD3 6.74E-03  3047581 INHBA 7.38E-03  2699145 SLC9A9 7.98E-03  3011830 DPY19L2P4 8.53E-03 
2593464 ANKRD44 6.74E-03  3680953 CPPED1 7.39E-03  3015276 CNPY4 7.99E-03  3899111 BFSP1 8.54E-03 
3891163 GNAS 6.76E-03  3948640 FBLN1 7.41E-03  3720817 RAPGEFL1 8.02E-03  2666566 NGLY1 8.57E-03 
3513147 HTR2A 6.76E-03  3113280 DEPDC6 7.43E-03  3973803 XK 8.03E-03  4027355 UBL4A 8.61E-03 
2943874 KIF13A 6.80E-03  3635456 MESDC2 7.43E-03  3816815 GNA15 8.06E-03  3611126 MEF2A 8.62E-03 
2454935 ANGEL2 6.82E-03  3226160 SIAT7F 7.44E-03  3836217 KLC3 8.09E-03  2809245 ITGA2 8.63E-03 
3453592 MLL2 6.85E-03  2593670 SF3B1 7.51E-03  2734992 NUDT9 8.09E-03  3000276 RAMP3 8.66E-03 
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3817316 CREB3L3 8.68E-03  3972093 POLA1 9.35E-03  2969886 FYN 0.010  2324634 CDC42 0.011 
2405192 YARS 8.69E-03  3759410 GFAP 9.37E-03  3293244 SAR1A 0.010  3003228 SUMF2 0.011 
2952927 KCNK16 8.75E-03  2644418 CLDN18 9.39E-03  2779992 UBE2D3 0.010  3315712 B4GALNT4 0.011 
2691798 IQCB1 8.77E-03  3986412 --- 9.41E-03  2584520 FIGN 0.010  3863060 EXOSC5 0.011 
3883690 EPB41L1 8.77E-03  3834439 DMRTC2 9.47E-03  3970833 PDHA1 0.010  3119572 RHPN1 0.011 
3721886 MLX 8.79E-03  3379597 MTL5 9.49E-03  3354293 ROBO3 0.010  3992408 FHL1 0.011 
3744300 C17orf44 8.79E-03  2661992 OXTR 9.50E-03  3343008 TMEM126A 0.010  3735392 ZACN 0.011 
2523419 ALS2CR8 8.81E-03  3124353 --- 9.53E-03  3406195 C12orf60 0.010  3458819 CYP27B1 0.011 
3090697 CDCA2 8.84E-03  3883309 CEP250 9.56E-03  2930957 ULBP2 0.010  3815014 BSG 0.011 
2343334 GIPC2 8.85E-03  3722739 G6PC3 9.57E-03  3770029 CDC42EP4 0.010  3399545 NCAPD3 0.011 
2428405 RHOC 8.89E-03  3601840 CSK 9.61E-03  3131916 WHSC1L1 0.010  2880905 CSNK1A1 0.011 
3437500 GLT1D1 8.90E-03  3429008 ASCL1 9.63E-03  3884922 DHX35 0.010  2379009 PPP2R5A 0.011 
2777333 PPM1K 8.95E-03  2484970 EHBP1 9.64E-03  3244539 ZNF22 0.010  3042952 HOXA10 0.011 
2607757 CNTN6 8.95E-03  3017068 NFE4 9.64E-03  3186191 ATP6V1G1 0.010  3478957 DDX51 0.011 
2650357 ARL14 9.00E-03  2949038 BAT1 9.66E-03  2456805 BPNT1 0.010  2527856 RQCD1 0.011 
3185643 RGS3 9.01E-03  4018194 CAPN6 9.67E-03  3892456 SS18L1 0.010  3978999 UBQLN2 0.011 
3790259 MALT1 9.04E-03  2368840 FAM5B 9.68E-03  2689452 ZNF80 0.011  2488252 DYSF 0.011 
3883819 DLGAP4 9.06E-03  2933536 TULP4 9.71E-03  3441542 ANO2 0.011  3638337 POLG 0.011 
3402836 LEPREL2 9.06E-03  2622026 CCDC36 9.71E-03  3128954 TRIM35 0.011  3012677 C7orf64 0.011 
3665083 B3GNT9 9.07E-03  2597552 ERBB4 9.73E-03  3631964 PKM2 0.011  2889486 AGXT2L2 0.011 
3434490 CABP1 9.10E-03  3555492 TMEM55B 9.76E-03  3026495 AKR1D1 0.011  3571634 COQ6 0.011 
3850990 ZNF653 9.13E-03  2460551 EGLN1 9.76E-03  3932148 BRWD1 0.011  3160500 C9orf70 0.011 
3632671 STOML1 9.16E-03  2361697 C1orf66 9.77E-03  2792161 TKTL2 0.011  3829049 RGS9BP 0.011 
2701081 P2RY12 9.18E-03  2925510 L3MBTL3 9.77E-03  3872733 ZNF329 0.011  3113180 MAL2 0.011 
2500875 CHCHD5 9.23E-03  2889698 CLK4 9.79E-03  2903673 PHF1 0.011  3633403 SIN3A 0.011 
2551189 SIX2 9.26E-03  3421897 CNOT2 9.81E-03  2648535 ARHGEF26 0.011  3005995 TYW1 0.011 
3427282 C12orf63 9.28E-03  3008108 LIMK1 9.84E-03  3903952 GDF5 0.011  3205834 ANKRD18A 0.011 
3887241 SLC12A5 9.28E-03  3871043 PPP1R12C 9.85E-03  3564071 NIN 0.011  3593652 USP8 0.011 
3907320 WFDC6 9.30E-03  3193482 COL5A1 9.94E-03  2437801 ARHGEF2 0.011  3674960 LUC7L 0.011 
3507710 SLC7A1 9.32E-03  3764103 SRSF1 9.94E-03  3723627 CRHR1 0.011  3203636 SUGT1P1 0.011 
3415148 ACVR1B 9.33E-03  2892262 --- 9.95E-03  3855660 SUGP1 0.011  3848651 TIMM44 0.011 
2444363 SLC9A11 9.35E-03  2336585 SCP2 9.96E-03  2326463 CD52 0.011  3049522 TNS3 0.011 
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2730714 DCK 0.012  3126191 PSD3 0.012  3401804 RAD51AP1 0.013  3056226 STX1A 0.013 
2614663 LRRC3B 0.012  3842768 ZNF471 0.012  2358221 RPRD2 0.013  2360633 EFNA4 0.013 
2487082 ANTXR1 0.012  3878308 CSRP2BP 0.012  3728820 PPM1E 0.013  3260957 LZTS2 0.013 
3403224 LOC283314 0.012  2323951 VWA5B1 0.012  2929870 STXBP5 0.013  3886453 HNF4A 0.013 
3415915 PFDN5 0.012  3294576 USP54 0.012  3930781 SETD4 0.013  2647109 CPA3 0.013 
2773719 CDKL2 0.012  3348608 SIK2 0.012  2460817 SIPA1L2 0.013  3822322 MRI1 0.013 
2434490 ENSA 0.012  2638886 FAM162A 0.012  3465274 DCN 0.013  3891278 TH1L 0.014 
2796790 KIAA1430 0.012  2435149 CELF3 0.012  3747288 ZNF287 0.013  2796553 ACSL1 0.014 
2894689 TMEM14C 0.012  2707824 MCCC1 0.012  3766549 SCN4A 0.013  2593733 HSPD1 0.014 
2678526 C3orf67 0.012  3696697 NOB1 0.012  3031383 REPIN1 0.013  2956593 CRISP1 0.014 
2556529 SERTAD2 0.012  3360874 HPX 0.012  3189422 FAM125B 0.013  3455865 KRT4 0.014 
3320301 CTR9 0.012  3652338 VWA3A 0.012  2903507 RING1 0.013  3683549 UMOD 0.014 
2640263 ROPN1B 0.012  3070183 AASS 0.012  2398193 CROCCP3 0.013  2633039 OR5AC2 0.014 
3838004 PPP1R15A 0.012  2622590 GNAT1 0.012  3462630 CAPS2 0.013  3259920 ANKRD2 0.014 
2487527 SNRNP27 0.012  3580498 CDC42BPB 0.012  2586845 SLC25A12 0.013  3682028 MYH11 0.014 
2339139 INADL 0.012  3638819 CIB1 0.012  3174224 SMC5 0.013  2758298 LRPAP1 0.014 
2888385 GPRIN1 0.012  3953033 TRMT2A 0.012  2988336 KIAA0415 0.013  2547751 MYADML 0.014 
3618736 RASGRP1 0.012  2410470 PIK3R3 0.012  3970338 NHS 0.013  3823488 FLJ25328 0.014 
2969406 SLC22A16 0.012  3358049 RNH1 0.012  3377091 MAP4K2 0.013  2672532 SETD2 0.014 
3741171 KIAA0664 0.012  3260423 CUTC 0.012  2401347 TCEA3 0.013  3008220 CLIP2 0.014 
2915268 DOPEY1 0.012  4052378 SNRNP35 0.012  3916290 FLJ42200 0.013  3873777 TGM6 0.014 
3595846 FAM63B 0.012  3630736 ITGA11 0.012  2380991 IARS2 0.013  2527971 STK36 0.014 
2843091 RGS14 0.012  3223872 RAB14 0.012  3261165 BTRC 0.013  3415368 KRT86 0.014 
2426676 C1orf59 0.012  3762040 TAC4 0.012  2635184 HHLA2 0.013  3659888 HEATR3 0.014 
3692735 CES5A 0.012  3007829 FZD9 0.012  3871935 ZNF667 0.013  3318186 MMP26 0.013 
3753452 NLE1 0.012  3350850 RNF214 0.013  2878943 PCDH1 0.013  2835213 PPARGC1B 0.014 
2589255 FKBP7 0.012  3564997 DDHD1 0.013  4053462 KLHL17 0.013  3888613 CEBPB 0.014 
2488732 CCT7 0.012  3441685 VWF 0.013  2899768 HIST1H4I 0.013  2910236 EFHC1 0.014 
3377226 EHD1 0.012  2620685 SACM1L 0.013  2692816 ITGB5 0.013  3075742 KLRG2 0.014 
3886639 YWHAB 0.012  3337168 GSTP1 0.013  3977067 PLP2 0.013  3446355 PLCZ1 0.014 
2412529 NRD1 0.012  2419219 C1orf118 0.013  4026902 NAA10 0.013  3128411 EBF2 0.014 
2697652 FOXL2 0.012  3182489 RNF20 0.013  3861037 ZNF607 0.013  3512527 TPT1 0.014 
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3893287 ARFGAP1 0.014  3394192 DPAGT1 0.015  3157132 SLURP1 0.016  3956226 MN1 0.016 
2408855 FOXJ3 0.014  3852880 EMR2 0.015  3563734 SOS2 0.016  3226138 AK1 0.016 
3409127 ARNTL2 0.014  3399004 OPCML 0.015  2394784 NOL9 0.016  4007086 ZNF41 0.016 
2997272 EEPD1 0.014  3944620 MPST 0.015  2687255 CBLB 0.016  3259253 ENTPD1 0.016 
3975987 RBM10 0.014  3723348 HEXIM1 0.015  3386737 C11orf75 0.016  3895614 SIGLEC1 0.016 
4054437 GJB5 0.014  2324341 NBPF3 0.015  2581000 NEB 0.016  3933243 PRDM15 0.016 
3828887 ZNF507 0.014  3019158 LRRN3 0.015  3677592 ZNF434 0.016  2416218 ITGB3BP 0.016 
2734784 AFF1 0.014  3976240 ZNF157 0.015  2626802 PTPRG 0.016  3168032 CCDC107 0.016 
2949148 BAT3 0.014  2954506 CRIP3 0.015  3899404 OVOL2 0.016  2701109 IGSF10 0.016 
2674963 MON1A 0.014  3049700 PKD1L1 0.015  3841134 CACNG7 0.016  3868587 SHANK1 0.017 
3705539 RNMTL1 0.014  2390050 NLRP3 0.015  3451670 PUS7L 0.016  2667181 AZI2 0.017 
3936442 PEX26 0.014  3996142 OPN1LW 0.015  2653114 NAALADL2 0.016  2409820 BEST4 0.017 
3873185 RBCK1 0.014  3642993 C16orf11 0.015  3182930 OR13D1 0.016  3980170 EFNB1 0.017 
2773872 NAAA 0.014  3260001 MARVELD1 0.015  2719617 BST1 0.016  3094157 ZNF703 0.017 
3564250 TRIM9 0.014  3854627 JAK3 0.014  2519038 FSIP2 0.016  3832830 PAK4 0.017 
3944147 MCM5 0.014  3867374 IZUMO1 0.015  2331771 RLF 0.016  3135340 OPRK1 0.017 
2348702 SLC35A3 0.014  2617041 GOLGA4 0.015  2625546 SPATA12 0.016  2824483 YTHDC2 0.017 
2645951 TRPC1 0.015  2874794 RAPGEF6 0.015  2799509 C5orf38 0.016  2440440 ITLN2 0.017 
3906709 GTSF1L 0.015  2914777 TTK 0.015  3131720 BRF2 0.016  2356115 TXNIP 0.017 
3334304 DNAJC4 0.015  2515783 RAPGEF4 0.015  3347431 ELMOD1 0.016  3736232 SYNGR2 0.017 
4025771 CD99L2 0.015  3175494 GCNT1 0.015  2824872 AP3S1 0.016  3907473 ACOT8 0.017 
2462415 LGALS8 0.015  3899551 RBBP9 0.015  2695200 PIK3R4 0.016  2781138 LEF1 0.017 
2892170 WRNIP1 0.015  3687889 ZNF785 0.015  3972551 MAGEB10 0.016  3191724 ABL1 0.017 
2329920 TFAP2E 0.015  3716664 SUZ12P 0.015  3125116 DLC1 0.016  2900269 ZSCAN16 0.017 
2812539 SREK1 0.015  3842675 ZNF542 0.015  3643019 PIGQ 0.016  2492015 MRPL35 0.017 
3934837 C21orf122 0.015  3335643 MUS81 0.015  3361072 DCHS1 0.016  2458921 ITPKB 0.017 
3238761 MSRB2 0.015  3020192 TES 0.015  3203753 UBAP2 0.016  2926802 MYB 0.017 
4027009 IRAK1 0.015  2681195 UBA3 0.015  3643892 TELO2 0.016  3392332 CADM1 0.017 
3357237 JAM3 0.015  3157563 NAPRT1 0.015  2939034 SERPINB9 0.016  3876084 C20orf103 0.017 
3632806 STRA6 0.015  3226644 ZDHHC12 0.016  3857523 --- 0.016  3630701 CLN6 0.017 
2345128 SH3GLB1 0.015  3301713 BLNK 0.016  3800116 MC2R 0.016  3389745 CWF19L2 0.017 
2655476 AP2M1 0.015  3747792 RASD1 0.016  2633166 OR5K2 0.016  3843797 ZNF274 0.017 
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3168508 MELK 0.017  2620256 KIF15 0.018  3815685 C19orf24 0.019  2717518 AFAP1 0.020 
3501661 ARHGEF7 0.017  3529237 DHRS2 0.018  2925871 ENPP3 0.019  7385683 VPS41 0.020 
3391653 DRD2 0.017  3659670 FLJ44674 0.018  2360989 MSTO1 0.019  3972025 PDK3 0.020 
2609824 CPNE9 0.017  2583631 RBMS1 0.018  2489071 TET3 0.019  3330700 OR4P4 0.020 
3854066 C19orf42 0.017  3751164 DHRS13 0.018  3708528 TNK1 0.019  2865860 CCNH 0.020 
3977205 GAGE12G 0.017  3190762 ENDOG 0.018  3869714 ZNF611 0.019  3653398 TNRC6A 0.020 
2390180 TRIM58 0.017  3914786 ABCC13 0.018  3991650 PHF6 0.019  3694657 CDH11 0.020 
3224556 --- 0.017  3855633 TM6SF2 0.018  3867734 SLC6A16 0.019  3109191 POLR2K 0.020 
2623413 GPR62 0.017  3580769 CKB 0.018  2639225 PDIA5 0.019  2441940 LMX1A 0.020 
3359469 NAP1L4 0.017  3560403 EGLN3 0.018  3262490 C10orf78 0.019  2511603 GALNT5 0.020 
3963289 LDOC1L 0.017  2770469 IGFBP7 0.018  3064024 C7orf61 0.019  3571944 LTBP2 0.020 
3107661 INTS8 0.017  3832292 KCNK6 0.018  3595315 CGNL1 0.019  2835576 SYNPO 0.020 
2362723 FCRL6 0.017  3330965 OR8U1 0.018  3891048 NPEPL1 0.019  3812385 CD226 0.020 
2325002 KDM1A 0.017  2455699 USH2A 0.018  3757423 KLHL11 0.019  4015661 TAF7L 0.020 
3677795 CREBBP 0.017  2475678 LBH 0.018  3709213 CYB5D1 0.019  2771839 TMPRSS11D 0.020 
3603405 --- 0.017  3675205 C16orf13 0.018  3656151 MYLPF 0.019  3920385 TTC3 0.020 
3688381 ZNF843 0.017  2413685 SSBP3 0.018  2675457 C3orf18 0.019  3284073 EPC1 0.020 
2805078 CDH6 0.017  3417075 DGKA 0.018  2677723 ARHGEF3 0.019  2901970 DDR1 0.020 
2451419 RABIF 0.017  3056131 TBL2 0.018  3928620 KRTAP11-1 0.019  3090053 SLC25A37 0.020 
2620985 TMIE 0.018  3849267 ZNF558 0.018  2730554 RUFY3 0.019  3884640 RALGAPB 0.020 
2620150 ZNF660 0.018  3610982 SYNM 0.018  3526831 RASA3 0.019  3710108 GLP2R 0.020 
3835467 ZNF234 0.018  3511031 ELF1 0.018  3848907 KANK3 0.019  2451309 KDM5B 0.020 
2487882 VAX2 0.018  3459801 DPY19L2 0.018  2948259 TRIM26 0.019  3843386 ZNF530 0.020 
3722195 AOC3 0.018  3459434 FAM19A2 0.018  3791482 PHLPP1 0.019  3601348 LOXL1 0.020 
3643100 WFIKKN1 0.018  3991109 MST4 0.018  3715614 SLC13A2 0.019  3939470 MMP11 0.020 
3854297 NR2F6 0.018  2469157 GRHL1 0.018  3527662 RNASE6 0.019  3669171 CNTNAP4 0.020 
2928930 PHACTR2 0.017  3271687 PPP2R2D 0.018  3743194 SLC13A5 0.019  2910477 FBXO9 0.020 
3734270 DNAI2 0.017  3910724 CBLN4 0.018  3737140 GAA 0.019  3869237 FPR1 0.020 
3759335 GJC1 0.017  2672190 LRRC2 0.018  3260636 WNT8B 0.019  3179551 FGD3 0.020 
2963929 RNGTT 0.017  3393622 SCN4B 0.018  3133233 PLAT 0.019  2318157 RNF207 0.020 
3758317 BRCA1 0.017  2716124 HGFAC 0.019  3705967 SERPINF1 0.019  3358174 IRF7 0.020 
3919952 MORC3 0.017  3669092 TERF2IP 0.019  2326410 CCDC21 0.019  3198346 PTPRD 0.020 
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2558844 CLEC4F 0.020  2964553 BACH2 0.021  3644593 MLST8 0.022  2780143 BDH2 0.023 
3709327 CNTROB 0.020  3347658 ATM 0.021  3747966 SREBF1 0.022  2695941 TOPBP1 0.023 
3594825 PIGB 0.020  3501999 SOX1 0.021  3401259 TEAD4 0.022  2574984 LIMS2 0.023 
3643431 CHTF18 0.020  2757751 MXD4 0.021  3453882 MCRS1 0.022  3673583 IL17C 0.023 
3818468 TNFSF9 0.020  2339454 ANGPTL3 0.021  3717539 RHOT1 0.022  3514879 TPTE2P2 0.023 
2362323 OR6K6 0.020  3931112 HLCS 0.021  3181302 NCBP1 0.022  2955691 RCAN2 0.023 
3354380 HEPN1 0.020  3693240 CCDC102A 0.021  2953435 C6orf130 0.022  2343170 CCDC55 0.023 
2732391 CCNG2 0.020  3310413 ATE1 0.021  3825713 GATAD2A 0.022  2831519 C5orf32 0.023 
3629494 CLPX 0.020  2879927 LARS 0.021  3624513 MYO5C 0.022  2323087 ACTL8 0.023 
2853642 C5orf42 0.020  3892561 FLJ44790 0.021  3354719 --- 0.022  2828520 SLC22A5 0.023 
3195034 PTGDS 0.021  3994610 MAGEA8 0.021  3960246 ANKRD54 0.022  3902764 C20orf112 0.023 
3304746 USMG5 0.020  3587495 SCG5 0.021  2961929 HMGN3 0.022  3621080 TGM5 0.023 
2345196 HS2ST1 0.021  3451375 PRICKLE1 0.021  3589212 FAM98B 0.022  3874498 MAVS 0.023 
3592109 SORD 0.021  3644625 E4F1 0.021  3937814 AIFM3 0.022  3215395 BARX1 0.023 
2553192 ASB3 0.021  3476457 NCOR2 0.021  2521479 HSPE1 0.022  3340697 UVRAG 0.023 
3553531 TNFAIP2 0.021  3810542 CCBE1 0.021  2605674 ILKAP 0.022  2476671 RASGRP3 0.023 
3593452 DTWD1 0.021  3557430 MYH6 0.021  3735847 SEPT9 0.022  3903999 C20orf173 0.023 
3347549 CUL5 0.021  3282016 ABI1 0.021  2702610 SHOX2 0.022  3402039 KCNA5 0.023 
4018436 LHFPL1 0.021  2527939 BCS1L 0.021  3699178 WDR59 0.022  2992243 DNAH11 0.023 
3841184 CACNG6 0.021  3302805 HPS1 0.022  2880463 C5orf46 0.022  3870733 LILRB2 0.023 
2456204 GPATCH2 0.021  3823982 MYO9B 0.022  2361342 SEMA4A 0.022  3200762 SLC24A2 0.023 
3864286 PSG9 0.021  3606304 AKAP13 0.022  3734236 TTYH2 0.022  3894727 SIRPB1 0.023 
3683879 DNAH3 0.021  2960146 COL9A1 0.022  3673600 MGC23284 0.022  2427930 WDR77 0.023 
3882949 DYNLRB1 0.021  3319018 NLRP14 0.022  3681956 KIAA0430 0.022  3212420 SLC28A3 0.023 
3960302 SOX10 0.021  2764478 CCKAR 0.022  2606741 ANKMY1 0.022  3071878 KCP 0.023 
3762625 MBTD1 0.021  3931946 --- 0.022  3025740 TMEM140 0.023  3975893 PHF16 0.023 
3025005 EXOC4 0.021  2318455 CAMTA1 0.022  3965447 IL17REL 0.023  3655665 MAZ 0.023 
3318961 OR10A5 0.021  3589756 PAK6 0.022  3065244 RASA4 0.023  2693569 ZXDC 0.023 
3559690 HEATR5A 0.021  3289392 FLJ31958 0.022  3614901 HERC2 0.023  2435443 TCHH 0.024 
3820469 ICAM5 0.021  3653516 SLC5A11 0.022  3378830 CORO1B 0.023  2376799 IKBKE 0.024 
3562671 KLHL28 0.021  3258966 CYP2C18 0.022  3791254 TNFRSF11A 0.023  2712236 MUC4 0.024 
3127878 ENTPD4 0.021  3252382 MYST4 0.022  3607698 C15orf42 0.023  3418610 XRCC6BP1 0.024 
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2982270 FLJ27255 0.024  3719980 LASP1 0.024  2906333 DAAM2 0.025  2654394 FXR1 0.026 
3853761 CIB3 0.024  3673806 ACSF3 0.025  3064293 EPHB4 0.025  4002809 APOO 0.026 
3994915 HMGB3 0.024  3860737 ZNF585A 0.025  3869312 ZNF649 0.026  3695916 CENPT 0.026 
3250278 HK1 0.024  3623552 ATP8B4 0.025  3212706 --- 0.026  3884892 FAM83D 0.026 
3896078 SLC23A2 0.024  3842839 ZNF470 0.025  3258384 CYP26A1 0.026  3359910 NUP98 0.026 
3603408 PSMA4 0.024  2855542 CCL28 0.025  3145149 TP53INP1 0.026  2742829 INTU 0.026 
2564816 ANKRD36B 0.024  3164312 ACER2 0.025  3204928 HINT2 0.026  3473586 KSR2 0.026 
3375340 CPSF7 0.024  3849688 ZNF266 0.025  3815649 CIRBP 0.026  2828135 LYRM7 0.027 
3127745 TNFRSF10D 0.024  3869396 ZNF841 0.025  3401325 TSPAN9 0.026  2924851 RSPO3 0.027 
2970086 LAMA4 0.024  3904119 CPNE1 0.025  2791419 FAM198B 0.026  2468105 LOC150622 0.027 
3917155 USP16 0.024  2672016 FYCO1 0.025  2698565 TFDP2 0.026  3248470 C10orf107 0.027 
3534128 FAM179B 0.024  2331857 SMAP2 0.025  3499632 ERCC5 0.026  3331603 C11orf31 0.027 
3239437 GPR158 0.024  2524743 FASTKD2 0.025  3815888 APC2 0.026  3833893 CYP2B7P1 0.027 
4007765 PRAF2 0.024  3005069 ZNF92 0.025  2511153 KCNJ3 0.026  3161042 INSL4 0.027 
3784783 MOCOS 0.024  3755934 ORMDL3 0.025  2475116 PLB1 0.026  3934785 C21orf67 0.027 
2358855 ZNF687 0.024  2394817 KLHL21 0.025  2799184 NDUFS6 0.026  3212143 UBQLN1 0.027 
3751625 SSH2 0.024  3718185 CCL11 0.025  3929664 TMEM50B 0.026  2536531 FARP2 0.027 
3863597 CNFN 0.024  2476075 SPAST 0.025  3072630 TSGA13 0.026  2841491 C5orf41 0.027 
3323413 HTATIP2 0.024  3708462 ACAP1 0.025  2878809 ARAP3 0.026  3878220 C20orf72 0.027 
2530539 MFF 0.024  2882747 HAND1 0.025  2534252 MLPH 0.026  2496628 C2orf29 0.027 
3772661 TIMP2 0.024  3833757 SNRPA 0.025  2602770 DNER 0.026  3840224 ZNF528 0.027 
3457752 STAT2 0.024  2609870 BRPF1 0.025  3757770 STAT5B 0.026  3742236 PELP1 0.027 
2875685 FSTL4 0.024  2877314 CDC23 0.025  3830320 MAG 0.026  3830649 COX6B1 0.027 
3647993 CIITA 0.024  2595560 RAPH1 0.025  3067250 SLC26A3 0.026  2472054 GDF7 0.027 
2909263 MEP1A 0.024  2334319 TOE1 0.025  2497161 IL18RAP 0.026  2522247 AOX1 0.027 
3957790 PIK3IP1 0.024  3300211 FGFBP3 0.025  3190190 LCN2 0.026  2756029 FRG1 0.027 
3527785 SLC39A2 0.024  2554975 BCL11A 0.025  3402874 GNB3 0.026  2957314 GSTA2 0.027 
3320123 ADM 0.024  2685944 CPOX 0.025  3922100 MX1 0.026  3216529 ZNF782 0.027 
2425212 DBT 0.024  2675720 IQCF1 0.025  4021508 ZNF280C 0.026  3063968 ZCWPW1 0.027 
2620894 RTP3 0.024  3469319 APPL2 0.025  3983105 APOOL 0.026  2453036 FCAMR 0.027 
2649532 RSRC1 0.024  2443575 KIFAP3 0.025  3388631 TMEM123 0.026  2461786 ARID4B 0.027 
3769779 SLC39A11 0.024  2544625 POMC 0.025  2603987 NGEF 0.026  3257268 IFIT5 0.027 
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2920327 NR2E1 0.027  4023467 ARHGEF6 0.028  3330685 OR4C15 0.029  2346625 EPHX4 0.030 
3507686 LOC728437 0.027  3528115 TOX4 0.028  3447129 KIAA0528 0.029  3319937 WEE1 0.030 
2440664 B4GALT3 0.027  3192062 BAT2L1 0.028  2652669 --- 0.029  3603840 C15orf37 0.030 
3456688 GPR84 0.027  3316447 AP2A2 0.028  3512769 ZC3H13 0.029  4005392 BCOR 0.030 
3452664 ENDOU 0.027  2658595 HES1 0.028  3267678 WDR11 0.029  2617433 VILL 0.030 
3456130 AAAS 0.027  3643143 WDR90 0.028  2818079 ZCCHC9 0.029  3845899 TIMM13 0.030 
3173974 FAM189A2 0.027  2901393 TRIM40 0.028  3181728 TGFBR1 0.029  2363084 NCSTN 0.030 
3860596 ZNF461 0.027  3844822 MED16 0.028  3431892 SH2B3 0.029  2709750 SST 0.030 
2452977 FAIM3 0.027  2830450 NPY6R 0.028  2562685 IMMT 0.029  3770361 CD300LF 0.030 
3502411 F7 0.027  3381038 PHOX2A 0.028  3533397 SIP1 0.029  3680249 PRM3 0.030 
2662956 VGLL4 0.027  2363784 HSPA6 0.028  2372169 OCLM 0.029  3209060 TRPM3 0.030 
2743370 C4orf33 0.027  3512294 TSC22D1 0.028  3883013 TP53INP2 0.029  3693214 DOK4 0.030 
2677356 WNT5A 0.027  3159735 DMRT3 0.028  3778601 VAPA 0.029  3493448 PIBF1 0.030 
3909777 SALL4 0.027  2572601 CCDC93 0.028  2871617 TRIM36 0.029  2854824 HEATR7B2 0.030 
3834176 TMEM91 0.027  3604267 C15orf26 0.028  2319550 RBP7 0.029  3331217 P2RX3 0.030 
3752709 MYO1D 0.027  2717857 CPZ 0.028  2674047 LAMB2 0.029  2987523 CHST12 0.030 
3251566 OIT3 0.027  3764199 MKS1 0.028  2412834 ZCCHC11 0.029  4042392 MIB2 0.030 
2562343 GGCX 0.027  3577360 PRIMA1 0.028  2328750 CCDC28B 0.029  3223776 C5 0.030 
3944637 KCTD17 0.027  2643901 PPP2R3A 0.028  3835035 CD177 0.029  2440586 PVRL4 0.031 
2880679 SH3TC2 0.027  2378019 CAMK1G 0.028  3191352 NCS1 0.029  3119516 ZNF696 0.031 
3551566 EVL 0.027  2784027 ANXA5 0.028  3690470 ABCC11 0.029  3301141 CYP2C8 0.031 
3260829 FAM178A 0.027  3646434 UBN1 0.028  3621728 FRMD5 0.029  3443868 CD69 0.031 
2399765 CAPZB 0.027  3994451 CXorf40A 0.028  3821079 DOCK6 0.029  3930942 CLDN14 0.031 
3555736 NDRG2 0.028  3455914 KRT78 0.028  3894637 NSFL1C 0.029  3502259 MCF2L 0.031 
3346584 BIRC2 0.028  2973376 PTPRK 0.029  3377569 SLC25A45 0.030  3746675 CDRT4 0.031 
3845120 C19orf23 0.028  3467720 GOLGA2B 0.029  3712835 LRRC48 0.030  2635741 CD96 0.031 
3482219 NUPL1 0.028  2380440 SPATA17 0.029  3094611 LETM2 0.030  3999148 GPR143 0.031 
3336652 SYT12 0.028  2690715 IGSF11 0.029  3344861 C11orf54 0.030  2663295 TMEM40 0.031 
3553998 TDRD9 0.028  3670918 PLCG2 0.029  2629345 GPR27 0.030  2322226 CLCNKA 0.031 
3461795 PTPRB 0.028  2853102 PRLR 0.029  3884191 SRC 0.030  3227696 RAPGEF1 0.031 
3715703 SUPT6H 0.028  2337217 C1orf175 0.029  3561381 NKX2-1 0.030  3518766 EDNRB 0.031 
3987029 TMEM164 0.028  2796623 SLED1 0.029  2587730 SP9 0.030  2452754 SLC26A9 0.031 
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3742708 C1QBP 0.031  2664760 DAZL 0.032  3335338 FAM89B 0.033  3503164 CDC16 0.034 
2573326 LOC84931 0.031  3675266 JMJD8 0.032  3175274 PCSK5 0.033  3623865 SPPL2A 0.034 
2552368 LHCGR 0.031  3942124 CABP7 0.032  3149843 RAD21 0.033  3955102 GSTT1 0.034 
2623662 DNAH1 0.031  2545534 C2orf53 0.032  2888674 MXD3 0.033  3704567 CBFA2T3 0.034 
3646000 DNASE1 0.031  3870135 ZNF347 0.032  2358700 GABPB2 0.033  2856995 ESM1 0.034 
3315584 NLRP6 0.031  3079576 SMARCD3 0.032  3418394 SLC26A10 0.033  3932270 HMGN1 0.034 
3263944 PDCD4 0.031  3907234 SDC4 0.032  2417016 WDR78 0.033  3555461 OSGEP 0.034 
3101851 C8orf45 0.031  3447348 SOX5 0.032  3818515 TRIP10 0.033  2364438 NUF2 0.034 
4009288 HSD17B10 0.031  3481296 SGCG 0.032  3545634 NRXN3 0.033  2771718 UBA6 0.034 
2338487 FGGY 0.031  3363266 DKK3 0.032  2876213 CDKN2AIP 0.033  2351854 C1orf162 0.034 
3974957 GPR82 0.031  2702307 CCNL1 0.032  2903343 BRD2 0.033  2608765 ARL8B 0.034 
3022422 FSCN3 0.031  3628832 DAPK2 0.032  3951302 POTEM 0.033  3566383 C14orf105 0.034 
2669979 CX3CR1 0.031  3890099 MC3R 0.032  2942306 TBC1D7 0.033  3059464 SEMA3A 0.034 
2559849 SLC4A5 0.031  2398073 FBXO42 0.032  3580832 XRCC3 0.033  2974671 C6orf192 0.034 
3315952 RASSF7 0.032  3476012 MPHOSPH9 0.032  3176999 RMI1 0.033  2926969 PDE7B 0.034 
3973692 PRRG1 0.032  3674659 GAS8 0.032  3472755 TBX3 0.033  3312045 C10orf90 0.034 
2914070 MYO6 0.032  3740664 C17orf91 0.032  3571347 NUMB 0.033  3573870 DIO2 0.034 
2975867 MAP3K5 0.032  3913018 LAMA5 0.033  2453365 PLXNA2 0.033  4023006 ZNF75D 0.034 
2327677 EPB41 0.032  2708066 KLHL6 0.033  2594773 ALS2CR12 0.033  3284882 CUL2 0.034 
3414029 KCNH3 0.032  3111530 ENY2 0.033  3643047 RAB40C 0.033  3739162 TBCD 0.034 
3977347 CCNB3 0.032  2714407 IDUA 0.033  2464129 --- 0.033  2738146 TET2 0.034 
3675101 MRPL28 0.032  2408499 SCMH1 0.033  3349437 --- 0.033  4007186 ELK1 0.034 
3289631 CSTF2T 0.032  3578089 C14orf49 0.033  2998192 POU6F2 0.033  3415988 AMHR2 0.035 
2770039 NMU 0.032  2980870 NOX3 0.033  3011675 ZNF804B 0.033  3969455 OFD1 0.035 
3819312 SNAPC2 0.032  2367154 BAT2L2 0.033  3738490 GPS1 0.034  3324162 LUZP2 0.035 
3949229 TBC1D22A 0.032  3269373 ZRANB1 0.033  2673873 IMPDH2 0.034  3299970 ANKRD1 0.035 
3303109 COX15 0.032  2902804 C2 0.033  3453169 LALBA 0.034  3432394 RPH3A 0.035 
2477438 QPCT 0.032  3316234 NS3BP 0.033  3144740 FP6628 0.034  3884830 PPP1R16B 0.035 
3603295 CRABP1 0.032  3376046 LRRN4CL 0.033  2357845 FCGR1A 0.034  3864390 PHLDB3 0.035 
2922881 RFX6 0.032  3048468 GCK 0.033  3867693 C19orf73 0.034  3820501 PDE4A 0.035 
3860793 ZNF585B 0.032  3901851 ABHD12 0.033  3753935 LYZL6 0.034  2644461 ARMC8 0.035 
4004035 FTHL17 0.032  2621583 ZNF589 0.033  2447246 C1orf14 0.034  2842157 HRH2 0.035 







Table B11: C9ORF72vCtrl Alternatively Spliced List (n=2,511) [Partek® p-value (alt. splicing) <0.05]  
 537 
 
2828757 ANKRD43 0.035  3393257 BACE1 0.036  2727587 KIT 0.037  3952880 TXNRD2 0.038 
2973694 ARHGAP18 0.035  4001029 --- 0.036  3139035 ARFGEF1 0.037  3023246 IRF5 0.038 
3902682 PLAGL2 0.035  3817380 EBI3 0.036  2340078 CACHD1 0.037  2505779 GPR148 0.038 
3015241 AP4M1 0.035  3837866 SULT2B1 0.036  2891768 FOXC1 0.037  3783435 DSG4 0.038 
3230811 DPP7 0.035  4000944 RBBP7 0.036  3437780 FZD10 0.037  2491686 RNF181 0.038 
3304116 C10orf76 0.035  3806366 LOXHD1 0.036  2900497 ZKSCAN3 0.037  3374224 OR10W1 0.038 
2701892 C3orf33 0.035  2622359 RBM6 0.036  3111695 EBAG9 0.037  2790999 ACCN5 0.039 
2405576 CSMD2 0.035  3870824 LAIR1 0.036  3543857 PTGR2 0.038  2685034 CGGBP1 0.039 
2528504 SPEG 0.035  3202528 LINGO2 0.036  3319119 OLFML1 0.038  3001345 VWC2 0.039 
3360622 TRIM5 0.035  3397951 FLJ45950 0.036  2321960 PLEKHM2 0.038  3914021 GMEB2 0.039 
3150844 SNTB1 0.035  2881923 SLC36A3 0.036  2897172 RNF144B 0.038  3070507 RNF148 0.039 
2362333 MNDA 0.035  3601387 PML 0.037  2738664 SGMS2 0.038  2387126 RYR2 0.039 
2487639 PCBP1 0.035  2359993 CREB3L4 0.037  3726465 RSAD1 0.038  2971801 MAN1A1 0.039 
4026346 PNMA5 0.035  2318242 --- 0.037  3090294 ADAMDEC1 0.038  3944778 GGA1 0.039 
2647647 TSC22D2 0.035  3887069 SNX21 0.037  3009520 UPK3B 0.038  2772450 SULT1E1 0.039 
2949859 PBX2 0.035  3725779 MYST2 0.037  3819263 MAP2K7 0.038  3615556 NDNL2 0.039 
3532353 FAM177A1 0.036  3788302 SMAD4 0.037  3989826 SH2D1A 0.038  3450234 PKP2 0.039 
3332964 C11orf66 0.036  2518889 ZNF804A 0.037  2430762 WARS2 0.038  3755510 PLXDC1 0.039 
3429159 STAB2 0.036  3398076 NFRKB 0.037  3241601 C10orf68 0.038  3765580 BRIP1 0.039 
2633737 GPR128 0.036  3590498 TYRO3 0.037  3825523 SLC25A42 0.038  2601648 DOCK10 0.039 
3318543 OR52E5 0.036  3255361 RGR 0.037  2585701 STK39 0.038  3403539 FOXJ2 0.039 
2908423 SLC29A1 0.036  2989141 C7orf26 0.037  3671935 CRISPLD2 0.038  2949330 CLIC1 0.039 
3632037 PARP6 0.036  4009667 FGD1 0.037  3815936 REEP6 0.038  3533184 SSTR1 0.039 
2964139 GABRR2 0.036  2830861 EGR1 0.037  2912416 BAI3 0.038  3955875 TFIP11 0.039 
2573112 SCTR 0.036  3780287 RNMT 0.037  3753568 SLFN13 0.038  3695235 CCDC79 0.039 
2619480 CCBP2 0.036  4014387 RPSA 0.037  4015548 XKRX 0.038  3333417 SCGB2A1 0.039 
3914050 STMN3 0.036  3318390 TRIM6-34 0.037  3506093 FAM123A 0.038  3143970 NBN 0.039 
2434872 TMOD4 0.036  2901503 TRIM39 0.037  3015519 PILRA 0.038  2445643 SEC16B 0.039 
2713555 KIAA0226 0.036  3239667 GAD2 0.037  3317056 TNNI2 0.038  2383999 OBSCN 0.039 
3190420 CERCAM 0.036  3124180 PINX1 0.037  2715476 FAM193A 0.038  3807261 SMAD7 0.039 
3045570 TBX20 0.036  3468103 GNPTAB 0.037  3572340 TMED10 0.038  3890640 PCK1 0.039 
2339328 --- 0.036  3895330 SLC4A11 0.037  2691014 GSK3B 0.038  3224366 RC3H2 0.039 
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2357961 BOLA1 0.039  2610136 CRELD1 0.041  2663396 IQSEC1 0.042  3924424 COL6A2 0.043 
2970044 TUBE1 0.040  3057520 TMEM120A 0.041  2351940 DDX20 0.042  3291682 JMJD1C 0.043 
3085065 ERI1 0.040  3890154 CSTF1 0.041  2746269 LSM6 0.042  2412082 FAF1 0.043 
3145107 CCNE2 0.040  3767531 CCDC46 0.041  2850676 CDH18 0.042  3532560 BRMS1L 0.043 
3072014 TNPO3 0.040  4010183 SPIN3 0.041  3719231 MRM1 0.042  3662723 COQ9 0.043 
3944873 PDXP 0.040  2768354 TXK 0.041  3168136 RGP1 0.042  3851493 ZNF443 0.043 
3589822 DISP2 0.040  2415266 CYP2J2 0.041  3869078 SIGLEC12 0.042  3786471 SETBP1 0.043 
3557268 PPP1R3E 0.040  3625326 CCPG1 0.041  3224220 LHX6 0.042  2459587 TRIM17 0.043 
2460189 PGBD5 0.040  3545183 C14orf166B 0.041  3527418 PARP2 0.042  3661065 RBL2 0.043 
3652271 C16orf52 0.040  3947627 TSPO 0.041  3758209 LOC388387 0.042  2875954 VDAC1 0.043 
3661940 GNAO1 0.040  3770588 NT5C 0.041  2966636 ASCC3 0.042  2532021 PTMA 0.043 
3807965 MRO 0.040  2454343 RD3 0.041  3475764 GPR81 0.042  3266408 EMX2 0.043 
3357397 GLB1L2 0.040  2322786 PADI1 0.041  2744597 NAA15 0.042  3825446 DDX49 0.043 
3119213 LY6K 0.040  3952566 CLTCL1 0.041  3821159 LPPR2 0.042  2694314 GATA2 0.043 
3254468 DYDC2 0.040  2632919 ARL6 0.041  4019599 RNF113A 0.042  3389566 KBTBD3 0.043 
3420713 CAND1 0.040  3059667 SEMA3D 0.041  2551786 MCFD2 0.042  2427981 ADORA3 0.043 
3377177 CDC42BPG 0.040  2322894 PADI6 0.041  2978050 SHPRH 0.042  3349719 ZBTB16 0.043 
3880467 TMEM90B 0.040  3305017 OBFC1 0.041  3580876 PPP1R13B 0.042  3332838 DAK 0.043 
2493813 ZNF2 0.040  3737430 FLJ35220 0.041  2553771 CCDC88A 0.042  3316057 DRD4 0.043 
3978706 PAGE5 0.040  3768703 ABCA9 0.041  3535674 C14orf166 0.042  2498911 SULT1C2 0.043 
2327572 RAB42 0.040  2404209 SDC3 0.041  3924041 ADARB1 0.042  2356300 PIAS3 0.043 
3548538 C14orf159 0.040  3722060 VPS25 0.041  3645322 PRSS41 0.042  2770023 PDCL2 0.044 
3086206 FDFT1 0.040  2887309 DUSP1 0.041  2340350 DNAJC6 0.043  3893338 COL20A1 0.044 
2686371 TOMM70A 0.040  3309383 PRDX3 0.041  2943236 DTNBP1 0.043  2330334 THRAP3 0.044 
2962998 KIAA1009 0.040  3115504 MYC 0.042  3959918 TST 0.043  3876645 BTBD3 0.044 
2779823 SLC39A8 0.040  2405284 TMEM54 0.042  2460296 AGT 0.043  3129588 KIF13B 0.044 
2949971 C6orf10 0.040  2503374 GLI2 0.042  3708961 WRAP53 0.043  2471316 GEN1 0.044 
3359461 PHLDA2 0.040  3763656 TRIM25 0.042  3844152 ZNF324 0.043  3304797 CALHM3 0.044 
2655606 ECE2 0.041  2546409 ALK 0.042  3759105 FAM171A2 0.043  3035223 MICALL2 0.044 
3631517 THAP10 0.041  3456306 ATF7 0.042  3015299 MBLAC1 0.043  3848492 FCER2 0.044 
3907711 CDH22 0.041  2997231 PP13004 0.042  3174643 TMC1 0.043  3838809 PRMT1 0.044 
3136229 SDR16C5 0.041  2475710 LCLAT1 0.042  3743340 ASGR2 0.043  3469687 CKAP4 0.044 
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3363979 PSMA1 0.044  2451428 KLHL12 0.045  3285119 FZD8 0.046  3603436 CHRNA5 0.048 
3924518 MCM3AP-AS 0.044  3680254 PRM2 0.045  2399718 AKR7A2 0.046  3256074 BMPR1A 0.048 
3385509 FZD4 0.044  2349211 HEJ1 0.045  3873057 DEFB125 0.047  3579546 WARS 0.048 
3840562 HERV-V1 0.044  2832447 PCDHB13 0.045  2400718 USP48 0.047  2324919 EPHB2 0.048 
3695433 TRADD 0.044  2772160 --- 0.045  3988638 LONRF3 0.047  3975869 RP2 0.048 
3757602 DHX58 0.044  3861557 LGALS4 0.045  3977611 CXorf67 0.047  2840002 CCDC99 0.048 
3935486 S100B 0.044  2451816 C1orf157 0.045  2374414 GPR25 0.047  3635198 BCL2A1 0.048 
3351711 FOXR1 0.044  3382216 ARRB1 0.045  3066297 SRPK2 0.047  3855011 ELL 0.048 
3766373 FTSJ3 0.044  3435362 KNTC1 0.045  3452417 SLC38A4 0.047  2900940 MOG 0.048 
3717052 NF1 0.044  3605780 SCAND2 0.046  3923426 AGPAT3 0.047  3044597 PDE1C 0.048 
2468811 ASAP2 0.044  2768056 GABRA4 0.046  2438117 VHLL 0.047  2951881 PXT1 0.048 
3625234 RSL24D1 0.044  2902013 GTF2H4 0.046  2517013 MTX2 0.047  2434178 MTMR11 0.048 
3715809 NEK8 0.044  3569814 ACTN1 0.046  2365872 RCSD1 0.047  3652902 SCNN1B 0.048 
3016380 CUX1 0.044  2359885 SLC27A3 0.046  3118651 DENND3 0.047  2844479 SQSTM1 0.048 
2644014 PCCB 0.044  3322521 KCNC1 0.046  3642875 RAB11FIP3 0.047  3743571 YBX2 0.048 
2830742 KDM3B 0.044  3148582 EIF3E 0.046  2833078 NDFIP1 0.047  2953481 TREML1 0.048 
3346453 YAP1 0.044  3996404 GDI1 0.046  3360333 OR51A2 0.047  2350922 GSTM4 0.048 
2350741 ATXN7L2 0.044  3818732 ARHGEF18 0.046  2615060 RBMS3 0.047  3094245 ERLIN2 0.048 
3756997 KRT32 0.044  2536874 GAL3ST2 0.046  3714779 KCNJ12 0.047  3448744 PTHLH 0.049 
3417435 MYL6B 0.045  3113894 ZHX2 0.046  3448481 TM7SF3 0.047  3156193 EIF2C2 0.049 
3375990 INTS5 0.045  2838462 GABRG2 0.046  2505833 ARHGEF4 0.047  2602304 TM4SF20 0.049 
3696142 DPEP2 0.045  3361381 CYB5R2 0.046  3393993 BCL9L 0.047  4001223 RAI2 0.049 
3062576 ASNS 0.045  3845944 GNG7 0.046  2435383 S100A10 0.047  3738353 ASPSCR1 0.049 
3101385 MTFR1 0.045  2806517 SKP2 0.046  2429613 NHLH2 0.047  3728037 SCPEP1 0.049 
3838444 CCDC155 0.045  2350316 FNDC7 0.046  2560317 C2orf65 0.047  2876897 SPOCK1 0.049 
2435347 THEM4 0.045  2332144 CTPS 0.046  3421300 MDM2 0.047  2677200 LRTM1 0.049 
3091000 BNIP3L 0.045  2749191 GLRB 0.046  3079336 FASTK 0.047  3837464 GLTSCR2 0.049 
2443370 F5 0.045  2360850 FDPS 0.046  3843180 ZNF304 0.047  2432647 POLR3C 0.049 
2659521 LRRC33 0.045  3221571 RNF183 0.046  3772158 TK1 0.048  2516853 HOXD9 0.049 
3380065 CCND1 0.045  3502497 CUL4A 0.046  3764592 TEX14 0.048  2888399 SNCB 0.049 
3540839 --- 0.045  2961816 PHIP 0.046  2438612 INSRR 0.048  2829416 SEC24A 0.049 
2404546 COL16A1 0.045  3679503 TMEM186 0.046  3885537 PLCG1 0.048  3180342 C9orf3 0.049 
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3544251 YLPM1 0.049  3217194 TBC1D2 0.049  3633578 CSPG4 0.049  3940751 MYO18B 0.049 
3894365 C20orf54 0.049  2797771 TRIML2 0.049  3042001 CYCS 0.049  3743440 DVL2 0.049 
3015786 ZAN 0.049  3841881 NCR1 0.049  3757840 STAT3 0.049  3095766 GINS4 0.049 
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Transcript Symbol p-value  Transcript Symbol p-value  Transcript Symbol p-value  Transcript  Symbol p-value 
2979871 SYNE1 0.000  3928866 SFRS15 3.02E-13  3843848 ZNF544 8.80E-11  2843091 RGS14 1.70E-09 
2715076 WHSC1 1.96E-38  2971267 ROS1 5.56E-13  2367963 RABGAP1L 8.88E-11  3895722 CENPB 2.12E-09 
3377044 SF1 2.44E-36  2845591 BRD9 6.18E-13  2664099 MRPS25 1.02E-10  2334052 C1orf228 2.24E-09 
3653317 RBBP6 8.93E-32  3509910 FAM48A 6.18E-13  3712835 LRRC48 1.10E-10  2348634 AGL 2.43E-09 
2321238 PRDM2 1.51E-23  3036985 RNF216 7.43E-13  3620457 VPS39 1.11E-10  3659156 PHKB 2.52E-09 
3771513 PRPSAP1 3.09E-23  3529609 PSME1 7.53E-13  2723997 KLF3 1.11E-10  2870113 FBXL17 2.54E-09 
3896621 FERMT1 7.71E-23  3310479 NSMCE4A 9.13E-13  3869361 ZNF615 1.16E-10  3253683 ZMIZ1 2.80E-09 
2548970 SRSF7 2.13E-22  3430776 ISCU 1.03E-12  3629811 DENND4A 1.18E-10  2871821 TMED7 3.06E-09 
3081862 PTPRN2 3.72E-22  3368054 PAX6 1.10E-12  3398076 NFRKB 1.22E-10  3536706 LGALS3 3.54E-09 
3194635 C9orf86 6.83E-22  2622469 RBM5 1.19E-12  2662087 SRGAP3 1.37E-10  3661559 IRX5 3.56E-09 
3771800 SRSF2 2.81E-21  3816264 DOT1L 2.27E-12  3597125 TLN2 2.04E-10  3318390 TRIM6-34 4.45E-09 
3868183 NUP62 6.28E-20  3249886 TET1 2.31E-12  3908149 ZMYND8 2.23E-10  3746881 NCOR1 4.63E-09 
2593464 ANKRD44 6.87E-20  3604287 IL16 2.62E-12  2928930 PHACTR2 2.44E-10  3036476 RADIL 4.72E-09 
3240340 WAC 8.72E-18  2967151 HACE1 2.64E-12  2927506 TNFAIP3 2.52E-10  3661065 RBL2 5.00E-09 
3882012 DNMT3B 4.11E-17  2818079 ZCCHC9 5.22E-12  3470831 MMAB 2.57E-10  2610336 VHL 5.55E-09 
3708663 CHRNB1 5.43E-17  2358743 SCNM1 1.09E-11  2675801 PCBP4 2.72E-10  3159946 SMARCA2 6.50E-09 
3778252 ANKRD12 1.23E-16  3557268 PPP1R3E 1.20E-11  3427820 SLC25A3 2.82E-10  3228373 TSC1 6.55E-09 
3962997 EFCAB6 1.82E-16  3645253 SRRM2 1.41E-11  3222534 ASTN2 2.98E-10  3553690 MARK3 7.30E-09 
3764103 SRSF1 1.86E-16  3335517 KAT5 1.74E-11  2548500 PRKD3 3.21E-10  2752478 WDR17 8.06E-09 
3499453 TPP2 5.02E-16  3403015 ENO2 1.79E-11  3017547 MLL5 3.41E-10  2496727 MAP4K4 8.56E-09 
2520291 GLS 2.00E-15  2317512 DFFB 2.11E-11  4027708 MTCP1 3.48E-10  3341440 RN28S1 9.52E-09 
3571347 NUMB 4.36E-15  3257031 STAMBPL1 2.12E-11  3737430 FLJ35220 3.58E-10  2897899 SOX4 9.75E-09 
2962998 KIAA1009 4.38E-15  2708720 EHHADH 2.69E-11  2935475 QKI 3.82E-10  3500055 DAOA 9.79E-09 
3249738 HNRNPH3 1.50E-14  2459793 C1orf96 3.47E-11  3168415 CLTA 3.84E-10  2617687 XYLB 1.01E-08 
2943236 DTNBP1 2.25E-14  2407755 GJA9 3.73E-11  3614087 UBE3A 4.58E-10  3151473 ZHX1 1.01E-08 
2575054 WDR33 2.63E-14  2705266 TNIK 3.81E-11  2662331 CAMK1 5.81E-10  3167731 UNC13B 1.02E-08 
3336857 ANKRD13D 2.78E-14  3239760 APBB1IP 4.00E-11  2943874 KIF13A 6.75E-10  2343473 IFI44L 1.20E-08 
2704894 PHC3 4.67E-14  3848745 FBN3 5.20E-11  2395245 RERE 7.11E-10  2524743 FASTKD2 1.31E-08 
3634852 RASGRF1 5.00E-14  3517251 DACH1 6.16E-11  2785282 SCLT1 7.58E-10  2789266 LRBA 1.47E-08 
3199790 PSIP1 6.47E-14  2642911 UBA5 6.65E-11  3940901 SEZ6L 9.96E-10  3907524 PLTP 1.50E-08 
3543411 RBM25 1.38E-13  3933999 U2AF1 7.02E-11  3708764 TNFSF12-13 1.09E-09  3868587 SHANK1 1.63E-08 
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3886704 STK4 1.79E-08  3400034 WNK1 5.55E-08  2727226 PDGFRA 1.68E-07  3851267 ZNF625 4.00E-07 
3452145 SRSF2IP 1.94E-08  2376548 MFSD4 5.97E-08  3251848 SEC24C 1.71E-07  3267036 GRK5 4.61E-07 
3154700 ZFAT 1.94E-08  3304718 PCGF6 6.19E-08  3320717 MICAL2 1.72E-07  3647993 CIITA 4.64E-07 
3470597 SSH1 1.99E-08  3837431 EHD2 6.26E-08  3413344 PFKM 1.75E-07  3294499 PPP3CB 4.86E-07 
2417791 ANKRD13C 2.12E-08  3064082 LRCH4 6.27E-08  2645690 RNF7 1.93E-07  2372924 TROVE2 4.88E-07 
3282519 ARMC4 2.22E-08  3911177 ZBP1 6.32E-08  2451428 KLHL12 1.95E-07  2452754 SLC26A9 5.40E-07 
3701481 PKD1L2 2.23E-08  3764592 TEX14 6.40E-08  3547696 TTC8 1.98E-07  3726618 CACNA1G 5.47E-07 
3351531 ARCN1 2.49E-08  3377358 BATF2 6.48E-08  3923257 PDXK 2.02E-07  2360468 FLAD1 5.61E-07 
2909263 MEP1A 2.80E-08  2779163 ADH6 7.29E-08  2606574 NDUFA10 2.03E-07  3919860 DOPEY2 5.70E-07 
2400322 HP1BP3 2.90E-08  3134034 PRKDC 7.98E-08  2712794 TCTEX1D2 2.19E-07  3607275 ISG20 5.78E-07 
2346074 ZNF326 2.92E-08  2424524 DPYD 8.30E-08  3924674 DIP2A 2.22E-07  2328320 TINAGL1 5.82E-07 
3893760 TPD52L2 2.99E-08  3839206 MYH14 8.94E-08  3893338 COL20A1 2.22E-07  3381241 ARAP1 6.04E-07 
3091000 BNIP3L 3.02E-08  2488959 STAMBP 9.00E-08  3129731 DUSP4 2.27E-07  2320411 AGTRAP 6.16E-07 
3741997 ANKFY1 3.13E-08  2366490 BLZF1 9.01E-08  2904563 DEF6 2.28E-07  3188299 RABGAP1 6.27E-07 
3168136 RGP1 3.18E-08  2450568 CACNA1S 9.04E-08  2531233 SP140 2.36E-07  3672455 COX4I1 6.46E-07 
3708399 SLC2A4 3.26E-08  3978819 RRAGB 9.28E-08  3645881 ZNF174 2.51E-07  3108901 VPS13B 6.50E-07 
2404546 COL16A1 3.60E-08  3014957 ZNF498 9.32E-08  3125342 SGCZ 2.51E-07  2853388 C5orf33 6.83E-07 
3434193 CCDC64 3.65E-08  2925871 ENPP3 9.42E-08  2407163 SNIP1 2.55E-07  3894098 C20orf96 6.86E-07 
3064039 TSC22D4 3.72E-08  2429147 DENND2C 9.47E-08  3762753 CA10 2.65E-07  3823982 MYO9B 7.11E-07 
2927873 CCDC28A 3.77E-08  3605395 ADAMTSL3 9.68E-08  3252382 MYST4 2.71E-07  3524999 LIG4 7.17E-07 
3223738 TRAF1 3.94E-08  3430959 ACACB 1.01E-07  3389566 KBTBD3 2.78E-07  3041875 OSBPL3 7.24E-07 
2877314 CDC23 4.07E-08  3529877 LTB4R2 1.02E-07  3064204 ACTL6B 2.81E-07  3962530 CYB5R3 7.27E-07 
3340913 C11orf30 4.15E-08  2798586 AHRR 1.04E-07  3738969 FOXK2 2.98E-07  2969677 REV3L 7.45E-07 
2419235 FUBP1 4.27E-08  3947604 BIK 1.06E-07  3387771 CCDC82 3.11E-07  2621705 ATRIP 7.50E-07 
3720921 RARA 4.34E-08  2549455 THUMPD2 1.15E-07  3421446 CPSF6 3.16E-07  2333794 DMAP1 7.97E-07 
3740838 SMG6 4.34E-08  3503164 CDC16 1.20E-07  3989721 STAG2 3.18E-07  2534126 COPS8 8.06E-07 
3471264 VPS29 4.46E-08  3258671 PDE6C 1.36E-07  2678400 ACOX2 3.49E-07  2780522 PPA2 8.67E-07 
2612175 NR2C2 4.50E-08  3510755 --- 1.38E-07  3758692 MPP2 3.51E-07  3756630 KRT40 9.60E-07 
3716481 GOSR1 4.57E-08  2546008 SUPT7L 1.40E-07  3980078 STARD8 3.75E-07  2622970 DOCK3 9.71E-07 
3923436 TRAPPC10 4.58E-08  3653398 TNRC6A 1.43E-07  3707214 PLD2 3.78E-07  2508520 KYNU 9.93E-07 
3553872 KLC1 5.12E-08  3845647 MKNK2 1.55E-07  3584443 SNRPN 3.80E-07  2824872 AP3S1 1.03E-06 
2341565 SRSF11 5.16E-08  3804143 RPRD1A 1.55E-07  3620741 CDAN1 3.80E-07  3427352 NEDD1 1.05E-06 
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3843419 ZNF211 1.23E-06  3177880 DAPK1 2.46E-06  2405576 CSMD2 4.35E-06  2369252 C1orf49 6.54E-06 
3336277 BBS1 1.29E-06  3677498 ZNF200 2.50E-06  2678526 C3orf67 4.38E-06  3409605 FAR2 6.64E-06 
3090326 ADAM7 1.33E-06  3347658 ATM 2.51E-06  3454006 FMNL3 4.52E-06  3674303 CDK10 6.69E-06 
2929870 STXBP5 1.40E-06  3892409 LSM14B 2.60E-06  2475407 CLIP4 4.56E-06  3868857 KLK12 6.74E-06 
3357885 SIGIRR 1.40E-06  3377789 RELA 2.63E-06  3820758 DNM2 4.61E-06  2559386 SFXN5 6.76E-06 
3501661 ARHGEF7 1.42E-06  2821347 ERAP2 2.74E-06  3653516 SLC5A11 4.64E-06  3372253 CELF1 6.90E-06 
3178952 SYK 1.42E-06  3158516 CPSF1 2.74E-06  3604006 ARNT2 4.66E-06  3644764 CCNF 7.28E-06 
3878220 C20orf72 1.43E-06  3844978 SBNO2 2.76E-06  2522728 CASP8 4.68E-06  3824395 PGLS 7.36E-06 
2599901 C2orf24 1.49E-06  2454935 ANGEL2 2.83E-06  3048413 POLD2 4.74E-06  3190190 LCN2 7.40E-06 
2891241 DUSP22 1.59E-06  3933243 PRDM15 2.87E-06  2431886 PDE4DIP 4.76E-06  3528944 REM2 7.45E-06 
3757037 KRT36 1.60E-06  2666478 TOP2B 3.07E-06  3948953 PPARA 4.84E-06  3185976 COL27A1 7.56E-06 
3010503 CD36 1.64E-06  3904594 C20orf117 3.09E-06  3751323 MYO18A 4.90E-06  3601675 ARID3B 7.73E-06 
3545183 C14orf166B 1.64E-06  2902326 HCP5 3.11E-06  3654111 JMJD5 4.98E-06  2724377 --- 7.75E-06 
3091301 PTK2B 1.67E-06  3881261 REM1 3.13E-06  2434776 CDC42SE1 4.99E-06  3914050 STMN3 7.77E-06 
3870478 OSCAR 1.83E-06  3709327 CNTROB 3.18E-06  3819374 CCL25 5.17E-06  3580498 CDC42BPB 7.78E-06 
2375664 BTG2 1.84E-06  3486383 COG6 3.19E-06  3371114 SYT13 5.20E-06  3918959 MRPS6 8.07E-06 
3837276 DHX34 1.86E-06  3245783 WDFY4 3.20E-06  3770944 H3F3B 5.23E-06  2353988 FAM46C 8.56E-06 
2666566 NGLY1 1.87E-06  3883309 CEP250 3.22E-06  3706071 DPH1 5.29E-06  2638824 CASR 8.62E-06 
3710515 DNAH9 1.91E-06  2362892 ATP1A2 3.22E-06  3031181 ATP6V0E2 5.30E-06  2486811 PLEK 8.65E-06 
3469319 APPL2 1.96E-06  2570238 NPHP1 3.36E-06  2474019 DPYSL5 5.35E-06  3326461 EHF 8.73E-06 
3273601 IDI1 2.03E-06  3854132 CPAMD8 3.39E-06  3678231 FAM100A 5.40E-06  3016380 CUX1 8.76E-06 
2692573 CCDC14 2.11E-06  3959451 MYH9 3.42E-06  3188050 MRRF 5.69E-06  3033728 RNF32 8.79E-06 
3048373 POLM 2.16E-06  2758733 STX18 3.54E-06  3035795 C7orf27 5.81E-06  3758234 AARSD1 8.86E-06 
2360850 FDPS 2.18E-06  3260829 FAM178A 3.58E-06  3604147 KIAA1199 6.04E-06  2550122 COX7A2L 8.91E-06 
2746693 ARHGAP10 2.19E-06  2731417 MTHFD2L 3.61E-06  3471538 FAM109A 6.09E-06  2623662 DNAH1 8.95E-06 
2326954 TMEM222 2.23E-06  2954678 XPO5 3.71E-06  3343202 EED 6.12E-06  2948630 IER3 9.25E-06 
3226160 SIAT7F 2.23E-06  3913018 LAMA5 3.77E-06  2435005 SELENBP1 6.23E-06  2343511 IFI44 9.49E-06 
3891664 CDH26 2.28E-06  3747657 FLCN 3.83E-06  3743611 NEURL4 6.25E-06  3505937 CENPJ 9.51E-06 
4006841 SLC9A7 2.29E-06  3451814 NELL2 3.91E-06  2336439 GPX7 6.26E-06  3417201 IKZF4 9.72E-06 
3189864 LRSAM1 2.34E-06  3309345 SFXN4 3.93E-06  2387126 RYR2 6.38E-06  2899216 HIST1H4E 9.90E-06 
3147286 RRM2B 2.39E-06  2319661 KIF1B 3.98E-06  3326635 CD44 6.44E-06  3811339 BCL2 1.01E-05 
3531736 NPAS3 2.40E-06  2738146 TET2 4.10E-06  3906062 ZHX3 6.47E-06  3266408 EMX2 1.03E-05 
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3010439 GNAI1 1.06E-05  3657041 ITGAX 1.80E-05  3590460 ITPKA 2.44E-05  3825650 MAU2 3.48E-05 
3557614 AP1G2 1.06E-05  2605674 ILKAP 1.84E-05  3888055 ARFGEF2 2.45E-05  2367495 C1orf105 3.51E-05 
2645906 PLS1 1.07E-05  3595846 FAM63B 1.84E-05  2939034 SERPINB9 2.47E-05  3697434 HYDIN 3.52E-05 
3304012 MGEA5 1.11E-05  2892170 WRNIP1 1.86E-05  2617041 GOLGA4 2.50E-05  2523689 ABI2 3.56E-05 
3849923 COL5A3 1.12E-05  2967550 ATG5 1.88E-05  3244061 ZNF487P 2.56E-05  2524653 ADAM23 3.62E-05 
3705911 WDR81 1.14E-05  3938113 HIC2 1.95E-05  2479640 PPM1B 2.57E-05  3107724 C8orf38 3.63E-05 
3768791 ABCA6 1.16E-05  3740264 INPP5K 1.96E-05  3540862 GPHN 2.64E-05  3590853 CAPN3 3.65E-05 
2350596 CELSR2 1.18E-05  3011317 CROT 1.98E-05  3344861 C11orf54 2.68E-05  3378043 CATSPER1 3.74E-05 
2674919 MST1R 1.19E-05  3212008 FRMD3 1.98E-05  3071630 --- 2.68E-05  2698844 ATR 3.77E-05 
2951541 TULP1 1.19E-05  2577482 TMEM163 2.01E-05  3030799 KRBA1 2.70E-05  2451958 PLEKHA6 3.87E-05 
3882652 ZNF341 1.25E-05  3314630 C10orf92 2.01E-05  3723378 FMNL1 2.71E-05  3676279 RPL3L 3.92E-05 
2939593 PECI 1.26E-05  2927722 HEBP2 2.04E-05  3965314 BRD1 2.73E-05  3966929 GYG2 3.92E-05 
3737488 RPTOR 1.29E-05  3531032 SCFD1 2.04E-05  2986546 PDCD2 2.92E-05  3860296 COX7A1 3.97E-05 
4009560 FAM120C 1.29E-05  2819779 GPR98 2.06E-05  2553730 MTIF2 2.96E-05  3376914 NRXN2 3.97E-05 
3241601 C10orf68 1.33E-05  3841949 EPS8L1 2.06E-05  3438027 RAN 2.98E-05  2345239 --- 3.97E-05 
3130244 TEX15 1.35E-05  2603544 NMUR1 2.07E-05  2787459 INPP4B 3.00E-05  2749699 RAPGEF2 4.03E-05 
3349293 NCAM1 1.35E-05  3537967 KIAA0586 2.08E-05  2957499 ICK 3.01E-05  3451318 ZCRB1 4.12E-05 
3086100 GATA4 1.39E-05  2840036 DOCK2 2.10E-05  2581000 NEB 3.03E-05  3840224 ZNF528 4.34E-05 
2406926 GRIK3 1.40E-05  3374083 MED19 2.11E-05  3464589 C12orf50 3.03E-05  2954489 C6orf108 4.38E-05 
3854627 JAK3 1.50E-05  3815649 CIRBP 2.15E-05  2326410 CCDC21 3.03E-05  2686727 ZBTB11 4.39E-05 
3300211 FGFBP3 1.50E-05  3155489 FAM135B 2.16E-05  2399908 TMCO4 3.07E-05  3452865 COL2A1 4.42E-05 
3883690 EPB41L1 1.50E-05  3703129 C16orf74 2.16E-05  2757427 LETM1 3.08E-05  3263944 PDCD4 4.45E-05 
3891048 NPEPL1 1.56E-05  2664288 METTL6 2.17E-05  3971845 CXorf58 3.08E-05  2950384 COL11A2 4.46E-05 
2951664 CLPS 1.58E-05  3016791 LRWD1 2.17E-05  3847112 PTPRS 3.10E-05  3427282 C12orf63 4.47E-05 
3282213 YME1L1 1.58E-05  3338783 C11orf76 2.18E-05  2401448 E2F2 3.10E-05  2573641 CLASP1 4.47E-05 
3717539 RHOT1 1.61E-05  2420642 MCOLN2 2.21E-05  2374746 NAV1 3.13E-05  3909064 TMEM189 4.48E-05 
2476510 LTBP1 1.63E-05  3308378 C10orf82 2.21E-05  3018605 SLC26A4 3.17E-05  3512527 TPT1 4.61E-05 
3315114 TUBGCP2 1.63E-05  3936256 BCL2L13 2.26E-05  3515009 VPS36 3.19E-05  2688180 DPPA4 4.74E-05 
3992304 SAGE1 1.67E-05  2712417 TNK2 2.27E-05  3103494 TMEM70 3.23E-05  3437801 PIWIL1 4.92E-05 
3501219 COL4A2 1.70E-05  3571944 LTBP2 2.33E-05  3754797 HNF1B 3.24E-05  2522616 CFLAR 4.93E-05 
3855660 SUGP1 1.73E-05  2410158 TESK2 2.38E-05  2404344 NKAIN1 3.26E-05  3302886 HPSE2 5.00E-05 
2941784 NEDD9 1.77E-05  3644593 MLST8 2.43E-05  2920619 ARMC2 3.33E-05  2548871 HNRPLL 5.16E-05 
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3609592 MCTP2 5.24E-05  2734784 AFF1 6.66E-05  3225096 NR6A1 8.89E-05  3985615 TCEAL4 1.08E-04 
2560178 LBX2 5.27E-05  3704299 MVD 6.69E-05  3821183 C19orf39 8.92E-05  3258477 PLCE1 1.09E-04 
2528407 TUBA4B 5.28E-05  3438617 EP400 6.75E-05  3191805 LAMC3 9.00E-05  2452977 FAIM3 1.11E-04 
3468009 ARL1 5.29E-05  2637980 POGLUT1 6.83E-05  2545653 MPV17 9.11E-05  4021508 ZNF280C 1.13E-04 
3918779 ITSN1 5.36E-05  3815268 KISS1R 6.85E-05  3257670 PCGF5 9.19E-05  3802980 DSC2 1.14E-04 
2648991 KCNAB1 5.55E-05  3311157 OAT 6.95E-05  2337147 ACOT11 9.20E-05  3542275 SMOC1 1.14E-04 
2945741 FAM65B 5.69E-05  2402493 PAFAH2 7.08E-05  3005363 ASL 9.21E-05  2979111 LRP11 1.15E-04 
3040518 MACC1 5.70E-05  3713794 EPN2 7.14E-05  3447933 IFLTD1 9.24E-05  2930592 TAB2 1.15E-04 
3476457 NCOR2 5.76E-05  3867195 FAM83E 7.22E-05  3795866 ENOSF1 9.51E-05  3874249 ITPA 1.16E-04 
2788366 ZNF827 5.81E-05  3274934 CALML5 7.31E-05  3453592 MLL2 9.51E-05  3360622 TRIM5 1.16E-04 
2778727 C4orf37 5.83E-05  2327338 XKR8 7.37E-05  2949885 GPSM3 9.56E-05  2674808 TRAIP 1.16E-04 
3296386 DLG5 5.83E-05  3371339 PHF21A 7.39E-05  3036844 FBXL18 9.58E-05  2438892 FCRL5 1.17E-04 
2368198 CACYBP 5.88E-05  3644297 GFER 7.40E-05  2786657 SETD7 9.59E-05  3903089 NECAB3 1.18E-04 
3164601 KIAA1797 5.93E-05  2942432 C6orf114 7.41E-05  3760957 SCRN2 9.61E-05  3887049 UBE2C 1.20E-04 
4018729 IL13RA2 5.94E-05  3558145 CIDEB 7.45E-05  2335922 CDKN2C 9.63E-05  2327375 ATPIF1 1.22E-04 
2667181 AZI2 5.96E-05  2358520 SETDB1 7.54E-05  2889382 PROP1 9.66E-05  2755053 CYP4V2 1.22E-04 
2686458 ABI3BP 5.96E-05  3777263 ARHGAP28 7.70E-05  3338552 CTTN 9.68E-05  3035408 PSMG3 1.24E-04 
2403027 MAP3K6 5.98E-05  2891556 FOXQ1 7.76E-05  2726396 ZAR1 9.87E-05  3851589 C19orf56 1.24E-04 
2956904 PKHD1 6.04E-05  3642200 PCSK6 7.79E-05  3672059 KIAA0513 9.94E-05  3293963 DNAJB12 1.25E-04 
3035281 INTS1 6.14E-05  2353021 SYCP1 7.82E-05  3255220 GHITM 9.98E-05  3474885 CAMKK2 1.25E-04 
3995885 PLXNB3 6.15E-05  3569441 ZFYVE26 7.82E-05  3662851 GPR97 9.99E-05  3059226 PCLO 1.26E-04 
3907987 SLC13A3 6.16E-05  2910138 IL17A 7.85E-05  3854693 IL12RB1 1.00E-04  2537290 TMEM18 1.26E-04 
3866845 PLA2G4C 6.18E-05  2694001 MGLL 7.87E-05  3393993 BCL9L 1.00E-04  3723627 CRHR1 1.27E-04 
3135340 OPRK1 6.18E-05  4000538 FIGF 7.88E-05  3941907 EWSR1 1.01E-04  3924573 PCNT 1.29E-04 
3032243 GALNT11 6.19E-05  3776504 TGIF1 7.94E-05  3835131 ZNF576 1.01E-04  3149161 CSMD3 1.29E-04 
3902983 CDK5RAP1 6.24E-05  2321813 CELA2A 8.02E-05  3843947 ZSCAN22 1.03E-04  2379863 CENPF 1.32E-04 
3250486 COL13A1 6.26E-05  3549264 KIAA1409 8.12E-05  3996227 TKTL1 1.03E-04  3439268 NHP2L1 1.32E-04 
3389330 CASP5 6.27E-05  3218041 BAAT 8.24E-05  3359171 INS 1.03E-04  2880679 SH3TC2 1.32E-04 
2378019 CAMK1G 6.34E-05  4026842 ARHGAP4 8.34E-05  3560527 C14orf147 1.03E-04  3238962 KIAA1217 1.33E-04 
3417249 ERBB3 6.38E-05  3821159 LPPR2 8.48E-05  2588066 ATF2 1.04E-04  3561532 SLC25A21 1.33E-04 
2585400 SCN9A 6.44E-05  3721851 COASY 8.53E-05  2491615 MAT2A 1.07E-04  3094286 PROSC 1.34E-04 
2806091 RAI14 6.48E-05  2398820 PADI2 8.62E-05  3015865 SLC12A9 1.08E-04  3157751 SCRIB 1.36E-04 
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3633890 SCAPER 1.38E-04  3225952 FAM129B 1.61E-04  3437500 GLT1D1 1.89E-04  2594905 ALS2CR11 2.27E-04 
2401193 LUZP1 1.39E-04  3815757 MUM1 1.61E-04  4021469 AIFM1 1.89E-04  3683549 UMOD 2.28E-04 
2425118 SASS6 1.39E-04  3736162 TMC8 1.61E-04  3003107 ZNF713 1.90E-04  3701297 CDYL2 2.28E-04 
3726691 ABCC3 1.39E-04  3706753 GSG2 1.64E-04  3686750 RABEP2 1.90E-04  2590736 NCKAP1 2.28E-04 
2483016 CCDC104 1.40E-04  3894601 FKBP1A 1.64E-04  3575567 FOXN3 1.91E-04  2363525 NDUFS2 2.30E-04 
3393311 DSCAML1 1.41E-04  3711869 ADORA2B 1.64E-04  2949038 BAT1 1.91E-04  3600283 THSD4 2.30E-04 
3940001 SPECC1L 1.42E-04  3489644 TRIM13 1.64E-04  3656990 ITGAM 1.92E-04  2394478 CHD5 2.31E-04 
3762519 SPAG9 1.43E-04  3264391 VTI1A 1.64E-04  3952718 UFD1L 1.94E-04  3110341 DCAF13 2.33E-04 
2485784 ACTR2 1.44E-04  2970086 LAMA4 1.68E-04  3988596 ZCCHC12 1.94E-04  2439314 OR10K2 2.35E-04 
3671552 NECAB2 1.46E-04  2793054 CBR4 1.69E-04  2673830 DALRD3 1.96E-04  3894322 SRXN1 2.40E-04 
3611126 MEF2A 1.46E-04  2413633 CYB5RL 1.72E-04  2876011 SKP1 1.96E-04  3336906 SSH3 2.40E-04 
2360346 CHRNB2 1.47E-04  3620380 PLA2G4D 1.72E-04  3592755 SEMA6D 1.96E-04  2519981 PMS1 2.41E-04 
3545564 ADCK1 1.47E-04  3443464 PZP 1.73E-04  3087813 PCM1 1.97E-04  2880905 CSNK1A1 2.43E-04 
3502259 MCF2L 1.47E-04  3951927 BID 1.73E-04  2949859 PBX2 1.98E-04  2436283 DENND4B 2.44E-04 
3146103 STK3 1.49E-04  3526378 PCID2 1.75E-04  3848651 TIMM44 1.98E-04  3685610 ARHGAP17 2.46E-04 
3415668 TENC1 1.50E-04  2560881 LRRTM4 1.75E-04  2775562 HNRPDL 1.98E-04  2669803 SCN11A 2.47E-04 
3724591 C17orf57 1.50E-04  3234277 GATA3 1.75E-04  3293215 TYSND1 1.99E-04  3965631 TUBGCP6 2.47E-04 
3862661 BLVRB 1.50E-04  3497659 RAP2A 1.76E-04  3419585 TMEM5 2.00E-04  2905432 TBC1D22B 2.51E-04 
2606859 KIF1A 1.51E-04  2926323 EYA4 1.77E-04  3765299 APPBP2 2.05E-04  3166880 NFX1 2.51E-04 
2920377 LACE1 1.51E-04  3662696 CX3CL1 1.78E-04  2401994 RUNX3 2.07E-04  3465227 KERA 2.53E-04 
3878972 C20orf26 1.52E-04  3450655 CPNE8 1.78E-04  3062794 TECPR1 2.09E-04  3397003 KIRREL3 2.55E-04 
3712978 MYO15A 1.52E-04  3697712 TAT 1.79E-04  3617830 ZNF770 2.10E-04  3756046 NR1D1 2.55E-04 
2461786 ARID4B 1.53E-04  2742829 INTU 1.80E-04  3916138 C21orf74 2.11E-04  2989050 RAC1 2.56E-04 
3855633 TM6SF2 1.54E-04  3243846 RET 1.80E-04  3303652 MRPL43 2.11E-04  2816030 POLK 2.56E-04 
3833323 ZNF546 1.54E-04  2810015 DDX4 1.81E-04  4005392 BCOR 2.13E-04  3608427 FES 2.58E-04 
2583631 RBMS1 1.55E-04  3913960 PRIC285 1.81E-04  3478457 STX2 2.15E-04  2479746 C2orf34 2.60E-04 
3589141 SPRED1 1.55E-04  3458857 AVIL 1.82E-04  3441280 AKAP3 2.17E-04  3301263 SORBS1 2.60E-04 
3822100 DAND5 1.56E-04  2841699 CPEB4 1.84E-04  3913737 NKAIN4 2.17E-04  3074531 SLC13A4 2.60E-04 
2900195 ZNF165 1.57E-04  3888383 SLC9A8 1.84E-04  4023006 ZNF75D 2.19E-04  3549033 GOLGA5 2.62E-04 
2615808 GPD1L 1.57E-04  3646366 C16orf71 1.85E-04  2984543 PRR18 2.23E-04  3304004 NPM3 2.62E-04 
2619120 TRAK1 1.58E-04  3893287 ARFGAP1 1.86E-04  3226340 PTGES2 2.23E-04  3064501 MOGAT3 2.62E-04 
3049025 TBRG4 1.58E-04  3894637 NSFL1C 1.88E-04  3673892 CDH15 2.24E-04  3821377 ZNF441 2.64E-04 
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3836243 CD3EAP 2.66E-04  3638607 ANPEP 3.06E-04  3874023 PTPRA 3.60E-04  2712236 MUC4 4.30E-04 
3490741 SUGT1 2.66E-04  2913123 RIMS1 3.07E-04  3903836 EIF6 3.62E-04  3375894 EML3 4.31E-04 
3405207 BCL2L14 2.66E-04  2359664 S100A9 3.08E-04  3742212 ALOX15 3.62E-04  3715642 FOXN1 4.35E-04 
3066496 ATXN7L1 2.66E-04  2771718 UBA6 3.10E-04  2631556 CADM2 3.63E-04  2459837 ACTA1 4.36E-04 
3389647 GUCY1A2 2.67E-04  3537884 ARID4A 3.10E-04  3856554 ZNF100 3.64E-04  3194284 GPSM1 4.38E-04 
2892979 CDYL 2.69E-04  3421706 RAB3IP 3.10E-04  2539387 C2orf46 3.64E-04  3696194 DDX28 4.38E-04 
2359036 SNX27 2.70E-04  3627363 NARG2 3.10E-04  2925013 C6orf58 3.66E-04  2901552 RPP21 4.39E-04 
3010082 PHTF2 2.71E-04  3278057 CCDC3 3.11E-04  2438042 SMG5 3.66E-04  2813060 PIK3R1 4.39E-04 
3497586 MBNL2 2.72E-04  3272027 LRRC27 3.13E-04  3823681 KLF2 3.67E-04  3289631 CSTF2T 4.41E-04 
3699335 LDHD 2.73E-04  2672016 FYCO1 3.15E-04  3456666 NFE2 3.68E-04  2479698 SLC3A1 4.42E-04 
2583014 BAZ2B 2.75E-04  3531355 NUBPL 3.15E-04  2599670 CRYBA2 3.72E-04  3230760 C9orf140 4.44E-04 
2334932 CYP4B1 2.78E-04  3572975 NGB 3.17E-04  3661684 MMP2 3.81E-04  2360728 TRIM46 4.45E-04 
3868998 NKG7 2.79E-04  3268222 BTBD16 3.17E-04  2407496 POU3F1 3.90E-04  2339139 INADL 4.46E-04 
4012299 PHKA1 2.85E-04  3095223 IDO1 3.18E-04  2799184 NDUFS6 3.90E-04  3157647 PYCRL 4.51E-04 
3695450 EXOC3L 2.88E-04  3838845 CPT1C 3.19E-04  2655955 VPS8 3.92E-04  3662723 COQ9 4.52E-04 
3501471 ING1 2.88E-04  3752258 EVI2B 3.22E-04  2627390 ATXN7 3.95E-04  3846709 STAP2 4.55E-04 
2365391 FMO9P 2.89E-04  2740067 ANK2 3.24E-04  3894047 PCMTD2 3.95E-04  3743440 DVL2 4.57E-04 
3734683 ARMC7 2.92E-04  2469825 GREB1 3.26E-04  3390195 EXPH5 3.99E-04  3126191 PSD3 4.58E-04 
3332449 C11orf64 2.92E-04  3528994 ACIN1 3.27E-04  3676421 PKD1 4.00E-04  2875454 SEPT8 4.59E-04 
3904797 C20orf132 2.95E-04  3853108 NOTCH3 3.31E-04  2772968 COX18 4.02E-04  3739668 VPS53 4.60E-04 
3809826 ATP8B1 2.96E-04  4021149 SMARCA1 3.32E-04  3438847 FBRSL1 4.04E-04  3518086 TBC1D4 4.62E-04 
3621417 CATSPER2 2.98E-04  3499585 BIVM 3.36E-04  3325052 EIF2AK2 4.09E-04  3838809 PRMT1 4.63E-04 
2550522 ZFP36L2 2.99E-04  3847858 SLC25A41 3.37E-04  3833620 LTBP4 4.12E-04  3848020 TNFSF14 4.67E-04 
3632424 HCN4 3.00E-04  2491386 TCF7L1 3.45E-04  2381368 HLX 4.13E-04  2664452 ANKRD28 4.68E-04 
2320392 C1orf187 3.00E-04  3863606 LIPE 3.45E-04  2953435 C6orf130 4.13E-04  3853658 CYP4F11 4.68E-04 
2992766 NUPL2 3.01E-04  2569649 EDAR 3.46E-04  2879927 LARS 4.15E-04  3615579 TJP1 4.71E-04 
3999148 GPR143 3.03E-04  2340529 PDE4B 3.46E-04  3835855 TOMM40 4.16E-04  2585236 TTC21B 4.72E-04 
3291435 RTKN2 3.03E-04  2327630 YTHDF2 3.46E-04  2367743 PRDX6 4.16E-04  3361811 STK33 4.72E-04 
3089597 KIAA1967 3.04E-04  3881404 COX4I2 3.53E-04  2449559 ASPM 4.17E-04  3089740 RHOBTB2 4.73E-04 
3707041 SMTNL2 3.04E-04  3154263 SLA 3.55E-04  3697933 PKD1L3 4.17E-04  3261723 TMEM180 4.76E-04 
2716025 RGS12 3.05E-04  3246141 CHAT 3.57E-04  3226138 AK1 4.28E-04  2556017 C2orf86 4.76E-04 
3442785 CLEC4C 3.06E-04  3864375 LYPD3 3.57E-04  2332999 WDR65 4.28E-04  2380055 KCTD3 4.78E-04 
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2652027 CLDN11 4.88E-04  2675088 IFRD2 5.91E-04  2377332 CR1 6.66E-04  2915268 DOPEY1 7.58E-04 
2946324 HIST1H3D 4.90E-04  2812273 PPWD1 5.92E-04  3357397 GLB1L2 6.77E-04  3020804 NAA38 7.64E-04 
2593796 RFTN2 4.91E-04  3504526 LATS2 6.01E-04  3513147 HTR2A 6.80E-04  3126368 PSD3 7.64E-04 
3227070 PTGES 4.95E-04  2676182 NT5DC2 6.05E-04  2891644 FOXF2 6.83E-04  3910347 SUMO1P1 7.70E-04 
3741875 ZZEF1 4.97E-04  2618702 ZNF620 6.07E-04  3409432 CCDC91 6.85E-04  3484768 PDS5B 7.80E-04 
2610732 ATG7 5.01E-04  3487360 C13orf30 6.11E-04  3680213 SOCS1 6.87E-04  3895702 SPEF1 7.83E-04 
3406880 PIK3C2G 5.06E-04  3644810 C16orf59 6.13E-04  2592356 STAT4 6.87E-04  3534923 KLHDC2 7.87E-04 
3865776 IRF2BP1 5.12E-04  3204833 GBA2 6.14E-04  3421579 FRS2 6.89E-04  3867458 PLEKHA4 7.89E-04 
2777333 PPM1K 5.12E-04  3644249 TBL3 6.15E-04  2601995 IRS1 6.89E-04  2817731 ZFYVE16 7.91E-04 
3120613 PPP1R16A 5.13E-04  3062193 SLC25A13 6.21E-04  2717059 LOC93622 6.90E-04  3831620 ZNF568 7.92E-04 
2641263 RAB7A 5.14E-04  3944543 NCF4 6.21E-04  3480508 IL17D 6.90E-04  3091699 PNOC 7.93E-04 
2422612 HFM1 5.14E-04  2474791 BRE 6.22E-04  2950823 IP6K3 6.93E-04  2769182 SCFD2 7.94E-04 
3981027 TAF1 5.15E-04  2860666 TAF9 6.22E-04  3192525 GTF3C4 6.95E-04  3734609 KCTD2 7.99E-04 
2423422 BCAR3 5.16E-04  2437577 YY1AP1 6.25E-04  3893642 LIME1 6.95E-04  3835318 ZNF155 8.03E-04 
3645683 ZNF213 5.16E-04  2353396 C1orf161 6.31E-04  2714132 PDE6B 7.00E-04  2949488 SLC44A4 8.04E-04 
3396726 PATE2 5.17E-04  3379644 CPT1A 6.32E-04  2796790 KIAA1430 7.03E-04  3489350 CDADC1 8.05E-04 
3062868 BAIAP2L1 5.17E-04  3985169 NXF4 6.32E-04  3100166 RAB2A 7.03E-04  3726465 RSAD1 8.05E-04 
2346738 RPAP2 5.17E-04  3861372 RASGRP4 6.40E-04  2328767 IQCC 7.04E-04  3350908 CEP164 8.06E-04 
3651509 ERI2 5.18E-04  2321911 DDI2 6.43E-04  3946146 FAM83F 7.08E-04  2799758 IRX1 8.12E-04 
3015299 MBLAC1 5.19E-04  2479433 PLEKHH2 6.44E-04  2875555 AFF4 7.11E-04  3730161 EFCAB3 8.24E-04 
2356181 RBM8A 5.25E-04  3352040 PDZD3 6.44E-04  3622176 DUOX2 7.15E-04  3015241 AP4M1 8.26E-04 
3642875 EFERIN 5.28E-04  2429277 CSDE1 6.44E-04  2952497 BTBD9 7.21E-04  3557350 SLC22A17 8.31E-04 
2730531 UTP3 5.34E-04  3820727 QTRT1 6.45E-04  3669552 VAT1L 7.24E-04  3475926 PITPNM2 8.32E-04 
2725779 GUF1 5.37E-04  3559690 HEATR5A 6.46E-04  3687277 SEZ6L2 7.25E-04  3339812 ARHGEF17 8.33E-04 
2326993 SYTL1 5.51E-04  2845450 TPPP 6.47E-04  3715558 SARM1 7.28E-04  3761127 CBX1 8.34E-04 
2877171 FAM13B 5.51E-04  2964553 BACH2 6.48E-04  3474831 OASL 7.37E-04  3744965 GAS7 8.40E-04 
2326912 WDTC1 5.58E-04  3102372 SULF1 6.49E-04  2622696 SEMA3B 7.38E-04  3322700 SAA1 8.42E-04 
3417184 SUOX 5.62E-04  3884612 SNHG11 6.53E-04  2574646 BIN1 7.39E-04  2375144 LGR6 8.45E-04 
3158581 SLC39A4 5.62E-04  3947227 SEPT3 6.55E-04  2694314 GATA2 7.41E-04  3269939 DOCK1 8.48E-04 
3868659 C19orf48 5.66E-04  2697490 CEP70 6.55E-04  3644510 RAB26 7.48E-04  3932524 DSCAM 8.56E-04 
2669888 GORASP1 5.77E-04  3236958 VIM 6.59E-04  2756630 CPLX1 7.55E-04  3597914 SNX22 8.59E-04 
3179669 C9orf89 5.84E-04  3299578 CH25H 6.59E-04  3409127 ARNTL2 7.56E-04  2486520 ETAA1 8.61E-04 
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3887210 MMP9 8.89E-04  2811812 LRRC70 9.91E-04  3853036 SLC1A6 1.07E-03  2519756 WDR75 1.21E-03 
3976299 ARAF 9.01E-04  3638590 MESP1 9.92E-04  3606682 AGBL1 1.07E-03  3941623 HSCB 1.22E-03 
2491089 DNAH6 9.01E-04  3308489 KIAA1598 9.93E-04  2687840 IFT57 1.08E-03  2768197 CORIN 1.22E-03 
2327542 TRNAU1AP 9.08E-04  3085270 TNKS 9.93E-04  3655687 PRRT2 1.08E-03  3731228 CCDC45 1.22E-03 
2333195 KIAA0467 9.10E-04  3067250 SLC26A3 9.99E-04  3865618 SIX5 1.08E-03  3902674 TSPY26P 1.23E-03 
2779527 DDIT4L 9.12E-04  3651294 ACSM5 9.99E-04  2830450 NPY6R 1.08E-03  2408855 FOXJ3 1.23E-03 
2988726 FSCN1 9.15E-04  3897431 MKKS 1.00E-03  3466110 CCDC41 1.08E-03  3238231 MLLT10 1.23E-03 
3723005 FZD2 9.15E-04  4027135 TEX28 1.00E-03  3336197 NPAS4 1.09E-03  2486178 MEIS1 1.23E-03 
2828564 RAD50 9.17E-04  2777447 NAP1L5 1.01E-03  3990727 RAB33A 1.10E-03  4023467 ARHGEF6 1.24E-03 
3873480 RAD21L1 9.21E-04  2459042 CDC42BPA 1.01E-03  3382830 GDPD4 1.10E-03  3954729 --- 1.24E-03 
3851150 ZNF433 9.25E-04  3046739 AMPH 1.01E-03  3138978 COPS5 1.10E-03  3742130 MYBBP1A 1.24E-03 
3830789 LIN37 9.28E-04  4011464 PJA1 1.01E-03  2669732 SCN10A 1.11E-03  2993727 SNX10 1.24E-03 
3119656 GSDMD 9.28E-04  3281703 PRTFDC1 1.01E-03  2558150 AAK1 1.13E-03  3019793 FOXP2 1.24E-03 
2648535 ARHGEF26 9.31E-04  3733911 SSTR2 1.02E-03  3235293 C10orf47 1.13E-03  2902013 GTF2H4 1.24E-03 
3629125 CSNK1G1 9.41E-04  2700828 SIAH2 1.02E-03  3858993 CEBPA 1.14E-03  3267314 BAG3 1.25E-03 
2397847 ZBTB17 9.42E-04  2864118 DMGDH 1.02E-03  2984655 RPS6KA2 1.15E-03  2571457 CKAP2L 1.25E-03 
2500275 BCL2L11 9.44E-04  3652867 SCNN1G 1.03E-03  3651672 ANKS4B 1.15E-03  4027176 FLNA 1.25E-03 
3721956 TUBG2 9.49E-04  3984702 DRP2 1.03E-03  3259503 DNTT 1.15E-03  3521372 DZIP1 1.25E-03 
3863597 CNFN 9.51E-04  2353773 TTF2 1.04E-03  3893520 RTEL1 1.15E-03  2807686 CARD6 1.25E-03 
4006210 MAOB 9.54E-04  2950199 PSMB8 1.04E-03  3329404 ATG13 1.16E-03  3316834 BRSK2 1.26E-03 
3065740 RELN 9.55E-04  2779992 UBE2D3 1.04E-03  2743800 PCDH10 1.16E-03  3900091 RALGAPA2 1.26E-03 
3151970 MTSS1 9.56E-04  3779950 C18orf1 1.04E-03  2969289 WASF1 1.16E-03  3168210 TMEM8B 1.26E-03 
2826159 SNCAIP 9.58E-04  4027639 F8 1.04E-03  3269694 FANK1 1.16E-03  2929168 UTRN 1.26E-03 
2332812 ERMAP 9.63E-04  3320604 USP47 1.05E-03  3989678 XIAP 1.18E-03  2614369 RARB 1.27E-03 
2992197 SP4 9.63E-04  3770923 GALK1 1.05E-03  3078520 ZNF746 1.19E-03  2554975 BCL11A 1.27E-03 
3446297 RERGL 9.65E-04  3913335 C20orf166 1.05E-03  3762339 MRPL27 1.19E-03  2391255 UBE2J2 1.28E-03 
3065963 ORC5 9.67E-04  2874920 ACSL6 1.06E-03  3509677 C13orf38 1.19E-03  3995105 CNGA2 1.28E-03 
3806366 LOXHD1 9.70E-04  2404958 MTMR9LP 1.06E-03  2604138 USP40 1.19E-03  2756309 ABCA11P 1.31E-03 
3204721 TPM2 9.70E-04  3190242 DNM1 1.06E-03  3849044 MYO1F 1.19E-03  3319352 TUB 1.31E-03 
2969886 FYN 9.72E-04  3639601 RGMA 1.07E-03  3416996 MMP19 1.20E-03  3624697 ARPP19 1.31E-03 
2508611 ARHGAP15 9.76E-04  2910477 FBXO9 1.07E-03  3893973 MYT1 1.20E-03  2837232 ITK 1.32E-03 
2904329 ANKS1A 9.76E-04  3882413 C20orf114 1.07E-03  2625793 SLMAP 1.21E-03  2772450 SULT1E1 1.32E-03 
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2579439 GTDC1 1.34E-03  3223425 CDK5RAP2 1.46E-03  4026119 MAGEA10 1.60E-03  3986291 TBC1D8B 1.76E-03 
3944690 CYTH4 1.35E-03  3666542 HAS3 1.46E-03  3833827 EGLN2 1.60E-03  2889916 ADAMTS2 1.76E-03 
3435548 HIP1R 1.35E-03  3357723 BET1L 1.46E-03  2648677 MME 1.61E-03  2467691 TTC15 1.77E-03 
3896594 LRRN4 1.35E-03  2589011 TTC30A 1.47E-03  2888385 GPRIN1 1.61E-03  3651152 IQCK 1.78E-03 
2826343 SNX24 1.35E-03  3098378 RGS20 1.47E-03  4008427 NUDT11 1.62E-03  4018218 DCX 1.79E-03 
3027538 NDUFB2 1.35E-03  2453006 PIGR 1.47E-03  2480619 SOCS5 1.62E-03  3337042 CARNS1 1.80E-03 
3000342 ADCY1 1.36E-03  3746040 ELAC2 1.47E-03  3871302 HSPBP1 1.62E-03  3318239 OR51F2 1.80E-03 
2388794 ZNF238 1.36E-03  2638676 EAF2 1.48E-03  3132940 ANK1 1.62E-03  3657168 ARMC5 1.81E-03 
3899404 OVOL2 1.36E-03  3216476 ZNF510 1.48E-03  3469865 CRY1 1.64E-03  3623717 FLJ10038 1.81E-03 
3377226 EHD1 1.37E-03  3258221 HHEX 1.49E-03  2342176 FPGT 1.65E-03  3957429 GAL3ST1 1.82E-03 
2618940 CTNNB1 1.37E-03  3807965 MRO 1.49E-03  3591650 SERF2 1.65E-03  2434925 PI4KB 1.82E-03 
3200762 SLC24A2 1.37E-03  3021377 PTPRZ1 1.49E-03  3458735 AGAP2 1.65E-03  3916290 FLJ42200 1.82E-03 
3209060 TRPM3 1.37E-03  2782822 NDST4 1.50E-03  3381540 FAM168A 1.66E-03  3343452 PRSS23 1.82E-03 
3768627 ABCA8 1.38E-03  4025339 IDS 1.51E-03  2320048 TARDBP 1.66E-03  3976406 ZNF81 1.83E-03 
3204019 C9orf25 1.38E-03  2988410 RNF216L 1.54E-03  3861037 ZNF607 1.67E-03  3642687 HBQ1 1.83E-03 
3815888 APC2 1.38E-03  2634153 ZPLD1 1.54E-03  2877028 KLHL3 1.67E-03  3567050 RTN1 1.83E-03 
3846982 TICAM1 1.39E-03  3852407 RFX1 1.55E-03  3697632 ZNF23 1.68E-03  2913983 SENP6 1.85E-03 
2369713 FAM163A 1.40E-03  2970044 TUBE1 1.55E-03  3455344 KRT82 1.69E-03  3151719 ANXA13 1.87E-03 
2388525 SDCCAG8 1.40E-03  3738138 HGS 1.56E-03  2474637 C2orf16 1.69E-03  3260700 PAX2 1.87E-03 
3429754 KIAA1033 1.41E-03  3940631 ADRBK2 1.56E-03  2559849 SLC4A5 1.69E-03  2476075 SPAST 1.87E-03 
3929325 SYNJ1 1.41E-03  2753732 WWC2 1.57E-03  3676669 RNPS1 1.70E-03  3743074 PITPNM3 1.87E-03 
2491523 ELMOD3 1.41E-03  3675020 RGS11 1.57E-03  2383859 GUK1 1.70E-03  3753760 MMP28 1.88E-03 
3629610 IGDCC3 1.41E-03  3452417 SLC38A4 1.57E-03  2766893 APBB2 1.70E-03  3293469 C10orf27 1.88E-03 
2810395 C5orf35 1.42E-03  2406579 COL8A2 1.57E-03  3241316 ZEB1 1.70E-03  2509740 MBD5 1.88E-03 
3790704 PMAIP1 1.42E-03  2849056 DNAH5 1.58E-03  3571553 C14orf43 1.70E-03  3803917 ZNF24 1.89E-03 
3012064 CDK14 1.42E-03  3000010 ZMIZ2 1.58E-03  3667508 CALB2 1.71E-03  3315802 PKP3 1.89E-03 
3015338 STAG3 1.42E-03  3418610 XRCC6BP1 1.58E-03  3602264 COMMD4 1.73E-03  3779817 CEP192 1.90E-03 
3378895 PITPNM1 1.42E-03  3655826 TAOK2 1.59E-03  3016070 MUC17 1.74E-03  2801694 ROPN1L 1.91E-03 
2585972 ABCB11 1.43E-03  2995811 C7orf16 1.59E-03  3838185 SNRNP70 1.74E-03  3021009 KCND2 1.91E-03 
2359453 SMCP 1.43E-03  3772437 DNAH17 1.59E-03  3457947 BAZ2A 1.74E-03  3956909 NIPSNAP1 1.91E-03 
3942502 SLC35E4 1.44E-03  3761395 HOXB6 1.59E-03  2901503 TRIM39 1.75E-03  3865344 PPP1R13L 1.91E-03 
3601229 CD276 1.44E-03  3472755 TBX3 1.60E-03  3267678 WDR11 1.75E-03  3965784 MAPK11 1.92E-03 
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2982319 SOD2 1.93E-03  2973694 ARHGAP18 2.11E-03  3704939 C16orf7 2.26E-03  2759038 CRMP1 2.47E-03 
3332276 MS4A2 1.95E-03  2340078 CACHD1 2.11E-03  2900074 HIST1H2BN 2.26E-03  3380126 FGF19 2.47E-03 
3581442 JAG2 1.95E-03  2386867 LGALS8 2.11E-03  2513758 XIRP2 2.27E-03  3456081 RARG 2.48E-03 
3647504 PMM2 1.96E-03  3190420 CERCAM 2.12E-03  3608787 SLCO3A1 2.27E-03  3360941 ARFIP2 2.49E-03 
3282601 MPP7 1.96E-03  3339774 P2RY6 2.12E-03  3042001 CYCS 2.28E-03  2424740 MIR137 2.49E-03 
3721989 CNTNAP1 1.97E-03  3839910 FPR2 2.12E-03  2495279 VWA3B 2.30E-03  2620641 LIMD1 2.49E-03 
3082874 ARHGEF10 1.97E-03  3334659 SLC22A12 2.12E-03  2532894 DGKD 2.30E-03  3887479 EYA2 2.50E-03 
3529725 REC8 1.98E-03  2328750 CCDC28B 2.13E-03  3827427 ZNF254 2.31E-03  2439801 CCDC19 2.51E-03 
3781654 RIOK3 1.98E-03  3838683 PRRG2 2.13E-03  2435443 TCHH 2.32E-03  2962113 ELOVL4 2.52E-03 
3031383 REPIN1 1.99E-03  2734270 CDS1 2.13E-03  3962469 RRP7B 2.32E-03  3498589 CLYBL 2.52E-03 
2430422 SPAG17 2.00E-03  2947283 ZSCAN12 2.14E-03  3181976 NR4A3 2.32E-03  3719231 MRM1 2.53E-03 
3743734 C17orf61 2.00E-03  3761551 TTLL6 2.14E-03  3335751 TSGA10IP 2.33E-03  3367788 DCDC5 2.54E-03 
3489212 FNDC3A 2.00E-03  3599432 FEM1B 2.15E-03  3543857 PTGR2 2.33E-03  2318656 PER3 2.54E-03 
3403482 NANOGP1 2.00E-03  3851493 ZNF443 2.15E-03  3603932 FAH 2.34E-03  3442322 CDCA3 2.54E-03 
3842481 NLRP8 2.01E-03  3182063 INVS 2.16E-03  3217194 TBC1D2 2.34E-03  4014191 POF1B 2.54E-03 
3934652 UBE2G2 2.01E-03  3242839 ANKRD30A 2.17E-03  3225560 LOC51145 2.34E-03  2854737 PRKAA1 2.55E-03 
3506093 FAM123A 2.01E-03  3788560 DCC 2.17E-03  2428855 AP4B1 2.36E-03  3986647 VSIG1 2.56E-03 
3185522 SLC31A1 2.02E-03  2368590 PAPPA2 2.18E-03  3520934 DCT 2.37E-03  2584712 GRB14 2.57E-03 
2620160 ZNF197 2.02E-03  3738842 HEXDC 2.18E-03  3120917 ZNF7 2.39E-03  3829857 ZNF302 2.57E-03 
3918535 IL10RB 2.03E-03  3298557 GRID1 2.18E-03  3532313 SRP54 2.39E-03  3914786 ABCC13 2.58E-03 
2977949 EPM2A 2.03E-03  3940124 UPB1 2.19E-03  3976930 PQBP1 2.40E-03  2674963 MON1A 2.59E-03 
3767169 LRRC37A3 2.04E-03  2901660 PRR3 2.20E-03  3662876 CCDC135 2.41E-03  3608520 UNC45A 2.59E-03 
3882343 BASE 2.04E-03  2936564 FGFR1OP 2.20E-03  3483468 MTUS2 2.41E-03  3532785 --- 2.60E-03 
3695235 CCDC79 2.04E-03  2325593 CLIC4 2.20E-03  2439960 KCNJ10 2.44E-03  3879699 PAX1 2.60E-03 
3633048 EDC3 2.05E-03  2552643 NRXN1 2.20E-03  3469597 NUAK1 2.45E-03  3549757 SERPINA3 2.60E-03 
2640485 C3orf46 2.07E-03  3347533 RAB39 2.22E-03  2582562 ACVR1 2.45E-03  3841881 NCR1 2.61E-03 
3203753 UBAP2 2.07E-03  2808308 MGC42105 2.23E-03  2987843 SDK1 2.45E-03  4011637 PDZD11 2.62E-03 
3957699 PLA2G3 2.07E-03  2317317 TP73 2.23E-03  3458451 R3HDM2 2.45E-03  3671448 HSBP1 2.62E-03 
3633109 ULK3 2.08E-03  3990927 ARHGAP36 2.24E-03  2768981 SGCB 2.45E-03  3880629 CST7 2.63E-03 
2757751 MXD4 2.09E-03  3645901 NAT15 2.24E-03  2394588 ICMT 2.46E-03  3791254 RANK 2.63E-03 
3542847 SIPA1L1 2.09E-03  3490073 FAM124A 2.24E-03  3738439 LRRC45 2.46E-03  3682182 ABCC6 2.64E-03 
3746809 CDRT1 2.09E-03  3952880 TXNRD2 2.25E-03  3646613 RBFOX1 2.47E-03  3358262 DEAF1 2.66E-03 
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3861617 HNRNPL 2.67E-03  2385797 KIAA1804 2.84E-03  3548929 RIN3 3.50E-03  2447066 GLUL 3.77E-03 
3637818 NTRK3 2.67E-03  3652902 SCNN1B 3.20E-03  3726537 EPN3 3.50E-03  3271687 PPP2R2D 3.78E-03 
3027915 SSBP1 2.67E-03  3842456 NLRP4 3.21E-03  2672774 C3orf75 3.51E-03  3359267 TRPM5 3.78E-03 
2916502 SPACA1 2.67E-03  2739792 ALPK1 3.22E-03  2876213 CDKN2AIP 3.51E-03  3379708 MRPL21 3.78E-03 
3132927 NKX6-3 2.68E-03  3335643 MUS81 3.22E-03  2621122 NBEAL2 3.52E-03  3376023 UBXN1 3.79E-03 
3761348 HOXB4 2.68E-03  2832325 PCDHB5 3.22E-03  3792273 CDH7 3.53E-03  2442800 ADCY10 3.80E-03 
3965536 MLC1 2.68E-03  3873017 MZF1 3.24E-03  3522644 GPR18 3.54E-03  3004628 ZNF107 3.81E-03 
2754673 ANKRD37 2.68E-03  3101851 C8orf45 3.24E-03  2647216 HPS3 3.55E-03  2998192 POU6F2 3.81E-03 
3673723 TRAPPC2L 2.69E-03  3861948 GMFG 3.25E-03  3724360 GOSR2 3.56E-03  3771259 EVPL 3.85E-03 
2771342 EPHA5 2.69E-03  3141809 MRPS28 3.25E-03  3203086 DDX58 3.56E-03  3051907 PHKG1 3.85E-03 
3315549 PSMD13 2.70E-03  3832256 SPINT2 3.28E-03  2551651 ATP6V1E2 3.56E-03  3079313 CDK5 3.87E-03 
3331487 CTNND1 2.70E-03  2724338 LIAS 3.30E-03  3379597 MTL5 3.56E-03  3799415 AFG3L2 3.87E-03 
2486927 ARHGAP25 2.71E-03  2643312 TF 3.31E-03  2835715 GPX3 3.57E-03  2348992 VCAM1 3.89E-03 
2677388 ERC2 2.71E-03  3557791 FAM158A 3.34E-03  2817708 SPZ1 3.57E-03  2516967 HOXD1 3.90E-03 
2964092 GABRR1 2.71E-03  3775808 CLUL1 3.37E-03  3748188 FLII 3.60E-03  2328936 ZBTB8A 3.91E-03 
2655511 ABCF3 2.72E-03  3459120 LRIG3 3.37E-03  2809245 ITGA2 3.61E-03  2436576 C1orf43 3.92E-03 
3816424 SPPL2B 2.72E-03  2458082 WDR26 3.38E-03  3352485 TMEM136 3.61E-03  3304624 NT5C2 3.93E-03 
2708066 KLHL6 2.72E-03  3839057 TBC1D17 3.39E-03  3332334 MS4A14 3.61E-03  3597702 FBXL22 3.93E-03 
2907568 KLHDC3 2.72E-03  3862785 C19orf54 3.40E-03  3387537 MAML2 3.65E-03  3389529 KIAA1826 3.94E-03 
2556215 VPS54 2.73E-03  2987038 GPER 3.40E-03  3464622 CEP290 3.65E-03  3302240 RRP12 3.94E-03 
3268059 TACC2 2.75E-03  2905469 RNF8 3.41E-03  2488114 ZNF638 3.67E-03  3952825 C22orf29 3.96E-03 
3945815 TAB1 2.75E-03  3062576 ASNS 3.41E-03  3872945 SLC27A5 3.68E-03  3315217 C10orf125 3.97E-03 
2949830 AGER 2.76E-03  3307580 NRAP 3.41E-03  2521239 CCDC150 3.68E-03  2451918 KISS1 3.97E-03 
3594129 MAPK6 2.77E-03  3993515 MAGEC1 3.42E-03  3535515 FRMD6 3.69E-03  3872678 ZSCAN18 3.98E-03 
2485433 AFTPH 2.77E-03  3219788 EPB41L4B 3.42E-03  3364878 ABCC8 3.69E-03  3852966 OR7A10 3.99E-03 
3612763 POTEB 2.80E-03  3259978 PI4K2A 3.42E-03  2845043 TRIM41 3.70E-03  3771160 FBF1 3.99E-03 
3458551 ARHGAP9 2.81E-03  3643431 CHTF18 3.45E-03  3878373 ZNF133 3.70E-03  3927446 ADAMTS1 4.00E-03 
3593408 FGF7 2.81E-03  3016692 PRKRIP1 3.45E-03  3479355 GOLGA3 3.71E-03  3274898 TUBAL3 4.00E-03 
3495968 SLITRK5 2.82E-03  2623821 PHF7 3.46E-03  2528020 TTLL4 3.71E-03  3687839 ZNF747 4.00E-03 
3866958 CARD8 2.82E-03  2895841 CD83 3.46E-03  2720584 SLIT2 3.75E-03  3095766 GINS4 4.00E-03 
2589017 PDE11A 2.83E-03  3026834 TTC26 3.49E-03  3755198 SRCIN1 3.75E-03  2363876 FCRLB 4.01E-03 
3836614 IGFL2 2.83E-03  2369339 RALGPS2 3.49E-03  3318354 OR52D1 3.76E-03  3266583 CASC2 4.02E-03 
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2807621 PTGER4 4.02E-03  3950846 MIOX 4.36E-03  2332091 KCNQ4 4.71E-03  3555272 TTC5 5.15E-03 
3679959 EMP2 4.05E-03  2871801 FEM1C 4.36E-03  3794458 ZNF236 4.71E-03  4024493 SPANXE 5.16E-03 
2746164 MMAA 4.06E-03  2823326 FER 4.36E-03  2436985 SHC1 4.73E-03  2522247 AOX1 5.18E-03 
3757770 STAT5B 4.06E-03  2520533 OBFC2A 4.38E-03  3063727 TAF6 4.73E-03  3188478 CRB2 5.18E-03 
3103187 TERF1 4.06E-03  3676328 NOXO1 4.40E-03  3070873 GPR37 4.74E-03  2531310 SP140L 5.18E-03 
4011889 ZMYM3 4.06E-03  2351572 CD53 4.42E-03  3920566 DYRK1A 4.79E-03  2356115 TXNIP 5.20E-03 
3743167 MED31 4.07E-03  2469910 LPIN1 4.45E-03  3221633 HDHD3 4.81E-03  3071700 IMPDH1 5.20E-03 
3485292 NBEA 4.07E-03  3177563 NAA35 4.46E-03  3695157 CMTM4 4.81E-03  3439549 SLC6A13 5.21E-03 
3762198 COL1A1 4.08E-03  3818596 EMR1 4.46E-03  4041300 FAM195B 4.82E-03  2489035 DGUOK 5.22E-03 
2519577 COL3A1 4.10E-03  2515783 RAPGEF4 4.48E-03  3895679 C20orf27 4.84E-03  2541944 SMC6 5.23E-03 
3643580 CACNA1H 4.10E-03  3899173 RRBP1 4.49E-03  3725517 IGF2BP1 4.84E-03  3529467 CPNE6 5.24E-03 
3607510 FANCI 4.13E-03  3843690 ZSCAN1 4.50E-03  2780143 BDH2 4.84E-03  3461121 IL26 5.26E-03 
3166718 DNAJA1 4.13E-03  3132333 TM2D2 4.51E-03  3467720 GOLGA2B 4.85E-03  2517588 OSBPL6 5.27E-03 
2556010 ELP1P 4.13E-03  3407683 SLCO1B1 4.51E-03  3833728 ITPKC 4.87E-03  3379452 C11orf24 5.28E-03 
3834732 PRR19 4.13E-03  2707909 MCF2L2 4.51E-03  3870990 GP6 4.87E-03  3276421 KIN 5.30E-03 
2757621 POLN 4.14E-03  3455388 KRT75 4.52E-03  3774883 CD7 4.87E-03  3934903 --- 5.30E-03 
2654394 FXR1 4.16E-03  3352813 TBCEL 4.53E-03  3973768 LANCL3 4.88E-03  3726298 TMEM92 5.31E-03 
3571059 DPF3 4.17E-03  2358092 CA14 4.53E-03  2545509 PREB 4.93E-03  2348854 RTCD1 5.32E-03 
3723348 HEXIM1 4.18E-03  3380080 ORAOV1 4.54E-03  2888399 SNCB 4.97E-03  3417988 NXPH4 5.32E-03 
2393538 WDR8 4.18E-03  3723204 CCDC103 4.55E-03  3887241 SLC12A5 4.97E-03  3179706 WNK2 5.34E-03 
2542816 PUM2 4.19E-03  2515276 DYNC1I2 4.60E-03  3961325 ENTHD1 4.99E-03  2880361 JAKMIP2 5.35E-03 
2794792 VEGFC 4.20E-03  3982689 TBX22 4.61E-03  2866704 ARRDC3 4.99E-03  3634682 CHRNB4 5.35E-03 
2688955 CD200R1 4.24E-03  2643592 EPHB1 4.61E-03  2448232 TPR 5.01E-03  3522398 DOCK9 5.35E-03 
2812539 SREK1 4.24E-03  3726114 DLX4 4.62E-03  2811145 PART1 5.03E-03  2817212 BHMT2 5.37E-03 
2752725 NEIL3 4.28E-03  3189311 PBX3 4.64E-03  3240095 RAB18 5.03E-03  2442587 CD247 5.38E-03 
2493858 MAL 4.28E-03  3920385 TTC3 4.64E-03  3753729 GAS2L2 5.04E-03  3762040 TAC4 5.38E-03 
3872584 C19orf18 4.29E-03  3643360 HAGHL 4.66E-03  2613386 RAB5A 5.05E-03  3846860 SEMA6B 5.38E-03 
3760894 OSBPL7 4.30E-03  2445876 --- 4.67E-03  3894288 TCF15 5.06E-03  2584957 SCN3A 5.38E-03 
3512948 C13orf18 4.30E-03  2999334 HECW1 4.67E-03  2489440 DOK1 5.06E-03  2397948 EPHA2 5.39E-03 
2772805 GC 4.32E-03  2436973 PYGO2 4.68E-03  3234083 ITIH2 5.07E-03  3581404 GPR132 5.39E-03 
3378433 SPTBN2 4.34E-03  2988336 KIAA0415 4.69E-03  2528476 DES 5.08E-03  3315341 SYCE1 5.40E-03 
2971692 MCM9 4.35E-03  3681705 RRN3 4.71E-03  2911226 BEND6 5.09E-03  3744094 ALOXE3 5.40E-03 
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2943434 ATXN1 5.41E-03  3982975 POU3F4 5.77E-03  3772581 USP36 6.18E-03  2883440 ADAM19 6.71E-03 
2487918 ATP6V1B1 5.41E-03  3655012 SH2B1 5.80E-03  3353914 VWA5A 6.20E-03  3756546 KRT12 6.72E-03 
3390860 POU2AF1 5.42E-03  2989493 MIOS 5.80E-03  2759582 AFAP1 6.21E-03  3914181 UCKL1 6.72E-03 
2601414 SERPINE2 5.43E-03  2416522 JAK1 5.80E-03  3406015 ATF7IP 6.22E-03  3120682 MFSD3 6.76E-03 
3737192 CARD14 5.44E-03  3284302 NRP1 5.82E-03  2369609 C1orf125 6.23E-03  3662774 GPR114 6.79E-03 
2509900 KIF5C 5.46E-03  2339511 ATG4C 5.83E-03  3758845 HDAC5 6.24E-03  2988594 SLC29A4 6.79E-03 
3526831 RASA3 5.48E-03  3947434 SERHL 5.83E-03  3851250 ZNF20 6.26E-03  2830818 REEP2 6.80E-03 
2772876 ADAMTS3 5.51E-03  2827057 GRAMD3 5.84E-03  3683584 PDILT 6.27E-03  3033307 EN2 6.80E-03 
3224650 DENND1A 5.52E-03  2556302 PELI1 5.85E-03  3527831 RNASE7 6.27E-03  3789680 ST8SIA3 6.80E-03 
3767230 LRRC37A3 5.52E-03  2735362 HERC6 5.85E-03  3227634 BAT2L1 6.31E-03  3072546 TSGA14 6.80E-03 
2527747 SLC11A1 5.53E-03  3159132 COMMD5 5.85E-03  3813840 ZNF516 6.34E-03  3082990 MYOM2 6.82E-03 
3376367 SLC22A8 5.53E-03  3941076 CRYBA4 5.89E-03  2677922 ASB14 6.35E-03  3214749 NOL8 6.82E-03 
3661940 GNAO1 5.53E-03  3784670 C18orf21 5.92E-03  3032446 ACTR3B 6.38E-03  2955076 NFKBIE 6.83E-03 
3721010 IGFBP4 5.55E-03  3908901 KCNB1 5.93E-03  3574121 STON2 6.43E-03  3085403 MSRA 6.83E-03 
3906709 GTSF1L 5.55E-03  3479438 CHFR 5.94E-03  3113352 COL14A1 6.43E-03  2413879 PARS2 6.84E-03 
3403140 EMG1 5.58E-03  2374414 GPR25 5.98E-03  2364438 NUF2 6.45E-03  4002011 CXorf23 6.85E-03 
3985305 GPRASP2 5.63E-03  2378584 RCOR3 5.99E-03  3771068 TRIM47 6.47E-03  3614774 OCA2 6.85E-03 
2853275 CAPSL 5.63E-03  3127505 --- 6.00E-03  2327283 C1orf38 6.50E-03  3259400 CCNJ 6.87E-03 
2390253 OR2L8 5.64E-03  2487063 GKN1 6.00E-03  2607020 MTERFD2 6.52E-03  3191877 AIF1L 6.89E-03 
3303059 SLC25A28 5.64E-03  2323347 PAX7 6.01E-03  2591643 COL5A2 6.55E-03  3498315 UBAC2 6.92E-03 
3628650 HERC1 5.65E-03  3928070 CCT8 6.01E-03  2412082 FAF1 6.56E-03  2324084 CDA 6.93E-03 
3037944 RPA3 5.66E-03  2907943 ABCC10 6.02E-03  2621032 PTH1R 6.56E-03  3934623 KAP12.2 6.93E-03 
3464276 SLC6A15 5.67E-03  3544562 JDP2 6.05E-03  3815416 ABCA7 6.59E-03  2359885 SLC27A3 6.94E-03 
2830504 PKD2L2 5.67E-03  3934479 C21orf2 6.06E-03  3336117 TMEM151 6.60E-03  2964350 MDN1 6.95E-03 
3085933 C8orf12 5.68E-03  3031399 ZNF775 6.08E-03  3414326 AQP6 6.61E-03  3601889 LMAN1L 6.98E-03 
3251068 CDH23 5.68E-03  3845081 C19orf26 6.10E-03  3597338 TPM1 6.62E-03  4035017 UTY 6.99E-03 
2817464 CMYA5 5.68E-03  2379974 KCNK2 6.11E-03  3070543 SLC13A1 6.63E-03  3551029 C14orf177 7.00E-03 
2382467 CNIH3 5.70E-03  2736060 GRID2 6.11E-03  3575241 KCNK10 6.64E-03  3550139 TCL1B 7.01E-03 
3624513 MYO5C 5.71E-03  3560403 EGLN3 6.12E-03  3840562 HERV-V1 6.65E-03  2594569 ORC2 7.01E-03 
2837029 SGCD 5.71E-03  3023825 C7orf45 6.13E-03  3560575 EAPP 6.65E-03  3363091 GALNTL4 7.03E-03 
3131916 WHSC1L1 5.74E-03  3774535 DCXR 6.14E-03  3257268 IFIT5 6.67E-03  2585129 GALNT3 7.04E-03 
3182229 TMEFF1 5.74E-03  2527672 PNKD 6.16E-03  2924081 NKAIN2 6.70E-03  3096271 C8orf40 7.10E-03 
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2891015 TRIM7 7.16E-03  3145586 MTERFD1 7.64E-03  3742236 PELP1 8.13E-03  2461531 IRF2BP2 8.50E-03 
2606643 MYEOV2 7.17E-03  3712582 MED9 7.64E-03  2324594 CELA3A 8.13E-03  2501178 IL1F10 8.53E-03 
2396781 MAD2L2 7.17E-03  3089049 NPM2 7.66E-03  2401493 ID3 8.13E-03  3543756 DNAL1 8.57E-03 
3715839 TRAF4 7.18E-03  3188780 GPR144 7.67E-03  3886576 WISP2 8.14E-03  2985781 THBS2 8.58E-03 
2742935 HSPA4L 7.18E-03  3918104 C21orf63 7.69E-03  2511432 GPD2 8.15E-03  3632037 PARP6 8.59E-03 
2345128 SH3GLB1 7.18E-03  2550175 KCNG3 7.69E-03  2867836 GLRX 8.17E-03  3665049 CES4A 8.61E-03 
2417008 INSL5 7.20E-03  3698081 PMFBP1 7.71E-03  2922246 FLJ34503 8.17E-03  3579458 DEGS2 8.62E-03 
3000276 RAMP3 7.23E-03  3455186 KRT5 7.72E-03  3826542 ZNF738 8.19E-03  2742581 FAT4 8.64E-03 
3913483 TCFL5 7.24E-03  2704188 PDCD10 7.72E-03  3521484 UGGT2 8.24E-03  3659691 C16orf78 8.65E-03 
3955102 GSTT1 7.25E-03  3883013 TP53INP2 7.75E-03  3791341 ZCCHC2 8.26E-03  2580635 MMADHC 8.67E-03 
2774365 CCNI 7.26E-03  2672629 KIF9 7.75E-03  3743038 AIPL1 8.26E-03  3420497 HELB 8.67E-03 
3851911 PRG6 7.27E-03  2951916 STK38 7.76E-03  2586038 LRP2 8.26E-03  3457872 MIP 8.72E-03 
3391029 PPP2R1B 7.27E-03  3757399 NT5C3L 7.77E-03  3796335 LPIN2 8.26E-03  3066297 SRPK2 8.73E-03 
3089102 EPB49 7.27E-03  2653902 ZNF639 7.78E-03  3291682 JMJD1C 8.30E-03  2566764 REV1 8.76E-03 
4017747 GUCY2F 7.29E-03  3523156 TMTC4 7.79E-03  3336220 PELI3 8.34E-03  2949118 LTB 8.77E-03 
3636216 AP3B2 7.29E-03  3230697 NPDC1 7.80E-03  3075742 KLRG2 8.34E-03  3675369 NARFL 8.79E-03 
2903507 RING1 7.29E-03  3815097 FSTL3 7.82E-03  3468888 GLT8D2 8.35E-03  3513794 RCBTB1 8.80E-03 
2906872 MDFI 7.30E-03  3867796 TEAD2 7.86E-03  2622435 RBM6 8.35E-03  2827177 C5orf48 8.82E-03 
3545403 GSTZ1 7.30E-03  3283920 ARHGAP12 7.88E-03  3538403 LRRC9 8.35E-03  3824666 KCNN1 8.85E-03 
2956586 PGK2 7.30E-03  3952956 ARVCF 7.88E-03  3591327 CCNDBP1 8.37E-03  2950515 VPS52 8.89E-03 
2633773 TFG 7.31E-03  3374189 OR9I1 7.89E-03  2682088 EIF4E3 8.37E-03  3931112 HLCS 8.90E-03 
4003017 PCYT1B 7.31E-03  3136229 SDR16C5 7.92E-03  3341137 B3GNT6 8.38E-03  3190796 PHYHD1 8.90E-03 
2890148 HNRNPH1 7.33E-03  3305313 ITPRIP 7.92E-03  3529799 GMPR2 8.38E-03  2532626 C2orf82 8.91E-03 
2681044 FAM19A4 7.38E-03  3467637 SHIP164 7.93E-03  3722060 VPS25 8.40E-03  2713382 BDH1 8.91E-03 
3904119 CPNE1 7.38E-03  3216529 ZNF782 7.94E-03  3359601 OSBPL5 8.40E-03  3138929 LRRC67 8.92E-03 
2435410 S100A11 7.41E-03  2405469 PHC2 7.95E-03  3638871 ATG8D 8.41E-03  3339406 FOLR1 8.93E-03 
3360874 HPX 7.41E-03  3084950 CLDN23 7.98E-03  3695631 TPPP3 8.42E-03  3642747 ARHGDIG 8.94E-03 
3272566 KNDC1 7.45E-03  3597603 USP3 7.99E-03  3964049 CELSR1 8.42E-03  2379399 RPS6KC1 8.94E-03 
2373406 CFHR3 7.46E-03  2497082 IL1RL1 8.00E-03  2717014 MAN2B2 8.43E-03  3621117 TGM7 8.97E-03 
2475678 LBH 7.52E-03  3995765 DUSP9 8.00E-03  2975680 BCLAF1 8.48E-03  2602653 PID1 8.97E-03 
4020655 ODZ1 7.55E-03  2791419 FAM198B 8.06E-03  3589905 IVD 8.48E-03  3680223 PRM1 8.99E-03 
2837499 LSM11 7.56E-03  2721777 PI4K2B 8.11E-03  2337407 PCSK9 8.48E-03  2343289 DNAJB4 8.99E-03 
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3699133 FA2H 9.02E-03  2489322 TTC31 9.63E-03  3984840 ARMCX4 0.010  3865586 FBXO46 0.011 
2439373 SPTA1 9.03E-03  2632832 EPHA6 9.67E-03  3541073 MPP5 0.010  3831774 ZNF383 0.011 
3625234 RSL24D1 9.05E-03  2371346 RGL1 9.72E-03  3678279 ANKS3 0.010  2688499 ZBED2 0.011 
3936442 PEX26 9.05E-03  2832431 PCDHB11 9.73E-03  2758658 TMEM128 0.010  2577106 NCKAP5 0.011 
2896177 JARID2 9.05E-03  2955164 --- 9.74E-03  2501120 IL1F9 0.010  2439101 FCRL1 0.011 
2612100 FGD5 9.05E-03  2781387 AGXT2L1 9.75E-03  2322211 C1orf64 0.010  4036497 TTTY5 0.011 
3173673 PIP5K1B 9.08E-03  2769095 --- 9.75E-03  2892734 --- 0.010  3501999 SOX1 0.011 
2441386 RGS5 9.09E-03  3029646 ARHGEF5 9.77E-03  3913272 GATA5 0.010  3361021 TAF10 0.011 
2892393 BPHL 9.09E-03  2783916 TNIP3 9.80E-03  3625823 ZNF280D 0.010  3146898 YWHAZ 0.011 
3408966 FGFR1OP2 9.10E-03  2906105 GLP1R 9.86E-03  3219215 KLF4 0.010  3840406 ZNF137P 0.011 
2377094 PFKFB2 9.14E-03  2772614 GRSF1 9.87E-03  3811000 RNF152 0.010  3794341 FLJ44313 0.011 
3714779 KCNJ12 9.19E-03  3461496 BEST3 9.90E-03  2545869 IFT172 0.010  3754227 MYO19 0.011 
3972025 PDK3 9.19E-03  3683879 DNAH3 9.92E-03  3977651 MAGED1 0.010  3289445 A1CF 0.011 
2925237 LAMA2 9.20E-03  2412690 KTI12 9.93E-03  3642060 CHSY1 0.010  3910980 BMP7 0.011 
2408111 TRIT1 9.21E-03  3680249 PRM3 9.94E-03  3413643 CCDC65 0.011  3433929 SRRM4 0.011 
3548538 C14orf159 9.25E-03  2946106 SLC17A3 9.97E-03  3278401 FRMD4A 0.011  3416651 PDE1B 0.011 
3808745 CCDC68 9.26E-03  3654175 IL4R 9.98E-03  3000984 ABCA13 0.011  3643679 TPSD1 0.011 
3633081 CYP1A1 9.27E-03  3553998 TDRD9 9.99E-03  3866117 DACT3 0.011  2689286 KIAA1407 0.011 
3760137 KIAA1267 9.30E-03  3329537 C11orf49 0.010  2532852 SAG 0.011  3023103 CCDC136 0.011 
2632051 C3orf38 9.30E-03  3817437 FSD1 0.010  2325358 GRHL3 0.011  3259631 LCOR 0.011 
2985368 FRMD1 9.31E-03  2924898 RNF146 0.010  2436754 ADAR 0.011  2673312 PFKFB4 0.011 
3082373 VIPR2 9.34E-03  3376121 ZBTB3 0.010  3235516 CAMK1D 0.011  3800779 ESCO1 0.011 
4009990 USP51 9.34E-03  2913564 DDX43 0.010  2832403 PCDHB9 0.011  3249788 CCAR1 0.011 
3923537 C21orf33 9.36E-03  3042973 HOXA11 0.010  3738081 TSPAN10 0.011  2761503 --- 0.011 
2980870 NOX3 9.38E-03  3209726 ALDH1A1 0.010  3871792 ZSCAN5A 0.011  3596263 FOXB1 0.011 
2389130 EFCAB2 9.38E-03  2494064 FAHD2A 0.010  3987228 PAK3 0.011  2623568 PPM1M 0.011 
3195238 GRIN1 9.39E-03  3760552 RPRML 0.010  3012381 AKAP9 0.011  3722681 C17orf88 0.011 
3417767 GPR182 9.41E-03  3981592 CDX4 0.010  2378662 TRAF5 0.011  2536531 FARP2 0.011 
2776305 NKX6-1 9.43E-03  3602526 FBXO22 0.010  3663287 NDRG4 0.011  2670481 ULK4 0.011 
3576014 C14orf102 9.46E-03  3613725 NDN 0.010  3555088 KIAA0125 0.011  3252577 VDAC2 0.011 
3815710 EFNA2 9.47E-03  2939213 TUBB2A 0.010  3711165 COX10 0.011  2400027 PLA2G2A 0.011 
2440625 DEDD 9.51E-03  3262715 SORCS3 0.010  3147985 LRP12 0.011  3636956 WDR73 0.011 
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3011454 DBF4 0.011  2522693 CASP10 0.012  2829562 TXNDC15 0.013  2334986 CYP4X1 0.013 
3086181 NEIL2 0.011  2521278 CCDC150 0.012  2739308 EGF 0.013  2623611 GLYCTK 0.013 
3958157 SLC5A4 0.011  4016955 TEX13A 0.012  3922793 PDE9A 0.013  3984468 SRPX2 0.013 
2465753 OR2C3 0.011  3669092 TERF2IP 0.012  3862650 SERTAD3 0.013  2460487 C1orf131 0.013 
3951302 POTEM 0.011  2437417 ASH1L 0.012  3994610 MAGEA8 0.013  3623552 ATP8B4 0.013 
3602423 ODF3L1 0.011  3107661 INTS8 0.012  3201144 IFNB1 0.013  2473026 C2orf84 0.013 
2318398 PHF13 0.011  3655723 MVP 0.012  3598199 ANKDD1A 0.013  3023279 TPI1P2 0.013 
2405192 YARS 0.011  2678029 DNAH12 0.012  3934187 HSF2BP 0.013  2361241 ROBLD3 0.013 
3378758 CLCF1 0.011  2458701 ACBD3 0.012  3819880 ZNF317 0.013  3883236 MMP24 0.013 
3190762 ENDOG 0.011  3307795 C10orf118 0.012  2647647 TSC22D2 0.013  3157217 CYP11B1 0.013 
3042730 HOXA1 0.011  3677268 PRSS22 0.012  3204174 C9orf23 0.013  2374126 NR5A2 0.013 
3333595 GNG3 0.011  3256689 PTEN 0.012  3392973 APOA4 0.013  3020646 CFTR 0.013 
3474104 CIT 0.012  2609608 SETD5 0.012  2783715 MAD2L1 0.013  3063463 CYP3A7 0.013 
3830712 MLL4 0.012  3583638 CYFIP1 0.012  2468351 RSAD2 0.013  2829275 UBE2B 0.013 
3310041 FGFR2 0.012  2961647 HTR1B 0.012  3359529 CARS 0.013  2789957 FBXW7 0.013 
3203996 C9orf24 0.012  3884524 BPI 0.012  2778440 UNC5C 0.013  3343252 C11orf73 0.013 
3863380 GRIK5 0.012  3030873 ZNF862 0.012  3554452 KIAA0284 0.013  3893891 --- 0.013 
2709235 DGKG 0.012  3974838 DDX3X 0.012  3257559 RPP30 0.013  3959918 TST 0.013 
3336951 RAD9A 0.012  2669184 LRRFIP2 0.012  2921086 CDC40 0.013  2845362 SLC9A3 0.013 
2663785 CHCHD4 0.012  3301713 BLNK 0.012  2533670 AGAP1 0.013  3850331 CDC37 0.014 
3934529 C21orf29 0.012  2440664 B4GALT3 0.012  3638337 POLG 0.013  3317569 --- 0.014 
2429069 TRIM33 0.012  2910364 TMEM14A 0.012  3379777 MRGPRF 0.013  2831719 ANKHD1 0.014 
2743315 PHF17 0.012  2376799 IKBKE 0.012  3169043 RG9MTD3 0.013  3028011 MGAM 0.014 
3786471 SETBP1 0.012  3200648 PLIN2 0.012  3023835 CPA2 0.013  2764678 FLJ45721 0.014 
2987410 NUDT1 0.012  2567167 LONRF2 0.012  3067644 THAP5 0.013  2867392 C5orf36 0.014 
3272455 GPR123 0.012  3593014 SLC24A5 0.012  2713837 ZNF718 0.013  2874794 RAPGEF6 0.014 
2324820 EPHA8 0.012  2953481 TREML1 0.012  3334749 PPP2R5B 0.013  3660075 NKD1 0.014 
3665722 PARD6A 0.012  3551407 HHIPL1 0.013  3869215 HAS1 0.013  3061046 KRIT1 0.014 
3414029 KCNH3 0.012  2905296 PI16 0.013  2666807 NEK10 0.013  3393536 TMPRSS13 0.014 
3553947 ZFYVE21 0.012  3474495 TRIAP1 0.013  3335465 SIPA1 0.013  3819968 ZNF177 0.014 
3642837 DECR2 0.012  2717757 C4orf23 0.013  3680524 ZC3H7A 0.013  2946056 SLC17A1 0.014 
3436544 BRI3BP 0.012  3846076 TLE2 0.013  2878943 PCDH1 0.013  2947219 ZKSCAN4 0.014 
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3555736 NDRG2 0.014  3788976 RAB27B 0.014  3182019 STX17 0.015  3334325 VEGFB 0.016 
3948590 RIBC2 0.014  3415763 SOAT2 0.014  3146723 SNX31 0.015  3913220 C20orf151 0.016 
3689981 MYLK3 0.014  3445768 ERP27 0.014  3352159 --- 0.015  2333707 CCDC24 0.016 
3376235 WDR74 0.014  3208640 PRKACG 0.014  2546054 RBKS 0.015  2479510 DYNC2LI1 0.016 
2840393 GABRP 0.014  2535976 AGXT 0.014  2330133 EIF2C3 0.015  3927105 MRPL39 0.016 
3820458 ICAM4 0.014  2809793 GZMK 0.014  3377474 SYVN1 0.015  2674646 AMIGO3 0.016 
2947248 ZNF323 0.014  2382781 DNAH14 0.014  3568534 SPTB 0.015  2981976 OSTCL 0.016 
3984125 RPA4 0.014  2693682 TXNRD3 0.014  3562557 FSCB 0.015  3781245 GATA6 0.016 
3929237 TCP10L 0.014  3766013 MARCH10 0.014  3953033 TRMT2A 0.015  3359134 IGF2 0.016 
3332530 MS4A10 0.014  3835911 APOC4 0.014  2947681 OR2W1 0.015  2851511 CDH9 0.016 
3015786 ZAN 0.014  2909404 CD2AP 0.015  2650357 ARL14 0.015  2769810 KDR 0.016 
3090006 SLC25A37 0.014  2549092 SOS1 0.015  3336094 CNIH2 0.015  2775994 HPSE 0.016 
2638988 PARP15 0.014  3223157 DBC1 0.015  2371255 SMG7 0.015  3371928 ARFGAP2 0.016 
3015682 PCOLCE 0.014  2975867 MAP3K5 0.015  3014808 ZNF789 0.015  3862188 FCGBP 0.016 
3950629 TRABD 0.014  2671422 ZNF445 0.015  3079172 TMEM176B 0.015  3991006 OR13H1 0.016 
3105749 ATP6V0D2 0.014  3882214 BPIL3 0.015  3371719 CKAP5 0.016  3835361 ZNF222 0.016 
3079257 ATG9B 0.014  2954527 ZNF318 0.015  3851801 RTBDN 0.016  2626802 PTPRG 0.016 
3965447 IL17REL 0.014  2837192 PPP1R2P3 0.015  3474418 PXN 0.016  2362950 ATP1A4 0.016 
3555492 TMEM55B 0.014  3846507 DAPK3 0.015  2968652 SESN1 0.016  3619690 PPP1R14D 0.016 
3347118 GRIA4 0.014  4051619 EXD3 0.015  3715512 TNFAIP1 0.016  2716124 HGFAC 0.016 
3504213 GJB6 0.014  3836217 KLC3 0.015  3414440 C12orf62 0.016  3238702 ARMC3 0.016 
3152558 FAM84B 0.014  3259836 ZDHHC16 0.015  3693141 PLLP 0.016  2622359 RBM6 0.016 
2708457 CLCN2 0.014  3401878 NDUFA9 0.015  3371225 CHST1 0.016  3718401 LIG3 0.016 
3527390 OR11H4 0.014  3729569 BCAS3 0.015  3075531 ZC3HAV1L 0.016  3332729 CD5 0.016 
3269328 ZRANB1 0.014  2481308 KLRAQ1 0.015  3322638 MRGPRX3 0.016  3526544 DCUN1D2 0.017 
3934245 CSTB 0.014  3699581 TMEM170A 0.015  3957679 SELM 0.016  3992148 DDX26B 0.017 
3852586 LPHN1 0.014  2819044 RASA1 0.015  2722291 TBC1D19 0.016  3387033 MRE11A 0.017 
2420681 MCOLN3 0.014  2600155 DNPEP 0.015  3842130 TMEM190 0.016  3754677 SYNRG 0.017 
2783316 SEC24D 0.014  3458837 METTL1 0.015  3978999 UBQLN2 0.016  2628081 SLC25A26 0.017 
2521574 PLCL1 0.014  3388696 MMP20 0.015  2951567 FKBP5 0.016  3726252 SGCA 0.017 
2602304 TM4SF20 0.014  2855285 SEPP1 0.015  2687255 CBLB 0.016  3334604 --- 0.017 
3311694 MMP21 0.014  2946219 HIST1H2AB 0.015  2794704 ASB5 0.016  2333574 ARTN 0.017 
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3976716 WDR13 0.017  3950452 CRELD2 0.017  2840789 FGF18 0.018  3994100 FMR1 0.019 
2767159 PHOX2B 0.017  3678542 C16orf89 0.017  3459604 PPM1H 0.018  2476219 BIRC6 0.019 
3742627 C17orf87 0.017  3834341 CEACAM5 0.017  3468743 NT5DC3 0.018  3867400 FUT1 0.019 
2669533 ACAA1 0.017  3268274 PLEKHA1 0.017  3221205 SLC46A2 0.018  3655060 ATP2A1 0.019 
3455651 KRT72 0.017  3197231 C9orf68 0.017  3759704 MAP3K14 0.018  3753538 SLFN12 0.019 
3296046 KCNMA1 0.017  3951493 CCT8L2 0.017  2397999 ARHGEF19 0.018  2686213 FILIP1L 0.019 
2623308 GRM2 0.017  2607757 CNTN6 0.018  3833793 RAB4B 0.019  2351763 CHIA 0.019 
4054204 APOD 0.017  3746625 TEKT3 0.018  3903952 GDF5 0.019  2716246 FLJ35424 0.019 
3239667 GAD2 0.017  3986087 NRK 0.018  2529782 MRPL44 0.019  3362191 SCUBE2 0.019 
3762185 HILS1 0.017  3545022 ESRRB 0.018  2868265 LIX1 0.019  2610972 SYN2 0.019 
3741040 MNT 0.017  2953262 FLJ41649 0.018  2800477 SRD5A1 0.019  3456212 MAP3K12 0.019 
2528198 CDK5R2 0.017  2321960 PLEKHM2 0.018  3631397 UACA 0.019  3486096 FREM2 0.020 
3033397 RBM33 0.017  2418700 ASB17 0.018  3968303 SHROOM2 0.019  2990043 PHF14 0.020 
3408733 RASSF8 0.017  2446567 STX6 0.018  2746507 --- 0.019  3740479 PRPF8 0.020 
3289948 PCDH15 0.017  3928559 KRTAP6-1 0.018  3791782 SERPINB5 0.019  3649811 NDE1 0.020 
3345940 CNTN5 0.017  2716432 ZBTB49 0.018  2854445 DAB2 0.019  2977510 FUCA2 0.020 
3509473 DCLK1 0.017  3414846 DAZAP2 0.018  3157441 MAFA 0.019  3658561 MGC34800 0.020 
3220846 SUSD1 0.017  3675620 C1QTNF8 0.018  2907444 PTCRA 0.019  3127610 PEBP4 0.020 
3826306 ZNF85 0.017  2726828 DCUN1D4 0.018  3198974 MPDZ 0.019  3185643 RGS3 0.020 
2318212 C1orf211 0.017  3974708 USP9X 0.018  2992243 DNAH11 0.019  3969713 MOSPD2 0.020 
2827299 MEGF10 0.017  3444195 MAGOHB 0.018  3217361 ANKS6 0.019  2558736 ADD2 0.020 
3432798 SDSL 0.017  2337217 C1orf175 0.018  2735459 HERC3 0.019  3541497 RAD51L1 0.020 
2592598 TMEFF2 0.017  3226237 DPM2 0.018  3901401 CST5 0.019  3693788 SLC38A7 0.020 
3202421 C9orf72 0.017  2389718 CNST 0.018  2500919 SLC20A1 0.019  3664952 PDP2 0.020 
3339971 PLEKHB1 0.017  2635812 PLCXD2 0.018  3936992 SEPT5 0.019  2542990 HS1BP3 0.020 
3825292 CRTC1 0.017  4014251 CHM 0.018  2762468 DCAF16 0.019  3340066 PAAF1 0.020 
2443305 C1orf114 0.017  3773558 FLJ90757 0.018  2352275 MOV10 0.019  2409847 PTCH2 0.020 
3744127 HES7 0.017  3864414 PHLDB3 0.018  3075778 HIPK2 0.019  3272795 PAOX 0.020 
4008078 PAGE1 0.017  3980867 GJB1 0.018  3621276 PPIP5K1 0.019  3229449 C9orf116 0.020 
3540155 C14orf50 0.017  2790626 FGA 0.018  3752709 MYO1D 0.019  2510485 RIF1 0.020 
2734421 ARHGAP24 0.017  3854477 TMEM221 0.018  3662750 POLR2C 0.019  3418153 MARS 0.020 
2894790 SYCP2L 0.017  3125915 MTUS1 0.018  3231846 WDR37 0.019  3697005 EXOSC6 0.020 
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3079576 SMARCD3 0.020  3922921 NDUFV3 0.021  3589972 CHST14 0.022  3384718 DLG2 0.023 
3475511 DIABLO 0.020  2333481 ST3GAL3 0.021  3664779 --- 0.022  3939125 GNAZ 0.023 
3654956 LAT 0.020  2399988 RNF186 0.021  2641232 --- 0.022  2565082 ADRA2B 0.023 
3375840 TUT1 0.020  3231010 PNPLA7 0.021  3179646 SUSD3 0.022  3994451 CXorf40A 0.023 
2863964 ARSB 0.020  2681195 UBA3 0.021  3072014 TNPO3 0.022  2788195 OTUD4 0.023 
3835085 ZNF575 0.020  3139035 ARFGEF1 0.021  3851630 FBXW9 0.022  3526772 FAM70B 0.023 
3755089 GPR179 0.020  3840253 ZNF534 0.021  3996289 EMD 0.022  3720695 THRA 0.023 
3886444 R3HDML 0.020  2392095 C1orf86 0.021  2452571 ELK4 0.022  3955940 CRYBB1 0.023 
3481890 ATP12A 0.020  3987876 HTR2C 0.021  2405036 BSDC1 0.022  3242425 CCNY 0.023 
2420790 C1orf52 0.020  3959411 APOL2 0.021  3434594 ACADS 0.022  2644619 ESYT3 0.023 
3192609 GFI1B 0.020  2567669 RFX8 0.021  2953711 TFEB 0.022  2413943 USP24 0.023 
2709402 CRYGS 0.020  3963990 PKDREJ 0.021  3947627 TSPO 0.022  2759857 ACOX3 0.023 
3718185 CCL11 0.020  2523540 NBEAL1 0.021  3214050 --- 0.022  3939450 C22orf15 0.023 
3177111 NTRK2 0.020  3341221 MYO7A 0.021  3697183 MTSS1L 0.022  2468138 --- 0.023 
3666146 SLC7A6 0.020  3320819 MICALCL 0.021  3000953 UPP1 0.022  2887164 SH3PXD2B 0.023 
3688120 STX1B 0.020  3899495 C20orf12 0.021  3300115 PPP1R3C 0.022  3239437 GPR158 0.023 
2641769 RHO 0.020  2597273 C2orf67 0.021  3969115 TLR8 0.022  2316953 PRDM16 0.023 
3581373 --- 0.020  3039247 DGKB 0.021  2773545 BTC 0.022  3572929 ZDHHC22 0.023 
2413484 YIPF1 0.020  2326846 TRNP1 0.021  4011189 OPHN1 0.022  3702499 KIAA1609 0.023 
3818395 ALKBH7 0.020  3094980 HTRA4 0.021  3162529 C9orf150 0.022  2782292 C4orf21 0.023 
3842059 BRSK1 0.021  3157563 NAPRT1 0.021  2924514 NCOA7 0.022  2757278 FAM53A 0.023 
3851545 MAN2B1 0.021  3226097 ENG 0.021  3932397 C21orf88 0.022  2400247 KIF17 0.023 
2884727 ATP10B 0.021  3824497 MAP1S 0.021  2349211 HEJ1 0.022  4051723 ENTPD8 0.023 
3676356 ZNF598 0.021  3373630 APLNR 0.021  3048886 PURB 0.022  3557504 MYH7 0.023 
3717052 NF1 0.021  4030162 DDX3Y 0.021  2793441 AADAT 0.022  3828067 PLEKHF1 0.023 
2427500 HBXIP 0.021  3975893 PHF16 0.021  3753966 CCL14-15 0.022  2613293 KCNH8 0.023 
3662612 RSPRY1 0.021  3923608 AIRE 0.021  3709540 PFAS 0.022  3851776 PRDX2 0.023 
3731543 RGS9 0.021  3852079 STX10 0.021  3774906 SECTM1 0.022  3822122 NFIX 0.023 
3938215 CCDC116 0.021  3402899 USP5 0.021  3381682 CHCHD8 0.022  3326826 FJX1 0.023 
3323413 HTATIP2 0.021  3917549 KAP13-1 0.021  3720402 ERBB2 0.022  2908052 POLR1C 0.023 
4015440 SYTL4 0.021  2514304 DHRS9 0.021  3817933 ZNRF4 0.022  2535859 CAPN10 0.024 
2447107 TEDDM1 0.021  3351688 UPK2 0.022  2339454 ANGPTL3 0.022  3242555 GJD4 0.024 
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3783481 DSG3 0.024  2322036 FBLIM1 0.024  2545144 GPR113 0.025  2545144 GPR113 0.025 
2814527 BDP1 0.024  3071304 PAX4 0.024  2700727 SERP1 0.025  2700727 SERP1 0.025 
2456687 SLC30A10 0.024  3837193 CCDC9 0.024  3269587 C10orf137 0.025  3269587 C10orf137 0.025 
2926437 MGC34034 0.024  3362096 C11orf16 0.024  3791815 SERPINB12 0.025  3791815 SERPINB12 0.025 
2466002 SH3BP5L 0.024  3168309 RECK 0.024  3872542 ZNF418 0.025  3872542 ZNF418 0.025 
3887069 SNX21 0.024  2852742 AMACR 0.024  3180342 C9orf3 0.025  3180342 C9orf3 0.025 
3835544 ZNF227 0.024  3846363 APBA3 0.024  3026969 C7orf55 0.025  3026969 C7orf55 0.025 
3607927 SEMA4B 0.024  3352948 SORL1 0.024  3334484 ESRRA 0.025  3334484 ESRRA 0.025 
2640449 CHST13 0.024  3820906 C19orf52 0.025  3491948 TDRD3 0.025  3491948 TDRD3 0.025 
3143575 DCAF4L2 0.024  3402150 NTF3 0.025  2735759 MMRN1 0.025  2735759 MMRN1 0.025 
3468473 PAH 0.024  2887048 STK10 0.025  3187834 DAB2IP 0.025  3187834 DAB2IP 0.025 
3516228 PCDH20 0.024  2591614 DIRC1 0.025  3193725 OLFM1 0.025  3193725 OLFM1 0.025 
3860261 THAP8 0.024  3799461 SPIRE1 0.025  3907040 LOC79015 0.025  3907040 LOC79015 0.025 
2752085 --- 0.024  3334831 ZFPL1 0.025  2438792 ETV3 0.025  2438792 ETV3 0.025 
2976768 CITED2 0.024  3957738 RNF185 0.025  2495446 INPP4A 0.025  2495446 INPP4A 0.025 
2843283 B4GALT7 0.024  3931765 ERG 0.025  2672966 MAP4 0.025  2672966 MAP4 0.025 
3747522 TNFRSF13 0.024  3189800 SLC2A8 0.025  2730933 NPFFR2 0.025  2730933 NPFFR2 0.025 
3830065 HPN 0.024  2911413 PRIM2 0.025  3836705 HIF3A 0.025  3836705 HIF3A 0.025 
3114365 FAM91A1 0.024  2493992 KCNIP3 0.025  3911217 PMEPA1 0.025  3911217 PMEPA1 0.025 
3594825 PIGB 0.024  4003155 ARX 0.025  3706736 TMEM93 0.026  3706736 TMEM93 0.026 
3106539 OTUD6B 0.024  3457667 CNPY2 0.025  3869030 SIGLEC10 0.026  3869030 SIGLEC10 0.026 
3422215 THAP2 0.024  3246046 C10orf71 0.025  2745067 ELMOD2 0.026  2745067 ELMOD2 0.026 
2631940 HTR1F 0.024  2366156 SFT2D2 0.025  2415910 DOCK7 0.026  2415910 DOCK7 0.026 
2655845 EPHB3 0.024  3344897 MED17 0.025  3976670 EBP 0.026  3976670 EBP 0.026 
3261063 TLX1 0.024  2888800 DBN1 0.025  3961955 PHF5A 0.026  3961955 PHF5A 0.026 
2550542 THADA 0.024  3015395 PVRIG 0.025  2726234 NIPAL1 0.026  2726234 NIPAL1 0.026 
3138618 CRH 0.024  3049522 TNS3 0.025  2923868 PKIB 0.026  2923868 PKIB 0.026 
3611744 LRRK1 0.024  3029475 OR6B1 0.025  3153961 HHLA1 0.026  3153961 HHLA1 0.026 
2850071 MYO10 0.024  2812690 MAST4 0.025  2887633 BOD1 0.026  2887633 BOD1 0.026 
3007960 CLDN4 0.024  3180142 PTPDC1 0.025  4037778 DMBT1 0.026  4037778 DMBT1 0.026 
2717253 SORCS2 0.024  3333942 RTN3 0.025  2380440 SPATA17 0.026  2380440 SPATA17 0.026 
2362323 OR6K6 0.024  2830698 FAM53C 0.025  2769346 LNX1 0.026  2769346 LNX1 0.026 
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3645656 ZNF205 0.026  2336585 SCP2 0.027  2721809 ZCCHC4 0.028  2756497 ATP5I 0.029 
3444086 KLRK1 0.026  2442397 TADA1 0.027  3841862 FCAR 0.028  3323052 NAV2 0.029 
2902609 C6orf25 0.026  3819130 CLEC4M 0.027  3511031 ELF1 0.028  3743937 --- 0.029 
3832865 NCCRP1 0.026  2700332 TM4SF18 0.027  3158011 PARP10 0.028  2398040 C1orf89 0.029 
3258713 LGI1 0.026  3812074 DSEL 0.027  2376168 NFASC 0.028  2318157 RNF207 0.029 
3747812 PEMT 0.026  3292169 CTNNA3 0.027  2772341 UGT2B4 0.028  2957314 GSTA2 0.029 
3866491 MEIS3 0.026  2874686 HINT1 0.027  2900453 PGBD1 0.028  3354719 --- 0.029 
2750476 TRIM60 0.026  3415068 ANKRD33 0.027  2797393 FAT1 0.028  2409344 MED8 0.029 
3345593 CEP57 0.026  3735089 --- 0.027  2651989 SKIL 0.028  3293537 PCBD1 0.029 
3123541 MFHAS1 0.026  3675101 MRPL28 0.027  4054414 GJB3 0.028  3331355 SERPING1 0.029 
2404122 MATN1 0.026  3774516 STRA13 0.027  3001345 VWC2 0.028  2324634 CDC42 0.029 
3770422 GRIN2C 0.027  3270224 FOXI2 0.027  3674349 ZNF276 0.028  3836401 GIPR 0.029 
3037535 ZNF12 0.027  3852133 CACNA1A 0.028  3978518 MAGED2 0.028  4009751 ITIH5L 0.029 
3535186 ATL1 0.027  3048134 C7orf44 0.028  2711957 C3orf21 0.028  3840194 ZNF880 0.029 
3592054 TRIM69 0.027  2423017 EVI5 0.028  3941793 KREMEN1 0.028  3359224 ASCL2 0.029 
3610804 IGF1R 0.027  3588346 ZNF770 0.028  3046197 ELMO1 0.028  3922602 UBASH3A 0.029 
2897453 ID4 0.027  2542651 WDR35 0.028  2433432 GJA5 0.028  2604223 DNAJB3 0.029 
3982721 FAM46D 0.027  2620410 EXOSC7 0.028  3961042 FLJ23865 0.028  3265918 PNLIPRP1 0.029 
3858285 TSHZ3 0.027  2962525 IBTK 0.028  3632107 CELF6 0.028  3757020 KRT35 0.029 
3934837 C21orf122 0.027  2823880 CAMK4 0.028  2459487 TRIM11 0.028  2771839 TMPRSS11D 0.029 
3945014 GCAT 0.027  2472651 KLHL29 0.028  2950753 BAK1 0.028  3094778 TACC1 0.029 
3721485 KLHL10 0.027  3371964 PACSIN3 0.028  2881165 TIGD6 0.028  3026988 LUC7L2 0.029 
3273578 IDI2 0.027  3688254 PRSS8 0.028  3544071 VSX2 0.028  3848907 KANK3 0.029 
3529775 TSSK4 0.027  2576526 NOC2L 0.028  2359504 SPRR3 0.029  3408831 SSPN 0.029 
2930418 UST 0.027  3061319 CDK6 0.028  3480013 MPP8 0.029  2516332 SCRN3 0.029 
3930942 CLDN14 0.027  3249641 MYPN 0.028  3431143 UBE3B 0.029  3954596 RTDR1 0.029 
3096368 HOOK3 0.027  3575371 EML5 0.028  2754538 SLC25A4 0.029  2400373 EIF4G3 0.030 
2390335 OR2M2 0.027  2427898 OVGP1 0.028  3458248 MYO1A 0.029  3790259 MALT1 0.030 
3833238 LGALS14 0.027  3722700 NAGS 0.028  2360541 DCST1 0.029  3448744 PTHLH 0.030 
2439052 FCRL2 0.027  2713664 IQCG 0.028  3970714 PPEF1 0.029  3824713 ARRDC2 0.030 
3915569 CHODL 0.027  2940987 SLC35B3 0.028  2612278 CAPN7 0.029  3330864 OR5AS1 0.030 
3696524 COG8 0.027  2322103 SPEN 0.028  3443206 AICDA 0.029  2462511 HEATR1 0.030 
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3442579 RBP5 0.030  3949097 TRMU 0.032  2888341 RNF44 0.033  3826504 ZNF431 0.033 
3843452 ZSCAN4 0.030  2434233 OTUD7B 0.032  2437205 GBAP1 0.033  3727449 TOM1L1 0.033 
3449910 AMN1 0.030  2617276 CTDSPL 0.032  3695541 FHOD1 0.033  3906390 PTPRT 0.033 
2874371 FBN2 0.030  2432851 NBPF11 0.032  3446845 GYS2 0.033  2448382 PTGS2 0.033 
3366519 FANCF 0.030  2953852 MED20 0.032  3421824 C12orf28 0.033  3701000 MAF 0.034 
2375596 ADORA1 0.030  3821410 ZNF440 0.032  2475911 EHD3 0.033  2566504 C2orf55 0.034 
3942940 FLJ20464 0.030  2431031 HMGCS2 0.032  2857204 PPAP2A 0.033  3873086 DEFB129 0.034 
2673594 CELSR3 0.030  2565410 KIAA1310 0.032  3352847 TECTA 0.033  3430086 TCP11L2 0.034 
2443575 KIFAP3 0.030  3822976 CASP14 0.032  3882949 DYNLRB1 0.033  2906990 BYSL 0.034 
3770345 CD300E 0.030  3935374 C21orf58 0.032  3110171 ATP6V1C1 0.033  2332711 PPIH 0.034 
2892277 NQO2 0.030  3444820 LRP6 0.032  2910680 LRRC1 0.033  3063273 PTCD1 0.034 
4019412 CXorf56 0.030  2448710 FAM5C 0.032  3105506 CA13 0.033  3455890 KRT79 0.034 
3067890 IMMP2L 0.030  2699145 SLC9A9 0.032  3607332 ACAN 0.033  3679643 --- 0.034 
3734399 C17orf77 0.030  2623859 NISCH 0.032  3845944 GNG7 0.033  2491745 GNLY 0.034 
2602403 SLC19A3 0.030  2697372 TXNDC6 0.032  3869062 SIGLEC8 0.033  3717635 ZNF207 0.034 
3230610 ABCA2 0.030  2460817 SIPA1L2 0.032  2731782 C4orf26 0.033  3935192 FTCD 0.034 
2808438 NNT 0.030  2807195 EGFLAM 0.032  3111375 TTC35 0.033  2783207 PRSS12 0.034 
2672333 PRSS45 0.030  3184408 PALM2 0.032  2731542 AREG 0.033  4007009 NDUFB11 0.034 
3108859 OSR2 0.030  3870449 VSTM1 0.032  2875491 SHROOM1 0.033  3843058 ZNF264 0.034 
2524016 PARD3B 0.030  2586603 TLK1 0.032  3053312 --- 0.033  3868816 KLK9 0.034 
2403446 PTAFR 0.030  3219547 IKBKAP 0.032  2503257 INHBB 0.033  3303392 BLOC1S2 0.034 
3190514 GLE1 0.030  3643196 WDR90 0.032  3644664 DNASE1L2 0.033  2407224 RSPO1 0.034 
3354380 HEPN1 0.030  2674168 C3orf62 0.032  3023211 ATP6V1F 0.033  3860793 ZNF585B 0.034 
3300597 MYOF 0.030  4007550 PCSK1N 0.032  2504595 PROC 0.033  3564620 NID2 0.034 
3579114 BCL11B 0.030  2724671 RHOH 0.032  2329386 HMGB4 0.033  2452859 LGTN 0.034 
3660858 CHD9 0.031  3248470 C10orf107 0.032  2404254 PUM1 0.033  3934263 --- 0.034 
3391653 DRD2 0.031  3677516 MEFV 0.032  3332465 MS4A8B 0.033  3579969 DIO3-OS 0.034 
3331822 GLYATL1 0.031  2443370 F5 0.032  3378228 B3GNT1 0.033  3354293 ROBO3 0.034 
3713951 SLC47A1 0.031  3977347 CCNB3 0.032  3233605 PFKFB3 0.033  3091403 EPHX2 0.034 
2816506 S100Z 0.031  2662956 VGLL4 0.032  3657219 SLC5A2 0.033  2952198 TMEM217 0.034 
2871241 MCC 0.031  3960440 HS5O6A 0.032  3416740 OR6C74 0.033  3899346 SNX5 0.034 
2756404 ZNF721 0.031  3699178 WDR59 0.033  3956670 C22orf31 0.033  2673902 QRICH1 0.034 
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2772160 --- 0.034  2443235 NME7 0.036  2375795 LAX1 0.036  3638699 C15orf38 0.037 
3352438 POU2F3 0.035  3314720 C10orf93 0.036  3642993 C16orf11 0.036  3454157 FAIM2 0.037 
3194567 FAM69B 0.035  3551566 EVL 0.036  3512719 SIAH3 0.036  3026495 AKR1D1 0.037 
2985342 C6orf54 0.035  3873744 TGM3 0.036  3391724 TMPRSS5 0.036  3506936 MTIF3 0.037 
3554315 INF2 0.035  3900833 FOXA2 0.036  3715460 PYY2 0.036  2708203 MAP6D1 0.037 
3461105 IFNG 0.035  3886810 RBPJL 0.036  3223687 PHF19 0.036  2383639 PRSS38 0.037 
2502686 MARCO 0.035  3017080 ARMC10 0.036  3592420 C15orf21 0.036  3263624 MXI1 0.037 
3737697 BAIAP2 0.035  4054639 NOC2L 0.036  3635198 BCL2A1 0.037  3830825 C19orf55 0.037 
3527722 RNASE2 0.035  3079336 FASTK 0.036  3914021 GMEB2 0.037  3515088 LECT1 0.037 
3400730 CACNA1C 0.035  3807474 C18orf32 0.036  3874198 OXT 0.037  2685304 PROS1 0.037 
3348990 TEX12 0.035  2754937 TLR3 0.036  3864107 PSG7 0.037  3656318 PRR14 0.037 
2383524 ZNF678 0.035  2902884 SKIV2L 0.036  3953879 MGC16703 0.037  3436987 --- 0.038 
2547114 XDH 0.035  2932593 CLDN20 0.036  3994158 FMR1NB 0.037  3220740 C9orf84 0.038 
4054690 HES4 0.035  2536965 FLJ38379 0.036  2934801 MAP3K4 0.037  2326774 SFN 0.038 
2843855 ZFP2 0.035  2515471 DLX1 0.036  3268548 PSTK 0.037  3936009 IL17RA 0.038 
2805939 RXFP3 0.035  2322848 PADI4 0.036  2755111 KLKB1 0.037  2875685 FSTL4 0.038 
3729910 TBX4 0.035  2422967 GFI1 0.036  2503109 EPB41L5 0.037  2427688 C1orf103 0.038 
3461883 PTPRR 0.035  3838004 PPP1R15A 0.036  4015693 TIMM8A 0.037  2638017 C3orf1 0.038 
3441190 FGF6 0.035  3462567 KCNC2 0.036  2656598 AHSG 0.037  3330769 OR5D13 0.038 
2577958 DARS 0.035  3882265 C20orf186 0.036  2905664 ZFAND3 0.037  3839718 CD33 0.038 
2752006 SAP30 0.035  4026624 PNCK 0.036  2600881 PAX3 0.037  2343418 PTGFR 0.038 
3660213 CYLD 0.035  3773742 SLC38A10 0.036  2577028 NCKAP5 0.037  2373511 CFHR5 0.038 
3907514 NEURL2 0.035  2906824 FOXP4 0.036  2941546 C6orf218 0.037  3371003 TP53I11 0.038 
3877892 PCSK2 0.035  3939875 SUSD2 0.036  3351931 HINFP 0.037  3292779 SLC25A16 0.038 
3033127 HTR5A 0.035  3377569 SLC25A45 0.036  3540839 --- 0.037  3779612 SLMO1 0.038 
3945314 KDELR3 0.035  3048212 MRPS24 0.036  3070658 NDUFA5 0.037  3662150 MT1M 0.038 
2322598 CROCC 0.035  2899756 H2AFP 0.036  3806711 IER3IP1 0.037  3376155 NXF1 0.038 
3581221 AHNAK2 0.035  3807261 SMAD7 0.036  3837934 FUT2 0.037  3971451 PHEX 0.038 
3471769 TMEM116 0.035  3727583 HLF 0.036  3549605 PPP4R4 0.037  3332663 CD6 0.038 
3376193 STX5 0.035  2443952 MYOC 0.036  3221571 RNF183 0.037  3450775 KIF21A 0.038 
3121751 CSMD1 0.035  2336809 DMRTB1 0.036  3934642 KAP12-1 0.037  3674659 GAS8 0.038 
3863723 CEACAM8 0.036  3360277 OR52R1 0.036  3186191 ATP6V1G1 0.037  2982524 SLC22A2 0.038 
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2440413 ITLN1 0.038  2528645 ACCN4 0.040  3471753 C12orf47 0.041  3611684 LRRK1 0.043 
3335697 CTSW 0.038  3603295 CRABP1 0.040  3752424 C17orf79 0.041  2852712 SLC45A2 0.043 
3810413 RAX 0.038  3602634 ISL2 0.040  3351975 ABCG4 0.041  2831897 TMCO6 0.043 
4002394 SMPX 0.038  2577644 YSK4 0.040  3004768 ZNF273 0.041  3661645 IRX6 0.043 
2889753 ZNF354A 0.038  3537030 RPL13AP3 0.040  3333572 C11orf83 0.041  2649182 LEKR1 0.043 
3041294 FAM126A 0.038  3807809 CXXC1 0.040  3373392 OR8H1 0.041  3398145 PRDM10 0.043 
2911303 ZNF451 0.039  2334319 TOE1 0.040  3502475 PROZ 0.041  3736204 C17orf99 0.043 
3846214 DOHH 0.039  3044938 RP9P 0.040  3712922 C17orf39 0.041  3815936 REEP6 0.043 
3749432 RNFT1 0.039  3675205 C16orf13 0.040  2766492 C4orf34 0.041  3664924 CA7 0.043 
3507134 CDX2 0.039  2410574 LRRC41 0.040  3461795 PTPRB 0.041  3543355 DCAF4 0.043 
3349719 ZBTB16 0.039  2916307 C6orf165 0.040  3549517 OTUB2 0.041  3559936 C14orf128 0.043 
2624639 CACNA2D3 0.039  3321592 CALCB 0.040  3765642 INTS2 0.041  3318329 OR51M1 0.043 
2551284 UNQ6975 0.039  2638869 CSTA 0.040  2500875 CHCHD5 0.041  3210497 PRUNE2 0.043 
3425108 C12orf29 0.039  2416218 ITGB3BP 0.040  3357346 GLB1L3 0.042  2790999 ACCN5 0.043 
2521556 MARS2 0.039  3837707 ZNF114 0.040  3969802 BMX 0.042  3074362 CNOT4 0.043 
3288707 ERCC6 0.039  3533435 PNN 0.040  2926447 TCF21 0.042  3341539 KCTD21 0.043 
2561182 REG1B 0.039  3145509 GDF6 0.040  3315584 NLRP6 0.042  2315739 PUSL1 0.043 
3377826 RNASEH2C 0.039  2379314 VASH2 0.040  2501204 IL1RN 0.042  2617659 SLC22A14 0.043 
3650861 SYT17 0.039  3097580 C8orf22 0.040  2326237 EXTL1 0.042  2877257 BRD8 0.043 
3551485 EML1 0.039  3371660 HARBI1 0.041  3379269 UNC93B1 0.042  3159483 KANK1 0.043 
3190151 SLC25A25 0.039  2453370 PLXNA2 0.041  3638068 DET1 0.042  3654699 NUPR1 0.043 
3362159 NRIP3 0.039  3191113 PRRX2 0.041  3673661 FAM38A 0.042  3059258 PCLO 0.043 
3836057 LRRC68 0.039  3352130 RNF26 0.041  3450180 YARS2 0.042  2829864 SLC25A48 0.043 
2394699 TNFRSF25 0.039  3644887 TBC1D24 0.041  2437645 GON4L 0.042  3250602 H2AFY2 0.043 
3589570 EIF2AK4 0.039  2358646 BNIPL 0.041  2359646 LOR 0.042  3165780 IFT74 0.043 
2514745 MYO3B 0.039  3551935 WDR25 0.041  3039177 ETV1 0.042  2453065 C1orf116 0.043 
3708938 ATP1B2 0.039  3865635 DMPK 0.041  3164181 RRAGA 0.042  3318329 OR51M1 0.043 
3970476 SCML1 0.039  2491572 SH2D6 0.041  2493813 ZNF2 0.042  3210497 PRUNE2 0.043 
3680130 DEXI 0.039  3845439 ATP8B3 0.041  3159330 DOCK8 0.042  2790999 ACCN5 0.043 
2548699 CYP1B1 0.039  3490433 CCDC70 0.041  2360677 EFNA1 0.042  3074362 CNOT4 0.043 
3749767 TMEM11 0.039  3445741 MGP 0.041  3980614 GDPD2 0.042  3341539 KCTD21 0.043 
2671936 SLC6A20 0.040  2773997 NUP54 0.041  3829471 KCTD15 0.042  2315739 PUSL1 0.043 
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2877257 BRD8 0.043  3630378 --- 0.044  3283613 ZNF438 0.044  3830649 COX6B1 0.045 
3159483 KANK1 0.043  2521997 C2orf69 0.044  3917555 KAP13-4 0.044  3606034 PDE8A 0.045 
3654699 NUPR1 0.043  3355860 KCNJ5 0.044  2954324 MEA1 0.045  3996467 PLXNA3 0.045 
3059258 PCLO 0.043  3358425 LRDD 0.044  2906934 PRICKLE4 0.045  3256669 CFLP1 0.045 
2829864 SLC25A48 0.043  2326327 CNKSR1 0.044  3042994 HOXA13 0.045  3330943 OR8K1 0.045 
3250602 H2AFY2 0.043  3559570 HECTD1 0.044  2607055 PASK 0.045  3938792 VPREB1 0.046 
3165780 IFT74 0.043  2436526 TPM3 0.044  3830649 COX6B1 0.045  3759587 PLCD3 0.046 
2453065 C1orf116 0.043  3540398 FNTB 0.044  3606034 PDE8A 0.045  3095114 ADAM5P 0.046 
3283613 ZNF438 0.044  3734903 LLGL2 0.044  3996467 PLXNA3 0.045  2958325 DST 0.046 
3917555 KAP13-4 0.044  3577545 IFI27L2 0.044  3834046 AXL 0.045  2966496 MCHR2 0.046 
3816686 ZNF556 0.044  3642390 TARSL2 0.044  3490892 OLFM4 0.045  2401581 GALE 0.046 
2988536 WIPI2 0.044  3308560 VAX1 0.044  3750685 SLC46A1 0.045  3260265 CNNM1 0.046 
3186324 DEC1 0.044  3740704 SMYD4 0.044  2883541 SOX30 0.045  2695453 CPNE4 0.046 
3451708 TWF1 0.044  3911485 APCDD1L 0.044  2620985 TMIE 0.045  3250806 ADAMTS14 0.046 
2986906 GET4 0.044  3302693 LOXL4 0.044  3664664 CDH5 0.045  3413852 PRPH 0.046 
3630378 --- 0.044  2827772 ADAMTS19 0.044  3932917 PLAC4 0.045  2834579 SPINK6 0.046 
2521997 C2orf69 0.044  3679564 USP7 0.044  3339423 INPPL1 0.045  3751625 SSH2 0.046 
3355860 KCNJ5 0.044  3830925 KIRREL2 0.044  3214451 NFIL3 0.045  3128372 KCTD9 0.046 
3358425 LRDD 0.044  2676471 TMEM110 0.044  3373411 OR5R1 0.045  2603844 ECEL1 0.046 
2326327 CNKSR1 0.044  2817291 JMY 0.044  3834046 AXL 0.045  2317686 AJAP1 0.046 
3559570 HECTD1 0.044  2825514 DMXL1 0.044  3490892 OLFM4 0.045  3403841 RIMKLB 0.046 
2436526 TPM3 0.044  4015884 ARMCX2 0.044  3750685 SLC46A1 0.045  3737677 --- 0.046 
3540398 FNTB 0.044  2791197 PDGFC 0.044  2883541 SOX30 0.045  3318639 CCKBR 0.046 
3734903 LLGL2 0.044  3816686 ZNF556 0.044  2620985 TMIE 0.045  2656627 FETUB 0.046 
3577545 IFI27L2 0.044  2988536 WIPI2 0.044  3664664 CDH5 0.045  4046481 ING5 0.046 
3642390 TARSL2 0.044  3186324 DEC1 0.044  3932917 PLAC4 0.045  2611504 HDAC11 0.046 
3679564 USP7 0.044  3451708 TWF1 0.044  3339423 INPPL1 0.045  3871142 C19orf51 0.046 
3830925 KIRREL2 0.044  2986906 GET4 0.044  3214451 NFIL3 0.045  2435323 THEM5 0.046 
2676471 TMEM110 0.044  3308560 VAX1 0.044  3373411 OR5R1 0.045  3064024 C7orf61 0.046 
2817291 JMY 0.044  3740704 SMYD4 0.044  2954324 MEA1 0.045  3852735 PTGER1 0.047 
2825514 DMXL1 0.044  3911485 APCDD1L 0.044  2906934 PRICKLE4 0.045  3658925 ORC6 0.047 
4015884 ARMCX2 0.044  3302693 LOXL4 0.044  3042994 HOXA13 0.045  3042063 NPVF 0.047 
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3437780 FZD10 0.047  3065684 SLC26A5 0.047  2385146 TRIM67 0.048  3067592 PNPLA8 0.049 
3815610 ATP5D 0.047  2351465 PROK1 0.047  3194613 TMEM141 0.048  2545007 KIF3C 0.049 
3174816 ANXA1 0.047  2675315 CACNA2D2 0.048  3449008 OVCH1 0.048  3133233 PLAT 0.049 
3902081 ZNF337 0.047  2661992 OXTR 0.048  3552083 DLK1 0.048  4054481 GABRD 0.049 
3379091 ALDH3B2 0.047  3566176 OTX2 0.048  3148463 ANGPT1 0.048  3945781 SYNGR1 0.049 
3552847 DYNC1H1 0.047  3945006 H1F0 0.048  3857171 ZNF675 0.048  2467855 SOX11 0.049 
3614012 --- 0.047  3262535 GSTO2 0.048  3105467 E2F5 0.048  3393704 MPZL3 0.049 
3581090 TMEM179 0.047  3688362 COX6A2 0.048  3849117 ADAMTS10 0.048  2599798 IHH 0.049 
3959953 TMPRSS6 0.047  2426840 WDR47 0.048  2615360 TGFBR2 0.048  3691193 SNX20 0.049 
2317434 TPRG1L 0.047  3382216 ARRB1 0.048  2353749 CD101 0.048  3120653 GPT 0.049 
3854836 KIAA1683 0.047  3977646 GSPT2 0.048  2448073 IVNS1ABP 0.049  2730281 ODAM 0.049 
2652217 --- 0.047  2702724 LXN 0.048  2460551 EGLN1 0.049  3416483 HNRNPA1 0.049 
2562729 REEP1 0.047  2919399 LIN28B 0.048  2518743 NUP35 0.049  3576411 GPR68 0.049 
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Transcript ID Symbol Fold p-value  Transcript ID Symbol Fold p-value  Transcript ID Symbol Fold p-value 
3718555 SLFN5 ⇧ 2.49 5.10E-03  2423175 FAM69A ⇩ 1.65 0.034  2734047 AGPAT9 ⇩ 1.48 0.045 
2548699 CYP1B1 ⇩ 2.30 0.042  3507282 FLT1 ⇧ 1.65 0.026  2459173 PRO2012 ⇧ 1.48 0.029 
2940202 F13A1 ⇧ 2.21 0.020  3945314 KDELR3 ⇩ 1.65 0.011  3838094 FTL ⇩ 1.47 0.048 
2940145 NRN1 ⇧ 2.17 0.022  2378068 G0S2 ⇩ 1.63 0.019  2522094 SPATS2L ⇧ 1.47 0.028 
3174510 GDA ⇧ 2.13 1.87E-03  3494137 LMO7 ⇧ 1.62 1.09E-03  3018866 DNAJB9 ⇩ 1.47 0.033 
2678298 DNASE1L3 ⇩ 2.08 9.05E-03  3496409 GPC5 ⇧ 1.61 0.011  3309602 RGS10 ⇧ 1.47 0.018 
2738378 NPNT ⇩ 1.97 0.045  3065244 RASA4 ⇩ 1.60 0.010  2582124 NR4A2 ⇩ 1.47 1.25E-03 
3445908 EPS8 ⇧ 1.95 0.015  3020496 ST7 ⇩ 1.60 7.63E-04  3663074 MMP15 ⇧ 1.46 9.89E-03 
3409605 FAR2 ⇧ 1.93 5.93E-03  3403841 RIMKLB ⇧ 1.60 0.041  3925639 NRIP1 ⇧ 1.46 0.031 
3560403 EGLN3 ⇧ 1.91 1.52E-03  3273667 ADARB2 ⇧ 1.59 4.10E-03  2375212 PPP1R12B ⇩ 1.46 1.86E-03 
2902707 HSPA1A ⇩ 1.91 2.29E-04  3969946 ZRSR2 ⇧ 1.59 1.56E-03  3316344 CD151 ⇩ 1.46 0.010 
3141755 HEY1 ⇧ 1.89 0.013  2902725 HSPA1B ⇩ 1.58 2.16E-03  3958658 LARGE ⇩ 1.46 0.015 
2523801 CD28 ⇧ 1.88 0.021  3450899 SLC2A13 ⇧ 1.58 1.60E-03  3215146 NINJ1 ⇩ 1.46 0.038 
3972929 GK ⇧ 1.84 3.19E-04  3856646 ZNF208 ⇧ 1.58 0.024  3202316 MOBKL2B ⇧ 1.46 0.012 
2665199 SATB1 ⇧ 1.81 0.049  2761837 FGFBP2 ⇩ 1.56 9.43E-03  2877939 DNAJC18 ⇩ 1.46 9.36E-03 
2399743 AKR7A3 ⇩ 1.79 4.55E-03  2474240 KHK ⇩ 1.55 0.033  2950145 HLA-DOB ⇩ 1.46 0.027 
3566383 C14orf105 ⇧ 1.78 0.049  3540552 FUT8 ⇩ 1.54 0.027  2471978 RHOB ⇧ 1.45 0.022 
3382216 ARRB1 ⇧ 1.77 0.040  3705151 DBNDD1 ⇧ 1.54 0.024  2363248 LY9 ⇩ 1.45 0.031 
3214451 NFIL3 ⇧ 1.76 2.01E-03  3447863 KRAS ⇧ 1.54 3.00E-05  2902574 LY6G5B ⇩ 1.45 3.43E-03 
3449068 TMTC1 ⇧ 1.75 0.018  3263944 PDCD4 ⇧ 1.53 6.53E-04  2469910 LPIN1 ⇩ 1.45 2.99E-03 
2816459 F2R ⇩ 1.72 0.019  3623031 FBN1 ⇧ 1.53 0.023  3434490 CABP1 ⇧ 1.45 1.50E-03 
2452691 SLC41A1 ⇩ 1.70 1.34E-03  3141589 IL7 ⇧ 1.52 0.016  3507798 UBL3 ⇧ 1.45 1.47E-03 
2781138 LEF1 ⇧ 1.69 0.020  3703885 SLC7A5 ⇩ 1.52 7.95E-03  3945545 APOBEC3B ⇩ 1.45 0.023 
2664209 SH3BP5 ⇩ 1.68 7.17E-03  3944129 HMOX1 ⇩ 1.51 0.017  3824993 GDF15 ⇩ 1.45 0.042 
2973376 PTPRK ⇧ 1.68 0.040  3841621 LILRB4 ⇩ 1.51 0.034  3216276 SLC35D2 ⇧ 1.45 8.79E-03 
2400518 ECE1 ⇩ 1.67 0.015  2768981 SGCB ⇩ 1.51 0.049  2820865 ARSK ⇩ 1.45 0.021 
2362333 MNDA ⇩ 1.67 0.022  3892812 SLCO4A1 ⇩ 1.50 9.17E-04  2324634 CDC42 ⇩ 1.44 6.43E-03 
3369249 APIP ⇧ 1.66 0.025  3385175 PICALM ⇧ 1.50 0.018  3208355 CBWD3 ⇧ 1.44 0.032 
2626097 ABHD6 ⇩ 1.65 2.18E-03  2845274 CCDC127 ⇩ 1.49 1.92E-03  3257204 IFIT3 ⇧ 1.44 0.023 
3896078 SLC23A2 ⇩ 1.65 0.016  3887210 MMP9 ⇧ 1.49 0.026  3936442 PEX26 ⇧ 1.44 7.27E-04 
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3876645 BTBD3 ⇧ 1.44 0.022  2604390 ARL4C ⇩ 1.40 0.011  2500919 SLC20A1 ⇩ 1.37 0.028 
3851072 ACP5 ⇩ 1.44 0.015  3761632 SNF8 ⇧ 1.40 2.35E-03  3434393 DYNLL1 ⇧ 1.36 9.68E-03 
4035833 CD24 ⇧ 1.43 0.038  3969422 RAB9A ⇧ 1.40 4.33E-03  3204243 SIGMAR1 ⇩ 1.36 0.044 
3409211 PPFIBP1 ⇧ 1.43 0.015  3409127 ARNTL2 ⇧ 1.40 2.19E-03  3981735 NCRNA00183 ⇧ 1.36 0.012 
3727712 PCTP ⇧ 1.43 0.010  3447694 BCAT1 ⇧ 1.40 0.032  3397589 ETS1 ⇧ 1.36 1.50E-03 
2775909 PLAC8 ⇧ 1.43 7.86E-03  2948169 HCG8 ⇩ 1.40 7.97E-03  3594031 TMOD2 ⇧ 1.36 0.018 
3055608 TYW1B ⇩ 1.43 0.015  2932508 TIAM2 ⇩ 1.39 0.024  3293537 PCBD1 ⇧ 1.36 0.016 
2990342 TMEM106B ⇩ 1.43 0.029  3464967 GALNT4 ⇧ 1.39 3.48E-05  3517793 KLF12 ⇧ 1.36 3.20E-03 
3103523 LY96 ⇩ 1.43 0.011  3167383 NUDT2 ⇧ 1.39 9.11E-03  2330773 CDCA8 ⇩ 1.36 0.015 
3101153 BHLHE22 ⇧ 1.43 0.039  2320727 TNFRSF1B ⇩ 1.39 4.13E-03  2841699 CPEB4 ⇩ 1.36 5.10E-03 
2638988 PARP15 ⇩ 1.43 0.047  2877893 MGC29506 ⇩ 1.39 0.044  3791482 PHLPP1 ⇧ 1.36 0.041 
2970897 FRK ⇧ 1.42 3.99E-03  2764192 SEL1L3 ⇩ 1.39 0.042  2714376 TMEM175 ⇩ 1.36 0.022 
2437247 GBA ⇩ 1.42 0.046  3450655 CPNE8 ⇧ 1.39 0.010  2997376 ANLN ⇩ 1.36 8.35E-03 
2361342 SEMA4A ⇩ 1.42 3.30E-03  3149528 TRPS1 ⇧ 1.39 0.031  3645836 ZNF75A ⇧ 1.36 9.21E-03 
2327677 EPB41 ⇩ 1.42 6.09E-03  2351004 GSTM5 ⇩ 1.39 9.83E-03  3577246 MOAP1 ⇧ 1.36 0.011 
3893849 PRPF6 ⇧ 1.42 4.30E-03  2888879 DOK3 ⇩ 1.38 1.57E-04  2360633 EFNA4 ⇩ 1.36 0.025 
3466284 NDUFA12 ⇧ 1.41 1.48E-04  3812385 CD226 ⇩ 1.38 7.26E-03  2780172 CENPE ⇩ 1.35 0.014 
3900091 RALGAPA2 ⇧ 1.41 0.015  3375091 SLC15A3 ⇩ 1.37 0.026  2621583 ZNF589 ⇩ 1.35 0.011 
3916527 JAM2 ⇩ 1.41 0.011  3382061 XRRA1 ⇧ 1.37 0.047  3927081 NCRNA00158 ⇧ 1.35 0.017 
2420467 CTBS ⇩ 1.41 0.016  2902178 TCF19 ⇩ 1.37 7.96E-03  2331679 MFSD2A ⇩ 1.35 3.48E-03 
3624145 DMXL2 ⇧ 1.41 1.27E-03  2866590 LYSMD3 ⇩ 1.37 0.012  3390641 ARHGAP20 ⇧ 1.35 3.77E-03 
3166844 CHMP5 ⇧ 1.41 0.036  3132940 ANK1 ⇧ 1.37 0.049  3004768 ZNF273 ⇩ 1.35 0.025 
2626167 PXK ⇩ 1.41 8.78E-03  2425118 SASS6 ⇩ 1.37 9.10E-04  2601414 SERPINE2 ⇩ 1.35 0.012 
2454661 TMEM206 ⇩ 1.41 8.47E-03  2371346 RGL1 ⇩ 1.37 0.035  2360989 MSTO1 ⇩ 1.35 3.63E-03 
3081525 C7orf13 ⇩ 1.41 0.030  2452977 FAIM3 ⇩ 1.37 0.012  3540353 CHURC1 ⇧ 1.35 9.26E-03 
3005684 KCTD7 ⇩ 1.41 7.87E-04  3089360 SLC39A14 ⇩ 1.37 0.044  2492496 NCRNA00152 ⇩ 1.35 0.020 
3023883 CPA4 ⇩ 1.41 0.033  2603320 GPR55 ⇩ 1.37 0.048  2830638 KIF20A ⇩ 1.35 0.010 
3845352 UQCR11 ⇧ 1.41 4.96E-03  3242425 CCNY ⇧ 1.37 2.03E-03  2446198 TOR1AIP2 ⇩ 1.35 1.58E-04 
3175119 OSTF1 ⇧ 1.40 8.46E-03  2892277 NQO2 ⇩ 1.37 1.93E-03  3824666 KCNN1 ⇧ 1.35 0.012 
3538213 DAAM1 ⇧ 1.40 0.041  3994451 CXorf40A ⇧ 1.37 3.29E-03  2914777 TTK ⇩ 1.34 5.24E-03 
2766492 C4orf34 ⇧ 1.40 0.041  3344861 C11orf54 ⇧ 1.37 3.95E-03  2957462 GSTA4 ⇩ 1.34 7.95E-03 
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2829562 TXNDC15 ⇩ 1.34 6.58E-03  3860101 NFKBID ⇩ 1.32 0.021  3882949 DYNLRB1 ⇧ 1.30 3.62E-03 
3824212 DDA1 ⇧ 1.34 0.021  3403077 C12orf57 ⇧ 1.32 3.61E-03  3666649 VPS4A ⇧ 1.30 3.22E-03 
3518169 COMMD6 ⇧ 1.34 4.11E-03  3706659 ASPA ⇧ 1.32 0.013  2676182 NT5DC2 ⇩ 1.30 0.018 
2413423 TMEM48 ⇩ 1.34 0.030  2436826 KCNN3 ⇩ 1.31 0.011  3494102 UCHL3 ⇧ 1.30 6.78E-03 
2841491 C5orf41 ⇩ 1.34 0.043  3827218 RPSAP58 ⇧ 1.31 0.031  3485292 NBEA ⇧ 1.29 0.031 
2571457 CKAP2L ⇩ 1.34 1.30E-03  3706651 OR3A3 ⇩ 1.31 9.19E-03  2946845 ZNF204P ⇩ 1.29 3.94E-03 
2442698 CREG1 ⇩ 1.34 0.026  3111695 EBAG9 ⇩ 1.31 2.33E-03  3426257 SOCS2 ⇧ 1.29 0.010 
3441941 VAMP1 ⇩ 1.33 0.027  3978169 TSPYL2 ⇩ 1.31 8.45E-03  2444842 KIAA0040 ⇩ 1.29 0.039 
2838656 HMMR ⇩ 1.33 0.039  2639225 PDIA5 ⇩ 1.31 0.032  2402431 PAQR7 ⇩ 1.29 0.032 
3332615 TMEM109 ⇩ 1.33 0.044  2820893 RFESD ⇩ 1.31 0.016  3726498 MYCBPAP ⇩ 1.29 0.024 
2336302 ZFYVE9 ⇧ 1.33 8.56E-04  2411799 BEND5 ⇧ 1.31 2.84E-03  3066818 NAMPT ⇩ 1.29 0.025 
3462843 NAP1L1 ⇧ 1.33 0.031  3892452 LSM14B ⇧ 1.31 0.046  2579572 ZEB2 ⇧ 1.29 0.032 
2638789 CD86 ⇩ 1.33 0.048  3820370 P2RY11 ⇩ 1.31 0.047  3894098 C20orf96 ⇩ 1.29 5.77E-04 
3139580 SLCO5A1 ⇧ 1.33 0.027  3332886 TMEM138 ⇩ 1.31 0.026  3353914 VWA5A ⇩ 1.29 0.011 
3712041 UBB ⇧ 1.33 0.011  3451264 YAF2 ⇧ 1.31 5.03E-03  3611049 LRRC28 ⇧ 1.29 4.86E-03 
2925724 AKAP7 ⇧ 1.33 5.53E-03  2317317 TP73 ⇩ 1.31 0.033  3067592 PNPLA8 ⇩ 1.29 0.036 
3476330 CCDC92 ⇧ 1.33 0.029  2411228 STIL ⇩ 1.31 0.020  2681157 TMF1 ⇩ 1.29 1.30E-03 
3413950 SPATS2 ⇧ 1.33 9.23E-04  2899413 BTN3A3 ⇩ 1.31 5.82E-03  2494484 NCAPH ⇩ 1.29 0.019 
2612401 BTD ⇩ 1.33 0.019  2515050 GORASP2 ⇩ 1.31 0.014  2757319 SLBP ⇩ 1.29 0.028 
2956438 MUT ⇩ 1.33 6.14E-03  3072435 TMEM209 ⇩ 1.31 0.026  2437401 FDPS ⇩ 1.29 2.74E-03 
2334098 KIF2C ⇩ 1.32 9.72E-03  3427014 SNRPF ⇧ 1.31 0.043  4003895 CXorf21 ⇧ 1.29 0.042 
3513995 DLEU2 ⇧ 1.32 0.031  3435980 TCTN2 ⇩ 1.30 0.046  3487432 DNAJC15 ⇩ 1.29 0.036 
3016636 SH2B2 ⇩ 1.32 0.024  2950277 HLA-DMA ⇩ 1.30 0.047  3382698 GUCY2E ⇩ 1.29 0.014 
3869954 ZNF321 ⇧ 1.32 0.017  2749560 ETFDH ⇩ 1.30 0.020  3807595 MYO5B ⇧ 1.29 0.014 
2835792 GM2A ⇩ 1.32 8.90E-03  3584728 SNRPN ⇧ 1.30 0.017  2375664 BTG2 ⇩ 1.29 0.029 
3774096 PDE6G ⇧ 1.32 7.04E-03  3254488 C10orf58 ⇩ 1.30 0.045  3753538 SLFN12 ⇧ 1.29 0.013 
3936550 USP18 ⇧ 1.32 0.028  3272205 INPP5A ⇧ 1.30 0.020  3705412 C17orf97 ⇧ 1.29 1.09E-03 
2495446 INPP4A ⇩ 1.32 0.017  2949801 AGPAT1 ⇩ 1.30 3.58E-03  3846742 SH3GL1 ⇧ 1.29 0.011 
3147020 ZNF706 ⇧ 1.32 0.027  3726406 ACSF2 ⇩ 1.30 0.022  2955061 SLC35B2 ⇩ 1.29 0.041 
3142932 C8orf59 ⇧ 1.32 2.16E-03  4002148 EIF1AX ⇧ 1.30 0.015  2610241 FANCD2 ⇩ 1.29 0.015 
3417457 MYL6 ⇧ 1.32 0.016  3870135 ZNF347 ⇧ 1.30 0.023  2690850 TMEM39A ⇩ 1.29 0.036 
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3005956 C7orf42 ⇩ 1.28 2.20E-03  2690900 CD80 ⇩ 1.27 0.020  3829768 UBA2 ⇧ 1.26 7.29E-03 
2784113 CCNA2 ⇩ 1.28 0.013  2367843 DARS2 ⇩ 1.27 0.014  3840224 ZNF528 ⇧ 1.26 0.046 
3670700 BCMO1 ⇧ 1.28 0.031  2487549 MXD1 ⇩ 1.27 0.035  3633699 NRG4 ⇧ 1.26 0.049 
2949471 NEU1 ⇩ 1.28 9.42E-03  3571542 PNMA1 ⇧ 1.27 6.05E-04  2608765 ARL8B ⇩ 1.26 2.95E-03 
3058156 TMEM60 ⇩ 1.28 0.015  3283920 ARHGAP12 ⇧ 1.27 2.94E-03  3725083 SNX11 ⇧ 1.26 0.021 
3512050 CCDC122 ⇧ 1.28 0.010  3088213 SH2D4A ⇧ 1.27 0.022  2546008 SUPT7L ⇩ 1.26 3.01E-03 
2940551 SSR1 ⇩ 1.28 0.031  2599433 USP37 ⇩ 1.27 4.63E-03  3665230 HSF4 ⇩ 1.26 0.037 
3244539 ZNF22 ⇧ 1.28 0.032  3624273 LYSMD2 ⇧ 1.27 0.017  3348189 FDX1 ⇧ 1.26 1.78E-04 
2379863 CENPF ⇩ 1.28 0.036  3120358 HSF1 ⇩ 1.27 0.040  2645579 RASA2 ⇩ 1.26 0.019 
3998632 PNPLA4 ⇧ 1.28 1.55E-04  2611848 SLC6A6 ⇩ 1.27 0.026  3756344 SMARCE1 ⇧ 1.26 5.22E-04 
2435251 LINGO4 ⇧ 1.28 0.040  2773348 PF4 ⇧ 1.27 0.034  3521174 ABCC4 ⇧ 1.26 0.032 
2428796 PTPN22 ⇩ 1.28 1.51E-03  3210179 C9orf95 ⇧ 1.27 0.013  2909723 CENPQ ⇩ 1.26 0.017 
2364438 NUF2 ⇩ 1.28 0.011  3406421 STRAP ⇧ 1.27 5.70E-03  3227454 QRFP ⇧ 1.26 0.036 
3609592 MCTP2 ⇧ 1.28 0.016  2673547 SLC26A6 ⇩ 1.27 5.17E-03  3750685 SLC46A1 ⇩ 1.26 0.010 
3486728 SLC25A15 ⇧ 1.28 9.00E-03  4000132 TRAPPC2 ⇧ 1.27 0.011  2816298 IQGAP2 ⇩ 1.26 0.046 
2475407 CLIP4 ⇩ 1.28 0.011  2570616 BUB1 ⇩ 1.27 0.018  3053691 GUSB ⇩ 1.26 0.016 
3101385 MTFR1 ⇩ 1.28 0.025  2366184 TBX19 ⇩ 1.27 4.17E-03  3832292 KCNK6 ⇩ 1.26 9.77E-03 
3168700 ZCCHC7 ⇧ 1.28 5.84E-03  3830216 FXYD5 ⇩ 1.27 0.048  3693511 C16orf80 ⇧ 1.26 0.014 
2716655 MSX1 ⇧ 1.28 0.022  3383227 GAB2 ⇩ 1.27 0.041  3710870 ARHGAP44 ⇩ 1.25 0.043 
3126504 CSGALNACT1 ⇧ 1.28 0.038  3191338 GPR107 ⇩ 1.27 0.013  2872471 DTWD2 ⇧ 1.25 0.021 
3373487 OR5M1 ⇧ 1.28 3.63E-03  3869714 ZNF611 ⇧ 1.27 8.48E-03  3341440 RN28S1 ⇧ 1.25 0.047 
2608419 SETMAR ⇩ 1.28 0.013  3289235 SGMS1 ⇧ 1.27 0.024  4009288 HSD17B10 ⇧ 1.25 0.037 
3656760 STX4 ⇧ 1.28 3.83E-03  2384562 RAB4A ⇧ 1.27 0.024  3914286 SOX18 ⇧ 1.25 0.045 
2499158 RANBP2 ⇩ 1.27 4.30E-03  3945376 TOMM22 ⇧ 1.27 0.013  2633587 TBC1D23 ⇩ 1.25 0.016 
3740432 SCARF1 ⇧ 1.27 0.026  2908179 VEGFA ⇩ 1.27 0.047  2639309 SEC22A ⇩ 1.25 0.017 
2862380 ANKRA2 ⇩ 1.27 0.014  2708407 ALG3 ⇩ 1.27 0.015  3490251 WDFY2 ⇧ 1.25 2.41E-03 
3421762 RAB3IP ⇧ 1.27 3.33E-03  2522509 NIF3L1 ⇩ 1.26 1.86E-03  3010082 PHTF2 ⇩ 1.25 0.019 
3454680 TFCP2 ⇧ 1.27 1.24E-03  2482230 ERLEC1 ⇩ 1.26 0.042  3756856 KRTAP17-1 ⇧ 1.25 0.036 
4027532 GAB3 ⇧ 1.27 0.011  2390976 NCRNA00115 ⇩ 1.26 0.041  2913594 MTO1 ⇩ 1.25 4.97E-03 
3421706 RAB3IP ⇧ 1.27 3.39E-03  3470964 GLTP ⇧ 1.26 0.015  3782166 IMPACT ⇧ 1.25 0.038 
2722377 STIM2 ⇩ 1.27 0.028  2486927 ARHGAP25 ⇩ 1.26 0.036  2988882 AIMP2 ⇩ 1.25 0.045 
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2829416 SEC24A ⇩ 1.25 0.014  3978706 PAGE5 ⇩ 1.24 0.039  3781124 MIB1 ⇧ 1.23 2.96E-03 
3708826 EIF4A1 ⇧ 1.25 0.047  3978819 RRAGB ⇧ 1.24 0.013  3851441 ZNF442 ⇧ 1.23 0.022 
3868905 CTU1 ⇧ 1.25 0.033  3037385 KDELR2 ⇩ 1.24 0.034  3948590 RIBC2 ⇧ 1.23 6.13E-03 
2712906 RNF168 ⇩ 1.25 0.026  2841184 ERGIC1 ⇩ 1.24 0.011  3911814 SLMO2 ⇧ 1.23 0.021 
2694397 RPN1 ⇩ 1.25 0.017  3514849 NEK3 ⇧ 1.24 0.026  2360158 HAX1 ⇩ 1.23 0.040 
2478748 EML4 ⇩ 1.25 0.043  2436228 GATAD2B ⇩ 1.24 2.41E-05  2316245 PRKCZ ⇩ 1.23 0.032 
3439063 ZNF26 ⇧ 1.25 4.42E-03  3828162 C19orf2 ⇧ 1.24 4.12E-03  3890109 C20orf108 ⇧ 1.23 7.28E-03 
2782292 C4orf21 ⇩ 1.25 0.039  3707481 ZFP3 ⇧ 1.24 0.030  2883609 CLINT1 ⇩ 1.23 0.037 
3186207 C9orf91 ⇧ 1.25 0.041  3822805 TECR ⇩ 1.24 0.023  3535780 PTGER2 ⇧ 1.23 0.032 
3335070 CDC42EP2 ⇧ 1.25 0.011  2974188 MED23 ⇩ 1.24 4.06E-03  3017795 RINT1 ⇩ 1.23 0.027 
3471264 VPS29 ⇧ 1.25 0.035  2456746 EPRS ⇩ 1.24 3.55E-03  3078656 ZNF767 ⇩ 1.23 0.047 
3082824 CLN8 ⇩ 1.25 6.03E-03  2623515 ALAS1 ⇩ 1.24 4.96E-03  3488942 NUDT15 ⇧ 1.23 0.015 
2559494 C2orf7 ⇩ 1.25 0.049  3042603 KIAA0087 ⇧ 1.24 8.01E-03  2708817 TMEM41A ⇩ 1.23 0.039 
2651782 SEC62 ⇩ 1.25 0.047  3099561 T1560 ⇧ 1.24 0.042  3859622 ZNF792 ⇧ 1.23 5.87E-03 
3048778 TMED4 ⇩ 1.25 8.52E-03  2750594 SC4MOL ⇩ 1.24 0.046  3489481 PHF11 ⇧ 1.23 7.69E-03 
2687739 CD47 ⇩ 1.25 0.024  3670918 PLCG2 ⇩ 1.24 0.030  3499585 BIVM ⇧ 1.23 5.27E-03 
3540862 GPHN ⇧ 1.25 5.28E-03  3854954 LRRC25 ⇩ 1.24 0.026  3969455 OFD1 ⇧ 1.23 0.031 
3181193 TDRD7 ⇧ 1.25 7.08E-03  2949210 BAT4 ⇩ 1.24 0.012  2353773 TTF2 ⇩ 1.23 0.044 
2652675 ECT2 ⇩ 1.25 0.029  2353881 MAN1A2 ⇩ 1.24 0.042  2678367 PDHB ⇩ 1.23 0.017 
2738146 TET2 ⇩ 1.25 4.34E-03  3490741 SUGT1 ⇧ 1.24 0.039  3428088 ACTR6 ⇧ 1.23 0.029 
3089740 RHOBTB2 ⇩ 1.25 0.013  2962767 PGM3 ⇩ 1.24 0.049  2356181 RBM8A ⇩ 1.23 0.017 
3697563 FTSJD1 ⇧ 1.25 0.011  3347549 CUL5 ⇧ 1.24 1.01E-03  3040073 SNX13 ⇩ 1.23 0.022 
3531479 ARHGAP5 ⇧ 1.25 0.038  2813414 CCNB1 ⇩ 1.24 0.044  3319613 RPL27A ⇩ 1.23 2.92E-03 
3407926 CMAS ⇧ 1.24 0.027  2984655 RPS6KA2 ⇧ 1.24 0.046  2772968 COX18 ⇩ 1.23 0.018 
3845647 MKNK2 ⇧ 1.24 0.010  2608469 ITPR1 ⇩ 1.24 9.91E-03  2617041 GOLGA4 ⇩ 1.23 0.041 
3713575 PRPSAP2 ⇧ 1.24 0.037  2908423 SLC29A1 ⇩ 1.24 0.026  2378180 C1orf107 ⇩ 1.23 8.47E-03 
3260666 HIF1AN ⇧ 1.24 7.75E-03  3846280 TBXA2R ⇧ 1.24 7.25E-03  3851150 ZNF433 ⇧ 1.23 1.40E-03 
3668898 ZFP1 ⇧ 1.24 4.20E-03  3726375 EME1 ⇩ 1.24 0.040  2879509 YIPF5 ⇩ 1.23 0.026 
2326410 CCDC21 ⇩ 1.24 5.93E-03  3048869 H2AFV ⇩ 1.24 0.027  2735459 HERC3 ⇩ 1.23 0.022 
3726960 NME2 ⇧ 1.24 0.015  2622359 RBM6 ⇩ 1.23 0.031  3243078 ZNF33A ⇧ 1.23 0.010 
2436338 CRTC2 ⇩ 1.24 1.05E-04  3328214 ALKBH3 ⇧ 1.23 0.020  2358171 PRPF3 ⇩ 1.23 1.22E-04 
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3475324 TMEM120B ⇧ 1.23 0.037  2817291 JMY ⇩ 1.22 0.048  2336963 C1orf83 ⇩ 1.21 0.039 
2878368 APBB3 ⇩ 1.23 5.72E-03  2711644 ATP13A3 ⇩ 1.22 0.042  3869339 ZNF350 ⇧ 1.21 5.58E-03 
2731831 USO1 ⇩ 1.23 0.026  3458911 CTDSP2 ⇧ 1.22 0.037  3282268 ACBD5 ⇧ 1.21 0.031 
3464912 POC1B ⇧ 1.23 0.023  2342576 ACADM ⇩ 1.22 0.025  3843399 ZNF134 ⇧ 1.21 0.031 
2417528 DEPDC1 ⇩ 1.23 0.044  3016692 PRKRIP1 ⇩ 1.22 0.040  2954527 ZNF318 ⇩ 1.21 0.025 
2433209 PRKAB2 ⇩ 1.23 0.036  3366519 FANCF ⇧ 1.22 0.032  2818454 XRCC4 ⇩ 1.21 0.042 
3903598 GGT7 ⇩ 1.23 0.014  2862716 GFM2 ⇩ 1.22 8.03E-03  3409364 KLHDC5 ⇧ 1.21 9.71E-03 
3840944 ZNF525 ⇧ 1.23 0.044  4021341 ZDHHC9 ⇩ 1.22 0.047  3730899 DDX42 ⇧ 1.21 0.021 
2899437 BTN2A1 ⇩ 1.23 0.011  2524743 FASTKD2 ⇩ 1.22 0.017  3870162 ZNF665 ⇧ 1.21 5.37E-04 
3334847 C11orf2 ⇧ 1.22 9.22E-03  3989678 XIAP ⇧ 1.22 0.018  3602039 PPCDC ⇧ 1.21 0.011 
3860491 ZNF260 ⇧ 1.22 9.42E-03  2437307 SCAMP3 ⇩ 1.22 0.048  2514441 PPIG ⇩ 1.21 2.66E-03 
3412296 IRAK4 ⇧ 1.22 0.026  3716337 CCDC55 ⇧ 1.22 0.015  3664952 PDP2 ⇩ 1.21 0.041 
3209497 FAM108B1 ⇧ 1.22 5.26E-03  2902348 MICB ⇩ 1.22 0.027  3497659 RAP2A ⇧ 1.21 0.038 
3438027 RAN ⇧ 1.22 0.013  3734453 SLC9A3R1 ⇧ 1.22 0.028  3763270 MMD ⇧ 1.21 0.031 
2659521 LRRC33 ⇩ 1.22 0.020  3079005 RARRES2 ⇧ 1.22 6.94E-03  2759857 ACOX3 ⇩ 1.21 5.62E-03 
3803120 B4GALT6 ⇧ 1.22 0.034  3361811 STK33 ⇧ 1.22 0.025  2346863 RPL5 ⇩ 1.21 0.043 
3221633 HDHD3 ⇩ 1.22 0.032  3439305 ZNF84 ⇧ 1.22 5.61E-03  2466039 ZNF692 ⇩ 1.21 9.61E-03 
2456849 RAB3GAP2 ⇩ 1.22 3.79E-03  2349863 NTNG1 ⇩ 1.22 0.039  3625761 MNS1 ⇧ 1.21 0.031 
3282117 ANKRD26 ⇧ 1.22 0.018  2542737 LAPTM4A ⇩ 1.22 0.018  2560122 MOGS ⇩ 1.21 0.046 
2553730 MTIF2 ⇩ 1.22 0.021  3750785 SPAG5 ⇩ 1.22 0.020  3334501 PRDX5 ⇧ 1.21 0.036 
2451200 UBE2T ⇩ 1.22 0.022  4053534 ISG15 ⇧ 1.22 0.041  3566304 EXOC5 ⇧ 1.21 3.84E-03 
2783316 SEC24D ⇩ 1.22 0.048  2814642 MCCC2 ⇩ 1.22 0.022  2380991 IARS2 ⇩ 1.21 0.033 
3702689 ZDHHC7 ⇧ 1.22 6.43E-03  2830010 SMAD5 ⇩ 1.22 9.43E-03  3037142 PMS2 ⇩ 1.21 8.60E-03 
3064361 ACHE ⇧ 1.22 0.036  2708610 MAGEF1 ⇧ 1.22 0.025  2596162 INO80D ⇩ 1.21 3.77E-03 
2528620 GMPPA ⇩ 1.22 0.016  3859915 U2AF1L4 ⇩ 1.22 0.035  3130211 PPP2CB ⇧ 1.21 0.044 
2712632 TFRC ⇩ 1.22 0.011  3916576 GABPA ⇧ 1.22 3.64E-03  2604223 DNAJB3 ⇧ 1.21 6.39E-03 
3140640 STAU2 ⇧ 1.22 0.022  3352813 TBCEL ⇧ 1.22 0.021  3119376 C8orf31 ⇩ 1.21 0.023 
2739242 GAR1 ⇧ 1.22 0.035  3619595 FAM82A2 ⇩ 1.21 0.024  3441011 PARP11 ⇧ 1.21 0.016 
3510858 FOXO1 ⇧ 1.22 0.048  2979056 NUP43 ⇩ 1.21 0.024  2907018 TAF8 ⇩ 1.21 0.015 
3311715 UROS ⇧ 1.22 0.024  3761054 COPZ2 ⇧ 1.21 2.99E-03  3956290 PITPNB ⇧ 1.21 4.35E-03 
3595979 CCNB2 ⇩ 1.22 0.025  3092663 WRN ⇩ 1.21 0.029  2363919 ATF6 ⇩ 1.21 0.029 
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2694785 MBD4 ⇩ 1.21 0.023  2588827 NFE2L2 ⇩ 1.20 0.040  2693937 TPRA1 ⇩ 1.20 8.58E-03 
2577896 MCM6 ⇩ 1.21 0.040  3428131 SCYL2 ⇧ 1.20 0.034  3814063 MBP ⇧ 1.20 0.040 
3860824 ZNF569 ⇧ 1.21 2.35E-03  3929664 TMEM50B ⇧ 1.20 0.031  2835848 SLC36A1 ⇩ 1.20 0.020 
3766960 SMURF2 ⇧ 1.21 0.036  3737647 CHMP6 ⇧ 1.20 0.012  3890870 RAB22A ⇧ 1.20 0.015 
3215701 FANCC ⇧ 1.21 0.032  2586989 DLX2 ⇧ 1.20 4.61E-03  3433538 RNFT2 ⇩ 1.20 0.028 
3346548 BIRC3 ⇧ 1.21 0.026  2531779 ARMC9 ⇩ 1.20 0.028  3737140 GAA ⇩ 1.20 0.012 
2369796 TOR1AIP1 ⇩ 1.21 0.027  3088983 XPO7 ⇩ 1.20 8.56E-03  3740171 CRK ⇧ 1.20 0.048 
3489957 RNASEH2B ⇧ 1.21 8.01E-03  3212728 AGTPBP1 ⇧ 1.20 0.014  2548776 ATL2 ⇩ 1.20 0.045 
3419641 SRGAP1 ⇧ 1.21 5.66E-03  3164601 KIAA1797 ⇧ 1.20 0.035  3081707 MNX1 ⇧ 1.20 0.012 
3602569 C15orf27 ⇧ 1.20 6.61E-03  2786578 NDUFC1 ⇧ 1.20 0.041  3432754 PLBD2 ⇩ 1.20 0.044 
2784131 BBS7 ⇩ 1.20 0.034  3210130 C9orf41 ⇧ 1.20 0.034  3636956 WDR73 ⇧ 1.20 0.019 
2541230 NBAS ⇩ 1.20 6.58E-03  2690776 B4GALT4 ⇩ 1.20 9.35E-03  3738205 MRPL12 ⇧ 1.20 0.038 
3418298 KIF5A ⇧ 1.20 3.82E-03  2893847 SNRNP48 ⇩ 1.20 0.027  2714230 PCGF3 ⇩ 1.20 0.019 
3261886 C10orf26 ⇧ 1.20 0.048  3784509 ZNF271 ⇧ 1.20 0.048  2900299 ZNF192 ⇩ 1.20 0.010 
3611126 MEF2A ⇧ 1.20 4.73E-03  2801608 MARCH6 ⇩ 1.20 7.71E-03  3860596 ZNF461 ⇧ 1.20 6.97E-03 
2437329 CLK2 ⇩ 1.20 0.033  3614087 UBE3A ⇧ 1.20 0.014  3704896 CHMP1A ⇧ 1.20 3.48E-03 
3739162 TBCD ⇧ 1.20 0.017  3465409 BTG1 ⇧ 1.20 2.52E-03  3806913 SMAD2 ⇧ 1.20 0.012 
3710681 MAP2K4 ⇧ 1.20 0.016  2619344 NKTR ⇩ 1.20 8.93E-03  3131844 LSM1 ⇧ 1.20 0.033 
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Transcript ID Symbol Fold p-value  Transcript ID Symbol Fold p-value  Transcript ID Symbol Fold p-value 
4048241 HLA-DRB5 ⇩ 8.28 1.78E-03  2437247 GBA ⇩ 1.52 0.014  2408189 PPT1 ⇩ 1.44 0.043 
4048265 HLA-DRB1 ⇩ 5.58 0.015  3797295 L3MBTL4 ⇧ 1.51 9.05E-03  2899413 BTN3A3 ⇩ 1.43 1.71E-04 
3841621 LILRB4 ⇩ 1.91 6.96E-04  3790479 SEC11C ⇩ 1.50 8.48E-03  3743734 C17orf61 ⇧ 1.43 2.38E-03 
2821347 ERAP2 ⇧ 1.89 0.028  3507798 UBL3 ⇧ 1.50 3.30E-04  2325192 RPL11 ⇧ 1.43 8.87E-03 
3369249 APIP ⇧ 1.77 8.99E-03  2505993 POTEKP ⇧ 1.50 5.07E-03  3927226 APP ⇩ 1.43 5.68E-03 
2399743 AKR7A3 ⇩ 1.75 4.50E-03  3761632 SNF8 ⇧ 1.50 1.72E-04  3727712 PCTP ⇧ 1.43 8.20E-03 
2913694 CD109 ⇩ 1.73 5.45E-03  3550328 C14orf129 ⇧ 1.50 8.83E-03  3913483 TCFL5 ⇧ 1.43 0.027 
2845274 CCDC127 ⇩ 1.72 2.22E-05  2436826 KCNN3 ⇩ 1.50 1.48E-04  2407478 FHL3 ⇧ 1.43 0.013 
2909020 ENPP4 ⇩ 1.72 3.90E-03  3385175 PICALM ⇧ 1.50 0.015  2452691 SLC41A1 ⇩ 1.43 0.023 
2643592 EPHB1 ⇩ 1.72 0.043  3053691 GUSB ⇩ 1.49 3.33E-05  3470964 GLTP ⇧ 1.42 2.05E-04 
2678298 DNASE1L3 ⇩ 1.70 0.045  3618736 RASGRP1 ⇩ 1.49 0.044  3470523 SELPLG ⇩ 1.42 0.048 
3142217 PAG1 ⇩ 1.68 5.43E-03  3936442 PEX26 ⇧ 1.49 1.48E-04  2447824 EDEM3 ⇩ 1.42 0.014 
3892812 SLCO4A1 ⇩ 1.68 1.87E-05  3864551 PLAUR ⇩ 1.48 6.09E-03  3244539 ZNF22 ⇧ 1.42 1.96E-03 
2820865 ARSK ⇩ 1.67 1.05E-03  3824212 DDA1 ⇧ 1.48 1.67E-03  2418929 PIGK ⇩ 1.42 0.039 
2768981 SGCB ⇩ 1.64 0.015  3208355 CBWD3 ⇧ 1.47 0.019  2514563 KLHL23 ⇧ 1.42 0.013 
3403841 RIMKLB ⇧ 1.62 0.029  3407793 PYROXD1 ⇧ 1.47 2.67E-03  2319225 H6PD ⇩ 1.42 0.019 
3856646 ZNF208 ⇧ 1.61 0.014  4002148 EIF1AX ⇧ 1.47 2.60E-04  3428268 GAS2L3 ⇩ 1.42 0.035 
2671101 ANO10 ⇩ 1.61 0.031  2454661 TMEM206 ⇩ 1.47 2.14E-03  3035892 GNA12 ⇧ 1.42 4.68E-03 
3018866 DNAJB9 ⇩ 1.60 7.21E-03  3375999 C11orf48 ⇧ 1.46 6.47E-03  3435490 DENR ⇧ 1.42 2.16E-03 
3916527 JAM2 ⇩ 1.59 4.79E-04  2673547 SLC26A6 ⇩ 1.46 8.96E-06  3434393 DYNLL1 ⇧ 1.42 2.78E-03 
3309602 RGS10 ⇧ 1.57 3.97E-03  3202316 MOBKL2B ⇧ 1.46 8.38E-03  3770290 CD300LB ⇩ 1.41 4.57E-03 
3166844 CHMP5 ⇧ 1.57 4.57E-03  3476330 CCDC92 ⇧ 1.46 2.89E-03  2877639 SIL1 ⇩ 1.41 9.28E-03 
3925639 NRIP1 ⇧ 1.57 8.74E-03  2877893 MGC29506 ⇩ 1.46 0.017  3656223 ITGAL ⇩ 1.41 0.033 
3518086 TBC1D4 ⇧ 1.55 0.010  2949256 BAT5 ⇩ 1.46 4.08E-04  2950307 HLA-DOA ⇩ 1.41 0.011 
3333899 RARRES3 ⇧ 1.55 5.12E-03  3167383 NUDT2 ⇧ 1.46 2.20E-03  3130211 PPP2CB ⇧ 1.41 2.56E-04 
3892452 LSM14B ⇧ 1.54 1.11E-03  3462843 NAP1L1 ⇧ 1.45 3.78E-03  3845352 UQCR11 ⇧ 1.41 3.05E-03 
3023883 CPA4 ⇩ 1.54 5.61E-03  3782166 IMPACT ⇧ 1.45 4.94E-04  3827218 RPSAP58 ⇧ 1.41 4.79E-03 
3263944 PDCD4 ⇧ 1.53 3.93E-04  3703885 SLC7A5 ⇩ 1.45 0.014  3917204 C21orf7 ⇧ 1.41 7.47E-03 
3160658 SLC1A1 ⇩ 1.53 0.015  2899437 BTN2A1 ⇩ 1.44 9.18E-06  3403077 C12orf57 ⇧ 1.41 2.09E-04 
2626097 ABHD6 ⇩ 1.52 6.82E-03  3994451 CXorf40A ⇧ 1.44 4.06E-04  4006416 FUNDC1 ⇧ 1.41 4.32E-04 
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3820370 P2RY11 ⇩ 1.40 0.010  3023060 CALU ⇩ 1.37 0.013  2836451 MFAP3 ⇩ 1.35 0.014 
3406421 STRAP ⇧ 1.40 8.01E-05  3712041 UBB ⇧ 1.37 3.51E-03  2794902 AGA ⇩ 1.35 0.027 
2409104 SLC2A1 ⇩ 1.40 5.48E-03  3716993 RNF135 ⇧ 1.37 8.50E-05  3257670 PCGF5 ⇧ 1.35 1.11E-03 
2320727 TNFRSF1B ⇩ 1.40 2.61E-03  2336302 ZFYVE9 ⇧ 1.37 1.68E-04  3341440 RN28S1 ⇧ 1.35 6.88E-03 
3540353 CHURC1 ⇧ 1.40 2.69E-03  2645764 ATP1B3 ⇩ 1.37 0.025  3410695 DNM1L ⇧ 1.35 0.036 
3253438 RPS24 ⇧ 1.40 0.013  2361342 SEMA4A ⇩ 1.37 6.16E-03  3076753 KIAA1147 ⇩ 1.35 0.012 
2865050 RPS23 ⇧ 1.40 0.014  2714376 TMEM175 ⇩ 1.37 0.016  2594497 CLK1 ⇩ 1.35 0.019 
2643324 SRPRB ⇩ 1.39 0.013  2611848 SLC6A6 ⇩ 1.36 2.94E-03  2878662 DIAPH1 ⇩ 1.35 1.37E-03 
3537030 RPL13AP3 ⇧ 1.39 8.58E-03  3055608 TYW1B ⇩ 1.36 0.027  3020496 ST7 ⇩ 1.35 0.022 
2975385 AHI1 ⇩ 1.39 0.022  2990342 TMEM106B ⇩ 1.36 0.048  3851267 ZNF625 ⇧ 1.35 3.90E-04 
3473727 WSB2 ⇧ 1.39 1.17E-03  3557947 CHMP4A ⇧ 1.36 4.32E-03  3417457 MYL6 ⇧ 1.35 7.19E-03 
2420467 CTBS ⇩ 1.39 0.016  2373842 PTPRC ⇩ 1.36 0.010  2413423 TMEM48 ⇩ 1.35 0.022 
3890870 RAB22A ⇧ 1.39 1.75E-05  3184218 C9orf6 ⇧ 1.36 0.040  3634811 CTSH ⇩ 1.35 0.022 
3114832 SQLE ⇩ 1.39 2.50E-03  3747199 CENPV ⇧ 1.36 0.019  3878934 NAA20 ⇧ 1.35 4.71E-04 
3950452 CRELD2 ⇩ 1.39 8.37E-03  3861302 YIF1B ⇩ 1.36 0.011  2504883 UGGT1 ⇩ 1.34 0.046 
3432754 PLBD2 ⇩ 1.39 2.73E-04  3010082 PHTF2 ⇩ 1.36 1.09E-03  2835021 PCYOX1L ⇩ 1.34 3.75E-03 
2960955 SLC17A5 ⇩ 1.39 2.50E-03  3645836 ZNF75A ⇧ 1.36 6.51E-03  2949801 AGPAT1 ⇩ 1.34 8.41E-04 
3842301 ZNF581 ⇧ 1.39 3.74E-03  2830638 KIF20A ⇩ 1.36 6.15E-03  3708245 SLC16A13 ⇩ 1.34 0.019 
3494102 UCHL3 ⇧ 1.39 4.80E-04  2375212 PPP1R12B ⇩ 1.36 8.16E-03  2318736 PARK7 ⇧ 1.34 1.52E-04 
4015763 GLA ⇩ 1.39 0.037  2409004 LEPRE1 ⇩ 1.36 9.52E-04  3458911 CTDSP2 ⇧ 1.34 2.10E-03 
2536996 FLJ41327 ⇩ 1.38 0.032  3453556 PRKAG1 ⇧ 1.36 1.59E-04  2971801 MAN1A1 ⇩ 1.34 0.020 
3447863 KRAS ⇧ 1.38 7.97E-04  2528159 WNT10A ⇩ 1.36 0.038  3741528 TAX1BP3 ⇧ 1.34 0.037 
3726960 NME2 ⇧ 1.38 2.60E-04  3837464 GLTSCR2 ⇧ 1.36 2.39E-03  3849797 ZNF561 ⇧ 1.34 1.16E-04 
3936550 USP18 ⇧ 1.38 8.05E-03  3893033 DPH3P1 ⇧ 1.36 0.047  3198289 C9orf123 ⇧ 1.34 1.82E-03 
2726483 OCIAD1 ⇩ 1.38 1.52E-03  3475324 TMEM120B ⇧ 1.35 1.56E-03  2620538 LARS2 ⇩ 1.34 6.48E-03 
3725083 SNX11 ⇧ 1.38 8.67E-04  3433843 SUDS3 ⇧ 1.35 0.018  2668205 GLB1 ⇩ 1.34 0.025 
3969946 ZRSR2 ⇧ 1.38 0.020  3072435 TMEM209 ⇩ 1.35 8.96E-03  2442134 TMCO1 ⇩ 1.34 3.02E-03 
2320411 AGTRAP ⇩ 1.38 3.68E-03  3868905 CTU1 ⇧ 1.35 3.07E-03  2690850 TMEM39A ⇩ 1.34 0.011 
3507962 KATNAL1 ⇧ 1.38 3.85E-03  3216276 SLC35D2 ⇧ 1.35 0.025  3197318 AK3 ⇧ 1.34 7.77E-04 
3447694 BCAT1 ⇧ 1.38 0.032  3490741 SUGT1 ⇧ 1.35 2.61E-03  2815965 HMGCR ⇩ 1.34 2.64E-03 
2384562 RAB4A ⇧ 1.38 1.72E-03  3420854 DYRK2 ⇧ 1.35 0.023  3988987 NDUFA1 ⇧ 1.34 0.028 
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2450668 TMEM9 ⇩ 1.34 3.27E-03  2363084 NCSTN ⇩ 1.33 0.024  2639225 PDIA5 ⇩ 1.32 0.023 
3774096 PDE6G ⇧ 1.34 3.56E-03  3962448 RRP7A ⇧ 1.33 9.47E-03  3486728 SLC25A15 ⇧ 1.32 2.61E-03 
2426791 CLCC1 ⇩ 1.33 5.96E-03  2780172 CENPE ⇩ 1.32 0.020  3406493 DERA ⇧ 1.32 9.17E-03 
2608469 ITPR1 ⇩ 1.33 4.41E-04  2705748 NCEH1 ⇩ 1.32 0.027  2413907 DHCR24 ⇩ 1.32 0.022 
3430389 C12orf23 ⇧ 1.33 7.78E-03  3442854 SLC2A3 ⇩ 1.32 0.015  3722338 IFI35 ⇧ 1.32 0.020 
3421523 YEATS4 ⇧ 1.33 3.90E-03  3075136 CREB3L2 ⇩ 1.32 0.029  2502424 INSIG2 ⇩ 1.32 0.047 
3078656 ZNF767 ⇩ 1.33 5.20E-03  4005627 CXorf38 ⇧ 1.32 0.024  3633699 NRG4 ⇧ 1.32 0.015 
3821015 LDLR ⇩ 1.33 1.38E-03  3388914 DCUN1D5 ⇧ 1.32 0.028  3191338 GPR107 ⇩ 1.32 3.05E-03 
3185063 UGCG ⇩ 1.33 6.29E-03  2704267 GOLIM4 ⇩ 1.32 2.48E-03  2955061 SLC35B2 ⇩ 1.32 0.021 
3828162 C19orf2 ⇧ 1.33 1.24E-04  3444252 CSDA ⇧ 1.32 2.04E-03  3173479 FOXD4L3 ⇧ 1.31 0.020 
2884647 C5orf54 ⇩ 1.33 0.022  2892277 NQO2 ⇩ 1.32 4.29E-03  3260423 CUTC ⇧ 1.31 7.72E-03 
2899340 BTN2A2 ⇩ 1.33 2.64E-03  3989678 XIAP ⇧ 1.32 7.05E-04  3394488 PVRL1 ⇩ 1.31 2.57E-03 
2452977 FAIM3 ⇩ 1.33 0.019  2708610 MAGEF1 ⇧ 1.32 1.04E-03  2379280 FLVCR1 ⇩ 1.31 0.018 
3460584 LLPH ⇧ 1.33 9.39E-03  3674146 RPL13 ⇧ 1.32 0.049  2518272 ITGA4 ⇩ 1.31 0.024 
2816298 IQGAP2 ⇩ 1.33 0.012  2876257 SAR1B ⇩ 1.32 0.019  3129731 DUSP4 ⇩ 1.31 0.044 
3665116 CBFB ⇧ 1.33 1.26E-03  3836432 QPCTL ⇩ 1.32 1.09E-03  3130850 RNF122 ⇩ 1.31 0.028 
3642815 NME4 ⇧ 1.33 2.24E-03  3470689 ALKBH2 ⇧ 1.32 1.46E-03  2560122 MOGS ⇩ 1.31 3.95E-03 
2415084 JUN ⇩ 1.33 0.041  2324634 CDC42 ⇩ 1.32 0.029  3758775 PYY ⇧ 1.31 0.026 
2529421 SGPP2 ⇩ 1.33 2.36E-04  3303300 CHUK ⇧ 1.32 5.82E-03  3946351 ADSL ⇧ 1.31 2.52E-04 
2568968 UXS1 ⇩ 1.33 0.025  3868963 ETFB ⇧ 1.32 1.39E-04  3665230 HSF4 ⇩ 1.31 0.010 
3435681 ARL6IP4 ⇧ 1.33 2.40E-04  3996381 ATP6AP1 ⇩ 1.32 3.64E-03  3397589 ETS1 ⇧ 1.31 3.53E-03 
2514122 LASS6 ⇩ 1.33 0.027  3427014 SNRPF ⇧ 1.32 0.027  3175119 OSTF1 ⇧ 1.31 0.027 
3255284 C10orf99 ⇩ 1.33 0.029  3822805 TECR ⇩ 1.32 2.30E-03  2692411 PTPLB ⇩ 1.31 0.022 
3629103 KIAA0101 ⇧ 1.33 0.038  3426215 MRPL42 ⇧ 1.32 6.81E-03  3969047 PRPS2 ⇧ 1.31 1.05E-04 
3031967 CHPF2 ⇩ 1.33 5.66E-03  3066751 SYPL1 ⇩ 1.32 7.06E-03  2841184 ERGIC1 ⇩ 1.31 9.53E-04 
3866302 AP2S1 ⇧ 1.33 2.92E-05  3434760 P2RX4 ⇩ 1.32 8.92E-03  3358950 CTSD ⇩ 1.31 0.015 
3277468 USP6NL ⇧ 1.33 0.015  3129121 CCDC25 ⇧ 1.32 8.52E-04  3099561 T1560 ⇧ 1.31 7.77E-03 
3625271 RAB27A ⇧ 1.33 0.020  3942161 UQCR10 ⇧ 1.32 3.31E-05  3840224 ZNF528 ⇧ 1.31 0.015 
3758148 CCDC56 ⇧ 1.33 1.23E-03  3969422 RAB9A ⇧ 1.32 0.013  3466284 NDUFA12 ⇧ 1.31 1.68E-03 
3806253 ATP5A1 ⇧ 1.33 3.51E-03  2997376 ANLN ⇩ 1.32 0.012  2878368 APBB3 ⇩ 1.31 2.76E-04 
3041260 TOMM7 ⇧ 1.33 0.032  2370317 MR1 ⇩ 1.32 0.015  2599955 ATG9A ⇩ 1.31 5.87E-04 
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2930863 PCMT1 ⇩ 1.31 6.75E-03  3723348 HEXIM1 ⇧ 1.30 6.64E-04  2948522 KIAA1949 ⇩ 1.29 1.97E-03 
3665857 NUTF2 ⇧ 1.31 3.99E-04  3584728 SNRPN ⇧ 1.30 0.014  2829562 TXNDC15 ⇩ 1.29 0.013 
2902574 LY6G5B ⇩ 1.31 0.026  3103523 LY96 ⇩ 1.30 0.048  3293537 PCBD1 ⇧ 1.29 0.039 
3413787 TUBA1C ⇧ 1.31 7.96E-03  3682135 C16orf63 ⇧ 1.30 6.34E-03  3579205 SETD3 ⇧ 1.29 1.17E-03 
2853388 C5orf33 ⇧ 1.31 2.10E-05  3344861 C11orf54 ⇧ 1.30 0.012  3195344 MRPL41 ⇧ 1.29 0.027 
2412668 TXNDC12 ⇩ 1.31 0.029  2977621 PLAGL1 ⇩ 1.30 0.036  2542737 LAPTM4A ⇩ 1.29 2.31E-03 
2628682 ARL6IP5 ⇩ 1.31 0.032  3934669 SUMO3 ⇧ 1.30 0.018  2604254 HJURP ⇩ 1.29 0.015 
3916576 GABPA ⇧ 1.31 6.26E-05  3954525 ZNF280B ⇧ 1.30 2.63E-03  3311715 UROS ⇧ 1.29 3.02E-03 
3996467 PLXNA3 ⇩ 1.31 9.08E-04  2541230 NBAS ⇩ 1.30 1.16E-04  3463522 PAWR ⇧ 1.29 0.022 
3451318 ZCRB1 ⇧ 1.30 5.33E-04  3528895 LRP10 ⇩ 1.30 0.022  3726325 XYLT2 ⇩ 1.29 4.04E-03 
3480681 MRP63 ⇧ 1.30 2.47E-03  3850576 YIPF2 ⇩ 1.30 0.018  3518169 COMMD6 ⇧ 1.29 9.44E-03 
3566304 EXOC5 ⇧ 1.30 5.52E-05  2964327 LYRM2 ⇧ 1.30 4.92E-05  2443335 SLC19A2 ⇩ 1.29 0.047 
3426257 SOCS2 ⇧ 1.30 6.07E-03  3865568 SNRPD2 ⇧ 1.29 0.039  3555340 TEP1 ⇩ 1.29 4.58E-04 
3976670 EBP ⇩ 1.30 0.020  3956984 ZMAT5 ⇧ 1.29 4.34E-04  3513995 DLEU2 ⇧ 1.29 0.043 
2889698 CLK4 ⇩ 1.30 5.43E-03  3617412 LPCAT4 ⇩ 1.29 9.00E-04  3242425 CCNY ⇧ 1.29 9.11E-03 
3886512 TTPAL ⇧ 1.30 0.024  2968144 OSTM1 ⇩ 1.29 3.37E-03  3625234 RSL24D1 ⇧ 1.29 0.011 
3349918 RBM7 ⇧ 1.30 0.016  3882949 DYNLRB1 ⇧ 1.29 2.67E-03  3377826 RNASEH2C ⇧ 1.29 5.80E-05 
3790704 PMAIP1 ⇧ 1.30 0.011  3726406 ACSF2 ⇩ 1.29 0.019  2758298 LRPAP1 ⇩ 1.29 0.023 
3943207 YWHAH ⇧ 1.30 0.015  3338424 FADD ⇧ 1.29 1.92E-03  3877776 SNRPB2 ⇧ 1.29 0.045 
3438027 RAN ⇧ 1.30 8.25E-04  3441011 PARP11 ⇧ 1.29 9.82E-04  2601414 SERPINE2 ⇩ 1.28 0.032 
3240095 RAB18 ⇧ 1.30 8.62E-03  3380697 DHCR7 ⇩ 1.29 0.019  2815331 BTF3 ⇧ 1.28 3.13E-04 
3719362 AATF ⇧ 1.30 4.50E-04  2614142 NR1D2 ⇧ 1.29 0.037  2721777 PI4K2B ⇧ 1.28 3.48E-03 
2330773 CDCA8 ⇩ 1.30 0.030  3130113 GTF2E2 ⇧ 1.29 4.10E-03  3697563 FTSJD1 ⇧ 1.28 3.36E-03 
3339167 FAM86C ⇧ 1.30 0.016  2930243 SASH1 ⇩ 1.29 0.019  3362795 RNF141 ⇧ 1.28 4.53E-03 
3263624 MXI1 ⇧ 1.30 0.037  3137875 GGH ⇩ 1.29 0.025  2908179 VEGFA ⇩ 1.28 0.028 
2520138 MFSD6 ⇩ 1.30 7.99E-03  3833443 PLD3 ⇩ 1.29 7.58E-03  4021341 ZDHHC9 ⇩ 1.28 9.22E-03 
2363919 ATF6 ⇩ 1.30 1.85E-03  3982423 ATP7A ⇩ 1.29 0.047  3451264 YAF2 ⇧ 1.28 6.37E-03 
3870135 ZNF347 ⇧ 1.30 0.018  3060117 ABCB4 ⇩ 1.29 0.019  3404436 CLEC2D ⇩ 1.28 0.028 
3630099 TIPIN ⇧ 1.30 0.011  2656569 DNAJB11 ⇩ 1.29 0.023  3432333 PTPN11 ⇧ 1.28 5.73E-03 
2325290 LYPLA2 ⇧ 1.30 3.77E-03  4004819 DYNLT3 ⇧ 1.29 0.028  3318844 DNHD1 ⇩ 1.28 7.32E-04 
3886179 IFT52 ⇧ 1.30 8.32E-04  2970897 FRK ⇧ 1.29 0.027  2866590 LYSMD3 ⇩ 1.28 0.037 
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3559794 C14orf126 ⇧ 1.28 0.012  3315549 PSMD13 ⇧ 1.27 9.06E-05  3379390 SUV420H1 ⇧ 1.27 5.76E-03 
3361041 TPP1 ⇩ 1.28 7.74E-03  2724671 RHOH ⇧ 1.27 3.42E-03  3368707 CD59 ⇩ 1.27 0.020 
3864921 ZNF180 ⇧ 1.28 2.44E-03  3739108 FN3KRP ⇧ 1.27 2.49E-03  3064638 RABL5 ⇧ 1.27 5.98E-04 
3988740 PGRMC1 ⇩ 1.28 0.026  3996815 VBP1 ⇧ 1.27 0.028  3441955 MRPL51 ⇧ 1.27 1.19E-04 
3409127 ARNTL2 ⇧ 1.28 0.017  3347549 CUL5 ⇧ 1.27 2.04E-04  2390976 NCRNA00115 ⇩ 1.27 0.032 
2874686 HINT1 ⇧ 1.28 0.025  3131844 LSM1 ⇧ 1.27 4.36E-03  3464967 GALNT4 ⇧ 1.27 1.60E-03 
3722739 G6PC3 ⇩ 1.28 0.024  2330253 ADPRHL2 ⇧ 1.27 0.036  3728509 DYNLL2 ⇧ 1.27 1.57E-03 
3843399 ZNF134 ⇧ 1.28 4.29E-03  3866276 SLC1A5 ⇩ 1.27 0.020  3130161 GSR ⇧ 1.27 0.035 
3775157 WDR45L ⇧ 1.28 0.045  3727962 DGKE ⇩ 1.27 0.030  2781693 CASP6 ⇧ 1.27 6.76E-03 
3269328 ZRANB1 ⇧ 1.28 2.65E-03  3734479 TMEM104 ⇩ 1.27 0.021  3666649 VPS4A ⇧ 1.27 5.18E-03 
2902736 C6orf48 ⇧ 1.28 4.73E-03  3378790 PPP1CA ⇧ 1.27 5.25E-03  2599371 TMBIM1 ⇩ 1.27 4.19E-03 
3352813 TBCEL ⇧ 1.28 2.88E-03  3142519 ZFAND1 ⇧ 1.27 0.025  2562233 RETSAT ⇩ 1.27 0.024 
3336378 RBM14 ⇩ 1.28 0.023  3303392 BLOC1S2 ⇧ 1.27 0.015  2835792 GM2A ⇩ 1.27 0.020 
2750594 SC4MOL ⇩ 1.28 0.017  3941010 SRRD ⇧ 1.27 0.041  2924492 HEY2 ⇧ 1.26 0.019 
3976519 RBM3 ⇧ 1.28 3.13E-04  4000132 TRAPPC2 ⇧ 1.27 7.25E-03  4011768 SNX12 ⇧ 1.26 1.51E-03 
3707990 TXNDC17 ⇧ 1.28 0.016  3328214 ALKBH3 ⇧ 1.27 5.63E-03  2712632 TFRC ⇩ 1.26 1.96E-03 
2611779 TMEM43 ⇩ 1.28 6.30E-03  3190420 CERCAM ⇩ 1.27 0.027  3730899 DDX42 ⇧ 1.26 3.70E-03 
3991698 HPRT1 ⇧ 1.28 4.98E-03  3619595 FAM82A2 ⇩ 1.27 3.07E-03  2363202 SLAMF7 ⇩ 1.26 0.028 
3369762 COMMD9 ⇧ 1.28 0.022  3681674 NTAN1 ⇧ 1.27 7.24E-03  2320762 VPS13D ⇩ 1.26 6.85E-04 
3830216 FXYD5 ⇩ 1.28 0.034  3849865 FBXL12 ⇧ 1.27 9.86E-03  3642358 TM2D3 ⇩ 1.26 0.036 
3759305 CCDC43 ⇧ 1.28 3.64E-03  3703112 GINS2 ⇧ 1.27 0.033  3738205 MRPL12 ⇧ 1.26 5.94E-03 
3708826 EIF4A1 ⇧ 1.28 0.025  2370123 XPR1 ⇩ 1.27 0.014  3064541 PLOD3 ⇩ 1.26 1.44E-03 
3824395 PGLS ⇧ 1.28 7.68E-05  3280902 DNAJC1 ⇩ 1.27 0.010  3929931 ATP5O ⇧ 1.26 8.41E-03 
3784509 ZNF271 ⇧ 1.27 7.02E-03  3333622 POLR2G ⇧ 1.27 2.41E-03  3487432 DNAJC15 ⇩ 1.26 0.043 
3224197 NDUFA8 ⇧ 1.27 0.019  3394123 HYOU1 ⇩ 1.27 0.035  2515933 ZAK ⇧ 1.26 0.024 
2413578 TMEM59 ⇩ 1.27 0.030  3890109 C20orf108 ⇧ 1.27 1.51E-03  3303255 ERLIN1 ⇩ 1.26 0.040 
3770632 SUMO2 ⇧ 1.27 0.024  4022106 MBNL3 ⇧ 1.27 0.034  2612401 BTD ⇩ 1.26 0.042 
3043165 HIBADH ⇧ 1.27 0.011  2916345 SLC35A1 ⇩ 1.27 0.031  3422703 ATXN7L3B ⇧ 1.26 4.76E-03 
2663551 NUP210 ⇩ 1.27 5.47E-03  3922793 PDE9A ⇧ 1.27 0.023  3840164 ZNF610 ⇧ 1.26 0.014 
3412296 IRAK4 ⇧ 1.27 6.37E-03  3421630 CCT2 ⇧ 1.27 1.72E-03  2428501 SLC16A1 ⇩ 1.26 0.021 
2364155 UHMK1 ⇧ 1.27 1.59E-04  3822347 C19orf53 ⇧ 1.27 0.049  3862167 FBL ⇧ 1.26 1.52E-05 
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3878025 DSTN ⇧ 1.26 0.030  2640579 PLXNA1 ⇩ 1.26 0.016  3325680 EIF3M ⇧ 1.25 2.26E-03 
3387483 MTMR2 ⇧ 1.26 2.04E-03  3821727 ZNF136 ⇧ 1.26 7.98E-04  3704896 CHMP1A ⇧ 1.25 1.67E-04 
3945056 EIF3L ⇧ 1.26 3.06E-03  3708074 XAF1 ⇧ 1.26 5.36E-03  3432678 TPCN1 ⇩ 1.25 2.62E-03 
3770944 H3F3B ⇧ 1.26 0.049  3770606 HN1 ⇧ 1.26 0.016  3142932 C8orf59 ⇧ 1.25 8.39E-03 
3577246 MOAP1 ⇧ 1.26 0.041  3522225 STK24 ⇧ 1.26 0.013  3391255 IL18 ⇧ 1.25 0.041 
3860491 ZNF260 ⇧ 1.26 1.94E-03  3009229 POR ⇩ 1.26 0.036  3855506 TMEM161A ⇩ 1.25 9.60E-03 
2924604 HINT3 ⇧ 1.26 0.036  3617920 ATPBD4 ⇧ 1.26 6.28E-03  3947123 SREBF2 ⇩ 1.25 8.65E-05 
3629350 SPG21 ⇧ 1.26 2.02E-03  3678147 NMRAL1 ⇧ 1.26 0.012  3719515 DUSP14 ⇧ 1.25 4.06E-03 
3221633 HDHD3 ⇩ 1.26 9.84E-03  3507710 SLC7A1 ⇩ 1.26 0.028  3843058 ZNF264 ⇧ 1.25 0.015 
2440664 B4GALT3 ⇩ 1.26 0.034  2572601 CCDC93 ⇩ 1.26 8.33E-05  3536663 MAPK1IP1L ⇧ 1.25 6.79E-04 
3690084 DNAJA2 ⇧ 1.26 8.25E-03  2331679 MFSD2A ⇩ 1.26 0.019  3705412 C17orf97 ⇧ 1.25 2.27E-03 
2395890 CLSTN1 ⇩ 1.26 0.013  3468925 NFYB ⇧ 1.26 2.39E-05  3706651 OR3A3 ⇩ 1.25 0.024 
2777447 NAP1L5 ⇧ 1.26 2.40E-03  2908052 POLR1C ⇧ 1.26 6.36E-04  3829857 ZNF302 ⇧ 1.25 1.06E-03 
4017519 PSMD10 ⇧ 1.26 2.26E-03  3860596 ZNF461 ⇧ 1.26 4.12E-04  3668898 ZFP1 ⇧ 1.25 2.70E-03 
3376023 UBXN1 ⇧ 1.26 0.028  3345107 ANKRD49 ⇧ 1.26 7.13E-03  3563814 L2HGDH ⇧ 1.25 5.00E-04 
2766192 TLR10 ⇩ 1.26 0.039  3020192 TES ⇩ 1.26 5.62E-03  3788270 ELAC1 ⇧ 1.25 6.22E-03 
2621122 NBEAL2 ⇩ 1.26 7.93E-03  3719150 PIGW ⇧ 1.26 0.021  2583254 LY75 ⇩ 1.25 0.022 
2523213 BMPR2 ⇩ 1.26 0.020  3421706 RAB3IP ⇧ 1.26 3.81E-03  3994795 MTM1 ⇧ 1.25 0.049 
3304004 NPM3 ⇧ 1.26 0.029  3019401 ZNF277 ⇧ 1.26 0.011  2690776 B4GALT4 ⇩ 1.25 9.39E-04 
3838665 RCN3 ⇩ 1.26 2.77E-03  3403140 EMG1 ⇧ 1.26 0.031  3869714 ZNF611 ⇧ 1.25 9.29E-03 
2594435 KCTD18 ⇧ 1.26 2.23E-03  2514516 KLHL23 ⇧ 1.26 0.032  3471374 PPP1CC ⇧ 1.25 1.22E-04 
2369796 TOR1AIP1 ⇩ 1.26 5.45E-03  3812385 CD226 ⇩ 1.26 0.044  3685306 NDUFAB1 ⇧ 1.25 0.023 
3845175 GAMT ⇧ 1.26 0.049  3048778 TMED4 ⇩ 1.25 4.89E-03  3190659 SET ⇧ 1.25 6.53E-04 
2655168 YEATS2 ⇩ 1.26 4.08E-03  3962000 PMM1 ⇧ 1.25 5.55E-04  3890218 C20orf43 ⇧ 1.25 0.014 
3250019 DDX50 ⇧ 1.26 0.023  2815791 HEXB ⇩ 1.25 7.68E-03  3806913 SMAD2 ⇧ 1.25 1.56E-03 
3354764 STT3A ⇩ 1.26 0.027  2599993 ABCB6 ⇩ 1.25 3.40E-03  3434413 RNF10 ⇧ 1.25 5.42E-03 
3887117 CTSA ⇩ 1.26 0.018  2439975 IGSF8 ⇩ 1.25 3.89E-03  3114600 TRMT12 ⇧ 1.25 5.08E-04 
2694397 RPN1 ⇩ 1.26 0.010  2888243 KIAA1191 ⇧ 1.25 0.017  4015693 TIMM8A ⇧ 1.25 2.65E-03 
3822657 CD97 ⇩ 1.26 1.70E-03  3557898 TM9SF1 ⇩ 1.25 0.042  2482230 ERLEC1 ⇩ 1.25 0.043 
3831260 ZNF146 ⇧ 1.26 4.64E-03  3360364 OR52A4 ⇧ 1.25 0.031  3195296 SSNA1 ⇧ 1.25 0.031 
3624448 GNB5 ⇧ 1.26 1.68E-03  3340449 SLCO2B1 ⇩ 1.25 0.033  3357785 SIRT3 ⇧ 1.25 3.04E-03 
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3325052 EIF2AK2 ⇧ 1.25 0.031  2406139 KIAA0319L ⇩ 1.24 5.53E-03  2773655 RCHY1 ⇧ 1.24 0.018 
3014411 TRRAP ⇩ 1.25 1.66E-03  3426917 METAP2 ⇧ 1.24 8.04E-03  3744039 TRAPPC1 ⇧ 1.24 3.17E-04 
3884100 RPN2 ⇩ 1.25 0.015  3779756 SEH1L ⇧ 1.24 9.16E-03  3851603 DHPS ⇧ 1.24 0.026 
2868131 ERAP1 ⇩ 1.25 0.025  2466039 ZNF692 ⇩ 1.24 2.42E-03  2398736 ATP13A2 ⇩ 1.24 0.042 
2634494 ALCAM ⇩ 1.25 0.015  3376867 TRMT112 ⇧ 1.24 7.98E-03  3233547 RBM17 ⇧ 1.24 2.19E-03 
2404521 PEF1 ⇧ 1.25 0.014  3832777 MRPS12 ⇧ 1.24 2.20E-03  2666904 SLC4A7 ⇩ 1.24 0.021 
3917851 SOD1 ⇧ 1.25 0.043  3104698 ZBTB10 ⇧ 1.24 0.015  2365958 MPZL1 ⇩ 1.24 5.49E-03 
3415273 C12orf44 ⇧ 1.25 0.013  3934591 KRTAP10-5 ⇧ 1.24 0.026  3820906 C19orf52 ⇧ 1.24 1.39E-04 
2903782 ITPR3 ⇩ 1.25 4.47E-03  3553607 EIF5 ⇧ 1.24 3.26E-03  3775147 FOXK2 ⇩ 1.24 0.013 
3998632 PNPLA4 ⇧ 1.25 4.24E-04  2681157 TMF1 ⇩ 1.24 3.82E-03  2828146 CDC42SE2 ⇧ 1.24 1.88E-03 
3850040 EIF3G ⇧ 1.25 1.11E-04  3387259 SESN3 ⇧ 1.24 0.018  3212728 AGTPBP1 ⇧ 1.24 2.95E-03 
3221543 CDC26 ⇧ 1.25 0.016  3608466 MAN2A2 ⇩ 1.24 7.02E-03  2527672 PNKD ⇩ 1.24 0.028 
2437307 SCAMP3 ⇩ 1.25 0.021  3474104 CIT ⇩ 1.24 0.011  3457523 RNF41 ⇧ 1.24 2.72E-03 
3033397 RBM33 ⇩ 1.25 1.53E-03  3821301 ZNF627 ⇧ 1.24 0.038  2327259 PPP1R8 ⇧ 1.24 2.23E-04 
3636956 WDR73 ⇧ 1.25 3.55E-03  3742727 DHX33 ⇧ 1.24 2.95E-04  2404819 PTP4A2 ⇧ 1.24 0.022 
3340066 PAAF1 ⇧ 1.25 6.48E-03  3025740 TMEM140 ⇩ 1.24 0.049  3781124 MIB1 ⇧ 1.24 1.90E-03 
3535922 STYX ⇧ 1.25 0.019  3590422 RTF1 ⇧ 1.24 8.92E-03  2321849 DNAJC16 ⇩ 1.23 0.033 
2334374 AKR1A1 ⇧ 1.24 0.014  2474322 C2orf28 ⇩ 1.24 2.76E-03  3191589 FUBP3 ⇧ 1.23 9.27E-03 
3893760 TPD52L2 ⇧ 1.24 6.78E-03  3031345 LRRC61 ⇧ 1.24 1.34E-03  3223605 FBXW2 ⇧ 1.23 4.09E-05 
3380980 C11orf59 ⇧ 1.24 0.013  2363902 DUSP12 ⇧ 1.24 2.64E-03  4015838 ARMCX6 ⇩ 1.23 7.14E-03 
3482977 POLR1D ⇧ 1.24 2.02E-03  2565246 TMEM127 ⇩ 1.24 3.85E-03  3593261 EID1 ⇧ 1.23 0.012 
3138414 ARMC1 ⇧ 1.24 6.46E-03  3534923 KLHDC2 ⇧ 1.24 4.02E-03  2336271 BTF3L4 ⇧ 1.23 4.03E-03 
2960010 LMBRD1 ⇩ 1.24 0.033  3823613 FAM32A ⇧ 1.24 0.030  3633550 IMP3 ⇧ 1.23 0.013 
2360989 MSTO1 ⇩ 1.24 0.028  2654855 ATP11B ⇩ 1.24 0.016  2413203 LRP8 ⇩ 1.23 2.67E-03 
2472914 UBXN2A ⇧ 1.24 0.019  2437401 FDPS ⇩ 1.24 7.71E-03  2977949 EPM2A ⇧ 1.23 5.27E-04 
3633460 PTPN9 ⇧ 1.24 0.023  2408681 HIVEP3 ⇩ 1.24 0.028  3737140 GAA ⇩ 1.23 3.10E-03 
3007438 POM121 ⇩ 1.24 0.031  2359817 INTS3 ⇩ 1.24 1.19E-04  3985644 TCEAL3 ⇩ 1.23 0.045 
3713575 PRPSAP2 ⇧ 1.24 0.033  3743906 TP53 ⇧ 1.24 0.042  2954280 PEX6 ⇩ 1.23 8.98E-04 
2759303 MRFAP1L1 ⇧ 1.24 0.032  2320472 CLCN6 ⇩ 1.24 0.019  2620315 TMEM42 ⇧ 1.23 8.94E-04 
2944491 MBOAT1 ⇩ 1.24 0.015  2358171 PRPF3 ⇩ 1.24 3.66E-05  3235255 ECHDC3 ⇧ 1.23 1.67E-03 
2706791 ZMAT3 ⇧ 1.24 0.017  2571457 CKAP2L ⇩ 1.24 0.013  2906591 APOBEC2 ⇧ 1.23 0.020 
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3323443 PRMT3 ⇧ 1.23 2.11E-03  2877141 HNRNPA0 ⇧ 1.23 3.99E-04  2999544 BLVRA ⇧ 1.23 0.042 
3569200 ATP6V1D ⇧ 1.23 0.022  3750625 POLDIP2 ⇧ 1.23 4.56E-03  3969396 TCEANC ⇧ 1.23 2.63E-03 
3886050 SRSF6 ⇧ 1.23 5.56E-05  3119339 LY6E ⇩ 1.23 0.021  3565361 GMFB ⇧ 1.23 0.014 
2872471 DTWD2 ⇧ 1.23 0.022  2437645 GON4L ⇩ 1.23 1.16E-03  2349848 PRMT6 ⇧ 1.23 0.019 
2324743 ZBTB40 ⇩ 1.23 2.91E-03  2940987 SLC35B3 ⇩ 1.23 0.021  3563317 RPS29 ⇧ 1.23 0.023 
3806905 SMAD2 ⇧ 1.23 0.016  3339880 RELT ⇩ 1.23 1.00E-03  3459956 C12orf66 ⇧ 1.22 1.01E-03 
3428131 SCYL2 ⇧ 1.23 0.013  2608801 EDEM1 ⇩ 1.23 0.011  2828115 LYRM7 ⇧ 1.22 1.64E-03 
2722377 STIM2 ⇩ 1.23 0.047  3504791 EFHA1 ⇧ 1.23 9.86E-03  3829751 PDCD2L ⇧ 1.22 0.010 
2335986 RNF11 ⇧ 1.23 5.14E-03  2963313 SNX14 ⇩ 1.23 0.022  3591909 CTDSPL2 ⇧ 1.22 7.09E-04 
3778823 NAPG ⇧ 1.23 0.012  3879467 XRN2 ⇧ 1.23 3.40E-03  3301512 ALDH18A1 ⇩ 1.22 0.041 
3364119 CYP2R1 ⇧ 1.23 0.016  2961317 TMEM30A ⇩ 1.23 0.032  3581132 AKT1 ⇧ 1.22 2.94E-03 
3659966 ADCY7 ⇩ 1.23 8.62E-03  2334404 NASP ⇧ 1.23 0.041  3260666 HIF1AN ⇧ 1.22 0.010 
3819104 TRAPPC5 ⇧ 1.23 5.77E-04  2690900 CD80 ⇩ 1.23 0.036  2500615 TMEM87B ⇩ 1.22 9.41E-03 
3815538 GPX4 ⇧ 1.23 0.023  2427074 PSMA5 ⇧ 1.23 0.044  2968054 SEC63 ⇩ 1.22 0.025 
3223551 MEGF9 ⇩ 1.23 0.039  3326400 CAT ⇧ 1.23 0.013  2331213 MACF1 ⇩ 1.22 0.012 
3576889 ATXN3 ⇧ 1.23 0.020  3707352 RNF167 ⇩ 1.23 2.49E-03  3168841 GRHPR ⇧ 1.22 0.017 
3977299 CLCN5 ⇩ 1.23 5.64E-03  3338552 CTTN ⇧ 1.23 9.18E-03  3851826 DNASE2 ⇩ 1.22 0.043 
3433538 RNFT2 ⇩ 1.23 0.012  3728097 AKAP1 ⇩ 1.23 0.024  3210130 C9orf41 ⇧ 1.22 0.014 
3548346 CALM1 ⇧ 1.23 0.020  3996667 DKC1 ⇧ 1.23 0.015  2376799 IKBKE ⇩ 1.22 0.017 
3440017 FBXL14 ⇩ 1.23 3.15E-03  3844897 C19orf6 ⇩ 1.23 9.92E-03  2716655 MSX1 ⇧ 1.22 0.048 
2732611 MRPL1 ⇧ 1.23 0.018  3375147 VPS37C ⇧ 1.23 4.12E-03  3454680 TFCP2 ⇧ 1.22 4.68E-03 
3639007 HDDC3 ⇧ 1.23 3.12E-03  3458614 DCTN2 ⇧ 1.23 8.20E-03  3224259 RBM18 ⇧ 1.22 8.53E-03 
3472225 DDX54 ⇧ 1.23 7.55E-04  3334501 PRDX5 ⇧ 1.23 0.021  3320251 LOC100129827 ⇧ 1.22 0.045 
3517793 KLF12 ⇧ 1.23 0.038  2484752 COMMD1 ⇧ 1.23 0.029  2369843 CEP350 ⇩ 1.22 3.16E-04 
3127334 REEP4 ⇩ 1.23 0.035  2353881 MAN1A2 ⇩ 1.23 0.041  3825141 C19orf50 ⇧ 1.22 7.76E-04 
2352106 CTTNBP2NL ⇩ 1.23 0.029  2429842 CD58 ⇩ 1.23 5.02E-03  3506431 RNF6 ⇧ 1.22 0.025 
3864286 PSG9 ⇧ 1.23 0.010  3168938 POLR1E ⇧ 1.23 0.047  3719161 GGNBP2 ⇧ 1.22 0.012 
3375545 FADS1 ⇩ 1.23 0.026  3135184 RB1CC1 ⇧ 1.23 1.67E-03  3821908 RNASEH2A ⇧ 1.22 6.44E-03 
3686080 NSMCE1 ⇧ 1.23 0.038  2724472 UBE2K ⇧ 1.23 3.91E-03  3687698 CD2BP2 ⇧ 1.22 0.035 
2540157 ODC1 ⇧ 1.23 0.027  3535780 PTGER2 ⇧ 1.23 0.031  2383479 BTF3P9 ⇧ 1.22 0.011 
3580947 C14orf2 ⇧ 1.23 6.97E-03  3401099 FKBP4 ⇧ 1.23 3.15E-03  3088213 SH2D4A ⇧ 1.22 0.046 
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2411799 BEND5 ⇧ 1.22 0.020  3960875 DNAL4 ⇧ 1.22 3.41E-04  3883787 C20orf4 ⇧ 1.22 7.02E-04 
3464912 POC1B ⇧ 1.22 0.023  3849549 ZNF562 ⇧ 1.22 0.035  3944922 TRIOBP ⇧ 1.22 7.25E-03 
2610241 FANCD2 ⇩ 1.22 0.043  3860793 ZNF585B ⇧ 1.22 0.039  3248897 NRBF2 ⇧ 1.22 4.43E-03 
3729123 DHX40 ⇧ 1.22 3.98E-03  3712098 SNORD49A ⇧ 1.22 5.23E-03  3632940 UBL7 ⇧ 1.21 1.68E-03 
3636470 BTBD1 ⇧ 1.22 1.61E-03  2589255 FKBP7 ⇩ 1.22 0.017  3430552 PWP1 ⇧ 1.21 2.90E-03 
3804143 RPRD1A ⇧ 1.22 2.06E-03  3409330 MRPS35 ⇧ 1.22 0.017  2550122 COX7A2L ⇧ 1.21 6.58E-03 
2427688 C1orf103 ⇩ 1.22 0.017  3608113 IQGAP1 ⇩ 1.22 0.013  3680130 DEXI ⇧ 1.21 0.041 
3527684 RNASE3 ⇧ 1.22 0.038  2539765 ITGB1BP1 ⇧ 1.22 0.029  2339139 INADL ⇩ 1.21 0.032 
3486807 WBP4 ⇧ 1.22 7.92E-03  3923537 C21orf33 ⇧ 1.22 4.96E-03  2438504 MRPL24 ⇧ 1.21 0.029 
3820443 ICAM1 ⇩ 1.22 0.026  3560617 SNX6 ⇧ 1.22 9.66E-03  3334783 SNX15 ⇧ 1.21 2.79E-03 
3227645 UCK1 ⇧ 1.22 1.10E-03  2837479 THG1L ⇧ 1.22 0.031  3446868 LDHB ⇧ 1.21 0.019 
3014714 ARPC1B ⇧ 1.22 0.013  3417345 RPL41 ⇧ 1.22 0.025  2438282 IQGAP3 ⇩ 1.21 0.014 
3838795 BCL2L12 ⇧ 1.22 1.72E-03  3012381 AKAP9 ⇩ 1.22 8.89E-03  3820177 PIN1 ⇧ 1.21 0.025 
3474228 RAB35 ⇧ 1.22 3.88E-03  2675304 TMEM115 ⇩ 1.22 9.71E-03  3716579 LRRC37BP1 ⇧ 1.21 0.042 
3250055 DDX21 ⇧ 1.22 0.028  2949471 NEU1 ⇩ 1.22 0.032  4027813 F8A1 ⇧ 1.21 0.034 
3282268 ACBD5 ⇧ 1.22 0.020  2639054 PARP14 ⇩ 1.22 0.015  3954238 MAPK1 ⇧ 1.21 5.82E-03 
3883941 TGIF2 ⇧ 1.22 8.33E-03  3439063 ZNF26 ⇧ 1.22 8.56E-03  3752002 CRLF3 ⇧ 1.21 0.020 
3902609 PDRG1 ⇧ 1.22 0.018  3854892 LSM4 ⇧ 1.22 0.049  3600212 LRRC49 ⇧ 1.21 0.020 
2691718 GOLGB1 ⇩ 1.22 2.51E-03  3203855 DCAF12 ⇧ 1.22 3.92E-03  2437753 KIAA0907 ⇩ 1.21 8.73E-03 
3510858 FOXO1 ⇧ 1.22 0.041  3136129 RPS20 ⇧ 1.22 0.017  3742384 SLC25A11 ⇧ 1.21 5.28E-03 
3108901 VPS13B ⇩ 1.22 0.022  2324571 CELA3B ⇩ 1.22 6.77E-03  3376529 PLA2G16 ⇧ 1.21 8.47E-03 
3821847 ASNA1 ⇧ 1.22 0.012  3560575 EAPP ⇧ 1.22 8.27E-03  2909499 GPR115 ⇧ 1.21 0.023 
3740171 CRK ⇧ 1.22 0.028  3317309 CD81 ⇩ 1.22 8.40E-04  3816834 NCLN ⇩ 1.21 0.017 
3402039 KCNA5 ⇧ 1.22 9.11E-03  2786578 NDUFC1 ⇧ 1.22 0.022  3348189 FDX1 ⇧ 1.21 1.10E-03 
3652424 EEF2K ⇩ 1.22 2.04E-03  2842570 FAF2 ⇩ 1.22 0.046  3893072 C20orf11 ⇧ 1.21 0.043 
3056131 TBL2 ⇩ 1.22 0.012  2619344 NKTR ⇩ 1.22 3.10E-03  2639309 SEC22A ⇩ 1.21 0.034 
3035049 C7orf50 ⇧ 1.22 0.012  3914346 NPBWR2 ⇧ 1.22 4.21E-03  3895795 RNF24 ⇩ 1.21 0.030 
3381817 UCP2 ⇧ 1.22 5.27E-03  3147591 AZIN1 ⇧ 1.22 2.89E-03  2916825 ANKRD6 ⇧ 1.21 9.13E-04 
3726375 EME1 ⇩ 1.22 0.046  3643813 GNPTG ⇩ 1.22 0.024  2899022 TRIM38 ⇩ 1.21 5.29E-03 
3911795 ATP5E ⇧ 1.22 0.028  2415728 TM2D1 ⇩ 1.22 0.036  2950590 RGL2 ⇩ 1.21 0.021 
3656760 STX4 ⇧ 1.22 0.012  3758157 BECN1 ⇧ 1.22 0.017  3734575 ICT1 ⇧ 1.21 0.024 
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3829768 UBA2 ⇧ 1.21 0.019  2813364 SLC30A5 ⇩ 1.21 0.026  3919124 FAM165B ⇧ 1.20 1.19E-03 
3956290 PITPNB ⇧ 1.21 3.09E-03  2674748 CDHR4 ⇧ 1.21 0.012  3762416 ANKRD40 ⇧ 1.20 0.020 
3434525 MLEC ⇩ 1.21 0.017  3428573 SPIC ⇧ 1.21 0.020  3311775 DHX32 ⇧ 1.20 0.027 
2367537 C1orf9 ⇩ 1.21 0.043  2331158 AKIRIN1 ⇧ 1.21 0.019  2694617 ISY1 ⇧ 1.20 0.028 
3851441 ZNF442 ⇧ 1.21 0.034  2436938 PBXIP1 ⇩ 1.21 0.019  3261971 CNNM2 ⇩ 1.20 0.020 
2706938 GNB4 ⇧ 1.21 0.038  3000010 ZMIZ2 ⇩ 1.21 0.018  3474344 RPLP0 ⇧ 1.20 1.40E-03 
3710681 MAP2K4 ⇧ 1.21 7.74E-03  3558226 RIPK3 ⇩ 1.20 6.14E-03  4011844 IL2RG ⇩ 1.20 0.013 
3407926 CMAS ⇧ 1.21 0.044  3335070 CDC42EP2 ⇧ 1.20 0.027  3429365 TDG ⇧ 1.20 0.040 
2758043 MFSD10 ⇩ 1.21 8.90E-03  2479640 PPM1B ⇧ 1.20 7.67E-03  3845782 PLEKHJ1 ⇧ 1.20 9.86E-03 
3951732 CECR5 ⇧ 1.21 0.042  2403557 SNORA44 ⇩ 1.20 0.041  3725035 NFE2L1 ⇩ 1.20 0.034 
3184940 DNAJC25 ⇩ 1.21 0.039  3394068 RPS25 ⇧ 1.20 0.013  3375951 GANAB ⇩ 1.20 0.025 
2446198 TOR1AIP2 ⇩ 1.21 9.74E-03  3708798 SENP3 ⇧ 1.20 8.95E-03  2916716 PNRC1 ⇧ 1.20 0.015 
2448232 TPR ⇩ 1.21 1.89E-03  2999948 OGDH ⇩ 1.20 0.032  2423264 TMED5 ⇩ 1.20 0.045 
3676649 DCI ⇧ 1.21 2.96E-03  2829416 SEC24A ⇩ 1.20 0.033  2974188 MED23 ⇩ 1.20 8.85E-03 
3934245 CSTB ⇧ 1.21 3.99E-03  2642562 NUDT16 ⇧ 1.20 6.72E-03  3575567 FOXN3 ⇧ 1.20 0.025 
3971923 ZFX ⇧ 1.21 0.025  3977646 GSPT2 ⇧ 1.20 0.020  2380991 IARS2 ⇩ 1.20 0.031 
3333433 SCGB2A2 ⇧ 1.21 0.036  2503618 TSN ⇧ 1.20 0.017  3903598 GGT7 ⇩ 1.20 0.022 
3504691 ZDHHC20 ⇩ 1.21 0.035  2698738 XRN1 ⇩ 1.20 2.29E-03  3860824 ZNF569 ⇧ 1.20 1.78E-03 
3821701 ZNF788 ⇧ 1.21 5.07E-03  2345196 HS2ST1 ⇩ 1.20 0.042  3768103 PSMD12 ⇧ 1.20 0.012 
3939545 MIF ⇧ 1.21 0.030  3740998 TSR1 ⇧ 1.20 8.90E-03  3454740 PHB ⇧ 1.20 0.045 
3824153 C19orf62 ⇧ 1.21 7.05E-03  3893910 TCEA2 ⇧ 1.20 0.040  3872441 ZNF552 ⇧ 1.20 0.038 
2327418 MED18 ⇧ 1.21 2.83E-03  2618702 ZNF620 ⇧ 1.20 7.04E-04  3496916 GPR180 ⇩ 1.20 0.028 
3959631 EIF3D ⇧ 1.21 2.65E-03  3144235 TMEM55A ⇧ 1.20 0.019  3065015 POLR2J ⇧ 1.20 0.027 
3633148 SCAMP2 ⇩ 1.21 0.025  3688424 C16orf58 ⇩ 1.20 0.011  3466740 LTA4H ⇧ 1.20 0.035 
4027532 GAB3 ⇧ 1.21 0.037  3160735 CDC37L1 ⇧ 1.20 0.012  3823390 OR10H3 ⇧ 1.20 0.038 
3856594 ZNF43 ⇧ 1.21 0.013  3864597 C19orf61 ⇩ 1.20 0.015  3413950 SPATS2 ⇧ 1.20 0.022 
2671652 ZDHHC3 ⇩ 1.21 0.020  3005332 CRCP ⇧ 1.20 0.016  2328633 TMEM39B ⇩ 1.20 0.012 
2723391 MGC42157 ⇧ 1.21 0.018  3893086 SLC17A9 ⇩ 1.20 7.29E-03  2468138 LOC400940 ⇧ 1.20 2.09E-03 
3617230 C15orf24 ⇩ 1.21 0.040  3203482 BAG1 ⇧ 1.20 0.013  2330002 EIF2C4 ⇧ 1.20 0.011 
3894228 CSNK2A1 ⇧ 1.21 8.59E-03  2390298 OR2L2 ⇧ 1.20 0.040  2588319 KIAA1715 ⇩ 1.20 0.026 
3903836 EIF6 ⇧ 1.21 2.72E-03  3980560 KIF4A ⇩ 1.20 0.045  3845620 BTBD2 ⇧ 1.20 0.033 
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3978819 RRAGB ⇧ 1.20 0.027  2801608 MARCH6 ⇩ 1.20 5.37E-03  3326842 TRIM44 ⇧ 1.20 0.014 
2437417 ASH1L ⇩ 1.20 9.06E-03  2465324 AHCTF1 ⇧ 1.20 0.015  3974838 DDX3X ⇧ 1.20 9.16E-03 
2482505 SPTBN1 ⇩ 1.20 4.48E-03  2514658 UBR3 ⇩ 1.20 8.17E-03  2460325 C1orf198 ⇧ 1.20 8.21E-03 
3200689 RPS6 ⇧ 1.20 6.01E-03  3476265 EIF2B1 ⇧ 1.20 2.71E-03  3202171 PLAA ⇧ 1.20 0.030 
3819880 ZNF317 ⇧ 1.20 2.62E-03  3797015 ZFP161 ⇧ 1.20 0.023  3734797 KIAA0195 ⇩ 1.20 4.37E-03 
2599433 USP37 ⇩ 1.20 0.023  3961981 POLR3H ⇧ 1.20 0.038  3121023 C8orf33 ⇧ 1.20 4.32E-03 
3872542 ZNF418 ⇧ 1.20 0.026  3515009 VPS36 ⇧ 1.20 9.91E-03  2746164 MMAA ⇩ 1.20 0.028 
2982319 SOD2 ⇧ 1.20 0.042  2903189 HLA-DRA ⇩ 1.20 9.92E-03  3816919 NFIC ⇧ 1.20 0.013 
3462949 OSBPL8 ⇧ 1.20 0.034  2672712 SCAP ⇩ 1.20 0.037  3657286 KIAA0664L3 ⇩ 1.20 0.046 
3488942 NUDT15 ⇧ 1.20 0.026  3740304 PITPNA ⇧ 1.20 0.039  2359444 LCE1B ⇧ 1.20 0.030 
3149754 EIF3H ⇧ 1.20 1.63E-03  3829020 PDCD5 ⇧ 1.20 0.021  3765299 APPBP2 ⇧ 1.20 6.07E-03 
2397732 AGMAT ⇧ 1.20 1.37E-03  3389273 CASP4 ⇧ 1.20 0.040  4012868 RLIM ⇧ 1.20 8.53E-03 
3479438 CHFR ⇧ 1.20 8.80E-03  3725456 ATP5G1 ⇧ 1.20 0.024  2486740 PNO1 ⇧ 1.20 0.031 
2414998 MYSM1 ⇩ 1.20 0.022  3696057 SLC12A4 ⇩ 1.20 0.031  3837796 GRWD1 ⇧ 1.20 0.034 
3627076 BNIP2 ⇧ 1.20 0.013  3507003 LNX2 ⇧ 1.20 8.47E-03  3201999 TUSC1 ⇩ 1.20 0.031 
3307680 DCLRE1A ⇧ 1.20 8.67E-03  3091797 EXTL3 ⇩ 1.20 0.033  3736162 TMC8 ⇩ 1.20 0.032 
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Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value 
2350981 GSTM1 ⇧ 3.05 0.022  2973376 PTPRK ⇩ 1.66 0.011  3944404 APOL1 ⇩ 1.49 4.16E-03 
3566383 C14orf105 ⇩ 2.09 1.66E-03  2936657 CCR6 ⇩ 1.65 0.013  2427208 GSTM3 ⇧ 1.48 5.30E-03 
2440385 CD244 ⇩ 2.01 2.51E-03  2477073 CRIM1 ⇩ 1.63 0.011  3409605 FAR2 ⇩ 1.48 0.033 
3388673 MMP7 ⇩ 1.99 0.016  3209384 TMEM2 ⇩ 1.62 0.013  3662201 MT1H ⇧ 1.48 0.043 
3507282 FLT1 ⇩ 1.97 1.84E-04  3791254 TNFRSF11A ⇩ 1.62 9.00E-03  3754797 HNF1B ⇩ 1.47 0.012 
2607568 CHL1 ⇩ 1.90 9.38E-03  2705445 PLD1 ⇩ 1.61 8.38E-03  2849992 FAM134B ⇩ 1.47 6.84E-03 
3456805 GTSF1 ⇧ 1.90 0.013  2485406 HSPC159 ⇧ 1.60 6.41E-04  2615360 TGFBR2 ⇩ 1.47 7.52E-03 
3692999 MT1G ⇧ 1.89 3.78E-03  3129361 FBXO16 ⇧ 1.59 0.016  2973232 C6orf174 ⇩ 1.47 6.06E-03 
2915828 NT5E ⇩ 1.88 0.013  3599709 GLCE ⇩ 1.59 6.10E-03  3201319 IFNA2 ⇩ 1.46 0.036 
3623031 FBN1 ⇩ 1.88 3.87E-05  3494137 LMO7 ⇩ 1.58 1.10E-04  2730746 SLC4A4 ⇩ 1.46 0.016 
3791958 SERPINB10 ⇧ 1.84 0.020  2403446 PTAFR ⇩ 1.56 0.021  2732844 ANXA3 ⇩ 1.46 7.32E-03 
3445908 EPS8 ⇩ 1.84 4.82E-03  3323891 GAS2 ⇩ 1.56 0.012  2818517 VCAN ⇩ 1.46 0.044 
2459042 CDC42BPA ⇩ 1.84 5.71E-03  3174510 GDA ⇩ 1.56 0.018  3420442 IRAK3 ⇩ 1.45 0.028 
3569814 ACTN1 ⇩ 1.81 2.33E-03  3141755 HEY1 ⇩ 1.55 0.027  3450775 KIF21A ⇩ 1.45 0.021 
2853102 PRLR ⇩ 1.81 4.53E-03  3138204 CYP7B1 ⇩ 1.55 3.00E-03  2775735 SCD5 ⇩ 1.45 6.58E-04 
4022370 GPC4 ⇩ 1.80 8.64E-03  4002081 MAP7D2 ⇩ 1.55 0.014  3519309 SPRY2 ⇩ 1.45 0.025 
3778504 RAB31 ⇧ 1.74 0.012  2664209 SH3BP5 ⇧ 1.55 4.18E-03  3895118 CPXM1 ⇩ 1.45 0.010 
2731636 PARM1 ⇩ 1.74 1.24E-03  3841357 LILRA2 ⇩ 1.54 1.34E-03  2325593 CLIC4 ⇧ 1.45 3.01E-03 
3284596 PARD3 ⇩ 1.73 8.10E-04  3382216 ARRB1 ⇩ 1.54 0.046  3721989 CNTNAP1 ⇩ 1.45 0.011 
2898746 LRRC16A ⇩ 1.72 1.82E-03  3996598 NCRNA00204 ⇧ 1.52 0.040  2809128 ITGA1 ⇩ 1.44 0.011 
3150579 ENPP2 ⇩ 1.72 5.00E-03  2760869 HS3ST1 ⇩ 1.52 0.021  3396593 FEZ1 ⇧ 1.44 0.015 
2699564 PLOD2 ⇩ 1.71 5.40E-03  2459173 PRO2012 ⇩ 1.51 3.54E-03  3139580 SLCO5A1 ⇩ 1.44 4.89E-04 
3512948 C13orf18 ⇧ 1.71 4.37E-03  3941848 EMID1 ⇩ 1.51 1.37E-03  3852880 EMR2 ⇩ 1.44 0.038 
3393446 FXYD2 ⇩ 1.70 5.83E-03  2924253 RNF217 ⇩ 1.51 0.033  2830861 EGR1 ⇧ 1.43 0.026 
3718555 SLFN5 ⇩ 1.70 0.035  3560403 EGLN3 ⇩ 1.51 9.31E-03  2362333 MNDA ⇧ 1.43 0.040 
2571483 IL1A ⇧ 1.70 0.013  3461341 CPM ⇩ 1.51 0.031  3724545 ITGB3 ⇩ 1.43 0.033 
2635741 CD96 ⇩ 1.69 0.018  3212848 GOLM1 ⇩ 1.50 4.65E-03  3091077 DPYSL2 ⇧ 1.43 7.30E-03 
2738664 SGMS2 ⇩ 1.69 0.010  2422035 GBP5 ⇩ 1.49 2.48E-03  2879105 SPRY4 ⇩ 1.43 2.47E-03 
3496409 GPC5 ⇩ 1.68 5.20E-04  2986999 GPR146 ⇩ 1.49 0.011  3061997 PON2 ⇩ 1.42 0.047 
3944129 HMOX1 ⇧ 1.67 2.41E-04  2462160 NID1 ⇩ 1.49 5.43E-03  3344142 NAALAD2 ⇩ 1.42 0.027 
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2584018 DPP4 ⇩ 1.41 0.033  3761313 HOXB3 ⇩ 1.35 3.82E-06  3005444 TPST1 ⇩ 1.33 0.017 
3385752 RAB38 ⇩ 1.41 0.025  3273667 ADARB2 ⇩ 1.35 0.016  3057955 FGL2 ⇩ 1.33 8.85E-03 
3402757 LAG3 ⇩ 1.41 2.34E-03  2425400 EXTL2 ⇩ 1.35 7.11E-03  2351004 GSTM5 ⇧ 1.33 4.03E-03 
3705151 DBNDD1 ⇩ 1.41 0.022  3816827 S1PR4 ⇩ 1.35 8.34E-03  3570373 SLC8A3 ⇩ 1.33 0.029 
3753500 SLFN11 ⇩ 1.40 4.71E-05  3887302 CD40 ⇩ 1.35 9.46E-04  2777487 FAM13A ⇩ 1.33 0.014 
2910868 TINAG ⇩ 1.40 4.73E-03  3016636 SH2B2 ⇧ 1.35 2.31E-03  3712062 TRPV2 ⇩ 1.33 3.02E-04 
3011838 STEAP1 ⇩ 1.40 4.89E-03  2912649 COL19A1 ⇩ 1.35 6.12E-03  3447348 SOX5 ⇩ 1.33 0.010 
2533999 CXCR7 ⇩ 1.40 0.048  3067302 LAMB1 ⇩ 1.35 0.015  3082590 LOC286161 ⇧ 1.33 9.64E-03 
3887210 MMP9 ⇩ 1.40 0.017  3796620 DLGAP1 ⇩ 1.35 0.028  3141589 IL7 ⇩ 1.33 0.038 
2522094 SPATS2L ⇩ 1.40 0.016  3136178 PLAG1 ⇧ 1.34 0.026  3443891 CLEC2B ⇩ 1.33 0.036 
2748923 GUCY1B3 ⇩ 1.40 0.045  3150455 TNFRSF11B ⇩ 1.34 0.022  3714068 ALDH3A2 ⇧ 1.33 3.32E-04 
2446240 TOR1AIP2 ⇧ 1.39 0.013  2338625 HOOK1 ⇩ 1.34 0.014  3712062 TRPV2 ⇩ 1.33 3.02E-04 
2328273 SERINC2 ⇩ 1.39 0.042  3734379 CD300A ⇩ 1.34 1.50E-04  3447348 SOX5 ⇩ 1.33 0.010 
3972929 GK ⇩ 1.39 0.011  2848265 CMBL ⇧ 1.34 8.85E-03  3082590 LOC286161 ⇧ 1.33 9.64E-03 
4005859 CASK ⇩ 1.39 4.60E-03  3220846 SUSD1 ⇩ 1.34 0.013  3141589 IL7 ⇩ 1.33 0.038 
2327677 EPB41 ⇧ 1.38 1.28E-03  3228523 GBGT1 ⇩ 1.34 0.013  3443891 CLEC2B ⇩ 1.33 0.036 
3609592 MCTP2 ⇩ 1.38 1.17E-04  3103818 HNF4G ⇩ 1.34 0.020  3714068 ALDH3A2 ⇧ 1.33 3.32E-04 
3054165 SBDS ⇧ 1.38 0.013  3302177 ARHGAP19 ⇧ 1.34 0.022  2902178 TCF19 ⇧ 1.32 3.14E-03 
2842561 HIGD2A ⇧ 1.38 1.46E-03  2879028 GNPDA1 ⇧ 1.34 4.99E-03  2902178 TCF19 ⇧ 1.32 3.14E-03 
3766533 CD79B ⇩ 1.38 7.82E-03  3011492 ADAM22 ⇩ 1.34 3.92E-03  3424442 TMTC2 ⇩ 1.32 2.36E-04 
3788049 SKA1 ⇧ 1.38 1.01E-03  2848265 CMBL ⇧ 1.34 8.85E-03  2929127 STX11 ⇧ 1.32 0.022 
3132940 ANK1 ⇩ 1.37 0.012  3220846 SUSD1 ⇩ 1.34 0.013  4018080 CHRDL1 ⇩ 1.32 0.018 
3065244 RASA4 ⇧ 1.37 0.028  3228523 GBGT1 ⇩ 1.34 0.013  3067644 THAP5 ⇧ 1.32 4.95E-04 
3236538 RPP38 ⇧ 1.37 0.019  3103818 HNF4G ⇩ 1.34 0.020  2449711 DENND1B ⇧ 1.32 0.045 
2626167 PXK ⇧ 1.37 2.39E-03  3302177 ARHGAP19 ⇧ 1.34 0.022  2946219 HIST1H2AB ⇧ 1.32 0.047 
2932508 TIAM2 ⇧ 1.37 7.33E-03  2879028 GNPDA1 ⇧ 1.34 4.99E-03  3825013 SSBP4 ⇩ 1.32 4.95E-03 
2323559 MRTO4 ⇧ 1.36 1.15E-03  3011492 ADAM22 ⇩ 1.34 3.92E-03  3040897 CDCA7L ⇧ 1.32 0.018 
2956052 TNFRSF21 ⇩ 1.36 0.023  3005444 TPST1 ⇩ 1.33 0.017  2601287 AP1S3 ⇧ 1.32 4.10E-04 
2933175 ZDHHC14 ⇩ 1.36 0.024  3057955 FGL2 ⇩ 1.33 8.85E-03  2336585 SCP2 ⇧ 1.32 6.03E-03 
3847112 PTPRS ⇧ 1.36 0.042  2351004 GSTM5 ⇧ 1.33 4.03E-03  3424442 TMTC2 ⇩ 1.32 2.36E-04 
2538600 ADI1 ⇧ 1.36 4.76E-03  3570373 SLC8A3 ⇩ 1.33 0.029  2929127 STX11 ⇧ 1.32 0.022 
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3067644 THAP5 ⇧ 1.32 4.95E-04  2608419 SETMAR ⇧ 1.30 8.10E-04  2861952 MRPS27 ⇧ 1.28 1.51E-04 
2449711 DENND1B ⇧ 1.32 0.045  2514441 PPIG ⇧ 1.30 1.24E-06  3624145 DMXL2 ⇩ 1.28 2.87E-03 
2946219 HIST1H2AB ⇧ 1.32 0.047  2715440 RNF4 ⇧ 1.30 0.011  2582124 NR4A2 ⇧ 1.28 7.31E-03 
3825013 SSBP4 ⇩ 1.32 4.95E-03  3009399 HSPB1 ⇧ 1.30 0.026  3740432 SCARF1 ⇩ 1.28 4.31E-03 
3040897 CDCA7L ⇧ 1.32 0.018  3259978 PI4K2A ⇧ 1.30 0.017  3887107 ZSWIM1 ⇧ 1.28 4.59E-03 
2601287 AP1S3 ⇧ 1.32 4.10E-04  2385696 C1orf57 ⇧ 1.29 0.026  3385769 CTSC ⇩ 1.28 0.033 
2336585 SCP2 ⇧ 1.32 6.03E-03  3234277 GATA3 ⇩ 1.29 0.011  3278813 FAM107B ⇧ 1.28 0.030 
3761291 HOXB2 ⇩ 1.31 8.05E-03  3074912 DGKI ⇩ 1.29 6.79E-03  2403470 DNAJC8 ⇧ 1.28 0.017 
2712906 RNF168 ⇧ 1.31 6.94E-04  2438482 ISG20L2 ⇧ 1.29 2.27E-04  3848243 INSR ⇩ 1.28 0.034 
3663074 MMP15 ⇩ 1.31 0.019  2604390 ARL4C ⇧ 1.29 0.013  3018652 CBLL1 ⇧ 1.28 4.79E-05 
2350489 KIAA1324 ⇩ 1.31 0.041  2331178 NDUFS5 ⇧ 1.29 0.018  2910680 LRRC1 ⇩ 1.28 0.036 
3345222 AMOTL1 ⇩ 1.31 2.73E-03  2471978 RHOB ⇩ 1.29 0.045  2723710 PGM2 ⇧ 1.28 7.12E-04 
2826295 SNX2 ⇧ 1.31 7.47E-03  3450655 CPNE8 ⇩ 1.29 0.011  3245783 WDFY4 ⇩ 1.28 4.65E-05 
2350489 KIAA1324 ⇩ 1.31 0.041  3931112 HLCS ⇩ 1.29 7.78E-05  2437893 UBQLN4 ⇩ 1.28 0.012 
3345222 AMOTL1 ⇩ 1.31 2.73E-03  3396107 ESAM ⇩ 1.29 0.021  3635198 BCL2A1 ⇧ 1.28 0.041 
2826295 SNX2 ⇧ 1.31 7.47E-03  2316245 PRKCZ ⇧ 1.29 1.37E-03  2442424 ILDR2 ⇩ 1.27 0.032 
3761291 HOXB2 ⇩ 1.31 8.05E-03  3845944 GNG7 ⇧ 1.29 7.26E-03  2728189 PAICS ⇧ 1.27 1.41E-03 
2712906 RNF168 ⇧ 1.31 6.94E-04  3803120 B4GALT6 ⇩ 1.29 9.87E-04  3747522 TNFRSF13B ⇩ 1.27 0.037 
3663074 MMP15 ⇩ 1.31 0.019  3402506 CD27 ⇧ 1.29 0.046  2434159 SF3B4 ⇧ 1.27 7.22E-03 
2925590 TMEM200A ⇩ 1.31 0.045  2682568 SHQ1 ⇧ 1.29 3.23E-03  3851493 ZNF443 ⇩ 1.27 0.014 
2427791 DENND2D ⇩ 1.31 0.012  3044753 LSM5 ⇧ 1.29 4.37E-03  2900059 HIST1H2BM ⇧ 1.27 4.51E-03 
2744734 MGST2 ⇩ 1.31 0.046  2325479 RCAN3 ⇧ 1.29 1.54E-03  2748346 TLR2 ⇩ 1.27 0.019 
3687494 MAPK3 ⇧ 1.31 3.50E-03  2676182 NT5DC2 ⇧ 1.29 3.46E-03  2350922 GSTM4 ⇧ 1.27 0.043 
2805176 C5orf22 ⇧ 1.31 2.06E-03  2558483 C2orf42 ⇧ 1.29 6.99E-03  2961300 COX7A2 ⇧ 1.27 0.024 
3284188 ITGB1 ⇩ 1.31 2.01E-03  3674659 GAS8 ⇩ 1.28 0.038  3332886 TMEM138 ⇧ 1.27 0.012 
2829275 UBE2B ⇧ 1.30 4.67E-03  3590239 DLL4 ⇩ 1.28 0.044  3289235 SGMS1 ⇩ 1.27 3.90E-03 
2692060 PARP9 ⇧ 1.30 0.017  2478748 EML4 ⇧ 1.28 4.42E-03  3503119 ZNF828 ⇧ 1.27 4.65E-03 
3161113 PDCD1LG2 ⇩ 1.30 0.025  2927722 HEBP2 ⇧ 1.28 2.87E-03  3538087 DACT1 ⇩ 1.27 0.019 
3245881 WDFY4 ⇩ 1.30 5.72E-03  4003895 CXorf21 ⇩ 1.28 0.013  2655113 KLHL24 ⇧ 1.27 0.028 
3004768 ZNF273 ⇧ 1.30 0.013  2371346 RGL1 ⇧ 1.28 0.033  2820893 RFESD ⇧ 1.27 6.91E-03 
2827525 SLC12A2 ⇩ 1.30 3.39E-03  2505957 PLEKHB2 ⇧ 1.28 2.40E-03  2689208 NAA50 ⇧ 1.27 8.49E-04 
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2638962 DTX3L ⇧ 1.27 0.027  2336913 LRRC42 ⇧ 1.26 1.48E-04  2703217 KPNA4 ⇧ 1.24 2.27E-03 
2713111 MFI2 ⇩ 1.27 0.016  3279982 PTPLA ⇩ 1.26 0.039  2367963 RABGAP1L ⇧ 1.24 0.047 
2434139 SV2A ⇩ 1.27 0.025  2520069 C2orf88 ⇩ 1.26 0.024  3816264 DOT1L ⇩ 1.24 4.29E-03 
3291601 EGR2 ⇧ 1.27 0.045  2364189 UAP1 ⇧ 1.26 6.33E-03  2905404 PIM1 ⇧ 1.24 0.024 
3342426 C11orf82 ⇧ 1.26 0.015  3286975 ANUBL1 ⇧ 1.26 2.81E-03  2758686 LYAR ⇧ 1.24 8.94E-04 
3508898 STARD13 ⇩ 1.26 0.032  2898562 ACOT13 ⇧ 1.26 0.011  3927081 NCRNA00158 ⇩ 1.24 0.027 
2659887 FYTTD1 ⇧ 1.26 7.46E-03  3622386 GATM ⇧ 1.25 0.011  3344990 PANX1 ⇩ 1.24 0.014 
2871241 MCC ⇩ 1.26 9.38E-03  3073981 AKR1B1 ⇧ 1.25 0.027  3288518 C10orf72 ⇩ 1.24 0.046 
2696379 ANAPC13 ⇧ 1.26 0.012  2469910 LPIN1 ⇧ 1.25 0.020  2813442 CENPH ⇧ 1.24 0.023 
2626258 KCTD6 ⇧ 1.26 4.82E-03  2766456 UGDH ⇧ 1.25 7.14E-03  2363444 USP21 ⇧ 1.24 1.85E-04 
3350775 SIDT2 ⇩ 1.26 9.52E-05  3316375 TSPAN4 ⇩ 1.25 0.047  3037304 C7orf70 ⇧ 1.24 0.015 
3880827 GINS1 ⇧ 1.26 0.024  3670700 BCMO1 ⇩ 1.25 0.014  2560141 MRPL53 ⇧ 1.24 1.89E-04 
3091699 PNOC ⇧ 1.26 0.015  2724094 FAM114A1 ⇧ 1.25 0.040  2945645 TDP2 ⇧ 1.24 8.23E-03 
3101385 MTFR1 ⇧ 1.26 7.72E-03  2538000 RNASEH1 ⇧ 1.25 5.58E-03  3438617 EP400 ⇩ 1.24 2.04E-03 
2979679 ZBTB2 ⇧ 1.26 2.85E-03  2564599 MRPS5 ⇧ 1.25 8.70E-03  3833238 LGALS14 ⇧ 1.24 0.044 
2957462 GSTA4 ⇧ 1.26 7.23E-03  3311157 OAT ⇧ 1.25 0.036  2444790 MRPS14 ⇧ 1.24 2.68E-04 
2334279 UROD ⇧ 1.26 4.43E-04  3850660 SPC24 ⇧ 1.25 0.035  3758291 VAT1 ⇧ 1.24 0.047 
3498837 PCCA ⇩ 1.26 8.25E-03  3272205 INPP5A ⇩ 1.25 0.012  2931683 C6orf211 ⇧ 1.24 0.020 
3655574 SPN ⇩ 1.26 6.84E-04  2624147 ITIH1 ⇩ 1.25 0.015  3864430 ETHE1 ⇧ 1.24 0.013 
3934407 ICOSLG ⇩ 1.26 1.01E-04  3118451 CHRAC1 ⇧ 1.25 3.16E-03  3736087 TNRC6C ⇩ 1.24 2.56E-03 
2443989 VAMP4 ⇧ 1.26 0.018  2814642 MCCC2 ⇧ 1.25 1.25E-03  2815455 UTP15 ⇧ 1.24 6.43E-03 
2724338 LIAS ⇧ 1.26 7.91E-03  2359433 LCE1E ⇧ 1.25 7.71E-03  3914273 SAMD10 ⇩ 1.24 0.017 
2332767 C1orf50 ⇧ 1.26 3.93E-03  2523354 FAM117B ⇧ 1.25 1.76E-03  3079803 PRKAG2 ⇧ 1.24 4.69E-04 
3521484 UGGT2 ⇩ 1.26 0.037  2317317 TP73 ⇧ 1.25 0.025  3704376 FAM38A ⇩ 1.24 4.67E-03 
3005717 RABGEF1 ⇧ 1.26 1.17E-03  2901660 PRR3 ⇧ 1.25 1.10E-03  3454576 SLC11A2 ⇩ 1.24 9.89E-03 
3267382 INPP5F ⇧ 1.26 0.018  3742067 UBE2G1 ⇧ 1.25 5.67E-03  2798915 TRIP13 ⇧ 1.23 0.030 
2633460 C3orf26 ⇧ 1.26 7.48E-03  3222128 TNFSF15 ⇩ 1.24 8.11E-03  3561110 RALGAPA1 ⇩ 1.23 0.013 
2745220 ZNF330 ⇧ 1.26 3.49E-03  2479943 SIX3 ⇩ 1.24 9.88E-03  2838042 TTC1 ⇧ 1.23 0.014 
2636272 GTPBP8 ⇧ 1.26 3.59E-03  3596109 FAM81A ⇧ 1.24 3.45E-03  2434862 LYSMD1 ⇧ 1.23 3.44E-03 
4024160 ATP11C ⇩ 1.26 3.09E-03  3662247 MT1X ⇧ 1.24 0.014  3904527 NDRG3 ⇧ 1.23 0.017 
2489172 MTHFD2 ⇧ 1.26 0.016  3394412 THY1 ⇩ 1.24 0.040  2413943 USP24 ⇧ 1.23 0.046 
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3164601 KIAA1797 ⇩ 1.23 2.34E-03  3416909 BLOC1S1 ⇧ 1.23 0.038  3293724 C10orf54 ⇩ 1.22 0.039 
2855443 LOC100132356 ⇧ 1.23 3.67E-03  3841574 LILRB1 ⇩ 1.23 0.037  2559494 C2orf7 ⇧ 1.22 0.027 
3106243 RIPK2 ⇧ 1.23 0.039  2907568 KLHDC3 ⇧ 1.23 1.77E-04  3094286 PROSC ⇧ 1.22 0.017 
2636483 SIDT1 ⇩ 1.23 7.39E-03  3590108 GCHFR ⇧ 1.23 0.027  2541699 FAM49A ⇧ 1.22 0.048 
2885099 NUDCD2 ⇧ 1.23 2.96E-03  3487095 DGKH ⇩ 1.23 0.021  3634458 TBC1D2B ⇩ 1.22 1.35E-03 
2443518 C1orf156 ⇧ 1.23 0.013  2934167 MRPL18 ⇧ 1.23 3.15E-03  3757745 GHDC ⇩ 1.22 2.78E-03 
3920385 TTC3 ⇧ 1.23 0.024  2327630 YTHDF2 ⇧ 1.22 0.048  3448152 ITPR2 ⇩ 1.21 0.044 
3936887 MRPL40 ⇧ 1.23 0.015  2334350 MMACHC ⇧ 1.22 0.033  3648247 C16orf75 ⇧ 1.21 0.044 
3852565 ASF1B ⇧ 1.23 0.030  3829313 CEBPG ⇧ 1.22 0.029  3651955 METTL9 ⇧ 1.21 7.92E-03 
2877465 ETF1 ⇧ 1.23 6.98E-03  2342576 ACADM ⇧ 1.22 3.80E-03  2911903 PTP4A1 ⇧ 1.21 7.01E-03 
3328389 EXT2 ⇩ 1.23 9.44E-03  2492496 NCRNA00152 ⇧ 1.22 0.044  2949210 BAT4 ⇧ 1.21 3.48E-03 
2548617 CDC42EP3 ⇧ 1.23 0.035  2339414 USP1 ⇧ 1.22 0.014  3929395 GCFC1 ⇧ 1.21 0.022 
3434490 CABP1 ⇩ 1.23 0.020  3542689 PCNX ⇩ 1.22 1.71E-03  3940992 ASPHD2 ⇩ 1.21 0.019 
3539724 SYNE2 ⇩ 1.23 0.014  3396179 LOC100130428 ⇩ 1.22 0.023  3006133 STAG3L4 ⇧ 1.21 0.044 
2694644 CNBP ⇧ 1.23 7.62E-03  3489481 PHF11 ⇩ 1.22 1.15E-03  2881413 RPS14 ⇧ 1.21 0.031 
2889753 ZNF354A ⇧ 1.23 9.43E-03  2596955 CRYGC ⇧ 1.22 0.011  3836317 VASP ⇩ 1.21 4.00E-03 
2964200 UBE2J1 ⇧ 1.23 0.013  2693149 SNX4 ⇧ 1.22 6.54E-03  2597273 C2orf67 ⇩ 1.21 4.10E-03 
3771675 ST6GALNAC2 ⇧ 1.23 0.027  3662444 NLRC5 ⇩ 1.22 1.33E-03  2359780 NPR1 ⇩ 1.21 0.030 
2645579 RASA2 ⇧ 1.23 7.98E-03  2403215 FGR ⇩ 1.22 0.013  2398789 SDHB ⇧ 1.21 6.33E-03 
2986350 DLL1 ⇩ 1.23 0.013  3255938 OPN4 ⇧ 1.22 0.044  3175597 VPS13A ⇩ 1.21 7.84E-03 
3660175 NOD2 ⇩ 1.23 1.62E-03  2700500 COMMD2 ⇧ 1.22 0.013  3005684 KCTD7 ⇧ 1.21 0.015 
2976727 TXLNB ⇧ 1.23 0.018  3339812 ARHGEF17 ⇩ 1.22 0.045  2666566 NGLY1 ⇧ 1.21 5.76E-03 
3721926 TUBG1 ⇧ 1.23 0.010  3048869 H2AFV ⇧ 1.22 9.23E-03  2712858 UBXN7 ⇧ 1.21 2.43E-03 
2356205 PEX11B ⇧ 1.23 3.13E-04  3919033 SLC5A3 ⇩ 1.22 1.67E-03  2595443 WDR12 ⇧ 1.21 9.71E-03 
2351872 RAP1A ⇧ 1.23 1.16E-03  2515183 DCAF17 ⇧ 1.22 4.14E-03  3800070 C18orf19 ⇧ 1.21 0.041 
2396121 DFFA ⇧ 1.23 1.18E-03  2544164 C2orf44 ⇧ 1.22 0.015  3445643 HIST4H4 ⇩ 1.21 0.035 
2435195 MRPL9 ⇧ 1.23 6.45E-03  3907934 ZNF334 ⇩ 1.22 0.046  3015178 ZSCAN21 ⇧ 1.21 1.57E-03 
2489806 MRPL19 ⇧ 1.23 0.010  2654069 NDUFB5 ⇧ 1.22 8.23E-03  3818897 PNPLA6 ⇩ 1.21 3.03E-04 
2389016 PPPDE1 ⇧ 1.23 0.028  2723752 TBC1D1 ⇧ 1.22 3.18E-03  2598099 BARD1 ⇧ 1.21 8.11E-04 
3830993 HCST ⇩ 1.23 0.022  2555630 CCT4 ⇧ 1.22 1.20E-04  3072368 ZC3HC1 ⇧ 1.21 1.51E-04 
2835006 GRPEL2 ⇧ 1.23 3.99E-03  3665997 DUS2L ⇧ 1.22 6.61E-03  3824427 FAM129C ⇧ 1.21 0.022 
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3521174 ABCC4 ⇩ 1.21 0.027  2385258 C1orf124 ⇧ 1.21 8.12E-03  2356181 RBM8A ⇧ 1.20 7.20E-03 
2999816 YKT6 ⇧ 1.21 5.69E-03  2802398 TRIO ⇩ 1.20 1.17E-03  3148963 KCNV1 ⇩ 1.20 2.02E-03 
3860101 NFKBID ⇧ 1.21 0.044  3747717 COPS3 ⇧ 1.20 8.37E-04  2842911 FGFR4 ⇩ 1.20 0.018 
3536905 KTN1 ⇩ 1.21 1.17E-03  3934695 PTTG1IP ⇩ 1.20 9.67E-03  2409220 EBNA1BP2 ⇧ 1.20 0.046 
2319802 PGD ⇧ 1.21 0.022  2946268 HIST1H2BC ⇧ 1.20 0.019  3018509 DUS4L ⇧ 1.20 1.64E-04 
3323052 NAV2 ⇩ 1.21 5.62E-03  3774218 DYSFIP1 ⇧ 1.20 3.88E-03  3325820 DEPDC7 ⇩ 1.20 0.010 
2662473 PRRT3 ⇩ 1.21 0.027  3859915 U2AF1L4 ⇧ 1.20 0.013  2317434 TPRG1L ⇧ 1.20 0.013 
3337516 LRP5 ⇩ 1.21 0.024  3275690 IL15RA ⇩ 1.20 1.14E-03  2379132 ATF3 ⇧ 1.20 0.022 
2750227 C4orf43 ⇧ 1.21 2.07E-03  3715874 ERAL1 ⇧ 1.20 0.012  3282974 SVIL ⇩ 1.20 0.011 
2979056 N⇧43 ⇧ 1.21 4.94E-03  2739160 CCDC109B ⇧ 1.20 0.020  2807862 C5orf51 ⇧ 1.20 0.023 
2621583 ZNF589 ⇧ 1.21 0.043  2534564 UBE2F ⇧ 1.20 0.046  3563395 POLE2 ⇧ 1.20 0.049 
2519140 ZC3H15 ⇧ 1.21 1.24E-03  2991103 BZW2 ⇧ 1.20 0.033  3283920 ARHGAP12 ⇩ 1.20 4.54E-03 
3831475 ZNF382 ⇧ 1.21 0.038  2831567 PURA ⇧ 1.20 3.65E-04  3329904 NDUFS3 ⇧ 1.20 4.10E-03 
2475407 CLIP4 ⇧ 1.21 0.011  2863535 WDR41 ⇧ 1.20 1.50E-04  2990464 ARL4A ⇧ 1.20 5.10E-03 
3537264 C14orf101 ⇩ 1.21 2.45E-03  3000167 CCM2 ⇧ 1.20 0.013  2852274 MTMR12 ⇧ 1.20 1.25E-03 
2484970 EHBP1 ⇩ 1.21 0.032  2952834 KCNK5 ⇩ 1.20 0.047  2716432 ZBTB49 ⇧ 1.20 1.39E-03 
3302495 AVPI1 ⇧ 1.21 5.28E-03  2963614 CGA ⇧ 1.20 9.74E-03  3556966 HAUS4 ⇧ 1.20 0.036 
3352948 SORL1 ⇩ 1.21 4.21E-03  3542145 KIAA0247 ⇩ 1.20 0.031  3048413 POLD2 ⇧ 1.20 1.61E-03 
3944690 CYTH4 ⇩ 1.21 0.024  3139722 NCOA2 ⇩ 1.20 8.39E-03  2767378 ATP8A1 ⇩ 1.20 0.019 
2942578 CCDC90A ⇧ 1.21 1.69E-03  2685776 MINA ⇧ 1.20 9.32E-03  3101802 SGK3 ⇧ 1.20 1.15E-03 
2549260 MAP4K3 ⇧ 1.21 0.025  2443537 SCYL3 ⇧ 1.20 5.33E-04  2951221 C6orf106 ⇧ 1.20 0.010 
2847264 MED10 ⇧ 1.21 0.012  2827388 PRRC1 ⇧ 1.20 3.03E-03  3662106 MT1A ⇧ 1.20 0.049 
2825629 TNFAIP8 ⇧ 1.21 4.27E-03  2950214 TAP1 ⇩ 1.20 1.47E-03  3191147 TOR1B ⇩ 1.20 0.013 
3304746 USMG5 ⇧ 1.21 0.020  3048212 MRPS24 ⇧ 1.20 4.37E-04  3244622 ALOX5 ⇧ 1.20 0.025 
2901352 PPP1R11 ⇧ 1.21 6.81E-03  3590086 RAD51 ⇧ 1.20 0.031  3781429 RBBP8 ⇧ 1.20 0.010 
3610982 SYNM ⇩ 1.21 4.97E-03  3015603 AGFG2 ⇧ 1.20 7.54E-03  3153428 ASAP1 ⇧ 1.20 5.04E-03 
3654956 LAT ⇩ 1.21 4.02E-03  3675116 TMEM8A ⇩ 1.20 1.23E-03  3901665 C20orf3 ⇩ 1.20 3.91E-03 
3416522 COPZ1 ⇧ 1.21 0.044  3019981 MDFIC ⇧ 1.20 0.023  2519860 ASNSD1 ⇧ 1.20 0.015 
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Transcript ID Symbol Fold p-value  Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value 
2421995 GBP4 ⇧ 2.90 4.49E-03  2452691 SLC41A1 ⇩ 1.80 0.015  2845274 CCDC127 ⇩ 1.57 0.026 
2523801 CD28 ⇧ 2.68 0.040  3055608 TYW1B ⇩ 1.79 3.88E-04  3016636 SH2B2 ⇩ 1.57 0.010 
3174510 GDA ⇧ 2.54 0.021  3726498 MYCBPAP ⇩ 1.76 1.96E-03  2320727 TNFRSF1B ⇩ 1.57 0.016 
2497161 IL18RAP ⇧ 2.50 0.032  2869438 NUDT12 ⇧ 1.75 0.011  3645836 ZNF75A ⇧ 1.57 0.012 
2742109 FGF2 ⇧ 2.49 4.96E-04  4035833 CD24 ⇧ 1.74 0.020  2775259 RASGEF1B ⇧ 1.56 9.88E-03 
2821347 ERAP2 ⇧ 2.49 0.039  3203382 SMU1 ⇧ 1.74 0.011  3250093 KIAA1279 ⇧ 1.56 0.011 
3141755 HEY1 ⇧ 2.41 9.20E-03  3238962 KIAA1217 ⇩ 1.72 0.016  3066818 NAMPT ⇩ 1.56 0.015 
2678298 DNASE1L3 ⇩ 2.37 0.045  3382061 XRRA1 ⇧ 1.71 9.10E-03  3434393 DYNLL1 ⇧ 1.56 0.028 
2522094 SPATS2L ⇧ 2.36 4.11E-05  3916527 JAM2 ⇩ 1.70 0.024  2502424 INSIG2 ⇩ 1.55 0.024 
3748449 CCDC144B ⇩ 2.23 0.030  3175119 OSTF1 ⇧ 1.70 0.013  2902574 LY6G5B ⇩ 1.54 0.014 
3433466 NCRNA00173 ⇩ 2.23 0.012  3840224 ZNF528 ⇧ 1.69 6.06E-03  3856184 ZNF737 ⇧ 1.54 7.04E-03 
2973376 PTPRK ⇧ 2.22 0.015  2422035 GBP5 ⇧ 1.69 0.042  3375091 SLC15A3 ⇩ 1.54 0.043 
3409605 FAR2 ⇧ 2.17 0.020  3149528 TRPS1 ⇧ 1.69 0.030  3857105 ZNF91 ⇧ 1.53 0.043 
3652902 SCNN1B ⇩ 2.08 0.030  3100497 CLVS1 ⇧ 1.68 0.019  4007216 UXT ⇧ 1.52 0.030 
2760869 HS3ST1 ⇧ 2.03 0.041  3494137 LMO7 ⇧ 1.68 0.034  3969422 RAB9A ⇧ 1.52 0.021 
3840194 ZNF880 ⇧ 1.97 6.99E-04  3184218 C9orf6 ⇧ 1.66 9.56E-03  3565524 GCH1 ⇧ 1.52 0.027 
2734047 AGPAT9 ⇩ 1.96 0.022  2324634 CDC42 ⇩ 1.66 0.016  3883064 ACSS2 ⇩ 1.52 8.22E-03 
3156307 PTK2 ⇧ 1.96 5.47E-03  3444086 KLRK1 ⇧ 1.65 4.97E-03  3876645 BTBD3 ⇧ 1.51 0.030 
2528159 WNT10A ⇩ 1.95 1.36E-03  2638728 SLC15A2 ⇩ 1.65 0.023  2469910 LPIN1 ⇩ 1.51 0.013 
3214451 NFIL3 ⇧ 1.94 0.027  3216276 SLC35D2 ⇧ 1.60 0.046  4027585 MPP1 ⇧ 1.51 0.045 
3453036 ASB8 ⇧ 1.89 8.76E-03  3101153 BHLHE22 ⇧ 1.60 0.021  2343231 NEXN ⇧ 1.51 0.036 
3839103 ATF5 ⇩ 1.88 0.036  3581637 ADAM6 ⇩ 1.60 0.034  3830216 FXYD5 ⇩ 1.50 0.023 
3519309 SPRY2 ⇧ 1.88 0.024  2908179 VEGFA ⇩ 1.60 0.016  3851441 ZNF442 ⇧ 1.50 1.54E-03 
2777564 FAM13A ⇧ 1.87 0.047  2957462 GSTA4 ⇩ 1.60 9.60E-03  3375735 AHNAK ⇩ 1.50 0.028 
3703885 SLC7A5 ⇩ 1.87 5.16E-03  3507798 UBL3 ⇧ 1.60 0.014  3142485 IMPA1 ⇧ 1.50 1.62E-03 
2877893 MGC29506 ⇩ 1.86 0.019  3651639 TMEM159 ⇧ 1.59 0.017  2361342 SEMA4A ⇩ 1.50 0.040 
3841357 LILRA2 ⇧ 1.84 3.67E-03  3227816 RAPGEF1 ⇩ 1.59 8.38E-03  3577246 MOAP1 ⇧ 1.50 0.027 
3450899 SLC2A13 ⇧ 1.84 6.29E-04  3382698 GUCY2E ⇩ 1.59 0.014  3413875 TROAP ⇩ 1.49 3.70E-04 
3944129 HMOX1 ⇩ 1.82 0.047  3311715 UROS ⇧ 1.58 2.65E-04  2620641 LIMD1 ⇩ 1.49 0.021 
3892812 SLCO4A1 ⇩ 1.81 4.13E-03  3476330 CCDC92 ⇧ 1.58 0.017  3846831 PLIN5 ⇩ 1.49 0.040 
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2691575 POLQ ⇩ 1.49 0.035  3088213 SH2D4A ⇧ 1.45 0.031  3590108 GCHFR ⇩ 1.41 0.022 
3726375 EME1 ⇩ 1.49 0.020  3090697 CDCA2 ⇩ 1.45 0.045  3716664 SUZ12P ⇩ 1.41 0.030 
3325052 EIF2AK2 ⇧ 1.49 0.029  3904508 SLA2 ⇧ 1.45 0.033  3320169 AMPD3 ⇩ 1.41 5.18E-03 
3727712 PCTP ⇧ 1.48 0.043  3366519 FANCF ⇧ 1.45 0.011  2603897 TIGD1 ⇩ 1.41 0.014 
3137875 GGH ⇩ 1.48 0.030  3286393 ZNF32 ⇧ 1.45 0.011  2866045 TMEM161B ⇩ 1.41 0.045 
3167383 NUDT2 ⇧ 1.48 0.011  2579572 ZEB2 ⇧ 1.45 0.027  2330393 C1orf113 ⇩ 1.41 4.42E-03 
2327677 EPB41 ⇩ 1.48 0.023  2949801 AGPAT1 ⇩ 1.45 0.014  3860491 ZNF260 ⇧ 1.40 3.03E-05 
3531479 ARHGAP5 ⇧ 1.48 3.18E-03  3860824 ZNF569 ⇧ 1.45 9.59E-05  3845352 UQCR11 ⇧ 1.40 0.037 
2878622 TAF7 ⇧ 1.48 0.046  3075932 PARP12 ⇧ 1.44 0.035  3890218 C20orf43 ⇧ 1.40 0.021 
2914777 TTK ⇩ 1.48 0.038  3670668 ATMIN ⇧ 1.44 9.86E-03  2332711 PPIH ⇩ 1.40 0.040 
2735362 HERC6 ⇧ 1.48 0.040  4014191 POF1B ⇩ 1.44 0.038  3633460 PTPN9 ⇧ 1.40 0.015 
2673547 SLC26A6 ⇩ 1.47 3.57E-03  2813414 CCNB1 ⇩ 1.44 0.038  3986230 CXorf57 ⇩ 1.40 2.49E-03 
3351895 C2CD2L ⇩ 1.47 0.012  2432851 NBPF11 ⇩ 1.44 0.026  3375935 B3GAT3 ⇩ 1.40 0.016 
3517793 KLF12 ⇧ 1.47 0.022  3724989 CDK5RAP3 ⇩ 1.44 6.35E-03  3251353 ANAPC16 ⇧ 1.40 0.019 
2782292 C4orf21 ⇩ 1.47 0.030  3881874 ASXL1 ⇩ 1.43 5.08E-03  3976670 EBP ⇩ 1.40 0.032 
3697563 FTSJD1 ⇧ 1.47 2.02E-03  3380996 C11orf51 ⇧ 1.43 0.016  3494706 SLAIN1 ⇧ 1.40 0.037 
3665230 HSF4 ⇩ 1.47 0.012  3882949 DYNLRB1 ⇧ 1.43 4.54E-03  3376556 ATL3 ⇧ 1.39 0.045 
3120358 HSF1 ⇩ 1.47 0.029  3648306 SNN ⇧ 1.43 0.021  3854877 JUND ⇩ 1.39 4.23E-03 
2360989 MSTO1 ⇩ 1.46 0.027  3409127 ARNTL2 ⇧ 1.43 0.041  3140640 STAU2 ⇧ 1.39 0.013 
2908261 C6orf223 ⇩ 1.46 0.026  3894098 C20orf96 ⇩ 1.43 2.46E-03  2878368 APBB3 ⇩ 1.39 6.54E-03 
3511698 EPSTI1 ⇧ 1.46 0.012  3439356 ZNF140 ⇧ 1.43 0.048  2391425 DVL1 ⇩ 1.39 0.013 
3518169 COMMD6 ⇧ 1.46 0.017  2396009 LZIC ⇧ 1.42 0.019  4010768 ZC4H2 ⇧ 1.39 0.015 
2475678 LBH ⇧ 1.46 0.016  3968664 HCCS ⇧ 1.42 0.036  3911814 SLMO2 ⇧ 1.39 5.18E-03 
3145240 C8orf37 ⇧ 1.46 0.040  3242425 CCNY ⇧ 1.42 0.038  3139950 LACTB2 ⇧ 1.39 0.023 
3177111 NTRK2 ⇧ 1.46 0.011  3909395 DPM1 ⇧ 1.42 6.12E-03  3440192 DCP1B ⇧ 1.38 0.047 
2604254 HJURP ⇩ 1.45 0.030  2925724 AKAP7 ⇧ 1.42 0.025  2957499 ICK ⇧ 1.38 0.020 
3426215 MRPL42 ⇧ 1.45 6.73E-03  2336302 ZFYVE9 ⇧ 1.42 8.46E-03  3841474 LENG8 ⇩ 1.38 4.22E-03 
3403244 CLSTN3 ⇩ 1.45 0.014  3351359 ATP5L ⇧ 1.42 0.042  2411799 BEND5 ⇧ 1.38 0.028 
3686080 NSMCE1 ⇧ 1.45 0.017  2941784 NEDD9 ⇧ 1.42 0.018  2458742 LIN9 ⇩ 1.38 0.021 
2485784 ACTR2 ⇧ 1.45 0.023  3793760 CNDP2 ⇧ 1.41 6.82E-03  3507710 SLC7A1 ⇩ 1.38 0.018 
3512050 CCDC122 ⇧ 1.45 0.014  3514849 NEK3 ⇧ 1.41 0.027  2924492 HEY2 ⇧ 1.37 0.037 
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3397589 ETS1 ⇧ 1.37 0.037  3464967 GALNT4 ⇧ 1.35 5.57E-03  2349848 PRMT6 ⇧ 1.33 0.037 
3318443 TRIM22 ⇧ 1.37 0.015  3996467 PLXNA3 ⇩ 1.35 4.69E-03  3788270 ELAC1 ⇧ 1.33 0.036 
3931112 HLCS ⇧ 1.37 4.56E-03  3680213 SOCS1 ⇩ 1.35 0.027  3462949 OSBPL8 ⇧ 1.33 0.041 
3364119 CYP2R1 ⇧ 1.37 0.026  3253683 ZMIZ1 ⇩ 1.35 0.030  2437753 KIAA0907 ⇩ 1.33 0.025 
3750785 SPAG5 ⇩ 1.37 0.017  2949118 LTB ⇧ 1.35 0.036  2758043 MFSD10 ⇩ 1.33 0.019 
3643938 TMEM204 ⇧ 1.37 0.031  2571457 CKAP2L ⇩ 1.35 0.019  3541137 EIF2S1 ⇧ 1.33 0.020 
3608095 ZNF774 ⇧ 1.37 8.89E-03  4052881 FAM72D ⇩ 1.35 0.042  3929395 GCFC1 ⇩ 1.33 0.030 
3344897 MED17 ⇧ 1.37 1.36E-03  3079005 RARRES2 ⇧ 1.35 9.57E-03  2673312 PFKFB4 ⇩ 1.33 0.012 
2706791 ZMAT3 ⇧ 1.37 0.026  3432754 PLBD2 ⇩ 1.35 0.027  3893086 SLC17A9 ⇩ 1.33 4.66E-03 
2426791 CLCC1 ⇩ 1.37 0.042  3553607 EIF5 ⇧ 1.35 0.024  3198289 C9orf123 ⇧ 1.33 0.047 
3294438 ANXA7 ⇧ 1.37 7.52E-03  3197318 AK3 ⇧ 1.35 0.012  3839305 POLD1 ⇩ 1.33 5.90E-03 
2621122 NBEAL2 ⇩ 1.36 0.028  2528275 FAM134A ⇩ 1.34 0.017  2777639 GPRIN3 ⇧ 1.32 0.033 
3706659 ASPA ⇧ 1.36 0.017  3656760 STX4 ⇧ 1.34 7.97E-03  3942384 MTFP1 ⇩ 1.32 0.029 
2899437 BTN2A1 ⇩ 1.36 7.34E-03  3644057 MAPK8IP3 ⇩ 1.34 9.73E-05  2888879 DOK3 ⇩ 1.32 0.045 
3521174 ABCC4 ⇧ 1.36 0.047  2642543 NUDT16P1 ⇧ 1.34 0.037  2335922 CDKN2C ⇧ 1.32 4.96E-03 
3127334 REEP4 ⇩ 1.36 0.040  3677612 ZNF597 ⇧ 1.34 0.026  3256689 PTEN ⇧ 1.32 3.32E-04 
3470964 GLTP ⇧ 1.36 0.039  3441011 PARP11 ⇧ 1.34 0.013  3864921 ZNF180 ⇧ 1.32 0.035 
2422885 GLMN ⇩ 1.36 0.039  3903598 GGT7 ⇩ 1.34 0.033  3367036 CCDC34 ⇩ 1.32 1.01E-03 
3474104 CIT ⇩ 1.36 0.020  3374856 MRPL16 ⇧ 1.34 0.039  3114600 TRMT12 ⇧ 1.32 6.32E-04 
2560122 MOGS ⇩ 1.36 0.036  3381241 ARAP1 ⇩ 1.34 2.41E-03  2974469 STX7 ⇧ 1.32 6.38E-03 
3611744 LRRK1 ⇩ 1.36 0.020  3447863 KRAS ⇧ 1.34 0.040  3007438 POM121 ⇩ 1.32 0.033 
3494102 UCHL3 ⇧ 1.36 0.031  3257268 IFIT5 ⇧ 1.34 0.030  2356142 LIX1L ⇧ 1.32 0.030 
2739242 GAR1 ⇧ 1.36 0.027  2902427 LST1 ⇧ 1.34 0.035  3836432 QPCTL ⇩ 1.32 0.017 
3885537 PLCG1 ⇩ 1.35 0.019  3771602 RHBDF2 ⇩ 1.34 0.016  3970130 SYAP1 ⇧ 1.32 0.044 
2422227 GEMIN8P4 ⇩ 1.35 0.032  3704980 FANCA ⇩ 1.34 0.024  3310413 ATE1 ⇧ 1.32 0.030 
2741901 KIAA1109 ⇩ 1.35 7.49E-03  2528620 GMPPA ⇩ 1.34 0.042  3282268 ACBD5 ⇧ 1.32 0.023 
3226181 ST6GALNAC4 ⇩ 1.35 0.012  3742783 NLRP1 ⇩ 1.34 0.030  3569200 ATP6V1D ⇧ 1.32 0.031 
2629782 EBLN2 ⇩ 1.35 0.018  3865586 FBXO46 ⇩ 1.33 0.016  3630668 CALML4 ⇩ 1.32 6.85E-03 
3767465 AXIN2 ⇩ 1.35 0.030  3387483 MTMR2 ⇧ 1.33 5.04E-03  3603408 PSMA4 ⇧ 1.31 0.032 
3644764 CCNF ⇩ 1.35 0.037  3954238 MAPK1 ⇧ 1.33 9.97E-03  3303478 SEC31B ⇩ 1.31 6.08E-03 
3019401 ZNF277 ⇧ 1.35 0.019  3696035 LCAT ⇩ 1.33 0.012  3945376 TOMM22 ⇧ 1.31 0.039 
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3253880 PPIF ⇩ 1.31 0.019  2327259 PPP1R8 ⇧ 1.30 1.38E-03  3333622 POLR2G ⇧ 1.28 0.046 
3945863 MGAT3 ⇩ 1.31 0.033  3536663 MAPK1IP1L ⇧ 1.30 9.78E-03  3025500 BPGM ⇧ 1.28 0.017 
3256590 PAPSS2 ⇧ 1.31 9.40E-03  3480508 IL17D ⇧ 1.30 0.028  3620054 RPAP1 ⇩ 1.28 0.030 
2619344 NKTR ⇩ 1.31 7.86E-03  3302328 EXOSC1 ⇧ 1.30 0.023  2365958 MPZL1 ⇩ 1.28 0.024 
3716893 ATAD5 ⇩ 1.31 0.035  7385611 HPCAL1 ⇩ 1.30 0.028  2694617 ISY1 ⇧ 1.28 0.038 
3000010 ZMIZ2 ⇩ 1.31 0.035  2891092 TRIM52 ⇩ 1.30 0.015  3475545 VPS33A ⇧ 1.28 0.039 
3657286 KIAA0664L3 ⇩ 1.31 0.023  3319613 RPL27A ⇩ 1.30 0.017  3405531 DDX47 ⇧ 1.28 0.046 
2944021 NHLRC1 ⇧ 1.31 0.048  3051753 FKBP9 ⇧ 1.30 0.039  3707352 RNF167 ⇩ 1.28 0.022 
3928040 RWDD2B ⇧ 1.31 0.027  3005332 CRCP ⇧ 1.29 0.039  3751164 DHRS13 ⇩ 1.28 0.031 
3303392 BLOC1S2 ⇧ 1.31 0.033  3969396 TCEANC ⇧ 1.29 0.034  3649052 MKL2 ⇧ 1.28 0.022 
2744674 RAB33B ⇧ 1.31 0.046  3452970 SENP1 ⇧ 1.29 0.031  2982319 SOD2 ⇧ 1.28 0.048 
3996755 BRCC3 ⇧ 1.31 0.023  3209497 FAM108B1 ⇧ 1.29 0.017  3960388 PLA2G6 ⇩ 1.28 0.011 
2681157 TMF1 ⇩ 1.31 0.037  3947123 SREBF2 ⇩ 1.29 3.00E-03  3826601 ZNF493 ⇧ 1.28 0.030 
2386828 EDARADD ⇧ 1.31 6.83E-03  3719362 AATF ⇧ 1.29 0.022  3843346 ZNF549 ⇧ 1.28 7.51E-03 
3027503 ADCK2 ⇩ 1.31 0.013  2439975 IGSF8 ⇩ 1.29 0.027  3594066 TMOD3 ⇧ 1.28 6.23E-04 
3578089 C14orf49 ⇩ 1.31 0.035  3591674 C15orf63 ⇩ 1.29 0.037  3965393 ALG12 ⇩ 1.28 0.037 
2786567 C4orf49 ⇧ 1.31 0.013  3333358 INCENP ⇩ 1.29 6.72E-03  3756344 SMARCE1 ⇧ 1.28 0.011 
2954355 CUL7 ⇩ 1.31 0.019  3339880 RELT ⇩ 1.29 0.014  3891643 C20orf177 ⇧ 1.28 0.043 
3310479 NSMCE4A ⇧ 1.31 6.16E-03  3378895 PITPNM1 ⇩ 1.29 0.015  3882533 CBFA2T2 ⇩ 1.28 0.040 
3835280 ZNF221 ⇧ 1.30 0.013  3260586 SCD ⇩ 1.29 9.20E-04  3031383 REPIN1 ⇩ 1.28 0.035 
3399623 THYN1 ⇩ 1.30 0.049  4027387 FAM3A ⇩ 1.29 4.91E-03  2913594 MTO1 ⇩ 1.28 0.046 
2771654 CENPC1 ⇩ 1.30 0.039  3414512 LARP4 ⇧ 1.29 0.049  2622859 HEMK1 ⇩ 1.27 0.013 
3325680 EIF3M ⇧ 1.30 0.022  3580876 PPP1R13B ⇧ 1.29 0.020  3317309 CD81 ⇩ 1.27 8.99E-04 
3765299 APPBP2 ⇧ 1.30 0.019  3948590 RIBC2 ⇧ 1.29 0.019  2955025 MRPL14 ⇩ 1.27 0.046 
2715580 SH3BP2 ⇩ 1.30 0.032  2559619 NAT8 ⇧ 1.29 0.047  3192653 GTF3C5 ⇩ 1.27 0.016 
3695916 CENPT ⇩ 1.30 2.56E-03  3428573 SPIC ⇧ 1.29 0.039  3439305 ZNF84 ⇧ 1.27 0.011 
3899551 RBBP9 ⇧ 1.30 0.027  3347549 CUL5 ⇧ 1.29 0.016  2544012 ATAD2B ⇩ 1.27 0.046 
2674963 MON1A ⇧ 1.30 0.035  3931329 DSCR3 ⇧ 1.29 0.027  3617412 LPCAT4 ⇩ 1.27 0.035 
2404521 PEF1 ⇧ 1.30 0.043  2436283 DENND4B ⇩ 1.29 0.010  3823625 AP1M1 ⇧ 1.27 0.021 
3204721 TPM2 ⇧ 1.30 0.038  3623683 GABPB1 ⇧ 1.29 0.025  2333168 C1orf84 ⇩ 1.27 0.039 
3099566 FAM110B ⇧ 1.30 7.69E-03  3499585 BIVM ⇧ 1.29 0.016  3576441 CCDC88C ⇩ 1.27 9.55E-03 
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3600212 LRRC49 ⇧ 1.27 0.035  3887049 UBE2C ⇩ 1.26 0.031  3689922 VPS35 ⇧ 1.25 0.013 
3841545 LILRA1 ⇧ 1.27 5.12E-03  3848871 CD320 ⇩ 1.26 0.024  3985218 ARMCX5 ⇧ 1.24 0.016 
2890859 MGAT1 ⇩ 1.27 0.043  3157138 LYPD2 ⇧ 1.26 0.026  3327906 API5 ⇧ 1.24 2.81E-03 
2950474 RXRB ⇩ 1.27 0.022  3692895 NUDT21 ⇧ 1.26 0.022  2900299 ZNF192 ⇩ 1.24 0.048 
3672661 FOXL1 ⇩ 1.27 0.027  3226709 C9orf114 ⇧ 1.26 0.040  2407729 RRAGC ⇧ 1.24 0.030 
3611049 LRRC28 ⇧ 1.27 0.037  3504392 N6AMT2 ⇧ 1.26 0.020  2904528 ZNF76 ⇩ 1.24 0.028 
3688424 C16orf58 ⇩ 1.27 0.030  3860208 ALKBH6 ⇩ 1.26 0.042  3244061 ZNF487P ⇧ 1.24 0.039 
3201277 KLHL9 ⇧ 1.27 0.022  2852742 AMACR ⇧ 1.26 0.029  3602526 FBXO22 ⇧ 1.24 0.023 
3918696 SON ⇧ 1.27 0.015  2609608 SETD5 ⇩ 1.25 0.015  2375011 ELF3 ⇧ 1.24 0.025 
2954423 MRPL2 ⇩ 1.27 0.048  2806376 SPEF2 ⇧ 1.25 0.015  2711225 ATP13A4 ⇩ 1.24 9.82E-03 
2888674 MXD3 ⇩ 1.27 0.021  3229797 QSOX2 ⇩ 1.25 0.037  2607020 MTERFD2 ⇩ 1.24 0.044 
3843399 ZNF134 ⇧ 1.26 0.045  3657367 ZNF267 ⇧ 1.25 0.027  3275611 ANKRD16 ⇧ 1.24 0.020 
3184940 DNAJC25 ⇩ 1.26 0.048  2493813 ZNF2 ⇧ 1.25 6.67E-03  3892561 FLJ44790 ⇧ 1.24 0.037 
3636470 BTBD1 ⇧ 1.26 0.014  2451155 PTPN7 ⇩ 1.25 6.46E-03  2903782 ITPR3 ⇩ 1.24 0.036 
3212277 C9orf64 ⇧ 1.26 0.024  3774635 FASN ⇩ 1.25 0.040  3294242 ECD ⇧ 1.24 0.028 
2395626 GPR157 ⇩ 1.26 0.042  3709327 CNTROB ⇩ 1.25 0.014  3224259 RBM18 ⇧ 1.24 0.041 
3487600 C13orf31 ⇧ 1.26 5.34E-03  3739827 GLOD4 ⇧ 1.25 0.011  3334749 PPP2R5B ⇩ 1.24 0.049 
4051226 SEMA4D ⇩ 1.26 4.91E-03  3391029 PPP2R1B ⇧ 1.25 1.91E-03  2907018 TAF8 ⇩ 1.23 0.047 
3599432 FEM1B ⇧ 1.26 0.020  2440018 DCAF8 ⇩ 1.25 4.58E-03  3377358 BATF2 ⇧ 1.23 0.041 
3482977 POLR1D ⇧ 1.26 7.06E-03  3677315 PKMYT1 ⇩ 1.25 0.036  2715076 WHSC1 ⇩ 1.23 0.032 
3555340 TEP1 ⇩ 1.26 0.037  3340410 NEU3 ⇧ 1.25 0.023  3204692 C9orf100 ⇩ 1.23 0.035 
2620985 TMIE ⇧ 1.26 0.047  3895297 DDRGK1 ⇩ 1.25 0.011  2633166 OR5K2 ⇩ 1.23 0.027 
3363979 PSMA1 ⇧ 1.26 0.016  4011768 SNX12 ⇧ 1.25 0.012  2348792 CCDC76 ⇩ 1.23 0.014 
3645253 SRRM2 ⇩ 1.26 2.65E-04  3590422 RTF1 ⇧ 1.25 0.036  3820921 SMARCA4 ⇩ 1.23 0.041 
3168309 RECK ⇧ 1.26 0.022  3334325 VEGFB ⇩ 1.25 0.031  2621917 WDR6 ⇩ 1.23 9.49E-03 
2488114 ZNF638 ⇩ 1.26 0.043  3874438 CDC25B ⇩ 1.25 0.010  3677356 HCFC1R1 ⇩ 1.23 0.018 
3195363 ARRDC1 ⇧ 1.26 0.013  3294476 ZMYND17 ⇩ 1.25 0.034  2325358 GRHL3 ⇧ 1.23 0.049 
3908631 PREX1 ⇩ 1.26 3.91E-03  3865776 IRF2BP1 ⇩ 1.25 1.17E-03  2333678 B4GALT2 ⇩ 1.23 0.036 
3221646 POLE3 ⇧ 1.26 0.045  2892738 PRPF4B ⇩ 1.25 0.049  2949588 DOM3Z ⇩ 1.23 0.034 
3228373 TSC1 ⇩ 1.26 0.021  3181600 GALNT12 ⇩ 1.25 0.049  3751323 MYO18A ⇩ 1.23 0.013 
3719150 PIGW ⇧ 1.26 0.041  3695631 TPPP3 ⇧ 1.25 0.048  3863021 TGFB1 ⇩ 1.23 0.014 
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3418513 MARCH9 ⇩ 1.23 0.037  2436338 CRTC2 ⇩ 1.22 0.036  3652424 EEF2K ⇩ 1.20 0.021 
2500875 CHCHD5 ⇩ 1.23 0.026  2949148 BAT3 ⇩ 1.22 0.012  3513883 KPNA3 ⇧ 1.20 0.036 
2829463 CAMLG ⇩ 1.23 0.039  2662956 VGLL4 ⇩ 1.22 0.025  3830712 MLL4 ⇩ 1.20 0.027 
3139722 NCOA2 ⇧ 1.23 0.034  3325307 ELP4 ⇧ 1.22 0.036  3016098 TRIM56 ⇩ 1.20 0.036 
3653619 LCMT1 ⇧ 1.23 0.015  3077766 TPK1 ⇧ 1.22 0.048  2655438 DVL3 ⇩ 1.20 1.84E-03 
3853063 ILVBL ⇩ 1.23 0.036  2358520 SETDB1 ⇩ 1.22 0.039  3195174 MAN1B1 ⇩ 1.20 7.53E-03 
2410574 LRRC41 ⇩ 1.23 0.032  2756673 GAK ⇩ 1.21 0.039  3863435 POU2F2 ⇩ 1.20 0.030 
3855410 SUGP2 ⇩ 1.22 4.99E-03  3432438 OAS1 ⇧ 1.21 0.012  2560149 CCDC142 ⇩ 1.20 4.94E-03 
2402601 UBXN11 ⇩ 1.22 6.18E-03  2977471 ADAT2 ⇩ 1.21 0.048  3642060 CHSY1 ⇩ 1.20 0.045 
2834093 TCERG1 ⇩ 1.22 0.030  3064230 GIGYF1 ⇩ 1.21 0.012  3224087 TTLL11 ⇧ 1.20 0.034 
3645881 ZNF174 ⇧ 1.22 0.028  3645402 FLYWCH1 ⇩ 1.21 0.030  2358171 PRPF3 ⇩ 1.20 0.016 
3475350 LOC338799 ⇩ 1.22 0.039  2335048 CYP4A22 ⇧ 1.21 8.26E-03  3742236 PELP1 ⇩ 1.20 8.47E-03 
3834674 CIC ⇩ 1.22 3.13E-03  2964052 SRSF12 ⇧ 1.21 0.016  3963754 SMC1B ⇧ 1.20 0.039 
3826542 ZNF738 ⇧ 1.22 0.012  3742384 SLC25A11 ⇧ 1.21 0.024  3223605 FBXW2 ⇧ 1.20 0.017 
3264004 SHOC2 ⇧ 1.22 0.040  3373962 UBE2L6 ⇧ 1.21 6.52E-03  2713016 C3orf34 ⇧ 1.20 0.041 
2643095 BFSP2 ⇧ 1.22 0.034  2641532 COPG ⇩ 1.21 0.049  2536625 BOK ⇧ 1.20 0.033 
3334604 LOC439914 ⇩ 1.22 0.044  3228097 TTF1 ⇩ 1.21 6.66E-03  2867145 FAM172A ⇧ 1.20 0.049 
3754227 MYO19 ⇩ 1.22 0.024  3742212 ALOX15 ⇧ 1.21 0.022  3748909 SLC47A2 ⇧ 1.20 0.033 
3807370 DYM ⇧ 1.22 0.045  3845365 TCF3 ⇩ 1.21 0.042  3707258 MINK1 ⇩ 1.20 4.83E-03 
3549708 SERPINA4 ⇧ 1.22 0.040  2582562 ACVR1 ⇧ 1.21 0.026  3595096 TCF12 ⇧ 1.20 7.03E-03 
3135452 ATP6V1H ⇧ 1.22 0.015  3483348 POMP ⇧ 1.20 0.046  2894711 TMEM14B ⇧ 1.20 9.40E-03 
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Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value 
4048241 HLA-DRB5 ⇩ 11.7 0.018  2766492 C4orf34 ⇧ 1.77 0.015  3257204 IFIT3 ⇧ 1.65 0.044 
3718555 SLFN5 ⇧ 2.97 0.023  2768981 SGCB ⇩ 1.77 0.046  3351841 HMBS ⇧ 1.65 0.019 
2821347 ERAP2 ⇧ 2.44 0.026  3507798 UBL3 ⇧ 1.76 1.62E-03  2899437 BTN2A1 ⇩ 1.65 2.24E-05 
2678298 DNASE1L3 ⇩ 2.40 0.026  2528159 WNT10A ⇩ 1.76 2.51E-03  3453036 ASB8 ⇧ 1.65 0.021 
3175971 PSAT1 ⇩ 2.26 0.019  2820865 ARSK ⇩ 1.76 0.013  3061805 SGCE ⇩ 1.64 0.014 
3456805 GTSF1 ⇧ 2.05 0.052  3945314 KDELR3 ⇩ 1.76 0.031  3782166 IMPACT ⇧ 1.64 4.75E-03 
3841621 LILRB4 ⇩ 2.04 0.020  3840194 ZNF880 ⇧ 1.76 1.55E-03  3380996 C11orf51 ⇧ 1.63 6.78E-04 
3856646 ZNF208 ⇧ 1.97 0.046  4007216 UXT ⇧ 1.75 2.47E-03  3916527 JAM2 ⇩ 1.63 0.022 
3892812 SLCO4A1 ⇩ 1.93 7.09E-04  3354443 SLC37A2 ⇩ 1.75 0.030  3761714 GNGT2 ⇧ 1.63 1.46E-03 
2887490 STC2 ⇩ 1.91 9.30E-03  3458587 DDIT3 ⇩ 1.74 0.018  3849752 ZNF426 ⇧ 1.63 1.15E-03 
3023883 CPA4 ⇩ 1.90 0.024  3433466 NCRNA00173 ⇩ 1.74 0.049  3911814 SLMO2 ⇧ 1.63 3.50E-05 
2734047 AGPAT9 ⇩ 1.90 0.017  3309602 RGS10 ⇧ 1.74 4.03E-03  3137875 GGH ⇩ 1.63 4.24E-03 
3439178 PXMP2 ⇧ 1.89 5.99E-03  2475678 LBH ⇧ 1.73 3.47E-04  3707199 PSMB6 ⇧ 1.62 8.93E-03 
2400518 ECE1 ⇩ 1.88 0.028  3741528 TAX1BP3 ⇧ 1.73 0.011  3311715 UROS ⇧ 1.62 4.57E-05 
3764738 SKA2 ⇧ 1.86 0.015  3216276 SLC35D2 ⇧ 1.72 0.014  3175119 OSTF1 ⇧ 1.62 0.013 
3913483 TCFL5 ⇧ 1.85 0.022  3236538 RPP38 ⇧ 1.72 2.73E-03  2638728 SLC15A2 ⇩ 1.62 0.016 
3925639 NRIP1 ⇧ 1.85 0.039  2786322 SLC7A11 ⇩ 1.72 0.024  3969422 RAB9A ⇧ 1.62 4.70E-03 
3333899 RARRES3 ⇧ 1.85 0.010  2909020 ENPP4 ⇩ 1.71 0.021  4035833 CD24 ⇧ 1.62 0.025 
3127745 TNFRSF10D ⇩ 1.84 7.50E-03  3727712 PCTP ⇧ 1.71 3.78E-03  3651639 TMEM159 ⇧ 1.62 7.43E-03 
2877893 MGC29506 ⇩ 1.84 0.012  3721989 CNTNAP1 ⇩ 1.71 0.029  3840142 ZNF480 ⇧ 1.62 0.031 
3043936 FKBP14 ⇩ 1.81 0.036  3839103 ATF5 ⇩ 1.70 0.050  3403244 CLSTN3 ⇩ 1.61 9.55E-04 
3703885 SLC7A5 ⇩ 1.81 3.73E-03  3402315 CD9 ⇩ 1.70 0.039  2756029 FRG1 ⇩ 1.61 0.021 
3476330 CCDC92 ⇧ 1.80 1.27E-03  3132016 FGFR1 ⇩ 1.69 0.019  2594497 CLK1 ⇩ 1.61 0.021 
3550328 C14orf129 ⇧ 1.80 0.010  3618736 RASGRP1 ⇩ 1.69 0.041  3670668 ATMIN ⇧ 1.61 5.26E-04 
3676262 SEPX1 ⇧ 1.79 8.12E-03  2908179 VEGFA ⇩ 1.69 4.18E-03  2949256 BAT5 ⇩ 1.61 1.28E-03 
3577940 CLMN ⇧ 1.79 0.053  2601414 SERPINE2 ⇩ 1.68 4.75E-03  3202316 MOBKL2B ⇧ 1.60 0.027 
3969946 ZRSR2 ⇧ 1.78 4.52E-03  3382061 XRRA1 ⇧ 1.68 5.68E-03  2725013 UCHL1 ⇩ 1.60 0.052 
3018866 DNAJB9 ⇩ 1.78 0.024  3936550 USP18 ⇧ 1.68 9.55E-03  2877639 SIL1 ⇩ 1.60 0.019 
3453405 FKBP11 ⇩ 1.78 7.39E-03  2845274 CCDC127 ⇩ 1.66 7.47E-03  3987446 ALG13 ⇧ 1.59 0.025 
3203382 SMU1 ⇧ 1.78 4.19E-03  2742109 FGF2 ⇧ 1.66 0.021  3057755 POMZP3 ⇧ 1.59 5.94E-03 
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3543673 ACOT2 ⇧ 1.59 0.021  3866276 SLC1A5 ⇩ 1.54 5.21E-03  3224197 NDUFA8 ⇧ 1.49 0.011 
3251353 ANAPC16 ⇧ 1.59 8.06E-04  2502424 INSIG2 ⇩ 1.54 0.015  3719362 AATF ⇧ 1.49 3.16E-04 
3994451 CXorf40A ⇧ 1.59 7.19E-04  3184218 C9orf6 ⇧ 1.54 0.015  3114832 SQLE ⇩ 1.49 7.36E-03 
2356115 TXNIP ⇧ 1.59 0.051  2452691 SLC41A1 ⇩ 1.54 0.046  3557947 CHMP4A ⇧ 1.49 0.014 
3663055 C16orf57 ⇧ 1.58 1.83E-03  2892277 NQO2 ⇩ 1.53 7.22E-03  3716411 CPD ⇩ 1.49 0.034 
3355021 FAM118B ⇧ 1.58 0.015  4010768 ZC4H2 ⇧ 1.53 8.94E-04  3890218 C20orf43 ⇧ 1.49 4.00E-03 
3840224 ZNF528 ⇧ 1.58 8.10E-03  3666686 NIP7 ⇧ 1.53 0.012  2320727 TNFRSF1B ⇩ 1.49 0.020 
3936442 PEX26 ⇧ 1.58 3.63E-03  4022106 MBNL3 ⇧ 1.53 0.012  2640579 PLXNA1 ⇩ 1.49 0.011 
2407478 FHL3 ⇧ 1.58 0.038  3996467 PLXNA3 ⇩ 1.52 6.71E-05  3507710 SLC7A1 ⇩ 1.48 1.93E-03 
2438892 FCRL5 ⇩ 1.58 0.052  3416909 BLOC1S1 ⇧ 1.52 7.43E-03  3333711 SLC3A2 ⇩ 1.48 2.90E-03 
3375999 C11orf48 ⇧ 1.58 0.035  3992408 FHL1 ⇧ 1.52 0.045  3244539 ZNF22 ⇧ 1.48 0.011 
3747199 CENPV ⇧ 1.58 0.023  3988538 IL13RA1 ⇩ 1.52 0.047  3101153 BHLHE22 ⇧ 1.48 0.033 
3156307 PTK2 ⇧ 1.58 0.031  3976670 EBP ⇩ 1.52 4.64E-03  3857105 ZNF91 ⇧ 1.48 0.040 
2643324 SRPRB ⇩ 1.57 0.016  3055608 TYW1B ⇩ 1.52 3.33E-03  3665230 HSF4 ⇩ 1.48 5.56E-03 
3263944 PDCD4 ⇧ 1.57 0.013  2384562 RAB4A ⇧ 1.52 4.18E-03  3190420 CERCAM ⇩ 1.48 6.54E-03 
3645338 PRSS21 ⇩ 1.57 0.034  2349848 PRMT6 ⇧ 1.52 1.68E-03  3907111 TOMM34 ⇧ 1.48 0.012 
3734355 GPRC5C ⇩ 1.56 0.047  3023060 CALU ⇩ 1.52 0.024  3866094 PTGIR ⇩ 1.48 0.013 
3893033 DPH3P1 ⇧ 1.56 0.048  2821981 FAM174A ⇩ 1.52 0.018  2409104 SLC2A1 ⇩ 1.48 0.027 
2837810 UBLCP1 ⇧ 1.56 0.033  3238962 KIAA1217 ⇩ 1.52 0.038  2794902 AGA ⇩ 1.48 0.040 
2826295 SNX2 ⇧ 1.56 6.84E-03  2443335 SLC19A2 ⇩ 1.51 0.026  3543619 C14orf169 ⇧ 1.48 0.044 
2379280 FLVCR1 ⇩ 1.56 0.015  2690850 TMEM39A ⇩ 1.51 0.034  3256560 MINPP1 ⇩ 1.47 0.019 
2324634 CDC42 ⇩ 1.56 0.018  2673547 SLC26A6 ⇩ 1.51 9.18E-04  3242425 CCNY ⇧ 1.47 0.014 
2562821 VPS24 ⇧ 1.56 2.44E-03  3100497 CLVS1 ⇧ 1.51 0.039  2951567 FKBP5 ⇧ 1.47 2.59E-03 
3002873 LANCL2 ⇧ 1.56 0.026  3407793 PYROXD1 ⇧ 1.51 0.032  3821015 LDLR ⇩ 1.47 1.21E-03 
3387537 MAML2 ⇧ 1.55 0.043  2954324 MEA1 ⇧ 1.51 4.40E-03  3440192 DCP1B ⇧ 1.47 0.011 
2375212 PPP1R12B ⇩ 1.55 5.78E-03  2560122 MOGS ⇩ 1.51 3.16E-03  3404436 CLEC2D ⇩ 1.47 0.024 
3434726 P2RX7 ⇩ 1.55 0.026  3053691 GUSB ⇩ 1.50 6.74E-03  3397589 ETS1 ⇧ 1.47 6.66E-03 
3697563 FTSJD1 ⇧ 1.55 2.21E-04  3945376 TOMM22 ⇧ 1.50 1.49E-03  3659966 ADCY7 ⇩ 1.47 6.84E-04 
3605268 TM6SF1 ⇩ 1.55 0.047  3633460 PTPN9 ⇧ 1.50 2.06E-03  3826803 ZNF492 ⇧ 1.47 0.047 
4013434 TAF9B ⇧ 1.55 0.011  3198289 C9orf123 ⇧ 1.49 3.05E-03  2320581 PLOD1 ⇩ 1.47 0.016 
3414695 ATF1 ⇧ 1.55 0.029  3950452 CRELD2 ⇩ 1.49 0.026  3254488 C10orf58 ⇩ 1.47 0.050 
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2318736 PARK7 ⇧ 1.47 2.98E-03  3130211 PPP2CB ⇧ 1.44 0.011  2395890 CLSTN1 ⇩ 1.42 0.017 
2899216 HIST1H4E ⇧ 1.47 0.030  3177111 NTRK2 ⇧ 1.44 7.62E-03  3225398 HSPA5 ⇩ 1.42 0.052 
3434393 DYNLL1 ⇧ 1.46 0.037  3617920 ATPBD4 ⇧ 1.44 2.84E-03  3628923 FAM96A ⇧ 1.42 0.035 
3230141 NOTCH1 ⇩ 1.46 5.98E-03  4027585 MPP1 ⇧ 1.43 0.053  2436826 KCNN3 ⇩ 1.42 0.040 
3726325 XYLT2 ⇩ 1.46 4.69E-03  3790704 PMAIP1 ⇧ 1.43 0.015  3590422 RTF1 ⇧ 1.42 7.71E-04 
3243908 CSGALNACT2 ⇩ 1.46 0.019  3986933 NXT2 ⇧ 1.43 4.54E-03  2829171 TCF7 ⇧ 1.42 0.038 
2899413 BTN3A3 ⇩ 1.46 6.13E-03  3380980 C11orf59 ⇧ 1.43 4.69E-03  4000132 TRAPPC2 ⇧ 1.42 0.021 
2439508 OR6N2 ⇧ 1.46 0.019  2888243 KIAA1191 ⇧ 1.43 7.89E-03  2562233 RETSAT ⇩ 1.42 0.014 
3595846 FAM63B ⇩ 1.46 8.19E-03  3277468 USP6NL ⇧ 1.43 0.049  3904527 NDRG3 ⇧ 1.42 0.011 
3888949 MOCS3 ⇧ 1.46 4.65E-03  3725083 SNX11 ⇧ 1.43 0.023  3076753 KIAA1147 ⇩ 1.42 0.039 
3928040 RWDD2B ⇧ 1.46 1.31E-03  3708826 EIF4A1 ⇧ 1.43 0.041  2639225 PDIA5 ⇩ 1.42 0.048 
4004819 DYNLT3 ⇧ 1.45 0.035  3931329 DSCR3 ⇧ 1.43 1.18E-03  3184940 DNAJC25 ⇩ 1.42 2.29E-03 
3892918 C20orf20 ⇧ 1.45 0.013  3860491 ZNF260 ⇧ 1.43 3.97E-06  3590341 CHP ⇧ 1.42 6.68E-03 
2495806 MRPL30 ⇧ 1.45 0.013  2912889 SMAP1 ⇧ 1.43 8.85E-03  3856184 ZNF737 ⇧ 1.42 0.016 
3793760 CNDP2 ⇧ 1.45 1.73E-03  3010082 PHTF2 ⇩ 1.43 0.014  3557898 TM9SF1 ⇩ 1.42 0.019 
3771602 RHBDF2 ⇩ 1.45 1.12E-03  3954525 ZNF280B ⇧ 1.43 4.68E-03  3387483 MTMR2 ⇧ 1.41 4.16E-04 
3886512 TTPAL ⇧ 1.45 0.013  3369762 COMMD9 ⇧ 1.43 0.027  2529546 ACSL3 ⇩ 1.41 0.029 
3564872 GNPNAT1 ⇧ 1.45 0.029  3840164 ZNF610 ⇧ 1.43 0.028  2706791 ZMAT3 ⇧ 1.41 7.57E-03 
2620538 LARS2 ⇩ 1.45 0.012  3899551 RBBP9 ⇧ 1.43 1.96E-03  3565524 GCH1 ⇧ 1.41 0.042 
2941784 NEDD9 ⇧ 1.45 6.68E-03  3625326 CCPG1 ⇩ 1.43 0.029  3836432 QPCTL ⇩ 1.41 1.71E-03 
2426791 CLCC1 ⇩ 1.45 9.54E-03  3375935 B3GAT3 ⇩ 1.43 6.17E-03  2878368 APBB3 ⇩ 1.41 2.04E-03 
3167383 NUDT2 ⇧ 1.45 8.25E-03  3747522 TNFRSF13B ⇩ 1.42 0.023  3201437 CDKN2A ⇧ 1.41 0.029 
3738629 SLC16A3 ⇩ 1.45 3.41E-03  3881282 HM13 ⇩ 1.42 0.015  3850576 YIPF2 ⇩ 1.41 0.025 
3883064 ACSS2 ⇩ 1.44 0.010  3227816 RAPGEF1 ⇩ 1.42 0.024  2957499 ICK ⇧ 1.41 7.36E-03 
2539765 ITGB1BP1 ⇧ 1.44 0.011  3954238 MAPK1 ⇧ 1.42 8.90E-04  3453556 PRKAG1 ⇧ 1.41 2.11E-03 
3031967 CHPF2 ⇩ 1.44 0.024  3340589 SERPINH1 ⇩ 1.42 0.038  3325680 EIF3M ⇧ 1.41 1.89E-03 
3489538 ARL11 ⇧ 1.44 9.86E-03  2356142 LIX1L ⇧ 1.42 3.62E-03  3394123 HYOU1 ⇩ 1.41 0.042 
3406421 STRAP ⇧ 1.44 6.13E-03  3607927 SEMA4B ⇩ 1.42 0.017  3351895 C2CD2L ⇩ 1.41 0.013 
3648306 SNN ⇧ 1.44 0.010  3531479 ARHGAP5 ⇧ 1.42 3.31E-03  2611848 SLC6A6 ⇩ 1.41 0.016 
3722338 IFI35 ⇧ 1.44 0.021  3494102 UCHL3 ⇧ 1.42 7.34E-03  3474104 CIT ⇩ 1.41 5.09E-03 
3486728 SLC25A15 ⇧ 1.44 0.015  3629378 MTFMT ⇧ 1.42 2.95E-03  3303300 CHUK ⇧ 1.41 0.035 
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3073981 AKR1B1 ⇧ 1.41 0.027  2565579 ANKRD39 ⇧ 1.40 8.68E-05  3434760 P2RX4 ⇩ 1.38 0.031 
2450668 TMEM9 ⇩ 1.41 0.029  3687789 DCTPP1 ⇧ 1.40 0.026  3742067 UBE2G1 ⇧ 1.38 4.47E-03 
3815014 BSG ⇩ 1.41 7.98E-03  2599955 ATG9A ⇩ 1.40 0.011  2704267 GOLIM4 ⇩ 1.38 0.014 
3558145 CIDEB ⇧ 1.41 0.018  3406493 DERA ⇧ 1.40 0.019  3078656 ZNF767 ⇩ 1.38 0.016 
3849797 ZNF561 ⇧ 1.41 3.39E-03  2464484 FAM36A ⇩ 1.39 0.017  2360989 MSTO1 ⇩ 1.38 0.038 
3946351 ADSL ⇧ 1.41 1.21E-03  2835576 SYNPO ⇧ 1.39 0.015  3328214 ALKBH3 ⇧ 1.38 8.33E-03 
3588658 C15orf41 ⇧ 1.41 0.016  3317309 CD81 ⇩ 1.39 6.95E-06  3597977 TRIP4 ⇧ 1.38 5.27E-03 
3861302 YIF1B ⇩ 1.41 0.047  2815965 HMGCR ⇩ 1.39 0.019  2899333 BTN3A2 ⇩ 1.38 0.031 
3197318 AK3 ⇧ 1.40 2.07E-03  3881874 ASXL1 ⇩ 1.39 4.56E-03  3712363 MPRIP ⇩ 1.38 0.021 
2396461 SRM ⇧ 1.40 9.65E-03  2758043 MFSD10 ⇩ 1.39 3.58E-03  2621122 NBEAL2 ⇩ 1.38 0.014 
3442854 SLC2A3 ⇩ 1.40 0.022  3708074 XAF1 ⇧ 1.39 9.97E-03  3824197 MRPL34 ⇧ 1.38 0.015 
3517793 KLF12 ⇧ 1.40 0.026  3065638 DNAJC2 ⇩ 1.39 0.024  2741901 KIAA1109 ⇩ 1.38 2.33E-03 
2567583 RNF149 ⇩ 1.40 0.011  3607183 MRPS11 ⇧ 1.39 2.60E-03  3677612 ZNF597 ⇧ 1.38 8.47E-03 
2579572 ZEB2 ⇧ 1.40 0.025  3257670 PCGF5 ⇧ 1.39 0.018  2730531 UTP3 ⇧ 1.38 0.029 
2739242 GAR1 ⇧ 1.40 8.12E-03  3748432 FAM106A ⇩ 1.39 2.10E-03  3145240 C8orf37 ⇧ 1.38 0.053 
3579205 SETD3 ⇧ 1.40 2.97E-03  2617563 MYD88 ⇧ 1.39 0.017  3148582 EIF3E ⇧ 1.38 0.027 
3750685 SLC46A1 ⇩ 1.40 0.020  3023384 AHCYL2 ⇧ 1.39 0.018  3617412 LPCAT4 ⇩ 1.38 3.27E-03 
3962219 NAGA ⇩ 1.40 0.019  3986514 PRPS1 ⇧ 1.39 0.040  3698055 TXNL4B ⇧ 1.37 0.026 
2813414 CCNB1 ⇩ 1.40 0.035  3127334 REEP4 ⇩ 1.39 0.017  2574798 MAP3K2 ⇧ 1.37 5.40E-03 
3589972 CHST14 ⇩ 1.40 7.09E-03  2407729 RRAGC ⇧ 1.39 7.77E-04  3704376 FAM38A ⇩ 1.37 7.78E-03 
3820370 P2RY11 ⇩ 1.40 0.028  3317915 STIM1 ⇩ 1.39 9.63E-03  3686080 NSMCE1 ⇧ 1.37 0.023 
2503200 RALB ⇧ 1.40 0.027  2409004 LEPRE1 ⇩ 1.39 0.020  3872560 ZNF256 ⇧ 1.37 4.99E-03 
2620641 LIMD1 ⇩ 1.40 0.031  2439975 IGSF8 ⇩ 1.39 2.91E-03  3260586 SCD ⇩ 1.37 2.49E-05 
2889698 CLK4 ⇩ 1.40 0.028  3285552 ZNF248 ⇩ 1.39 0.045  2696379 ANAPC13 ⇧ 1.37 0.029 
3806253 ATP5A1 ⇧ 1.40 0.022  3590164 SPINT1 ⇩ 1.39 0.037  3774096 PDE6G ⇧ 1.37 0.027 
2594435 KCTD18 ⇧ 1.40 1.45E-03  3823625 AP1M1 ⇧ 1.39 1.12E-03  3982811 SH3BGRL ⇧ 1.37 7.51E-03 
4027813 F8A1 ⇧ 1.40 7.34E-03  3453120 ZNF641 ⇧ 1.39 0.030  3064541 PLOD3 ⇩ 1.37 6.08E-03 
2668035 DYNC1LI1 ⇧ 1.40 0.016  2721777 PI4K2B ⇧ 1.39 0.027  2642543 NUDT16P1 ⇧ 1.37 0.014 
3657286 KIAA0664L3 ⇩ 1.40 2.92E-03  3535628 GNG2 ⇧ 1.38 0.027  3452970 SENP1 ⇧ 1.37 5.06E-03 
2331158 AKIRIN1 ⇧ 1.40 6.05E-03  3848871 CD320 ⇩ 1.38 9.95E-04  3559794 C14orf126 ⇧ 1.37 0.017 
2929036 LTV1 ⇧ 1.40 0.028  3441011 PARP11 ⇧ 1.38 3.18E-03  3893086 SLC17A9 ⇩ 1.37 7.84E-04 
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3575567 FOXN3 ⇧ 1.37 4.13E-03  2934308 IGF2R ⇩ 1.36 7.87E-03  4002148 EIF1AX ⇧ 1.35 0.050 
3692895 NUDT21 ⇧ 1.37 1.15E-03  3699707 ADAT1 ⇧ 1.36 0.029  3380697 DHCR7 ⇩ 1.35 0.052 
2402111 C1orf63 ⇩ 1.37 0.016  2473149 NCOA1 ⇧ 1.36 0.023  3294438 ANXA7 ⇧ 1.35 4.88E-03 
3833443 PLD3 ⇩ 1.37 0.016  3823583 HSH2D ⇧ 1.36 0.035  2437753 KIAA0907 ⇩ 1.35 0.010 
3075932 PARP12 ⇧ 1.37 0.046  2902633 MSH5 ⇩ 1.36 0.011  2694617 ISY1 ⇧ 1.35 7.40E-03 
3841474 LENG8 ⇩ 1.37 2.48E-03  2599993 ABCB6 ⇩ 1.36 4.94E-03  3852565 ASF1B ⇧ 1.35 0.024 
3974904 NYX ⇧ 1.37 0.032  2494749 CNNM3 ⇩ 1.36 0.016  3717737 PSMD11 ⇧ 1.35 0.012 
2815455 UTP15 ⇧ 1.37 0.037  3354764 STT3A ⇩ 1.36 0.026  3592484 PLDN ⇧ 1.35 0.025 
3114600 TRMT12 ⇧ 1.37 6.13E-05  3823613 FAM32A ⇧ 1.36 0.028  2901333 ZNRD1 ⇧ 1.35 0.017 
2713789 ZNF595 ⇧ 1.37 0.039  3480681 MRP63 ⇧ 1.36 0.036  2404521 PEF1 ⇧ 1.35 0.013 
3743906 TP53 ⇧ 1.37 0.043  2903782 ITPR3 ⇩ 1.36 1.92E-03  3031345 LRRC61 ⇧ 1.35 3.26E-03 
3375545 FADS1 ⇩ 1.37 0.014  3996381 ATP6AP1 ⇩ 1.36 0.019  2403557 SNORA44 ⇩ 1.35 0.012 
2782292 C4orf21 ⇩ 1.37 0.052  3886639 YWHAB ⇧ 1.36 0.015  3412296 IRAK4 ⇧ 1.35 0.011 
3600212 LRRC49 ⇧ 1.36 3.72E-03  3824471 GLT25D1 ⇩ 1.36 0.034  2674748 CDHR4 ⇧ 1.35 6.32E-03 
2656569 DNAJB11 ⇩ 1.36 0.041  4017519 PSMD10 ⇧ 1.36 4.72E-03  2982319 SOD2 ⇧ 1.35 0.011 
2320472 CLCN6 ⇩ 1.36 0.026  3886179 IFT52 ⇧ 1.35 2.93E-03  3724989 CDK5RAP3 ⇩ 1.34 0.013 
3845352 UQCR11 ⇧ 1.36 0.036  3619595 FAM82A2 ⇩ 1.35 8.86E-03  3678147 NMRAL1 ⇧ 1.34 0.028 
3318731 DNHD1 ⇩ 1.36 0.032  2872471 DTWD2 ⇧ 1.35 0.026  3417371 ESYT1 ⇩ 1.34 0.034 
3980035 YIPF6 ⇩ 1.36 3.78E-03  3042012 C7orf31 ⇧ 1.35 0.027  3976120 INE1 ⇩ 1.34 4.45E-03 
3816834 NCLN ⇩ 1.36 2.46E-03  2949471 NEU1 ⇩ 1.35 0.019  3685610 ARHGAP17 ⇧ 1.34 0.027 
2898499 ALDH5A1 ⇧ 1.36 8.02E-03  3209497 FAM108B1 ⇧ 1.35 2.77E-03  2968144 OSTM1 ⇩ 1.34 0.011 
3728097 AKAP1 ⇩ 1.36 1.28E-03  2726483 OCIAD1 ⇩ 1.35 0.043  3991698 HPRT1 ⇧ 1.34 0.031 
3389273 CASP4 ⇧ 1.36 0.023  2336706 CPT2 ⇧ 1.35 4.40E-03  3373893 SLC43A1 ⇩ 1.34 0.025 
3687452 YPEL3 ⇧ 1.36 0.039  3304746 USMG5 ⇧ 1.35 0.038  3554282 INF2 ⇩ 1.34 0.026 
4011768 SNX12 ⇧ 1.36 3.76E-04  2365958 MPZL1 ⇩ 1.35 3.53E-03  4006416 FUNDC1 ⇧ 1.34 0.041 
2485784 ACTR2 ⇧ 1.36 0.036  3303478 SEC31B ⇩ 1.35 1.23E-03  3290785 CCDC6 ⇧ 1.34 9.95E-03 
3962054 NHP2L1 ⇧ 1.36 9.55E-03  3319685 C11orf17 ⇧ 1.35 0.026  2899506 HMGN4 ⇧ 1.34 0.012 
3832616 EIF3K ⇧ 1.36 9.32E-03  2564634 ZNF514 ⇩ 1.35 0.011  3476097 CDK2AP1 ⇧ 1.34 0.048 
3318844 DNHD1 ⇩ 1.36 3.96E-03  3970130 SYAP1 ⇧ 1.35 0.018  3653619 LCMT1 ⇧ 1.34 3.37E-04 
3943207 YWHAH ⇧ 1.36 0.053  2392584 TNFRSF14 ⇩ 1.35 0.023  2824286 SRP19 ⇧ 1.34 0.031 
3831260 ZNF146 ⇧ 1.36 6.04E-03  3255402 FAM190B ⇧ 1.35 8.76E-03  3286921 MARCH8 ⇧ 1.34 9.38E-03 
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3210457 RFK ⇧ 1.34 7.65E-03  3280902 DNAJC1 ⇩ 1.33 0.037  3129121 CCDC25 ⇧ 1.32 0.016 
3846900 C19orf10 ⇩ 1.34 0.015  3850832 TMEM205 ⇩ 1.33 0.017  3578089 C14orf49 ⇩ 1.32 0.016 
2642562 NUDT16 ⇧ 1.34 3.89E-03  3413875 TROAP ⇩ 1.33 3.31E-03  3879467 XRN2 ⇧ 1.32 7.14E-03 
3555340 TEP1 ⇩ 1.34 5.43E-03  2726323 SLAIN2 ⇧ 1.33 6.02E-04  4017281 N⇧62CL ⇩ 1.32 0.042 
3927226 APP ⇩ 1.34 0.051  3873629 SIRPA ⇩ 1.33 0.039  3806913 SMAD2 ⇧ 1.32 9.08E-03 
3591044 HAUS2 ⇧ 1.34 0.011  2489035 DGUOK ⇧ 1.33 0.020  3758148 CCDC56 ⇧ 1.32 0.030 
3682135 C16orf63 ⇧ 1.34 0.024  3843399 ZNF134 ⇧ 1.33 9.33E-03  3644057 MAPK8IP3 ⇩ 1.32 4.93E-05 
3496916 GPR180 ⇩ 1.34 0.015  3643813 GNPTG ⇩ 1.33 0.037  3775147 FOXK2 ⇩ 1.32 0.012 
3260666 HIF1AN ⇧ 1.34 7.48E-03  3560575 EAPP ⇧ 1.33 1.93E-03  2690776 B4GALT4 ⇩ 1.32 0.018 
3227121 C9orf78 ⇧ 1.34 0.017  3173831 FXN ⇧ 1.33 0.029  3757745 GHDC ⇩ 1.32 5.30E-03 
3565361 GMFB ⇧ 1.34 0.032  3226138 AK1 ⇩ 1.33 0.038  3378895 PITPNM1 ⇩ 1.32 4.06E-03 
2414998 MYSM1 ⇩ 1.34 0.014  2815791 HEXB ⇩ 1.33 0.020  4053534 ISG15 ⇧ 1.32 0.037 
3896034 RASSF2 ⇧ 1.34 9.45E-03  2986825 SUN1 ⇩ 1.33 9.93E-03  3142554 SNX16 ⇩ 1.32 0.040 
3914307 RGS19 ⇧ 1.34 0.031  2878662 DIAPH1 ⇩ 1.33 0.028  3007438 POM121 ⇩ 1.32 0.019 
3104260 PKIA ⇧ 1.34 4.52E-03  3416522 COPZ1 ⇧ 1.33 0.047  2694397 RPN1 ⇩ 1.32 0.042 
2734992 NUDT9 ⇩ 1.33 0.036  3909395 DPM1 ⇧ 1.33 0.014  3629350 SPG21 ⇧ 1.32 0.011 
2824872 AP3S1 ⇧ 1.33 0.036  3340066 PAAF1 ⇧ 1.33 0.024  3226709 C9orf114 ⇧ 1.32 8.82E-03 
3127878 ENTPD4 ⇩ 1.33 0.024  2505957 PLEKHB2 ⇧ 1.33 0.026  3969396 TCEANC ⇧ 1.32 0.013 
3855910 ATP13A1 ⇩ 1.33 0.038  3339880 RELT ⇩ 1.33 3.47E-03  3719150 PIGW ⇧ 1.32 8.16E-03 
3952543 SLC25A1 ⇧ 1.33 0.047  2899340 BTN2A2 ⇩ 1.33 0.030  2672712 SCAP ⇩ 1.32 0.027 
3687475 GDPD3 ⇩ 1.33 0.013  3851826 DNASE2 ⇩ 1.33 0.037  3714068 ALDH3A2 ⇧ 1.32 0.027 
3056414 RFC2 ⇧ 1.33 0.047  3980560 KIF4A ⇩ 1.33 0.035  2703217 KPNA4 ⇧ 1.32 0.021 
3667766 KIAA0174 ⇧ 1.33 0.026  2848464 DAP ⇧ 1.33 0.033  3996755 BRCC3 ⇧ 1.32 0.010 
2676041 WDR82 ⇧ 1.33 0.036  3869379 ZNF614 ⇧ 1.33 0.035  3632940 UBL7 ⇧ 1.32 3.88E-05 
3444180 KLRAP1 ⇩ 1.33 0.053  3318443 TRIM22 ⇧ 1.33 0.016  3362795 RNF141 ⇧ 1.32 0.022 
2398789 SDHB ⇧ 1.33 0.031  3783749 RNF138 ⇧ 1.33 0.013  2729884 UGT2B10 ⇩ 1.32 0.012 
3893910 TCEA2 ⇧ 1.33 4.16E-03  3240095 RAB18 ⇧ 1.33 0.049  3934867 POFUT2 ⇩ 1.32 0.025 
3742783 NLRP1 ⇩ 1.33 0.019  3611049 LRRC28 ⇧ 1.32 8.09E-03  3759305 CCDC43 ⇧ 1.32 0.016 
2538000 RNASEH1 ⇧ 1.33 0.018  3625271 RAB27A ⇧ 1.32 0.043  2722377 STIM2 ⇩ 1.32 0.044 
2484752 COMMD1 ⇧ 1.33 0.053  3765299 APPBP2 ⇧ 1.32 7.09E-03  2428501 SLC16A1 ⇩ 1.32 0.022 
3806689 HDHD2 ⇧ 1.33 7.71E-03  3064638 RABL5 ⇧ 1.32 2.51E-03  3014714 ARPC1B ⇧ 1.32 0.016 
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3726960 NME2 ⇧ 1.32 0.035  3986230 CXorf57 ⇩ 1.31 6.15E-03  3893760 TPD52L2 ⇧ 1.30 0.015 
3569200 ATP6V1D ⇧ 1.32 0.018  3866605 NAPA ⇧ 1.31 0.012  3936256 BCL2L13 ⇧ 1.30 9.74E-03 
3567984 PPP2R5E ⇧ 1.32 0.017  2374422 C1orf106 ⇩ 1.31 0.013  3844897 C19orf6 ⇩ 1.30 0.015 
2454378 SLC30A1 ⇩ 1.32 0.029  2542737 LAPTM4A ⇩ 1.31 0.016  2707359 DNAJC19 ⇩ 1.30 0.014 
3891643 C20orf177 ⇧ 1.32 0.013  3446868 LDHB ⇧ 1.31 0.024  2359329 LCE3B ⇧ 1.30 0.016 
3202171 PLAA ⇧ 1.32 0.029  3302328 EXOSC1 ⇧ 1.31 0.010  3822805 TECR ⇩ 1.30 0.032 
2327259 PPP1R8 ⇧ 1.32 3.11E-04  3191338 GPR107 ⇩ 1.31 0.031  3752002 CRLF3 ⇧ 1.30 0.022 
2761941 TAPT1 ⇩ 1.32 0.042  3348852 DLAT ⇧ 1.31 2.78E-03  2572601 CCDC93 ⇩ 1.30 1.39E-03 
3458614 DCTN2 ⇧ 1.32 7.00E-03  2711644 ATP13A3 ⇩ 1.31 0.029  3134922 PCMTD1 ⇧ 1.30 0.037 
2954280 PEX6 ⇩ 1.32 3.88E-03  3990512 SASH3 ⇧ 1.31 0.050  3436236 ZNF664 ⇧ 1.30 1.03E-03 
3969047 PRPS2 ⇧ 1.32 5.00E-03  3432678 TPCN1 ⇩ 1.31 0.019  3828032 POP4 ⇧ 1.30 0.018 
2434633 ARNT ⇧ 1.32 5.74E-03  3734453 SLC9A3R1 ⇧ 1.31 0.024  2327630 YTHDF2 ⇧ 1.30 0.038 
3945863 MGAT3 ⇩ 1.32 0.019  3945056 EIF3L ⇧ 1.31 6.88E-03  2528275 FAM134A ⇩ 1.30 0.021 
3629206 OAZ2 ⇧ 1.32 9.51E-03  3888850 BCAS4 ⇧ 1.31 0.042  3368707 CD59 ⇩ 1.30 0.023 
3882949 DYNLRB1 ⇧ 1.32 0.014  3608095 ZNF774 ⇧ 1.31 0.013  3603199 IDH3A ⇧ 1.30 0.010 
2330393 C1orf113 ⇩ 1.32 0.010  3426215 MRPL42 ⇧ 1.31 0.027  3743486 GABARAP ⇧ 1.30 6.13E-04 
3377933 EFEMP2 ⇩ 1.32 0.022  3774635 FASN ⇩ 1.31 8.79E-03  2916246 C6orf162 ⇧ 1.30 0.033 
3580876 PPP1R13B ⇧ 1.32 6.69E-03  2712632 TFRC ⇩ 1.31 0.013  3256689 PTEN ⇧ 1.30 2.66E-04 
3662041 OGFOD1 ⇧ 1.32 0.013  3825141 C19orf50 ⇧ 1.31 6.42E-04  2377427 CD46 ⇩ 1.30 3.09E-03 
3005332 CRCP ⇧ 1.32 0.017  3364119 CYP2R1 ⇧ 1.31 0.036  3464983 ATP2B1 ⇩ 1.30 0.030 
3665116 CBFB ⇧ 1.31 0.026  4003954 TAB3 ⇧ 1.31 4.64E-03  2358171 PRPF3 ⇩ 1.30 4.99E-04 
3205162 RNF38 ⇧ 1.31 4.12E-04  3127579 FLJ14107 ⇩ 1.31 0.051  3310413 ATE1 ⇧ 1.30 0.026 
2902427 LST1 ⇧ 1.31 0.033  3864921 ZNF180 ⇧ 1.31 0.027  3841231 PRPF31 ⇧ 1.30 0.014 
3048778 TMED4 ⇩ 1.31 0.027  2695648 ACAD11 ⇩ 1.31 0.016  2406597 TRAPPC3 ⇧ 1.30 0.023 
2924492 HEY2 ⇧ 1.31 0.053  2367537 C1orf9 ⇩ 1.31 0.045  2822215 PAM ⇩ 1.30 0.016 
3421523 YEATS4 ⇧ 1.31 0.052  3687870 ZNF688 ⇧ 1.31 7.27E-03  3828162 C19orf2 ⇧ 1.30 0.019 
3168841 GRHPR ⇧ 1.31 6.66E-03  3644764 CCNF ⇩ 1.31 0.041  3563734 SOS2 ⇧ 1.30 1.15E-03 
2610317 C3orf10 ⇧ 1.31 4.24E-03  3666649 VPS4A ⇧ 1.31 0.037  3636470 BTBD1 ⇧ 1.30 2.86E-03 
3742384 SLC25A11 ⇧ 1.31 8.78E-04  3566304 EXOC5 ⇧ 1.31 7.39E-03  2708610 MAGEF1 ⇧ 1.30 0.015 
3513883 KPNA3 ⇧ 1.31 1.51E-03  3380769 KRTAP5-11 ⇧ 1.30 0.031  3451318 ZCRB1 ⇧ 1.30 5.80E-03 
3740304 PITPNA ⇧ 1.31 0.026  2901620 HLA-E ⇩ 1.30 0.013  3965393 ALG12 ⇩ 1.30 0.014 
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3883787 C20orf4 ⇧ 1.30 2.96E-03  3690084 DNAJA2 ⇧ 1.29 0.053  2901660 PRR3 ⇧ 1.28 0.044 
3818897 PNPLA6 ⇩ 1.30 1.14E-03  3757630 KAT2A ⇩ 1.29 0.032  3699044 RFWD3 ⇧ 1.28 0.037 
2484552 AHSA2 ⇩ 1.30 0.023  2622859 HEMK1 ⇩ 1.29 4.99E-03  3878934 NAA20 ⇧ 1.28 0.048 
3513096 ESD ⇧ 1.30 0.023  3885537 PLCG1 ⇩ 1.29 0.028  3347549 CUL5 ⇧ 1.28 9.37E-03 
2903285 PSMB9 ⇧ 1.30 0.019  3191589 FUBP3 ⇧ 1.29 0.039  3944922 TRIOBP ⇧ 1.28 1.13E-03 
3988874 UBE2A ⇧ 1.30 0.021  2364155 UHMK1 ⇧ 1.29 6.03E-03  3435681 ARL6IP4 ⇧ 1.28 0.020 
3775842 TYMS ⇧ 1.30 0.029  2771654 CENPC1 ⇩ 1.29 0.031  3779684 PSMG2 ⇧ 1.28 0.019 
3680610 GSPT1 ⇧ 1.30 9.36E-03  3696454 CHTF8 ⇧ 1.29 0.022  3252170 ADK ⇧ 1.28 8.02E-03 
3375582 FADS3 ⇩ 1.30 0.023  3418436 OS9 ⇩ 1.29 0.053  2603897 TIGD1 ⇩ 1.28 0.043 
3831168 CAPNS1 ⇧ 1.30 3.58E-03  3190737 TBC1D13 ⇧ 1.29 8.39E-03  3139950 LACTB2 ⇧ 1.28 0.051 
3352813 TBCEL ⇧ 1.30 0.050  3869954 ZNF321 ⇧ 1.29 0.047  3817072 GIPC3 ⇧ 1.28 0.011 
3772090 TMC6 ⇩ 1.30 9.35E-03  3788270 ELAC1 ⇧ 1.29 0.041  3872542 ZNF418 ⇧ 1.28 0.020 
3333622 POLR2G ⇧ 1.30 0.022  3860824 ZNF569 ⇧ 1.29 1.67E-03  3063337 ZNF394 ⇧ 1.28 0.018 
3933331 C2CD2 ⇩ 1.30 0.014  3774701 CCDC57 ⇩ 1.29 0.035  3707352 RNF167 ⇩ 1.28 0.012 
3447863 KRAS ⇧ 1.30 0.040  2776998 KLHL8 ⇧ 1.29 5.52E-03  3217123 TRIM14 ⇧ 1.28 0.031 
3633794 ETFA ⇧ 1.30 0.014  3315549 PSMD13 ⇧ 1.29 9.36E-03  3710681 MAP2K4 ⇧ 1.28 0.028 
3434142 PRKAB1 ⇧ 1.30 0.010  2336302 ZFYVE9 ⇧ 1.29 0.032  3645881 ZNF174 ⇧ 1.28 3.83E-03 
2571457 CKAP2L ⇩ 1.30 0.022  3035049 C7orf50 ⇧ 1.29 0.018  2681157 TMF1 ⇩ 1.28 0.033 
3750625 POLDIP2 ⇧ 1.30 7.60E-03  2622359 RBM6 ⇩ 1.29 0.044  3329904 NDUFS3 ⇧ 1.28 0.023 
3681674 NTAN1 ⇧ 1.30 0.034  3706659 ASPA ⇧ 1.29 0.031  3849865 FBXL12 ⇧ 1.28 0.031 
3454662 CSRNP2 ⇧ 1.30 0.049  3751164 DHRS13 ⇩ 1.29 0.016  2553576 RTN4 ⇩ 1.28 0.021 
2950590 RGL2 ⇩ 1.29 0.050  3822657 CD97 ⇩ 1.29 9.23E-03  3945877 SMCR7L ⇧ 1.28 1.29E-03 
3536663 MAPK1IP1L ⇧ 1.29 5.48E-03  3688424 C16orf58 ⇩ 1.29 0.012  3859026 PEPD ⇧ 1.28 0.029 
3505937 CENPJ ⇩ 1.29 0.020  3375951 GANAB ⇩ 1.29 0.021  3653123 PRKCB ⇧ 1.28 0.021 
3405531 DDX47 ⇧ 1.29 0.024  3269065 LHPP ⇧ 1.29 5.33E-03  2404999 MARCKSL1 ⇧ 1.28 0.023 
3887107 ZSWIM1 ⇧ 1.29 0.022  3056108 BCL7B ⇧ 1.29 0.030  3764384 S⇧T4H1 ⇧ 1.28 7.35E-03 
3721548 CNP ⇧ 1.29 0.053  3851603 DHPS ⇧ 1.29 3.39E-03  3140640 STAU2 ⇧ 1.28 0.035 
2921022 GPR6 ⇧ 1.29 0.017  2320762 VPS13D ⇩ 1.29 0.012  2589255 FKBP7 ⇩ 1.28 0.051 
3855506 TMEM161A ⇩ 1.29 0.025  2877257 BRD8 ⇩ 1.29 0.027  3758157 BECN1 ⇧ 1.28 0.036 
3591674 C15orf63 ⇩ 1.29 0.023  3462949 OSBPL8 ⇧ 1.29 0.042  3415273 C12orf44 ⇧ 1.28 0.036 
2536298 SEPT2 ⇧ 1.29 3.97E-03  3475545 VPS33A ⇧ 1.29 0.020  3971367 YY2 ⇩ 1.28 0.043 
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2939814 RPP40 ⇧ 1.28 3.79E-03  3580319 CINP ⇧ 1.27 0.028  3015216 COPS6 ⇧ 1.26 0.031 
2458513 TMEM63A ⇩ 1.28 0.041  2427342 ALX3 ⇧ 1.27 0.011  3005280 VKORC1L1 ⇧ 1.26 0.020 
2384956 COG2 ⇧ 1.28 0.032  3706651 OR3A3 ⇩ 1.27 0.041  3722152 PSME3 ⇧ 1.26 0.050 
2892738 PRPF4B ⇩ 1.28 0.019  3553607 EIF5 ⇧ 1.27 0.042  3757664 RAB5C ⇧ 1.26 4.95E-03 
3809324 TXNL1 ⇧ 1.28 0.010  2486811 PLEK ⇧ 1.27 0.042  3381241 ARAP1 ⇩ 1.26 6.16E-03 
3035682 FTSJ2 ⇧ 1.28 0.039  2827156 PHAX ⇧ 1.27 0.025  3471374 PPP1CC ⇧ 1.26 2.72E-03 
3581132 AKT1 ⇧ 1.28 8.65E-03  3195174 MAN1B1 ⇩ 1.27 3.78E-04  3057650 YWHAG ⇧ 1.26 0.027 
3807370 DYM ⇧ 1.28 8.12E-03  2336497 ZYG11B ⇧ 1.27 0.034  3506648 GPR12 ⇧ 1.26 2.50E-03 
3894228 CSNK2A1 ⇧ 1.28 2.46E-03  3896524 TRMT6 ⇧ 1.27 0.039  3843346 ZNF549 ⇧ 1.26 6.15E-03 
2893847 SNRNP48 ⇩ 1.28 0.030  3301218 PDLIM1 ⇧ 1.27 0.030  2866576 MBLAC2 ⇧ 1.26 0.027 
2924619 TRMT11 ⇩ 1.28 0.040  3541137 EIF2S1 ⇧ 1.27 0.029  3961981 POLR3H ⇧ 1.26 0.044 
3923218 RRP1B ⇧ 1.28 9.75E-03  3578152 TCL1A ⇧ 1.27 0.039  2899519 ABT1 ⇧ 1.26 0.029 
3929821 CRYZL1 ⇩ 1.28 0.035  2545092 HADHA ⇧ 1.27 0.014  3816424 SPPL2B ⇩ 1.26 0.032 
3624697 ARPP19 ⇧ 1.27 0.013  3264004 SHOC2 ⇧ 1.27 8.61E-03  3698919 GLG1 ⇩ 1.26 0.015 
2610136 CRELD1 ⇩ 1.27 0.042  3435853 TMED2 ⇩ 1.27 7.10E-03  3502632 TMCO3 ⇩ 1.26 0.021 
3391029 PPP2R1B ⇧ 1.27 3.57E-04  3909064 TMEM189 ⇧ 1.27 0.017  2817386 PAPD4 ⇧ 1.26 0.011 
3976519 RBM3 ⇧ 1.27 4.65E-03  2619344 NKTR ⇩ 1.27 0.010  3880706 ENTPD6 ⇩ 1.26 0.025 
3866302 AP2S1 ⇧ 1.27 5.59E-03  2890292 C5orf45 ⇩ 1.27 0.032  2361697 C1orf66 ⇩ 1.26 0.031 
3645204 KCTD5 ⇧ 1.27 8.44E-03  3723572 MGC57346 ⇩ 1.27 0.037  2924898 RNF146 ⇧ 1.26 0.035 
2877141 HNRNPA0 ⇧ 1.27 0.011  3695433 TRADD ⇧ 1.27 0.016  3868283 VRK3 ⇧ 1.26 9.86E-03 
3238491 BMI1 ⇧ 1.27 0.043  3235255 ECHDC3 ⇧ 1.27 0.025  2519140 ZC3H15 ⇧ 1.26 0.033 
3099561 T1560 ⇧ 1.27 0.046  2547386 DPY30 ⇧ 1.27 0.048  2833024 RNF14 ⇧ 1.26 0.029 
2391647 SSU72 ⇧ 1.27 0.046  2989537 GLCCI1 ⇧ 1.27 0.042  3256669 CFLP1 ⇧ 1.26 3.13E-03 
3338424 FADD ⇧ 1.27 0.026  3850040 EIF3G ⇧ 1.27 1.30E-03  3456700 ZNF385A ⇧ 1.26 0.022 
3282268 ACBD5 ⇧ 1.27 0.030  2922521 NT5DC1 ⇧ 1.26 0.017  3656760 STX4 ⇧ 1.26 0.020 
3466740 LTA4H ⇧ 1.27 0.036  2816506 S100Z ⇧ 1.26 0.017  3025500 BPGM ⇧ 1.26 0.015 
3972025 PDK3 ⇧ 1.27 0.050  3666732 CYB5B ⇧ 1.26 7.64E-03  3560617 SNX6 ⇧ 1.26 0.046 
2436132 ILF2 ⇧ 1.27 0.053  3954331 TOP3B ⇩ 1.26 0.028  3560864 PPP2R3C ⇧ 1.26 0.035 
2899393 BTN2A3 ⇩ 1.27 0.025  3426917 METAP2 ⇧ 1.26 0.035  3377964 FIBP ⇧ 1.26 0.011 
3878533 DTD1 ⇧ 1.27 0.043  2777639 GPRIN3 ⇧ 1.26 0.048  3590709 PLA2G4B ⇩ 1.26 4.13E-03 
3750842 SGK494 ⇩ 1.27 1.78E-03  3837731 EMP3 ⇩ 1.26 7.49E-03  3164914 MTAP ⇧ 1.26 0.022 
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2440625 DEDD ⇧ 1.26 6.35E-03  3051753 FKBP9 ⇧ 1.25 0.046  3147591 AZIN1 ⇧ 1.25 0.018 
2352501 LRIG2 ⇩ 1.26 0.018  3964154 CERK ⇧ 1.25 0.036  2768273 NFXL1 ⇩ 1.25 0.038 
3846280 TBXA2R ⇧ 1.26 0.025  3589141 SPRED1 ⇩ 1.25 0.049  4041923 CCNL2 ⇩ 1.25 0.036 
3830246 LSR ⇩ 1.26 0.034  3077766 TPK1 ⇧ 1.25 0.016  3535922 STYX ⇧ 1.25 0.044 
3220977 ROD1 ⇧ 1.26 2.02E-03  3434193 CCDC64 ⇩ 1.25 3.20E-03  3221135 C9orf80 ⇧ 1.25 0.031 
3129948 TMEM66 ⇩ 1.26 2.56E-03  2317434 TPRG1L ⇧ 1.25 0.034  3294242 ECD ⇧ 1.25 0.012 
3815210 AZU1 ⇧ 1.26 4.86E-03  3378007 C11orf68 ⇧ 1.25 0.017  2443537 SCYL3 ⇧ 1.25 0.035 
3830712 MLL4 ⇩ 1.26 3.52E-03  4007086 ZNF41 ⇧ 1.25 2.70E-03  3633048 EDC3 ⇧ 1.25 0.025 
3666282 ZFP90 ⇧ 1.26 0.050  3684782 RRN3P3 ⇧ 1.25 0.038  3225003 PSMB7 ⇧ 1.25 0.033 
3705135 CENPBD1 ⇧ 1.26 5.21E-03  3482977 POLR1D ⇧ 1.25 5.21E-03  3405032 ETV6 ⇧ 1.25 1.04E-03 
2801608 MARCH6 ⇩ 1.26 0.016  2359817 INTS3 ⇩ 1.25 0.016  3226181 ST6GALNAC4 ⇩ 1.25 0.037 
3820443 ICAM1 ⇩ 1.26 0.044  3725481 UBE2Z ⇧ 1.25 0.012  3971923 ZFX ⇧ 1.25 0.044 
4051226 SEMA4D ⇩ 1.26 2.44E-03  3283378 MTPAP ⇧ 1.25 0.026  3985218 ARMCX5 ⇧ 1.25 7.80E-03 
2536625 BOK ⇧ 1.26 4.16E-03  3418513 MARCH9 ⇩ 1.25 0.015  3739827 GLOD4 ⇧ 1.24 7.64E-03 
3005069 ZNF92 ⇧ 1.26 0.035  3405207 BCL2L14 ⇧ 1.25 0.030  3864597 C19orf61 ⇩ 1.24 0.037 
3363979 PSMA1 ⇧ 1.26 8.91E-03  2858793 C5orf43 ⇧ 1.25 7.80E-03  3337390 TCIRG1 ⇩ 1.24 0.041 
3712582 MED9 ⇧ 1.26 0.022  3014159 LMTK2 ⇩ 1.25 0.053  2525182 CCNYL1 ⇧ 1.24 9.96E-03 
3644220 NDUFB10 ⇧ 1.26 0.051  2724472 UBE2K ⇧ 1.25 0.041  2759404 GRPEL1 ⇧ 1.24 0.032 
2608469 ITPR1 ⇩ 1.26 0.025  3723264 NMT1 ⇧ 1.25 0.010  3643703 UBE2I ⇧ 1.24 0.014 
3959631 EIF3D ⇧ 1.26 0.013  2575980 CCDC115 ⇧ 1.25 0.040  2545869 IFT172 ⇩ 1.24 8.93E-03 
3722417 NBR1 ⇧ 1.26 0.032  2488959 STAMBP ⇧ 1.25 0.013  2620315 TMEM42 ⇧ 1.24 0.012 
3168245 LOC92973 ⇩ 1.26 0.040  2666904 SLC4A7 ⇩ 1.25 0.050  3841545 LILRA1 ⇧ 1.24 5.20E-03 
4026669 BCAP31 ⇩ 1.25 0.045  3453774 LMBR1L ⇩ 1.25 0.036  3329793 SLC39A13 ⇩ 1.24 0.043 
3737140 GAA ⇩ 1.25 0.033  2698565 TFDP2 ⇧ 1.25 0.043  2548274 STRN ⇧ 1.24 0.020 
3638048 MRPL46 ⇧ 1.25 0.052  2890859 MGAT1 ⇩ 1.25 0.035  3662265 N⇧93 ⇧ 1.24 0.050 
3135452 ATP6V1H ⇧ 1.25 3.35E-03  2964327 LYRM2 ⇧ 1.25 0.011  2429842 CD58 ⇩ 1.24 0.042 
3713195 SMCR8 ⇧ 1.25 7.36E-03  3275611 ANKRD16 ⇧ 1.25 8.20E-03  3223605 FBXW2 ⇧ 1.24 2.77E-03 
3902609 PDRG1 ⇧ 1.25 0.042  3185558 PRPF4 ⇧ 1.25 0.035  4014251 CHM ⇧ 1.24 0.047 
3677592 ZNF434 ⇧ 1.25 0.011  4043943 INPP5B ⇧ 1.25 0.028  3421706 RAB3IP ⇧ 1.24 0.046 
3549708 SERPINA4 ⇧ 1.25 0.013  3195363 ARRDC1 ⇧ 1.25 8.28E-03  3322048 C11orf58 ⇧ 1.24 0.051 
3497790 IPO5 ⇧ 1.25 2.43E-03  3382319 GDPD5 ⇩ 1.25 0.047  3851441 ZNF442 ⇧ 1.24 0.048 
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3470793 KCTD10 ⇧ 1.24 0.049  3623683 GABPB1 ⇧ 1.24 0.035  3386638 SLC36A4 ⇩ 1.23 0.029 
3479181 POLE ⇩ 1.24 0.049  3821727 ZNF136 ⇧ 1.24 0.013  3453370 ARF3 ⇧ 1.23 7.96E-03 
3074640 LUZP6 ⇧ 1.24 0.024  3962734 TTLL1 ⇧ 1.24 0.044  2831209 PAIP2 ⇧ 1.23 0.050 
3620276 EHD4 ⇧ 1.24 0.045  3433538 RNFT2 ⇩ 1.24 0.038  3268588 ACADSB ⇧ 1.23 0.044 
3942998 SFI1 ⇩ 1.24 0.022  2333168 C1orf84 ⇩ 1.24 0.044  3642060 CHSY1 ⇩ 1.23 0.015 
2405893 C1orf212 ⇧ 1.24 0.042  3394092 SLC37A4 ⇩ 1.24 0.044  3696035 LCAT ⇩ 1.23 0.042 
3311775 DHX32 ⇧ 1.24 0.053  4026722 IDH3G ⇧ 1.24 0.042  2336099 OSBPL9 ⇧ 1.23 0.044 
2643095 BFSP2 ⇧ 1.24 0.013  3515009 VPS36 ⇧ 1.24 0.041  3602873 HMG20A ⇧ 1.23 0.016 
3702293 MBTPS1 ⇩ 1.24 0.049  3819880 ZNF317 ⇧ 1.24 0.027  3865464 OPA3 ⇧ 1.23 4.69E-03 
3310675 CUZD1 ⇩ 1.24 0.031  2474527 NRBP1 ⇧ 1.24 0.034  3887017 DNTTIP1 ⇧ 1.23 0.024 
3377886 CFL1 ⇧ 1.24 0.050  3867195 FAM83E ⇧ 1.24 0.048  2400220 DDOST ⇩ 1.23 0.023 
2446198 TOR1AIP2 ⇩ 1.24 0.048  3027503 ADCK2 ⇩ 1.24 0.029  3371673 ARHGAP1 ⇧ 1.23 0.022 
3421630 CCT2 ⇧ 1.24 0.035  3231389 ZMYND11 ⇧ 1.23 0.051  3986672 ATG4A ⇧ 1.23 0.051 
3903836 EIF6 ⇧ 1.24 0.011  3551303 CCNK ⇧ 1.23 2.03E-03  3705641 TIMM22 ⇧ 1.23 0.011 
2428405 RHOC ⇧ 1.24 3.77E-03  3619650 DNAJC17 ⇧ 1.23 0.030  3476265 EIF2B1 ⇧ 1.23 9.20E-03 
3603687 TMED3 ⇩ 1.24 0.027  3847989 CD70 ⇩ 1.23 0.015  3459604 PPM1H ⇧ 1.23 0.036 
3719515 DUSP14 ⇧ 1.24 0.032  3421579 FRS2 ⇧ 1.23 0.053  3751323 MYO18A ⇩ 1.23 7.24E-03 
3466284 NDUFA12 ⇧ 1.24 0.047  3327948 TTC17 ⇩ 1.23 2.67E-03  3382948 CLNS1A ⇧ 1.23 0.028 
2413203 LRP8 ⇩ 1.24 0.050  3432030 ACAD10 ⇩ 1.23 0.011  2488114 ZNF638 ⇩ 1.23 0.048 
3778823 NAPG ⇧ 1.24 0.047  3960388 PLA2G6 ⇩ 1.23 0.016  3225348 PPP6C ⇧ 1.23 0.042 
2436283 DENND4B ⇩ 1.24 0.014  2320347 FBXO44 ⇩ 1.23 0.022  2325479 RCAN3 ⇧ 1.23 0.032 
3577078 LGMN ⇩ 1.24 0.047  2659577 PAK2 ⇧ 1.23 0.034  3192525 GTF3C4 ⇧ 1.23 0.044 
3292590 PBLD ⇧ 1.24 0.044  2406139 KIAA0319L ⇩ 1.23 0.039  2853388 C5orf33 ⇧ 1.23 0.029 
3037344 DAGLB ⇩ 1.24 0.041  3340410 NEU3 ⇧ 1.23 0.019  3430552 PWP1 ⇧ 1.23 0.023 
2336271 BTF3L4 ⇧ 1.24 0.052  3294816 NDST2 ⇩ 1.23 0.022  3558012 TINF2 ⇧ 1.23 4.38E-03 
3159167 ZNF252 ⇧ 1.24 0.022  3795466 RBFA ⇧ 1.23 0.052  3639007 HDDC3 ⇧ 1.23 0.017 
3557614 AP1G2 ⇩ 1.24 0.012  3862167 FBL ⇧ 1.23 2.90E-03  3757487 DNAJC7 ⇧ 1.23 0.016 
2828146 CDC42SE2 ⇧ 1.24 0.023  3689922 VPS35 ⇧ 1.23 0.011  2899110 HFE ⇩ 1.23 0.040 
3759356 EFTUD2 ⇧ 1.24 0.013  3755714 MED1 ⇧ 1.23 6.41E-03  3952453 DGCR2 ⇩ 1.23 0.046 
3372368 MTCH2 ⇧ 1.24 0.018  4012204 HDAC8 ⇧ 1.23 0.041  3860596 ZNF461 ⇧ 1.23 0.026 
3534201 PRPF39 ⇩ 1.24 0.025  3079005 RARRES2 ⇧ 1.23 0.040  3479438 CHFR ⇧ 1.23 0.046 
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3623424 COPS2 ⇧ 1.22 0.047  3865776 IRF2BP1 ⇩ 1.22 1.23E-03  3683783 THUMPD1 ⇧ 1.22 0.028 
3602526 FBXO22 ⇧ 1.22 0.021  2786567 C4orf49 ⇧ 1.22 0.037  3439305 ZNF84 ⇧ 1.22 0.022 
3299255 ATAD1 ⇩ 1.22 0.033  2431031 HMGCS2 ⇧ 1.22 0.040  3440017 FBXL14 ⇩ 1.22 0.049 
2844461 LTC4S ⇧ 1.22 5.79E-03  2363902 DUSP12 ⇧ 1.22 0.024  3467315 IKBIP ⇩ 1.22 0.041 
2780999 PAPSS1 ⇧ 1.22 0.038  3327906 API5 ⇧ 1.22 2.62E-03  3981959 SLC16A2 ⇧ 1.22 0.028 
3645850 OR2C1 ⇧ 1.22 0.026  3915087 USP25 ⇧ 1.22 0.027  3819104 TRAPPC5 ⇧ 1.22 0.020 
3831143 TBCB ⇧ 1.22 0.012  3382861 PAK1 ⇧ 1.22 0.036  2624110 SPCS1 ⇩ 1.22 0.017 
2928392 VTA1 ⇧ 1.22 0.050  3597857 SNX1 ⇧ 1.22 0.050  3074362 CNOT4 ⇧ 1.21 0.051 
3435946 GTF2H3 ⇧ 1.22 0.039  2964052 SRSF12 ⇧ 1.22 6.16E-03  2475628 YPEL5 ⇧ 1.21 0.049 
3225224 GOLGA1 ⇩ 1.22 1.22E-03  3754227 MYO19 ⇩ 1.22 0.012  3565303 CNIH ⇩ 1.21 0.023 
2392528 PANK4 ⇩ 1.22 0.016  3708798 SENP3 ⇧ 1.22 0.048  3847005 PLIN3 ⇧ 1.21 0.016 
3818376 CLPP ⇧ 1.22 0.017  2600068 TUBA4A ⇧ 1.22 0.033  3333358 INCENP ⇩ 1.21 0.022 
3691193 SNX20 ⇧ 1.22 0.039  2397732 AGMAT ⇧ 1.22 0.046  2538924 FLJ42418 ⇧ 1.21 0.033 
2902884 SKIV2L ⇩ 1.22 0.011  3599432 FEM1B ⇧ 1.22 0.025  3226005 PTRH1 ⇧ 1.21 8.37E-03 
3970833 PDHA1 ⇧ 1.22 6.50E-03  3417842 LRP1 ⇩ 1.22 0.047  3576812 TRIP11 ⇩ 1.21 0.029 
3853063 ILVBL ⇩ 1.22 0.026  2460325 C1orf198 ⇧ 1.22 0.012  3099566 FAM110B ⇧ 1.21 0.030 
2977949 EPM2A ⇧ 1.22 0.023  2324743 ZBTB40 ⇩ 1.22 0.043  3704717 ANKRD11 ⇩ 1.21 0.029 
2586989 DLX2 ⇧ 1.22 0.040  2834093 TCERG1 ⇩ 1.22 0.018  3825225 C19orf60 ⇧ 1.21 0.040 
3681377 PARN ⇧ 1.22 9.30E-03  2606643 MYEOV2 ⇧ 1.22 0.031  3529547 DCAF11 ⇧ 1.21 0.029 
3119735 ZNF623 ⇧ 1.22 0.030  2675836 ABHD14B ⇧ 1.22 0.038  2365496 POGK ⇧ 1.21 0.013 
3895297 DDRGK1 ⇩ 1.22 0.012  3269328 ZRANB1 ⇧ 1.22 0.049  3462693 KRR1 ⇧ 1.21 0.037 
3645253 SRRM2 ⇩ 1.22 5.24E-04  3282016 ABI1 ⇧ 1.22 0.050  3645377 FLYWCH2 ⇧ 1.21 0.044 
3571542 PNMA1 ⇧ 1.22 0.053  2838598 CCNG1 ⇧ 1.22 0.033  3548152 TDP1 ⇧ 1.21 2.29E-03 
2436716 UBE2Q1 ⇧ 1.22 0.037  3457696 PAN2 ⇩ 1.22 0.033  3128362 GNRH1 ⇩ 1.21 0.017 
3688197 VKORC1 ⇩ 1.22 0.025  2886977 FBXW11 ⇧ 1.22 0.024  3882069 MAPRE1 ⇧ 1.21 0.039 
2358044 PLEKHO1 ⇧ 1.22 0.053  2571979 SLC35F5 ⇩ 1.22 0.050  3996339 TAZ ⇩ 1.21 0.012 
3802129 SS18 ⇧ 1.22 0.030  3976848 HDAC6 ⇩ 1.22 2.53E-03  4007376 SSX3 ⇧ 1.21 0.053 
2560141 MRPL53 ⇧ 1.22 0.011  3947863 PARVB ⇧ 1.22 0.011  2966253 SFRS18 ⇩ 1.21 0.036 
3230282 AGPAT2 ⇩ 1.22 0.048  3755396 CWC25 ⇩ 1.22 0.027  3845620 BTBD2 ⇧ 1.21 0.042 
2642325 ATP2C1 ⇩ 1.22 0.051  2495555 UNC50 ⇩ 1.22 0.013  2561955 SUCLG1 ⇧ 1.21 0.027 
2620222 ZNF501 ⇧ 1.22 0.048  3837836 CYTH2 ⇧ 1.22 0.011  3865378 ERCC1 ⇧ 1.21 0.052 
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3756344 SMARCE1 ⇧ 1.21 0.029  3377358 BATF2 ⇧ 1.21 0.040  3445786 ARHGDIB ⇧ 1.20 0.016 
2391188 SDF4 ⇩ 1.21 0.026  3922100 MX1 ⇧ 1.21 0.047  3675116 TMEM8A ⇩ 1.20 0.044 
3345340 KDM4D ⇧ 1.21 0.029  3624448 GNB5 ⇧ 1.21 0.011  3656800 ZNF646 ⇩ 1.20 0.037 
3708306 ACADVL ⇩ 1.21 3.95E-03  3742727 DHX33 ⇧ 1.21 0.019  2386828 EDARADD ⇧ 1.20 0.036 
3919124 FAM165B ⇧ 1.21 0.017  2904528 ZNF76 ⇩ 1.20 0.037  3770699 MIF4GD ⇧ 1.20 0.038 
2614054 UBE2E1 ⇧ 1.21 0.029  3812426 RTTN ⇩ 1.20 0.028  3755580 CACNB1 ⇩ 1.20 0.015 
4007643 OTUD5 ⇧ 1.21 0.034  3538470 C14orf135 ⇩ 1.20 0.024  3167511 GALT ⇩ 1.20 0.032 
2950214 TAP1 ⇩ 1.21 0.052  3228373 TSC1 ⇩ 1.20 0.037  3159132 COMMD5 ⇧ 1.20 8.68E-03 
3832777 MRPS12 ⇧ 1.21 0.045  3251926 KIAA0913 ⇩ 1.20 0.032  3015706 MOSPD3 ⇧ 1.20 0.046 
3159013 ZNF34 ⇧ 1.21 0.042  2676352 NEK4 ⇧ 1.20 0.049  3628994 PPIB ⇩ 1.20 0.021 
3696571 TERF2 ⇧ 1.21 7.84E-03  3332838 DAK ⇧ 1.20 0.042  2530599 AGFG1 ⇧ 1.20 0.015 
3956854 THOC5 ⇧ 1.21 0.018  3571810 ABCD4 ⇩ 1.20 0.024  2881370 CD74 ⇩ 1.20 7.51E-03 
4016045 TCEAL6 ⇩ 1.21 0.032  3502710 TFDP1 ⇧ 1.20 0.033  3774975 C17orf101 ⇩ 1.20 0.016 
3748126 ATPAF2 ⇧ 1.21 0.021  3855410 SUGP2 ⇩ 1.20 4.59E-03  3033397 RBM33 ⇩ 1.20 0.043 
3301713 BLNK ⇧ 1.21 5.12E-03  3934407 ICOSLG ⇩ 1.20 0.015  3294348 MRPS16 ⇧ 1.20 0.031 
2351872 RAP1A ⇧ 1.21 0.026  3654227 IL21R ⇩ 1.20 0.036  3924674 DIP2A ⇩ 1.20 0.018 
3224366 RC3H2 ⇧ 1.21 5.12E-03  2874794 RAPGEF6 ⇩ 1.20 0.048  3824226 GTPBP3 ⇩ 1.20 0.027 
3994846 MTMR1 ⇧ 1.21 0.020  3673921 ZNF778 ⇧ 1.20 0.022  2321942 RSC1A1 ⇧ 1.20 0.045 
3878429 POLR3F ⇧ 1.21 6.67E-03  3696295 SLC7A6OS ⇧ 1.20 0.017  3332626 TMEM132A ⇩ 1.20 0.046 
3686164 GTF3C1 ⇩ 1.21 0.012  3458033 ATP5B ⇧ 1.20 2.42E-03  3429312 HSP90B1 ⇩ 1.20 0.018 
3948590 RIBC2 ⇧ 1.21 0.045  2333195 KIAA0467 ⇩ 1.20 0.012  2562198 TGOLN2 ⇩ 1.20 0.014 
2348792 CCDC76 ⇩ 1.21 0.013  3872983 CHMP2A ⇧ 1.20 0.022  3668898 ZFP1 ⇧ 1.20 0.036 
2325274 C1orf128 ⇧ 1.21 0.026  3483348 POMP ⇧ 1.20 0.031  3545403 GSTZ1 ⇧ 1.20 0.037 
3591909 CTDSPL2 ⇧ 1.21 0.010  3377149 MEN1 ⇩ 1.20 0.016  3695916 CENPT ⇩ 1.20 0.019 
3504392 N6AMT2 ⇧ 1.21 0.028  2863535 WDR41 ⇧ 1.20 0.035  4050485 TUBB2C ⇧ 1.20 0.032 
3702382 TAF1C ⇩ 1.21 0.024  3815610 ATP5D ⇧ 1.20 0.011  3334954 CAPN1 ⇧ 1.20 0.045 
3538703 MNAT1 ⇧ 1.21 0.038  3831917 ZNF570 ⇧ 1.20 0.034  3442812 SLC2A14 ⇩ 1.20 2.73E-03 
2921086 CDC40 ⇧ 1.21 7.07E-03  3047202 C7orf11 ⇧ 1.20 0.043  2894711 TMEM14B ⇧ 1.20 6.07E-03 
2983030 AGPAT4 ⇩ 1.21 0.035  3869339 ZNF350 ⇧ 1.20 0.052  2402942 SLC9A1 ⇩ 1.20 0.024 
3709540 PFAS ⇩ 1.21 0.021  3509910 FAM48A ⇧ 1.20 8.39E-03  3414390 SMARCD1 ⇧ 1.20 0.020 
3645901 NAT15 ⇧ 1.21 0.037  3056264 ABHD11 ⇧ 1.20 0.040  3541073 MPP5 ⇧ 1.20 0.019 
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3435050 PSMD9 ⇧ 1.20 0.020  3456006 CSAD ⇩ 1.20 0.036  3212277 C9orf64 ⇧ 1.20 0.049 
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Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value 
3662201 MT1H ⇧ 2.05 0.023  3847873 SLC25A23 ⇧ 1.39 7.79E-03  3931112 HLCS ⇩ 1.30 8.65E-03 
3433796 PEBP1 ⇧ 1.76 0.033  2986350 DLL1 ⇩ 1.39 0.040  3901665 C20orf3 ⇩ 1.30 5.70E-03 
2933522 GTF2H5 ⇧ 1.74 0.046  2356818 BCL9 ⇧ 1.38 6.15E-03  2362157 CD1D ⇩ 1.30 0.016 
3507282 FLT1 ⇩ 1.73 0.033  3788049 SKA1 ⇧ 1.38 0.033  3839006 PTOV1 ⇧ 1.30 0.040 
3212848 GOLM1 ⇩ 1.72 0.034  3974556 ATP6AP2 ⇩ 1.38 0.035  3856075 ZNF682 ⇧ 1.29 0.030 
3948543 FAM118A ⇩ 1.67 0.049  2992963 CCDC126 ⇧ 1.38 0.040  3767465 AXIN2 ⇧ 1.29 0.042 
3318500 OR52N4 ⇧ 1.66 0.019  3188231 OR1L4 ⇧ 1.38 2.73E-03  3251648 FAM149B1 ⇧ 1.29 0.039 
3933625 RSPH1 ⇧ 1.66 0.030  3120358 HSF1 ⇧ 1.38 0.043  3392871 ZNF259 ⇧ 1.29 0.025 
2775735 SCD5 ⇩ 1.64 8.04E-03  3016636 SH2B2 ⇧ 1.37 0.042  3454576 SLC11A2 ⇩ 1.29 0.045 
2676854 CHDH ⇧ 1.60 0.035  3730240 TLK2 ⇧ 1.36 0.025  3275690 IL15RA ⇩ 1.28 2.08E-03 
2703377 B3GALNT1 ⇩ 1.60 0.049  3894098 C20orf96 ⇧ 1.36 4.01E-03  2606574 NDUFA10 ⇧ 1.28 0.012 
3444476 TAS2R20 ⇩ 1.57 0.047  2803329 BASP1 ⇧ 1.35 9.34E-03  3458133 PRIM1 ⇧ 1.28 0.029 
2950125 HLA-DQB2 ⇩ 1.54 0.032  2832081 ZMAT2 ⇧ 1.35 7.91E-03  2861952 MRPS27 ⇧ 1.28 0.029 
3325503 RCN1 ⇩ 1.53 0.017  2774971 ANTXR2 ⇩ 1.35 0.036  3567187 DHRS7 ⇩ 1.28 0.012 
2869438 NUDT12 ⇩ 1.53 0.031  3498589 CLYBL ⇧ 1.35 0.028  3677356 HCFC1R1 ⇧ 1.27 3.61E-03 
3841357 LILRA2 ⇩ 1.52 0.023  2360939 POU5F1P4 ⇩ 1.34 0.010  3302495 AVPI1 ⇧ 1.27 0.042 
3917582 KRTAP6-3 ⇩ 1.51 0.018  3590086 RAD51 ⇧ 1.34 0.035  2438531 HDGF ⇧ 1.27 0.033 
2893392 LY86 ⇩ 1.49 0.043  2422227 GEMIN8P4 ⇧ 1.34 0.024  3735505 AANAT ⇧ 1.27 0.014 
3903361 AHCY ⇧ 1.46 0.023  2723752 TBC1D1 ⇧ 1.33 0.015  3334325 VEGFB ⇧ 1.27 0.012 
3850660 SPC24 ⇧ 1.46 0.039  3990795 RBMX2 ⇩ 1.33 0.032  3811459 KDSR ⇩ 1.27 9.42E-03 
3868659 C19orf48 ⇧ 1.46 7.85E-03  4019849 LAMP2 ⇩ 1.33 0.034  3325839 TCP11L1 ⇧ 1.26 0.018 
3830993 HCST ⇩ 1.45 0.024  2666566 NGLY1 ⇧ 1.32 0.028  2383550 ZNF678 ⇧ 1.26 0.035 
3959593 TXN2 ⇧ 1.45 0.019  3354879 HYLS1 ⇧ 1.32 0.024  3713093 ALKBH5 ⇧ 1.26 0.042 
3164181 RRAGA ⇩ 1.43 0.018  2728189 PAICS ⇧ 1.32 0.032  2440476 F11R ⇩ 1.26 0.021 
3450899 SLC2A13 ⇩ 1.42 0.020  2673873 IMPDH2 ⇧ 1.31 0.011  2334279 UROD ⇧ 1.26 0.043 
2842561 HIGD2A ⇧ 1.41 0.038  3328389 EXT2 ⇩ 1.31 0.032  3203482 BAG1 ⇧ 1.26 0.026 
2610417 C3orf42 ⇧ 1.41 0.018  3168309 RECK ⇩ 1.31 4.94E-03  3816699 ZNF57 ⇧ 1.26 0.044 
2520069 C2orf88 ⇩ 1.40 0.049  3191147 TOR1B ⇩ 1.31 0.046  3918696 SON ⇩ 1.26 9.81E-03 
3726498 MYCBPAP ⇧ 1.40 0.033  2712794 TCTEX1D2 ⇧ 1.31 0.046  2335922 CDKN2C ⇩ 1.25 0.011 
3124537 CTSB ⇩ 1.40 0.027  2359433 LCE1E ⇧ 1.31 0.034  3844855 C19orf22 ⇧ 1.25 0.036 
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3261419 HPS6 ⇧ 1.25 0.049  3079756 RHEB ⇧ 1.23 9.25E-03  3862564 C19orf47 ⇧ 1.21 9.43E-03 
2444117 PIGC ⇩ 1.25 0.029  2881554 DCTN4 ⇧ 1.23 0.038  3724931 SP2 ⇧ 1.21 0.033 
3142485 IMPA1 ⇩ 1.25 0.044  3157138 LYPD2 ⇩ 1.23 0.029  3883941 TGIF2 ⇧ 1.21 0.048 
3016177 AP1S1 ⇧ 1.25 0.045  2831875 SLC35A4 ⇧ 1.23 0.040  3216319 ZNF367 ⇧ 1.21 0.018 
3855071 FKBP8 ⇧ 1.24 0.017  2878726 HDAC3 ⇧ 1.22 0.024  2737069 METAP1 ⇧ 1.21 0.033 
2399718 AKR7A2 ⇧ 1.24 0.013  3920512 DSCR9 ⇩ 1.22 7.15E-03  3417485 OBFC2B ⇧ 1.20 0.013 
2955025 MRPL14 ⇧ 1.24 0.048  3712517 NT5M ⇧ 1.22 3.85E-03  3822195 NACC1 ⇧ 1.20 0.019 
2390489 ZNF672 ⇧ 1.24 0.039  3401197 C12orf32 ⇧ 1.22 4.28E-03  2943236 DTNBP1 ⇧ 1.20 0.018 
3637006 SEC11A ⇩ 1.24 0.027  2832467 PCDHB18 ⇩ 1.21 0.023  3643552 SSTR5 ⇧ 1.20 9.87E-03 
3621140 LCMT2 ⇩ 1.24 0.049  3200689 RPS6 ⇧ 1.21 3.58E-03  3673684 CDT1 ⇧ 1.20 0.033 
2363042 PEA15 ⇧ 1.24 2.72E-03  2450865 CSRP1 ⇧ 1.21 0.048  3240012 MASTL ⇧ 1.20 0.040 
3029213 TAS2R41 ⇩ 1.23 0.030  2619120 TRAK1 ⇧ 1.21 0.015  3620515 TMEM87A ⇩ 1.20 0.015 
3980745 FOXO4 ⇧ 1.23 0.017  2410330 GPBP1L1 ⇧ 1.21 0.017  3536396 CGRRF1 ⇩ 1.20 0.023 
2363444 USP21 ⇧ 1.23 0.018  3644541 TRAF7 ⇧ 1.21 7.47E-03  3825496 ARMC6 ⇧ 1.20 0.043 
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2940145 NRN1 ⇧ 3.24 0.018  2534324 PRLH ⇩ 1.80 7.39E-03  2826295 SNX2 ⇩ 1.64 2.64E-03 
3369249 APIP ⇧ 2.54 2.58E-03  2474240 KHK ⇩ 1.80 0.043  2902178 TCF19 ⇩ 1.64 3.85E-03 
3560403 EGLN3 ⇧ 2.51 1.33E-03  2761837 FGFBP2 ⇩ 1.79 0.023  2773907 SDAD1 ⇩ 1.64 8.43E-03 
2902707 HSPA1A ⇩ 2.50 5.88E-04  2477933 GALM ⇩ 1.78 0.028  3444436 TAS2R14 ⇧ 1.63 0.023 
3385175 PICALM ⇧ 2.39 2.77E-04  3020496 ST7 ⇩ 1.77 4.54E-03  3151943 TATDN1 ⇧ 1.63 0.013 
3972929 GK ⇧ 2.38 6.17E-04  2371346 RGL1 ⇩ 1.76 7.66E-03  3009399 HSPB1 ⇩ 1.62 0.031 
2662581 C3orf10 ⇩ 2.38 3.78E-03  3635198 BCL2A1 ⇩ 1.75 4.18E-03  2638962 DTX3L ⇩ 1.62 0.010 
3449068 TMTC1 ⇧ 2.29 0.018  3444493 TAS2R19 ⇧ 1.75 0.030  3147020 ZNF706 ⇧ 1.62 0.014 
3403841 RIMKLB ⇧ 2.29 0.016  2454661 TMEM206 ⇩ 1.74 3.82E-03  3466284 NDUFA12 ⇧ 1.61 4.88E-04 
4022370 GPC4 ⇧ 2.23 0.048  2638988 PARP15 ⇩ 1.74 0.037  2893392 LY86 ⇩ 1.61 5.63E-03 
2944025 TPMT ⇩ 2.21 2.86E-03  2638789 CD86 ⇩ 1.74 0.012  3818395 ALKBH7 ⇧ 1.61 0.026 
2950125 HLA-DQB2 ⇩ 2.21 0.040  2895841 CD83 ⇩ 1.73 0.012  2351004 GSTM5 ⇩ 1.61 0.016 
4002081 MAP7D2 ⇧ 2.19 6.23E-03  3447863 KRAS ⇧ 1.72 3.61E-04  2841491 C5orf41 ⇩ 1.60 0.013 
3945545 APOBEC3B ⇩ 2.14 4.01E-03  2708855 LIPH ⇩ 1.72 0.036  2626097 ABHD6 ⇩ 1.60 0.032 
2399743 AKR7A3 ⇩ 2.12 7.82E-03  3324713 METT5D1 ⇧ 1.72 0.041  2350922 GSTM4 ⇩ 1.60 0.026 
2633191 GPR15 ⇩ 2.05 0.021  3893849 PRPF6 ⇧ 1.72 1.58E-03  3887107 ZSWIM1 ⇩ 1.60 4.51E-03 
3617458 GOLGA8A ⇧ 2.01 0.025  3513995 DLEU2 ⇧ 1.71 8.52E-03  2443518 C1orf156 ⇩ 1.59 1.18E-03 
2878246 PFDN1 ⇩ 1.96 0.022  2638017 C3orf1 ⇩ 1.71 0.037  2587618 OLA1 ⇧ 1.59 2.30E-03 
3577443 ASB2 ⇩ 1.96 0.040  3851072 ACP5 ⇩ 1.70 0.013  2447414 NCF2 ⇩ 1.59 0.043 
2902725 HSPA1B ⇩ 1.95 1.14E-03  2950307 HLA-DOA ⇩ 1.69 0.014  2334350 MMACHC ⇩ 1.58 0.010 
2362333 MNDA ⇩ 1.94 0.030  2946364 HIST1H3F ⇧ 1.68 0.041  3742627 C17orf87 ⇩ 1.58 0.034 
2677723 ARHGEF3 ⇩ 1.93 0.011  3288013 BMS1P1 ⇧ 1.68 1.53E-03  2515050 GORASP2 ⇩ 1.58 6.37E-03 
2950145 HLA-DOB ⇩ 1.92 0.012  2976113 IFNGR1 ⇩ 1.67 0.025  2608419 SETMAR ⇩ 1.57 8.38E-04 
2991233 AHR ⇩ 1.87 3.80E-03  3103523 LY96 ⇩ 1.66 9.76E-03  2367843 DARS2 ⇩ 1.57 1.10E-03 
3797295 L3MBTL4 ⇧ 1.86 0.014  2378068 G0S2 ⇩ 1.66 0.039  3427014 SNRPF ⇧ 1.57 0.028 
3273667 ADARB2 ⇧ 1.84 6.04E-03  3263944 PDCD4 ⇧ 1.66 2.81E-03  3074039 SLC35B4 ⇩ 1.57 0.024 
2408189 PPT1 ⇩ 1.84 0.026  3518086 TBC1D4 ⇧ 1.66 0.040  2711818 LSG1 ⇩ 1.56 0.025 
3434490 CABP1 ⇧ 1.82 2.15E-04  2970897 FRK ⇧ 1.66 8.35E-03  2837810 UBLCP1 ⇩ 1.56 0.025 
2664209 SH3BP5 ⇩ 1.82 0.019  3812385 CD226 ⇩ 1.65 5.67E-03  3981735 NCRNA00183 ⇧ 1.56 0.021 
4037708 ND6 ⇧ 1.81 0.023  3281621 ARHGAP21 ⇩ 1.65 0.029  2950277 HLA-DMA ⇩ 1.56 0.030 
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3848243 INSR ⇧ 1.56 0.021  2403470 DNAJC8 ⇩ 1.50 0.020  3444195 MAGOHB ⇧ 1.47 1.02E-03 
3304970 SH3PXD2A ⇧ 1.55 0.038  2501317 LOC654433 ⇧ 1.50 0.042  3494137 LMO7 ⇧ 1.47 0.046 
3761632 SNF8 ⇧ 1.54 2.80E-03  3210179 C9orf95 ⇧ 1.50 1.82E-03  3705412 C17orf97 ⇧ 1.47 1.99E-03 
3743734 C17orf61 ⇧ 1.54 5.69E-03  2612401 BTD ⇩ 1.50 0.024  2626167 PXK ⇩ 1.47 0.030 
3420497 HELB ⇧ 1.54 2.29E-03  2835792 GM2A ⇩ 1.50 0.012  2409368 HYI ⇩ 1.47 0.027 
3462843 NAP1L1 ⇧ 1.54 0.026  3334847 C11orf2 ⇧ 1.50 8.79E-04  2708407 ALG3 ⇩ 1.47 7.26E-03 
3373487 OR5M1 ⇧ 1.54 8.66E-04  2375212 PPP1R12B ⇩ 1.49 0.023  2633773 TFG ⇩ 1.47 0.011 
2499158 RANBP2 ⇩ 1.54 1.79E-04  2790570 PLRG1 ⇩ 1.49 5.77E-03  2692411 PTPLB ⇩ 1.46 0.040 
3624145 DMXL2 ⇧ 1.54 2.18E-03  3250019 DDX50 ⇧ 1.49 7.54E-03  3221543 CDC26 ⇧ 1.46 5.90E-03 
3471264 VPS29 ⇧ 1.54 4.08E-03  3362468 SBF2 ⇧ 1.49 0.030  3845647 MKNK2 ⇧ 1.46 2.64E-03 
3458400 NDUFA4L2 ⇧ 1.54 0.013  2668205 GLB1 ⇩ 1.49 0.046  2845274 CCDC127 ⇩ 1.46 0.035 
2420467 CTBS ⇩ 1.54 0.040  3712041 UBB ⇧ 1.49 0.011  2744674 RAB33B ⇩ 1.46 0.031 
3513856 EBPL ⇧ 1.54 7.49E-03  3058156 TMEM60 ⇩ 1.49 6.09E-03  3609592 MCTP2 ⇧ 1.46 0.018 
3564919 FERMT2 ⇧ 1.54 7.84E-03  2628682 ARL6IP5 ⇩ 1.49 0.036  2495446 INPP4A ⇩ 1.46 0.026 
2500919 SLC20A1 ⇩ 1.53 0.042  3403077 C12orf57 ⇧ 1.48 4.02E-03  3260423 CUTC ⇧ 1.46 0.012 
3413950 SPATS2 ⇧ 1.53 1.37E-03  2604390 ARL4C ⇩ 1.48 0.026  2464129 LOC100506975 ⇧ 1.46 0.011 
2836451 MFAP3 ⇩ 1.53 0.019  2939034 SERPINB9 ⇩ 1.48 0.017  3009198 RHBDD2 ⇩ 1.46 0.016 
2716655 MSX1 ⇧ 1.53 5.88E-03  3405515 APOLD1 ⇧ 1.48 0.019  3978819 RRAGB ⇧ 1.46 4.80E-03 
3951732 CECR5 ⇧ 1.53 3.16E-03  3460584 LLPH ⇧ 1.48 0.021  2621583 ZNF589 ⇩ 1.46 0.035 
3332886 TMEM138 ⇩ 1.53 0.026  2879028 GNPDA1 ⇩ 1.48 0.028  2342576 ACADM ⇩ 1.46 3.71E-03 
3714068 ALDH3A2 ⇩ 1.53 1.89E-03  2331679 MFSD2A ⇩ 1.48 9.46E-03  3347615 ACAT1 ⇩ 1.46 0.039 
3683018 RPS15A ⇧ 1.52 0.043  2888879 DOK3 ⇩ 1.48 7.98E-04  3595846 FAM63B ⇧ 1.46 0.029 
2946845 ZNF204P ⇩ 1.52 1.35E-03  2979056 N⇧43 ⇩ 1.48 1.19E-03  3451264 YAF2 ⇧ 1.46 7.09E-03 
2385095 ARV1 ⇩ 1.52 0.049  2428796 PTPN22 ⇩ 1.48 8.06E-04  3216529 ZNF782 ⇧ 1.46 0.018 
2879739 PRELID2 ⇧ 1.52 0.019  3719112 ZNHIT3 ⇧ 1.48 9.97E-03  3475324 TMEM120B ⇧ 1.46 9.55E-03 
2330773 CDCA8 ⇩ 1.52 0.018  2369557 SOAT1 ⇩ 1.48 0.029  3829768 UBA2 ⇧ 1.46 2.57E-03 
2752725 NEIL3 ⇩ 1.51 0.036  3547375 GPR65 ⇩ 1.48 0.027  3464967 GALNT4 ⇧ 1.46 1.60E-03 
3865223 TRAPPC6A ⇧ 1.51 0.038  3825823 NDUFA13 ⇧ 1.48 0.021  3507962 KATNAL1 ⇧ 1.46 0.026 
3864551 PLAUR ⇩ 1.51 0.035  3490741 SUGT1 ⇧ 1.48 0.013  3111695 EBAG9 ⇩ 1.45 5.52E-03 
3633699 NRG4 ⇧ 1.51 0.017  3936442 PEX26 ⇧ 1.48 9.34E-03  3996083 TMEM187 ⇧ 1.45 2.63E-03 
3485292 NBEA ⇧ 1.51 0.018  2805176 C5orf22 ⇩ 1.47 0.021  2831519 C5orf32 ⇩ 1.45 0.037 
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2871176 REEP5 ⇩ 1.45 0.026  2750594 SC4MOL ⇩ 1.42 0.026  3428088 ACTR6 ⇧ 1.40 0.013 
2954022 TRERF1 ⇧ 1.45 0.032  3005684 KCTD7 ⇩ 1.42 8.00E-03  2363919 ATF6 ⇩ 1.40 7.38E-03 
3762625 MBTD1 ⇧ 1.45 5.91E-04  2522439 BZW1 ⇩ 1.42 0.032  3421706 RAB3IP ⇧ 1.40 5.23E-03 
2378180 C1orf107 ⇩ 1.45 1.64E-03  2616932 MLH1 ⇩ 1.42 0.018  2973168 ECHDC1 ⇩ 1.40 0.022 
2845078 TRIM52 ⇧ 1.45 0.023  3384321 RAB30 ⇩ 1.42 0.027  3540353 CHURC1 ⇧ 1.40 0.013 
2820893 RFESD ⇩ 1.44 0.017  3807753 MBD1 ⇧ 1.42 0.023  3841901 NLRP2 ⇩ 1.40 4.23E-03 
2792069 NAF1 ⇩ 1.44 0.016  3354879 HYLS1 ⇧ 1.42 4.01E-04  2363202 SLAMF7 ⇩ 1.40 0.028 
3335124 TIGD3 ⇧ 1.44 0.045  3942384 MTFP1 ⇧ 1.42 0.033  2796911 CCDC110 ⇧ 1.40 0.025 
3035892 GNA12 ⇧ 1.44 0.015  2425212 DBT ⇩ 1.42 0.010  2731831 USO1 ⇩ 1.40 0.011 
3438027 RAN ⇧ 1.44 1.77E-03  3464912 POC1B ⇧ 1.41 9.95E-03  2876257 SAR1B ⇩ 1.39 0.039 
2639309 SEC22A ⇩ 1.44 6.79E-03  3470689 ALKBH2 ⇧ 1.41 7.77E-03  3426257 SOCS2 ⇧ 1.39 0.016 
3020273 CAV2 ⇧ 1.44 0.026  2411228 STIL ⇩ 1.41 0.023  2900269 ZSCAN16 ⇩ 1.39 0.011 
3025740 TMEM140 ⇩ 1.43 0.042  2970985 TSPYL4 ⇩ 1.41 8.86E-03  4002148 EIF1AX ⇧ 1.39 0.023 
2636185 SLC35A5 ⇩ 1.43 0.030  2777070 HSD17B11 ⇩ 1.41 0.044  3554592 BTBD6 ⇩ 1.39 0.023 
2608469 ITPR1 ⇩ 1.43 4.68E-03  3396770 CDON ⇧ 1.41 8.47E-03  3361811 STK33 ⇧ 1.39 6.28E-03 
2743370 C4orf33 ⇩ 1.43 7.49E-03  3221633 HDHD3 ⇩ 1.41 6.62E-03  2366156 SFT2D2 ⇩ 1.39 0.010 
2409770 TMEM53 ⇩ 1.43 0.014  3179669 C9orf89 ⇧ 1.41 5.58E-03  2506903 MGAT5 ⇩ 1.39 0.041 
2333658 ATP6V0B ⇩ 1.43 0.046  3864430 ETHE1 ⇩ 1.41 0.037  3537030 RPL13AP3 ⇧ 1.39 0.036 
2452977 FAIM3 ⇩ 1.43 0.046  2436228 GATAD2B ⇩ 1.41 1.05E-06  2784113 CCNA2 ⇩ 1.39 0.019 
3488942 NUDT15 ⇧ 1.43 2.67E-03  3098977 LYN ⇩ 1.41 5.79E-03  2437401 FDPS ⇩ 1.39 6.95E-03 
2668035 DYNC1LI1 ⇩ 1.43 4.74E-03  2807862 C5orf51 ⇩ 1.41 0.015  3784509 ZNF271 ⇧ 1.39 7.91E-03 
3706651 OR3A3 ⇩ 1.43 0.029  3168700 ZCCHC7 ⇧ 1.41 0.012  3462630 CAPS2 ⇧ 1.39 8.11E-05 
2870397 PJA2 ⇩ 1.43 5.50E-03  2682568 SHQ1 ⇩ 1.41 0.012  2770427 C4orf14 ⇩ 1.39 0.030 
3061456 SAMD9L ⇩ 1.43 0.043  3292634 RUFY2 ⇧ 1.41 0.013  3756856 KRTAP17-1 ⇧ 1.39 0.027 
2841699 CPEB4 ⇩ 1.43 9.14E-03  3584728 SNRPN ⇧ 1.41 0.049  3998632 PNPLA4 ⇧ 1.39 4.14E-04 
2446198 TOR1AIP2 ⇩ 1.43 1.37E-03  2531377 SP100 ⇩ 1.41 0.045  3359751 ZNF195 ⇧ 1.39 6.76E-03 
2878474 HARS ⇩ 1.43 5.34E-03  2773348 PF4 ⇧ 1.40 0.025  2596162 INO80D ⇩ 1.39 1.79E-04 
3005956 C7orf42 ⇩ 1.43 1.87E-03  3807261 SMAD7 ⇧ 1.40 5.76E-03  3439063 ZNF26 ⇧ 1.39 7.02E-03 
2588827 NFE2L2 ⇩ 1.42 9.86E-03  2690900 CD80 ⇩ 1.40 0.028  4043943 INPP5B ⇩ 1.39 3.20E-03 
3283920 ARHGAP12 ⇧ 1.42 8.24E-04  2894663 PAK1IP1 ⇩ 1.40 0.037  3344861 C11orf54 ⇧ 1.39 0.038 
3458911 CTDSP2 ⇧ 1.42 0.017  3716664 SUZ12P ⇧ 1.40 0.024  2348702 SLC35A3 ⇩ 1.38 0.031 
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3487095 DGKH ⇧ 1.38 0.039  3846742 SH3GL1 ⇧ 1.37 0.034  3402978 DSTNP2 ⇧ 1.36 0.013 
2334459 TMEM69 ⇩ 1.38 9.21E-04  2442134 TMCO1 ⇩ 1.37 0.031  2523213 BMPR2 ⇩ 1.36 0.036 
3788833 POLI ⇧ 1.38 5.59E-03  2738146 TET2 ⇩ 1.37 6.46E-03  3332131 STX3 ⇧ 1.36 1.75E-03 
3636956 WDR73 ⇧ 1.38 5.38E-03  2522509 NIF3L1 ⇩ 1.37 5.88E-03  3716579 LRRC37BP1 ⇧ 1.36 0.036 
3414440 C12orf62 ⇧ 1.38 0.021  3836317 VASP ⇧ 1.37 9.33E-03  2911413 PRIM2 ⇩ 1.36 0.035 
2903435 HLA-DPB2 ⇩ 1.38 0.023  3853453 RASAL3 ⇧ 1.37 0.047  3409127 ARNTL2 ⇧ 1.36 0.045 
3994451 CXorf40A ⇧ 1.38 0.039  2820925 RHOBTB3 ⇩ 1.37 0.035  3781124 MIB1 ⇧ 1.36 1.22E-03 
2866590 LYSMD3 ⇩ 1.38 0.036  2369796 TOR1AIP1 ⇩ 1.37 0.012  2835021 PCYOX1L ⇩ 1.36 0.049 
3353914 VWA5A ⇩ 1.38 0.035  2351940 DDX20 ⇩ 1.37 0.026  3939545 MIF ⇧ 1.36 8.34E-03 
2608765 ARL8B ⇩ 1.38 2.21E-03  3914286 SOX18 ⇧ 1.37 0.036  2356181 RBM8A ⇩ 1.36 0.011 
3822216 IER2 ⇧ 1.38 4.17E-03  2899022 TRIM38 ⇩ 1.37 6.49E-04  2524743 FASTKD2 ⇩ 1.36 5.41E-03 
3417457 MYL6 ⇧ 1.38 0.044  2899243 HIST1H4F ⇩ 1.37 0.031  2457261 DUSP10 ⇩ 1.36 0.047 
3368398 CCDC73 ⇧ 1.38 0.023  2386747 GPR137B ⇩ 1.37 0.026  2544164 C2orf44 ⇩ 1.36 0.047 
3753500 SLFN11 ⇧ 1.38 0.022  2413484 YIPF1 ⇩ 1.37 0.036  2474322 C2orf28 ⇩ 1.36 5.42E-03 
2321849 DNAJC16 ⇩ 1.38 0.026  2649113 TIPARP ⇩ 1.37 0.026  3454680 TFCP2 ⇧ 1.36 2.59E-03 
2814642 MCCC2 ⇩ 1.38 9.52E-03  2476075 SPAST ⇩ 1.37 6.47E-03  3985644 TCEAL3 ⇩ 1.36 0.039 
2956438 MUT ⇩ 1.38 0.030  3444525 TAS2R46 ⇧ 1.37 0.014  2829562 TXNDC15 ⇩ 1.36 0.042 
3434413 RNF10 ⇧ 1.38 7.12E-03  2372781 RGS1 ⇩ 1.37 0.028  3589141 SPRED1 ⇧ 1.36 0.021 
2451544 MYOG ⇩ 1.38 0.026  3738205 MRPL12 ⇧ 1.37 0.018  3851150 ZNF433 ⇧ 1.36 2.54E-03 
3840372 ZNF701 ⇧ 1.38 0.045  3416943 GDF11 ⇧ 1.37 0.039  2902348 MICB ⇩ 1.36 0.022 
3431220 MVK ⇧ 1.38 9.02E-04  2599433 USP37 ⇩ 1.37 0.010  2457573 AIDA ⇧ 1.36 0.019 
4027532 GAB3 ⇧ 1.38 0.029  2678367 PDHB ⇩ 1.37 5.90E-03  2604254 HJURP ⇩ 1.36 0.047 
2855443 LOC100132356 ⇩ 1.37 0.014  2859195 DIMT1L ⇩ 1.37 0.010  2494484 NCAPH ⇩ 1.36 0.047 
2575949 TUBA3E ⇧ 1.37 1.54E-03  2336913 LRRC42 ⇩ 1.37 2.91E-03  2501697 ACTR3 ⇩ 1.36 1.66E-04 
2429338 SIKE1 ⇩ 1.37 4.50E-03  3044753 LSM5 ⇩ 1.37 0.033  3227454 QRFP ⇧ 1.36 0.048 
3854756 RAB3A ⇩ 1.37 0.020  3869714 ZNF611 ⇧ 1.37 0.026  3761054 COPZ2 ⇧ 1.36 8.49E-04 
3726960 NME2 ⇧ 1.37 9.19E-03  2527253 IGFBP2 ⇧ 1.37 0.049  2892277 NQO2 ⇩ 1.36 0.015 
2551786 MCFD2 ⇩ 1.37 0.015  3830277 USF2 ⇧ 1.36 8.24E-03  2784131 BBS7 ⇩ 1.35 0.011 
2818454 XRCC4 ⇩ 1.37 1.19E-03  3662444 NLRC5 ⇧ 1.36 7.37E-03  3230490 EDF1 ⇧ 1.35 5.01E-03 
2495782 LIPT1 ⇩ 1.37 0.022  3644887 TBC1D24 ⇩ 1.36 0.027  2330334 THRAP3 ⇩ 1.35 5.42E-03 
3738629 SLC16A3 ⇧ 1.37 0.047  3668898 ZFP1 ⇧ 1.36 9.63E-03  3223551 MEGF9 ⇩ 1.35 0.045 
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3029030 CASP2 ⇩ 1.35 0.017  3490251 WDFY2 ⇧ 1.34 3.56E-03  3385003 CREBZF ⇧ 1.33 0.021 
2642791 DNAJC13 ⇩ 1.35 2.04E-03  3644541 TRAF7 ⇧ 1.34 0.015  3705967 SERPINF1 ⇧ 1.33 0.043 
2835006 GRPEL2 ⇩ 1.35 0.029  2546008 S⇧T7L ⇩ 1.34 5.45E-03  2512330 MARCH7 ⇩ 1.33 1.92E-03 
2316245 PRKCZ ⇩ 1.35 0.033  3884793 SLC32A1 ⇧ 1.34 0.043  3835966 RELB ⇧ 1.33 0.034 
3468925 NFYB ⇧ 1.35 5.14E-04  2676219 PBRM1 ⇩ 1.34 0.019  2477302 CCDC75 ⇧ 1.33 0.031 
3666649 VPS4A ⇧ 1.35 0.014  3665997 DUS2L ⇩ 1.34 0.026  3571542 PNMA1 ⇧ 1.33 2.50E-03 
2425118 SASS6 ⇩ 1.35 0.013  3225096 NR6A1 ⇧ 1.34 0.026  3315024 ADAM8 ⇧ 1.33 0.016 
2355615 SEC22B ⇩ 1.35 2.53E-03  2954527 ZNF318 ⇩ 1.34 0.015  3851703 C19orf43 ⇧ 1.33 0.019 
3739162 TBCD ⇧ 1.35 7.60E-03  3510858 FOXO1 ⇧ 1.34 0.047  2517737 PLEKHA3 ⇧ 1.33 0.033 
3119376 C8orf31 ⇩ 1.35 0.015  2708817 TMEM41A ⇩ 1.34 0.033  2460519 EXOC8 ⇩ 1.33 0.014 
3108433 MTDH ⇩ 1.35 0.046  3346584 BIRC2 ⇧ 1.34 4.57E-03  2734018 MRPS18C ⇧ 1.33 0.018 
3182409 ZNF189 ⇧ 1.35 0.016  2366184 TBX19 ⇩ 1.34 7.12E-03  2906607 NFYA ⇩ 1.32 3.62E-03 
3673091 BANP ⇧ 1.35 5.70E-04  2362394 IFI16 ⇩ 1.34 4.80E-04  3892660 RPS21 ⇧ 1.32 0.018 
3824395 PGLS ⇧ 1.35 2.64E-03  2673902 QRICH1 ⇩ 1.34 6.02E-03  2541944 SMC6 ⇩ 1.32 3.27E-03 
2636726 QTRTD1 ⇩ 1.35 7.39E-03  3421762 RAB3IP ⇧ 1.34 2.84E-03  3770699 MIF4GD ⇩ 1.32 0.011 
2385258 C1orf124 ⇩ 1.35 0.026  2434892 VPS72 ⇩ 1.34 0.019  2835531 NDST1 ⇩ 1.32 0.032 
2447993 C1orf25 ⇩ 1.35 5.97E-04  3195296 SSNA1 ⇧ 1.34 0.036  2986493 PSMB1 ⇩ 1.32 3.30E-03 
3191338 GPR107 ⇩ 1.35 0.032  3989678 XIAP ⇧ 1.34 0.011  3468301 PMCH ⇧ 1.32 1.38E-03 
3456313 ATP5G2 ⇧ 1.35 0.035  2757319 SLBP ⇩ 1.34 0.049  3204261 CCL27 ⇧ 1.32 0.020 
3816264 DOT1L ⇧ 1.35 0.034  3346147 ARHGAP42 ⇧ 1.34 0.028  2339511 ATG4C ⇩ 1.32 0.019 
2439345 OR6Y1 ⇩ 1.35 5.79E-03  2899146 HIST1H4C ⇧ 1.34 0.048  3421824 C12orf28 ⇧ 1.32 0.016 
3476665 SCARB1 ⇧ 1.35 0.012  2404254 PUM1 ⇩ 1.33 1.76E-06  3448428 C12orf11 ⇧ 1.32 4.28E-03 
2559807 MOBKL1B ⇩ 1.35 0.020  2342665 MSH4 ⇧ 1.33 4.84E-03  2519756 WDR75 ⇩ 1.32 0.030 
2318637 VAMP3 ⇩ 1.35 5.88E-03  3837464 GLTSCR2 ⇧ 1.33 0.044  3870162 ZNF665 ⇧ 1.32 4.48E-04 
2603395 HTR2B ⇩ 1.34 0.031  2456849 RAB3GAP2 ⇩ 1.33 7.80E-04  2575196 SAP130 ⇩ 1.32 3.22E-03 
3752097 C17orf42 ⇧ 1.34 0.036  3985665 TCEAL1 ⇧ 1.33 0.016  3334501 PRDX5 ⇧ 1.32 0.034 
3564210 PYGL ⇧ 1.34 0.048  3409432 CCDC91 ⇧ 1.33 0.038  3601840 CSK ⇧ 1.32 0.026 
3929395 GCFC1 ⇧ 1.34 0.044  3836044 GEMIN7 ⇧ 1.33 0.027  3855071 FKBP8 ⇧ 1.32 4.37E-03 
3726772 LUC7L3 ⇧ 1.34 0.019  3864286 PSG9 ⇧ 1.33 0.033  3825838 YJEFN3 ⇧ 1.32 5.28E-03 
2893895 BMP6 ⇧ 1.34 0.011  4019465 NKRF ⇧ 1.33 0.039  2841184 ERGIC1 ⇩ 1.32 0.020 
2986084 PHF10 ⇧ 1.34 0.045  2997952 STARD3NL ⇩ 1.33 0.040  3103494 TMEM70 ⇩ 1.32 0.015 
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3348189 FDX1 ⇧ 1.32 5.30E-03  2723710 PGM2 ⇩ 1.31 0.028  2694785 MBD4 ⇩ 1.30 0.011 
3828162 C19orf2 ⇧ 1.32 7.18E-03  3418513 MARCH9 ⇧ 1.31 9.44E-03  2811745 IPO11 ⇩ 1.30 0.037 
2328936 ZBTB8A ⇩ 1.32 0.048  2892341 RIPK1 ⇩ 1.31 0.046  3075550 ZC3HAV1L ⇧ 1.30 0.049 
2550959 PREPL ⇩ 1.32 3.36E-03  2545092 HADHA ⇩ 1.31 0.017  3831168 CAPNS1 ⇩ 1.30 0.047 
3761313 HOXB3 ⇧ 1.32 0.023  2358221 RPRD2 ⇩ 1.31 0.023  3409364 KLHDC5 ⇧ 1.30 0.014 
2901660 PRR3 ⇩ 1.32 0.014  3197014 GLIS3 ⇩ 1.31 0.029  2950515 VPS52 ⇩ 1.30 0.038 
3693837 GOT2 ⇧ 1.32 0.045  3578089 C14orf49 ⇧ 1.31 0.030  2430370 GDAP2 ⇩ 1.30 0.010 
3947627 TSPO ⇧ 1.32 0.049  2636272 GTPBP8 ⇩ 1.31 0.025  3923896 KRTAP10-12 ⇧ 1.30 9.09E-03 
2516332 SCRN3 ⇩ 1.32 0.027  3229591 UBAC1 ⇧ 1.30 0.012  2429069 TRIM33 ⇩ 1.30 1.23E-03 
3081707 MNX1 ⇧ 1.32 7.74E-03  2930753 C6orf72 ⇩ 1.30 0.032  3766960 SMURF2 ⇧ 1.30 0.042 
3337168 GSTP1 ⇧ 1.32 6.93E-03  3673684 CDT1 ⇧ 1.30 0.020  2555630 CCT4 ⇩ 1.30 1.24E-03 
2909723 CENPQ ⇩ 1.32 0.037  3809671 NARS ⇩ 1.30 0.010  3670772 CMIP ⇧ 1.30 0.025 
2659887 FYTTD1 ⇩ 1.32 0.029  3655723 MVP ⇧ 1.30 6.94E-03  3402935 TPI1 ⇧ 1.30 0.042 
2662491 TMEM111 ⇩ 1.31 0.044  2595443 WDR12 ⇩ 1.30 0.037  3608787 SLCO3A1 ⇧ 1.30 8.82E-03 
3418298 KIF5A ⇧ 1.31 8.72E-03  2949210 BAT4 ⇩ 1.30 0.024  3135184 RB1CC1 ⇧ 1.30 4.99E-03 
3697090 ST3GAL2 ⇧ 1.31 0.033  2631845 CHMP2B ⇩ 1.30 0.032  2458649 C1orf55 ⇩ 1.30 0.022 
2826064 SRFBP1 ⇩ 1.31 6.21E-03  3432333 PTPN11 ⇧ 1.30 0.043  3737647 CHMP6 ⇧ 1.29 0.012 
3712098 SNORD49A ⇧ 1.31 0.014  3636879 UBE2Q2P1 ⇧ 1.30 9.41E-03  3530002 KHNYN ⇧ 1.29 6.36E-03 
2398789 SDHB ⇩ 1.31 0.012  2446244 TOR1AIP1 ⇩ 1.30 0.037  3611126 MEF2A ⇧ 1.29 5.06E-03 
3503224 ⇧F3A ⇧ 1.31 3.68E-03  2336706 CPT2 ⇩ 1.30 0.013  3822723 PKN1 ⇧ 1.29 0.015 
3784727 ELP2 ⇧ 1.31 0.012  3423184 ZDHHC17 ⇧ 1.30 0.022  3642604 MPG ⇧ 1.29 4.58E-04 
3821847 ASNA1 ⇧ 1.31 8.07E-03  2676319 GLT8D1 ⇩ 1.30 0.041  3642390 TARSL2 ⇧ 1.29 0.026 
3707715 RPAIN ⇧ 1.31 8.62E-03  4026842 ARHGAP4 ⇧ 1.30 0.025  3424442 TMTC2 ⇧ 1.29 0.041 
3947310 C22orf32 ⇧ 1.31 0.029  3308864 RAB11FIP2 ⇧ 1.30 0.038  3570599 MAP3K9 ⇧ 1.29 1.13E-03 
2623515 ALAS1 ⇩ 1.31 8.37E-03  3338552 CTTN ⇧ 1.30 0.016  2726323 SLAIN2 ⇩ 1.29 0.011 
2325526 SRRM1 ⇩ 1.31 0.016  2344542 RPF1 ⇩ 1.30 0.021  2328990 RBBP4 ⇩ 1.29 0.046 
2876046 PPP2CA ⇩ 1.31 0.021  3476457 NCOR2 ⇧ 1.30 7.62E-03  3713195 SMCR8 ⇩ 1.29 0.035 
3292413 DNAJC12 ⇧ 1.31 0.015  2437645 GON4L ⇩ 1.30 4.30E-03  2822407 PPIP5K2 ⇩ 1.29 0.032 
2548274 STRN ⇩ 1.31 5.60E-03  3026599 TRIM24 ⇩ 1.30 8.24E-03  3417435 MYL6B ⇧ 1.29 0.018 
3882720 RALY ⇧ 1.31 0.017  2542737 LAPTM4A ⇩ 1.30 0.036  3304718 PCGF6 ⇧ 1.29 0.010 
3465409 BTG1 ⇧ 1.31 9.38E-04  3834519 ARHGEF1 ⇧ 1.30 0.018  3241601 C10orf68 ⇧ 1.29 0.048 
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3829020 PDCD5 ⇧ 1.29 0.039  2745288 IL15 ⇧ 1.28 6.72E-03  3348891 C11orf57 ⇧ 1.28 0.024 
3161566 KDM4C ⇧ 1.29 0.016  3218496 OR13C9 ⇧ 1.28 0.030  2744597 NAA15 ⇩ 1.28 0.018 
2396121 DFFA ⇩ 1.29 0.021  3331129 OR5AK2 ⇧ 1.28 0.015  3303530 NDUFB8 ⇧ 1.28 3.94E-03 
2336099 OSBPL9 ⇩ 1.29 6.17E-03  2548402 EIF2AK2 ⇩ 1.28 0.020  2559649 DUSP11 ⇩ 1.28 0.035 
3537164 PELI2 ⇧ 1.29 0.028  2360083 UBAP2L ⇩ 1.28 1.62E-04  2363444 USP21 ⇩ 1.28 0.021 
3088983 XPO7 ⇩ 1.29 6.96E-03  3015178 ZSCAN21 ⇩ 1.28 0.025  2570616 BUB1 ⇩ 1.28 0.049 
3389745 CWF19L2 ⇧ 1.29 0.025  3381241 ARAP1 ⇧ 1.28 0.040  3747324 ZNF624 ⇧ 1.28 1.48E-03 
2928392 VTA1 ⇩ 1.29 0.017  3243078 ZNF33A ⇧ 1.28 0.031  3415812 ZNF740 ⇧ 1.28 5.93E-03 
3697125 COG4 ⇧ 1.29 0.041  3229943 SDCCAG3 ⇧ 1.28 6.68E-03  3538789 SLC38A6 ⇧ 1.27 0.039 
3396883 RPUSD4 ⇧ 1.29 0.015  3614087 UBE3A ⇧ 1.28 0.018  3992148 DDX26B ⇧ 1.27 0.020 
3535515 FRMD6 ⇧ 1.29 0.013  3578069 C14orf139 ⇧ 1.28 0.028  2601021 FARSB ⇩ 1.27 0.027 
3177563 NAA35 ⇧ 1.29 6.44E-03  2349086 DPH5 ⇧ 1.28 0.043  2522728 CASP8 ⇩ 1.27 0.033 
3037142 PMS2 ⇩ 1.29 0.011  3195174 MAN1B1 ⇧ 1.28 3.14E-03  3018484 GPR22 ⇧ 1.27 9.27E-04 
3687715 TBC1D10B ⇧ 1.29 0.021  3865511 EML2 ⇧ 1.28 0.018  3851267 ZNF625 ⇧ 1.27 0.047 
3472225 DDX54 ⇧ 1.29 7.96E-03  3390852 C11orf92 ⇧ 1.28 0.038  3191176 USP20 ⇧ 1.27 5.65E-04 
3181193 TDRD7 ⇧ 1.29 0.026  3383081 INTS4 ⇩ 1.28 0.026  2528020 TTLL4 ⇩ 1.27 0.014 
2484305 PAPOLG ⇩ 1.29 0.023  3761127 CBX1 ⇧ 1.28 7.23E-03  3730899 DDX42 ⇧ 1.27 0.028 
3829857 ZNF302 ⇧ 1.29 7.44E-03  3403224 LOC283314 ⇧ 1.28 0.024  3349014 PTS ⇧ 1.27 0.010 
2436338 CRTC2 ⇩ 1.29 6.15E-04  2474527 NRBP1 ⇩ 1.28 0.033  2681157 TMF1 ⇩ 1.27 0.030 
3416344 HOXC9 ⇧ 1.29 6.41E-03  3386638 SLC36A4 ⇧ 1.28 0.048  3942161 UQCR10 ⇧ 1.27 5.85E-03 
3088544 ATP6V1B2 ⇩ 1.29 0.020  3382015 CHRDL2 ⇧ 1.28 0.029  3429555 EID3 ⇧ 1.27 4.09E-03 
3067080 COG5 ⇩ 1.29 0.015  3320604 USP47 ⇧ 1.28 4.16E-03  2671652 ZDHHC3 ⇩ 1.27 0.041 
2877465 ETF1 ⇩ 1.29 0.045  2693937 TPRA1 ⇩ 1.28 0.014  3243164 ZNF37A ⇧ 1.27 0.032 
4013224 ATRX ⇧ 1.29 0.010  2950329 HLA-DPA1 ⇩ 1.28 0.040  2714230 PCGF3 ⇩ 1.27 0.032 
3932148 BRWD1 ⇧ 1.29 0.024  2531522 CAB39 ⇩ 1.28 0.048  2717059 LOC93622 ⇧ 1.27 0.021 
3464622 CEP290 ⇧ 1.29 5.10E-03  2356205 PEX11B ⇩ 1.28 0.012  3803418 KLHL14 ⇧ 1.27 0.034 
2866225 MEF2C ⇩ 1.28 2.81E-03  3292735 SLC25A16 ⇧ 1.28 7.85E-03  3474228 RAB35 ⇧ 1.27 7.94E-03 
3831698 ZNF420 ⇧ 1.28 1.59E-03  2320210 UBIAD1 ⇩ 1.28 0.035  3009959 PTPN12 ⇩ 1.27 0.025 
3345774 JRKL ⇧ 1.28 0.023  2827388 PRRC1 ⇩ 1.28 0.022  3424379 C12orf26 ⇧ 1.27 0.020 
2515183 DCAF17 ⇩ 1.28 0.024  3447129 KIAA0528 ⇧ 1.28 2.01E-03  2347788 RWDD3 ⇧ 1.27 8.87E-03 
2920962 FIG4 ⇩ 1.28 0.020  3272795 PAOX ⇧ 1.28 5.97E-03  3975987 RBM10 ⇧ 1.27 0.014 
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2384375 DUSP5P ⇧ 1.27 0.024  4007734 TFE3 ⇧ 1.26 0.029  3962165 CENPM ⇧ 1.25 0.031 
3655877 INO80E ⇧ 1.27 7.36E-03  2721809 ZCCHC4 ⇩ 1.26 0.016  3847515 NDUFA11 ⇧ 1.25 6.94E-03 
2596201 NDUFS1 ⇩ 1.27 0.021  2436132 ILF2 ⇩ 1.26 0.038  3982560 P2RY10 ⇩ 1.25 0.047 
2421782 CCBL2 ⇩ 1.27 0.046  3757602 DHX58 ⇧ 1.26 0.045  3735346 C17orf106 ⇧ 1.25 0.011 
2600068 TUBA4A ⇩ 1.27 0.034  2411638 LOC100128922 ⇧ 1.26 0.033  3271220 CTAGE7P ⇧ 1.25 0.027 
3504134 GJA3 ⇧ 1.27 0.040  2943808 N⇧153 ⇩ 1.26 4.44E-03  2359036 SNX27 ⇩ 1.25 0.019 
3914230 ZNF512B ⇧ 1.27 4.61E-03  2741768 EXOSC9 ⇩ 1.26 9.17E-03  3489957 RNASEH2B ⇧ 1.25 0.032 
2662520 CIDECP ⇩ 1.27 6.96E-03  3815493 HMHA1 ⇧ 1.26 0.019  3756344 SMARCE1 ⇧ 1.25 0.022 
3514711 CTAGE3P ⇧ 1.27 0.016  2766359 RFC1 ⇩ 1.26 0.031  3939707 CABIN1 ⇧ 1.25 0.018 
2695200 PIK3R4 ⇩ 1.27 0.047  2772968 COX18 ⇩ 1.26 0.033  3459956 C12orf66 ⇧ 1.25 0.017 
3466826 CDK17 ⇧ 1.27 8.12E-03  3846114 AES ⇧ 1.26 0.049  3228097 TTF1 ⇧ 1.25 0.046 
3476012 MPHOSPH9 ⇧ 1.27 0.022  3320717 MICAL2 ⇩ 1.26 0.038  2862716 GFM2 ⇩ 1.25 0.017 
3955940 CRYBB1 ⇩ 1.27 0.014  3015216 COPS6 ⇩ 1.26 0.036  2641263 RAB7A ⇩ 1.25 0.013 
3110171 ATP6V1C1 ⇩ 1.27 0.026  3859622 ZNF792 ⇧ 1.26 0.025  3816686 ZNF556 ⇧ 1.25 4.84E-03 
3457315 WIBG ⇧ 1.26 0.034  3849688 ZNF266 ⇧ 1.26 0.025  3944620 MPST ⇧ 1.25 0.024 
2616317 PDCD6IP ⇩ 1.26 5.02E-03  3866302 AP2S1 ⇧ 1.26 0.025  3808096 MEX3C ⇧ 1.25 0.030 
2860614 CCDC125 ⇩ 1.26 0.042  2466039 ZNF692 ⇩ 1.26 0.026  2908100 POLH ⇩ 1.25 0.015 
3372235 RAPSN ⇩ 1.26 0.022  2688070 GUCA1C ⇧ 1.26 0.028  3317223 IGF2AS ⇧ 1.25 0.021 
3674559 DEF8 ⇧ 1.26 0.044  3169043 RG9MTD3 ⇧ 1.26 0.041  3886050 SRSF6 ⇧ 1.25 1.25E-03 
3768880 ABCA10 ⇧ 1.26 0.040  3212728 AGTPBP1 ⇧ 1.26 0.020  2621949 NDUFAF3 ⇩ 1.25 0.020 
2821417 LNPEP ⇩ 1.26 0.033  4053462 KLHL17 ⇧ 1.26 5.62E-04  3830002 GRAMD1A ⇧ 1.25 0.013 
4000269 GEMIN8 ⇧ 1.26 0.032  3478457 STX2 ⇧ 1.26 0.030  3202224 LRRC19 ⇧ 1.25 7.29E-03 
3214359 AUH ⇧ 1.26 1.89E-03  3299782 FLJ37201 ⇧ 1.26 0.019  2526759 ATIC ⇩ 1.25 0.034 
3949097 TRMU ⇧ 1.26 5.11E-04  3708160 ALOX12 ⇧ 1.25 1.51E-03  3352813 TBCEL ⇧ 1.25 0.025 
3704896 CHMP1A ⇧ 1.26 7.89E-03  2541230 NBAS ⇩ 1.25 0.011  3923632 PFKL ⇧ 1.25 1.70E-03 
3197479 INSL6 ⇧ 1.26 0.022  3343202 EED ⇧ 1.25 0.035  3710681 MAP2K4 ⇧ 1.25 0.031 
3741383 OR1E2 ⇧ 1.26 5.36E-03  3735847 SEPT9 ⇧ 1.25 0.046  3224650 DENND1A ⇧ 1.25 0.040 
3056292 CLDN3 ⇧ 1.26 3.53E-03  2963929 RNGTT ⇩ 1.25 6.19E-03  2595252 SUMO1 ⇧ 1.25 0.024 
2462456 HEATR1 ⇩ 1.26 0.028  3846783 UBXN6 ⇧ 1.25 8.89E-03  3702689 ZDHHC7 ⇧ 1.25 0.025 
2978989 LATS1 ⇩ 1.26 0.014  2712632 TFRC ⇩ 1.25 0.047  3870054 ZNF160 ⇧ 1.25 0.033 
3729123 DHX40 ⇧ 1.26 0.018  3817167 MRPL54 ⇧ 1.25 0.041  3199790 PSIP1 ⇧ 1.25 0.027 







Table B19: C9-LongvShort Gene List (n=1,024) MALE ONLY SAMPLES [Partek® unadjusted p<0.05, FC ≥ ±1.20]   
 622 
 
3671850 KLHL36 ⇧ 1.25 0.014  3637006 SEC11A ⇧ 1.24 0.044  2396480 EXOSC10 ⇩ 1.23 6.36E-04 
3394183 H2AFX ⇧ 1.25 0.035  3804143 RPRD1A ⇧ 1.24 0.027  3758845 HDAC5 ⇧ 1.23 0.027 
3030448 ZNF398 ⇩ 1.25 0.044  3427876 APAF1 ⇧ 1.24 0.036  3833323 ZNF546 ⇧ 1.23 0.035 
2852333 ZFR ⇩ 1.25 3.52E-03  2525272 PIKFYVE ⇩ 1.24 0.014  3747966 SREBF1 ⇧ 1.23 0.017 
2882555 FAM114A2 ⇩ 1.25 0.014  3716337 CCDC55 ⇧ 1.24 0.047  2659918 LRCH3 ⇩ 1.23 0.032 
3761348 HOXB4 ⇧ 1.24 0.041  2544925 ASXL2 ⇩ 1.24 0.013  3713874 MAPK7 ⇧ 1.23 1.83E-03 
2759857 ACOX3 ⇩ 1.24 0.038  3416114 TARBP2 ⇧ 1.24 0.011  2843619 HNRNPAB ⇩ 1.23 0.040 
3845365 TCF3 ⇧ 1.24 0.021  3045739 HERPUD2 ⇩ 1.24 0.034  3481543 SPATA13 ⇧ 1.23 0.046 
3949229 TBC1D22A ⇧ 1.24 0.016  3724989 CDK5RAP3 ⇧ 1.24 0.045  3303913 FBXW4 ⇧ 1.23 4.40E-03 
2890859 MGAT1 ⇧ 1.24 0.025  2392421 PEX10 ⇩ 1.24 0.035  2564816 ANKRD36B ⇧ 1.23 0.039 
2729884 UGT2B10 ⇧ 1.24 0.027  2389789 SCCPDH ⇩ 1.24 0.030  3414632 DIP2B ⇧ 1.23 0.045 
3431426 IFT81 ⇧ 1.24 0.015  3027808 AGK ⇩ 1.24 0.026  2456746 EPRS ⇩ 1.23 0.022 
2331511 BMP8A ⇧ 1.24 0.046  3046556 TARP ⇧ 1.24 0.032  3412008 PPHLN1 ⇧ 1.23 0.031 
3671448 HSBP1 ⇧ 1.24 0.026  2742093 BBS12 ⇩ 1.24 9.65E-03  3015778 EPO ⇩ 1.23 0.029 
2612175 NR2C2 ⇩ 1.24 1.94E-03  3791168 KIAA1468 ⇧ 1.24 0.023  2320374 FBXO6 ⇩ 1.23 0.022 
3829575 LSM14A ⇧ 1.24 0.032  2678029 DNAH12 ⇧ 1.24 0.019  3131720 BRF2 ⇧ 1.23 0.019 
3843525 ZNF586 ⇧ 1.24 0.022  3018652 CBLL1 ⇩ 1.24 0.033  2975680 BCLAF1 ⇩ 1.23 0.044 
3662170 MT1DP ⇧ 1.24 1.67E-03  3747657 FLCN ⇧ 1.24 0.013  2693569 ZXDC ⇩ 1.23 0.010 
2796384 IRF2 ⇩ 1.24 0.026  3874249 ITPA ⇩ 1.24 0.035  2504645 MYO7B ⇩ 1.23 0.024 
3601675 ARID3B ⇧ 1.24 0.040  3860596 ZNF461 ⇧ 1.23 0.027  3740201 MYO1C ⇧ 1.23 0.027 
2815331 BTF3 ⇧ 1.24 0.034  3834651 ZNF526 ⇧ 1.23 6.27E-03  2675628 VPRBP ⇩ 1.23 0.031 
3359469 NAP1L4 ⇧ 1.24 0.023  3474344 RPLP0 ⇧ 1.23 0.013  2535927 GPR35 ⇩ 1.23 0.024 
2647898 MED12L ⇧ 1.24 0.043  2604223 DNAJB3 ⇧ 1.23 0.036  3687849 ZNF764 ⇧ 1.23 0.044 
3928534 KRTAP19-4 ⇧ 1.24 0.048  3851250 ZNF20 ⇧ 1.23 0.032  2831719 ANKHD1 ⇩ 1.23 6.43E-03 
3960827 SUN2 ⇧ 1.24 0.035  3185205 HSDL2 ⇩ 1.23 0.026  3946563 RBX1 ⇧ 1.23 2.85E-04 
3419239 MON2 ⇧ 1.24 2.31E-03  2739079 SEC24B ⇩ 1.23 0.011  3421446 CPSF6 ⇧ 1.23 5.81E-03 
3145953 RPL30 ⇧ 1.24 0.029  3378867 TMEM134 ⇧ 1.23 0.028  3018696 DLD ⇩ 1.23 0.019 
4019900 CUL4B ⇧ 1.24 0.028  3245783 WDFY4 ⇧ 1.23 0.035  3701297 CDYL2 ⇩ 1.23 0.037 
3272027 LRRC27 ⇧ 1.24 0.011  3642707 ITFG3 ⇧ 1.23 0.032  3358174 IRF7 ⇧ 1.23 0.038 
2851274 CDH10 ⇧ 1.24 1.72E-03  3894098 C20orf96 ⇩ 1.23 0.041  3540862 GPHN ⇧ 1.23 0.046 
3856720 ZNF99 ⇧ 1.24 0.038  2901841 ATAT1 ⇩ 1.23 0.011  2950242 PPP1R2P1 ⇧ 1.23 8.19E-03 
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2419235 FUBP1 ⇩ 1.23 4.11E-05  3401099 FKBP4 ⇧ 1.22 0.037  3893796 DNAJC5 ⇧ 1.21 0.049 
2837499 LSM11 ⇧ 1.23 8.67E-03  3479438 CHFR ⇧ 1.22 0.040  3908786 STAU1 ⇧ 1.21 0.028 
3276421 KIN ⇧ 1.23 0.045  2408855 FOXJ3 ⇩ 1.22 0.026  3817222 ITGB1BP3 ⇧ 1.21 0.023 
3592366 SPATA5L1 ⇧ 1.22 0.033  2400373 EIF4G3 ⇩ 1.22 8.98E-03  3824713 ARRDC2 ⇧ 1.21 4.12E-03 
3708462 ACAP1 ⇧ 1.22 6.82E-03  2333907 RNF220 ⇩ 1.22 3.58E-03  3478957 DDX51 ⇧ 1.21 3.80E-03 
3119735 ZNF623 ⇩ 1.22 0.032  2971692 MCM9 ⇧ 1.22 0.026  3419849 TBK1 ⇧ 1.21 0.011 
2878446 NDUFA2 ⇩ 1.22 0.034  3458783 CDK4 ⇧ 1.22 0.046  4009062 KDM5C ⇧ 1.21 0.015 
2909404 CD2AP ⇩ 1.22 0.012  3696016 PSMB10 ⇧ 1.22 2.28E-03  3938113 HIC2 ⇧ 1.21 0.043 
2877314 CDC23 ⇩ 1.22 6.26E-03  3135156 FAM150A ⇧ 1.22 0.037  2502952 TMEM177 ⇩ 1.21 0.036 
2470654 DDX1 ⇩ 1.22 0.039  2532510 GIGYF2 ⇩ 1.22 2.12E-03  2545750 EIF2B4 ⇩ 1.21 0.026 
3589947 BAHD1 ⇧ 1.22 0.026  3892409 LSM14B ⇧ 1.22 0.020  2459866 N⇧133 ⇩ 1.21 0.038 
2352228 CAPZA1 ⇩ 1.22 3.27E-03  3260957 LZTS2 ⇧ 1.22 0.010  3667902 DHX38 ⇧ 1.21 0.012 
2662020 RAD18 ⇩ 1.22 0.030  3407229 AEBP2 ⇧ 1.22 0.015  3063727 TAF6 ⇩ 1.21 0.025 
3850409 KRI1 ⇧ 1.22 0.039  2717049 MRFAP1 ⇧ 1.22 0.044  3840642 ZNF818P ⇧ 1.21 0.024 
3962293 CYP2D7P1 ⇧ 1.22 0.047  3602569 C15orf27 ⇧ 1.22 0.035  3279410 FAM188A ⇧ 1.21 0.020 
3668834 ZNRF1 ⇧ 1.22 0.045  2618940 CTNNB1 ⇩ 1.22 8.41E-03  2806231 BRIX1 ⇩ 1.21 0.041 
3869761 ZNF600 ⇧ 1.22 0.033  2435044 POGZ ⇩ 1.22 0.010  2507495 UBXN4 ⇩ 1.21 0.033 
3438417 SFSWAP ⇧ 1.22 0.016  3250726 KIAA1274 ⇧ 1.22 0.038  3347549 CUL5 ⇧ 1.21 0.040 
3924100 C21orf89 ⇧ 1.22 0.048  3159754 DMRT2 ⇧ 1.22 1.27E-03  3292448 HERC4 ⇧ 1.21 0.027 
2358171 PRPF3 ⇩ 1.22 8.26E-03  3770588 NT5C ⇧ 1.22 6.42E-03  3816988 FZR1 ⇧ 1.21 0.015 
2947572 TRIM27 ⇩ 1.22 0.038  3662265 N⇧93 ⇩ 1.22 0.038  2835960 G3BP1 ⇩ 1.21 3.30E-03 
2594569 ORC2 ⇩ 1.22 0.027  2452319 RBBP5 ⇩ 1.21 9.16E-04  3566304 EXOC5 ⇧ 1.21 0.043 
3216476 ZNF510 ⇧ 1.22 0.037  2775756 SEC31A ⇩ 1.21 2.46E-03  3230371 LCN10 ⇩ 1.21 5.27E-03 
3980981 ITGB1BP2 ⇧ 1.22 0.013  3959829 IFT27 ⇧ 1.21 0.043  3202293 C9orf11 ⇧ 1.21 0.019 
3916576 GABPA ⇧ 1.22 7.22E-03  2773756 G3BP2 ⇩ 1.21 0.031  2319881 PEX14 ⇩ 1.21 0.011 
3674349 ZNF276 ⇧ 1.22 0.034  3358361 PDDC1 ⇧ 1.21 0.048  3603295 CRABP1 ⇧ 1.21 0.017 
2477980 GEMIN6 ⇩ 1.22 0.042  2800906 MTRR ⇩ 1.21 0.033  2964327 LYRM2 ⇧ 1.21 0.038 
3358262 DEAF1 ⇧ 1.22 0.043  3658980 GPT2 ⇧ 1.21 0.013  2545653 MPV17 ⇩ 1.21 5.25E-03 
3504526 LATS2 ⇧ 1.22 0.035  2407191 GNL2 ⇩ 1.21 0.045  3267273 GRK5 ⇧ 1.21 0.044 
2519140 ZC3H15 ⇩ 1.22 0.025  2461786 ARID4B ⇩ 1.21 0.041  2464499 HNRNPU ⇩ 1.21 0.017 
2815043 TNPO1 ⇩ 1.22 5.05E-03  2695941 TOPBP1 ⇩ 1.21 0.031  3844656 POLRMT ⇧ 1.21 0.037 
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2756831 SLC26A1 ⇩ 1.21 9.71E-03  2902013 GTF2H4 ⇩ 1.20 0.048  3060300 SRI ⇩ 1.20 0.048 
2367154 BAT2L2 ⇩ 1.21 1.55E-03  2451139 ARL8A ⇩ 1.20 0.036  2993639 CBX3 ⇧ 1.20 0.014 
3281068 PIP4K2A ⇧ 1.21 0.011  3832865 NCCRP1 ⇧ 1.20 0.029  3545403 GSTZ1 ⇧ 1.20 0.019 
3559497 STRN3 ⇧ 1.21 0.031  3514488 INTS6 ⇧ 1.20 0.021  3977083 CCDC22 ⇧ 1.20 0.014 
2512601 TANK ⇩ 1.21 0.040  3299469 ANKRD22 ⇧ 1.20 0.014  3929272 TCP10L ⇧ 1.20 0.031 
3406195 C12orf60 ⇧ 1.21 4.83E-03  2440143 COPA ⇩ 1.20 0.013  3532560 BRMS1L ⇧ 1.20 0.028 
3441955 MRPL51 ⇧ 1.21 0.038  3157901 PLEC ⇧ 1.20 0.038  2536531 FARP2 ⇩ 1.20 0.047 
3923498 PWP2 ⇧ 1.21 0.028  3740479 PRPF8 ⇩ 1.20 9.92E-03  3732885 PRKAR1A ⇩ 1.20 0.024 
3503976 PSPC1 ⇧ 1.21 0.037  3362934 ZBED5 ⇧ 1.20 0.036  3330919 OR5T3 ⇧ 1.20 0.018 
3862167 FBL ⇧ 1.21 0.019  3339423 INPPL1 ⇧ 1.20 3.16E-03  3157311 LY6H ⇧ 1.20 0.011 
3832830 PAK4 ⇧ 1.21 1.77E-03  3334257 FERMT3 ⇧ 1.20 0.033  3873185 RBCK1 ⇧ 1.20 0.011 
3825201 UBA52 ⇧ 1.21 0.011  3458337 STAT6 ⇧ 1.20 0.022  3955327 C22orf13 ⇧ 1.20 0.026 
3029213 TAS2R41 ⇩ 1.21 0.043  2602901 TRIP12 ⇩ 1.20 1.98E-03  3742727 DHX33 ⇧ 1.20 0.049 
3849190 ACTL9 ⇧ 1.21 0.042  3091628 ELP3 ⇩ 1.20 0.023  3739867 NXN ⇧ 1.20 0.016 
2336383 PRPF38A ⇩ 1.21 0.030  3633109 ULK3 ⇧ 1.20 0.011  3488253 COG3 ⇧ 1.20 0.032 
2321911 DDI2 ⇩ 1.21 0.044  2333599 IPO13 ⇩ 1.20 0.049  2908572 CDC5L ⇩ 1.20 0.036 
3699133 FA2H ⇩ 1.21 0.015  3315835 PTDSS2 ⇧ 1.20 0.025  2684851 VGLL3 ⇧ 1.20 0.011 
2895159 HIVEP1 ⇩ 1.21 0.019  2514441 PPIG ⇩ 1.20 0.033  3468080 SYCP3 ⇧ 1.20 0.011 
3074362 CNOT4 ⇩ 1.21 0.021  3572869 C14orf4 ⇧ 1.20 0.037  2832431 PCDHB11 ⇩ 1.20 0.047 
2508611 ARHGAP15 ⇩ 1.21 0.031  3075566 ZC3HAV1 ⇩ 1.20 0.013  2921086 CDC40 ⇩ 1.20 6.63E-03 
3727499 TOM1L1 ⇧ 1.21 0.026  2396201 CASZ1 ⇩ 1.20 0.026  3629272 PIF1 ⇧ 1.20 0.016 
3290368 IPMK ⇧ 1.20 0.032  3576545 SMEK1 ⇧ 1.20 0.024  2479640 PPM1B ⇧ 1.20 0.037 
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Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value 
3369249 APIP ⇧ 2.93 5.73E-04  3743734 C17orf61 ⇧ 1.75 4.87E-04  3035892 GNA12 ⇧ 1.62 1.62E-03 
3403841 RIMKLB ⇧ 2.43 9.61E-03  3208355 CBWD3 ⇧ 1.75 0.027  2638789 CD86 ⇩ 1.62 0.026 
3617574 GOLGA8B ⇧ 2.42 0.014  3444336 PRR4 ⇧ 1.75 0.023  3760945 MRPL10 ⇧ 1.61 0.012 
3385175 PICALM ⇧ 2.27 5.14E-04  2363618 SDHC ⇩ 1.74 0.017  3074039 SLC35B4 ⇩ 1.61 0.016 
2899095 HIST1H4A ⇧ 2.17 8.67E-03  2946364 HIST1H3F ⇧ 1.74 0.029  2514122 LASS6 ⇩ 1.61 0.027 
2671101 ANO10 ⇩ 2.17 0.021  2437247 GBA ⇩ 1.73 0.036  2727762 SRD5A3 ⇩ 1.61 0.021 
2913694 CD109 ⇩ 2.00 0.021  2735362 HERC6 ⇩ 1.73 0.027  3564919 FERMT2 ⇧ 1.61 3.24E-03 
3945545 APOBEC3B ⇩ 2.00 7.73E-03  3324713 METT5D1 ⇧ 1.72 0.040  2766893 APBB2 ⇧ 1.60 0.037 
2878246 PFDN1 ⇩ 1.97 0.020  3507962 KATNAL1 ⇧ 1.71 1.77E-03  2668205 GLB1 ⇩ 1.60 0.018 
2638077 PLA1A ⇩ 1.96 0.013  2501317 LOC654433 ⇧ 1.71 8.02E-03  2788511 SLC10A7 ⇩ 1.59 0.019 
3577443 ASB2 ⇩ 1.96 0.038  2946319 HIST1H4D ⇧ 1.70 0.011  2820865 ARSK ⇩ 1.58 0.041 
2708855 LIPH ⇩ 1.93 0.012  3188111 PTGS1 ⇩ 1.70 0.049  2836451 MFAP3 ⇩ 1.58 0.011 
2633191 GPR15 ⇩ 1.92 0.033  3403077 C12orf57 ⇧ 1.68 2.50E-04  3818395 ALKBH7 ⇧ 1.58 0.030 
3942472 TCN2 ⇩ 1.92 0.028  2991233 AHR ⇩ 1.67 0.015  3260423 CUTC ⇧ 1.58 2.82E-03 
2409069 CCDC23 ⇧ 1.90 0.042  3470689 ALKBH2 ⇧ 1.67 1.47E-04  3619165 SRP14 ⇧ 1.58 9.88E-03 
2893392 LY86 ⇩ 1.90 3.16E-04  3410695 DNM1L ⇧ 1.66 0.019  2325192 RPL11 ⇧ 1.58 0.021 
2399743 AKR7A3 ⇩ 1.89 0.022  2514563 KLHL23 ⇧ 1.66 0.017  3166844 CHMP5 ⇧ 1.57 0.046 
3518086 TBC1D4 ⇧ 1.88 0.011  3160658 SLC1A1 ⇩ 1.65 0.033  3633699 NRG4 ⇧ 1.57 8.72E-03 
3617458 GOLGA8A ⇧ 1.85 0.044  2505993 POTEKP ⇧ 1.65 0.017  3903361 AHCY ⇧ 1.56 0.015 
3275729 IL2RA ⇩ 1.83 0.049  3173479 FOXD4L3 ⇧ 1.64 8.54E-03  3927226 APP ⇩ 1.56 0.033 
3142217 PAG1 ⇩ 1.82 0.043  3797295 L3MBTL4 ⇧ 1.64 0.046  3253438 RPS24 ⇧ 1.56 0.027 
3841621 LILRB4 ⇩ 1.81 0.023  2468622 ID2 ⇩ 1.64 0.020  3020273 CAV2 ⇧ 1.56 6.81E-03 
2418929 PIGK ⇩ 1.80 0.026  3427014 SNRPF ⇧ 1.64 0.016  3513995 DLEU2 ⇧ 1.56 0.027 
2369557 SOAT1 ⇩ 1.80 1.43E-03  3761632 SNF8 ⇧ 1.64 7.65E-04  3420854 DYRK2 ⇧ 1.55 0.037 
2395564 SLC2A5 ⇩ 1.78 0.040  3226097 ENG ⇩ 1.64 0.020  3851072 ACP5 ⇩ 1.55 0.036 
2963859 CNR1 ⇩ 1.78 0.031  4002148 EIF1AX ⇧ 1.63 1.06E-03  2766192 TLR10 ⇩ 1.55 6.06E-03 
2944025 TPMT ⇩ 1.78 0.026  3490741 SUGT1 ⇧ 1.63 1.97E-03  2587618 OLA1 ⇧ 1.55 3.61E-03 
2845274 CCDC127 ⇩ 1.77 2.06E-03  3462843 NAP1L1 ⇧ 1.63 0.012  3892452 LSM14B ⇧ 1.55 0.036 
2950145 HLA-DOB ⇩ 1.76 0.027  3288013 BMS1P1 ⇧ 1.63 2.42E-03  3770944 H3F3B ⇧ 1.55 0.015 
3362468 SBF2 ⇧ 1.76 2.50E-03  2792800 DDX60 ⇩ 1.63 0.046  3842301 ZNF581 ⇧ 1.55 0.012 
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3405515 APOLD1 ⇧ 1.54 9.47E-03  3512527 TPT1 ⇧ 1.50 6.16E-03  2608469 ITPR1 ⇩ 1.46 2.85E-03 
2370317 MR1 ⇩ 1.54 0.013  3444195 MAGOHB ⇧ 1.50 5.36E-04  3824212 DDA1 ⇧ 1.46 0.021 
3854454 BST2 ⇩ 1.54 0.042  3634811 CTSH ⇩ 1.50 0.038  3827218 RPSAP58 ⇧ 1.46 0.042 
3733911 SSTR2 ⇩ 1.54 0.038  3513856 EBPL ⇧ 1.50 0.010  3704495 APRT ⇧ 1.46 0.019 
2930243 SASH1 ⇩ 1.54 0.013  3916527 JAM2 ⇩ 1.50 0.023  2835021 PCYOX1L ⇩ 1.46 0.017 
3221543 CDC26 ⇧ 1.54 2.04E-03  2628682 ARL6IP5 ⇩ 1.50 0.031  3451264 YAF2 ⇧ 1.46 6.90E-03 
3542145 KIAA0247 ⇩ 1.53 9.98E-03  3784509 ZNF271 ⇧ 1.50 1.32E-03  2899022 TRIM38 ⇩ 1.46 7.33E-05 
3438027 RAN ⇧ 1.53 3.09E-04  3435490 DENR ⇧ 1.50 0.019  2320411 AGTRAP ⇩ 1.45 0.025 
3595846 FAM63B ⇧ 1.53 0.014  3447863 KRAS ⇧ 1.49 6.10E-03  2442134 TMCO1 ⇩ 1.45 0.010 
3169331 ALDH1B1 ⇧ 1.53 0.021  3250019 DDX50 ⇧ 1.49 6.95E-03  2970897 FRK ⇧ 1.45 0.046 
3072435 TMEM209 ⇩ 1.53 0.017  3103523 LY96 ⇩ 1.49 0.038  3458911 CTDSP2 ⇧ 1.45 0.012 
2542795 SDC1 ⇧ 1.53 0.033  2692411 PTPLB ⇩ 1.49 0.032  3917204 C21orf7 ⇧ 1.45 0.045 
3864551 PLAUR ⇩ 1.53 0.029  3962448 RRP7A ⇧ 1.49 0.015  3556966 HAUS4 ⇧ 1.45 0.025 
2977621 PLAGL1 ⇩ 1.53 0.017  3053691 GUSB ⇩ 1.48 3.26E-03  3712041 UBB ⇧ 1.45 0.016 
3263624 MXI1 ⇧ 1.53 0.027  3951732 CECR5 ⇧ 1.48 5.59E-03  3289392 FLJ31958 ⇧ 1.44 0.033 
2960955 SLC17A5 ⇩ 1.52 0.011  2363919 ATF6 ⇩ 1.48 2.10E-03  3341440 RN28S1 ⇧ 1.44 0.030 
2865050 RPS23 ⇧ 1.52 0.049  3837464 GLTSCR2 ⇧ 1.48 5.85E-03  2705748 NCEH1 ⇩ 1.44 0.046 
2330773 CDCA8 ⇩ 1.52 0.016  3167383 NUDT2 ⇧ 1.48 0.046  3189311 PBX3 ⇩ 1.44 6.07E-03 
2454661 TMEM206 ⇩ 1.52 0.025  3025740 TMEM140 ⇩ 1.48 0.027  3407793 PYROXD1 ⇧ 1.44 0.043 
3263944 PDCD4 ⇧ 1.52 0.012  2352106 CTTNBP2NL ⇩ 1.48 3.93E-03  2415084 JUN ⇩ 1.44 0.042 
3185063 UGCG ⇩ 1.52 0.011  3414440 C12orf62 ⇧ 1.48 5.67E-03  3336378 RBM14 ⇩ 1.44 0.035 
3742708 C1QBP ⇧ 1.52 0.019  3812385 CD226 ⇩ 1.48 0.028  3510963 SUGT1P3 ⇧ 1.44 0.024 
2796911 CCDC110 ⇧ 1.51 5.96E-03  3254337 C10orf57 ⇩ 1.48 0.038  3391255 IL18 ⇧ 1.44 0.042 
3475324 TMEM120B ⇧ 1.51 4.39E-03  3939545 MIF ⇧ 1.48 1.10E-03  3868905 CTU1 ⇧ 1.44 0.014 
3453837 TUBA1A ⇧ 1.51 0.041  3468925 NFYB ⇧ 1.47 1.41E-05  2437736 RIT1 ⇩ 1.44 0.034 
3388914 DCUN1D5 ⇧ 1.51 0.020  3061456 SAMD9L ⇩ 1.47 0.027  3770290 CD300LB ⇩ 1.44 0.033 
3147020 ZNF706 ⇧ 1.51 0.031  2523213 BMPR2 ⇩ 1.47 8.64E-03  3923702 TRPM2 ⇩ 1.44 0.047 
2946681 HIST1H2BJ ⇧ 1.51 0.029  3726960 NME2 ⇧ 1.47 1.97E-03  3547375 GPR65 ⇩ 1.44 0.038 
3712197 CCDC144A ⇧ 1.51 3.70E-03  3989678 XIAP ⇧ 1.47 1.29E-03  2820925 RHOBTB3 ⇩ 1.43 0.016 
2324616 HSPC157 ⇧ 1.50 0.021  3463522 PAWR ⇧ 1.46 0.024  2841184 ERGIC1 ⇩ 1.43 3.03E-03 
3433843 SUDS3 ⇧ 1.50 0.047  2403261 IFI6 ⇩ 1.46 0.018  2989435 C1GALT1 ⇩ 1.43 0.032 
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3345107 ANKRD49 ⇧ 1.43 6.11E-03  2939034 SERPINB9 ⇩ 1.41 0.035  2520138 MFSD6 ⇩ 1.39 0.026 
3892812 SLCO4A1 ⇩ 1.43 0.028  3985644 TCEAL3 ⇩ 1.41 0.021  3474344 RPLP0 ⇧ 1.39 1.70E-04 
3373487 OR5M1 ⇧ 1.43 4.61E-03  2437645 GON4L ⇩ 1.41 2.86E-04  3580769 CKB ⇧ 1.39 0.033 
3589141 SPRED1 ⇧ 1.43 7.47E-03  3130113 GTF2E2 ⇧ 1.41 7.46E-03  3997946 PRKX ⇧ 1.39 0.012 
2370123 XPR1 ⇩ 1.43 0.018  3748659 GRAP ⇧ 1.41 0.049  3916576 GABPA ⇧ 1.39 3.09E-05 
3942161 UQCR10 ⇧ 1.43 7.00E-05  3886050 SRSF6 ⇧ 1.41 3.21E-06  3962000 PMM1 ⇧ 1.39 1.30E-03 
3475838 VPS37B ⇧ 1.43 0.036  3829857 ZNF302 ⇧ 1.41 4.51E-04  2815331 BTF3 ⇧ 1.39 1.67E-03 
3928534 KRTAP19-4 ⇧ 1.43 1.55E-03  3720322 PPP1R1B ⇩ 1.41 3.98E-04  2367843 DARS2 ⇩ 1.39 0.013 
3221633 HDHD3 ⇩ 1.43 4.77E-03  3948047 PARVG ⇩ 1.40 0.025  3857171 ZNF675 ⇩ 1.39 0.029 
2409368 HYI ⇩ 1.43 0.037  3473727 WSB2 ⇧ 1.40 0.042  3762625 MBTD1 ⇧ 1.39 1.85E-03 
3460584 LLPH ⇧ 1.43 0.035  2876257 SAR1B ⇩ 1.40 0.036  3468301 PMCH ⇧ 1.39 2.19E-04 
2321849 DNAJC16 ⇩ 1.43 0.014  2398736 ATP13A2 ⇩ 1.40 0.040  3665857 NUTF2 ⇧ 1.39 1.57E-03 
3466284 NDUFA12 ⇧ 1.42 7.30E-03  2941784 NEDD9 ⇩ 1.40 0.024  2386867 LGALS8 ⇩ 1.39 0.011 
3864286 PSG9 ⇧ 1.42 9.19E-03  2363202 SLAMF7 ⇩ 1.40 0.027  3417345 RPL41 ⇧ 1.39 0.010 
2899146 HIST1H4C ⇧ 1.42 0.018  2949801 AGPAT1 ⇩ 1.40 5.05E-03  3390852 C11orf92 ⇧ 1.39 7.21E-03 
2726483 OCIAD1 ⇩ 1.42 0.016  2830638 KIF20A ⇩ 1.40 0.037  3042001 CYCS ⇧ 1.39 2.06E-03 
3722739 G6PC3 ⇩ 1.42 0.038  2372781 RGS1 ⇩ 1.40 0.020  3470964 GLTP ⇧ 1.39 0.018 
2336302 ZFYVE9 ⇧ 1.42 3.49E-03  3207241 FLJ20444 ⇧ 1.40 0.038  3454740 PHB ⇧ 1.39 0.021 
3824395 PGLS ⇧ 1.42 4.49E-04  2899413 BTN3A3 ⇩ 1.40 0.016  3304004 NPM3 ⇧ 1.38 0.039 
2369796 TOR1AIP1 ⇩ 1.42 5.67E-03  3636956 WDR73 ⇧ 1.40 3.45E-03  4015693 TIMM8A ⇧ 1.38 7.68E-04 
3878934 NAA20 ⇧ 1.42 5.16E-03  2835792 GM2A ⇩ 1.40 0.031  2488596 EMX1 ⇩ 1.38 0.019 
3430389 C12orf23 ⇧ 1.42 0.023  3396770 CDON ⇧ 1.40 8.80E-03  2462589 MT1H ⇩ 1.38 0.037 
3936442 PEX26 ⇧ 1.42 0.018  3705412 C17orf97 ⇧ 1.40 5.50E-03  3223551 MEGF9 ⇩ 1.38 0.030 
3368398 CCDC73 ⇧ 1.42 0.014  2868904 ST8SIA4 ⇩ 1.40 0.030  3952703 C22orf39 ⇧ 1.38 0.017 
3738205 MRPL12 ⇧ 1.41 9.07E-03  2973995 EPB41L2 ⇩ 1.40 0.043  2708407 ALG3 ⇩ 1.38 0.020 
3774385 SIRT7 ⇧ 1.41 0.046  2773655 RCHY1 ⇧ 1.40 9.77E-03  3417457 MYL6 ⇧ 1.38 0.042 
2527253 IGFBP2 ⇧ 1.41 0.029  4019465 NKRF ⇧ 1.40 0.016  3947310 C22orf32 ⇧ 1.38 9.75E-03 
3712098 SNORD49A ⇧ 1.41 2.24E-03  2922215 MARCKS ⇧ 1.40 0.029  2750594 SC4MOL ⇩ 1.38 0.038 
3729123 DHX40 ⇧ 1.41 5.61E-04  3432333 PTPN11 ⇧ 1.40 0.011  3441955 MRPL51 ⇧ 1.38 8.08E-04 
3428088 ACTR6 ⇧ 1.41 0.011  2384375 DUSP5P ⇧ 1.39 2.38E-03  3435681 ARL6IP4 ⇧ 1.38 6.08E-03 
3630099 TIPIN ⇧ 1.41 0.012  3331487 CTNND1 ⇩ 1.39 0.014  2875929 C5orf15 ⇩ 1.38 0.048 
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3121228 ERICH1 ⇧ 1.38 0.038  2474322 C2orf28 ⇩ 1.36 4.85E-03  2964327 LYRM2 ⇧ 1.35 1.95E-03 
3108901 VPS13B ⇩ 1.38 9.62E-03  3426257 SOCS2 ⇧ 1.36 0.024  3687698 CD2BP2 ⇧ 1.35 0.042 
2542226 RDH14 ⇩ 1.38 0.019  3869714 ZNF611 ⇧ 1.36 0.027  3394488 PVRL1 ⇩ 1.35 0.017 
2482683 RPL23AP32 ⇩ 1.38 0.029  3413787 TUBA1C ⇧ 1.36 0.034  3468103 GNPTAB ⇩ 1.35 0.044 
3376867 TRMT112 ⇧ 1.38 6.01E-03  2878662 DIAPH1 ⇩ 1.36 0.029  3815566 STK11 ⇧ 1.35 0.032 
3119339 LY6E ⇩ 1.38 0.013  2708610 MAGEF1 ⇧ 1.36 0.019  3292634 RUFY2 ⇧ 1.35 0.027 
2986084 PHF10 ⇧ 1.38 0.028  3804143 RPRD1A ⇧ 1.36 1.92E-03  2716655 MSX1 ⇧ 1.35 0.047 
3056292 CLDN3 ⇧ 1.38 8.99E-05  2813060 PIK3R1 ⇩ 1.36 0.026  3422703 ATXN7L3B ⇧ 1.35 0.013 
2558150 AAK1 ⇩ 1.38 0.033  2930863 PCMT1 ⇩ 1.36 0.047  3716993 RNF135 ⇧ 1.34 0.021 
3856554 ZNF100 ⇧ 1.38 0.042  3195296 SSNA1 ⇧ 1.36 0.029  3372235 RAPSN ⇩ 1.34 4.00E-03 
2423017 EVI5 ⇧ 1.37 0.042  3346147 ARHGAP42 ⇧ 1.36 0.022  3056656 GTF2IRD2 ⇧ 1.34 3.92E-03 
2457573 AIDA ⇧ 1.37 0.014  3292735 SLC25A16 ⇧ 1.36 1.27E-03  2386747 GPR137B ⇩ 1.34 0.036 
2331511 BMP8A ⇧ 1.37 4.16E-03  2902736 C6orf48 ⇧ 1.36 0.021  3728509 DYNLL2 ⇧ 1.34 0.012 
3462630 CAPS2 ⇧ 1.37 1.43E-04  4011844 IL2RG ⇩ 1.35 8.47E-03  2428796 PTPN22 ⇩ 1.34 8.95E-03 
3434413 RNF10 ⇧ 1.37 8.16E-03  2427074 PSMA5 ⇧ 1.35 0.032  3060182 ABCB1 ⇩ 1.34 0.040 
2671652 ZDHHC3 ⇩ 1.37 6.57E-03  3822805 TECR ⇩ 1.35 0.032  3018484 GPR22 ⇧ 1.34 6.82E-05 
3332131 STX3 ⇧ 1.37 1.11E-03  3442785 CLEC4C ⇧ 1.35 0.025  3459956 C12orf66 ⇧ 1.34 1.99E-03 
3210179 C9orf95 ⇧ 1.37 0.012  3716579 LRRC37BP1 ⇧ 1.35 0.035  3191338 GPR107 ⇩ 1.34 0.037 
3872441 ZNF552 ⇧ 1.37 0.029  3665116 CBFB ⇧ 1.35 0.023  3522225 STK24 ⇧ 1.34 0.013 
3799615 PTPN2 ⇧ 1.37 0.042  2842570 FAF2 ⇩ 1.35 0.040  3225096 NR6A1 ⇧ 1.34 0.024 
2908052 POLR1C ⇧ 1.37 1.45E-03  3338552 CTTN ⇧ 1.35 6.18E-03  3005956 C7orf42 ⇩ 1.34 8.80E-03 
2541230 NBAS ⇩ 1.37 5.41E-04  2559696 TPRKB ⇧ 1.35 9.06E-03  2465324 AHCTF1 ⇧ 1.34 0.017 
3996083 TMEM187 ⇧ 1.37 9.45E-03  3752097 C17orf42 ⇧ 1.35 0.031  2864237 HOMER1 ⇧ 1.34 0.049 
3540353 CHURC1 ⇧ 1.37 0.018  3464967 GALNT4 ⇧ 1.35 9.39E-03  3474228 RAB35 ⇧ 1.34 1.28E-03 
3828162 C19orf2 ⇧ 1.37 2.39E-03  2868131 ERAP1 ⇩ 1.35 0.043  3749432 RNFT1 ⇧ 1.34 0.021 
3716664 SUZ12P ⇧ 1.37 0.035  3066751 SYPL1 ⇩ 1.35 0.030  3725083 SNX11 ⇧ 1.33 0.026 
3829768 UBA2 ⇧ 1.37 0.010  2415910 DOCK7 ⇩ 1.35 0.024  3978819 RRAGB ⇧ 1.33 0.029 
3406421 STRAP ⇧ 1.37 9.11E-03  3292413 DNAJC12 ⇧ 1.35 6.99E-03  2717518 AFAP1 ⇧ 1.33 0.015 
3046556 TARP ⇧ 1.37 2.06E-03  3391234 TIMM8B ⇧ 1.35 0.042  3758148 CCDC56 ⇧ 1.33 0.024 
2342665 MSH4 ⇧ 1.36 1.92E-03  3944620 MPST ⇧ 1.35 2.77E-03  3135184 RB1CC1 ⇧ 1.33 2.04E-03 
3421523 YEATS4 ⇧ 1.36 0.041  3464912 POC1B ⇧ 1.35 0.024  2544925 ASXL2 ⇩ 1.33 1.22E-03 
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3308864 RAB11FIP2 ⇧ 1.33 0.025  3518169 COMMD6 ⇧ 1.32 0.047  3323443 PRMT3 ⇧ 1.31 0.012 
3642815 NME4 ⇧ 1.33 0.026  3695359 FAM96B ⇧ 1.32 0.023  2977265 HIVEP2 ⇩ 1.31 0.028 
3494102 UCHL3 ⇧ 1.33 0.040  2477302 CCDC75 ⇧ 1.32 0.033  2707824 MCCC1 ⇩ 1.31 0.023 
3435902 DDX55 ⇧ 1.33 5.83E-03  3668898 ZFP1 ⇧ 1.32 0.018  3633550 IMP3 ⇧ 1.31 0.033 
2950515 VPS52 ⇩ 1.33 0.023  3829020 PDCD5 ⇧ 1.32 0.024  3402935 TPI1 ⇧ 1.31 0.035 
2883878 EBF1 ⇩ 1.33 0.020  3784727 ELP2 ⇧ 1.32 0.010  2447993 C1orf25 ⇩ 1.31 1.64E-03 
3892660 RPS21 ⇧ 1.33 0.014  2501697 ACTR3 ⇩ 1.32 4.80E-04  3862167 FBL ⇧ 1.30 1.47E-03 
3741305 OR1D2 ⇧ 1.33 0.018  3439063 ZNF26 ⇧ 1.32 0.019  3730899 DDX42 ⇧ 1.30 0.014 
2954527 ZNF318 ⇩ 1.33 0.016  3535515 FRMD6 ⇧ 1.32 6.79E-03  3741383 OR1E2 ⇧ 1.30 1.44E-03 
2893895 BMP6 ⇧ 1.33 0.014  3378790 PPP1CA ⇧ 1.32 0.038  2676219 PBRM1 ⇩ 1.30 0.029 
3361041 TPP1 ⇩ 1.33 0.043  3402978 DSTNP2 ⇧ 1.32 0.022  2835531 NDST1 ⇩ 1.30 0.041 
3563814 L2HGDH ⇧ 1.33 3.97E-03  3197014 GLIS3 ⇩ 1.31 0.024  3421706 RAB3IP ⇧ 1.30 0.024 
2545645 UCN ⇧ 1.33 0.029  3334847 C11orf2 ⇧ 1.31 0.018  2742009 ADAD1 ⇧ 1.30 0.012 
3961664 ST13 ⇧ 1.33 0.020  2425212 DBT ⇩ 1.31 0.040  3257670 PCGF5 ⇧ 1.30 0.044 
3403299 PEX5 ⇧ 1.33 8.49E-03  3385003 CREBZF ⇧ 1.31 0.025  2654855 ATP11B ⇩ 1.30 0.036 
2961317 TMEM30A ⇩ 1.33 0.049  3415915 PFDN5 ⇧ 1.31 0.029  3136129 RPS20 ⇧ 1.30 0.038 
2729884 UGT2B10 ⇧ 1.33 4.20E-03  3488942 NUDT15 ⇧ 1.31 0.019  2734018 MRPS18C ⇧ 1.30 0.025 
3608113 IQGAP1 ⇩ 1.33 0.024  3472225 DDX54 ⇧ 1.31 4.50E-03  3453556 PRKAG1 ⇧ 1.30 0.030 
3838665 RCN3 ⇩ 1.33 6.86E-03  2411638 LOC100128922 ⇧ 1.31 0.012  3860596 ZNF461 ⇧ 1.30 6.14E-03 
3420497 HELB ⇧ 1.33 0.036  2777447 NAP1L5 ⇧ 1.31 0.019  3094778 TACC1 ⇩ 1.30 1.50E-03 
3821847 ASNA1 ⇧ 1.33 5.20E-03  3190659 SET ⇧ 1.31 9.40E-03  3418513 MARCH9 ⇧ 1.30 9.71E-03 
3624448 GNB5 ⇧ 1.32 0.021  3820906 C19orf52 ⇧ 1.31 1.40E-03  3566304 EXOC5 ⇧ 1.30 4.93E-03 
3051928 CHCHD2 ⇧ 1.32 0.010  3218496 OR13C9 ⇧ 1.31 0.017  2438504 MRPL24 ⇧ 1.30 0.048 
2565246 TMEM127 ⇩ 1.32 0.015  2548402 EIF2AK2 ⇩ 1.31 9.94E-03  2717049 MRFAP1 ⇧ 1.30 8.00E-03 
2971692 MCM9 ⇧ 1.32 2.55E-03  3159040 RPL8 ⇧ 1.31 2.94E-04  3471704 BRAP ⇧ 1.30 0.011 
3739108 FN3KRP ⇧ 1.32 0.027  3998632 PNPLA4 ⇧ 1.31 2.64E-03  2639309 SEC22A ⇩ 1.30 0.043 
2508520 KYNU ⇩ 1.32 0.015  3457523 RNF41 ⇧ 1.31 0.013  2362394 IFI16 ⇩ 1.30 1.53E-03 
2871717 CCDC112 ⇧ 1.32 0.018  2415728 TM2D1 ⇩ 1.31 0.039  2748198 KIAA0922 ⇩ 1.30 2.51E-03 
3781124 MIB1 ⇧ 1.32 2.78E-03  3225292 SCAI ⇧ 1.31 2.20E-03  3409364 KLHDC5 ⇧ 1.30 0.013 
2916825 ANKRD6 ⇧ 1.32 2.10E-04  3451318 ZCRB1 ⇧ 1.31 0.027  3750685 SLC46A1 ⇩ 1.30 0.025 
2437307 SCAMP3 ⇩ 1.32 0.047  3243078 ZNF33A ⇧ 1.31 0.017  3890109 C20orf108 ⇧ 1.30 0.014 
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2499158 RANBP2 ⇩ 1.30 0.016  3307680 DCLRE1A ⇧ 1.29 0.020  2915133 TPBG ⇧ 1.28 0.029 
3929931 ATP5O ⇧ 1.30 0.045  3825201 UBA52 ⇧ 1.29 1.10E-03  3131844 LSM1 ⇧ 1.28 0.045 
2888879 DOK3 ⇩ 1.30 0.020  2599433 USP37 ⇩ 1.29 0.036  2534483 RBM44 ⇧ 1.28 0.029 
2915268 DOPEY1 ⇩ 1.30 9.31E-03  3530002 KHNYN ⇧ 1.29 6.02E-03  2867432 ANKRD32 ⇧ 1.28 0.026 
3444525 TAS2R46 ⇧ 1.30 0.039  2573641 CLASP1 ⇩ 1.29 7.98E-04  3961253 RPS19BP1 ⇧ 1.28 0.038 
3396883 RPUSD4 ⇧ 1.30 0.012  3898224 ESF1 ⇧ 1.29 4.23E-03  3707715 RPAIN ⇧ 1.28 0.015 
3502829 GAS6 ⇧ 1.30 2.70E-03  3053827 NCRNA00174 ⇩ 1.29 0.032  2715476 FAM193A ⇩ 1.28 0.012 
2330334 THRAP3 ⇩ 1.30 0.014  2731831 USO1 ⇩ 1.28 0.049  3976519 RBM3 ⇧ 1.28 0.020 
3636442 C15orf40 ⇧ 1.30 8.38E-03  3375147 VPS37C ⇧ 1.28 0.015  3562721 FKBP3 ⇧ 1.28 0.037 
2545092 HADHA ⇩ 1.29 0.020  2706938 GNB4 ⇧ 1.28 0.023  2542737 LAPTM4A ⇩ 1.28 0.044 
2521479 HSPE1 ⇧ 1.29 0.044  3143330 FAM82B ⇧ 1.28 0.011  3033397 RBM33 ⇩ 1.28 0.021 
3673684 CDT1 ⇧ 1.29 0.023  3676156 IGFALS ⇩ 1.28 0.046  3279857 TRDMT1 ⇧ 1.28 0.038 
3421630 CCT2 ⇧ 1.29 0.028  3821701 ZNF788 ⇧ 1.28 8.36E-03  3458783 CDK4 ⇧ 1.28 0.013 
2993639 CBX3 ⇧ 1.29 7.78E-04  3761054 COPZ2 ⇧ 1.28 5.26E-03  3080033 MLL3 ⇩ 1.28 0.011 
3937743 SERPIND1 ⇩ 1.29 0.040  3386638 SLC36A4 ⇧ 1.28 0.047  3580947 C14orf2 ⇧ 1.28 0.022 
2489440 DOK1 ⇧ 1.29 0.015  3742727 DHX33 ⇧ 1.28 7.02E-03  2436228 GATAD2B ⇩ 1.27 1.89E-04 
2946845 ZNF204P ⇩ 1.29 0.040  3233547 RBM17 ⇧ 1.28 0.025  3779756 SEH1L ⇧ 1.27 0.037 
2349086 DPH5 ⇧ 1.29 0.037  2648378 RAP2B ⇧ 1.28 0.020  3229591 UBAC1 ⇧ 1.27 0.020 
2599371 TMBIM1 ⇩ 1.29 0.038  2958117 HMGCLL1 ⇧ 1.28 6.84E-03  2353021 SYCP1 ⇧ 1.27 0.017 
2376799 IKBKE ⇩ 1.29 0.029  3673091 BANP ⇧ 1.28 3.22E-03  4012868 RLIM ⇧ 1.27 8.89E-03 
2369325 C1orf220 ⇧ 1.29 2.21E-03  3849797 ZNF561 ⇧ 1.28 0.024  3923896 KRTAP10-12 ⇧ 1.27 0.014 
3413950 SPATS2 ⇧ 1.29 0.045  2688070 GUCA1C ⇧ 1.28 0.020  3831698 ZNF420 ⇧ 1.27 1.80E-03 
2514566 SSB ⇧ 1.29 0.011  2359444 LCE1B ⇧ 1.28 0.023  3873160 TRIB3 ⇧ 1.27 0.043 
2601230 SCG2 ⇧ 1.29 0.026  3332325 MS4A6E ⇧ 1.28 0.015  3838795 BCL2L12 ⇧ 1.27 0.013 
3534923 KLHDC2 ⇧ 1.29 0.028  2541944 SMC6 ⇩ 1.28 8.82E-03  3416344 HOXC9 ⇧ 1.27 8.85E-03 
3204261 CCL27 ⇧ 1.29 0.032  2347732 TMEM56 ⇧ 1.28 0.019  3747236 C17orf76 ⇩ 1.27 3.75E-03 
3883941 TGIF2 ⇧ 1.29 0.028  3855071 FKBP8 ⇧ 1.28 0.011  2781693 CASP6 ⇧ 1.27 0.048 
3977646 GSPT2 ⇧ 1.29 0.040  3203482 BAG1 ⇧ 1.28 0.023  3761127 CBX1 ⇧ 1.27 9.09E-03 
3962054 NHP2L1 ⇧ 1.29 0.026  2698738 XRN1 ⇩ 1.28 9.40E-04  2550122 COX7A2L ⇧ 1.27 0.024 
3530982 G2E3 ⇧ 1.29 0.020  3250726 KIAA1274 ⇧ 1.28 0.010  2978989 LATS1 ⇩ 1.27 1.00E-02 
2821417 LNPEP ⇩ 1.29 0.020  3576545 SMEK1 ⇧ 1.28 3.41E-03  2659918 LRCH3 ⇩ 1.27 0.014 
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3676649 DCI ⇧ 1.27 0.011  2328909 TSSK3 ⇧ 1.26 0.013  2405284 TMEM54 ⇧ 1.25 5.90E-03 
3431220 MVK ⇧ 1.27 0.010  3817167 MRPL54 ⇧ 1.26 0.035  3347549 CUL5 ⇧ 1.25 0.016 
3421824 C12orf28 ⇧ 1.27 0.037  3932148 BRWD1 ⇧ 1.26 0.039  2713555 KIAA0226 ⇩ 1.25 0.023 
3671448 HSBP1 ⇧ 1.27 0.015  3315549 PSMD13 ⇧ 1.26 5.96E-03  3675815 C16orf42 ⇧ 1.25 0.024 
2945677 C6orf62 ⇧ 1.27 0.034  3062576 ASNS ⇧ 1.26 0.031  2363902 DUSP12 ⇧ 1.25 0.049 
2596162 INO80D ⇩ 1.27 4.22E-03  3403224 LOC283314 ⇧ 1.26 0.037  2731417 MTHFD2L ⇧ 1.25 9.26E-03 
3351166 IL10RA ⇩ 1.27 0.041  3960875 DNAL4 ⇧ 1.26 6.89E-03  3417435 MYL6B ⇧ 1.25 0.037 
4046481 ING5 ⇧ 1.27 0.035  3656622 CTF1 ⇧ 1.26 8.13E-03  2629693 PPP4R2 ⇧ 1.25 0.035 
3229943 SDCCAG3 ⇧ 1.27 7.66E-03  3318390 TRIM6-TRIM34 ⇩ 1.26 0.045  3226181 ST6GALNAC4 ⇧ 1.25 0.014 
3821727 ZNF136 ⇧ 1.27 0.029  2642791 DNAJC13 ⇩ 1.26 0.015  2684851 VGLL3 ⇧ 1.25 2.17E-03 
3923312 RRP1 ⇧ 1.27 0.016  3177563 NAA35 ⇧ 1.26 0.013  2903488 HSD17B8 ⇧ 1.25 0.034 
3529064 BCL2L2 ⇧ 1.27 0.010  3454680 TFCP2 ⇧ 1.26 0.022  3581386 CDCA4 ⇧ 1.25 0.017 
3890870 RAB22A ⇧ 1.27 0.026  2436920 PMVK ⇧ 1.26 0.014  2479640 PPM1B ⇧ 1.25 0.012 
3718382 ZNF830 ⇧ 1.27 0.016  3654614 SULT1A1 ⇩ 1.26 2.21E-03  3407229 AEBP2 ⇧ 1.25 6.39E-03 
3401099 FKBP4 ⇧ 1.26 0.015  2899437 BTN2A1 ⇩ 1.26 0.044  2674526 NICN1 ⇩ 1.25 0.022 
2655168 YEATS2 ⇩ 1.26 0.038  2644333 SOX14 ⇧ 1.26 4.53E-03  2380554 RRP15 ⇧ 1.25 0.036 
3288337 ARHGAP22 ⇩ 1.26 0.045  3227645 UCK1 ⇧ 1.26 8.20E-03  2978026 FBXO30 ⇧ 1.25 0.020 
3259253 ENTPD1 ⇩ 1.26 0.044  3346584 BIRC2 ⇧ 1.25 0.025  3642390 TARSL2 ⇧ 1.25 0.046 
3230490 EDF1 ⇧ 1.26 0.026  3228097 TTF1 ⇧ 1.25 0.040  3352813 TBCEL ⇧ 1.25 0.022 
3819104 TRAPPC5 ⇧ 1.26 0.012  3465409 BTG1 ⇧ 1.25 4.25E-03  2500615 TMEM87B ⇩ 1.25 0.049 
3837504 SEPW1 ⇧ 1.26 0.046  3870162 ZNF665 ⇧ 1.25 3.29E-03  2369843 CEP350 ⇩ 1.25 9.84E-04 
2597010 IDH1 ⇩ 1.26 0.034  3812589 GTSCR1 ⇧ 1.25 0.023  3404496 KLRF1 ⇧ 1.25 0.036 
2427688 C1orf103 ⇩ 1.26 0.032  2723391 MGC42157 ⇧ 1.25 0.046  2762334 QDPR ⇧ 1.25 0.042 
3558226 RIPK3 ⇩ 1.26 0.018  3336351 CCS ⇧ 1.25 7.60E-03  3221571 RNF183 ⇧ 1.25 0.025 
2900453 PGBD1 ⇧ 1.26 9.51E-03  3642604 MPG ⇧ 1.25 1.59E-03  3503224 UPF3A ⇧ 1.25 0.016 
3212728 AGTPBP1 ⇧ 1.26 0.021  2851274 CDH10 ⇧ 1.25 9.29E-04  2828115 LYRM7 ⇧ 1.25 0.033 
3300869 PIPSL ⇧ 1.26 0.033  3330927 OR5T1 ⇧ 1.25 0.015  3555492 TMEM55B ⇧ 1.25 0.013 
2678367 PDHB ⇩ 1.26 0.038  3478457 STX2 ⇧ 1.25 0.033  3657318 ZNF720 ⇧ 1.25 0.039 
3358262 DEAF1 ⇧ 1.26 0.021  2324743 ZBTB40 ⇩ 1.25 0.037  2772375 UGT2A1 ⇧ 1.25 0.031 
3676209 C16orf73 ⇧ 1.26 0.036  3999395 MID1 ⇧ 1.25 0.036  3348891 C11orf57 ⇧ 1.25 0.041 
2837499 LSM11 ⇧ 1.26 3.26E-03  3892941 OGFR ⇧ 1.25 0.043  2437417 ASH1L ⇩ 1.25 0.037 







Table B20: C9-Long Specific Gene List (n=894) MALE ONLY SAMPLES [Partek® unadjusted p<0.05, FC ≥ ±1.20]   
 632 
 
2320762 VPS13D ⇩ 1.25 0.024  2612175 NR2C2 ⇩ 1.24 1.95E-03  2790652 FGG ⇧ 1.23 9.01E-03 
2834574 SPINK14 ⇧ 1.25 5.88E-03  2581430 STAM2 ⇩ 1.24 0.017  2835166 ARHGEF37 ⇧ 1.23 0.011 
3334783 SNX15 ⇧ 1.25 0.025  3824153 C19orf62 ⇧ 1.24 0.048  2377427 CD46 ⇩ 1.23 0.047 
3200689 RPS6 ⇧ 1.25 0.042  2476219 BIRC6 ⇩ 1.24 1.58E-03  2514365 BBS5 ⇧ 1.23 4.12E-03 
2448232 TPR ⇩ 1.24 2.44E-03  2832115 PCDHA12 ⇧ 1.24 0.045  3202293 C9orf11 ⇧ 1.23 0.010 
2451139 ARL8A ⇩ 1.24 0.014  3471374 PPP1CC ⇧ 1.24 0.016  2730281 ODAM ⇧ 1.23 6.95E-03 
3348189 FDX1 ⇧ 1.24 0.024  3476012 MPHOSPH9 ⇧ 1.24 0.038  3191113 PRRX2 ⇩ 1.23 8.60E-04 
3469844 MTERFD3 ⇧ 1.24 0.037  2977949 EPM2A ⇧ 1.24 0.016  2572601 CCDC93 ⇩ 1.23 0.019 
2373494 CFHR2 ⇧ 1.24 0.037  2895159 HIVEP1 ⇩ 1.24 8.89E-03  2711139 ATP13A5 ⇧ 1.23 0.047 
2951057 C6orf1 ⇧ 1.24 0.020  2966636 ASCC3 ⇩ 1.24 0.047  3418298 KIF5A ⇧ 1.23 0.044 
2903189 HLA-DRA ⇩ 1.24 0.042  3337168 GSTP1 ⇧ 1.24 0.032  2943808 NUP153 ⇩ 1.23 9.51E-03 
2954678 XPO5 ⇩ 1.24 0.036  2389789 SCCPDH ⇩ 1.24 0.028  3183757 RAD23B ⇧ 1.23 0.022 
3712517 NT5M ⇧ 1.24 0.012  3012910 GNGT1 ⇧ 1.24 0.040  2693937 TPRA1 ⇩ 1.23 0.039 
2336271 BTF3L4 ⇧ 1.24 0.036  3349014 PTS ⇧ 1.24 0.020  2691718 GOLGB1 ⇩ 1.23 7.89E-03 
2745288 IL15 ⇧ 1.24 0.014  3424379 C12orf26 ⇧ 1.24 0.039  3271220 CTAGE7P ⇧ 1.23 0.040 
2532699 INPP5D ⇩ 1.24 5.36E-03  3647632 C16orf72 ⇧ 1.24 8.96E-03  3882854 ITCH ⇧ 1.23 0.020 
3272027 LRRC27 ⇧ 1.24 9.65E-03  2564816 ANKRD36B ⇧ 1.24 0.033  3792952 SOCS6 ⇧ 1.23 0.037 
3435653 OGFOD2 ⇧ 1.24 0.024  2633631 NIT2 ⇩ 1.24 0.045  2974188 MED23 ⇩ 1.23 0.035 
2878630 SLC25A2 ⇧ 1.24 4.73E-03  3513953 C13orf1 ⇧ 1.23 0.038  3131720 BRF2 ⇧ 1.23 0.020 
3969115 TLR8 ⇧ 1.24 5.37E-03  3317223 IGF2AS ⇧ 1.23 0.027  2828146 CDC42SE2 ⇧ 1.23 0.046 
3747324 ZNF624 ⇧ 1.24 4.89E-03  2334459 TMEM69 ⇩ 1.23 0.025  2400373 EIF4G3 ⇩ 1.23 5.54E-03 
3882720 RALY ⇧ 1.24 0.049  2923270 PLN ⇧ 1.23 0.018  3360982 RRP8 ⇧ 1.23 0.035 
2815139 FCHO2 ⇧ 1.24 0.014  3376529 PLA2G16 ⇧ 1.23 0.045  2346657 BTBD8 ⇧ 1.23 0.036 
2576788 ANKRD30BL ⇧ 1.24 1.03E-03  2435044 POGZ ⇩ 1.23 6.69E-03  3440017 FBXL14 ⇩ 1.23 0.047 
3850040 EIF3G ⇧ 1.24 0.013  3145567 UQCRB ⇧ 1.23 5.75E-03  3135156 FAM150A ⇧ 1.23 0.031 
3016211 ZNHIT1 ⇧ 1.24 0.033  4007734 TFE3 ⇧ 1.23 0.046  3064024 C7orf61 ⇧ 1.23 0.047 
2840036 DOCK2 ⇩ 1.24 6.66E-04  3846538 EEF2 ⇧ 1.23 4.04E-03  3331129 OR5AK2 ⇧ 1.23 0.040 
3843525 ZNF586 ⇧ 1.24 0.021  2418700 ASB17 ⇧ 1.23 0.016  3665846 THAP11 ⇧ 1.23 0.044 
3854877 JUND ⇧ 1.24 0.048  2987410 NUDT1 ⇧ 1.23 0.012  3591909 CTDSPL2 ⇧ 1.23 0.026 
2391465 MXRA8 ⇧ 1.24 3.15E-03  2664891 TBC1D5 ⇩ 1.23 0.011  2608765 ARL8B ⇩ 1.23 0.039 
3971877 EIF2S3 ⇧ 1.24 0.018  3157844 NRBP2 ⇩ 1.23 0.010  3258997 CYP2C19 ⇧ 1.23 0.020 
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3045739 HERPUD2 ⇩ 1.23 0.035  3029213 TAS2R41 ⇩ 1.22 0.036  3257750 HECTD2 ⇧ 1.21 0.026 
3114358 FAM91A1 ⇧ 1.22 0.031  2519038 FSIP2 ⇧ 1.22 0.026  2618702 ZNF620 ⇧ 1.21 0.017 
3715809 NEK8 ⇧ 1.22 0.011  3584443 SNRPN ⇧ 1.22 0.040  3713874 MAPK7 ⇧ 1.21 4.06E-03 
2512330 MARCH7 ⇩ 1.22 0.027  2830742 KDM3B ⇩ 1.22 1.04E-03  3956290 PITPNB ⇧ 1.21 0.022 
3907373 WFDC9 ⇧ 1.22 0.046  3894194 TBC1D20 ⇧ 1.22 0.027  3236395 HSPA14 ⇧ 1.21 5.16E-03 
4021149 SMARCA1 ⇧ 1.22 0.040  2486851 APLF ⇧ 1.22 0.044  2544238 ITSN2 ⇩ 1.21 9.07E-03 
2318736 PARK7 ⇧ 1.22 0.044  2550959 PREPL ⇩ 1.22 0.031  3464622 CEP290 ⇧ 1.21 0.027 
2575949 TUBA3E ⇧ 1.22 0.038  3662170 MT1DP ⇧ 1.22 3.87E-03  3330961 OR8J1 ⇧ 1.21 8.52E-03 
3974838 DDX3X ⇧ 1.22 0.042  3514488 INTS6 ⇧ 1.22 0.013  3874023 PTPRA ⇩ 1.21 0.029 
3704896 CHMP1A ⇧ 1.22 0.020  3466826 CDK17 ⇧ 1.21 0.029  3507003 LNX2 ⇧ 1.21 0.042 
2347788 RWDD3 ⇧ 1.22 0.029  3430552 PWP1 ⇧ 1.21 0.047  3846783 UBXN6 ⇧ 1.21 0.022 
3892409 LSM14B ⇧ 1.22 0.016  2862716 GFM2 ⇩ 1.21 0.036  2516780 HOXD13 ⇧ 1.21 6.56E-03 
2404254 PUM1 ⇩ 1.22 2.25E-04  3511817 ENOX1 ⇧ 1.21 5.76E-03  2413203 LRP8 ⇩ 1.21 0.046 
3121023 C8orf33 ⇧ 1.22 0.038  2676397 ITIH4 ⇩ 1.21 0.031  3832865 NCCRP1 ⇧ 1.21 0.023 
3735346 C17orf106 ⇧ 1.22 0.019  2817576 THBS4 ⇧ 1.21 0.024  3149754 EIF3H ⇧ 1.21 0.033 
2367154 BAT2L2 ⇩ 1.22 9.55E-04  2351572 CD53 ⇩ 1.21 0.019  3488253 COG3 ⇧ 1.21 0.024 
3476130 SBNO1 ⇧ 1.22 0.036  3835339 ZNF230 ⇧ 1.21 0.037  3982410 COX7B ⇧ 1.21 0.040 
2546008 SUPT7L ⇩ 1.22 0.047  3300115 PPP1R3C ⇧ 1.21 0.033  2692909 HEG1 ⇩ 1.20 0.040 
3829575 LSM14A ⇧ 1.22 0.045  3226311 NAIF1 ⇧ 1.21 0.044  3360702 OR52L1 ⇧ 1.20 0.028 
3899641 HSPC072 ⇧ 1.22 0.037  7385683 VPS41 ⇩ 1.21 0.045  3727499 TOM1L1 ⇧ 1.20 0.031 
3429555 EID3 ⇧ 1.22 0.013  3407629 SLCO1B3 ⇧ 1.21 0.017  3447129 KIAA0528 ⇧ 1.20 0.017 
3758845 HDAC5 ⇧ 1.22 0.031  2559849 SLC4A5 ⇧ 1.21 0.032  2961647 HTR1B ⇧ 1.20 0.034 
3954746 IGLL1 ⇩ 1.22 5.85E-03  3856908 ZNF99 ⇧ 1.21 0.044  2573570 TFCP2L1 ⇧ 1.20 0.040 
3026599 TRIM24 ⇩ 1.22 0.038  3721851 COASY ⇧ 1.21 0.012  3555272 TTC5 ⇧ 1.20 2.10E-03 
2816030 POLK ⇩ 1.22 0.041  2607923 CNTN4 ⇧ 1.21 3.39E-03  2340819 TCTEX1D1 ⇧ 1.20 9.05E-03 
3127610 PEBP4 ⇩ 1.22 0.014  3871576 FIZ1 ⇧ 1.21 0.014  2780296 TACR3 ⇧ 1.20 0.018 
2556667 RAB1A ⇧ 1.22 0.033  3419849 TBK1 ⇧ 1.21 9.99E-03  3154185 TMEM71 ⇧ 1.20 0.036 
3923498 PWP2 ⇧ 1.22 0.022  3202224 LRRC19 ⇧ 1.21 0.019  2519480 GULP1 ⇧ 1.20 0.034 
2675088 IFRD2 ⇧ 1.22 0.013  2423422 BCAR3 ⇧ 1.21 0.022  2678029 DNAH12 ⇧ 1.20 0.038 
2907190 UBR2 ⇩ 1.22 2.75E-03  3928545 KRTAP19-6 ⇧ 1.21 7.33E-04  2950242 PPP1R2P1 ⇧ 1.20 0.015 
3431426 IFT81 ⇧ 1.22 0.024  3223605 FBXW2 ⇧ 1.21 0.011  2717757 C4orf23 ⇩ 1.20 0.042 
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3955327 C22orf13 ⇧ 1.20 0.020  2977122 NMBR ⇧ 1.20 0.016  3696194 DDX28 ⇧ 1.20 6.19E-03 
3348990 TEX12 ⇧ 1.20 0.035  2672532 SETD2 ⇩ 1.20 2.76E-03  2318416 THAP3 ⇧ 1.20 0.017 
2326640 ARID1A ⇩ 1.20 0.036  3453348 RND1 ⇧ 1.20 0.034  2811145 PART1 ⇧ 1.20 0.033 
2620315 TMEM42 ⇧ 1.20 0.049  2327418 MED18 ⇧ 1.20 0.047  2880463 C5orf46 ⇧ 1.20 0.043 
3934903 NCRNA00205 ⇩ 1.20 0.038  3344897 MED17 ⇩ 1.20 0.037  2353477 ATP1A1 ⇩ 1.20 0.041 
3788560 DCC ⇧ 1.20 0.021  2627390 ATXN7 ⇩ 1.20 7.66E-03  3702352 HSDL1 ⇧ 1.20 3.66E-03 
2761321 BOD1L ⇩ 1.20 0.026  3834651 ZNF526 ⇧ 1.20 0.016  2824144 FLJ11235 ⇧ 1.20 0.040 
2525272 PIKFYVE ⇩ 1.20 0.035  3833827 EGLN2 ⇧ 1.20 1.16E-03  3755359 PIP4K2B ⇧ 1.20 0.045 
3836266 FOSB ⇧ 1.20 0.043  2594569 ORC2 ⇩ 1.20 0.042  2491046 FUNDC2P2 ⇧ 1.20 0.030 
3337329 ALDH3B1 ⇧ 1.20 0.018  3321269 FAR1 ⇧ 1.20 0.045  2959596 EYS ⇧ 1.20 8.56E-03 
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Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value   Transcript ID Symbol Fold p-value 
3566383 C14orf105 ⇩ 2.69 2.33E-03  3754797 HNF1B ⇩ 1.87 6.98E-03  3852880 EMR2 ⇩ 1.61 0.031 
2459042 CDC42BPA ⇩ 2.53 2.29E-03  3496409 GPC5 ⇩ 1.86 9.06E-04  2899243 HIST1H4F ⇧ 1.60 2.19E-05 
2440385 CD244 ⇩ 2.45 2.61E-03  3129361 FBXO16 ⇧ 1.86 9.40E-03  2362333 MNDA ⇧ 1.60 0.027 
3718555 SLFN5 ⇩ 2.39 3.18E-03  2973376 PTPRK ⇩ 1.85 0.023  2371547 C1orf21 ⇩ 1.60 0.034 
3393446 FXYD2 ⇩ 2.30 2.16E-03  3382216 ARRB1 ⇩ 1.85 0.027  3344142 NAALAD2 ⇩ 1.59 0.033 
3388673 MMP7 ⇩ 2.25 0.044  3996598 NCRNA00204 ⇧ 1.82 0.026  3944404 APOL1 ⇩ 1.59 5.96E-03 
2607568 CHL1 ⇩ 2.22 0.027  2924253 RNF217 ⇩ 1.82 0.020  2730746 SLC4A4 ⇩ 1.58 0.026 
3456805 GTSF1 ⇧ 2.19 0.027  3560403 EGLN3 ⇩ 1.82 2.41E-03  3841357 LILRA2 ⇩ 1.58 0.012 
2569908 SEPT10 ⇧ 2.15 0.028  3944129 HMOX1 ⇧ 1.80 2.53E-04  3174510 GDA ⇩ 1.58 0.041 
3445908 EPS8 ⇩ 2.13 0.010  2477073 CRIM1 ⇩ 1.79 0.034  2902707 HSPA1A ⇧ 1.58 0.010 
2731636 PARM1 ⇩ 2.13 2.22E-03  2571483 IL1A ⇧ 1.79 0.045  2973232 C6orf174 ⇩ 1.58 0.015 
3623031 FBN1 ⇩ 2.13 3.10E-04  3209384 TMEM2 ⇩ 1.78 0.024  3609592 MCTP2 ⇩ 1.57 1.38E-04 
3507282 FLT1 ⇩ 2.12 2.93E-03  3955102 GSTT1 ⇧ 1.78 0.015  4005859 CASK ⇩ 1.56 6.24E-03 
3150579 ENPP2 ⇩ 2.10 3.12E-03  3599709 GLCE ⇩ 1.76 8.10E-03  3396593 FEZ1 ⇧ 1.56 0.034 
3132016 FGFR1 ⇩ 2.06 9.91E-04  2403446 PTAFR ⇩ 1.74 0.018  2584018 DPP4 ⇩ 1.56 0.037 
2898746 LRRC16A ⇩ 2.04 3.14E-03  2485406 HSPC159 ⇧ 1.73 9.30E-04  2378068 G0S2 ⇧ 1.55 0.011 
2699564 PLOD2 ⇩ 2.02 8.64E-03  3494137 LMO7 ⇩ 1.72 1.53E-04  2879105 SPRY4 ⇩ 1.55 2.46E-03 
2635741 CD96 ⇩ 2.02 0.022  3351675 CXCR5 ⇧ 1.70 0.022  2899223 HIST1H2AE ⇧ 1.55 0.036 
4022370 GPC4 ⇩ 2.02 0.014  3972929 GK ⇩ 1.70 2.19E-03  2895244 EDN1 ⇩ 1.54 0.034 
3512948 C13orf18 ⇧ 2.01 6.44E-03  3791254 TNFRSF11A ⇩ 1.68 0.031  3420442 IRAK3 ⇩ 1.54 0.037 
3778504 RAB31 ⇧ 2.01 0.011  2615360 TGFBR2 ⇩ 1.68 7.10E-03  3082590 LOC286161 ⇧ 1.54 1.62E-03 
3569814 ACTN1 ⇩ 2.01 4.22E-03  2705445 PLD1 ⇩ 1.68 0.022  2351854 C1orf162 ⇧ 1.54 0.027 
3933566 TMPRSS3 ⇩ 1.99 0.042  3724545 ITGB3 ⇩ 1.66 0.015  3644191 FAHD1 ⇧ 1.54 5.11E-04 
2915828 NT5E ⇩ 1.98 0.035  3941848 EMID1 ⇩ 1.66 3.73E-03  2633691 TMEM45A ⇩ 1.54 0.013 
3449068 TMTC1 ⇩ 1.98 5.42E-03  2986999 GPR146 ⇩ 1.65 8.46E-03  3450899 SLC2A13 ⇩ 1.54 7.46E-03 
2853102 PRLR ⇩ 1.97 0.011  3323891 GAS2 ⇩ 1.64 0.031  3197955 GLDC ⇧ 1.53 0.048 
2459173 PRO2012 ⇩ 1.95 9.66E-04  2662581 C3orf10 ⇧ 1.64 0.015  3164825 IFNA1 ⇩ 1.53 7.19E-03 
4002081 MAP7D2 ⇩ 1.91 1.41E-03  3409605 FAR2 ⇩ 1.63 0.045  2879028 GNPDA1 ⇧ 1.53 1.06E-03 
3692999 MT1G ⇧ 1.89 0.017  3139580 SLCO5A1 ⇩ 1.63 3.23E-04  2439001 FCRL3 ⇧ 1.53 0.030 
2664209 SH3BP5 ⇧ 1.87 6.83E-04  3417583 RBMS2 ⇧ 1.62 0.028  3132940 ANK1 ⇩ 1.52 0.011 
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3624145 DMXL2 ⇩ 1.52 4.26E-05  2396461 SRM ⇧ 1.47 6.74E-05  3712062 TRPV2 ⇩ 1.42 4.59E-04 
3054165 SBDS ⇧ 1.52 0.011  3245881 WDFY4 ⇩ 1.47 1.21E-03  3424442 TMTC2 ⇩ 1.42 1.19E-04 
3136178 PLAG1 ⇧ 1.51 9.63E-03  3091077 DPYSL2 ⇧ 1.46 0.019  2351004 GSTM5 ⇧ 1.42 0.010 
3899173 RRBP1 ⇩ 1.51 8.97E-05  2331178 NDUFS5 ⇧ 1.46 5.48E-03  3302177 ARHGAP19 ⇧ 1.42 0.037 
3225855 ANGPTL2 ⇩ 1.51 0.022  3402757 LAG3 ⇩ 1.46 8.55E-03  4018080 CHRDL1 ⇩ 1.42 0.029 
3887210 MMP9 ⇩ 1.50 0.024  2336585 SCP2 ⇧ 1.46 3.38E-03  2471978 RHOB ⇩ 1.42 0.048 
2338625 HOOK1 ⇩ 1.50 0.020  3851493 ZNF443 ⇩ 1.45 3.59E-03  3005444 TPST1 ⇩ 1.41 0.046 
2849992 FAM134B ⇩ 1.50 0.024  3101153 BHLHE22 ⇩ 1.45 0.047  2371346 RGL1 ⇧ 1.41 0.017 
2932508 TIAM2 ⇧ 1.49 3.28E-03  3663074 MMP15 ⇩ 1.45 0.017  2325479 RCAN3 ⇧ 1.41 2.55E-03 
3403244 CLSTN3 ⇩ 1.49 1.08E-03  3352438 POU2F3 ⇩ 1.45 0.028  2732844 ANXA3 ⇩ 1.41 0.042 
3273667 ADARB2 ⇩ 1.49 9.47E-03  2427208 GSTM3 ⇧ 1.45 0.034  3714068 ALDH3A2 ⇧ 1.41 3.72E-04 
2422035 GBP5 ⇩ 1.49 0.015  3687789 DCTPP1 ⇧ 1.45 1.29E-03  2316245 PRKCZ ⇧ 1.41 7.76E-04 
2902725 HSPA1B ⇧ 1.48 4.61E-03  3447348 SOX5 ⇩ 1.44 9.78E-03  3203382 SMU1 ⇧ 1.41 0.026 
3184218 C9orf6 ⇧ 1.48 0.015  3234277 GATA3 ⇩ 1.44 3.68E-03  2385696 C1orf57 ⇧ 1.40 0.026 
3946095 GRAP2 ⇧ 1.48 0.016  2946219 HIST1H2AB ⇧ 1.44 0.027  2586744 METTL8 ⇧ 1.40 1.29E-03 
2933175 ZDHHC14 ⇩ 1.48 0.021  3838094 FTL ⇧ 1.44 0.036  2692060 PARP9 ⇧ 1.40 0.012 
2829275 UBE2B ⇧ 1.48 9.66E-04  3351841 HMBS ⇧ 1.44 0.013  2767295 BEND4 ⇩ 1.40 0.040 
3252071 VCL ⇩ 1.48 0.014  2327677 EPB41 ⇧ 1.44 6.56E-03  3708644 FGF11 ⇩ 1.40 0.025 
3101622 RRS1 ⇧ 1.48 2.44E-03  4007164 CFP ⇩ 1.44 0.043  2601287 AP1S3 ⇧ 1.40 8.20E-04 
2362351 PYHIN1 ⇧ 1.47 0.031  2626258 KCTD6 ⇧ 1.44 5.42E-04  2885099 NUDCD2 ⇧ 1.40 1.86E-05 
3727449 TOM1L1 ⇩ 1.47 0.024  3766533 CD79B ⇩ 1.44 0.017  3887302 CD40 ⇩ 1.40 3.58E-03 
3538213 DAAM1 ⇩ 1.47 0.017  2449711 DENND1B ⇧ 1.44 0.029  3840327 ZNF808 ⇧ 1.40 8.51E-03 
2626167 PXK ⇧ 1.47 2.10E-03  3734379 CD300A ⇩ 1.44 1.66E-04  3103818 HNF4G ⇩ 1.40 0.027 
3543619 C14orf169 ⇧ 1.47 6.04E-03  3753500 SLFN11 ⇩ 1.44 4.12E-04  3734355 GPRC5C ⇩ 1.39 0.042 
3825013 SSBP4 ⇩ 1.47 1.60E-03  2826295 SNX2 ⇧ 1.44 1.65E-03  3067302 LAMB1 ⇩ 1.39 0.033 
2651835 GPR160 ⇧ 1.47 0.037  3761313 HOXB3 ⇩ 1.43 6.58E-05  2848265 CMBL ⇧ 1.39 0.030 
2956052 TNFRSF21 ⇩ 1.47 0.040  3236538 RPP38 ⇧ 1.43 0.044  2319225 H6PD ⇩ 1.39 0.032 
2912649 COL19A1 ⇩ 1.47 0.012  3020302 CAV1 ⇧ 1.43 0.036  2323559 MRTO4 ⇧ 1.39 6.75E-03 
3914273 SAMD10 ⇩ 1.47 1.57E-03  3011838 STEAP1 ⇩ 1.43 9.03E-03  3738629 SLC16A3 ⇩ 1.39 3.45E-03 
3230141 NOTCH1 ⇩ 1.47 1.40E-04  4027176 FLNA ⇩ 1.43 4.33E-03  3453252 ADCY6 ⇩ 1.39 1.87E-03 
2369339 RALGPS2 ⇧ 1.47 0.035  2437893 UBQLN4 ⇩ 1.42 6.86E-03  2992863 IGF2BP3 ⇧ 1.39 8.80E-04 
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3450655 CPNE8 ⇩ 1.39 0.014  2495806 MRPL30 ⇧ 1.37 2.44E-03  3286975 ANUBL1 ⇧ 1.35 1.42E-03 
3592484 PLDN ⇧ 1.39 6.37E-03  3788049 SKA1 ⇧ 1.37 0.016  2608419 SETMAR ⇧ 1.35 1.33E-03 
2855443 LOC100132356 ⇧ 1.38 4.82E-04  2492496 NCRNA00152 ⇧ 1.37 0.021  3758510 ETV4 ⇩ 1.35 0.017 
3848243 INSR ⇩ 1.38 0.015  3199207 NFIB ⇩ 1.37 0.037  2715440 RNF4 ⇧ 1.35 0.021 
3687494 MAPK3 ⇧ 1.38 0.010  3564872 GNPNAT1 ⇧ 1.37 6.51E-03  2549260 MAP4K3 ⇧ 1.35 3.63E-03 
2871241 MCC ⇩ 1.38 6.29E-03  2604390 ARL4C ⇧ 1.37 0.011  3893849 PRPF6 ⇩ 1.35 9.82E-03 
3628923 FAM96A ⇧ 1.38 2.85E-03  3004768 ZNF273 ⇧ 1.37 0.020  3824890 MPV17L2 ⇧ 1.35 0.038 
2531522 CAB39 ⇧ 1.38 4.41E-04  3396107 ESAM ⇩ 1.37 9.47E-03  2478748 EML4 ⇧ 1.35 7.56E-03 
3538087 DACT1 ⇩ 1.38 5.88E-03  3816827 S1PR4 ⇩ 1.37 0.030  3161113 PDCD1LG2 ⇩ 1.35 0.035 
3937755 SNAP29 ⇧ 1.38 7.15E-03  3429566 CHST11 ⇩ 1.37 4.31E-05  2929036 LTV1 ⇧ 1.35 3.40E-03 
3245783 WDFY4 ⇩ 1.38 1.93E-05  3168385 GLIPR2 ⇧ 1.36 0.011  3988987 NDUFA1 ⇧ 1.35 0.029 
3278813 FAM107B ⇧ 1.38 0.018  3900091 RALGAPA2 ⇩ 1.36 0.013  2443518 C1orf156 ⇧ 1.34 2.63E-03 
2999640 UBE2D4 ⇧ 1.38 4.44E-03  2712906 RNF168 ⇧ 1.36 6.66E-03  3414695 ATF1 ⇧ 1.34 0.035 
3288518 C10orf72 ⇩ 1.38 0.026  3761291 HOXB2 ⇩ 1.36 0.024  3651955 METTL9 ⇧ 1.34 2.28E-03 
2558483 C2orf42 ⇧ 1.38 4.93E-03  3892918 C20orf20 ⇧ 1.36 0.022  3553531 TNFAIP2 ⇩ 1.34 0.023 
2341645 HHLA3 ⇧ 1.38 7.48E-03  2842561 HIGD2A ⇧ 1.36 0.017  2835006 GRPEL2 ⇧ 1.34 2.49E-03 
2713111 MFI2 ⇩ 1.38 0.010  2775735 SCD5 ⇩ 1.36 0.029  3402736 PTMS ⇩ 1.34 0.029 
2626141 RPP14 ⇧ 1.38 9.26E-03  2376894 DYRK3 ⇧ 1.36 5.84E-03  3332886 TMEM138 ⇧ 1.34 0.025 
3748323 SHMT1 ⇧ 1.38 0.016  3333247 FADS2 ⇩ 1.36 5.75E-03  3130850 RNF122 ⇩ 1.34 0.023 
3926138 C21orf91 ⇧ 1.38 8.50E-03  2777487 FAM13A ⇩ 1.36 0.029  3875195 MCM8 ⇧ 1.34 2.71E-03 
2538600 ADI1 ⇧ 1.38 0.027  3833238 LGALS14 ⇧ 1.36 0.028  3279982 PTPLA ⇩ 1.34 0.043 
2805176 C5orf22 ⇧ 1.38 6.78E-03  2636272 GTPBP8 ⇧ 1.36 4.08E-04  3816264 DOT1L ⇩ 1.34 3.86E-03 
2362537 FCER1A ⇧ 1.37 0.033  4003895 CXorf21 ⇩ 1.36 0.027  3118451 CHRAC1 ⇧ 1.34 6.19E-03 
2902178 TCF19 ⇧ 1.37 6.68E-03  2350489 KIAA1324 ⇩ 1.36 0.041  3508898 STARD13 ⇩ 1.34 0.032 
3009399 HSPB1 ⇧ 1.37 0.041  2997907 EPDR1 ⇩ 1.35 0.021  2778980 EIF4E ⇧ 1.34 0.018 
2676182 NT5DC2 ⇧ 1.37 1.07E-03  3005717 RABGEF1 ⇧ 1.35 6.78E-04  3074912 DGKI ⇩ 1.34 0.011 
3048869 H2AFV ⇧ 1.37 4.14E-04  2724338 LIAS ⇧ 1.35 9.75E-03  2327375 ATPIF1 ⇧ 1.34 2.00E-03 
2514441 PPIG ⇧ 1.37 2.68E-06  3011492 ADAM22 ⇩ 1.35 0.022  3944690 CYTH4 ⇩ 1.34 0.014 
2427791 DENND2D ⇩ 1.37 0.027  3289235 SGMS1 ⇩ 1.35 5.85E-03  3015395 PVRIG ⇩ 1.34 0.046 
2682568 SHQ1 ⇧ 1.37 1.05E-03  3259978 PI4K2A ⇧ 1.35 0.036  3803120 B4GALT6 ⇩ 1.34 4.39E-03 
2425400 EXTL2 ⇩ 1.37 0.018  3336402 RBM14 ⇩ 1.35 8.23E-03  2655113 KLHL24 ⇧ 1.34 0.045 
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3267382 INPP5F ⇧ 1.33 0.027  3934407 ICOSLG ⇩ 1.32 1.08E-03  3982612 GPR174 ⇩ 1.31 0.026 
2746024 ABCE1 ⇧ 1.33 9.82E-03  3005684 KCTD7 ⇧ 1.32 2.70E-03  3284188 ITGB1 ⇩ 1.31 0.027 
2515183 DCAF17 ⇧ 1.33 2.94E-04  3521484 UGGT2 ⇩ 1.32 0.042  3417371 ESYT1 ⇩ 1.31 0.028 
3733590 SOX9 ⇩ 1.33 0.043  2945645 TDP2 ⇧ 1.32 5.18E-03  2352743 DCLRE1B ⇧ 1.31 2.36E-03 
2674168 C3orf62 ⇧ 1.33 4.17E-04  3377933 EFEMP2 ⇩ 1.32 0.029  3866094 PTGIR ⇩ 1.31 0.030 
2560141 MRPL53 ⇧ 1.33 3.93E-04  3329343 MDK ⇩ 1.32 0.039  3164601 KIAA1797 ⇩ 1.30 2.55E-03 
2659887 FYTTD1 ⇧ 1.33 1.53E-03  3057650 YWHAG ⇧ 1.32 2.53E-04  2544164 C2orf44 ⇧ 1.30 0.014 
3539724 SYNE2 ⇩ 1.33 0.014  2723710 PGM2 ⇧ 1.32 1.58E-03  2900059 HIST1H2BM ⇧ 1.30 0.011 
3379708 MRPL21 ⇧ 1.33 0.017  3596109 FAM81A ⇧ 1.32 5.63E-03  3698055 TXNL4B ⇧ 1.30 0.024 
2389016 PPPDE1 ⇧ 1.33 0.014  2477980 GEMIN6 ⇧ 1.32 1.55E-04  3318666 SMPD1 ⇩ 1.30 0.031 
2548459 CEBPZ ⇧ 1.33 1.15E-03  2654069 NDUFB5 ⇧ 1.32 8.17E-03  4024160 ATP11C ⇩ 1.30 0.014 
2332767 C1orf50 ⇧ 1.33 4.58E-03  3079803 PRKAG2 ⇧ 1.32 8.91E-04  3498837 PCCA ⇩ 1.30 0.016 
3635198 BCL2A1 ⇧ 1.33 0.031  2523478 NBEAL1 ⇧ 1.32 0.012  2320581 PLOD1 ⇩ 1.30 0.021 
2827525 SLC12A2 ⇩ 1.33 0.017  3741800 ATP2A3 ⇩ 1.32 0.025  2559494 C2orf7 ⇧ 1.30 7.97E-03 
2491676 VAMP5 ⇧ 1.33 0.039  3044129 GGCT ⇧ 1.32 0.027  3317915 STIM1 ⇩ 1.30 2.38E-03 
2638962 DTX3L ⇧ 1.33 0.027  3255938 OPN4 ⇧ 1.32 0.030  3073981 AKR1B1 ⇧ 1.30 0.048 
3106243 RIPK2 ⇧ 1.33 0.038  3485292 NBEA ⇩ 1.32 0.022  2356142 LIX1L ⇧ 1.30 0.046 
3836317 VASP ⇩ 1.33 9.36E-04  2548617 CDC42EP3 ⇧ 1.32 0.044  2412988 C1orf163 ⇧ 1.30 6.12E-04 
3438617 EP400 ⇩ 1.33 2.44E-03  3771602 RHBDF2 ⇩ 1.31 6.76E-03  3015769 POP7 ⇧ 1.30 0.018 
3649890 ABCC1 ⇩ 1.32 7.34E-04  2766456 UGDH ⇧ 1.31 0.012  3635125 MTHFS ⇧ 1.30 0.023 
4019412 CXorf56 ⇧ 1.32 1.32E-03  2562271 CAPG ⇩ 1.31 0.037  2877465 ETF1 ⇧ 1.30 3.39E-03 
3761348 HOXB4 ⇩ 1.32 3.51E-04  3740432 SCARF1 ⇩ 1.31 0.020  2596763 FZD5 ⇩ 1.30 0.039 
2367743 PRDX6 ⇧ 1.32 3.63E-04  3996306 RPL10 ⇧ 1.31 0.045  3654956 LAT ⇩ 1.30 1.81E-03 
2343289 DNAJB4 ⇧ 1.32 0.018  2403470 DNAJC8 ⇧ 1.31 0.024  2447148 RGS16 ⇩ 1.30 0.027 
3002873 LANCL2 ⇧ 1.32 0.033  2779408 MAPKSP1 ⇧ 1.31 3.05E-03  3146103 STK3 ⇩ 1.30 6.13E-03 
2325274 C1orf128 ⇧ 1.32 4.69E-04  3340589 SERPINH1 ⇩ 1.31 0.046  3845944 GNG7 ⇧ 1.30 0.016 
3707199 PSMB6 ⇧ 1.32 0.042  2758686 LYAR ⇧ 1.31 1.35E-03  2773872 NAAA ⇧ 1.30 0.029 
3583541 GOLGA6L1 ⇧ 1.32 0.019  3035682 FTSJ2 ⇧ 1.31 9.17E-04  3094286 PROSC ⇧ 1.30 0.015 
2396121 DFFA ⇧ 1.32 5.04E-04  4027345 LAGE3 ⇧ 1.31 1.20E-03  3489481 PHF11 ⇩ 1.30 1.13E-03 
2696379 ANAPC13 ⇧ 1.32 0.025  2815455 UTP15 ⇧ 1.31 3.52E-03  3670668 ATMIN ⇧ 1.30 0.011 
2494749 CNNM3 ⇩ 1.32 2.13E-03  2775909 PLAC8 ⇩ 1.31 0.034  3205488 ZBTB5 ⇧ 1.30 0.018 
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2745220 ZNF330 ⇧ 1.30 8.23E-03  2505957 PLEKHB2 ⇧ 1.29 0.020  3251298 CHST3 ⇩ 1.28 0.035 
2898562 ACOT13 ⇧ 1.30 0.026  3655574 SPN ⇩ 1.29 3.99E-03  2802398 TRIO ⇩ 1.28 5.47E-04 
3714659 DHRS7B ⇩ 1.30 0.015  2931683 C6orf211 ⇧ 1.29 0.013  3542689 PCNX ⇩ 1.28 3.43E-03 
2582124 NR4A2 ⇧ 1.30 0.033  2730313 CSN3 ⇧ 1.29 0.023  2798915 TRIP13 ⇧ 1.28 0.039 
3487095 DGKH ⇩ 1.30 0.018  2621122 NBEAL2 ⇩ 1.29 2.67E-03  2769512 RPL21P44 ⇧ 1.28 3.51E-03 
2821761 RGMB ⇧ 1.30 2.34E-05  2438482 ISG20L2 ⇧ 1.29 5.36E-03  2861952 MRPS27 ⇧ 1.28 3.18E-03 
2603531 C2orf52 ⇧ 1.30 3.77E-03  3766960 SMURF2 ⇩ 1.29 4.85E-03  2942578 CCDC90A ⇧ 1.28 3.56E-03 
2706985 MRPL47 ⇧ 1.30 0.031  2820893 RFESD ⇧ 1.29 0.018  2336913 LRRC42 ⇧ 1.28 8.33E-04 
3193900 MRPS2 ⇧ 1.30 0.024  2472914 UBXN2A ⇧ 1.29 8.28E-03  2564599 MRPS5 ⇧ 1.28 0.021 
3662444 NLRC5 ⇩ 1.30 1.55E-03  2432607 GNRHR2 ⇧ 1.29 8.29E-04  3590108 GCHFR ⇧ 1.28 0.043 
3798291 PPP4R1 ⇧ 1.30 0.020  3139722 NCOA2 ⇩ 1.29 8.64E-03  3893458 PPDPF ⇧ 1.28 0.023 
2773907 SDAD1 ⇧ 1.30 0.041  3690034 C16orf87 ⇧ 1.29 8.57E-03  3476665 SCARB1 ⇩ 1.28 3.48E-03 
3101385 MTFR1 ⇧ 1.29 0.019  3323052 NAV2 ⇩ 1.29 6.22E-03  2409770 TMEM53 ⇧ 1.28 0.015 
4007216 UXT ⇧ 1.29 0.042  3697090 ST3GAL2 ⇩ 1.29 5.34E-03  3766651 ERN1 ⇩ 1.28 0.017 
3708938 ATP1B2 ⇧ 1.29 0.018  3704376 FAM38A ⇩ 1.29 0.011  4026669 BCAP31 ⇩ 1.28 0.018 
3945133 POLR2F ⇧ 1.29 0.025  3939707 CABIN1 ⇩ 1.29 2.24E-04  3316234 NS3BP ⇧ 1.28 2.47E-03 
3272205 INPP5A ⇩ 1.29 0.025  3561110 RALGAPA1 ⇩ 1.29 0.030  2633460 C3orf26 ⇧ 1.28 0.032 
3350775 SIDT2 ⇩ 1.29 4.34E-04  2838688 MAT2B ⇧ 1.29 5.87E-03  2317317 TP73 ⇧ 1.28 0.045 
3849752 ZNF426 ⇧ 1.29 7.36E-03  3751042 TLCD1 ⇧ 1.29 0.037  2873785 ALDH7A1 ⇧ 1.28 0.037 
3721926 TUBG1 ⇧ 1.29 0.015  3015178 ZSCAN21 ⇧ 1.29 1.31E-03  3040454 TWISTNB ⇧ 1.28 1.36E-04 
2689208 NAA50 ⇧ 1.29 7.67E-03  3940992 ASPHD2 ⇩ 1.29 0.031  2954324 MEA1 ⇧ 1.28 0.030 
2767378 ATP8A1 ⇩ 1.29 0.014  3548929 RIN3 ⇩ 1.29 0.025  2492938 RPIA ⇧ 1.28 0.015 
2957462 GSTA4 ⇧ 1.29 0.014  3020444 CAPZA2 ⇧ 1.29 0.045  3545311 KIAA1737 ⇧ 1.28 2.88E-03 
2538000 RNASEH1 ⇧ 1.29 0.018  2908144 MAD2L1BP ⇧ 1.29 2.14E-03  3837731 EMP3 ⇩ 1.28 2.98E-04 
2465493 ZNF670 ⇧ 1.29 0.011  3529908 NFATC4 ⇩ 1.29 0.014  3850817 RAB3D ⇩ 1.28 8.01E-03 
2961300 COX7A2 ⇧ 1.29 0.015  2847264 MED10 ⇧ 1.28 0.010  3832383 PSMD8 ⇧ 1.28 0.011 
2360257 IL6R ⇧ 1.29 0.016  2754538 SLC25A4 ⇧ 1.28 0.043  3831514 ZNF567 ⇧ 1.28 0.017 
2924492 HEY2 ⇧ 1.29 0.013  3736162 TMC8 ⇩ 1.28 2.27E-03  2814642 MCCC2 ⇧ 1.28 4.83E-03 
3074260 WDR91 ⇩ 1.29 4.18E-03  2475407 CLIP4 ⇧ 1.28 3.31E-03  2709486 RFC4 ⇧ 1.27 0.045 
3535922 STYX ⇧ 1.29 0.012  2595443 WDR12 ⇧ 1.28 5.55E-03  2979679 ZBTB2 ⇧ 1.27 0.014 
2842911 FGFR4 ⇩ 1.29 5.97E-03  3822347 C19orf53 ⇧ 1.28 0.032  2649113 TIPARP ⇧ 1.27 0.014 
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2484970 EHBP1 ⇩ 1.27 0.021  2911903 PTP4A1 ⇧ 1.27 5.98E-03  2435849 SPRR2D ⇧ 1.26 0.034 
2360818 HCN3 ⇩ 1.27 0.014  3969455 OFD1 ⇩ 1.27 0.014  3485074 RFC3 ⇧ 1.26 0.026 
3740367 SLC43A2 ⇩ 1.27 0.044  3712675 RAI1 ⇩ 1.27 0.016  2642325 ATP2C1 ⇩ 1.26 6.33E-03 
2465182 TFB2M ⇧ 1.27 2.48E-03  3283920 ARHGAP12 ⇩ 1.27 1.20E-03  2519140 ZC3H15 ⇧ 1.26 4.04E-04 
3340449 SLCO2B1 ⇩ 1.27 0.038  2960872 C6orf150 ⇧ 1.27 0.012  3454006 FMNL3 ⇩ 1.26 6.24E-03 
3304746 USMG5 ⇧ 1.27 0.015  3228463 RALGDS ⇩ 1.27 4.69E-03  2574798 MAP3K2 ⇧ 1.26 3.07E-03 
2458629 LEFTY2 ⇧ 1.27 0.018  2346863 RPL5 ⇧ 1.27 0.017  2407729 RRAGC ⇧ 1.26 0.010 
3101802 SGK3 ⇧ 1.27 1.24E-03  2319802 PGD ⇧ 1.27 0.027  2619323 SS18L2 ⇧ 1.26 0.042 
2374422 C1orf106 ⇩ 1.27 5.45E-03  2889753 ZNF354A ⇧ 1.27 0.026  2331959 DEM1 ⇧ 1.26 2.74E-04 
2351872 RAP1A ⇧ 1.27 5.66E-03  2934308 IGF2R ⇩ 1.27 9.66E-03  2618640 RPL14 ⇧ 1.26 2.58E-03 
2434490 ENSA ⇧ 1.27 0.041  3728325 FLJ11710 ⇩ 1.26 0.034  2379132 ATF3 ⇧ 1.26 0.016 
2721809 ZCCHC4 ⇧ 1.27 5.07E-04  2588827 NFE2L2 ⇧ 1.26 0.013  3489538 ARL11 ⇧ 1.26 0.012 
3540862 GPHN ⇩ 1.27 1.17E-03  2417272 GNG12 ⇧ 1.26 5.62E-03  3316344 CD151 ⇧ 1.26 0.047 
2434862 LYSMD1 ⇧ 1.27 0.012  2786657 SETD7 ⇧ 1.26 5.63E-03  2334279 UROD ⇧ 1.26 5.72E-03 
2378180 C1orf107 ⇧ 1.27 3.07E-03  2597273 C2orf67 ⇩ 1.26 8.21E-03  2435195 MRPL9 ⇧ 1.26 0.013 
3660175 NOD2 ⇩ 1.27 7.90E-03  3417574 SPRYD4 ⇧ 1.26 0.016  2859494 SREK1IP1 ⇧ 1.26 0.020 
2895721 NOL7 ⇧ 1.27 0.022  2988459 RBAK ⇧ 1.26 0.028  3631214 TLE3 ⇩ 1.26 3.51E-03 
3995254 GABRQ ⇧ 1.27 0.047  2336497 ZYG11B ⇧ 1.26 4.71E-03  4054117 TAF13 ⇧ 1.26 0.039 
2339414 USP1 ⇧ 1.27 0.012  3175597 VPS13A ⇩ 1.26 0.013  2773756 G3BP2 ⇧ 1.26 4.07E-04 
2404521 PEF1 ⇧ 1.27 0.012  2700828 SIAH2 ⇧ 1.26 9.84E-03  3864597 C19orf61 ⇩ 1.26 3.86E-03 
2954489 C6orf108 ⇧ 1.27 0.035  2636483 SIDT1 ⇩ 1.26 0.020  2635983 ABHD10 ⇧ 1.26 0.017 
3740201 MYO1C ⇩ 1.27 4.26E-04  3578089 C14orf49 ⇩ 1.26 7.28E-03  2460325 C1orf198 ⇧ 1.26 3.59E-03 
2555630 CCT4 ⇧ 1.27 4.22E-05  4026842 ARHGAP4 ⇩ 1.26 5.34E-03  2700500 COMMD2 ⇧ 1.25 0.028 
3941010 SRRD ⇧ 1.27 0.023  2407128 MEAF6 ⇧ 1.26 0.013  3829160 C19orf40 ⇧ 1.25 3.68E-03 
2385258 C1orf124 ⇧ 1.27 0.011  3527684 RNASE3 ⇧ 1.26 0.018  3662265 NUP93 ⇧ 1.25 9.11E-04 
2534126 COPS8 ⇧ 1.27 1.88E-05  2819747 POLR3G ⇧ 1.26 7.93E-03  2519860 ASNSD1 ⇧ 1.25 0.015 
2336383 PRPF38A ⇧ 1.27 2.58E-04  3742067 UBE2G1 ⇧ 1.26 0.031  2320657 MIIP ⇧ 1.25 4.13E-04 
2383550 ZNF678 ⇧ 1.27 1.21E-03  2408681 HIVEP3 ⇩ 1.26 0.016  3818897 PNPLA6 ⇩ 1.25 1.45E-03 
2523354 FAM117B ⇧ 1.27 0.011  3829313 CEBPG ⇧ 1.26 0.048  2601341 WDFY1 ⇧ 1.25 0.025 
3325820 DEPDC7 ⇩ 1.27 0.019  2694644 CNBP ⇧ 1.26 0.020  3904527 NDRG3 ⇧ 1.25 0.048 
2562821 VPS24 ⇧ 1.27 0.018  3456260 ATF7 ⇩ 1.26 6.69E-03  2364189 UAP1 ⇧ 1.25 0.039 
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2662473 PRRT3 ⇩ 1.25 0.043  3748026 TOM1L2 ⇩ 1.25 8.61E-04  2500838 POLR1B ⇧ 1.24 0.038 
2489806 MRPL19 ⇧ 1.25 0.028  3715874 ERAL1 ⇧ 1.25 0.022  3376235 WDR74 ⇧ 1.24 2.19E-03 
2612278 CAPN7 ⇧ 1.25 8.60E-03  3161566 KDM4C ⇩ 1.24 3.33E-03  3453592 MLL2 ⇩ 1.24 0.010 
3131741 RAB11FIP1 ⇧ 1.25 0.031  4009315 HUWE1 ⇩ 1.24 3.07E-04  2433209 PRKAB2 ⇧ 1.24 0.030 
2342576 ACADM ⇧ 1.25 0.013  3063337 ZNF394 ⇧ 1.24 3.13E-03  3936887 MRPL40 ⇧ 1.24 0.042 
3195174 MAN1B1 ⇩ 1.25 2.81E-04  2934167 MRPL18 ⇧ 1.24 8.22E-03  2825629 TNFAIP8 ⇧ 1.24 9.68E-03 
3415763 SOAT2 ⇩ 1.25 1.08E-03  3185205 HSDL2 ⇧ 1.24 1.27E-03  2827388 PRRC1 ⇧ 1.24 5.19E-03 
3963676 C22orf9 ⇩ 1.25 0.025  3383322 NARS2 ⇧ 1.24 0.019  2693149 SNX4 ⇧ 1.24 0.026 
2685776 MINA ⇧ 1.25 8.74E-03  3847959 TUBB4 ⇧ 1.24 0.019  3591044 HAUS2 ⇧ 1.24 4.39E-03 
2833286 ARHGAP26 ⇩ 1.25 0.032  3216023 C9orf130 ⇧ 1.24 0.011  3441849 TNFRSF1A ⇩ 1.24 0.045 
3747717 COPS3 ⇧ 1.25 2.77E-03  3710870 ARHGAP44 ⇧ 1.24 0.012  2728189 PAICS ⇧ 1.24 0.019 
2367086 FMO4 ⇧ 1.25 7.62E-03  2401275 HNRNPR ⇧ 1.24 4.34E-04  3564210 PYGL ⇩ 1.24 0.039 
2371694 RNF2 ⇧ 1.25 0.023  2886977 FBXW11 ⇧ 1.24 1.63E-03  2356181 RBM8A ⇧ 1.24 0.012 
3611744 LRRK1 ⇩ 1.25 0.026  2639874 UMPS ⇧ 1.24 0.032  2317434 TPRG1L ⇧ 1.24 0.032 
3382972 RSF1 ⇧ 1.25 0.039  2921374 RPF2 ⇧ 1.24 0.035  2451544 MYOG ⇧ 1.24 0.033 
2963614 CGA ⇧ 1.25 7.28E-03  3923354 AGPAT3 ⇩ 1.24 8.41E-04  2361279 LMNA ⇩ 1.24 0.014 
2831567 PURA ⇧ 1.25 2.85E-04  3537264 C14orf101 ⇩ 1.24 8.67E-03  3852783 DNAJB1 ⇧ 1.24 0.025 
3157901 PLEC ⇩ 1.25 4.47E-04  2950214 TAP1 ⇩ 1.24 4.62E-03  2838598 CCNG1 ⇧ 1.24 0.012 
2904000 HMGA1 ⇧ 1.25 4.79E-04  2709414 TBCCD1 ⇧ 1.24 8.95E-04  3535000 ARF6 ⇧ 1.24 0.018 
2905327 FGD2 ⇩ 1.25 8.58E-03  3058156 TMEM60 ⇧ 1.24 0.027  2779486 H2AFZ ⇧ 1.23 6.24E-03 
3707352 RNF167 ⇩ 1.25 1.03E-03  3629206 OAZ2 ⇧ 1.24 0.023  2377094 PFKFB2 ⇧ 1.23 0.016 
3044753 LSM5 ⇧ 1.25 0.028  2979056 NUP43 ⇧ 1.24 8.28E-03  2934801 MAP3K4 ⇩ 1.23 0.019 
3153428 ASAP1 ⇧ 1.25 0.011  2906607 NFYA ⇧ 1.24 1.12E-03  3240095 RAB18 ⇧ 1.23 0.043 
2830010 SMAD5 ⇧ 1.25 3.58E-03  2343231 NEXN ⇧ 1.24 0.046  2405893 C1orf212 ⇧ 1.23 0.013 
3197318 AK3 ⇧ 1.25 0.018  2460487 C1orf131 ⇧ 1.24 7.67E-04  3693837 GOT2 ⇩ 1.23 0.030 
3709244 CHD3 ⇩ 1.25 2.18E-03  2739160 CCDC109B ⇧ 1.24 0.025  2982319 SOD2 ⇧ 1.23 0.030 
3959986 IL2RB ⇩ 1.25 0.028  2805581 SUB1 ⇧ 1.24 0.019  2901660 PRR3 ⇧ 1.23 7.67E-03 
3417767 GPR182 ⇧ 1.25 9.06E-03  2664288 METTL6 ⇧ 1.24 0.011  3368814 LMO2 ⇧ 1.23 4.97E-03 
3020804 NAA38 ⇧ 1.25 0.016  3607183 MRPS11 ⇧ 1.24 0.011  3434525 MLEC ⇩ 1.23 0.017 
2489071 TET3 ⇩ 1.25 0.015  2413519 HSPB11 ⇧ 1.24 0.018  2857416 IL6ST ⇩ 1.23 0.044 
3959451 MYH9 ⇩ 1.25 6.69E-04  3307939 ABLIM1 ⇧ 1.24 0.010  2434527 GOLPH3L ⇧ 1.23 8.04E-03 







Table B21: C9-Short Specific Gene List (n=916) MALE ONLY SAMPLES [Partek® unadjusted p<0.05, FC ≥ ±1.20]   
 642 
 
3325052 EIF2AK2 ⇧ 1.23 0.026  2575980 CCDC115 ⇧ 1.23 0.047  2901352 PPP1R11 ⇧ 1.22 0.027 
3334749 PPP2R5B ⇩ 1.23 0.025  3828887 ZNF507 ⇧ 1.23 5.96E-03  3377091 MAP4K2 ⇩ 1.22 0.023 
2486740 PNO1 ⇧ 1.23 9.50E-03  3056414 RFC2 ⇧ 1.23 0.024  2491788 ATOH8 ⇧ 1.22 2.23E-04 
3601931 CPLX3 ⇩ 1.23 0.011  3739962 ABR ⇩ 1.23 7.97E-03  3304853 SH3PXD2A ⇩ 1.22 5.11E-03 
3757745 GHDC ⇩ 1.23 0.016  3666282 ZFP90 ⇧ 1.23 0.031  2458649 C1orf55 ⇧ 1.22 0.013 
3919033 SLC5A3 ⇩ 1.23 0.011  3110171 ATP6V1C1 ⇧ 1.23 6.98E-03  3883971 C20orf24 ⇧ 1.22 0.015 
2610336 VHL ⇧ 1.23 6.63E-03  3048886 PURB ⇧ 1.23 9.65E-03  2859195 DIMT1L ⇧ 1.22 0.019 
3725456 ATP5G1 ⇧ 1.23 0.027  2743370 C4orf33 ⇧ 1.22 0.028  2783484 C4orf3 ⇧ 1.22 0.039 
3816424 SPPL2B ⇩ 1.23 9.98E-03  3261820 TRIM8 ⇩ 1.22 0.022  3536905 KTN1 ⇩ 1.22 0.012 
3869379 ZNF614 ⇧ 1.23 0.042  3757154 KRT14 ⇩ 1.22 0.013  3335465 SIPA1 ⇩ 1.22 5.74E-04 
3119735 ZNF623 ⇧ 1.23 2.28E-03  3822657 CD97 ⇩ 1.22 0.013  3222128 TNFSF15 ⇩ 1.22 0.011 
2949210 BAT4 ⇧ 1.23 0.012  3329904 NDUFS3 ⇧ 1.22 0.011  3544346 DLST ⇧ 1.22 0.017 
2438344 GPATCH4 ⇧ 1.23 0.037  3098454 MRPL15 ⇧ 1.22 0.025  2712858 UBXN7 ⇧ 1.22 0.020 
2327219 STX12 ⇧ 1.23 0.011  3048212 MRPS24 ⇧ 1.22 3.24E-03  3830002 GRAMD1A ⇩ 1.22 1.26E-03 
3267314 BAG3 ⇧ 1.23 3.61E-03  2356205 PEX11B ⇧ 1.22 3.89E-03  3354879 HYLS1 ⇩ 1.22 2.40E-03 
3854477 TMEM221 ⇧ 1.23 0.016  3362795 RNF141 ⇧ 1.22 0.024  3408018 ETNK1 ⇩ 1.22 0.013 
3705641 TIMM22 ⇧ 1.23 4.70E-03  3017795 RINT1 ⇧ 1.22 0.029  2495782 LIPT1 ⇧ 1.22 0.032 
3705491 FAM57A ⇩ 1.23 0.014  2812315 C5orf44 ⇧ 1.22 5.11E-03  2602997 SLC16A14 ⇧ 1.22 0.013 
3204744 TLN1 ⇩ 1.23 3.27E-03  3307120 ZDHHC6 ⇩ 1.22 0.033  2351940 DDX20 ⇧ 1.22 0.040 
3261886 C10orf26 ⇩ 1.23 0.027  3282974 SVIL ⇩ 1.22 0.022  2906824 FOXP4 ⇩ 1.22 0.034 
3624697 ARPP19 ⇧ 1.23 0.016  3642707 ITFG3 ⇩ 1.22 4.08E-03  2472955 MFSD2B ⇧ 1.22 0.012 
2645579 RASA2 ⇧ 1.23 0.034  2903782 ITPR3 ⇩ 1.22 0.019  2501238 PSD4 ⇩ 1.22 0.029 
3031827 SLC4A2 ⇩ 1.23 0.012  3926080 BTG3 ⇧ 1.22 0.034  2567242 CHST10 ⇧ 1.22 0.049 
2964200 UBE2J1 ⇧ 1.23 0.037  3426828 VEZT ⇩ 1.22 0.048  3634458 TBC1D2B ⇩ 1.22 7.82E-03 
3041875 OSBPL3 ⇩ 1.23 0.031  2807862 C5orf51 ⇧ 1.22 0.040  2694785 MBD4 ⇧ 1.22 5.02E-03 
2403215 FGR ⇩ 1.23 0.018  3090922 PPP2R2A ⇧ 1.22 0.026  3047202 C7orf11 ⇧ 1.22 8.50E-03 
3665997 DUS2L ⇧ 1.23 0.020  2863535 WDR41 ⇧ 1.22 1.34E-03  3922664 SLC37A1 ⇩ 1.22 5.57E-03 
2363444 USP21 ⇧ 1.23 5.21E-03  3960827 SUN2 ⇩ 1.22 6.12E-03  2999816 YKT6 ⇧ 1.22 0.026 
3337516 LRP5 ⇩ 1.23 0.048  3996467 PLXNA3 ⇩ 1.22 0.019  2757720 HAUS3 ⇧ 1.22 2.26E-03 
3146012 NIPAL2 ⇩ 1.23 2.60E-03  2503618 TSN ⇧ 1.22 0.016  2903574 B3GALT4 ⇩ 1.22 9.46E-03 
2708229 PARL ⇧ 1.23 0.020  2536800 D2HGDH ⇩ 1.22 0.035  2899206 HIST1H2BF ⇧ 1.22 0.013 
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3100166 RAB2A ⇧ 1.22 4.98E-03  2750227 C4orf43 ⇧ 1.21 9.65E-03  3614901 HERC2 ⇩ 1.21 0.011 
2921456 KIAA1919 ⇩ 1.22 0.032  2927993 HECA ⇧ 1.21 2.78E-03  3753372 RFFL ⇩ 1.21 0.010 
3675116 TMEM8A ⇩ 1.22 6.18E-03  2484752 COMMD1 ⇧ 1.21 0.036  3851703 C19orf43 ⇩ 1.21 0.022 
2948648 NCRNA00243 ⇧ 1.22 0.018  3880706 ENTPD6 ⇩ 1.21 6.59E-03  3683845 DCUN1D3 ⇧ 1.21 3.57E-03 
3050367 FIGNL1 ⇧ 1.22 0.047  3743486 GABARAP ⇧ 1.21 7.52E-03  2678090 ARF4 ⇧ 1.21 0.044 
2852274 MTMR12 ⇧ 1.22 6.99E-03  2903703 SYNGAP1 ⇧ 1.21 1.29E-03  3315024 ADAM8 ⇩ 1.21 0.019 
3759778 ARHGAP27 ⇩ 1.22 0.013  3032243 GALNT11 ⇧ 1.21 0.016  2870397 PJA2 ⇧ 1.21 0.028 
3693533 CSNK2A2 ⇩ 1.22 4.95E-03  2950885 MLN ⇧ 1.21 0.041  3701297 CDYL2 ⇧ 1.21 5.71E-03 
2827156 PHAX ⇧ 1.22 6.10E-03  3855538 MEF2B ⇧ 1.21 6.80E-03  3934695 PTTG1IP ⇩ 1.21 0.041 
3434374 GATC ⇧ 1.22 0.047  2398789 SDHB ⇧ 1.21 0.012  4017810 ACSL4 ⇩ 1.21 0.049 
2642562 NUDT16 ⇧ 1.22 4.49E-03  2548776 ATL2 ⇧ 1.21 0.042  3839489 GPR32 ⇩ 1.21 0.032 
3835645 PVR ⇩ 1.21 5.35E-03  3610982 SYNM ⇩ 1.21 0.032  2623388 PARP3 ⇧ 1.21 0.048 
3363091 GALNTL4 ⇩ 1.21 0.011  3874313 ATRN ⇩ 1.21 0.043  3565303 CNIH ⇩ 1.21 0.015 
2822215 PAM ⇩ 1.21 0.035  2315739 PUSL1 ⇧ 1.21 1.71E-03  3880767 PYGB ⇩ 1.20 0.038 
2444790 MRPS14 ⇧ 1.21 1.25E-03  3375545 FADS1 ⇩ 1.21 0.049  3918104 C21orf63 ⇩ 1.20 5.35E-03 
3978706 PAGE5 ⇧ 1.21 0.022  2947572 TRIM27 ⇧ 1.21 5.78E-03  4026722 IDH3G ⇧ 1.20 0.021 
3819401 LASS4 ⇩ 1.21 0.013  3884191 SRC ⇩ 1.21 7.62E-03  2843619 HNRNPAB ⇧ 1.20 8.60E-03 
3003153 GBAS ⇧ 1.21 8.19E-03  2596955 CRYGC ⇧ 1.21 0.047  2451200 UBE2T ⇧ 1.20 0.025 
2907568 KLHDC3 ⇧ 1.21 7.02E-03  2327188 FAM76A ⇧ 1.21 5.68E-03  3945863 MGAT3 ⇩ 1.20 0.028 
3830712 MLL4 ⇩ 1.21 7.87E-03  2522014 C2orf47 ⇧ 1.21 1.40E-03  2977471 ADAT2 ⇧ 1.20 0.033 
3564250 TRIM9 ⇩ 1.21 0.022  2545509 PREB ⇧ 1.21 6.53E-03  3639007 HDDC3 ⇧ 1.20 0.014 
3328520 CD82 ⇩ 1.21 0.010  2560704 C2orf3 ⇧ 1.21 0.021  3179551 FGD3 ⇩ 1.20 0.027 
3189714 GARNL3 ⇧ 1.21 0.025  2444451 CENPL ⇧ 1.21 4.35E-03  3551303 CCNK ⇧ 1.20 5.05E-03 
3325768 QSER1 ⇩ 1.21 0.013  3770029 CDC42EP4 ⇩ 1.21 4.57E-03  2649609 MLF1 ⇧ 1.20 0.018 
3558270 CBLN3 ⇩ 1.21 0.033  3552847 DYNC1H1 ⇩ 1.21 0.028  3774218 DYSFIP1 ⇧ 1.20 0.024 
2641577 C3orf37 ⇧ 1.21 0.022  2452311 TMEM81 ⇧ 1.21 2.70E-03  3729569 BCAS3 ⇩ 1.20 0.017 
3775038 C17orf62 ⇩ 1.21 9.27E-03  2318637 VAMP3 ⇧ 1.21 0.012  3928477 KRTAP26-1 ⇧ 1.20 0.049 
3841901 NLRP2 ⇧ 1.21 0.016  3851545 MAN2B1 ⇩ 1.21 0.015  2641479 GP9 ⇩ 1.20 0.015 
3717452 LRRC37BP1 ⇩ 1.21 0.015  2916246 C6orf162 ⇧ 1.21 0.018  3867400 FUT1 ⇩ 1.20 0.019 
3048749 DDX56 ⇧ 1.21 6.52E-03  2678116 FAM116A ⇧ 1.21 6.92E-03  3221135 C9orf80 ⇧ 1.20 0.030 
2845591 BRD9 ⇧ 1.21 0.012  2565143 STARD7 ⇧ 1.21 0.021  2855614 C5orf34 ⇧ 1.20 0.047 
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2951221 C6orf106 ⇧ 1.20 0.045  3259400 CCNJ ⇧ 1.20 1.00E-03  2382336 FBXO28 ⇧ 1.20 0.015 
3655723 MVP ⇩ 1.20 6.94E-03  3181728 TGFBR1 ⇩ 1.20 0.036  3816664 ZNF555 ⇧ 1.20 8.84E-03 
3995848 ABCD1 ⇩ 1.20 2.58E-03  3923218 RRP1B ⇧ 1.20 0.038  3192171 POMT1 ⇩ 1.20 2.32E-03 
3472000 C12orf51 ⇩ 1.20 0.043  4017519 PSMD10 ⇧ 1.20 0.020  3648412 RUNDC2A ⇩ 1.20 0.049 
2663551 NUP210 ⇩ 1.20 0.036  3396144 C11orf61 ⇩ 1.20 0.036  3992148 DDX26B ⇩ 1.20 0.012 
3375990 INTS5 ⇧ 1.20 0.024  2598099 BARD1 ⇧ 1.20 7.07E-03  3484005 USPL1 ⇧ 1.20 0.025 
2832431 PCDHB11 ⇧ 1.20 5.42E-03  3251926 KIAA0913 ⇩ 1.20 6.55E-03  3937294 LOC150197 ⇩ 1.20 3.34E-03 
3432678 TPCN1 ⇩ 1.20 0.013  3190558 SPTAN1 ⇩ 1.20 0.020  2695941 TOPBP1 ⇧ 1.20 4.05E-03 
2949830 AGER ⇩ 1.20 5.99E-03  3635456 MESDC2 ⇩ 1.20 0.042  2966232 COQ3 ⇧ 1.20 5.25E-03 
3257559 RPP30 ⇧ 1.20 0.022  3865422 RTN2 ⇩ 1.20 1.91E-04  2565579 ANKRD39 ⇧ 1.20 0.041 
2921296 AMD1 ⇧ 1.20 0.013  2878474 HARS ⇧ 1.20 0.036  3341362 AQP11 ⇧ 1.20 7.88E-03 
2916952 CASP8AP2 ⇧ 1.20 0.037  3255220 GHITM ⇧ 1.20 0.014  2995189 PLEKHA8 ⇩ 1.20 2.09E-03 
2367287 METTL13 ⇧ 1.20 0.014  3269587 C10orf137 ⇩ 1.20 0.011  2886535 LOC100133106 ⇧ 1.20 0.041 
3442514 C1RL ⇩ 1.20 0.013  2877141 HNRNPA0 ⇧ 1.20 1.11E-03  3029646 ARHGEF5 ⇧ 1.20 0.010 
3695541 FHOD1 ⇩ 1.20 0.018  2662087 SRGAP3 ⇧ 1.20 0.015  3352618 GRIK4 ⇩ 1.20 0.019 
2403585 TAF12 ⇧ 1.20 0.046  3540136 HSPA2 ⇧ 1.20 7.83E-03  3809671 NARS ⇧ 1.20 0.012 
3014714 ARPC1B ⇧ 1.20 0.027  3933331 C2CD2 ⇩ 1.20 0.020  2724235 WDR19 ⇧ 1.20 0.022 
2735027 SPP1 ⇧ 1.20 0.045  4026956 HCFC1 ⇩ 1.20 0.026  2437801 ARHGEF2 ⇩ 1.20 7.97E-03 
2878446 NDUFA2 ⇧ 1.20 7.55E-03             
 
 
